PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	LU, XY; XU, L; MEISSNER, G				LU, XY; XU, L; MEISSNER, G			ACTIVATION OF THE SKELETAL-MUSCLE CALCIUM-RELEASE CHANNEL BY A CYTOPLASMIC LOOP OF THE DIHYDROPYRIDINE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM VESICLES; ADENINE-NUCLEOTIDE; CA-2+ RELEASE; RYANODINE; MG-2+; MODULATION; JUNCTION; BINDING; PROTEIN; CELLS	Expression studies with skeletal and cardiac muscle cDNAs have suggested that the putative cytoplasmic loop region of the dihydropyridine receptor (DHPR) alpha 1 subunit between transmembrane repeats II and III (DCL) is a major determinant of the type of excitation contraction coupling (skeletal or cardiac) in rescued dysgenic muscle cells (Tanabe, T., Beam, K. G., Adams, B. A., Niidome, T., and Numa, S. (1990) Nature 346, 567-569). In this study, the possibility of a direct functional interaction with the sarcoplasmic reticulum ryanodine receptor/Ca2+ release channel has been tested by expressing the DCLs of the mammalian skeletal and cardiac muscle DHPR alpha 1 subunit in Escherichia coli. The purified peptides activated the skeletal muscle ryanodine receptor/Ca2+ release channel in single channel and [H-3]ryanodine binding measurements, by increasing channel open probability and the affinity of [H-3]ryanodine binding, respectively. The two peptides did not activate the cardiac muscle Ca2+ release channel. Other proteins (polylysine, serum albumin) also increased [H-3]ryanodine binding and Ca2+ release channel activity, but their activation mechanisms were distinguishable from DCLs. These results show that the II-III cytoplasmic loop of the skeletal and cardiac DHPR alpha 1 subunit functionally interacts with the skeletal, but not cardiac, muscle Ca2+ release channel. Furthermore, our studies suggest that in addition to the DHPR, the sarcoplasmic reticulum Ca2+ release channel may determine the type of E-C coupling that exists in muscle.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHYSIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018687, R37AR018687] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 18687] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; BEAM KG, 1986, NATURE, V320, P168, DOI 10.1038/320168a0; BEUCKELMANN DJ, 1988, J PHYSIOL-LONDON, V405, P233, DOI 10.1113/jphysiol.1988.sp017331; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; CIFUENTES ME, 1989, ARCH BIOCHEM BIOPHYS, V273, P554, DOI 10.1016/0003-9861(89)90515-8; CORBETT AM, 1985, J MEMBRANE BIOL, V86, P267, DOI 10.1007/BF01870606; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; HAWKES MJ, 1992, J BIOL CHEM, V267, P6702; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MA J, 1993, J GEN PHYSIOL, V102, P423, DOI 10.1085/jgp.102.3.423; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1992, MOL CELL BIOCHEM, V114, P119; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; THIELECZEK R, 1989, J BIOL CHEM, V264, P7349	30	163	163	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6511	6516						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120002				2022-12-27	WOS:A1994MZ50300040
J	CURTIS, JE; HELGERSON, SL; PARKER, ET; LOLLAR, P				CURTIS, JE; HELGERSON, SL; PARKER, ET; LOLLAR, P			ISOLATION AND CHARACTERIZATION OF THROMBIN-ACTIVATED HUMAN FACTOR-VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; FACTOR-IXA; A1/A3-C1-C2 DIMER; PHOSPHOLIPID-VESICLES; PROCOAGULANT ACTIVITY; SUBUNIT STRUCTURE; A2 SUBUNIT; FACTOR-XA; PROTEINS; RECONSTITUTION	Recombinant human factor VIII (fVIII) was activated by thrombin at pH 7.4, followed by CM-Sepharose chromatography at pH values ranging from 3.5 to 7.4. Optimal coagulant activity was recovered at pH 5.5 and was associated with the isolation of an A1/A2/A3-C1-C2 heterotrimer. The activity was stable at -80 degrees C, but decayed slowly (t(1/2) approximate to 1 week) and nonproteolytically at room temperature or 4 degrees C. The coagulant activity of the pH 5.5 fVIIIa preparation assayed in human hemophilia A plasma was only 20% that of porcine factor VIIIa. However, its activity was approximately 75% that of porcine fVIIIa in a plasma-free assay, indicating that human fVIIIa is unstable relative to porcine fVIIIa during the coagulation assay. The first-order rate constant for spontaneous, nonproteolytic loss of activity of human fVIIIa at pH 7.4 was decreased 8-fold by fIXa and phospholipid, indicating that human fVIIIa is stabilized when incorporated into the intrinsic pathway factor X activation complex.	EMORY UNIV,DEPT MED,ATLANTA,GA 30322; BAXTER HEALTHCARE CORP,BAXTER BIOTECH GRP,DUARTE,CA 91010	Emory University; Baxter International Inc					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046215] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46215] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; COOPER HA, 1975, J CLIN INVEST, V56, P751, DOI 10.1172/JCI108146; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1987, BIOCHIM BIOPHYS ACTA, V952, P181; HULTIN MB, 1981, BLOOD, V57, P476; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; LOLLAR P, 1992, METHOD ENZYMOL, V222, P128; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NEUENSCHWANDER P, 1988, BLOOD, V72, P1761; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; PIETERS J, 1989, BLOOD, V74, P1021; PITTMAN DD, 1992, BLOOD, V79, P389; PITTMAN DD, 1993, BLOOD, V81, P2925; PRIVALOV PL, 1990, CRIT REV BIOCHEM MOL, V25, P281, DOI 10.3109/10409239009090612	27	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6246	6251						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119969				2022-12-27	WOS:A1994MY84000113
J	GIANNONI, F; BONEN, DK; FUNAHASHI, T; BURANT, CF; DAVIDSON, NO; HADJIAGAPIOU, C				GIANNONI, F; BONEN, DK; FUNAHASHI, T; BURANT, CF; DAVIDSON, NO; HADJIAGAPIOU, C			COMPLEMENTATION OF APOLIPOPROTEIN-B MESSENGER-RNA EDITING BY HUMAN LIVER ACCOMPANIED BY SECRETION OF APOLIPOPROTEIN B48	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; RAT-LIVER; INTESTINE	Mammalian small intestine secretes a truncated apolipoprotein B (apoB48) species as a result of tissue-specific post-transcriptional RNA editing. The human liver, by contrast, contains only unedited apoB mRNA and secretes only apoB100. We have recently isolated a cDNA clone from rat small intestine which encodes an apoB mRNA editing protein, REPR (Teng, B., Burant, C. F., and Davidson, N. O. (1993) Science 260, 1816-1819). The current study demonstrates that homogenates of Xenopus oocytes expressing REPR confer editing ability upon S100 extracts prepared from human liver when tested on a synthetic apoB RNA template in vitro. Transfection of REPR into HepG2 cells resulted in editing of endogenous apoB mRNA and the appearance of an apoB48-like protein in the media. Extracts prepared hom these transfected cells edit mammalian apoB RNA templates when incubated alone and with enhanced efficiency in the presence of chicken intestinal S100 extracts. The results suggest that human liver expresses factor(s) which are critical to apoB mRNA editing and which allow functional complementation of REPR in vivo.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago			Giannoni, Federico/A-6577-2013; Burant, Charles/GPC-5690-2022	Giannoni, Federico/0000-0001-5521-512X; Burant, Charles/0000-0001-9189-5003	NHLBI NIH HHS [HL-38180, HL-02166] Funding Source: Medline; NIDDK NIH HHS [DK-42086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002166, R37HL038180, R01HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAUM CL, 1990, J BIOL CHEM, V265, P19263; BOSTROM K, 1989, J BIOL CHEM, V264, P15701; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHHEN SH, 1991, SCIENCE, V238, P363; DAVIDSON NO, 1988, J BIOL CHEM, V263, P13482; DAVIES MS, 1989, J BIOL CHEM, V264, P13395; GARCIA ZC, 1992, ARTERIOSCLER THROMB, V12, P172, DOI 10.1161/01.ATV.12.2.172; GIANNONI F, 1994, IN PRESS J LIPID RES; GREEVE J, 1993, J LIPID RES, V34, P1367; HIGUCHI K, 1992, J LIPID RES, V33, P1753; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SEISHIMA M, 1991, J LIPID RES, V32, P941; SPRING DJ, 1992, J LIPID RES, V33, P233; TENG BB, 1990, J BIOL CHEM, V265, P20616; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; TENG BB, 1992, J BIOL CHEM, V267, P21265; WU JH, 1990, J BIOL CHEM, V265, P12312	20	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5932	5936						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119937				2022-12-27	WOS:A1994MY84000070
J	GROSKREUTZ, DJ; SLIWKOWSKI, MX; GORMAN, CM				GROSKREUTZ, DJ; SLIWKOWSKI, MX; GORMAN, CM			GENETICALLY-ENGINEERED PROINSULIN CONSTITUTIVELY PROCESSED AND SECRETED AS MATURE, ACTIVE INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILISIN-LIKE PROTEASE; STIMULATES TYROSINE PHOSPHORYLATION; MONOMERIC INSULINS; INTACT-CELLS; CLEAVAGE; FAMILY; DNA; IDENTIFICATION; EXPRESSION; MEMBER	The conversion of human proinsulin to insulin occurs only in specialized cells which contain the appropriate processing enzymes. To allow proinsulin processing to occur in a wide variety of cell types, we engineered human proinsulin to be cleaved in the constitutive secretory pathway. Using site directed mutagenesis, we have introduced furin consensus cleavage sequences (Arg-X-Lys-Arg) into the human proinsulin cDNA. These mutations allowed for efficient proteolytic maturation of human proinsulin to insulin within cells containing only a constitutive pathway of secretion. Additionally, a naturally occurring mutation (histidine B10 to aspartic acid) yields a form of human insulin which accumulates 10- to over 100-fold more mature insulin when compared to the mutants lacking this change. Engineering furin-specific cleavage sites into each junction of the human proinsulin cDNA results in the secretion of peptides that display the expected molecular weights for the A and B chains of insulin. The accumulation of mature, processed, human insulin was measured in the supernatants by radioimmunoassay, and the bioactivity of this molecule was measured by its ability to stimulate autophosphorylation of the insulin receptor. Our results suggest that any cell type might be engineered to produce mature, active, and stable insulin in the constitutive pathway of secretion.	GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech								AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; BAILYES EM, 1992, BIOCHEM J, V285, P391, DOI 10.1042/bj2850391; BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BRANGE J, 1988, NATURE, V333, P679, DOI 10.1038/333679a0; BRANGE J, 1990, DIABETES CARE, V13, P923, DOI 10.2337/diacare.13.9.923; BREMS DN, 1992, PROTEIN ENG, V5, P519, DOI 10.1093/protein/5.6.519; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CHAN SJ, 1987, P NATL ACAD SCI USA, V84, P2194, DOI 10.1073/pnas.84.8.2194; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; IZUMI T, 1987, J BIOL CHEM, V262, P1282; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KORNER J, 1991, P NATL ACAD SCI USA, V88, P11393, DOI 10.1073/pnas.88.24.11393; KUNKEL TA, 1987, NUCLEIC ACIDS MOL BI, pR20; MARRIOTT D, 1992, MOL ENDOCRINOL, V6, P1441, DOI 10.1210/me.6.9.1441; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHWARTZ GP, 1987, P NATL ACAD SCI USA, V84, P6408, DOI 10.1073/pnas.84.18.6408; SHOELSON SE, 1992, BIOCHEMISTRY-US, V31, P1757, DOI 10.1021/bi00121a025; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; STEINER DF, 1979, ENDOCRINOLOGY, P921; SURES I, 1980, SCIENCE, V208, P57, DOI 10.1126/science.6927840; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VOLLENWEIDER F, 1992, J BIOL CHEM, V267, P14629; WEISS MA, 1991, BIOCHEMISTRY-US, V30, P7373, DOI 10.1021/bi00244a004; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; YANAGITA M, 1992, FEBS LETT, V311, P55, DOI 10.1016/0014-5793(92)81366-T; ZOLLER MJ, 1987, METHOD ENZYMOL, V154, P329	37	113	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6241	6245						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119968				2022-12-27	WOS:A1994MY84000112
J	QU, ZQ; FUJIMOTO, S; TANIGUCHI, T				QU, ZQ; FUJIMOTO, S; TANIGUCHI, T			ENHANCEMENT OF INTERFERON-GAMMA-INDUCED MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II GENE-EXPRESSION BY EXPRESSING AN ANTISENSE RNA OF POLY(ADP-RIBOSE) SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE DIPHOSPHORIBOSYL TRANSFERASE; INDUCED ACTIVATION PROCESS; MACROPHAGE TUMOR-CELLS; C-INDEPENDENT PATHWAY; NECROSIS-FACTOR; CDNA SEQUENCE; HLA-DR; DNA; POLYMERASE; KINASE	We studied the effect of poly(ADP-ribose) synthetase on the interferon-gamma (IFN-gamma)-inducible expression of major histocompatibility complex (MHC) class II molecules by expressing an antisense RNA of poly(ADP-ribose) synthetase. We constructed two expression plasmids capable of expressing an antisense RNA for poly(ADP-ribose) synthetase, carrying 0.7-kilobase long fragment of 5'-coding region (pAS-5') and full-length cDNA (pAS-FL) of poly(ADP-ribose) synthetase in an antisense orientation under control of metallothionein I promoter. We transfected the plasmid into human leukemia THP-1 cells and isolated transformants. Metal-inducible reduction in poly(ADP-ribose) synthetase activity wars observed in two pAS-5'-transfected clones out of 72 neo-resistant clones examined, and metal-independent reduction in the activity was exhibited in pAS-FL-transfected clones. The antisense RNA was induced in a metal-dependent manner in the clones transfected with pAS-5', as judged by hybridizing with a sense riboprobe of the synthetase gene. The mRNA of the synthetase decreased 1 day after an addition of metal ions, and the synthetase activity of the transformants decreased by more than 90% 3 days after an addition of metal ions. Thus, we incubated the transformant clones in the presence of metal ions for 3 days and then treated them with IFN-gamma. The IFN-gamma-inducible expression of MHC class II molecules was amplified in the transformant clones, as judged by RNA blot analysis and flow cytometry. These results indicate that the decrease in poly(ADP-ribose) synthetase makes THP-1 cells favorable to induce MHC class II molecules by IFN-gamma.	KOCHI MED SCH,MED RES LAB,KOCHI 783,JAPAN; KOCHI MED SCH,DEPT IMMUNOL,KOCHI 783,JAPAN	Kochi University; Kochi University								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; BUKI KG, 1991, BIOCHEM BIOPH RES CO, V180, P496, DOI 10.1016/S0006-291X(05)81092-7; CELADA A, 1991, J IMMUNOL, V146, P114; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; COROMINAS M, 1985, J BIOL CHEM, V260, P6269; DING RC, 1992, J BIOL CHEM, V267, P12804; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; EKI T, 1991, J BIOL CHEM, V266, P3087; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; HAMILTON TA, 1985, J BIOL CHEM, V260, P1378; HAYAISHI O, 1977, ANNU REV BIOCHEM, V46, P95, DOI 10.1146/annurev.bi.46.070177.000523; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; IZANT JG, 1985, SCIENCE, V229, P345, DOI 10.1126/science.2990048; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KLEIN JB, 1987, BIOCHEM BIOPH RES CO, V145, P1295, DOI 10.1016/0006-291X(87)91578-6; KOIDE Y, 1988, P NATL ACAD SCI USA, V85, P3120, DOI 10.1073/pnas.85.9.3120; KUROSAKI T, 1987, J BIOL CHEM, V262, P15990; MANDEL P, 1982, PROG NUCLEIC ACID RE, V27, P1, DOI 10.1016/S0079-6603(08)60596-6; MELTON DA, 1985, P NATL ACAD SCI USA, V82, P144, DOI 10.1073/pnas.82.1.144; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NOMURA I, 1991, BIOCHEM BIOPH RES CO, V175, P685, DOI 10.1016/0006-291X(91)91620-R; OHASHI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7132, DOI 10.1073/pnas.81.22.7132; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; OSTROWSKI J, 1988, J BIOL CHEM, V263, P13786; PETERLIN BM, 1987, MOL CELL BIOL, V7, P1967, DOI 10.1128/MCB.7.5.1967; Purnell MR, 1980, BIOCHEM SOC T, V8, P215, DOI 10.1042/bst0080215; SASTRY SS, 1990, BIOCHEM BIOPH RES CO, V167, P842, DOI 10.1016/0006-291X(90)92102-6; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SULLIVAN KE, 1987, IMMUNOL TODAY, V8, P289, DOI 10.1016/0167-5699(87)90013-2; TANIGUCHI T, 1988, BIOCHEM BIOPH RES CO, V154, P1034, DOI 10.1016/0006-291X(88)90244-6; TANIGUCHI T, 1988, EUR J BIOCHEM, V171, P571, DOI 10.1111/j.1432-1033.1988.tb13826.x; TANIGUCHI T, 1991, EUR J BIOCHEM, V195, P557, DOI 10.1111/j.1432-1033.1991.tb15737.x; TOMODA T, 1992, BIOCHIM BIOPHYS ACTA, V1135, P79, DOI 10.1016/0167-4889(92)90169-C; TOMODA T, 1991, BIOCHIM BIOPHYS ACTA, V1088, P359, DOI 10.1016/0167-4781(91)90125-6; UCHIDA K, 1987, BIOCHEM BIOPH RES CO, V148, P617, DOI 10.1016/0006-291X(87)90921-1; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; YAMAGOE S, 1991, MOL CELL BIOL, V11, P3522, DOI 10.1128/MCB.11.7.3522	41	16	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5543	5547						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119888				2022-12-27	WOS:A1994MY84000014
J	BANERJEE, P; BOYERS, MJ; BERRYKRAVIS, E; DAWSON, G				BANERJEE, P; BOYERS, MJ; BERRYKRAVIS, E; DAWSON, G			PREFERENTIAL BETA-HEXOSAMINIDASE (HEX)-A (ALPHA-BETA) FORMATION IN THE ABSENCE OF BETA-HEX-B (BETA-BETA) DUE TO HETEROZYGOUS POINT MUTATIONS PRESENT IN BETA-HEX BETA-CHAIN ALLELES OF A MOTOR-NEURON DISEASE PATIENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAY-SACHS DISEASE; GENE; PROTEIN; DEFICIENCY; CHROMOSOME-5; ASSIGNMENT; ARGININE; SUBUNIT; VARIANT; ENZYME	Deficiency of the lysosomal enzyme beta-hexosaminidase B (beta-Hex B) (a homodimer, beta beta), caused by a defect in the HEX B gene encoding the beta-chain, is usually accompanied by an absence of beta-Hex A (a heterodimer, alpha beta), thereby causing Sandhoff disease. However, we have earlier demonstrated the presence of partial beta-Hex A (30-50% of normal) even in the absence of beta-Hex B in an adult with motor neuron disease. The patient is a compound heterozygote with normal beta-chain message and one HEX B point mutation originating from each asymptomatic parent. Since the non-expression of beta-Hex B was post transcriptional, we transfected COS-7 cells to understand the effect of each mutation on beta-Hex B activity. Transfection of the A(1367) --> C mutant (maternal allele) construct produced no overexpressed beta-Hex B, indicating that the encoded Tyr(456) --> Ser beta-chain was non-functional. Chou-Fasman analysis predicted that the Tyr(456) --> Ser mutation would cause a dramatic change in beta-chain folding (which often inhibits formation of functional dimers). This explains the complete lack of beta-Hex B in the transfectants and a partial deficiency of beta-Hex A and B (50% of normal) in the patient's mother. Since immunoprecipitated beta-Hex A (alpha beta) protein from patient fibroblasts showed the presence of mature beta-chains even though there was no beta-Hex B (beta beta) protein, the mutant beta-chain inherited from the father (who has normal beta-Hex A and B) must undergo preferential association with the normal alpha-chains in the patient, thus producing only beta-Hex A. Transient expression of the A(619) --> G mu- tent (paternal allele) construct produced beta(-)Hex B activity comparable to the wild type (similar to 10-20-fold over mock-transfected) whereas stable expression produced normal message but no beta-Hex B activity (wild type beta-Hex B expression: only 2-fold over mock-transfected). The lack of increased beta-Hex B after stable expression of the Ile(207) --> Val beta-chains at a lower copy number indicates the absence of self-association at low concentrations of Ile(207) --> Val beta-chain. In the patient who also has a nonfunctional Tyr(456) --> Ser allele, the effective concentration of beta-chains is reduced to 50% of normal and the remaining Ile(207) --> Val beta-chains fail to self-associate but can still dimerize with the abundant normal alpha-chains thus producing partial beta-Hex A and no beta-Hex B.	UNIV CHICAGO,DEPT BIOCHEM,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOLEC BIOL,CHICAGO,IL 60637; RUSH PRESBYTERIAN HOSP,DEPT PEDIAT,CHICAGO,IL 60612	University of Chicago; University of Chicago; Rush University	BANERJEE, P (corresponding author), UNIV CHICAGO,DEPT PEDIAT,5841 S MARYLAND AVE,BOX MC 4068,CHICAGO,IL 60637, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD006426] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-06426] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BANERJEE P, 1991, BIOCHEM BIOPH RES CO, V181, P108, DOI 10.1016/S0006-291X(05)81388-9; BANERJEE P, 1993, BIOCHEM BIOPH RES CO, V192, P14; BOEDECKER HJ, 1975, EXP CELL RES, V93, P468, DOI 10.1016/0014-4827(75)90473-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN CA, 1991, J BIOL CHEM, V266, P15855; BURG J, 1985, ANN HUM GENET, V49, P41, DOI 10.1111/j.1469-1809.1985.tb01674.x; CASHMAN NR, 1986, ANN NEUROL, V19, P568, DOI 10.1002/ana.410190608; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; DAWSON G, 1988, NEUROCHEM PATHOL, V8, P203; GILBERT F, 1975, P NATL ACAD SCI USA, V72, P263, DOI 10.1073/pnas.72.1.263; HANCOCK LW, 1985, BIOCHEM BIOPH RES CO, V130, P1185, DOI 10.1016/0006-291X(85)91740-1; MANIATIS T, 1982, MOL CLONING LABORATO, P468; NAKANO T, 1988, J NEUROCHEM, V51, P984, DOI 10.1111/j.1471-4159.1988.tb01836.x; NAKANO T, 1990, ANN NEUROL, V27, P465, DOI 10.1002/ana.410270503; NEUFELD EF, 1989, J BIOL CHEM, V264, P10927; OHNO K, 1988, J NEUROCHEM, V50, P316, DOI 10.1111/j.1471-4159.1988.tb13266.x; PAW BH, 1990, J BIOL CHEM, V265, P9452; SANDBERG WS, 1989, SCIENCE, V245, P54, DOI 10.1126/science.2787053; STRUHL K, 1985, Biotechniques, V3, P452; WAKAMATSU N, 1992, J BIOL CHEM, V267, P2406; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X	22	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4819	4826						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106452				2022-12-27	WOS:A1994MX57100021
J	KAETZEL, MA; CHAN, HC; DUBINSKY, WP; DEDMAN, JR; NELSON, DJ				KAETZEL, MA; CHAN, HC; DUBINSKY, WP; DEDMAN, JR; NELSON, DJ			A ROLE FOR ANNEXIN-IV IN EPITHELIAL-CELL FUNCTION - INHIBITION OF CALCIUM-ACTIVATED CHLORIDE CONDUCTANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPID-BINDING-PROTEIN; CYSTIC-FIBROSIS; ANTICOAGULANT PROTEIN; LIPID MONOLAYERS; LINE T84; CHANNELS; EXPRESSION; CRYSTALLIZATION; PURIFICATION	The cellular function of annexin IV was evaluated by correlating tissue expression, cellular localization, and whole-cell electrophysiology. Immunolocalization and biochemical data demonstrate that annexin IV is concentrated along the apical membranes of many epithelia. Introduction of purified exogenous annexin IV into colonic T84 cells through a patch pipette specifically prevented Ca2+-dependent Cl- current activation. Affinity-purified antibody against annexin IV applied in the same manner enhanced the activation. Reduction of the endogenous level of annexin IV with a derivatized oligodeoxynucleotide antisense to annexin IV mRNA lowered the threshold for the Ca2+-induced current response, mimicking the enhancement of current activation exerted by anti-annexin TV antibody. The inhibitory effect of annexin IV on Ca2+-dependent Cl- conductance represents a novel mechanism by which Ca2+-binding proteins modulate membrane channel activity.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT NEUROL,CHICAGO,IL 60637; UNIV TEXAS,SCH MED,DEPT PHYSIOL & CELL BIOL,HOUSTON,TX 77235	University of Chicago; University of Chicago; University of Texas System	KAETZEL, MA (corresponding author), UNIV CINCINNATI,COLL MED,DEPT PHYSIOL & BIOPHYS,231 BETHESDA AVE,CINCINNATI,OH 45267, USA.		Chan, Hsiao Chang/E-1507-2016					ANDREE HAM, 1992, J BIOL CHEM, V267, P17907; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; CHAN HC, 1992, J BIOL CHEM, V267, P8411; CHAN HC, 1992, J BIOL CHEM, V262, pC1273; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; CONCHA NO, 1992, FEBS LETT, V314, P159, DOI 10.1016/0014-5793(92)80964-I; CONCHA NO, 1993, SCIENCE, V261, P1321, DOI 10.1126/science.8362244; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DAVIDSON FF, 1987, J BIOL CHEM, V262, P1698; DEDMAN JR, 1978, J BIOL CHEM, V253, P7515; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; DIAZMUNOZ M, 1990, J BIOL CHEM, V265, P15894; DISANTAGNESE PA, 1953, PEDIATRICS, V12, P549; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; JUNKER M, 1993, BIOCHEMISTRY-US, V32, P9968, DOI 10.1021/bi00089a012; KACHINTORN U, 1992, AM J PHYSIOL, V262, pC15, DOI 10.1152/ajpcell.1992.262.1.C15; KAETZEL MA, 1990, BIOCHEM SOC T, V18, P1108, DOI 10.1042/bst0181108; KAETZEL MA, 1989, J BIOL CHEM, V264, P14463; KAPLAN R, 1988, J BIOL CHEM, V263, P8037; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; LIN HC, 1992, CELL, V70, P283, DOI 10.1016/0092-8674(92)90102-I; LOTAN I, 1988, NEURON, V1, P963, DOI 10.1016/0896-6273(88)90153-5; MASSEY D, 1992, BIOL CELL, V73, P151; Moss S. E, 1992, ANNEXINS; MOSSER G, 1991, J MOL BIOL, V217, P241, DOI 10.1016/0022-2836(91)90538-H; NEWMAN R, 1989, J MOL BIOL, V206, P213, DOI 10.1016/0022-2836(89)90534-2; NEWMAN RH, 1991, FEBS LETT, V279, P21, DOI 10.1016/0014-5793(91)80240-4; POLLARD HB, 1992, BIOPHYS J, V62, P15, DOI 10.1016/S0006-3495(92)81764-2; PRESTON CL, 1992, AM J PHYSIOL, V263, pC879, DOI 10.1152/ajpcell.1992.263.4.C879; QUINTON PM, 1983, NEW ENGL J MED, V308, P1185, DOI 10.1056/NEJM198305193082002; SCHLAEPFER DD, 1992, BIOCHEMISTRY-US, V31, P1886, DOI 10.1021/bi00121a043; SCHOPPA N, 1989, J MEMBRANE BIOL, V108, P73, DOI 10.1007/BF01870427; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; SEATON BA, 1990, J BIOL CHEM, V265, P4567; SOBOTA A, 1993, FEBS LETT, V315, P178, DOI 10.1016/0014-5793(93)81158-V; SORSCHER EJ, 1991, P NATL ACAD SCI USA, V88, P7759, DOI 10.1073/pnas.88.17.7759; SUN J, 1993, THROMB RES, V69, P289, DOI 10.1016/0049-3848(93)90026-K; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WEBER K, 1987, EMBO J, V6, P1599, DOI 10.1002/j.1460-2075.1987.tb02406.x; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877	47	80	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5297	5302						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106514				2022-12-27	WOS:A1994MX57100091
J	MIYAZAKI, A; SAKAI, M; SUGINOHARA, Y; HAKAMATA, H; SAKAMOTO, YI; MORIKAWA, W; HORIUCHI, S				MIYAZAKI, A; SAKAI, M; SUGINOHARA, Y; HAKAMATA, H; SAKAMOTO, YI; MORIKAWA, W; HORIUCHI, S			ACETYLATED LOW-DENSITY-LIPOPROTEIN REDUCES ITS LIGAND ACTIVITY FOR THE SCAVENGER RECEPTOR AFTER INTERACTION WITH RECONSTITUTED HIGH-DENSITY-LIPOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; CYTOPLASMIC CHOLESTERYL ESTERS; CULTURED-CELLS; ATHEROSCLEROTIC LESIONS; PERITONEAL-MACROPHAGES; MEDIATED ENDOCYTOSIS; PLASMA-LIPOPROTEINS; CROSS-LINKING; ADIPOSE-CELLS; LDL	Complexes of apolipoprotein A-I (apoA-I) with phospholipids are known to induce cholesterol efflux from cells. In a cholesteryl ester accumulation system in which rat peritoneal macrophages were incubated with acetylated low density lipoprotein (acetyl-LDL) and either dimyristoylphosphatidylcholine complexes (DMPC/apoA-I) or native high density lipoprotein (HDL), DMPC/apoA-I exhibited a much stronger effect than native HDL in preventing cholesteryl ester accumulation. The mechanism for this phenomenon was investigated in the present study. After 18 h incubation with DMPC/apoA-I in a cell-free system, acetyl-LDL was re-isolated from DMPC/apoA-I by Sephacryl S-300 gel filtration chromatography, Re-isolated acetyl-LDL exhibited an increase in its phospholipid content by 86% as well as a reduction in the electrophoretic mobility. Its endocytic degradation by macrophages was reduced by 60% when compared with control acetyl-LDL, suggesting a significant reduction in the ligand activity for the macrophage scavenger receptor. Transfer of apolipoproteins between acetyl-LDL and DMPC/apoA-I did not occur. These results indicate that transfer of DMPC from DMPC/apoA-I to acetyl-LDL weakens the ligand activity for the scavenger receptor due probably to a decrease in net negative charge, This study demonstrated for the first time that lipid modification (change in the lipid moiety) of acetyl-LDL can induce alteration in its apolipoprotein moiety, leading to a significant loss of its biological activity. Because discoidal HDLs are known to occur in vivo, this phenomenon may explain one of the anti-atherogenic functions of HDL in vivo.	KUMAMOTO UNIV, SCH MED, DEPT BIOCHEM, KUMAMOTO 860, JAPAN; CHEMO-SERO-THERAPEUT RES INST, KUMAMOTO 860, JAPAN	Kumamoto University								ALLAIN CC, 1974, CLIN CHEM, V20, P470; ARAI H, 1989, BIOCHEM BIOPH RES CO, V159, P1375, DOI 10.1016/0006-291X(89)92262-6; AVIRAM M, 1988, J BIOL CHEM, V263, P15416; AVIRAM M, 1991, J BIOL CHEM, V266, P11567; BARBARAS R, 1986, BIOCHIM BIOPHYS ACTA, V888, P143, DOI 10.1016/0167-4889(86)90015-7; BOYD HC, 1989, AM J PATHOL, V135, P815; BREWER HB, 1986, METHOD ENZYMOL, V128, P223; BROWN MS, 1980, J BIOL CHEM, V255, P9344; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Fields R, 1972, Methods Enzymol, V25, P464, DOI 10.1016/S0076-6879(72)25042-X; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GUPTA AK, 1992, J LIPID RES, V33, P1741; HARA H, 1991, J BIOL CHEM, V266, P3080; HIGGS DW, 1984, ARTERIOSCLEROSIS, V4, P208, DOI 10.1161/01.ATV.4.3.208; HO YK, 1980, J LIPID RES, V21, P391; HUNTER JA, 1982, BIOCHEM BIOPH RES CO, V105, P828, DOI 10.1016/0006-291X(82)91044-0; INNERARITY TL, 1982, ARTERIOSCLEROSIS, V2, P114, DOI 10.1161/01.ATV.2.2.114; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1988, J LIPID RES, V29, P1349; JONAS A, 1986, METHOD ENZYMOL, V128, P553; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1085, P71, DOI 10.1016/0005-2760(91)90233-8; KUNITAKE ST, 1992, P NATL ACAD SCI USA, V89, P6993, DOI 10.1073/pnas.89.15.6993; MAHLBERG FH, 1991, J BIOL CHEM, V266, P19930; MCCALL MR, 1988, J LIPID RES, V29, P1127; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MIYAZAKI A, 1992, BIOCHIM BIOPHYS ACTA, V1126, P73, DOI 10.1016/0005-2760(92)90219-L; MIYAZAKI A, 1990, ARTERIOSCLEROSIS, V10, pA793; MIYAZAKI A, 1991, BIOCHIM BIOPHYS ACTA, V1082, P143; MURAKAMI M, 1987, J BIOCHEM-TOKYO, V101, P729, DOI 10.1093/jb/101.3.729; MUSLINER TA, 1991, J LIPID RES, V32, P917; NICHOLS AV, 1980, BIOCHIM BIOPHYS ACTA, V617, P480, DOI 10.1016/0005-2760(80)90014-4; OHTA T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P119, DOI 10.1016/0005-2760(92)90083-8; OHTA T, 1989, FEBS LETT, V257, P435, DOI 10.1016/0014-5793(89)81590-X; PARKS JS, 1985, J BIOL CHEM, V260, P3155; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; ROBERTS DCK, 1985, BIOCHEM J, V226, P319, DOI 10.1042/bj2260319; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SAKAI M, 1992, FEBS LETT, V314, P199, DOI 10.1016/0014-5793(92)80974-L; SLOOP CH, 1987, J LIPID RES, V28, P225; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; SPAYD RW, 1978, CLIN CHEM, V24, P1343; STEIN O, 1986, BIOCHIM BIOPHYS ACTA, V878, P7, DOI 10.1016/0005-2760(86)90337-1; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINMETZ A, 1990, J BIOL CHEM, V265, P7859; TAKATA K, 1989, BIOCHIM BIOPHYS ACTA, V984, P273, DOI 10.1016/0005-2736(89)90293-9; TAKAYAMA M, 1977, CLIN CHIM ACTA, V79, P93, DOI 10.1016/0009-8981(77)90465-X; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	50	62	65	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5264	5269						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106510				2022-12-27	WOS:A1994MX57100087
J	REID, RJD; BODLEY, JW; ANDERSON, D				REID, RJD; BODLEY, JW; ANDERSON, D			CHARACTERIZATION OF THE PROHEAD-PRNA INTERACTION OF BACTERIOPHAGE-PHI-29	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; T7 RNA-POLYMERASE; RESTRICTION FRAGMENTS; PHENOTYPIC SELECTION; DNA; SEQUENCE; PROTEIN; DNA-GP3; ATPASE; SIZE	The small prohead RNA(pRNA) of the Bacillus subtilis bacteriophage phi 29 is essential for ATP dependent packaging of viral DNA. The 174-, 124-, and 120-residue forms of pRNA produced in vitro using T7 RNA polymerase were equivalent in prohead binding and DNA packaging activity to pRNAs produced in phi 29-infected cells. pRNA binding to proheads, characterized by the use of Northern hybridization and filter binding assays, was specific, rapid, and irreversible in the presence of 10 mM Mg2+. Proheads produced in phage-infected cells carried 5.8 +/- 2.7 copies of pRNA, and proheads assembled in Escherichia coli in the absence of pRNA bound 6.0 +/- 3.5 copies of pRNA. Footprints of proheads on pRNA generated with the ribonucleases A, T1, and V1 showed that nucleotides 22-84, 5' to 3', were protected from ribonuclease attack. Enhanced cleavage at nucleotides 37-40 with ribonuclease V1 suggested a conformational change of pRNA upon prohead binding.	UNIV MINNESOTA, DEPT GENET & CELL BIOL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT MICROBIOL & ORAL SCI, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Reid, Robert/AAR-1560-2020	Reid, Robert/0000-0002-7424-3537				BAILEY S, 1990, J BIOL CHEM, V265, P22365; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; CHAPMAN KA, 1987, NUCLEIC ACIDS RES, V15, P5413, DOI 10.1093/nar/15.13.5413; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; CUNNINGHAM PR, 1990, BIOTECHNIQUES, V9, P713; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; GRIMES S, 1990, J MOL BIOL, V215, P559, DOI 10.1016/S0022-2836(05)80168-8; GRIMES S, 1989, J MOL BIOL, V209, P101, DOI 10.1016/0022-2836(89)90173-3; GRIMES S, 1989, J MOL BIOL, V209, P91, DOI 10.1016/0022-2836(89)90172-1; GUO PX, 1987, NUCLEIC ACIDS RES, V15, P7081, DOI 10.1093/nar/15.17.7081; GUO PX, 1987, J MOL BIOL, V197, P229, DOI 10.1016/0022-2836(87)90121-5; GUO PX, 1991, VIROLOGY, V185, P395, DOI 10.1016/0042-6822(91)90787-C; GUO PX, 1987, SCIENCE, V236, P690, DOI 10.1126/science.3107124; GUO PX, 1991, VIROLOGY, V183, P366, DOI 10.1016/0042-6822(91)90149-6; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOWARY P, 1986, STRUCTURE DYNAMICS R, P69; Maniatis T., 1982, MOL CLONING; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WICHITWECHKARN J, 1989, NUCLEIC ACIDS RES, V17, P3459, DOI 10.1093/nar/17.9.3459; WICHITWECHKARN J, 1992, J MOL BIOL, V223, P991, DOI 10.1016/0022-2836(92)90257-K; YARUS M, 1993, FASEB J, V7, P31, DOI 10.1096/fasebj.7.1.8422972	23	78	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5157	5162						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106496				2022-12-27	WOS:A1994MX57100073
J	ZHANG, MJ; HUQUE, E; VOGEL, HJ				ZHANG, MJ; HUQUE, E; VOGEL, HJ			CHARACTERIZATION OF TRIMETHYLLYSINE-115 IN CALMODULIN BY N-14 AND C-13 NMR-SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; SITE-SPECIFIC MUTAGENESIS; AMINO-ACID SEQUENCE; LIGHT CHAIN KINASE; DICTYOSTELIUM-DISCOIDEUM; PROTEOLYTIC FRAGMENTS; PROTEIN-DEGRADATION; N-METHYLTRANSFERASE; ESCHERICHIA-COLI; METHYLATION	In this paper we describe three approaches to study the single trimethyllysine 115 in calmodulin. First, N-14 NMR spectroscopy has been used as a novel spectroscopic tool. Because of the unique symmetrical tetrahedral substitution of its side chain, the trimethyllysine residue gives rise to a sharp N-14 NMR resonance; hence, this has allowed the detection and quantitation of the level of trimethylation. Trimethyllysine side chains of bovine testis calmodulin and yeast cytochrome c were shown to have a high mobility in aqueous solution as determined by N-14 NMR relaxation measurements. Second, we have purified mammalian calmodulin from an overproducing Escherichia coli strain. By comparison of the H-1-C-13 heteronuclear multiple quantum coherence spectra of C-13-dimethylated calmodulin samples from bovine testis and E. coli, the resonance for Lys-115 in bacterially expressed calmodulin could be identified. pH titration experiments showed that the epsilon-NH2 group of Lys-115 has a normal pK alpha value both in the apo and Ca2+ forms of the protein and in a complex of calmodulin with a 22-residue calmodulin-binding peptide derived from myosin light chain kinase. Third, we have shown that mutation of Lys-115 to the uncharged Gln residue does not alter the ability of the protein to stimulate the enzymes cyclic nucleotide phosphodiesterase and myosin light chain kinase. These results show that the trimethylation of Lys-115 is not caused by an unusual pK alpha and reactivity of its epsilon-NH2 group and that its side chain remains flexible. Moreover, our data suggest that the introduction of a permanent positive charge on Lys-115 by trimethylation is also not the major reason for this specific post-translational modification.	UNIV CALGARY,DEPT BIOL SCI,CALGARY T2N 1N4,AB,CANADA	University of Calgary				Zhang, Mingjie/0000-0001-9404-0190				ANDERSSON A, 1983, BIOCHEMISTRY-US, V22, P2309, DOI 10.1021/bi00279a001; ARAI K, 1980, P NATL ACAD SCI-BIOL, V77, P1326, DOI 10.1073/pnas.77.3.1326; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BLOMBERG F, 1976, P NATL ACAD SCI USA, V73, P1409, DOI 10.1073/pnas.73.5.1409; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BRODIN P, 1989, PROTEIN ENG, V2, P353, DOI 10.1093/protein/2.5.353; BRODIN P, 1986, BIOCHEMISTRY-US, V25, P5371, DOI 10.1021/bi00367a004; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; COHEN EA, 1975, ORG MAGN RESONANCE, V7, P605, DOI 10.1002/mrc.1270071210; DELANGE RJ, 1970, J BIOL CHEM, V245, P3325; GEROTHANASSIS IP, 1987, J MAGN RESON, V75, P513, DOI 10.1016/0022-2364(87)90107-7; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GREGORI L, 1987, J BIOL CHEM, V262, P2562; GREGORI L, 1985, J BIOL CHEM, V260, P5232; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HUQUE ME, 1989, THESIS U CALGARY; HUQUE ME, 1993, J PROTEIN CHEM, V12, P693; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JENNISSEN HP, 1992, FEBS LETT, V296, P51, DOI 10.1016/0014-5793(92)80401-2; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; KEIM P, 1974, J BIOL CHEM, V249, P4149; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LING KY, 1992, PROTEINS, V12, P365, DOI 10.1002/prot.340120408; LUKAS TJ, 1985, PLANT PHYSIOL, V78, P477, DOI 10.1104/pp.78.3.477; LUKAS TJ, 1989, P NATL ACAD SCI USA, V86, P7331, DOI 10.1073/pnas.86.19.7331; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARSHAK DR, 1984, BIOCHEMISTRY-US, V23, P2891, DOI 10.1021/bi00308a007; MCINTYRE DD, 1989, J MAGN RESON, V83, P377, DOI 10.1016/0022-2364(89)90199-6; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; MOLLA A, 1981, J BIOL CHEM, V256, P15; MORINO H, 1987, J NEUROCHEM, V48, P1201, DOI 10.1111/j.1471-4159.1987.tb05647.x; OH SH, 1990, PLANT PHYSIOL, V93, P880, DOI 10.1104/pp.93.3.880; OH SH, 1992, ARCH BIOCHEM BIOPHYS, V297, P28, DOI 10.1016/0003-9861(92)90636-B; PAIK WK, 1989, BIOCHEM CELL BIOL, V67, P602; PUTKEY JA, 1985, J BIOL CHEM, V260, P4704; PUTKEY JA, 1988, J BIOL CHEM, V263, P11242; PUTKEY JA, 1986, J BIOL CHEM, V261, P9896; RAO ST, 1993, PROTEIN SCI, V2, P436; RICHARDS RE, 1974, J CHEM SOC P1, V2, P368; ROBERTS DM, 1986, J BIOL CHEM, V261, P1491; ROBERTS DM, 1985, BIOCHEMISTRY-US, V24, P5090, DOI 10.1021/bi00340a020; ROBERTS DM, 1992, P NATL ACAD SCI USA, V89, P8394, DOI 10.1073/pnas.89.17.8394; ROWE PM, 1986, J BIOL CHEM, V261, P7060; Ruben L., 1984, Molecular biology of host-parasite interactions. Proc. UCLA Symp., Park City, Utah, USA, 30 Jan.-4 Feb. 1983. (UCLA Symposia on Molecular and Cellular Biology New Series, Vol. 13)., P267; SAUTER A, 1993, COMP BIOCH PHYSL B, V114, P119; SCHAEFER WH, 1987, J BIOL CHEM, V262, P1025; Sharma R K, 1979, Adv Cyclic Nucleotide Res, V10, P187; TZALMONA A, 1974, J CHEM PHYS, V61, P2637, DOI 10.1063/1.1682391; VOGEL HJ, 1983, FEBS LETT, V157, P241, DOI 10.1016/0014-5793(83)80554-7; VOGEL HJ, 1987, CALCIUM DRUG ACTIONS, P57; ZHANG MJ, 1993, J BIOL CHEM, V268, P22420; ZHANG MJ, 1993, PROTEIN SCI, V2, P1931, DOI 10.1002/pro.5560021114; [No title captured]	56	21	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5099	5105						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106489				2022-12-27	WOS:A1994MX57100064
J	ZHANG, Y; FILLINGAME, RH				ZHANG, Y; FILLINGAME, RH			ESSENTIAL ASPARTATE IN SUBUNIT-C OF F1F0 ATP SYNTHASE - EFFECT OF POSITION-61 SUBSTITUTIONS IN HELIX-2 ON FUNCTION OF ASP(24) IN HELIX-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1F0; POLAR LOOP REGION; H+-ATPASE; PROTEOLIPID SUBUNIT; PH HOMEOSTASIS; DICYCLOHEXYLCARBODIIMIDE; F0; IDENTIFICATION; ORGANIZATION; MUTATIONS	Subunit c of the F1F0 type, H+-transporting ATP synthase contains an essential Asp that is thought to function in H+ transport. Subunit c folds as a helical hairpin of two transmembrane helices with the essential Asp centered at residue 61 in transmembrane helix-2. Miller et al. (Miller, M. J., Olderburg, M., and Fillingame, R. H. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 4900-4904) have described a functional subunit c variant in which the essential Asp was moved from helix-2 to residue 24 on helix-1 with replacement of Asp(61) by Gly. The function of the A24D/D61G subunit c variant is not optimal. In this study, 11 position 61 variants of an A24D subunit c were generated by site-directed mutagenesis in order to test the importance of the position 61 residue. Three functional combinations were found with activities in the order: A24D/D61N > A24D/D61G greater than or equal to A24D/D61S. Other substitutions at position 61, including Ala and Cys, did not support function in the A24D protein. Although the A24D/D61N variant showed the highest rates of ATPase-coupled H+ transport, its F-0 was inactive in passive H+ transport when F-1 was stripped from the membrane. On the other hand, passive H+ transport by A24D/D61G and A24D/D61S stripped membranes approached that of wild type. The defect in function in these two mutants must be ascribed to events related to coupling ATPase and H+ transport. An A24D subunit c (with Asp at both position 24 and 61) was also generated. Its function proved to be pH-dependent. Activity approaching that of wild type was observed at pH 7.0, but function was almost completely lost at pH 7.8. The pH dependent loss of ATP synthase function led to a slowing of growth on succinate as carbon source on raising the pH from 7.0 to 7.8. In the A24D mutant, with a second Asp at position 61, we postulate that 1 Asp must be protonated before the other can function in H+ transport.	UNIV WISCONSIN,SCH MED,DEPT BIOMOLEC CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison			Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601	NIGMS NIH HHS [GM23105] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023105, R37GM023105] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		EVANS DJ, 1970, J BACTERIOL, V104, P1203, DOI 10.1128/JB.104.3.1203-1212.1970; FILLINGAME RH, 1991, J BIOL CHEM, V266, P20934; FILLINGAME RH, 1975, J BACTERIOL, V124, P870, DOI 10.1128/JB.124.2.870-883.1975; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRAGA D, 1991, J BACTERIOL, V173, P2639, DOI 10.1128/jb.173.8.2639-2643.1991; GIBSON F, 1977, BIOCHEM J, V162, P665, DOI 10.1042/bj1620665; GIRVIN ME, 1989, BIOCHEMISTRY-US, V28, P4340, DOI 10.1021/bi00436a032; Haddock B A, 1974, Biochem J, V142, P703; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; HOPPE J, 1984, BIOCHIM BIOPHYS ACTA, V768, P1, DOI 10.1016/0304-4173(84)90005-3; HOPPE J, 1980, EUR J BIOCHEM, V112, P17, DOI 10.1111/j.1432-1033.1980.tb04981.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; Miller J.H., 1972, EXPT MOL GENETICS; MILLER MJ, 1989, J BIOL CHEM, V264, P305; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; PADAN E, 1981, BIOCHIM BIOPHYS ACTA, V650, P151, DOI 10.1016/0304-4157(81)90004-6; PAULE CR, 1989, ARCH BIOCHEM BIOPHYS, V274, P270, DOI 10.1016/0003-9861(89)90439-6; ROISIN MP, 1973, BIOCHIM BIOPHYS ACTA, V305, P249, DOI 10.1016/0005-2728(73)90173-4; ROISIN MP, 1972, BIOCHIM BIOPHYS ACTA, V275, P333, DOI 10.1016/0005-2728(72)90214-9; Sambrook J, 1989, MOL CLONING LABORATO; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SLONCZEWSKI JL, 1981, P NATL ACAD SCI-BIOL, V78, P6271, DOI 10.1073/pnas.78.10.6271; TAYER J, 1985, NUCLEIC ACIDS RES, V13, P8764; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X	29	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5473	5479						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106529				2022-12-27	WOS:A1994MX57100114
J	LANGE, Y				LANGE, Y			CHOLESTEROL MOVEMENT FROM PLASMA-MEMBRANE TO ROUGH ENDOPLASMIC-RETICULUM - INHIBITION BY PROGESTERONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEYDIG TUMOR-CELLS; TRANSPORT; OXIDASE	The effect of progesterone on the movement of sterols from the cell surface to the rough endoplasmic reticulum (ER) was examined in rat hepatoma cells. Plasma membranes were labeled exogenously with [H-3]cholesterol or [H-3]zymosterol. Translocation of the labeled sterols to the rough ER was inferred from their conversion to [H-3]cholesteryl esters and [H-3]cholesterol, respectively. Progesterone inhibited both of these reactions by more than 90%. The concentration for half-maximal inhibition was 0.7 mug/ml. Progesterone did not inhibit acyl-/CoA:cholesterol acyltransferase activity itself, since the steroid had no effect on the esterification of [H-3]cholesterol synthesized in vitro in the rough ER from [H-3]zymosterol. Moreover, the small amount of [H-3]cholesterol synthesized from plasma membrane [H-3]zymosterol in progesterone-treated intact cells was esterified at the same fractional rate as cholesterol in control cells. Subcellular fractionation of cells pulse-labeled with [H-3]cholesterol and treated with progesterone suggested that the block in plasma membrane cholesterol transfer to the rough ER occurred at the level of the plasma membrane.			LANGE, Y (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT PATHOL,CHICAGO,IL 60612, USA.		Lange, Yvonne/A-7794-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028448, R55HL028448] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-28448] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1980, J BIOL CHEM, V255, P9344; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; ECHEVARRIA F, 1990, J BIOL CHEM, V265, P8484; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; LANGE Y, 1992, J LIPID RES, V33, P315; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LANGE Y, 1991, J BIOL CHEM, V266, P21439; LISCUM L, 1992, J LIPID RES, V33, P1239; NAGY L, 1990, ENDOCRINOLOGY, V126, P2267, DOI 10.1210/endo-126-5-2267; NAGY L, 1990, BIOCHEM J, V271, P809, DOI 10.1042/bj2710809; QIAN XD, 1990, J BIOL CHEM, V265, P18753; REINHART MP, 1990, EXPERIENTIA, V46, P599, DOI 10.1007/BF01939699; SUCKLING KE, 1985, J LIPID RES, V26, P647; TABAS I, 1988, J BIOL CHEM, V263, P1266	15	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3411	3414						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106380				2022-12-27	WOS:A1994MV63100044
J	STEWART, AFR; LARKIN, SB; FARRANCE, IKG; MAR, JH; HALL, DE; ORDAHL, CP				STEWART, AFR; LARKIN, SB; FARRANCE, IKG; MAR, JH; HALL, DE; ORDAHL, CP			MUSCLE-ENRICHED TEF-1 ISOFORMS BIND M-CAT ELEMENTS FROM MUSCLE-SPECIFIC PROMOTERS AND DIFFERENTIALLY ACTIVATE TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TROPONIN-T-GENE; CELLS; EXPRESSION; CLONING; ANTIGEN; MOTIF	M-CAT elements mediate cardiac- and embryonic skeletal muscle-specific expression of the cardiac troponin T gene and a number of other cardiac-specific genes. M-CAT binding factor was shown to be related to cloned human TEF-1, a transcriptional regulator of the SV40 viral enhancer. Here we describe the cloning of TEF-I from chick heart and the identification of several novel isoforms. We show that TEF-1 mRNA is considerably enriched in cardiac and skeletal muscle, consistent with a proposed role in muscle gene transcription. The predominant TEF-1 isoforms, TEF-1A and a novel isoform TEF-1B, bind M-CAT elements with high affinity and in a sequence-specific manner. We further demonstrate that the C-terminal portion of TEF-1B, which contains the 13-amino acid exon that distinguishes this isoform, can activate transcription when linked to a heterologous DNA binding domain, while the same domain of TEF-1A cannot. Therefore, isoforms of TEF-1 may play different roles in the regulation of M-CAT-dependent promoters in striated muscle cells.	UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Stewart, Alexandre F.R./A-5677-2011	Stewart, Alexandre/0000-0003-2673-9164	NHLBI NIH HHS [HL35561] Funding Source: Medline; NIGMS NIH HHS [GM32018] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032018] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRIANOPOULOS A, 1991, PLANT CELL, V3, P747, DOI 10.1105/tpc.3.8.747; ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; ARAMAYO R, 1993, EMBO J, V12, P2039, DOI 10.1002/j.1460-2075.1993.tb05853.x; BLATT C, 1993, NUCLEIC ACIDS RES, V21, P747, DOI 10.1093/nar/21.3.747; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; CASAZ P, 1991, J VIROL, V65, P6535, DOI 10.1128/JVI.65.12.6535-6543.1991; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COULOMBE J, 1992, J VIROL, V66, P4591, DOI 10.1128/JVI.66.7.4591-4596.1992; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FLINK IL, 1992, J BIOL CHEM, V267, P9917; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRUDA MC, 1993, MOL CELL BIOL, V13, P961, DOI 10.1128/MCB.13.2.961; GULICK J, 1991, J BIOL CHEM, V266, P9180; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARIYA K, 1994, J BIOL CHEM, V269, P3775; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LALOUX I, 1990, MOL CELL BIOL, V10, P3541, DOI 10.1128/MCB.10.7.3541; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; MIRABITO PM, 1989, CELL, V57, P859, DOI 10.1016/0092-8674(89)90800-3; ORDAHL CP, 1992, CURR TOP DEV BIOL, V26, P145, DOI 10.1016/S0070-2153(08)60444-5; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; Sambrook J, 1989, MOL CLONING LABORATO; SHIMIZU N, 1992, MOL CELL BIOL, V12, P619, DOI 10.1128/MCB.12.2.619; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G	33	105	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3147	3150						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106348				2022-12-27	WOS:A1994MV63100007
J	THIBONNIER, M; AUZAN, C; MADHUN, Z; WILKINS, P; BERTIMATTERA, L; CLAUSER, E				THIBONNIER, M; AUZAN, C; MADHUN, Z; WILKINS, P; BERTIMATTERA, L; CLAUSER, E			MOLECULAR-CLONING, SEQUENCING, AND FUNCTIONAL EXPRESSION OF A CDNA-ENCODING THE HUMAN-V(1A) VASOPRESSIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; CELLS; RAT	Vasopressin (AVP), the antidiuretic hormone, is a cyclic nonapeptide that acts through binding to G protein-coupled specific membrane receptors pharmacologically divided into three subtypes (V1a, V1b, and V2) linked to distinct second messengers. Within the family of human AVP receptors, the V2 AVP receptor has been cloned, but the structure of the human V1a and V1b AVP receptors remains unknown. We report here the structure and functional expression of a human V1a AVP receptor complementary DNA isolated from human liver cDNA libraries. Cloning and sequencing of a full-length clone isolated a 1472-nucleotide sequence encoding a 418-amino acid polypeptide with seven putative transmembrane domains typical of G protein-coupled receptors. Amino acid sequence identity with the rat liver V1a AVP receptor, the human and rat V2 AVP receptors, and the human oxytocin receptor was 72, 36, 37, and 45%, respectively. Functional characterization of the cloned receptor was done by transient expression in COS-7 cells and stable expression in Chinese hamster ovary cells. Localization of the expressed receptor at the cellular surface was illustrated by using the fluorescent linear analog phenylacetyl-D-Tyr(Et)-Phe-Gln-Asn-Lys-Pro-Arg-NH2 coupled to fluorescein-avidin by dodecabiotin. Competition binding experiments with phenylacetyl-D-Tyr(Et)-Phe-Val-Asn-Lys-Pro-[I-125]Tyr-NH2 and AVP analogs revealed high affinity specific binding sites of the V1a subtype. Saturation binding experiments with [H-3]AVP confirmed the presence of a single class of high affinity binding sites. Measurement of AVP-induced inositol phosphate production and calcium mobilization confirmed that the expressed V1a AVP receptor is coupled to phospholipase C via a pertussis toxin-insensitive pathway. Thus, the human V1a AVP receptor belongs to''the superfamily of seven-transmembrane segment receptors with a significant sequence identity with the other members of the AVP-oxytocin family of receptors.	COLL FRANCE,INSERM,U36,F-75005 ULM,FRANCE; UNIV HOSP CLEVELAND,DEPT MED,CLEVELAND,OH 44106	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; University Hospitals of Cleveland	THIBONNIER, M (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,DIV ENDOCRINOL & HYPERTENS,RM W147,10900 EUCLID AVE,CLEVELAND,OH 44106, USA.			, Marc/0000-0002-4546-180X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041618, R01HL039757] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL39757, P01 HL41618] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; DUBYAK GR, 1988, J BIOL CHEM, V263, P18108; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GRIFFIN HD, 1978, BIOCHEM J, V176, P541, DOI 10.1042/bj1760541; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; Michell R H, 1979, Biochem Soc Trans, V7, P861; MIZUNO T, 1992, BIOCHEM J, V287, P305, DOI 10.1042/bj2870305; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; TEUTSCH B, 1992, BIOCHEM BIOPH RES CO, V187, P1381, DOI 10.1016/0006-291X(92)90455-T; THIBONNIER M, 1985, J CLIN INVEST, V76, P1857, DOI 10.1172/JCI112179; THIBONNIER M, 1992, REGUL PEPTIDES, V38, P1, DOI 10.1016/0167-0115(92)90067-5; THIBONNIER M, 1987, J CARDIOVASC PHARM, V10, P24, DOI 10.1097/00005344-198707000-00004; THIBONNIER M, 1991, ENDOCRINOLOGY, V129, P2845, DOI 10.1210/endo-129-6-2845; THIBONNIER M, 1993, AM J PHYSIOL, V264, pC1336; THIBONNIER M, 1993, NEUROENDOCRINOLOGY C, V5, P19; THIBONNIER M, 1993, IN PRESS AM J PHYSL, V265; ZHOU J, 1993, HYPERTENSION, V21, P1035, DOI 10.1161/01.HYP.21.6.1035	24	260	267	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3304	3310						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106369				2022-12-27	WOS:A1994MV63100030
J	WU, QY; PICARD, V; AIACH, M; SADLER, JE				WU, QY; PICARD, V; AIACH, M; SADLER, JE			ACTIVATION-INDUCED EXPOSURE OF THE THROMBIN ANION-BINDING EXOSITE - INTERACTIONS OF RECOMBINANT MUTANT PROTHROMBINS WITH THROMBOMODULIN AND A THROMBIN EXOSITE-SPECIFIC ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; FACTOR-XA; EQUILIBRIUM BINDING; BOVINE PROTHROMBIN; CRYSTAL-STRUCTURE; MAJOR PRODUCT; FACTOR-VA; MEIZOTHROMBIN; HIRUDIN; PLASMA	The activation of serine protease zymogens involves conformational changes that increase the affinity of substrate binding and the activity of the catalytic center. The activation of prothrombin is particularly complex and requires several cleavages in the proenzyme region in addition to the conserved activation cleavage after Arg320. To understand how these cleavages lead to the exposure of the thrombin anion-binding exosite, a major macromolecular recognition site, interactions of recombinant human prothrombin derivatives with thrombomodulin, and an exosite-specific antibody were studied by competition binding and immunoprecipitation. By either method, the anion-binding exosite is not functional on prethrombin 2, which is cleaved after Arg271 and lacks fragment 1.2, nor on meizothrombin, which is cleaved only after Arg320. In contrast, the exosite is fully exposed on meizothrombin des-Fl, which is cleaved after both Arg320 and Arg155 and therefore lacks amino-terminal fragment 1 (Fl). Thus, two events are required to create the exosite. First, cleavage after Arg320 causes conformational changes that are much more extensive than those accompanying the activation of trypsinogen. Second, removal of amino-terminal Fl is necessary, perhaps to relieve steric hindrance. These results indicate that the F1 fragment regulates access to the thrombin exosite. The properties of meizothrombin des-Fl suggest that this prothrombin derivative could have a biological function.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,HOWARD HUGHES MED INST,660 S EUCLID,POB 8022,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT BIOCHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MOLEC BIOPHYS,ST LOUIS,MO 63110; HOP BROUSSAIS,INSERM,UFR SCI PHARMACEUT & BIOL,F-75674 PARIS 14,FRANCE	Barnes-Jewish Hospital; Howard Hughes Medical Institute; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Sadler, Evan/D-8556-2011	Wu, Qingyu/0000-0003-0561-9315; Sadler, J. Evan/0000-0001-5705-469X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147] Funding Source: NIH RePORTER; NHLBI NIH HHS [HLBI14147] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNAUD E, 1993, THROMB HAEMOSTASIS, V69, P555; ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; CARLISLE TL, 1990, J BIOL CHEM, V265, P22044; COSTA JM, 1992, THROMB HAEMOSTASIS, V67, P193; DEGEN SJF, 1990, DNA CELL BIOL, V9, P487, DOI 10.1089/dna.1990.9.487; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; DIHANICH M, 1990, NUCLEIC ACIDS RES, V18, P4251, DOI 10.1093/nar/18.14.4251; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; ESMON NL, 1988, CIRCULATION, V78, P317; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FOLZ RJ, 1987, BIOCHEM BIOPH RES CO, V146, P870, DOI 10.1016/0006-291X(87)90611-5; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HIBBARD LS, 1982, BIOCHEMISTRY-US, V21, P2285, DOI 10.1021/bi00539a003; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P486; KOTKOW KJ, 1993, J BIOL CHEM, V268, P15633; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LENTZ SR, 1991, BLOOD, V77, P542; LIU LW, 1991, J BIOL CHEM, V266, P23632; MACGILLIVRAY RTA, 1984, BIOCHEMISTRY-US, V23, P1626, DOI 10.1021/bi00303a007; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1990, BLOOD, V76, P1; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MORITA T, 1981, METHOD ENZYMOL, V80, P303; NESHEIM ME, 1988, J BIOL CHEM, V263, P1037; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; NGAI PK, 1991, BIOCHEM J, V280, P805, DOI 10.1042/bj2800805; RABIET MJ, 1986, J BIOL CHEM, V261, P3210; ROSING J, 1988, THROMB HAEMOSTASIS, V60, P355; ROSING J, 1986, J BIOL CHEM, V261, P4224; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SADLER JE, 1993, HAEMOSTASIS, V23, P183; SHUMAN MA, 1976, J CLIN INVEST, V58, P1249, DOI 10.1172/JCI108579; STEVENS WK, 1993, BIOCHEMISTRY-US, V32, P2787, DOI 10.1021/bi00062a008; TANS G, 1991, J BIOL CHEM, V266, P21864; TSIANG M, 1992, J BIOL CHEM, V267, P6164; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; WU Q, 1991, P NATL ACAD SCI USA, V8, P6775; WU QY, 1992, J BIOL CHEM, V267, P24408; WU QY, 1992, J BIOL CHEM, V267, P7083	44	50	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3725	3730						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106418				2022-12-27	WOS:A1994MV63100087
J	YANG, W; BOSS, WF				YANG, W; BOSS, WF			REGULATION OF PHOSPHATIDYLINOSITOL 4-KINASE BY THE PROTEIN ACTIVATOR PIK-A49 - ACTIVATION REQUIRES PHOSPHORYLATION OF PIK-A49	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-I; SEA-URCHIN EGGS; PLASMA-MEMBRANE; SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPASE-C; PHOSPHOINOSITIDE KINASES; DIACYLGLYCEROL KINASE; BINDING PROTEIN; F-ACTIN; CALCIUM	PIK-A49 is a 49-kDa soluble protein that was isolated as an activator of the plasma membrane phosphatidylinositol (PI) 4-kinase from carrot cells (Yang, W., Burkhart, W., Cavallius, J., Merrick, W. C., and Boss, W. F. (1993) J. Biol. Chem. 268, 392-398). PIK-A49 is a multifunctional protein that binds and bundles F-actin and has translational elongation factor-1alpha activity. In this paper, we have investigated the mechanism of activation of PI 4-kinase by PIK-A49. PIK-A49 decreased the K(m) of PI 4-kinase for ATP from 0.40 to 0.19 mm. GTP and GDP, which affect the elongation factor-1alpha function of the protein, inhibited the activation of PI 4-kinase by PIK-A49. Phosphorylation of purified PIK-A49 by a calcium-dependent protein kinase enhanced activation of PI 4-kinase. When dephosphorylated by alkaline phosphatase PIK-A49 no longer activated PI 4-kinase; however, rephosphorylation of PIK-A49 by calcium-dependent protein kinase fully restored activation. Western blots using anti-PIK-A49 serum showed that PIK-A49 was associated with the plasma membrane and the F-actin fraction isolated from plasma membranes, indicating that PIK-A49 would be in a position to regulate plasma membrane PI 4-kinase. Based on these data, we propose a mechanism for feed-forward regulation of polyphosphoinositide biosynthesis in response to increases in cytosolic calcium.	N CAROLINA STATE UNIV, DEPT BOT, BOX 7612, RALEIGH, NC 27695 USA	University of North Carolina; North Carolina State University								BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHAUHAN A, 1989, BIOCHEMISTRY-US, V28, P4952, DOI 10.1021/bi00438a007; CHEN QY, 1990, PLANT PHYSIOL, V94, P1820, DOI 10.1104/pp.94.4.1820; CHEN QY, 1991, PLANT PHYSIOL, V96, P340, DOI 10.1104/pp.96.1.340; CHO MH, 1992, LC GC-MAG SEP SCI, V10, P464; CHO MH, 1993, PLANT PHYSIOL, V103, P637, DOI 10.1104/pp.103.2.637; COTE GG, 1993, ANNU REV PLANT PHYS, V44, P333, DOI 10.1146/annurev.pp.44.060193.002001; DHARMAWARDHANE S, 1991, CELL MOTIL CYTOSKEL, V20, P279, DOI 10.1002/cm.970200404; DIDICHENKO SA, 1991, EUR J BIOCHEM, V198, P705, DOI 10.1111/j.1432-1033.1991.tb16070.x; DROBAK BK, 1993, PLANT PHYSIOL, V102, P705, DOI 10.1104/pp.102.3.705; FAIN JN, 1990, BIOCHIM BIOPHYS ACTA, V1053, P81, DOI 10.1016/0167-4889(90)90029-D; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; Gross W., 1993, Control of plant gene expression., P17; GROSS W, 1992, BIOCHIM BIOPHYS ACTA, V1134, P73, DOI 10.1016/0167-4889(92)90029-B; HOLLAND KM, 1988, J BACTERIOL, V170, P828, DOI 10.1128/jb.170.2.828-833.1988; HUBER JLA, 1992, BIOCHEM J, V283, P877, DOI 10.1042/bj2830877; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KATO H, 1989, J BIOL CHEM, V264, P3116; KNIGHT MR, 1992, P NATL ACAD SCI USA, V89, P4967, DOI 10.1073/pnas.89.11.4967; KURIYAMA R, 1990, J CELL SCI, V95, P231; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MEMON AR, 1990, J BIOL CHEM, V265, P14817; MISSIAEN L, 1989, BIOCHEM J, V261, P1055, DOI 10.1042/bj2611055; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHTA K, 1990, J BIOL CHEM, V265, P3240; PALEN E, 1990, FEBS LETT, V274, P12, DOI 10.1016/0014-5793(90)81317-H; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; PIKE LJ, 1992, ENDOCR REV, V13, P692, DOI 10.1210/er.13.4.692; PUTNAMEVANS C, 1989, CELL MOTIL CYTOSKEL, V12, P12, DOI 10.1002/cm.970120103; PUTNAMEVANS CL, 1990, BIOCHEMISTRY-US, V29, P2488, DOI 10.1021/bi00462a008; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; RINCON M, 1990, PLANT BIOL, V9, P173; Roberts DM, 1993, CURR OPIN CELL BIOL, V5, P242, DOI 10.1016/0955-0674(93)90110-C; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; SAHYOUN NE, 1989, J BIOL CHEM, V264, P1062; SCHALLER GE, 1992, BIOCHEMISTRY-US, V31, P1721, DOI 10.1021/bi00121a020; SHACKLOCK PS, 1992, NATURE, V358, P753, DOI 10.1038/358753a0; TAN Z, 1992, PLANT PHYSIOL, V100, P2116, DOI 10.1104/pp.100.4.2116; TAYLOR MV, 1984, NATURE, V312, P462, DOI 10.1038/312462a0; VANDONGEN CJ, 1985, BIOCHEM BIOPH RES CO, V128, P1219, DOI 10.1016/0006-291X(85)91070-8; VENEMA RC, 1991, J BIOL CHEM, V266, P11993; VOGEL S, 1986, EUR J BIOCHEM, V154, P253, DOI 10.1111/j.1432-1033.1986.tb09390.x; WALKER DH, 1990, BIOCHIM BIOPHYS ACTA, V1055, P295, DOI 10.1016/0167-4889(90)90046-G; WHEELER JJ, 1987, PLANT PHYSIOL, V85, P389, DOI 10.1104/pp.85.2.389; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; YANG WN, 1993, J BIOL CHEM, V268, P392; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382	54	62	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3852	3857						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106430				2022-12-27	WOS:A1994MV63100105
J	HUANG, CS; ANDERSON, ME; MEISTER, A				HUANG, CS; ANDERSON, ME; MEISTER, A			AMINO-ACID-SEQUENCE AND FUNCTION OF THE LIGHT SUBUNIT OF RAT-KIDNEY GAMMA-GLUTAMYLCYSTEINE SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE; SULFOXIMINE; INHIBITION; SITE	The heavy subunit (M(r) 72,614) of rat kidney gamma-glutamylcysteine synthetase, the enzyme that catalyzes the first step of glutathione (GSH) synthesis, mediates the catalytic activity of this enzyme and its feedback inhibition by GSH. There is evidence that the light subunit has a regulatory function (Huang, C.-S., Chang, L.-S., Anderson, M. E., and Meister, A. (1993) J. Biol. Chem. 268, 19675-19680). In the present work the cDNA for the light subunit was isolated, sequenced, and expressed in Escherichia coli. The cDNA was found to code for a protein of 274 amino acid residues (M(r) 30, 548). Recombinant holoenzyme was obtained by co-expression of the heavy and light subunits and by mixing of the separately expressed proteins. These recombinant holoenzyme preparations exhibit catalytic and GSH feedback inhibitory properties that are virtually identical to those of the isolated holoenzyme. These studies establish that the light subunit is an integral part of the enzyme and that the light and heavy subunits, are coded for separately. Possibly significant similarity of sequence of amino acids was found between the light subunit and E. coli gamma-glutamylcysteine synthetase, which is a single polypeptide.			HUANG, CS (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021, USA.				NIDDK NIH HHS [2 R37 DK 12034] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK012034] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM., 1988, CURRENT PROTOCOLS MO; DOLPHIN D, 1989, GLUTATHIONE CHEM B B, V3; DOLPHIN D, 1989, GLUTATHIONE CHEM A B, V3; DOOLITTLE RF, 1987, URFS ORFS PRIMER ANA; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1988, P NATL ACAD SCI USA, V85, P2464, DOI 10.1073/pnas.85.8.2464; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MEISTER A, 1992, JNCI-J NATL CANCER I, V84, P1601, DOI 10.1093/jnci/84.20.1601-a; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MEISTER A, 1979, CANCER TREAT REP, V63, P1115; MEISTER A, 1989, METABOLIC BASIS INHE, P855; OZOLS RF, 1988, BRISTOL MYERS S, V9, P289; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RICHARDS F, 1974, ARCH INTERN MED, V134, P534, DOI 10.1001/archinte.134.3.534; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; RICHMAN PG, 1975, THESIS CORNELL U; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEELIG GF, 1985, METHOD ENZYMOL, V113, P379; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; SEKURA R, 1977, J BIOL CHEM, V252, P2599; Taniguchi N., 1989, GLUTATHIONE CENTENNI; VISTICA DT, 1989, GLUTATHIONE CENTENNI, P301; YAN N, 1990, J BIOL CHEM, V265, P1588	26	208	212	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20578	20583						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8104188				2022-12-27	WOS:A1993LY01900094
J	NUEDA, A; LOPEZCABRERA, M; VARA, A; CORBI, AL				NUEDA, A; LOPEZCABRERA, M; VARA, A; CORBI, AL			CHARACTERIZATION OF THE CD11A (ALPHA-L, LFA-1-ALPHA) INTEGRIN GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE MONONUCLEAR PHAGOCYTES; FUNCTION-ASSOCIATED ANTIGEN-1; PLATELET GLYCOPROTEIN IIB; CELL-ADHESION; LEUKOCYTE INTEGRINS; MAMMALIAN-CELLS; DOWN-REGULATION; T-CELLS; LFA-1; EXPRESSION	Human lymphocyte function-associated antigen-1 (LFA-1, CD11a/CD 1 8, alphaL/beta2) is a cell surface heterodimer, which, together with Mac-1 (CD11b/CD18, alphaM/beta2) and p150,95 (CD11c/CD18, alphaX/beta2), constitutes the leukocyte integrin beta2 (CD18) subfamily. LFA-1 is the only integrin expressed on all leukocyte lineages and functions both as a key adhesion receptor in immune and inflammatory processes and as a signal-transducing molecule. To elucidate the molecular basis for the leukocyte-restricted expression of LFA-1, the promoter region of the CD11a gene has been isolated and functionally characterized. The 5' region of the CD11a gene exhibits a similar exon/intron organization as the CD11b, CD11c, and VLA-2alpha genes but is different from that of the genes encoding VLA-4alpha, VLA-5alpha, and gpIIb. Several tightly clustered transcription initiation sites have been identified on the CD11a gene, with the major site resembling the ''initiator'' sequence. Transient expression of CD11a promoter-based reporter gene constructs in both LFA1+ and LFA1- cell lines demonstrated that the fragment spanning from -880 to +83 is involved in the tissue-specific expression of LFA-1. Functional analysis of different fragments within the -880/+83 fragment suggested the presence of negative regulatory elements between -880 and -226 and demonstrated that the proximal region of the CD11a gene promoter exhibits tissue-specific activity.	HOSP PRINCESA, UNIDAD BIOL MOLEC, E-28006 MADRID, SPAIN; HOSP PRINCESA, SERV INMUNOL, E-28006 MADRID, SPAIN	Hospital de La Princesa; Hospital de La Princesa			Corbi, Angel/B-7194-2011; Cabrera, Manuel López/AAA-5463-2019; Corbí, Angel L./ABC-8146-2020	Corbi, Angel/0000-0003-1980-5733; Corbí, Angel L./0000-0003-1980-5733; Nueda, Arsenio/0000-0001-8373-500X; Lopez Cabrera, Manuel/0000-0002-0976-9719				AGURA ED, 1992, BLOOD, V79, P602; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; BACK AL, 1992, J IMMUNOL, V148, P710; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; CORBI AL, 1988, J EXP MED, V167, P1597, DOI 10.1084/jem.167.5.1597; CORBI AL, 1990, J BIOL CHEM, V265, P2782; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEIDENREICH R, 1990, BIOCHEMISTRY-US, V29, P1232, DOI 10.1021/bi00457a020; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HICKSTEIN DD, 1992, P NATL ACAD SCI USA, V89, P2105, DOI 10.1073/pnas.89.6.2105; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IGNOTZ RA, 1989, J BIOL CHEM, V264, P389; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; KIPGSTON RE, 1987, CURRENT PROTOCOLS MO; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEBEAU MM, 1985, NATURE, V313, P709, DOI 10.1038/313709a0; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; MENTZER SJ, 1986, J IMMUNOL, V137, P108; MISHRA GC, 1986, J IMMUNOL, V137, P1590; MOY VT, 1992, J EXP MED, V175, P1, DOI 10.1084/jem.175.1.1; OKRET S, 1986, P NATL ACAD SCI USA, V83, P5899, DOI 10.1073/pnas.83.16.5899; PAHL HL, 1992, BLOOD, V79, P865; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; PRANDINI MH, 1988, BIOCHEM BIOPH RES CO, V156, P595, DOI 10.1016/S0006-291X(88)80884-2; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; ROSMARIN AG, 1992, BLOOD, V79, P2598; ROUSSET F, 1989, J IMMUNOL, V143, P1490; Sambrook J, 1989, MOL CLONING LABORATO; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHELLEY CS, 1991, P NATL ACAD SCI USA, V88, P10525, DOI 10.1073/pnas.88.23.10525; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; STRASSMAN G, 1985, CELL IMMUNOL, V94, P265, DOI 10.1016/0008-8749(85)90103-0; STRASSMANN G, 1985, J IMMUNOL, V135, P147; UZAN G, 1991, J BIOL CHEM, V266, P8932; VANNOESEL C, 1988, NATURE, V333, P850, DOI 10.1038/333850a0; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; WACHOLTZ MC, 1989, J EXP MED, V170, P431, DOI 10.1084/jem.170.2.431; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988	51	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19305	19311						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8103515				2022-12-27	WOS:A1993LW81900026
J	DEVAJYOTHI, C; KALVAKOLANU, I; BABCOCK, GT; VASAVADA, HA; HOWE, PH; RANSOHOFF, RM				DEVAJYOTHI, C; KALVAKOLANU, I; BABCOCK, GT; VASAVADA, HA; HOWE, PH; RANSOHOFF, RM			INHIBITION OF INTERFERON-GAMMA-INDUCED MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II GENE-TRANSCRIPTION BY INTERFERON-BETA AND TYPE-BETA-1 TRANSFORMING GROWTH-FACTOR IN HUMAN ASTROCYTOMA-CELLS - DEFINITION OF CIS-ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DR ANTIGEN EXPRESSION; X-BOX-BINDING; DOWN-REGULATION; IA-ANTIGEN; HLA-DR; MESSENGER-RNA; DAUDI CELLS; RIFN-GAMMA; ALPHA-BETA; PROMOTER	To address mechanisms by which cytokines inhibit interferon-gamma (IFNgamma)-induced gene expression in astrocytic cells, we have been studying effects of type beta1 transforming growth factor (TGFbeta1) and interferon-beta (IFNbeta) on IFNgamma-induced expression of the well-characterized human major histocompatibility complex (MHC) class II gene DRA. This investigation was motivated by the observations that IFNgamma-induced expression of MHC class II antigen expression on astrocytic cells can be blocked in a tissue-specific fashion by several cytokines and neurotransmitters in tissue culture and that astrocyte expression of MHC class II is severely restricted in vivo. We previously showed that IFNbeta inhibited IFNgamma-induced DRA expression at the transcriptional level. This inhibition was not global, since IFNgamma-induction of intercellular adhesion molecule-1 was not affected. Here, TGFbeta1-mediated inhibition of DRA is shown to exhibit similar characteristics. To address the mechanism of this inhibition, sequence requirements for IFNbeta and TGFbeta1 to suppress IFNgamma-induced transcription of DRA were determined. A 135-base pair DRA sequence element containing the IFNgamma-responsive region and transcriptional start site was sufficient to direct IFNbeta- or TGFbeta1-mediated suppression of a reporter gene. These experiments suggested that either IFNbeta or TGFbeta1 could repress IFNgamma-induced DRA transcription directly, without requiring a cis-element extrinsic to the IFNgamma-inducible DRA sequences. Consistently similar effects of IFNbeta and TGFbeta1 observed in these experiments prompted comparison of other gene regulatory effects of the two cytokines. TGFbeta1, unlike IFNbeta, induced gene expression directed by upstream elements of the gene encoding plasminogen activator inhibitor type-1. IFNbeta, unlike TGFbeta1, enhanced levels of 2'-5'-oligoadenylate synthetase activity. Additionally, direct assay of TGFbeta1 and monoclonal anti-TGFbeta antibody blocking experiments were used to determine that cells treated with IFNbeta did not produce increased amounts of active or latent TGFbeta. These data argued that IFNbeta and TGFbeta1 utilized distinct pathways to mediate the inhibition of IFNgamma-induced DRA transcription.	CLEVELAND CLIN FDN,RES INST,MELLEN CTR MULTIPLE SCLEROSIS TREATMENT & RES,CLEVELAND,OH 44195; MILES RES CTR,INST ARTHRITIS & AUTOIMMUN,W HAVEN,CT 06516	Cleveland Clinic Foundation					NINDS NIH HHS [NS-KO8-01265] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001265] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLDRIDGE LC, 1991, EXP CELL RES, V195, P546, DOI 10.1016/0014-4827(91)90410-V; BARNA BP, 1989, J NEUROIMMUNOL, V23, P45, DOI 10.1016/0165-5728(89)90072-6; BASTA PV, 1988, P NATL ACAD SCI USA, V85, P8618, DOI 10.1073/pnas.85.22.8618; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CZARNIECKI CW, 1988, J IMMUNOL, V140, P4217; DAS HK, 1983, P NATL ACAD SCI-BIOL, V80, P3543, DOI 10.1073/pnas.80.12.3543; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; ESTES ML, 1990, J NEUROSCI RES, V27, P697, DOI 10.1002/jnr.490270430; FERTSCH D, 1987, J IMMUNOL, V139, P244; FERTSCHRUGGIO D, 1988, J IMMUNOL, V141, P1582; GHOSH SK, 1991, J BIOL CHEM, V266, P15293; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOWE PH, 1990, BIOCHEM J, V266, P537, DOI 10.1042/bj2660537; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; INABA K, 1986, J EXP MED, V163, P1030, DOI 10.1084/jem.163.4.1030; JOHNS LD, 1992, BRAIN RES, V585, P229, DOI 10.1016/0006-8993(92)91211-V; JONAK GJ, 1984, P NATL ACAD SCI-BIOL, V81, P1747, DOI 10.1073/pnas.81.6.1747; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KERR LD, 1988, J BIOL CHEM, V263, P16999; KNIGHT E, 1985, P NATL ACAD SCI USA, V82, P1151, DOI 10.1073/pnas.82.4.1151; LING PD, 1985, J IMMUNOL, V135, P1857; LOH JE, 1992, EMBO J, V11, P1351, DOI 10.1002/j.1460-2075.1992.tb05180.x; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MCGEADY ML, 1986, DNA-J MOLEC CELL BIO, V5, P289, DOI 10.1089/dna.1986.5.289; MOSES H, 1992, J IMMUNOL, V148, P3643; MOSES H, 1991, J NEUROIMMUNOL, V35, P273; OLIVEIRA IC, 1992, P NATL ACAD SCI USA, V89, P9049, DOI 10.1073/pnas.89.19.9049; ONO SJ, 1991, P NATL ACAD SCI USA, V88, P4309, DOI 10.1073/pnas.88.10.4309; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; RANSOHOFF RM, 1991, J NEUROIMMUNOL, V33, P103, DOI 10.1016/0165-5728(91)90054-B; RANSOHOFF RM, UNPUB; ROY C, 1990, NUCLEIC ACIDS RES, V18, P2125, DOI 10.1093/nar/18.8.2125; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; SHAN B, 1990, EMBO J, V9, P4307, DOI 10.1002/j.1460-2075.1990.tb07879.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TWARDZIK DR, 1990, ANN NY ACAD SCI, V593, P276, DOI 10.1111/j.1749-6632.1990.tb16119.x; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WRIGHT KL, 1992, P NATL ACAD SCI USA, V89, P7601, DOI 10.1073/pnas.89.16.7601; ZUBER P, 1988, EUR J IMMUNOL, V18, P1623, DOI 10.1002/eji.1830181023	44	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18794	18800						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8103050				2022-12-27	WOS:A1993LV65900065
J	PARKS, GD; LAMB, RA				PARKS, GD; LAMB, RA			ROLE OF NH2-TERMINAL POSITIVELY CHARGED RESIDUES IN ESTABLISHING MEMBRANE-PROTEIN TOPOLOGY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL SIGNAL SEQUENCE; ENDOPLASMIC-RETICULUM MEMBRANE; INFLUENZA-B VIRUS; HEMAGGLUTININ-NEURAMINIDASE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; AMINO-ACIDS; DIRECTED MUTAGENESIS; INVARIANT CHAIN; SIMIAN VIRUS-5	The paramyxovirus HN polypeptide is a model type II membrane protein, containing an internal uncleaved signal/anchor (S/A) and is oriented in the membrane with an NH2-terminal cytoplasmic domain and COOH-terminal ectodomain (N(cyt) topology). To test the role of NH2-terminal positively charged residues in directing the HN membrane topology, the 3 arginine (Arg) residues within the 17-amino-acid NH2-terminal domain were systematically converted to a glutamine or glutamate, and the topology of the mutant proteins was examined after expression in CV-1 cells. The data indicate that: (i) each of the NH2-terminal Arg residues contributes to the signal directing proper HN topology, since substitutions in any of the three positions resulted in approximately 13-23% inversion into the N(exo) form; (ii) substitutions in the Arg directly flanking the signal/anchor domain resulted in slightly more inversion than those which were located more distally; and (iii) substitution with a negatively charged glutamate led to more inversion than did replacement with an uncharged glutamine. The effect of a single Arg to Glu substitution on the HN topology was enhanced when present in the context of a truncated NH2-terminal cytoplasmic tail (3 residues). A comparison of the sequences flanking the signal/anchor of well documented type III proteins showed that the majority of three proteins contain a negatively charged residue flanking the NH2-terminal side. An exception to this rule is the NB protein which contains a single positively charged Arg residue in this position. A chimeric protein containing the NB ectodomain and the HN S/A and HN ectodomain lead to a significant fraction (70%) of the chimeric protein adopting type II topology suggesting that the positive charge flanking the S/A domain is important for establishing type II topology. These data are discussed in the context of the loop model for the biogenesis of integral membrane proteins and the possible signals necessary for establishing differing orientations.	NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,2153 SHERIDAN RD,EVANSTON,IL 60208; NORTHWESTERN UNIV,HOWARD HUGHES MED INST,EVANSTON,IL 60208	Northwestern University; Howard Hughes Medical Institute; Northwestern University								ADAMS GA, 1985, MOL CELL BIOL, V5, P1442, DOI 10.1128/MCB.5.6.1442; AKITA M, 1990, J BIOL CHEM, V265, P8164; ANDERSSON H, 1992, J BIOL CHEM, V267, P1491; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BERGMANN C, 1989, EMBO J, V5, P1543; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; ERICKSON AH, 1979, J BIOL CHEM, V254, P1771; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HAEUPTLE MT, 1989, J CELL BIOL, V108, P1227, DOI 10.1083/jcb.108.4.1227; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIEBERT SW, 1985, J VIROL, V54, P1; HIGH S, 1987, BIOCHEM J, V243, P277, DOI 10.1042/bj2430277; HIGH S, 1992, Current Opinion in Cell Biology, V4, P581, DOI 10.1016/0955-0674(92)90075-N; HULL JD, 1988, J CELL BIOL, V106, P1489, DOI 10.1083/jcb.106.5.1489; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LAMB RA, 1982, VIROLOGY, V123, P237, DOI 10.1016/0042-6822(82)90258-6; LAMB RA, 1976, VIROLOGY, V74, P504, DOI 10.1016/0042-6822(76)90356-1; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LIPP J, 1986, J CELL BIOL, V102, P2169, DOI 10.1083/jcb.102.6.2169; LIU DX, 1991, VIROLOGY, V185, P911, DOI 10.1016/0042-6822(91)90572-S; MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205; MALFROY B, 1988, FEBS LETT, V229, P206, DOI 10.1016/0014-5793(88)80828-7; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; NELSON DR, 1988, J BIOL CHEM, V263, P6038; NG DTW, 1990, MOL CELL BIOL, V10, P1989, DOI 10.1128/MCB.10.5.1989; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; NOTHWEHR SF, 1989, J BIOL CHEM, V264, P3979; PARKS GD, 1990, J VIROL, V64, P3605, DOI 10.1128/JVI.64.8.3605-3616.1990; PARKS GD, 1989, J CELL BIOL, V109, P2023, DOI 10.1083/jcb.109.5.2023; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PATERSON RG, 1990, J CELL BIOL, V110, P999, DOI 10.1083/jcb.110.4.999; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PORTER TD, 1985, P NATL ACAD SCI USA, V82, P973, DOI 10.1073/pnas.82.4.973; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; SAKAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P16, DOI 10.1073/pnas.89.1.16; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZMAN RC, 1986, MOL CELL BIOL, V6, P1329, DOI 10.1128/MCB.6.4.1329; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SCHOFIELD PR, 1987, NUCLEIC ACIDS RES, V15, P3636, DOI 10.1093/nar/15.8.3636; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SHAW MW, 1982, P NATL ACAD SCI-BIOL, V79, P6817, DOI 10.1073/pnas.79.22.6817; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; VONHEIJNE G, 1984, EMBO J, V3, P2315, DOI 10.1002/j.1460-2075.1984.tb02132.x; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P6711; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WILLIAMS MA, 1986, MOL CELL BIOL, V6, P4317, DOI 10.1128/MCB.6.12.4317; WILSON C, 1990, MOL CELL BIOL, V10, P449, DOI 10.1128/MCB.10.2.449; ZERIAL M, 1987, CELL, V48, P147, DOI 10.1016/0092-8674(87)90365-5	65	54	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19101	19109						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8103052				2022-12-27	WOS:A1993LV65900107
J	ARRIZA, JL; KAVANAUGH, MP; FAIRMAN, WA; WU, YN; MURDOCH, GH; NORTH, RA; AMARA, SG				ARRIZA, JL; KAVANAUGH, MP; FAIRMAN, WA; WU, YN; MURDOCH, GH; NORTH, RA; AMARA, SG			CLONING AND EXPRESSION OF A HUMAN NEUTRAL AMINO-ACID TRANSPORTER WITH STRUCTURAL SIMILARITY TO THE GLUTAMATE TRANSPORTER GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT-BRAIN; GLYCINE TRANSPORTER; CARRIER; IDENTIFICATION; RECEPTOR	A cDNA was isolated from human brain that encodes an amino acid sequence 34-39% identical to previously published glutamate transporter sequences. Injection of RNA transcribed from this cDNA into Xenopus oocytes resulted in expression of a transport activity with the properties of the neutral amino acid uptake system ASC. Superfusion of alanine, serine, and cysteine evoked sodium-dependent inward currents in voltage-clamped oocytes expressing the transporter. These currents were dose-dependent, stereospecific, and saturable, with K(m) values ranging from 29 to 88 muM. Northern blot analyses revealed ubiquitous expression of this gene, termed ASCT1, consistent with the general metabolic role ascribed to system ASC.			ARRIZA, JL (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES L-474,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.		North, Richard/GQA-6156-2022	Amara, Susan/0000-0001-8914-1106	NATIONAL INSTITUTE ON DRUG ABUSE [R37DA007595, R37DA003160, R01DA003160, R01DA007595] Funding Source: NIH RePORTER; NIDA NIH HHS [DA07595, DA03160] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BUSSOLATI O, 1992, J BIOL CHEM, V267, P8330; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTENSEN HN, 1984, BIOCHIM BIOPHYS ACTA, V779, P255, DOI 10.1016/0304-4157(84)90012-1; CHRISTENSEN HN, 1967, J BIOL CHEM, V242, P5237; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; ENGELKE T, 1989, J BACTERIOL, V171, P5551, DOI 10.1128/jb.171.10.5551-5560.1989; ERICINSKA M, 1983, J BIOL CHEM, V258, P9069; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KONG CT, 1993, J BIOL CHEM, V268, P1509; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREIG PA, 1984, NUCLEIC ACIDS RES, V12, P7057; LUI QR, 1992, FEBS LETT, V305, P110; MAENZ DD, 1992, J BIOL CHEM, V267, P1510; MAKOWSKE M, 1982, J BIOL CHEM, V257, P4635; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; OLNEY JW, 1990, SCIENCE, V248, P596, DOI 10.1126/science.2185543; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; STEIN WD, 1986, TRANSPORT DIFFUSION, P467; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; WALLACE B, 1990, J BACTERIOL, V172, P3214, DOI 10.1128/jb.172.6.3214-3220.1990; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0	27	329	334	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15329	15332						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8101838				2022-12-27	WOS:A1993LN30500002
J	MURAKAMI, Y; HURWITZ, J				MURAKAMI, Y; HURWITZ, J			FUNCTIONAL INTERACTIONS BETWEEN SV40 T-ANTIGEN AND OTHER REPLICATION PROTEINS AT THE REPLICATION FORK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; CELL NUCLEAR ANTIGEN; LAGGING STRAND SYNTHESIS; POLYMERASE-ALPHA; INVITRO REPLICATION; PURIFIED PROTEINS; SACCHAROMYCES-CEREVISIAE; ENZYMATIC-SYNTHESIS; INITIATION; ORIGIN	The functional interaction of simian virus 40 (SV40) large tumor antigen (T antigen) with DNA polymerase alpha (pol alpha)-primase complex, human single-stranded DNA binding protein (HSSB), and DNA polymerase delta (pol delta) holoenzyme, which includes pol delta, activator I (also called replication factor C), and proliferating cell nuclear antigen, at the replication fork was examined using the purified components that support SV40 DNA replication. Dilution of reaction mixtures during RNA primer synthesis revealed that T antigen remained associated continuously with the fork, while the pol alpha-primase complex dissociated from the complex during oligoribonucleotide synthesis. T antigen unwound duplex DNA from the SV40 core origin at a rate of 200 base pairs/min. Pol alpha-primase complex inhibited the rate of the unwinding reaction, and HSSB, pol alpha, and primase were all required for this effect. These requirements are the same as those essential for DNA primase-catalyzed oligoribonucleotide synthesis (Matsumoto, T., Eki, T., and Hurwitz, J. (1990) Proc. NatL Acad. Sci. U. S. A. 87, 9712-9716). This result suggests that the pol alpha-primase complex interacts with T antigen and HSSB during the unwinding reaction to synthesize RNA primers and that the interaction decreases the rate of T antigen movement. While pol delta holoenzyme can elongate primed DNA chains at a rate of 400-600 nucleotides/min on singly primed phiX174 DNA, the rate of the leading strand synthesis catalyzed by pol delta holoenzyme in the SV40 replication system in vitro was about 200 nucleotides/min. This rate was similar to the unwinding rate catalyzed by T antigen. Thus, the rate of leading strand synthesis catalyzed by pol delta holoenzyme in vitro appears to be limited by the unwinding reaction catalyzed by T antigen.			MURAKAMI, Y (corresponding author), MEM SLOAN KETTERING CANC CTR,DEPT MOLEC BIOL,NEW YORK,NY 10021, USA.							AMIN AA, 1992, J BIOL CHEM, V267, P18612; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; Baker T. A., 1992, DNA REPLICATION; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BULLOCK PA, 1989, P NATL ACAD SCI USA, V86, P3944, DOI 10.1073/pnas.86.11.3944; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; EDENBRG HJ, 1975, ANNU REV GENET, V9, P4077; EKI T, 1991, J BIOL CHEM, V266, P3087; EKI T, 1992, J BIOL CHEM, V267, P7284; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; GANNON J V, 1990, New Biologist, V2, P84; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GRONOSTAJSKI RM, 1984, J BIOL CHEM, V259, P9479; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1991, J BIOL CHEM, V266, P16141; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11018; MURAKAMI Y, 1986, P NATL ACAD SCI USA, V83, P2869, DOI 10.1073/pnas.83.9.2869; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; SINHA NK, 1980, J BIOL CHEM, V255, P4290; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; SO AG, 1988, BIOCHEMISTRY-US, V27, P4591, DOI 10.1021/bi00413a001; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; TAPPER DP, 1979, BIOCHIM BIOPHYS ACTA, V565, P84, DOI 10.1016/0005-2787(79)90084-4; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P2869; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WU CA, 1992, J BIOL CHEM, V267, P4030; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950	50	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11008	11017						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8098707				2022-12-27	WOS:A1993LD46600047
J	SCHINKEL, AH; KEMP, S; DOLLE, M; RUDENKO, G; WAGENAAR, E				SCHINKEL, AH; KEMP, S; DOLLE, M; RUDENKO, G; WAGENAAR, E			N-GLYCOSYLATION AND DELETION MUTANTS OF THE HUMAN MDR1 P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PHENOTYPE; MONOCLONAL-ANTIBODIES; COMPLEMENTARY-DNA; GENE FAMILY; HUMAN-CELLS; EXPRESSION; TRANSPORTER; MUTATIONS; PROTEINS; MELANOMA	P-glycoproteins are heavily glycosylated plasma membrane proteins, which confer multidrug resistance by pumping a range of different drugs from the cell. To investigate the significance of the conserved N-glycosylation sites present in the putative first extracellular loop of P-glycoproteins, we mutated one, two, or all three of these sites present in the human MDR1 P-glycoprotein. We also deleted a stretch of 20 amino acids, containing two of the three N-glycosylation sites. The effects of these mutations were studied by transfection into drug-sensitive cells. In vincristine-resistant transfected clones selected for similar steady state levels of membrane-bound P-glycoprotein, the absence of N-glycosylation did not alter the level or pattern of (cross-)resistance. However, the absence of N-glycosylation sites drastically reduced the efficiency with which drug-resistant clones could be generated. These findings suggest that N-glycosylation contributes to proper routing or stability of P-glycoprotein but not to drug transport per se. The deletion mutants demonstrated a clearly decreased and altered drug resistance pattern, even with a high level of P-glycoprotein in the plasma membrane. This, and possibly the observed lack of glycosylation of the remaining intact glycosylation sequence, suggests a constrained P-glycoprotein structure. Our findings support the current model for P-glycoprotein structure.			SCHINKEL, AH (corresponding author), NETHERLANDS CANC INST,DIV MOLEC BIOL,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.		Rudenko, Gabrielle (Gabby)/O-7938-2018; Kemp, Stephan/A-3935-2008	Rudenko, Gabrielle (Gabby)/0000-0002-7372-0530; Kemp, Stephan/0000-0003-2023-064X				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BECK WT, 1982, CANCER RES, V42, P184; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CROOP JM, 1988, J CLIN INVEST, V81, P1303, DOI 10.1172/JCI113455; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DHIR R, 1992, BIOCHEMISTRY-US, V31, P6103, DOI 10.1021/bi00141a021; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ENDICOTT JA, 1991, SEQUENCING MAPPING, V2, P89; GEENBERGER LM, 1987, J BIOL CHEM, V262, P13685; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERGER LM, 1989, FEBS LETT, V257, P419, DOI 10.1016/0014-5793(89)81586-8; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRETZ KA, 1990, P NATL ACAD SCI USA, V87, P2541, DOI 10.1073/pnas.87.7.2541; KUCHLER K, 1992, P NATL ACAD SCI USA, V89, P2302, DOI 10.1073/pnas.89.6.2302; LINCKE CR, 1990, CANCER RES, V50, P1779; LING V, 1983, CANCER TREAT REP, V67, P869; LOCKSHIN A, 1985, CANCER RES, V45, P345; Parekh RB, 1991, CURR OPIN STRUC BIOL, V1, P750, DOI 10.1016/0959-440X(91)90174-R; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; RICHERT ND, 1988, BIOCHEMISTRY-US, V27, P7607, DOI 10.1021/bi00420a006; Sambrook J, 1989, MOL CLONING LABORATO; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Schinkel A H, 1991, Semin Cancer Biol, V2, P213; SCHINKEL AH, 1991, CANCER RES, V51, P2628; SILVERMAN JA, 1991, GENE, V106, P229, DOI 10.1016/0378-1119(91)90203-N; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; ZHANG JT, 1991, J BIOL CHEM, V266, P18224	41	169	175	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7474	7481						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8096511				2022-12-27	WOS:A1993KV14100093
J	CROOKE, E; AKIYAMA, M; RAO, NN; KORNBERG, A				CROOKE, E; AKIYAMA, M; RAO, NN; KORNBERG, A			GENETICALLY ALTERED LEVELS OF INORGANIC POLYPHOSPHATE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; MAP	The ppk gene encoding polyphosphate kinase (PPK), the enzyme in Escherichia coli that makes long chains of polyphosphate (polyP) reversibly from ATP, was disrupted by insertion of a kanamycin resistance gene. Expression of the exopolyphosphatase gene (ppx) immediately downstream of ppk in the operon was likewise disrupted. Cells were also transformed with a high-copy-number plasmid bearing ppk. Genetically altered polyP levels were estimated in cell extracts by the PPK conversion of ADP to ATP. PolyP levels (mu g/10(11) cells) near 2.0 were reduced in the ppk(-)-ppx(-) mutants to 0.16 and increased more than 100-fold (e.g. 220) in cells transformed with multiple copies of ppk. Mutant cells, lacking the long polyP chains, showed a growth lag following dilution of a stationary-phase culture. PolyP-deficient cells exhibit a striking phenotype in their failure to survive in stationary phase and loss of resistance to heat (55 degrees C) and to oxidants (42 mM H2O2). High polyP levels are also associated with reduced survival.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University								AHN KH, 1990, J BIOL CHEM, V265, P11734; AKIYAMA M, 1993, J BIOL CHEM, V268, P633; AKIYAMA M, 1992, J BIOL CHEM, V267, P22556; AMES BN, 1960, J BIOL CHEM, V235, P769; ARCHIBALD FS, 1982, ARCH BIOCHEM BIOPHYS, V215, P589, DOI 10.1016/0003-9861(82)90120-5; AULING G, 1991, APPL ENVIRON MICROB, V57, P3583; Ausubel FM, 1991, CURRENT PROTOCOLS MO, V1; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BONTING CFC, 1991, J BACTERIOL, V173, P6484, DOI 10.1128/jb.173.20.6484-6488.1991; Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; HENGGEARONIS R, 1993, CELL, V72, P165, DOI 10.1016/0092-8674(93)90655-A; HSIEH PC, 1993, PROTEIN EXPRES PURIF, V4, P76, DOI 10.1006/prep.1993.1012; KEASLING JD, 1993, P NATL ACAD SCI USA, V90, P7029, DOI 10.1073/pnas.90.15.7029; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KORNBERG A, 1956, BIOCHIM BIOPHYS ACTA, V20, P215, DOI 10.1016/0006-3002(56)90280-3; KORNBERG SR, 1957, BIOCHIM BIOPHYS ACTA, V26, P294, DOI 10.1016/0006-3002(57)90008-2; Kulaev IS, 1979, BIOCH INORGANIC POLY; LAVINTHAL C, 1962, P NATL ACAD SCI USA, V48, P1230; MCCANN MP, 1991, J BACTERIOL, V173, P4188, DOI 10.1128/jb.173.13.4188-4194.1991; Miller J.H., 1972, EXPT MOL GENETICS; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; PHILLIPS NF, 1993, ARCH BIOCHEM BIOPHYS, V300, P609; PICK U, 1991, PLANT PHYSIOL, V97, P1234, DOI 10.1104/pp.97.3.1234; PISONI RL, 1992, J BIOL CHEM, V267, P3626; RAO NN, 1985, J BACTERIOL, V162, P242, DOI 10.1128/JB.162.1.242-247.1985; REUSCH RN, 1988, P NATL ACAD SCI USA, V85, P4176, DOI 10.1073/pnas.85.12.4176; SIEGELE DA, 1992, J BACTERIOL, V174, P345, DOI 10.1128/jb.174.2.345-348.1992; VANVEEN HW, 1993, J BIOL CHEM, V268, P19377; WOOD HG, 1988, ANNU REV BIOCHEM, V57, P235, DOI 10.1146/annurev.bi.57.070188.001315; ZAMBRANO MM, 1993, SCIENCE, V259, P1757, DOI 10.1126/science.7681219	30	110	112	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6290	6295						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119977				2022-12-27	WOS:A1994MZ50300009
J	JIANG, Y; TRIEZENBERG, SJ; GRALLA, JD				JIANG, Y; TRIEZENBERG, SJ; GRALLA, JD			DEFECTIVE TRANSCRIPTIONAL ACTIVATION BY DIVERSE VP16 MUTANTS ASSOCIATED WITH A COMMON INABILITY TO FORM OPEN PROMOTER COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RNA POLYMERASE-II; EARLY GENE-EXPRESSION; TATA-BINDING PROTEIN; TERMINAL DOMAIN; NONPHOSPHORYLATED FORM; CELLULAR PROTEINS; GAL4 DERIVATIVES; DNA-SEQUENCE; MECHANISM; ELONGATION	Three different types of VP16 mutants were assayed in vitro. These included deletion of the C-terminal activation subdomain and alterations in either the acidic or non-acidic components of the minimal activation domain. The mutant GAL4-VP16 proteins were found to be transcriptionally defective using a HeLa cell nuclear extract. In all three cases the loss of transcription activity was accompanied by a commensurate loss in ability to form open transcription complexes. The comparison implies that the diverse components of GAL4-VP16 activate transcription by the common facilitation of steps required for open complex formation. The results further imply that open complex formation may be a common target for mammalian transcriptional activation, as known previously to be the case in bacterial systems.	UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA; MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	University of California System; University of California Los Angeles; Michigan State University				Triezenberg, Steven/0000-0003-4184-5221	NIAID NIH HHS [AI 27323] Funding Source: Medline; NIGMS NIH HHS [GM49048] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027323, R21AI027323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049048] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GRALLA JD, 1990, METHOD ENZYMOL, V185, P37; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; JIANG Y, 1993, MOL CELL BIOL, V13, P4572, DOI 10.1128/MCB.13.8.4572; JIANG Y, 1993, J BIOL CHEM, V268, P6535; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; LI Z, 1989, GENE DEV, V3, P1814, DOI 10.1101/gad.3.11.1814; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MCKNIGHT JLC, 1987, P NATL ACAD SCI USA, V84, P7061, DOI 10.1073/pnas.84.20.7061; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WALKER S, 1993, MOL CELL BIOL, V13, P5233, DOI 10.1128/MCB.13.9.5233; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S	45	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5505	5508						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119881				2022-12-27	WOS:A1994MY84000007
J	MARECHAL, E; BLOCK, MA; JOYARD, J; DOUCE, R				MARECHAL, E; BLOCK, MA; JOYARD, J; DOUCE, R			KINETIC-PROPERTIES OF MONOGALACTOSYLDIACYLGLYCEROL SYNTHASE FROM SPINACH CHLOROPLAST ENVELOPE MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL GALACTOSYLTRANSFERASE ACTIVITY; MIXED MICELLES; UDP-GALACTOSE; PHOSPHATIDATE PHOSPHATASE; OUTER-MEMBRANE; SOLUBILIZATION; PURIFICATION; PHOSPHATIDYLCHOLINE; THYLAKOIDS; METABOLISM	We have investigated the functioning of monogalactosyldiacylglycerol (MGDG) synthase activity partially purified from spinach chloroplast envelope membranes, using mixed micelles containing diacylglycerol (the substrate for MGDG synthase), CHAPS (3-[(cholamidopropyl)dimethylammonio]-1-propanesulfonic acid), and phosphatidylglycerol. The presence of this anionic phospholipid was essential for optimal MGDG synthase activity because it strongly improves diacylglycerol solubilization by CHAPS. We have demonstrated that the ''surface dilution'' kinetic model proposed by Deems ct al. (Deems, R. A., Eaten, B. R., and Dennis, E.A. (1975) J. Biol. Chem. 250, 9013-9020) is valid for MGDG synthase assayed in mixed micelles within a narrow range of CHAPS concentration. However, the experimental conditions we have set up in this study led to the description of defined equilibrium and kinetic parameters of the interaction of the envelope MGDG synthase with diacylglycerol. Two-substrate kinetic studies were performed with varied UDP-galactose molar concentrations and varied dioleoylglycerol surface concentrations. The families of reciprocal plots obtained were shown to intersect at a single point of the 1/[substrate] axis thus demonstrating that MGDG synthase is a sequential, either random or ordered, bireactant system. Therefore, MGDG synthase possesses two distinct and independent substrate-binding sites, a hydrophilic one for UDP-galactose and a hydrophobic one for diacylglycerol. The dependence of kinetic parameters on the diacylglycerol mel fraction allows a comparison of the affinity of the enzyme for a wide range of diacylglycerol molecular species. The K-m values obtained were ranging between 0.0089 mol fraction (52 mu M) for dilinoleoylglycerol (18:2/18:2) to 0.0666 mol fraction (416 mu M for distearoylglycerol (18:0/18:0), but the differences observed were not really related to the unsaturation of the molecule since the K-m value for dilinoleoylglycerol was much lower than that (0.040 mol fraction) for dilinoleoylglycerol (18:3/18:3). The K-m values for dioleoylglycerol (18:1/18:1) and for the diacylglycerol molecular species synthesized within chloroplasts, i.e. containing 18:1/ 16:0, were in the average range, i.e. lower than 0.030 mol fraction (around 170 mu M).	UNIV JOSEPH FOURIER,F-38054 GRENOBLE 9,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	MARECHAL, E (corresponding author), CEN GRENOBLE,DEPT BIOL MOLEC & STRUCT,PHYSIOL CELLULAIRE VEGETALE LAB,CNRS,UA 576,F-38054 GRENOBLE 9,FRANCE.							[Anonymous], METHODS CHLOROPLAST; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BENSON AA, 1964, ANN REV PLANT PHYSIO, V15, P1, DOI 10.1146/annurev.pp.15.060164.000245; BLIGNY R, 1990, J BIOL CHEM, V265, P1319; BLOCK MA, 1983, J BIOL CHEM, V258, P3281; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; COVES J, 1986, FEBS LETT, V208, P401, DOI 10.1016/0014-5793(86)81057-2; COVES J, 1988, P NATL ACAD SCI USA, V85, P4966, DOI 10.1073/pnas.85.14.4966; COVES J, 1987, PLANT MEMBRANES STRU, P103; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DENNIS E A, 1974, Journal of Supramolecular Structure, V2, P682, DOI 10.1002/jss.400020513; DENNIS EA, 1983, ENZYMES, V16, P308; DORNE AJ, 1990, P NATL ACAD SCI USA, V87, P71, DOI 10.1073/pnas.87.1.71; DORNE AJ, 1985, J CELL BIOL, V100, P1690, DOI 10.1083/jcb.100.5.1690; DORNE AJ, 1982, FEBS LETT, V145, P30, DOI 10.1016/0014-5793(82)81200-3; Douce, 1987, BIOCH PLANTS, P215, DOI 10.1016/B978-0-12-675409-4.50015-0; DOUCE R, 1974, SCIENCE, V183, P852, DOI 10.1126/science.183.4127.852; Douce R., 1980, The biochemistry of plants. A comprehensive treatise. Volume 4. Lipids: structure and function., P321; DOUCE R, 1990, METHODS PLANT BIOCH, V4, P71; FERRARI RA, 1961, ARCH BIOCHEM BIOPHYS, V93, P185, DOI 10.1016/0003-9861(61)90248-X; FLUGGE UI, 1984, FEBS LETT, V169, P85, DOI 10.1016/0014-5793(84)80294-X; FRENTZEN M, 1983, EUR J BIOCHEM, V129, P629; HAJRA AK, 1974, LIPIDS, V9, P502, DOI 10.1007/BF02532495; HEBER U, 1981, ANNU REV PLANT PHYS, V32, P139, DOI 10.1146/annurev.pp.32.060181.001035; HEEMSKERK JWM, 1987, BIOCHIM BIOPHYS ACTA, V918, P189, DOI 10.1016/0005-2760(87)90194-9; Heinz E., 1977, Lipids and lipid polymers in higher plants., P102; HEIRWEGH KPM, 1988, BIOCHEM J, V254, P101, DOI 10.1042/bj2540101; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; JOYARD J, 1986, BIOCHIM BIOPHYS ACTA, V879, P78, DOI 10.1016/0005-2760(86)90269-9; JOYARD J, 1976, BIOCHIM BIOPHYS ACTA, V424, P125, DOI 10.1016/0005-2760(76)90057-6; KUCERA GL, 1988, J BIOL CHEM, V263, P1920; LICHTENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285, DOI 10.1016/0304-4157(83)90004-7; LIN YP, 1990, J BIOL CHEM, V265, P166; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALHERBE A, 1992, J BIOL CHEM, V267, P23546; MANTEL CR, 1993, BIOCHEM J, V289, P815, DOI 10.1042/bj2890815; MARECHAL E, 1991, CR ACAD SCI III-VIE, V313, P521; MILLER JC, 1981, J BIOL CHEM, V256, P2662; MUDD JB, 1969, J LIPID RES, V10, P623; NEUFELD EF, 1964, BIOCHEM BIOPH RES CO, V14, P503, DOI 10.1016/0006-291X(64)90259-1; ROUGHAN PG, 1982, ANNU REV PLANT PHYS, V33, P97, DOI 10.1146/annurev.pp.33.060182.000525; SAKAKI T, 1990, PLANT PHYSIOL, V94, P773, DOI 10.1104/pp.94.2.773; SCHMIDT H, 1990, P NATL ACAD SCI USA, V87, P9477, DOI 10.1073/pnas.87.23.9477; Segel I.H., 1975, ENZYME KINETICS; SEIFERT U, 1992, BOT ACTA, V105, P197, DOI 10.1111/j.1438-8677.1992.tb00287.x; SIEBERTZ HP, 1980, EUR J BIOCHEM, V108, P177, DOI 10.1111/j.1432-1033.1980.tb04710.x; SIEBERTZ HP, 1979, EUR J BIOCHEM, V101, P429, DOI 10.1111/j.1432-1033.1979.tb19736.x; TEUCHER T, 1991, PLANTA, V184, P319, DOI 10.1007/BF00195332; URBANEJA MA, 1990, BIOCHEM J, V270, P305, DOI 10.1042/bj2700305; VANBESOUW A, 1979, FEBS LETT, V102, P33; VANBESOUW A, 1978, BIOCHIM BIOPHYS ACTA, V529, P44, DOI 10.1016/0005-2760(78)90102-9; WARNER TG, 1975, J BIOL CHEM, V250, P8004; WELSH GR, 1988, J THEOR BIOL, V130, P407; WILCOX RW, 1991, LIPIDS, V26, P283, DOI 10.1007/BF02537138	54	42	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5788	5798						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119920				2022-12-27	WOS:A1994MY84000050
J	MASTICK, CC; AEBERSOLD, R; LIENHARD, GE				MASTICK, CC; AEBERSOLD, R; LIENHARD, GE			CHARACTERIZATION OF A MAJOR PROTEIN IN GLUT4 VESICLES - CONCENTRATION IN THE VESICLES AND INSULIN-STIMULATED TRANSLOCATION TO THE PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR GLUCOSE TRANSPORTERS; 3T3-L1 ADIPOCYTES; RAT ADIPOCYTES; LOCALIZATION	GLUT4-enriched vesicles from fat and muscle cells contain a major protein of 165 kDa. In the present study we have prepared GLUT4 vesicles from a large number of rat adipocytes, isolated the 165-kDa protein by SDS-gel electrophoresis, and obtained the sequences of four tryptic peptides. Comparison of the sequences with those in protein data banks showed that the 165-kDa protein had not previously been sequenced. An antibody preparation against one of the peptides immunoblotted the 165-kDa protein. By this means it was found that the 165-kDa protein was concentrated in GLUT4 vesicles, and that insulin treatment of rat adipocytes caused a translocation of the protein to the plasma membrane that paralleled the translocation of GLUT4	DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER V6T 1W5,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER V6T 1W5,BC,CANADA	Dartmouth College; University of British Columbia; University of British Columbia			Mastick, Cynthia/G-9841-2017	Mastick, Cynthia/0000-0003-4769-5412	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025336, R55DK025336] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25336] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; BRAND SH, 1993, EMBO J, V12, P3753, DOI 10.1002/j.1460-2075.1993.tb06053.x; BROWN SJ, 1988, BIOCHIM BIOPHYS ACTA, V971, P339, DOI 10.1016/S0005-2728(88)80049-5; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; HESS D, 1993, PROTEIN SCI, V2, P1342, DOI 10.1002/pro.5560020817; KELLER SR, 1991, J BIOL CHEM, V266, P12817; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; LEINHARD GE, 1982, BIOCHEM BIOPH RES CO, V105, P1150; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; WEBER TM, 1988, RECEPTOR BIOCH METHO, P171; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	22	114	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6089	6092						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119954				2022-12-27	WOS:A1994MY84000092
J	TANTI, JF; GREMEAUX, T; VANOBBERGHEN, E; LEMARCHANDBRUSTEL, Y				TANTI, JF; GREMEAUX, T; VANOBBERGHEN, E; LEMARCHANDBRUSTEL, Y			SERINE/THREONINE PHOSPHORYLATION OF INSULIN-RECEPTOR SUBSTRATE-1 MODULATES INSULIN-RECEPTOR SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; OKADAIC ACID; RAT ADIPOCYTES; PROTEIN-KINASE; GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE; CONFORMATIONAL-CHANGES; PHOSPHATASE INHIBITOR; SKELETAL-MUSCLE; HEPATOMA-CELLS	Treatment of cells with okadaic acid, a protein phosphatase inhibitor, leads to an insulin-resistant state without modification in the tyrosine kinase activity of the receptor toward exogenous substrates. In 3T3-L1 adipocytes, okadaic acid induced a similar dose dependent inhibition of the insulin effect on deoxyglucose uptake, phosphatidylinositol 3-kinase (PI 3-kinase) activation, and insulin receptor substrate (IRS) 1 tyrosine phosphorylation. Simultaneously, in okadaic acid-treated 3T3-L1 adipocytes, the reduced IRS 1 tyrosine phosphorylation was linked to a decrease in its electrophoretic mobility due to phosphorylation on serine/threonine residues. This phosphorylation appeared to result from the activation of cytosolic kinase(s). Furthermore, using in vitro reconstitution, we show that, compared to IRS 1 immunopurified from untreated cells, the IRS 1 obtained from okadaic acid-treated cells had a reduced capacity to be phosphorylated by insulin receptors and, concomitantly, to bind PI and kinase, Taken together these data suggest that serine/threonine phosphorylation of IRS 1 induced by okadaic acid reduces the ability of the insulin receptor to phosphorylate IRS 1 and to dock one of its interacting molecules, i.e. PI 3-kinase. Finally, the inhibitory effect of okadaic acid on the stimulatory action of insulin on glucose transport suggests that the serine/threonine phosphorylation of IRS 1 might represent a key regulatory mechanism of insulin action.			TANTI, JF (corresponding author), FAC MED NICE,INST NATL SANT & RECH MED,U 145,AVE VALOMBROSE,F-06107 NICE 02,FRANCE.			Tanti, Jean-Francois/0000-0003-1782-1318				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BARON V, 1992, J BIOL CHEM, V267, P23290; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; BROWN NA, 1993, BIOCHEMISTRY-US, V32, P4659, DOI 10.1021/bi00068a025; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CORVERA S, 1991, J BIOL CHEM, V266, P9271; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DOWNING JR, 1991, MOL CELL BIOL, V11, P2489, DOI 10.1128/MCB.11.5.2489; EGAN SE, 1993, SCIENCE, V363, P45; FOLLI F, 1992, J BIOL CHEM, V267, P22171; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GIORGETTI S, 1992, EUR J BIOCHEM, V207, P599; GIORGINO F, 1992, ENDOCRINOLOGY, V130, P1433, DOI 10.1210/en.130.3.1433; GIORGINO F, 1993, J CLIN INVEST, V91, P2020, DOI 10.1172/JCI116424; HARING H, 1986, BIOCHEM J, V234, P59; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HESS SL, 1991, J CELL BIOCHEM, V45, P374, DOI 10.1002/jcb.240450411; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; JULLIEN D, 1993, J BIOL CHEM, V268, P15246; KEATING MT, 1988, J BIOL CHEM, V263, P12805; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MIRALPEIX M, 1992, BIOCHEMISTRY-US, V31, P9031, DOI 10.1021/bi00152a046; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SHISHEVA A, 1991, ENDOCRINOLOGY, V129, P2279; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STADTMAUER L, 1986, J BIOL CHEM, V261, P3402; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; TANTI JF, 1991, J BIOL CHEM, V266, P2099; TANTI JF, 1987, BIOCHEM J, V245, P19, DOI 10.1042/bj2450019; TANTI JF, 1993, AM J PHYSIOL, V265, pE868; WHITE MF, 1987, J BIOL CHEM, V262, P9769; YU KT, 1987, J BIOL CHEM, V262, P16677	51	262	273	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6051	6057						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119950				2022-12-27	WOS:A1994MY84000087
J	WITTUNG, P; NORDEN, B; KIM, SK; TAKAHASHI, M				WITTUNG, P; NORDEN, B; KIM, SK; TAKAHASHI, M			INTERACTIONS BETWEEN DNA-MOLECULES BOUND TO RECA FILAMENT - EFFECTS OF BASE COMPLEMENTARITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LINEAR DICHROISM; STRAND EXCHANGE; GENETIC-RECOMBINATION; ELECTRON-MICROSCOPY; PROTEIN-BINDING; DUPLEX DNA; COMPLEXES; STOICHIOMETRY; ACCESSIBILITY	To gain information about the mechanism of RecA-promoted strand exchange reactions in genetic recombination, we have investigated the environment of and interactions between DNA strands accommodated in complexes with Beck protein. DNA bound in different sites in the Reck filament was tested by adding stoichiometric amounts of DNAs of variable base compositions. For this purpose, poly(dA) labeled by fluorescent benzo(a)pyrenediol epoxide (BPDE), which binds covalently to N-6 of adenine, was used. The fluorescence intensity, anisotropy, and quenching by acrylamide provide information about the DNA environment in the complexes with Reck In the absence of extra DNA, binding of Reck to BPDE-poly(dA) only slightly affects both the intensity of the BPDE fluorescence and the accessibility of BPDE to acrylamide. However, a strongly increased fluorescence anisotropy shows that the mobility of the BPDE fluorophore is restricted in the Reck complex. Binding of a second and third single-stranded DNA to the RecA.BPDE-poly(dA) complex reduces the fluorescence intensity in a manner that depends on base complementarity. The change is large when the second and third DNAs are poly(dT), i.e. complementary to the already bound poly(dA) strand. In such a complex, the accessibility of BPDE to quencher is also reduced. When BPDE-poly(dA) was added as the second or third DNA in the Reck filament, the fluorescence intensity became smaller when the earlier bound DNA was complementary to the added DNA. These results indicate that all three DNA strands are interacting with each other in the Beck filament. BPDE-modified poly(dA) forms a duplex with poly(dT), whereupon the fluorescence of BPDE is strongly decreased. Binding of Reck to this duplex DNA increases the BPDE fluorescence, suggesting a destabilization of the duplex. Finally, we also find indications of base complementary interactions between single-stranded and double-stranded DNAs bound to the Beck filament.	YEUNGNAM UNIV,DEPT CHEM,KYOUNG BUK 712749,SOUTH KOREA; UNIV PARIS 11,INST CURIE,ETUD MUTAGENESE & CANCEROGENESE GRP,CNRS,URA 1342,F-91405 ORSAY,FRANCE	Yeungnam University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	WITTUNG, P (corresponding author), CHALMERS UNIV TECHNOL,DEPT PHYS CHEM,S-41296 GOTHENBURG,SWEDEN.		Norden, Bengt/ABE-3675-2020; wittung-stafshede, pernilla/AAV-4392-2021	Norden, Bengt/0000-0002-7946-200X; wittung-stafshede, pernilla/0000-0003-1058-1964				Cantor C.R., 1980, BIOPHYS CHEM; CHABBERT M, 1991, J BIOL CHEM, V266, P5395; CHOW SA, 1988, J BIOL CHEM, V263, P3335; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; DICAPUA E, 1987, EMBO J, V6, P2493, DOI 10.1002/j.1460-2075.1987.tb02531.x; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; EGELMAN EH, 1993, CURR OPIN STRUC BIOL, V3, P189, DOI 10.1016/S0959-440X(05)80151-4; GEACINTOV NE, 1990, MOL BASIS SPECIFICIT, P433; GRIFFITH JD, 1988, CRC CR REV BIOCH MOL, V23, pS43, DOI 10.3109/10409238809083375; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; KIM SK, 1988, BASIC LIFE SCI, V51, P187; KUBISTA M, 1990, J BIOL CHEM, V265, P18891; KURAMITSU S, 1981, J BIOCHEM-TOKYO, V90, P1033, DOI 10.1093/oxfordjournals.jbchem.a133555; LEAHY MC, 1986, J BIOL CHEM, V261, P6954; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; MULLER B, 1990, J MOL BIOL, V212, P97, DOI 10.1016/0022-2836(90)90307-8; NORDEN B, 1992, J MOL BIOL, V226, P1175, DOI 10.1016/0022-2836(92)91060-3; OGAWA T, 1993, SCIENCE, V259, P1892; PUGH BF, 1989, J MOL BIOL, V205, P487, DOI 10.1016/0022-2836(89)90219-2; PUGH BF, 1987, J BIOL CHEM, V262, P1337; RADDING CM, 1991, J BIOL CHEM, V266, P5355; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SMITH GR, 1989, CELL, V58, P807, DOI 10.1016/0092-8674(89)90929-X; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; TAKAHASHI M, 1991, FEBS LETT, V279, P270, DOI 10.1016/0014-5793(91)80165-Y; TAKAHASHI M, 1989, EUR J BIOCHEM, V183, P617, DOI 10.1111/j.1432-1033.1989.tb21091.x; TAKAHASHI M, 1989, J MOL BIOL, V205, P137, DOI 10.1016/0022-2836(89)90371-9; TAKAHASHI M, 1991, BIOCHIMIE, V73, P219, DOI 10.1016/0300-9084(91)90205-F; TAKAHASHI M, 1989, J BIOL CHEM, V264, P288; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WILLIAMS RC, 1986, J MOL BIOL, V187, P109, DOI 10.1016/0022-2836(86)90410-9	33	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5799	5803						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119921				2022-12-27	WOS:A1994MY84000051
J	AMIN, J; FERNANDEZ, M; ANANTHAN, J; LIS, JT; VOELLMY, R				AMIN, J; FERNANDEZ, M; ANANTHAN, J; LIS, JT; VOELLMY, R			COOPERATIVE FINDING OF HEAT-SHOCK TRANSCRIPTION FACTOR TO THE HSP70 PROMOTER IN-VIVO AND IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; NUCLEAR FACTOR-I; DROSOPHILA-MELANOGASTER; BINDING-SITES; TATA BOX; 70 GENE; SEQUENCE; UPSTREAM; ELEMENTS; PROTEIN	The minimal promoter of the Drosophila hsp70 gene contains a TATA box and two nonidentical HSE sequences, HSEI and HSEII that synergistically activate the promoter. We have examined stereospecific alignment and spatial constraints in this promoter. Similar to deletion of HSEII, insertion in the spacer between the HSEs of 1 to 5 or 11 to 14 nucleotides (nt) reduced promoter activity to about 10%. In contrast, HSEII was capable of contributing to promoter activity when the spacer was either shortened by 2 or 4 nt or extended by 6 to 10 or 16 or 18 nt. Hence, half of the possible helical arrangements of HSEs are compatible, whereas the other half are essentially incompatible with efficient promoter function. HSEII was ineffective when its distance to HSEI was increased by more than 18 nt. In vitro, HSEII is a weak and HSEI a strong binding site for heat shock transcription factor HSF, and HSF binds to HSEII cooperatively. To find out whether the above periodicity reflects cooperative binding of HSF in vivo or represents the need of stereoalignment for synergistic activation of transcription, the weak HSF binding site HSEII was replaced with the strong binding site HSEI. This substitution greatly attenuated promoter periodicity, suggesting that the periodic effects are caused by cooperative binding of HSF to HSEII, and that stereoalignment of HSEs is not required for transcription activation. In agreement, in vitro assays using spacer mutants revealed cooperative binding of purified, recombinant HSF to HSEII with a similar periodicity as observed in vivo. Changing the distance between TATA and the HSEs did not produce promoter periodicity, indicating that stereoalignment of these elements is not important.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,MIAMI,FL 33101	Cornell University; University of Miami			Amin, Jahanshah/I-7174-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025232, R37GM025232] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31125, GM25232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; AMIN J, 1985, MOL CELL BIOL, V5, P197, DOI 10.1128/MCB.5.1.197; AMIN J, 1987, MOL CELL BIOL, V7, P1055, DOI 10.1128/MCB.7.3.1055; ASHBURNER M, 1979, CELL, V17, P241, DOI 10.1016/0092-8674(79)90150-8; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BUETTI E, 1989, NUCLEIC ACIDS RES, V17, P3065, DOI 10.1093/nar/17.8.3065; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; CHOW KL, 1991, P NATL ACAD SCI USA, V88, P1301, DOI 10.1073/pnas.88.4.1301; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; COHEN RS, 1988, NATURE, V332, P856, DOI 10.1038/332856a0; CORCES V, 1981, P NATL ACAD SCI-BIOL, V78, P7038, DOI 10.1073/pnas.78.11.7038; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; DUDLER R, 1984, CELL, V38, P391, DOI 10.1016/0092-8674(84)90494-X; DUNN TM, 1984, P NATL ACAD SCI-BIOL, V81, P5017, DOI 10.1073/pnas.81.16.5017; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GILMOUR DS, 1985, MOL CELL BIOL, V5, P2009, DOI 10.1128/MCB.5.8.2009; GILMOUR DS, 1986, MOL CELL BIOL, V6, P3984, DOI 10.1128/MCB.6.11.3984; GLASER RL, 1990, J MOL BIOL, V211, P751, DOI 10.1016/0022-2836(90)90075-W; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; KNOX JJ, 1991, MOL CELL BIOL, V11, P2946, DOI 10.1128/MCB.11.6.2946; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; LENNARD AC, 1989, NUCLEIC ACIDS RES, V17, P6903, DOI 10.1093/nar/17.17.6903; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; MIRAULT ME, 1982, EMBO J, V1, P1279, DOI 10.1002/j.1460-2075.1982.tb00025.x; NOVER L, 1984, BIOL ZBL, V103, P357; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; PARKER CS, 1984, CELL, V37, P273, DOI 10.1016/0092-8674(84)90323-4; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; RUDEN DM, 1988, P NATL ACAD SCI USA, V85, P4262, DOI 10.1073/pnas.85.12.4262; Sambrook J, 1989, MOL CLONING LABORATO; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; Schlesinger M. J., 1982, HEAT SHOCK BACTERIA; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; TOPOL J, 1985, CELL, V42, P527, DOI 10.1016/0092-8674(85)90110-2; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; WU C, 1984, NATURE, V309, P229, DOI 10.1038/309229a0; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; WU L, 1988, GENE DEV, V2, P403, DOI 10.1101/gad.2.4.403; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608; XIAO H, 1991, CELL, V64, P585, DOI 10.1016/0092-8674(91)90242-Q	54	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4804	4811						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106450				2022-12-27	WOS:A1994MX57100019
J	ARGAET, VP; WILSON, T; DAVIDSON, BE				ARGAET, VP; WILSON, T; DAVIDSON, BE			PURIFICATION OF THE ESCHERICHIA-COLI REGULATORY PROTEIN TYRR AND ANALYSIS OF ITS INTERACTIONS WITH ATP, TYROSINE, PHENYLALANINE, AND TRYPTOPHAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T7 RNA-POLYMERASE; NUCLEOTIDE-SEQUENCE; BINDING-PROTEIN; TRANSCRIPTION; GENE; K-12; REPRESSOR; EXPRESSION; OPERATOR; CHROMATOGRAPHY	A plasmid that directs the overexpression of the Escherichia coli regulatory protein TyrR was constructed. Cell extracts of an E. coli strain harboring the plasmid were used to develop a two-step procedure for purifying homogenous TyrR. The weight-average molecular weight of the pure protein was determined by sedimentation equilibrium analyses to be 110,000 +/- 5,000, indicating that native TyrR is a homodimer. The binding of ligands to TyrR was investigated by the techniques of sedimentation velocity meniscus depletion and steady state dialysis. One mol of ATP bound per mol of TyrR subunit with half-maximal saturation at 5-7 mu M ATP. ATP binding curves exhibited positive cooperativity, with a value of 1.3 for the Hill constant, n(H). The binding was not significantly affected by the presence of either 500 mu M tyrosine or 2 mM phenylalanine. Binding of tyrosine to TyrR (40 mu M subunit) could not be detected in the absence of ATP, indicating that the TyrR-tyrosine complex has a dissociation constant (K-d) in excess of 180 mu M. However, binding was observed in the presence of saturating ATP (200 mu M), where 1 mol of tyrosine bound per mol of TyrR subunit with half-maximal saturation at 50 mu M tyrosine. The binding exhibited positive cooperativity (n(H) of 1.2). There was no detectable binding of either phenylalanine or tryptophan to TyrR (40 mu M) in the absence or presence of 200 mu M ATP, indicating that any binding of these amino acids to TyrR or TyrR.ATP also has a Rd in excess of 180 mu M. Each of these amino acids was found to inhibit the binding of tyrosine by TyrR.ATP when present in large molar excess (20 mu M tyrosine and 2 or 10 mM phenylalanine or tryptophan), indicating that TyrR binds each of these amino acids, albeit more weakly than it binds tyrosine.	UNIV MELBOURNE,RUSSELL GRIMWADE SCH BIOCHEM,PARKVILLE,VIC 3052,AUSTRALIA	University of Melbourne								ANDERSON WF, 1981, NATURE, V290, P754, DOI 10.1038/290754a0; ARGYROPOULOS VP, 1989, THESIS U MELBOURNE; ARGYROPOULOS VP, 1988, P AUST BIOCHEM SOC, V20, pSP34; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; BALDWIN GS, 1981, ARCH BIOCHEM BIOPHYS, V211, P76, DOI 10.1016/0003-9861(81)90431-8; BASEGGIO N, 1990, J BACTERIOL, V172, P2547, DOI 10.1128/jb.172.5.2547-2557.1990; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BORCK K, 1976, MOL GEN GENET, V146, P199, DOI 10.1007/BF00268089; BROWN KD, 1968, GENETICS, V60, P31; BROWN KD, 1970, J BACTERIOL, V104, P177, DOI 10.1128/JB.104.1.177-188.1970; CAMAKARIS H, 1982, J BACTERIOL, V150, P70, DOI 10.1128/JB.150.1.70-75.1982; CAMAKARIS J, 1974, J BACTERIOL, V120, P590, DOI 10.1128/JB.120.2.590-597.1974; CAMPBELL JL, 1978, P NATL ACAD SCI USA, V75, P2276, DOI 10.1073/pnas.75.5.2276; CHYE ML, 1987, J BACTERIOL, V169, P386, DOI 10.1128/jb.169.1.386-393.1987; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; CORNISH EC, 1982, J BACTERIOL, V152, P1276; CORNISH EC, 1986, J BIOL CHEM, V261, P403; CUI JS, 1993, J BIOL CHEM, V268, P13023; CUI JS, 1993, J BIOL CHEM, V268, P5040; DUDZINSKI PK, 1976, PREP BIOCHEM, V6, P113, DOI 10.1080/00327487608061606; DUSHA I, 1976, BIOCHIM BIOPHYS ACTA, V438, P563, DOI 10.1016/0005-2744(76)90272-2; FOLKMANIS A, 1976, P NATL ACAD SCI USA, V73, P2249, DOI 10.1073/pnas.73.7.2249; GARNER CC, 1985, J BIOL CHEM, V260, P3820; GAVINI N, 1991, J BIOL CHEM, V266, P7750; GETHING MJ, 1978, EUR J BIOCHEM, V86, P165, DOI 10.1111/j.1432-1033.1978.tb12296.x; GETHING MJH, 1976, EUR J BIOCHEM, V71, P317, DOI 10.1111/j.1432-1033.1976.tb11118.x; GIBSON F, 1968, BIOCHEM PREP, V12, P94; GREGO B, 1985, EUR J BIOCHEM, V148, P485, DOI 10.1111/j.1432-1033.1985.tb08865.x; HEATWOLE VM, 1991, J BACTERIOL, V173, P108, DOI 10.1128/jb.173.1.108-115.1991; HENIKOFF S, 1988, NUCLEIC ACIDS RES, V16, P6191, DOI 10.1093/nar/16.13.6191; Hershey JW., 1987, ESCHERICHIA COLI SAL, P613; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; HOWLETT GJ, 1978, ARCH BIOCHEM BIOPHYS, V190, P809, DOI 10.1016/0003-9861(78)90341-7; HUDSON GS, 1983, J BIOL CHEM, V258, P3114; HUDSON GS, 1984, J MOL BIOL, V180, P1023, DOI 10.1016/0022-2836(84)90269-9; ITO J, 1969, J BACTERIOL, V97, P734, DOI 10.1128/JB.97.2.734-742.1969; JOACHIMIAK A, 1983, P NATL ACAD SCI-BIOL, V80, P668, DOI 10.1073/pnas.80.3.668; KASIAN PA, 1986, J BACTERIOL, V167, P556, DOI 10.1128/jb.167.2.556-561.1986; KASIAN PA, 1987, THESIS U MELBOURNE V; Miller J.H., 1972, EXPT MOL GENETICS; MOFFATT BA, 1987, CELL, V49, P221, DOI 10.1016/0092-8674(87)90563-0; MUDAY GK, 1991, J BACTERIOL, V173, P3930, DOI 10.1128/JB.173.12.3930-3932.1991; PITTARD AJ, 1991, MOL MICROBIOL, V5, P1585, DOI 10.1111/j.1365-2958.1991.tb01904.x; PITTARD AJ, 1987, ESCHERICHIA COLI SAL, P368; RANDERATH K, 1966, J CHROMATOGR, V22, P110, DOI 10.1016/S0021-9673(01)97076-1; REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6; RODRIGUEZ R, 1976, MOL MECHANISMS CONTR; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J, 1989, MOL CLONING LABORATO; SARSERO JP, 1991, J BACTERIOL, V1734, P133; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIMPSON RJ, 1971, J BACTERIOL, V107, P798, DOI 10.1128/JB.107.3.798-805.1971; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VIDALINGIGLIARDI D, 1985, NUCLEIC ACIDS RES, V13, P5919, DOI 10.1093/nar/13.16.5919; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WHIPP MJ, 1977, J BACTERIOL, V132, P453, DOI 10.1128/JB.132.2.453-461.1977; YANG J, 1993, J BACTERIOL, V175, P1767, DOI 10.1128/JB.175.6.1767-1776.1993; YANOFSKY C, 1984, J BACTERIOL, V158, P1018, DOI 10.1128/JB.158.3.1018-1024.1984; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; ZAMYATNIN AA, 1972, PROG BIOPHYS MOL BIO, V24, P109	62	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5171	5178						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106498				2022-12-27	WOS:A1994MX57100075
J	CHAPMAN, AB; AGABIAN, N				CHAPMAN, AB; AGABIAN, N			TRYPANOSOMA-BRUCEI RNA-POLYMERASE-II IS PHOSPHORYLATED IN THE ABSENCE OF CARBOXYL-TERMINAL DOMAIN HEPTAPEPTIDE REPEATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGEST SUBUNIT GENES; MESSENGER-RNAS; TRANSCRIPTION UNIT; POLYCISTRONIC TRANSCRIPTION; SACCHAROMYCES-CEREVISIAE; RIBOSOMAL-RNA; T-BRUCEI; VSG GENE; INITIATION; KINASE	Formation of an RNA polymerase II transcription initiation complex requires binding of a polymerase that contains a non-phosphorylated largest subunit carboxyl-terminal domain (CTD). Polymerase binding is followed by elongation after phosphorylation of the CTD by a CTD kinase. Phosphorylation sites are within the repeating heptapeptide motifs which characterize the CTD of all eukaryotic RNA polymerase IIs. In contrast to all other eukaryotes studied, the trypanosome genome contains two genetic loci which encode the large subunit of RNA polymerase II; both genes lack CTD heptapeptide repeat structures. We have examined whether Trypanosoma brucei RNA polymerase II, despite its unique CTD domain, is phosphorylated when isolated from elongating transcription complexes. Elongating trypanosome RNA polymerases were photoaffinity labeled during nuclear run-on assays. The identity of the labeled proteins was established by immunoblotting and immunoprecipitation using polymerase-specific antisera, Analysis of the largest subunit of RNA polymerase II revealed the expected 195-kDa species and an additional larger 220-kDa species. The apparent molecular weight of this larger form of RNA polymerase II decreased incrementally as a function of incubation with increasing concentrations of calf intestinal phosphatase. These results show that extensive phosphorylation of the largest subunit of RNA polymerase-II is a conserved feature between trypanosomes and higher eukaryotes despite the absence of a typical CTD domain.	UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INTERCAMPUS PROGRAM MOLEC PARASITOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	CHAPMAN, AB (corresponding author), UNIV CALIF BERKELEY,INTERCAMPUS PROGRAM MOLEC PARASITOL,BERKELEY,CA 94720, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021975] Funding Source: NIH RePORTER; NIAID NIH HHS [AI00986, AI21975] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDRE S, 1988, MOL CELL BIOL, V8, P2367, DOI 10.1128/MCB.8.6.2367; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ALTSCHUL SF, 1986, B MATH BIOL, V48, P603, DOI 10.1016/S0092-8240(86)90010-8; AMAR MFB, 1991, NUCLEIC ACIDS RES, V19, P5857; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHRISTMANN JL, 1981, J BIOL CHEM, V256, P1798; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CLAYTON CE, 1990, MOL CELL BIOL, V10, P3036, DOI 10.1128/MCB.10.6.3036; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DAHMUS ME, 1983, J BIOL CHEM, V258, P2303; DVIR A, 1993, J BIOL CHEM, V268, P10440; EVERS R, 1990, NUCLEIC ACIDS RES, V18, P5089, DOI 10.1093/nar/18.17.5089; EVERS R, 1989, CELL, V56, P585, DOI 10.1016/0092-8674(89)90581-3; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; GILEADI O, 1992, SCIENCE, V257, P2389; GRONDAL EJM, 1989, EMBO J, V8, P3383, DOI 10.1002/j.1460-2075.1989.tb08502.x; HARLOW E, 1988, ANTIBODIES LABORATOR; IMBODEN MA, 1987, NUCLEIC ACIDS RES, V15, P7357, DOI 10.1093/nar/15.18.7357; JESS W, 1989, FEBS LETT, V249, P123, DOI 10.1016/0014-5793(89)80029-8; JESS W, 1990, CURR GENET, V18, P547, DOI 10.1007/BF00327026; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KOCK J, 1988, NUCLEIC ACIDS RES, V16, P8753, DOI 10.1093/nar/16.18.8753; KOOTER JM, 1984, NUCLEIC ACIDS RES, V12, P9457, DOI 10.1093/nar/12.24.9457; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD PW, 1987, EMBO J, V6, P1055, DOI 10.1002/j.1460-2075.1987.tb04858.x; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MOYLE M, 1989, MOL CELL BIOL, V9, P5750, DOI 10.1128/MCB.9.12.5750; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PAYNE JM, 1993, J BIOL CHEM, V268, P80; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; RUDENKO G, 1989, EMBO J, V8, P4259, DOI 10.1002/j.1460-2075.1989.tb08611.x; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHWARTZ LB, 1975, J BIOL CHEM, V250, P3221; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SHEA C, 1987, CELL, V50, P603, DOI 10.1016/0092-8674(87)90033-X; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH JL, 1989, CELL, V56, P815, DOI 10.1016/0092-8674(89)90686-7; SMITH JL, 1989, J BIOL CHEM, V264, P18091; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; STONE N, 1992, J BIOL CHEM, V267, P6353; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; TSCHUDI C, 1988, EMBO J, V7, P455, DOI 10.1002/j.1460-2075.1988.tb02833.x; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; ZHANG J, 1991, J BIOL CHEM, V266, P2290	62	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4754	4760						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106443				2022-12-27	WOS:A1994MX57100012
J	LEHEL, C; OLAH, Z; MISCHAK, H; MUSHINSKI, JF; ANDERSON, WB				LEHEL, C; OLAH, Z; MISCHAK, H; MUSHINSKI, JF; ANDERSON, WB			OVEREXPRESSED PROTEIN-KINASE C-DELTA AND C-EPSILON SUBTYPES IN NIH 3T3 CELLS EXHIBIT DIFFERENTIAL SUBCELLULAR-LOCALIZATION AND DIFFERENTIAL REGULATION OF SODIUM-DEPENDENT PHOSPHATE-UPTAKE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LLC-PK1 CELLS; PKC-EPSILON; RAT-BRAIN; EXPRESSION; COTRANSPORT; ACTIVATION; CDNA; SPECIFICITY; STIMULATION; MECHANISMS	To examine the biological properties of protein kinase C (PHC)-delta and -epsilon NIH 3T3 cells were stably transfected with metallothionein-based expression vectors that overexpressed these isoforms. In addition to their inducibility by Zn2+, the protein levels of these two PKC subtypes, but not that of endogenous PKC-alpha, increased with increasing cell density. An unexpected role for Mg2+ in the subcellular localization of PKC-delta was found. This isoenzyme was predominantly membrane-associated when cell fractionation was carried out in the absence of Mg2+ but cytosolic when the fractionation was performed in the presence of 10 mM Mg2+. In contrast, the predominant localization of cytosolic PKC-alpha and of membrane-associated PKC-epsilon was not influenced by Mg2+. In vivo and in vitro studies of [H-3]phorbol 12,13-dibutyrate binding in the overexpressing cell lines confirmed the cytosolic localization of PHC-alpha, the membrane-associated state of PHC-epsilon, and the presence of PKC-delta at both locations. Readdition of serum for 5 min to serum-starved, quiescent cell lines initiated the redistribution of PKC-alpha to the particulate fraction, while the location of PKC-delta and PKC-epsilon was not affected. Zn2+-induced overexpression of PKC-delta- and PKC-epsilon-stimulated sodium dependent phosphate uptake. Overexpression of PKC-delta caused an increase in the V-max of Na+/P-i uptake, while overexpression of PKC-epsilon resulted in a decrease in K-m, for orthophosphate. A further stimulation of Na+/P-i uptake in the overexpressing cells could be achieved by phorbol ester activation of endogenous PKC-alpha. These results suggest that each of the three PKC isotypes contribute to the regulation of sodium-dependent phosphate uptake, but through distinct mechanisms.	NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892; NCI,GENET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Mischak, Harald/E-8685-2011	Mischak, Harald/0000-0003-0323-0306				BAXTER G, 1992, J BIOL CHEM, V267, P1910; EXTON JH, 1990, J BIOL CHEM, V265, P1; GROSS JL, 1991, ANAL BIOCHEM, V193, P149, DOI 10.1016/0003-2697(91)90055-X; GUSOVSKY F, 1991, MOL PHARMACOL, V39, P124; HEIDENREICH KA, 1990, J BIOL CHEM, V265, P15076; HILBORN DA, 1975, J CELL PHYSL, V87, P111; HOMAN EC, 1991, J BIOL CHEM, V266, P5676; HUANG K-P, 1990, Biofactors, V2, P171; HUBBARD SR, 1991, SCIENCE, V254, P1776; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KINOSHITA Y, 1987, BIOCHEM BIOPH RES CO, V144, P741, DOI 10.1016/S0006-291X(87)80027-X; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; LEACH KL, 1983, P NATL ACAD SCI-BIOL, V80, P4208, DOI 10.1073/pnas.80.14.4208; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; MOHRMANN I, 1986, BIOCHIM BIOPHYS ACTA, V860, P35, DOI 10.1016/0005-2736(86)90495-5; MURER H, 1991, AM J PHYSIOL, V260, pC885, DOI 10.1152/ajpcell.1991.260.5.C885; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OLAH Z, 1993, BIOCHIM BIOPHYS ACTA, V1176, P333, DOI 10.1016/0167-4889(93)90063-U; OLAH Z, 1990, NEUROCHEM RES, V15, P515, DOI 10.1007/BF00966209; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; PEARS C, 1991, BIOCHEM J, V276, P257, DOI 10.1042/bj2760257; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; QUAMME G, 1989, AM J PHYSIOL, V257, pF967, DOI 10.1152/ajprenal.1989.257.6.F967; RAYMOND JR, 1989, J BIOL CHEM, V264, P21943; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SHARMA P, 1991, BIOCHEM BIOPH RES CO, V177, P1033, DOI 10.1016/0006-291X(91)90642-K; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608	36	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4761	4766						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106444				2022-12-27	WOS:A1994MX57100013
J	ISSAKIDIS, E; SAARINEN, M; DECOTTIGNIES, P; JACQUOT, JP; CRETIN, C; GADAL, P; MIGINIACMASLOW, M				ISSAKIDIS, E; SAARINEN, M; DECOTTIGNIES, P; JACQUOT, JP; CRETIN, C; GADAL, P; MIGINIACMASLOW, M			IDENTIFICATION AND CHARACTERIZATION OF THE 2ND REGULATORY DISULFIDE BRIDGE OF RECOMBINANT SORGHUM LEAF NADP-MALATE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PHENOTYPIC SELECTION; LIGHT-ACTIVATION; THIOREDOXIN; SEQUENCE; FERREDOXIN; REFINEMENT; ENZYMES; SYSTEM	Unique among malate dehydrogenases, the NADP-dependent chloroplastic form undergoes a reductive activation in the light. This process is thioredoxin-mediated and involves at least two disulfides. Only one of them, situated near the N terminus, has been localized. The enzyme also bears 2 cysteines at the C terminus. The possible role of these cysteines was investigated by replacing them separately, or together, by alanines, by site-directed mutagenesis. The proteins altered at the C terminus were still dithiol-dependent for full activation, with activation kinetics similar to those of the wild type enzyme. However, they exhibited a weak activity in the oxidized form with a dramatically increased K(m) for oxalacetate. Their activation was not inhibited by NADP. When C-terminal Cys mutations were combined with N-terminal Cys mutations, permanently active, thioredoxin-independent enzymes were obtained. They exhibited the biochemical properties of the activated wild type protein. Clearly, the 2 C-terminal cysteines constitute the second thioredoxin-dependent regulatory disulfide of NADP-malate dehydrogenase. Integrating our data about the characteristics of each of the regulatory disulfides and information from three-dimensional structure modeling, we propose a model for the redox control of NADP-malate dehydrogenase.	UNIV PARIS 11,PHYSIOL VEGETALE MOLEC LAB,CNRS,UNITE 1128,BAT 430,F-91405 ORSAY,FRANCE; UPPSALA BIOMED CTR,S-75124 UPPSALA,SWEDEN	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			; Jacquot, Jean-Pierre/A-1571-2012	Issakidis-Bourguet, Emmanuelle/0000-0002-6144-4364; Jacquot, Jean-Pierre/0000-0003-4975-8587				AGOSTINO A, 1992, PLANT PHYSIOL, V98, P1506, DOI 10.1104/pp.98.4.1506; BIRKTOFT JJ, 1989, BIOCHEMISTRY-US, V28, P6065, DOI 10.1021/bi00440a051; BIRKTOFT JJ, 1983, J BIOL CHEM, V258, P472; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUCHANAN BB, 1991, ARCH BIOCHEM BIOPHYS, V288, P1, DOI 10.1016/0003-9861(91)90157-E; CRETIN C, 1990, EUR J BIOCHEM, V192, P299, DOI 10.1111/j.1432-1033.1990.tb19227.x; DECOTTIGNIES P, 1988, J BIOL CHEM, V263, P11780; DECOTTIGNIES P, 1991, EUR J BIOCHEM, V198, P505, DOI 10.1111/j.1432-1033.1991.tb16043.x; DROUX M, 1987, ARCH BIOCHEM BIOPHYS, V256, P372, DOI 10.1016/0003-9861(87)90458-9; FICKENSCHER K, 1988, ARCH BIOCHEM BIOPHYS, V260, P771, DOI 10.1016/0003-9861(88)90507-3; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HATCH MD, 1992, PLANT PHYSIOL, V100, P360, DOI 10.1104/pp.100.1.360; ISSAKIDIS E, 1993, FEBS LETT, V321, P55, DOI 10.1016/0014-5793(93)80620-A; ISSAKIDIS E, 1992, J BIOL CHEM, V267, P21577; JACKSON RM, 1992, J COMPUT AID MOL DES, V6, P1, DOI 10.1007/BF00124383; JACQUOT JP, 1983, THESIS PARIS 11 U OR, P199; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMPFENKEL K, 1992, BIOCHIM BIOPHYS ACTA, V1156, P71, DOI 10.1016/0304-4165(92)90098-F; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; METZLER MC, 1989, PLANT MOL BIOL, V12, P713, DOI 10.1007/BF00044162; MIGINIACMASLOW M, 1990, BIOCHIM BIOPHYS ACTA, V1017, P273, DOI 10.1016/0005-2728(90)90193-8; MIGINIACMASLOW M, 1992, RES PHOTOSYNTHESIS, V3, P705; MILANEZ S, 1991, J BIOL CHEM, V266, P10694; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NISHIYAMA M, 1993, J BIOL CHEM, V268, P4656; OCHERETINA O, 1992, RES PHOTOSYNTHESIS, V2, P587; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIBE R, 1983, PLANTA, V157, P548, DOI 10.1007/BF00396887; SCHEIBE R, 1993, ARCH BIOCHEM BIOPHYS, V300, P635, DOI 10.1006/abbi.1993.1088; SCHURMANN P, 1979, BIOCHIM BIOPHYS ACTA, V569, P309, DOI 10.1016/0005-2744(79)90067-6; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WOOD DC, 1981, J BIOL CHEM, V256, P2377	36	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3511	3517						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106392				2022-12-27	WOS:A1994MV63100059
J	JINDAL, HK; YONG, CB; WILSON, GM; TAM, P; ASTELL, CR				JINDAL, HK; YONG, CB; WILSON, GM; TAM, P; ASTELL, CR			MUTATIONS IN THE NTP-BINDING MOTIF OF MINUTE VIRUS OF MICE (MVM) NS-1 PROTEIN UNCOUPLE ATPASE AND DNA HELICASE FUNCTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-T-PROTEINS; TRANS-ACTIVATION; AUTONOMOUS PARVOVIRUS; SIMIAN VIRUS-40; P38 PROMOTER; NONSTRUCTURAL PROTEIN; MAMMALIAN-CELLS; SV40 VIRUSES; TRANSCRIPTION; REPLICATION	The NS-1 protein of minute virus of mice (MVM) is required for viral DNA replication and transcriptional regulation. To define the domain structure of NS-1 we have generated point mutations in its putative NTP-binding/ATPase domain. We show that all mutants were unable to support replication of MVM DNA in a transient DNA replication assay. Furthermore, all mutants, except for the K405S substitution, were able to transactivate the P38 promoter in transient transfection experiments. NS-1 proteins bearing COOH-terminal deletions of 29 and 33 amino acid residues were also transcriptionally inert. Biochemical analysis of recombinant NS-1 expressed in insect cells shows that mutations in the putative NTP-binding/ATPase domain severely reduced helicase activity in vitro. However, affinity labeling experiments indicate that none of these mutations, except for K469T, impaired NTP-binding activity. Finally, all point mutants retained significant levels of ATPase activity, except for the E444Q mutant (1%). These findings suggest that the replication and transcription activities of NS-1 reside in separate functional domains. In addition, NS-1 proteins with mutations in the putative nucleotide binding fold have lost helicase activity, whereas most retain nucleotide binding and ATPase functions, suggesting that the mutations have uncoupled the ATPase and helicase activities.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia			Wilson, Gerald/AAF-3874-2019					AHN JK, 1992, J VIROL, V66, P3776, DOI 10.1128/JVI.66.6.3776-3783.1992; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ASTELL CR, 1985, J VIROL, V54, P171, DOI 10.1128/JVI.54.1.171-177.1985; ASTELL CR, 1987, J GEN VIROL, V68, P885, DOI 10.1099/0022-1317-68-3-885; BRADLEY MK, 1984, P NATL ACAD SCI-BIOL, V81, P6574, DOI 10.1073/pnas.81.21.6574; BRADLEY MK, 1987, P NATL ACAD SCI USA, V84, P4026, DOI 10.1073/pnas.84.12.4026; BRADLEY MK, 1990, J VIROL, V64, P4939, DOI 10.1128/JVI.64.10.4939-4947.1990; BRANDENBURGER A, 1990, VIROLOGY, V174, P576, DOI 10.1016/0042-6822(90)90110-D; CAILLETFAUQUET P, 1990, EMBO J, V9, P2989, DOI 10.1002/j.1460-2075.1990.tb07491.x; CLERTANT P, 1982, J BIOL CHEM, V257, P6300; CLERTANT P, 1984, J BIOL CHEM, V259, P5196; COTMORE SF, 1992, J VIROL, V66, P420, DOI 10.1128/JVI.66.1.420-431.1992; COTMORE SF, 1986, VIRUS RES, V4, P243, DOI 10.1016/0168-1702(86)90003-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOERIG C, 1988, J GEN VIROL, V69, P2563, DOI 10.1099/0022-1317-69-10-2563; DOERIG C, 1990, J VIROL, V64, P387, DOI 10.1128/JVI.64.1.387-396.1990; GILL G, 1990, P NATL ACAD SCI USA, V87, P2127, DOI 10.1073/pnas.87.6.2127; GORBALENYA AE, 1990, FEBS LETT, V262, P145, DOI 10.1016/0014-5793(90)80175-I; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARRIS C, 1993, IUBMB S NUCLEIC ACID, P24; IM DS, 1990, CELL, V61, P447, DOI 10.1016/0092-8674(90)90526-K; LEGENDRE D, 1992, J VIROL, V66, P5705, DOI 10.1128/JVI.66.10.5705-5713.1992; LI X, 1990, J VIROL, V64, P4654, DOI 10.1128/JVI.64.10.4654-4660.1990; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; MCCARTY DM, 1992, J VIROL, V66, P4050, DOI 10.1128/JVI.66.7.4050-4057.1992; NUESCH JPF, 1992, VIROLOGY, V191, P406; PINTEL D, 1983, NUCLEIC ACIDS RES, V11, P1019, DOI 10.1093/nar/11.4.1019; POSSEE RD, 1987, NUCLEIC ACIDS RES, V15, P10233, DOI 10.1093/nar/15.24.10233; RHODE SL, 1985, J VIROL, V55, P886, DOI 10.1128/JVI.55.3.886-889.1985; RHODE SL, 1987, J VIROL, V61, P2807, DOI 10.1128/JVI.61.9.2807-2815.1987; SKIADOPOULOS MH, 1992, VIROLOGY, V188, P122, DOI 10.1016/0042-6822(92)90741-7; SKIADOPOULOS MH, 1993, VIROLOGY, V194, P509, DOI 10.1006/viro.1993.1289; SNYDER RO, 1990, CELL, V60, P105, DOI 10.1016/0092-8674(90)90720-Y; Summers MD, 1987, TEXAS AGR EXPT STATI; TAM P, 1993, VIROLOGY, V193, P812, DOI 10.1006/viro.1993.1190; TATTERSALL P, 1990, CRC HDB PARVOVIRUSES; TULLIS GE, 1988, J VIROL, V64, P2736; TUTEJA N, 1993, NUCLEIC ACIDS RES, V21, P2325; WEINER BM, 1991, J VIROL, V65, P4973, DOI 10.1128/JVI.65.9.4973-4984.1991; WILSON GM, 1991, VIROLOGY, V185, P90, DOI 10.1016/0042-6822(91)90757-3; YEUNG DE, 1991, VIROLOGY, V181, P35, DOI 10.1016/0042-6822(91)90467-P	41	68	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3283	3289						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106366				2022-12-27	WOS:A1994MV63100027
J	KIM, KS; LEE, MK; CARROLL, J; JOH, TH				KIM, KS; LEE, MK; CARROLL, J; JOH, TH			BOTH THE BASAL AND INDUCIBLE TRANSCRIPTION OF THE TYROSINE-HYDROXYLASE GENE ARE DEPENDENT UPON A CAMP RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; RAT SOMATOSTATIN GENE; NERVE GROWTH-FACTOR; NUCLEAR FACTOR CREB; CYCLIC-AMP; REGULATORY ELEMENTS; FUNCTIONAL-ANALYSIS; ALPHA-SUBUNIT; C-FOS	The cAMP response element (CRE) mediates cAMP responsiveness in many eukaryotic genes (Roesler, W. J., Vandenbark, G. R., and Hansen, R. W. (1988) J. Biol. Chem. 263, 9063-9066). The tyrosine hydroxylase gene (TH) contains a single copy of a consensus CRE at -45 to -38 base pair (bp) upstream of the transcription initiation site. Deletional and mutational analyses of the upstream 2400-base pair region of the rat TH gene using transient transfection assay demonstrated that the CRE was essential for both cAMP-mediated induction and basal transcription of the TH gene. Another domain between -365 and -151 bp, containing the AP1 site, contributed to transcription to a smaller degree. Thus, the CRE appears to play an important dual role as a basal promoter element and an inducible enhancer for TH transcription. Interactions between the DNA binding factors in nuclear extract and CRE-containing oligonucleotides were investigated by gel retardation and competition assays. Oligonucleotides corresponding to the CRE regions of the TH or somatostatin gene gave rise to a pair of distinct protein-DNA complexes with identical mobilities in the gel retardation assay, suggesting that similar nuclear factor(s) might bind to the CREs of the TH and somatostatin genes. This study emphasizes a fundamental role of the CRE in transcriptional activation of the TH gene in catecholaminergic cells.	CORNELL UNIV,COLL MED,BURKE MED RES INST,MOLEC NEUROBIOL LAB,785 MAMARONECK AVE,WHITE PLAINS,NY 10605	Cornell University					NIMH NIH HHS [MH 48866, MH 24285] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH048866, R01MH048866, R37MH024285, R01MH024285] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDRISANI OM, 1987, NUCLEIC ACIDS RES, V15, P5715, DOI 10.1093/nar/15.14.5715; BLACK IB, 1987, SCIENCE, V236, P1263, DOI 10.1126/science.2884727; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; CAMBI F, 1989, J NEUROCHEM, V53, P1656, DOI 10.1111/j.1471-4159.1989.tb08567.x; CARROLL JM, 1991, J MOL NEUROSCI, V3, P65, DOI 10.1007/BF02885527; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DEAN DC, 1989, MOL CELL BIOL, V9, P1498, DOI 10.1128/MCB.9.4.1498; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FADER D, 1990, MOL BRAIN RES, V8, P25, DOI 10.1016/0169-328X(90)90005-X; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FUNG BP, 1992, J NEUROCHEM, V58, P2044, DOI 10.1111/j.1471-4159.1992.tb10945.x; GANDELMAN KY, 1990, J NEUROCHEM, V55, P2149, DOI 10.1111/j.1471-4159.1990.tb05811.x; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HARRINGTON CA, 1987, NUCLEIC ACIDS RES, V15, P2363, DOI 10.1093/nar/15.5.2363; HAWLEY RJ, 1992, J NEUROSCI, V12, P2573; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HUANG ZM, 1991, MOL BRAIN RES, V11, P309, DOI 10.1016/0169-328X(91)90040-5; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; ISHIGURO H, 1993, IN PRESS J BIOL CHEM; JOH TH, 1978, P NATL ACAD SCI USA, V75, P4744, DOI 10.1073/pnas.75.10.4744; KANEDA N, 1991, NEURON, V6, P583, DOI 10.1016/0896-6273(91)90061-4; KIM KS, 1993, P NATL ACAD SCI USA, V90, P3471, DOI 10.1073/pnas.90.8.3471; KOBAYASHI K, 1988, J BIOCHEM, V103, P907, DOI 10.1093/oxfordjournals.jbchem.a122386; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSS RA, 1981, CELL MOL NEUROBIOL, V1, P301, DOI 10.1007/BF00710685; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SHORT S, 1991, J BIOL CHEM, V266, P22164; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; THOENEN H, 1969, J PHARMACOL EXP THER, V169, P249; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	53	206	208	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15689	15695						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8101843				2022-12-27	WOS:A1993LN30500056
J	DOHI, DF; SUTTON, RC; FRAZIER, ML; NAKAMORI, S; MCISAAC, AM; IRIMURA, T				DOHI, DF; SUTTON, RC; FRAZIER, ML; NAKAMORI, S; MCISAAC, AM; IRIMURA, T			REGULATION OF SIALOMUCIN PRODUCTION IN COLON-CARCINOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC EPITHELIAL MUCIN; HUMAN COLORECTAL-CARCINOMA; HUMAN SEMINAL PLASMA; MONOCLONAL-ANTIBODIES; MOLECULAR-WEIGHT; MUCUS GLYCOPROTEINS; DIFFERENTIATION ANTIGENS; N-ACETYLGALACTOSAMINE; EXPRESSION; METASTASES	In this study, we investigated the biochemical basis for the induction of sialomucin production in HT-29 LMM human colon carcinoma cells. Previous studies showed that conditioned medium from organ cultures of normal human colonic connective tissues (NCCM) stimulated the biosynthesis of high molecular weight sialoglycoproteins (M(r) 740,000 and 450,000) by colon carcinoma cells in vitro. Using monoclonal antibodies specific for human milk mucin, we determined that the polypeptide core of these sialomucins was the polymorphic epithelial mucin core peptide coded by the MUC1 gene. Northern analysis showed that cells treated with NCCM expressed a higher level of MUC1 poly(A)+ mRNA than untreated cells. The UDP-GalNAC: polypeptide N-acetylgalactosaminyltransferase activity in microsomal fractions from these cells did not change upon NCCM treatment. The ratios of oligosaccharides with various negative charges secreted by HT-29 LMM cells in the presence of benzyl-alpha-D-N-acetylgalactosaminide were not affected by NCCM treatment indicating that the degree of sialylation of O-linked carbohydrate chains is not influenced by NCCM treatment. [H-3]Glucosamine pulse-chase labeling studies using antibodies specific for a COOH-terminal unglycosylated region of the MUC1 mucin core peptides suggested that NCCM treatment of HT-29 LMM cells did not change the rate of MUC1-related sialomucin processing.	UNIV TOKYO, FAC PHARMACEUT SCI,DIV CHEM TOXICOL & IMMUNOCHEM, HONGO 7-3-1,BUNKYO KU, TOKYO 113, JAPAN; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MED ONCOL, HOUSTON, TX 77030 USA	University of Tokyo; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA050231, R01CA039319] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA50231, R01-CA39319] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARKLIE J, 1981, INT J CANCER, V28, P23, DOI 10.1002/ijc.2910280105; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BURCHELL J, 1983, J IMMUNOL, V131, P508; BURCHELL J, 1987, CANCER RES, V47, P5476; COLCHER D, 1981, P NATL ACAD SCI-BIOL, V78, P3199, DOI 10.1073/pnas.78.5.3199; DEVINE PL, 1991, BIOCHEM BIOPH RES CO, V178, P593, DOI 10.1016/0006-291X(91)90149-2; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; HAGOPIAN A, 1968, ARCH BIOCHEM BIOPHYS, V128, P422, DOI 10.1016/0003-9861(68)90048-9; HANISCH FG, 1989, J BIOL CHEM, V264, P872; HANISCH FG, 1986, EUR J BIOCHEM, V155, P239, DOI 10.1111/j.1432-1033.1986.tb09482.x; HANISCH FG, 1985, EUR J BIOCHEM, V152, P343, DOI 10.1111/j.1432-1033.1985.tb09204.x; HILKENS J, 1988, J BIOL CHEM, V263, P4215; HILKENS J, 1984, INT J CANCER, V34, P197, DOI 10.1002/ijc.2910340210; HOFF SD, 1989, CANCER RES, V49, P6883; IRIMURA T, 1991, CANCER RES, V51, P5728; IRIMURA T, 1987, CANCER RES, V47, P881; IRIMURA T, 1988, CANCER RES, V48, P2353; IRIMURA T, 1990, CANCER RES, V50, P3331; Irimura T, 1991, Semin Cancer Biol, V2, P129; IRIMURA T, 1988, J CELL BIOCHEM, V37, P1, DOI 10.1002/jcb.240370102; KITAGAWA H, 1991, BIOCHEM BIOPH RES CO, V178, P1429, DOI 10.1016/0006-291X(91)91053-F; KUAN SF, 1989, J BIOL CHEM, V264, P19271; LAN MS, 1990, J BIOL CHEM, V265, P15294; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; MATSUSHITA Y, 1990, LAB INVEST, V63, P780; MAWHINNEY TP, 1987, J BIOL CHEM, V262, P2994; PEAT N, 1992, CANCER RES, V52, P1954; PEMBERTON L, 1992, BIOCHEM BIOPH RES CO, V185, P167, DOI 10.1016/S0006-291X(05)80971-4; PODOLSKY DK, 1985, J BIOL CHEM, V260, P5510; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; PRICE JE, 1989, CLIN EXP METASTAS, V7, P55, DOI 10.1007/BF02057181; Sambrook J, 1989, MOL CLONING LABORATO; SMITH AC, 1987, J CLIN INVEST, V80, P300, DOI 10.1172/JCI113073; SUGIURA M, 1982, J BIOL CHEM, V257, P9501; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TARTAKOFF AM, 1983, METHOD ENZYMOL, V98, P47; UEMURA M, 1988, CANCER RES, V48, P5335; YAMORI T, 1987, CANCER RES, V47, P2741; YAMORI T, 1989, CANCER RES, V49, P887; YUREWICZ EC, 1987, J BIOL CHEM, V262, P4733; ZOTTER S, 1985, VIRCHOWS ARCH A, V406, P237, DOI 10.1007/BF00737089; ZOTTER S, 1987, LAB INVEST, V57, P193	46	25	26	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10133	10138						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8098036				2022-12-27	WOS:A1993LB80000031
J	TAGUCHI, H; YOSHIDA, M				TAGUCHI, H; YOSHIDA, M			CHAPERONIN FROM THERMUS-THERMOPHILUS CAN PROTECT SEVERAL ENZYMES FROM IRREVERSIBLE HEAT DENATURATION BY CAPTURING DENATURATION INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK PROTEINS; ATP HYDROLYSIS; GROEL; RECONSTITUTION; CARBOXYLASE; AGGREGATION; INVITRO; BINDING	Chaperonin isolated from Thermus thermophilus is stable up to 80-degrees-C. Taking advantage of this heat stability, we have studied the effects of chaperonin on heat denaturation of several relatively heat labile enzymes. When the enzymes are incubated at their denaturating temperatures, the presence of T. thermophilus chaperonin in the solution has little effect on the rate of apparent inactivation of the enzyme. However, this inactivation is not irreversible since most activity is recovered when the solution is shifted to the second incubation at a moderate temperature with concomitant addition of MgATP. When the chaperonin is omitted from the solution, no recovery is observed. Recovery of the activity is also dependent on MgATP in the second incubation and 50% of recovery is attained at 5 muM MgATP. When the chaperonin is added after starting the incubation at a denaturing temperature, recovery of the activity becomes poorer as the delay of chaperonin addition increases. The critical temperature of the incubation at which irreversible denaturation occurs to the enzymes is elevated 8-15-degrees-C by inclusion of T. thermophilus chaperonin in the solution. The heat stability of captured proteins by the chaperonin, assessed as retention of the ability to resume productive folding under optimal conditions, is measured more accurately using chemically produced folding intermediate-chaperonin complexes. The ability is lost at about 78-degrees-C being irrespective of variable heat stability of individual enzymes. These results indicate that during heat denaturation proteins assume a common structure which is recognizable by the chaperonin. Once a protein with this structure is captured by T. thermophilus chaperonin, it retains the ability to resume productive folding even after exposure to the otherwise denaturing high temperature. Its heat stability seems to be limited solely by heat stability of chaperonin.	TOKYO INST TECHNOL,RESOURCES UTILIZAT RES LAB,4259 NAGATSUTA,YOKOHAMA,KANAGAWA 227,JAPAN	Tokyo Institute of Technology			Taguchi, Hideki/B-6946-2009; taguchi, hideki/AAM-2663-2021	Taguchi, Hideki/0000-0002-6612-9339; taguchi, hideki/0000-0002-6612-9339				BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LORIMER GH, 1992, CURR OPIN STRUC BIOL, V2, P26; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TAGUCHI H, 1991, J BIOL CHEM, V266, P22411; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003	21	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5371	5375						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8095496				2022-12-27	WOS:A1993KR82200008
J	ADELHORST, K; HEDEGAARD, BB; KNUDSEN, LB; KIRK, O				ADELHORST, K; HEDEGAARD, BB; KNUDSEN, LB; KIRK, O			STRUCTURE-ACTIVITY STUDIES OF GLUCAGON-LIKE PEPTIDE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PIG SMALL-INTESTINE; PREPROGLUCAGON CONTAINS; RECEPTOR-BINDING; INSULIN; PANCREAS; ANALOGS; GENE; EXPRESSION; SEQUENCE; INCRETIN	A series of analogs of glucagon-like peptide-1 (GLP-1) was made replacing each amino acid with L-alanine to identify side chain functional groups required for inter action with the GLP-1 receptor. In the case of L-alanine being the parent amino acid, substitution was made with the amino acid found in the corresponding position in glucagon. Binding assays were performed using the cloned rat GLP-1 receptor, and receptor activation was monitored using RIN 2A18 plasma membranes. The analogs that showed the weakest receptor binding were further compared with native GLP-1 by circular dichroism spectroscopy to investigate possible conformational changes. We conclude that the side chains in positions 7, 10, 12, 13, and 15 are directly involved in the receptor interaction while positions 28 and 29 are important for GLP-1 to adapt the conformation recognized by the receptor.	NOVO NORDISK AS,DIABET DISCOVERY,DK-2880 BAGSVAERD,DENMARK	Novo Nordisk				Knudsen, Lotte Bjerre/0000-0002-2439-7116				BELL GI, 1983, NATURE, V302, P716, DOI 10.1038/302716a0; CAMPBELL RM, 1992, GROWTH REGULAT, V2, P175; DREJER K, 1991, DIABETES, V40, P1488, DOI 10.2337/diabetes.40.11.1488; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; EPAND RM, 1990, COMPREHENSIVE MED CH, V3, P901; GAUSEPOHL H, 1988, PEPTIDES 1988, P241; GEFEL D, 1990, ENDOCRINOLOGY, V126, P2164, DOI 10.1210/endo-126-4-2164; GOKE R, 1993, J BIOL CHEM, V268, P19650; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056/NEJM199205143262003; HEINRICH G, 1984, J BIOL CHEM, V259, P716; HOLST JJ, 1987, FEBS LETT, V211, P169, DOI 10.1016/0014-5793(87)81430-8; HRUBY VJ, 1986, BIOPOLYMERS, V25, P135; KAWAI K, 1991, DIABETES, V40, pA71; KAWAI K, 1988, BIOMED RES, V9, P213; KOFOD H, 1992, ACTA ENDOCRINOL-COP, V126, P9; KREYMANN B, 1987, LANCET, V2, P1300; LOPEZ LC, 1983, P NATL ACAD SCI-BIOL, V80, P5485, DOI 10.1073/pnas.80.18.5485; MOSJOV S, 1986, J BIOL CHEM, V261, P11880; MOSJOV S, 1992, INT J PEPT PROT RES, V40, P333; MOSJOV S, 1987, J CLIN INVEST, V79, P616; NATHAN DM, 1992, DIABETES CARE, V15, P270, DOI 10.2337/diacare.15.2.270; NAUCK MA, 1993, DIABETOLOGIA, V36, P741, DOI 10.1007/BF00401145; NISHI M, 1990, MOL ENDOCRINOL, V4, P1192, DOI 10.1210/mend-4-8-1192; ODONNEL M, 1990, J BIOL CHEM, V266, P6389; OHNEDA A, 1991, TOHOKU J EXP MED, V165, P209, DOI 10.1620/tjem.165.209; ORSKOV C, 1989, J BIOL CHEM, V264, P12826; ORSKOV C, 1986, ENDOCRINOLOGY, V119, P1467, DOI 10.1210/endo-119-4-1467; RAUFMAN JP, 1992, J BIOL CHEM, V267, P21432; SEINO S, 1986, FEBS LETT, V203, P25, DOI 10.1016/0014-5793(86)81429-6; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; UNSON CG, 1991, J BIOL CHEM, V266, P2763; VINTHER A, 1993, ELECTROPHORESIS, V14, P486, DOI 10.1002/elps.1150140175; YANAIHARA M, 1990, GASTROINTEST ENDOSC, P359	34	221	284	1	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6275	6278						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119974				2022-12-27	WOS:A1994MZ50300005
J	JOHANNES, FJ; PRESTLE, J; EIS, S; OBERHAGEMANN, P; PFIZENMAIER, K				JOHANNES, FJ; PRESTLE, J; EIS, S; OBERHAGEMANN, P; PFIZENMAIER, K			PKCU IS A NOVEL, ATYPICAL MEMBER OF THE PROTEIN-KINASE-C FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; NPKC; PHOSPHORYLATION; ACTIVATION; THREONINE; MESSENGER; DNA	We have isolated the full-length cDNA of a novel human serine/threonine protein kinase gene. The deduced protein sequence shows strong homology to conserved domains of members of the protein kinase C (PRC) subfamily. Homologies reside in the duplex zinc-finger-like cysteine-rich motif and in the protein kinase domain. The lack of the C-2 domain of the Ca2(+)-dependent PKCs and the presence of a unique NH2-terminal sequence with a potential signal peptide and a transmembrane domain suggest that PKC mu is a novel member of the subgroup of atypical PKCs. An open reading frame coding for 912 amino acids directs an in vitro translation product with an apparent M(r) of 115,000. In vitro phorbol ester binding studies and kinase assays with lysates of cells overexpressing PKC mu showed phorbol ester-independent kinase activity, autophosphorylation, and, in normal rat kidney (NRK) cells, predominant phosphorylation of a 30-kDa protein at serine residues. Southern analysis revealed that PKC mu is a single copy gene located on human chromosome 21. There is constitutive low level expression of the human PKC mu gene in normal tissues with a single transcript of 3.8 kilobases and elevated expression levels in selected tumor cell lines. These data suggest a role of PKC mu in signal transduction pathways related to growth control.	UNIV STUTTGART,INST CELL BIOL & IMMUNOL,D-70569 STUTTGART,GERMANY	University of Stuttgart								ADEN DP, 1978, NATURE, V271, P375, DOI 10.1038/271375a0; AKITA Y, 1990, J BIOL CHEM, V265, P354; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BELL RM, 1991, J BIOL CHEM, V266, P4661; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P59; BLOCK C, 1992, J BIOL CHEM, V267, P19824; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Devereux J., 1984, NUCLEIC ACIDS RES, V12, P287; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FISCHER T, 1990, Cytokine, V2, P157, DOI 10.1016/1043-4666(90)90010-Q; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JOHANNES FJ, 1992, TRENDS GENET, V8, P48; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; OSADA S, 1990, J BIOL CHEM, V265, P22434; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKIGUCHI M, 1985, BIOMED PHARMACOTHER, V39, P372; TOKUNAGA KY, 1982, CANCER RES, V47, P5616; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATANABE S, 1991, CURR OPIN BIOTECH, V2, P227, DOI 10.1016/0958-1669(91)90015-W; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	38	517	526	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6140	6148						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119958				2022-12-27	WOS:A1994MY84000099
J	KOCH, WJ; HAWES, BE; INGLESE, J; LUTTRELL, LM; LEFKOWITZ, RJ				KOCH, WJ; HAWES, BE; INGLESE, J; LUTTRELL, LM; LEFKOWITZ, RJ			CELLULAR EXPRESSION OF THE CARBOXYL-TERMINUS OF A G-PROTEIN-COUPLED RECEPTOR KINASE ATTENUATES G(BETA-GAMMA)-MEDIATED SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; MUSCARINIC ACETYLCHOLINE-RECEPTORS; PHOSPHOLIPASE-C; ADENYLYL CYCLASE; DEPENDENT PHOSPHORYLATION; STIMULATION; ACTIVATION; TRANSDUCTION; HYDROLYSIS	The beta gamma subunits (G(beta gamma)) of heterotrimeric G proteins modulate the activity of several signal-transducing effector molecules including G protein-coupled receptor kinases. G(beta gamma) binds to the carboxyl terminus of the beta-adrenergic receptor kinase (beta ARK) and regulates its activity. To investigate the effect of such a G(beta gamma)-binding domain on heterologous G(beta gamma) interactions, various receptors that can stimulate phospholipase C and/or type II adenylate cyclase were coexpressed in COS-7 cells with the carboxyl terminus of beta ARK1. Phosphoinositol hydrolysis in response to activation of receptors that stimulate phospholipase C via G(i beta gamma) (alpha(2)-adrenergic and M2-muscarinic cholinergic receptors) was markedly inhibited by the coexpressed beta ARK1 polypeptide, whereas that mediated by G(q alpha) subunits (alpha(1)-adrenergic and M1-muscarinic cholinergic receptors) was unaffected. Increased cellular cAMP levels due to stimulation of receptors and coexpressed adenylate cyclase II displayed marked inhibition in the presence of the beta ARK1 polypeptide. Moreover, inhibition of adenylate cyclase produced by alpha(2)-adrenergic receptor stimulation (a G(i alpha)-mediated process) was unaffected, indicating that the beta ARK1 polypeptide provides a useful tool for distinguishing between G(alpha) and G(beta gamma) pathways.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BLANK JL, 1992, J BIOL CHEM, V267, P23069; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; COROZZI A, 1993, FEBS LETT, V315, P340; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; EASON MG, 1992, J BIOL CHEM, V267; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; PARK DG, 1993, J BIOL CHEM, V268, P4573; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; WU DQ, 1992, J BIOL CHEM, V267, P25798	35	377	381	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6193	6197						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119963				2022-12-27	WOS:A1994MY84000106
J	MCCORMACK, FX; CALVERT, HM; WATSON, PA; SMITH, DL; MASON, RJ; VOELKER, DR				MCCORMACK, FX; CALVERT, HM; WATSON, PA; SMITH, DL; MASON, RJ; VOELKER, DR			THE STRUCTURE AND FUNCTION OF SURFACTANT PROTEIN-A - HYDROXYPROLINE-DEFICIENT AND CARBOHYDRATE-DEFICIENT MUTANT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY SURFACTANT; II CELLS; SP-A; HIGH-AFFINITY; PHOSPHOLIPID SECRETION; RECOGNITION DOMAINS; COLLAGENOUS DOMAIN; CALCIUM-IONS; LUNG; RAT	Pulmonary surfactant protein A (SP-A) regulates the uptake and secretion of phospholipid by alveolar type II cells and is an important component of surfactant lipid aggregates. In an attempt to understand how specific structural domains of SP-A relate to the function of the protein, we used site-directed mutagenesis of the cDNA for SP-A and heterologous expression with baculovirus vectors. Synthesis of the wild type SP-A in insect cells resulted in a form of the protein in which proline residues were not hydroxylated and that is denoted Sp-A(hyp). Three mutant SP-As with substitutions in the consensus sequences for glycosylation (Sp-A(hyp,glc)) to prevent N-linked oligosaccharide attachment at Asn(1) and Asn(187) were produced, individually and in tandem. The Sp-A(hyp) was glycosylated at both the Asn(1) and Asn(187) positions, demonstrated partial sulfhydryl-dependent oligomerization, and formed incomplete oligomers in solution. The Sp-A(hyp) and Sp-A(hyp,glc) bound to immobilized carbohydrate and to phospholipid liposomes and partially competed for occupancy of a plasma membrane receptor for SP-A. The SP-A(hyp) and the Sp-A(hyp,glc) were equally effective inhibitors of the secretion of surfactant lipids from isolated type II cells (IC50 = 0.5 mu g/ml) and aggregated phospholipid liposomes at 20 degrees C. All of the recombinant SP As demonstrated markedly reduced aggregation of lipid at 37 degrees C. We conclude that the hydroxylation of proline residues is required for perfect oligomerization of SP-A and for thermal stability in the interaction with lipid. Furthermore, recombinant SP-A is able to inhibit the secretion of phospholipid from isolated type II cells and to aggregate lipid vesicles independent of the presence of N-linked carbohydrate or the site of glycosylation.	UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV PULM SCI & CRIT CARE MED,DENVER,CO 80206	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	MCCORMACK, FX (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,LORD & TAYLOR LAB LUNG BIOCHEM,K-601,1400 JACKSON ST,DENVER,CO 80206, USA.		McCormack, Francis X./ABE-8398-2020	McCormack, Francis X./0000-0001-7168-9464	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045286] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-02423, HL-45286] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS E, 1978, SCIENCE, V202, P591, DOI 10.1126/science.212833; AKINO T, 1990, American Review of Respiratory Disease, V141, pA698; Ausubel FM, 1988, MOL REPROD DEV; BENSON BJ, 1984, BIOCHIM BIOPHYS ACTA, V793, P18, DOI 10.1016/0005-2760(84)90048-1; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAAGSMAN HP, 1991, BIOCHEM J, V275, P273, DOI 10.1042/bj2750273; HAWGOOD S, 1985, BIOCHEM SOC T, V13, P1092, DOI 10.1042/bst0131092; HAWGOOD S, 1987, P NATL ACAD SCI USA, V84, P66, DOI 10.1073/pnas.84.1.66; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KAWADA H, 1989, AM REV RESPIR DIS, V140, P460, DOI 10.1164/ajrccm/140.2.460; KING RJ, 1989, BIOCHIM BIOPHYS ACTA, V1001, P294, DOI 10.1016/0005-2760(89)90114-8; KING RJ, 1972, AM J PHYSIOL, V223, P707, DOI 10.1152/ajplegacy.1972.223.3.707; KIVIRIKKO KI, 1986, ANN NY ACAD SCI, V460, P187; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; KUROKI Y, 1991, BIOCHEM INT, V24, P225; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1988, J BIOL CHEM, V263, P17596; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MCCORMACK FX, 1990, BIOCHIM BIOPHYS ACTA, V1087, P190, DOI 10.1016/0167-4781(90)90204-F; OREILLY MA, 1988, BIOCHIM BIOPHYS ACTA, V969, P176, DOI 10.1016/0167-4889(88)90073-0; PROCKOP DJ, 1976, BIOCH COLLAGEN, P161; RICE WR, 1988, BIOCHIM BIOPHYS ACTA, V958, P205, DOI 10.1016/0005-2760(88)90178-6; ROSS GF, 1986, J BIOL CHEM, V261, P14283; RYAN RM, 1989, J HISTOCHEM CYTOCHEM, V37, P429, DOI 10.1177/37.4.2926121; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO K, 1987, BIOCHEM BIOPH RES CO, V144, P367, DOI 10.1016/S0006-291X(87)80519-3; SEE PM, 1988, PROTEIN STRUCTURE PR, P1; SUMMERS MD, 1988, MANUAL BACULOVIRUS V; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; VANNESS KP, 1988, COMP BIOCHEM PHYS B, V91, P531, DOI 10.1016/0305-0491(88)90017-X; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WRIGHT JR, 1986, J APPL PHYSIOL, V60, P817, DOI 10.1152/jappl.1986.60.3.817; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; WRIGHT JR, 1989, P NATL ACAD SCI USA, V86, P5410, DOI 10.1073/pnas.86.14.5410	46	72	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5833	5841						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119925				2022-12-27	WOS:A1994MY84000056
J	MIKI, H; MIURA, K; MATUOKA, K; NAKATA, T; HIROKAWA, N; ORITA, S; KAIBUCHI, R; TAKAI, Y; TAKENAWA, T				MIKI, H; MIURA, K; MATUOKA, K; NAKATA, T; HIROKAWA, N; ORITA, S; KAIBUCHI, R; TAKAI, Y; TAKENAWA, T			ASSOCIATION OF ASH/GRB-2 WITH DYNAMIN THROUGH THE SRC HOMOLOGY-3 DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TYROSINE KINASES; SH3 DOMAINS; PROTEIN; MICROTUBULES; SHIBIRE	Ash/Grb-2 is an adaptor protein composed only of Src homology (SH) 2 and SH3 domains that is considered to be essential for Res activation. To clarify the downstream of Ash signaling, we investigated Ash-bound proteins. Ash-glutathione S-transferase (GST) fusion proteins were used to affinity-purify proteins bound to Ash. We found 180-, 150-, 100, and 70-kDa proteins bound to GST-Ash, among which the 100 kDa protein was found to be dynamin by amino acid sequencing and Western blot with anti-dynamin antibody. Next, the in vitro and in vivo associations between Ash and dynamin were examined using PC12 cells. Dynamin in PC12 cell lysates bound to GST-Ash independent of NGF treatment. Also, Ash and dynamin co-precipitated when cell lysates of PC12 were immunoprecipitated with anti-Ash antibody or anti-dynamin antibody, Using various GST-Ash constructs, we studied the importance of the individual domains in binding and found that the SH3 domain is necessary for binding, This binding was inhibited by a synthetic peptide (GPPPQVPSRPNRC, amino acids 827-838 in dynamin). These data show that Ash SH3 domains bind to the proline-rich region of dynamin. Considering the function of dynamin in membrane trafficking, Ash may regulate endocytosis in addition to Res activation.	UNIV TOKYO,INST MED SCI,DEPT MOLEC ONCOL,MINATO KU,TOKYO,TOKYO 108,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,ITABASHI KU,TOKYO,TOKYO 173,JAPAN; UNIV TOKYO,SCH MED,DEPT ANAT & CELL BIOL,BUNKYO KU,TOKYO,TOKYO 113,JAPAN; UNIV KOBE,SCH MED,DEPT BIOCHEM,KOBE,HYOGO 650,JAPAN	University of Tokyo; Tokyo Metropolitan Institute of Gerontology; University of Tokyo; Kobe University								BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; NAKATA Y, 1994, IN PRESS BIOPHYS J; NODA Y, 1993, NEUROSCIENCE, V55, P113, DOI 10.1016/0306-4522(93)90459-S; OLIVIER JP, 1993, CELL, V73, P169; ROBINSON DJ, 1993, NATURE, V365, P163; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHOLNIK EY, 1993, EMBO J, V12, P1929; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; TOBE K, 1993, J BIOL CHEM, V268; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0	25	125	130	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5489	5492						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119878				2022-12-27	WOS:A1994MY84000003
J	MORINELLI, TA; ZHANG, LM; NEWMAN, WH; MEIER, KE				MORINELLI, TA; ZHANG, LM; NEWMAN, WH; MEIER, KE			THROMBOXANE A(2) PROSTAGLANDIN H-2-STIMULATED MITOGENESIS OF CORONARY-ARTERY SMOOTH-MUSCLE CELLS INVOLVES ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE AND S6 KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODULATES DNA-SYNTHESIS; GROWTH-FACTOR; SIGNALING PATHWAYS; EPITHELIAL-CELLS; RECEPTORS; PLATELET; CALCIUM; RAT; PROLIFERATION; INHIBITION	Prostaglandin H-2 (PGH(2)) and thromboxane A(2) (TXA(2)) are potent activators of platelets and vascular smooth muscle whose responses are mediated through a common G protein coupled receptor (TXA(2)/PGH(2) receptor). Despite the many studies describing their ability to aggregate platelets and contract vascular smooth muscle, little is known concerning the potential mitogenic capabilities of these autocoids. Mitogen-activated protein kinases (MAP kinases) and ribosomal S6 kinases are well characterized intracelluIar mediators involved in proliferation of cells. The present study was designed to examine the activation of MAP kinase and S6 kinase in guinea pig coronary artery smooth muscle cells (CASMC) in response to stimulation by a TXA(2)/PGH(2) mimetic, I-BOP ([1S-(1 alpha,2 beta(5Z),3 alpha(1E,3R*),4 alpha)]-7-[3-(3-hydroxy- 4-(4'-iodophenoxy)-1-butenyl)-7-oxabicyclo[2.2.1]heptan-2-yl]-5-heptenoic acid), Equilibrium radioligand binding assays using [I-125]BOP defined a single class of high affinity TXA(2)/PGH(2), receptors on monolayers of guinea pig CASMC (K-d = 0.18 +/- 0.03 nM; 26,476 +/- 3,600 sites/cell; 0.08 +/- 0.01 pmol/mg of protein; n = 12). I-BOP produced a concentration-dependent increase in [H-3]thymidine incorporation in these cells (EC(50) = 0.3 nM) which was inhibited by a series of TXA(2)/PGH(2) recep tor antagonists as well as by verapamil and staurosporine. I-BOP also produced a time-dependent increase in the activation of kinases phosphorylating myelin basic protein (MBP; a substrate for MAP kinase) and RRLSSLRA (S6 peptide; a substrate for pp85(rsk) kinase), reaching a peak activation between 5 and 10 min. Stimulated MBP kinases were identified as ERK1 and ERK2. The activation of these kinases by I-BOP was inhibited by the TXA(2)/PGH(2) receptor antagonist SQ29548 and also by staurosporine. These results indicate that I-BOP, a TXA(2)/PGH(2) mimetic, produces growth of coronary artery vascular smooth muscle cells, which is preceded by activation of MAP kinase and S6 kinase.	MED UNIV S CAROLINA,DEPT CELL & MOLEC PHARMACOL & EXPTL THERAPEUT,CHARLESTON,SC 29425; MED CTR CENT GEORGIA,MACON,GA 31201; MERCER UNIV,SCH MED,DEPT ANESTHESIOL,MACON,GA 31201	Medical University of South Carolina; Mercer University	MORINELLI, TA (corresponding author), MED UNIV S CAROLINA,DEPT MED,DIV CLIN PHARM,CHARLESTON,SC 29425, USA.							COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DORN GW, 1992, J BIOL CHEM, V267, P24897; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; GILLARD JW, 1989, PROSTAGLANDINS CLIN, P579; GRANOT Y, 1993, J BIOL CHEM, V268, P9564; HALUSHKA PV, 1989, ANN REV PHARM TOXICO, V10, P213; HANASAKI K, 1990, BIOCHEM PHARMACOL, V40, P2535, DOI 10.1016/0006-2952(90)90096-4; HANASAKI K, 1988, BIOCHEM BIOPH RES CO, V150, P1170, DOI 10.1016/0006-291X(88)90752-8; HANSSON A, 1991, CELL SIGNAL, V3, P293, DOI 10.1016/0898-6568(91)90057-2; HE CJ, 1992, J CELL PHYSIOL, V150, P475, DOI 10.1002/jcp.1041500307; HEBDERG A, 1988, J PHARMACOL EXP THER, V245, P786; HIDAKA J, 1992, ANN REV PHARM TOXICO, V32, P377; ISHIMITSU T, 1988, HYPERTENSION, V12, P46, DOI 10.1161/01.HYP.12.1.46; ISSANDOU M, 1991, J BIOL CHEM, V266, P21037; KENT TA, 1992, J CEREBR BLOOD F MET, V12, P139, DOI 10.1038/jcbfm.1992.17; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LUMLEY P, 1989, BRIT J PHARMACOL, V97, P783, DOI 10.1111/j.1476-5381.1989.tb12017.x; MARTINPERE J, 1983, P NATL ACAD SCI USA, V80, P929; MASUDA A, 1991, CIRC RES, V69, P638, DOI 10.1161/01.RES.69.3.638; MASUDA A, 1991, BIOCHEM PHARMACOL, V42, P537, DOI 10.1016/0006-2952(91)90316-W; MEIER KE, 1990, J BIOL CHEM, V265, P4635; MEIER KE, 1991, J BIOL CHEM, V266, P1914; MIHARA S, 1989, EUR J PHARMACOL, V160, P313, DOI 10.1016/0014-2999(89)90086-1; MIKI I, 1992, THROMB HAEMOSTASIS, V67, P582; MORINELLI TA, 1989, J PHARMACOL EXP THER, V251, P557; MORINELLI TA, 1990, LIFE SCI, V46, P1765, DOI 10.1016/0024-3205(90)90140-M; NAGATA T, 1992, AM J PHYSIOL, V263, pH1331, DOI 10.1152/ajpheart.1992.263.5.H1331; PARIS S, 1991, ANN NY ACAD SCI, V638, P139, DOI 10.1111/j.1749-6632.1991.tb49024.x; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; ROE MW, 1989, J CELL PHYSIOL, V139, P100, DOI 10.1002/jcp.1041390115; SAURO MD, 1991, J CELL PHYSIOL, V148, P133, DOI 10.1002/jcp.1041480116; SMITH CD, 1988, BIOCHEM BIOPH RES CO, V156, P1250, DOI 10.1016/S0006-291X(88)80767-8; SPERTI G, 1991, EUR J PHARM-MOLEC PH, V206, P279, DOI 10.1016/0922-4106(91)90110-4; SUSA M, 1992, J BIOL CHEM, V267, P6905; TAKUWA N, 1991, J BIOL CHEM, V266, P1403; THYBERG J, 1987, BIOL CELL, V60, P125, DOI 10.1111/j.1768-322X.1987.tb00552.x; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; UEHARA Y, 1988, PROSTAGLANDINS, V36, P847, DOI 10.1016/0090-6980(88)90061-5	41	104	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5693	5698						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119906				2022-12-27	WOS:A1994MY84000035
J	SEELIG, GF; PROSISE, WW; SCHEFFLER, JE				SEELIG, GF; PROSISE, WW; SCHEFFLER, JE			A ROLE FOR THE CARBOXYL-TERMINUS OF HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN THE BINDING OF LIGAND TO THE ALPHA-SUBUNIT OF THE HIGH-AFFINITY RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; HUMAN CELL-LINE; GM-CSF; RADIOACTIVITIES; RECONSTITUTION; ESTABLISHMENT; EXPRESSION; LEUKEMIA; CLONING; IL-3	A synthetic segment (110-127) of the carboxyl terminus of recombinant human granulocyte-macrophage colony-stimulating factor (rh-GM-CSF) was used to generate a rabbit polyclonal antibody (345-6), which recognized both peptide and full-length Escherichia coli-derived rh-GM-CSF in a direct enzyme-linked immunosorbent assay. Antibody 345-6 was shown to antagonize the binding of I-125-labeled rh-GM-CSF to its receptor on the KG-1 cell line and to inhibit human GM-CSF-dependent proliferation of the AML-193 cell line. The purified IgG fraction of neutralizing antibody 345-6 was used as immunogen to obtain sheep antiserum 1418. Antibody 1418 recognized antibody 345-6 on direct enzyme-linked immunosorbent assay but did not recognize rh-GM-CSF or the peptide 110-127 to which antibody 345-6 was raised. Antiserum 1418, as well as a purified IgG fraction of this serum, inhibited both rh-GM-CSF-stimulated cell proliferation and I-126-labeled rh-GM-CSF receptor binding but not I-125- labeled recombinant human interleukin-4 receptor binding. The anti-idiotypic antibody response derived from the anti-(110-127) antibody strongly suggests that the carboxyl-terminal region of rh-GM-CSF may be directly involved in the receptor-ligand interaction of this protein. The high affinity receptor consists of two different components (GM-R alpha beta) a cytokine-specific alpha-subunit and a beta-subunit that is shared by human GM-CSF, interleukin-3, and interleukin-5. In an effort to localize the epitope of antibody 1418 to either GMR alpha or GMRB beta several cell lines containing high, low, or both high and low affinity receptors were examined. Each was specifically and completely inhibited by antibody 1418. Interleukin-3-dependent cell proliferation of the AML-193 cell line was found to be unaffected by the antibody 1418. Thus, the carboxyl-terminal region of rh-GM-CSF is likely to be involved in the interaction of the ligand with the a-subunit of the high affinity receptor.			SEELIG, GF (corresponding author), SCHERING PLOUGH CORP,RES INST,KENILWORTH,NJ 07033, USA.							BALDWIN GC, 1988, P NATL ACAD SCI USA, V85, P2763, DOI 10.1073/pnas.85.8.2763; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, J MOL BIOL, V221, P55, DOI 10.1016/0022-2836(91)90803-E; DISPERSIO J, 1988, J BIOL CHEM, V263, P1834; GASSON JC, 1986, P NATL ACAD SCI USA, V83, P669, DOI 10.1073/pnas.83.3.669; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GREENBERG R, 1988, CURR MICROBIOL, V17, P321, DOI 10.1007/BF01570872; GROOPMAN JE, 1987, NEW ENGL J MED, V317, P593, DOI 10.1056/NEJM198709033171003; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; LANGE B, 1987, BLOOD, V70, P192; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSIS AJ, 1980, P NATL ACAD SCI-BIOL, V77, P5346, DOI 10.1073/pnas.77.9.5346; MADJIC O, 1984, INT J CANCER, V33, P617; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; METCALF D, 1986, BLOOD, V67, P257; MONROY RL, 1987, BLOOD, V70, P1096; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SHANAFELT AB, 1991, J BIOL CHEM, V266, P13804; SHANAFELT AB, 1992, J BIOL CHEM, V267, P25466; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; TROTTA P, 1987, Patent No. 883064214; TROTTA PP, 1989, 9TH P SAT S EUR C CL, P6; VANDHANRAJ S, 1987, NEW ENGL J MED, V317, P1545; WALTER MR, 1992, J MOL BIOL, V224, P1075, DOI 10.1016/0022-2836(92)90470-5	31	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5548	5553						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119889				2022-12-27	WOS:A1994MY84000015
J	YANG, B; IBRAGHIMOVBESKROVNAYA, O; MOOMAW, CR; SLAUGHTER, CA; CAMPBELL, KP				YANG, B; IBRAGHIMOVBESKROVNAYA, O; MOOMAW, CR; SLAUGHTER, CA; CAMPBELL, KP			HETEROGENEITY OF THE 59-KDA DYSTROPHIN-ASSOCIATED PROTEIN REVEALED BY CDNA CLONING AND EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN COMPLEX; SKELETAL-MUSCLE; PURIFICATION	The 59-kDa dystrophin-associated protein triplet (59-DAP) is a component of the dystrophin-glycoprotein complex which may directly associate with dystrophin. The cDNA encoding one component (59-1 DAP) of the 59-DAP triplet has now been cloned from rabbit skeletal muscle. The deduced amino acid sequence of 59-1 DAP predicts a 505-amino acid polypeptide containing nine potential phosphorylation sites and no predicted transmembrane domains. This is consistent with the 59-1 DAP being a peripheral membrane protein associated with the cytoplasmic face of the dystrophin-glycoprotein complex. Affinity-purified antibodies against rabbit 59-1 DAP fusion proteins only recognize the lowest band of the 59-DAP triplet in skeletal muscle sarcolemma and isolated dystrophin-glycopratein complex. The tissue-specific expression of 59-1 DAP mRNA, which is most prominent in skeletal and cardiac muscle and is also detected in brain, parallels that of dystrophin but not of utrophin. Levels of 59-1 DAP mRNA are unaffected in mdx mouse skeletal and cardiac muscles, although all dystrophin-associated proteins, including 59-DAP, are greatly reduced in mdx mouse skeletal muscle. However, in mdx mouse cardiac muscle, the up-regulation of utrophin preserves all dystrophin-associated proteins except 59-DAP. Our results suggest that the 59-DAP triplet may contain different protein species and that the 59-1 DAP may associate more specifically with dystrophin than with utrophin.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,BIOPOLYMER FACIL,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Iowa; University of Iowa; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Campbell, Kevin/0000-0003-2066-5889				ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BUTLER MH, 1992, J BIOL CHEM, V267, P6213; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CARTAUD A, 1993, J BIOL CHEM, V268, P13019; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; KOZAK M, 1991, J BIOL CHEM, V266, P19867; MATSUMURA K, 1993, FEBS LETT, V320, P276, DOI 10.1016/0014-5793(93)80602-Q; MATSUMURA K, 1993, J CLIN INVEST, V92, P866, DOI 10.1172/JCI116661; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; YAMAMOTO H, 1993, J BIOCHEM-TOKYO, V114, P132, DOI 10.1093/oxfordjournals.jbchem.a124128; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	25	112	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6040	6044						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119949				2022-12-27	WOS:A1994MY84000085
J	ROFFEY, RA; VANWIJK, KJ; SAYRE, RT; STYRING, S				ROFFEY, RA; VANWIJK, KJ; SAYRE, RT; STYRING, S			SPECTROSCOPIC CHARACTERIZATION OF TYROSINE-Z IN HISTIDINE-190 MUTANTS OF THE D1 PROTEIN IN PHOTOSYSTEM-II (PSII) IN CHLAMYDOMONAS-REINHARDTII - IMPLICATIONS FOR THE STRUCTURAL MODEL OF THE DONOR SIDE OF PSII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION CENTER; RIBONUCLEOTIDE REDUCTASE; RESONANCE SPECTROSCOPY; DIRECTED MUTAGENESIS; CHARGE ACCUMULATION; THYLAKOID MEMBRANE; MANGANESE CLUSTER; COMPLEX; PHOTOINHIBITION; CHLOROPLASTS	EPR spectra attributed to the redox active tyrosine residues on the oxidizing side of photosystem II (Tyr(Z) and Tyr(D)) have almost identical line shapes, although the tyrosyl radicals differ in stability and redox characteristics. Strongly modified spectra of oxidized Tyr(D) in site-directed mutants in a histidine residue, H189 on the D2 reaction center protein in the cyanobacterium Synechocystis 6803, support a structural model where H189 interacts closely, probably via a hydrogen bond, to Tyr(D) (Tommos, C., Davidsson, L., Svensson, B., Madsen, C., Vermaas, W., and Styring, S. (1993) Biochemistry 32, 5436-5441). To determine whether Tyr(Z) and the corresponding histidine on the D1 protein (D1-H190) interacts similarly, we have generated His-Phe (H190F) and His-Tyr (H190Y) mutations in the C2 symmetry related H190 residue on the D1 reaction center protein by site-directed mutagenesis in Chlamydomonas reinhardtii. The H190F and H190Y mutants assemble photosystem II reaction centers capable of primary photochemistry but unable to oxidize water. We have obtained kinetic spectra of a flash-induced transient EPR signal that we assign to oxidized Tyr(Z) in the D1-H190 mutants. The spectra are identical in line width (18-20 G) and hyperfine structure to the wild-type spectrum from oxidized Tyr(Z) and exhibit decay kinetics (t(1/2) approximate to 500 ms) typical for the Tyr(Z) radical in managenese-depleted photosystem II membranes, However, both Tyr(Z) and Tyr(D) were oxidized with reduced (10-15%) quantum yield in these mutants, indicating that the kinetics of electron donation to P-680(+), were significantly modified as a result of the mutation. Thus, the altered kinetics of Tyr(Z) in the mutants suggest that there is an interaction between TyrZ and His-190 on the D1 protein. However, unlike the situation on the D2 side, the presence of a hydrogen bond between Tyr(Z) and H190 on the D1 protein is improbable.	STOCKHOLM UNIV, ARRHENIUS LABS NAT SCI, DEPT BIOCHEM, S-10691 STOCKHOLM, SWEDEN; OHIO STATE UNIV, DEPT PLANT BIOL, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT BIOCHEM, COLUMBUS, OH 43210 USA	Stockholm University; Ohio State University; Ohio State University			Styring, Stenbjörn/L-8414-2016	Styring, Stenbjörn/0000-0002-2803-9244; Sayre, Richard/0000-0002-3153-7084				ANDERSSON B., 1991, CURR TOP BIOENERG, V16, P1; BABCOCK GT, 1973, BIOCHIM BIOPHYS ACTA, V325, P483, DOI 10.1016/0005-2728(73)90209-0; BABCOCK GT, 1976, FEBS LETT, V61, P286; BABCOCK GT, 1989, BIOCHEMISTRY-US, V28, P9557, DOI 10.1021/bi00451a001; BARRY BA, 1987, P NATL ACAD SCI USA, V84, P709; BENDER CJ, 1989, J AM CHEM SOC, V111, P8076, DOI 10.1021/ja00203a002; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; BLUBAUGH DJ, 1991, BIOCHEMISTRY-US, V30, P7586, DOI 10.1021/bi00244a030; BOERNER RJ, 1992, BIOCHEMISTRY-US, V31, P6660, DOI 10.1021/bi00144a005; BRETTEL K, 1984, BIOCHIM BIOPHYS ACTA, V766, P403, DOI 10.1016/0005-2728(84)90256-1; CALLAHAN FE, 1986, PLANT PHYSIOL, V82, P261, DOI 10.1104/pp.82.1.261; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; HOGANSON CW, 1992, BIOCHEMISTRY-US, V31, P11874, DOI 10.1021/bi00162a028; JEGERSCHOLD C, 1990, BIOCHEMISTRY-US, V29, P6179, DOI 10.1021/bi00478a010; LJUNGBERG U, 1986, EUR J BIOCHEM, V158, P477, DOI 10.1111/j.1432-1033.1986.tb09779.x; METZ JG, 1989, BIOCHEMISTRY-US, V28, P6960, DOI 10.1021/bi00443a028; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; MILLER AF, 1991, BIOCHIM BIOPHYS ACTA, V1056, P1, DOI 10.1016/S0005-2728(05)80067-2; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P942, DOI 10.1021/bi00118a041; NIXON PJ, 1992, PLANT PROTEIN ENG, P93; ROFFEY RA, 1991, P NATL ACAD SCI USA, V88, P9122, DOI 10.1073/pnas.88.20.9122; RUFFLE SV, 1992, PHOTOSYNTH RES, V34, P287, DOI 10.1007/BF00033446; Rutherford A.W., 1992, PHOTOSYSTEMS STRUCTU, P179; RUTHERFORD AW, 1986, PROGR PHOTOSYNTHESIS, V1, P277; SAYRE RT, 1986, CELL, V47, P601, DOI 10.1016/0092-8674(86)90624-0; SHIM HS, 1990, PHOTOSYNTH RES, V26, P223, DOI 10.1007/BF00033135; STYRING S, 1993, PHOTOSYNTHETICA, V28, P225; SVENSSON B, 1990, EMBO J, V9, P2051, DOI 10.1002/j.1460-2075.1990.tb07372.x; SVENSSON B, 1991, Z NATURFORSCH C, V46, P767; SVENSSON B, 1992, RES PHOTOSYNTHESIS, V2, P147; THEG SM, 1986, BIOCHIM BIOPHYS ACTA, V849, P104, DOI 10.1016/0005-2728(86)90101-5; TOMMOS C, 1993, BIOCHEMISTRY-US, V32, P5436, DOI 10.1021/bi00071a020; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREBST A, 1986, Z NATURFORSCH C, V41, P240; VASS I, 1991, BIOCHEMISTRY-US, V30, P830, DOI 10.1021/bi00217a037; VERMAAS WFJ, 1988, P NATL ACAD SCI USA, V85, P8477, DOI 10.1073/pnas.85.22.8477; VERMAAS WFJ, 1991, CELL CULTURE SOMAT B, V7, P25; VIRGIN I, 1988, FEBS LETT, V233, P408, DOI 10.1016/0014-5793(88)80472-1; YARKES CT, 1980, BIOCHIM BIOPHYS ACTA, V590, P360; [No title captured]	45	69	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5115	5121						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106491				2022-12-27	WOS:A1994MX57100066
J	WALL, D; ZYLICZ, M; GEORGOPOULOS, C				WALL, D; ZYLICZ, M; GEORGOPOULOS, C			THE NH2-TERMINAL 108 AMINO-ACIDS OF THE ESCHERICHIA-COLI DNAJ PROTEIN STIMULATE THE ATPASE ACTIVITY OF DNAK AND ARE SUFFICIENT FOR LAMBDA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; BACTERIOPHAGE-LAMBDA; CHAPERONE; GRPE; PURIFICATION; INITIATION; BINDING; GENE; SEQUENCE; MUTANTS	The Escherichia coli heat shock proteins DnaK and DnaJ function cooperatively as molecular chaperones. Central to their biochemical functions is the ability of DnaJ to interact with DnaK and to stimulate its ATPase activity. Here, we report the genetic isolation of dnaJ12, which has a nonsense mutation at codon 109, yet was able to support lambda growth at 30 degrees C. The 12-kDa DnaJ12 protein was purified to homogeneity and shown to be active in an in vitro lambda-DNA replication system and to be capable of stimulating DnaK's ATPase activity, specifically at the step of ATP hydrolysis. The previously web studied and characterized dnaJ259 mutation was also cloned and sequenced, revealing a single His --> Gln amino acid change at codon 33. The purified DnaJ259 protein was inactive in an in vitro lambda-DNA replication system and was unable to stimulate DnaK's ATPase activity. Consistent with this, an NH2-terminal deletion of the first 34 amino acids or an Asp insertion at residue 35 of DnaJ resulted in a protein that completely lacked DnaJ activity. Collectively, these results demonstrate that the highly conserved NH2-terminal region of DnaJ, the so-called J region, is necessary and sufficient for stimulating both DnaK's ATPase activity and lambda-DNA replication. These results may be applicable to other eukaryotic proteins that contain this conserved J domain as proteins that interact and stimulate the hydrolysis of ATP by their cognate HSP70 proteins.	CTR MED UNIV GENEVA, DEPT BIOCHIM MED, CH-1211 GENEVA 4, SWITZERLAND; UNIV GDANSK, DIV BIOPHYS, DEPT MOLEC BIOL, PL-80822 GDANSK, POLAND	University of Geneva; Fahrenheit Universities; University of Gdansk	WALL, D (corresponding author), UNIV UTAH, MED CTR, DEPT CELLULAR VIRAL & MOLEC BIOL, SALT LAKE CITY, UT 84132 USA.			Wall, Daniel/0000-0002-0273-1371	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023917, R01GM023917] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23917] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFANO C, 1989, J BIOL CHEM, V264, P10709; ANG D, 1991, J BIOL CHEM, V266, P24233; BORK P, 1992, TRENDS BIOCHEM SCI, V17, P129, DOI 10.1016/0968-0004(92)90319-5; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CRAIG EA, 1990, STRESS PROTEINS BIOL, P279; CYR DM, 1992, J BIOL CHEM, V267, P20927; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HOFFMANN HJ, 1992, P NATL ACAD SCI USA, V89, P12108, DOI 10.1073/pnas.89.24.12108; HUMPHREYS GO, 1976, MOL GEN GENET, V145, P101, DOI 10.1007/BF00331564; KANG PJ, 1990, J BACTERIOL, V172, P2055, DOI 10.1128/jb.172.4.2055-2064.1990; KURIHARA T, 1992, MEMBRANE BIOGENESIS, P309; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1993, P NATL ACAD SCI USA, V90, P11019, DOI 10.1073/pnas.90.23.11019; LIBEREK K, 1990, J BIOL CHEM, V265, P3022; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; Miller J.H., 1972, EXPT MOL GENETICS; OHKI M, 1986, J BIOL CHEM, V261, P1778; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; SAITO H, 1977, J MOL BIOL, V113, P1, DOI 10.1016/0022-2836(77)90038-9; Sambrook J, 1989, MOL CLONING LABORATO; SELL SM, 1990, J BACTERIOL, V172, P4827, DOI 10.1128/jb.172.9.4827-4835.1990; SELL SM, 1987, THESIS U UTAH; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SUNSHINE M, 1977, MOL GEN GENET, V151, P27, DOI 10.1007/BF00446909; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165; ZHANG SG, 1992, EMBO J, V11, P3787, DOI 10.1002/j.1460-2075.1992.tb05464.x; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	40	250	255	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5446	5451						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106526				2022-12-27	WOS:A1994MX57100110
J	CHANG, SC; CHANG, PC; LEE, YHW				CHANG, SC; CHANG, PC; LEE, YHW			THE ROLES OF PROPEPTIDE IN MATURATION AND SECRETION OF NPR PROTEASE FROM STREPTOMYCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LYTIC PROTEASE; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; NEUTRAL PROTEASE; PRO-REGION; EXTRACELLULAR METALLOPROTEASE; DENATURED SUBTILISIN; NUCLEOTIDE-SEQUENCE; DELETION MUTATION; CLONED GENE	The cloned npr gene of Streptomyces cacaoi encodes a 60-kDa protein (prepro-Npr) consisting of a typical secretory signal peptide, a propeptide (22 kDa), and the 35-kDa mature metalloprotease (Npr). The maturation of Npr occurs extracellularly via an autocatalytic cleavage of the secreted intermediate pro-Npr (Chang, P. C., and Lee, Y.-H. W. (1992) J. Biol. Chem. 267,3952-3958). In this study, we investigated the roles of the propeptide in the maturation and secretion of Npr. Partial deletion of the propeptide region while leaving the signal peptide and the mature Npr sequence intact all led to abolishment of Npr activity and caused concomitant slight and transient accumulation of low molecular weight forms of Npr or pro-Npr derivatives extracellularly. The intact propeptide and its truncated form alone could be secreted into the medium if their NH2 termini were directly fused with the signal peptide sequence of Npr. However, similar fusion of the mature protease domain to the signal peptide without the propeptide sequence completely abolished the Npr production intracellularly and extracellularly. All these results demonstrate that the propeptide plays an important role in maturation and secretion of Npr protease, as in the case of alpha-lytic protease and subtilisin. In addition, our data suggest that an intact propeptide region is essential for the formation of mature active Npr, but not for the secretion of Npr and its derivatives. This distinguishes the maturation and secretion of S. cacaoi Npr from those of other propeptide-containing bacterial serine proteases and thermolysin-like protease.	NATL YANG MING MED COLL,INST BIOCHEM,TAIPEI 112,TAIWAN	National Yang Ming Chiao Tung University				Lee Wu, Yan-Hwa/0000-0001-7299-7354				BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; CHANG PC, 1992, J BIOL CHEM, V267, P3952; CHANG PC, 1990, GENE, V88, P87, DOI 10.1016/0378-1119(90)90063-W; Chater K. F., 1982, CURR TOP MICROBIOL I, V96, P69; CHAVIRA R, 1984, ANAL BIOCHEM, V136, P446, DOI 10.1016/0003-2697(84)90242-2; FUJISHIGE A, 1992, J CELL BIOL, V118, P33, DOI 10.1083/jcb.118.1.33; GASCUEL O, 1988, COMPUT APPL BIOSCI, V4, P357; GENNITY J, 1990, J BIOENERG BIOMEMBR, V22, P233, DOI 10.1007/BF00763167; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HENDERSON G, 1987, J BACTERIOL, V169, P3778, DOI 10.1128/jb.169.8.3778-3784.1987; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Hopwood D.A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1983, J GEN MICROBIOL, V129, P2257; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; OLIVER D, 1985, ANNU REV MICROBIOL, V39, P615; POHLNER J, 1987, NATURE, V325, P458, DOI 10.1038/325458a0; PUGSLEY AP, 1990, ANNU REV GENET, V24, P67; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SILEN JL, 1988, GENE, V69, P237, DOI 10.1016/0378-1119(88)90434-9; SLOMA A, 1990, J BACTERIOL, V172, P1024, DOI 10.1128/jb.172.2.1024-1029.1990; STAHL ML, 1984, J BACTERIOL, V158, P411, DOI 10.1128/JB.158.2.411-418.1984; TAKAGI M, 1985, J BACTERIOL, V163, P824, DOI 10.1128/JB.163.3.824-831.1985; TERADA I, 1990, J BIOL CHEM, V265, P6576; VASANTHA N, 1984, J BACTERIOL, V159, P811, DOI 10.1128/JB.159.3.811-819.1984; WANDERSMAN C, 1989, MOL MICROBIOL, V3, P1825, DOI 10.1111/j.1365-2958.1989.tb00169.x; WETMORE DR, 1992, MOL MICROBIOL, V6, P1593, DOI 10.1111/j.1365-2958.1992.tb00884.x; WONG SL, 1986, J BIOL CHEM, V261, P176; YANG MY, 1984, J BACTERIOL, V160, P15, DOI 10.1128/JB.160.1.15-21.1984; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	36	22	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3548	3554						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106397				2022-12-27	WOS:A1994MV63100065
J	DAVIS, JT; HIRANI, S; BARTLETT, C; REID, BR				DAVIS, JT; HIRANI, S; BARTLETT, C; REID, BR			H-1-NMR STUDIES ON AN ASN-LINKED GLYCOPEPTIDE - GLCNAC-1 C2-N2 BOND IS RIGID IN H2O	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL ENERGY CALCULATIONS; MAGNETIC-RESONANCE SPECTROSCOPY; TWO-DIMENSIONAL NMR; N-TERMINAL PORTION; CIRCULAR-DICHROISM; OLIGOSACCHARIDES; GLYCOSYLATION; GLYCOPROTEINS; COMPLEX; H-1-NMR	The conformation of an Asn-linked glycopeptide in H2O was studied by two-dimensional H-1 NMR. Nonexchangeable proton and exchangeable amide (NH) proton resonances were assigned for the hen ovomucoid glycopeptide 1, Ser-Ile-Glu-Phe-Gly-Thr-Asn*Ile-Ser-Lys, with pentasaccharide Manalpha1-3 (Manalpha1-6)Manbeta1-4GIcNAcbeta1-4GlcNAcbeta1-NH attached to the Asn7 gamma-carboxamide. The pentasaccharide increases the local correlation times of amino acid residues near the N-glycosylation site. Nuclear Overhauser effect (NOE) measurements on 1 and the corresponding Man3GlcNAc2 pentasaccharide 3 show that the attached peptide does not perturb 0-glycoside conformation. Sequential d(NN) (i, i+l) NOEs in the Thr6-Ser9 region indicate populations of folded structure near the N-glycosylation site of both glycopeptide 1 and aglycosyl peptide 2. However, the Man3GlcNAC2 pentasaccharide does not dramatically affect the average conformation of either the peptide backbone or the Asn7 side chain. GlcNAc NH protons were studied at pH 3.0; and NOE and 3J(NH) data were used to constrain the glycopeptide' s GlcNAc-I side chain dihedral angle (tau) (Cl-C2-N2-C7(Ac)). The glycopeptide's core GlcNAc-1 C2-N2 side chain bond is not flexible in H2O. A strong GlcNAc-1 NH2-H3 NOE, a medium strength NH2-Hl NOE, and a weak NH2-H2 interaction suggest that GlcNAc-I has a rigid C2-N2 bond, with tau between 95 and 115-degrees. No evidence was found for intramolecular hydrogen bonds restricting this C2 side chain torsion. It may be that GlcNAc-l's rigid planar N-glycosidic linkage limits the conformational space available to the adjacent C2 acetamido side chain.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; GENZYME CORP,CAMBRIDGE,MA 02139; UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; Sanofi-Aventis; Genzyme Corporation; University of Washington; University of Washington Seattle	DAVIS, JT (corresponding author), UNIV MARYLAND,DEPT CHEM & BIOCHEM,COLL PK,MD 20742, USA.				NIGMS NIH HHS [R44 GM39656-02, F32 GM14340-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014340, R44GM039656] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBADI A, 1986, INT J BIOL MACROMOL, V8, P252, DOI 10.1016/0141-8130(86)90036-X; ANDREOTTI AH, 1993, J AM CHEM SOC, V115, P3352, DOI 10.1021/ja00061a053; BAUSE E, 1981, BIOCHEM J, V195, P639, DOI 10.1042/bj1950639; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BAX A, 1981, J MAGN RESON, V44, P542, DOI 10.1016/0022-2364(81)90287-0; BEELEY JG, 1976, BIOCHEM J, V159, P335, DOI 10.1042/bj1590335; BEINTEMA JJ, 1986, BIOSCIENCE REP, V6, P709, DOI 10.1007/BF01116537; BERMAN E, 1988, CARBOHYD RES, V176, P1, DOI 10.1016/0008-6215(88)84053-9; BERMAN E, 1981, J BIOL CHEM, V256, P3853; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P3680, DOI 10.1021/bi00284a022; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P3671, DOI 10.1021/bi00284a021; BROCKBANK RL, 1990, BIOCHEMISTRY-US, V29, P5574, DOI 10.1021/bi00475a023; BUSH CA, 1980, BIOCHEMISTRY-US, V19, P501, DOI 10.1021/bi00544a017; BUSH CA, 1982, BIOPOLYMERS, V21, P535, DOI 10.1002/bip.360210305; BUSH CA, 1982, J BIOL CHEM, V257, P8199; CAGAS P, 1991, J AM CHEM SOC, V113, P6815, DOI 10.1021/ja00018a016; CUNG MT, 1982, BIOPOLYMERS, V21, P953, DOI 10.1002/bip.360210508; DABROWSKI J, 1989, J AM CHEM SOC, V111, P1510, DOI 10.1021/ja00186a063; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DILL K, 1990, J PROTEIN CHEM, V9, P129, DOI 10.1007/BF01025303; DILL K, 1986, PROG NUCL MAG RES SP, V18, P307, DOI 10.1016/0079-6565(86)80002-4; DROBNY G, 1979, FARADAY DIV CHEM SOC, V13, P49; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; HIRANI S, 1987, ANAL BIOCHEM, V162, P485, DOI 10.1016/0003-2697(87)90424-6; HOMANS SW, 1986, BIOCHEMISTRY-US, V25, P6342, DOI 10.1021/bi00368a076; HOMANS SW, 1987, BIOCHEMISTRY-US, V26, P6553, DOI 10.1021/bi00394a040; HOMANS SW, 1987, BIOCHEMISTRY-US, V26, P6549; IMPERIALI B, 1991, BIOCHEMISTRY-US, V30, P4374, DOI 10.1021/bi00232a002; IMPERIALI B, 1992, J AM CHEM SOC, V114, P7942, DOI 10.1021/ja00046a068; ISHII H, 1985, POLYM J, V17, P693, DOI 10.1295/polymj.17.693; JAO HC, 1992, FEBS LETT, V7, P343; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P4212, DOI 10.1021/ja00221a020; KESSLER H, 1991, J AM CHEM SOC, V113, P7550, DOI 10.1021/ja00020a016; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUMAR A, 1981, J AM CHEM SOC, V103, P3654, DOI 10.1021/ja00403a008; MAEJI NJ, 1987, BIOPOLYMERS, V26, P1753, DOI 10.1002/bip.360261008; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; OHANESSIAN J, 1980, CARBOHYD RES, V80, P1, DOI 10.1016/S0008-6215(00)85309-4; PERCZEL A, 1991, J AM CHEM SOC, V113, P9772, DOI 10.1021/ja00026a010; PINCUS MR, 1976, BIOPOLYMERS, V15, P2485, DOI 10.1002/bip.1976.360151212; POPPE L, 1990, J AM CHEM SOC, V112, P7762, DOI 10.1021/ja00177a042; ROBERTSON AD, 1991, BIOCHEMISTRY-US, V30, P9907, DOI 10.1021/bi00105a014; SAVVIDOU G, 1984, BIOCHEMISTRY-US, V23, P3736, DOI 10.1021/bi00311a026; SKLENAR V, 1987, J MAGN RESON, V74, P469, DOI 10.1016/0022-2364(87)90269-1; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STUIKEPRILL R, 1990, EUR J BIOCHEM, V194, P903, DOI 10.1111/j.1432-1033.1990.tb19485.x; VLIEGENTHART JFG, 1983, ADV CARBOHYDR CHEM B, V41, P279; WORMALD MR, 1991, EUR J BIOCHEM, V198, P131, DOI 10.1111/j.1432-1033.1991.tb15995.x; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P169; YET MG, 1988, J BIOL CHEM, V263, P111	52	65	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3331	3338						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106372				2022-12-27	WOS:A1994MV63100034
J	MA, CP; VU, JH; PROSKE, RJ; SLAUGHTER, CA; DEMARTINO, GN				MA, CP; VU, JH; PROSKE, RJ; SLAUGHTER, CA; DEMARTINO, GN			IDENTIFICATION, PURIFICATION, AND CHARACTERIZATION OF A HIGH-MOLECULAR-WEIGHT, ATP-DEPENDENT ACTIVATOR (PA700) OF THE 20-S PROTEASOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; RABBIT RETICULOCYTE LYSATE; ENDOGENOUS INHIBITOR; SOLUBLE EXTRACTS; LATENT FORM; MACROPAIN; UBIQUITIN; PROTEOLYSIS; DEGRADATION; FIBROBLASTS	In order to identify protein complexes consisting of the proteasome and specific proteasome regulators, crude soluble lysates of red blood cells were fractionated by gel filtration chromatography and by velocity sedimentation centrifugation. The fractionated lysates were then tested for the relative distribution of proteasome activity, proteasome protein, and protein of a known proteasome activator, PA28. At least two proteasome complexes containing PA28 were identified. One of these complexes had an apparent molecular weight of approximately 1,750,000, and appeared to have much more proteasome activity than could be accounted for by its relative concentrations of proteasome and PA28 protein. We hypothesized that this complex contained another activator of the proteasome, and we sought to purify this activator from extracts of red blood cells. A proteasome activator with an apparent molecular weight of approximately 700,000 was identified, purified, and characterized. This activator, termed PA700, greatly stimulated the peptidase activities of the proteasome in an ATP-dependent fashion. PA700 was composed of about 16 polypeptides ranging in molecular weight from 20,000 to 100,000. The ATP-dependent activation of the proteasome by PA700 was closely linked to the formation of a high molecular weight complex that required no additional ATP for activated proteolysis. These results indicate that PA700 is a regulatory protein of the proteasome and is a component of at least one high molecular weight proteasome-containing complex occurring in cell extracts.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED CTR,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006296] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06296] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARRIBAS J, 1990, J BIOL CHEM, V265, P13969; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEMARTINO GN, 1991, BIOCHIM BIOPHYS ACTA, V1073, P299, DOI 10.1016/0304-4165(91)90135-4; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DRISCOLL J, 1992, P NATL ACAD SCI USA, V89, P4986, DOI 10.1073/pnas.89.11.4986; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; GRAY CB, 1994, IN PRESS J MOL BIOL; HERESHKO A, 1992, ANN REV BIOCH, V61, P761; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOUGH R, 1987, J BIOL CHEM, V262, P8303; LI XC, 1991, BIOCHEMISTRY-US, V30, P9709, DOI 10.1021/bi00104a020; MA CP, 1992, BIOCHIM BIOPHYS ACTA, V1119, P303, DOI 10.1016/0167-4838(92)90218-3; MA CP, 1992, J BIOL CHEM, V267, P10515; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; MCGUIRE MJ, 1989, BIOCHEM BIOPH RES CO, V160, P911, DOI 10.1016/0006-291X(89)92521-7; MCGUIRE MJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P273, DOI 10.1016/0003-9861(88)90189-0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MURAKAMI K, 1986, P NATL ACAD SCI USA, V83, P7588, DOI 10.1073/pnas.83.20.7588; ORLOWSKI M, 1991, BIOCHEMISTRY-US, V30, P5999, DOI 10.1021/bi00238a025; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; TANAKA K, 1990, CELL STRUCT FUNCT, V15, P127, DOI 10.1247/csf.15.127; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; WAXMAN L, 1987, J BIOL CHEM, V262, P2451	28	227	230	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3539	3547						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106396				2022-12-27	WOS:A1994MV63100064
J	RIFKIND, AB; KANETOSHI, A; ORLINICK, J; CAPDEVILA, JH; LEE, C				RIFKIND, AB; KANETOSHI, A; ORLINICK, J; CAPDEVILA, JH; LEE, C			PURIFICATION AND BIOCHEMICAL-CHARACTERIZATION OF 2 MAJOR CYTOCHROME-P-450 ISOFORMS INDUCED BY 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN IN CHICK-EMBRYO LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID EPOXYGENASE; RAT-LIVER; EPOXYEICOSATRIENOIC ACIDS; BETA-NAPHTHOFLAVONE; MICROSOMAL CYTOCHROME-P-450; MESSENGER-RNAS; C-FOS; ISOZYMES; FORMS; ACTIVATION	Two cytochrome P-450 isoforms induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in chick embryo liver microsomes were purified. The P-450s exhibit catalytic selectivity either for arachidonic acid metabolism, particularly epoxygenation (P-450 TCDD(AA), 55 kDa), or for aryl hydrocarbon hydroxylase (AHH) and 7-ethoxyresorufin deethylase (7-EROD) (P-450 TCDD(AHH), 54.5 kDa). Turnover numbers for arachidonic acid epoxygenation, AHH, and 7-EROD, respectively, were 24.2, 0.23, and 0.45 for TCDD(AA) and 0.57, 9.7, and 35.5 for TCDD(AHH). Both P-450s were low spin, with carbon monoxide-binding peaks at 448 nm. Their N-terminal amino acid sequences showed 80% homology and contained the sequence: PXXXSATEXL, common to CYP1A P-450s but not others. Polyclonal antibodies to TCDD(AA) and TCDD(AHH) cross-reacted with both P-450s on Western blots and immunoinhibited all TCDD-induced liver microsomal arachidonic acid metabolism, AHH, and 7-EROD. Immunoquantitation using antibodies made monospecific by immunoadsorption against the heterologous P-450 showed that TCDD(AA) and TCDD(AHH) were coinduced in liver in equal amounts and accounted for all of the TCDD-induced P-450. Enzyme assays and Western blots also showed expression of both TCDD(AA) and TCDD(AHH) in kidney but only of TCDD(AHH) in heart, indicating that these P-450s can be independently regulated and selectively induced. On Western blots non-immunopurified anti-TCDD(AA) and anti-TCDD(AHH) antisera recognized rat and guinea pig CYPlA1 and CYP1A2. Immunopurified TCDD(AA) antiserum only recognized rat CYP1A2, indicating that TCDD(AA) is more closely related immunochemically to CYP1A2 than to CYP1A1. The evidence that pleotropic responses to Ah receptor ligands can include induction of a P-450 that can form biologically active products from the endogenous membrane lipid, arachidonic acid, suggests that organ- and cell-specific expression of TCDD-induced P-450s could affect responses to TCDD.	CORNELL UNIV, MED CTR, COLL MED, DEPT MED, NEW YORK, NY 10021 USA; VANDERBILT UNIV, DEPT MED, NASHVILLE, TN 37232 USA	Cornell University; Vanderbilt University	RIFKIND, AB (corresponding author), CORNELL UNIV, MED CTR, COLL MED, DEPT PHARMACOL, 1300 YORK AVE, NEW YORK, NY 10021 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003606] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES-03606] Funding Source: Medline; NIGMS NIH HHS [GM-37922] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD J, 1990, BIOCHEM SOC T, V18, P503, DOI 10.1042/bst0180503; BLACK SD, 1987, ADV ENZYMOL RAMB, V60, P35; CANGA L, 1988, P NATL ACAD SCI USA, V85, P905, DOI 10.1073/pnas.85.3.905; CANGA L, 1993, IN PRESS MOL PHARM; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; CAPDEVILA JH, 1990, J BIOL CHEM, V265, P10865; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; ESCALANTE B, 1993, EUR J PHARMACOL, V235, P1, DOI 10.1016/0014-2999(93)90812-V; FALCK JR, 1990, J BIOL CHEM, V265, P10244; GONZALEZ FJ, 1984, MOL PHARMACOL, V26, P117; GUENGERICH FP, 1982, BIOCHEMISTRY-US, V21, P6019, DOI 10.1021/bi00266a045; GUPTA RP, 1990, ARCH BIOCHEM BIOPHYS, V282, P170, DOI 10.1016/0003-9861(90)90101-4; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HANSEN AJ, 1989, DNA-J MOLEC CELL BIO, V8, P179, DOI 10.1089/dna.1.1989.8.179; HARLOW E, 1988, ANTIBODIES, P506; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; HOBBS AA, 1986, J BIOL CHEM, V261, P9444; IMAOKA S, 1988, J BIOCHEM-TOKYO, V104, P481, DOI 10.1093/oxfordjournals.jbchem.a122494; JAISWAL AK, 1985, SCIENCE, V228, P80, DOI 10.1126/science.3838385; KANETOSHI A, 1992, MOL PHARMACOL, V42, P1020; KARARA A, 1992, BIOCHEM BIOPH RES CO, V182, P1320, DOI 10.1016/0006-291X(92)91877-S; KARARA A, 1993, J BIOL CHEM, V268, P13565; KAWAJIRI K, 1984, J BIOL CHEM, V259, P145; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAETHEM RM, 1992, J PHARMACOL EXP THER, V262, P433; LAETHEM RM, 1992, MOL PHARMACOL, V42, P958; LAETHEM RM, 1993, J BIOL CHEM, V268, P12912; LENTNEK M, 1991, BIOCHEM BIOPH RES CO, V174, P1267, DOI 10.1016/0006-291X(91)91558-T; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADHUN ZT, 1991, J CLIN INVEST, V88, P456, DOI 10.1172/JCI115325; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; NAGATA K, 1985, J BIOCHEM-TOKYO, V97, P1755, DOI 10.1093/oxfordjournals.jbchem.a135234; NAKAI K, 1992, J BIOL CHEM, V267, P19503; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; OKINO ST, 1992, J BIOL CHEM, V267, P6991; OLIW EH, 1982, J BIOL CHEM, V257, P3771; OMATA K, 1992, AM J PHYSIOL, V262, pF8, DOI 10.1152/ajprenal.1992.262.1.F8; OMURA T, 1964, J BIOL CHEM, V239, P2370; PARKINSON A, 1983, ARCH BIOCHEM BIOPHYS, V225, P203, DOI 10.1016/0003-9861(83)90024-3; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; RIFKIND AB, 1984, TOXICOL APPL PHARM, V72, P343, DOI 10.1016/0041-008X(84)90319-3; RIFKIND AB, 1990, BIOCHEM BIOPH RES CO, V172, P1180, DOI 10.1016/0006-291X(90)91573-B; RIFKIND AB, 1984, BANBURY REPORT, V18, P255; SINCLAIR JF, 1990, BIOCHEM J, V269, P85, DOI 10.1042/bj2690085; SINCLAIR JF, 1992, HDB EXPT PHARM, V105, P259; SNYDER GD, 1989, AM J PHYSIOL, V256, pE221, DOI 10.1152/ajpendo.1989.256.2.E221; THOMAS PE, 1983, J BIOL CHEM, V258, P4590; THOMAS PE, 1976, J BIOL CHEM, V251, P1385; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSYRLOV IB, 1990, XENOBIOTICA, V20, P1163, DOI 10.3109/00498259009046836; WAXMAN DJ, 1982, J BIOL CHEM, V257, P446; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; WRIGHTON SA, 1986, MOL PHARMACOL, V29, P405; YOSHIDA S, 1990, ARCH BIOCHEM BIOPHYS, V280, P346, DOI 10.1016/0003-9861(90)90340-5	57	92	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3387	3396						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106378				2022-12-27	WOS:A1994MV63100041
J	ZHU, Y; CONNER, GE				ZHU, Y; CONNER, GE			INTERMOLECULAR ASSOCIATION OF LYSOSOMAL PROTEIN PRECURSORS DURING BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYL PHOSPHODIESTERASE; I-CELL DISEASE; CATHEPSIN-D; ENDOPLASMIC-RETICULUM; MEMBRANE ASSOCIATION; PARTIAL-PURIFICATION; HEPG2 CELLS; ACTIVATOR; ENZYMES; FIBROBLASTS	To study the mechanism involved in mannose-6-phosphate (Man-6-P) independent lysosomal proenzyme membrane association, we used a reversible cross-linker to probe radiolabeled human HepG2 cells permeabilized with saponin in the presence of Man-6-P. After immunoprecipitation of the extracted and cross-linked cells with anti-cathepsin D antibody, followed by complete reduction of the immunoprecipitates and SDS-polyacrylamide gel electrophoresis analysis, we found that procathepsin D was specifically and transiently associated, independent of Man-6-P, with two co-synthesized glycoproteins having molecular masses of 68 and 72 kDa. Pulse-chase and cell fractionation experiments showed that the Man-6-P independent association of procathepsin D with the 68-kDa protein started in the rough endoplasmic reticulum, continued in the Golgi, but had no association with either membrane. The Man-6-P independent association of procathepsin D with the 72-kDa protein and the membrane was found in compartments all the way from the Golgi to the dense lysosome, where processing of procathepsin D is believed to occur and where procathepsin D dissociated from the 72-kDa protein and the membrane. Endo H digestion of the 72-kDa protein showed that this protein was partially resistant to Endo H, suggesting that membrane association of the procathepsin D-72.kDa protein complex probably began in a late Golgi compartment. Endo F digestion of the proteins showed both have the same molecular mass around 58 kDa. Using antiserum against human saposin C, we identified the two glycoproteins as forms of prosaposin with different glycosylation. The transient, Man-6-P independent, membrane association of the procathepsin D-prosaposin complex and the presence of this complex in heavy lysosomes indicated that the proteins were transported to the lysosome as a complex. The association of two lysosomal proteins in the endoplasmic reticulum early after synthesis suggested that preassembly of some lysosomal components occurs before the earliest previously identified steps in the sorting pathway.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33101	University of Miami			Conner, Gregory/AAI-1285-2021	Conner, Gregory/0000-0003-2217-2252				BRETZ R, 1977, EUR J BIOCHEM, V77, P187; BURGE V, 1991, BIOCHEM J, V275, P797, DOI 10.1042/bj2750797; CONNER GE, 1989, BIOCHEMISTRY-US, V28, P3530, DOI 10.1021/bi00434a057; CONNER GE, 1992, J BIOL CHEM, V267, P2738; DIMENT S, 1988, J BIOL CHEM, V263, P6901; FISHER PA, 1982, J CELL BIOL, V92, P674, DOI 10.1083/jcb.92.3.674; FUJIBAYASHI S, 1986, BIOCHIM BIOPHYS ACTA, V875, P554; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339; GRASSEL S, 1992, BIOCHEM BIOPH RES CO, V182, P276, DOI 10.1016/S0006-291X(05)80141-X; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; IOANNOU YA, 1992, J CELL BIOL, V119, P1137, DOI 10.1083/jcb.119.5.1137; JINSEL LA, 1991, CELL BIOL INT REP, V15, P1167; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEROY JG, 1972, PEDIATR RES, V6, P752, DOI 10.1203/00006450-197210000-00002; LITTLE L, 1987, BIOCHEM J, V248, P151, DOI 10.1042/bj2480151; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MORIMOTO S, 1990, J BIOL CHEM, V265, P1933; MORREAU H, 1992, J BIOL CHEM, V267, P17949; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; NEUFELD EF, 1983, METABOLIC BASIS INHE, P787; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; OWADA M, 1982, BIOCHEM BIOPH RES CO, V105, P814, DOI 10.1016/0006-291X(82)91042-7; PATTHY L, 1991, J BIOL CHEM, V266, P6035; REITMAN ML, 1981, J BIOL CHEM, V256, P4275; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; SOEDA S, 1993, J BIOL CHEM, V268, P18519; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; TONDEUR M, 1971, J PEDIATR-US, V79, P366, DOI 10.1016/S0022-3476(71)80143-9; TONG PY, 1989, J BIOL CHEM, V264, P7970; TSUJI A, 1987, BIOCHEM INT, V15, P945; VANWEELY S, 1990, EUR J BIOCHEM, V191, P669; VARKI A, 1981, J BIOL CHEM, V256, P9937; VONFIGURA K, 1977, EUR J BIOCHEM, V80, P525; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1982, J BIOL CHEM, V257, P2322; WAHEED A, 1981, J BIOL CHEM, V256, P5717; WYNN CH, 1986, BIOCHEM J, V240, P921, DOI 10.1042/bj2400921	43	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3846	3851						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106429				2022-12-27	WOS:A1994MV63100104
J	MANTILE, G; MIELE, L; CORDELLAMIELE, E; SINGH, G; KATYAL, SL; MUKHERJEE, AB				MANTILE, G; MIELE, L; CORDELLAMIELE, E; SINGH, G; KATYAL, SL; MUKHERJEE, AB			HUMAN CLARA CELL 10-KDA PROTEIN IS THE COUNTERPART OF RABBIT UTEROGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIINFLAMMATORY PEPTIDES ANTIFLAMMINS; BACTERIOPHAGE-T7 RNA-POLYMERASE; PLATELET-ACTIVATING-FACTOR; DISULFIDE BOND FORMATION; HIGH-LEVEL EXPRESSION; PHOSPHOLIPASE-A2 ACTIVITY; PANCREATIC PHOSPHOLIPASE-A2; QUATERNARY STRUCTURE; ESCHERICHIA-COLI; LIPOCORTIN-I	Human Clara cell 10-kDa protein has been suggested to be a counterpart of rabbit uteroglobin, an immunomodulatory and antiinflammatory secretory protein. Since this human protein is not readily available in substantial quantity for detailed characterization of its biochemical, biological, and pharmacological properties, we sought to express it in Escherichia coli in order to study its structure-function relationship. However, bacterial overproduction of homodimeric proteins with interchain disulfide bonds, such as Clara cell 10-kDa protein, was thought to be impossible until we achieved expression of native uteroglobin (Miele, L., Cordella-Miele, E., and Mukherjee, A. B. (1990) J. Biol. Chem. 265, 6427-6435). Here, we report high level production of recombinant native dimeric human Clara cell 10-kDa protein in E. coli and its characterization. Recombinant human Clara cell 10-kDa protein forms its disulfide bonds within the bacterial cytoplasm. The purified protein possesses two of the most important activities characteristic of uteroglobin: (i) it is an excellent substrate of transglutaminase, and (ii) it is a potent inhibitor of porcine pancreatic and, more importantly, human synovial phospholipase A2. These results demonstrate that human Clara cell 10-kDa protein and rabbit uteroglobin have very similar biochemical properties. Our data suggest that this protein may possess immunomodulatory and antiinflammatory activities of potential physiological and pharmacological importance.	NICHHD, DEV GENET SECT,HUMAN GENET BRANCH,BLDG 10,RM 95242, BETHESDA, MD 20892 USA; UNIV PITTSBURGH, SCH MED, DEPT PATHOL, PITTSBURGH, PA 15261 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; AMIRKHANIAN JD, 1993, BIOCHIM BIOPHYS ACTA, V1165, P321, DOI 10.1016/0005-2760(93)90143-W; ANDREWS PC, 1987, ANAL BIOCHEM, V161, P524, DOI 10.1016/0003-2697(87)90484-2; ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P716, DOI 10.1073/pnas.90.2.716; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BEIER HM, 1968, BIOCHIM BIOPHYS ACTA, V160, P289, DOI 10.1016/0005-2795(68)90108-6; BOURBON JR, 1991, PULMONARY SURFACTANT, P37; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY MK, 1990, METHOD ENZYMOL, V182, P112; CABRE F, 1992, BIOCHEM PHARMACOL, V44, P519, DOI 10.1016/0006-2952(92)90444-N; CAMUSSI G, 1990, J EXP MED, V171, P913, DOI 10.1084/jem.171.3.913; CAMUSSI G, 1990, ADV EXP MED BIOL, V279, P161; CHAN CC, 1990, INT CONGR SER, V918, P467; CHAN CC, 1991, ARCH OPHTHALMOL-CHIC, V109, P278, DOI 10.1001/archopht.1991.01080020124058; CHUNG SI, 1975, ISOZYMES, V1, P259; CORDELLAMIELE E, 1990, J BIOL CHEM, V265, P17180; CORDELLAMIELE E, 1993, J BIOCHEM-TOKYO, V113, P164, DOI 10.1093/oxfordjournals.jbchem.a124021; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; DAS A, 1990, METHOD ENZYMOL, V182, P93; Davies P J, 1988, Adv Exp Med Biol, V250, P391; DEMAYO FJ, 1991, MOL ENDOCRINOL, V5, P311, DOI 10.1210/mend-5-3-311; DIROSA M, 1990, PROG CLIN BIOL RES, V349, P81; FACCHIANO A, 1991, LIFE SCI, V48, P453, DOI 10.1016/0024-3205(91)90501-2; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FOLK JE, 1973, ADV ENZYMOL RAMB, V38, P109; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GUY J, 1992, BIOCHEM BIOPH RES CO, V189, P662, DOI 10.1016/0006-291X(92)92252-S; HAGEN G, 1990, NUCLEIC ACIDS RES, V18, P2939, DOI 10.1093/nar/18.10.2939; HAIGLER HT, 1987, J BIOL CHEM, V262, P6921; HEINRIKSON RL, 1990, ADV EXP MED BIOL, V279, P37; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; IALENTI A, 1990, AGENTS ACTIONS, V29, P48, DOI 10.1007/BF01964716; KOHNO T, 1990, METHOD ENZYMOL, V185, P187; KRISHNAN RS, 1967, SCIENCE, V158, P490, DOI 10.1126/science.158.3800.490; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN SW, 1986, LIFE SCI, V38, P1813, DOI 10.1016/0024-3205(86)90135-9; LLORET S, 1992, BIOCHEM PHARMACOL, V44, P1437, DOI 10.1016/0006-2952(92)90546-U; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1971, ANAL BIOCHEM, V44, P221, DOI 10.1016/0003-2697(71)90363-0; MANJUNATH R, 1984, BIOCHEM BIOPH RES CO, V121, P400, DOI 10.1016/0006-291X(84)90736-8; MANJUNATH R, 1987, BIOCHEM PHARMACOL, V36, P741, DOI 10.1016/0006-2952(87)90728-3; MATSUDAIRA PT, 1987, PRACTICAL GUIDE PROT; MIELE L, 1990, ADV EXP MED BIOL, V279, P137; MIELE L, 1987, ENDOCR REV, V8, P474, DOI 10.1210/edrv-8-4-474; MIELE L, 1990, J BIOL CHEM, V265, P6427; MIELE L, 1988, NATURE, V335, P726, DOI 10.1038/335726a0; MORIZE I, 1987, J MOL BIOL, V194, P725, DOI 10.1016/0022-2836(87)90250-6; MORRISON SL, 1989, ADV IMMUNOL, V44, P65, DOI 10.1016/S0065-2776(08)60640-9; Mukherjee A B, 1988, Adv Exp Med Biol, V231, P135; MUKHERJEE AB, 1992, DNA CELL BIOL, V11, P233, DOI 10.1089/dna.1992.11.233; MUKHERJEE AB, 1982, AM J REPROD IMMUNOL, V2, P135, DOI 10.1111/j.1600-0897.1982.tb00154.x; MUKHERJEE DC, 1983, SCIENCE, V219, P989, DOI 10.1126/science.6130601; MUKHERJEE M, RATIONAL DRUG DESIGN; NIETO A, 1977, ARCH BIOCHEM BIOPHYS, V180, P82, DOI 10.1016/0003-9861(77)90011-X; NORDLUNDMOLLER L, 1990, J BIOL CHEM, V265, P12690; PERRETTI M, 1991, BRIT J PHARMACOL, V103, P1327, DOI 10.1111/j.1476-5381.1991.tb09788.x; POLLITT S, 1983, J BACTERIOL, V153, P27, DOI 10.1128/JB.153.1.27-32.1983; PORTA R, 1986, BIOL REPROD, V35, P965, DOI 10.1095/biolreprod35.4.965; PRUZANSKI W, 1990, ADV EXP MED BIOL, V279, P239; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J, 1989, MOL CLONING LABORATO; SCHIFFMAN E, 1983, AGENTS ACTIONS S, V2, P106; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; SINGH G, 1988, BIOCHIM BIOPHYS ACTA, V950, P329, DOI 10.1016/0167-4781(88)90129-7; SINGH G, 1988, J HISTOCHEM CYTOCHEM, V36, P73, DOI 10.1177/36.1.3275712; SINGH G, 1990, BIOCHIM BIOPHYS ACTA, V1039, P348, DOI 10.1016/0167-4838(90)90270-P; SINGH G, 1993, EXP LUNG RES, V19, P67, DOI 10.3109/01902149309071081; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TETTA C, 1991, J PHARMACOL EXP THER, V257, P616; UMLAND TC, 1992, J MOL BIOL, V224, P441, DOI 10.1016/0022-2836(92)91006-B; VASANTHAKUMAR G, 1988, BIOCHEM PHARMACOL, V37, P389, DOI 10.1016/0006-2952(88)90204-3; Wolf Markus, 1992, Human Molecular Genetics, V1, P371, DOI 10.1093/hmg/1.6.371	75	131	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20343	20351						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8104186				2022-12-27	WOS:A1993LY01900064
J	LIAO, JK; HOMCY, CJ				LIAO, JK; HOMCY, CJ			THE RELEASE OF ENDOTHELIUM-DERIVED RELAXING FACTOR VIA ALPHA(2)-ADRENERGIC RECEPTOR ACTIVATION IS SPECIFICALLY MEDIATED BY G(I-ALPHA-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; NUCLEOTIDE-BINDING PROTEINS; PERTUSSIS-TOXIN; ADENYLATE-CYCLASE; ALPHA-SUBUNITS; REGULATORY PROTEINS; ADRENERGIC-RECEPTOR; GTPASE ACTIVITY; ANTIBODIES; GI2	The purpose of this study is to determine which pertussis toxin-sensitive guanine nucleotide-binding protein (G(i)) mediates alpha2-adrenergic receptor stimulation of endothelium-derived relaxing factor (EDRF) release. Bovine aortic endothelial cells were treated with pertussis toxin (0-100 ng/ml) for 16 h and stimulated with an alpha2-adrenergic receptor agonist, UK14304, to release EDRF in a bioassay system. Pertussis toxin produced a concentration-dependent decrease in EDRF release with maximal inhibition (80%) occurring at 5 ng/ml. This correlated with a decrease in receptor-G protein coupling as measured by 87% loss of high affinity agonist binding sites and 94% decrease in agonist-stimulated GTPase activity. Immunoprecipitation of [P-32]NAD-ribosylated membranes using specific G(i) protein antisera demonstrated that complete ADP-ribosylation of G(ialpha2) occurred at 5 ng/ml compared to 30 ng/ml for G(ialpha3). When bovine aortic endothelial cell membranes were treated with carboxyl terminus-directed antisera to G(ialpha2) (P4) and G(ialpha3) (EC), the P4 antisera abolished 86% of the high affinity agonist binding sites and 93% decrease in agonist-stimulated GTPase activity, while the EC antisera had minimal effect (12%). These results indicate that G(ialpha2) mediates most of the EDRF released via the alpha2-adrenergic receptor.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; AMER CYANAMID CO,LEDERLE LABS,DIV MED RES,PEARL RIVER,NY 10965	Harvard University; Harvard Medical School; Columbia University	LIAO, JK (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,221 LONGWOOD AVE,LMRC-307,BOSTON,MA 02115, USA.				NHLBI NIH HHS [HL02508] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002508] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; DANIELISSAKANI S, 1989, J BIOL CHEM, V264, P20240; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HUFF RM, 1986, J BIOL CHEM, V261, P1105; KATADA T, 1986, J BIOL CHEM, V261, P8182; KIM MH, 1987, BIOCHEMISTRY-US, V26, P3664, DOI 10.1021/bi00386a061; KIM SY, 1987, P NATL ACAD SCI USA, V85, P4153; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KUROSE H, 1983, J BIOL CHEM, V258, P4870; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO JK, 1992, CIRC RES, V70, P1018, DOI 10.1161/01.RES.70.5.1018; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MCKENZIE FR, 1988, BIOCHEM J, V249, P653, DOI 10.1042/bj2490653; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEER EJ, 1984, J BIOL CHEM, V259, P4222; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RIBEIRONETO FAP, 1985, METHOD ENZYMOL, V109, P566; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809	27	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19528	19533						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8103519				2022-12-27	WOS:A1993LW81900059
J	SHENG, S; MORAGAAMADOR, DA; VANHEEKE, G; ALLISON, RD; RICHARDS, NGJ; SCHUSTER, SM				SHENG, S; MORAGAAMADOR, DA; VANHEEKE, G; ALLISON, RD; RICHARDS, NGJ; SCHUSTER, SM			GLUTAMINE INHIBITS THE AMMONIA-DEPENDENT ACTIVITIES OF 2 CYS-1 MUTANTS OF HUMAN ASPARAGINE SYNTHETASE THROUGH THE FORMATION OF AN ABORTIVE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; AMIDE TRANSFER-FUNCTION; ESCHERICHIA-COLI; PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; METHIONINE AMINOPEPTIDASE; MONOCLONAL-ANTIBODIES; LINKED GLYCOSYLATION; CARBAMYL-PHOSPHATE; EXPRESSION; CYSTEINE	Cys-1 mutants of recombinant human asparagine synthetase were constructed and their ability to catalyze the glutamine-dependent nitrogen transfer reaction required for asparagine biosynthesis was determined. In agreement with previous work, altering Cys-1 to either Ala or Ser eliminated the glutamine-dependent activity while only minimally affecting the kinetic properties of the ammonia-dependent reaction. A lack of glutaminase activity in these mutants also allowed examination of glutamine binding in studies of the ability of glutamine to inhibit the ammonia-dependent production of asparagine. In both mutants, analysis of the observed kinetics indicated that glutamine inhibited ammonia-dependent asparagine synthesis through the formation of an abortive complex. This unanticipated observation suggests that the commonly accepted mechanism for nitrogen transfer from the primary amide of glutamine to aspartic acid in asparagine synthetase may have to be re-examined. A novel mechanistic proposal which is consistent with the formation of an abortive complex in the two Cys-1 mutants is presented.	UNIV FLORIDA, ICBR, BOX 110580, GAINESVILLE, FL 32610 USA; UNIV FLORIDA, SCH MED, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA; UNIV FLORIDA, DEPT CHEM, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida			van Opstal, John/D-1907-2010		NATIONAL CANCER INSTITUTE [R01CA028725] Funding Source: NIH RePORTER; NCI NIH HHS [CA28725] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON RD, 1977, J BIOL CHEM, V252, P6046; AMURO N, 1985, J BIOL CHEM, V260, P4844; ANDRULIS IL, 1987, MOL CELL BIOL, V7, P2435, DOI 10.1128/MCB.7.7.2435; BAKER EN, 1976, J MOL BIOL, V101, P185, DOI 10.1016/0022-2836(76)90371-5; BARTLETT PA, 1983, BIOCHEMISTRY-US, V22, P4618, DOI 10.1021/bi00289a002; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CEDAR H, 1969, J BIOL CHEM, V244, P4122; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; COLLETTA G, 1992, BIOCHEM BIOPH RES CO, V183, P265, DOI 10.1016/0006-291X(92)91638-7; COONEY DA, 1980, INT J BIOCHEM, V11, P519, DOI 10.1016/0020-711X(80)90261-X; COONEY DA, 1976, CANCER TREAT REP, V60, P1493; DRENNTH J, 1971, ENZYMES, P609; DRENTH J, 1968, NATURE, V218, P929, DOI 10.1038/218929a0; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GIBBS RA, 1992, SCIENCE, V258, P803, DOI 10.1126/science.1439788; GONG SS, 1990, NUCLEIC ACIDS RES, V18, P3509, DOI 10.1093/nar/18.12.3509; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HONGO S, 1989, BIOCHEM INT, V18, P661; HONGO S, 1990, LEUKEMIA, V4, P708; HUANG CY, 1978, FED PROC, V37, P1423; HUANG YZ, 1975, ENZYME, V19, P314, DOI 10.1159/000459006; IMPERIALI B, 1991, BIOCHEMISTRY-US, V30, P4374, DOI 10.1021/bi00232a002; IMPERIALI B, 1992, J AM CHEM SOC, V114, P7944, DOI 10.1021/ja00046a069; IMPERIALI B, 1992, J AM CHEM SOC, V114, P7942, DOI 10.1021/ja00046a068; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1971, BIOCHEMISTRY-US, V10, P3371, DOI 10.1021/bi00794a009; LUEHR CA, 1985, ARCH BIOCHEM BIOPHYS, V237, P335, DOI 10.1016/0003-9861(85)90285-1; LUSTY CJ, 1993, BIOCHEMISTRY-US, V32, P1278, DOI 10.1021/bi00056a012; MANTSALA P, 1984, J BIOL CHEM, V259, P4230; MEHLHAFF PM, 1985, BIOCHEMISTRY-US, V24, P1104, DOI 10.1021/bi00326a006; MEI B, 1989, J BIOL CHEM, V264, P16613; MILMAN HA, 1979, BIOCHEM J, V181, P51, DOI 10.1042/bj1810051; NAKAGAWA S, 1989, ANAL BIOCHEM, V181, P75, DOI 10.1016/0003-2697(89)90395-3; OBRIEN WE, 1976, ANAL BIOCHEM, V76, P423, DOI 10.1016/0003-2697(76)90337-7; PFEIFFER NE, 1987, J BIOL CHEM, V262, P11565; RICHARDS NGJ, 1992, FEBS LETT, V313, P98, DOI 10.1016/0014-5793(92)81421-H; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; Sambrook J, 1989, MOL CLONING LABORATO; SHAW E, 1990, ADV ENZYMOL RAMB, V63, P271; SHENG SJ, 1992, PROTEIN EXPRES PURIF, V3, P337, DOI 10.1016/1046-5928(92)90010-T; TRECO DA, 1987, CURRENT PROTOCOLS MO; TSO JY, 1982, J BIOL CHEM, V257, P3525; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; UNNITHAN S, 1984, ANAL BIOCHEM, V136, P195, DOI 10.1016/0003-2697(84)90325-7; UREN JR, 1977, BIOCHEM PHARMACOL, V26, P1405, DOI 10.1016/0006-2952(77)90365-3; VANHEEKE G, 1989, J BIOL CHEM, V264, P19475; VANHEEKE G, 1989, J BIOL CHEM, V264, P5503; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WALSH C, 1979, ENZYMATIC REACTION M, P170; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; WINTERBU.PJ, 1971, BIOCHEM J, V121, P701, DOI 10.1042/bj1210701; ZAHN H, 1969, CHEM BER-RECL, V102, P2158, DOI 10.1002/cber.19691020645; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203	55	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16771	16780						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8102140				2022-12-27	WOS:A1993LQ33600097
J	SKERJANC, IS; TOYOFUKU, T; RICHARDSON, C; MACLENNAN, DH				SKERJANC, IS; TOYOFUKU, T; RICHARDSON, C; MACLENNAN, DH			MUTATION OF GLUTAMATE-309 TO GLUTAMINE ALTERS ONE CA2+-BINDING SITE IN THE CA2+-ATPASE OF SARCOPLASMIC-RETICULUM EXPRESSED IN SF9 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAIN; FUNCTIONAL CONSEQUENCES; AMINO-ACIDS; TRANSMEMBRANE DOMAIN; ADENOSINE-TRIPHOSPHATASE; CA-2+-ATPASE; ATPASE; CALCIUM; MUSCLE; ANTIBODIES	Sf9 cells infected with a baculovirus vector containing SERCA1 cDNA expressed immunoreactive rabbit fast-twitch muscle Ca2+-ATPase at levels up to 3 mg/liter. The microsomal fraction isolated from infected Sf9 cells catalyzed Ca2+ transport at rates 6-fold above control values. To obtain direct evidence for the postulate (Clarke, D. M., Loo, T. W., Inesi, G., and MacLennan, D. H., et al. (1989) Nature 339, 476-478) that Glu309 contributes to a Ca2+-binding site in the transmembrane sector of the Ca2+-ATPase, Ca2+ binding to wild type and mutant (Glu309 to Gln) Ca2+-ATPases was measured. The wild type Ca2+-ATPase, expressed in Sf9 cells and purified using a monoclonal antibody bound to Sepharose beads, bound approximately 1.6-1.7 mol Ca2+/mol of enzyme at 2 muM Ca2+ in a buffer favoring the E1 conformation of the enzyme and at 10 muM Ca2+ in a buffer favoring the E2 conformation. Under identical conditions, the mutant Ca2+-ATPase bound less than 0.1 mol of Ca2+/mol of enzyme in E1 buffer, but 0.8 mol Ca2+/mol in the E2 buffer. In spite of the ability of the Glu309 to Gln mutant enzyme to bind about 1 mol of Ca2+/mol of enzyme, E2P formation was not inhibited by up to 100 muM Ca2+, and E1P formation from ATP and Ca2+ was not observed with up to 100 muM Ca2+ in intact microsomal vesicles from Sf9 cells. Nevertheless, with detergent-solubilized and purified mutant Ca2+-ATPases, E2P formation was inhibited with a K0.5 of 2 muM Ca2+. These observations are consistent with the view that a single intact Ca2+-binding site is present in the mutant Ca2+-ATPase, which is accessible to Ca2+ only from the lumenal side and only in the E2 conformation. Transition from E2 to E1-Ca2+ may occur during or following Ca2+ binding, accounting for the relatively high Ca2+ affinity and inhibition by Ca2+ of phosphorylation from P(i).	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO M5G 1L6, ONTARIO, CANADA; NATL RES COUNCIL CANADA, INST BIOTECHNOL RES, MONTREAL H4P 2R2, PQ, CANADA	University of Toronto; National Research Council Canada			Skerjanc, Ilona/AAN-3318-2020					ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; HANEL AM, 1991, BIOCHEMISTRY-US, V30, P11320, DOI 10.1021/bi00111a019; IKEMOTO N, 1982, ANNU REV PHYSIOL, V44, P297, DOI 10.1146/annurev.ph.44.030182.001501; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1980, J BIOL CHEM, V255, P3025; INESI G, 1985, ANNU REV PHYSIOL, V45, P574; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MACLENNAN DH, 1991, 1991 HASSL S ION PUM, P54; MACLENNAN DH, 1985, STRUCTURE FUNCTION S, P91; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MOLNAR E, 1990, BIOCHIM BIOPHYS ACTA, V1023, P147, DOI 10.1016/0005-2736(90)90410-P; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P11331, DOI 10.1021/bi00111a020; RICHARDSON C, 1992, BACULOVIRUS RECOMBIN, P67; ROSSI B, 1979, J BIOL CHEM, V254, P2302; SKERJANC IS, 1991, MOL BIOL MUSCLE; SUMMERS MD, 1988, TEX AGR EXP STN B, V1555; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; VILSEN B, 1992, FEBS LETT, V306, P247, DOI 10.1016/0014-5793(92)81010-J; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WEBER K, 1969, J BIOL CHEM, V244, P4406; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	35	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15944	15950						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8101845				2022-12-27	WOS:A1993LN30500088
J	BRANDSCH, R; BICHLER, V; MAUCH, L; DECKER, K				BRANDSCH, R; BICHLER, V; MAUCH, L; DECKER, K			CYSTEINE TO SERINE REPLACEMENTS IN 6-HYDROXY-D-NICOTINE OXIDASE - CONSEQUENCES FOR ENZYME-ACTIVITY, COFACTOR INCORPORATION, AND FORMATION OF HIGH-MOLECULAR-WEIGHT PROTEIN COMPLEXES WITH MOLECULAR CHAPERONES (GROEL)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY BOUND FLAVIN; BINDING; IDENTIFICATION; SITE; FAD	6-Hydroxy-D-nicotine oxidase, an enzyme with FAD covalently attached to the protein, contains 6 cysteine residues in positions 45 (Cys1), 59 (Cys2), 136 (Cys3), 173 (Cys4), 260 (Cys5) and 433 (Cys6). Cys2, 3, 5, and 6 were replaced with serine by site-directed mutagenesis. The effects of these exchanges on enzyme activity, the autocatalytic incorporation of the cofactor, and the interaction of the mutant proteins with molecular chaperones were analyzed. The flavinylation of 6-hydroxy-D-nicotine oxidase is dependent on the presence of allosteric effectors, e.g. glycerol 3-phosphate or other phosphorylated tricarbon compounds. Replacement of Cys2 or Cys5 abolished this dependence. Covalent incorporation of FAD was reduced to an undetectable level in the Cys3 and Cys5 mutants. Replacement of Cys6 by Ser had no significant effect on enzyme activity and cofactor attachment. Deletion of two amino acids, Phe and Arg, situated 12 and 11 amino acid residues, respectively, from the carboxyl terminus of the protein, resulted in an inactive enzyme with no covalently bound FAD. This result indicates that almost the entire protein chain has to be synthesized before the cofactor can be incorporated, making a cotranslational flavinylation step rather unlikely. The distribution of the 6-hydroxy-D-nicotine oxidase polypeptide between the high molecular weight complexes and the free soluble form was analyzed by gel filtration on Sephacryl S-200. The wild-type holoenzyme as well as the wild-type apoenzyme were recovered in the eluent fraction of the column while the mutant proteins were retained in high molecular weight complexes, predominantly in those associated with GroEL, as revealed by immunoprecipitation. The extent of complex formation with this molecular chaperone depended on the position of the mutated Cys residue within the protein. Complex formation was highest with protein from the mutants Cys2 and Cys3, less with the Cys5, and absent with the Cys6 mutant protein. Thus, alterations in the amino-terminal part of the 6-hydroxy-D-nicotine oxidase appear more important for the interaction with molecular chaperones than alterations situated in the carboxyl-terminal part of the protein.			BRANDSCH, R (corresponding author), UNIV FREIBURG,INST BIOCHEM,HERMANN HERDER STR 7,W-7800 FREIBURG,GERMANY.							Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDSCH R, 1992, J BIOL CHEM, V267, P20844; BRANDSCH R, 1991, J BIOL CHEM, V266, P19056; BRANDSCH R, 1989, EUR J BIOCHEM, V182, P125, DOI 10.1111/j.1432-1033.1989.tb14808.x; DECKER K, 1991, BIOFACTORS, V3, P669; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; HEDERSTEDT L, 1989, BIOCHEM J, V260, P491, DOI 10.1042/bj2600491; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MAGUIRE JJ, 1986, BIOCHEMISTRY-US, V25, P5202, DOI 10.1021/bi00366a033; Maniatis T., 1982, MOL CLONING; MAUCH L, 1989, FEBS LETT, V257, P86, DOI 10.1016/0014-5793(89)81792-2; MAUCH L, 1990, THESIS U FREIBURG FR; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MOHLER H, 1972, EUR J BIOCHEM, V29, P152, DOI 10.1111/j.1432-1033.1972.tb01969.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6	18	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12724	12729						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8099585				2022-12-27	WOS:A1993LG65800074
J	CARROLL, K; ELROYSTEIN, O; MOSS, B; JAGUS, R				CARROLL, K; ELROYSTEIN, O; MOSS, B; JAGUS, R			RECOMBINANT VACCINIA VIRUS K3L GENE-PRODUCT PREVENTS ACTIVATION OF DOUBLE-STRANDED RNA-DEPENDENT, INITIATION FACTOR-2-ALPHA-SPECIFIC PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON; TRANSLATION; EIF-2-ALPHA; INHIBITION; BINDING; CELLS; DNA; AUTOPHOSPHORYLATION; PHOSPHORYLATION; PURIFICATION	Deletion of the vaccinia virus K3L gene, a homologue of the alpha subunit of protein synthesis initiation factor 2, has been reported to reduce the ability of the virus to grow in interferon-treated cells (Beattie, E., Tattaglia, J., and Paoletti, E. (1991) Virology 183, 419-422). Purified recombinant K3L gene product, pK3r, has potent effects on activation of double-stranded (ds) RNA-dependent, initiation factor-2alpha (eIF-2alpha)-specific protein kinase (PKR) in in vitro reactions. Recombinant pK3 prevents the inhibition of protein synthesis by dsRNA in a cell-free translation system from rabbit reticulocytes at levels equal to, or lower than, the level of endogenous eIF-2alpha. In the cell-free translation system, pK3r exerts its effects at all dsRNA concentrations tested, by preventing phosphorylation of eIF-2alpha. In addition, pK3r reduces the autophosphorylation of immunopurified PKR, as well as its ability to phosphorylate the alpha subunit of purified eIF-2. At 400 mM NaCl, in vitro translated [S-35]methionine-radiolabeled pK3 can be co-immunoprecipitated with human PKR, using a monoclonal antibody to PKR. This tight binding is consistent with a role for pK3 as a pseudosubstrate for the kinase, and identifies the amino-terminal 30% of eIF-2alpha as the domain recognized by the eIF-2alpha-specific protein kinases. In addition, the tight binding opens up the possibility of using binding assays to identify functional domains within the kinase and pK3. Recombinant pK3 also prevents activation of the heme-sensitive eIF-2alpha-specific protein kinase, eIF-2alpha-PK(h), in both cell-free translation systems as well as in partially purified preparations. This suggests some similarity between the eIF-2alpha binding domains of the two eIF-2alpha specific protein kinases.	CTR MARINE BIOTECHNOL,600 E LOMBARD ST,BALTIMORE,MD 21202; NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Elroy-Stein, Orna/0000-0002-3716-1540; Moss, Bernard/0000-0002-2154-8564				AKKARAJU GR, 1989, J BIOL CHEM, V264, P10321; BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; BLACK TL, 1989, J VIROL, V63, P2244, DOI 10.1128/JVI.63.5.2244-2251.1989; BOURSNELL MEG, 1988, J GEN VIROL, V69, P2995, DOI 10.1099/0022-1317-69-12-2995; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG HW, 1992, P NATL ACAD SCI USA, V89, P4825, DOI 10.1073/pnas.89.11.4825; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CLEMENS M, 1992, NATURE, V360, P210, DOI 10.1038/360210a0; CLEMENS MJ, 1993, IN PRESS J INTERFERO; DAVIES MV, 1992, J VIROL, V66, P1943, DOI 10.1128/JVI.66.4.1943-1950.1992; DESTEFANO J, 1990, J VIROL, V64, P4445, DOI 10.1128/JVI.64.9.4445-4453.1990; ESPOSITO J, 1981, J VIROL METHODS, V2, P175, DOI 10.1016/0166-0934(81)90036-7; GALABRU J, 1985, CELL, V43, P685, DOI 10.1016/0092-8674(85)90241-7; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GUPTA SL, 1982, VIROLOGY, V120, P495, DOI 10.1016/0042-6822(82)90051-4; HINNEBUSCH AG, 1993, TRANSLATIONAL REGULA, P87; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; IMANI F, 1988, P NATL ACAD SCI USA, V85, P7887, DOI 10.1073/pnas.85.21.7887; JAGUS R, 1987, METHOD ENZYMOL, V152, P296; JAGUS R, 1987, METHOD ENZYMOL, V152, P267; JAGUS R, 1983, POSTTRANSLATIONAL CO, P159; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KATZE MG, 1988, J VIROL, V62, P3710, DOI 10.1128/JVI.62.10.3710-3717.1988; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KATZE MG, 1992, J INTERFERON RES, V12, P241, DOI 10.1089/jir.1992.12.241; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; LEE TG, 1992, J BIOL CHEM, V267, P14238; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MAURIDES PA, 1989, ANAL BIOCHEM, V183, P144, DOI 10.1016/0003-2697(89)90182-6; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NILSEN TW, 1982, J BIOL CHEM, V257, P4593; ONIELL RE, 1989, J VIROL, V63, P5069; RICE AP, 1985, J VIROL, V54, P894, DOI 10.1128/JVI.54.3.894-898.1985; ROY S, 1990, SCIENCE, V247, P1216, DOI 10.1126/science.2180064; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; SAFER B, 1990, EUR J BIOCHEM, V89, P696; SAMUEL CE, 1988, PROG NUCLEIC ACID RE, V35, P27, DOI 10.1016/S0079-6603(08)60609-1; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SAMUEL CE, 1984, J BIOL CHEM, V259, P3451; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; SONENBERG N, 1990, New Biologist, V2, P402; STUDIER FW, 1990, METHOD ENZYMOL, V185, P49; WATSON JC, 1991, VIROLOGY, V185, P206, DOI 10.1016/0042-6822(91)90768-7; WHITAKERDOWLING P, 1983, VIROLOGY, V131, P128, DOI 10.1016/0042-6822(83)90539-1; WHITAKERDOWLING P, 1984, VIROLOGY, V137, P171, DOI 10.1016/0042-6822(84)90020-5	52	158	167	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12837	12842						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8099586				2022-12-27	WOS:A1993LG65800089
J	CHEN, HM; PAHL, HL; SCHEIBE, RJ; ZHANG, DE; TENEN, DG				CHEN, HM; PAHL, HL; SCHEIBE, RJ; ZHANG, DE; TENEN, DG			THE SP1 TRANSCRIPTION FACTOR BINDS THE CD11B PROMOTER SPECIFICALLY IN MYELOID CELLS INVIVO AND IS ESSENTIAL FOR MYELOID-SPECIFIC PROMOTER ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUCIFERASE REPORTER GENE; FACTOR GATA-1; DNA-BINDING; RECEPTOR; DIFFERENTIATION; EXPRESSION; MOUSE; ACTIVATION; ENHANCER; SEQUENCE	The myeloid integrin CD11b is expressed selectively on the surface of mature macrophages, monocytes, neutrophils, and natural killer cells. Lineage-specific expression is controlled at the level of mRNA transcription. Recent isolation of the CD11b promoter shows that 92 base pairs (bp) of 5'-flanking DNA are sufficient to direct myeloid-specific expression of a reporter gene. To characterize regulatory sequences important for promoter activity, we performed linker scanning analysis of the 92-bp CD11b promoter and demonstrate that a sequence at bp-60 is essential for CD11b promoter activity. We show that this sequence binds the transcription factor Sp1 in vitro and in vivo. In vivo the Sp1 site is bound only in myeloid (U937) cells, not in cervical carcinoma (HeLa) cells. In addition, the macrophage transcription factor PU.1 binds the CD11b promoter in vitro and in vivo close to the Sp1 site. We propose a model in which binding of a myeloid-specific factor (PU.1) allows a general factor (Sp1) to bind in a tissue-specific fashion thereby contributing to the myeloid-specific expression of CD11b.	HARVARD UNIV,BETH ISRAEL HOSP,DEPT MED,DIV HEMATOL ONCOL,RES & RM 219B,330 BROOKLINE AVE,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Pahl, Heike/AGM-5260-2022	Tenen, Daniel/0000-0002-6423-3888	NCI NIH HHS [CA41456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEMANY J, 1992, BIOCHEM BIOPH RES CO, V183, P659, DOI 10.1016/0006-291X(92)90533-Q; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BORELLINI F, 1991, J BIOL CHEM, V266, P15850; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DARROW AL, 1990, MOL CELL BIOL, V10, P5883, DOI 10.1128/MCB.10.11.5883; DINGHAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FLEMING JC, 1993, J IMMUNOL, V150, P480; HOHN PA, 1989, J BIOL CHEM, V264, P13412; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; LAW SKA, 1987, EMBO J, V6, P915, DOI 10.1002/j.1460-2075.1987.tb04838.x; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P506; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PAHL HL, 1992, BLOOD, V79, P865; PAHL HL, 1991, EXP HEMATOL, V19, P1038; PAHL HL, 1993, IN PRESS J BIOL CHEM; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; ROSMARIN AG, 1989, BLOOD, V73, P131; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SHAPIRO LH, 1991, J BIOL CHEM, V266, P11999; SPANOPOULOU E, 1991, MOL CELL BIOL, V11, P2216, DOI 10.1128/MCB.11.4.2216; TODD RF, 1981, J IMMUNOL, V126, P1435; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	38	190	193	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8230	8239						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8096519				2022-12-27	WOS:A1993KW97900093
J	BERTHIAUME, L; DEICHAITE, I; PESECKIS, S; RESH, MD				BERTHIAUME, L; DEICHAITE, I; PESECKIS, S; RESH, MD			REGULATION OF ENZYMATIC-ACTIVITY BY ACTIVE-SITE FATTY ACYLATION - A NEW ROLE FOR LONG-CHAIN FATTY-ACID ACYLATION OF PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLMALONATE-SEMIALDEHYDE DEHYDROGENASE; ISOLATED RAT HEPATOCYTES; PALMITOYL COENZYME-A; PROPIONIC-ACID; METABOLISM; LIVER; INHIBITION; OXIDATION; CARNITINE; COA	Methylmalonate semialdehyde dehydrogenase (MMSDH) is a mitochondrial enzyme which can be acylated by myristoyl-CoA analogs (Deichaite, I., Berthiaume, L., Peseckis, S. M., Patton, W. F., and Resh, M. D. (1993) J. Biol. Chem. 268, 13788-13747). Here we describe the mechanisms which mediate regulation of the enzymatic activity of bovine MMSDH by long chain fatty acylation. The substrate specificity of the acylation reaction was measured in vitro using purified MMSDH and the coenzyme A derivative of an I-125-labeled long chain fatty acid (13-iodotridecanoate), an analog of myristoyl-CoA. Long chain fatty acyl CoAs (>8 carbons) were able to inhibit radiolabeling of MMSDH. In order to study the physiological role of the acylation process in vivo, a system using highly purified mitochondria from COS-1 cells overexpressing MMSDH was exploited. MMSDH was shown to be processed properly, targeted to the mitochondrial fraction, and enzymatically active. The extent of fatty acylation of MMSDH as well as of other mitochondrial proteins was correlated with the mitochondrial energy level. Biochemical evidence as well as site-specific mutagenesis of cysteine 319 revealed that this highly conserved active site cysteine of MMSDH was the target of the fatty acylation. Another member of the aldehyde dehydrogenase family, yeast aldehyde dehydrogenase was also covalently modified by [I-125]13-iodotridecanoyl-CoA and thereby inactivated. Furthermore, we demonstrate that glutamate dehydrogenase, an enzyme that has been previously shown to be strongly inhibited by palmitoyl-CoA, is fatty acylated by the I-125-labeled myristoyl-CoA analog. Our data suggest that attachment of long chain fatty acids to proteins is a new and potentially widespread type of enzyme regulation mechanism that we denote active site fatty acylation.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center				Deichaite, Ida/0000-0001-8839-0573; Berthiaume, Luc/0000-0003-0926-059X; Resh, Marilyn/0000-0001-6118-9466	NATIONAL CANCER INSTITUTE [P30CA008748, R01CA052405] Funding Source: NIH RePORTER; NCI NIH HHS [CA52405, NCI-P30-CA 08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERTHIAUME L, 1991, J BIOL CHEM, V266, P17099; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; BRASS EP, 1986, BIOCHIM BIOPHYS ACTA, V888, P18, DOI 10.1016/0167-4889(86)90065-0; BRASS EP, 1986, BIOCHEM J, V236, P131, DOI 10.1042/bj2360131; BRASS EP, 1988, BIOCHEM J, V250, P819, DOI 10.1042/bj2500819; BREMER J, 1978, BIOCHIM BIOPHYS ACTA, V528, P269, DOI 10.1016/0005-2760(78)90016-4; BREMER J, 1983, PHYSIOL REV, V63, P1420, DOI 10.1152/physrev.1983.63.4.1420; BRYLA J, 1967, BIOCHIM BIOPHYS ACTA, V143, P285, DOI 10.1016/0005-2728(67)90082-5; BUFFINGTON CK, 1979, J BIOL CHEM, V254, P453; DEICHAITE I, 1993, J BIOL CHEM, V268, P1378; Deschenes RJ, 1990, CURR OPIN CELL BIOL, V2, P1108, DOI 10.1016/0955-0674(90)90164-A; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; GLASGOW AM, 1976, PEDIATR RES, V10, P683, DOI 10.1203/00006450-197610070-00010; GOLDBERG AL, 1978, FED PROC, V37, P2301; GOODWIN GW, 1989, J BIOL CHEM, V264, P14965; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HOCHACHKA PW, 1977, FED PROC, V36, P2009; JAKOBY WB, 1963, ENZYMES, V7, P203; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JOHNSON WA, 1972, BIOCHEMISTRY-US, V11, P1967, DOI 10.1021/bi00760a036; KASINATHAN C, 1990, J BIOL CHEM, V265, P5139; KAWAGUCHI A, 1974, J BIOL CHEM, V249, P5793; KAWAGUCHI A, 1976, J BIOL CHEM, V251, P1406; KEDISHVILI NY, 1992, J BIOL CHEM, V267, P19724; LATIPAA PM, 1986, BIOCHIM BIOPHYS ACTA, V875, P293, DOI 10.1016/0005-2760(86)90179-7; MOREL F, 1974, FEBS LETT, V39, P133, DOI 10.1016/0014-5793(74)80035-9; OLOWE Y, 1980, EUR J BIOCHEM, V109, P425, DOI 10.1111/j.1432-1033.1980.tb04811.x; PESECKIS SM, 1993, J BIOL CHEM, V268, P5107; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; RYDSTROM J, 1972, EUR J BIOCHEM, V31, P496, DOI 10.1111/j.1432-1033.1972.tb02557.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SCHULZ H, 1985, BIOCH LIPIDS MEMBRAN, P118; SCHWARZ H, 1992, BIOTECHNIQUES, V13, P205; SOBOLL S, 1985, BIOCHIM BIOPHYS ACTA, V807, P245, DOI 10.1016/0005-2728(85)90255-5; STORRIE B, 1990, METHOD ENZYMOL, V182, P214; STUCKI JW, 1989, J BIOL CHEM, V264, P6376; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WHITMER JT, 1978, J BIOL CHEM, V253, P4305; WILLIAMSON JR, 1979, J BIOL CHEM, V254, P1511; WOJTCZAK L, 1976, J BIOENERG BIOMEMBR, V8, P293	44	59	61	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6498	6505						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120000				2022-12-27	WOS:A1994MZ50300038
J	PERTOVAARA, L; KAIPAINEN, A; MUSTONEN, T; ORPANA, A; FERRARA, N; SAKSELA, O; ALITALO, K				PERTOVAARA, L; KAIPAINEN, A; MUSTONEN, T; ORPANA, A; FERRARA, N; SAKSELA, O; ALITALO, K			VASCULAR ENDOTHELIAL GROWTH-FACTOR IS INDUCED IN RESPONSE TO TRANSFORMING GROWTH-FACTOR-BETA IN FIBROBLASTIC AND EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PERMEABILITY FACTOR; TYROSINE KINASE; MESSENGER-RNA; FACTOR FAMILY; C-FOS; DIFFERENTIATION; ANGIOGENESIS; MITOGEN; PROTEIN; STIMULATION	Transforming growth factor beta (TGF-beta) is a multifunctional polypeptide that regulates the proliferation and differentiation of various cells and has an angiogenic effect in vivo although it inhibits the growth of cultured endothelial cells. We report here that TGF-beta treatment of quiescent cultures of mouse embryo-derived AKR-2B cells, which are growth-stimulated by TGF-beta, and human lung adenocarcinoma A549 cells, which are growth-inhibited by TGF-beta, results in the induction of vascular endothelial growth factor (VEGF) mRNA and protein. Maximal VEGF mRNA levels occurred 4-8 h after stimulation with a decline to background levels in 24 h. In contrast, the related placenta growth factor mRNA was not induced by TGF-beta in these cells. No VEGF receptor mRNA was seen in AKR SB cells. Also, TGF-beta treatment of endothelial cells, which express the FLT1 and KDR/FLK-1 receptors for VEGF, did not cause VEGF induction. Because VEGF is known to be a strong angiogenic factor for endothelial cells, the results suggest that the angiogenic effect of TGF-beta on endothelial cells in blood vessels may be mediated at least partly by a paracrine induction of VEGF in other surrounding cell types.	UNIV HELSINKI,DEPT PATHOL,MOLEC CANC BIOL LAB,SF-00290 HELSINKI 29,FINLAND; UNIV HELSINKI,DEPT VIROL,SF-00290 HELSINKI 29,FINLAND; UNIV HELSINKI,DEPT OBSTET & GYNECOL,SF-00290 HELSINKI 29,FINLAND; GENENTECH INC,S SAN FRANCISCO,CA 94080	University of Helsinki; University of Helsinki; University of Helsinki; Roche Holding; Genentech			Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Mustonen, Tuija/0000-0002-2429-5064				ANDREASEN PA, 1986, FEBS LETT, V209, P213, DOI 10.1016/0014-5793(86)81113-9; BAIRD A, 1986, BIOCHEM BIOPH RES CO, V138, P476, DOI 10.1016/0006-291X(86)90305-0; BREIER G, 1992, DEVELOPMENT, V114, P521; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HEIMARK RL, 1986, SCIENCE, V233, P1078, DOI 10.1126/science.3461562; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937; KLAGSBRUN M, 1991, PEPTIDE GROWTH FACTO, P549; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MILLAUER B, 1993, CELL, V72, P1; MOSES HL, 1985, CANCER CELL, V3, P65; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PERTOVAARA L, 1993, GROWTH FACTORS, V9, P81, DOI 10.3109/08977199308991584; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Risau W, 1992, GROWTH FACTORS, V7, P261, DOI 10.3109/08977199209046408; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; Sambrook J, 1989, MOL CLONING LABORATO; SHIPLEY GD, 1985, P NATL ACAD SCI USA, V82, P4147, DOI 10.1073/pnas.82.12.4147; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0	38	609	637	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6271	6274						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119973				2022-12-27	WOS:A1994MZ50300004
J	CLEVENGER, CV; TORIGOE, T; REED, JC				CLEVENGER, CV; TORIGOE, T; REED, JC			PROLACTIN INDUCES RAPID PHOSPHORYLATION AND ACTIVATION OF PROLACTIN RECEPTOR-ASSOCIATED RAF-1 KINASE IN A T-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; SERINE-THREONINE KINASE; PROTEIN-TYROSINE KINASE; CLONED LYMPHOCYTES-T; RAT LYMPHOMA-CELLS; MONOCLONAL-ANTIBODIES; HYPOPHYSECTOMIZED RATS; SIGNAL TRANSDUCTION; NB2 LYMPHOMA; C-RAF	The receptor for prolactin (PRL) is a member of the hematopoietic receptor family that also includes the receptors for interleukins 2-7. PRL is synthesized and is secreted by human T lymphocytes and acts as a lymphokine necessary, but not sufficient, for T lymphocyte progression through the G(1) phase of the cell cycle. Although data now indicate that PRL serves an immunomodulatory role in vitro and in vivo, the mechanisms. of PRL receptor signal transduction in T cells have not been defined. We demonstrate here that PRL induced the phosphorylation of the p72-74 serine/threonine kinase c-Raf-1 in the PRL-dependent rat T-cell line Nb2. Associated with this inducible phosphorylation of Raf-1 was a concentration- and time-dependent activation of in vitro Raf-1 autokinase and substrate kinase activities, which correlated with the PRL-induced proliferation of Nb2 cells. Co-immunoprecipitation studies revealed association of Raf-1 with PRL receptors in Nb2 cells. These results revealed that all isoforms of the PRL receptor (short, intermediate, and long) are expressed in Nb2 cells and associate with Raf-1. In contrast to the PRL-dependent Nb2 cells, phosphorylation and activation of Raf-1 were constitutive in the Nb2-derived, PRL-independent, T-cell line Sp. These studies demonstrate for the first time an association between the PRL receptor and a serine/threonine kinase affiliated with signal transduction.	UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	University of Pennsylvania; Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA054957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI033510] Funding Source: NIH RePORTER; NCI NIH HHS [CA-54957] Funding Source: Medline; NIAID NIH HHS [AI-33510] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALI S, 1991, J BIOL CHEM, V266, P20110; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BANARJEE R, 1992, MOL CELL ENDOCRINOL, V90, P61; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERNTON EW, 1988, SCIENCE, V239, P401, DOI 10.1126/science.3122324; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLEVENGER CV, 1990, ENDOCRINOLOGY, V127, P3151, DOI 10.1210/endo-127-6-3151; CLEVENGER CV, 1991, SCIENCE, V253, P77, DOI 10.1126/science.2063207; CLEVENGER CV, 1990, P NATL ACAD SCI USA, V87, P6460, DOI 10.1073/pnas.87.16.6460; CLEVENGER CV, 1992, ENDOCRINOLOGY, V130, P3216, DOI 10.1210/en.130.6.3216; CLEVENGER CV, 1987, J CELL PHYSIOL, V130, P336, DOI 10.1002/jcp.1041300305; ELBERG G, 1990, J BIOL CHEM, V265, P14770; GOUT PW, 1980, CANCER RES, V40, P2433; HARTMANN DP, 1989, FASEB J, V3, P2194, DOI 10.1096/fasebj.3.10.2787766; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; KANAKURA Y, 1991, BLOOD, V77, P243; KATOH M, 1987, ENDOCRINOLOGY, V120, P739, DOI 10.1210/endo-120-2-739; KAVACINA KS, 1990, J BIOL CHEM, V265, P12115; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NAGY E, 1978, ACTA ENDOCRINOL-COP, V89, P530; NAGY E, 1983, IMMUNOPHARMACOLOGY, V6, P231, DOI 10.1016/0162-3109(83)90023-1; NAGY E, 1991, ENDOCRINOLOGY, V128, P2776, DOI 10.1210/endo-128-6-2776; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; RAYHEL EJ, 1990, J CELL BIOCHEM, V43, P327, DOI 10.1002/jcb.240430405; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; RILLEMA JA, 1989, BIOCHIM BIOPHYS ACTA, V1014, P78, DOI 10.1016/0167-4889(89)90243-7; RILLEMA JA, 1992, ENDOCRINOLOGY, V131, P973, DOI 10.1210/en.131.2.973; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; RUI H, 1992, J BIOL CHEM, V267, P24076; SISSOM JF, 1988, AM J PATHOL, V133, P589; SOZERI O, 1992, ONCOGENE, V7, P2259; TAKACS L, 1985, CLIN EXP IMMUNOL, V59, P37; TAMAKI T, 1992, CANCER RES, V52, P566; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; TOO CKL, 1989, ENDOCRINOLOGY, V124, P2185, DOI 10.1210/endo-124-5-2185; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WILLIAMS LT, 1991, COLD SH Q B, V56, P243; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; YULEE LY, 1990, MOL CELL ENDOCRINOL, V68, P21; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087	48	119	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5559	5565						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119890				2022-12-27	WOS:A1994MY84000017
J	DECHERT, U; ADAM, M; HARDER, KW; CLARKLEWIS, I; JIRIK, F				DECHERT, U; ADAM, M; HARDER, KW; CLARKLEWIS, I; JIRIK, F			CHARACTERIZATION OF PROTEIN-TYROSINE-PHOSPHATASE SH-PTP2 - STUDY OF PHOSPHOPEPTIDE SUBSTRATES AND POSSIBLE REGULATORY ROLE OF SH2 DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; STIMULATING FACTOR-I; KINASE INSERT; SEQUENCE SIMILARITY; CSF-1 RECEPTOR; HUMAN-PLACENTA; PDGF RECEPTOR; PURIFICATION; AUTOPHOSPHORYLATION; PHOSPHORYLATION	The src homology 2 (SH2) domain containing protein-tyrosine-phosphatase SH-PTP2, was over-expressed in Escherichia coli for a kinetic study employing a set of synthetic 13- to 14-mer phosphopeptide substrates. The full-length SH-PTP2 protein, as well as a truncated form, lacking the two amino terminus SH2 domains (SH-PTP2(Delta SH2)), exhibited Michaelis-Menten kinetics, and demonstrated striking substrate preferences on phosphopeptides having sequences based on sites of intracellular protein tyrosine phosphorylation. For example, while a K-M of 59 mu M and k(cat)/K-M of 1.1 x 10(5) were obtained using SH-PTP2(Delta SH2) and PDGFR(Y1021), a phosphorylation site within the platelet-derived growth factor receptor, other peptides revealed no detectable phosphate release. PDGFR(Y1009), modeled after a sequence identified as an in vivo binding site for SH-PTP2, was also a good substrate for this enzyme. The truncated form, lacking the SH2 domains demonstrated higher catalytic efficiency than the full-length enzyme. Interestingly, soluble SH2 domains were found to inhibit the catalytic activity of SH-PTP2 in a concentration-dependent manner. There was also evidence of a non-phosphotyrosine-mediated association between the two domains, These observations suggested that the SH2 domains have a direct role in regulating the catalytic activity of SH(-)PTP2.	UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER V6T 1Z3, BC, CANADA; MERCK FROSST CTR THERAPEUT RES, POINTE CLAIRE H9R 4P8, PQ, CANADA	University of British Columbia; University of British Columbia; Merck & Company								ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BASTIEN L, 1993, BIOCHEM BIOPH RES CO, V196, P124, DOI 10.1006/bbrc.1993.2224; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHO HJ, 1993, PROTEIN SCI, V2, P977, DOI 10.1002/pro.5560020611; CHO HJ, 1991, BIOCHEMISTRY-US, V30, P6210, DOI 10.1021/bi00239a019; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FENG GS, 1993, NATURE, V259, P1607; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GILBERT DG, 1982, ENZYME KINETICS; HASEGAWA H, 1982, ANAL BIOCHEM, V120, P360, DOI 10.1016/0003-2697(82)90358-X; HIRAGA A, 1992, EUR J BIOCHEM, V209, P195, DOI 10.1111/j.1432-1033.1992.tb17277.x; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; ITOH M, 1992, J BIOL CHEM, V267, P12356; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LEE AWM, 1992, CURR TOP CELL REGUL, V32, P73; MAEGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P208, DOI 10.1006/bbrc.1993.1805; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; RUZZENE M, 1993, EUR J BIOCHEM, V211, P289, DOI 10.1111/j.1432-1033.1993.tb19897.x; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; VOGEL W, 1993, NATURE, V259, P1611; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	92	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5602	5611						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119896				2022-12-27	WOS:A1994MY84000023
J	SCHNITZER, JE; OH, P				SCHNITZER, JE; OH, P			ALBONDIN-MEDIATED CAPILLARY-PERMEABILITY TO ALBUMIN - DIFFERENTIAL ROLE OF RECEPTORS IN ENDOTHELIAL TRANSCYTOSIS AND ENDOCYTOSIS OF NATIVE AND MODIFIED ALBUMINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; BLOOD-BRAIN-BARRIER; PERFUSED RAT LUNGS; SERUM-ALBUMIN; MICROVASCULAR ENDOTHELIUM; BINDING-PROTEINS; FATTY-ACIDS; TRANSENDOTHELIAL TRANSPORT; GLYCOSYLATED ALBUMIN; CELL-SURFACE	Specific albumin binding to the surface of endothelium initiates its transcytosis across continuous endothelium via noncoated plasmalemmal vesicles. Past work has identified several putative albumin-binding proteins (SPARC, gp60, gp30, and gp18). In this study, we examined the specific role of these proteins in the binding of bovine serum albumin (BSA) to endothelium. The 60-kDa albumin-binding protein (gp60, now called albondin) was purified from cultured rat microvascular endothelial cells for antibody production. Anti-albondin antibodies (alpha gp60) specifically recognized albondin expressed by rat, bovine, and human endothelial cells (EC). alpha gp60 and unlabeled native BSA inhibited I-125-BSA binding to confluent EC monolayers and to both albondin and SPARC extracts immobilized on filters. Modification of BSA by maleic anhydride treatment (Mal-BSA) or by surface adsorption to colloidal gold particles (A-Au) renders the Ligand specific for gp30 and gp18 while eliminating its ability to inhibit I-125-BSA binding to EC and to both albondin and SPARC extracts. Mal-BSA and A-Au interacted with EC via distinct binding sites not recognizing native BSA EC internalization of I-125-BSA is inhibited by unlabeled BSA and alpha gp60 IgG but not nonimmune IgG, Mal-BSA, or A-Au. Conversely internalization of modified BSA is inhibited by unlabeled modified BSA but not BSA or alpha gp60 IgG. Specific (125)Ig-BSA transendothelial transport in rat lungs perfused in situ and for EC monolayers in vitro is inhibited (greater than or equal to 90%) by unlabeled BSA and alpha gp60 IgG but not nonimmune IgG and Mal-BSA. No specific transport of I-125-Mal-BSA is detected across bovine lung microvascular endothelial cell monolayers, only paracellular and/or fluid-phase transport. Low temperatures reduce BSA transport by 5-fold and Mal-BSA by 2-fold. Interestingly, 3-fold more native BSA is transported than Mal-BSA at 37 degrees C, whereas at 8-10 degrees C they are nearly equal, suggesting facilitation of BSA transport. Cumulatively, it appears that gp30 and gp18 mediate the binding, endocytosis, and degradation of modified albumins, whereas albondin mediates native albumin binding which significantly enhances its transcytosis and capillary permeability.	UNIV CALIF SAN DIEGO,SCH MED,INST BIOMED ENGN,DEPT MED & PATHOL,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093	University of California System; University of California San Diego	SCHNITZER, JE (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT PATHOL,RES N,330 BROOKLINE AVE,BOSTON,MA 02215, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043278] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43278] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUMBASIREVIC V, 1990, J SUBMICR CYTOL PATH, V22, P135; CURRY FRE, 1985, FED PROC, V44, P2610; CZARTOLOMNA J, 1991, J APPL PHYSIOL, V70, P1854, DOI 10.1152/jappl.1991.70.4.1854; DRINKER CK, 1927, J PHYSIOL-LONDON, V98, P109; FARRELL CL, 1991, P NATL ACAD SCI USA, V88, P5779, DOI 10.1073/pnas.88.13.5779; FRIDEN PM, 1991, P NATL ACAD SCI USA, V88, P4771, DOI 10.1073/pnas.88.11.4771; GALIS Z, 1988, EUR J CELL BIOL, V47, P358; GAMBLE J, 1983, J PHYSIOL-LONDON, V387, P69; GEOFFROY JS, 1984, J ULTRA MOL STRUCT R, V89, P223, DOI 10.1016/S0022-5320(84)80039-8; GHINEA N, 1989, J BIOL CHEM, V264, P4755; GHINEA N, 1988, J CELL BIOL, V107, P231, DOI 10.1083/jcb.107.1.231; GHITESCU L, 1992, J CELL BIOL, V117, P745, DOI 10.1083/jcb.117.4.745; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; HARALDSSON B, 1987, ACTA PHYSIOL SCAND, V129, P127, DOI 10.1111/j.1748-1716.1987.tb08047.x; HE P, 1993, AM J PHYSIOL, V265, pH74, DOI 10.1152/ajpheart.1993.265.1.H74; HUTTER JF, 1984, BASIC RES CARDIOL, V79, P274; HUXLEY VH, 1991, AM J PHYSIOL, V260, pH1645, DOI 10.1152/ajpheart.1991.260.5.H1645; HUXLEY VH, 1985, AM J PHYSIOL, V248, pH264, DOI 10.1152/ajpheart.1985.248.2.H264; JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0; KERN DF, 1983, AM J PHYSIOL, V245, pH229, DOI 10.1152/ajpheart.1983.245.2.H229; KING GL, 1985, SCIENCE, V227, P1583, DOI 10.1126/science.3883490; LEVICK JR, 1973, Q J EXP PHYSIOL CMS, V58, P87, DOI 10.1113/expphysiol.1973.sp002194; MANN GE, 1981, J PHYSIOL-LONDON, V319, P311, DOI 10.1113/jphysiol.1981.sp013910; MELSERT R, 1991, MOL CELL ENDOCRINOL, V82, P23, DOI 10.1016/0303-7207(91)90005-D; MILICI AJ, 1987, J CELL BIOL, V105, P2603, DOI 10.1083/jcb.105.6.2603; Palade GE, 1988, ENDOTHELIAL CELL BIO, P3; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; PREDESCU D, 1988, J CELL BIOL, V107, P1729, DOI 10.1083/jcb.107.5.1729; RENKIN EM, 1985, J APPL PHYSIOL, V134, P375; SAGE H, 1984, J BIOL CHEM, V259, P3993; SAXENA U, 1991, P NATL ACAD SCI USA, V88, P2254, DOI 10.1073/pnas.88.6.2254; SCHAEFFER RC, 1992, AM J PHYSIOL, V263, pL27, DOI 10.1152/ajplung.1992.263.1.L27; SCHNEEBERGER EE, 1984, AM J PHYSIOL, V247, pH206, DOI 10.1152/ajpheart.1984.247.2.H206; SCHNITZER JE, 1990, EUR J CELL BIOL, V52, P241; SCHNITZER JE, 1988, P NATL ACAD SCI USA, V85, P6773, DOI 10.1073/pnas.85.18.6773; SCHNITZER JE, 1990, P NATL ACAD SCI USA, V87, P6843, DOI 10.1073/pnas.87.17.6843; SCHNITZER JE, 1993, J BIOL CHEM, V268, P7562; SCHNITZER JE, 1992, J BIOL CHEM, V267, P24544; SCHNITZER JE, 1993, TRENDS CARDIOVAS MED, V3, P124, DOI 10.1016/1050-1738(93)90012-U; SCHNITZER JE, 1988, AM J PHYSIOL, V254, pH425, DOI 10.1152/ajpheart.1988.254.3.H425; SCHNITZER JE, 1992, AM J PHYSIOL, V263, pH1872, DOI 10.1152/ajpheart.1992.263.6.H1872; SCHNITZER JE, 1992, AM J PHYSIOL, V262, pH246, DOI 10.1152/ajpheart.1992.262.1.H246; SCHNITZER JE, 1992, AM J PHYSIOL, V263, pH48, DOI 10.1152/ajpheart.1992.263.1.H48; SCHNITZER JE, 1992, MOL BIOL CELL, V3, P59; Sober HA, 1970, HDB BIOCH; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; TAVASSOLI M, 1986, J CELL BIOL, V102, P1298, DOI 10.1083/jcb.102.4.1298; TAYLOR AE, 1984, HDB PHYSL 2, P467; VASILE E, 1983, J CELL BIOL, V96, P1677, DOI 10.1083/jcb.96.6.1677; VILLASCHI S, 1986, MICROVASC RES, V32, P190, DOI 10.1016/0026-2862(86)90053-1; WAGNER RC, 1983, MICROVASC RES, V25, P387, DOI 10.1016/0026-2862(83)90028-6; WEISIGER R, 1981, SCIENCE, V211, P1048, DOI 10.1126/science.6258226; WILLIAMS SK, 1981, P NATL ACAD SCI-BIOL, V78, P2393, DOI 10.1073/pnas.78.4.2393; YOKOTA S, 1983, BIOMED RES-TOKYO, V4, P577, DOI 10.2220/biomedres.4.577	56	262	278	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6072	6082						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119952				2022-12-27	WOS:A1994MY84000090
J	TAUSSIG, R; TANG, WJ; HEPLER, JR; GILMAN, AG				TAUSSIG, R; TANG, WJ; HEPLER, JR; GILMAN, AG			DISTINCT PATTERNS OF BIDIRECTIONAL REGULATION OF MAMMALIAN ADENYLYL CYCLASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; ISLET-ACTIVATING PROTEIN; AMINO-TERMINAL REGION; GS-ALPHA; EXPRESSION; CLONING; CELLS; CALMODULIN; BRAIN; IDENTIFICATION	The capacities of the cu subunits of pertussis toxin-sensitive guanine nucleotide-binding regulatory proteins (G proteins) to inhibit different isoforms of mammalian adenylyl cyclases were assessed. Membranes from Sf9 cells infected with recombinant baculoviruses encoding either type I, II, V, or VI adenylyI cyclase were reconstituted with purified G protein subunits. Types V and VI adenylyl cyclase are most sensitive to inhibition by G(i alpha 1) G(i alpha 2) and G(i alpha 3); type I adenylyl cyclase can be inhibited by these three G(i alpha) proteins and by G(o alpha) as well. Type II adenylyl cyclase appears to be immune to inhibition by these proteins. Examination of the effects of native and mutant G(i alpha) proteins, as well as analysis of competition for binding of G(s alpha) to adenylyl cyclases, indicate that at least certain adenylyl cyclases have independent sites for interaction with G(s alpha) (site 1, stimulatory) and G(i alpha) (site 2, inhibitory). High concentrations of G(i alpha) can interact with site 1 on types I and II adenylyl cyclase and activate the enzymes. Types I and II adenylyl cyclase also appear to have independent sites for interaction with G protein beta gamma subunits. The type I enzyme is strongly inhibited, while type II adenyIyI cyclase is activated if G(s alpha) is also present.			TAUSSIG, R (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235, USA.			Tang, Wei-Jen/0000-0002-8267-8995	NIGMS NIH HHS [GM13569, GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497, F32GM013569] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEBERNARDI MA, 1993, MOL PHARMACOL, V43, P451; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HAZEKI O, 1981, J BIOL CHEM, V256, P2856; HELLEVUO K, 1993, BIOCHEM BIOPH RES CO, V192, P311, DOI 10.1006/bbrc.1993.1415; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; ITOH H, 1991, J BIOL CHEM, V266, P16226; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; KATADA T, 1982, J BIOL CHEM, V257, P3739; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOZASA T, 1993, P NATL ACAD SCI USA, V90, P9176, DOI 10.1073/pnas.90.19.9176; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEE E, 1993, IN PRESS METHODS ENZ; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; NAVON SE, 1987, J BIOL CHEM, V262, P15746; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PARMA J, 1991, BIOCHEM BIOPH RES CO, V179, P455, DOI 10.1016/0006-291X(91)91392-P; PREMONT RT, 1992, ENDOCRINOLOGY, V131, P2774, DOI 10.1210/en.131.6.2774; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Summers MD, 1987, MANUAL METHODS BACUL; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; UEDA N, 1994, J BIOL CHEM, V269, P4388; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604	50	285	292	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6093	6100						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119955				2022-12-27	WOS:A1994MY84000093
J	AKIYAMA, Y; SHIRAI, Y; ITO, K				AKIYAMA, Y; SHIRAI, Y; ITO, K			INVOLVEMENT OF FTSH IN PROTEIN ASSEMBLY INTO AND THROUGH THE MEMBRANE .2. DOMINANT MUTATIONS AFFECTING FTSH FUNCTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENE; SELECTION; ENCODES	FtsH is an Escherichia coli protein with its amino-terminal region anchored to the cytoplasmic membrane and with its cytoplasmic domain significantly homologous to the members of an ATPase family found in eukaryotic cells. We previously showed that the loss of ftsH function results in reduced cytoplasmic retention of the alkaline phosphatase moiety that was attached to cytoplasmic regions of membrane proteins (the Std phenotype) and also in translocation retardation of some exported proteins. We now report that expression of some FtsH variants from plasmids causes dominant Std and translocation phenotypes. Such variants include carboxyl-terminally truncated forms of FtsH and some missense mutations in the cytoplasmic domain, notably Lys to Asn changes at the two ATP binding consensus sequences. In contrast, amino-terminally truncated variants lacked the dominant phenotypes. It was suggested that the amino-terminal membrane region of FtsH interacts with other component(s), and that the two putative ATP binding sites are of vital importance for the FtsH functions.			AKIYAMA, Y (corresponding author), KYOTO UNIV,INST VIRUS RES,KYOTO 60601,JAPAN.							AKIYAMA Y, 1994, J BIOL CHEM, V269, P5218; CHIN DT, 1988, J BIOL CHEM, V263, P11718; DEGNEN GE, 1974, J BACTERIOL, V117, P477, DOI 10.1128/JB.117.2.477-487.1974; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; HERMAN C, 1993, P NATL ACAD SCI USA, V90, P10861, DOI 10.1073/pnas.90.22.10861; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1015, DOI 10.1073/pnas.84.4.1015; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TOMOYASU T, 1993, J BACTERIOL, V175, P1352, DOI 10.1128/JB.175.5.1352-1357.1993; TOMOYASU T, 1993, J BACTERIOL, V175, P1344, DOI 10.1128/JB.175.5.1344-1351.1993; VANDERWOLK J, 1993, MOL MICROBIOL, V8, P31; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3	20	81	82	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5225	5229						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106505				2022-12-27	WOS:A1994MX57100082
J	IBRAHIM, HR; YAMADA, M; MATSUSHITA, K; KOBAYASHI, R; KATO, A				IBRAHIM, HR; YAMADA, M; MATSUSHITA, K; KOBAYASHI, R; KATO, A			ENHANCED BACTERICIDAL ACTION OF LYSOZYME TO ESCHERICHIA-COLI BY INSERTING A HYDROPHOBIC PENTAPEPTIDE INTO ITS C-TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; EGG-WHITE LYSOZYME; SACCHAROMYCES-CEREVISIAE; MEMBRANE; PROTEIN; CONVERSION; BINDING; MODEL; ACID	The mechanism of the enhanced bactericidal action to Escherichia coli of the lysozyme having a hydrophobic pentapeptide (Phe-Phe-Val-Ala-Pro) at its C terminus was investigated. The modified lysozyme, hydrophobic pentapeptide-fused lysozyme (HLz), was secreted in the culture medium from yeast harboring the expression plasmid, in which a synthetic DNA fragment encoding a hydrophobic pentapeptide was introduced to the 3'-end of the coding region of the lysozyme cDNA. Although CD analysis showed that HLz was considerably different from wild-type lysozyme (WLz) in the secondary and tertiary structures, it retained 76% of the lytic activity of WLz. When E. coli cells were exposed to the WLz or HLz, the survival cells were significantly reduced only in the case of HLz. Periplasmic proteins from the HLz-treated cells were released to an extent similar to that from the WLz-treated cells, indicating that HLz has nearly the same action as WLz with respect to the disruption of the outer membrane and peptidoglycan. Experiments with E. coli phospholipid liposomes revealed that HLz dissipated the valinomycin-induced transmembrane electrochemical potential, but WLz did not. These results suggest that the enhanced bactericidal action of HLz to E. coli is due to disruption of the electrochemical potential of the inner membrane in cooperation with the inherent function of the lysozyme to the outer membrane and peptidoglycan.	YAMAGUCHI UNIV,FAC AGR,DEPT BIOL CHEM,YAMAGUCHI 753,JAPAN	Yamaguchi University			Ibrahim, Hisham/AAB-3945-2021	Ibrahim, Hisham/0000-0002-7809-900X; Yamada, Mamoru/0000-0003-4354-7324				ALDERTON G, 1946, J BIOL CHEM, V164, P1; CITTI JE, 1965, J BACTERIOL, V89, P937, DOI 10.1128/JB.89.4.937-942.1965; DEPETRIS S, 1967, J ULTRA MOL STRUCT R, V19, P45, DOI 10.1016/S0022-5320(67)80059-5; HOVDE CJ, 1986, INFECT IMMUN, V52, P90, DOI 10.1128/IAI.52.1.90-95.1986; IBRAHIM HR, 1991, J AGR FOOD CHEM, V39, P2077, DOI 10.1021/jf00011a039; IBRAHIM HR, 1992, BIOSCI BIOTECH BIOCH, V56, P1361, DOI 10.1271/bbb.56.1361; INOUYE M, 1974, P NATL ACAD SCI USA, V71, P2396, DOI 10.1073/pnas.71.6.2396; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOLLES P, 1984, MOL CELL BIOCHEM, V63, P165; KITA K, 1982, J BIOL CHEM, V257, P7933; KONINGS WN, 1973, P NATL ACAD SCI USA, V70, P3376, DOI 10.1073/pnas.70.12.3376; KUMAGAI I, 1989, J BIOCHEM-TOKYO, V105, P946, DOI 10.1093/oxfordjournals.jbchem.a122784; KUMAGAI I, 1987, J BIOCHEM-TOKYO, V102, P733, DOI 10.1093/oxfordjournals.jbchem.a122111; LEAR JD, 1988, SCIENCE, V240, P1177, DOI 10.1126/science.2453923; LEIVE L, 1974, ANN NY ACAD SCI, V235, P109, DOI 10.1111/j.1749-6632.1974.tb43261.x; Malymy M., 1966, METHODS ENZYMOLOGY, V9, P639, DOI [10.1016/0076-6879(66)09129-8, DOI 10.1016/0076-6879(66)09129-8]; MILLER GL, 1959, ANAL CHEM, V31, P964, DOI 10.1021/ac60149a611; MIYANOHARA A, 1986, J VIROL, V59, P176, DOI 10.1128/JVI.59.1.176-180.1986; MURRAY RGE, 1965, CAN J MICROBIOL, V11, P547, DOI 10.1139/m65-072; OHNO N, 1989, J BIOL CHEM, V264, P4434; OSTERMAN DG, 1985, J CELL BIOCHEM, V29, P57, DOI 10.1002/jcb.240290202; SHAFER WM, 1991, J BIOL CHEM, V266, P112; SHAFER WM, 1990, MOL MICROBIOL, V4, P1269, DOI 10.1111/j.1365-2958.1990.tb00706.x; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WILKINSON RG, 1972, J GEN MICROBIOL, V70, P527, DOI 10.1099/00221287-70-3-527; YOSHIMURA K, 1987, BIOCHEM BIOPH RES CO, V145, P712, DOI 10.1016/0006-291X(87)91023-0	27	98	110	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5059	5063						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106483				2022-12-27	WOS:A1994MX57100058
J	MASUDA, S; STRUGNELL, S; CALVERLEY, MJ; MAKIN, HLJ; KREMER, R; JONES, G				MASUDA, S; STRUGNELL, S; CALVERLEY, MJ; MAKIN, HLJ; KREMER, R; JONES, G			IN-VITRO METABOLISM OF THE ANTIPSORIATIC VITAMIN-D ANALOG, CALCIPOTRIOL, IN 2 CULTURED HUMAN KERATINOCYTE MODELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOSARCOMA CELLS; TUMOR PROGRESSION; MC-903; 1,25-DIHYDROXYVITAMIN-D3; INVITRO; OSTEOCALCIN; RECEPTOR; PROTEIN; AFFINITY; BINDING	Calcipotriol (MC903) is a side chain analog of the vitamin D hormone calcitriol, containing a 22-23 double bond, a 24(S)-hydroxyl function, and carbons 25, 26, and 27 incorporated into a cyclopropane ring which has been developed for treating psoriasis. The in vitro metabolism of calcipotriol was studied in two keratinocyte cell models, HPK1A and HPK1A-ras. Calcipotriol was initially converted into the 24-ketone (MC1046) and its 22,23-hydrogenated derivative (MC1080), metabolites observed in osteosarcoma, kidney, and hepatoma cell lines. We also observed the formation of further metabolites, identified as the two 23-hydroxylated derivatives of MC1080 (MC1439 and MC1441), the two 23,24-dihydroxylated compounds (MC1575 and 1577), and the side chain-cleaved compounds, tetranor-1,23-(OH)(2)D-3 and calcitroic acid, the end products of catabolism of calcitriol. These findings suggest that calcitriol and calcipotriol may share catabolic enzymes. The biological activity of each of the principal metabolites of calcipotriol, assessed using a growth hormone reporter gene transcriptional activation system and a vitamin D receptor assay, was found to be lower than that of calcipotriol. If the extensive in vitro metabolism of calcipotriol is also found in normal and psoriatic keratinocytes in vivo, then this may explain the lack of systemic calcemic activity of topically applied drug.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ON,CANADA; QUEENS UNIV,DEPT MED,KINGSTON K7L 3N6,ON,CANADA; LEO PHARMACEUT PROD LTD,CHEM RES DEPT,DK-2750 BALLERUP,DENMARK; UNIV LONDON LONDON HOSP,COLL MED,DEPT CHEM PATHOL,LONDON E1 2AD,ENGLAND; MCGILL UNIV,DEPT MED,MONTREAL H3A 1A1,PQ,CANADA	Queens University - Canada; Queens University - Canada; University of London; University College London; McGill University				Kremer, Richard/0000-0002-7053-2139				BIKLE DD, 1986, BIOCHEMISTRY-US, V25, P1545, DOI 10.1021/bi00355a013; BINDERUP L, 1988, BIOCHEM PHARMACOL, V37, P889, DOI 10.1016/0006-2952(88)90177-3; BINDERUP L, 1992, REV CONTEMP PHARMACO, V3, P357; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOUILLON R, 1991, J BONE MINER RES, V6, P1051; BOWER M, 1991, LANCET, V337, P701, DOI 10.1016/0140-6736(91)90280-3; Calverley M. J., 1992, ANTITUMOR STEROIDS, P193; CALVERLEY MJ, 1987, TETRAHEDRON, V43, P4609, DOI 10.1016/S0040-4020(01)86903-9; CALVERLEY RKS, 1990, METHODS NEUROSCIENCE, V3, P155; EVANS DB, 1991, J BONE MINER RES, V6, P1307; HENDERSON J, 1991, CANCER RES, V51, P6521; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; JONES G, 1991, J BONE MINER RES, V6, pS123; KISSMEYER AM, 1991, BIOCHEM PHARMACOL, V41, P1601, DOI 10.1016/0006-2952(91)90160-7; KRAGBALLE K, 1991, LANCET, V337, P193, DOI 10.1016/0140-6736(91)92157-W; LOHNES D, 1987, J BIOL CHEM, V262, P14394; MAKIN G, 1989, BIOCHEM J, V262, P173, DOI 10.1042/bj2620173; MARIE PJ, 1990, BONE, V11, P171, DOI 10.1016/8756-3282(90)90211-G; MILLER BE, 1990, J BONE MINER RES, V5, P597; MORRISON NA, 1991, J BONE MINER RES, V6, P893; NAPOLI JL, 1983, BIOCHEMISTRY-US, V22, P5843; POLS HAP, 1991, BONE MINER, V14, P103, DOI 10.1016/0169-6009(91)90087-G; QAW F, 1993, J BIOL CHEM, V268, P282; Sambrook J, 1989, MOL CLONING LABORATO; SEBAG M, 1992, J BIOL CHEM, V267, P12162; SORENSEN H, 1990, BIOCHEM PHARMACOL, V39, P391, DOI 10.1016/0006-2952(90)90039-N; STRUGNELL S, 1990, BIOCHEM PHARMACOL, V40, P333, DOI 10.1016/0006-2952(90)90696-I; SUDA T, 1990, ANNU REV NUTR, V10, P195, DOI 10.1146/annurev.nu.10.070190.001211; TERPENING CM, 1991, MOL ENDOCRINOL, V5, P373, DOI 10.1210/mend-5-3-373; TOMON M, 1990, AM J PHYSIOL, V358, pG557; VALAJA T, 1990, BIOCHEM PHARMACOL, V40, P1827, DOI 10.1016/0006-2952(90)90363-P	31	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4794	4803						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106449				2022-12-27	WOS:A1994MX57100018
J	MINOGUCHI, K; SWAIM, WD; BERENSTEIN, EH; SIRAGANIAN, RP				MINOGUCHI, K; SWAIM, WD; BERENSTEIN, EH; SIRAGANIAN, RP			SRC FAMILY TYROSINE KINASE P53/56(LYN), A SERINE KINASE AND FC-EPSILON-RI ASSOCIATE WITH ALPHA-GALACTOSYL DERIVATIVES OF GANGLIOSIDE GD(1B) IN RAT BASOPHILIC LEUKEMIA RBL-2H3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; HISTAMINE-RELEASE; IMMUNOGLOBULIN-E; MAST-CELLS; PROTEIN; PHOSPHORYLATION; SURFACE	The monoclonal antibody (mAb) AA4 recognizes two alpha-galactosyl derivatives of the GD(1b) ganglioside on rat mast cells and on the rat basophilic leukemia RBL-2H3 cultured cell line. Here we demonstrate that mAb AA4 coprecipitated both protein tyrosine and serine kinases. In contrast, a monoclonal antibody to the GD(3) ganglioside did not coprecipitate any kinase activity. In kinase assays of mAb AA4 immunoprecipitates there were phosphorylated proteins of 71-80, 53/56, and 41/42 kDa. All proteins were phosphorylated on tyrosine, whereas the 71-80- and 41/42-kDa proteins were also phosphorylated on serine residues. The precipitation of these proteins by mAb AA4 correlated with the presence of the alpha-galactosyl derivatives of GD(1b). The 53/56-kDa proteins were identified as the Src-related tyrosine kinase p53/56(lyn). The presence of p53/56(lyn) in the mAb AA4 immunoprecipitates was specific and was observed when several different detergents were used. The same 71-80-kDa tyrosine-phosphorylated proteins were immunoprecipitated by mAb AA4 and anti-Lyn antibodies and may play a role in the interaction of p53/56(lyn) with the gangliosides. Although there is a weak association of the high affinity IgE receptor with these gangliosides, the coprecipitation of p53/56(lyn) with mAb AA4 was not secondary to the association of this kinase with receptor. These complexes of gangliosides and several proteins that include p53/56(lyn), a serine kinase, and the high affinity IgE receptor could play an important role in receptor-mediated signal transduction.			MINOGUCHI, K (corresponding author), NIDR, IMMUNOL LAB, BLDG 10-1N-106, BETHESDA, MD 20892 USA.							BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BOHUSLAV J, 1993, EUR J IMMUNOL, V23, P825, DOI 10.1002/eji.1830230409; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; CMEK T, 1992, J IMMUNOL, V149, P2262; DIPPOLD WG, 1980, P NATL ACAD SCI-BIOL, V77, P6114, DOI 10.1073/pnas.77.10.6114; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; DRABEROVA L, 1989, EUR J IMMUNOL, V19, P1715, DOI 10.1002/eji.1830190928; EISEMAN E, 1992, NATURE, V355, P78; ESTES KAS, 1988, THESIS CORNELL U ITH; GUO N, 1989, J BIOL CHEM, V264, P13267; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HAMAWY MM, 1992, J IMMUNOL, V148, P524; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; HANAI N, 1988, J BIOL CHEM, V263, P10915; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HOOK WA, 1991, J IMMUNOL, V147, P2670; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; IGARASHI Y, 1989, METHOD ENZYMOL, V179, P521; KINET JP, 1985, BIOCHEMISTRY-US, V24, P7342, DOI 10.1021/bi00346a048; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KITANI S, 1991, J BIOL CHEM, V266, P1903; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLIVER C, 1992, J CELL BIOL, V116, P635, DOI 10.1083/jcb.116.3.635; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; STEFANOVA I, 1991, J IMMUNOL, V147, P1587; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; STEPHAN V, 1991, J IMMUNOL, V146, P4271; STRACKE ML, 1987, MOL IMMUNOL, V24, P347, DOI 10.1016/0161-5890(87)90176-3; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; YATES AJ, 1993, EXP CELL RES, V204, P38, DOI 10.1006/excr.1993.1006; ZELLER CB, 1992, AM J PHYSIOL, V262, pC1341, DOI 10.1152/ajpcell.1992.262.6.C1341	47	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5249	5254						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106508				2022-12-27	WOS:A1994MX57100085
J	SHORE, SK; LACAVA, M; YENDAPALLI, S; REDDY, EP				SHORE, SK; LACAVA, M; YENDAPALLI, S; REDDY, EP			STRUCTURAL ALTERATIONS IN THE CARBOXYL-TERMINAL DOMAIN OF THE BCRABL GENE-PRODUCT ACTIVATE ITS FIBROBLASTIC TRANSFORMING POTENTIAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL TYROSINE KINASE; OSTEO-SARCOMA VIRUS; C-ABL; PHILADELPHIA CHROMOSOME; NUCLEOTIDE-SEQUENCE; NUCLEIC-ACID; PROVIRAL DNA; V-ABL; PROTEIN; ONCOGENE	Activation of the c-abl protooncogene occurs in Abelson murine leukemia virus, Hardy-Zuckerman-2 feline sarcoma virus, and during the chromosomal translocation that generates the BCRABL fusion gene. The three genes exhibit varying degrees of transforming activity; the two viral genes transform NIH-3T3 cells in vitro, whereas the BCRABL gene is incapable of transforming these cells. To determine whether genetic alterations can enhance the transforming potential of the BCRABL gene, we employed genetic selection techniques which led to the isolation of a mutant form of the BCRABL gene with high levels of fibroblastic transforming activity. Molecular analysis of this clone shows that it suffered a deletion of 3' ABL sequences and their replacement with a cellular sequence of unknown origin, termed X. This tripartite gene is capable of inducing 35 foci/10 ng of DNA. Deletion of 3' ABL sequences analogous to that seen in the activated BCRABL protein without the addition of X yields 5 foci/100 ng of DNA. These results suggest that carboxyl-terminal truncations unmask the fibroblastic transforming activity of the BCRABL gene product and the addition of X sequences dramatically enhances this transforming potential, indicating a dominant contribution by the X reading frame.	TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	SHORE, SK (corresponding author), TEMPLE UNIV,SCH MED,FELS INST MOLEC BIOL & CANC RES,PHILADELPHIA,PA 19140, USA.		Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [P30CA012227, R01CA047937] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47937-01, CA-12227] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARLINGHAUS RB, 1991, CHRONIC MYELOGENOUS, P283; BERGOLD PJ, 1987, J VIROL, V61, P1193, DOI 10.1128/JVI.61.4.1193-1202.1987; COLLINS S, 1987, MOL CELL BIOL, V7, P2870, DOI 10.1128/MCB.7.8.2870; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DHUT S, 1991, ONCOGENE, V6, P1459; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; FAINSTEIN E, 1989, ONCOGENE, V4, P1477; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GROFFEN J, 1991, CHRONIC MYELOGENOUS, P181; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JENUWEIN T, 1985, CELL, V41, P629, DOI 10.1016/S0092-8674(85)80035-0; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; Kuzrock R, 1988, NEW ENGL J MED, V319, P990; LI WJ, 1989, ONCOGENE, V4, P127; LIU J, 1992, ONCOGENE, V8, P101; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MCWHIRTER JR, 1993, MOL CELL BIOL, V12, P1533; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REDDY EPA, 1988, ONCOGENE HDB; Sambrook J, 1989, MOL CLONING LABORATO; SCHER CD, 1975, NATURE, V253, P792; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SHORE SK, 1989, ONCOGENE, V4, P1411; SHORE SK, 1991, CHRONIC MYELOGENOUS, P153; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	45	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5413	5419						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106523				2022-12-27	WOS:A1994MX57100106
J	VLAHOS, CJ; MATTER, WF; HUI, KY; BROWN, RF				VLAHOS, CJ; MATTER, WF; HUI, KY; BROWN, RF			A SPECIFIC INHIBITOR OF PHOSPHATIDYLNOSITOL 3-KINASE, 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE (LY294002)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; GROWTH-FACTOR RECEPTORS; FACTOR-I RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; PHOSPHOINOSITIDE 3-KINASE; ACTIN POLYMERIZATION; HUMAN NEUTROPHILS; PHOSPHOLIPASE-C; HUMAN PLATELETS	Phosphatidylinositol (PtdIns) 3-kinase is an enzyme implicated in growth factor signal transduction by associating with receptor and nonreceptor tyrosine kinases, including the platelet-derived growth factor receptor. Inhibitors of PtdIns 3-kinase could potentially give a better understanding of the function and regulatory mechanisms of the enzyme. Quercetin, a naturally occurring bioflavinoid, was previously shown to inhibit PtdIns 3-kinase with an IC50 of 1.3 mu/ml (3.8 mu M); inhibition appeared to be directed at the ATP-binding site of the kinase. Analogs of quercetin were investigated as PtdIns 3-kinase inhibitors, with the most potent ones exhibiting IC50, values in the range of 1.7-8.4 mu g/mI. In contrast, genistein, a potent tyrosine kinase inhibitor of the isoflavone class, did not inhibit PtdIns 3-kinase significantly (IC50 > 30 mu g/ml). Since quercetin has also been shown to inhibit other PtdIns and protein kinases, other chromones were evaluated as inhibitors of PtdIns 3-kinase without affecting PtdIns 4-kinase or selected protein kinases. One such compound, 2-(4-morpholinyl)8-phenyl-4H-1-benzopyran-4-one (also known as 2-(4-morpholinyl-8-phenylchromone, LY294002), completely and specifically abolished PtdIns 3-kinase activity (IC50 = 0.43 mu g/ml; 1.40 mu M) but did not inhibit PtdIns 4-kinase or tested protein and lipid kinases. Analogs of LY294002 demonstrated a very selective structure-activity relationship, with slight changes in structure causing marked decreases in inhibition. LY294002 was shown to completely abolish PtdIns 3-kinase activity in fMet-Leu-Phe-stimulated human neutrophils, as well as inhibit proliferation of smooth muscle cells in cultured rabbit aortic segments. Since PtdIns 3-kinase appears to be centrally involved with growth factor signal transduction, the development of specific inhibitors against the kinase may be beneficial in the treatment of proliferative diseases as well as in elucidating the biological role of the kinase in cellular proliferation and growth factor response.			VLAHOS, CJ (corresponding author), ELI LILLY & CO, LILLY RES LABS, CARDIOVASC RES, INDIANAPOLIS, IN 46285 USA.							AHN NG, 1990, J BIOL CHEM, V265, P11487; AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BANTICK JR, 1981, J HETEROCYCLIC CHEM, V18, P679, DOI 10.1002/jhet.5570180407; BLANK RS, 1990, J CELL PHYSIOL, V142, P635, DOI 10.1002/jcp.1041420325; BRAUN S, 1984, J BIOL CHEM, V259, P2051; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COCHET C, 1982, BIOCHEM PHARMACOL, V31, P1357, DOI 10.1016/0006-2952(82)90028-4; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; DOBOS GJ, 1992, J IMMUNOL, V149, P609; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; EBERLE M, 1990, J BIOL CHEM, V265, P16725; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FRANK DA, 1988, CANCER RES, V48, P52; FUKUI Y, 1991, ONCOGENE, V6, P407; GRAZIANI Y, 1983, EUR J BIOCHEM, V135, P583, DOI 10.1111/j.1432-1033.1983.tb07692.x; GSCHWENDT M, 1983, BIOCHEM BIOPH RES CO, V117, P444, DOI 10.1016/0006-291X(83)91220-2; HUANG RS, 1991, J BIOL CHEM, V266, P18435; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JONES LR, 1985, J BIOL CHEM, V260, P7721; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; KUMARAVEL G, 1993, J MED CHEM, V36, P177, DOI 10.1021/jm00053a024; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEVY J, 1984, BIOCHEM BIOPH RES CO, V123, P1227, DOI 10.1016/S0006-291X(84)80264-8; LING LE, 1989, J BIOL CHEM, V264, P5080; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MATTER WF, 1992, BIOCHEM BIOPH RES CO, V186, P624, DOI 10.1016/0006-291X(92)90792-J; MITCHELL CA, 1990, P NATL ACAD SCI USA, V87, P9396, DOI 10.1073/pnas.87.23.9396; NISHIOKA H, 1989, J ANTIBIOT, V42, P823, DOI 10.7164/antibiotics.42.823; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; RUBOTTOM GM, 1983, J ORG CHEM, V48, P1550, DOI 10.1021/jo00157a038; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHUTTE B, 1987, J HISTOCHEM CYTOCHEM, V35, P1343, DOI 10.1177/35.11.3116075; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; SMIRNOV VN, 1990, ANN NY ACAD SCI, V598, P167, DOI 10.1111/j.1749-6632.1990.tb42288.x; SRIVASTAVA AK, 1985, BIOCHEM BIOPH RES CO, V131, P1, DOI 10.1016/0006-291X(85)91761-9; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; SULTAN C, 1990, BIOCHEM J, V269, P831, DOI 10.1042/bj2690831; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VALE RD, 1991, CELL, V64, P827, DOI 10.1016/0092-8674(91)90511-V; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VLAHOS CJ, 1993, J CELL BIOCHEM, V52, P404, DOI 10.1002/jcb.240520405; VLAHOS CJ, 1992, FEBS LETT, V309, P242, DOI 10.1016/0014-5793(92)80781-B; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	57	2921	3083	2	70	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5241	5248						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106507				2022-12-27	WOS:A1994MX57100084
J	OLSON, CL; NADEAU, KC; SULLIVAN, MA; WINQUIST, AG; DONELSON, JE; WALSH, CT; ENGMAN, DM				OLSON, CL; NADEAU, KC; SULLIVAN, MA; WINQUIST, AG; DONELSON, JE; WALSH, CT; ENGMAN, DM			MOLECULAR AND BIOCHEMICAL-COMPARISON OF THE 70-KDA HEAT-SHOCK PROTEINS OF TRYPANOSOMA-CRUZI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HSP70 GENES; NUCLEOLAR LOCALIZATION; PEPTIDE-BINDING; POLYPEPTIDE; EXPRESSION; CATALYSTS; SEQUENCE; DOMAINS; NUCLEAR; CELLS	An analysis of the genetic organization, regulated expression and biochemical properties of the cytoplasmic/nuclear (hsp70) and mitochondrial (mtp70) 70-kDa heat shock proteins of Trypanosoma cruzi is presented. The two proteins are encoded by tandemly arranged gene families that are located on different chromosomes. Both are mildly heat-inducible but have different optimal temperatures for expression. During the switch from proliferation to differentiation that occurs during the growth of T cruzi in culture, the hsp70 level decreases dramatically while the mtp70 level falls only slightly. The subcellular locations of the two proteins differ during heat shock. While mtp70 remains associated with the kinetoplast at all temperatures, hsp70 becomes more concentrated in the nucleus at higher temperatures. Biochemical analysis of hsp70 and mtp70 revealed both to be potent ATPases. Each protein binds ATP with a K(m) of about 70 mum and hydrolyzes ATP with a k(cat) of about 100 min-1, 100 times greater than the k(cat) of human hsp70. The high ATPase activities of hsp70 and mtp70 are further stimulated by incubation with peptides, suggesting that these trypanosome heat shock proteins have protein chaperone activity. Finally, mtp70, but not hsp70, was found to possess autophosphorylation activity in vitro, a property that it shares with prokaryotic hsp70. These findings demonstrate unique cellular and biochemical characteristics of T. cruzi mtp70 and hsp70 that suggest that they play distinct physiologic roles in the biology of the cell.	NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,303 E CHICAGO AVE,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT MICROBIOL IMMUNOL,CHICAGO,IL 60611; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; UNIV IOWA,HOWARD HUGHES MED INST,IOWA CITY,IA 52242	Northwestern University; Northwestern University; Harvard University; Harvard Medical School; University of Iowa; Howard Hughes Medical Institute; University of Iowa			Engman, David/T-6747-2018; Donelson, John E/F-5795-2010	Engman, David/0000-0001-5869-9844; 	NIGMS NIH HHS [GM20011] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020011, R01GM020011] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DAVIS CE, 1987, MOL STRATEGIES PARAS, P169; DECARVALHO EF, 1990, J CELL PHYSIOL, V143, P439, DOI 10.1002/jcp.1041430306; EFFRON PN, 1993, MOL BIOCHEM PARASIT, V59, P191, DOI 10.1016/0166-6851(93)90217-L; ENGMAN DM, 1987, MOL BIOCHEM PARASIT, V22, P115, DOI 10.1016/0166-6851(87)90041-7; ENGMAN DM, 1990, J IMMUNOL, V144, P3987; ENGMAN DM, 1992, MOL BIOCHEM PARASIT, V51, P153, DOI 10.1016/0166-6851(92)90210-B; ENGMAN DM, 1989, MOL BIOCHEM PARASIT, V37, P285, DOI 10.1016/0166-6851(89)90161-8; ENGMAN DM, 1989, MOL CELL BIOL, V9, P5163, DOI 10.1128/MCB.9.11.5163; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; Hahn GM, 1990, STRESS PROTEINS BIOL, P79; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; KIRCHHOFF LV, 1984, J IMMUNOL, V133, P2731; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Maniatis T., 1982, MOL CLONING; MILARSKI KL, 1989, J CELL BIOL, V108, P413, DOI 10.1083/jcb.108.2.413; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NADEAU K, 1992, PROTEIN SCI, V1, P970, DOI 10.1002/pro.5560010802; NADLER S, 1992, SCIENCE, V256, P180; NEUPERT W, 1993, PHIL T R SOC LONDO B, V339, P335; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PELHAM HRB, 1990, STRESS PROTEINS BIOL, P287; REQUENA JM, 1988, NUCLEIC ACIDS RES, V16, P1393, DOI 10.1093/nar/16.4.1393; REQUENA JM, 1992, MOL BIOCHEM PARASIT, V53, P201, DOI 10.1016/0166-6851(92)90022-C; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SMEJKAL RM, 1988, EXP PARASITOL, V65, P1, DOI 10.1016/0014-4894(88)90101-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERPLOEG LHT, 1985, SCIENCE, V228, P1443, DOI 10.1126/science.4012301; VELAZQUEZ JM, 1984, CELL, V36, P655, DOI 10.1016/0092-8674(84)90345-3; WAGNER W, 1990, INFECT IMMUN, V58, P3217, DOI 10.1128/IAI.58.10.3217-3224.1990; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568; WU BJ, 1985, P NATL ACAD SCI USA, V82, P6070, DOI 10.1073/pnas.82.18.6070	39	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3868	3874						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106432				2022-12-27	WOS:A1994MV63100107
J	BENDIXEN, E; BORTH, W; HARPEL, PC				BENDIXEN, E; BORTH, W; HARPEL, PC			TRANSGLUTAMINASES CATALYZE CROSS-LINKING OF PLASMINOGEN TO FIBRONECTIN AND HUMAN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRIN-STABILIZING FACTOR; ALPHA-2-PLASMIN INHIBITOR; CELLULAR TRANSGLUTAMINASE; TISSUE TRANSGLUTAMINASE; EXTRACELLULAR-MATRIX; POTENTIAL ROLE; LIPOPROTEIN(A); BINDING; ACTIVATOR; COMPLEXES	We have previously reported that apolipoprotein (a) is a substrate for transglutaminases. We now demonstrate that plasminogen which is homologous to apolipoprotein (a), is also modified by these enzymes. Transglutaminases from different sources mediated the incorporation of monodansyl-cadaverine into plasminogen, indicating the presence of reactive glutamine(s) in plasminogen. Reactive lysines were also identified using the lysine-decorating peptide dansyl-PGGQQIV. In addition, transglutaminases catalyzed the formation of plasminogen homopolymers and plasminogen-fibronectin heteropolymers. Human umbilical vein endothelial cells cross-linked plasminogen into high molecular mass aggregates. Cross-linked plasminogen was cell associated, and no cross-linking of plasminogen was seen in the fluid-phase. Large molecular mass plasminogen generated on the human umbilical vein endothelial cell (HUVEC) surface could not be eluted with epsilon-aminocapoic acid and was activatable by tissue plasminogen activator. These results suggest that, following non-covalent association of plasminogen with the HUVEC surface, cell surface-associated transglutaminase catalyzes cross-linking of plasminogen into large molecular mass aggregates that can be converted into functional plasmin. It is proposed that transglutaminases may function to localize plasminogen to cell surfaces and matrices of tissues.	CUNY MT SINAI SCH MED,DEPT MED,DIV HEMATOL,BOX 1079,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018828] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-18828] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; BARSIGIAN C, 1991, J BIOL CHEM, V266, P22501; BEERS WH, 1975, CELL, V6, P387, DOI 10.1016/0092-8674(75)90188-9; BISHOP PD, 1990, BIOCHEMISTRY-US, V29, P1861, DOI 10.1021/bi00459a028; BORTH W, 1991, J BIOL CHEM, V266, P18149; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; COCUZZI ET, 1986, J BIOL CHEM, V261, P8122; DANO K, 1985, ADV CANCER RES, V44, P146; DAVIDSON JF, 1978, PROGR CHEM FIBRINOLY, V3; GENTILE V, 1991, J BIOL CHEM, V266, P478; GONZALEZGRONOW M, 1989, BIOCHEMISTRY-US, V28, P2374, DOI 10.1021/bi00432a005; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HAJJAR KA, 1987, J CLIN INVEST, V80, P1712, DOI 10.1172/JCI113262; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1988, J CLIN INVEST, V82, P1769, DOI 10.1172/JCI113790; HALL SW, 1991, J BIOL CHEM, V266, P12319; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; HARPEL PC, 1992, P NATL ACAD SCI USA, V89, P10193, DOI 10.1073/pnas.89.21.10193; HARPEL PC, 1981, J CLIN INVEST, V68, P46, DOI 10.1172/JCI110253; HARPEL PC, 1991, J BIOL CHEM, V264, P616; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KINSELLA MG, 1990, J BIOL CHEM, V265, P17891; KNUDSEN BS, 1986, J BIOL CHEM, V261, P765; LAKI K, 1972, ANN NY ACAD SCI, V202, P235, DOI 10.1111/j.1749-6632.1972.tb16337.x; LAWN RM, 1992, SCI AM, V266, P54, DOI 10.1038/scientificamerican0692-54; LEMOSY EK, 1992, J BIOL CHEM, V267, P7880; LORAND L, 1991, P NATL ACAD SCI USA, V88, P82, DOI 10.1073/pnas.88.1.82; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1968, BIOCHEMISTRY-US, V7, P1214, DOI 10.1021/bi00843a043; LORAND L, 1981, METHOD ENZYMOL, V80, P33; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; MARTINEZ J, 1989, J BIOL CHEM, V264, P20502; MCFARLANE AS, 1956, BIOCHEM J, V62, P135, DOI 10.1042/bj0620135; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; MOSHER DF, 1976, J BIOL CHEM, V251, P1639; MOSHER DF, 1984, MOL CELL BIOCHEM, V58, P63, DOI 10.1007/BF00240605; NACHMAN RL, 1992, BLOOD, V79, P1897, DOI 10.1182/blood.V79.8.1897.bloodjournal7981897; Patthy L, 1991, CURR OPIN STRUC BIOL, V1, P351, DOI 10.1016/0959-440X(91)90033-P; ROUY D, 1991, ARTERIOSCLER THROMB, V11, P629, DOI 10.1161/01.ATV.11.3.629; SAKATA Y, 1980, J CLIN INVEST, V65, P290, DOI 10.1172/JCI109671; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SALONEN EM, 1985, J BIOL CHEM, V260, P2302; SANE DC, 1991, BIOCHEM BIOPH RES CO, V174, P465, DOI 10.1016/0006-291X(91)91439-J; SILVERSTEIN RL, 1984, J CLIN INVEST, V74, P1625, DOI 10.1172/JCI111578; TYRELL DJ, 1988, J BIOL CHEM, V263, P8464; UPCHURCH HF, 1991, J CELL PHYSIOL, V149, P375, DOI 10.1002/jcp.1041490304; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WIEBE RI, 1991, BIOCHEM CELL BIOL, V69, P821, DOI 10.1139/o91-122; WU CY, 1991, J BIOL CHEM, V266, P18802	52	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21962	21967						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8104945				2022-12-27	WOS:A1993MC80900079
J	LOO, TW; CLARKE, DM				LOO, TW; CLARKE, DM			FUNCTIONAL CONSEQUENCES OF PHENYLALANINE MUTATIONS IN THE PREDICTED TRANSMEMBRANE DOMAIN OF P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANT CELLS; ENDOPLASMIC-RETICULUM; SARCOPLASMIC-RETICULUM; DEPENDENT TRANSPORT; PHOTOACTIVE ANALOGS; PLASMA-MEMBRANE; ATP HYDROLYSIS; TUMOR-CELLS; BINDING; PROTEINS	Site-directed mutagenesis was used to investigate whether phenylalanine residues in predicted transmembrane sequences play essential roles in the function of human P-glycoprotein. Mutant cDNAs, in which codons for each of the 31 phenylalanine residues were changed to alanine, were expressed in mouse NIH 3T3 cells and analyzed with respect to their ability to confer resistance to various drugs. Mutation of either Phe-335 to Ala in transmembrane segment 6, or Phe-978 to Ala in transmembrane segment 12, drastically altered the drug resistance profile conferred by the mutant P-glycoprotein in transfected cells. Mutant Phe-335 --> Ala conferred little resistance to vinblastine or actinomycin D but retained the ability to confer resistance to colchicine and adriamycin. The mutant also showed increased binding of azidopine, which could be inhibited by lower levels of vinblastine, relative to the wild-type enzyme. By contrast, mutant Phe-978 --> Ala conferred little or no resistance to colchicine or adriamycin, while its ability to confer resistance to vinblastine or actinomycin D was retained. These results suggest that Phe-335 and Phe-978 play important roles in the recognition and transport of specific substrates by P-glycoprotein. Mutation of Phe-777 to Ala affected the biosynthesis of the transporter. Mutation of the other 28 phenylalanine residues yielded protein products with structural and functional characteristics that were indistinguishable froin the wild-type enzyme.	UNIV TORONTO,DEPT MED,1 KINGS COLL CIRCLE,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto; University of Toronto			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				ALLEY MC, 1988, CANCER RES, V48, P589; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; BECK WT, 1992, BIOCHEM PHARMACOL, V43, P89, DOI 10.1016/0006-2952(92)90665-6; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BRUGGEMAN EP, 1992, J BIOL CHEM, V264, P21020; BUSCHE R, 1989, EUR J BIOCHEM, V183, P189, DOI 10.1111/j.1432-1033.1989.tb14912.x; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; CURRIER SJ, 1989, J BIOL CHEM, V264, P15483; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HIGGINS CF, 1990, PHILOS T R SOC B, V326, P353, DOI 10.1098/rstb.1990.0017; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P553; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOO TW, 1993, J BIOL CHEM, V268, P3143; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; NAITO M, 1988, J BIOL CHEM, V263, P11887; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.med.42.1.277; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; QIAN XD, 1990, CANCER RES, V50, P1132; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; ROBINSON IB, 1991, MOL CELLULAR BIOL MU; SAFA AR, 1989, BIOCHEM BIOPH RES CO, V162, P1402, DOI 10.1016/0006-291X(89)90830-9; SAFA AR, 1988, P NATL ACAD SCI USA, V85, P7187, DOI 10.1073/pnas.85.19.7187; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; TAMAI I, 1991, J BIOL CHEM, V266, P16796; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YANG CPH, 1988, BIOCHEM PHARMACOL, V37, P1417; YUSA K, 1989, CANCER RES, V49, P5002; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	48	147	148	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					19965	19972						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8104183				2022-12-27	WOS:A1993LY01900011
J	GURISH, MF; NADEAU, JH; JOHNSON, KR; MCNEIL, HP; GRATTAN, KM; AUSTEN, KF; STEVENS, RL				GURISH, MF; NADEAU, JH; JOHNSON, KR; MCNEIL, HP; GRATTAN, KM; AUSTEN, KF; STEVENS, RL			A CLOSELY LINKED COMPLEX OF MOUSE MAST CELL-SPECIFIC CHYMASE GENES ON CHROMOSOME-14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC LYMPHOCYTE-T; RECEPTOR ALPHA-CHAIN; SERINE PROTEASE; CARBOXYPEPTIDASE-A; MOLECULAR-CLONING; GEL-ELECTROPHORESIS; NEUTRAL PROTEASES; PEPTIDE CORE; CDNA; DNA	Mouse mast cells differentially express at least four chymases (mouse mast cell protease (mMCP) 1, mMCP-2, mMCP-4, and mMCP-5), a tryptase (mMCP-6), and an exopeptidase (mouse mast cell carboxypeptidase A (mMC-CPA)). The previously uncharacterized 2.5-kilobase mMCP-2 gene was isolated and found to consist of 5 exons. The 5'-flanking region of this gene is 89, 93, and 42% similar to that of the mMCP-1, mMCP-4, and mMCP-5 genes, respectively. Inheritance patterns of restriction-enzyme fragment length polymorphisms of these six mast cell protease genes in recombinant inbred mouse strains and interspecific backcrosses were used to determine their chromosomal locations. The mMCP-6 and mMC-CPA genes are located on chromosomes 17 and 3, respectively, whereas the four mast cell chymase genes all reside on chromosome 14 linked to a gene complex that encodes four cytotoxic T lymphocyte granzymes. Pulsed-field gel electrophoresis of genomic DNA digests demonstrated that the mMCP-1, mMCP-2, and mMCP-5 genes are within 850 kilobases of each other. Although clustering of the serine protease genes on chromosome 14 may be important at a higher level of genomic organization, the ability to independently induce or suppress the steady-state levels of the four chymase transcripts by treatment of mast cells with cytokines suggests that gene clustering is not the most critical factor for coordinate expression of these proteases. Because of the unique features of their tertiary structures, the substrate specificities of the serine proteases encoded by genes at the chromosome 14 complex are predicted to be more limited than those of pancreatic chymotrypsin and pancreatic trypsin, whose genes reside on chromosomes 8 and 6, respectively. Based on present day genomic distribution and sequence similarities, we propose that a primordial gene that encoded a serine protease with restricted substrate specificity underwent extensive duplication and divergence to form a family of cytokine-regulated transcripts from genes on chromosome 14.	HARVARD UNIV, SCH MED,DEPT MED,SEELEY G MUDD BLDG,RM 617, 250 LONGWOOD AVE, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT RHEUMATOL & IMMUNOL, BOSTON, MA 02115 USA; JACKSON LAB, BAR HARBOR, ME 04609 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Jackson Laboratory				McNeil, Hugh Patrick/0000-0003-4336-2960	NIAID NIH HHS [AI-23483, AI-22531, AI31599] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022531, U01AI031599, U19AI031599, R01AI023483, R01AI022531] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AVRAHAM S, 1988, J BIOL CHEM, V263, P7292; AVRAHAM S, 1989, J BIOL CHEM, V264, P16719; BLEACKLEY RC, 1988, FEBS LETT, V234, P153, DOI 10.1016/0014-5793(88)81323-1; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRUNET JF, 1986, NATURE, V322, P268, DOI 10.1038/322268a0; CARLE GF, 1987, METHOD ENZYMOL, V155, P468; CAUGHEY GH, 1991, J BIOL CHEM, V266, P12956; CROSBY JL, 1990, GENOMICS, V6, P252, DOI 10.1016/0888-7543(90)90564-B; CUYPERS HT, 1984, CELL, V37, P141; DEMBIC Z, 1985, NATURE, V314, P271, DOI 10.1038/314271a0; DUBUSKE L, 1984, J IMMUNOL, V133, P1535; GERSHENFELD HK, 1986, SCIENCE, V232, P854, DOI 10.1126/science.2422755; GHILDYAL N, 1992, J IMMUNOL, V149, P2123; GHILDYAL N, 1992, J BIOL CHEM, V267, P8473; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; HARPER K, 1988, IMMUNOGENETICS, V28, P439, DOI 10.1007/BF00355376; HEUSEL JW, 1991, J BIOL CHEM, V266, P6152; HONEY NK, 1984, SOMAT CELL MOLEC GEN, V10, P377, DOI 10.1007/BF01535633; HONEY NK, 1986, HUM GENET, V72, P27, DOI 10.1007/BF00278813; HUANG RY, 1991, EUR J IMMUNOL, V21, P1611, DOI 10.1002/eji.1830210706; JENNE D, 1988, P NATL ACAD SCI USA, V85, P4814, DOI 10.1073/pnas.85.13.4814; JENNE D, 1988, J IMMUNOL, V140, P318; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; JOHNSON KR, 1992, GENOMICS, V12, P503, DOI 10.1016/0888-7543(92)90441-T; KWON BS, 1988, J EXP MED, V168, P1839, DOI 10.1084/jem.168.5.1839; LEDER A, 1981, NATURE, V293, P196, DOI 10.1038/293196a0; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; NADEAU JH, 1991, GENOMICS, V9, P78, DOI 10.1016/0888-7543(91)90223-2; NEWLANDS GFJ, 1987, IMMUNOLOGY, V62, P629; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1988, J BIOL CHEM, V263, P12783; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERER G, 1989, GENOMICS, V5, P275, DOI 10.1016/0888-7543(89)90058-X; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STONE JC, 1989, GENOMICS, V5, P70, DOI 10.1016/0888-7543(89)90088-8; TANTRAVAHI RV, 1986, P NATL ACAD SCI USA, V83, P9207, DOI 10.1073/pnas.83.23.9207; TAYLOR BA, 1978, ORIGINS INBRED MICE, P4323; Trong H Le, 1989, BIOCHEMISTRY-US, V28, P391, DOI 10.1021/BI00427A054; WATANABE T, 1976, BIOCHEM GENET, V14, P999, DOI 10.1007/BF00485132; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220; ZON LI, 1991, J BIOL CHEM, V266, P22948	48	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11372	11379						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8098710				2022-12-27	WOS:A1993LD46600095
J	HERZOG, H; BAUMGARTNER, M; VIVERO, C; SELBIE, LA; AUER, B; SHINE, J				HERZOG, H; BAUMGARTNER, M; VIVERO, C; SELBIE, LA; AUER, B; SHINE, J			GENOMIC ORGANIZATION, LOCALIZATION, AND ALLELIC DIFFERENCES IN THE GENE FOR THE HUMAN NEUROPEPTIDE-Y Y1 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION; EXPRESSION; INDUCTION; PROTEINS	A 14-kilobase pair (kb) region of genomic DNA encoding the human neuropeptide Y Y1-receptor gene including 3'- and 5'-flanking sequences has been cloned and the human gene localized to chromosome 4q(31.3-32). In contrast to the contiguous structure of most G protein-coupled receptor genes, the NPY Y1 receptor gene is divided into three exons. A small 5'-exon of the mRNA untranslated region is separated by a 6-kb intron from the second exon. The coding region of the receptor is interrupted by a small intron, containing an in-frame stop codon, shortly after the proposed fifth transmembrane domain. In the 5'-flanking region a potential cAMP-response element and an AP-2 site, in addition to a TATA-like sequence and a typical CAAT, box are present. A single point mutation within the 6-kb intron generates a PstI polymorphic site with a highly informative allele frequency of 54:46% in the population.	UNIV INNSBRUCK, INST BIOCHEM, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck	HERZOG, H (corresponding author), ST VINCENTS HOSP, GARVAN INST MED RES, 384 VICTORIA ST, DARLINGHURST, NSW 2010, AUSTRALIA.		Herzog, Herbert/B-8294-2008					AAKERLUND L, 1990, FEBS LETT, V260, P73, DOI 10.1016/0014-5793(90)80069-U; BAUMGARTNER M, 1991, CELL, V64, P761, DOI 10.1016/0092-8674(91)90505-S; BECKSICKINGER AG, 1992, EUR J BIOCHEM, V206, P957, DOI 10.1111/j.1432-1033.1992.tb17006.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DUMANT Y, 1992, PROG NEUROBIOL, V38, P125; FUHLENDORFF J, 1990, P NATL ACAD SCI USA, V87, P182, DOI 10.1073/pnas.87.1.182; HEILIG M, 1990, ACTA PSYCHIAT SCAND, V82, P95, DOI 10.1111/j.1600-0447.1990.tb01366.x; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KRAUSE J, 1992, MOL PHARMACOL, V41, P817; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MORRISON N, 1990, HUM GENET, V85, P130; NAHON JL, 1987, P NATL ACAD SCI USA, V84, P2135, DOI 10.1073/pnas.84.8.2135; POTTER EK, 1991, EUR J PHARMACOL, V193, P15, DOI 10.1016/0014-2999(91)90194-U; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Sambrook J, 1989, MOL CLONING LABORATO; SELBIE LA, 1989, DNA-J MOLEC CELL BIO, V8, P683, DOI 10.1089/dna.1.1989.8.683; TERMAN BI, 1992, CYTOGENET CELL GENET, V60, P214, DOI 10.1159/000133341; WAHLESTEDT C, 1986, REGUL PEPTIDES, V13, P307, DOI 10.1016/0167-0115(86)90048-0; WHARTON J, 1993, IN PRESS P NATL ACAD	24	72	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6703	6707						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8095935				2022-12-27	WOS:A1993KT36800089
J	EYERS, SAC; RIDGWELL, K; MAWBY, WJ; TANNER, MJA				EYERS, SAC; RIDGWELL, K; MAWBY, WJ; TANNER, MJA			TOPOLOGY AND ORGANIZATION OF HUMAN RH (RHESUS) BLOOD GROUP-RELATED POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; RED-CELL MEMBRANE; RH(D) POLYPEPTIDE; MOLECULAR-CLONING; PROTEINS; IDENTIFICATION; ANTIGENS; SEQUENCE; LOCALIZATION; GLYCOPROTEIN	The Rh blood group antigens are associated with nonglycosylated human erythrocyte membrane proteins of molecular mass 30 kDa (the Rh-30 polypeptides) and a glycoprotein of 40-100 kDa (the Rh glycoprotein). We have studied the topology of this family of proteins in the erythrocyte membrane. We confirmed the predicted cytosolic localization of the C and N termini of the Rh protein family. We located Lys-196 and Arg-323 of the Rh glycoprotein to the cytosol, and Glu-34 to the extracellular side of the plasma membrane in erythrocytes, by N-terminal sequencing of Rh glycoprotein peptides produced by proteolysis at the cytoplasmic or extracellular side of the membrane. We also show that a glycan chain is present on only one (Asn-37) of the three potential N-glycan addition sites in the Rh glycoprotein. Studies of the Rh glycoprotein fragments that co-immunoprecipitated with the Rh-30 polypeptides suggest there is an interaction between the Rh-30 polypeptides and amino acids 35-196 of the Rh glycoprotein. A model for the organization of the components of the Rh complex in the red cell membrane is proposed.	UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,ENGLAND	University of Bristol								AGRE P, 1991, BLOOD, V78, P551, DOI 10.1182/blood.V78.3.551.bloodjournal783551; ALEXANDER S, 1982, METHOD ENZYMOL, V79, P505; ANSTEE DJ, 1993, BAILLIERE CLIN HAEM, V6, P401, DOI 10.1016/S0950-3536(05)80152-0; AVENT N, 1988, BIOCHEM J, V251, P499, DOI 10.1042/bj2510499; AVENT ND, 1990, BIOCHEM J, V271, P821, DOI 10.1042/bj2710821; AVENT ND, 1992, J BIOL CHEM, V267, P15134; AVENT ND, 1988, BIOCHEM J, V256, P1043, DOI 10.1042/bj2561043; BARKER RN, 1992, BRIT J HAEMATOL, V82, P126, DOI 10.1111/j.1365-2141.1992.tb04604.x; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BLOY C, 1990, J BIOL CHEM, V265, P21482; BLOY C, 1988, BLOOD, V72, P661; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GAHMBERG CG, 1982, FEBS LETT, V140, P93, DOI 10.1016/0014-5793(82)80528-0; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; HADLEY AG, 1993, BAILLIERE CLIN HAEM, V6, P423, DOI 10.1016/S0950-3536(05)80153-2; HARTELSCHENK S, 1992, J BIOL CHEM, V267, P5569; KAJII E, 1993, HUM GENET, V91, P157; KAJII E, 1992, P JPN ACAD B-PHYS, V68, P51, DOI 10.2183/pjab.68.51; KRAHMER M, 1987, FEBS LETT, V226, P105, DOI 10.1016/0014-5793(87)80560-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVANKIM C, 1992, P NATL ACAD SCI USA, V89, P10925, DOI 10.1073/pnas.89.22.10925; LEVANKIM C, 1992, BLOOD, V80, P1074; MALLINSON G, 1986, BIOCHEM J, V234, P649, DOI 10.1042/bj2340649; MOORE S, 1982, NATURE, V295, P529, DOI 10.1038/295529a0; MOORE S, 1987, BIOCHEM J, V244, P735, DOI 10.1042/bj2440735; Race R. R, 1968, BLOOD GROUPS MAN; RIDGWELL K, 1992, BIOCHEM J, V287, P223, DOI 10.1042/bj2870223; RIDGWELL K, 1994, J BIOL CHEM, V269, P6410; RIDGWELL K, 1983, BIOCHEM J, V213, P267, DOI 10.1042/bj2130267; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SUYAMA K, 1992, BLOOD, V79, P808; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; WANG DN, 1993, EMBO J, V12, P2233, DOI 10.1002/j.1460-2075.1993.tb05876.x	35	91	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6417	6423						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119991				2022-12-27	WOS:A1994MZ50300027
J	SARIBAS, AS; SCHINDLER, JF; VIOLA, RE				SARIBAS, AS; SCHINDLER, JF; VIOLA, RE			MUTAGENIC INVESTIGATION OF CONSERVED FUNCTIONAL AMINO-ACIDS IN ESCHERICHIA-COLI L-ASPARTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NUCLEOTIDE-SEQUENCE; SUBSTRATE-SPECIFICITY; CHEMICAL MODIFICATION; PHENOTYPIC SELECTION; ORTHO-PHTHALALDEHYDE; CLONING; GENE; FUMARASE; ACTIVATION	The potential importance of several functional amino acids in the activity of L-aspartase from Escherichia coli has been examined by site-directed mutagenesis. Amino acids whose importance in enzyme activity was suggested by chemical modification and pH dependence studies were chosen as candidates for investigation. The selection of the particular amino acid targets was guided by homology comparisons among the other sequenced bacterial L-aspartases and by the broader comparison among the fumarase-aspartase enzyme family, Substitution of the most highly conserved cysteine with either serine or alanine, or the most highly conserved histidine with leucine, had no significant effect on the activity of L-aspartase or on the sensitivity of these mutated L-aspartases to cysteine and histidine specific modifying reagents. However, alteration of each of the two conserved lysines to arginine did cause dramatic changes in the catalytic properties of the enzyme. Modification of lysine 54 results in the complete loss of enzyme activity, However, this activity loss appears to be related to changes in the subunit association properties of the arginine 54 mutant. Lysine 326 appears to be involved in substrate binding. Modification of this residue causes a 5-fold increase in the K-m for aspartic acid, a drastic decrease in K-cat/K-m, and a change in the divalent metal ion requirements of the enzyme.	UNIV AKRON,DEPT CHEM,AKRON,OH 44325	University System of Ohio; University of Akron			Viola, Ronald/C-5904-2011		NIGMS NIH HHS [GM34542] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034542] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACUNA G, 1991, J GEN MICROBIOL, V137, P991, DOI 10.1099/00221287-137-4-991; AIMI J, 1990, J BIOL CHEM, V265, P9011; ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; CHAPMAN MS, 1993, PROTEIN SCI, V2, P459; CRAIK CS, 1985, SCIENCE, V228, P291, DOI 10.1126/science.3838593; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FALZONE CJ, 1988, BIOCHEMISTRY-US, V27, P9089, DOI 10.1021/bi00426a004; GUEST JR, 1984, J GEN MICROBIOL, V130, P1271; IDA N, 1985, J BIOCHEM-TOKYO, V98, P793, DOI 10.1093/oxfordjournals.jbchem.a135336; IDA N, 1984, J BIOCHEM-TOKYO, V96, P1315, DOI 10.1093/oxfordjournals.jbchem.a134959; KARSTEN WE, 1991, ARCH BIOCHEM BIOPHYS, V287, P60, DOI 10.1016/0003-9861(91)90388-Y; KARSTEN WE, 1986, BIOCHEMISTRY-US, V25, P1299, DOI 10.1021/bi00354a016; KARSTEN WE, 1985, ANAL BIOCHEM, V147, P336, DOI 10.1016/0003-2697(85)90280-5; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUNKEL TA, 1988, NUCLEIC ACIDS MOL BI, V2, P124; MEAD DA, 1986, PROTEIN ENG, V1, P61; Miles E W, 1977, Methods Enzymol, V47, P431; MIZUTA K, 1975, BIOCHIM BIOPHYS ACTA, V403, P221, DOI 10.1016/0005-2744(75)90024-8; MURASE S, 1991, BIOCHEM BIOPH RES CO, V177, P414, DOI 10.1016/0006-291X(91)91999-S; MURASE S, 1992, J PROTEIN CHEM, V11, P409; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; Sambrook J, 1989, MOL CLONING LABORATO; SARIBAS AS, 1993, COMMENTS, V20, P68; SHI W, 1993, IN PRESS J MOL BIOL; SIMONS SS, 1978, J ORG CHEM, V43, P2886, DOI 10.1021/jo00408a030; SUN DX, 1991, J BACTERIOL, V173, P3831, DOI 10.1128/JB.173.12.3831-3845.1991; TAKAGI JS, 1986, BIOCHEM BIOPH RES CO, V138, P568, DOI 10.1016/S0006-291X(86)80534-4; TAKAGI JS, 1986, J BIOCHEM-TOKYO, V100, P697, DOI 10.1093/oxfordjournals.jbchem.a121762; TAKAGI JS, 1985, NUCLEIC ACIDS RES, V13, P2063, DOI 10.1093/nar/13.6.2063; TAKAGI T, 1985, J BACTERIOL, V161, P1; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; WILLIAMS SE, 1992, BIOCHEMISTRY-US, V31, P9768, DOI 10.1021/bi00155a033; WILLIAMS VR, 1967, J BIOL CHEM, V242, P2973; WONG OS, 1985, J AM CHEM SOC, V107, P6421, DOI 10.1021/ja00308a060; WOODS SA, 1986, BIOCHEM J, V237, P547, DOI 10.1042/bj2370547; WOODS SA, 1988, FEMS MICROBIOL LETT, V51, P181, DOI 10.1111/j.1574-6968.1988.tb02994.x	38	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6313	6319						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119980				2022-12-27	WOS:A1994MZ50300012
J	SPEH, S; ELIAS, H				SPEH, S; ELIAS, H			THE EFFECT OF ELECTROSTATIC AND HYDROPHOBIC INTERACTIONS ON THE RATE OF CYTOCHROME-C REDUCTION BY RUTHENIUM(II) COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORSE HEART; FERROCYTOCHROME-C; AQUEOUS-SOLUTION; PREFERRED SITES; IONIC-STRENGTH; CANDIDA-KRUSEI; OXIDATION; PROTEINS; TRIS(1,10-PHENANTHROLINE)COBALT(III); METALLOPROTEINS	Stopped-flow spectrophotometry was used to study the reduction of cytochrome c by a series of Ru-II complexes including Ru-II(py-R(1-11))(x) (where L(3-) is the anion of N-2-hydroxyethylethylenediaminetriacetic acid; py-R is 4-R-substituted pyridine; x = 0, -1, -2) at 298 K under pseudo-first order conditions at pH 7 (phosphate buffer) and I = 0.1 M (NaCl). The variation in R(x) was as follows: R(1), H (-1); R2, CH2-OH (-1); R(3), (CH2)(2)-SO3- (-2); R(4), CH2-COO- (-2); R(5), CH2-NH3+ (O); R(6), (CH2)(2)-NH2+-cyclohexyl (O); R(7), n-pentyl (-1); R(8), n-tridecyl(-1); R(9), benzyl(-1); R(10), (CH2)(2)-NH-phenyl (-1); R(11) (CH2)(2)-NH-(4-n-hexylphenyl) (-1). Cyclovoltammetry and the MLCT band of RuL(py-R)(x) complexes prove that all of the Ru-II complexes have the same redox potential of 0.13 +/- 0.01 V (versus NHE). The electron transfer follows a second order rate law with rate constant It ranging from (30.5 +/- 1.2).10(5) M(-1) s(-1) (R = R(4), x = -2) to (1.9 +/- 0.1).10(5) M(-1)s(-1) (R = R(6), x = 0). For the reduction by Ru(II)L(py-R(1))(-), Delta H-double dagger = 9.2 +/- 1.2 kJ mol(-1) and Delta S-double dagger = -97 +/- 4 J mol(-1) K-1 are obtained. The study of the cross-reaction between Co(phen)(3)(3+) and Ru-II(py-R)(x) led to k(22), the rate constant for self-exchange in the Ru-II/Ru-III redox couple, which was found to be 440 (R(1)), 455 (R(3)), and 550 (R(5)) M(-1) s(-1) (298 K). The effect of the hydrophobic groups R(7)-R(11) is small and rate reducing for long chains (R(8) and R(11)). The change in the charge x from -1 to -2 is rate enhancing, the change from -1 to 0 is rate reducing. The electrostatic effects on the rate of electron transfer are compatible with the interpretation that the Run reductants dock at the exposed heme edge of cytochrome c and see there a local charge of +3.3 +/- 0.6.	TH DARMSTADT, INST ANORGAN CHEM, D-64289 DARMSTADT, GERMANY	Technical University of Darmstadt								AHMED AJ, 1981, J BIOL CHEM, V256, P1611; ARMSTRONG GD, 1986, J CHEM SOC DALTON, P755, DOI 10.1039/dt9860000755; BAJAJ HC, 1989, INORG CHEM, V28, P1980, DOI 10.1021/ic00309a042; BOWLER BE, 1990, PROG INORG CHEM, V38, P259; BUTLER J, 1983, J BIOL CHEM, V258, P6400; BUTLER J, 1981, J AM CHEM SOC, V103, P469, DOI 10.1021/ja00392a042; CHAPMAN SK, 1983, J CHEM SOC CHEM COMM, P1152, DOI 10.1039/c39830001152; CREUTZ C, 1974, J BIOL CHEM, V249, P6788; CUMMINS D, 1977, J AM CHEM SOC, V99, P5158, DOI 10.1021/ja00457a042; DRAKE PL, 1989, INORG CHEM, V28, P1361, DOI 10.1021/ic00306a029; DREXLER C, 1991, FRESEN J ANAL CHEM, V340, P605, DOI 10.1007/BF00321521; ELIAS H, 1980, INORG CHEM, V19, P869, DOI 10.1021/ic50206a016; EWALL RX, 1974, J AM CHEM SOC, V96, P940, DOI 10.1021/ja00810a063; FURST H, 1958, CHEM TECHN, V10, P693; HEREMANS K, 1982, FARADAY DISCUSS, V74, P343, DOI 10.1039/dc9827400343; HODGES HL, 1974, J AM CHEM SOC, V96, P3132, DOI 10.1021/ja00817a019; HOLWERDA RA, 1980, J AM CHEM SOC, V102, P1142, DOI 10.1021/ja00523a034; HUBER R, 1990, EUR J BIOCHEM, V187, P283, DOI 10.1111/j.1432-1033.1990.tb15305.x; ISIED SS, 1984, PROG INORG CHEM, V32, P443, DOI 10.1002/9780470166338.ch5; KOPPENOL WH, 1982, J BIOL CHEM, V257, P4426; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MARGALIT R, 1973, EUR J BIOCHEM, V32, P492, DOI 10.1111/j.1432-1033.1973.tb02633.x; MARGOLIASH E, 1959, BIOCHEM J, V71, P559, DOI 10.1042/bj0710559; MAUK AG, 1979, J AM CHEM SOC, V101, P5054, DOI 10.1021/ja00511a041; MCARDLE JV, 1974, J AM CHEM SOC, V96, P5737, DOI 10.1021/ja00825a009; MCLENDON G, 1988, ACCOUNTS CHEM RES, V21, P160, DOI 10.1021/ar00148a005; MERCER EE, 1965, INORG CHEM, V4, P1692, DOI 10.1021/ic50034a004; MEYER TE, 1984, BIOCHEMISTRY-US, V23, P4761, DOI 10.1021/bi00315a035; MOORE GR, 1982, FARADAY DISCUSS, V74, P311, DOI 10.1039/dc9827400311; Phillip A. T., 1970, AUST J CHEM, V23, P491; RUSH JD, 1987, J AM CHEM SOC, V109, P2679, DOI 10.1021/ja00243a020; RUSH JD, 1988, J BIOL CHEM, V263, P7514; SAILASUTA N, 1979, J AM CHEM SOC, V101, P455, DOI 10.1021/ja00496a031; SCHILT AA, 1959, J INORG NUCL CHEM, V9, P211, DOI 10.1016/0022-1902(59)80224-4; WEAST RC, 1977, HDB CHEM PHYSICS; Wherland S., 1977, BIOL ASPECTS INORGAN, P289; WISHART JF, 1992, INORG CHEM, V31, P3986, DOI 10.1021/ic00045a024; ZHANG S, 1990, INORG CHEM, V29, P1012, DOI 10.1021/ic00330a022	38	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6370	6375						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119987				2022-12-27	WOS:A1994MZ50300020
J	YAMAMOTO, T; ROBY, KF; KWOK, SCM; SOARES, MJ				YAMAMOTO, T; ROBY, KF; KWOK, SCM; SOARES, MJ			TRANSCRIPTIONAL ACTIVATION OF CYTOCHROME-P450 SIDE-CHAIN CLEAVAGE ENZYME EXPRESSION DURING TROPHOBLAST CELL-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; HUMAN GROWTH-HORMONE; PLACENTAL-LACTOGEN; GENE-EXPRESSION; PROLACTIN FAMILY; RAT; PROTEIN; STEROIDOGENESIS; IDENTIFICATION; ESTABLISHMENT	The purpose of this study was to investigate P450scc expression during trophoblast differentiation. Biochemical characteristics of P450scc protein and mRNA identified in rat trophoblast tissues were similar to those identified in the rat adrenal gland. Furthermore, P450scc was localized to trophoblast giant cells. This observation prompted an examination of progesterone biosynthesis and P450scc expression in Rcho-1 cells. Rcho-1 cells were derived from a transplantable rat choriocarcinoma, their differentiation can be regulated, and they have the capacity to express the trophoblast giant cell phenotype. Progesterone was produced by Rcho-1 cells and increased approximately 100-fold as the cells progressed from proliferation to differentiation. P450scc protein and mRNA accumulation also increased during trophoblast differentiation. P450scc expression within the Rcho-1 cell line was restricted to trophoblast giant cells. To further investigate the regulation of P450scc expression during trophoblast differentiation, we examined a plasmid construct, containing 894 base pairs of DNA 5' upstream from the P450scc transcriptional start site linked to a human growth hormone reporter gene, following stable transfection into Rcho-1 cells. The transfected P450scc regulatory DNA permitted the expression of human growth hormone which paralleled expression of the endogenous P450scc gene, In conclusion, transcriptional activation of the P450scc gene accompanies trophoblast giant cell differentiation.	UNIV KANSAS, MED CTR, DEPT PHYSIOL, KANSAS CITY, KS 66160 USA; ALBERT EINSTEIN MED CTR, DEPT OBSTET & GYNECOL, PHILADELPHIA, PA 19141 USA	University of Kansas; University of Kansas Medical Center; Yeshiva University				Kwok, Simon/0000-0001-6003-5350	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD020676] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029036] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-20676, HD29036, HD 07502] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BOTTE V, 1966, J ENDOCRINOL, V34, P179, DOI 10.1677/joe.0.0340179; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL WJ, 1989, ENDOCRINOLOGY, V125, P1565, DOI 10.1210/endo-125-3-1565; CARNEY EW, 1993, MOL REPROD DEV, V34, P357, DOI 10.1002/mrd.1080340403; DEANE HW, 1962, ENDOCRINOLOGY, V70, P407, DOI 10.1210/endo-70-3-407; DURKEE TJ, 1992, ENDOCRINOLOGY, V130, P1309, DOI 10.1210/en.130.3.1309; FARIA TN, 1991, ENDOCRINOLOGY, V129, P2895, DOI 10.1210/endo-129-6-2895; FARIA TN, 1990, ENDOCRINOLOGY, V127, P3131, DOI 10.1210/endo-127-6-3131; GIBORI G, 1988, RECENT PROG HORM RES, V44, P377; GOLDRING NB, 1987, ENDOCRINOLOGY, V120, P1942, DOI 10.1210/endo-120-5-1942; HUM DW, 1993, CLIN CHEM, V39, P333; JAMESON JL, 1993, ENDOCR REV, V14, P203, DOI 10.1210/er.14.2.203; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; MARTIAL JA, 1979, SCIENCE, V205, P602, DOI 10.1126/science.377496; MCMASTERS KM, 1987, GENE, V57, P1, DOI 10.1016/0378-1119(87)90170-3; MOORE CCD, 1992, MOL ENDOCRINOL, V6, P2045, DOI 10.1210/me.6.12.2045; NILSON JH, 1991, BIOL REPROD, V44, P231, DOI 10.1095/biolreprod44.2.231; OONK RB, 1990, J BIOL CHEM, V265, P22392; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; RINGER GE, 1990, ENDOCR REV, V111, P105; ROBY KF, 1991, MOL CELL ENDOCRINOL, V79, P13, DOI 10.1016/0303-7207(91)90090-F; SCHIFF R, 1993, ENDOCRINOLOGY, V133, P529, DOI 10.1210/en.133.2.529; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHALEM Z, 1988, J STEROID BIOCHEM, V31, P835, DOI 10.1016/0022-4731(88)90293-2; SHEMESH M, 1988, J STEROID BIOCHEM, V29, P21, DOI 10.1016/0022-4731(88)90371-8; SHEMESH M, 1984, P NATL ACAD SCI-BIOL, V81, P6403, DOI 10.1073/pnas.81.20.6403; SHERMAN M, 1993, BIOL TROPHOBLAST, P401; SHIDA MM, 1993, MOL ENDOCRINOL, V7, P181, DOI 10.1210/me.7.2.181; SOARES MJ, 1988, J ENDOCRINOL, V116, P101, DOI 10.1677/joe.0.1160101; SOARES MJ, 1987, J REPROD FERTIL, V79, P93; SOARES MJ, 1991, ENDOCR REV, V12, P402, DOI 10.1210/edrv-12-4-402; SOARES MJ, 1985, DEV BIOL, V107, P520, DOI 10.1016/0012-1606(85)90332-X; SOARES MJ, 1987, DEV BIOL, V124, P134, DOI 10.1016/0012-1606(87)90466-0; STRAUSS JF, 1992, PLACENTA, V13, P389, DOI 10.1016/0143-4004(92)90047-W; TESHIMA S, 1983, JPN J CANCER RES, V74, P205; VALENZUELA P, 1981, NATURE, V289, P650, DOI 10.1038/289650a0; WATERMAN MR, 1989, RECENT PROG HORM RES, V45, P533	37	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6517	6523						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120003				2022-12-27	WOS:A1994MZ50300041
J	LUESCHER, IF; CEROTTINI, JC; ROMERO, P				LUESCHER, IF; CEROTTINI, JC; ROMERO, P			PHOTOAFFINITY-LABELING OF THE T-CELL RECEPTOR ON CLONED CYTOTOXIC T-LYMPHOCYTES BY COVALENT PHOTOREACTIVE LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; HISTOCOMPATIBILITY COMPLEX-MOLECULES; MONOCLONAL-ANTIBODIES; ANTIGENIC PEPTIDES; LIVING CELLS; HEAVY-CHAINS; MHC; CD8; BINDING; SURFACE	The interaction of the T cell antigen receptor with a photoreactive antigenic peptide derivative bound covalently to the H-2K(d) (K-d) molecule was studied by photoaffinity labeling on cloned, CD8 positive cytotoxic T lymphocytes. The K-d-restricted Plasmodium berghei circumsporozoite peptide 253-260 (YIPS-AEKI) was conjugated with iodo-4-azidosalicylic acid at the N terminus and with 4-azidobenzoic acid at the T cell receptor residue Lys-259. Cell-associated or soluble K-d molecules were photoaffinity-labeled with the peptide derivative by selective photoactivation of the N-terminal photoreactive group. Incubation of cell-associated or soluble covalent K-d-peptide derivative complexes (ligands) with cytotoxic T lymphocytes that recognized this peptide derivative and activation of the orthogonal photoreactive group resulted in specific photoaffinity labeling of the T cell receptor. The labeling was inhibitable by an anti-K-d antibody and was absent on K-d-restricted cytotoxic T lymphocytes of different specificity. The binding of the soluble ligand reached a maximum after 2-4 min at 37 degrees C, after 30 min at 18 degrees C, and after 3 h at 4 degrees C. In contrast, binding of the cell-associated ligand reached a transient maxima after 50 and 110 min at 37 and 18 degrees C, respectively. The degree of binding at 37 degrees C was approximately 30% lower than that at 18 degrees C. No binding took place at 4 degrees C. Inhibition studies with antibodies and drugs indicated that the binding of the cell-associated, but not the soluble ligand, was highly dependent on T cell-target cell conjugate formation, whereas the binding of the soluble ligand was greatly dependent on CD8.			LUESCHER, IF (corresponding author), LUDWIG INST CANC RES,LAUSANNE BRANCH,CHEMIN BOVERESSES 155,CH-1066 EPALINGES,SWITZERLAND.							BALEY H, 1984, AZIDES NITRENES REAC, P434; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; CEROTTINI JC, 1972, NATURE-NEW BIOL, V237, P272, DOI 10.1038/newbio237272a0; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CHRISTINCK ER, 1991, NATURE, V352, P67, DOI 10.1038/352067a0; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; ELLIOTT T, 1992, EUR J IMMUNOL, V22, P2085, DOI 10.1002/eji.1830220819; GLASEBROOK AL, 1978, J IMMUNOL, V121, P1870; GODEAU F, 1992, INT IMMUNOL, V4, P265, DOI 10.1093/intimm/4.2.265; GOLSTEIN P, 1982, IMMUNOL REV, V68, P5, DOI 10.1111/j.1600-065X.1982.tb01058.x; INGOLD AL, 1991, NATURE, V352, P721, DOI 10.1038/352721a0; ISAKOV N, 1993, MOL IMMUNOL, V30, P197, DOI 10.1016/0161-5890(93)90092-P; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; LUESCHER IF, 1987, ELECTROPHORESIS, V8, P508, DOI 10.1002/elps.1150081103; LUESCHER IF, 1991, NATURE, V351, P72, DOI 10.1038/351072a0; LUESCHER IF, 1992, J IMMUNOL, V148, P1003; MALEFYT RD, 1993, EUR J IMMUNOL, V23, P418; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; NEEFJES JJ, 1993, EUR J IMMUNOL, V23, P840, DOI 10.1002/eji.1830230411; OJCIUS DM, 1993, EUR J IMMUNOL, V23, P1118, DOI 10.1002/eji.1830230521; OROURKE AM, 1991, J EXP MED, V173, P241, DOI 10.1084/jem.173.1.241; OROURKE AM, 1993, IMMUNOL TODAY, V14, P183; OROURKE AM, 1990, NATURE, V346, P187, DOI 10.1038/346187a0; RATNOFSKY SE, 1987, J EXP MED, V166, P1747, DOI 10.1084/jem.166.6.1747; ROCK KL, 1991, CELL, V65, P611, DOI 10.1016/0092-8674(91)90093-E; ROMERO P, 1992, J IMMUNOL, V148, P1871; ROMERO P, 1993, J EXP MED, V177, P1247, DOI 10.1084/jem.177.5.1247; ROMERO P, 1993, J IMMUNOL, V150, P3825; ROURKE AM, 1992, NATURE, V358, P253; SAMELSON LE, 1985, J IMMUNOL, V134, P2529; SARMIENTO M, 1982, IMMUNOL REV, V68, P135, DOI 10.1111/j.1600-065X.1982.tb01063.x; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SMITH JD, 1992, P NATL ACAD SCI USA, V89, P7767, DOI 10.1073/pnas.89.16.7767; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VANSNICK J, 1982, EUR J IMMUNOL, V12, P905, DOI 10.1002/eji.1830121102; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0	40	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5574	5582						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119892				2022-12-27	WOS:A1994MY84000019
J	PATEL, YM; YUN, JS; LIU, JS; MCGRANE, MM; HANSON, RW				PATEL, YM; YUN, JS; LIU, JS; MCGRANE, MM; HANSON, RW			AN ANALYSIS OF REGULATORY ELEMENTS IN THE PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP) GENE WHICH ARE RESPONSIBLE FOR ITS TISSUE-SPECIFIC EXPRESSION AND METABOLIC CONTROL IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE GENE; ENRICHED TRANSCRIPTIONAL ACTIVATOR; ENHANCER-BINDING-PROTEIN; RAT-LIVER; CYCLIC-AMP; PYRUVATE-CARBOXYLASE; DIETARY-REGULATION; THYROID-HORMONE; MESSENGER-RNA; IDENTIFICATION	Sequences in the gene for P-enolpyruvate carboxykinase (PEPCK) which are responsible for its complex pattern of transcriptional control were determined using transgenic mice containing a chimeric PEPCK-bovine growth hormone (bGH) gene consisting of a segment of the PEPCK promoter from -460 to +73, with mutations in specific regulatory domains. A mutation in the cAMP response element (CRE) (-87 to -74), which binds CCATT/enhancer-binding protein beta (C/EBP beta) and/or cAMP response element-binding protein (CREE), resulted in a 4- and 20-fold elevation in the level of bGH mRNA in the liver and kidney of transgenic mice, respectively. Expression of the PEPCK bGH gene in the liver was reduced 60% by a mutation in the P3 (I) region (-248 to -230), whereas expression in the kidney was increased 10-fold by the same mutation. A mutation in the P2 region (-200 to -164) greatly reduced expression of the PEPCK-bGH gene in the kidney but not in the liver Induction of hepatic PEPCK-bGH gene expression by Bt(2)cAMP was eliminated by mutations in the CRE, P1, P3(I), or by a double mutation of the CRE and P3(I). Mutations in the CRE or P3(I) regions of the PEPCK promoter did not interfere with the expected induction of the PEPCK-bGH gene in the liver at birth. None of the mutations in the PEPCK promoter interfered with the induction of transcription of the PEPCK-bGH gene in the liver when mice were fed a carbohydrate free diet or the deinduction of transcription from the PEPCK promoter caused by a diet high in carbohydrate, whereas a mutation in P2 (an HNF-1 binding domain) eliminated dietary regulation of transcription of the transgene in the kidney. A model to explain the role of the various elements in the PEPCK promoter on the control of PEPCK gene transcription in the liver and kidney is presented.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT NUTR,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,PEW CTR MOLEC NUTR,CLEVELAND,OH 44106; OHIO UNIV,EDISON ANIM BIOTECHNOL CTR,ATHENS,OH 45107	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Ohio University					NIDDK NIH HHS [DK-24451, DK-07319, DK-21859] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021859, R01DK021859] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON JW, 1970, BIOCHIM BIOPHYS ACTA, V208, P165, DOI 10.1016/0304-4165(70)90066-8; BALLARD FJ, 1967, BIOCHEM J, V104, P866, DOI 10.1042/bj1040866; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUTCHER FR, 1972, CANCER RES, V32, P2141; CHEE PP, 1991, PLANT MOL BIOL MANUA, P19; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Davis R W, 1980, Methods Enzymol, V65, P404; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; EISENBERGER CL, 1992, MOL CELL BIOL, V12, P1396, DOI 10.1128/MCB.12.3.1396; FABER S, 1993, J BIOL CHEM, V268, P24976; FRIEDMAN JE, 1993, J BIOL CHEM, V268, P12952; GARCIARUIZ JP, 1983, ENZYME, V30, P265; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GIRARD JR, 1973, J CLIN INVEST, V52, P3190, DOI 10.1172/JCI107519; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HANSON RW, 1972, AM J CLIN NUTR, V25, P1010; HENNING HV, 1966, BIOCHEM Z, V344, P274; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; IYNEDJIAN PB, 1975, J BIOL CHEM, V250, P5596; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KAISER S, 1991, J BIOL CHEM, V266, P9397; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU JS, 1990, BIOTECHNIQUES, V9, P738; LOOSE DS, 1985, BIOCHEMISTRY-US, V24, P4509, DOI 10.1021/bi00338a004; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NECHUSHTAN H, 1987, NUCLEIC ACIDS RES, V15, P6405, DOI 10.1093/nar/15.16.6405; NORDLIE RC, 1963, J BIOL CHEM, V238, P2259; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; PERET J, 1976, J NUTR, V106, P103, DOI 10.1093/jn/106.1.103; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; RESHEFF L, 1970, J BIOL CHEM, V245, P5979; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SALAVERT A, 1982, J BIOL CHEM, V257, P13404; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; WAGNER TE, 1981, P NATL ACAD SCI-BIOL, V78, P6376, DOI 10.1073/pnas.78.10.6376; WOYCHIK RP, 1982, NUCLEIC ACIDS RES, V10, P7197, DOI 10.1093/nar/10.22.7197	50	83	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5619	5628						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119898				2022-12-27	WOS:A1994MY84000025
J	TSAI, MY; WANG, C				TSAI, MY; WANG, C			UNCOUPLING OF PEPTIDE-STIMULATED ATPASE AND CLATHRIN-UNCOATING ACTIVITY IN DELETION MUTANT OF HSC70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; STRESS PROTEINS; COATED VESICLES; DNAJ; HOMOLOG	The recombinant 60-kDa fragment of rat hsc70 has been overexpressed in Escherichia coli. The recombinant protein is not capable of disassembling clathrin from coated vesicles. However, the affinity for peptides and the peptide-stimulated ATPase activity of the intact protein are retained in the 60-kDa fragment. The dissociation constants of peptide P3a (the recognition sequence of clathrin light chain LCa by hsc70) and S peptide of ribonuclease for 60-kDa protein are 13 and 7 mu M, respectively. The maximal velocities of stimulated ATPase activity by peptides P3a and GT4 are 0.25 and 0.31 nmol/h/mu g of protein, respectively, and the EC(50) values (the concentration of peptides that brought about half-maximum hydrolysis) for peptides P3a and GT4 are 0.56 and 0.30 mM, respectively. These results indicate that peptide-stimulated ATPase activity of hsc70 is not sufficient for clathrin uncoating. We suggest that other activities or cellular components as yet unidentified associated with the C-terminal 10-kDa fragment of hsc70 are required for clathrin uncoating.	ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN	Academia Sinica - Taiwan								CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHEETHAM ME, 1992, BIOCHEM J, V284, P469, DOI 10.1042/bj2840469; CYR DM, 1992, J BIOL CHEM, V267, P20927; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREENE LE, 1990, J BIOL CHEM, V265, P6682; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; Holmes Ken C., 1993, Trends in Cell Biology, V3, P53, DOI 10.1016/0962-8924(93)90161-S; HUANG SP, 1993, J BIOL CHEM, V268, P2063; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; OMALLEY K, 1985, MOL CELL BIOL, V5, P3476, DOI 10.1128/MCB.5.12.3476; RAABE T, 1991, NUCLEIC ACIDS RES, V19, P6645, DOI 10.1093/nar/19.23.6645; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; WANG C, 1993, BIOCHEM J, V294, P69, DOI 10.1042/bj2940069; ZHU JK, 1993, PLANT CELL, V5, P341, DOI 10.1105/tpc.5.3.341	21	38	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5958	5962						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119940				2022-12-27	WOS:A1994MY84000074
J	MINTZ, KP; FISHER, LW; GRZESIK, WJ; HASCALL, VC; MIDURA, RJ				MINTZ, KP; FISHER, LW; GRZESIK, WJ; HASCALL, VC; MIDURA, RJ			CHLORATE-INDUCED INHIBITION OF TYROSINE SULFATION ON BONE SIALOPROTEIN SYNTHESIZED BY A RAT OSTEOBLAST-LIKE CELL-LINE (UMR 106-01 BSP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSYLPROTEIN SULFOTRANSFERASE; BALANCE-SHEET; PROTEINS; PROTEOGLYCANS; INVITRO; SECRETION; RESIDUES; PURIFICATION; SUBSTRATE; CULTURES	Bone sialoprotein (BSP) is a major noncollagenous, RGD-containing glycoprotein found in the extracellular matrix of bone. The RGD sequence is flanked by two tyrosine-rich regions, which fit the established consensus requirements for tyrosine sulfation. Tyrosine sulfation is suggested to be important in the regulation of protein secretion and function. The role of this posttranslational modification on the cell attachment activity and secretion of a highly sulfated form of BSP isolated from a rat osteoblast-like cell line (UMR 106-01 BSP) was investigated by inhibiting sulfation with chlorate. [S-35]Sulfate, [H-3]glucosamine, and [H-3]tyrosine were used as metabolic precursors to monitor biosynthetic products. Chlorate was effective in inhibiting to tal [S-35]sulfate incorporation by 90% without altering overall protein synthesis and secretion in cultures up to 72 h under serum-free conditions. Isolated proteoglycans and purified BSP were analyzed for sulfate incorporation. Proteoglycans isolated from the medium of cells treated with chlorate displayed a difference in the hydrodynamic properties of the molecules as compared with control cultures. An increase in the specific activity of proteoglycans labeled with [H-3]glucosamine isolated from chlorate-treated cells was also observed suggesting a change in hexosamine metabolism induced by chlorate. BSP purified from the medium of chlorate-treated cells contained similar to 7% of the S-35 incorporation as compared with nontreated control cultures. Quantification of sulfate incorporation into glycoconjugates versus tyrosine sulfate of BSP indicates that the amount of sulfate associated with N- and O-linked oligosaccharides was reduced by similar to 97%, while that on tyrosine residues was reduced by similar to 90%. Using normal human bone cells, the cell attachment activity of the reduced sulfate form of BSP was nearly equivalent to that of the fully sulfated product.	NIDR, BONE RES BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; DECHERNEY GS, 1989, BIOCHEM BIOPH RES CO, V159, P755, DOI 10.1016/0006-291X(89)90059-4; ECAROTCHARRIER B, 1989, J BIOL CHEM, V264, P20049; FISHER LW, 1983, J BIOL CHEM, V258, P2723; FISHER LW, 1990, J BIOL CHEM, V265, P2347; FISHER LW, 1987, J BIOL CHEM, V262, P9702; FRIEDERICH E, 1988, J CELL BIOL, V107, P1655, DOI 10.1083/jcb.107.5.1655; GRZESIK WJ, 1994, IN PRESS J BONE MINE; HILLE A, 1984, FEBS LETT, V177, P129, DOI 10.1016/0014-5793(84)80996-5; HILLE A, 1990, EUR J BIOCHEM, V188, P577, DOI 10.1111/j.1432-1033.1990.tb15438.x; HILLE A, 1990, EUR J BIOCHEM, V188, P587, DOI 10.1111/j.1432-1033.1990.tb15439.x; HIROSE S, 1988, J BIOL CHEM, V263, P7426; HORTIN G, 1986, BIOCHEM BIOPH RES CO, V141, P326, DOI 10.1016/S0006-291X(86)80372-2; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V150, P342, DOI 10.1016/0006-291X(88)90526-8; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V151, P417, DOI 10.1016/0006-291X(88)90609-2; HORTIN GL, 1989, P NATL ACAD SCI USA, V86, P1338, DOI 10.1073/pnas.86.4.1338; HUMPHRIES DE, 1988, BIOCHEM BIOPH RES CO, V154, P365, DOI 10.1016/0006-291X(88)90694-8; HUTTNER WB, 1984, METHOD ENZYMOL, V107, P200; HUTTNER WB, 1982, NATURE, V299, P273, DOI 10.1038/299273a0; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; JUKKOLA A, 1990, BIOCHEM BIOPH RES CO, V170, P264, DOI 10.1016/0006-291X(90)91269-X; KUMARASAMY R, 1986, J BIOL CHEM, V261, P6473; LEE RWH, 1985, P NATL ACAD SCI USA, V82, P6143, DOI 10.1073/pnas.82.18.6143; LEE RWH, 1983, J BIOL CHEM, V258, P1326; LEYTE A, 1991, J BIOL CHEM, V266, P740; LIU N, 1986, J BIOL CHEM, V261, P856; MCQUILLAN DJ, 1991, BIOCHEM J, V277, P199, DOI 10.1042/bj2770199; MCQUILLAN DJ, 1992, BIOCHEM J, V285, P25, DOI 10.1042/bj2850025; MIDURA RJ, 1990, J BIOL CHEM, V265, P5285; MINTZ KP, 1993, J BONE MINER RES, V8, P985; NAGATA T, 1991, MATRIX, V11, P86, DOI 10.1016/S0934-8832(11)80212-X; NIEHRS C, 1990, J BIOL CHEM, V265, P9314; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826; ROBEY PG, 1989, ENDOCRIN METAB CLIN, V18, P859, DOI 10.1016/S0889-8529(18)30347-5; SOMERMAN MJ, 1988, CALCIFIED TISSUE INT, V43, P50, DOI 10.1007/BF02555169; YANAGISHITA M, 1989, METHOD ENZYMOL, V179, P435; YANAGISHITA M, 1987, METHOD ENZYMOL, V138, P279	41	20	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4845	4852						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106456				2022-12-27	WOS:A1994MX57100025
J	CARLIER, MF; DIDRY, D; ERK, I; LEPAULT, J; PANTALONI, D				CARLIER, MF; DIDRY, D; ERK, I; LEPAULT, J; PANTALONI, D			MYOSIN SUBFRAGMENT-1-INDUCED POLYMERIZATION OF G-ACTIN - FORMATION OF PARTIALLY DECORATED FILAMENTS AT HIGH ACTIN-S(1) RATIOS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; F-ACTIN; BINDING; ATP; TROPOMYOSIN; INTERACTS; PROTEINS; KINETICS	Myosin subfragment-1-induced polymerization of G-actin into arrowhead-decorated F-actin-myosin subfragment-1 (S1) filaments has been studied at low ionic strength and in the absence of ATP, using a combination of light scattering, fluorescence of 4-nitrobenz-2-oxa-1,3-diazol-7-yl- or pyrenyl-labeled actin, sedimentation, and electron microscopy techniques. When G-actin is in excess over myosin subfragment-1, the initial formation of fully decorated F-actin-S1 filaments, in which the actin:S1 molar ratio is 1:1, is followed by further incorporation of G-actin subunits in the polymer concomitant with the redistribution of the myosin heads along the polymer, leading to partially decorated filaments containing less than one S1/actin, in equilibrium with G-actin. This process leads to an overshoot in the light-scattering polymerization curves at high actin:S1 ratios. The concentration of G-actin at equilibrium with partially decorated filaments is a nonlinear function of the molar fraction of S1 in the polymer, indicating that actin-actin-S1 interactions are energetically more favorable than actin-actin or actin-S1-actin-S1 interactions.	CNRS,CTR GENET MOLEC,F-91128 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	CARLIER, MF (corresponding author), CNRS,ENZYMOL LAB,F-91128 GIF SUR YVETTE,FRANCE.		Lepault, Jean/AAN-8859-2020					CARLIER MF, 1984, J BIOL CHEM, V259, P9983; COMBEAU C, 1992, J BIOL CHEM, V267, P14038; DEROSIER DJ, 1970, J MOL BIOL, V52, P255; DETMERS P, 1981, J BIOL CHEM, V256, P99; EGELMAN EH, 1986, ULTRAMICROSCOPY, V19, P367, DOI 10.1016/0304-3991(86)90096-3; GERGELY J, 1957, C CHEM MUSCLE CONTRA; GORDON DJ, 1976, J BIOL CHEM, V251, P7474; GRAZI E, 1909, EUR J BIOCHEM, V182, P277; GRAZI E, 1990, FEBS LETT, V112, P67; HILL TL, 1987, LINEAR AGGREGATION 1, P110; KEANE AM, 1990, NATURE, V344, P265, DOI 10.1038/344265a0; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOSCALZO J, 1975, P NATL ACAD SCI USA, V72, P3412, DOI 10.1073/pnas.72.9.3412; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MILLER L, 1988, J BIOL CHEM, V263, P1996; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; MORNET D, 1981, NATURE, V292, P301, DOI 10.1038/292301a0; OFFER G, 1973, J MOL BIOL, V74, P653, DOI 10.1016/0022-2836(73)90055-7; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TESI C, 1990, BIOCHEMISTRY-US, V29, P1846, DOI 10.1021/bi00459a026; VALENTINRANC C, 1992, J BIOL CHEM, V267, P21543; VALENTINRANC C, 1991, J BIOL CHEM, V266, P17872; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8	27	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3829	3837						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106427				2022-12-27	WOS:A1994MV63100102
J	LEE, RJ; LOW, PS				LEE, RJ; LOW, PS			DELIVERY OF LIPOSOMES INTO CULTURED KB CELLS VIA FOLATE RECEPTOR-MEDIATED ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; LINES; SIZE	Folic acid was covalently conjugated to 66-nm liposomes via spacers of various lengths in an attempt to target the liposomes to KB cells expressing folate receptors. Spacers of short and intermediate lengths were unable to mediate association of folate-conjugated liposomes with receptor-bearing cells, however, use of a 250 angstrom polyethyleneglycol spacer (PEG, M(r) approximately 3350) permitted avid uptake of the liposomes at approximately 2.5 x 10(5) sites/cell. The binding of folate-PEG liposomes to KB cells could be competitively inhibited by excess free folate or by antiserum against the folate receptor, demonstrating the interaction is mediated by the cell surface folate-binding protein. Following binding, cell-associated folate-PEG liposomes were internalized by folate-receptor-mediated endocytosis at 37-degrees-C but not at 4-degrees-C. These folate-PEG liposomes show potential for delivering large quantities of low molecular weight compounds non-destructively into folate receptor-bearing cells.	PURDUE UNIV, DEPT CHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Low, Philip/0000-0001-9042-5528				ALLEN TM, 1991, BIOCHIM BIOPHYS ACTA, V1066, P29, DOI 10.1016/0005-2736(91)90246-5; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; BERINSTEIN N, 1987, CANCER RES, V47, P5954; BOLHUIS RLH, 1992, INT J CANCER, P78; CANEVARI S, 1992, INT J CANCER, P42; GARELLI N, 1992, BIOCHIM BIOPHYS ACTA, V1127, P41, DOI 10.1016/0005-2760(92)90199-6; ITZINGER DC, 1992, BIOCHIM BIOPHYS ACTA, V1113, P201; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KANE MA, 1986, J BIOL CHEM, V261, P44; KLIBANOV AL, 1991, BIOCHIM BIOPHYS ACTA, V1062, P142, DOI 10.1016/0005-2736(91)90385-L; LEAMON CP, 1991, P NATL ACAD SCI USA, V88, P5572, DOI 10.1073/pnas.88.13.5572; LEAMON CP, 1993, BIOCHEM J, V291, P855, DOI 10.1042/bj2910855; LEAMON CP, 1992, J BIOL CHEM, V267, P24966; LESERMAN LD, 1980, P NATL ACAD SCI-BIOL, V77, P4089, DOI 10.1073/pnas.77.7.4089; LITZINGER DC, 1992, BIOCHIM BIOPHYS ACTA, V1104, P179, DOI 10.1016/0005-2736(92)90148-F; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MAYER LD, 1989, CANCER RES, V49, P5922; MILHAUD PG, 1989, BIOCHIM BIOPHYS ACTA, V987, P15, DOI 10.1016/0005-2736(89)90449-5; MOGHIMI SM, 1992, BIOCHIM BIOPHYS ACTA, V1135, P269; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460; PHILLIPS NC, 1991, IMMUNOL LETT, V30, P291, DOI 10.1016/0165-2478(91)90040-H; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; STEWART JC, 1980, ANAL BIOCHEM, V104, P486; TUREK JJ, 1993, J CELL SCI, V106, P423; WEITMAN SD, 1992, CANCER RES, V52, P3396; [No title captured]	26	631	708	0	71	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3198	3204						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106354				2022-12-27	WOS:A1994MV63100015
J	MOL, CD; MUIR, AKS; CYGLER, M; LEE, JS; ANDERSON, WF				MOL, CD; MUIR, AKS; CYGLER, M; LEE, JS; ANDERSON, WF			STRUCTURE OF AN IMMUNOGLOBULIN FAB FRAGMENT SPECIFIC FOR TRIPLE-STRANDED DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFINED CRYSTAL-STRUCTURE; MULTIWIRE AREA DETECTOR; HELIX FORMATION; NEUTRAL PH; FORM; RESOLUTION; CHROMATIN; COMPLEXES; CRYSTALLIZATION; DIFFRACTOMETER	Triple-stranded DNA of the form poly(Pyr).poly(Pur).poly(Pyr) (where Pyr represents a pyrimidine, and Pur represents a purine) has become the subject of intense research because of its potential use in the control of gene expression and in the development of sequence-specific reagents for cleaving DNA. In a triplex of this type, the second pyrimidine strand is in a parallel orientation to the purine strand and forms Hoogsteen base pairs with it via the major groove. We describe here the three-dimensional crystal structure determination of the antigen-binding fragment (Fab) from the murine monoclonal antibody Jel 318. Jel 318 is specific for triple-stranded DNA, with a preference for the sequence poly[d(T.m5C)].poly[d(G.A)].poly[(d(m5C+.T)]. The structure has been solved by the molecular replacement method and refined by molecular. dynamics to an R value of 0.20 at a resolution of 2.8 angstrom. The crystals have cell dimensions that are very similar to those of the previously determined structure of Fab Kol, but the Fab fragments pack within the unit cell in a completely different manner. The protein is in an extended conformation, with an elbow angle of 154-degrees. The shape and electrostatic surface potential of the antibody combining site suggest a possible model for the recognition of triplex DNA in which residues of CDR-H2 (where CDR represents complementarity-determining region) make specific contact with the DNA bases in the minor groove of the triplex.	VANDERBILT UNIV,DEPT BIOCHEM,NASHVILLE,TN 37232; NATL RES COUNCIL CANADA,DIV BIOL SCI,OTTAWA K1A 0R6,ONTARIO,CANADA; UNIV SASKATCHEWAN,DEPT BIOCHEM,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA; NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,MONTREAL H4P 2R2,PQ,CANADA	Vanderbilt University; National Research Council Canada; University of Saskatchewan; National Research Council Canada					NIDDK NIH HHS [DK42502] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; ARNOTT S, 1976, NUCLEIC ACIDS RES, V11, P4141; ARTYMIUK PJ, 1982, ACTA CRYSTALLOGR B, V38, P778, DOI 10.1107/S0567740882004075; BARRY MM, 1994, J BIOL CHEM, V269, P3623; BHAT TN, 1988, J APPL CRYSTALLOGR, V21, P279, DOI 10.1107/S0021889887012755; BIRG F, 1990, NUCLEIC ACIDS RES, V18, P2901, DOI 10.1093/nar/18.10.2901; BIRNBOIM HC, 1979, EUR J BIOCHEM, V98, P301, DOI 10.1111/j.1432-1033.1979.tb13189.x; BOODHOO A, 1988, J BIOL CHEM, V263, P18578; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURKHOLDER GD, 1991, CHROMOSOMA, V101, P11, DOI 10.1007/BF00360681; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; CYGLER M, 1989, ACTA CRYSTALLOGR A, V45, P563, DOI 10.1107/S0108767389003818; CYGLER M, 1987, J BIOL CHEM, V262, P643; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DAVIES DR, 1971, METHOD ENZYMOL, V22, P266, DOI DOI 10.1016/0076-6879(71)22027-9; DELOSSANTOS C, 1989, BIOCHEMISTRY-US, V28, P7282, DOI 10.1021/bi00444a021; ELGIN SCR, 1982, NATURE, V300, P402, DOI 10.1038/300402a0; FELSENFE.G, 1967, ANNU REV BIOCHEM, V36, P407, DOI 10.1146/annurev.bi.36.070167.002203; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P517, DOI 10.1107/S0021889887086102; GLOVER JNM, 1990, J MOL BIOL, V215, P653, DOI 10.1016/S0022-2836(05)80175-5; HAMPEL KJ, 1991, BIOCHEMISTRY-US, V30, P4455, DOI 10.1021/bi00232a012; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HOWARD FB, 1964, BIOCHEM BIOPH RES CO, V17, P93, DOI 10.1016/0006-291X(64)90306-7; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; JOHNSTON BH, 1988, SCIENCE, V241, P1800, DOI 10.1126/science.2845572; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE JS, 1979, NUCLEIC ACIDS RES, V6, P3073, DOI 10.1093/nar/6.9.3073; LEE JS, 1984, NUCLEIC ACIDS RES, V12, P6603, DOI 10.1093/nar/12.16.6603; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; LIPSETT MN, 1964, J BIOL CHEM, V239, P1256; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; LYAMICHEV VI, 1986, J BIOMOL STRUCT DYN, V3, P667, DOI 10.1080/07391102.1986.10508454; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MATSUSHIMA M, 1978, J MOL BIOL, V121, P441, DOI 10.1016/0022-2836(78)90393-5; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MOL CD, 1994, J BIOL CHEM, V269, P3605; MOOREN MMW, 1990, NUCLEIC ACIDS RES, V18, P6523, DOI 10.1093/nar/18.22.6523; MORGAN AR, 1968, J MOL BIOL, V37, P63, DOI 10.1016/0022-2836(68)90073-9; PILCH DS, 1990, P NATL ACAD SCI USA, V87, P1942, DOI 10.1073/pnas.87.5.1942; POVSIC TJ, 1990, J AM CHEM SOC, V112, P9428, DOI 10.1021/ja00181a075; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RILEY M, 1966, J MOL BIOL, V20, P359, DOI 10.1016/0022-2836(66)90069-6; ROSSMANN MG, 1990, ACTA CRYSTALLOGR A, V46, P73, DOI 10.1107/S0108767389009815; SAUL FA, 1992, PROTEINS, V14, P363, DOI 10.1002/prot.340140305; SCHON E, 1983, CELL, V35, P837, DOI 10.1016/0092-8674(83)90116-2; STEIPE B, 1992, J MOL BIOL, V225, P739, DOI 10.1016/0022-2836(92)90398-4; STROBEL SA, 1990, SCIENCE, V249, P73, DOI 10.1126/science.2195655; SUH S W, 1986, Proteins Structure Function and Genetics, V1, P74, DOI 10.1002/prot.340010112; TORMO J, 1992, PROTEIN SCI, V1, P1174; TULIP WR, 1992, J MOL BIOL, V227, P122, DOI 10.1016/0022-2836(92)90687-F; WEINER SJ, 1984, J AM CHEM SOC, V106, P6243, DOI 10.1021/ja00333a021; WEINTRAUB H, 1983, CELL, V32, P1191, DOI 10.1016/0092-8674(83)90302-1; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WILSON AJC, 1949, ACTA CRYSTALLOGR, V2, P318, DOI 10.1107/S0365110X49000813; XUONG NH, 1985, ACTA CRYSTALLOGR B, V41, P267, DOI 10.1107/S0108768185002105	64	39	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3615	3622						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106406				2022-12-27	WOS:A1994MV63100074
J	MURAMOTO, K; SUGIYAMA, S; CRAGOE, EJ; IMAE, Y				MURAMOTO, K; SUGIYAMA, S; CRAGOE, EJ; IMAE, Y			SUCCESSIVE INACTIVATION OF THE FORCE-GENERATING UNITS OF SODIUM-DRIVEN BACTERIAL FLAGELLAR MOTORS BY A PHOTOREACTIVE AMILORIDE ANALOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALOPHILIC BACILLUS; PROTEIN; TRANSPORT; MOTILITY; SUBTILIS; STRAIN	Like amiloride, 6-iodoamiloride (6-IA) competitively and reversibly inhibits rotation of the Na+-driven flagellar motors of alkalophilic Bacillus cells. However, when 6-IA-treated cells are irradiated with UV light, motility is irreversibly inhibited. This treatment does not alter the membrane potential or affect Na+-coupled alpha-aminoisobutyrate transport. An increase in the Na+ concentration during UV irradiation substantially protects the motors from irreversible inhibition. Thus, photoactivated 6-IA seems to bind specifically and covalently at or around the Na-interaction site of the force-generating units of the motors to inhibit motor rotation irreversibly. Rotation of each motor, which is monitored using tethered alkalophilic Bacillus cells, is also inhibited by photoactivated 6-IA. In this case, however, the rotation rate during UV irradiation decreases stepwise, suggesting the presence of several independently functioning force-generating units in a motor. From the data of 14 tethered cells, the number of units/motor is estimated to be 5-9.			MURAMOTO, K (corresponding author), NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA 46401,JAPAN.							ATSUMI T, 1990, J BACTERIOL, V172, P1634, DOI 10.1128/jb.172.3.1634-1639.1990; BENOS DJ, 1978, SCIENCE, V199, P1205, DOI 10.1126/science.305114; Blair D F, 1990, Semin Cell Biol, V1, P75; BLAIR DF, 1990, CELL, V60, P439, DOI 10.1016/0092-8674(90)90595-6; BLAIR DF, 1988, SCIENCE, V242, P1678, DOI 10.1126/science.2849208; BLOCK SM, 1984, NATURE, V309, P470, DOI 10.1038/309470a0; COBB MH, 1981, EXPERIENTIA, V37, P68, DOI 10.1007/BF01965574; CRAGOE EJ, 1967, J MED CHEM, V10, P66, DOI 10.1021/jm00313a014; FRANCIS NR, 1992, P NATL ACAD SCI USA, V89, P6304, DOI 10.1073/pnas.89.14.6304; HIROTA N, 1983, J BIOL CHEM, V258, P577; IMAE Y, 1986, METHOD ENZYMOL, V125, P582; IMAE Y, 1989, J BIOENERG BIOMEMBR, V21, P705, DOI 10.1007/BF00762688; IWAZAWA J, 1993, BIOPHYS J, V64, P925, DOI 10.1016/S0006-3495(93)81454-1; KHAN S, 1988, J MOL BIOL, V202, P575, DOI 10.1016/0022-2836(88)90287-2; KHAN S, 1992, J BACTERIOL, V174, P5123, DOI 10.1128/JB.174.15.5123-5126.1992; KLEYMAN TR, 1989, J BIOL CHEM, V264, P11995; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; KRULWICH TA, 1982, J BIOL CHEM, V257, P1885; MATSUURA S, 1977, FEBS LETT, V82, P187, DOI 10.1016/0014-5793(77)80581-4; NAKAMURA N, 1975, BIOCHIM BIOPHYS ACTA, V397, P188, DOI 10.1016/0005-2744(75)90192-8; OH Y, 1992, J BIOL CHEM, V267, P18498; SHIOI J, 1980, J BACTERIOL, V144, P891, DOI 10.1128/JB.144.3.891-897.1980; SUGIYAMA S, 1988, J BIOL CHEM, V263, P8215; UOZUMI T, 1977, MOL GEN GENET, V152, P65, DOI 10.1007/BF00264941	24	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3374	3380						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106377				2022-12-27	WOS:A1994MV63100039
J	HUANG, CS; CHANG, LS; ANDERSON, ME; MEISTER, A				HUANG, CS; CHANG, LS; ANDERSON, ME; MEISTER, A			CATALYTIC AND REGULATORY PROPERTIES OF THE HEAVY SUBUNIT OF RAT-KIDNEY GAMMA-GLUTAMYLCYSTEINE SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; GLUTATHIONE BIOSYNTHESIS; ESCHERICHIA-COLI; INHIBITION; SULFOXIMINE; EXPRESSION; METABOLISM; PROTEINS; GENES	Gamma-glutamylcysteine synthetase (rat kidney), which catalyzes the first step of GSH synthesis, can be dissociated into subunits (M(r) 73,000 and 27,700) by native gel electrophoresis after treatment with dithiothreitol (DTT); the heavy subunit, which exhibits catalytic activity and feedback inhibition by GSH (Seelig, G. F., Simondsen, R. P., and Meister, A. (1984) J. Biol. Chem. 259, 9345-9347), was cloned and sequenced (Yan, N., and Meister, A. (1990) J. Biol. Chem. 265, 1588-1593). Here, the cDNA for the heavy sub unit was expressed in Escherichia coli, and the recombinant enzyme was separated from E. coli gamma-glutamylcysteine synthetase and purified. The recombinant enzyme and the isolated heavy subunit have much lower affinity for glutamate and higher sensitivity to GSH inhibition than the holoenzyme, suggesting that the heavy subunit alone would not be very active in vivo. A GSH analog, gamma-Glu-alpha-aminobutyryl-Gly (ophthalmic acid), inhibits only slightly, but inhibits much more after treatment of the holoenzyme with DTT. In contrast, ophthalmic acid inhibits the recombinant and isolated heavy subunit enzymes substantially without DTT treatment. We conclude that (a) the light subunit has a regulatory function affecting the affinity of the enzyme for glutamate and GSH and (b) feedback inhibition by GSH involves reduction of the enzyme and also competition between GSH and glutamate for the glutamate site.			HUANG, CS (corresponding author), CORNELL UNIV, MED CTR, COLL MED, DEPT BIOCHEM, NEW YORK, NY 10021 USA.				NIDDK NIH HHS [2-R37-DK-12034] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK012034] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAMER RL, 1980, J BIOL CHEM, V255, P1732; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DOLPHIN D, 1989, GLUTATHIONE CHEM B B, V3; DOLPHIN D, 1989, GLUTATHIONE CHEM B A, V3; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; GRIFFITH OW, 1979, J BIOL CHEM, V254, P1205; GUZMANBARRON ES, 1951, ADV ENZYMOL, V11, P201; Hopkins FG, 1922, J BIOL CHEM, V54, P527; HUANG CS, 1988, P NATL ACAD SCI USA, V85, P2464, DOI 10.1073/pnas.85.8.2464; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MEISTER A, 1992, CHEMTRACTS BIOCH MOL, V3, P75; MOORE W, 1987, J BIOL CHEM, V262, P16771; OMAHONY DJ, 1990, GENE, V91, P275, DOI 10.1016/0378-1119(90)90100-6; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; RICHMAN PG, 1973, J BIOL CHEM, V248, P6684; RICHMAN PG, 1975, THESIS CORNELL U; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SEELIG GF, 1985, METHOD ENZYMOL, V113, P379; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; SEELIG GF, 1982, J BIOL CHEM, V257, P5092; SEKURA R, 1977, J BIOL CHEM, V252, P2599; SIMONDSEN RP, 1986, J BIOL CHEM, V261, P7134; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR CW, 1987, J BIOL CHEM, V262, P16037; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Taniguchi N., 1989, GLUTATHIONE CENTENNI; Wells W W, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P149; YAN N, 1990, J BIOL CHEM, V265, P1588; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	34	329	335	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19675	19680						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8103521				2022-12-27	WOS:A1993LW81900081
J	VAANDRAGER, AB; VANDERWIEL, E; DEJONGE, HR				VAANDRAGER, AB; VANDERWIEL, E; DEJONGE, HR			HEAT-STABLE ENTEROTOXIN ACTIVATION OF IMMUNOPURIFIED GUANYLYL CYCLASE-C - MODULATION BY ADENINE-NUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL ELECTROLYTE TRANSPORT; PROTEIN-KINASE; DIARRHEAL DISEASE; HUMAN RECEPTOR; EXPRESSION; MEMBRANES; BINDING; DOMAIN	We studied the activation and inactivation of recombinant guanylyl cyclase (GC) C stably expressed in human kidney 293 cells. Activation of GC-C by heat-stable enterotoxin (STa), Cd2+, hemin, or the detergent Triton X-100 was followed by a rapid inactivation of the enzyme. Adenine nucleotides were found to prevent the inactivation process in native membranes, as well as following enzyme solubilization and immunopurification. Inactivation of GC-C was not associated with dephosphorylation. However, the phosphorylation of GC-C was promoted by phorbol esters, known activators of protein kinase C. The activation of purified GC-C by STa required the presence of a nonspecific factor as exemplified by bovine serum albumin. When immunopurified GC-C, stabilized by ATP and bovine serum albumin, was analyzed by SDS-polyacrylamide gel electrophoresis under nonreducing conditions, proteins with almost twice the molecular mass (220 and 245 kDa) of the monomer were observed. The mobility of these high M(r) GC-C forms was reduced by STa, suggesting that STa induces a conformation change in a preexisting GC-C dimer. These results indicate that ATP interacts directly with GC-C, stabilizing its active conformation and that the activation of GC-C may occur in the absence of other specific regulatory factors.			VAANDRAGER, AB (corresponding author), ERASMUS UNIV ROTTERDAM,FAC MED,DEPT BIOCHEM,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.			Vaandrager, Arie/0000-0001-9394-9239				BENTLY KJ, 1986, J BIOL CHEM, V261, P14859; BRASITUS TA, 1980, BIOCHIM BIOPHYS ACTA, V630, P152, DOI 10.1016/0304-4165(80)90147-6; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CRANE JK, 1992, INFECT IMMUN, V60, P5004, DOI 10.1128/IAI.60.12.5004-5012.1992; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DEJONGE HR, 1984, BIOCHEM SOC T, V12, P180, DOI 10.1042/bst0120180; DEJONGE HR, 1990, TXB SECRETORY DIARRH, P190; DEJONGE HR, 1986, ZENTRALBL BAKTERIO S, V15, P335; DESAUVAGE FJ, 1991, J BIOL CHEM, V266, P17912; DESAUVAGE FJ, 1992, J BIOL CHEM, V267, P6479; DUDA T, 1993, FEBS LETT, V315, P143, DOI 10.1016/0014-5793(93)81151-O; ELDEIB MMR, 1987, BIOCHIM BIOPHYS ACTA, V928, P83, DOI 10.1016/0167-4889(87)90088-7; FIELD M, 1989, NEW ENGL J MED, V321, P879; FIELD M, 1989, NEW ENGL J MED, V321, P800; GAZZANO H, 1991, INFECT IMMUN, V59, P1552, DOI 10.1128/IAI.59.4.1552-1557.1991; GIANNELLA RA, 1981, ANNU REV MED, V32, P341, DOI 10.1146/annurev.me.32.020181.002013; IWATA T, 1991, J BIOCHEM-TOKYO, V110, P35, DOI 10.1093/oxfordjournals.jbchem.a123539; JEWITT JRS, 1993, EMBO J, V12, P769; KATWA LC, 1992, BIOCHEM J, V283, P727, DOI 10.1042/bj2830727; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; KOLLER KJ, 1993, J BIOL CHEM, V268, P5997; LOWE DG, 1992, BIOCHEMISTRY-US, V31, P10421, DOI 10.1021/bi00158a001; POTTER LR, 1992, J BIOL CHEM, V267, P14531; SCHULZ S, 1992, J BIOL CHEM, V267, P16019; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SINGH S, 1991, BIOCHEM BIOPH RES CO, V179, P1455, DOI 10.1016/0006-291X(91)91736-V; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P2174; VAANDRAGER AB, 1992, GASTROENTEROLOGY, V102, P1161; VAANDRAGER AB, 1993, CYCLIC GMP SYNTHESIS; WILSON SP, 1988, SEC MESS PHOSPHOPROT, V12, P1; WONG SKF, 1992, J CLIN INVEST, V90, P299, DOI 10.1172/JCI115862	34	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19598	19603						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8103520				2022-12-27	WOS:A1993LW81900070
J	PADMANABHAN, K; PADMANABHAN, KP; FERRARA, JD; SADLER, JE; TULINSKY, A				PADMANABHAN, K; PADMANABHAN, KP; FERRARA, JD; SADLER, JE; TULINSKY, A			THE STRUCTURE OF ALPHA-THROMBIN INHIBITED BY A 15-MER SINGLE-STRANDED-DNA APTAMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CRYSTALLOGRAPHIC REFINEMENT; CRYSTAL-STRUCTURE; TELOMERIC DNA; SPECIFICITY; COMPLEXES; RESIDUES; SITE; FORM	The structure of a complex between human alpha-thrombin and a GGTTGGTGTGGTTGG 15-nucleotide consensus sequence has been solved by x-ray crystallography and refined at 2.9-angstrom resolution to an R value of 0.159. As in solution, in the complex the single-stranded DNA folds into a structure with two G-quartets. The DNA is sandwiched between two different positively charged regions of two symmetry-related thrombin molecules in the crystal structure making ionic and hydrophobic interactions. One region is the fibrinogen recognition exosite and the other, the putative heparin binding site. The lack of inhibition of fibrinogen clotting and platelet activation by the DNA 15-mer with the Arg75 --> Glu mutant of thrombin is consistent with the several salt bridges of the DNA in the fibrinogen exosite. The association of DNA with the heparin site of a neighboring molecule appears to simply compensate residual charge. Differences in the 15-mer loop conformations between the complex and NMR solution structures can be attributed to conformational changes upon thrombin binding. Although G-quadruplexes are favored in the presence of monovalent cations, there is no evidence of the latter in the thrombin complex.	MICHIGAN STATE UNIV, DEPT CHEM, E LANSING, MI 48824 USA; MOLEC STRUCT CORP, THE WOODLANDS, TX USA; WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MED & BIOCHEM, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOLEC BIOPHYS, ST LOUIS, MO 63110 USA	Michigan State University; Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)			Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043229, P50HL014147] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43229, HL14147] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BODE W, 1992, PROTEIN SCI, V1, P426; BRUNGER A, 1992, X PLOR MANUAL; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; HARDIN CC, 1992, BIOCHEMISTRY-US, V31, P833, DOI 10.1021/bi00118a028; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HIGASHI T, 1990, J APPL CRYSTALLOGR, V23, P253, DOI 10.1107/S0021889890002461; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KARSHIKOV A, 1992, PROTEIN SCI, V1, P727, DOI 10.1002/pro.5560010605; MACAYA RF, 1993, P NATL ACAD SCI USA, V90, P3745, DOI 10.1073/pnas.90.8.3745; PANYUTIN IG, 1990, P NATL ACAD SCI USA, V87, P867, DOI 10.1073/pnas.87.3.867; PINNAVAIA TJ, 1978, J AM CHEM SOC, V100, P3625, DOI 10.1021/ja00479a070; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; Sen D, 1991, CURR OPIN STRUC BIOL, V1, P435, DOI 10.1016/0959-440X(91)90044-T; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; WANG KY, 1993, BIOCHEMISTRY-US, V32, P1899, DOI 10.1021/bi00059a003; WANG Y, 1992, BIOCHEMISTRY-US, V31, P8112, DOI 10.1021/bi00150a002; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; WU QY, 1992, J BIOL CHEM, V267, P24408; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0	30	439	483	2	82	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17651	17654						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8102368				2022-12-27	WOS:A1993LT74300001
J	CALLAGHAN, R; RIORDAN, JR				CALLAGHAN, R; RIORDAN, JR			SYNTHETIC AND NATURAL OPIATES INTERACT WITH P-GLYCOPROTEIN IN MULTIDRUG-RESISTANT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-CHANNEL BLOCKERS; MEMBRANE GLYCOPROTEIN; BIOCHEMICAL-CHARACTERIZATION; BINDING; VINBLASTINE; VESICLES; MORPHINE; TISSUES; LINES; RAT	The ability of P-glycoprotein (P-gp) to transport naturally occurring and synthetic opiate analgesics was investigated. Multidrug-resistant Chinese hamster ovary cells (B30) were found to accumulate significantly lower amounts of morphine than their drug-sensitive counterparts (B1). This decreased accumulation was reversed upon depletion of cellular stores of ATP. In addition, morphine bound to plasma membranes from B30 cells in a specific, saturable fashion. Verapamil and vinblastine, compounds transported by P-gp, were able to increase accumulation and displace the binding of morphine in B30 cells. In turn, the synthetic opiates meperidine, pentazocine, and methadone were able to increase the accumulation of vinblastine in resistant cells. These compounds were also able to displace the specific binding of vinblastine and the photoaffinity labeling of P-gp in plasma membranes by the radioiodinated anthracycline, iodomycin. The implications of these findings in relation to the distribution, tolerance, and gastrointestinal side effects of opiates are discussed.	UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT BIOCHEM,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT CLIN BIOCHEM,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Callaghan, Richard/ABG-1638-2020; Callaghan, Richard/B-7032-2012	Callaghan, Richard/0000-0001-6136-3532; Callaghan, Richard/0000-0001-6136-3532				BECK WT, 1984, ADV ENZYME REGUL, V22, P207, DOI 10.1016/0065-2571(84)90015-3; BOWMAN WC, 1984, TXB PHARM; BUSCHE R, 1989, MOL PHARMACOL, V35, P414; CANOGAUCI DF, 1987, BIOCHEM PHARMACOL, V36, P2115, DOI 10.1016/0006-2952(87)90139-0; CHARUK JHM, 1992, BIOCHEM BIOPH RES CO, V186, P796, DOI 10.1016/0006-291X(92)90816-4; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; CORNWELL MM, 1986, J BIOL CHEM, V261, P7921; CORNWELL MM, 1987, J BIOL CHEM, V262, P2166; ENDICOTT JA, 1989, ANN REV BIOCH, V58, P367; FORD JM, 1990, CANCER RES, V50, P1748; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HIAT WN, 1992, BIOCHEM PHARMACOL, V43, P103; HORN AS, 1977, J PHARM PHARMACOL, V29, P257, DOI 10.1111/j.2042-7158.1977.tb11308.x; ICHIKAWA M, 1990, BIOCHEM BIOPH RES CO, V166, P74, DOI 10.1016/0006-291X(90)91913-D; INABA M, 1979, CANCER RES, V39, P2200; IWAMOTO K, 1977, J PHARMACOL EXP THER, V200, P236; KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059; LING V, 1983, CANCER TREAT REP, V67, P869; RIORDAN JR, 1985, PHARMACOL THERAPEUT, V28, P51, DOI 10.1016/0163-7258(85)90082-8; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SAFA AR, 1986, J BIOL CHEM, V261, P6137; SAFA AR, 1987, J BIOL CHEM, V262, P1261; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SNYDER SH, 1977, SCI AM, V236, P44, DOI 10.1038/scientificamerican0377-44; SUZUKI S, 1990, J PHYSIOL-LONDON, V421, P645, DOI 10.1113/jphysiol.1990.sp017967; TAMAI I, 1991, J BIOL CHEM, V266, P16796; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WALSH CT, 1975, J PHARMACOL EXP THER, V195, P303; ZAMORA JM, 1988, MOL PHARMACOL, V33, P454	31	126	130	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					16059	16064						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8101846				2022-12-27	WOS:A1993LN30500102
J	NG, L; MCCONNELL, M; TAN, CK; DOWNEY, KM; FISHER, PA				NG, L; MCCONNELL, M; TAN, CK; DOWNEY, KM; FISHER, PA			INTERACTION OF DNA POLYMERASE-DELTA, PROLIFERATING CELL NUCLEAR ANTIGEN, AND SYNTHETIC OLIGONUCLEOTIDE TEMPLATE-PRIMERS - ANALYSIS BY POLYACRYLAMIDE-GEL ELECTROPHORESIS-BAND MOBILITY SHIFT ASSAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMOLOGICAL CHARACTERIZATION; AUXILIARY PROTEIN; CALF THYMUS; REPLICATION INVITRO; MOLECULAR-CLONING; ABASIC SITES; PCNA CYCLIN; KB-CELLS; BINDING; RECOGNITION	A polyacrylamide gel electrophoresis band-mobility shift assay was developed to study the binding of synthetic oligonucleotides by DNA polymerase delta (pol delta) and proliferating cell nuclear antigen (PCNA). As measured by this assay, neither calf thymus pol delta core enzyme nor PCNA alone bind DNA stably. However, mammalian PCNA but not Drosophila PCNA promotes the formation of a distinct pol delta.PCNA.template-primer complex. Appearance of this complex is primer-dependent but does not require Mg2+. Complex stability is also influenced by the presence or absence of individual dNTPs. A model for the ordered sequential interaction of pol delta, PCNA, and DNA template-primers is proposed.	SUNY, HLTH SCI CTR, DEPT PHARMACOL SCI, STONY BROOK, NY 11794 USA; UNIV MIAMI, SCH MED, DEPT MED, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, DEPT BIOCHEM, MIAMI, FL 33101 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College; University of Miami; University of Miami					NIDDK NIH HHS [DK-26206] Funding Source: Medline; NIEHS NIH HHS [ES-04068] Funding Source: Medline; NIGMS NIH HHS [GM-35943] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES004068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035943] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; DOWNEY KM, 1988, CANCER CELLS EUKARYO, V6, P403; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4570, DOI 10.1021/bi00519a009; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4560, DOI 10.1021/bi00519a008; FISHER PA, 1979, J BIOL CHEM, V254, P6128; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LEIBOVICI M, 1990, DEV BIOL, V141, P183, DOI 10.1016/0012-1606(90)90113-W; MATSUMOTO K, 1987, EMBO J, V6, P637, DOI 10.1002/j.1460-2075.1987.tb04802.x; NG L, 1989, J BIOL CHEM, V264, P13018; NG L, 1991, J BIOL CHEM, V266, P11699; NG L, 1990, J BIOL CHEM, V265, P11948; OGATA K, 1987, EXP CELL RES, V168, P475, DOI 10.1016/0014-4827(87)90020-6; OLINS DE, 1989, J CELL BIOL, V109, P1399, DOI 10.1083/jcb.109.4.1399; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SUZUKA I, 1989, P NATL ACAD SCI USA, V86, P3189, DOI 10.1073/pnas.86.9.3189; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TAN CK, 1986, J BIOL CHEM, V261, P2310; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; WONG SW, 1986, J BIOL CHEM, V261, P7958; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872; ZUBER M, 1989, EXP CELL RES, V182, P384, DOI 10.1016/0014-4827(89)90243-7	27	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13571	13576						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8099910				2022-12-27	WOS:A1993LH55300079
J	BEDELLHOGAN, D; TRACKMAN, P; ABRAMS, W; ROSENBLOOM, J; KAGAN, H				BEDELLHOGAN, D; TRACKMAN, P; ABRAMS, W; ROSENBLOOM, J; KAGAN, H			OXIDATION, CROSS-LINKING, AND INSOLUBILIZATION OF RECOMBINANT TROPOELASTIN BY PURIFIED LYSYL OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS	The use of recombinant human tropoelastin (rTE) and selected variants thereof as substrates for the assay of lysyl oxidase activity in vitro was explored. The possibility was also assessed that an insoluble elastin-like product could be generated from this elastin precursor in the absence of other macromolecules found associated with elastin in vivo. rTE was more efficiently oxidized by lysyl oxidase than the insoluble chick aorta elastin substrate conventionally used. Anionic amphiphilic elastin ligands strongly inhibited rTE oxidation consistent with the importance of electrostatic enzyme-substrate interactions previously noted with the insoluble elastin substrate. An rTE variant, rTEDELTA26A, lacking the hydrophilic sequence coded by exon 26A, was a less effective substrate than rTE, largely due to an increase in K(m), while the kinetic parameters for the oxidation of rTEDELTA36, lacking the C-terminal polybasic sequence coded by exon 36, were quite similar to those for rTE. Incubation of rTEDELTA26A with lysyl oxidase not only resulted in the generation of peptidyl alpha-aminoadipic-delta-semialdehyde and lysine-derived cross-linkages, but also yielded a product insoluble in hot 0.1 N NaOH, consistent with the properties of insoluble elastin. Thus, oxidation, cross-linking and insolubilization of elastin substrates by lysyl oxidase can occur in the absence of other macromolecules implicated as being involved in this process in vivo, although such macromolecules may be essential to obtain the proper alignment between tropoelastin units for specifically placed cross-linkages and optimally functional elastic fibers.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; UNIV PENN,SCH DENT MED,DEPT ANAT & HISTOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH DENT MED,ORAL BIOL RES CTR,PHILADELPHIA,PA 19104	Boston University; University of Pennsylvania; University of Pennsylvania				Trackman, Philip/0000-0001-5064-614X	NHLBI NIH HHS [HL 13262, HL 46902] Funding Source: Medline; NIAMS NIH HHS [AR 18880] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046902, P01HL013262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018880, R37AR018880] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARONE LM, 1985, BIOCHIM BIOPHYS ACTA, V840, P245, DOI 10.1016/0304-4165(85)90125-4; BASHIR MM, 1989, J BIOL CHEM, V264, P8887; Cleary E.G., 1987, CONNECTIVE TISSUE DI, V12, P55; DIEDRICH DL, 1978, P NATL ACAD SCI USA, V75, P3708, DOI 10.1073/pnas.75.8.3708; FORNIERI C, 1987, J CELL BIOL, V105, P1463, DOI 10.1083/jcb.105.3.1463; INDIK Z, 1990, ARCH BIOCHEM BIOPHYS, V280, P80, DOI 10.1016/0003-9861(90)90521-Y; KAGAN HM, 1984, J BIOL CHEM, V259, P1203; KAGAN HM, 1981, J BIOL CHEM, V256, P5417; KAGAN HM, 1982, METHOD ENZYMOL, V82, P637; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANSING AI, 1952, ANAT REC, V114, P55; MECHAM RP, 1991, J CELL BIOL, V113, P187, DOI 10.1083/jcb.113.1.187; MIRELMAN D, 1979, J BIOL CHEM, V254, P571; NARAYANAN AS, 1972, BIOCHIM BIOPHYS ACTA, V35, P126; RICH CB, 1982, METHOD ENZYMOL, V82, P665; TANG SS, 1983, J BIOL CHEM, V258, P4331; TRACKMAN PC, 1981, ANAL BIOCHEM, V113, P336, DOI 10.1016/0003-2697(81)90086-5; WILLIAMS MA, 1985, ANAL BIOCHEM, V149, P430, DOI 10.1016/0003-2697(85)90594-9	18	132	146	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10345	10350						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8098038				2022-12-27	WOS:A1993LB80000056
J	BUTTA, N; URCELAY, E; GONZALEZMANCHON, C; PARRILLA, R; AYUSO, MS				BUTTA, N; URCELAY, E; GONZALEZMANCHON, C; PARRILLA, R; AYUSO, MS			PERTUSSIS TOXIN INHIBITION OF ALPHA-1-ADRENERGIC OR VASOPRESSIN-INDUCED CA2+ FLUXES IN RAT-LIVER - SELECTIVE-INHIBITION OF THE ALPHA-1-ADRENERGIC RECEPTOR-COUPLED METABOLIC-ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MEMBRANE CA-2+ INFLOW; PHOSPHOLIPASE-C; CA-2+-MOBILIZING HORMONES; INOSITOL TRISPHOSPHATE; SIGNAL TRANSDUCTION; REGULATORY PROTEIN; ADENYLATE-CYCLASE; BINDING-PROTEINS; 2ND MESSENGERS	Pretreatment with pertussis toxin produced a impairment of the response to the alpha-adrenergic agonist phenylephrine in perfused isolated rat livers. The sustained phases of phenylephrine-induced increases in respiration, glucose mobilization, gluconeogenesis, vascular resistance, and efflux of H+ and Ca2+ were inhibited to variable degrees in livers from pertussis toxin-treated animals. The susceptibility of such a diversity of receptor-mediated effects suggests that a common, most likely early step(s) of the alpha1-receptor-coupled signaling pathway may be regulated by a pertussis toxin-sensitive G(i) protein(s) that appears to be involved in the control of the rate of these processes. The most significant effect of pertussis toxin has been to almost entirely prevent the phenylephrine-induced sustained release of Ca2+. Pertussis toxin also inhibited the vasopressin-mediated influx of Ca2+. These findings indicate that G proteins associated with receptor-operated calcium channels are a site of interaction of pertussis toxin. The following observations support the conclusion that pertussis toxin per se does not perturb the hepatic metabolism. Its effects are specifically linked to functional responses mediated by alpha1-type adrenergic receptors: 1) polypeptide receptor-mediated metabolic effects, as those induced by vasopressin, were not affected by pertussis toxin; 2) non-receptor-mediated effects, such as fatty acid-induced stimulation of respiration and gluconeogenesis, were not impaired by pertussis toxin; and 3) neither the hepatic responses to alpha2-(clonidine) nor to beta-(isoproterenol) adrenergic receptor agonists were altered in livers from pertussis toxin-treated rats. The differential effects of pertussis toxin in the metabolic actions of phenylephrine and vasopressin, in spite of apparently similar effects in perturbing their actions on Ca2+ fluxes, suggest that pertussis toxin-sensitive alpha1-receptor-associated G protein(s) other than those controlling Ca2+ channels, were also specifically affected in the alpha1-agonist-signaling pathway. The finding that increasing concentrations of phenylephrine were capable of overcoming these pertussis toxin actions indicates that alpha1-adrenoreceptors' ligand affinity is controlled by G(i) proteins.	CSIC, CTR INVEST BIOL, ENDOCRINE PHYSIOL UNIT, VELAZQUEZ 144, E-28006 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consiglio Nazionale delle Ricerche (CNR)			Gonzalez-Manchon, Consuelo/H-9257-2015; Milagros Rodriguez, Biblioteca-CIB/H-7697-2015; Ayuso, Matilde Sánchez/B-2777-2008; Parrilla, Roberto/B-6307-2008	Gonzalez-Manchon, Consuelo/0000-0002-3081-0253; Ayuso, Matilde Sánchez/0000-0003-2504-0925; Urcelay, Elena/0000-0001-8470-8396				AIYAR N, 1989, BIOCHEM J, V261, P63, DOI 10.1042/bj2610063; ALTHAUSSALZMANN M, 1980, EUR J BIOCHEM, V106, P241; ALTIN JG, 1986, BIOCHEM J, V238, P653, DOI 10.1042/bj2380653; ALTIN JG, 1987, BIOCHEM J, V242, P43, DOI 10.1042/bj2420043; Bergmeyer H.U., 1975, METHODS ENZYMATIC AN; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOYER JL, 1984, J BIOL CHEM, V259, P8076; BUTTA N, 1991, 4 PORT SPAN BIOCH C; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; DUDDY SK, 1989, J BIOL CHEM, V264, P20863; EXTON JH, 1988, FASEB J, V2, P2670, DOI 10.1096/fasebj.2.11.2456243; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GONZALEZMANCHON C, 1988, ARCH BIOCHEM BIOPHYS, V265, P258, DOI 10.1016/0003-9861(88)90126-9; HALLAM TJ, 1989, TRENDS PHARMACOL SCI, V10, P8, DOI 10.1016/0165-6147(89)90092-8; HUGHES BP, 1987, BIOCHEM J, V245, P41, DOI 10.1042/bj2450041; HUGHES BP, 1987, BIOCHEM J, V248, P911, DOI 10.1042/bj2480911; JOSEPH SK, 1985, J BIOL CHEM, V260, P2508; KASS GEN, 1990, J BIOL CHEM, V265, P17486; LIMBIRD LE, 1981, BIOCHEM J, V195, P1; LITOSCH I, 1985, J BIOL CHEM, V260, P5464; LYNCH CJ, 1986, MOL PHARMACOL, V29, P196; MENAYA J, 1987, BIOCHEM J, V248, P903, DOI 10.1042/bj2480903; NAKAMURA T, 1985, J BIOL CHEM, V260, P3584; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; POBINER BF, 1985, J BIOL CHEM, V260, P6200; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; RASHED SM, 1991, EUR J BIOCHEM, V197, P805, DOI 10.1111/j.1432-1033.1991.tb15975.x; REINHART PH, 1984, BIOCHEM J, V220, P35, DOI 10.1042/bj2200035; REQUERO AM, 1986, ARCH BIOCHEM BIOPHYS, V246, P114; ROSS EM, 1980, ANNU REV BIOCHEM, V49, P553, DOI 10.1146/annurev.bi.49.070180.002533; SAZ JM, 1989, BIOCHEM BIOPH RES CO, V160, P480, DOI 10.1016/0006-291X(89)92458-3; SMITH CD, 1985, J BIOL CHEM, V260, P5875; SPIEGEL AM, 1987, MOL CELL ENDOCRINOL, V49, P1, DOI 10.1016/0303-7207(87)90058-X; TAYLOR WM, 1986, HORMONAL CONTROL GLU, V2, P147; TOHKIN M, 1990, EUR J BIOCHEM, V194, P81, DOI 10.1111/j.1432-1033.1990.tb19430.x; UHING RJ, 1985, FEBS LETT, V188, P317, DOI 10.1016/0014-5793(85)80394-X; WILLIAMSON JR, 1985, AM J PHYSIOL, V248, pC203, DOI 10.1152/ajpcell.1985.248.3.C203; YANG LJ, 1991, J BIOL CHEM, V266, P22451	39	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6081	6089						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8095934				2022-12-27	WOS:A1993KT36800005
J	LI, X; DRUCKER, DJ				LI, X; DRUCKER, DJ			PARATHYROID HORMONE-RELATED PEPTIDE IS A DOWNSTREAM TARGET FOR RAS AND SRC ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ISLET CELL-LINE; GENE-EXPRESSION; GROWTH-FACTORS; HUMORAL HYPERCALCEMIA; HUMAN KERATINOCYTES; RAPID INDUCTION; SODIUM-BUTYRATE; HUMAN-TUMOR; PROTEIN; RNA	Neoplastic transformation may be associated with the development of paraneoplastic syndromes that complicate the management of patients with malignant disease. One of these syndromes, humoral hypercalcemia of malignancy, has been shown to be attributable to increased secretion of a parathyroid hormone-related peptide (PTHrP). The gene encoding PTHrP is expressed at low levels in a growth factor dependent manner in normal tissues, and the mechanisms underlying selective tumor-associated induction of PTHrP gene expression remain unclear. Here we show that cellular transformation by the EJ-Ha-ras and v-src oncogenes is associated with a marked increase in PTHrP gene expression. Ha-ras and v-src-transfected NRK 49F cells and ras-transfected RCB 2.2 cell lines secreted increased amounts of immunoreactive PTHrP. Northern blot analysis also demonstrated increased levels of PTHrP mRNA transcripts in oncogene-transfected stable cell lines. No significant change in the half-life of PTHrP mRNA transcripts was detected in Ha-ras and v-src-transformed cells. In contrast, nuclear run-on assays demonstrated an increased rate of PTHrP gene transcription in oncogene-transformed cells. These observations demonstrate that the gene encoding PTHrP is a downstream target for ras and src, potentially providing a molecular basis for understanding the activation of PTHrP gene expression in malignancy-associated hypercalcemia.	UNIV TORONTO, DEPT CLIN BIOCHEM, TORONTO M5G 2C4, ON, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET & MED, TORONTO M5G 2C4, ON, CANADA	University of Toronto; University of Toronto			Drucker, Daniel J/A-4092-2010					ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ADACHI N, 1990, BIOCHEM BIOPH RES CO, V166, P1088, DOI 10.1016/0006-291X(90)90978-V; ALLINSON ET, 1992, CANCER RES, V52, P3103; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; AUBIN JE, 1988, J BONE MINER RES, V3, P333; BROADUS AE, 1988, NEW ENGL J MED, V319, P556; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; BURTON PBJ, 1992, FEBS LETT, V305, P228, DOI 10.1016/0014-5793(92)80674-6; BURTON PBJ, 1990, BIOCHEM BIOPH RES CO, V167, P1134, DOI 10.1016/0006-291X(90)90641-Y; CAMPOS RV, 1992, MOL ENDOCRINOL, V6, P1642, DOI 10.1210/me.6.10.1642; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DEMETRI GD, 1990, J CLIN INVEST, V86, P1261, DOI 10.1172/JCI114833; DITTMER J, 1993, J VIROL, V67, P6087, DOI 10.1128/JVI.67.10.6087-6095.1993; EJIMA E, 1993, BLOOD, V81, P1017; ENOMOTO H, 1993, BIOCHEM BIOPH RES CO, V191, P1261, DOI 10.1006/bbrc.1993.1353; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; HORIUCHI N, 1987, SCIENCE, V238, P1566, DOI 10.1126/science.3685994; IKEDA K, 1990, J BIOL CHEM, V265, P5398; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KAISER SM, 1992, J BIOL CHEM, V267, P13623; KEMP BE, 1987, SCIENCE, V238, P1568, DOI 10.1126/science.3685995; KIRIYAMA T, 1993, MOL CELL ENDOCRINOL, V92, P55, DOI 10.1016/0303-7207(93)90074-T; KREIDER BL, 1992, ONCOGENE, V7, P135; KREMER R, 1991, J CLIN INVEST, V87, P884, DOI 10.1172/JCI115094; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LI X, 1993, CANCER RES, V53, P2980; LIAPIS H, 1993, AM J PATHOL, V143, P1169; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MANGIN M, 1988, P NATL ACAD SCI USA, V85, P597, DOI 10.1073/pnas.85.2.597; MANGIN M, 1990, MOL ENDOCRINOL, V4, P851, DOI 10.1210/mend-4-6-851; MERENDINO JJ, 1986, SCIENCE, V231, P388, DOI 10.1126/science.2417317; MOSELEY JM, 1987, P NATL ACAD SCI USA, V84, P5048, DOI 10.1073/pnas.84.14.5048; PHILIPPE J, 1987, MOL CELL BIOL, V7, P560, DOI 10.1128/MCB.7.1.560; RABBANI SA, 1988, ENDOCRINOLOGY, V123, P2709; RODAN SB, 1988, J CLIN INVEST, V81, P924, DOI 10.1172/JCI113404; RODAN SB, 1989, J ENDOCRINOL, V122, P219, DOI 10.1677/joe.0.1220219; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STEWART AF, 1988, J CLIN INVEST, V81, P596, DOI 10.1172/JCI113358; STREUTKER C, 1991, MOL ENDOCRINOL, V5, P703, DOI 10.1210/mend-5-5-703; STREWLER GJ, 1987, J CLIN INVEST, V80, P1803, DOI 10.1172/JCI113275; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; THIEDE MA, 1988, P NATL ACAD SCI USA, V85, P4605, DOI 10.1073/pnas.85.13.4605; THIEDE MA, 1988, SCIENCE, V242, P278, DOI 10.1126/science.3175653; VASAVADA RC, 1993, MOL ENDOCRINOL, V7, P273, DOI 10.1210/me.7.2.273; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; YASUDA T, 1989, MOL ENDOCRINOL, V3, P518, DOI 10.1210/mend-3-3-518	50	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6263	6266						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119972				2022-12-27	WOS:A1994MZ50300002
J	TRAN, CM; HUSTON, EE; FARLEY, RA				TRAN, CM; HUSTON, EE; FARLEY, RA			PHOTOCHEMICAL LABELING AND INHIBITION OF NA,K-ATPASE BY 2-AZIDO-ATP - IDENTIFICATION OF AN AMINO-ACID LOCATED WITHIN THE ATP BINDING-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; ACTIVE-SITE; ADENOSINE-TRIPHOSPHATASE; ESSENTIAL RESIDUE; SEQUENCE; KIDNEY; (NA++K+)-ATPASE; (NA,K)-ATPASE; LYSINE-480; PROTEINS	2-Azido-ATP (2-N-3-ATP) was investigated as a reagent for the identification of amino acids located within the catalytic ATP binding site of Na,K-ATPase. The enzymatic activity of Na,K-ATPase was inhibited up to 50% by 2-N-3-ATP (K-0.5 = 5-10 mu M) after irradiation with ultraviolet light, and inhibition was prevented by 0.2 mM ATP. The binding of ATP to Na,K-ATPase (K-D = 0.1 mu M) was inhibited competitively by 2-N-3-ATP. [alpha-P-32]2-N-3-ATP labels the alpha subunit of Na,K-ATPase, and the stoichiometry of covalent ATP-protectable incorporation of the probe into the protein is approximately equal to the stoichiometry of high-affinity binding of ATP to the Na,K-ATPase. 2-N-3-ATP is also hydrolyzed by Na,K-ATPase as a substrate. From these data, it is concluded that 2-N-3-ATP photochemically labels the Na,K-ATPase from within the catalytic ATP site on the protein. Trypsin digestion of Na,K-ATPase after photochemical labeling with [alpha-P-32]2-N-3-ATP generated a large 30-kDa fragment containing the radiolabeled nucleotide. This fragment was resistant to further cleavage by trypsin, but it could be digested further after denaturation in urea. High pressure liquid chromatography separation of tryptic peptides from the 30-kDa fragment and subsequent amino acid sequence analysis of the radiolabeled peptides identified the region between His(496) and Arg(510) of the Na,K-ATPase alpha subunit as the region labeled by [alpha(32)P]2-N-3-ATP. Gly(502) was absent from all sequences of the radiolabeled peptides from this region, consistent with the derivatization of this amino acid by 2-N-3-ATP and localization of Gly(502) within the ATP binding site.	UNIV SO CALIF, SCH MED, DEPT PHYSIOL & BIOPHYS, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, DEPT BIOCHEM, LOS ANGELES, CA 90033 USA	University of Southern California; University of Southern California					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028673] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28673] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOULAY F, 1985, BIOCHEMISTRY-US, V24, P7372, DOI 10.1021/bi00346a052; CZARNECKI JJ, 1984, BIOCHIM BIOPHYS ACTA, V800, P41, DOI 10.1016/0304-4165(84)90092-8; DAVIS CB, 1990, J BIOL CHEM, V265, P1300; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; Fiske CH, 1925, J BIOL CHEM, V66, P375; HINZ HR, 1990, J BIOL CHEM, V265, P10260; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P291; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KIRLEY TL, 1984, BIOCHEM BIOPH RES CO, V125, P767, DOI 10.1016/0006-291X(84)90605-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; MELESE T, 1985, J BIOL CHEM, V260, P5398; MICHELSON AM, 1964, BIOCHIM BIOPHYS ACTA, V91, P1, DOI 10.1016/0926-6550(64)90164-1; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P111, DOI 10.1016/0014-5793(87)81253-X; PEDEMONTE CH, 1992, FEBS LETT, V314, P97, DOI 10.1016/0014-5793(92)81470-7; RUSH J, 1990, J BIOL CHEM, V265, P4821; SCHAEFFER HJ, 1958, J AM CHEM SOC, V80, P3738, DOI 10.1021/ja01547a068; SCHEINERBOBIS G, 1985, EUR J BIOCHEM, V152, P739, DOI 10.1111/j.1432-1033.1985.tb09255.x; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SYMONS RH, 1968, BIOCHIM BIOPHYS ACTA, V155, P609, DOI 10.1016/0005-2787(68)90205-0; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; TOMASZ J, 1978, NUCLEIC ACID CHEM, V3, P765; TRAN CM, 1988, BIOPHYS J, V53, pA343; WANG K, 1992, J BIOL CHEM, V267, P3577; XU KY, 1989, BIOCHEMISTRY-US, V28, P5764, DOI 10.1021/bi00440a010; YOSHIKAWA M, 1967, TETRAHEDRON LETT, P5065	29	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6558	6565						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120008				2022-12-27	WOS:A1994MZ50300047
J	KOVACS, T; CORVAZIER, E; PAPP, B; MAGNIER, C; BREDOUX, R; ENYEDI, A; SARKADI, B; ENOUF, J				KOVACS, T; CORVAZIER, E; PAPP, B; MAGNIER, C; BREDOUX, R; ENYEDI, A; SARKADI, B; ENOUF, J			CONTROLLED PROTEOLYSIS OF CA2+-ATPASES IN HUMAN PLATELET AND NONMUSCLE CELL-MEMBRANE VESICLES - EVIDENCE FOR A MULTI-SARCO/ENDOPLASMIC RETICULUM CA2+-ATPASE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; CALCIUM-PUMP; PLASMA-MEMBRANE; CA-2+ PUMP; CA-2+-TRANSPORT ATPASE; CA-2+-ATPASE GENE; SKELETAL-MUSCLE; MESSENGER-RNA; SMOOTH-MUSCLE; EXPRESSION	Two sarco/endoplasmic reticulum Ca2+-ATPases (SERCAs) have been previously identified in platelets: the 100-kDa SERCA(2b), and the 97-kDa SERCA(3) isoforms. Analysis of the acylphosphate intermediate (E similar to P) formation and the immunoreactivity of the platelet Ca2+-ATPases and their proteolytic fragments upon controlled trypsinolysis revealed the presence of an additional 97-kDa Ca2+-ATPase that comigrates with SERCA(3) on SDS-polyacrylamide gels. At a trypsin/membrane protein ratio of 0.025 at 4 degrees C, tryptic fragments of 73-, 68- and 40-kDa, previously unknown in the SERCA family, could be detected by using the PL/IM 430 anti-Ca2+-ATPase antibody that had been shown to recognize a 97-kDa Ca2+-ATPase. The 73- and 68-kDa fragments were precursors of the 40-kDa one. Ca2+-dependent phospholabeling of the 73-kDa fragment and immunostaining of all these proteolytic products by another antibody raised against SERCA(1) established the SERCA nature of the 97-kDa parent enzyme. The SERCA(3)-related E similar to P-forming 80-kDa tryptic fragment appeared during trypsinolysis with a different time course from that of the 73-, 68-, and 40-kDa ones. At a trypsin/membrane protein ratio of 0.125 at 37 degrees C, it reached its maximum level at 5 min of digestion, while the 73-, 68-, and 40-kDa fragments were fully degraded at 2 min of trypsinization. This 80-kDa species was immunostained neither with the PL/IM 430, nor with the anti-SERCA(1) antibodies. Similar results were found in some megakaryoblastoid and lymphoblastoid cell lines. All these data indicate the presence of two distinct tryptic fragmentation patterns attributed to two 97-kDa SERCA isoforms and point to the existence of a multi-SERCA system in different human non-muscle cells.	NATL INST HAEMATOL & BLOOD TRANSFUS,H-1113 BUDAPEST,HUNGARY		KOVACS, T (corresponding author), HOP LARIBOISIERE,INSERM,U348,8 RUE GUY PATIN,F-75475 PARIS 10,FRANCE.		Kovács, Tünde/O-6020-2017; Enyedi, Agnes/N-9742-2013; Sarkadi, Balazs/I-5024-2013	Kovács, Tünde/0000-0003-1064-2616; Enyedi, Agnes/0000-0002-7366-9376; Papp, Bela/0000-0002-5025-3087				BOBE R, 1994, J BIOL CHEM, V269, P1417; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; DEAN WL, 1984, J BIOL CHEM, V259, P7343; DEAN WL, 1989, CELL CALCIUM, V10, P289, DOI 10.1016/0143-4160(89)90055-9; DEAN WL, 1982, J BIOL CHEM, V257, P4390; DUX L, 1983, J BIOL CHEM, V258, P111; EGGERMONT JA, 1989, BIOCHEM J, V260, P757, DOI 10.1042/bj2600757; ENOUF J, 1988, J BIOL CHEM, V263, P13922; ENOUF J, 1992, BIOCHEM J, V286, P135, DOI 10.1042/bj2860135; ENOUF J, 1987, J BIOL CHEM, V262, P9293; ENYEDI A, 1986, J BIOL CHEM, V261, P9558; FISCHER TH, 1985, J BIOL CHEM, V260, P8996; GREENBERG SM, 1988, BLOOD, V72, P1968; HACK N, 1988, BIOSCIENCE REP, V8, P379, DOI 10.1007/BF01115229; HACK N, 1988, BIOCHEM J, V250, P355, DOI 10.1042/bj2500355; IKEMOTO N, 1982, ANNU REV PHYSIOL, V44, P297, DOI 10.1146/annurev.ph.44.030182.001501; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; JAVORS MA, 1982, BIOCHIM BIOPHYS ACTA, V691, P220, DOI 10.1016/0005-2736(82)90410-2; JENCKS WP, 1992, ANN NY ACAD SCI, V671, P49, DOI 10.1111/j.1749-6632.1992.tb43783.x; KASERGLANZMANN R, 1977, BIOCHIM BIOPHYS ACTA, V466, P429, DOI 10.1016/0005-2736(77)90336-4; KASERGLANZMANN R, 1978, BIOCHIM BIOPHYS ACTA, V512, P1, DOI 10.1016/0005-2736(78)90213-4; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; LEVITSKY DO, 1993, J BIOL CHEM, V268, P8325; LOMPRE AM, 1989, FEBS LETT, V249, P35, DOI 10.1016/0014-5793(89)80010-9; LYTTON J, 1992, J BIOL CHEM, V267, P14483; MACLENNAN DH, 1992, ANN NY ACAD SCI, V671, P1, DOI 10.1111/j.1749-6632.1992.tb43779.x; MAGNIER C, 1992, J BIOL CHEM, V267, P15808; MENASHI S, 1984, BIOCHEM J, V222, P413, DOI 10.1042/bj2220413; MISSIAEN L, 1991, PHARMACOL THERAPEUT, V50, P191, DOI 10.1016/0163-7258(91)90014-D; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; PAPP B, 1993, CELL CALCIUM, V14, P531, DOI 10.1016/0143-4160(93)90074-G; PAPP B, 1992, BIOCHEM J, V288, P297, DOI 10.1042/bj2880297; PAPP B, 1989, J BIOL CHEM, V264, P4577; PAPP B, 1993, BIOCHEM J, V295, P685, DOI 10.1042/bj2950685; PAPP B, 1991, J BIOL CHEM, V266, P14592; ROBBLEE LS, 1973, J GEN PHYSIOL, V61, P462, DOI 10.1085/jgp.61.4.462; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SARKADI B, 1988, BIOCHIM BIOPHYS ACTA, V939, P40, DOI 10.1016/0005-2736(88)90044-2; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; WUYTACK F, 1992, J BIOENERG BIOMEMBR, V24, P285; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670; [No title captured]	48	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6177	6184						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119962				2022-12-27	WOS:A1994MY84000104
J	QUEMENEUR, E; GUTHAPFEL, R; GUEGUEN, P				QUEMENEUR, E; GUTHAPFEL, R; GUEGUEN, P			A MAJOR PHOSPHOPROTEIN OF THE ENDOPLASMIC-RETICULUM IS PROTEIN DISULFIDE-ISOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							THIN-LAYER CHROMATOGRAPHY; HORMONE BINDING-PROTEIN; ESCHERICHIA-COLI; HEAT-SHOCK; MEMBRANE; LIVER; LUMEN; SITE; ATP; PHOSPHORYLATION	One of the effects of ATP in the endoplasmic reticulum is to induce the phosphorylation of several proteins among which a 57-kDa protein (pp57) prevails in our labeling conditions. We provide evidence that pp57 is protein disulfide isomerase (PDI), an abundant ubiquitous protein of the endoplasmic reticulum involved in various important cellular functions. This phosphorylation does not result from the activity of a microsomal protein kinase but from an autophosphorylation as described for other microsomal proteins such as chaperones. Phosphoamino acid analysis and cyanogen bromide cleavage indicate that the modification site lies on a threonine residue within the central region of the protein outside the thioredoxin-like domains. For the pure PDI, only the dimer is able to phosphorylate, while some experiments suggest that within the endoplasmic reticulum the phosphorylated form of PDI is mainly mobilized in larger size oligomers. Thus a possible role for this phosphorylation may be to modulate the association of PDI with its different partners.			QUEMENEUR, E (corresponding author), CTR ETUD SACLAY, CEA, DEPT INGN & ETUD PROT, BATIMENT 152, F-91191 GIF SUR YVETTE, FRANCE.							AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; BEHARBANNELIER M, 1980, BIOCHEM J, V187, P147, DOI 10.1042/bj1870147; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; CHENG SY, 1987, J BIOL CHEM, V262, P11221; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; Freedman R. B., 1992, PROTEIN FOLDING, P457; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; HARLOW E, 1988, ANTIBODIES LABORATOR; HASUMURA S, 1986, BIOCHEMISTRY-US, V25, P7881, DOI 10.1021/bi00372a014; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; LAMBERT N, 1989, PROTEIN PURIFICATION, P101; MAYINGER P, 1993, EMBO J, V12, P659, DOI 10.1002/j.1460-2075.1993.tb05699.x; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MILLS ENC, 1983, BIOCHEM J, V213, P245, DOI 10.1042/bj2130245; NEUFELD E, 1989, ANAL BIOCHEM, V177, P138, DOI 10.1016/0003-2697(89)90028-6; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; PIGIET V, 1978, J BIOL CHEM, V253, P1910; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; SHERMAN MY, 1992, NATURE, V357, P167, DOI 10.1038/357167a0; TSIBRIS JCM, 1989, J BIOL CHEM, V264, P13967; VUORI K, 1992, J BIOL CHEM, V267, P7211; WADA I, 1991, J BIOL CHEM, V266, P19599; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; YAMAUCHI K, 1987, BIOCHEM BIOPH RES CO, V146, P1485, DOI 10.1016/0006-291X(87)90817-5	32	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5485	5488						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119877				2022-12-27	WOS:A1994MY84000002
J	HYDE, H; DAVIES, AA; BENSON, FE; WEST, SC				HYDE, H; DAVIES, AA; BENSON, FE; WEST, SC			RESOLUTION OF RECOMBINATION INTERMEDIATES BY A MAMMALIAN ACTIVITY FUNCTIONALLY ANALOGOUS TO ESCHERICHIA-COLI RUVC RESOLVASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 ENDONUCLEASE-I; HOLLIDAY JUNCTIONS INVITRO; DNA-REPAIR GENE; SACCHAROMYCES-CEREVISIAE; RECA PROTEIN; SCID MUTATION; MUTANTS; IDENTIFICATION; PURIFICATION; CLEAVAGE	A mammalian endonuclease that resolves Holliday junctions has been partially purified from extracts of calf thymus and Chinese hamster ovary cells. The activity acts upon (i) synthetic Holliday junctions and (ii) recombination intermediates made by the Escherichia coli RecA protein and appears to be functionally analogous to the E. coli RuvC protein. Cleavage occurs by the introduction of symmetrically related nicks in strands of like polarity to produce nicked duplex DNA products. The nicks can be repaired by DNA ligase. The resolvase is specific for Holliday junctions and does not act upon Y junctions, G/A mismatches, or heterologous loops. The substrate specificity is therefore similar to that of E. coli RuvC protein and contrasts with the broad range specificity of other junction resolvases such as T4 endonuclease VII. The mammalian resolvase activity has been observed at normal levels in extracts prepared from a series of DNA repair-defective cells. These include the x-ray or UV-sensitive hamster lines xrs-5, xrs-6, and Chinese hamster ovary 43-3B (defective in ERCC-1), and murine cells that are severely immunodeficient and defective in both V(D)J rejoining and DNA repair.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND					Benson, Fiona Elizabeth/0000-0002-3918-7015				BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; BENSON FE, 1994, J BIOL CHEM, V269, P5195; BHATTACHARYYA A, 1991, J MOL BIOL, V221, P1191, DOI 10.1016/0022-2836(91)90928-Y; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; CONNOLLY B, 1990, P NATL ACAD SCI USA, V87, P8476, DOI 10.1073/pnas.87.21.8476; COUTURE C, 1992, NUCLEIC ACIDS RES, V20, P4355, DOI 10.1093/nar/20.16.4355; DEMASSY B, 1987, J MOL BIOL, V193, P359, DOI 10.1016/0022-2836(87)90224-5; DICKIE P, 1987, J BIOL CHEM, V262, P14826; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; DUNDERDALE HJ, 1994, J BIOL CHEM, V269, P5187; ELBOROUGH KM, 1990, EMBO J, V9, P2931, DOI 10.1002/j.1460-2075.1990.tb07484.x; EVANS DH, 1988, J MOL BIOL, V201, P69, DOI 10.1016/0022-2836(88)90439-1; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; JAYASEELAN R, 1988, BIOCHEM BIOPH RES CO, V156, P1054; JEGGO PA, 1983, MUTAT RES, V112, P313, DOI 10.1016/0167-8817(83)90026-3; JEGGO PA, 1992, P NATL ACAD SCI USA, V89, P6423, DOI 10.1073/pnas.89.14.6423; JENSCH F, 1986, EMBO J, V5, P181, DOI 10.1002/j.1460-2075.1986.tb04194.x; KEMPER B, 1976, J VIROL, V18, P992, DOI 10.1128/JVI.18.3.992-999.1976; KEMPER B, 1990, STRUCTURE METHODS, V1, P215; KLEFF S, 1988, EMBO J, V7, P1527, DOI 10.1002/j.1460-2075.1988.tb02972.x; KLEFF S, 1992, EMBO J, V11, P699, DOI 10.1002/j.1460-2075.1992.tb05102.x; LILLEY DMJ, 1984, CELL, V36, P413, DOI 10.1016/0092-8674(84)90234-4; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; MANDAL TN, 1993, J BACTERIOL, V175, P4325, DOI 10.1128/JB.175.14.4325-4334.1993; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; Maxam A M, 1980, Methods Enzymol, V65, P499; MIZUUCHI K, 1982, CELL, V29, P357, DOI 10.1016/0092-8674(82)90152-0; MOSIG G, 1987, ANNU REV GENET, V21, P347, DOI 10.1146/annurev.ge.21.120187.002023; MULLER B, 1990, NUCLEIC ACIDS RES, V18, P5633, DOI 10.1093/nar/18.19.5633; MULLER B, 1990, CELL, V60, P329, DOI 10.1016/0092-8674(90)90747-3; MULLER B, 1992, EMBO J, V11, P2685, DOI 10.1002/j.1460-2075.1992.tb05334.x; MURCHIE AIH, 1993, J MOL BIOL, V233, P77, DOI 10.1006/jmbi.1993.1486; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PARSONS CA, 1990, NUCLEIC ACIDS RES, V18, P4377, DOI 10.1093/nar/18.15.4377; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SAMBROOK E, 1989, MOL CLONING LABORATO; SHARPLES GJ, 1991, J BACTERIOL, V173, P7711, DOI 10.1128/jb.173.23.7711-7715.1991; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; SYMINGTON LS, 1985, P NATL ACAD SCI USA, V82, P7247, DOI 10.1073/pnas.82.21.7247; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TAKAHAGI M, 1991, J BACTERIOL, V173, P5747, DOI 10.1128/jb.173.18.5747-5753.1991; WALDMAN AS, 1988, NUCLEIC ACIDS RES, V16, P10249, DOI 10.1093/nar/16.21.10249; WEST SC, 1982, MOL GEN GENET, V187, P209, DOI 10.1007/BF00331119; WEST SC, 1985, P NATL ACAD SCI USA, V82, P6445, DOI 10.1073/pnas.82.19.6445; WEST SC, 1982, MOL GEN GENET, V186, P333, DOI 10.1007/BF00729451; WESTERVELD A, 1984, NATURE, V310, P425, DOI 10.1038/310425a0; WOOD RD, 1982, MUTAT RES, V95, P505, DOI 10.1016/0027-5107(82)90281-0	56	64	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5202	5209						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106502				2022-12-27	WOS:A1994MX57100079
J	LI, Q; GARDNER, DG				LI, Q; GARDNER, DG			NEGATIVE REGULATION OF THE HUMAN ATRIAL-NATRIURETIC-PEPTIDE GENE BY 1,25-DIHYDROXYVITAMIN D-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D RECEPTOR; PARATHYROID-HORMONE GENE; HUMAN OSTEOCALCIN GENE; RETINOID X-RECEPTOR; THYROID-HORMONE; MUSCLE CELLS; CHLORAMPHENICOL ACETYLTRANSFERASE; CARDIOVASCULAR FUNCTION; RESPONSE ELEMENTS; CARDIAC-MUSCLE	We have examined the effect of 1,25 dihydroxyvitamin D-3 on the promoter activity of the atrial natriuretic peptide (ANP) gene in cultured neonatal rat atrial myocytes. In acute transfection studies 1,25-dihydroxyvitamin D-3 inhibited the expression of a human ANP (hANP) promoter-driven chloramphenicol acetyltransferase reporter (-1150 hANP CAT) in a dose-dependent fashion (10-(10)-10-(8) M). When an expression vector for the vitamin D receptor (VDR) (pSVL-VDR) was introduced together with the reporter plasmid, there was a significant ligand-dependent amplification of the vitamin D-dependent inhibition. Deletion analysis of the 5'-flanking sequence localized the suppressible promoter sequence to within 104 base pairs of the transcription start site of the hANP gene. Thyroid hormone, glucocorticoid, estrogen, and retinoic acid receptor were incapable of mimicking the VDR-dependent inhibition. Retinoid X receptor, on the other hand, effected a significant reduction in hANP promoter activity which was at least additive with that produced by the liganded VDR The VDR-dependent inhibition displayed promoter selectivity. Both the SV40 promoter and a conventional vitamin D response element linked to a truncated SV40 promoter were activated by the liganded vitamin D receptor, whereas the Rous sarcoma virus promoter was unaffected. On the other hand, the cardiac-specific troponin T promoter was suppressed in a fashion similar to ANP. These findings imply a potentially important role for vitamin D-3 in the regulation of gene transcription in myocardial cells.	UNIV CALIF SAN FRANCISCO,METAB RES UNIT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [R01 HL 35753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BAUER RF, 1976, IN VITRO CELL DEV B, V12, P558; BIDMON HJ, 1991, EXPERIENTIA, V47, P958, DOI 10.1007/BF01929891; BORTELL R, 1992, P NATL ACAD SCI USA, V89, P6119, DOI 10.1073/pnas.89.13.6119; BUGAISKY LB, 1991, HEART CARDIOVASCULAR, P1621; DELUCA HF, 1992, ANN NY ACAD SCI, V669, P59; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; ENOMOTO H, 1992, ENDOCRINOLOGY, V130, P3467, DOI 10.1210/en.130.6.3467; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRAMPTON RJ, 1983, CANCER RES, V43, P4443; GARDNER DG, 1990, J CLIN INVEST, V86, P52, DOI 10.1172/JCI114714; GARDNER DG, 1987, MOL ENDOCRINOL, V1, P260, DOI 10.1210/mend-1-3-260; GARDNER DG, 1988, J CLIN INVEST, V82, P1275, DOI 10.1172/JCI113726; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GILL RK, 1993, P NATL ACAD SCI USA, V90, P2984, DOI 10.1073/pnas.90.7.2984; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HOSOMI J, 1983, ENDOCRINOLOGY, V113, P1950, DOI 10.1210/endo-113-6-1950; KAWAGUCHI N, 1992, P NATL ACAD SCI USA, V89, P4569, DOI 10.1073/pnas.89.10.4569; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOVACICMILIVOJEVIC B, 1992, MOL CELL BIOL, V12, P292, DOI 10.1128/MCB.12.1.292; LAPOINTE MC, 1988, J BIOL CHEM, V263, P9075; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; MERKE J, 1989, J CLIN INVEST, V83, P1903, DOI 10.1172/JCI114097; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; MITSUHASHI T, 1991, J CLIN INVEST, V87, P1889, DOI 10.1172/JCI115213; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OKAZAKI T, 1991, J BIOL CHEM, V266, P21903; OKAZAKI T, 1988, J BIOL CHEM, V263, P2203; OSMUNDSEN BC, 1989, J STEROID BIOCHEM, V34, P339, DOI 10.1016/0022-4731(89)90105-2; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SONE T, 1991, J BIOL CHEM, V266, P23296; STUMPF WE, 1979, SCIENCE, V206, P1188, DOI 10.1126/science.505004; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WALTERS MR, 1987, J BIOL CHEM, V262, P2536; WALTERS MR, 1986, J MOL CELL CARDIOL, V18, P67, DOI 10.1016/S0022-2828(86)80983-X; WALTERS MR, 1987, EXCERPTA MED INT C S, V735, P479; WEISHAAR RE, 1990, AM J PHYSIOL, V258, pE134, DOI 10.1152/ajpendo.1990.258.1.E134; WEISHAAR RE, 1987, J CLIN INVEST, V79, P1706, DOI 10.1172/JCI113010; WU JP, 1991, MOL ENDOCRINOL, V5, P1311, DOI 10.1210/mend-5-9-1311; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	52	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4934	4939						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106467				2022-12-27	WOS:A1994MX57100039
J	LU, TB; LI, Q; KATOH, A; HERNANDEZ, J; DUFFIN, K; JACKSONMACHELSKI, E; KNOLL, LJ; GOKEL, GW; GORDON, JI				LU, TB; LI, Q; KATOH, A; HERNANDEZ, J; DUFFIN, K; JACKSONMACHELSKI, E; KNOLL, LJ; GOKEL, GW; GORDON, JI			THE SUBSTRATE-SPECIFICITY OF SACCHAROMYCES-CEREVISIAE MYRISTOYL-COA-PROTEIN N-MYRISTOYLTRANSFERASE - POLAR PROBES OF THE ENZYMES MYRISTOYL-COA RECOGNITION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; FATTY-ACID ANALOGS; YEAST; TRANSFERASE; AUXOTROPHY; ENZYMOLOGY; ACYLATION; KINASE; ASSAY	Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase (Nmt1p) is a monomeric enzyme that is essential for vegetative growth. Nmt1p catalyzes the co-translational transfer of myristate from CoA to the amino-terminal Gly of cellular proteins in an ordered Bi Bi reaction mechanism that initially involves binding of myristoyl-CoA to the apoenzyme. Forty one fatty acid analogs were synthesized to define features in the acyl chain of myristoyl-CoA which are important determinants of its recognition by Nmt1p's acyl-CoA binding site as well as to help us deduce the structure of the binding site itself. These analogs included dicarboxylic acids, omega-nitrocarboxylic acids, analogs equivalent in length to C13:0-C15:0 which contain electronegative halogens at their omega-termini, hydroxytetradecanoic acids with hydrogen replaced by OH from C3 to C13, and azidophenyl-containing fatty acids with the linear azide unit attached either meta or para to phenyl and with variations in the length of their methylene chains. These compounds were converted to their CoA derivatives using Pseudomonas acyl-CoA synthetase and then surveyed as substrates for purified Nmt1p in an in vitro assay system that included an octapeptide derived from residues 1-8 of the human immunodeficiency virus Pr-55gag polyprotein precursor. The results suggest that the myristoyl-CoA binding site contains a conical-shaped ''receptor'' that interacts with the omega-terminus of the bound acyl chain of acyl-CoAs. The acuteness of this cone determines the enzyme's capacity to accommodate steric bulk at the omega-terminus as well as Nmt1p's sensitivity to the distance between the eclipsed C5-C6 bond of a bound acyl chain and its omega-terminus. The activity profile of the various analog-CoAs also indicates that the enzyme's myristoyl-CoA binding site can accommodate fatty acid analogs with marked increases in polarity st their omega-terminus (compared to C14:0) as long as their chain length is equivalent to that of myristate.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; MONSANTO CO,CORP RES LABS,CHESTERFIELD,MO 63198; UNIV MIAMI,DEPT CHEM,CORAL GABLES,FL 33124	Washington University (WUSTL); Monsanto; University of Miami					NIAID NIH HHS [AI30188, AI27179] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI030188, U01AI027179] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DEVADAS B, 1992, J BIOL CHEM, V267, P7224; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; DURONIO RJ, 1991, J CELL BIOL, V113, P1313, DOI 10.1083/jcb.113.6.1313; DURONIO RJ, 1992, LIPID MODIFICATIONS, P21; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HERMAN PK, 1991, EMBO J, V10, P4049, DOI 10.1002/j.1460-2075.1991.tb04981.x; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V85, P8795, DOI 10.1073/pnas.85.23.8795; ICHIHARA K, 1991, J LIPID RES, V32, P1709; JOHNSON DR, 1993, J BIOL CHEM, V268, P483; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KISHORE NS, 1993, J BIOL CHEM, V268, P4889; PESECKIS SM, 1993, J BIOL CHEM, V268, P5107; ROCQUE WJ, 1993, J BIOL CHEM, V268, P9964; RUDNICK DA, 1992, J BIOL CHEM, V267, P23852; RUDNICK DA, 1993, ADV ENZYMOL RAMB, V67, P375; RUDNICK DA, 1993, P NATL ACAD SCI USA, V90, P1087, DOI 10.1073/pnas.90.3.1087; RUDNICK DA, 1992, P NATL ACAD SCI USA, V89, P10507, DOI 10.1073/pnas.89.21.10507; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STONE DE, 1991, GENE DEV, V5, P1969, DOI 10.1101/gad.5.11.1969; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TOWLER DA, 1987, J BIOL CHEM, V262, P1030	28	24	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5346	5357						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106519				2022-12-27	WOS:A1994MX57100097
J	ZHANG, LL; PAKRASI, HB; WHITMARSH, J				ZHANG, LL; PAKRASI, HB; WHITMARSH, J			PHOTOAUTOTROPHIC GROWTH OF THE CYANOBACTERIUM SYNECHOCYSTIS SP PCC-6803 IN THE ABSENCE OF CYTOCHROME C(553) AND PLASTOCYANIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC ELECTRON-TRANSPORT; ANABAENA SP PCC-7937; PHOTOSYSTEM-I; RHODOPSEUDOMONAS-CAPSULATA; TARGETED MUTAGENESIS; B/F COMPLEX; GENE; COPPER; SEQUENCE; CLONING	In the cyanobacterium Synechocystis sp. PCC 6803, photosynthetic electron transport from the cytochrome bf complex to photosystem I can be mediated by cytochrome c(553) Or plastocyanin. The concentration of copper in the growth medium determines which protein is synthesized. To investigate the role of cytochrome c(553) in photosynthetic and respiratory electron transport, we cloned the petJ gene encoding cytochrome c(553) from Synechocystis 6803 and determined its nucleotide sequence. The 360-base pair open reading frame encodes an 85-amino acid mature protein (predicted molecular mass = 8,742 Da) with a 35-amino acid presequence. Two mutants were constructed, one in which the petJ gene for cytochrome c(553) was deleted and another in which the petE gene for plastocyanin was insertionally inactivated. The cytochrome c(553) deletion mutant (M109) grew photoautotrophically, even in the absence of copper that prevented the synthesis of plastocyanin, as did the plastocyanin-deficient mutant (M114) grown in the presence of copper that prevented the synthesis of cytochrome c(553). The M109 strain exhibited photosynthetic electron transport rates similar to those of wild-type cells when grown under conditions that prevented the synthesis of plastocyanin. Moreover, in M109 cells grown without copper, cytochrome f was completely photooxidized in less than 10 ms by photosystem I. These observations show that electrons can be transferred from the cytochrome bf complex to photosystem I in the absence of both cytochrome c(553) and plastocyanin. Additionally, the M109 cells exhibited dark respiration rates comparable with those of wild-type cells, indicating that cytochrome c(553) is not obligately required for respiratory electron transport in Synechocystis 6803.	UNIV ILLINOIS, DEPT PLANT BIOL, URBANA, IL 61801 USA; WASHINGTON UNIV, DEPT BIOL, ST LOUIS, MO 63130 USA; USDA ARS, PHOTOSYNTH RES UNIT, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; Washington University (WUSTL); United States Department of Agriculture (USDA)					NIGMS NIH HHS [GM 41841] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1976, NATURE, V263, P793, DOI 10.1038/263793a0; BINDER A, 1984, BIOCHIM BIOPHYS ACTA, V765, P241, DOI 10.1016/0005-2728(84)90161-0; BOVY A, 1992, MOL MICROBIOL, V6, P1507, DOI 10.1111/j.1365-2958.1992.tb00871.x; BOVY A, 1992, PLANT MOL BIOL, V19, P491, DOI 10.1007/BF00023397; BRIGGS LM, 1990, PLANT MOL BIOL, V15, P633, DOI 10.1007/BF00017837; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; DALDAL F, 1986, P NATL ACAD SCI USA, V83, P2012, DOI 10.1073/pnas.83.7.2012; FITCH J, 1989, ARCH BIOCHEM BIOPHYS, V271, P502, DOI 10.1016/0003-9861(89)90301-9; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GRAY JC, 1982, METHODS CHLOROPLAST, P917; HO KK, 1984, BIOCHIM BIOPHYS ACTA, V766, P310, DOI 10.1016/0005-2728(84)90246-9; HOLTON RW, 1967, BIOCHIM BIOPHYS ACTA, V131, P362, DOI 10.1016/0005-2728(67)90150-8; HOLTON RW, 1967, BIOCHIM BIOPHYS ACTA, V131, P375, DOI 10.1016/0005-2728(67)90151-X; IZAWA S, 1978, BIOCHEM BIOPH RES CO, V83, P1171, DOI 10.1016/0006-291X(78)91518-8; JENNEY FE, 1993, EMBO J, V12, P1283, DOI 10.1002/j.1460-2075.1993.tb05773.x; JONES RW, 1988, BIOCHIM BIOPHYS ACTA, V933, P258, DOI 10.1016/0005-2728(88)90033-3; LAUDENBACH DE, 1990, PLANT CELL, V2, P913, DOI 10.1105/tpc.2.9.913; LI HH, 1992, J BIOL CHEM, V267, P9368; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; MERCHANT S, 1987, J BIOL CHEM, V262, P9062; MERCHANT S, 1986, J BIOL CHEM, V261, P5850; MEYER TE, 1982, ADV PROTEIN CHEM, V35, P105, DOI 10.1016/S0065-3233(08)60469-6; NAKAMURA M, 1992, J BIOCHEM, V111, P219, DOI 10.1093/oxfordjournals.jbchem.a123740; NYHUS KJ, 1990, CURRENT RES PHOTOSYN, V1, P367; OBINGER C, 1990, BIOCHEM BIOPH RES CO, V169, P492, DOI 10.1016/0006-291X(90)90358-T; PAKRASI HB, 1988, EMBO J, V7, P325, DOI 10.1002/j.1460-2075.1988.tb02816.x; PHILBRICK JB, 1988, MOL GEN GENET, V212, P418, DOI 10.1007/BF00330845; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; PRINCE RC, 1986, BIOCHEMISTRY-US, V25, P5208, DOI 10.1021/bi00366a034; REDDY KJ, 1990, BIOTECHNIQUES, V8, P250; REITH M, 1993, PLANT CELL, V5, P465, DOI 10.1105/tpc.5.4.465; SALEMME FR, 1977, ANNU REV BIOCHEM, V46, P299, DOI 10.1146/annurev.bi.46.070177.001503; Sambrook J, 1989, MOL CLONING LABORATO; SANDMANN G, 1986, ARCH MICROBIOL, V145, P76, DOI 10.1007/BF00413030; SCHERER S, 1988, PHOTOSYNTH RES, V15, P95, DOI 10.1007/BF00035255; SELAK MA, 1984, PHOTOCHEM PHOTOBIOL, V39, P485; SERRANO A, 1990, CURRENT RES PHOTOSYN, V4, P95; VANDERPLAS J, 1989, MOL MICROBIOL, V3, P275; Whitmarsh J., 1986, ENCY PLANT PHYSL, V19, P508; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x; WYNN RM, 1989, BIOCHEMISTRY-US, V28, P5554, DOI 10.1021/bi00439a032; ZHANG L, 1992, J BIOL CHEM, V267, P19054; Zieger R., 1965, BEITR BIOL PFLANZ, V41, P11	44	61	63	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5036	5042						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106479				2022-12-27	WOS:A1994MX57100054
J	WOLF, FW; SARMA, V; SELDIN, M; DRAKE, S; SUCHARD, SJ; SHAO, H; OSHEA, KS; DIXIT, VM				WOLF, FW; SARMA, V; SELDIN, M; DRAKE, S; SUCHARD, SJ; SHAO, H; OSHEA, KS; DIXIT, VM			B94, A PRIMARY RESPONSE GENE INDUCIBLE BY TUMOR-NECROSIS-FACTOR-ALPHA, IS EXPRESSED IN DEVELOPING HEMATOPOIETIC TISSUES AND THE SPERM ACROSOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; DEVELOPING RAT; RECEPTOR; CELLS; FERTILIZATION; PRODUCTS; THYMUS; LIGAND; EMBRYO; KINASE	B94 was originally described as a novel tumor necrosis factor-alpha-inducible primary response gene in endothelial cells which was also induced in an in vitro model of angiogenesis. To further characterize its expression, we cloned the mouse homologue and mapped its developmental and tissue specific expression. The predicted amino acid sequence of mouse B94 was found to be 83% similar to its human homologue. The gene was localized to mouse chromosome 12 just centromeric to the immunoglobulin heavy chain locus, in a region that is often rearranged in T-cell neoplasms. To explore the possibility that B94 is expressed during vasculogenesis and other developmental processes, the expression of its transcript was determined during mouse development by in situ hybridization. In 10-day embryos B94 was expressed prominently in the myocardium and in the aortic arch. By the 15th day of gestation, expression was restricted largely to the liver, the bone forming regions of the jaw, the aortic endothelium, and the nasopharynx: a pattern that was maintained until just prior to birth. Postnatally, expression shifted to the red pulp of the spleen and the thymic medulla. B94 expression was extinguished in most adult tissues but was detectable in lymphopoietic tissues including the spleen, tonsil, and lymphatic aggregates in the gut. Consistent with this was the finding that mononuclear progenitor cells in bone marrow and mature peripheral blood monocytes expressed B94. A truncated testis-specific transcript previously identified by Northern blot analysis was determined to result from the use of an alternate polyadenylation signal which was surprisingly located within the open reading frame. This shorter transcript was expressed at high levels exclusively in late stage spermatids. Immuno-staining with an affinity-purified polyclonal antiserum revealed B94 to be localized to the acrosomal compartment of mature sperm. These studies demonstrate that B94 expression is tightly regulated during development and suggests distinct roles for B94 in myelopoiesis and spermatogenesis.	UNIV MICHIGAN, SCH MED, DEPT PATHOL, 1301 CATHERINE ST, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT PEDIAT, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT ANAT & CELL BIOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, PROGRAM CELLULAR & MOLEC BIOL, ANN ARBOR, MI 48109 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MICROBIOL, DURHAM, NC 27710 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Duke University; Duke University			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NHLBI NIH HHS [HL45351] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045351] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BEUTLER B, 1988, ADV IMMUNOL, V42, P213, DOI 10.1016/S0065-2776(08)60846-9; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; DEKOSSODO S, 1992, J EXP MED, V176, P1259, DOI 10.1084/jem.176.5.1259; Deman J, 1992, Dev Immunol, V2, P103, DOI 10.1155/1992/48713; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; FAJARDO LF, 1992, AM J PATHOL, V140, P539; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FU YM, 1991, J CELL BIOL, V114, P1261, DOI 10.1083/jcb.114.6.1261; GIROIR BP, 1992, P NATL ACAD SCI USA, V89, P4864, DOI 10.1073/pnas.89.11.4864; GOODWIN RG, 1993, CELL, V73, P447, DOI 10.1016/0092-8674(93)90133-B; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KEW D, 1990, P NATL ACAD SCI USA, V87, P9143, DOI 10.1073/pnas.87.23.9143; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; MACGROGAN D, 1992, J NEUROCHEM, V59, P1381, DOI 10.1111/j.1471-4159.1992.tb08451.x; MANTHORPE M, 1989, DISSECTION TISSUE CU; Mundy G R, 1992, Immunol Ser, V56, P483; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; ORRURTREGER A, 1992, DEVELOPMENT, V115, P1045; OZAWA K, 1992, GENOMICS, V12, P214, DOI 10.1016/0888-7543(92)90368-3; PALMITER RD, 1984, CELL, V36, P869, DOI 10.1016/0092-8674(84)90036-9; Peltz Stuart W., 1992, Current Opinion in Cell Biology, V4, P979, DOI 10.1016/0955-0674(92)90129-Z; PERSSON H, 1989, P NATL ACAD SCI USA, V86, P6166, DOI 10.1073/pnas.86.16.6166; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; Sambrook J, 1989, MOL CLONING LABORATO; SARMA V, 1992, J IMMUNOL, V148, P3302; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; STOREY BT, 1991, ANN NY ACAD SCI, V637, P459, DOI 10.1111/j.1749-6632.1991.tb27330.x; TAVASSOLI M, 1991, BLOOD CELLS, V17, P269; Trinchieri G, 1992, Immunol Ser, V56, P289; Vilcek J, 1992, Immunol Ser, V56, P269; WATSON MA, 1990, DEVELOPMENT, V110, P173; Weiss L., 1983, HISTOLOGY CELL TISSU	38	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3633	3640						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106408				2022-12-27	WOS:A1994MV63100076
J	BROWSE, J; MCCONN, M; JAMES, D; MIQUEL, M				BROWSE, J; MCCONN, M; JAMES, D; MIQUEL, M			MUTANTS OF ARABIDOPSIS DEFICIENT IN THE SYNTHESIS OF ALPHA-LINOLENATE - BIOCHEMICAL AND GENETIC-CHARACTERIZATION OF THE ENDOPLASMIC-RETICULUM LINOLEOYL DESATURASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER-PROTEIN DESATURASE; FATTY-ACID COMPOSITION; CARTHAMUS-TINCTORIUS L; OLEOYL-PHOSPHATIDYLCHOLINE; LIPID-SYNTHESIS; RAT-LIVER; SAFFLOWER; CHLOROPLASTS; COTYLEDONS; MEMBRANES	The overall fatty compositions of leaf and root lipids from a mutant of Arabidopsis thaliana were characterized by reduced levels of linolenate (18:3) and correspondingly elevated levels of linoleate (18:2) as a consequence of a single nuclear mutation at the fad3 locus. Comparison of the fatty acid compositions of individual lipids from wild type and mutant plants showed that chloroplast lipids were largely unaffected by the mutation, whereas each of the phospholipids synthesized on the endoplasmic reticulum in the mutant exhibited a marked reduction in the proportion of 18:3 relative to wild type. These and other results indicate that the fad3 mutants are deficient in the activity of an endoplasmic reticulum 18:2 desaturase. In root tissues, this enzyme appears to account for over 80% of the 18:3 present. However, in young leaves of the mutant, phosphatidylcholine (the major phospholipid) contains 16% 18:3 compared with 29% in the wild type, and the proportion of 18:3 in this lipid increases with plant age in both wild type and mutant plants. These results reflect an exchange of lipid between the chloroplast and endoplasmic reticulum that allows the chloroplast desaturases to provide highly unsaturated lipids to the extrachloroplast membranes of leaf cells.	DNA PLANT TECHNOL CORP,OAKLAND,CA 94608		BROWSE, J (corresponding author), WASHINGTON STATE UNIV,INST BIOL CHEM,PULLMAN,WA 99164, USA.			Browse, John/0000-0002-2554-2821				ARONDEL V, 1992, SCIENCE, V258, P1353, DOI 10.1126/science.1455229; BROWSE J, 1989, PLANT PHYSIOL, V90, P522, DOI 10.1104/pp.90.2.522; BROWSE J, 1986, PLANT PHYSIOL, V81, P859, DOI 10.1104/pp.81.3.859; BROWSE J, 1985, SCIENCE, V227, P763, DOI 10.1126/science.227.4688.763; BROWSE J, 1986, BIOCHEM J, V235, P25, DOI 10.1042/bj2350025; BROWSE J, 1991, ANNU REV PLANT PHYS, V42, P467, DOI 10.1146/annurev.pp.42.060191.002343; Browse J, 1989, BIOL ROLE PLANT LIPI, P335; BROWSE JA, 1981, FEBS LETT, V1321, P111; FELDMANN KA, 1987, MOL GEN GENET, V208, P1, DOI 10.1007/BF00330414; FUJIWARA Y, 1984, ARCH BIOCHEM BIOPHYS, V233, P402, DOI 10.1016/0003-9861(84)90461-2; Harwood J. L., 1980, The biochemistry of plants. A comprehensive treatise. Volume 4. Lipids: structure and function., P1; HARWOOD JL, 1986, LIPID HDB, P527; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JAMES DW, 1990, THEOR APPL GENET, V80, P241, DOI 10.1007/BF00224393; KEARNS EV, 1991, ARCH BIOCHEM BIOPHYS, V284, P431, DOI 10.1016/0003-9861(91)90319-E; KUNST L, 1989, PLANT PHYSIOL, V91, P401, DOI 10.1104/pp.91.1.401; LEMIEUX B, 1990, THEOR APPL GENET, V80, P234, DOI 10.1007/BF00224392; Marsh D., 2013, HDB LIPID BILAYERS; MCKEON TA, 1982, J BIOL CHEM, V257, P2141; MIQUEL M, 1992, J BIOL CHEM, V267, P1502; ROUGHAN PG, 1980, BIOCHEM J, V188, P17, DOI 10.1042/bj1880017; ROUGHAN PG, 1982, ANNU REV PLANT PHYS, V33, P97, DOI 10.1146/annurev.pp.33.060182.000525; ROUGHAN PG, 1979, BIOCHEM J, V184, P571, DOI 10.1042/bj1840571; SCHMIDT H, 1990, P NATL ACAD SCI USA, V87, P9477, DOI 10.1073/pnas.87.23.9477; SHANKLIN J, 1991, P NATL ACAD SCI USA, V88, P2510, DOI 10.1073/pnas.88.6.2510; SHIMAKATA T, 1982, P NATL ACAD SCI-BIOL, V79, P5808, DOI 10.1073/pnas.79.19.5808; SLACK CR, 1978, BIOCHEM J, V170, P421, DOI 10.1042/bj1700421; SMITH MA, 1990, BIOCHEM J, V272, P23, DOI 10.1042/bj2720023; SOMERVILLE C, 1991, SCIENCE, V252, P80, DOI 10.1126/science.252.5002.80; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; STYMNE S, 1980, PLANT SCI LETT, V17, P287, DOI 10.1016/0304-4211(80)90159-5; STYMNE S, 1978, EUR J BIOCHEM, V90, P223, DOI 10.1111/j.1432-1033.1978.tb12594.x; STYMNE S, 1992, ARCH BIOCHEM BIOPHYS, V296, P557; WADA H, 1990, NATURE, V347, P200, DOI 10.1038/347200a0	34	177	197	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16345	16351						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8102138				2022-12-27	WOS:A1993LQ33600041
J	HASELBECK, RJ; MCALISTERHENN, L				HASELBECK, RJ; MCALISTERHENN, L			FUNCTION AND EXPRESSION OF YEAST MITOCHONDRIAL NAD-SPECIFIC AND NADP-SPECIFIC ISOCITRATE DEHYDROGENASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; STRUCTURAL GENE; DISRUPTION; CLONING; TRANSFORMATION; PROTEINS	The three isozymes of isocitrate dehydrogenase in Saccharomyces cerevisiae differ in subunit structure, subcellular location, and cofactor specificity. The two mitochondrial isozymes, IDH and IDP1, are NAD- and NADP-specific, respectively. Several lines of evidence presented here confirm the importance of IDH to respiratory processes. Expression of IDH RNA and protein is low with growth on glucose and is elevated with growth on non-fermentable carbon sources, a pattern of expression similar to that seen for other tricarboxylic acid cycle enzymes. In addition, a disruption mutant lacking IDH activity exhibits reduced growth rates on non-fermentable carbon sources, and mitochondria isolated from this mutant are incapable of respiration with added citrate. In contrast, IDP1 expression levels appear to be unresponsive to carbon source, and an IDP1 disruption mutant is not significantly impaired for growth or mitochondrial respiration. These results strongly suggest that IDP1 is incapable of participating in tricarboxylic acid cycle-based respiration despite its mitochondrial location. Analysis of the IDP1 and IDH disruption mutants for glutamate auxotrophy showed that either enzyme can contribute alpha-ketoglutarate for endogenous glutamate synthesis. IDH expression levels were found to be repressed in response to added glutamate during growth on glucose, while IDP1 expression levels remained unchanged. A double mutant lacking both IDP1 and IDH activities proved to be auxotrophic for glutamate during growth on glucose, but was capable of growth independent of added glutamate on non-fermentable carbon sources. These results suggest that the cytosolic NADP-specific IDP2 isozyme may provide alpha-ketoglutarate both for tricarboxylic acid cycle carbon flux and for cytosolic glutamate synthesis during growth on non-fermentable carbon sources in the absence of mitochondrial isocitrate dehydrogenase activity.	UNIV CALIF IRVINE,SCH MED,DEPT BIOL CHEM,IRVINE,CA 92717	University of California System; University of California Irvine								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARNES LD, 1971, BIOCHEMISTRY-US, V10, P3939, DOI 10.1021/bi00797a022; BOTSTEIN D, 1979, GENE, V8, P12; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CUPP JR, 1992, J BIOL CHEM, V267, P16417; CUPP JR, 1991, J BIOL CHEM, V266, P22199; DAUM G, 1982, J BIOL CHEM, V257, P3028; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORSBACH V, 1989, MOL GEN GENET, V218, P57, DOI 10.1007/BF00330565; GANGLOFF SP, 1990, MOL CELL BIOL, V10, P3351; HASELBECK RJ, 1991, J BIOL CHEM, V266, P2339; HATHAWAY JA, 1963, J BIOL CHEM, V238, P2875; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KEYS DA, 1990, THESIS U CALIFORNIA; KIM KS, 1986, MOL CELL BIOL, V6, P1936, DOI 10.1128/MCB.6.6.1936; KORNBERG A, 1951, J BIOL CHEM, V189, P123; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; MCALISTER L, 1982, J BIOL CHEM, V257, P7181; MCALISTER L, 1980, J BACTERIOL, V143, P603, DOI 10.1128/JB.143.2.603-612.1980; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; OHNISHI T, 1966, J BIOL CHEM, V241, P1797; RALEIGH EA, 1988, NUCLEIC ACIDS RES, V16, P1563, DOI 10.1093/nar/16.4.1563; REPETTO B, 1989, MOL CELL BIOL, V9, P2695, DOI 10.1128/MCB.9.6.2695; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RydstroM J., 1976, ENZYME, V13, P51; Sherman F, 1979, METHODS YEAST GENETI; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; WRIGHT RM, 1986, J BIOL CHEM, V261, P7183; WRIGHT RM, 1989, NUCLEIC ACIDS RES, V17, P1103, DOI 10.1093/nar/17.3.1103	34	129	131	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12116	12122						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8099357				2022-12-27	WOS:A1993LF28400097
J	OSIFCHIN, NE; JIANG, D; OHTANIFUJITA, N; FUJITA, T; CARROZA, M; KIM, SJ; SAKAI, T; ROBBINS, PD				OSIFCHIN, NE; JIANG, D; OHTANIFUJITA, N; FUJITA, T; CARROZA, M; KIM, SJ; SAKAI, T; ROBBINS, PD			IDENTIFICATION OF A P53 BINDING-SITE IN THE HUMAN RETINOBLASTOMA SUSCEPTIBILITY GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; LARGE T-ANTIGEN; CELL-CYCLE; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; PROTEINS BIND; DNA-SEQUENCE; SV40 ORIGIN; RB GENE; PRODUCT	p53 is a tumor suppressor gene-found to be mutated in a wide variety of tumors. The encoded p53 protein has properties of a classical transcription factor, but the promoter targets for its regulation are largely unknown. We have investigated the ability of p53 to regulate activity of the human retinoblastoma susceptibility gene (Rb) promoter using a cotransfection assay in CCL-64 and Saos-2 cells, p53 was able to stimulate transcription from the Rb promoter at low input doses of p53 expression plasmid, whereas transcription was repressed at high input doses. The stimulatory effect of p53 on Rb promoter activity mapped to a region between 4 and 92 base pairs upstream from the start site of translation, whereas the region controlling repression by p53 mapped to the basal transcriptional control region of the promoter between -207 and -185. Moreover, an oligonucleotide containing Rb promoter sequences between -63 and -88 was sufficient to confer stimulation by p53 when inserted upstream from a minimal heterologous promoter. Gel mobility shift analysis was used to demonstrate that p53 can bind to a sequence within the -63 to -88 oligonucleotide with homology to a p53 binding site. The presence of a functional p53 binding site in the human retinoblastoma tumor suppressor gene promoter suggests that p53 can regulate Rb promoter activity.	UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT MED,PITTSBURGH,PA 15261; KYOTO PREFECTURAL UNIV MED,DEPT PREVENT MED,KAMIKYO KU,KYOTO 602,JAPAN; NATL CANC INST,CHEMOPREVENT LAB,BETHESDA,MD 20892	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Kyoto Prefectural University of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NATIONAL CANCER INSTITUTE [R01CA055227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007458] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55227] Funding Source: Medline; NIDDK NIH HHS [5 T32 DK07458] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6789; AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; AUSUBEL FM, CURRENT PROTOCOL MOL; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DUTTA Z, 1993, NATURE, V365, P79; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JIANG D, 1993, ONCOGENE, V8, P2805; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	54	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6383	6389						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119988				2022-12-27	WOS:A1994MZ50300022
J	JOUVIN, MHE; ADAMCZEWSKI, M; NUMEROF, R; LETOURNEUR, O; VALLE, A; KINET, JP				JOUVIN, MHE; ADAMCZEWSKI, M; NUMEROF, R; LETOURNEUR, O; VALLE, A; KINET, JP			DIFFERENTIAL CONTROL OF THE TYROSINE KINASES LYN AND SYK BY THE 2 SIGNALING CHAINS OF THE HIGH-AFFINITY IMMUNOGLOBULIN-E RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; T-CELL; ANTIGEN RECEPTOR; IGE RECEPTOR; ZETA-CHAIN; PHOSPHOLIPASE C-GAMMA-1; CYTOPLASMIC DOMAINS; MONOCLONAL-ANTIBODY; TRANSFECTED CELLS; MOLECULAR-CLONING	Nonreceptor tyrosine kinases such as the newly described 70-kDa (ZAP-70/Syk) and Src-related tyrosine kinases are coupled to a variety of receptors, including the antigen receptors on B- and T-cells and the Fc receptors for IgE (Fc epsilon RI) and IgG (Fc gamma RI, Fc gamma RIII/CD16). Various subunits of these receptors contain homologous activation motifs which appear capable of autonomously triggering cell activation. Two forms of this motif are present in the Fc epsilon RI multimeric complex: one in the beta chain and one in the gamma chain. Here we show that each of the two tyrosine kinases known to be involved in Fc epsilon RI signaling is controlled by a distinct motif-containing chain. Lyn associates with the nonactivated beta chain, whereas gamma promotes the activation of Syk. We also show that neither the beta nor the gamma motif alone can account for the full signaling capacity of the entire receptor. We propose that, upon triggering of the tetrameric receptor, Lyn already bound to beta becomes activated and phosphorylates beta and gamma; the phosphorylation of gamma induces the association of Syk with gamma and also the activation of Syk, resulting in the phosphorylation and activation of phospholipase C gamma(1). Cooperative recruitment of specific kinases by the various signaling chains found in this family of antigen receptors could represent a way to achieve the full signaling capacity of the multimeric complexes.	NIAID, MOLEC ALLERGY & IMMUNOL SECT, ROCKVILLE, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Valle, Angel/L-3194-2019					ADAMCZEWSKI M, 1992, J BIOL CHEM, V267, P18126; ALBER G, 1991, J BIOL CHEM, V266, P22613; AMIGORENA S, 1992, NATURE, V358, P337, DOI 10.1038/358337a0; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BELL GM, 1992, MOL CELL BIOL, V12, P5548, DOI 10.1128/MCB.12.12.5548; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BONNEROT C, 1992, EMBO J, V11, P2747, DOI 10.1002/j.1460-2075.1992.tb05340.x; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EISEMAN E, 1992, J BIOL CHEM, V267, P21027; EISEMAN E, 1992, NATURE, V355, P78; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; HEMLER ME, 1983, HUM IMMUNOL, V8, P153, DOI 10.1016/0198-8859(83)90010-1; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KINET JP, 1988, P NATL ACAD SCI USA, V85, P6483, DOI 10.1073/pnas.85.17.6483; KINET JP, 1987, BIOCHEMISTRY-US, V26, P4605, DOI 10.1021/bi00389a002; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEONARD WJ, 1982, NATURE, V300, P267, DOI 10.1038/300267a0; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; MILLER L, 1989, SCIENCE, V244, P334, DOI 10.1126/science.2523561; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUBIN LA, 1985, J IMMUNOL, V135, P3172; SALCEDO TW, 1993, J EXP MED, V177, P1475, DOI 10.1084/jem.177.5.1475; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YU KT, 1991, J BIOL CHEM, V266, P22564; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	348	351	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5918	5925						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119935				2022-12-27	WOS:A1994MY84000068
J	LADIAS, JAA				LADIAS, JAA			CONVERGENCE OF MULTIPLE NUCLEAR RECEPTOR SIGNALING PATHWAYS ONTO THE LONG TERMINAL REPEAT OF HUMAN IMMUNODEFICIENCY VIRUS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							9-CIS RETINOIC ACID; THYROID-HORMONE; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; X-RECEPTOR; GLUCOCORTICOID RECEPTOR; GENE-EXPRESSION; MEMBRANE DEPOLARIZATION; RESPONSE ELEMENTS; GROWTH-FACTORS	A composite element that interacts with multiple nuclear receptors has been identified in the long terminal repeat (LTR) of the human immunodeficiency virus-1 (HIV-1). This element, designated nuclear receptor-responsive element (NRRE), spans the -356 to -320 LTR region and contains tightly clustered binding sites for the retinoid X receptor-alpha (RXR alpha) and for five nuclear receptors with unknown ligands, apolipoprotein AT regulatory protein-1 (ARP-1), v-erbA-related proteins-2 and -3 (EAR-2 and EAR-3), hepatocyte nuclear factor-4 (HNF-4), and nerve growth factor-inducible protein-B (NGFI-B). The NRRE also interacts with heterodimers formed between RXR alpha and either ARP-1, EAR-2, EAR-3, the retinoic acid receptor-alpha (RAR alpha), or the peroxisome proliferator-activated receptor (PPAR). Remarkably, nuclear receptor binding is conserved in the LTRs of recently evolved HIV-1 strains but it is absent in the oldest and most divergent viral isolates, raising the intriguing possibility that the NRRE has been evolved recently in the viral genome. Cotransfection experiments in human choriocarcinoma JEG-3 cells have shown that the HIV-1 LTR-driven transcription is activated by RXR alpha and RAR alpha in the presence of 9-cis- and all-trans-retinoic acid, by PPAR and RXR alpha in the presence of clofibric acid and 9-cis-retinoic acid, and by the ''orphan'' receptors HNF-4 and NGFI-B. These findings suggest that a complex network of nuclear receptor signaling pathways, that include 9-cis- and all-trans-retinoic acid, fatty acids, peroxisome proliferators, growth factors, membrane depolarization, and possibly other signals, converge onto the HIV-1 NRRE and may participate in modulation of viral gene expression.	HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02215	Harvard University; Harvard Medical School	LADIAS, JAA (corresponding author), HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT MED,DIV HEMATOL ONCOL,RM 503A,BOSTON,MA 02215, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034270] Funding Source: NIH RePORTER; NIAID NIH HHS [1R29AI34270-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; CHENG-MAYER C, 1990, AIDS (London), V4, pS49; CHENGMAYER C, 1988, P NATL ACAD SCI USA, V85, P2815, DOI 10.1073/pnas.85.8.2815; COONEY AJ, 1991, J VIROL, V65, P2853, DOI 10.1128/JVI.65.6.2853-2860.1991; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; CORBOY JR, 1992, SCIENCE, V258, P1804, DOI 10.1126/science.1465618; DE LUCA LM, 1991, FASEB J, V5, P2924; DELEYS R, 1990, J VIROL, V64, P1207, DOI 10.1128/JVI.64.3.1207-1216.1990; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LI WH, 1988, MOL BIOL EVOL, V5, P313; LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MYERS G, 1991, DATABASE HUMAN RETRO; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; ORAM JD, 1990, AIDS RES HUM RETROV, V6, P1073, DOI 10.1089/aid.1990.6.1073; ORCHARD K, 1993, J ACQ IMMUN DEF SYND, V6, P440; ORCHARD K, 1990, J VIROL, V64, P3234, DOI 10.1128/JVI.64.7.3234-3239.1990; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; POLI G, 1992, P NATL ACAD SCI USA, V89, P2689, DOI 10.1073/pnas.89.7.2689; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SRINIVASAN A, 1989, AIDS RES HUM RETROV, V5, P121, DOI 10.1089/aid.1989.5.121; TURPIN JA, 1992, J IMMUNOL, V148, P2539; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; YANG ZY, 1993, NUCLEIC ACIDS RES, V21, P2831, DOI 10.1093/nar/21.12.2831; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	54	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5944	5951						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119938				2022-12-27	WOS:A1994MY84000072
J	BRAUN, JEA; FRITZ, BA; WONG, SME; LOWE, AW				BRAUN, JEA; FRITZ, BA; WONG, SME; LOWE, AW			IDENTIFICATION OF A VESICLE-ASSOCIATED MEMBRANE-PROTEIN (VAMP)-LIKE MEMBRANE-PROTEIN IN ZYMOGEN GRANULES OF THE RAT EXOCRINE PANCREAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILIZED CHROMAFFIN CELLS; BOTULINUM-A TOXIN; SYNAPTIC VESICLES; TETANUS TOXIN; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; STREPTOLYSIN-O; ACINAR-CELLS; LIGHT CHAIN; GENES	Zymogen granules of the exocrine pancreas are the secretory organelles responsible for the regulated secretion of digestive enzymes. Several proteins are associated with or are integral components of the lipid bilayer that forms the zymogen granule membrane. These proteins likely represent important components in the regulated secretion of digestive enzymes. VAMPs (vesicle-associated membrane proteins)/synaptobrevins are a family of 18-kDa integral membrane proteins originally characterized in synaptic vesicles. Polyclonal antisera raised against either a VAMP/glutathione S-transferase (GST) fusion protein or rat brain synaptic vesicles, defected an 18-kDa immunoreactive protein in zymogen granule membranes that co-migrates electrophoretically with rat brain synaptic vesicle VAMP. Rat brain synaptic vesicle VAMP was detected by both antisera. Botulinum-B toxin treatment of zymogen granule membranes did not result in cleavage of zymogen granule membrane VAMP, indicating that exocrine pancreatic VAMP is either VAMP1 or a novel VAMP-isoform Immunofluorescent studies demonstrated that exocrine pancreatic VAMP localized with GP2, a zymogen granule membrane protein, to the apical region of pancreatic acinar cells. No significant labeling was observed in basolateral regions of pancreatic acinar cells. These results establish the presence of a VAMP protein in the zymogen granule of the rat pancreas and suggest that VAMPs have a role in exocrine secretion.	STANFORD UNIV, SCH MED, DEPT MED, STANFORD, CA 94305 USA; STANFORD UNIV, CTR DIGEST DIS, STANFORD, CA 94305 USA	Stanford University; Stanford University					NIDDK NIH HHS [DK38707, DK43294-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707, R01DK043294, R29DK043294] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BEAUDOIN AR, 1993, J HISTOCHEM CYTOCHEM, V41, P225, DOI 10.1177/41.2.7678269; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BERGEY GK, 1987, J NEUROPHYSIOL, V57, P121, DOI 10.1152/jn.1987.57.1.121; BIGALKE H, 1981, N-S ARCH PHARMACOL, V316, P244, DOI 10.1007/BF00505657; BITTNER MA, 1989, J BIOL CHEM, V264, P10354; BITTNER MA, 1988, J NEUROCHEM, V51, P451, DOI 10.1111/j.1471-4159.1988.tb01059.x; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAND SH, 1991, J BIOL CHEM, V266, P18949; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CAMERON RS, 1986, J CELL BIOL, V103, P1299, DOI 10.1083/jcb.103.4.1299; CHIN AC, 1993, GENE, V131, P175, DOI 10.1016/0378-1119(93)90291-A; CHIN GJ, 1992, BRAIN RES, V571, P89, DOI 10.1016/0006-8993(92)90512-8; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DRENCKHAHN D, 1983, EUR J CELL BIOL, V30, P167; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; GREENBERG HB, 1983, J VIROL, V47, P267, DOI 10.1128/JVI.47.2.267-275.1983; HAVINGA JR, 1985, EUR J CELL BIOL, V39, P70; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE SM, 1992, EUR J CELL BIOL, V58, P12; LAURIE SM, 1992, J HISTOCHEM CYTOCHEM, V40, P1827, DOI 10.1177/40.12.1453001; LEBEL D, 1988, BIOCHEM BIOPH RES CO, V154, P818, DOI 10.1016/0006-291X(88)90213-6; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LINK E, 1993, J BIOL CHEM, V268, P18423; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; LOMNETH R, 1991, J NEUROCHEM, V57, P1413, DOI 10.1111/j.1471-4159.1991.tb08308.x; MACDONAL.RJ, 1972, BIOCHEM BIOPH RES CO, V49, P377, DOI 10.1016/0006-291X(72)90421-4; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MELDOLESI J, 1971, J CELL BIOL, V49, P109, DOI 10.1083/jcb.49.1.109; NEWMAN AP, 1992, MOL CELL BIOL, V12, P3663, DOI 10.1128/MCB.12.8.3663; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; RONZIO RA, 1978, BIOCHIM BIOPHYS ACTA, V508, P65, DOI 10.1016/0005-2736(78)90189-X; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHEFFER RCT, 1980, EUR J CELL BIOL, V23, P122; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STECHER B, 1989, FEBS LETT, V255, P391, DOI 10.1016/0014-5793(89)81129-9; STECHER B, 1992, BIOCHEM J, V283, P899, DOI 10.1042/bj2830899; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TRIMBLE WS, 1990, J NEUROSCI, V10, P1380; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; WISHART MJ, 1993, J BIOL CHEM, V268, P10303	55	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5328	5335						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106518				2022-12-27	WOS:A1994MX57100095
J	BREITTMAYER, JP; BERNARD, A; AUSSEL, C				BREITTMAYER, JP; BERNARD, A; AUSSEL, C			REGULATION BY SPHINGOMYELINASE AND SPHINGOSINE OF CA2+ SIGNALS ELICITED BY CD3 MONOCLONAL-ANTIBODY, THAPSIGARGIN, OR IONOMYCIN IN THE JURKAT T-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CALCIUM RELEASE; PHOSPHATIDIC-ACID; PHOSPHOLIPASE-D; INHIBITION; ACTIVATION; INFLUX; STORES; SPHINGOSINE-1-PHOSPHATE; SPHINGOLIPIDS; PROLIFERATION	Sphingomyelinase induces a marked rapid decrease of cytosolic Ca2+ concentration in Jurkat T cells treated with either CD3 monoclonal antibody; the Ca2+-ATPase inhibitor, thapsigargin; or the Ca2+ ionophore, ionomycin. Sphingomyelinase treatment of Jurkat cells results in a net decrease of cellular sphingomyelin content. Among the products generated by the catabolism of sphingomyelin, sphingosine displayed exactly the same effect as sphingomyelinase. Sphingosine decreases the cytosolic Ca2+ concentration in cells treated with CD3, thapsigargin, or ionomycin. Studying the effect of sphingosine in CD3-activated cells showed that this compound does not modify Ca2+ mobilization from intracellular stores but strongly inhibited the Ca2+ influx induced by the monoclonal antibody. The fact that sphingosine inhibits Ca2+ influx generated by thapsigargin and ionomycin supports the hypothesis that the drug activates the Ca2+ extrusion process. Derivatives of sphingosine such as erythrosphinganine and threosphinganine share the same inhibitory properties,	FAC MED NICE,INSERM,U343,INTERACT CELLULAIRES & MOLEC IMMUNOL LAB,F-06107 NICE,FRANCE; HOP ARCHET,LAB CENT IMMUNOL,F-06012 NICE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Cote d'Azur; CHU Nice								ALONSO MT, 1991, BIOCHEM J, V280, P783, DOI 10.1042/bj2800783; ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; ALVAREZ J, 1992, FASEB J, V6, P786, DOI 10.1096/fasebj.6.2.1537469; AUSSEL C, 1991, J LIPID MEDIATOR, V3, P267; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BREITTMAYER JP, 1993, J BIOL CHEM, V268, P20812; BREITTMAYER JP, 1991, IMMUNOLOGY, V73, P134; CHOW SC, 1990, BIOCHEM J, V267, P727, DOI 10.1042/bj2670727; CZARNY M, 1992, BIOCHEM BIOPH RES CO, V186, P1582, DOI 10.1016/S0006-291X(05)81588-8; DESAI NN, 1992, J BIOL CHEM, V267, P23122; DORNAND J, 1987, IMMUNOL LETT, V16, P101, DOI 10.1016/0165-2478(87)90115-5; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; JALINK K, 1990, J BIOL CHEM, V265, P12232; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KUBBIES M, 1989, EUR J IMMUNOL, V19, P1393, DOI 10.1002/eji.1830190807; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NORDSTROM T, 1991, CELL CALCIUM, V12, P449, DOI 10.1016/0143-4160(91)90027-C; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; PELASSY C, 1991, J LIPID MEDIATOR, V4, P199; PELASSY C, 1992, BIOCHEM J, V288, P785, DOI 10.1042/bj2880785; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1119, DOI 10.1152/ajpcell.1992.263.6.C1119; PUTNEY JW, 1986, CELL CALCIUM, V7, P11; RANDRIAMAMPITA C, 1990, J BIOL CHEM, V265, P18059; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SABBADINI RA, 1992, J BIOL CHEM, V267, P15475; SARKADI B, 1991, J MEMBRANE BIOL, V123, P9, DOI 10.1007/BF01993958; SPENCE MW, 1989, PHOSPHATIDYLCHOLINE, P185; SUGIYA H, 1991, FEBS LETT, V286, P113, DOI 10.1016/0014-5793(91)80953-Z; TORDAI A, 1989, IMMUNOL LETT, V20, P47, DOI 10.1016/0165-2478(89)90067-9; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	37	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5054	5058						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106482				2022-12-27	WOS:A1994MX57100057
J	CHA, Y; DEISSEROTH, AB				CHA, Y; DEISSEROTH, AB			HUMAN INTERFERON REGULATORY FACTOR-2 GENE - INTRON-EXON ORGANIZATION AND FUNCTIONAL-ANALYSIS OF 5'-FLANKING REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; FACTOR-I; IRF-1; ACTIVATOR; ALPHA; IFN; PROTEIN; ELEMENT; BIND; IDENTIFICATION	Interferon regulatory factor 2 (IRF-2) is a transcriptional regulatory protein that terminates interferon beta expression initiated by interferon regulatory factor 1. In this study, we isolated the genomic DNA for human IRF-2 gene, determined the intron-exon structure of the human IRF-2 gene, mapped the major transcription initiation site, identified a number of potential regulatory elements in the 5'-flanking region, and localized the IRF-2 gene on human chromosome 4. The IRF-2 promoter region contains a CpG island, with several GC boxes, a putative NF-kappa B-binding site, and a CAAT box, but no TATA box. When the promoter region was linked with a heterologous reporter gene, we found that the promoter region is inducible by both interferons (interferon-alpha and -gamma) and interferon regulatory factor 1. The region which induced these inductions was identified as being confined to 40 nucleotides 5' to the major transcriptional initiation site by testing a series of clones with truncated promoter of IRF-2. This region contains elements which are shared with the transcriptional enhancers of other genes including interferon regulatory factor 1, interferon beta, and interferon-inducible genes. These data suggest that interferon regulatory factor 1 not only triggers the activation of the interferon signal transduction pathway, but also may play a role in limiting the duration of this response by activating the transcription of IRF-2.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT HEMATOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [P01 CA55164, CA16672, P01 CA49639-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA055164, P01CA049639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; CHA Y, 1992, DNA CELL BIOL, V11, P605, DOI 10.1089/dna.1992.11.605; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; Goodbourn S, 1990, Semin Cancer Biol, V1, P89; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARROCH S, 1993, J BIOL CHEM, V268, P9092; ITOH S, 1989, NUCLEIC ACIDS RES, V17, P8372, DOI 10.1093/nar/17.20.8372; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NAF D, 1991, P NATL ACAD SCI USA, V88, P1369, DOI 10.1073/pnas.88.4.1369; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4; WHITESIDE ST, 1992, NUCLEIC ACIDS RES, V20, P1531, DOI 10.1093/nar/20.7.1531; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087	33	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5279	5287						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106512				2022-12-27	WOS:A1994MX57100089
J	CHAO, YP; LIAO, JC				CHAO, YP; LIAO, JC			METABOLIC RESPONSES TO SUBSTRATE FUTILE CYCLING IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE; TERMINAL OXIDASE; GENE; GLUCOSE; FUSIONS; MUTANTS	A cyclic pathway between phosphoenolpyruvate and oxaloacetate was created in Escherichia coli by simultaneous overexpression of phosphoenolpyruvate carboxykinase (encoded by pck) and phosphoenolpyruvate carboxylase (encoded by ppc) from a multicopy plasmid under the control of the tac promoter. The simultaneous overexpression of these two enzymes stimulated oxygen and glucose consumption, reduced growth yields, and resulted in high level excretion of pyruvate and acetate. These responses were abolished when either pck or ppc was deleted from the plasmic or when bath enzymes were inactivated by mutation. Therefore, the observed effects imply the existence of futile cycling. Incremental induction of futile cycling showed that stimulation of oxygen consumption was the first response, followed by the increased glucose consumption and the excretion of fermentation products. The specific growth rate of E. coli was insensitive to futile cycling per se, because the growth rate was also reduced by the overexpression of inactive enzymes at high levels, and the activity of the two enzymes did not inhibit growth further. Wild-type cells appear to be capable of compensating for the increased ATP drain due to futile cycling but cannot be as effective when a tricarboxylic acid cycle enzyme, alpha-ketoglutarate dehydrogenase, is defective.	TEXAS A&M UNIV,DEPT CHEM ENGN,COLL STN,TX 77843; TEXAS A&M UNIV,DEPT BIOCHEM & BIOPHYS,COLL STN,TX 77843	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station				Liao, James/0000-0002-4580-7276				AMARASINGHAM CR, 1965, J BIOL CHEM, V240, P3664; ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; AU DCT, 1985, J BACTERIOL, V161, P123, DOI 10.1128/JB.161.1.123-127.1985; CALHOUN MW, 1993, J BACTERIOL, V175, P3020, DOI 10.1128/JB.175.10.3020-3025.1993; CHAMBOST JP, 1980, J BIOL CHEM, V255, P2867; CHAO YP, 1993, APPL ENVIRON MICROB, V59, P4261, DOI 10.1128/AEM.59.12.4261-4265.1993; CHAO YP, 1993, J BACTERIOL, V173, P6939; CHEN WJ, 1992, GENE, V111, P143, DOI 10.1016/0378-1119(92)90617-X; DALDAL F, 1983, J BACTERIOL, V153, P390, DOI 10.1128/JB.153.1.390-394.1983; DEGNEN GE, 1974, J BACTERIOL, V117, P477, DOI 10.1128/JB.117.2.477-487.1974; GOLDIE AH, 1980, J BACTERIOL, V141, P1115, DOI 10.1128/JB.141.3.1115-1121.1980; GOLDIE AH, 1980, J BIOL CHEM, V255, P1399; GREEN GN, 1984, J BIOL CHEM, V259, P7994; GUNSALUS RP, 1992, J BACTERIOL, V174, P7069, DOI 10.1128/jb.174.22.7069-7074.1992; HERBERT AA, 1969, MOL GEN GENET, V105, P182, DOI 10.1007/BF00445687; IUCHI S, 1991, CELL, V66, P5, DOI 10.1016/0092-8674(91)90130-Q; IUCHI S, 1990, J BACTERIOL, V172, P6020, DOI 10.1128/jb.172.10.6020-6025.1990; IUCHI S, 1988, P NATL ACAD SCI USA, V85, P1888, DOI 10.1073/pnas.85.6.1888; JENSEN PR, 1992, J BACTERIOL, V174, P7635, DOI 10.1128/JB.174.23.7635-7641.1992; KATZ J, 1976, CURR TOP CELL REGUL, V10, P273; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; Miller J.H., 1972, EXPT MOL GENETICS; NAVAS MA, 1993, P NATL ACAD SCI USA, V90, P1290, DOI 10.1073/pnas.90.4.1290; Newsholme E A, 1976, Biochem Soc Symp, P61; NYSTROM T, 1993, J BACTERIOL, V175, P3949; PATNAIK R, 1992, J BACTERIOL, V174, P7527, DOI 10.1128/JB.174.23.7527-7532.1992; SPIRO S, 1991, TRENDS BIOCHEM SCI, V16, P310, DOI 10.1016/0968-0004(91)90125-F; YANO R, 1987, MOL GEN GENET, V207, P24, DOI 10.1007/BF00331486; [No title captured]	29	73	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5122	5126						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106492				2022-12-27	WOS:A1994MX57100067
J	SKIBA, MC; KNIGHT, KL				SKIBA, MC; KNIGHT, KL			FUNCTIONALLY IMPORTANT RESIDUES AT A SUBUNIT INTERFACE SITE IN THE RECA PROTEIN FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENTS; DNA	Assembly of RecA subunits into long, helical oligomers is required for its roles in recombinational DNA repair and homologous genetic recombination. The crystal structure of RecA reveals an extensive network of amino acid residues that lie at the subunit boundaries. We have introduced a large set of substitutions at 5 clustered residues, which are shown in the crystal structure to make specific contacts with positions in the neighboring monomer. We find that 3 of the 5 residues are important for RecA function (Lys216, Phe217, and Arg222), whereas the other 2 (Asn213 and Tyr218) are not. The patterns of functionally allowed substitutions provide insight into the chemical and steric constraints required at these positions.			SKIBA, MC (corresponding author), UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01655, USA.				NIGMS NIH HHS [GM 44772] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044772] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COX MM, 1991, MOL MICROBIOL, V5, P1295, DOI 10.1111/j.1365-2958.1991.tb00775.x; DUTREIX M, 1992, MOL GEN GENET, V232, P489, DOI 10.1007/BF00266254; HEINZ DW, 1992, P NATL ACAD SCI USA, V89, P3751, DOI 10.1073/pnas.89.9.3751; KOBAYASHI N, 1987, BIOCHEMISTRY-US, V26, P6801, DOI 10.1021/bi00395a033; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LOGAN KM, 1993, J MOL BIOL, V232, P1048, DOI 10.1006/jmbi.1993.1459; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; NGUYEN TT, 1993, J BIOL CHEM, V268, P3107; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; REIDHAAROLSON JF, 1991, METHOD ENZYMOL, V208, P564; RICHARDS FM, 1974, J MOL BIOL, V82, P1, DOI 10.1016/0022-2836(74)90570-1; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Stasiak A, 1988, GENETIC RECOMBINATIO, P265; STEVENS RC, 1991, PROTEIN ENG, V4, P391, DOI 10.1093/protein/4.4.391; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; YOSHIMURA Y, 1993, NUCLEIC ACIDS RES, V21, P1665, DOI 10.1093/nar/21.7.1665; YU X, 1992, J MOL BIOL, V225, P193, DOI 10.1016/0022-2836(92)91036-O; YU X, 1992, J MOL BIOL, V227, P334, DOI 10.1016/0022-2836(92)90702-L	20	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3823	3828						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106426				2022-12-27	WOS:A1994MV63100101
J	XU, Y; OOMEN, R; KLEIN, MH				XU, Y; OOMEN, R; KLEIN, MH			RESIDUE AT POSITION-331 IN THE IGG1 AND IGG4 CH2 DOMAINS CONTRIBUTES TO THEIR DIFFERENTIAL ABILITY TO BIND AND ACTIVATE COMPLEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EFFECTOR FUNCTIONS; IMMUNOGLOBULIN-G; HINGE REGION; C1Q BINDING; SEGMENTAL FLEXIBILITY; CHIMERIC HUMAN; ANTIBODIES; RABBIT; CARBOHYDRATE; EXPRESSION	A conserved proline residue is found at position 331 in the C(H)2 domains of human IgG subclasses which fix complement. This residue is replaced by a serine in IgG4 which is inactive. To determine the role of residue 331 in the differential ability of human IgGs to activate the complement cascade, a pair of genetically engineered anti-dinitrophenol IgG1 and IgG4 antibodies with reciprocal mutations at position 331 were tested for their hemolytic activity as well as for their ability to bind C1q, activate C1 and cleave C4. The IgG1 Ser331 mutant was virtually unable to mediate the lysis of trinitrobenzene-sulfonic acid-derivatized sheep red blood cells as a result of a marked defect in Clq binding activity. In contrast, the substitution of Pro for Ser331 in IgG4 bestowed partial hemolytic activity (40%) to the IgG4 Pro331 variant. Under low ionic strength conditions, this mutant was found to be approximately 50 and 75% as active as wild-type IgG1 in the Clq binding and C4b deposition assays, respectively. These results indicate that residue Pro''', which folds into close proximity to a previously identified Clq binding motif (Duncan, A. R., and Winter, G. (1988) Nature 332, 738-740), contributes to the architecture of the IgG1 Clq binding site and that its replacement by a serine residue in IgG4 is largely responsible for the functional inactivity of this isotype.	UNIV TORONTO,DEPT IMMUNOL,MED SCI BLDG,TORONTO M5S 1A8,ONTARIO,CANADA; CONNAUGHT CTR BIOTECHNOL RES,N YORK M2R 3T4,ON,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto; University of Toronto								BINDON CI, 1990, EUR J IMMUNOL, V20, P277, DOI 10.1002/eji.1830200208; BINDON CI, 1988, J EXP MED, V168, P127, DOI 10.1084/jem.168.1.127; BREKKE OH, 1993, NATURE, V363, P628, DOI 10.1038/363628a0; BRUGGEMANN M, 1987, J EXP MED, V166, P1351, DOI 10.1084/jem.166.5.1351; BURTON DR, 1992, ADV IMMUNOL, V51, P1, DOI 10.1016/S0065-2776(08)60486-1; BURTON DR, 1980, NATURE, V288, P338, DOI 10.1038/288338a0; CAMPBELL RD, 1980, BIOCHEM J, V189, P67, DOI 10.1042/bj1890067; CLARK M, 1989, EUR J IMMUNOL, V19, P381, DOI 10.1002/eji.1830190224; COLOMB M, 1975, BIOCHEM J, V145, P177, DOI 10.1042/bj1450177; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DANGL JL, 1988, EMBO J, V7, P1989, DOI 10.1002/j.1460-2075.1988.tb03037.x; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; HUGHESJONES NC, 1977, IMMUNOLOGY, V32, P191; ISENMAN DE, 1975, J IMMUNOL, V114, P1726; KLEIN M, 1981, P NATL ACAD SCI-BIOL, V78, P524, DOI 10.1073/pnas.78.1.524; LAW SKA, 1988, COMPLEMENT; LUND J, 1990, MOL IMMUNOL, V27, P1145, DOI 10.1016/0161-5890(90)90103-7; MATSUDA H, 1990, MOL IMMUNOL, V27, P51; MICHAELSEN TE, 1990, SCAND J IMMUNOL, V32, P517, DOI 10.1111/j.1365-3083.1990.tb03192.x; NORDERHAUG L, 1991, EUR J IMMUNOL, V21, P2379, DOI 10.1002/eji.1830211013; NOSE M, 1983, P NATL ACAD SCI-BIOL, V80, P6632, DOI 10.1073/pnas.80.21.6632; OI VT, 1984, NATURE, V307, P136, DOI 10.1038/307136a0; PERKINS SJ, 1991, J MOL BIOL, V221, P1345; POON PH, 1985, J BIOL CHEM, V260, P9357; RINFRET A, 1990, J IMMUNOL, V145, P925; RITTENBERG MB, 1969, P SOC EXP BIOL MED, V132, P575; SAMBROOK RJ, 1989, MOL CLONING LABORATO; SANDLIE I, 1989, EUR J IMMUNOL, V19, P1599, DOI 10.1002/eji.1830190912; SCHUMAKER VN, 1976, BIOCHEMISTRY-US, V15, P5175, DOI 10.1021/bi00668a035; TAN LK, 1990, P NATL ACAD SCI USA, V87, P162, DOI 10.1073/pnas.87.1.162; TAO MH, 1989, J IMMUNOL, V143, P2595; TAO MH, 1991, J EXP MED, V173, P1025, DOI 10.1084/jem.173.4.1025; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; TENNER AJ, 1981, J IMMUNOL, V127, P648; UTSUMI S, 1985, MOL IMMUNOL, V22, P811, DOI 10.1016/0161-5890(85)90147-6; WRIGHT JF, 1988, J BIOL CHEM, V263, P11221; YASMEEN D, 1976, J IMMUNOL, V116, P518	38	56	167	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3469	3474						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106388				2022-12-27	WOS:A1994MV63100053
J	PERLMAN, RK; GEHM, BD; KUO, WL; ROSNER, MR				PERLMAN, RK; GEHM, BD; KUO, WL; ROSNER, MR			FUNCTIONAL-ANALYSIS OF CONSERVED RESIDUES IN THE ACTIVE-SITE OF INSULIN-DEGRADING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; METALLOENDOPROTEASE INHIBITORS; DROSOPHILA-MELANOGASTER; DEGRADATION PRODUCTS; PROTEASE-III; FACTOR-ALPHA; RAT-LIVER; CELLS; PURIFICATION; THERMOLYSIN	Insulin-degrading enzyme (IDE), a nonlysosomal metalloprotease involved in metabolizing internalized insulin, has catalytic properties that have been strongly conserved through evolution. Two major properties distinguish IDE from the prototypic metalloprotease thermolysin. 1) It is inhibited by cysteine protease inhibitors as well as metalloprotease inhibitors; 2) it contains an inversion of the HEXXH active site motif of thermolysin, where the histidines coordinate zinc and the glutamate participates in catalysis. Furthermore, cysteine is adjacent to the glutamate residue (HXCEH) in human, rat, and Drosophila IDE, although it is not conserved in their close homologue, Escherichia coli protease III. This cysteine has been postulated to mediate the differential sensitivity of IDE and protease III to cysteine protease inhibitors and chelators. The role of the cysteine in IDE catalysis and inhibitor sensitivity was examined by mutating Cys110 to glycine or serine. To determine whether glutamate in this unusual motif participates in catalysis, we mutated Glu111 to aspartate, valine, or glutamine. Vectors containing wild type or mutant enzymes were transfected into COS cells, and expression was confirmed by Western blotting. Although the glutamate mutants were devoid of insulin degrading activity, the cysteine mutants were indistinguishable from wild type enzyme in both catalytic activity and sensitivity to inhibitors. The loss of activity in the glutamate mutants was not due to gross alterations in tertiary structure, as shown by retention of the ability to bind substrate and by conservative and nonconservative mutation of a neighboring residue with no apparent effect on catalysis. These results demonstrate that the conserved glutamate in the zinc-binding site of human insulin-degrading enzyme is a major catalytic residue, while a conserved cysteine in this region is not essential for catalysis or inhibitor sensitivity.	UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago	PERLMAN, RK (corresponding author), UNIV CHICAGO, BEN MAY INST, CHICAGO, IL 60637 USA.				NIGMS NIH HHS [2T32 GM07151-17] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007151] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFFHOLTER JA, 1990, MOL ENDOCRINOL, V4, P1125, DOI 10.1210/mend-4-8-1125; AFFHOLTER JA, 1988, SCIENCE, V242, P1415, DOI 10.1126/science.3059494; AFFHOLTER JA, 1990, BIOCHEMISTRY-US, V29, P7727, DOI 10.1021/bi00485a022; BAUMEISTER H, 1993, FEBS LETT, V317, P250, DOI 10.1016/0014-5793(93)81286-9; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; BIGNER SH, 1990, CANCER RES, V50, P8017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUSH JS, 1971, DIABETES, V20, P140, DOI 10.2337/diab.20.3.140; Creighton T. E., 1984, PROTEINS STRUCTURES, V2nd; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DUCKWORTH WC, 1988, J BIOL CHEM, V263, P1826; DUCKWORTH WC, 1988, ENDOCR REV, V9, P319, DOI 10.1210/edrv-9-3-319; Dunn BM., 1989, PROTEOLYTIC ENZYMES, P57; FAGAN JM, 1991, BIOCHEM J, V277, P779, DOI 10.1042/bj2770779; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P7695, DOI 10.1093/nar/14.19.7695; GARCIA JV, 1987, J CELL BIOL, V105, P449, DOI 10.1083/jcb.105.1.449; GARCIA JV, 1988, BIOCHEMISTRY-US, V27, P4237, DOI 10.1021/bi00412a006; GARCIA JV, 1989, J CELL BIOL, V109, P1301, DOI 10.1083/jcb.109.3.1301; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEHM BD, 1991, ENDOCRINOLOGY, V128, P1603, DOI 10.1210/endo-128-3-1603; GEHM BD, 1993, J BIOL CHEM, V268, P7943; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMEL FG, 1988, J BIOL CHEM, V263, P6703; HOLDEN HM, 1988, J BIOL CHEM, V263, P3256; KAYALAR C, 1989, J BIOL CHEM, V264, P8928; KAYALAR C, 1990, J CELL BIOCHEM, V44, P137, DOI 10.1002/jcb.240440303; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; KOLE HK, 1992, ARCH BIOCHEM BIOPHYS, V297, P199, DOI 10.1016/0003-9861(92)90662-G; KUO WL, 1990, MOL ENDOCRINOL, V4, P1580, DOI 10.1210/mend-4-10-1580; KUO WL, 1991, MOL ENDOCRINOL, V5, P1467, DOI 10.1210/mend-5-10-1467; KUO WL, 1993, ENDOCRINOLOGY, V132, P604, DOI 10.1210/en.132.2.604; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI D, 1992, J BIOL CHEM, V267, P2414; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P41, DOI 10.1038/newbio238041a0; MULLER D, 1992, BIOCHEMISTRY-US, V31, P11138; NEURATH H, 1989, PROTEOLYTIC ENZYMES, P1; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; RAWLINGS ND, 1991, BIOCHEM SOC T, V19, pS289, DOI 10.1042/bst019289s; ROTH RA, 1984, ENDOCR RES, V10, P101, DOI 10.3109/07435808409035411; Sambrook J, 1989, MOL CLONING LABORATO; SEMPLE JW, 1992, INT IMMUNOL, V4, P1161, DOI 10.1093/intimm/4.10.1161; SHII K, 1986, P NATL ACAD SCI USA, V83, P4147, DOI 10.1073/pnas.83.12.4147; SHII K, 1986, DIABETES, V35, P675, DOI 10.2337/diabetes.35.6.675; STOPPELLI MP, 1988, P NATL ACAD SCI USA, V85, P3469, DOI 10.1073/pnas.85.10.3469; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001	46	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21538	21544						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8104941				2022-12-27	WOS:A1993MC80900020
J	YAMAGUCHI, M; HATEFI, Y				YAMAGUCHI, M; HATEFI, Y			ENERGY-TRANSDUCING NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE - NUCLEOTIDE-BINDING PROPERTIES OF THE PURIFIED ENZYME AND PROTEOLYTIC FRAGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; ESCHERICHIA-COLI; MITOCHONDRIAL TRANSHYDROGENASE; BEEF-HEART; N,N'-DICYCLOHEXYLCARBODIIMIDE; DICYCLOHEXYLCARBODIIMIDE; SITE; N-(ETHOXYCARBONYL)-2-ETHOXY-1,2-DIHYDROQUINOLINE; PURIFICATION; PROTEINS	The mitochondrial energy-transducing nicotinamide nucleotide transhydrogenase is a homodimer of monomer M(r) = 109,065. It is composed of a 430-residue-long N-terminal hydrophilic domain, a 400-residue-long central hydrophobic domain, and a 200-residue-long C-terminal hydrophilic domain. The N- and the C-terminal hydrophilic domains extend into the mitochondrial matrix, and the central hydrophobic domain intercalates into the inner membrane. Equilibrium binding of [C-14]NADH and [C-14]NADPH was carried out to the purified transhydrogenase, transhydrogenase modified with N,N'-dicyclohexylcarbodiimide (DCCD) at the NADH-protectable Glu257, and to proteolytic fragments corresponding to dimers of the N-terminal and the C-terminal hydrophilic domains. The intact enzyme bound 1 mol of [C-14]NADH or [C-14] NADPH per dimer with K(d) values of 9.5 and 5.7 muM, respectively. The 90% DCCD-inhibited enzyme bound [C-14]NADPH with undiminished capacity and [C-14] NADH with 10% capacity as compared with unmodified enzyme. The K(d) values were unaltered. The N-terminal fragment bound [C-14]NADH at 0.76 mol/dimer with unaltered K(d) but did not bind [C-14]NADPH. The C-terminal fragment bound 0.32 mol of [C-14] NADPH/dimer with unaltered K(d) but did not bind [C-14] NADH. These results are consistent with our previous assignment of the NAD(H) and the NADP(H) binding sites to the N- and the C-terminal hydrophilic domains, respectively. The binding stoichiometries of 1 mol each of [C-14]NADH and [C-14]NADPH/dimeric transhydrogenase suggest half-of-the-sites reactivity, which is consistent with our previous findings that 100% inhibition by either p-[H-3]fluorosulfonylbenzoyl-5'-adenosine or [C-14]DCCD involved the incorporation of 1 mol of inhibitor/dimeric enzyme. We had shown earlier that N-(ethoxycarbonyl)2-ethoxy-1,2-dihydroquinoline (EEDQ) inhibits the transhydrogenase, apparently at the NAD binding site, but differently from DCCD. The enzyme was protected by 5'-AMP strongly against DCCD and weakly against EEDQ, whereas it was protected by NMNH strongly against EEDQ and not at all against DCCD. We have now determined the EEDQ binding sites to be Glu232 and Glu880. The different mononucleotide protections against DCCD and EEDQ suggest that the AMP moiety of NAD binds near Glu257 and its NMN portion near Glu232. They also suggest that the NMN moiety of NADP may bind near Glu880.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV BIOCHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024887] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24887] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD S, 1992, EUR J BIOCHEM, V207, P733, DOI 10.1111/j.1432-1033.1992.tb17103.x; BLAZYK JF, 1975, FEBS LETT, V50, P227, DOI 10.1016/0014-5793(75)80494-7; CLARKE DM, 1985, EUR J BIOCHEM, V149, P517, DOI 10.1111/j.1432-1033.1985.tb08955.x; CLARKE DM, 1986, EUR J BIOCHEM, V158, P647, DOI 10.1111/j.1432-1033.1986.tb09802.x; CUNNINGHAM IJ, 1992, BIOCHIM BIOPHYS ACTA, V1100, P332, DOI 10.1016/0167-4838(92)90490-5; FISHER R. R., 1982, PYRIDINE NUCLEOTIDE, P279; HANSON RL, 1979, J BIOL CHEM, V254, P888; HATEFI Y, 1980, J BIOL CHEM, V255, P9526; HATEFI Y, 1992, MOL MECHANISMS BIOEN, P265; HOU C, 1990, BIOCHIM BIOPHYS ACTA, V1018, P61, DOI 10.1016/0005-2728(90)90110-P; HOWLETT GJ, 1978, ARCH BIOCHEM BIOPHYS, V190, P809, DOI 10.1016/0003-9861(78)90341-7; HU PS, 1992, BIOCHIM BIOPHYS ACTA, V1102, P19, DOI 10.1016/0167-4838(92)90494-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIKIND PK, 1985, ARCH BIOCHEM BIOPHYS, V240, P904, DOI 10.1016/0003-9861(85)90100-6; LEE CP, 1989, BIOCHIM BIOPHYS ACTA, V1000, P371, DOI 10.1016/S0006-3002(89)80032-0; LEVER TM, 1991, EUR J BIOCHEM, V197, P247, DOI 10.1111/j.1432-1033.1991.tb15905.x; OLAUSSON T, 1992, ACTA PHYSIOL SCAND, V146, P13; PENNINGTON RM, 1981, J BIOL CHEM, V256, P8963; PERSSON B, 1984, J BIOL CHEM, V259, P8626; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PHELPS DC, 1984, BIOCHEMISTRY-US, V23, P6340, DOI 10.1021/bi00321a008; PHELPS DC, 1981, J BIOL CHEM, V256, P8217; PHELPS DC, 1984, BIOCHEMISTRY-US, V23, P4475, DOI 10.1021/bi00314a037; PHELPS DC, 1985, BIOCHEMISTRY-US, V24, P3503, DOI 10.1021/bi00335a017; PHELPS DC, 1985, ARCH BIOCHEM BIOPHYS, V243, P298, DOI 10.1016/0003-9861(85)90799-4; RAFTER GW, 1957, METHOD ENZYMOL, V3, P887, DOI 10.1016/S0076-6879(57)03471-0; RYDSTROM J, 1977, BIOCHIM BIOPHYS ACTA, V463, P155, DOI 10.1016/0304-4173(77)90007-6; RYDSTROM J, 1987, PYRIDINE NUCLEOTID B, V2, P433; SEGEL IH, 1975, ENZYME KINETICS BEHA, P218; WAKABAYASHI S, 1987, BIOCHEM INT, V15, P915; WAKABAYASHI S, 1987, BIOCHEM INT, V15, P667; WANG TP, 1954, J BIOL CHEM, V211, P465; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; YAMAGUCHI M, 1991, J BIOL CHEM, V266, P5728; YAMAGUCHI M, 1988, J BIOL CHEM, V263, P2761; YAMAGUCHI M, 1990, BIOCHEMISTRY-US, V29, P4136, DOI 10.1021/bi00469a017; YAMAGUCHI M, 1986, BIOCHEMISTRY-US, V25, P4864, DOI 10.1021/bi00365a021	37	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17871	17877						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8102370				2022-12-27	WOS:A1993LT74300037
J	CORNWELL, MM; SMITH, DE				CORNWELL, MM; SMITH, DE			A SIGNAL-TRANSDUCTION PATHWAY FOR ACTIVATION OF THE MDR1 PROMOTER INVOLVES THE PROTOONCOGENE C-RAF KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EGR-1 PROMOTER; V-RAF; RESISTANCE; GROWTH; EXPRESSION; CELLS; GENE; SITE	To investigate the regulation of expression of the human mdr1 gene, the response of the mdr1 promoter to signals involved in cell proliferation was examined. The activity of the mdr1 promoter was measured in transiently transfected NIH 3T3 cells, which were stimulated to enter the cell cycle by addition of serum, platelet-derived growth factor, or transforming growth factor alpha. Addition of serum to quiescent NIH 3T3 cells resulted in a 6-8-fold activation of mdr1 promoter activity, which peaked at 10 h, just prior to S-phase. Treatment of serum-starved cells with the serum mitogens platelet-derived growth factor and transforming growth factor alpha also activated the mdr1 promoter. To define components of the signal cascade resulting in mdr1 promoter activation, the role of c-Raf kinase, a serine/threonine kinase important in mitogen-activated signal transduction, was examined. We measured the effects of a constitutively activated Raf kinase, v-raf, and a dominant negative Raf mutant, c-Raf-C4, on mdr1 promoter activity in NIH 3T3 and HepG2 cells. In serum-starved NIH 3T3 cells, v-raf increased mdr1 promoter activity approximately 10-fold compared to a v-raf frame-shift control. Raf responsiveness of the mdr1 promoter was localized to sequences between -69 and -41, relative to the initiation site. Serum stimulation of the mdr1 promoter was blocked by co-transfection of NIH 3T3 cells with the dominant negative Raf mutant c-Raf-C4. In the human hepatoma cell line HepG2, which has high endogenous Raf kinase activity (Bruder, J. T., Heidecker, G., and Rapp, U. R. (1992) Genes & Dev. 6, 545-556), co-transfection with c-Raf-C4 decreased mdr1 promoter activity 20-fold. Taken together, these data suggest that the mdr1 gene is transcriptionally regulated by normal cellular signaling events involving activation of c-Raf kinase.			CORNWELL, MM (corresponding author), FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA.				NCI NIH HHS [CA51728] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051728, R01CA051728] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHIN KV, 1993, ADV CANCER RES, V60, P157; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CORNWELL MM, 1990, CELL GROWTH DIFFER, V1, P607; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GOTTESMAN MM, 1988, TRENDS PHARMACOL SCI, V9, P54, DOI 10.1016/0165-6147(88)90117-4; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MILTENBERGER R, 1993, IN PRESS J BIOL CHEM, V268; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; QURESHI SA, 1991, ONCOGENE, V6, P995; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1991, ONCOGENE, V6, P495; RIM M, 1992, ONCOGENE, V7, P2065; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; RONINSON IB, 1992, BIOCHEM PHARMACOL, V43, P95, DOI 10.1016/0006-2952(92)90666-7	23	85	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15347	15350						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8101839				2022-12-27	WOS:A1993LN30500007
J	HUANG, HM; GIBSON, GE				HUANG, HM; GIBSON, GE			ALTERED BETA-ADRENERGIC RECEPTOR-STIMULATED CAMP FORMATION IN CULTURED SKIN FIBROBLASTS FROM ALZHEIMER DONORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CYTOSOLIC FREE CALCIUM; ADENYLATE-CYCLASE; MESSENGER-RNA; BETA-2-ADRENERGIC RECEPTOR; DISEASE FIBROBLASTS; DOWN-REGULATION; NERVOUS-SYSTEM; PHOSPHORYLATION; BINDING	An alteration in signal transduction systems in Alzheimer's disease would likely be of pathophysiological significance, because these steps are critical to normal brain function. Since dynamic processes are difficult to study in autopsied brain, the current studies utilized cultured skin fibroblasts. The beta-adrenergic-stimulated increase in cAMP was reduced approximately 80% in fibroblasts from Alzheimer's disease compared with age-matched controls. The deficit in Alzheimer fibroblasts in response to various adrenergic agonists paralleled their beta-adrenergic potency, and enhancement of cAMP accumulation by a non-adrenergic agonist, such as prostaglandin E1, was similar in Alzheimer and control fibroblasts. Diminished adenylate cyclase activity did not underlie these abnormalities, since direct stimulation of adenylate cyclase by forskolin elevated cAMP production equally in Alzheimer and control fibroblasts. Cholera toxin equally stimulated cAMP formation in Alzheimer and control fibroblasts. Moreover, cholera toxin partially reduced isoproterenol-induced cAMP deficit in Alzheimer fibroblasts. Pertussis toxin, on the other hand, did not alter the Alzheimer deficits. The results suggest either that the coupling of the GTP-binding protein(s) to the beta-adrenergic receptor is abnormal or that the sensitivity of receptor is altered with Alzheimer's disease. Further, any hypothesis about Alzheimer's disease must explain why a reduced beta-adrenergic-stimulated cAMP formation persists in tissue culture.			HUANG, HM (corresponding author), CORNELL UNIV,COLL MED,BURKE MED RES INST,WHITE PLAINS,NY 10605, USA.				NIA NIH HHS [AG09014, AG03853] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG003853, R35AG009014] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BANCHER C, 1991, BRAIN RES, V539, P11, DOI 10.1016/0006-8993(91)90681-K; BAUZBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BLASS JP, 1991, REV NEUROL, V147, P513; BLASS JP, 1988, REV NEUROL, V144, P543; BORDEN LA, 1992, NEUROBIOL AGING, V13, P33, DOI 10.1016/0197-4580(92)90005-I; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEDID M, 1989, J IMMUNOL, V142, P4301; CLARK EA, 1991, LAB INVEST, V64, P35; COWBURN R F, 1992, Neurobiology of Aging, V13, pS60; Cristofalo VJ, 1980, J TISSUE CULTURE MET, V6, P117; DANIELSSON E, 1988, NEUROBIOL AGING, V9, P153, DOI 10.1016/S0197-4580(88)80045-9; DEKEYSER J, 1990, ARCH NEUROL-CHICAGO, V47, P761, DOI 10.1001/archneur.1990.00530070055011; DESHMUKH VD, 1990, MED HYPOTHESES, V32, P293, DOI 10.1016/0306-9877(90)90109-R; EBSTEIN RP, 1984, LIFE SCI, V34, P2239, DOI 10.1016/0024-3205(84)90211-X; FISHMAN PH, 1987, BIOCHEM BIOPH RES CO, V144, P620, DOI 10.1016/S0006-291X(87)80011-6; GANDY S, 1988, P NATL ACAD SCI USA, V85, P6218, DOI 10.1073/pnas.85.16.6218; GANDY SE, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P155; GIBSON G, 1987, BANBURY REPORTS, V27, P85; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P8415, DOI 10.1073/pnas.85.22.8415; HARRISON PJ, 1991, MOL BRAIN RES, V10, P71, DOI 10.1016/0169-328X(91)90058-6; HORSBURGH K, 1991, J NEUROCHEM, V56, P1121, DOI 10.1111/j.1471-4159.1991.tb11401.x; HUANG H-M, 1991, Journal of Cell Biology, V115, p16A; HUANG HM, 1991, NEUROBIOL AGING, V12, P469, DOI 10.1016/0197-4580(91)90075-U; HUANG HM, 1992, T AM SOC NEUROCHEM, V23, P105; KALARIA RN, 1989, NEUROSCI LETT, V106, P233, DOI 10.1016/0304-3940(89)90231-0; KALARIA RN, 1989, J NEUROCHEM, V53, P1772, DOI 10.1111/j.1471-4159.1989.tb09242.x; KOSIK KS, 1989, J GERONTOL, V44, P855; LI JC, 1985, BIOCHEM BIOPH RES CO, V129, P733, DOI 10.1016/0006-291X(85)91953-9; LIEBMANN C, 1991, PEPTIDES, V12, P265, DOI 10.1016/0196-9781(91)90009-E; Maguire M E, 1977, Adv Cyclic Nucleotide Res, V8, P1; MALOW BA, 1989, ARCH NEUROL-CHICAGO, V46, P1201, DOI 10.1001/archneur.1989.00520470057027; MASLIAH E, 1991, J NEUROSCI, V11, P2759; MCCOY K R, 1991, Journal of Cell Biology, V115, p8A; MCDONALD WM, 1991, PSYCHIAT CLIN N AM, V14, P421; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; NAKADA MT, 1990, J PHARMACOL EXP THER, V253, P221; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; PAPASOZOMENOS SC, 1991, P NATL ACAD SCI USA, V88, P4543, DOI 10.1073/pnas.88.10.4543; PETERSON C, 1986, P NATL ACAD SCI USA, V83, P7999, DOI 10.1073/pnas.83.20.7999; PETERSON C, 1986, P NATL ACAD SCI USA, V83, P2758, DOI 10.1073/pnas.83.8.2758; PETERSON C, 1985, NEW ENGL J MED, V312, P1063; PETERSON C, 1988, NEUROBIOL AGING, V9, P261, DOI 10.1016/S0197-4580(88)80063-0; REINIKAINEN KJ, 1990, J NEUROSCI RES, V27, P576, DOI 10.1002/jnr.490270419; ROPPER AH, 1980, NEUROLOGY, V30, P639, DOI 10.1212/WNL.30.6.639; Saitoh T, 1990, Adv Exp Med Biol, V265, P301; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SHAPIRO IP, 1991, J NEUROCHEM, V56, P1154, DOI 10.1111/j.1471-4159.1991.tb11405.x; SHEU KFR, 1985, ANN NEUROL, V17, P444; SHIMOHAMA S, 1987, J NEUROCHEM, V48, P1215, DOI 10.1111/j.1471-4159.1987.tb05649.x; SIMS NR, 1987, ANN NEUROL, V21, P451, DOI 10.1002/ana.410210507; SISKEN J E, 1989, Journal of Cell Biology, V109, p301A; SMITH CJ, 1987, NEUROSCI LETT, V82, P227, DOI 10.1016/0304-3940(87)90135-2; VANHUYNH T, 1989, ARCH NEUROL-CHICAGO, V46, P1195, DOI 10.1001/archneur.1989.00520470049026; VOLICER L, 1985, NEUROBIOL AGING, V6, P35, DOI 10.1016/0197-4580(85)90069-7; WARPMAN U, 1992, Neurobiology of Aging, V13, pS61, DOI 10.1016/0197-4580(92)90368-8; WEINER N, 1985, PHARMACOL BASIS THER, P145	61	68	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14616	14621						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8100816				2022-12-27	WOS:A1993LL75900016
J	AHMED, M; BORSCH, CM; NEYFAKH, AA; SCHULDINER, S				AHMED, M; BORSCH, CM; NEYFAKH, AA; SCHULDINER, S			MUTANTS OF THE BACILLUS-SUBTILIS MULTIDRUG TRANSPORTER BMR WITH ALTERED SENSITIVITY TO THE ANTIHYPERTENSIVE ALKALOID RESERPINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; MUTAGENESIS; RESISTANCE; BINDING	The Bacillus subtilis multidrug transporter Bmr effluxes structurally diverse toxic compounds out of bacterial cells. Antihypertensive alkaloid reserpine reverses Bmr-mediated multidrug resistance by inhibiting drug transport. We have obtained a mutant of the bmr gene that provides a normal level of multidrug resistance, which can, however, only be reversed by very high concentrations of reserpine. Reduction of Bmr sensitivity to reserpine has been caused by the substitution of Leu for Val286 in the Bmr molecule. This mutation also led to a dramatic decrease of [H-3]reserpine binding to membrane vesicles prepared from the Bmr-overexpressing bacteria. Leucine is larger than valine by one methylene group. Substitution of Val286 with a smaller residue, glycine, had an opposite effect. It led to increased sensitivity of Bmr to reserpine and increased affinity of reserpine binding to the membranes prepared from Bmr-overexpressing bacteria. Neither of the mutations significantly changed the sensitivity of Bmr to rescinnamine, a structural analog of reserpine. The results suggest that Val286 is involved in the formation of the reserpine-binding site of the Bmr molecule.	UNIV ILLINOIS,DEPT MED CHEM & PHARMACOGNOSY MC 781,CHICAGO,IL 60680; HEBREW UNIV JERUSALEM,INST LIFE SCI,IL-91904 JERUSALEM,ISRAEL	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Hebrew University of Jerusalem			Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237				BECK WT, 1988, BIOCHEM BIOPH RES CO, V153, P959, DOI 10.1016/S0006-291X(88)81321-4; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MERINO E, 1992, BIOTECHNIQUES, V12, P508; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NEYFAKH AA, 1992, ANTIMICROB AGENTS CH, V36, P484, DOI 10.1128/AAC.36.2.484; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NEYFAKH AA, 1993, ANTIMICROB AGENTS CH, V37, P128, DOI 10.1128/AAC.37.1.128; NJUS D, 1986, BIOCHIM BIOPHYS ACTA, V853, P237, DOI 10.1016/0304-4173(87)90003-6; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; RUDNICK G, 1990, BIOCHEMISTRY-US, V29, P603, DOI 10.1021/bi00455a002; SCHERMAN D, 1984, MOL PHARMACOL, V25, P113; SCHULDINER S, 1993, J BIOL CHEM, V268, P29; TSAI KJ, 1992, J BACTERIOL, V174, P116, DOI 10.1128/jb.174.1.116-121.1992; WEAVER JA, 1982, EUR J PHARMACOL, V80, P437, DOI 10.1016/0014-2999(82)90093-0	19	92	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11086	11089						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8098708				2022-12-27	WOS:A1993LD46600056
J	CHEN, CY; DION, SB; KIM, CM; BENOVIC, JL				CHEN, CY; DION, SB; KIM, CM; BENOVIC, JL			BETA-ADRENERGIC-RECEPTOR KINASE - AGONIST-DEPENDENT RECEPTOR-BINDING PROMOTES KINASE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSIN KINASE; SYNTHETIC PEPTIDES; PROTEIN-KINASE; PHOTOEXCITED RHODOPSIN; PHOSPHORYLATION; PURIFICATION; MECHANISM; SUBSTRATE; FAMILY; TRANSLOCATION	The beta-adrenergic receptor kinase (betaARK) specifically phosphorylates the activated form of multiple receptors such as the beta2-adrenergic receptor (beta2AR) and rhodopsin. betaARK also phosphorylates synthetic peptides, albeit with an approximately 10(4)-10(7)-fold lower V(max)/K(m) ratio as compared to receptors, with a clear preference for peptides containing acidic residues on the aminoterminal side of a serine or threonine. To further characterize the mechanism of substrate phosphorylation by betaARK, we designed a series of analogue peptides containing a single amino acid change (serine, glutamic acid, or phosphoserine) situated 2 or 4 residues amino-terminal to the target serine. While betaARK weakly phosphorylated peptides lacking an acidic residue, peptides containing either a single phosphoserine or glutamic acid were substantially better substrates with a 3.5- to 8-fold increase in V(max). Additional studies demonstrated that the interaction of betaARK with an activated receptor (beta2AR* or Rho*) also significantly enhanced peptide phosphorylation. Both Rho* and a truncated rhodopsin lacking its carboxyl-terminal phosphorylation sites activated peptide phosphorylation to a similar extent with EC50 values for activation of 0.65 and 1.34 muM, respectively. In contrast, the agonist-occupied beta2AR activated peptide phosphorylation by betaARK with a substantially higher affinity (EC50 of 0.012 muM) compared to Rho*. The V(max)/K(m) ratio for betaARK phosphorylation of a poor peptide substrate such as RRRASAAASAA was increased up to approximately 200-fold by the activated receptor while the phosphorylation of a good peptide substrate (RRREEEEESAAA) was increased only up to approximately 8-fold. Our results suggest that acidic residues (glutamic acid or phosphoserine) localized on the amino-terminal side of target serines are important but not essential determinants in directing peptide phosphorylation. The substrate specificity of betaARK appears to rely more strongly on the overall topological structure of the activated receptor which promotes the specific binding and activation of betaARK.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107	Jefferson University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1990, BRIT J CLIN PHARMACO, V30, pS3, DOI 10.1111/j.1365-2125.1990.tb05462.x; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; Cleland W W, 1979, Methods Enzymol, V63, P103; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; FOWLES C, 1988, FEBS LETT, V238, P56, DOI 10.1016/0014-5793(88)80224-2; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MAYOR F, 1987, J BIOL CHEM, V262, P6468; MEGGIO F, 1984, J BIOL CHEM, V259, P4576; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; SHICHI H, 1978, J BIOL CHEM, V253, P7040; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	37	122	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7825	7831						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8096517				2022-12-27	WOS:A1993KW97900039
J	GOLDSMITH, ME; MADDEN, MJ; MORROW, CS; COWAN, KH				GOLDSMITH, ME; MADDEN, MJ; MORROW, CS; COWAN, KH			A Y-BOX CONSENSUS SEQUENCE IS REQUIRED FOR BASAL EXPRESSION OF THE HUMAN MULTIDRUG RESISTANCE (MDR1) GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDINE KINASE GENE; DNA-BINDING PROTEINS; P-GLYCOPROTEIN; TRANSCRIPTION FACTORS; FUNCTIONAL-ANALYSIS; CP-1/CBF SUBUNITS; CHINESE-HAMSTER; CDNA CLONING; HUMAN-TUMORS; CELL-LINES	Basal transcription of the human multidrug resistance (mdr1) promoter was studied by chloramphenicol acetyltransferase (CAT) reporter fusion gene analysis in two parental and doxorubicin-resistant human tumor cell lines. Deletion of mdr1 DNA sequences to -89 relative to the start of transcription (at +1) had little effect on expression. Deletion of nucleotide sequences from -89 to -70, however, resulted in a 5-10-fold reduction in mdrCAT expression. DNase I footprint analysis demonstrated that the region from -85 to -70 was protected from nuclease digestion using nuclear extracts from these cell lines. The sequence between -82 and -73 is perfectly homologous with the 10-base pair Y-box consensus sequence found in the promoters of all major histocompatibility complex class-II (MHC II) genes. The Y-box sequence in MHC II genes is required for accurate and efficient transcription and contains the sequence CCAAT in the reverse orientation (Dorn, A., Durand, B., Marfing, C., Le Meur, M., Benoist, C., and Mathis, D. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 6249-6253). Mutations in the reverse CCAAT sequence of the Y-box consensus substantially reduced expression of an mdrCAT vector and eliminated nucleoprotein binding in an electrophoretic mobility shift assay. These results suggest that proteins which bind to the putative Y-box consensus sequence are critical for basal transcriptional regulation of the human mdr1 gene.			GOLDSMITH, ME (corresponding author), NCI,MED BRANCH,BLDG 10,RM 12N226,BETHESDA,MD 20892, USA.							ABRAHAM I, 1990, EXP CELL RES, V189, P133, DOI 10.1016/0014-4827(90)90265-C; ARCOT SS, 1989, J BIOL CHEM, V264, P2343; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; CHIN KV, 1990, J BIOL CHEM, V265, P221; CHIN KV, 1992, J CELL PHYSIOL, V152, P87, DOI 10.1002/jcp.1041520112; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHIN KV, 1990, CELL GROWTH DIFFER, V1, P361; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COHEN D, 1991, J BIOL CHEM, V266, P2239; CORNWELL MM, 1990, CELL GROWTH DIFFER, V1, P607; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, P NATL ACAD SCI USA, V84, P6249, DOI 10.1073/pnas.84.17.6249; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FAIRCHILD CR, 1987, P NATL ACAD SCI USA, V84, P7701, DOI 10.1073/pnas.84.21.7701; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; GANT TW, 1992, NUCLEIC ACIDS RES, V20, P2841, DOI 10.1093/nar/20.11.2841; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GOLDSMITH ME, 1983, P NATL ACAD SCI-BIOL, V80, P2318, DOI 10.1073/pnas.80.8.2318; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; IKEGUCHI M, 1991, DNA CELL BIOL, V10, P639, DOI 10.1089/dna.1991.10.639; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; KIOKA N, 1992, FEBS LETT, V301, P37, DOI 10.1016/0014-5793(92)80205-U; KOHNO K, 1990, J BIOL CHEM, V265, P19690; KOHNO K, 1989, BIOCHEM BIOPH RES CO, V165, P1415, DOI 10.1016/0006-291X(89)92761-7; LAI GM, 1991, INT J CANCER, V49, P696, DOI 10.1002/ijc.2910490512; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P6848, DOI 10.1073/pnas.86.18.6848; LIU JM, 1991, VIROLOGY, V182, P361, DOI 10.1016/0042-6822(91)90682-2; LOUIE KG, 1986, BIOCHEM PHARMACOL, V35, P467, DOI 10.1016/0006-2952(86)90221-2; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MEYERS MB, 1986, P NATL ACAD SCI USA, V83, P5521, DOI 10.1073/pnas.83.15.5521; MICKLEY LA, 1989, J BIOL CHEM, V264, P18031; MORROW CS, 1992, J BIOL CHEM, V267, P10544; MORROW CS, 1990, GENE, V88, P215, DOI 10.1016/0378-1119(90)90034-O; OGURA M, 1991, JPN J CANCER RES, V82, P1151, DOI 10.1111/j.1349-7006.1991.tb01770.x; RAYMOND M, 1990, MOL CELL BIOL, V10, P6036, DOI 10.1128/MCB.10.11.6036; RICHTER A, 1972, J NATL CANCER I, V49, P1705, DOI 10.1093/jnci/49.6.1705; SAKURA H, 1988, GENE, V73, P499; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TANIMURA H, 1992, BIOCHEM BIOPH RES CO, V183, P917, DOI 10.1016/0006-291X(92)90571-2; TEETER LD, 1991, CELL GROWTH DIFFER, V2, P429; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; UEDA K, 1987, J BIOL CHEM, V262, P17432; UEDA K, 1989, JPN J CANCER RES, V80, P1127, DOI 10.1111/j.1349-7006.1989.tb02269.x; VANHUIJSDUIJNEN RAMH, 1987, NUCLEIC ACIDS RES, V15, P7265, DOI 10.1093/nar/15.18.7265; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VICKERS PP, 1989, TRENDS PHARMACOL SCI, V10, P443; WOLFFE AP, 1992, NEW BIOL, V4, P290	56	112	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5856	5860						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8095499				2022-12-27	WOS:A1993KR82200075
J	DAWID, IB				DAWID, IB			INTERCELLULAR SIGNALING AND GENE-REGULATION DURING EARLY EMBRYOGENESIS OF XENOPUS-LAEVIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ERYTHROID-DIFFERENTIATION FACTOR; BONE MORPHOGENETIC PROTEIN-4; MATERNAL MESSENGER-RNA; MESODERM INDUCTION; GROWTH-FACTORS; ACTIVIN-A; AMPHIBIAN DEVELOPMENT; VENTRALIZING FACTOR; FROG EMBRYOS; TGF-BETA				DAWID, IB (corresponding author), NICHHD,MOLEC GENET LAB,BETHESDA,MD 20892, USA.							ALTABA AR, 1989, NATURE, V341, P33; ALTABA ARI, 1992, DEVELOPMENT, V116, P81; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1993, GENE DEV, V7, P1; CORNELL RA, 1994, IN PRESS DEVELOPMENT; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; CUNLIFFE V, 1993, IN PRESS EMBO J; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DALE L, 1987, DEVELOPMENT, V99, P527; DALE L, 1992, DEVELOPMENT, V115, P573; DAWID IB, 1993, CR ACAD SCI III-VIE, V316, P952; DAWID IB, 1994, IN PRESS GROWTH FACT; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; DOHRMANN CE, 1993, DEV BIOL, V157, P474, DOI 10.1006/dbio.1993.1150; FUJII T, 1994, IN PRESS DEV DYN; GERHART J, 1989, DEVELOPMENT, V107, P37; GILBERT SF, 1993, MECH DEVELOP, V41, P73, DOI 10.1016/0925-4773(93)90039-Z; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; ISAACS HV, 1992, DEVELOPMENT, V114, P711; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; JONES CM, 1992, DEVELOPMENT, V115, P639; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KIMELMAN D, 1992, DEVELOPMENT, V114, P261; KIMELMAN D, 1992, DEVELOPMENT, V116, P1; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KIMMEL CB, 1988, TRENDS GENET, V4, P68, DOI 10.1016/0168-9525(88)90043-1; KNOCHEL S, 1992, MECH DEVELOP, V38, P157, DOI 10.1016/0925-4773(92)90007-7; LABONNE C, 1994, IN PRESS DEVELOPMENT; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MOODY SA, 1987, DEV BIOL, V122, P300, DOI 10.1016/0012-1606(87)90296-X; MOON RT, 1993, BIOESSAYS, V15, P91, DOI 10.1002/bies.950150204; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; NIEHRS C, 1994, IN PRESS SCIENCE; Nieuwkoop P.D., 1977, Current Topics Dev Biol, V11, P115, DOI 10.1016/S0070-2153(08)60744-9; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; REBAGLIATI MR, 1993, DEV BIOL, V159, P574, DOI 10.1006/dbio.1993.1265; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SARGENT TD, 1986, DEV BIOL, V114, P238, DOI 10.1016/0012-1606(86)90399-4; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH JC, 1989, DEVELOPMENT, V105, P665; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STACHEL SE, 1993, DEVELOPMENT, V117, P1261; STEINBEISSER H, 1993, DEVELOPMENT, V118, P499; STEINBEISSER H, 1993, CR ACAD SCI III-VIE, V316, P966; STJOHNSTON D, 1992, CELL, V68, P201; STRAHLE U, 1993, GENE DEV, V7, P1436, DOI 10.1101/gad.7.7b.1436; SUDARWAT.S, 1971, ROUX ARCH DEV BIOL, V166, P189, DOI 10.1007/BF00650029; SUZUKI A, IN PRESS BIOCH J; TADANO T, 1993, DEV GENET, V14, P204, DOI 10.1002/dvg.1020140307; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THOMPSON J, 1992, MECH DEVELOP, V38, P175, DOI 10.1016/0925-4773(92)90051-K; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	77	63	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6259	6262						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119971				2022-12-27	WOS:A1994MZ50300001
J	COLAMONICI, OR; DOMANSKI, P; KROLEWSKI, JJ; FU, XY; REICH, NC; PFEFFER, LM; SWEET, ME; PLATANIAS, LC				COLAMONICI, OR; DOMANSKI, P; KROLEWSKI, JJ; FU, XY; REICH, NC; PFEFFER, LM; SWEET, ME; PLATANIAS, LC			INTERFERON-ALPHA (IFN-ALPHA) SIGNALING IN CELLS EXPRESSING THE VARIANT FORM OF THE TYPE-I IFN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; ESTABLISHMENT; DOMAINS; SYSTEM; GENES	Two different type I interferon receptors (IFN-R) have been described: the normal and the variant receptors. The a subunit of the Type I IFN-R has a molecular mass of 110 kDa in cells expressing normal and variant receptors. The beta subunit has a molecular mass of approximately 100 kDa in cells that express normal receptors and 55 kDa in cells expressing the variant form of the receptor. The IFN alpha-resistant U-937 cell line expresses variant receptors and fails to down-regulate and phosphorylate the alpha subunit on tyrosine residues. We report that two other myelomonocytic cell lines, YK-M2 and ML-2, also expressing the variant form of the receptor, fail to down-regulate and phosphorylate the a subunit on tyrosine residues. However, YK-M2 and ML-2 cells are sensitive to the antiproliferative and antiviral effects of IFN alpha 2, indicating that phosphorylation of the a subunit is not necessary to elicit an IFN alpha response and that expression of variant receptors is not a source of IFN alpha resistance. We also determined if other proteins involved in the IFN alpha signal transduction pathway had a different phosphorylation pattern. Treatment of cells expressing variant receptors induced tyrosine phosphorylation of the p135(tyk2) tyrosine kinase, and the three interferon-stimulated gene factor 3 alpha (ISGFS3 alpha) polypeptides (p113, p91, and p84), albeit at lower levels. These results indicate that cells expressing either form of the Type I IFN-R phosphorylate a similar set of proteins, with the exception of the alpha subunit.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,CTR CANC,NEW YORK,NY 10032; MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029; SUNY STONY BROOK,DEPT PATHOL,STONY BROOK,NY 11794; LOYOLA UNIV,DIV HEMATOL ONCOL,MAYWOOD,IL 60153; EDWARD HINES JR VET ADM MED CTR,MAYWOOD,IL 60153	Columbia University; Columbia University; Icahn School of Medicine at Mount Sinai; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital	COLAMONICI, OR (corresponding author), UNIV TENNESSEE,DEPT PATHOL,800 MADISON AVE,MEMPHIS,TN 38163, USA.			Pfeffer, Lawrence/0000-0003-2809-1234	NIGMS NIH HHS [GM36716] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036716] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUET M, 1980, NATURE, V284, P459, DOI 10.1038/284459a0; BENOIT P, 1993, J IMMUNOL, V150, P707; BERNARDS A, 1991, ONCOGENE, V6, P1185; BRANCA AA, 1988, IN VITRO CELL DEV B, V24, P155; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1992, BLOOD, V80, P744; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COLAMONICI OR, 1991, PHARMACOL THERAPEUT, V52, P227, DOI 10.1016/0163-7258(91)90010-J; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GAZDAR AF, 1986, BLOOD, V67, P1542; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; KRAFT IF, 1990, ONCOGENE, V5, P1329; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LEVY DE, 1989, GENE DEV, V3, P1203; OHNO H, 1986, CANCER RES, V46, P6400; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1991, PHARMACOL THERAPEUT, V52, P149, DOI 10.1016/0163-7258(91)90005-7; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; PLATANIAS LC, 1993, J IMMUNOL, V150, P3382; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEN GC, 1992, J BIOL CHEM, V267, P5017; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057	30	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5660	5665						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119902				2022-12-27	WOS:A1994MY84000030
J	MITSUI, T; KITAZAWA, T; IKEBE, M				MITSUI, T; KITAZAWA, T; IKEBE, M			CORRELATION BETWEEN HIGH-TEMPERATURE DEPENDENCE OF SMOOTH-MUSCLE MYOSIN LIGHT-CHAIN PHOSPHATASE-ACTIVITY AND MUSCLE-RELAXATION RATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE; SKELETAL-MUSCLE; KINASE; PHOSPHORYLATION; PURIFICATION; CONTRACTION	Q(10) values of the protein phosphatases that can dephosphorylate the regulatory light chain of smooth muscle myosin were determined. Six phosphatases were examined, i.e. skeletal muscle protein phosphatase 1c; protein phosphatase 2Ac; smooth muscle phosphatases (SMP) I, II, and IV; and myosin-associated protein phosphatase (MAP phosphatase). Among them, SMP-IV and MAP phosphatase, which can dephosphorylate intact smooth muscle myosin, showed extremely high Q(10) values (5.3 and 5.2, respectively). On the other hand, the Q(10) values of other tested phosphatases were within the range of the normal enzyme reaction (Q(10) = 2.0). The rate of dephosphorylation of the myosin light chain in alpha-toxin-skinned strips was measured at different temperatures. The results provided a Q(10) of 5.1, which was quite similar to those values obtained for SMP-IV and MAP phosphatase. These results suggest that the physiological myosin light chain phosphatases are SMP-IV and/or MAP phosphatase, i.e. type 1 protein phosphatases. The temperature dependence of maximum force, the steady-state extent of myosin light chain phosphorylation, and the relaxation rate of alpha-toxin-permeabilized rabbit postal vein smooth muscle strips were measured. Both maximum force and the extent of myosin light chain phosphorylation were significantly higher at lower temperature (15 degrees C) than at higher temperature (25 degrees C) under all pCa conditions tested, i.e. >8, 6.3, and 5. The temperature dependence of the relaxation rate was much steeper (decreased 4 times by lowering the temperature from 25 to 15 degrees C) than that of the initial rate of increase in force development (decreased 1.4 times by lowering the temperature from 25 to 15 degrees C). These results are consistent with the and to values of myosin light chain phosphatases (Q(10) = 5) and myosin light chain kinase (Q(10) = 1.7) and further show that the smooth muscle type 1 phosphatases are responsible for the dephosphorylation of smooth muscle myosin in situ.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA; UNIV VIRGINIA, SCH MED, DEPT PHYSIOL, CHARLOTTESVILLE, VA 22908 USA	Case Western Reserve University; University of Virginia			Mitsui, Toshiaki/N-9773-2017	Mitsui, Toshiaki/0000-0002-9165-8830	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653, R01AR038888] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37117] Funding Source: Medline; NIAMS NIH HHS [AR38888, AR41653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, METHOD ENZYMOL, V159, P390; CSABINA S, 1986, BIOCHIM BIOPHYS ACTA, V871, P311, DOI 10.1016/0167-4838(86)90213-X; DRISKA SP, 1981, AM J PHYSIOL, V240, pC222, DOI 10.1152/ajpcell.1981.240.5.C222; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HORIUTI K, 1988, J PHYSIOL-LONDON, V398, P131, DOI 10.1113/jphysiol.1988.sp017034; IKEBE M, 1987, J BIOL CHEM, V262, P9569; ISHIHARA H, 1989, BIOPHYS J, V55, P475; ITOH T, 1989, NATURE, V338, P164, DOI 10.1038/338164a0; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KLEMT P, 1978, PFLUG ARCH EUR J PHY, V378, P31, DOI 10.1007/BF00581955; MIRSUI T, 1992, J BIOL CHEM, V267, P16727; PATO MD, 1985, J BIOL CHEM, V260, P2359; PATO MD, 1983, EUR J BIOCHEM, V132, P283, DOI 10.1111/j.1432-1033.1983.tb07360.x; PATO MD, 1983, J BIOL CHEM, V258, P7047; PATO MD, 1983, J BIOL CHEM, V258, P7055; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; Smith R. M., 1977, CRITICAL STABILITY C, V1-4; TAKAI A, 1989, BIOCHEM J, V262, P617, DOI 10.1042/bj2620617; TULLOCH AG, 1991, J BIOL CHEM, V266, P20168; WALSH MP, 1983, METHOD ENZYMOL, V99, P279	25	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5842	5848						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119926				2022-12-27	WOS:A1994MY84000057
J	STURGES, MR; PECK, LJ				STURGES, MR; PECK, LJ			CALCIUM-DEPENDENT INACTIVATION OF RNA-POLYMERASE-III TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR DEVELOPMENTAL TRANSITION; ALU REPEATED SEQUENCES; EARLY XENOPUS-EMBRYOS; SACCHAROMYCES-CEREVISIAE; INVITRO TRANSCRIPTION; MULTIPLE FACTORS; GENE-PRODUCT; ACTIVE FORM; CALPAIN; ADENOVIRUS	Extracts from whole oocytes of Xenopus laevis are widely used as an efficient in vitro system for the transcription of cloned genes by RNA polymerase m. We have found that these extracts no longer support RNA polymerase III transcription in response to a brief incubation in the presence of Ca2+. However, when transcription complexes were first formed on the genes, a subsequent incubation in the presence of Ca2+ had little effect. Fractionation of extracts was used to show that transcription factors (TF) IIIC and, to a lesser extent, TFIIIB, but not RNA polymerase III, were targets of the Ca2+ dependent inactivation process. An additional component (not present in fractionated TFIIIC or TFIIIB) was required far the Ca2+-dependent destruction of transcription factor activity. The Ca2+-dependent inactivation process was blocked by protease inhibitors that inhibit known Ca2+-dependent proteases called calpains. These results suggest that TFIIIC and TFIIIB are inactivated by an endogenous calpain. The common use of Ca2+ as a second messenger and the widespread distribution of calpains suggest that the proteolytic degradation of transcription factors may be a general mechanism for the regulation of gene expression.	UNIV CALIF SANTA CRUZ,SINSHEIMER LABS,SANTA CRUZ,CA 95064	University of California System; University of California Santa Cruz					NIGMS NIH HHS [GM46232] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046232] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; CLARK ME, 1991, EMBO J, V10, P2941, DOI 10.1002/j.1460-2075.1991.tb07844.x; CLARK ME, 1990, MOL CELL BIOL, V10, P5106, DOI 10.1128/MCB.10.10.5106; COZZARELLI NR, 1983, CELL, V34, P829, DOI 10.1016/0092-8674(83)90540-8; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DATTA S, 1991, J VIROL, V65, P5297, DOI 10.1128/JVI.65.10.5297-5304.1991; DIECI G, 1993, J BIOL CHEM, V268, P11199; FOLK WR, 1983, CELL, V33, P585, DOI 10.1016/0092-8674(83)90439-7; FRADKIN LG, 1987, MOL CELL BIOL, V7, P3880, DOI 10.1128/MCB.7.11.3880; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GAYNOR RB, 1985, SCIENCE, V230, P447, DOI 10.1126/science.2996135; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GEIDUSCHEK EP, 1992, TRANSCRIPTIONAL REGU, V1, P247; GIARDINA CA, 1990, J BIOL CHEM, V265, P9121; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; HARTL P, 1993, J CELL BIOL, V120, P613, DOI 10.1083/jcb.120.3.613; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; HOEFFLER WK, 1985, CELL, V41, P955, DOI 10.1016/S0092-8674(85)80076-3; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; JAMES CBL, 1992, J GEN VIROL, V73, P3133, DOI 10.1099/0022-1317-73-12-3133; JANG KL, 1992, BIOCHEM J, V284, P667, DOI 10.1042/bj2840667; JANG KL, 1992, J ACQ IMMUN DEF SYND, V5, P1142; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KOVELMAN R, 1990, GENE DEV, V4, P646, DOI 10.1101/gad.4.4.646; KOVELMAN R, 1992, J BIOL CHEM, V267, P24446; LEFEBVRE O, 1992, P NATL ACAD SCI USA, V89, P10512, DOI 10.1073/pnas.89.21.10512; LUND E, 1992, GENE DEV, V6, P1097, DOI 10.1101/gad.6.6.1097; MAKI M, 1989, J BIOL CHEM, V264, P18866; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; PARSONS MC, 1992, J BIOL CHEM, V267, P2894; PECK LJ, 1987, MOL CELL BIOL, V7, P3503, DOI 10.1128/MCB.7.10.3503; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; ROEDER RG, 1974, J BIOL CHEM, V249, P241; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SEIDEL CW, 1992, J MOL BIOL, V227, P1009, DOI 10.1016/0022-2836(92)90517-N; SHASTRY BS, 1982, J BIOL CHEM, V257, P2979; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; SWANSON RN, 1991, P NATL ACAD SCI USA, V88, P4887, DOI 10.1073/pnas.88.11.4887; WALDSCHMIDT R, 1992, J BIOL CHEM, V267, P16359; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WHITE RJ, 1990, EMBO J, V9, P3713, DOI 10.1002/j.1460-2075.1990.tb07584.x; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; YOSHINAGA S, 1986, EMBO J, V5, P343, DOI 10.1002/j.1460-2075.1986.tb04218.x; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585; YOSHINAGA SK, 1989, J BIOL CHEM, V264, P10726; YOUNG LS, 1991, SCIENCE, V252, P542, DOI 10.1126/science.1708526	52	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5712	5719						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119909				2022-12-27	WOS:A1994MY84000038
J	ZHU, XY; SUEN, KL; BARBACID, M; BOLEN, JB; FARGNOLI, J				ZHU, XY; SUEN, KL; BARBACID, M; BOLEN, JB; FARGNOLI, J			INTERLEUKIN-2-INDUCED TYROSINE PHOSPHORYLATION OF SHC PROTEINS CORRELATES WITH FACTOR-DEPENDENT T-CELL PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BETA-CHAIN; HUMAN IL-2 RECEPTOR; COLONY-STIMULATING FACTOR; SIGNAL-TRANSDUCTION; LYMPHOCYTES-T; GROWTH-FACTOR; GAMMA-CHAIN; KINASES; ACTIVATION; SRC	Interleukin-2 (IL-2) is a growth factor involved in the clonal expansion of antigen-activated T lymphocytes. Interaction of IL-2 with its receptor triggers tyrosine phosphorylation of a series of proteins and results in the activation of p21(ras). We report here that Shc, an SH2-containing adaptor protein, is tyrosine-phosphorylated following IL-2 stimulation, IL-2-induced tyrosine phosphorylation of She was detectable within seconds following IL-2 addition, reaching its highest level by 15 min. Tyrosine phosphorylation of Shc was induced in multiple IL-2-dependent T cell lines and was found to correlate with IL-2-dependent cell proliferation. Tyrosine-phosphorylated She was found to be capable of associating with the SE2 domain of Grb2 following IL-2 stimulation. These results indicate that tyrosine phosphorylation of She and its association with Grb2 may be important events in IL-2-initiated signal transduction events in T cells.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543	Bristol-Myers Squibb								ASAO H, 1992, FEBS LETT, V304, P141, DOI 10.1016/0014-5793(92)80605-G; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FUNG MR, 1991, J IMMUNOL, V147, P1253; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GARCIA GG, 1992, BIOCHEM J, V285, P851, DOI 10.1042/bj2850851; GILLIS S, 1978, J IMMUNOL, V120, P2027; GRAVES JD, 1992, J IMMUNOL, V148, P2417; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; IZQUIERDO M, 1993, EUR J IMMUNOL, V23, P131, DOI 10.1002/eji.1830230121; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI ZH, 1992, BIOCHEM BIOPH RES CO, V187, P1536, DOI 10.1016/0006-291X(92)90477-3; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MILLS GB, 1992, INT IMMUNOL, V4, P1233, DOI 10.1093/intimm/4.11.1233; MINAMI Y, 1992, BIOCHIM BIOPHYS ACTA, V1114, P163, DOI 10.1016/0304-419X(92)90013-O; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; OTANI H, 1992, P NATL ACAD SCI USA, V89, P2789, DOI 10.1073/pnas.89.7.2789; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1992, J BIOL CHEM, V267, P2537; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHMANDT R, 1992, BAILLIERE CLIN HAEM, V5, P551, DOI 10.1016/S0950-3536(11)80007-7; SHACKELFORD DA, 1991, CELL REGUL, V2, P73, DOI 10.1091/mbc.2.1.73; SILICIANO J, 1992, P NATL ACAD SCI USA, V89, P1114; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681	45	46	46	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5518	5522						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119884				2022-12-27	WOS:A1994MY84000010
J	JOHNSON, AW; KOLODNER, RD				JOHNSON, AW; KOLODNER, RD			CHARACTERIZATION OF THE INTERACTION OF SACCHAROMYCES-CEREVISIAE STRAND EXCHANGE PROTEIN-1 WITH DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RECA-PROTEIN; ESCHERICHIA-COLI; BINDING; RECOMBINATION; PURIFICATION; MOLECULES; SYNAPSIS; JOINTS	We have analyzed in greater detail the interaction of strand exchange protein 1 (Sep1) from Saccharomyces cerevisiae with DNA. The binding site size of Sep1 on single-stranded DNA (ssDNA) was determined to be 70 nucleotides per protein monomer using a fluorescence assay and 100 nucleotides using an exonuclease titration technique. The amount of Sep1 required for maximum aggregation of ssDNA was the amount needed to saturate the DNA. When double-stranded DNA (dsDNA) and ssDNA were both present, the duplex DNA was efficiently aggregated only at protein concentrations above that required for saturation of ssDNA. Strand exchange reactions with blunt-ended linear dsDNA and homologous ssDNA substrates required saturation of the ssDNA with Sep1 since free Sep1 is needed for exonuclease activity to initiate pairing with the dsDNA substrate. Preincubation of Sep1 with resected duplex DNA before adding ssDNA allowed joint molecule formation to occur at protein concentrations at least 10-fold below that required for saturation of the ssDNA. However, preincubation of Sep1 with ssDNA before the addition of resected duplex DNA required saturating amounts of Sep1 for joint molecule formation to occur. These results suggest that pairing requires Sep1 on both the ssDNA and the resected ends of the dsDNA.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,44 BINNEY ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Johnson, Arlen/0000-0002-4742-085X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029383, F32GM013594] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM13594, GM29383] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1992, GENE DEV, V6, P1679, DOI 10.1101/gad.6.9.1679; ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BIANCHI M, 1983, CELL, V34, P931, DOI 10.1016/0092-8674(83)90550-0; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; DYKSTRA CC, 1990, J BIOL CHEM, V265, P10968; HALBROOK J, 1989, J BIOL CHEM, V264, P21403; HALL SD, 1993, IN PRESS P NATL ACAD; HEYER WD, 1988, J BIOL CHEM, V263, P15189; JOHNSON AW, 1994, J BIOL CHEM, V269, P3664; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KOWALCZYKOWSKI SC, 1981, ENZYMES, P373; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; NORRIS D, 1990, BIOCHEMISTRY-US, V29, P7911, DOI 10.1021/bi00486a019; RADDING CM, 1991, J BIOL CHEM, V266, P5355; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; RICHARDSON CC, 1966, J MOL BIOL, V15, P49, DOI 10.1016/S0022-2836(66)80208-5; RIDDLES PW, 1985, J BIOL CHEM, V260, P165; ROSELLI W, 1990, J MOL BIOL, V216, P335; SANDER M, 1993, J BIOL CHEM, V268, P2075; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STEENSGAARD J, 1992, PREPARATIVE CENTRIFU, P208; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; [No title captured]	32	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3673	3681						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106412				2022-12-27	WOS:A1994MV63100080
J	KARIYA, K; KARNS, LR; SIMPSON, PC				KARIYA, K; KARNS, LR; SIMPSON, PC			AN ENHANCER CORE ELEMENT MEDIATES STIMULATION OF THE RAT BETA-MYOSIN HEAVY-CHAIN PROMOTER BY AN ALPHA(1)-ADRENERGIC AGONIST AND ACTIVATED BETA-PROTEIN KINASE-C IN HYPERTROPHY OF CARDIAC MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCARDIAL-CELL HYPERTROPHY; MUSCLE-SPECIFIC EXPRESSION; CAT BINDING-FACTOR; ALPHA-ACTIN GENE; PHORBOL ESTER; VENTRICULAR MYOCYTES; REGULATORY DOMAIN; TRANSCRIPTIONAL ACTIVATION; CATALYTIC DOMAINS; HEART MYOCYTES	In hypertrophy of cultured rat cardiac myocytes, alpha1-adrenergic agonists activate protein kinase C (PKC) and up-regulate beta-myosin heavy chain (MHC). The 3300-base pair (bp) rat beta-MHC promoter is stimulated by both an alpha1-agonist and a constitutively activated mutant of beta-PKC (Kariya, K., Karns, L. R., Simpson, P. C. (1991) J. Biol. Chem. 266, 10023-10026). Here, we report the convergence of alpha1-adrenergic and beta-PKC signaling on the same element of the beta-MHC promoter. A 20-bp sequence in the beta-MHC promoter (-215/-196) was required for induction by both alpha1-adrenergic stimulation and beta-PKC and conferred induction on a heterologous promoter. This sequence bound myocyte nuclear factor(s) through a 9-bp ''enhancer core'' (5'-TGTGGTATG-3'). A 3-bp mutation within the enhancer core which abolished factor binding also abolished inducibility of a 215-bp beta-MHC promoter. These results support the idea that beta-PKC is in the pathway for al-adrenergic regulation of beta-MHC transcription during cardiac myocyte hypertrophy. The enhancer core is the first PKC response element mapped by transfection of an activated PKC mutant, rather than by treatment with phorbol esters.	VET AFFAIRS MED CTR DIV CARDIOL,111-C-8,4150 CLEMENT ST,SAN FRANCISCO,CA 94121; VET AFFAIRS MED CTR,RES SERV,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES CTR,SAN FRANCISCO,CA 94143	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031113] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL031113] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P25535; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1992, J BIOL CHEM, V267, P12892; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FLINK IL, 1992, J BIOL CHEM, V267, P9917; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GOODE N, 1992, J BIOL CHEM, V267, P16878; GREIF H, 1992, MOL CELL BIOL, V12, P1304, DOI 10.1128/MCB.12.3.1304; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HATA A, 1989, FEBS LETT, V252, P144, DOI 10.1016/0014-5793(89)80907-X; HATA A, 1993, J BIOL CHEM, V268, P9122; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HORI Y, 1990, ONCOGENE, V5, P1201; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KELLEHER D, 1992, FEBS LETT, V301, P310, DOI 10.1016/0014-5793(92)80264-H; KHALIL RA, 1992, AM J PHYSIOL, V263, pC714, DOI 10.1152/ajpcell.1992.263.3.C714; KOMURO I, 1991, J BIOL CHEM, V266, P1265; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE HS, 1993, J BIOL CHEM, V268, P5255; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LONG CS, 1991, CELL REGUL, V2, P1081, DOI 10.1091/mbc.2.12.1081; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; MANSER E, 1992, J BIOL CHEM, V267, P16025; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MARTIN TFJ, 1991, PHARMACOL THERAPEUT, V49, P329, DOI 10.1016/0163-7258(91)90062-Q; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MATTER N, 1993, J BIOL CHEM, V268, P732; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P2602; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; NAGAI R, 1987, CIRC RES, V60, P692, DOI 10.1161/01.RES.60.5.692; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLSON EN, 1992, TRENDS CARDIOVAS MED, V2, P163, DOI 10.1016/1050-1738(92)90044-S; ORDAHL CP, 1992, CURR TOP DEV BIOL, V26, P145, DOI 10.1016/S0070-2153(08)60444-5; OTTE AP, 1992, CELL, V68, P1021, DOI 10.1016/0092-8674(92)90074-M; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PARKER TG, 1991, J VASC MED BIOL, V3, P38; PERLETTI G, 1991, BIOCHEM BIOPH RES CO, V181, P348, DOI 10.1016/S0006-291X(05)81425-1; RINDT H, 1993, J BIOL CHEM, V268, P5332; ROGUE P, 1990, J BIOL CHEM, V265, P4161; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SASSONECORSI P, 1986, TRENDS GENET, V2, P215, DOI 10.1016/0168-9525(86)90233-7; SCHLUTER KD, 1992, AM J PHYSIOL, V263, pH1739, DOI 10.1152/ajpheart.1992.263.6.H1739; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIMIZU N, 1992, NUCLEIC ACIDS RES, V20, P1793, DOI 10.1093/nar/20.7.1793; SHIMIZU N, 1992, MOL CELL BIOL, V12, P619, DOI 10.1128/MCB.12.2.619; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; SIMPSON PC, 1989, J MOL CELL CARDIOL, V21, P79, DOI 10.1016/0022-2828(89)90774-8; SIMPSON PC, 1991, MOL CELL BIOCHEM, V104, P35; SPRINGHORN JP, 1992, J BIOL CHEM, V267, P14360; SPUDICH A, 1992, CELL MOTIL CYTOSKEL, V22, P2502; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; VONHARSDORF R, 1993, CIRC RES, V72, P688, DOI 10.1161/01.RES.72.3.688; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WILLIAMS PM, 1991, MOL CELL BIOL, V11, P4959, DOI 10.1128/MCB.11.10.4959; WOOTEN AP, 1992, CELL, V298, P74; WOOTEN MW, 1992, FEBS LETT, V298, P74, DOI 10.1016/0014-5793(92)80025-C; WU JP, 1991, MOL ENDOCRINOL, V5, P1311, DOI 10.1210/mend-5-9-1311; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G	98	132	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3775	3782						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106422				2022-12-27	WOS:A1994MV63100094
J	MAHRENHOLZ, AM; YEH, CH; SHIVELY, JE; HEFTA, SA				MAHRENHOLZ, AM; YEH, CH; SHIVELY, JE; HEFTA, SA			MICROSEQUENCE AND MASS-SPECTRAL ANALYSIS OF NONSPECIFIC CROSS-REACTING ANTIGEN-160, A CD15-POSITIVE NEUTROPHIL MEMBRANE GLYCOPROTEIN - DEMONSTRATION OF IDENTITY WITH BILIARY GLYCOPROTEIN-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CARCINOEMBRYONIC ANTIGEN; MONOCLONAL-ANTIBODIES; CROSSREACTING ANTIGEN; ADHESION MOLECULES; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; GENE FAMILY; CDNA CLONE; CEA; PROTEINS	Sequence information was obtained from low picomole amounts of nonspecific cross-reacting antigen (NCA) 160 (M(r) 160,000), a granulocyte membrane glycoprotein. Following affinity purification and SDS-polyacrylamide gel electrophoresis, the protein was electrotransferred to nitrocellulose, digested with trypsin, and the peptides were isolated using capillary reversed-phase liquid chromatography. Analysis of these peptides by Edman microsequencing and mass spectrometry established that NCA-160 was identical to biliary glycoprotein I, a protein that we previously cloned from a human colon library (1). NCA-160 from human granulocytes is a CD15-positive glycoprotein belonging to the carcinoembryonic antigen family and possesses putative transmembrane and cytoplasmic domains. Previous efforts to characterize this antigen at the protein level were hampered by a blocked NH2 terminus. In this study, we confirmed 20% of the deduced amino acid sequence starting with approximately 50 pmol of sample. Carbohydrate structural data is also presented on a single N-linked oligosaccharide moiety located in the A' domain. The capillary high performance liquid chromatography techniques used here, as well as mass spectrometry, were essential for high sensitivity analysis of the blotted, digested glycoprotein.	CITY HOPE NATL MED CTR, BECKMAN RES INT, DIV IMMUNOL, 1450 E DUARTE RD, DUARTE, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope					NATIONAL CANCER INSTITUTE [P30CA033572, R01CA037808] Funding Source: NIH RePORTER; NCI NIH HHS [CA37808, CA33572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ARAKAWA F, 1990, BIOCHEM BIOPH RES CO, V166, P1063, DOI 10.1016/0006-291X(90)90975-S; AUDETTE M, 1987, MOL IMMUNOL, V24, P1177, DOI 10.1016/0161-5890(87)90164-7; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; BERLING B, 1990, CANCER RES, V50, P6534; BUCHEGGER F, 1984, INT J CANCER, V33, P643, DOI 10.1002/ijc.2910330515; BURLINGAME AL, 1992, ANAL CHEM, V64, pR467, DOI 10.1021/ac00036a025; BURTIN P, 1975, NATURE, V255, P714, DOI 10.1038/255714a0; DAVIS MT, 1992, PROTEIN SCI, V1, P935, DOI 10.1002/pro.5560010712; FORSYTH KD, 1989, EUR J IMMUNOL, V19, P1331, DOI 10.1002/eji.1830190727; HAWKE DH, 1985, ANAL BIOCHEM, V147, P315, DOI 10.1016/0003-2697(85)90278-7; HEFTA SA, 1990, J BIOL CHEM, V265, P8618; HINODA Y, 1989, P NATL ACAD SCI USA, V86, P1668; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; KUROKI M, 1989, INT J CANCER, V44, P208, DOI 10.1002/ijc.2910440204; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUSCH HG, 1990, FEBS LETT, V261, P405, DOI 10.1016/0014-5793(90)80603-G; MELNICK DA, 1985, J IMMUNOL, V134, P3346; NEUMAIER M, 1985, J IMMUNOL, V135, P3604; NEUMAIER M, 1988, J BIOL CHEM, V263, P3202; SAUTER SL, 1991, INFECT IMMUN, V59, P2485, DOI 10.1128/IAI.59.7.2485-2493.1991; SKUBITZ KM, 1987, J IMMUNOL, V139, P1631; STOCKS SC, 1990, BIOCHEM J, V268, P275, DOI 10.1042/bj2680275; SVENBERG T, 1976, INT J CANCER, V17, P588, DOI 10.1002/ijc.2910170506; von Kleist S, 1972, Proc Natl Acad Sci U S A, V69, P2492; WATT SM, 1991, BLOOD, V78, P63; WEBB JW, 1988, ANAL BIOCHEM, V169, P337, DOI 10.1016/0003-2697(88)90293-X; XU QY, 1988, ANAL BIOCHEM, V170, P19, DOI 10.1016/0003-2697(88)90084-X	28	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13015	13018						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8099907				2022-12-27	WOS:A1993LH55300002
J	MISRA, I; NARASIMHAN, C; MIZIORKO, HM				MISRA, I; NARASIMHAN, C; MIZIORKO, HM			AVIAN 3-HYDROXY-3-METHYLGLUTARYL-COA SYNTHASE - CHARACTERIZATION OF A RECOMBINANT CHOLESTEROGENIC ISOZYME AND DEMONSTRATION OF THE REQUIREMENT FOR A SULFHYDRYL FUNCTIONALITY IN FORMATION OF THE ACETYL-ENZYME REACTION INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHASE; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; LIVER; MITOCHONDRIAL; QUANTITATION; GENES; DNA	cDNA encoding avian liver hydroxymethylglutaryl-CoA synthase has been cloned into a pET vector, and the resulting expression plasmid has been used to transform Escherichia coli BL21 (DE3). Heterologous expression of hydroxymethylglutaryl-CoA synthase occurs upon growth of this bacterial strain in the presence of isopropyl-1-thio-beta-D-galactopyranoside, with the target enzyme representing over 20% of total cellular protein. Recombinant enzyme is soluble and stable in crude E. coli extracts, facilitating its isolation in homogeneous form. With respect to specific activity, acylation stoichiometry, K(m, Ac-CoA), and binding of a spin-labeled substrate analog, the recombinant enzyme is equivalent to avian enzyme, suggesting its utility for mechanistic and structural studies. Our earlier prediction that this avian cDNA encodes the cholestero-genic cytosolic isozyme is supported by a series of experimental observations. Upon SDS-polyacrylamide gel electrophoresis, the recombinant synthase exhibits mobility in agreement with the 57.6-kDa deduced molecular mass, which exceeds the 53-kDa estimate and experimental observation for the ketogenic mitochondrial isozyme. Activity of the recombinant synthase is stimulated by Mg2+, as predicted for the cholesterogenic cytosolic isozyme and in contrast to the inhibition observed for the mitochondrial isozyme. Although antibody prepared against avian mitochondrial synthase effectively detects both avian mitochondrial and recombinant synthases on Western blots, antibody prepared against rodent cytosolic synthase discriminates between the two proteins, sensitively detecting recombinant enzyme while reacting poorly with authentic mitochondrial enzyme. Directed mutagenesis of the recombinant synthase has been performed to produce a C129S variant, in which the sulfhydryl previously implicated in formation of the acetyl-S-enzyme reaction intermediate is replaced by a hydroxyl group. EPR measurements on the binary C129S-spin-labeled acyl-CoA complex demonstrate that the mutant's substrate binding site is unperturbed in comparison with wild-type protein. These data illustrate the utility of spin-labeled substrate analogs as tools to stringently evaluate the structural integrity of engineered proteins. C129S is catalytically inactive (10(5)-fold decrease in k(cat) despite retaining the ability to form noncovalent complexes with acetyl-CoA or a spin-labeled acetyl-CoA analog. The demonstrated failure of C129S to form a covalent acyl-O-enzyme species accounts for these observations; data derived from experiments performed with a C129G mutant confirm this conclusion. These results distinguish hydroxymethylglutaryl-CoA synthase from beta-ketoacyl thiolase. Although thiolase catalyzes a mechanistically related reaction, it does not significantly discriminate between sulfhydryl and hydroxyl functionalities in forming a covalent acyl-enzyme intermediate (Thompson, S., Mayerl, F., Peoples, O. P., Masamune, S., Sinskey, A. J., and Walsh, C. T. (1989) Biochemistry 28, 5735-5742).	MED COLL WISCONSIN, DEPT BIOCHEM, 8701 WATERTOWN PLANK RD, MILWAUKEE, WI 53226 USA	Medical College of Wisconsin					NCRR NIH HHS [RR01008] Funding Source: Medline; NIDDK NIH HHS [DK 21491] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021491, R37DK021491] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYTE J, 1990, P NATL ACAD SCI USA, V87, P3874, DOI 10.1073/pnas.87.10.3874; BERNERT JT, 1977, J BIOL CHEM, V252, P6736; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASALS N, 1992, BIOCHEM J, V283, P261, DOI 10.1042/bj2830261; CLINKENBEARD KD, 1975, J BIOL CHEM, V250, P3124; DEV IK, 1988, P NATL ACAD SCI USA, V85, P1472, DOI 10.1073/pnas.85.5.1472; GRAVES KL, 1992, BIOCHEMISTRY-US, V31, P10315, DOI 10.1021/bi00157a020; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KATTARCOOLEY PA, 1990, ARCH BIOCHEM BIOPHYS, V283, P523, DOI 10.1016/0003-9861(90)90677-Q; KLEANTHOUS C, 1984, BIOCHEM J, V223, P211, DOI 10.1042/bj2230211; Maniatis T., 1982, MOL CLONING; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MEHRABIAN M, 1986, J BIOL CHEM, V261, P6249; Miller J. H., 1972, EXPT MOL GENETICS, P431; MIZIORKO HM, 1977, J BIOL CHEM, V252, P1414; MIZIORKO HM, 1975, J BIOL CHEM, V250, P5768; MIZIORKO HM, 1979, BIOCHEMISTRY-US, V18, P399, DOI 10.1021/bi00570a001; MIZIORKO HM, 1985, J BIOL CHEM, V260, P3513; MIZIORKO HM, 1985, BIOCHEMISTRY-US, V24, P3174, DOI 10.1021/bi00334a015; MIZIORKO HM, 1990, J BIOL CHEM, V265, P9606; MIZIORKO HM, 1990, BIOCHIM BIOPHYS ACTA, V1041, P273, DOI 10.1016/0167-4838(90)90284-M; MIZIORKO HM, 1985, METHOD ENZYMOL, V110, P19; OMURA S, 1987, J ANTIBIOT, V40, P1356, DOI 10.7164/antibiotics.40.1356; PAZIRANDEH M, 1991, J BIOL CHEM, V266, P20946; QUANT PA, 1989, BIOCHEM J, V262, P159, DOI 10.1042/bj2620159; REED WD, 1975, J BIOL CHEM, V250, P3117; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schneider D. J., 1989, BIOL MAGN RESON, V8, P1; SMITH JR, 1988, J BIOL CHEM, V263, P18480; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMPSON S, 1989, BIOCHEMISTRY-US, V28, P5735, DOI 10.1021/bi00440a006; VOLLMER SH, 1988, BIOCHEMISTRY-US, V27, P4288, DOI 10.1021/bi00412a014; WEIDMAN SW, 1973, BIOCHEMISTRY-US, V12, P1874, DOI 10.1021/bi00734a006; WITKOWSKI A, 1992, J BIOL CHEM, V267, P18488; [No title captured]	38	46	48	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12129	12135						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8099358				2022-12-27	WOS:A1993LF28400099
J	DIRKSEN, WP; HAMPSON, RK; SUN, Q; ROTTMAN, FM				DIRKSEN, WP; HAMPSON, RK; SUN, Q; ROTTMAN, FM			A PURINE-RICH EXON SEQUENCE ENHANCES ALTERNATIVE SPLICING OF BOVINE GROWTH-HORMONE PRE-MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; GENE-EXPRESSION; VARIANT; PLACENTA	A previous study has demonstrated that deletion of a region within the last exon of bovine growth hormone (bGH) pre-mRNA results in almost complete retention of the upstream intron (Hampson, R. K., LaFollette, L., and Rottman, F. M. (1989) Mol. Cell Biol. 9, 1604-1610), We now demonstrate that insertion of a simple purine-rich element (GGAAG), which is present within the deleted region, activates intron splicing upon expression in transfected cells. Moreover, several repeats of the GGAA(G) sequence restore splicing to near wild-type levels and direct the binding of a factor present in HeLa cell nuclear extracts. Mutation of the 5'-splice site toward U1 small nuclear RNA complementarity eliminates dependence on the downstream exon sequence for splicing. These results support a model for alternative intron retention in which purine-rich sequences function as part of an ''exonic splicing enhancer'' to complement a weak 5'-splice site and thereby facilitate intron removal. As a result, the majority of bGH mRNA is processed to remove intron D while still allowing a fraction of bGH mRNA containing the intact intron to reach the cytoplasm.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, CLEVELAND, OH 44106 USA	Case Western Reserve University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032770] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32770] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; COOKE NE, 1988, J BIOL CHEM, V263, P9001; CRABTREE GR, 1982, CELL, V31, P159, DOI 10.1016/0092-8674(82)90415-9; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HAMPSON RK, 1987, P NATL ACAD SCI USA, V84, P2673, DOI 10.1073/pnas.84.9.2673; HAMPSON RK, 1989, MOL CELL BIOL, V9, P1604, DOI 10.1128/MCB.9.4.1604; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; KAKIZUKA A, 1990, J BIOL CHEM, V265, P10102; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LIEBHABER SA, 1989, J CLIN INVEST, V83, P1985, DOI 10.1172/JCI114108; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; McKeown M, 1990, Genet Eng (N Y), V12, P139; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; Sambrook J, 1989, MOL CLONING LABORATO; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STERNER DA, 1993, MOL CELL BIOL, V13, P2677, DOI 10.1128/MCB.13.5.2677; SUN Q, 1993, J BIOL CHEM, V268, P15659; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WEIL D, 1990, MOL CELL BIOL, V10, P5865, DOI 10.1128/MCB.10.11.5865; WOYCHIK RP, 1984, P NATL ACAD SCI-BIOL, V81, P3944, DOI 10.1073/pnas.81.13.3944; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	25	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6431	6436						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119993				2022-12-27	WOS:A1994MZ50300029
J	DONG, AC; CAUGHEY, WS; DUCLOS, TW				DONG, AC; CAUGHEY, WS; DUCLOS, TW			EFFECTS OF CALCIUM, MAGNESIUM, AND PHOSPHORYLCHOLINE ON SECONDARY STRUCTURES OF HUMAN C-REACTIVE PROTEIN AND SERUM AMYLOID-P COMPONENT OBSERVED BY INFRARED-SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER FEMALE PROTEIN; SYRIAN-HAMSTER; AMIDE-I; BINDING-PROTEIN; PURPLE MEMBRANE; SPECTRA; WATER; RESOLUTION; PENTRAXIN; HISTONES	The secondary structures of human C-reactive protein (CRP) and serum amyloid P component (SAP) in D2O-based solutions in the presence or absence of calcium, magnesium, and phosphorylcholine have been investigated using Fourier transform infrared spectroscopy. Quantitative analysis provided estimations of about 50% beta-sheet, 12% alpha-helix, 24% beta-turn, and 14% unordered structure for CRP and about 54% beta-sheet, 12% alpha-helix, 25% beta-turn, and 9% unordered structure for SAP. With both proteins significant calcium dependent changes were observed in conformation-sensitive amide I regions assigned to each type of structure. The CRP spectrum was also affected by magnesium, but the changes differed from those induced by calcium. The SAP spectrum was not affected by magnesium. Phosphorylcholine in the presence of calcium also affected the spectrum of CRP but not the spectrum of SAP, Our present study provides the first direct comparison of the secondary structures of the pentraxins human CRP and SAP and hamster female protein (Dong, A., Caughey, B., Caughey, W. S., Bhat, K. S., and Coe, J. E. (1992) Biochemistry 32, 9364-9370), These findings suggest that the three pentraxins have similar secondary structure compositions and calcium dependent conformational changes, but differ significantly in their responses to phosphorylcholine and magnesium. Such properties are expected to be relevant to the incompletely understood roles of these highly conserved proteins including binding to nuclear proteins, complement activation, and association with amyloids,	COLORADO STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,FT COLLINS,CO 80523; VET ADM MED CTR,DEPT MED,ALBUQUERQUE,NM 87108; UNIV NEW MEXICO,ALBUQUERQUE,NM 87108	Colorado State University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of New Mexico					PHS HHS [A128358] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARRONDO JLR, 1988, BIOCHIM BIOPHYS ACTA, V952, P261, DOI 10.1016/0167-4838(88)90125-2; BANDEKAR J, 1992, BIOCHIM BIOPHYS ACTA, V1120, P123, DOI 10.1016/0167-4838(92)90261-B; BLADEN HA, 1966, J ULTRA MOL STRUCT R, V14, P449, DOI 10.1016/S0022-5320(66)80075-8; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CASAL HL, 1988, BIOCHIM BIOPHYS ACTA, V957, P11, DOI 10.1016/0167-4838(88)90152-5; CATHCART ES, 1965, NEW ENGL J MED, V273, P143, DOI 10.1056/NEJM196507152730306; CHIRGADZE YN, 1975, BIOPOLYMERS, V14, P679, DOI 10.1002/bip.1975.360140402; CHIRGADZE YN, 1976, BIOPOLYMERS, V15, P607, DOI 10.1002/bip.1976.360150402; COE JE, 1983, CONTEMP TOP MOLEC IM, V9, P211; COE JE, 1990, J EXP MED, V171, P1257, DOI 10.1084/jem.171.4.1257; COE JE, 1985, J CLIN INVEST, V76, P66, DOI 10.1172/JCI111978; COE JE, 1983, J EXP MED, V157, P1421, DOI 10.1084/jem.157.5.1421; COE JE, 1981, J EXP MED, V153, P977, DOI 10.1084/jem.153.4.977; DONG A, 1992, BIOCHEMISTRY-US, V31, P182, DOI 10.1021/bi00116a027; DONG A, 1992, BIOCHEMISTRY-US, V31, P9364, DOI 10.1021/bi00154a006; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; DONG AC, 1994, METHOD ENZYMOL, V232, P139; DOUSSEAU F, 1990, BIOCHEMISTRY-US, V29, P8771, DOI 10.1021/bi00489a038; DOWTON SB, 1991, BIOCHEMISTRY-US, V30, P9531, DOI 10.1021/bi00103a021; DUCLOS TW, 1988, J IMMUNOL, V141, P4266; DUCLOS TW, 1991, J BIOL CHEM, V266, P2167; DUCLOS TW, 1989, J IMMUNOL, V143, P2553; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; ETLINGER HM, 1986, INT ARCH ALLER A IMM, V81, P189, DOI 10.1159/000234132; GOTSCHLICH EC, 1967, P NATL ACAD SCI USA, V57, P706, DOI 10.1073/pnas.57.3.706; HARIS PI, 1988, BIOCHIM BIOPHYS ACTA, V943, P375, DOI 10.1016/0005-2736(88)90571-8; HICKS PS, 1992, J IMMUNOL, V149, P3689; HOLLOWAY PW, 1989, BIOCHEMISTRY-US, V28, P931, DOI 10.1021/bi00429a002; HOOKER TM, 1970, BIOPOLYMERS, V9, P1319, DOI 10.1002/bip.1970.360091104; KALB AJ, 1968, BIOCHEM J, V109, P669, DOI 10.1042/bj1090669; KAPLAN MH, 1974, J IMMUNOL, V112, P2135; KENNEDY DF, 1991, BIOCHEMISTRY-US, V30, P6541, DOI 10.1021/bi00240a026; KILPATRICK JM, 1982, MOL IMMUNOL, V19, P1159, DOI 10.1016/0161-5890(82)90326-1; KINOSHITA CM, 1992, PROTEIN SCI, V1, P700, DOI 10.1002/pro.5560010602; KINOSHITA CM, 1989, BIOCHEMISTRY-US, V28, P9840, DOI 10.1021/bi00451a044; KOENIG JL, 1980, NATO ADV STUDY I C, V57, P241; Kretsinger R.H., 1991, NOVEL CALCIUM BINDIN, P17; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; KRIMM S, 1982, SCIENCE, V216, P407, DOI 10.1126/science.6280277; LEE DC, 1990, BIOCHEMISTRY-US, V29, P9185, DOI 10.1021/bi00491a012; LIU TY, 1982, ANN NY ACAD SCI, V389, P151, DOI 10.1111/j.1749-6632.1982.tb22133.x; MANNING MC, 1989, BIOCHEMISTRY-US, V28, P8609, DOI 10.1021/bi00447a051; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MIYAZAWA T, 1961, J AM CHEM SOC, V83, P712, DOI 10.1021/ja01464a042; Moore C., 1993, CHEMTRACTS BIOCH MOL, V4, P67; NGUYEN NY, 1986, J BIOL CHEM, V261, P456; NGUYEN NY, 1986, J BIOL CHEM, V261, P450; OSMAND AP, 1977, P NATL ACAD SCI USA, V74, P739, DOI 10.1073/pnas.74.2.739; PAINTER RH, 1982, ANN NY ACAD SCI, V389, P199, DOI 10.1111/j.1749-6632.1982.tb22138.x; PARKER FS, 1983, APPLICATIONS INFRARE; PEPYS MB, 1977, LANCET, V1, P1029; PEPYS MB, 1987, BIOCHEM BIOPH RES CO, V148, P308, DOI 10.1016/0006-291X(87)91111-9; PEPYS MB, 1993, 7TH INT S AM; PRESTRELSKI SJ, 1991, BIOCHEMISTRY-US, V30, P133, DOI 10.1021/bi00215a020; ROBEY FA, 1984, J BIOL CHEM, V259, P7311; ROTHSCHILD KJ, 1979, BIOPHYS J, V25, P473, DOI 10.1016/S0006-3495(79)85317-5; SARVER RW, 1991, ANAL BIOCHEM, V194, P89, DOI 10.1016/0003-2697(91)90155-M; SAVITZKY A, 1964, ANAL CHEM, V36, P1628; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; SUSI H, 1986, METHOD ENZYMOL, V130, P290; SUSI H, 1987, ARCH BIOCHEM BIOPHYS, V258, P465, DOI 10.1016/0003-9861(87)90367-5; VOLANAKIS JE, 1981, J EXP MED, V153, P1604, DOI 10.1084/jem.153.6.1604; WHITEHEAD AS, 1990, BIOCHEM J, V266, P283, DOI 10.1042/bj2660283; WOO P, 1985, J BIOL CHEM, V260, P3384; YOUNG NM, 1978, J IMMUNOL, V121, P1893	67	35	37	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6424	6430						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119992				2022-12-27	WOS:A1994MZ50300028
J	CASTELLO, A; RODRIQUEZMANZANEQUE, JC; CAMPS, M; PEREZCASTILLO, A; TESTAR, X; PALACIN, M; SANTOS, A; ZORZANO, A				CASTELLO, A; RODRIQUEZMANZANEQUE, JC; CAMPS, M; PEREZCASTILLO, A; TESTAR, X; PALACIN, M; SANTOS, A; ZORZANO, A			PERINATAL HYPOTHYROIDISM IMPAIRS THE NORMAL TRANSITION OF GLUT4 AND GLUT1 GLUCOSE TRANSPORTERS FROM FETAL TO NEONATAL LEVELS IN HEART AND BROWN ADIPOSE-TISSUE - EVIDENCE FOR TISSUE-SPECIFIC REGULATION OF GLUT4 EXPRESSION BY THYROID-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-INDUCED TRANSLOCATION; MESSENGER-RIBONUCLEIC-ACID; RAT SKELETAL-MUSCLE; RETINOIC ACID; GENE-EXPRESSION; SOLEUS MUSCLE; DEVELOPMENTAL REGULATION; MATERNAL HYPOTHYROIDISM; NUCLEAR RECEPTORS; WHITE MUSCLE	GLUT1 and GLUT4 glucose transporter expression is highly regulated in muscle and adipose tissue during perinatal life. Here we have investigated the role of thyroid hormones in the regulation of GLUT4 induction and GLUT1 repression associated to neonatal development. Perinatal hypothyroidism markedly impaired GLUT4 protein induction in heart. This effect was heart specific, and a greater expression of GLUT4 was detected in brown adipose tissue from neonatal hypothyroid rats compared with controls. These changes in GLUT4 protein expression were not detected in brown adipose tissue or heart when hypothyroidism was induced in adult rats. These results indicate that GLUT4 induction during perinatal life is highly sensitive to thyroid hormones in both heart and adipose tissue. Perinatal hypothyroidism was characterized by decreased cardiac GLUT4 mRNA concentrations. T-3 injection caused a marked increase in cardiac levels of GLUT4 mRNA in hypothyroid neonates. Thus, in 18-day-old hypothyroid rats, GLUT4 mRNA levels increased 3-fold 1 h after T-3 injection. Under these conditions, retinoic acid also caused a rapid increase in cardiac GLUT4 mRNA levels from hypothyroid neonates. In addition, cardiac levels of GLUT4 protein markedly increased in fetuses and in neonates 24 h after T-3 injection. These findings suggest that a direct effect of thyroid hormones is the promotion of cardiac GLUT4 gene expression. GLUT1 protein expression was markedly enhanced in brown adipose tissue and heart during neonatal hypothyroidism as well, as in hypothyroidism induced in adult rats. This was concomitant to greater levels of GLUT1 mRNA in hearts from hypothyroid neonates, Immunofluorescence analysis indicated that cardiomyocytes from hypothyroid pups contained an enhanced level of GLUT1 protein. Furthermore, T-3 injection caused a decrease in cardiac levels of GLUT1 mRNA in hypothyroid neonates. These results indicate that thyroid hormone manipulation leads to inverse regulation of GLUT1 and GLUT4 glucose transporter gene expression in the neonatal heart. We conclude that thyroid hormones play a pivotal role controlling the transition of glucose transporter carriers from fetal to neonatal levels in heart and brown adipose tissue.	UNIV BARCELONA, FAC BIOL, DEPT BIOQUIM & FISIOL, E-08028 BARCELONA, SPAIN; UNIV COMPLUTENSE MADRID, FAC MED, DEPT BIOQUIM & BIOL MOLEC, E-28040 MADRID, SPAIN; CSIC, INST INVEST BIOMED, E-28029 MADRID, SPAIN	University of Barcelona; Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Zorzano, Antonio/R-5479-2018; Palacín, Manuel/G-9786-2015; Rodriguez-Manzaneque, Juan Carlos/F-3899-2012; Farré, Anna Castelló/K-9637-2015; Perez-Castillo, Ana/A-9505-2015; Santos, Angel/K-3744-2014	Rodriguez-Manzaneque, Juan Carlos/0000-0001-5951-7029; Farré, Anna Castelló/0000-0001-8497-6251; Palacin, Manuel/0000-0002-8670-293X; Perez-Castillo, Ana/0000-0002-2632-5853; Santos, Angel/0000-0002-7551-8483				ARGENTIN S, 1987, BIOCHEM BIOPH RES CO, V146, P1336, DOI 10.1016/0006-291X(87)90796-0; BALDWIN KM, 1978, AM J PHYSIOL, V235, pC97, DOI 10.1152/ajpcell.1978.235.3.C97; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BLOCK NE, 1991, J CLIN INVEST, V88, P1546, DOI 10.1172/JCI115465; BORNEMANN A, 1992, DIABETES, V41, P215, DOI 10.2337/diabetes.41.2.215; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CAMPS L, 1991, J LIPID RES, V32, P1877; CAMPS M, 1992, BIOCHEM J, V282, P765, DOI 10.1042/bj2820765; CASLA A, 1990, BIOCHEM BIOPH RES CO, V171, P182, DOI 10.1016/0006-291X(90)91374-2; CASTELLO A, 1993, J BIOL CHEM, V268, P14998; CHIZZONITE RA, 1984, J BIOL CHEM, V259, P2628; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK CM, 1971, AM J PHYSIOL, V220, P583; CODERRE L, 1992, ENDOCRINOLOGY, V131, P1821, DOI 10.1210/en.131.4.1821; DEESCOBAR GM, 1985, ENDOCRINOLOGY, V117, P1890, DOI 10.1210/endo-117-5-1890; DEONA CR, 1991, ENDOCRINOLOGY, V128, P422, DOI 10.1210/endo-128-1-422; DOUEN AG, 1990, FEBS LETT, V261, P256, DOI 10.1016/0014-5793(90)80566-2; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; FLIER JS, 1987, J CLIN INVEST, V79, P657, DOI 10.1172/JCI112864; FREAKE HC, 1987, P NATL ACAD SCI USA, V84, P3070, DOI 10.1073/pnas.84.9.3070; FRIEDMAN JE, 1991, DIABETES, V40, P150, DOI 10.2337/diabetes.40.1.150; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GUMA A, 1992, FEBS LETT, V310, P51, DOI 10.1016/0014-5793(92)81144-B; GUSTAFSON TA, 1987, P NATL ACAD SCI USA, V84, P3122, DOI 10.1073/pnas.84.10.3122; HENRIKSEN EJ, 1991, J APPL PHYSIOL, V70, P2322, DOI 10.1152/jappl.1991.70.5.2322; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KLIP A, 1992, J CELL BIOCHEM, V48, P51, DOI 10.1002/jcb.240480109; KURUVILLA AK, 1991, BIOCHIM BIOPHYS ACTA, V1094, P300, DOI 10.1016/0167-4889(91)90090-K; LADENSON PW, 1988, ENDOCRINOLOGY, V123, P652, DOI 10.1210/endo-123-1-652; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGAI R, 1989, P NATL ACAD SCI USA, V86, P2966, DOI 10.1073/pnas.86.8.2966; NATAF B, 1961, CR SOC BIOL, V155, P1235; ONTELL M, 1984, AM J ANAT, V171, P133, DOI 10.1002/aja.1001710202; ONTELL M, 1988, AM J ANAT, V181, P279, DOI 10.1002/aja.1001810306; PEREZCASTILLO A, 1985, ENDOCRINOLOGY, V117, P2457, DOI 10.1210/endo-117-6-2457; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PIPAON C, 1992, J BIOL CHEM, V267, P21, DOI 10.1016/S0021-9258(18)48449-9; PRACYK JB, 1992, J PHARMACOL EXP THER, V261, P951; ROHRER D, 1988, J BIOL CHEM, V263, P6941; Rosen K., 1990, FOCUS, V12, P23; SANTALUCIA T, 1992, ENDOCRINOLOGY, V130, P837, DOI 10.1210/en.130.2.837; SUGIE H, 1985, MUSCLE NERVE, V8, P654, DOI 10.1002/mus.880080805; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WANG C, 1985, P NATL ACAD SCI USA, V82, P3621, DOI 10.1073/pnas.82.11.3621; WEINSTEIN SP, 1992, BIOCHIM BIOPHYS ACTA, V1136, P302, DOI 10.1016/0167-4889(92)90121-Q; WEINSTEIN SP, 1991, ENDOCRINOLOGY, V129, P455, DOI 10.1210/endo-129-1-455; WEINSTEIN SP, 1990, ENDOCRINOLOGY, V126, P1421, DOI 10.1210/endo-126-3-1421; WERNER H, 1989, MOL ENDOCRINOL, V3, P273, DOI 10.1210/mend-3-2-273; WRUTNIAK C, 1983, J ENDOCRINOL, V99, P233, DOI 10.1677/joe.0.0990233; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	59	98	98	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5905	5912						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119934				2022-12-27	WOS:A1994MY84000066
J	CHAN, YL; OLVERA, J; GLUCK, A; WOOL, IG				CHAN, YL; OLVERA, J; GLUCK, A; WOOL, IG			A LEUCINE ZIPPER-LIKE MOTIF AND A BASIC REGION-LEUCINE ZIPPER-LIKE ELEMENT IN RAT RIBOSOMAL-PROTEIN L13A - IDENTIFICATION OF THE TUM(-) TRANSPLANTATION ANTIGEN P198	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAINS; SACCHAROMYCES-CEREVISIAE; HYPOTHETICAL STRUCTURE; AMINO-ACIDS; SEQUENCE; FAMILY; RNA; RECOGNITION; REPEATS; MODEL	The amino acid sequence of the rat 60 S ribosomal subunit protein L13a was deduced from the sequence of nucleotides in two recombinant cDNAs. Mature ribosomal protein L13a has 202 amino acids (the NH2-terminal methionine is removed after translation of the mRNA) and a M(r) of 23,330. Hybridization of the L13a cDNA to digests of nuclear DNA suggests that there are 9-11 copies of the L13a gene. The mRNA for the protein is similar to 800 nucleotides in length. Rat L13a is related to the Saccharomyces cerevisiae ribosomal proteins that have been provisionally designated rp22 and rp23 and to the eubacterial and archaebacterial family of L13 ribosomal proteins. The mouse tum(-) transplantation antigen P198 is a mutant of the mouse homolog of rat ribosomal protein L13a. Rat ribosomal protein L7 has, at its NH2 terminus, five tandem repeats of a similar sequence of 12 amino acids (Lin, A., Chan, Y. L., McNally, J., Peleg, D., Meyuhas, O., and Wool, I. G. (1987) J. Biol. Chem. 262, 12665-12671); L13a has, in its carboxyl-terminal region, amino acid sequences with significant identity to L7 repeats 1, 3, and 5. L13a also has a number of short amino acid sequences that are repeated, a leucine zipper-like moth at its NH2 terminus, and a potential basic region-leucine zipper element in its carboxyl-terminal region.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	University of Chicago					NIGMS NIH HHS [GM-21769] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021769] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHAN YL, 1987, J BIOL CHEM, V262, P12879; CHAN YL, 1990, ARCH BIOCHEM BIOPHYS, V283, P546, DOI 10.1016/0003-9861(90)90682-O; CHAN YL, 1993, NUCLEIC ACIDS RES, V21, P649, DOI 10.1093/nar/21.3.649; CHAN YL, 1988, J BIOL CHEM, V263, P2891; COLLATZ E, 1976, J BIOL CHEM, V251, P1808; DAYHOFF MO, 1978, ATLAS PROTEIN SEQUEN, V5, P1; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GLUCK A, 1989, EUR J BIOCHEM, V182, P105, DOI 10.1111/j.1432-1033.1989.tb14805.x; GONGADZE GM, 1986, FEBS LETT, V197, P74, DOI 10.1016/0014-5793(86)80301-5; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HEMMERICH P, 1993, NUCLEIC ACIDS RES, V21, P223, DOI 10.1093/nar/21.2.223; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KROMER WJ, 1991, J BIOL CHEM, V266, P24573; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIN A, 1987, J BIOL CHEM, V262, P12665; MATHESON AT, 1990, RIBOSOME, P617; MEYUHAS O, 1990, J BIOL CHEM, V265, P11465; MIZUTA K, 1992, NUCLEIC ACIDS RES, V20, P1011, DOI 10.1093/nar/20.5.1011; NIERHAUS KH, 1980, RIBOSOMES STRUCTURE, P267; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RICE PA, 1989, NUCLEIC ACIDS RES, V17, P3757, DOI 10.1093/nar/17.10.3757; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; SUZUKI K, 1993, J BIOL CHEM, V268, P2755; SZYMKOWSKI DE, 1989, NUCLEIC ACIDS RES, V17, P5393, DOI 10.1093/nar/17.13.5393; TAKAKURA H, 1992, J BIOL CHEM, V267, P5442; TSURUGI K, 1978, J BIOL CHEM, V253, P946; TSURUGI K, 1991, BIOCHEM BIOPH RES CO, V174, P1318, DOI 10.1016/0006-291X(91)91566-U; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1992, NEW BIOL, V4, P396; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WITTMANNLIEBOLD B, 1984, MOL GEN GENET, V196, P439, DOI 10.1007/BF00436191; WITTMANNLIEBOLD B, 1984, ADV PROTEIN CHEM, V36, P56; WOOL IG, 1993, TRANSLATIONAL APPARATUS, P727; WOOL IG, 1990, RIBOSOME, P203; WOOL IG, 1991, BIOCHIMIE, V73, P861, DOI 10.1016/0300-9084(91)90127-M; Woolford Jr JL, 1991, MOL CELLULAR BIOL YE, P587	48	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5589	5594						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119894				2022-12-27	WOS:A1994MY84000021
J	ERNST, TJ; SLATTERY, KE; GRIFFIN, JD				ERNST, TJ; SLATTERY, KE; GRIFFIN, JD			P210(BCR/ABL) AND P160(V-ABL) INDUCE AN INCREASE IN THE TYROSINE PHOSPHORYLATION OF P93(C-FES)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; FUJINAMI SARCOMA-VIRUS; V-ABL; C-FPS; PROTEIN-KINASE; CELL-LINE; ONCOGENE PRODUCTS; TRANSGENIC MICE; FES LOCUS; EXPRESSION	Chronic myelogenous leukemia is caused by a reciprocal chromosomal translocation of human chromosomes 9 and 22. The resulting fusion protein, p210(Bcr/Abl), has enhanced tyrosine kinase activity compared with the normal cellular homologue, p145(c-Abl). Expression of this chimeric protein in hematopoietic cell lines results in a rapid progression to growth factor independence and increased tyrosine phosphorylation of a number of unidentified cellular proteins. In this study, we show that the phosphorylation state of the hematopoietically restricted tyrosine kinase, p93(c-Fes), is increased. Increased phosphorylation of p93(c-Fes) was detected in p210(Bcr/Abl)(+) human leukemic cell lines, in primary leukemic cells from patients with chronic myelogenous leukemia, and in myeloid cell lines expressing p210(Bcr/Abl) after transfection. Furthermore, p93(c-Fes) phosphorylation was increased by p210(Bcr/Abl) even when coexpressed in NIH 3T3 fibroblasts. v-abl expression was also found to increase the tyrosine phosphorylation of p93(c-Fes) This increased phosphorylation was found to be accompanied by an increase in the ability of p93(c-Fes) to phosphorylate exogenous substrates. p93(c-Fes) could contribute to the transforming activity of the abl oncogenes.			ERNST, TJ (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,44 BINNEY ST,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [P01CA034183] Funding Source: NIH RePORTER; NCI NIH HHS [CA34183] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; CANNISTRA SA, 1985, BLOOD, V65, P414; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; DRUKER B, 1992, BLOOD, V79, P2215; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FRANCHINI G, 1981, NATURE, V290, P154, DOI 10.1038/290154a0; FUKUI Y, 1989, ONCOGENE RES, V4, P283; Gishizky M L, 1992, Curr Top Microbiol Immunol, V182, P65; Goldman J M, 1990, Curr Opin Oncol, V2, P49; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GREER P, 1990, MOL CELL BIOL, V10, P2521, DOI 10.1128/MCB.10.6.2521; GROFFEN J, 1983, VIROLOGY, V125, P480, DOI 10.1016/0042-6822(83)90219-2; HAMMOND CI, 1985, VIROLOGY, V143, P300, DOI 10.1016/0042-6822(85)90117-5; HANAZONO Y, 1993, BLOOD, V81, P3193; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAYNES JR, 1988, MOL CELL BIOL, V8, P2419, DOI 10.1128/MCB.8.6.2419; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MATHEYPREVOT B, 1988, MOL CELL BIOL, V8, P234, DOI 10.1128/MCB.8.1.234; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MECKLING GK, 1992, BIOCHIM BIOPHYS ACTA, V1137, P65; MOSS P, 1984, J VIROL, V52, P557, DOI 10.1128/JVI.52.2.557-565.1984; OKUDA K, 1992, BLOOD, V79, P2880; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PIKE LJ, 1982, P NATL ACAD SCI-BIOL, V79, P1443, DOI 10.1073/pnas.79.5.1443; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; SODROSKI JG, 1984, P NATL ACAD SCI-BIOL, V81, P3039, DOI 10.1073/pnas.81.10.3039; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WOOLFORD J, 1984, VIROLOGY, V135, P168, DOI 10.1016/0042-6822(84)90127-2; YEE SP, 1989, MOL CELL BIOL, V9, P5491, DOI 10.1128/MCB.9.12.5491; YOUNG JC, 1984, J VIROL, V52, P913, DOI 10.1128/JVI.52.3.913-918.1984	48	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5764	5769						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119916				2022-12-27	WOS:A1994MY84000046
J	JHUN, BH; MEINKOTH, JL; LEITNER, JW; DRAZNIN, B; OLEFSKY, JM				JHUN, BH; MEINKOTH, JL; LEITNER, JW; DRAZNIN, B; OLEFSKY, JM			INSULIN AND INSULIN-LIKE GROWTH FACTOR-I SIGNAL-TRANSDUCTION REQUIRES P21(RAS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; MAP KINASE; GENE-EXPRESSION; PC12 CELLS; H-RAS; PROTEIN; RECEPTOR; MICROINJECTION; STIMULATION; ACTIVATION	We have investigated the role of cellular p21(ras) protein in insulin and insulin-like growth factor-I (IGF-I) signaling pathways. Insulin stimulation increased Ras-GTP formation in Rat-1 fibroblasts overexpressing normal human insulin receptors (HIRc-B), far greater than in parental Rat-1 fibroblasts, indicating that competent insulin receptors mediate this response, Cellular microinjection of a dominant-negative mutant p21(ras) protein (N17 ras) or anti-pa21(ras) monoclonal antibody (Y13-259) into HIRc-B cells reduced insulin- and IGF-I-stimulated DNA synthesis by 75-90%. Insulin-induced c-fos protein expression was also inhibited by 74%. Microinjection of oncogenic p2l(ras) (T-24 ras) into HIRc-B cells activated the mitogenic pathway, and coinjection of N17 ras and T-24 ras showed that oncogenic p21(ras) rescued the cells from the N17 ras blockade. This later finding indicates that T-24 ras acts downstream of N17 ras. In conclusion, 1) microinjection of a dominant interferring ras mutant into quiescent cells abrogated subsequent insulin and IGF-I mitogenic signaling; 2) oncogenic ras protein rescued cells from the N17 ras blockade, indicating that T24 ras action is downstream of the site of N17 inhibition; and 3) p21(ras) is an intermediate signaling molecule in the insulin/IGF-I signal transduction pathway and is required for gene expression and DNA synthesis.	UNIV CALIF SAN DIEGO,CTR CANC,DEPT MED 9111G,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; VET ADM MED CTR,SAN DIEGO,CA 92161; VET ADM MED CTR,DEPT MED,DENVER,CO 80220	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)			Meinkoth, Judy L/G-2900-2010		NIDDK NIH HHS [DK33651] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, R01DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; CHOU CK, 1987, J BIOL CHEM, V262, P1842; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FEIG LA, 1988, MOL CELL BIOL, V8, P3255; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FERAMISCO JR, 1979, P NATL ACAD SCI USA, V76, P3967, DOI 10.1073/pnas.76.8.3967; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; MAASSEN JA, 1992, HORM METAB RES, V24, P214, DOI 10.1055/s-2007-1003296; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; OSTEROP APRM, 1992, J BIOL CHEM, V267, P14647; PORRAS A, 1992, J BIOL CHEM, V267, P21124; RAPP UR, 1991, ONCOGENE, V6, P495; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	39	68	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5699	5704						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119907				2022-12-27	WOS:A1994MY84000036
J	POLANS, AS; PALCZEWSKI, K; ASSONBATRES, MA; OHGURO, H; WITKOWSKA, D; HALEY, TL; BAIZER, L; CRABB, JW				POLANS, AS; PALCZEWSKI, K; ASSONBATRES, MA; OHGURO, H; WITKOWSKA, D; HALEY, TL; BAIZER, L; CRABB, JW			PURIFICATION AND PRIMARY STRUCTURE OF CAPL, AN S-100-RELATED CALCIUM-BINDING PROTEIN ISOLATED FROM BOVINE RETINA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED MOUSE CELLS; MESSENGER-RNA; GROWTH-FACTOR; MOLECULAR-CLONING; NEURITE EXTENSION; EPITHELIAL-CELLS; CYCLIC-GMP; BRAIN; GENE; EXPRESSION	Calcium protein placental homolog (Capl) is an S-100-related calcium-binding protein selectively expressed in cell lines that have been induced to grow or differentiate. In addition, the expression of Capl correlates with the induction of the metastatic phenotype in tumor cell lines and the transformation of normal cells by activated oncogenes or chemical carcinogens. Although not previously associated with the nervous system, in this study, Capl was purified from bovine neural retina by a combination of phenyl-Sepharose and organomercurial chromatography. The complete amino acid sequence of bovine Capl was established primarily by Edman degradation of peptides generated by cleavage of methionyl, lysyl, glutamyl, and aspartyl bonds. NH2-terminal methionyl and aspartyl peptides were analyzed by tandem mass spectrometry, which provided the sequence of the first 8 residues and identified the NH2-terminal blocking group as an acetyl moiety. The molecular mass of the intact protein determined by electrospray mass spectrometry (M(r) = 11,716.75 +/- 0.42) and the calculated molecular mass deduced from the amino acid composition (M(r) = 11,718) were in agreement, thus supporting the accuracy of the sequence assignment. Capl isolated from the retina was shown to be indistinguishable by mass and immunochemical. properties from its counterpart in the bovine aorta, which previously was the only source of purified Capl, Northern analysis using cloned Capl cDNA revealed that Capl mRNA is present not only in the retina but the choroid as well. Further support for choroidal localization came from immunohistochemical experiments using specific anti-Capl antibodies. The physiological significance of Capl in ocular tissues and the aorta is discussed.	GOOD SAMARITAN HOSP,DEPT OPHTHALMOL,PORTLAND,OR 97209; UNIV WASHINGTON,DEPT OPHTHALMOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	POLANS, AS (corresponding author), GOOD SAMARITAN HOSP,RS DOW NEUROL SCI INST,1120 NW 20TH AVE,PORTLAND,OR 97209, USA.		Witkowska, Danuta/O-3951-2019	Witkowska, Danuta/0000-0003-3494-8724	NATIONAL EYE INSTITUTE [R29EY007089, R01EY007089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038639] Funding Source: NIH RePORTER; NEI NIH HHS [EY07089, EY06603] Funding Source: Medline; NIDDK NIH HHS [DK38639] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V12, P8097, DOI 10.1093/nar/12.21.8097; BARRACLOUGH R, 1982, EUR J BIOCHEM, V129, P335, DOI 10.1111/j.1432-1033.1982.tb07056.x; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BRUNS GAP, 1989, CYTOGENET CELL GENET, V51, P67, DOI 10.1159/000132781; CAI L, 1990, J PROTEIN CHEM, V9, P623, DOI 10.1007/BF01025016; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; CRABB JW, 1986, BIOCHEMISTRY-US, V25, P4988, DOI 10.1021/bi00366a003; CRABB JW, 1988, J BIOL CHEM, V263, P16674; DAVIES BR, 1993, ONCOGENE, V8, P999; DAYHOFF MO, 1969, ATLAS PROTEIN SEQUEN, P75; DEVOUGE MW, 1992, ONCOGENE, V7, P109; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DORIN JR, 1990, GENOMICS, V8, P420, DOI 10.1016/0888-7543(90)90027-R; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; ENGELKAMP D, 1992, BIOCHEMISTRY-US, V31, P10258, DOI 10.1021/bi00157a012; ENGELKAMP D, 1993, P NATL ACAD SCI USA, V90, P6547, DOI 10.1073/pnas.90.14.6547; GERKE V, 1991, NOVEL CALCIUM BINDIN, P139; GEYSEN HM, 1985, P NATL ACAD SCI USA, V82, P178, DOI 10.1073/pnas.82.1.178; GHOSE T, 1990, CANCER RES, V50, P3737; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; HILT DC, 1991, NOVEL CALCIUM BINDIN, P65; HIRSCHHORN RR, 1984, P NATL ACAD SCI-BIOL, V81, P6004, DOI 10.1073/pnas.81.19.6004; ISOBE T, 1981, EUR J BIOCHEM, V116, P79, DOI 10.1111/j.1432-1033.1981.tb05303.x; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KINCAID RL, 1987, METHOD ENZYMOL, V139, P3, DOI 10.1016/0076-6879(87)39070-6; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; KORETSUNE Y, 1990, CIRCULATION, V82, P528, DOI 10.1161/01.CIR.82.2.528; Kretsinger R.H., 1991, NOVEL CALCIUM BINDIN, P17; Kretsinger RH, 1975, CALCIUM TRANSPORT CO, P469; LEREA CL, 1989, NEURON, V3, P367, DOI 10.1016/0896-6273(89)90261-4; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; NAGAO S, 1987, BIOCHEMISTRY-US, V26, P1659, DOI 10.1021/bi00380a026; NAKANO A, 1992, BIOCHEM BIOPH RES CO, V186, P1207, DOI 10.1016/S0006-291X(05)81534-7; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PALCZEWSKI K, 1991, J BIOL CHEM, V266; PASTEELS B, 1990, VISUAL NEUROSCI, V5, P1, DOI 10.1017/S0952523800000031; POCHET R, 1991, J COMP NEUROL, V314, P750, DOI 10.1002/cne.903140408; POLANS AS, 1988, INVEST OPHTH VIS SCI, V29, P1523; POLANS AS, 1993, INVEST OPHTH VIS SCI, V34, P81; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; POLANS AS, 1993, METH NEUROSCI, V15, P248; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; ROSEN KM, 1990, BIOTECHNIQUES, V8, P398; SANNA PP, 1990, NEUROSCI LETT, V118, P136, DOI 10.1016/0304-3940(90)90267-D; SANO T, 1991, CANCER RES, V51, P2926; SZENBENYI DME, 1981, NATURE, V294, P327; TAKAMATSU K, 1992, BRAIN RES, V571, P350, DOI 10.1016/0006-8993(92)90676-Z; TULCHINSKY EM, 1990, GENE, V87, P219, DOI 10.1016/0378-1119(90)90305-B; VIRCA GD, 1990, BIOTECHNIQUES, V8, P370; WATANABE Y, 1992, J BIOL CHEM, V267, P17136; WATANABE Y, 1992, ARCH BIOCHEM BIOPHYS, V292, P563, DOI 10.1016/0003-9861(92)90031-Q; WEST KA, 1992, TECHNIQUES PROTEIN C, V2, P233; WILKINSON M, 1991, ESSENTIAL MOL BIOL P, P69; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; WOLMAN SR, 1992, CANCER, V70, P1765, DOI 10.1002/1097-0142(19920915)70:4+<1765::AID-CNCR2820701618>3.0.CO;2-C; YAMAGATA K, 1990, NEURON, V2, P469	59	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6233	6240						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119967				2022-12-27	WOS:A1994MY84000111
J	ARRETZ, M; SCHNEIDER, H; GUIARD, B; BRUNNER, M; NEUPERT, W				ARRETZ, M; SCHNEIDER, H; GUIARD, B; BRUNNER, M; NEUPERT, W			CHARACTERIZATION OF THE MITOCHONDRIAL PROCESSING PEPTIDASE OF NEUROSPORA-CRASSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C REDUCTASE; YEAST MITOCHONDRIA; INTERMEMBRANE SPACE; PROTEIN IMPORT; ORNITHINE TRANSCARBAMYLASE; PROTEOLYTIC CLEAVAGE; PRECURSOR PROTEINS; TRANSLATION SYSTEM; TARGETING PEPTIDES; SENSITIVE METHOD	The mitochondrial processing peptidase (MPP) of Neurospora crassa is constituted by an alpha- and a beta-subunit. We have purified alpha-MPP after expression in Escherichia coli while beta-MPP was purified from mitochondria. A fusion protein between precytochrome b(2) and mouse dihydrofolate reductase was expressed in E. coli, and the purified protein was used as substrate for MPP. Both subunits of MPP are required for processing. MPP removes the matrix targeting signal of cytochrome b(2) by a single cut, and the resulting presequence peptide is 31 amino acid residues in length. It acts as a competitive inhibitor of processing but has a similar to 30-fold lower affinity for MPP than the preprotein. Competition assays show that MPP recognizes the COOH-terminal portion of the presequence of cytochrome b(2) rather than the NH2-terminal part which has the potential to form an amphiphilic helix. Substitution of arginine in position -2 of the matrix targeting sequence of cytochrome b(2) prevents processing but not import of a chimeric precursor. Substitution of the tyrosyl residue in position +1 also prevents processing, indicating that MPP interacts with sequences COOH-terminal to the cleavage site. Noncleavable preprotein is still recognized by MPP. Our data suggest that processing peptidase and import machinery recognize distinct structural elements in preproteins which, however, can be overlapping.	UNIV MUNICH,INST PHYSIOL CHEM,D-80336 MUNICH,GERMANY; UNIV PIERRE & MARIE CURIE,CNRS,CTR GENET MOLEC,F-91190 GIF SUR YVETTE,FRANCE	University of Munich; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay				Brunner, Michael/0000-0001-9798-3047				ARRETZ M, 1991, BIOMED BIOCHIM ACTA, V50, P403; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DAUM G, 1982, J BIOL CHEM, V257, P3028; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GELI V, 1990, J BIOL CHEM, V265, P19216; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; HORWICH AL, 1987, J CELL BIOL, V105, P669, DOI 10.1083/jcb.105.2.669; HURT EC, 1987, J BIOL CHEM, V262, P1420; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; KALOUSEK F, 1993, TRENDS BIOCHEM SCI, V18, P249, DOI 10.1016/0968-0004(93)90174-L; KALOUSEK F, 1988, P NATL ACAD SCI USA, V85, P7536, DOI 10.1073/pnas.85.20.7536; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; KOLL H, 1992, CELL, V68, P1163, DOI 10.1016/0092-8674(92)90086-R; NICHOLSON DW, 1988, PROTEIN TRANSFER ORG, P677; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; SCHULTE U, 1989, NATURE, V339, P147, DOI 10.1038/339147a0; Sebald W, 1979, Methods Enzymol, V55, P144; STUBER D, 1984, EMBO J, V3, P3143; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; YANG M, 1991, J BIOL CHEM, V266, P6416	41	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4959	4967						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106471				2022-12-27	WOS:A1994MX57100043
J	CHEETHAM, JJ; NIR, S; JOHNSON, E; FLANAGAN, TD; EPAND, RM				CHEETHAM, JJ; NIR, S; JOHNSON, E; FLANAGAN, TD; EPAND, RM			THE EFFECTS OF MEMBRANE PHYSICAL-PROPERTIES ON THE FUSION OF SENDAI VIRUS WITH HUMAN ERYTHROCYTE-GHOSTS AND LIPOSOMES - ANALYSIS OF KINETICS AND EXTENT OF FUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEXAGONAL PHASE; IMMUNODEFICIENCY-VIRUS; CHOLESTEROL SULFATE; ENVELOPED VIRUSES; CELLS; DESTABILIZATION; ACTIVATION; PROTEIN; MODEL; GLYCOPROTEINS	A number of amphiphiles which raise the bilayer to hexagonal phase transition temperature (T-H) of phosphatidylethanolamine (PE) have been shown to inhibit viral fusion. In this study we have further evaluated the mechanism of this inhibition, Several anionic amphiphiles, including cholesterol sulfate, a component of mammalian plasma membranes, lower the final extent of Sendai virus fusion with both human erythrocyte ghosts and liposomes composed of PE and 5% of the ganglioside, G(D1a). A cationic amphiphile slightly increased the final extent of fusion. The fusion rate constant is not greatly affected by the presence of as much as 20% cholesterol sulfate or other charged amphiphiles. The zwitterionic amphiphile, cholesterol phosphorylcholine has no effect on the final extent of fusion but it lowers the fusion rate constant. This amphiphile is potent in raising T-H. The amphiphile cholesterol hemisuccinate (CHEMS) stabilizes the bilayer relative to the hexagonal phase at neutral pH, while at acidic pH the formation of the hexagonal phase is promoted. When CHEMS is added to vesicles of egg PE containing 5% G(D1a), the rate of Sendai virus fusion is little affected at neutral pH but the rate is significantly enhanced at pH 5.0. These results demonstrate that viral fusion can be modulated, in part, by the tendency of the membrane to convert to the hexagonal phase.	MCMASTER UNIV, HLTH SCI CTR, DEPT BIOCHEM, HAMILTON L8N 3Z5, ON, CANADA; HEBREW UNIV JERUSALEM, FAC AGR, SEAGRAM CTR SOIL & WATER SCI, IL-76100 REHOVOT, ISRAEL; SUNY BUFFALO, SCH MED, DEPT MICROBIOL, BUFFALO, NY 14214 USA; SUNY BUFFALO, SCH BIOMED SCI, BUFFALO, NY 14214 USA	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; Hebrew University of Jerusalem; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			, Richard/R-2316-2019	, Richard/0000-0002-9602-9558				Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BENTZ J, 1988, BIOPHYS J, V54, P449, DOI 10.1016/S0006-3495(88)82978-3; BENTZ J, 1987, BIOCHEMISTRY-US, V26, P2105, DOI 10.1021/bi00382a008; BOTTEGA R, 1992, BIOCHEMISTRY-US, V31, P9025, DOI 10.1021/bi00152a045; BRYSZEWSKA M, 1991, Medical Science Research, V19, P791; CHEETHAM JJ, 1990, J BIOL CHEM, V265, P12404; CHEETHAM JJ, 1990, BIOCHIM BIOPHYS ACTA, V1024, P367, DOI 10.1016/0005-2736(90)90366-V; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; ELLENS H, 1989, BIOCHEMISTRY-US, V28, P3692, DOI 10.1021/bi00435a011; EPAND RM, 1992, BIOCHEMISTRY-US, V31, P1550, DOI 10.1021/bi00120a036; EPAND RM, 1985, BIOCHEMISTRY-US, V24, P7092, DOI 10.1021/bi00346a011; EPAND RM, 1988, BIOCHIM BIOPHYS ACTA, V940, P85, DOI 10.1016/0005-2736(88)90011-9; EPAND RM, 1990, BIOCHEM CELL BIOL, V68, P17, DOI 10.1139/o90-003; EPAND RM, 1990, CHEM PHYS LIPIDS, V55, P49, DOI 10.1016/0009-3084(90)90148-K; EPAND RM, 1993, TRENDS BIOCHEM SCI, V18, P81, DOI 10.1016/0968-0004(93)90157-I; EPAND RM, 1992, BIOPOLYMERS, V32, P309, DOI 10.1002/bip.360320403; EPAND RM, 1992, MEMBRANE INTERACTION, P99; GETHING MJ, 1978, P NATL ACAD SCI USA, V75, P2737, DOI 10.1073/pnas.75.6.2737; GRUNER SM, 1985, P NATL ACAD SCI USA, V82, P3665, DOI 10.1073/pnas.82.11.3665; HAYWOOD AM, 1981, BIOCHIM BIOPHYS ACTA, V646, P31, DOI 10.1016/0005-2736(81)90268-6; HAYWOOD AM, 1991, CELL AND MODEL MEMBRANE INTERACTIONS, P149; HAYWOOD AM, 1975, J GEN VIROL, V29, P63, DOI 10.1099/0022-1317-29-1-63; HOEKSTRA D, 1989, BIOSCIENCE REP, V9, P273, DOI 10.1007/BF01114682; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; HSU MC, 1981, J BIOL CHEM, V256, P3557; KITSON N, 1992, BIOCHIM BIOPHYS ACTA, V1111, P127, DOI 10.1016/0005-2736(92)90282-Q; KLAPPE K, 1986, BIOCHEMISTRY-US, V25, P8252, DOI 10.1021/bi00373a019; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; LITZINGER DC, 1992, BIOCHIM BIOPHYS ACTA, V1113, P201, DOI 10.1016/0304-4157(92)90039-D; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTE M, 1979, CHEM PHYS LIPIDS, V24, P45, DOI 10.1016/0009-3084(79)90094-X; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; NIR S, 1986, BIOCHEMISTRY-US, V25, P2155, DOI 10.1021/bi00356a046; NIR S, 1990, CELL BIOPHYS, V17, P181, DOI 10.1007/BF02990496; NIR S, 1986, BIOCHEMISTRY-US, V25, P8261, DOI 10.1021/bi00373a020; NOVICK SL, 1988, P NATL ACAD SCI USA, V85, P7433, DOI 10.1073/pnas.85.20.7433; OHKI S, 1991, BIOMED BIOCHIM ACTA, V50, P199; REED RA, 1987, BIOCHEMISTRY-US, V26, P824, DOI 10.1021/bi00377a025; SCHEID A, 1974, VIROLOGY, V57, P475, DOI 10.1016/0042-6822(74)90187-1; SIEGEL DP, 1993, VIRAL FUSION MECHANI, P475; Sobel AE, 1941, J AM CHEM SOC, V63, P3536, DOI 10.1021/ja01857a516; URYU T, 1992, BIOCHEM PHARMACOL, V43, P2385, DOI 10.1016/0006-2952(92)90317-C; VONECHE V, 1992, P NATL ACAD SCI USA, V89, P3810, DOI 10.1073/pnas.89.9.3810; WATARAI S, 1990, J BIOCHEM-TOKYO, V108, P507, DOI 10.1093/oxfordjournals.jbchem.a123230; YAN JS, 1990, J LIPID RES, V31, P160; YEAGLE PL, 1991, BIOCHIM BIOPHYS ACTA, V1065, P49, DOI 10.1016/0005-2736(91)90009-W	46	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5467	5472						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106528				2022-12-27	WOS:A1994MX57100113
J	DUNDERDALE, HJ; SHARPLES, GJ; LLOYD, RG; WEST, SC				DUNDERDALE, HJ; SHARPLES, GJ; LLOYD, RG; WEST, SC			CLONING, OVEREXPRESSION, PURIFICATION, AND CHARACTERIZATION OF THE ESCHERICHIA-COLI RUVC HOLLIDAY JUNCTION RESOLVASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR; CONJUGATIONAL RECOMBINATION; RECA PROTEIN; GENE-PRODUCT; K-12 REVEALS; ENDONUCLEASE; RESOLUTION; MUTANTS; EXPRESSION; DEFICIENT	The ruv(C) gene has been cloned into the plasmid pT7-7 under the control of the T7 phi 10 promoter. Following induction with isopropyl-1-thio-beta-D-galactopyranoside, the l9-kDa RuvC protein was overexpressed to 20-30% of total cell protein. RuvC has been purified to homogeneity by a simple procedure involving precipitation from the crude lysate, followed by three chromatographic steps. The purified protein resolves synthetic Holliday junctions (60 nucleotides in length) by cleavage at the 3'-side of a phosphate group, to produce nicked duplex DNA Under the same conditions no cleavage of linear duplex or single-stranded DNA was detected. However, low levels of cleavage were observed with supercoiled form I and single-stranded circular DNA substrates, consistent with the interaction of RuvC with secondary structures. Using synthetic Holliday junctions, we show that RuvC-mediated resolution requires Mg2+ (10 mM) and exhibits an alkaline pH optimum (pH 9.0). No energy cofactors are needed. When RuvC was analyzed by gel filtration and polyacrylamide gel electrophoresis, monomeric and dimeric forms of the protein were observed.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; UNIV NOTTINGHAM,QUEENS MED CTR,DEPT GENET,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham			Sharples, Gary/B-8638-2016	Sharples, Gary/0000-0003-2495-0062; West, Stephen/0000-0001-8848-9418				BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; BENSON FE, 1994, J BIOL CHEM, V269, P5195; BENSON FE, 1988, NUCLEIC ACIDS RES, V16, P1541, DOI 10.1093/nar/16.4.1541; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; CONNOLLY B, 1990, P NATL ACAD SCI USA, V87, P8476, DOI 10.1073/pnas.87.21.8476; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; IWASAKI H, 1989, MOL GEN GENET, V219, P328, DOI 10.1007/BF00261196; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; KOSAK HG, 1990, EUR J BIOCHEM, V194, P779, DOI 10.1111/j.1432-1033.1990.tb19469.x; LILLY DMJ, 1981, NUCLEIC ACIDS RES, V9, P1271, DOI 10.1093/nar/9.6.1271; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; LLOYD RG, 1987, J GEN MICROBIOL, V133, P2531; LUISIDELUCA C, 1989, GENETICS, V122, P269; MULLER B, 1993, J BIOL CHEM, V268, P17185; MULLER B, 1993, J BIOL CHEM, V268, P17179; OTSUJI N, 1974, J BACTERIOL, V117, P337, DOI 10.1128/JB.117.2.337-344.1974; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; SAMBROOK E, 1989, MOL CLONING LABORATO; SARGENTINI NJ, 1989, MUTAT RES, V215, P115, DOI 10.1016/0027-5107(89)90224-8; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SHARPLES GJ, 1991, J BACTERIOL, V173, P7711, DOI 10.1128/jb.173.23.7711-7715.1991; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; SHURVINTON CE, 1982, MOL GEN GENET, V185, P352, DOI 10.1007/BF00330811; STACEY KA, 1976, MOL GEN GENET, V143, P223, DOI 10.1007/BF00266925; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAKAHAGI M, 1991, J BACTERIOL, V173, P5747, DOI 10.1128/jb.173.18.5747-5753.1991; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WEST SC, 1980, P NATL ACAD SCI-BIOL, V77, P2569, DOI 10.1073/pnas.77.5.2569	37	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5187	5194						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106500				2022-12-27	WOS:A1994MX57100077
J	FARAH, CS; MIYAMOTO, CA; RAMOS, CHI; DASILVA, ACR; QUAGGIO, RB; FUJIMORI, K; SMILLIE, LB; REINACH, FC				FARAH, CS; MIYAMOTO, CA; RAMOS, CHI; DASILVA, ACR; QUAGGIO, RB; FUJIMORI, K; SMILLIE, LB; REINACH, FC			STRUCTURAL AND REGULATORY FUNCTIONS OF THE NH2- AND COOH-TERMINAL REGIONS OF SKELETAL-MUSCLE TROPONIN-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PROTON-MAGNETIC-RESONANCE; SITE-DIRECTED MUTAGENESIS; BIOLOGICAL-ACTIVITY; INHIBITORY REGION; BINDING-SITES; CROSS-LINKING; CONFORMATIONAL TRANSITION; PROTEOLYTIC FRAGMENTS; SYNTHETIC PEPTIDES	Calcium binding to regulatory sites located in the NH2-terminal domain of troponin C (TnC) induces a conformational change that blocks the inhibitory action of troponin I (TnI) and triggers muscle contraction. We used deletion mutants of TnI in conjunction with a series of TnC mutants to understand the structural and functional relationship between different TnI regions and TnC domains. Our results indicate that TnI is organized into structural and regulatory regions which interact in an antiparallel fashion with the corresponding structural and regulatory regions of TnC. Functional studies show that the COOH-terminal region of TnI, when linked to the inhibitory region (TnI(103-182)) can regulate actomyosin ATPase. A TnI lacking the first 57 amino acids (TnI(d57)) has been shown to have similar properties (Sheng, Z., Pan, B.-S., Miller, T.E., and Potter, J. D. (1992) J. Biol. Chem. 267, 25407-25413). Regulation was not observed with the COOH-terminal region alone (TnI(120-182)), with the NH2-terminal region alone (TnI(1-98)), or with the NH2-terminal linked to the inhibitory region (TnI(1-116)). Binding studies show that the NH2-terminal region of TnI interacts with the COOH-terminal domain of TnC in the presence of Ca2+ or Mg2+ and that the inhibitory plus COOH-terminal region of TnI (TnI(103-182)) interacts with the NH2-terminal domain of TnC in a Ca2+-dependent manner. Based on these results we propose a model for the Ca2+-induced conformational change. In our model the NH2-terminal domain of TnI is anchored strongly to the COOH-terminal domain of TnC in the absence and presence of Ca2+ while the inhibitory and COOH-terminal regions of TnI switch between actin-tropomyosin in the absence of Ca2+ to binding sites in bath NH2- and COOH-terminal domains of TnC in the presence of Ca2+.	UNIV SAO PAULO,INST QUIM,DEPT BIOQUIM,BR-01498 SAO PAULO,SP,BRAZIL; UNIV ALBERTA,MED RES COUNCIL GRP PROT STRUCT & FUNCT,EDMONTON T6G 2H7,AB,CANADA	Universidade de Sao Paulo; University of Alberta			Farah, Chuck Shaker/G-5565-2012; Ramos, CH/C-1571-2012	Farah, Chuck Shaker/0000-0003-3110-6302; Ramos, CH/0000-0002-7246-9081				BALDWIN AS, 1985, P NATL ACAD SCI USA, V82, P8080, DOI 10.1073/pnas.82.23.8080; BEALL CJ, 1991, J CELL BIOL, V114, P941, DOI 10.1083/jcb.114.5.941; CACHIA PJ, 1986, BIOCHEMISTRY-US, V25, P3553, DOI 10.1021/bi00360a013; CACHIA PJ, 1983, BIOCHEMISTRY-US, V22, P4145, DOI 10.1021/bi00286a024; CHEUNG HC, 1987, BIOCHEMISTRY-US, V26, P5904, DOI 10.1021/bi00392a049; DALGARNO DC, 1982, FEBS LETT, V150, P54, DOI 10.1016/0014-5793(82)81303-3; DOBROVOLSKY AB, 1984, BIOCHIM BIOPHYS ACTA, V789, P144, DOI 10.1016/0167-4838(84)90198-5; FUJIMORI K, 1990, NATURE, V345, P182, DOI 10.1038/345182a0; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; GRABAREK Z, 1992, J MUSCLE RES CELL M, V13, P383, DOI 10.1007/BF01738034; GRAND RJA, 1982, BIOCHEM J, V203, P61, DOI 10.1042/bj2030061; GREASER ML, 1971, J BIOL CHEM, V246, P4226; GREASER ML, 1973, J BIOL CHEM, V248, P2125; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HEAD JF, 1974, BIOCHEM J, V137, P145, DOI 10.1042/bj1370145; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HILL LE, 1992, J BIOL CHEM, V267, P16106; HITCHCOCKDEGREGORI SE, 1982, J BIOL CHEM, V257, P7372; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; KATAYAMA E, 1982, J BIOCHEM-TOKYO, V91, P1449, DOI 10.1093/oxfordjournals.jbchem.a133835; KOBAYASHI T, 1991, J BIOL CHEM, V266, P13746; KOBAYASHI T, 1989, J BIOL CHEM, V264, P1551; KOPPE RI, 1989, J BIOL CHEM, V264, P14327; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN JQ, 1989, BIOCHEMISTRY-US, V28, P7380, DOI 10.1021/bi00444a035; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P2821, DOI 10.1021/bi00408a024; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7042, DOI 10.1021/bi00396a028; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P6983, DOI 10.1021/bi00418a047; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; NEGELE JC, 1992, J BIOL CHEM, V267, P825; NGAI SM, 1992, J BIOL CHEM, V267, P15715; NOZAKI S, 1980, CHEM LETT, P345, DOI 10.1246/cl.1980.345; OHTSUKI I, 1986, ADV PROTEIN CHEM, V38, P1, DOI 10.1016/S0065-3233(08)60525-2; PAN BS, 1992, J BIOL CHEM, V267, P23052; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; PERRY SV, 1972, COLD SPRING HARB SYM, V37, P251; POTTER JD, 1975, J BIOL CHEM, V250, P4628; QUAGGIO RB, 1993, PROTEIN SCI, V2, P1053, DOI 10.1002/pro.5560020618; REINACH FC, 1982, J CELL BIOL, V95, P78, DOI 10.1083/jcb.95.1.78; REINACH FC, 1988, J BIOL CHEM, V263, P2371; REINACH FC, 1986, NATURE, V322, P80, DOI 10.1038/322080a0; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENG ZL, 1990, J BIOL CHEM, V265, P21554; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; SILVA A C R D, 1991, Trends in Biochemical Sciences, V16, P53; SILVA ACR, 1993, EUR J BIOCHEM, V213, P599; SMILLIE LB, 1988, J BIOL CHEM, V263, P18816; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWENSON CA, 1992, BIOCHEMISTRY-US, V31, P3420, DOI 10.1021/bi00128a017; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1979, J BIOL CHEM, V254, P3720; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; TAO T, 1989, BIOCHEMISTRY-US, V28, P5902, DOI 10.1021/bi00440a029; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; TSUDA S, 1992, J BIOCHEM-TOKYO, V112, P665, DOI 10.1093/oxfordjournals.jbchem.a123956; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; WADE R, 1990, GENOMICS, V7, P346, DOI 10.1016/0888-7543(90)90168-T; WANG CK, 1984, J MOL BIOL, V190, P509; WEEKS RA, 1978, BIOCHEM J, V173, P449, DOI 10.1042/bj1730449; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	69	196	201	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5230	5240						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106506				2022-12-27	WOS:A1994MX57100083
J	KIM, K; ROEDER, RG				KIM, K; ROEDER, RG			INVOLVEMENT OF THE BASIC REPEAT DOMAIN OF TATA-BINDING PROTEIN (TBP) IN TRANSCRIPTION BY RNA-POLYMERASE-I, RNA-POLYMERASE-II, AND RNA-POLYMERASE-III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHOLE-CELL EXTRACT; SACCHAROMYCES-CEREVISIAE; TFIID COMPLEX; YEAST; INITIATION; ACTIVATION; LESS; COMPONENTS; PROMOTER	The TATA-binding protein (TBP) plays a central role in transcription initiation by nuclear RNA polymerases I, II, and III. With knowledge of the three-dimensional structure of TBP, mutational analyses were focused on the highly exposed basic repeat domain in yeast TBP in order to identify amino acid residues which could discriminate transcription functions of different RNA polymerases. One mutation (K156L) was found to specifically abolish transcription by RNA polymerase I and another mutation (K138L) specifically abolished transcription by RNA polymerase III, while each maintained the ability to support in vitro transcription by the other two RNA polymerases. Along with previous studies, these results indicate that the basic repeat domain of TBP is important not only for transcription by RNA polymerase II but also for transcription by RNA polymerases I and III and, further, that the region has distinct sites for interactions which are specific for RNA polymerases I and III.	ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021	Rockefeller University								AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DYNLACHT BD, 1991, CELL, V68, P965; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GREENBLATT J, 1992, NATURE, V360, P16, DOI 10.1038/360016a0; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; POON D, 1993, J BIOL CHEM, V268, P15325; POON D, 1993, J BIOL CHEM, V268, P5005; PUGH BF, 1992, J BIOL CHEM, V267, P679; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; SCHULTZ MC, 1992, CELL, V69, P692; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SIMMEN KA, 1992, NUCLEIC ACIDS RES, V20, P5889, DOI 10.1093/nar/20.22.5889; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	37	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4891	4894						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106461				2022-12-27	WOS:A1994MX57100032
J	BIGNON, C; SAKAL, E; BELAIR, L; CHAPNIKCOHEN, N; DJIANE, J; GERTLER, A				BIGNON, C; SAKAL, E; BELAIR, L; CHAPNIKCOHEN, N; DJIANE, J; GERTLER, A			PREPARATION OF THE EXTRACELLULAR DOMAIN OF THE RABBIT PROLACTIN RECEPTOR EXPRESSED IN ESCHERICHIA-COLI AND ITS INTERACTION WITH LACTOGENIC HORMONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; MAMMARY-GLAND; BIOLOGICAL-ACTIVITIES; MONOCLONAL-ANTIBODIES; BINDING-PROPERTIES; MOLECULAR-CLONING; PURIFICATION; FRAGMENTS; TERMINUS; FAMILY	The cDNA of the extracellular domain of the rabbit prolactin receptor (rbPRLR-ECD) was cloned in the prokaryotic expression vector pTrc99A to enable its expression in Escherichia coli after induction with isopropyl-1-thio-beta-D-galactopyranoside. The bacterially expressed rbPRLR-ECD protein, contained within the refractile body pellet, was solubilized in 4.5 m urea, refolded, and purified on a Q-Sepharose column by stepwise elution with NaCl. The bioactive monomeric fraction was eluted in 0.05 m NaCl, yielding 15-20 mg/8 liters of induced culture. The purified protein was >98% homogeneous, as shown by SDS-polyacrylamide gel electrophoresis in the presence or absence of reducing agent and by chromatography on a Superdex column. Its molecular mass was 25 kDa as determined by SDS-polyacrylamide gel electrophoresis in the absence of reducing agent and 22 kDa as determined by gel filtration. Binding experiments revealed remarkable differences between rabbit and porcine prolactins (PRLs) and the other tested lactogenic hormones. Gel filtration was used to determine the stoichiometry of the rbPRLR-ECD interaction with ovine, rabbit, and porcine PRLs, with human growth hormone and its truncated des-7 analogue, and with bovine placental lactogen (bPL) and des-13-bPL. The formation of only 1:1 complexes was indicated, except with bPL, for which a 2:1 complex was detected. Identical stoichiometry was also obtained using excess radiolabeled rbPRLR-ECD in gel filtration experiments. Interaction of I-125-labeled ovine PRL with rbPRLR-ECD secreted into conditioned medium by rbPRLR-ECD cDNA-transfected COS 7 cells also indicated formation of 1:1 molar complexes. Despite the differences in binding potency and stoichiometries of the interaction with rbPRLR-ECD, all seven tested hormones were biologically active in inducing PRL receptor-mediated casein synthesis in explants of rabbit mammary gland. We therefore propose that the formation of the 1:2 complexes with soluble rbPRLR-ECD is not predictive of biological activity of the different lactogenic hormones.	HEBREW UNIV JERUSALEM,FAC AGR,DEPT BIOCHEM FOOD SCI & NUTR,POB 12,IL-76100 REHOVOT,ISRAEL; INRA,ENDOCRINOL MOLEC UNITE,F-78352 JOUY EN JOSAS,FRANCE	Hebrew University of Jerusalem; INRAE; UDICE-French Research Universities; Universite Paris Saclay								ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V86, P2112; AMMAN E, 1988, GENE, V69, P301; BINDER L, 1990, MOL ENDOCRINOL, V4, P1060, DOI 10.1210/mend-4-7-1060; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; BYATT JC, 1992, J ANIM SCI, V70, P2911, DOI 10.2527/1992.7092911x; CAHOREAU C, 1992, BIOCHIMIE, V74, P1053, DOI 10.1016/0300-9084(92)90003-W; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DJIANE J, 1985, J BIOL CHEM, V260, P1430; DUSANTERFOURT I, 1984, ENDOCRINOLOGY, V114, P1021, DOI 10.1210/endo-114-3-1021; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; ELBERG G, 1990, J BIOL CHEM, V265, P14770; FRITZ H, 1965, Z PHYSL CHEM, V342, P253; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GERTLER A, 1984, MOL CELL ENDOCRINOL, V34, P51, DOI 10.1016/0303-7207(84)90158-8; GERTLER A, 1992, J BIOL CHEM, V267, P12655; GERTLER A, 1993, FEBS LETT, V319, P277, DOI 10.1016/0014-5793(93)80562-9; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; JAHN G, 1987, P SOC EXP BIOL MED, V184, P19, DOI 10.3181/00379727-184-42440; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Martson F.A.O., 1986, BIOCHEM J, V240, P1; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT P, 1992, MOL CELL ENDOCRINOL, V89, P47, DOI 10.1016/0303-7207(92)90210-W; SHIU RPC, 1983, ENDOCRINOLOGY, V113, P159, DOI 10.1210/endo-113-1-159; TCHELET A, 1993, ADOLESC PEDIATR ENDO, V24, P114; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; TOWNS R, 1992, ENDOCRINOLOGY, V130, P1225, DOI 10.1210/en.130.3.1225; WATERS MJ, 1990, INT J BIOCHEM, V10, P1089	32	52	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3318	3324						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106371				2022-12-27	WOS:A1994MV63100032
J	GRAF, R; LEPIER, A; HARVEY, WR; WIECZOREK, H				GRAF, R; LEPIER, A; HARVEY, WR; WIECZOREK, H			A NOVEL 14-KDA V-ATPASE SUBUNIT IN THE TOBACCO HORNWORM MIDGUT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; TRANSPORTING PLASMA-MEMBRANES; PROTON PUMP; RECONSTITUTION; PURIFICATION; EXPRESSION; KIDNEY; DNA	A cDNA clone encoding a hydrophilic protein with a calculated molecular mass of 13,839 Da was isolated by shotgun screening with an anti-V-ATPase holoenzyme serum. The deduced amino acid sequence showed no significant homology to any other known protein. Southern blots revealed the existence of only one gene encoding the 14-kDa protein. Monospecific antibodies purified by affinity to the recombinant protein demonstrated the presence of a 14-kDa protein in the highly purified goblet cell apical membrane and inhibited ATP-dependent proton transport as well as V-ATPase activity to the same extent. Thus, the 14-kDa protein was shown to be a part of the V-ATPase holoenzyme. Binding of the monospecific antibodies to the ATPase seemed to require an ATP-dependent conformational change of the enzyme, since inhibition only occurred when ATP was present during the antibody binding step. The 14-kDa subunit could be stripped from the membrane by treatment with the chaotropic agent KI, confirming it to be part of the soluble complex of the V-ATPase. In immunoblots, the 14-kDa-specific antibodies showed no cross-reaction with several xenic V-ATPases.	UNIV MUNICH,INST ZOOL,D-80021 MUNICH,GERMANY	University of Munich			/AAU-6215-2020		NIAID NIH HHS [AI22444] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022444] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI I, 1990, J BIOL CHEM, V265, P960; ANRAKU Y, 1992, J EXP BIOL, V172, P67; BACHHAWAT AK, 1993, YEAST, V9, P175, DOI 10.1002/yea.320090208; BELL RA, 1976, ANN ENTOMOL SOC AM, V69, P365, DOI 10.1093/aesa/69.2.365; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BROWN D, 1992, J EXP BIOL, V172, P231; BROWN TA, 1991, ESSENTIAL MOL BIOL, V1; CHATTERJEE D, 1992, J EXP BIOL, V172, P193; CIOFFI M, 1983, TISSUE CELL, V15, P781, DOI 10.1016/0040-8166(83)90050-2; DOW JAT, 1992, GENE, V122, P355, DOI 10.1016/0378-1119(92)90226-F; GLUCK S, 1987, J BIOL CHEM, V262, P15780; GLUCK SL, 1992, J EXP BIOL, V172, P219; GRAF R, 1992, FEBS LETT, V300, P119, DOI 10.1016/0014-5793(92)80177-I; GRINSTEIN S, 1992, J EXP BIOL, V172, P179; HARVEY BJ, 1992, J EXP BIOL, V172, P289; HARVEY WR, 1992, J EXP BIOL, V172, P1; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; HIRATA R, 1993, J BIOL CHEM, V268, P961; HO MN, 1993, J BIOL CHEM, V268, P221; KLEIN U, 1992, J EXP BIOL, V172, P345; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LION T, 1990, ANAL BIOCHEM, V188, P335, DOI 10.1016/0003-2697(90)90616-H; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; NELSON N, 1992, J EXP BIOL, V172, P19; NOVAK FJS, 1992, BIOCHIM BIOPHYS ACTA, V1132, P67, DOI 10.1016/0167-4781(92)90053-3; PEREZCASTINEIRA JR, 1990, BIOCHEM J, V271, P127, DOI 10.1042/bj2710127; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUSTER H, 1992, COMMENTS USB CORP, V19, P36; SCHWEIKL H, 1989, J BIOL CHEM, V264, P11136; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; VANHEIJNE G, 1987, SEQUENCE ANAL MOL BI, P37; VANHILLE B, 1993, J BIOL CHEM, V268, P7075; WARD JM, 1992, PLANT PHYSIOL, V99, P925, DOI 10.1104/pp.99.3.925; WIECZOREK H, 1991, J BIOL CHEM, V266, P15340; WIECZOREK H, 1992, J EXP BIOL, V172, P335; WIECZOREK H, 1989, J BIOL CHEM, V264, P11143; WIECZOREK H, 1990, METHOD ENZYMOL, V192, P608	39	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3767	3774						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106421				2022-12-27	WOS:A1994MV63100093
J	JAYARAM, B; HALEY, BE				JAYARAM, B; HALEY, BE			IDENTIFICATION OF PEPTIDES WITHIN THE BASE BINDING DOMAINS OF THE GTP-SPECIFIC AND ATP-SPECIFIC BINDING-SITES OF TUBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BETA-TUBULIN; GUANOSINE TRIPHOSPHATE; ALPHA-TUBULIN; PORCINE BRAIN; MICROTUBULES; POLYMERIZATION; LOCALIZATION; NUCLEOTIDES; MECHANISM	Using gamma-P-32-labeled 8-azidopurine nucleotide photoaffinity probes of GTP and ATP, the respective purine ring binding domain peptides of tubulin have been identified. First, the location of the GTP-specific binding site was shown to be on the beta-subunit, whereas the major ATP-specific binding site was on the alpha-subunit. Using a combination of anion-exclusion and immobilized Al3+ column chromatography, the respective photolabeled tryptic peptides of both nucleotide binding sites were isolated, further purified by reverse phase high performance liquid chromatography (HPLC) and sequenced. Chymotryptic peptides were also generated for the GTP binding site. High retention of the photoinserted radiolabel was observed with many of the peptides on reverse phase HPLC at low flow rates. The stability of the photoinserted radiolabel to HPLC varied with different peptides. However, certain peptides were easily distinguished as being within the base binding domains of the GTP and ATP binding sites of tubulin. Two beta-tubulin peptides containing the majority of photoinserted [gamma-P-32]8-azidoguanosine 5'-triphosphate corresponded to N-terminal beta-tubulin amino acid residues 3EIVHIQAGQCGNQIGAK19 and 20FWEVISDEHGIDP-TGS35. The peptide containing the majority of photoinserted [gamma-P-32]8-azidoadenosine 5'-triphosphate corresponded to the C-terminal alpha-tubulin sequence 431DYEEVGVDSVEGEGEEEGEE450.	UNIV KENTUCKY,MED CTR,LUCILLE P MARKEY CANC CTR,COLL PHARM,800 ROSE ST,LEXINGTON,KY 40536	University of Kentucky					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035766] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35766] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI T, 1977, J BIOCHEM-TOKYO, V82, P1063, DOI 10.1093/oxfordjournals.jbchem.a131777; BONNE BJ, 1982, BIOCHEMISTRY-US, V21, P1075; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHAVAN AJ, 1992, J BIOL CHEM, V267, P14866; Chavan AJ, 1990, BIOCONJUGATE CHEM, V1, P337, DOI 10.1021/bc00005a007; Czarnecki J, 1979, Methods Enzymol, V56, P642; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P20638; GEAHLEN RL, 1979, J BIOL CHEM, V254, P1982; GEAHLEN RL, 1977, P NATL ACAD SCI USA, V74, P4375, DOI 10.1073/pnas.74.10.4375; HALEY BE, 1983, H-S Z PHYSIOL CHEM, V364, P1137; HALLAK ME, 1977, FEBS LETT, V73, P147, DOI 10.1016/0014-5793(77)80968-X; HESSE J, 1987, J BIOL CHEM, V262, P15472; KHATOON S, 1989, ANN NEUROL, V26, P210, DOI 10.1002/ana.410260205; KIM H, 1991, BIOCONJUGATE CHEM, V2, P142, DOI 10.1021/bc00009a002; KIM H, 1987, FASEB J, V46, P2229; KING S, 1991, METHOD ENZYMOL, V191, P449; KOBYASHI T, 1975, J BIOCHEM-TOKYO, V77, P1193; KRAUHS E, 1981, P NATL ACAD SCI-BIOL, V78, P4156, DOI 10.1073/pnas.78.7.4156; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINSE K, 1988, J BIOL CHEM, V263, P15205; LITTLE M, 1988, COMP BIOCHEM PHYS B, V90, P655, DOI 10.1016/0305-0491(88)90320-3; MEJILLANO MR, 1990, BIOCHEM BIOPH RES CO, V166, P653, DOI 10.1016/0006-291X(90)90859-L; MONASTERIO O, 1987, BIOCHEMISTRY-US, V26, P6091, DOI 10.1021/bi00393a022; NATH JP, 1985, BIOCHEMISTRY-US, V24, P1555, DOI 10.1021/bi00327a040; PATURLELAFANECHERE L, 1991, BIOCHEMISTRY-US, V30, P10523, DOI 10.1021/bi00107a022; PONSTINGL H, 1981, P NATL ACAD SCI-BIOL, V78, P2757, DOI 10.1073/pnas.78.5.2757; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; RAJAGOPALAN K, 1993, J BIOL CHEM, V268, P14230; RAYBIN D, 1977, BIOCHEMISTRY-US, V16, P2189, DOI 10.1021/bi00629a023; SALVUCCI ME, 1992, BIOCHEMISTRY-US, V31, P4479, DOI 10.1021/bi00133a014; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; SHOEMAKER MT, 1993, BIOCHEMISTRY-US, V32, P1883, DOI 10.1021/bi00058a023; STONE KL, 1989, PRACTICAL GUIDE PROT; TIMASHEFF SN, 1980, ANNU REV BIOCHEM, V49, P565, DOI 10.1146/annurev.bi.49.070180.003025; TRAD CH, 1993, ARCH BIOCHEM BIOPHYS, V304, P58, DOI 10.1006/abbi.1993.1321; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WEISENBERG RC, 1968, BIOCHEMISTRY-US, V7, P4466, DOI 10.1021/bi00852a043; WEISENBERG RC, 1972, SCIENCE, V177, P1104, DOI 10.1126/science.177.4054.1104; WEISENBERG RC, 1976, BIOCHEMISTRY-US, V15, P4248, DOI 10.1021/bi00664a018; ZABRECKY JR, 1983, ARCH BIOCHEM BIOPHYS, V225, P475, DOI 10.1016/0003-9861(83)90056-5; ZABRECKY JR, 1982, J BIOL CHEM, V257, P4633; ZABRECKY JR, 1982, NATURE, V296, P775, DOI 10.1038/296775a0	44	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3233	3242						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106359				2022-12-27	WOS:A1994MV63100020
J	OZAKI, K; TERAKITA, A; OZAKI, M; HARA, R; HARA, T; HARANISHIMURA, I; MORI, H; NISHIMURA, M				OZAKI, K; TERAKITA, A; OZAKI, M; HARA, R; HARA, T; HARANISHIMURA, I; MORI, H; NISHIMURA, M			MOLECULAR CHARACTERIZATION AND FUNCTIONAL EXPRESSION OF SQUID RETINAL-BINDING PROTEIN - A NOVEL SPECIES OF HYDROPHOBIC LIGAND-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT EPITHELIUM; BOVINE RETINA; VISUAL CELLS; RAT TISSUE; PHOTOISOMERASE; RETINOCHROME; SEQUENCE; EYES	The primary structure of squid retinal-binding protein (RALBP) was determined by cDNA and protein sequencing. Squid RALBP contains 342 amino acid residues in a single N-terminal-blocked chain with a molecular weight of 39,111. The N(alpha)-blocking group was identified as an acetyl moiety by mass spectrometry. The amino acid sequence revealed that the protein is highly hydrophilic and acidic, but it has several hydrophobic regions that are located mainly in the middle part of the polypeptide chain. It is also predicted that these hydrophobic regions form beta-sheet structures. The primary structure of RALBP is, however, quite distinct from those of other retinoid-binding proteins, showing that squid RALBP is a novel hydrophobic ligand-binding protein that functions in intracellular retinoid transport. Using the cloned cDNA, squid RALBP was expressed in vitro. By carrying out the translation at 20-degrees-C in reticulocyte lysates, the protein having retinol binding activity was produced.	NATL INST BASIC BIOL,DEPT CELL BIOL,OKAZAKI,AICHI 444,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	OZAKI, K (corresponding author), OSAKA UNIV,FAC SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN.		; Ozaki, Koichi/O-2798-2015	Terakita, Akihisa/0000-0002-8379-8913; Ozaki, Koichi/0000-0001-7268-5377; Nishimura, Mikio/0000-0001-7960-9721				ADLER AJ, 1982, BIOCHEM BIOPH RES CO, V108, P1601, DOI 10.1016/S0006-291X(82)80091-0; BASHOR MM, 1973, P NATL ACAD SCI USA, V70, P3483, DOI 10.1073/pnas.70.12.3483; BRIDGES CDB, 1984, VISION RES, V24, P1581, DOI 10.1016/0042-6989(84)90316-X; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CRABB JW, 1988, J BIOL CHEM, V263, P18678; FONG SL, 1988, VISION RES, V28, P563, DOI 10.1016/0042-6989(88)90106-X; FUTTERMAN S, 1977, J BIOL CHEM, V252, P3267; HARA R, 1987, RETINAL PROTEINS, P447; HARA T, 1991, PROGR RETINAL RES, V10, P1799; HARANISHIMURA I, 1990, FEBS LETT, V271, P106, DOI 10.1016/0014-5793(90)80383-T; HARANISHIMURA I, 1993, FEBS LETT, V317, P5, DOI 10.1016/0014-5793(93)81480-N; HELLER J, 1975, J BIOL CHEM, V250, P3613; KANAI M, 1968, J CLIN INVEST, V47, P2025, DOI 10.1172/JCI105889; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI YL, 1982, NATURE, V298, P848, DOI 10.1038/298848a0; LIN ZS, 1989, VISION RES, V29, P1699, DOI 10.1016/0042-6989(89)90152-1; Maniatis T., 1982, MOL CLONING; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; OKAJIMA TIL, 1990, P NATL ACAD SCI USA, V87, P6907, DOI 10.1073/pnas.87.17.6907; ONG DE, 1975, J BIOL CHEM, V250, P6113; OZAKI K, 1987, VISION RES, V27, P1057, DOI 10.1016/0042-6989(87)90020-4; OZAKI K, 1991, BIOPHYSICS-USSR, V31, P129; PEPE IM, 1980, VISION RES, V20, P97, DOI 10.1016/0042-6989(80)90150-9; PEPE IM, 1992, J PHOTOCH PHOTOBIO B, V13, P5, DOI 10.1016/1011-1344(92)80035-T; RANDO RR, 1991, PROGR RETINAL RES, V10, P161; SAARI JC, 1982, J BIOL CHEM, V257, P13329; TAKAHASHI K, 1982, BIOCHEM BIOPH RES CO, V106, P1099, DOI 10.1016/0006-291X(82)91225-6; TERAKITA A, 1989, VISION RES, V29, P639, DOI 10.1016/0042-6989(89)90026-6; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; ZIMMERMANN JG, 1988, TREND BIOCH SCI, V13, P64	31	17	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3838	3845						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106428				2022-12-27	WOS:A1994MV63100103
J	XU, QA; YU, LA; CHITNIS, VP; CHITNIS, PR				XU, QA; YU, LA; CHITNIS, VP; CHITNIS, PR			FUNCTION AND ORGANIZATION OF PHOTOSYSTEM-I IN A CYANOBACTERIAL MUTANT STRAIN THAT LACKS PSAF AND PSAJ SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP PCC-6803; CHEMICAL CROSS-LINKING; TARGETED MUTAGENESIS; MOLECULAR-CLONING; 2 SUBUNITS; PLASTOCYANIN; IDENTIFICATION; POLYPEPTIDE; FERREDOXIN; TOPOLOGY	Photosystem I functions as a light-driven plastocyanin-ferredoxin oxidoreductase in the photosynthetic membranes of cyanobacteria and chloroplasts. A mutant strain of the cyanobacterium Synechocystis sp. PCC 6803 that contains a deletion of the psaF gene and a transcriptionally inactive psaJ gene has assembled photosystem I complexes that lack PsaF, a lumenal protein and PsaJ, a 4-kDa hydrophobic protein. The cells of the mutant and wild type strains have similar rates of photosynthetic electron transfer and P700+ rereduction under linear and cyclic electron transfer conditions. Analysis of flash-induced absorption transients -at 700 nm demonstrate that the absence of PsaF in purified mutant photosystem I did not affect the rate of P700 rereduction by cytochrome c553. Therefore, PsaF is not essential for docking of cytochrome c553. We also studied the organization of the proteins of mutant and wild type photosystem I by comparing their accessibility to digestion by thermolysin or to removal by 1 m NaI. The PsaA-PsaB subunits were more easily degraded by thermolysin in the mutant photosystem I. Thermolysin cleavage of PsaB yielded two major fragments that were immunoreactive with an antibody raised against the C terminus of PsaB. The N termini of these PsaB peptides mapped at Ile482 and Ile498 residues, thus identifying a surface-exposed domain of the core of photosystem I. The PsaE subunit could be removed by 1 m NaI and was rapidly digested by thermolysin in the mutant but not in the wild type photosystem I. Therefore, PsaF and PsaJ subunits of photosystem I have dispensable accessory roles in the function and organization of the complex.	KANSAS STATE UNIV AGR & APPL SCI, DIV BIOL, MANHATTAN, KS 66506 USA; UNIV NEBRASKA, DEPT BIOCHEM, LINCOLN, NE 68583 USA	Kansas State University; University of Nebraska System; University of Nebraska Lincoln								ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BENGIS C, 1977, J BIOL CHEM, V252, P4564; BOTTIN H, 1987, BIOCHIM BIOPHYS ACTA, V894, P39, DOI 10.1016/0005-2728(87)90210-6; BOTTIN H, 1985, BIOCHEMISTRY-US, V24, P6453, DOI 10.1021/bi00344a022; BRYANT DA, 1992, PHOTOSYSTEMS STRUCTU, P501; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; CHITNIS PR, 1989, J BIOL CHEM, V264, P18374; CHITNIS PR, 1989, J BIOL CHEM, V264, P18381; CHITNIS PR, 1992, PLANT PHYSIOL, V99, P239, DOI 10.1104/pp.99.1.239; CHITNIS PR, 1991, PHOTOSYNTHETIC APPAR, P178; CHITNIS PR, 1992, CHLOROPLAST BIOGENES, P277; CHITNIS VP, 1993, J BIOL CHEM, V268, P11678; GOLBECK JH, 1993, P NATL ACAD SCI USA, V90, P1642, DOI 10.1073/pnas.90.5.1642; GOLDEN SS, 1987, METHOD ENZYMOL, V153, P215; HATANAKA H, 1993, BIOCHIM BIOPHYS ACTA, V1141, P45, DOI 10.1016/0005-2728(93)90187-K; HENRY RL, 1992, PLANT PHYSIOL BIOCH, V30, P357; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; HO KK, 1979, BIOCHIM BIOPHYS ACTA, V545, P236; IKEUCHI M, 1992, PLANT CELL PHYSIOL, V33, P1057; IKEUCHI M, 1991, FEBS LETT, V287, P5, DOI 10.1016/0014-5793(91)80003-L; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; LAGOUTTE B, 1992, EUR J BIOCHEM, V205, P1175, DOI 10.1111/j.1432-1033.1992.tb16888.x; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; MATTOO AK, 1989, CELL, V56, P241, DOI 10.1016/0092-8674(89)90897-0; NECHUSHTAI R, 1981, J BIOENERG BIOMEMBR, V13, P295, DOI 10.1007/BF00743207; REILLY P, 1988, J BIOL CHEM, V263, P17658; ROUSSEAU F, 1993, EMBO J, V12, P1755, DOI 10.1002/j.1460-2075.1993.tb05823.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMART LB, 1991, PLANT MOL BIOL, V17, P959, DOI 10.1007/BF00037136; SONOIKE K, 1993, BIOCHIM BIOPHYS ACTA, V1141, P52, DOI 10.1016/0005-2728(93)90188-L; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; WYNN RM, 1989, BIOCHEMISTRY-US, V28, P5554, DOI 10.1021/bi00439a032; YU L, 1993, PLANT PHYSIOL, V103, P171, DOI 10.1104/pp.103.1.171; ZANETTI G, 1987, EUR J BIOCHEM, V169, P143, DOI 10.1111/j.1432-1033.1987.tb13591.x; ZHANG L, 1992, J BIOL CHEM, V267, P19054; ZHAO JD, 1992, BIOCHEMISTRY-US, V31, P5093, DOI 10.1021/bi00137a001; ZILBER AL, 1988, PLANT PHYSIOL, V88, P810, DOI 10.1104/pp.88.3.810; ZILBER AL, 1992, PLANT PHYSIOL, V99, P901, DOI 10.1104/pp.99.3.901	41	103	108	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3205	3211						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106355				2022-12-27	WOS:A1994MV63100016
J	GLAVAS, N; AHMAD, S; BRAGG, PD; OLAUSSON, T; RYDSTROM, J				GLAVAS, N; AHMAD, S; BRAGG, PD; OLAUSSON, T; RYDSTROM, J			IDENTIFICATION OF N,N'-DICYCLOHEXYLCARBODIIMIDE-REACTIVE GLUTAMIC AND ASPARTIC-ACID RESIDUES IN ESCHERICHIA-COLI TRANSHYDROGENASE AND THE EXCHANGE OF THESE BY SITE-SPECIFIC MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE-NUCLEOTIDE TRANSHYDROGENASE; HEART MITOCHONDRIAL TRANSHYDROGENASE; ATP-DRIVEN TRANSHYDROGENASE; DICYCLOHEXYLCARBODIIMIDE; SEQUENCE; VESICLES; PROTEINS	Pyridine nucleotide transhydrogenase (EC 1.6.1.1) from Escherichia coli was investigated with respect to the role of glutamic and aspartic acid residues reactive to N,N'-dicyclohexylcarbodiimide (DCCD) and potentially involved in the proton-pumping mechanism of the enzyme. The E. coli transhydrogenase consists of an alpha (510 residues) and a beta (462 residues) subunit. DCCD reacts with the enzyme to inhibit catalytic activity and proton pumping. This reagent modifies Asp(alpha232), Glu(alpha238), and Glu(alpha240) as well as amino acid residue(s) in the beta subunit. Using the cloned and overexpressed E. coli transhydrogenase genes (Clarke, D. M., and Bragg, P. D. (1985) J. Bacteriol. 162, 367-373), Asp(alpha232) and Glu(alpha238) were replaced independently by site-specific mutagenesis. In addition, Asp(alpha232), Glu(alpha238), and Glu(alpha240) were replaced to generate triple mutants. The specific catalytic activities of the mutant transhydrogenases alphaD232N, alphaD232E, alphaD232K, alphaD232H, alphaE238K, and alphaE238Q as well as of the triple mutants alphaD232N,alphaE238Q,alphaE240Q and alphaD232H,alphaE238Q, alphaE240Q were in the range of 40-90% of the wild-type activity. Proton-pumping activity was present in all mutants. Examination of the extent of subunit modification by [C-14]DCCD revealed that the label was still incorporated into both alpha and beta subunits in the Asp(alpha232) mutants, but that the alpha subunit was not labeled in the triple mutants. Catalytic and proton-pumping activities were nearly insensitive to DCCD in the triple mutants. This suggests that loss of catalytic and proton pumping activities is associated with modification of the aspartic and glutamic acid residues of the a subunit. In the presence of the substrate NADPH, the rate of modification of the beta subunit by [C-14]DCCD was increased, and there was a greater extent of enzyme inactivation. By contrast, NADH and 3-acetylpyridine-NAD+ protected the catalytic activity of the transhydrogenase from inhibition by DCCD. The protection was particularly marked in the E238Q and E238K mutants. It is concluded that the Asp(alpha232), Glu(alpha238), and Glu(alpha240) residues are not essential for catalytic activity or proton pumping. The inactivation by DCCD is likely due to the introduction of a sterically hindering group that reacts with the identified acidic residues close to the NAD(H)-binding site.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM,2146 HLTH SCI MALL,VANCOUVER V6T 1Z3,BC,CANADA; CHALMERS UNIV TECHNOL,DEPT BIOCHEM & BIOPHYS,S-41296 GOTHENBURG,SWEDEN; ROYAL INST TECHNOL,DEPT BIOCHEM & BIOTECHNOL,S-10044 STOCKHOLM 70,SWEDEN	University of British Columbia; Chalmers University of Technology; Royal Institute of Technology			Ahmad, Suhail/AAJ-5456-2021; Rydström, Jan/A-7683-2010					AHMAD S, 1992, J BIOL CHEM, V267, P7007; AHMAD S, 1992, EUR J BIOCHEM, V207, P733, DOI 10.1111/j.1432-1033.1992.tb17103.x; ANDERSON WM, 1978, ARCH BIOCHEM BIOPHYS, V187, P180, DOI 10.1016/0003-9861(78)90021-8; CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431; CLARKE DM, 1985, J BACTERIOL, V162, P367, DOI 10.1128/JB.162.1.367-373.1985; CLARKE DM, 1985, EUR J BIOCHEM, V149, P517, DOI 10.1111/j.1432-1033.1985.tb08955.x; CLARKE DM, 1986, EUR J BIOCHEM, V158, P647, DOI 10.1111/j.1432-1033.1986.tb09802.x; EARLE SR, 1980, BIOCHEMISTRY-US, V19, P561, DOI 10.1021/bi00544a026; EARLE SR, 1980, J BIOL CHEM, V255, P827; EYTAN GD, 1987, J BIOL CHEM, V262, P5015; EYTAN GD, 1987, J BIOL CHEM, V262, P5008; EYTAN GD, 1990, J BIOL CHEM, V265, P12949; FISHER RR, 1982, PYRIDINE NUCLEOTIDE, P280; HOJEBERG B, 1977, BIOCHEM BIOPH RES CO, V78, P1183, DOI 10.1016/0006-291X(77)91418-8; HU PS, 1992, BIOCHIM BIOPHYS ACTA, V1102, P19, DOI 10.1016/0167-4838(92)90494-X; JACKSON JB, 1991, J BIOENERG BIOMEMBR, V23, P715, DOI 10.1007/BF00785998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; NORDLING M, 1991, FEBS LETT, V291, P327, DOI 10.1016/0014-5793(91)81313-W; OLSSON A, 1984, J BIOCHEM BIOPH METH, V10, P483; PENNINGTON RM, 1981, J BIOL CHEM, V256, P8963; PERSSON B, 1984, J BIOL CHEM, V259, P8626; PHELPS DC, 1984, BIOCHEMISTRY-US, V23, P6340, DOI 10.1021/bi00321a008; PHELPS DC, 1981, J BIOL CHEM, V256, P8217; PHELPS DC, 1984, BIOCHEMISTRY-US, V23, P4475, DOI 10.1021/bi00314a037; Rydstrom J, 1979, Methods Enzymol, V55, P261; RYDSTROM J, 1977, BIOCHIM BIOPHYS ACTA, V463, P155, DOI 10.1016/0304-4173(77)90007-6; RYDSTROM J, 1987, PYRIDINE NUCLEOTID B, V2, P433; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; TONG RCW, 1991, BIOCHIM BIOPHYS ACTA, V1080, P19, DOI 10.1016/0167-4838(91)90106-A; WAKABAYASHI S, 1987, BIOCHEM INT, V15, P667; WU LNY, 1982, J BIOL CHEM, V257, P4052; YAMAGUCHI M, 1988, J BIOL CHEM, V263, P2761	34	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14125	14130						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8100227				2022-12-27	WOS:A1993LJ82500052
J	CAMA, A; SIERRA, MD; QUON, MJ; OTTINI, L; GORDEN, P; TAYLOR, SI				CAMA, A; SIERRA, MD; QUON, MJ; OTTINI, L; GORDEN, P; TAYLOR, SI			SUBSTITUTION OF GLUTAMIC-ACID FOR ALANINE-1135 IN THE PUTATIVE CATALYTIC LOOP OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN-RECEPTOR - A MUTATION THAT IMPAIRS PROTEOLYTIC PROCESSING INTO SUBUNITS AND INHIBITS RECEPTOR TYROSINE KINASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; ACANTHOSIS NIGRICANS; CELL-SURFACE; RESISTANT PATIENT; PLASMA-MEMBRANE; MUTANT ALLELES; ALPHA-SUBUNIT; BINDING-SITE; GENE; TRANSPORT	The intracellular domain of the insulin receptor possesses activity as a tyrosine-specific protein kinase which is stimulated by insulin binding to the extracellular domain of the receptor. We have identified a patient with a genetic form of insulin resistance who is heterozygous for a mutation substituting Glu for Ala1135 in the putative ''catalytic loop'' of the tyrosine kinase domain of the receptor. In this investigation, the Glu1135 mutant receptor was expressed by transfection of mutant cDNA into NIH-3T3 cells. Like previously described mutations in the tyrosine kinase domain, the Glu1135 mutation impairs receptor tyrosine kinase activity and inhibits the ability of insulin to stimulate thymidine incorporation and receptor endocytosis. These data support the hypothesis that the receptor tyrosine kinase activity plays a necessary role in the ability of the receptor to mediate insulin action in vitro and in vivo. However, unlike previously described mutations in the intracellular domain of the receptor, the Glu1135 mutation impairs proteolytic cleavage of the proreceptor into separate subunits and impairs the transport of the receptor to the cell surface. These latter defects provide an explanation for the decrease in the number of receptors on the cell surface observed in the patient's circulating monocytes despite the fact that the mutant receptor is resistant to endocytosis and insulin-induced down-regulation.	UNIV CHIETI,FAC MED & SURG,IST PATOL UMANA & MED SOCIALE,CHIETI,ITALY	G d'Annunzio University of Chieti-Pescara	CAMA, A (corresponding author), NIDDKD,DIABET BRANCH,BETHESDA,MD 20892, USA.		Sierra, Maria/GYU-1134-2022; CAMA, Alessandro/J-3964-2018; Quon, Michael/B-1970-2008	CAMA, Alessandro/0000-0003-3647-1368; QUON, MICHAEL/0000-0002-5289-3707; Quon, Michael/0000-0002-9601-9915; OTTINI, LAURA/0000-0001-8030-0449				ACCILI D, 1992, J BIOL CHEM, V267, P586; ACCILI D, 1991, J BIOL CHEM, V266, P434; ACCILI D, 1989, EMBO J, V8, P2509, DOI 10.1002/j.1460-2075.1989.tb08388.x; BAR RS, 1980, DIABETOLOGIA, V18, P209, DOI 10.1007/BF00251918; BAR RS, 1978, J CLIN ENDOCR METAB, V47, P620, DOI 10.1210/jcem-47-3-620; BONISCHNETZLER M, 1986, J BIOL CHEM, V261, P5281; CAMA A, 1987, DIABETOLOGIA, V30, P631; CAMA A, 1988, DIABETES, V37, P982, DOI 10.2337/diabetes.37.7.982; CAMA A, 1992, J BIOL CHEM, V267, P8383; CAMA A, 1991, J CLIN ENDOCR METAB, V73, P894, DOI 10.1210/jcem-73-4-894; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COCOZZA S, 1992, DIABETES, V41, P521, DOI 10.2337/diabetes.41.4.521; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; FRATTALI AL, 1992, J BIOL CHEM, V267, P19521; GRUNBERGER G, 1984, J CLIN ENDOCR METAB, V59, P1152, DOI 10.1210/jcem-59-6-1152; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARI J, 1987, J BIOL CHEM, V262, P15341; HEDO JA, 1981, BIOCHEMISTRY-US, V20, P3385, DOI 10.1021/bi00515a013; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KADOWAKI T, 1990, P NATL ACAD SCI USA, V87, P658, DOI 10.1073/pnas.87.2.658; KADOWAKI T, 1990, J CLIN INVEST, V86, P254, DOI 10.1172/JCI114693; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KADOWAKI T, 1991, J BIOL CHEM, V266, P21224; KADOWAKI T, 1990, J BIOL CHEM, V265, P19143; KAHN CR, 1976, NEW ENGL J MED, V294, P739, DOI 10.1056/NEJM197604012941401; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KASUGA M, 1982, NATURE, V298, P667, DOI 10.1038/298667a0; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOBAYASHI M, 1988, DIABETES, V37, P653, DOI 10.2337/diabetes.37.5.653; KUSARI J, 1991, J BIOL CHEM, V266, P5260; LEVYTOLEDANO R, 1992, CLIN RES, V40, pA321; MAASSEN JA, 1991, BIOCHEMISTRY-US, V30, P10778, DOI 10.1021/bi00108a024; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MOLLER DE, 1988, NEW ENGL J MED, V319, P1526, DOI 10.1056/NEJM198812083192306; MOLLER DE, 1990, J BIOL CHEM, V265, P14979; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; MOLLER DE, 1990, MOL ENDOCRINOL, V4, P1183, DOI 10.1210/mend-4-8-1183; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; PILCH PF, 1979, J BIOL CHEM, V254, P3375; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; TAYLOR SI, 1982, J CLIN ENDOCR METAB, V155, P1108; TREADWAY JL, 1989, J BIOL CHEM, V264, P21450; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDERVORM ER, 1992, J BIOL CHEM, V267, P66; WILDEN PA, 1989, BIOCHEMISTRY-US, V28, P785, DOI 10.1021/bi00428a056; YAMAMOTOHONDA R, 1990, J BIOL CHEM, V265, P14777; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938	54	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8060	8069						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8096518				2022-12-27	WOS:A1993KW97900070
J	KIM, WK; RABIN, RA				KIM, WK; RABIN, RA			CHARACTERIZATION OF THE PURINERGIC P-2 RECEPTORS IN PC12 CELLS - EVIDENCE FOR A NOVEL SUBTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MAST-CELLS; TRANSFORMED MOUSE FIBROBLASTS; LIVER PLASMA-MEMBRANES; ADENOSINE 5'-TRIPHOSPHATE; EXTRACELLULAR ATP; SMOOTH-MUSCLE; ECTO-ENZYMES; CALCIUM; PERMEABILIZATION; CHANNELS	The properties of the purinergic receptors in the PC12 cells were studied. The rank order of potency to increase [Ca2+](i) was: adenosine 5'-O-(1-thiotriphosphate) > ATP > adenosine 5'-O-(3-thiotriphosphate) >>> 3'-O-(4-benzoylbenzoyl)ATP. ADP, AMP, GTP, UTP, alpha, beta- and beta,gamma-methylene adenosine 5'-triphosphates, 5'-adenylylimidodiphosphate, and adenosine analogues were ineffective. Although tetrabasic ATP(4-) was the form responsible for activation of the P-2 receptors, ATP(4-) did not cause cell membrane permeabilization. The binding of alpha-S-35-ATP to the intact cells showed a divalent cation dependency and a binding profile similar to the rank order of potency to increase [Ca2+](i). Scatchard plots of the equilibrium saturation binding data were nonlinear, and dissociation kinetics of the radioligand were best described using two kinetic rates. Different kinetic rates were, however, obtained when dissociation was initiated by the addition of excess ATP or by an 80-fold dilution. The present study describes a purinergic P-2 receptor on PC12 cells that does not fit the classification for the P(2)X, P(2)y, P(2)t, P(2)u, and P(2)z receptor subtypes.	SUNY BUFFALO,DEPT PHARMACOL & THERAPEUT,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006207] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA06207] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ARAV R, 1985, BIOCHIM BIOPHYS ACTA, V820, P183, DOI 10.1016/0005-2736(85)90111-7; Bean B P, 1990, Ion Channels, V2, P169; BEAN BP, 1990, J NEUROSCI, V10, P1; BEAN BP, 1992, TRENDS PHARMACOL SCI, V13, P87, DOI 10.1016/0165-6147(92)90032-2; BURGER RM, 1975, BIOCHEMISTRY-US, V14, P2362, DOI 10.1021/bi00682a014; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; Burnstock G., 1978, CELL MEMBRANE RECEPT, Vpp, P107; CARRAWAY CAC, 1980, BIOCHEM J, V191, P45, DOI 10.1042/bj1910045; COCKCROFT S, 1979, NATURE, V279, P541, DOI 10.1038/279541a0; COCKCROFT S, 1979, J PHYSIOL-LONDON, V296, P229, DOI 10.1113/jphysiol.1979.sp013002; DEPIERRE JW, 1974, J BIOL CHEM, V249, P7121; EVANS WH, 1973, BIOCHEM J, V133, P189, DOI 10.1042/bj1330189; FASOLATO C, 1990, J BIOL CHEM, V265, P20351; FRIEL DD, 1988, J PHYSIOL-LONDON, V401, P361, DOI 10.1113/jphysiol.1988.sp017167; GONZALEZ FA, 1989, J CELL PHYSIOL, V139, P109, DOI 10.1002/jcp.1041390116; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; GROHOVAZ F, 1991, J CELL BIOL, V113, P1341, DOI 10.1083/jcb.113.6.1341; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARLAN J, 1977, INFECT IMMUN, V15, P436, DOI 10.1128/IAI.15.2.436-443.1977; IGUSA Y, 1988, J PHYSIOL-LONDON, V405, P169, DOI 10.1113/jphysiol.1988.sp017327; IPATA PL, 1968, BIOCHEMISTRY-US, V7, P507, DOI 10.1021/bi00842a004; KELLEY LK, 1987, BIOCHEM BIOPH RES CO, V148, P126, DOI 10.1016/0006-291X(87)91085-0; KIM WK, 1993, MOL PHARMACOL, V44, P405; LIN SH, 1990, ANN NY ACAD SCI, V603, P394; MAJID MA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P283, DOI 10.1016/0167-4889(92)90118-U; MUNIZ O, 1984, ARTHRITIS RHEUM, V27, P184; MURRIN RJA, 1992, MOL PHARMACOL, V41, P561; NAKAZAWA K, 1991, J PHYSIOL-LONDON, V434, P647, DOI 10.1113/jphysiol.1991.sp018491; Pearson J.D., 1985, METHODS PHARM, V6, P83; PIEBER M, 1991, COMP BIOCHEM PHYS B, V100, P281, DOI 10.1016/0305-0491(91)90375-N; RATTO GM, 1988, J NEUROSCI, V8, P3240; SARKIS JJF, 1991, BRAIN RES BULL, V26, P871, DOI 10.1016/0361-9230(91)90251-E; SELA D, 1991, J BIOL CHEM, V266, P17990; SOLTOFF SP, 1992, AM J PHYSIOL, V262, pC934, DOI 10.1152/ajpcell.1992.262.4.C934; STEINBERG TH, 1990, ANN NY ACAD SCI, V603, P120; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; Tallarida RJ, 1981, MANUAL PHARM CALCULA; TATHAM PER, 1988, EUR J PHARMACOL, V147, P13, DOI 10.1016/0014-2999(88)90628-0; TORPPEDERSEN C, 1979, BIOCHIM BIOPHYS ACTA, V571, P94, DOI 10.1016/0005-2744(79)90229-8; TURNAY J, 1992, MOL CELL BIOCHEM, V117, P23; ZACCHETTI D, 1991, J BIOL CHEM, V266, P20152	42	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6471	6477						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119998				2022-12-27	WOS:A1994MZ50300034
J	LU, KP; KEMP, BE; MEANS, AR				LU, KP; KEMP, BE; MEANS, AR			IDENTIFICATION OF SUBSTRATE-SPECIFICITY DETERMINANTS FOR THE CELL-CYCLE-REGULATED NIMA PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; ACTIVATION; CALMODULIN; MITOSIS	NIMA is a cell cycle-regulated protein kinase required for the G(2)/M transition in the filamentous fungus Aspergillus nidulans. Previous biochemical characterization of the recombinant enzyme indicated that NIMA is a protein serine/threonine specific kinase with beta-casein being the best substrate from the many proteins and peptides tested (Lu, K. P., Osmani, S. A, and Means, A R. (1993) J. Biol. Chem. 268, 8769-8776). However, substrate specificity or physiologically relevant substrates for NIMA remained unknown. In search for a peptide substrate for this enzyme, we screened an assembled library of synthetic peptides that each contained a phosphorylation site for a known protein kinase and found an excellent peptide substrate for NIMA, phospholemman 42-72 (PLM(42-72)). NIMA kinase phosphorylated PLM(42-72) uniquely and stoichiometrically on Ser(63) with a V-max of 1.4 mu mol/min/mg and apparent K-m of 20.0 mu M. These kinetic constants were about 10-fold higher and 3-fold lower than those for beta-casein, respectively. A detailed analysis of substrate specificity determinants using synthetic peptide analogs of PLM(42-72) indicated that Phe-Arg-Xaa-Ser/Thr represents the optimal primary sequence for NIMA kinase phosphorylation. Replacement of the Arg at P-2 with Ala resulted in a 6-fold increase in K-m and 2-fold decrease in V-max, while substitution of the Phe at P-3 with Ala abolished NIMA phosphorylation. These results reveal the unique nature of substrate recognition by the NIMA kinase and should prove valuable in the search for biologically relevant NIMA substrates.	DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; ST VINCENTS INST MED RES, DEPT PHARMACOL, FITZROY, VIC 3065, AUSTRALIA	Duke University; St. Vincent's Institute of Medical Research			Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33976] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1038, DOI 10.1073/pnas.73.4.1038; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LEE RM, 1992, J BIOL CHEM, V267, P1088; LU KP, 1993, J CELL BIOL, V121, P621, DOI 10.1083/jcb.121.3.621; LU KP, 1993, J BIOL CHEM, V268, P8769; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI AH, 1991, EMBO J, V10, P2669, DOI 10.1002/j.1460-2075.1991.tb07810.x; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT, P265; SOBIESZEK A, 1991, J MOL BIOL, V220, P947, DOI 10.1016/0022-2836(91)90365-D; WALSH DA, 1991, METHOD ENZYMOL, V201, P304	17	57	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6603	6607						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120013				2022-12-27	WOS:A1994MZ50300054
J	BORG, C; LIM, CT; YEOMANS, DC; DIETER, JP; KOMIOTIS, D; ANDERSON, EG; LEBRETON, GC				BORG, C; LIM, CT; YEOMANS, DC; DIETER, JP; KOMIOTIS, D; ANDERSON, EG; LEBRETON, GC			PURIFICATION OF RAT-BRAIN, RABBIT AORTA, AND HUMAN PLATELET THROMBOXANE A(2) PROSTAGLANDIN H-2 RECEPTORS BY IMMUNOAFFINITY CHROMATOGRAPHY EMPLOYING ANTIPEPTIDE AND ANTIRECEPTOR ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BLOOD PLATELETS; 13-AZAPROSTANOIC ACID; POLYACRYLAMIDE GELS; A2 RECEPTOR; ANTAGONIST; PROTEINS; CELLS; AGGREGATION; BINDING; INVITRO	In the present study, a new polyclonal antibody (TxAb) was raised against native thromboxane A(2) (TXA(2))/prostaglandin H-2 (PGH(2)) receptor protein. Previously developed anti-peptide antibodies (P(1)Ab, P(2)Ab) and TxAb were then used to prepare immunoaffinity columns to purify TXA(2)/PGH(2) receptors from platelets, brain, and aorta. In platelets, SDS-polyacrylamide gel electrophoresis revealed the purification of a 55-kDa protein by each affinity column. Identification of this protein as the TXA(2)/PGH(2) receptor was based on: 1) an identical electrophoretic mobility to authentic receptor; 2) immunoblotting of TxAb against P(1)Ab and P(2)Ab-purified protein; 3) immunoblotting of P(1)Ab/P(2)Ab against TxAb-purified protein; and 4) specific [H-3]SQ29,548 binding to TxAb-purified protein. P(1)Ab/TxAb purification of receptors from brain revealed a major protein band at 55 kDa. Furthermore, the eluates from ligand affinity chromatography confirmed the presence of this 55-kDa protein in brain (which was immunoblotted with TxAb), and contained specific [H-3]SQ29,548 binding. In addition to the 55-kDa protein, P(1)Ab/TxAb also purified a minor protein in brain at 52 kDa, which when concentrated, cross-blotted with TxAb and P(1)Ab. This finding indicates sequence homology between the 55- and 52-kDa proteins. Independent identification of brain TXA(2)/PGH(2) receptors was provided by P(2)Ab/TxAb immunohistochemistry, which demonstrated specific labeling of discrete myelin-containing fiber tracts. P(2)Ab/TxAb purification of TXA(2)/PGH(2) receptors from aorta also revealed a major protein band at 55 kDa and a minor band at 52 kDa. These results represent the first purification of TXA(2)/PGH(2) receptors from either brain or aorta.	UNIV ILLINOIS,DEPT PHARMACOL MC 868,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Yeomans, David/0000-0002-9389-8539	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024530] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24530] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; ARMSTRONG RA, 1983, BRIT J PHARMACOL, V79, P953, DOI 10.1111/j.1476-5381.1983.tb10541.x; BORG C, 1993, BIOCHEM PHARMACOL, V45, P2071, DOI 10.1016/0006-2952(93)90018-R; BORG C, 1993, FASEB J, V7, P656; BORG C, 1992, BLOOD, V80, P57; BORN GVR, 1963, J PHYSIOL-LONDON, V168, P178, DOI 10.1113/jphysiol.1963.sp007185; BRACE LD, 1985, AM J PHYSIOL, V249, pH1, DOI 10.1152/ajpheart.1985.249.1.H1; HALUSHKA PV, 1987, FASEB J, V46, P149; HANASAKI K, 1988, BIOCHEM BIOPH RES CO, V151, P1352, DOI 10.1016/S0006-291X(88)80511-4; HORN PT, 1984, J CARDIOVASC PHARM, V6, P609, DOI 10.1097/00005344-198407000-00009; HUNG SC, 1983, BIOCHIM BIOPHYS ACTA, V728, P171, DOI 10.1016/0005-2736(83)90468-6; KIM SO, 1992, BIOCHEM PHARMACOL, V43, P313; KNEZEVIC I, 1992, J PHARMACOL EXP THER, V260, P947; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM SCT, 1991, J PHARMACOL EXP THER, V259, P1371; LEBRETON GC, 1979, P NATL ACAD SCI USA, V76, P4097; LOHSE MJ, 1984, N-S ARCH PHARMACOL, V326, P69, DOI 10.1007/BF00518781; LUMLEY P, 1989, BRIT J PHARMACOL, V97, P783, DOI 10.1111/j.1476-5381.1989.tb12017.x; MAIS D, 1984, TETRAHEDRON LETT, V25, P4207, DOI 10.1016/S0040-4039(01)81396-4; MAYEUX PR, 1989, J PHARMACOL EXP THER, V250, P923; MONCADA S, 1976, PROSTAGLANDINS, V12, P715, DOI 10.1016/0090-6980(76)90048-4; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAKAHATA N, 1990, EUR J PHARMACOL, V184, P233; NAKAHATA N, 1992, BRAIN RES, V583, P100, DOI 10.1016/S0006-8993(10)80013-7; NAKANO T, 1988, FEBS LETT, V234, P309, DOI 10.1016/0014-5793(88)80105-4; OGLETREE ML, 1987, FED PROC, V46, P133; OGLETREE ML, 1985, J PHARMACOL EXP THER, V234, P435; OWEN NE, 1981, AM J PHYSIOL, V241, pH613, DOI 10.1152/ajpheart.1981.241.4.H613; PARISE LV, 1982, J PHARMACOL EXP THER, V222, P276; PATSCHEKE H, 1984, THROMB RES, V33, P277, DOI 10.1016/0049-3848(84)90163-4; RYBICKI JP, 1983, BIOCHIM BIOPHYS ACTA, V751, P66, DOI 10.1016/0005-2760(83)90257-6; SWANSON ML, 1992, BIOL REPROD, V47, P105, DOI 10.1095/biolreprod47.1.105; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USHIKUBI F, 1989, J BIOL CHEM, V264, P16496; WILKES BM, 1989, AM J PHYSIOL, V256, pF1111, DOI 10.1152/ajprenal.1989.256.6.F1111	35	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6109	6116						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119956				2022-12-27	WOS:A1994MY84000095
J	GRONEMEIER, M; CONDIE, A; PROSSER, J; STEINMEYER, K; JENTSCH, TJ; JOCKUSCH, H				GRONEMEIER, M; CONDIE, A; PROSSER, J; STEINMEYER, K; JENTSCH, TJ; JOCKUSCH, H			NONSENSE AND MISSENSE MUTATIONS IN THE MUSCULAR CHLORIDE CHANNEL GENE CLC-1 OF MYOTONIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHYL-N-NITROSOUREA; SKELETAL-MUSCLE; MOUSE MUTANT; ETHYLNITROSOUREA; EXPRESSION; DISEASE; CLONING; LOCUS; ADR; P53	In mature vertebrate muscle, the chloride channel Clc-1 is necessary for the stabilization of the resting potential. Its functional defect leads to the disease myotonia. The ADR mouse (phenotype ADR, genotype adr/adr) is an animal model for human myotonias. The adr gene is a member of a family of non-complementing recessive autosomal mutations (''alleles'' of adr) that cause myotonia in the mouse. The standard allele adr has arisen by the insertion of a retroposon into the chloride channel gene Clc-1 (Steinmeyer, K., Klocke, R., Ortland, C., Gronemeier, M., Jockusch, H., Grunder, S., and Jentsch, T. J. (1991) Nature 354, 304-308). In order to study the nature of two other alleles, adr(mto) and adr(K), we have analyzed overlapping Clc-1 cDNA amplification products by the hydroxylamine and osmium tetroxide modification technique and direct sequencing. A comparison between ADR*MTO and C57BL/6 wild type showed six base pair substitutions, one of which resulted in a stop codon in position 47, whereas the five others are either silent or lead to amino acid substitutions in non-conserved regions of the Clc-1 sequence and were already present in the wild type inbred SWR/J strain from which adr(mto) was derived. The detection of the stop codon in the adr(mto) allele is further indication of the identity of the Clc-1 chloride channel with the adr myotonia gene in the mouse, because a chain termination close to the N terminus would necessarily destroy gene function. For the ethylnitrosourea-induced mutation adr(K), an Ile --> Thr exchange in codon 553 was identified. As this affects a conserved residue within a highly conserved region of the Clc-1 gene, a functional significance of this residue is suggested.	UNIV BIELEFELD,DEV BIOL UNIT,D-33501 BIELEFELD,GERMANY; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV HAMBURG,CTR MOLEC NEUROBIOL,D-20246 HAMBURG,GERMANY	University of Bielefeld; University of Edinburgh; University of Hamburg				Jentsch, Thomas/0000-0002-3509-2553				ABDALLA JA, 1992, AM J HUM GENET, V51, P579; ADKISON L, 1989, MOUSE NEWS LETT, V84, P89; ADRIAN RH, 1974, J PHYSIOL-LONDON, V240, P505, DOI 10.1113/jphysiol.1974.sp010620; BODE VC, 1984, GENETICS, V108, P457; BRYANT SH, 1971, J PHYSIOL-LONDON, V219, P367, DOI 10.1113/jphysiol.1971.sp009667; CHAUDHARI N, 1992, J BIOL CHEM, V267, P25636; CHIOCCA SM, 1992, P NATL ACAD SCI USA, V89, P5331, DOI 10.1073/pnas.89.12.5331; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONDIE A, 1993, HUM MUTAT, V2, P58, DOI 10.1002/humu.1380020111; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DAVISSON MT, 1989, MOUSE NEWS LETT, V83, P167; ECKERT KA, 1988, MOL CARCINOGEN, V1, P50, DOI 10.1002/mc.2940010111; GEORGE AL, 1993, NAT GENET, V3, P305, DOI 10.1038/ng0493-305; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HELLER AH, 1982, J NEUROSCI, V2, P924; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; JOCKUSCH H, 1988, GENET RES, V52, P203, DOI 10.1017/S001667230002766X; JOCKUSCH H, 1991, M MOUSE MOL GENETICS, P137; JOCKUSCH H, 1990, MOUSE GENOME, V86, P216; JOCKUSCH H, 1986, MOUSE NEWS LETT, V75, P19; JOCKUSCH H, 1990, MOUSE GENOME, V87, P72; KAWASAKI E, 1989, AMPLIFICATIONS FORUM, V3, P4; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; KOLTGEN D, 1991, MUSCLE NERVE, V14, P775, DOI 10.1002/mus.880140813; LEHMANNHORN F, 1993, NEUROMUSCULAR DISORD, V3, P161, DOI 10.1016/0960-8966(93)90009-9; MEHRKE G, 1988, MUSCLE NERVE, V11, P440, DOI 10.1002/mus.880110505; MONTANDON AJ, 1989, NUCLEIC ACIDS RES, V17, P3347, DOI 10.1093/nar/17.9.3347; NEUMANN P, 1989, MOUSE NEWS LETT, V83, P157; POWELL JA, 1973, J CELL PHYSIOL, V82, P21, DOI 10.1002/jcp.1040820104; PROSSER J, 1990, ONCOGENE, V5, P1573; PROSSER J, 1991, BRIT J CANCER, V63, P181, DOI 10.1038/bjc.1991.44; RIORDAN JR, 1989, SCIENCE, V245, P1066; RUDEL R, 1988, MUSCLE NERVE, V11, P202, DOI 10.1002/mus.880110303; RUSSELL LB, 1988, P NATL ACAD SCI USA, V85, P9167, DOI 10.1073/pnas.85.23.9167; RUSSELL WL, 1979, P NATL ACAD SCI USA, V76, P5818, DOI 10.1073/pnas.76.11.5818; Saleeba Jennifer A., 1992, Human Mutation, V1, P63, DOI 10.1002/humu.1380010110; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; WATKINS WJ, 1984, LAB ANIM, V18, P1, DOI 10.1258/002367784780865036; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266; WISCHMEYER E, 1993, NEUROMUSCULAR DISORD, V3, P267, DOI 10.1016/0960-8966(93)90019-G	41	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5963	5967						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119941				2022-12-27	WOS:A1994MY84000075
J	HIASA, H; MARIANS, KJ				HIASA, H; MARIANS, KJ			PRIMASE COUPLES LEADING-STRAND AND LAGGING-STRAND DNA-SYNTHESIS FROM ORIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; OKAZAKI FRAGMENT SIZE; REPLICATION FORK; ENZYMATIC REPLICATION; K-12 CHROMOSOME; TERMINUS REGION; PBR322 DNA; ORIGIN; PROTEIN; SEQUENCE	Coupling of leading- and lagging-strand DNA synthesis at replication forks formed at Escherichia coli oriC has been studied in vitro using a replication system reconstituted with purified proteins. At low concentrations of primase (8 nM), the major replication products were multigenome-length molecules, generated by a rolling circle-type mechanism, and unit-length molecules Rolling circle DNA replication was inhibited at high concentrations of primase (80 nM) and the major replication products were half-unit-length leading strands and a distinct population of short Okazaki fragments. At low primase concentrations, an asymmetric mode of DNA synthesis occurred. Each strand was made independently and initiation could occur outside of oriC. At high primase concentrations, initiation occurred exclusively at oriC and two coupled replication forks proceeded bidirectionally around the plasmid. Presumably, at low concentrations of primase, DnaB (the replication fork helicase) unwound the plasmid DNA before replication forks could form, leading to initiation at sites other than oriC. On the other hand, high concentrations of primase resulted in successful capture of the helicase leading to the formation at oriC of coupled replication forks capable of coordinated leading- and lagging-strand synthesis.			HIASA, H (corresponding author), MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM34558] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASAI T, 1990, EMBO J, V9, P4065, DOI 10.1002/j.1460-2075.1990.tb07628.x; BAKER TA, 1987, J BIOL CHEM, V262, P6877; BIRD RE, 1972, J MOL BIOL, V70, P549, DOI 10.1016/0022-2836(72)90559-1; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; HIDAKA M, 1988, CELL, V55, P467, DOI 10.1016/0092-8674(88)90033-5; HILL TM, 1988, J BACTERIOL, V170, P662, DOI 10.1128/jb.170.2.662-668.1988; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KUEMPEL PL, 1977, P NATL ACAD SCI USA, V74, P3927, DOI 10.1073/pnas.74.9.3927; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LOUARN J, 1979, MOL GEN GENET, V172, P7, DOI 10.1007/BF00276208; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MCMACKEN R, 1987, ESCHERICHIA COLI SAL, P564; MEIJER M, 1979, P NATL ACAD SCI USA, V76, P580, DOI 10.1073/pnas.76.2.580; MINDEN JS, 1986, J BIOL CHEM, V261, P1906; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MOK M, 1987, J BIOL CHEM, V262, P16644; MOK M, 1987, J BIOL CHEM, V262, P2304; OKA A, 1980, MOL GEN GENET, V178, P9, DOI 10.1007/BF00267207; PARADA CA, 1991, J BIOL CHEM, V266, P18895; PRESCOTT DM, 1972, P NATL ACAD SCI USA, V69, P2842, DOI 10.1073/pnas.69.10.2842; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; STAYTON MM, 1983, J BIOL CHEM, V258, P3205; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045; ZYSKIND JW, 1992, CELL, V69, P5, DOI 10.1016/0092-8674(92)90112-P	34	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6058	6063						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119951				2022-12-27	WOS:A1994MY84000088
J	FUKADA, Y; MATSUDA, T; KOKAME, K; TAKAO, T; SHIMONISHI, Y; AKINO, T; YOSHIZAWA, T				FUKADA, Y; MATSUDA, T; KOKAME, K; TAKAO, T; SHIMONISHI, Y; AKINO, T; YOSHIZAWA, T			EFFECTS OF CARBOXYL METHYLATION OF PHOTORECEPTOR G-PROTEIN GAMMA-SUBUNIT IN VISUAL TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL CYSTEINE; ROD OUTER SEGMENTS; BETA-GAMMA; ALPHA-SUBUNIT; MEMBRANE ATTACHMENT; BINDING PROTEIN; BOVINE BRAIN; GTP-BINDING; MYRISTOYLATION; ESTER	G protein gamma-subunits are isoprenylated and carboxyl-methylated at the C-terminal cysteine, which is indispensable for the function of photoreceptor G protein transducin (T alpha beta gamma). However, the physiological role of the methylation and its reversibility have been unclear, Here we isolated methylated and non-methylated forms of farnesylated T beta gamma, and demonstrated that the methylation remarkably facilitates not only the membrane association of T beta gamma but also the subunit interaction between T alpha and T beta gamma. Consequently, the functional coupling of transducin with light-activated receptor, metarhodopsin II, was stabilized by the methylation, resulting in acceleration of GTP gamma S (guanosine 5'-3-0-(thio) triphosphate) binding to T(alpha. An examination of the reversibility of the methylation suggested that T gamma is kept fully methylated in rod outer segments. These observations indicate that the methylation of T gamma plays an important role in the most efficient photon-signal transduction process in rod cells.	OSAKA UNIV,INST PROT RES,OSAKA 565,JAPAN	Osaka University	FUKADA, Y (corresponding author), UNIV TOKYO,COLL ARTS & SCI,DEPT PURE & APPL SCI,MEGURO KU,KOMABA 3-8-1,TOKYO 153,JAPAN.		吉孝, 深田/G-5090-2014	Kokame, Koichi/0000-0002-9654-6299				BASINGER S, 1976, J CELL BIOL, V69, P29, DOI 10.1083/jcb.69.1.29; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; BUTRYNSKI JE, 1992, BIOCHEMISTRY-US, V31, P8030, DOI 10.1021/bi00149a037; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FUKADA Y, 1989, J BIOL CHEM, V264, P5937; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUKADA Y, 1990, BIOCHEMISTRY-US, V29, P3133, DOI 10.1021/bi00464a033; FUNG BKK, 1990, FEBS LETT, V260, P313, DOI 10.1016/0014-5793(90)80132-3; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; Kuhn H., 1980, Neurochemistry International, V1, P269, DOI 10.1016/0197-0186(80)90066-2; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7672; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MORISHITA R, 1992, EUR J BIOCHEM, V210, P1061, DOI 10.1111/j.1432-1033.1992.tb17512.x; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MURAKAMI T, 1992, BIOCHEMISTRY-US, V31, P2905, DOI 10.1021/bi00126a009; OHGURO H, 1990, BIOCHEM BIOPH RES CO, V167, P1235, DOI 10.1016/0006-291X(90)90656-8; OHGURO H, 1991, EMBO J, V10, P3669, DOI 10.1002/j.1460-2075.1991.tb04934.x; OTA IM, 1989, J BIOL CHEM, V264, P12879; PEREZSALA D, 1991, P NATL ACAD SCI USA, V88, P3043, DOI 10.1073/pnas.88.8.3043; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; SCHAFER WR, 1992, ANNU REV GENET, V30, P209; SCHULTZ AM, 1987, BIOCHEM BIOPH RES CO, V146, P1234, DOI 10.1016/0006-291X(87)90780-7; SHIRATAKI H, 1991, J BIOL CHEM, V266, P20672; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; STEPHENSON RC, 1992, J BIOL CHEM, V267, P1314; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; SWANSON RJ, 1983, J BIOL CHEM, V258, P599; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAN EW, 1992, BIOCHEMISTRY-US, V31, P5572, DOI 10.1021/bi00139a021; VOLKER C, 1991, J BIOL CHEM, V266, P21515; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	42	108	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5163	5170						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106497				2022-12-27	WOS:A1994MX57100074
J	HALLAK, H; MUSZBEK, L; LAPOSATA, M; BELMONTE, E; BRASS, LF; MANNING, DR				HALLAK, H; MUSZBEK, L; LAPOSATA, M; BELMONTE, E; BRASS, LF; MANNING, DR			COVALENT BINDING OF ARACHIDONATE TO G-PROTEIN ALPHA-SUBUNITS OF HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FATTY-ACIDS; MYRISTOYLATION; MEMBRANE; ACYLATION; PALMITOYLATION; AFFINITY; THROMBIN; RELEASE; CELLS	The alpha subunits of GTP-binding regulatory proteins (G proteins) are subject to lipid modifications required for anchorage to membrane and/or interactions with other proteins, With the knowledge that alpha subunits are palmitoylated, which we demonstrate here for human platelets, we sought to determine whether these subunits also bind arachidonate and myristate in a covalent, post-translational manner. All alpha subunits examined were found to incorporate radioactivity upon incubation of human platelets with [H-3]palmitate, [H-3]arachidonate, and [H-3]myristate. The identity of [H-3]palmitate and [H-3]arachidonate as covalently bound fatty acids was confirmed by high pressure liquid chromatography following alkaline methanolysis. With [H-3]myristate, however, the bound fatty acid proved to be [H-3]palmitate, presumably generated by a 2-carbon chain elongation. Protein-bound [H-3]palmitate and [H-3]arachidonate were released by hydroxylamine at neutral pH, implying a thioester linkage between protein and fatty acid. Thus, post-translational modifications of G protein alpha subunits include palmitoylation and arachidonoylation, but not myristoylation, Given the different physical properties of saturated and unsaturated fatty acids and the large-scale release of arachidonate during platelet activation, changes in arachidonate incorporation may serve as an important regulator of a subunit function.	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED & PATHOL,PHILADELPHIA,PA 19104; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114; UNIV MED SCH DEBRECEN,DEPT CLIN CHEM,H-4012 DEBRECEN,HUNGARY	University of Pennsylvania; University of Pennsylvania; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Debrecen					NHLBI NIH HHS [HL45181] Funding Source: Medline; NIGMS NIH HHS [GM34781] Funding Source: Medline; NIMH NIH HHS [MH14654] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM034781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH014654] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BILLS TK, 1977, J CLIN INVEST, V60, P1, DOI 10.1172/JCI108745; BRASS LF, 1993, THROMB HAEMOSTASIS, V70, P217; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; FUJIMOTO T, 1993, J BIOL CHEM, V268, P11394; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HALLAK H, 1994, IN PRESS J BIOL CHEM, V269; HALLAQ Y, 1993, LIPIDS, V26, P355; HENNES AR, 1966, NATURE, V10, P839; HUANG EM, 1989, BIOCHIM BIOPHYS ACTA, V1011, P134, DOI 10.1016/0167-4889(89)90200-0; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MAGEE AI, 1984, BIOCHIM BIOPHYS ACTA, V798, P156, DOI 10.1016/0304-4165(84)90298-8; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUSZBEK L, 1993, J BIOL CHEM, V268, P18243; MUSZBEK L, 1989, BLOOD, V74, P1339; MUSZBEK L, 1993, J BIOL CHEM, V268, P8251; NEUBERT TA, 1992, J BIOL CHEM, V267; NEUFELD EJ, 1983, J CLIN INVEST, V72, P214, DOI 10.1172/JCI110959; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; OKUBO K, 1991, J BIOL CHEM, V266, P16420; PAPAC DI, 1992, J BIOL CHEM, V267, P16889; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WILLIAMS AG, 1990, BLOOD, V76, P721	31	109	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4713	4716						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106438				2022-12-27	WOS:A1994MX57100006
J	HERSHKO, A; GANOTH, D; SUDAKIN, V; DAHAN, A; COHEN, LH; LUCA, FC; RUDERMAN, JV; EYTAN, E				HERSHKO, A; GANOTH, D; SUDAKIN, V; DAHAN, A; COHEN, LH; LUCA, FC; RUDERMAN, JV; EYTAN, E			COMPONENTS OF A SYSTEM THAT LIGATES CYCLIN TO UBIQUITIN AND THEIR REGULATION BY THE PROTEIN-KINASE CDC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PURIFICATION; AMPHIBIAN EGGS; CELL-CYCLES; CLAM EMBRYO; M-PHASE; DEGRADATION; DESTRUCTION; PATHWAY; RESOLUTION; EXTRACTS	Cyclin B, a positive regulatory subunit of the cdc2 protein kinase complex, is synthesized across the cell cycle and then rapidly degraded at the end of mitosis. Degradation of cyclin B is triggered by increased levels of active cdc2 and is required for exit from mitosis. It was shown previously that cyclin degradation is carried out by the ubiquitin system, but the components responsible for the specificity and regulation of cyclin-ubiquitin ligation have not been identified. The formation of ubiquitin-protein conjugates usually requires the sequential action of three enzymes: a ubiquitin-activating enzyme (E(1)), a ubiquitin-carrier protein (E(2)), and a ubiquitin-protein ligase (E(3)). In this work we employed a fractionation approach to identify the components of a clam oocyte system responsible for specific ubiquitination of cyclin and to determine which components are regulated by cdc2. Experimental conditions were established under which a fusion protein containing an amino-terminal fragment of cyclin B is ligated to ubiquitin only in extracts from M-phase but not from interphase cells. Fractionation of M-phase extracts by DEAE-cellulose and high speed centrifugation yielded three fractions that were all required for cell cycle stage-specific cyclin-ubiquitin ligation. Only one of these fractions could be replaced by a previously known enzyme of the ubiquitin system, E(1). A second fraction contained a novel species of E(2), termed E(2)-C, which acts in the ligation of ubiquitin to cyclin but not to other endogenous proteins. A third component is associated with particulate material. Whereas E(2)-C from either M-phase or interphase extracts is active, the particulate component is active only in M-phase. Incubation of the particulate fraction from interphase cells with the protein kinase cdc2 activates it for cyclin-ubiquitin ligation, after a lag of about 30 min. These findings suggest that the particulate fraction may contain an E(3) enzyme that acts on cyclin, as well as additional factors activated by cdc2.	TECHNION ISRAEL INST TECHNOL, RAPPAPORT FAMILY INST RES MED SCI, IL-31096 HAIFA, ISRAEL; FOX CHASE CANC CTR, INST CANC RES, PHILADELPHIA, PA 19111 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; MARINE BIOL LAB, WOODS HOLE, MA 02543 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Fox Chase Cancer Center; Harvard University; Harvard Medical School; Marine Biological Laboratory - Woods Hole	HERSHKO, A (corresponding author), TECHNION ISRAEL INST TECHNOL, B RAPPAPORT FAC MED, BIOCHEM UNIT, IL-31096 HAIFA, ISRAEL.				NICHD NIH HHS [HD-23696] Funding Source: Medline; NIDDK NIH HHS [DK-25614] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025614] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GIROD PA, 1993, J BIOL CHEM, V268, P955; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; LABBE JC, 1991, METHOD ENZYMOL, V200, P291; LEISS D, 1992, J CELL SCI, V102, P285; LORCA T, 1991, MOL CELL BIOL, V11, P1171, DOI 10.1128/MCB.11.2.1171; LORCA T, 1992, EMBO J, V11, P2381, DOI 10.1002/j.1460-2075.1992.tb05302.x; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1986, J BIOL CHEM, V261, P210; PINES J, 1992, Current Opinion in Cell Biology, V4, P144, DOI 10.1016/0955-0674(92)90024-7; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; REISS Y, 1990, J BIOL CHEM, V265, P3685; ROSE IA, 1983, BIOCHEMISTRY-US, V22, P4234, DOI 10.1021/bi00287a012; RUDERMAN J, 1991, COLD SH Q B, V56, P495; SHERWOOD SW, 1993, P NATL ACAD SCI USA, V90, P3353, DOI 10.1073/pnas.90.8.3353	30	202	205	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4940	4946						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106468				2022-12-27	WOS:A1994MX57100040
J	HURWITZ, R; FERLINZ, K; VIELHABER, G; MOCZALL, H; SANDHOFF, K				HURWITZ, R; FERLINZ, K; VIELHABER, G; MOCZALL, H; SANDHOFF, K			PROCESSING OF HUMAN ACID SPHINGOMYELINASE IN NORMAL AND I-CELL FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIEMANN-PICK DISEASE; LYSOSOMAL-ENZYMES; NUCLEOTIDE-SEQUENCE; HUMAN-URINE; GENE; PURIFICATION; DEFICIENCY; IDENTIFICATION; BIOSYNTHESIS; ANTIBODIES	The biosynthesis of acid sphingomyelinase in normal and I-cell disease fibroblasts was investigated by metabolic labeling with [S-35]methionine and immunoprecipitation followed by polyacrylamide gel electrophoresis and fluorography. Two major polypeptides with apparent molecular masses of 75 and 72 kDa (peptide chains of 64 and 61 kDa, respectively) and a minor one with molecular mass of 57 kDa (peptide chain of 47 kDa) were found intracellularly soon after pulse labeling. The 75-kDa form is assumed to be the propropolypeptide of sphingomyelinase which is converted into the precursor form of 72 kDa, The precursor is subjected to two distinct processing events. A minor part is already cleaved in the endoplasmic reticulum-Golgi complex yielding the beta-endo-N-acetylglucosaminidase H-resistant form of 57 kDa; whereas, the major part of the precursor is processed within 4 h to a 70-kDa mature beta-endo-N-acetylglucosaminidase H-sensitive form of sphingomyelinase, which is subsequently converted into a polypeptide with molecular mass of 52 kDa within a chase of about 20 h. Both the precursor (72 kDa) as well as its early cleavage product of 57 kDa are secreted into the culture medium to a minor extent. Intracellular transport of sphingomyelinase into lysosomes depends on the phosphomannosyl specific receptor by following criteria: (i) about 80% of newly synthesized precursor was secreted in NH4Cl-treated fibroblasts as well as in I-cells, (ii) the maturation of sphingomyelinase was inhibited in normal fibroblasts exposed to NH4Cl as well as in I-cell fibroblasts, and (iii) the [P-32]phosphate associated with oligosaccharides was cleavable by beta-endo-N-acetylglucosaminidase H. However, endocytosis of radiolabeled extracellular precursor by fibroblasts was not prevented by the addition of mannose 6-phosphate, whereas uptake of arylsulfatase A and beta-hexosaminidase was almost completely blocked under these conditions. This indicates that endocytosis of acid sphingomyelinase by cultured fibroblasts might be mediated by an alternative pathway.	INST ORGAN CHEM & BIOCHEM,D-53121 BONN,GERMANY	University of Bonn								ANDERSON RGW, 1977, CELL, V10, P351, DOI 10.1016/0092-8674(77)90022-8; BEAUDET AL, 1980, CLIN CHIM ACTA, V108, P403, DOI 10.1016/0009-8981(80)90348-4; BRADY RO, 1966, P NATL ACAD SCI USA, V55, P367; FERLINZ K, 1991, BIOCHEM BIOPH RES CO, V179, P1187, DOI 10.1016/0006-291X(91)91697-B; FREEMAN SJ, 1984, ANAL BIOCHEM, V141, P248, DOI 10.1016/0003-2697(84)90453-6; GUPTA DK, 1984, H-S Z PHYSIOL CHEM, V365, P867, DOI 10.1515/bchm2.1984.365.2.867; HASILIK A, 1981, BIOCHEM BIOPH RES CO, V98, P761, DOI 10.1016/0006-291X(81)91177-3; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; JOBB EA, 1989, BIOCHEM CELL BIOL, V67, P801, DOI 10.1139/o89-118; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LEROY JG, 1972, PEDIATR RES, V6, P752, DOI 10.1203/00006450-197210000-00002; LEVRAN O, 1991, J CLIN INVEST, V88, P806, DOI 10.1172/JCI115380; LEVRAN O, 1991, P NATL ACAD SCI USA, V88, P3742; QUINTERN LE, 1989, EMBO J, V8, P2469, DOI 10.1002/j.1460-2075.1989.tb08382.x; QUINTERN LE, 1987, BIOCHIM BIOPHYS ACTA, V922, P323, DOI 10.1016/0005-2760(87)90055-5; ROUSSON R, 1993, J IMMUNOL METHODS, V160, P199, DOI 10.1016/0022-1759(93)90178-A; ROUSSON R, 1987, BIOCHIM BIOPHYS ACTA, V924, P522; SCHNABEL D, 1992, J BIOL CHEM, V267, P3312; SCHUCHMAN EH, 1992, GENOMICS, V12, P197, DOI 10.1016/0888-7543(92)90366-Z; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SPENCE MW, 1989, METABOLIC BASIS INHE, P1655; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; TAKAHASHI T, 1992, J BIOL CHEM, V267, P12552; WEITZ G, 1985, BIOCHIM BIOPHYS ACTA, V838, P92, DOI 10.1016/0304-4165(85)90254-5; WEITZ G, 1983, H-S Z PHYSIOL CHEM, V364, P863, DOI 10.1515/bchm2.1983.364.2.863; WENGER DA, 1976, LIFE SCI, V19, P413, DOI 10.1016/0024-3205(76)90047-3; WHERRETT JR, 1983, NEUROCHEM RES, V8, P89, DOI 10.1007/BF00965656	28	81	83	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5440	5445						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106525				2022-12-27	WOS:A1994MX57100109
J	O, IS; STITT, BL				O, IS; STITT, BL			8-AZIDO-ATP INACTIVATION OF ESCHERICHIA-COLI TRANSCRIPTION TERMINATION FACTOR-RHO - MODIFICATION OF ONE SUBUNIT INACTIVATES THE HEXAMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-BINDING DOMAIN; ATP-BINDING; ADENYLATE KINASE; PROTEIN-RHO; PHYSICAL-PROPERTIES; BETA-SUBUNIT; MUTANT-RHO; RNA; SITE	Escherichia coli transcription termination factor Rho (EC 3.6.1.3) releases nascent RNA from transcription complexes in a reaction which requires ATP hydrolysis. To understand the structure of the ATPase active site, we employed an analog of ATP, 8-azidoadenosine 5'-triphosphate (8-azido-ATP) as a photoaffinity labeling agent. 8-Azido-ATP interacts nearly normally with the active site of Rho. It binds to 3 sites per Rho hexamer with a 100 mu M K-D and is a substrate with a V-max 5% that of ATP and a K-m, of 18 mu M. Under UV irradiation, 8-azido-ATP makes covalent bonds with Rho, inactivating its ATPase. Rho is protected from this inactivation by the presence of ATP. We used [alpha-P-32]8-azido-ATP to label the active site and identify residues involved in ATP binding. Labeled tryptic peptides of the modified Rho were purified by Fe3+-iminodiacetic acid affinity chromatography and reverse-phase C-18 column high performance liquid chromatography. We identified a single peptide, Gly(174)-Lys(184), that is labeled by 8-azido-ATP and protected from labeling in the presence of ATP. The modified amino acid is Lys(181), whose conservative replacement by Gln(181) gives rise to a poorly active enzyme (Dombroski, A. J., Brennan, C. A., Spear, P., and Platt, T (1988a) J. Biol. Chem. 263, 18802-18809). Lys(181) probably participates in binding the phosphoryl groups of ATP. Incorporation of one 8-azido-ATP per Rho hexamer is sufficient to cause inactivation, a result that indicates that the active sites of Rho interact in RNA-dependent ATP hydrolysis.	TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA; NYU, DEPT BIOL, NEW YORK, NY 10003 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; New York University				O-Sullivan, InSug/0000-0003-0161-2028				BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BEAR DG, 1985, P NATL ACAD SCI USA, V82, P1911, DOI 10.1073/pnas.82.7.1911; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; CARTWRIGHT IL, 1976, NUCLEIC ACIDS RES, V3, P2331, DOI 10.1093/nar/3.9.2331; CHAVAN AJ, 1992, J BIOL CHEM, V267, P14866; Cleland W W, 1979, Methods Enzymol, V63, P103; Czarnecki J, 1979, Methods Enzymol, V56, P642; DOLAN JW, 1990, J BIOL CHEM, V265, P5747; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18802; DOMBROSKI AJ, 1988, P NATL ACAD SCI USA, V85, P2538, DOI 10.1073/pnas.85.8.2538; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18810; DREUSICKE D, 1986, FEBS LETT, V208, P301, DOI 10.1016/0014-5793(86)81037-7; DUNCAN TM, 1986, FEBS LETT, V208, P1, DOI 10.1016/0014-5793(86)81519-8; ENGEL D, 1984, NUCLEIC ACIDS RES, V17, P7389; EVANS RK, 1989, BIOCHEMISTRY-US, V28, P707, DOI 10.1021/bi00428a044; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P271; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GALLUPPI G, 1976, RNA POLYMERASE, P657; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P121, DOI 10.1021/bi00116a018; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P111, DOI 10.1021/bi00116a017; GIESELMANN J, 1992, PROTEIN SCI, V1, P850; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; HALEY BE, 1974, P NATL ACAD SCI USA, V71, P3367, DOI 10.1073/pnas.71.9.3367; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; HOWARD BH, 1976, J BIOL CHEM, V251, P2520; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KASHO VN, 1993, ARCH BIOCHEM BIOPHYS, V300, P293, DOI 10.1006/abbi.1993.1041; KING SM, 1991, METHOD ENZYMOL, V196, P449; LADINE J R, 1988, Journal of Cell Biology, V107, p854A; MORI H, 1989, J MOL BIOL, V210, P39, DOI 10.1016/0022-2836(89)90289-1; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; MUNEYAMA K, 1971, BIOCHEMISTRY-US, V10, P2390; ODA T, 1972, J MOL BIOL, V71, P799; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PALCZEWSKI K, 1987, BIOCHEMISTRY-US, V26, P3466, DOI 10.1021/bi00386a033; PARSONAGE D, 1987, J BIOL CHEM, V262, P6301; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PINKHAM JL, 1983, NUCLEIC ACIDS RES, V11, P3531, DOI 10.1093/nar/11.11.3531; PLATT T, 1992, TRANSCRIPTIONAL REGU, P365; PLATT T, 1988, MOL BIOL RNA, V94, P325; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7451, DOI 10.1021/bi00484a014; RICHARDSON JP, 1986, J MOL BIOL, V189, P413, DOI 10.1016/0022-2836(86)90313-X; SALVUCCI ME, 1992, BIOCHEMISTRY-US, V31, P4479, DOI 10.1021/bi00133a014; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SATRE M, 1986, METHOD ENZYMOL, V126, P712; SHOEMAKER MT, 1993, BIOCHEMISTRY-US, V32, P1883, DOI 10.1021/bi00058a023; STEINMETZ EJ, 1990, J BIOL CHEM, V265, P18408; STITT BL, 1986, J BIOL CHEM, V261, P5906; STITT BL, 1988, J BIOL CHEM, V263; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	59	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5009	5015						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106476				2022-12-27	WOS:A1994MX57100050
J	PERALA, M; ELIMA, K; METSARANTA, M; ROSATI, R; DECROMBRUGGHE, B; VUORIO, E				PERALA, M; ELIMA, K; METSARANTA, M; ROSATI, R; DECROMBRUGGHE, B; VUORIO, E			THE EXON STRUCTURE OF THE MOUSE ALPHA-2(IX) COLLAGEN GENE SHOWS UNEXPECTED DIVERGENCE FROM THE CHICK GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IX COLLAGEN; II COLLAGEN; MESSENGER-RNAS; 1ST INTRON; CARTILAGE; PROTEOGLYCAN; IDENTIFICATION; CLONING; CDNA; EXPRESSION	One cosmid and two overlapping phage clones covering the entire mouse alpha 2(IX) collagen gene including 12 kilobase pairs (kb) of 5'- and 8 kb of 3'-flanking sequences were isolated from two genomic libraries. The overall gene structure was determined by restriction mapping and nucleotide sequencing. The gene spans 16 kb from the start of transcription to the polyadenylation site and contains 32 exons. It codes for a mRNA of 3 kb that translates into a polypeptide of 688 amino acids. The intron-exon junctions and mRNA structure were confirmed by amplification of cDNA made for mouse cartilage RNA. The coding sequence of the mouse alpha 2(IX) collagen gene shows marked similarities to those for other type IX collagen chains. Although the overall exon-intron organization of the mouse gene is very similar to the chick alpha 2(IX) gene, some unexpected differences were observed at the splice junctions. Split codons characteristic for the central triple helical domain of the chick were not found in the mouse gene that thus exhibited a long stretch of exons with sizes that are multiples of 9 base pairs in this domain. The promoter of the mouse alpha 2(IX) collagen gene contains some G + C-rich elements including three Sp1 consensus recognition sites and a far upstream CCAAT box but no TATAA box. Both primer extension and RNase protection assays revealed several transcription start sites within 418 base pairs of the promoter. The present study reports the first complete nucleotide sequence of any type IX collagen gene and forms the basis for comparative structural studies on this collagen type and for experiments involving transgenic mice.	UNIV TURKU,DEPT MOLEC BIOL,SF-20520 TURKU,FINLAND; UNIV TURKU,DEPT MED BIOCHEM,SF-20520 TURKU,FINLAND; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	University of Turku; University of Turku; University of Texas System; UTMD Anderson Cancer Center				Vuorio, Eero/0000-0003-3404-2439	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040335] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 40335] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BREWTON RG, 1992, EUR J BIOCHEM, V205, P443, DOI 10.1111/j.1432-1033.1992.tb16798.x; BRUCKNER P, 1985, P NATL ACAD SCI USA, V82, P2608, DOI 10.1073/pnas.82.9.2608; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P133; ELIMA K, 1992, BIOCHIM BIOPHYS ACTA, V1130, P78, DOI 10.1016/0167-4781(92)90465-C; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; FITSCH JM, 1989, DEV CAMB, V105, P85; HAREL R, 1992, J BIOL CHEM, V267, P10070; HASTIE ND, 1990, GENETIC VARIATIONS S, P559; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; IRWIN MH, 1986, J BIOL CHEM, V261, P6281; KIMURA T, 1989, EUR J BIOCHEM, V179, P71, DOI 10.1111/j.1432-1033.1989.tb14522.x; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LOZANO G, 1985, P NATL ACAD SCI USA, V82, P4050, DOI 10.1073/pnas.82.12.4050; MCCORMICK D, 1987, P NATL ACAD SCI USA, V84, P4044, DOI 10.1073/pnas.84.12.4044; METSARANTA M, 1991, J BIOL CHEM, V266, P16862; MULLERGLAUSER W, 1986, J CELL BIOL, V102, P1931, DOI 10.1083/jcb.102.5.1931; MURAGAKI Y, 1990, EUR J BIOCHEM, V192, P703, DOI 10.1111/j.1432-1033.1990.tb19279.x; NAKATA K, 1993, P NATL ACAD SCI USA, V90, P2870, DOI 10.1073/pnas.90.7.2870; NINOMIYA Y, 1985, BIOCHEMISTRY-US, V24, P4223, DOI 10.1021/bi00336a061; NINOMIYA Y, 1984, P NATL ACAD SCI-BIOL, V81, P3014, DOI 10.1073/pnas.81.10.3014; NINOMIYA Y, 1990, EXTRACELLULAR MATRIX, P79; NISHIMURA I, 1989, J BIOL CHEM, V264, P20033; PERALA M, 1993, FEBS LETT, V319, P177, DOI 10.1016/0014-5793(93)80062-Y; Sambrook J, 1989, MOL CLONING LABORATO; SPRANGER J, 1992, EUR J PEDIATR, V151, P407; SWIDERSKI RE, 1992, DEVELOPMENT, V115, P169; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VANDERREST M, 1985, J BIOL CHEM, V260, P220; VASIOS G, 1988, J BIOL CHEM, V263, P2324; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; VIKKULA M, 1992, BIOCHEM J, V285, P287, DOI 10.1042/bj2850287; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WANG LQ, 1991, J BIOL CHEM, V266, P19878; WU JJ, 1992, J BIOL CHEM, V267, P23007; YAMADA Y, 1980, CELL, V22, P887, DOI 10.1016/0092-8674(80)90565-6	37	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5064	5071						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106484				2022-12-27	WOS:A1994MX57100059
J	GOPING, IS; SHORE, GC				GOPING, IS; SHORE, GC			INTERACTIONS BETWEEN REPRESSOR AND ANTI-REPRESSOR ELEMENTS IN THE CARBAMYL-PHOSPHATE SYNTHETASE-I PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXTINGUISHER; TRANSCRIPTION FACTOR-IIIA; C/EBP-RELATED PROTEINS; DNA-BINDING PROTEINS; GENE-EXPRESSION; ALBUMIN GENE; RAT-LIVER; INVITRO TRANSCRIPTION; HOMEODOMAIN PROTEIN; REGULATORY SUBUNIT	The proximal promoter of the rat carbamyl phosphate synthetase I gene contains four cis-acting regulatory regions, designated sites GAG, I, II, and III. The GAG site, which is located adjacent to the predicted TATA region, contains a direct repeat of the nonamer, GAGGAGGGG, and binds a factor which is unrelated to the other upstream binding site factors. Sites I-III, on the other hand, bind the same or similar factors, but with different affinities (site II > site III > site I). High affinity binding to site II requires the core octamer, GTTGCAAC. Sequential 5'-deletion of the promoter revealed that GAG is the predominant activating element in transient transfection analyses and, on its own, can sustain activity of a -67 promoter fragment. However, in the context of a -157 promoter in which the GTTGCAAC core of site II had been mutated, promoter activity was completely repressed, and this repression was due to sites I and III. Repression by sites I and III in the presence of mutated site II was relieved either by mutating sites I and III or by introducing a 76-bp random DNA fragment between GAG and site I. Our results suggest a model in which the carbamyl phosphate synthetase I promoter is controlled by a single activating element, GAG, and by two repressor elements, sites I and III. We conclude that the high affinity site II element binds an anti-repressor. Footprint analyses of the -157 promoter with and without a mutation of the GTTGCAAC element in site II suggest that the anti-repressor may interfere with the site I and site III repressors by quenching.	MCGILL UNIV,DEPT BIOCHEM,MCINTYRE MED SCI BLDG,MONTREAL H3G 1Y6,PQ,CANADA	McGill University								ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ADAMS TH, 1988, CELL, V54, P353, DOI 10.1016/0092-8674(88)90198-5; AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; BEMIS LT, 1988, MOL CELL BIOL, V8, P2125, DOI 10.1128/MCB.8.5.2125; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BESSEREAU JL, 1993, EMBO J, V12, P443, DOI 10.1002/j.1460-2075.1993.tb05676.x; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CLEARY MA, 1993, GENE DEV, V7, P72, DOI 10.1101/gad.7.1.72; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GOPING IS, 1992, GENE, V118, P283, DOI 10.1016/0378-1119(92)90201-Y; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HANSEN U, 1981, CELL, V27, P603, DOI 10.1016/0092-8674(81)90402-5; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; HOWELL BW, 1989, MOL CELL BIOL, V9, P2928, DOI 10.1128/MCB.9.7.2928; INOSTROZA JA, 1992, CELL, V70, P477; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KW, 1991, CELL, V66, P861, DOI 10.1016/0092-8674(91)90433-Y; JONES ME, 1965, ANNU REV BIOCHEM, V34, P381; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; LAGACE M, 1987, J BIOL CHEM, V262, P10415; LAGACE M, 1992, GENE, V118, P231, DOI 10.1016/0378-1119(92)90193-S; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MALAN TP, 1984, CELL, V39, P173, DOI 10.1016/0092-8674(84)90203-4; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MYERS RM, 1981, CELL, V25, P373, DOI 10.1016/0092-8674(81)90056-8; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P2289, DOI 10.1073/pnas.87.6.2289; PAULWEBER B, 1993, MOL CELL BIOL, V13, P1534, DOI 10.1128/MCB.13.3.1534; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; PTASHNE M, 1980, CELL, V19, P1, DOI 10.1016/0092-8674(80)90383-9; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; ROZEN R, 1983, BIOCHIM BIOPHYS ACTA, V741, P47, DOI 10.1016/0167-4781(83)90008-8; RYALL J, 1985, EUR J BIOCHEM, V152, P287, DOI 10.1111/j.1432-1033.1985.tb09196.x; RYALL JC, 1986, EUR J BIOCHEM, V156, P453, DOI 10.1111/j.1432-1033.1986.tb09603.x; Sambrook J, 1989, MOL CLONING LABORATO; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; STENLUND A, 1990, GENE DEV, V4, P123, DOI 10.1101/gad.4.1.123; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; TANIGUCHI T, 1979, P NATL ACAD SCI USA, V76, P5090, DOI 10.1073/pnas.76.10.5090; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	67	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3891	3896						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106435				2022-12-27	WOS:A1994MV63100111
J	ROBERTS, E; NASH, RA; ROBINS, P; LINDAHL, T				ROBERTS, E; NASH, RA; ROBINS, P; LINDAHL, T			DIFFERENT ACTIVE-SITES OF MAMMALIAN DNA LIGASE-I AND LIGASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; GEL-ELECTROPHORESIS; CATALYTIC DOMAIN; HUMAN-CELLS; RAT-LIVER; PURIFICATION; CDNA	Bovine DNA ligases I and II were adenylylated in the presence of [alpha-P-32]ATP and digested with limiting amounts of trypsin or V8 protease. The generation of radioactive peptides of decreasing size was monitored by polyacrylamide gel electrophoresis and autoradiography. Active site peptides obtained by complete proteolytic digestions with trypsin, V8, or Lys-C protease were also compared. The partial digestion products of DNA ligases I and II were entirely different, with no indication of extensive sequence homology. Furthermore, the sequence of the active site region of DNA ligase I is clearly different from that of DNA ligase II. Similar analysis of a third chromatographically distinct mammalian DNA ligase indicated that it is different from DNA ligase I but related to DNA ligase II.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND									ARRAND JE, 1986, J BIOL CHEM, V261, P9079; BARNES DE, 1990, P NATL ACAD SCI USA, V87, P6679, DOI 10.1073/pnas.87.17.6679; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CONG PJ, 1993, J BIOL CHEM, V268, P7256; ELDER RH, 1992, EUR J BIOCHEM, V203, P53, DOI 10.1111/j.1432-1033.1992.tb19826.x; ELDER RH, 1990, BIOCHEMISTRY-US, V29, P6009, DOI 10.1021/bi00477a019; ENGLER MJ, 1982, ENZYMES B, V15, P1; GUMPORT RI, 1971, P NATL ACAD SCI USA, V68, P2559, DOI 10.1073/pnas.68.10.2559; KODAMA K, 1991, NUCLEIC ACIDS RES, V19, P6093, DOI 10.1093/nar/19.22.6093; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE LC, 1978, ANAL BIOCHEM, V86, P655, DOI 10.1016/0003-2697(78)90792-3; LEHMAN IR, 1974, SCIENCE, V186, P790; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; NOGUIEZ P, 1992, NUCLEIC ACIDS RES, V20, P3845, DOI 10.1093/nar/20.15.3845; PANTAZIS P, 1981, J BIOL CHEM, V256, P4669; SODERHALL S, 1975, J BIOL CHEM, V250, P8438; TAKAHASHI M, 1990, EUR J BIOCHEM, V192, P735, DOI 10.1111/j.1432-1033.1990.tb19284.x; TERAOKA H, 1986, J BIOL CHEM, V261, P6888; THORGERSEN HC, 1985, EUR J BIOCHEM, V147, P325; TOMKINSON AE, 1991, J BIOL CHEM, V266, P21728; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; TOMKINSON AE, 1991, P NATL ACAD SCI USA, V88, P400, DOI 10.1073/pnas.88.2.400; YANG SW, 1990, J BIOL CHEM, V265, P18130; YANG SW, 1992, P NATL ACAD SCI USA, V89, P2227, DOI 10.1073/pnas.89.6.2227	24	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3789	3792						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106423				2022-12-27	WOS:A1994MV63100096
J	HOMOLYA, L; HOLLO, Z; GERMANN, UA; PASTAN, I; GOTTESMAN, MM; SARKADI, B				HOMOLYA, L; HOLLO, Z; GERMANN, UA; PASTAN, I; GOTTESMAN, MM; SARKADI, B			FLUORESCENT CELLULAR INDICATORS ARE EXTRUDED BY THE MULTIDRUG-RESISTANCE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							P-GLYCOPROTEIN; INSECT CELLS; TRANSPORTER; VINBLASTINE; EXPRESSION; CDNA; DYES	In this report we show that NIH-3T3 mouse fibroblasts stably expressing the human multidrug transporter (MDR1 or P-glycoprotein), in contrast to the control NIH-3T3 cells, actively extrude the hydrophobic acetoxymethyl ester (AM) derivatives used for cellular loading of various fluorescent calcium and pH indicators. This dye extrusion is blocked by competing substrates and inhibitors of the multidrug transporter, e.g. by verapamil, vincristine, sodium orthovanadate, oligomycin, and a monoclonal anti-MDR1 antibody. The hydrophilic free acid forms of the indicators are not exported by MDR1. We also demonstrate that in isolated cell membranes the MDR1-ATPase, similar to that by known substrates of the transporter, is stimulated by the AM derivatives of fluorescent dyes whereas the free acid forms of the dyes are without effect. Since (i) the AM derivatives of the fluorescent indicators rapidly permeate the cell membrane and are readily cleaved by high activity and large capacity cytoplasmic esterases and (ii) the free acid forms are not substrates for export by MDR1, the observations above suggest that dye extrusion by MDR1 may occur without a cytoplasmic appearance of the AM compounds. These data also call attention to the possible interaction of widely used hydrophobic fluorescent indicators with MDR1 and offer an efficient detection of MDR1-expressing tumor cells as well as a screening method for examining drug interactions with the multidrug transporter.	NATL INST HAEMATOL BLOOD TRANSFUS & IMMUNOL,DAROCZI U 24,H-1113 BUDAPEST,HUNGARY; NCI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			pastan, ira/P-9319-2019; Sarkadi, Balazs/I-5024-2013; Homolya, Laszlo/N-1154-2016	pastan, ira/0000-0002-9223-0270; Homolya, Laszlo/0000-0003-1639-8140				AMBDUKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GOTTESMAN M, 1988, J BIOL CHEM, V263; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KESSEL D, 1991, CANCER RES, V51, P4665; KONEN PL, 1989, J HISTOCHEM CYTOCHEM, V37, P1141, DOI 10.1177/37.7.2567301; MECHETNER EB, 1992, P NATL ACAD SCI USA, V89, P5824, DOI 10.1073/pnas.89.13.5824; NEYFAKH AA, 1988, EXP CELL RES, V174, P168, DOI 10.1016/0014-4827(88)90152-8; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; SARKADI B, 1992, J BIOL CHEM, V267, P4854; STEIN WD, 1993, IN PRESS MOL PHARM; TSIEN RY, 1983, ANNU REV BIOPHYS BIO, V12, P91, DOI 10.1146/annurev.bb.12.060183.000515; TSURUO T, 1983, CANCER RES, V43, P2905; WALL DM, 1993, EUR J CANCER, V29A, P1024, DOI 10.1016/S0959-8049(05)80216-3; YOSHIMURA A, 1990, CANCER LETT, V50, P45, DOI 10.1016/0304-3835(90)90177-Y	24	457	471	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21493	21496						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8104940				2022-12-27	WOS:A1993MC80900011
J	EDELMAN, GM; JONES, FS				EDELMAN, GM; JONES, FS			OUTSIDE AND DOWNSTREAM OF THE HOMEOBOX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HOMEODOMAIN-DNA INTERACTIONS; PROTEOGLYCAN LIGAND; CRYSTAL-STRUCTURE; PROMOTER ACTIVITY; AUTO-REGULATION; GENE-COMPLEX; GERM LAYERS; DROSOPHILA; CYTOTACTIN; EXPRESSION				EDELMAN, GM (corresponding author), SCRIPPS RES INST, DEPT NEUROBIOL, LA JOLLA, CA 92037 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009635, R37HD009635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK004256] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG009326] Funding Source: NIH RePORTER; NIA NIH HHS [AG09326] Funding Source: Medline; NICHD NIH HHS [HD09635] Funding Source: Medline; NIDDK NIH HHS [DK04256] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; CROSSIN KL, 1989, DEV BIOL, V136, P381, DOI 10.1016/0012-1606(89)90264-9; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; Edelman G. M., 1988, TOPOBIOLOGY INTRO MO; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EDELMAN GM, 1990, COLD SH Q B, V55, P303; EDELMAN GM, 1992, TRENDS BIOCHEM SCI, V17, P228, DOI 10.1016/0968-0004(92)90383-K; GOULD AP, 1992, DEVELOPMENT, V116, P1163; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HIRSCH MR, 1990, MOL CELL BIOL, V10, P1959, DOI 10.1128/MCB.10.5.1959; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; JEGALIAN BG, 1992, CELL, V71, P901, DOI 10.1016/0092-8674(92)90387-R; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; JONES FS, 1990, P NATL ACAD SCI USA, V87, P6497, DOI 10.1073/pnas.87.17.6497; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2091, DOI 10.1073/pnas.89.6.2091; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2086, DOI 10.1073/pnas.89.6.2086; JONES FS, 1993, P NATL ACAD SCI USA, V90, P6557, DOI 10.1073/pnas.90.14.6557; KAUFMAN TC, 1980, GENETICS, V94, P115; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOHL A, 1992, J NEUROSCI RES, V32, P167, DOI 10.1002/jnr.490320206; KOMURO I, 1993, EMBO J, V12, P1387, DOI 10.1002/j.1460-2075.1993.tb05783.x; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; KUZIORA MA, 1989, CELL, V59, P563, DOI 10.1016/0092-8674(89)90039-1; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; SALSER SJ, 1992, NATURE, V355, P255, DOI 10.1038/355255a0; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SPEMANN H, 1939, EMBRYONIC DEV INDUCT; TAN SS, 1987, P NATL ACAD SCI USA, V84, P7977, DOI 10.1073/pnas.84.22.7977; TOWNES PL, 1955, J EXP ZOOL, V128, P53, DOI 10.1002/jez.1401280105; TREISMAN J, 1989, CELL, V59, P553; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; ZAPPAVIGNA V, 1991, EMBO J, V10, P4177, DOI 10.1002/j.1460-2075.1991.tb04996.x	47	87	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20683	20686						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8104934				2022-12-27	WOS:A1993MA28800001
J	SAFAR, J; ROLLER, PP; GAJDUSEK, DC; GIBBS, CJ				SAFAR, J; ROLLER, PP; GAJDUSEK, DC; GIBBS, CJ			CONFORMATIONAL TRANSITIONS, DISSOCIATION, AND UNFOLDING OF SCRAPIE AMYLOID (PRION) PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM SPECTRA; MOLTEN GLOBULE STATE; SECONDARY STRUCTURE; PRECURSOR PROTEIN; LIPOSOMES; ABSORPTION; PURIFICATION; INFECTIVITY; TRYPTOPHAN; PEPTIDE	The infectious form of the scrapie amyloid (prion) precursor, PrP(Sc), is a host-derived protein and a component of the infectious agent causing scrapie. PrP(Sc) and the carboxyl-terminal proteinase K resistant core, PrP27-30, have the potential to form amyloid as a result of a post-translational event or conformational abnormality. We have studied the conformational transitions of both proteins reconstituted into liposomes, associated in solid state in thin films, and dissociated by guanidine HCl. The secondary structure of PrP(sc) in liposomes deduced from analysis of circular dichroism spectra contained approximately 34% beta-sheets, approximately 20% alpha-helix, and approximately 46% beta-turns and random coil. Cleavage of the amino-terminal region of PrP(Sc) resulted in all-beta PrP27-30, with an estimated approximately 43% beta-sheet, no alpha-helix, and approximately 57% beta-turns and random coil. The PrP(Sc) associated in thin films with a tertiary structure perturbation corresponding to unfolding, while the secondary structure was preserved. The PrP27-30 assembled into the solid state with a similar perturbation of tertiary structure but with a large increase in the beta-sheet content, probably due to an intermolecular alignment of the external beta-sheets, or to a secondary structure transition, or both. The various conformational states had little or no impact on infectivity. Equilibrium dissociation and unfolding demonstrated a greater resistance of PrP27-30 to denaturation. The dissociated monomers unfolded through intermediate(s), suggesting the presence of protein domains with distinct secondary structure stabilities. The results provide experimental evidence for the beta-sheet type assembly of scrapie amyloid PrP27-30 in the solid state and demonstrate the importance of amino-terminal cleavage in the stability and alignment of the amyloid-forming monomers.	NCI,DIV CANC TREATMENT,MEDICINAL CHEM LAB,DEV THERAPEUT PROGRAM,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SAFAR, J (corresponding author), NINCDS,CENT NERVOUS SYST STUDIES LAB,BLDG 36,RM 4A-15,BETHESDA,MD 20892, USA.		Safar, Jiri G/G-6512-2013					ANDREU JM, 1986, METHOD ENZYMOL, V130, P47; AUER HE, 1973, J AM CHEM SOC, V95, P3003, DOI 10.1021/ja00790a046; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BELLINGERKAWAHARA CG, 1988, VIROLOGY, V164, P537, DOI 10.1016/0042-6822(88)90569-7; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; Donovan J W, 1973, Methods Enzymol, V27, P497; GABIZON R, 1990, BIOCHEM J, V266, P1; GABIZON R, 1988, P NATL ACAD SCI USA, V85, P6617, DOI 10.1073/pnas.85.18.6617; GABIZON R, 1988, J BIOL CHEM, V263, P4950; GABIZON R, 1987, P NATL ACAD SCI USA, V84, P4017, DOI 10.1073/pnas.84.12.4017; GAJDUSEK DC, 1988, MT SINAI J MED, V55, P3; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GLAESER RM, 1985, BIOCHEMISTRY-US, V24, P6398, DOI 10.1021/bi00344a012; GORDON DJ, 1971, ARCH BIOCHEM BIOPHYS, V142, P481, DOI 10.1016/0003-9861(71)90511-X; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HSU MC, 1971, J AM CHEM SOC, V93, P3515; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; KOEPPE RE, 1992, PROTEINS, V12, P49, DOI 10.1002/prot.340120107; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANSBURY PT, 1992, BIOCHEMISTRY-US, V31, P6865, DOI 10.1021/bi00145a001; LONG MM, 1981, MEMBRANE SPECTROSCOP, P143; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MAO D, 1984, BIOCHEMISTRY-US, V23, P2667, DOI 10.1021/bi00307a020; MATTHEWS CR, 1987, METHOD ENZYMOL, V154, P498; MATTHEWS CR, 1981, BIOCHEMISTRY-US, V20, P784, DOI 10.1021/bi00507a021; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; NANDI PK, 1984, BIOCHEMISTRY-US, V23, P6661, DOI 10.1021/bi00321a058; Pace C N, 1986, Methods Enzymol, V131, P266; PERCZEL A, 1992, PROTEIN SCI, V1, P378; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1992, BIOCHEMISTRY-US, V31, P12277, DOI 10.1021/bi00164a001; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; ROBAKIS NK, 1986, P NATL ACAD SCI USA, V83, P6377, DOI 10.1073/pnas.83.17.6377; SAFAR J, 1990, P NATL ACAD SCI USA, V87, P6373, DOI 10.1073/pnas.87.16.6373; SAFAR J, 1991, J INFECT DIS, V163, P488, DOI 10.1093/infdis/163.3.488; SAFAR J, 1990, NEUROLOGY, V40, P503, DOI 10.1212/WNL.40.3_Part_1.503; SAFAR J, 1993, IN PRESS BIOPOLYMERS; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SPARROW JT, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P103; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; STEVENS ES, 1977, METHOD ENZYMOL, V49, P214; STEVENS L, 1968, BIOCHEMISTRY-US, V7, P3717, DOI 10.1021/bi00850a051; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; WANG JM, 1992, J PROTEIN CHEM, V11, P157, DOI 10.1007/BF01025220; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0; Woody RW, 1985, CONFORMATION BIOL DR, P15; YANG JT, 1986, METHOD ENZYMOL, V130, P208; ZETTLMEISSL G, 1982, EUR J BIOCHEM, V125, P605, DOI 10.1111/j.1432-1033.1982.tb06725.x	58	337	357	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20276	20284						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8104185				2022-12-27	WOS:A1993LY01900055
J	CORNWELL, MM; SMITH, DE				CORNWELL, MM; SMITH, DE			SP1 ACTIVATES THE MDR1 PROMOTER THROUGH ONE OF 2 DISTINCT G-RICH REGIONS THAT MODULATE PROMOTER ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; P-GLYCOPROTEIN; SECRETORY EPITHELIUM; NEGATIVE ELEMENT; DRUG-RESISTANCE; BINDING-SITE; RAT-LIVER; EXPRESSION; CELLS; TRANSCRIPTION	To define sequences in the human multidrug resistance (MDR1) promoter that influence transcription, we measured the activity of MDR1 promoter constructs using luciferase as a reporter gene. Deletion of promoter sequences to -121 (relative to the transcription initiation site) had very little effect on promoter activity in transiently transfected cells. Further deletion to -88 increased activity about 4-fold, while deletion to -51 decreased activity about 10-fold. The data indicated that between -121 and -88 and between -73 and -51 were sequences that modulated promoter activity. Because these two regions contain G-rich sequences, which are important for function in other promoters, the effect of mutation of the G-rich regions (-110 to -103 and -61 to -43) on MDR1 promoter activity was measured. Mutation of the -110 G-box (-110 to -103) resulted in a 6-fold increase in promoter activity and inhibited the formation of a specific nuclear protein complex, suggesting that this region functions as a transcriptional ''repressor'' binding site in cycling cells. In contrast, mutation of the -50 G-box (-61 to -43) reduced promoter activity 5-fold. DNase-I footprinting and electrophoretic mobility shift analysis indicated that specific but distinct protein-DNA complexes formed at each of these two G-rich regions. The -50 G-box contains overlapping sites to which both SP1 and EGR-1 bind specifically. Co-transfection of MDR1 promoter constructs with SP1 into cells that lack SP1 (Drosophila Schneider 2 cells) activated equivalently both the wild type MDR1 promoter and a synthetic promoter containing the MDR1 -50 GC box and MDR1 initiator element.			CORNWELL, MM (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV CLIN,MAIL STOP EP 310-N,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.				NCI NIH HHS [CA51728] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051728, R29CA051728] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; ARCECI RJ, 1990, MOL REPROD DEV, V25, P101, DOI 10.1002/mrd.1080250202; BAAS F, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P360; BATES SE, 1989, MOL CELL BIOL, V9, P4337, DOI 10.1128/MCB.9.10.4337; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CHIN KV, 1993, ADV CANCER RES, V60, P157; CHIN KV, 1990, J BIOL CHEM, V265, P221; CHIN KV, 1990, CELL GROWTH DIFFER, V1, P361; CORNWELL MM, 1990, CELL GROWTH DIFFER, V1, P607; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DALTON WS, 1989, J CLIN ONCOL, V7, P415, DOI 10.1200/JCO.1989.7.4.415; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FAISST S, 1991, NUCLEIC ACIDS RES, V20, P3; GANT TW, 1991, MOL CARCINOGEN, V4, P499, DOI 10.1002/mc.2940040614; GERLACH JH, 1987, J CLIN ONCOL, V5, P1452, DOI 10.1200/JCO.1987.5.9.1452; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN MM, 1988, TRENDS PHARMACOL SCI, V9, P54, DOI 10.1016/0165-6147(88)90117-4; HERZOG CE, 1993, J BIOL CHEM, V268, P2946; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HSU SIH, 1989, J BIOL CHEM, V264, P12053; IKEGUCHI M, 1991, DNA CELL BIOL, V10, P639, DOI 10.1089/dna.1991.10.639; KIOKA N, 1992, FEBS LETT, V301, P37, DOI 10.1016/0014-5793(92)80205-U; KOIKA N, 1992, FEBS LETT, V301, P307; LEMAIGRE FP, 1990, MOL CELL BIOL, V10, P1811, DOI 10.1128/MCB.10.4.1811; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MICKLEY LA, 1989, J BIOL CHEM, V264, P18031; OGURA M, 1992, NUCLEIC ACIDS RES, V20, P5811, DOI 10.1093/nar/20.21.5811; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN DW, 1986, J BIOL CHEM, V261, P7762; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TEETER LD, 1991, CELL GROWTH DIFFER, V2, P429; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; UEDA K, 1987, J BIOL CHEM, V262, P17432; UEDA K, 1987, J BIOL CHEM, V262, P505; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANHUIJSDUIJNEN RAMH, 1992, BIOTECHNIQUES, V12, P830; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0	44	137	138	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19505	19511						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8103518				2022-12-27	WOS:A1993LW81900056
J	WALLIS, KT; AZHAR, S; RHO, MB; LEWIS, SA; COWAN, NJ; MURPHY, DB				WALLIS, KT; AZHAR, S; RHO, MB; LEWIS, SA; COWAN, NJ; MURPHY, DB			THE MECHANISM OF EQUILIBRIUM BINDING OF MICROTUBULE-ASSOCIATED PROTEIN-2 TO MICROTUBULES - BINDING IS A MULTI-PHASIC PROCESS AND EXHIBITS POSITIVE COOPERATIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBULIN POLYMERIZATION INVITRO; TAU-PROTEIN; CHICKEN ERYTHROCYTES; BRAIN MICROTUBULES; LARGE LIGANDS; STEADY-STATE; MAP2; PHOSPHORYLATION; DYNAMICS; LATTICE	The mechanism of binding of microtubule-associated protein 2 (MAP2) to taxol-stabilized microtubules (MTs) was examined through Scatchard analysis of equilibrium binding and by immunoelectron microscopy. We demonstrate the following. 1) Binding is a cooperative process as indicated by sigmoidal binding curves, prominent humps in Scatchard plots, and an all-or-none response in binding during ligand titrations. At high tubulin/MAP2 ratios, the K(d) for noncontiguous binding (5-25 muM) is estimated to be 100-1500 times greater than that predicted for contiguous binding, suggesting a high degree of cooperativity. 2) Cooperativity is indicated independently by a highly clustered or patchy distribution of MAP2 on MTs as revealed by immunoelectron microscopy. 3) The binding of truncated constructs of mouse MAP2 protein suggests that a domain of MAP2 conferring cooperativity is located in or near the MT binding site near the carboxyl terminus. We speculate that in the cell, cooperativity may generate MTs with uniform biochemical properties and contribute to the segregation of MAPs in neuronal cell processes.	JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,725 N WOLFE ST,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009989] Funding Source: NIH RePORTER; NIA NIH HHS [AG09989] Funding Source: Medline; NIGMS NIH HHS [GM33171] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS RG, 1984, EUR J BIOCHEM, V141, P609, DOI 10.1111/j.1432-1033.1984.tb08236.x; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CACERES A, 1992, NEURON, V9, P607, DOI 10.1016/0896-6273(92)90025-9; CAPLOW M, 1982, EUR J BIOCHEM, V127, P319, DOI 10.1111/j.1432-1033.1982.tb06873.x; DENTLER WL, 1975, J CELL BIOL, V65, P237, DOI 10.1083/jcb.65.1.237; EPSTEIN IR, 1978, BIOPHYS CHEM, V8, P327, DOI 10.1016/0301-4622(78)80015-5; FARRELL KW, 1987, J CELL BIOL, V104, P1035, DOI 10.1083/jcb.104.4.1035; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; GOTTLIEB RA, 1983, J ULTRA MOL STRUCT R, V85, P175, DOI 10.1016/S0022-5320(83)90105-3; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JAMESON L, 1981, P NATL ACAD SCI-BIOL, V78, P3413, DOI 10.1073/pnas.78.6.3413; JOB D, 1985, J CELL BIOL, V101, P1680, DOI 10.1083/jcb.101.5.1680; KIM H, 1986, ANN NY ACAD SCI, V466, P218, DOI 10.1111/j.1749-6632.1986.tb38396.x; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEWIS SA, 1990, NATURE, V345, P674, DOI 10.1038/345674a0; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; MANDELKOW EM, 1986, J CELL BIOL, V102, P1067, DOI 10.1083/jcb.102.3.1067; MANDELKOW EM, 1985, J MOL BIOL, V185, P311, DOI 10.1016/0022-2836(85)90406-1; MATUS A, 1990, J PHYSIOL-PARIS, V84, P131; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MURPHY DB, 1987, J BIOL CHEM, V262, P14305; MURPHY DB, 1983, J BIOL CHEM, V258, P8357; MURTHY ASN, 1983, EUR J BIOCHEM, V137, P37, DOI 10.1111/j.1432-1033.1983.tb07792.x; OKABE S, 1989, P NATL ACAD SCI USA, V86, P4127, DOI 10.1073/pnas.86.11.4127; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; OLMSTED JB, 1989, J CELL BIOL, V109, P211, DOI 10.1083/jcb.109.1.211; ROTHWELL SW, 1986, ANN NY ACAD SCI, V466, P103, DOI 10.1111/j.1749-6632.1986.tb38387.x; SANDOVAL IV, 1981, J BIOL CHEM, V256, P8795; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHERSON T, 1984, J CELL BIOL, V99, P425, DOI 10.1083/jcb.99.2.425; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; WEGNER A, 1979, J MOL BIOL, V131, P839, DOI 10.1016/0022-2836(79)90204-3; WICHE G, 1989, BIOCHEM J, V259, P1; WILLE H, 1992, J STRUCT BIOL, V108, P49, DOI 10.1016/1047-8477(92)90006-V	41	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15158	15167						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8100819				2022-12-27	WOS:A1993LL75900089
J	GREENBERGER, LM				GREENBERGER, LM			MAJOR PHOTOAFFINITY DRUG LABELING SITES FOR IODOARYL AZIDOPRAZOSIN IN P-GLYCOPROTEIN ARE WITHIN, OR IMMEDIATELY C-TERMINAL TO, TRANSMEMBRANE DOMAIN-6 AND DOMAIN-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG RESISTANCE GENE; CYSTIC-FIBROSIS GENE; CLASS-II REGION; BACTERIAL TRANSPORT PROTEINS; ALPHA-1 SUBUNIT; CA2+ CHANNELS; HUMAN-CELLS; EXPRESSION; BINDING; IDENTIFICATION	P-glycoprotein can mediate multidrug resistance in tumor cells and is hypothesized to be an energy-dependent drug efflux pump. The protein is composed of two cassettes; each cassette contains six transmembrane domains followed by a nucleotide binding fold. The [I-125]iodoaryl azidoprazosin photoaffinity drug binding sites in P-glycoprotein have been mapped by immunological analysis. After complete digestion of P-glycoprotein with trypsin, two major photolabeled fragments have been mapped. The 5- and 4-kDa fragments are located within, or immediately C-terminal to, the last transmembrane domain of each cassette: transmembranes 6 and 12 of P-glycoprotein, respectively. The 4-kDa fragment maximally extends up to, but not including, the Walker A motif of the second nucleotide binding fold, whereas the 5-kDa fragment maximally extends a few residues beyond the Walker A motif of the first nucleotide binding fold. A minor photolabeling domain is also found between transmembrane domain 4 and up to, but not including, transmembrane domain 6. These data suggest that a portion of the drug binding site in P-glycoprotein is in close proximity to ATP binding regions. Furthermore, symmetrical regions in each cassette of P-glycoprotein are likely to participate in drug efflux.			GREENBERGER, LM (corresponding author), AMER CYANAMID CO,LEDERLE LABS,ONCOL & IMMUNOL RES SECT,PEARL RIVER,NY 10965, USA.							AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BECK WT, 1992, BIOCHEM PHARMACOL, V43, P89, DOI 10.1016/0006-2952(92)90665-6; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BRUGGEMANN EP, 1991, BIOTECHNIQUES, V10, P202; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; BUSHCE R, 1989, EUR J BIOCHEM, V183, P189; BUSHE R, 1989, MOL PHARMACOL, V35, P414; BUSHMAN E, 1991, MOL CELL BIOL, V11, P595; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHAN HSL, 1990, J CLIN ONCOL, V8, P689, DOI 10.1200/JCO.1990.8.4.689; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; CURRIER SJ, 1989, J BIOL CHEM, V264, P14376; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DHIR R, 1992, BIOCHEMISTRY-US, V31, P6103, DOI 10.1021/bi00141a021; FORD JM, 1990, PHARMACOL REV, V42, P155; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; GLOSSMANN H, 1987, TRENDS PHARMACOL SCI, V8, P95, DOI 10.1016/0165-6147(87)90082-4; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GREENBERGER IM, 1992, DRUG RESISTANCE BIOC, P63; GREENBERGER LM, 1987, J BIOL CHEM, V262, P13685; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HSU SIH, 1989, J BIOL CHEM, V264, P12053; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MILLER TP, 1991, J CLIN ONCOL, V9, P17, DOI 10.1200/JCO.1991.9.1.17; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MORRIS DI, 1991, BIOCHEMISTRY-US, V30, P8371, DOI 10.1021/bi00098a014; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; POWIS SH, 1992, P NATL ACAD SCI USA, V89, P1463, DOI 10.1073/pnas.89.4.1463; PRATT WB, 1990, PRINCIPLES DRUG ACTI, P595; REGULLA S, 1991, EMBO J, V10, P45, DOI 10.1002/j.1460-2075.1991.tb07919.x; RIORDAN JR, 1989, SCIENCE, V245, P1066; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; ROY SN, 1985, CANCER RES, V45, P3856; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7725; SALMON SE, 1989, J NATL CANCER I, V81, P696, DOI 10.1093/jnci/81.9.696; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SONNEVELD P, 1992, LANCET, V340, P255, DOI 10.1016/0140-6736(92)92353-H; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TAMAI I, 1991, J BIOL CHEM, V266, P16796; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WU JH, 1992, J BIOL CHEM, V267, P12570; Yang C. H., 1991, SYNERGISM ANTAGONISM, P311; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282; Young R. C., 1989, DRUG RESISTANCE CANC, P1; ZEHEB R, 1987, BIOCHEM BIOPH RES CO, V143, P732, DOI 10.1016/0006-291X(87)91415-X	69	189	190	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11417	11425						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8098711				2022-12-27	WOS:A1993LD46600101
J	CHEN, NY; JIANG, SQ; KLEIN, DA; PAULUS, H				CHEN, NY; JIANG, SQ; KLEIN, DA; PAULUS, H			ORGANIZATION AND NUCLEOTIDE-SEQUENCE OF THE BACILLUS-SUBTILIS DIAMINOPIMELATE OPERON, A CLUSTER OF GENES ENCODING THE 1ST 3 ENZYMES OF DIAMINOPIMELATE SYNTHESIS AND DIPICOLINATE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SEMIALDEHYDE DEHYDROGENASE; AMINO-ACID BIOSYNTHESIS; ESCHERICHIA-COLI; ASPARTOKINASE-II; CORYNEBACTERIUM-GLUTAMICUM; PEPTIDOGLYCAN SYNTHESIS; CHROMOSOMAL LOCATION; YEAST MITOCHONDRIA; OVERLAPPING GENES; PROTEASE-III	The nucleotide sequence of a 7-kilobase segment of the Bacillus subtilis chromosome containing the entire coding regions for the enzymes catalyzing the first three steps of diaminopimelate synthesis as well as dipicolinate synthase has been determined. This group of functionally related genes, termed the dap operon, were arranged in the order orfY, orfX, asd, dapG, and dapA and were bracketed by potential rho-independent transcription terminators. The asd locus could complement the growth defect of Escherichia coli strains with an asd deletion. Disruption of the dapG locus led to the loss of aspartokinase I, with a phenotype similar to that of the temperature-sensitive dapG mutants described earlier (Roten, C. A. H., Brandt, C., and Karamata, D. (1991) J. Gen. Microbiol. 137, 951-962). The amino acid sequences of the deduced products of the asd, dapG, and dapA loci had high degrees of similarity with those of other aspartate semialdehyde dehydrogenases, aspartokinases, and dihydrodipicolinate synthases, respectively. Disruption of orfX had no effect on growth but caused a sporulation defect, characterized by low sporulation frequencies and heat-sensitive spores, which could be cured by supplementation with dipicolinate, similar to the phenotype of mutants defective in spoVF, the putative structural gene for dipicolinate synthase. Two other open reading frames, upstream of spoVF, encoded the 380 COOH-terminal residues of a protein homologous to mitochondrial processing proteases and an 85-residue polypeptide of unknown function. Transcription initiation sites associated with the orfY-orfX-asd-dapG-dapA gene cluster were mapped by primer extension. The results indicate that during vegetative growth, the three distal genes of the dap operon, asd, dapG, and dapA, are transcribed as a unit and orfY and orfX are not expressed, whereas at stage 5 of sporulation two separate transcripts are produced, one comprising all five genes, the other just the three distal genes of the operon.	BOSTON BIOMED RES INST,DEPT METAB REGULAT,20 STANIFORD ST,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Boston Biomedical Research Institute; Harvard University; Harvard Medical School					NIGMS NIH HHS [R55-GM45879] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM045879] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFFHOLTER JA, 1988, SCIENCE, V242, P1415, DOI 10.1126/science.3059494; ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BALASSA G, 1979, J GEN MICROBIOL, V110, P365, DOI 10.1099/00221287-110-2-365; BARIL C, 1992, J GEN MICROBIOL, V138, P47, DOI 10.1099/00221287-138-1-47; BHATTACHARJEE JK, 1992, EVOLUTION METABOLIC, P47; BIELLMANN JF, 1980, EUR J BIOCHEM, V104, P53, DOI 10.1111/j.1432-1033.1980.tb04398.x; BONASSIE S, 1990, NUCLEIC ACIDS RES, V18, P6421; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT C, 1987, J GEN MICROBIOL, V133, P1159; BUXTON RS, 1980, J GEN MICROBIOL, V120, P283; BUXTON RS, 1978, J GEN MICROBIOL, V105, P175, DOI 10.1099/00221287-105-2-175; CARDINEAU GA, 1987, J BIOL CHEM, V262, P3344; CASSAN M, 1986, J BIOL CHEM, V261, P1052; CHEN NY, 1987, J BIOL CHEM, V262, P8787; CHEN NY, 1989, J GEN MICROBIOL, V135, P2931; CHEN NY, 1988, J BIOL CHEM, V263, P9526; CORUZZI GM, 1991, PLANT SCI, V74, P145, DOI 10.1016/0168-9452(91)90040-F; DAVIS RW, 1980, ADV BACTERIAL GENET, P201; DOI RH, 1986, MICROBIOL REV, V50, P227, DOI 10.1128/MMBR.50.3.227-243.1986; DUVALL EJ, 1983, GENE, V24, P171, DOI 10.1016/0378-1119(83)90077-X; EBBOLE DJ, 1987, J BIOL CHEM, V262, P8274; ERRINGTON J, 1988, J BACTERIOL, V170, P796, DOI 10.1128/jb.170.2.796-801.1988; FERRARI FA, 1983, J BACTERIOL, V154, P1513, DOI 10.1128/JB.154.3.1513-1515.1983; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P7695, DOI 10.1093/nar/14.19.7695; FREESE EB, 1979, MOL GEN GENET, V170, P67, DOI 10.1007/BF00268581; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GRANDONI JA, 1992, J BACTERIOL, V174, P3212, DOI 10.1128/jb.174.10.3212-3219.1992; GRAVES LM, 1990, J BACTERIOL, V172, P218, DOI 10.1128/JB.172.1.218-223.1990; Hager P. W., 1985, MOL BIOL BACILLI, V2, P1; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HAZIZA C, 1982, EMBO J, V1, P379, DOI 10.1002/j.1460-2075.1982.tb01178.x; HENNER DJ, 1984, GENE, V34, P169; HORINOUCHI S, 1980, P NATL ACAD SCI-BIOL, V77, P7079, DOI 10.1073/pnas.77.12.7079; JANSSEN FW, 1958, SCIENCE, V127, P26, DOI 10.1126/science.127.3288.26; KALINOWSKI J, 1991, MOL MICROBIOL, V5, P1197, DOI 10.1111/j.1365-2958.1991.tb01893.x; KALINOWSKI J, 1990, MOL GEN GENET, V224, P317, DOI 10.1007/BF00262424; KANEKO T, 1990, J BIOL CHEM, V265, P17451; KARSTEN WE, 1992, BIOCHIM BIOPHYS ACTA, V1121, P234, DOI 10.1016/0167-4838(92)90360-P; KATINKA M, 1980, P NATL ACAD SCI-BIOL, V77, P5730, DOI 10.1073/pnas.77.10.5730; KURODA MI, 1988, J BACTERIOL, V170, P3080, DOI 10.1128/jb.170.7.3080-3088.1988; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; Miller J.H., 1972, EXPT MOL GENETICS; MOIR D, 1977, J BIOL CHEM, V252, P4648; MOUNTAIN A, 1986, J BACTERIOL, V165, P1026, DOI 10.1128/jb.165.3.1026-1028.1986; Nicholson WL., 1990, MOL BIOL METHODS BAC, P391, DOI DOI 10.1111/J.1751-1097.1991.TB02087.X; PAULUS H, 1984, J BIOSCIENCE, V6, P403, DOI 10.1007/BF02703896; Paulus Henry, 1993, P237; PIGGOT PJ, 1981, SPORULATION GERMINAT, P29; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; QUINN CL, 1991, J BIOL CHEM, V266, P9113; RAFALSKI JA, 1990, J BIOL CHEM, V265, P15346; RAFALSKI JA, 1988, J BIOL CHEM, V263, P2146; RICHAUD F, 1986, J BACTERIOL, V166, P297, DOI 10.1128/jb.166.1.297-300.1986; ROSNER A, 1971, J BIOL CHEM, V246, P2965; ROTEN CAH, 1991, J GEN MICROBIOL, V137, P951, DOI 10.1099/00221287-137-4-951; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAEFFER P, 1965, P NATL ACAD SCI USA, V54, P704, DOI 10.1073/pnas.54.3.704; SCHENDEL FJ, 1992, APPL ENVIRON MICROB, V58, P2806, DOI 10.1128/AEM.58.9.2806-2814.1992; SETLOW P, 1988, ANNU REV MICROBIOL, V42, P319, DOI 10.1146/annurev.mi.42.100188.001535; SHIMOTSU H, 1986, J BACTERIOL, V166, P461, DOI 10.1128/jb.166.2.461-471.1986; SHIVAKUMAR AG, 1980, P NATL ACAD SCI-BIOL, V77, P3903, DOI 10.1073/pnas.77.7.3903; SIBILLI L, 1981, J BIOL CHEM, V256, P228; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; WARD JB, 1975, J BACTERIOL, V124, P668, DOI 10.1128/JB.124.2.668-678.1975; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; WU JJ, 1989, J BACTERIOL, V171, P692, DOI 10.1128/jb.171.2.692-698.1989; WYRICK PB, 1973, NATURE, V244, P505, DOI 10.1038/244505a0; YAMAKURA F, 1974, J BIOCHEM-TOKYO, V76, P611, DOI 10.1093/oxfordjournals.jbchem.a130605; YEH EC, 1978, MOL GEN GENET, V158, P287, DOI 10.1007/BF00267200; ZAKIN MM, 1983, J BIOL CHEM, V258, P3028; ZALKIN H, 1988, J BIOL CHEM, V263, P1595; ZHANG JJ, 1990, J BACTERIOL, V172, P701, DOI 10.1128/jb.172.2.701-708.1990; ZHANG JJ, 1990, J BACTERIOL, V172, P4690, DOI 10.1128/jb.172.8.4690-4693.1990; ZHENG LB, 1992, J MOL BIOL, V226, P1037, DOI 10.1016/0022-2836(92)91051-P	78	58	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9448	9465						18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8098035				2022-12-27	WOS:A1993LA68900048
J	GRIMM, R; DONALDSON, GK; VANDERVIES, SM; SCHAFER, E; GATENBY, AA				GRIMM, R; DONALDSON, GK; VANDERVIES, SM; SCHAFER, E; GATENBY, AA			CHAPERONIN-MEDIATED RECONSTITUTION OF THE PHYTOCHROME PHOTORECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVENA-SATIVA L; RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; GENE-EXPRESSION; HIGHER-PLANTS; PROTEINS; INVITRO; YEAST; GROE; CHROMOPHORE	The native phytochrome photoreceptor was purified to homogeneity from etiolated seedlings of oat (Avena sativa L.) and used for renaturation experiments. Light scattering measurements showed that the GroEL molecular chaperone interacts with non-native phytochrome to suppress aggregation of the refolding polypeptide, following its dilution from a chaotrope. The binary complex formed between non-native phytochrome and GroEL was stable and could be isolated by size exclusion chromatography. Discharge of the photoreceptor from GroEL was obtained with 2 mM MgATP, although 6 mM adenosine 5'-O-(3-thiotriphosphate) was also effective. Phytochrome released from GroEL with MgATP was found primarily in the form of 124-kDa monomers, as judged by size exclusion chromatography and nondenaturing gel electrophoresis, although dimers and other oligomeric forms were also observed. The reconstituted dimers, and other oligomeric forms, preferentially cross-reacted with a monoclonal antibody that recognizes native-like epitopes. In vitro folding reactions, using chemically denatured phytochrome, revealed that successful reconstitution of the photoreceptor required the presence of the GroEL chaperonin and MgATP under the conditions tested. Reconstitution in the presence of GroEL yielded phytochrome that could exhibit photoreversibility between the red-light absorbing and far-red absorbing forms.	DUPONT CO,CENT RES DEV,DIV MOLEC BIOL,WILMINGTON,DE 19880; INST BIOL 2,W-7800 FREIBURG,GERMANY	DuPont								BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BANEYX F, 1992, J BIOL CHEM, V267, P11637; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHOI JK, 1990, BIOCHEMISTRY-US, V29, P6883, DOI 10.1021/bi00481a018; DEFORCE L, 1991, P NATL ACAD SCI USA, V88, P10392, DOI 10.1073/pnas.88.23.10392; EDGERTON MD, 1992, PLANT CELL, V4, P161, DOI 10.1105/tpc.4.2.161; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; Furuya M, 1989, Adv Biophys, V25, P133, DOI 10.1016/0065-227X(89)90006-3; FURUYA M, 1987, PHYTOCHROME PHOTOREG; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRIMM R, 1986, Z NATURFORSCH C, V41, P988; Gross J, 1984, TECHNIQUES PHOTOMORP, P131; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JONES AM, 1989, PHOTOCHEM PHOTOBIOL, V49, P479, DOI 10.1111/j.1751-1097.1989.tb09198.x; JONES AM, 1985, PLANTA, V164, P501, DOI 10.1007/BF00395966; JONES AM, 1986, BIOCHEMISTRY-US, V25, P2987, DOI 10.1021/bi00358a038; KAUFMAN LS, 1984, SCIENCE, V226, P1447, DOI 10.1126/science.226.4681.1447; Kendrick RE., 2012, PHOTOMORPHOGENESIS P, P333; KUHLEMEIER C, 1987, ANNU REV PLANT PHYS, V38, P221; LAGARIAS JC, 1985, J BIOL CHEM, V260, P2415; LAGARIAS JC, 1980, J AM CHEM SOC, V102, P4821, DOI 10.1021/ja00534a042; LAGARIAS JC, 1989, P NATL ACAD SCI USA, V86, P5778, DOI 10.1073/pnas.86.15.5778; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; NAGATANI A, 1987, PHYTOCHROME PHOTOREG, P95; SONG PS, 1988, J PHOTOCH PHOTOBIO B, V2, P43, DOI 10.1016/1011-1344(88)85036-X; THOMAS B, 1984, PLANTA, V160, P382, DOI 10.1007/BF00393420; TOBIN EM, 1985, ANNU REV PLANT PHYS, V36, P569, DOI 10.1146/annurev.pp.36.060185.003033; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIERSTRA RD, 1982, P NATL ACAD SCI-BIOL, V79, P5272, DOI 10.1073/pnas.79.17.5272; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WAHLEITHNER JA, 1991, P NATL ACAD SCI USA, V88, P10387, DOI 10.1073/pnas.88.23.10387; WYNN RM, 1992, J BIOL CHEM, V267, P12400	40	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5220	5226						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8095267				2022-12-27	WOS:A1993KP88400094
J	INOUYE, CJ; SETO, E				INOUYE, CJ; SETO, E			RELIEF OF YY1-INDUCED TRANSCRIPTIONAL REPRESSION BY PROTEIN-PROTEIN INTERACTION WITH THE NUCLEOLAR PHOSPHOPROTEIN B23	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-EFFICIENCY TRANSFORMATION; ADENOVIRUS E1A PROTEIN; SERUM RESPONSE FACTOR; EXPRESSION VECTOR; TUMOR-CELLS; YEAST; YY1; DNA; SEQUENCE; CLONING	Previous studies have shown that the transcription factor YY1 can both activate and repress transcription of many mammalian genes (reviewed by Hahn (Hahn, S. (1992) Curr. Biol. 2, 152-154)). Given the diverse effects of the YY1 protein, it seems likely that its function depends on interaction with other cellular factors. We have used the yeast two-hybrid system to isolate mouse cDNAs encoding proteins capable of directly binding to YY1. Sequence analysis of one clone revealed it had an open reading frame with the potential to code for a protein nearly identical to the previously published mouse nucleolar phosphoprotein B23. The YY1.B23 complex is specific, and occurs in vivo and in vitro. Overexpression of the B23 protein can reverse the transcriptional repression exerted by YY1. These results suggest a role for a nucleolar protein as a component in transcription and provide a possible mechanism for transcriptional regulation by YY1.	UNIV TEXAS, HLTH SCI CTR, CTR MOLEC MED INST BIOTECHNOL, DEPT CELLULAR & STRUCT BIOL, SAN ANTONIO, TX 78245 USA	University of Texas System; University of Texas Health San Antonio								BASU A, 1993, J BIOL CHEM, V268, P4188; BAUKNECHT T, 1992, EMBO J, V11, P4607, DOI 10.1002/j.1460-2075.1992.tb05563.x; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BUSCH RK, 1984, LIFE SCI, V35, P1777, DOI 10.1016/0024-3205(84)90275-3; CHAN PK, 1989, CANCER RES, V49, P3271; CHAN PK, 1992, EXP CELL RES, V203, P174, DOI 10.1016/0014-4827(92)90053-B; CHAN PK, 1986, J BIOL CHEM, V261, P14335; CHAN PK, 1987, CANCER RES, V47, P3798; CHANG JH, 1989, J BIOL CHEM, V264, P11732; CHANG JH, 1990, J BIOL CHEM, V265, P18227; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FEUERSTEIN N, 1987, J BIOL CHEM, V262, P11389; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LETO E, 1993, NATURE, V365, P462; LI XZ, 1989, BIOCHEM BIOPH RES CO, V163, P72, DOI 10.1016/0006-291X(89)92100-1; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; NARAYANAN H, 1991, P NATL ACAD SCI USA, V88, P9799; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PRESTAYKO AW, 1974, BIOCHEMISTRY-US, V13, P1945, DOI 10.1021/bi00706a026; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMIDTZACHMANN MS, 1988, CHROMOSOMA, V96, P417, DOI 10.1007/BF00303035; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WANG DR, 1993, CELL MOL BIOL RES, V39, P33; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8	49	104	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6506	6510						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120001				2022-12-27	WOS:A1994MZ50300039
J	ARIELI, B; SHAHAK, Y; TAGLICHT, D; HAUSKA, G; PADAN, E				ARIELI, B; SHAHAK, Y; TAGLICHT, D; HAUSKA, G; PADAN, E			PURIFICATION AND CHARACTERIZATION OF SULFIDE-QUINONE REDUCTASE, A NOVEL ENZYME DRIVING ANOXYGENIC PHOTOSYNTHESIS IN OSCILLATORIA-LIMNETICA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ELECTRON-TRANSPORT; PROTEINS; THYLAKOIDS; OXIDOREDUCTASES; RECONSTITUTION; CYANOBACTERIA; CHLOROPLASTS; CHLOROBIUM; INDUCTION; COMPLEXES	An enzyme catalyzing sulfide quinone oxide-reduction (E.C.1.8.5.'.; SQR) has been purified in an active form, from thylakoids of the cyanobacterium Oscillatoria limnetica. It is composed of a single polypeptide of about 57 kDa. The catalytic activity of the purified enzyme is similar to the membrane-bound form in its kinetic parameters: apparent k(m) for sulfide equals 8 mu M; V(max)of 100-150 mu mol of plastoquinone-1 reduced/mg protein/h; quinone-substrate specificity; differential sensitivity to quinone analog inhibitors, the most potent of which being aurachin C (I-50 = 7 nm), and specific inducibility by sulfide. Taken together, they suggest that the purified SQR is the enzyme catalyzing anoxygenic photosynthesis in cyanobacteria. The UV and visible absorption and fluorescence spectra of the purified SQR are typical of a flavoprotein. Both the absorption and fluorescence intensities are reduced by sulfide. The SQR activity is inhibited by KCN, a flavoprotein inhibitor. We have sequenced so far 29 amino acid residues of the SQR NH2 terminus and found that from the second residue, this sequence contains the highly conserved fingerprint of the NAD/FAD binding domain of many NAD/FAD-binding enzymes (Wierenga, R. K., Terpstra, P., and Hol, W. G. S. (1986) J. Mol. Biol. 187, 101-107). This suggests that the SQR enzyme is a flavoprotein which contains binding sites for sulfide and quinone and that the electron transfer between the two is mediated by FAD.	HEBREW UNIV JERUSALEM,INST LIFE SCI,DIV MICROBIAL & MOLEC ECOL,IL-91904 JERUSALEM,ISRAEL; AGR RES ORG,VOLCANI CTR,INST HORT,IL-50250 BET DAGAN,ISRAEL; UNIV REGENSBURG,LEHRSTUHL ZELLBIOL & PFLANZENPHYSIOL,W-8400 REGENSBURG,GERMANY	Hebrew University of Jerusalem; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; University of Regensburg								ARIELI B, 1991, J BIOL CHEM, V266, P104; ARIELI B, 1989, J BACTERIOL, V171, P699, DOI 10.1128/jb.171.2.699-702.1989; BELKIN S, 1982, ISRAEL J BOT, V31, P199; BELKIN S, 1978, FEBS LETT, V94, P291, DOI 10.1016/0014-5793(78)80959-4; BELKIN S, 1987, METHOD ENZYMOL, V167, P380; BRUNE DC, 1989, BIOCHIM BIOPHYS ACTA, V975, P189, DOI 10.1016/S0005-2728(89)80251-8; CLINE JD, 1969, LIMNOL OCEANOGR, V14, P454, DOI 10.4319/lo.1969.14.3.0454; COHEN Y, 1975, NATURE, V257, P489, DOI 10.1038/257489a0; COHEN Y, 1975, J BACTERIOL, V123, P858; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; Ghisla S, 1980, Methods Enzymol, V66, P360; HAEHNEL W, 1982, J BIOENERG BIOMEMBR, V14, P181, DOI 10.1007/BF00745019; HANUKOGLU I, 1989, EUR J BIOCHEM, V180, P479, DOI 10.1111/j.1432-1033.1989.tb14671.x; HAUSKA G, 1986, METHOD ENZYMOL, V126, P271; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KUSAI A, 1973, BIOCHIM BIOPHYS ACTA, V304, P304; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacKinney G, 1941, J BIOL CHEM, V140, P315; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OETTMEIER W, 1990, Z NATURFORSCH C, V45, P311; OREN A, 1978, J BACTERIOL, V133, P558, DOI 10.1128/JB.133.2.558-563.1978; OREN A, 1977, P NATL ACAD SCI USA, V74, P2152, DOI 10.1073/pnas.74.5.2152; PADAN E, 1979, ANNU REV PLANT PHYS, V30, P27, DOI 10.1146/annurev.pp.30.060179.000331; PICK U, 1979, J BIOL CHEM, V254, P2793; PICK U, 1982, BIOCHEMISTRY-US, V24, P6144; RICH PR, 1987, BIOCHIM BIOPHYS ACTA, V892, P138, DOI 10.1016/0005-2728(87)90256-8; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SERRANO R, 1988, PLANT SCI, V56, P117, DOI 10.1016/0168-9452(88)90024-6; SHAHAK Y, 1987, ARCH BIOCHEM BIOPHYS, V259, P605, DOI 10.1016/0003-9861(87)90527-3; SHAHAK Y, 1992, FEBS LETT, V299, P127, DOI 10.1016/0014-5793(92)80230-E; Shahak Y, 1992, RES PHOTOSYNTHESIS, VII, P483; SLOOTEN L, 1989, BIOCHIM BIOPHYS ACTA, V973, P272, DOI 10.1016/S0005-2728(89)80432-3; STEINMETZ MA, 1983, ARCH MICROBIOL, V135, P186, DOI 10.1007/BF00414477; SYBESMA C, 1987, PROG PHOTOSYN RES, V2, P633; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILLIAMS CH, 1976, ENZYMES            C, V13, P90; Yamanaka T, 1976, FLAVINS FLAVOPROTEIN, P292	39	68	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5705	5711						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119908				2022-12-27	WOS:A1994MY84000037
J	CHEN, D; LEPAR, G; KEMPER, B				CHEN, D; LEPAR, G; KEMPER, B			A TRANSCRIPTIONAL REGULATORY ELEMENT COMMON TO A LARGE FAMILY OF HEPATIC CYTOCHROME-P450 GENES IS A FUNCTIONAL FINDING SITE OF THE ORPHAN RECEPTOR HNF-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; RETINOIC ACID RECEPTOR; NUCLEAR FACTOR-IV; HORMONE RECEPTOR; INVITRO TRANSCRIPTION; RESPONSE ELEMENT; X-RECEPTOR; LIVER; SUPERFAMILY; PROMOTER	Hepatic cytochrome P450 (CYP) genes, including members of CYP1 to CYP4 families, comprise the majority of the CYP gene superfamily. Previous study has demonstrated that HepG2-specific transcriptional activation of two CYP2C genes was dependent on a common element that bound a HepG2 nuclear protein designated HPF-1 (Venepally, P., Chen, D., and Kemper, B. (1992) J. Biol. Chem. 267, 17335-17338). This cis-acting element is highly homologous to the hepatocyte nuclear factor 4 (HNF-4) binding motif and is present in the promoters of more than 20 other CYP2 genes. To investigate the relationship between HPF-1 and HNF-4, we have compared their tissue distribution, DNA binding, and immunochemical characteristics, as well as transcriptional activity of their recognition elements. DNase I footprint analyses and gel-shift assays indicated that HPF-1, like HNF-4, was present in liver and kidney, but not brain and spleen. Both factors bound to either the HPF-1 site in the CYP2C2 promoter or an HNF-4 site in the human apolipoprotein CIII promoter. These complexes could be ''supershifted'' by an antiserum specific for HNF-4. When the sequence of the HPF-1 site in the CYP2C2 promoter was changed to that of the apolipoprotein CIII HNF-4 site, comparable transcriptional activities were obtained with the wildtype promoter and the HNF-4 mutant in transfected HepG2 cells. Cotransfection of HNF-4 with CYP2C2 promoter-luciferase constructs in COS-1 cells indicated that HNF-4 could trans activate the promoters containing the HPF-1 site. These results indicate that the HPF-1 motif is a functional HNF-4- binding site, and the common immunological properties indicate that HPF-1 and HNF-4 are closely related and possibly identical. HNF-4 therefore, may act as a common regulator for the liver-specific expression of many CYP2 genes.	UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,URBANA,IL 61801; UNIV ILLINOIS,COLL MED URBANA CHAMPAIGN,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NIGMS NIH HHS [GM39360] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039360] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BERRODIN TJ, 1992, MOL ENDOCRINOL, V6, P1468, DOI 10.1210/me.6.9.1468; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DESIMONE V, 1992, BIOCHIM BIOPHYS ACTA, V1132, P119, DOI 10.1016/0167-4781(92)90001-G; GONZALEZ FJ, 1990, PHARMACOL THERAPEUT, V45, P1, DOI 10.1016/0163-7258(90)90006-N; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRIFFO G, 1993, J CELL BIOL, V121, P887, DOI 10.1083/jcb.121.4.887; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; HE JS, 1991, J BIOL CHEM, V266, P7864; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HONDA S, 1993, J BIOL CHEM, V268, P7494; Kemper B., 1993, FRONTIERS BIOTRANSFO, V8, P1; KIMURA A, 1993, J BIOL CHEM, V268, P11125; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KRONBACH T, 1989, P NATL ACAD SCI USA, V86, P8262, DOI 10.1073/pnas.86.21.8262; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAETHEM RM, 1992, MOL PHARMACOL, V42, P958; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LEIGHTON JK, 1984, J BIOL CHEM, V259, P1165; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LUBET RA, 1992, BIOCHEM PHARMACOL, V43, P1067, DOI 10.1016/0006-2952(92)90614-O; Maxam A M, 1980, Methods Enzymol, V65, P499; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; POWER RF, 1992, SCIENCE, V13, P318; RANGARAJAN PN, 1989, P NATL ACAD SCI USA, V86, P3963, DOI 10.1073/pnas.86.11.3963; Sambrook J, 1989, MOL CLONING LABORATO; SCHWAB GE, 1985, BIOCHEMISTRY-US, V24, P7222, DOI 10.1021/bi00346a030; SHAW GC, 1993, J BIOL CHEM, V268, P2997; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3907; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UENO T, 1990, MOL CELL BIOL, V10, P4495, DOI 10.1128/MCB.10.9.4495; UPADHYA P, 1992, NUCLEIC ACIDS RES, V20, P557, DOI 10.1093/nar/20.3.557; VENEPALLY P, 1992, J BIOL CHEM, V267, P17333; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; YANO M, 1992, MOL CELL BIOL, V12, P2847, DOI 10.1128/MCB.12.6.2847; YOSHIOKA H, 1990, J BIOL CHEM, V265, P14612; ZHAO J, 1990, DNA CELL BIOL, V9, P37, DOI 10.1089/dna.1990.9.37	54	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5420	5427						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106524				2022-12-27	WOS:A1994MX57100107
J	GRIFFITHS, JT; TOMCHAK, LA; MILLS, JS; GRAVES, MC; COOK, ND; DUNN, BM; KAY, J				GRIFFITHS, JT; TOMCHAK, LA; MILLS, JS; GRAVES, MC; COOK, ND; DUNN, BM; KAY, J			INTERACTIONS OF SUBSTRATES AND INHIBITORS WITH A FAMILY HIV-1 AND HIV-2 HOMODIMERIC AND HETERODIMERIC PROTEINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ESCHERICHIA-COLI; ACTIVE-SITE; ASPARTIC PROTEASE; CRYSTAL-STRUCTURE; FORM; CONSTRUCTION; RESOLUTION; MECHANISM; PEPSIN	Genes were constructed to encode single-chain tethered human immunodeficiency virus HIV-1/HIV-1 and HIV-2/HIV-2 homodimeric proteinases and two HIV-1/ HIV-2 heterodimers which differed in the nature of the interface strands, Ah four constructs under the control of a heat-inducible promoter were expressed in E. coli and the resultant proteinases were purified therefrom. Kinetic parameters (K-m, k(cat) and k(cat)/K-m) were derived for the interaction of the tethered homo and heterodimeric proteinases with two distinct substrates at a variety of pH values. All four enzymes were comparably active toward one substrate. With the second substrate at pH 4.7, the k(cat)/K-m value was best for the HIV-1/1 tethered homodimer, 15-fold lower for the two heterodimeric proteinases, and was reduced by an additional 6-fold for the HIV-2/2 homodimer. From the K-i values determined for the interactions of the four tethered dimer proteinases with a systematic series of synthetic inhibitors, a parallel trend was observed. Whereas several inhibitors were equipotent against all four enzymes, two were discriminatory in that they inhibited strongly the HIV-1/1 homodimer and the two heterodimeric proteinases but had little effect on the HIV-2/2 tethered homodimer (or its untethered wild-type counterpart from HIV-2). The significance of these findings for active site interaction with HIV-proteinases is considered.	UNIV WALES COLL CARDIFF,DEPT BIOCHEM,CARDIFF CF1 1ST,WALES; ROCHE RES CTR,DEPT BIOTECHNOL,NUTLEY,NJ 07110; ROCHE RES CTR,DEPT MOLEC VIROL,WELWYN GARDEN CIT AL7 3AY,HERTS,ENGLAND; AMERSHAM INT PLC,CARDIFF CF4 7YT,S GLAM,WALES; UNIV FLORIDA,J HILLIS MILLER HLTH CTR,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610	Cardiff University; Roche Holding; Roche Holding; State University System of Florida; University of Florida					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI028571, R01AI028571] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-28571] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABE LM, 1991, BIOCHEMISTRY-US, V30, P106, DOI 10.1021/bi00215a016; BIZUB D, 1991, J BIOL CHEM, V266, P4951; BURSTEIN H, 1991, J VIROL, V65, P6165, DOI 10.1128/JVI.65.11.6165-6172.1991; CHENG YSE, 1990, P NATL ACAD SCI USA, V87, P9660, DOI 10.1073/pnas.87.24.9660; COOK ND, 1991, STRUCTURE FUNCTION A, P525; CROWL R, 1985, GENE, V38, P31, DOI 10.1016/0378-1119(85)90200-8; DEBOUCK C, 1987, P NATL ACAD SCI USA, V84, P8903, DOI 10.1073/pnas.84.24.8903; DIIANNI CL, 1990, J BIOL CHEM, V265, P17348; DILLON PJ, 1990, BIOTECHNIQUES, V9, P298; DREYER GB, 1992, BIOCHEMISTRY-US, V31, P6646, DOI 10.1021/bi00144a004; DUNN BM, 1994, IN PRESS METHODS ENZ; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; FRUTON JS, 1976, ADV ENZYMOL RAMB, V44, P1; GRAVES MC, 1988, P NATL ACAD SCI USA, V85, P2449, DOI 10.1073/pnas.85.8.2449; GRAVES MC, 1990, BIOCHEM BIOPH RES CO, V168, P30, DOI 10.1016/0006-291X(90)91670-N; GRIFFITHS JT, 1992, BIOCHEMISTRY-US, V31, P5193, DOI 10.1021/bi00137a015; GUSTCHINA A, 1991, PROTEINS, V10, P325, DOI 10.1002/prot.340100406; HYLAND LJ, 1991, BIOCHEMISTRY-US, V30, P8454, DOI 10.1021/bi00098a024; HYLAND LJ, 1991, BIOCHEMISTRY-US, V30, P8441, DOI 10.1021/bi00098a023; IDO E, 1991, J BIOL CHEM, V266, P24359; KRAUSSLICH HG, 1991, P NATL ACAD SCI USA, V88, P3213, DOI 10.1073/pnas.88.8.3213; LEGRICE SFJ, 1989, J BIOL CHEM, V264, P14902; LIN YZ, 1992, J BIOL CHEM, V267, P18413; MEEK TD, 1989, P NATL ACAD SCI USA, V86, P1841, DOI 10.1073/pnas.86.6.1841; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; MULICHAK AM, 1993, J BIOL CHEM, V268, P13103; MURTHY KHM, 1992, J BIOL CHEM, V267, P22770; PATTERSON CE, 1992, J VIROL, V66, P1228, DOI 10.1128/JVI.66.2.1228-1231.1992; PHYLIP LH, 1990, BIOCHEM BIOPH RES CO, V171, P439, DOI 10.1016/0006-291X(90)91412-L; RICHARDS AD, 1990, J BIOL CHEM, V265, P7733; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; STOLLER TJ, 1991, STRUCTURE FUNCTION A, P507; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P14675; TONG L, 1993, P NATL ACAD SCI USA, V90, P8387, DOI 10.1073/pnas.90.18.8387; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	38	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4787	4793						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106448				2022-12-27	WOS:A1994MX57100017
J	KUKULJAN, M; ROJAS, E; CATT, KJ; STOJILKOVIC, SS				KUKULJAN, M; ROJAS, E; CATT, KJ; STOJILKOVIC, SS			MEMBRANE-POTENTIAL REGULATES INOSITOL 1,4,5-TRISPHOSPHATE-CONTROLLED CYTOPLASMIC CA2+ OSCILLATIONS IN PITUITARY GONADOTROPHS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; CYTOSOLIC CALCIUM; XENOPUS OOCYTES; TRISPHOSPHATE; CHANNELS; RELEASE; ENTRY; MOBILIZATION; ACTIVATION; INFLUX	The influence of membrane potential (V-m) on cytoplasmic calcium ([Ca2+](i)) oscillations during the sustained extracellular Ca2+-dependent phase of the Ca2+ signaling response to gonadotropin-releasing hormone (GnRH) was analyzed in cultured pituitary gonadotrophs. In agonist- and inositol (1,4,5)-trisphosphate (Ins(1,4,5)P-3)-stimulated cells, sustained [Ca2+](i) oscillations were extinguished by hyperpolarization after 3-15 min despite the availability of Ca2+ in the extracellular medium. Single depolarizing pulses transiently restored the amplitude of the sustained spiking in a dihydropyridine- and extracellular Ca2+-sensitive manner. The responses to depolarization showed a marked dependence on V-m that was correlated with the steady state inward Ca2+ current. In addition, repetitive application of brief depolarizing pulses modulated the frequency of agonist- and Ins(1,4,5)Ps-controlled spiking; depolarization pulses at frequencies lower than the intrinsic rate of episodic Ca2+ release triggered large transients between the autonomous spikes, whereas higher frequencies of depolarizing pulses overcame the original Ca2+ spiking frequency. These extrinsically driven and extracellular Ca2+-dependent oscillations were sensitive to the Ca2+-ATPase blocker, thapsigargin, but not to ryanodine. On the other hand, spontaneous firing and application of depolarizing pulses to nonstimulated cells failed to induce thapsigargin-sensitive oscillations. These findings demonstrate that the pattern of Ca2+ signaling in gonadotrophs does not depend exclusively on the Ins(1,4,5)P-3 concentration, but also on the excitable status of the cell. Such modulation of the Ins(1,4,5)P-3-controlled Ca2+ signaling system by changes in V-m could provide a mechanism for the integration of multiple inputs that utilize diverse signal transduction pathways.	NICHHD,ENDOCRINOL & REPROD RES BRANCH,BETHESDA,MD 20892; NIDDKD,CELL BIOL & GENET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BALLA T, 1991, J BIOL CHEM, V266, P24719; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; CATT KJ, 1989, TRENDS ENDOCRIN MET, V1, P15, DOI 10.1016/1043-2760(89)90024-6; DAVIS TN, 1992, CELL, V71, P557, DOI 10.1016/0092-8674(92)90590-9; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DEYOUNG GW, 1992, P NATL ACAD SCI USA, V89, P9895, DOI 10.1073/pnas.89.20.9895; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FRIEL DD, 1992, NEURON, V8, P1109, DOI 10.1016/0896-6273(92)90132-W; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GIRARD S, 1993, SCIENCE, V260, P229, DOI 10.1126/science.8385801; GRAY PTA, 1988, J PHYSIOL-LONDON, V406, P35, DOI 10.1113/jphysiol.1988.sp017367; GUILLEMETTE G, 1987, P NATL ACAD SCI USA, V84, P8195, DOI 10.1073/pnas.84.23.8195; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IIDA T, 1991, MOL ENDOCRINOL, V5, P949, DOI 10.1210/mend-5-7-949; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; IZUMI SI, 1989, ARCH BIOCHEM BIOPHYS, V275, P410, DOI 10.1016/0003-9861(89)90388-3; KUKULJAN M, 1992, FEBS LETT, V301, P19, DOI 10.1016/0014-5793(92)80201-Q; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LEONG DA, 1991, J BIOL CHEM, V266, P916; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MORGAN RO, 1987, J BIOL CHEM, V262, P116; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RAWLINGS SR, 1991, J BIOL CHEM, V266, P22755; SHANGOLD GA, 1988, P NATL ACAD SCI USA, V85, P6566, DOI 10.1073/pnas.85.17.6566; STOJILKOVIC SS, 1990, SCIENCE, V248, P1663, DOI 10.1126/science.2163546; STOJILKOVIC SS, 1992, P NATL ACAD SCI USA, V89, P4081, DOI 10.1073/pnas.89.9.4081; STOJILKOVIC SS, 1991, J BIOL CHEM, V266, P10377; STOJILKOVIC SS, 1992, ENDOCR REV, V13, P256, DOI 10.1210/er.13.2.256; STOJILKOVIC SS, 1993, J BIOL CHEM, V268, P7713; STUTZIN A, 1989, AM J PHYSIOL, V257, pC865, DOI 10.1152/ajpcell.1989.257.5.C865; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TASAKA K, 1988, BIOCHEM BIOPH RES CO, V154, P398, DOI 10.1016/0006-291X(88)90699-7; TSE A, 1992, SCIENCE, V255, P462, DOI 10.1126/science.1734523; TSE A, 1993, ENDOCRINOLOGY, V132, P1475, DOI 10.1210/en.132.4.1475; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WATRAS J, 1991, J NEUROSCI, V11, P3239; YAO Y, 1992, J PHYSIOL-LONDON, V458, P319, DOI 10.1113/jphysiol.1992.sp019420; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390	45	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4860	4865						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106457				2022-12-27	WOS:A1994MX57100027
J	WENHAM, RM; LANDT, M; EASOM, RA				WENHAM, RM; LANDT, M; EASOM, RA			GLUCOSE ACTIVATES THE MULTIFUNCTIONAL CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE-II IN ISOLATED RAT PANCREATIC-ISLETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETION; CA-2+-INDEPENDENT FORM; BETA-CELLS; CALMODULIN; CA-2+; PHOSPHORYLATION; INHIBITION; CHANNELS; CA2+; AUTOPHOSPHORYLATION	The influence of the insulin secretagogues, glucose and K+, to activate the multifunctional, Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) in isolated rat pancreatic islets has been examined. Glucose (28 mM) and K+ (40 mM) were demonstrated to induce a 1.89 +/- 0.19- and 1.75 +/- 0.15-fold increase, respectively, in phosphorylation of a subunit of CaM kinase II immunoprecipitated by an anti-CaM kinase II alpha antibody. In intact islets, glucose and K+ also induced the generation of an autonomous, Ca2+/calmodulin-independent protein kinase II activity characteristic of autophosphorylated enzyme. Maximal activation, 2.9 +/- 0.2- and 3.0 +/- 0.5-fold for glucose and K+, respectively, relative to basal glucose control, was achieved at 2.5-5 min followed by a decline to near basal levels by 20 min. Glucose induced the production of autonomous CaM kinase II activity that, in terms of -fold stimulation, correlated closely with the extent of insulin release over a glucose concentration range of 3-28 mM. This stimulated activity was completely prevented by an inhibitor of glucose metabolism, mannoheptulose. These data demonstrate that the exposure of islets to stimulatory glucose concentrations activates CaM kinase II. The close correlation of enzyme activation with insulin secretion is consistent with the hypothesis that CaM kinase II plays an important role in the regulation of insulin secretion or related beta-cell processes.	UNIV N TEXAS,HLTH SCI CTR FT WORTH,DEPT BIOCHEM & MOLEC BIOL,FT WORTH,TX 76107; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110	University of North Texas System; University of North Texas Health Science Center; Washington University (WUSTL)								ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ASHCROFT SJ, 1970, BIOCHEM J, V118, P143, DOI 10.1042/bj1180143; ASHCROFT SJH, 1990, BIOCHEM SOC T, V18, P116, DOI 10.1042/bst0180116; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; COLCA JR, 1983, J BIOL CHEM, V258, P7260; COLCA JR, 1983, BIOCHEM J, V212, P819, DOI 10.1042/bj2120819; COOK DL, 1988, DIABETES, V37, P495, DOI 10.2337/diabetes.37.5.495; EASOM RA, 1990, J BIOL CHEM, V265, P14938; FUKUNAGA K, 1989, J BIOL CHEM, V264, P21830; GORELICK FS, 1988, J BIOL CHEM, V263, P17209; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HARRISON DE, 1982, BIOCHIM BIOPHYS ACTA, V714, P313, DOI 10.1016/0304-4165(82)90339-7; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HENQUIN JC, 1974, DIABETES, V23, P933, DOI 10.2337/diab.23.12.933; HENQUIN JC, 1980, DIABETOLOGIA, V18, P151, DOI 10.1007/BF00290493; HOWELL SL, 1984, EXPERIENTIA, V40, P1098, DOI 10.1007/BF01971457; HUGHES SJ, 1993, BIOCHEM J, V289, P795, DOI 10.1042/bj2890795; JEFFERSON AB, 1991, J BIOL CHEM, V266, P1484; JOHNSON JH, 1990, NEW ENGL J MED, V322, P653, DOI 10.1056/NEJM199003083221003; JONES PM, 1992, BIOCHEM J, V285, P973, DOI 10.1042/bj2850973; LANDT M, 1982, ARCH BIOCHEM BIOPHYS, V213, P148, DOI 10.1016/0003-9861(82)90449-0; LANDT M, 1992, DIABETES S1, V41, P103; LANZEN S, 1988, MOL PHARMACOL, V34, P395; LI GD, 1992, MOL PHARMACOL, V42, P489; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MACNICOL M, 1992, J BIOL CHEM, V267, P12197; MCDANIEL ML, 1984, METHODS DIABETES R A, V1, P153; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MILLER SG, 1985, J BIOL CHEM, V260, P9039; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; NIKI I, 1993, BIOCHEM BIOPH RES CO, V191, P255, DOI 10.1006/bbrc.1993.1210; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; SAITOH T, 1985, J CELL BIOL, V100, P835, DOI 10.1083/jcb.100.3.835; SCHULMAN H, 1993, NEUROCHEM RES, V18, P65, DOI 10.1007/BF00966924; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; STUTCHFIELD J, 1984, FEBS LETT, V175, P393, DOI 10.1016/0014-5793(84)80775-9; TOBIMATSU T, 1989, J BIOL CHEM, V264; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; WANG JL, 1990, BIOCHEM BIOPH RES CO, V171, P424, DOI 10.1016/0006-291X(90)91410-T; WENHAM RM, 1992, BIOCHEM BIOPH RES CO, V189, P128, DOI 10.1016/0006-291X(92)91534-W; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; ZAWALICH W, 1983, BIOCHEM BIOPH RES CO, V117, P448, DOI 10.1016/0006-291X(83)91221-4	50	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4947	4952						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106469				2022-12-27	WOS:A1994MX57100041
J	ALTIERI, DC				ALTIERI, DC			MOLECULAR-CLONING OF EFFECTOR CELL PROTEASE RECEPTOR-1, A NOVEL CELL-SURFACE RECEPTOR FOR THE PROTEASE FACTOR-XA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLASMINOGEN-ACTIVATOR; ENDOTHELIAL-CELLS; SERINE PROTEASE; COAGULATION; UROKINASE; MONOCYTES; THROMBIN; PHOSPHORYLATION; PROTHROMBIN; EXPRESSION	Cellular receptors for blood proteases regulate chemotaxis, extracellular proteolysis, and growth behavior of normal and malignant cells. Binding of the coagulation protease factor Xa to leukocytes is contributed by a recently identified molecule, denominated Effector cell Protease Receptor-1 (EPR-1). Monoclonal antibodies were generated against EPR-1+ MOLT13 lymphocytes and selected for reactivity with lymphocyte surface proteins by flow cytometry and with affinity-purified EPR-1 in Western blots. Antibody-based functional cloning of the cDNA for EPR-1 reveals the sequence of a novel molecule encoded by a prominent 1.9-kilobase mRNA. The cDNA predictes a glycoprotein of 337 amino acids, characterized by a unique cysteine-rich extracellular module, a single membrane-spanning domain, and a serine-rich (26%) cytoplasmic tail featuring at least 15 potential phosphorylation sites. Genetically engineered EPR-1 transfectants were recognized by monoclonal antibodies to EPR-1 and bound I-125-factor Xa in a specific and saturable manner (K(d) approximately 10-15 nM). In the absence of factor V/Va, EPR-1 transfectants promoted prothrombin activation in a factor Xa concentration-dependent reaction, inhibited by a monoclonal antibody to EPR-1. These findings define EPR-1 as a novel cell surface receptor for factor Xa potentially implicated in protease-dependent cellular effector functions.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	ALTIERI, DC (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, CVB-1, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NHLBI NIH HHS [HL-43773] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043773] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1990, J IMMUNOL, V145, P246; ALTIERI DC, 1989, J BIOL CHEM, V264, P2969; APPELLA E, 1987, J BIOL CHEM, V262, P4437; BARSHAVIT R, 1983, J CELL BIOL, V96, P282, DOI 10.1083/jcb.96.1.282; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GLENN KC, 1979, NATURE, V278, P711, DOI 10.1038/278711a0; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; HOFFMAN S, 1987, P NATL ACAD SCI USA, V84, P2523, DOI 10.1073/pnas.84.8.2523; KIRCHHEIMER JC, 1989, P NATL ACAD SCI USA, V86, P5424, DOI 10.1073/pnas.86.14.5424; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MCGEE MP, 1986, J EXP MED, V164, P1902, DOI 10.1084/jem.164.6.1902; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; PARIS S, 1984, J BIOL CHEM, V259, P989; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RAPOPORT TA, 1986, CRC CR REV BIOCH MOL, V20, P73, DOI 10.3109/10409238609115901; REEVES WH, 1989, J CLIN INVEST, V84, P562, DOI 10.1172/JCI114199; RODGERS GM, 1983, P NATL ACAD SCI-BIOL, V80, P7001, DOI 10.1073/pnas.80.22.7001; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P349; TRACY PB, 1985, J BIOL CHEM, V260, P2119; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WORFOLK LA, 1992, BLOOD, V80, P1989	25	86	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3139	3142						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106347				2022-12-27	WOS:A1994MV63100005
J	ASTERMARK, J; HOGG, PJ; STENFLO, J				ASTERMARK, J; HOGG, PJ; STENFLO, J			THE GAMMA-CARBOXYGLUTAMIC ACID AND EPIDERMAL GROWTH FACTOR-LIKE MODULES OF FACTOR-IXA-BETA - EFFECTS ON THE SERINE-PROTEASE MODULE AND FACTOR-X ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL BINDING; BOVINE FACTOR-X; FACTOR-LIKE DOMAINS; CALCIUM-BINDING; STRUCTURAL REQUIREMENTS; BLOOD-COAGULATION; CA2+ BINDING; ENZYME COMPLEXES; CHRISTMAS FACTOR; PROTHROMBIN	Blood coagulation factors IX and X are two serine proteases with a similar modular structure. The noncatalytic part of each protein consists of a gamma-carboxyglutamic acid (Gla)-containing module and two modules homologous to the epidermal growth factor (EGF) precursor. We have now found that the NH2-terminal EGF-like module of both factors IX and X inhibits factor Xa formation in a Gla-independent manner, both in the presence and absence of phospholipid and the cofactor, factor VIIIa. In contrast, the COOH-terminal EGF-like module has no such effect. Our data indicate that the NH2-terminal EGF-like module of factor IXabeta interacts either with the corresponding module or with the serine protease module in the substrate, factor X, without affecting the hydrolysis of low molecular weight substrates. Using antibodies as structural probes, we found that Ca2+ binding to the Gla module of factor IXabeta induces a conformational transition in the serine protease module. No evidence was found for a direct interaction between the Gla module and factor VIIIa. We therefore propose that the Gla module in factor IXabeta is indirectly involved in the cofactor interaction, in that Ca2+ binding to sites in this module induces a conformation in the serine protease module that is commensurate with factor VIIIa interaction. In addition, the immunochemical approach revealed a Gla-independent Ca2+ binding site in the serine protease module (apparent K(d) of almost-equal-to 120 gm) that also might influence its conformation. Antibodies against the EGF-like modules of factor IX were used to probe Ca2+ binding to these modules in intact and in Gla-domainless factor IXabeta. The data indicate a Ca2+ binding site with an apparent K(d) of almost-equal-to 50 mum in the NH2-terminal EGF-like module of both factor IX species.	LUND UNIV,MALMO GEN HOSP,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN; PRINCE WALES HOSP,DEPT HAEMATOL,RANDWICK,NSW 2031,AUSTRALIA	Lund University				Hogg, Philip/0000-0001-6486-2863				ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; ASTERMARK J, 1992, J BIOL CHEM, V267, P3249; ASTERMARK J, 1991, J BIOL CHEM, V266, P2438; BAJAJ SP, 1982, J BIOL CHEM, V257, P3726; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BAJAJ SP, 1985, J BIOL CHEM, V260, P1574; BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1975, FEBS LETT, V56, P139, DOI 10.1016/0014-5793(75)80128-1; CHATTOPADHYAY A, 1992, J BIOL CHEM, V267, P12323; CHEUNG WF, 1992, J BIOL CHEM, V267, P20529; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DERIAN CK, 1989, J BIOL CHEM, V264, P6615; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; FUJIKAWA K, 1973, BIOCHEMISTRY-US, V12, P4938, DOI 10.1021/bi00748a019; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V11, P2285; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GIANNELLI F, 1993, NUCLEIC ACIDS RES, V21, P3075, DOI 10.1093/nar/21.13.3075; GREEN PM, 1989, EMBO J, V8, P1067, DOI 10.1002/j.1460-2075.1989.tb03474.x; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HASHIMOTO N, 1985, J BIOCHEM, V97, P1347, DOI 10.1093/oxfordjournals.jbchem.a135187; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; JACKSON CM, 1972, BIOCHEMISTRY-US, V11, P4873, DOI 10.1021/bi00776a001; Jesty J, 1976, Methods Enzymol, V45, P95; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; LIN SW, 1990, J BIOL CHEM, V265, P144; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; MORITA T, 1985, J BIOL CHEM, V260, P2583; MORITA T, 1991, J BIOCHEM, V110, P990, DOI 10.1093/oxfordjournals.jbchem.a123701; MORITA T, 1988, J BIOCHEM, V104, P368, DOI 10.1093/oxfordjournals.jbchem.a122475; MORITA T, 1986, J BIOL CHEM, V261, P4015; MORITA T, 1984, J BIOL CHEM, V259, P5698; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; OWEN WG, 1974, J BIOL CHEM, V249, P594; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; PERSSON E, 1992, FEBS LETT, V314, P5, DOI 10.1016/0014-5793(92)81447-T; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PERSSON E, 1991, J BIOL CHEM, V266, P2444; PERSSON E, 1993, J BIOL CHEM, V268, P22531; PERSSON E, 1991, J BIOL CHEM, V266, P2453; ROBERTS HR, 1993, THROMB HAEMOSTASIS, V70, P1; RYAN J, 1989, J BIOL CHEM, V264, P20283; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; SEGEL IH, 1990, ENZYME KINETICS, P100; SKOGEN WF, 1984, J BIOL CHEM, V259, P2306; STENFLO J, 1976, J BIOL CHEM, V251, P355; SUGO T, 1984, J BIOL CHEM, V259, P5705; TOOMEY JR, 1992, BIOCHEMISTRY-US, V31, P1806, DOI 10.1021/bi00121a031; VALCARCE C, 1993, J BIOL CHEM, V268, P26673	52	20	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3682	3689						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106413				2022-12-27	WOS:A1994MV63100081
J	CHAMBREY, R; PAILLARD, M; PODEVIN, RA				CHAMBREY, R; PAILLARD, M; PODEVIN, RA			ENZYMATIC AND FUNCTIONAL EVIDENCE FOR ADAPTATION OF THE VACUOLAR H+-ATPASE IN PROXIMAL TUBULE APICAL MEMBRANES FROM RATS WITH CHRONIC METABOLIC-ACIDOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; BRUSH-BORDER MEMBRANES; NEM-SENSITIVE ATPASE; ANTIPORTER ACTIVITY; NA+/H+ ANTIPORTER; GOLGI MEMBRANES; TURTLE BLADDER; VESICLES; ALKALOSIS; EXCHANGE	The present work examined the effects of chronic metabolic acidosis on the vacuolar proton-translocating adenosine triphosphatase (H+-ATPase) activity both in rat renal cortical homogenates and in their luminal membranes. Moreover, to assess the effect of acidosis on H+ transport by the apical H+-ATPase, we have developed a detergent-dilution procedure, resulting in the formation of sealed vesicles having this enzyme at their external surface. NH4Cl loading for 4 days had no effect on homogenates H+-ATPase activity, estimated with either N-ethylmaleimide or bafilomycin A1. In contrast, H+-ATPase activities were increased significantly by about 30% in both native apical membranes prepared by Ca2+ aggregation and detergent-treated luminal vesicles from acidotic animal. Kinetic analysis revealed that this stimulation was solely through changes in the V(max) for ATP. In membranes prepared by Mg2+ aggregation, acidosis also caused significant stimulation of the H+ATPase activity. In addition, the initial rate of ATP-induced intravesicular acidification was 25% higher in reoriented H+-ATPase vesicles from acidotic rats, whereas passive proton permeability was identical in both groups. Finally, both vesicle enrichments and yields of luminal markers and de-enrichments and yields of intracellular membrane markers were identical in the two groups. These results provide enzymatic and functional evidence suggesting that chronic acidosis induces an adaptative change in the rat brush border H+-ATPase.	CTR RECH BIOMED CORDELIERS,INSERM,U356,15 RUE ECOLE MED,F-75270 PARIS 06,FRANCE; HOP HOTEL DIEU,FAC MED BROUSSAIS,F-75181 PARIS 04,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite								AKIBA T, 1987, J CLIN INVEST, V80, P308, DOI 10.1172/JCI113074; ALPERN RJ, 1990, PHYSIOL REV, V70, P79, DOI 10.1152/physrev.1990.70.1.79; AUBRY H, 1986, BIOCHIM BIOPHYS ACTA, V856, P647; BAIS R, 1975, ANAL BIOCHEM, V63, P271, DOI 10.1016/0003-2697(75)90215-8; BARBARAT B, 1986, J BIOL CHEM, V261, P4455; BASTANI B, 1991, J CLIN INVEST, V88, P126, DOI 10.1172/JCI115268; BLUMENTHAL SS, 1985, J LAB CLIN MED, V106, P17; BOUMENDILPODEVIN EF, 1981, AM J PHYSIOL, V240, pF185, DOI 10.1152/ajprenal.1981.240.3.F185; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN D, 1988, J CLIN INVEST, V82, P2114, DOI 10.1172/JCI113833; COHN DE, 1983, AM J PHYSIOL, V245, pF217, DOI 10.1152/ajprenal.1983.245.2.F217; DAHLQVIST A, 1968, ANAL BIOCHEM, V22, P99, DOI 10.1016/0003-2697(68)90263-7; FISHMAN WH, 1967, CLIN CHIM ACTA, V15, P435, DOI 10.1016/0009-8981(67)90008-3; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; GLUCK S, 1982, P NATL ACAD SCI-BIOL, V79, P4327, DOI 10.1073/pnas.79.14.4327; Harper AE, 1965, METHODS ENZYMATIC AN, P788; HAUSER H, 1980, BIOCHIM BIOPHYS ACTA, V602, P567, DOI 10.1016/0005-2736(80)90335-1; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; KHADOURI C, 1992, AM J PHYSIOL, V262, pF583, DOI 10.1152/ajprenal.1992.262.4.F583; KINSELLA J, 1984, P NATL ACAD SCI-BIOL, V81, P630, DOI 10.1073/pnas.81.2.630; KINSELLA J, 1984, J BIOL CHEM, V259, P3224; KULANTHAIVEL P, 1990, BIOCHEMISTRY-US, V29, P10807, DOI 10.1021/bi00500a013; KURTZ I, 1987, J CLIN INVEST, V80, P928, DOI 10.1172/JCI113184; LEABACK DH, 1961, BIOCHEM J, V78, P151, DOI 10.1042/bj0780151; MANGANEL M, 1985, AM J PHYSIOL, V249, pF400, DOI 10.1152/ajprenal.1985.249.3.F400; MARTINEK RG, 1964, CLIN CHEM, V10, P1087; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; MORIYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V980, P241, DOI 10.1016/0005-2736(89)90405-7; NORTHRUP TE, 1988, AM J PHYSIOL, V255, pF237, DOI 10.1152/ajprenal.1988.255.2.F237; PORTEOUS JW, 1965, BIOCHEM J, V96, P159, DOI 10.1042/bj0960159; PREISIG PA, 1988, J CLIN INVEST, V82, P1445, DOI 10.1172/JCI113750; RACKER E, 1972, J MEMBRANE BIOL, V10, P221, DOI 10.1007/BF01867856; REESJONES R, 1984, BIOCHEMISTRY-US, V23, P2236, DOI 10.1021/bi00305a022; SABATINI S, 1990, AM J PHYSIOL, V258, pF297, DOI 10.1152/ajprenal.1990.258.2.F297; SABOLIC I, 1984, BIOCHIM BIOPHYS ACTA, V772, P140, DOI 10.1016/0005-2736(84)90037-3; SCHWARTZ GJ, 1985, J CLIN INVEST, V75, P1638, DOI 10.1172/JCI111871; SIMON BJ, 1990, J MEMBRANE BIOL, V117, P141, DOI 10.1007/BF01868681; STETSON DL, 1983, AM J PHYSIOL, V245, pC113, DOI 10.1152/ajpcell.1983.245.1.C113; TSAI CJ, 1984, AM J PHYSIOL, V247, pF339, DOI 10.1152/ajprenal.1984.247.2.F339; TULSIANI DRP, 1982, J BIOL CHEM, V257, P3660; WERNER G, 1984, J ANTIBIOT, V37, P110, DOI 10.7164/antibiotics.37.110; YURKO MA, 1987, J BIOL CHEM, V262, P15770; ZIMOLO Z, 1992, J MEMBRANE BIOL, V126, P19	44	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3243	3250						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106360				2022-12-27	WOS:A1994MV63100021
J	COLAMONICI, OR; UYTTENDAELE, H; DOMANSKI, P; YAN, H; KROLEWSKI, JJ				COLAMONICI, OR; UYTTENDAELE, H; DOMANSKI, P; YAN, H; KROLEWSKI, JJ			P135(TYK2), AN INTERFERON-ALPHA-ACTIVATED TYROSINE KINASE, IS PHYSICALLY ASSOCIATED WITH AN INTERFERON-ALPHA RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; SH3 DOMAINS; PHOSPHORYLATION; FAMILY; SYSTEM; CD4; PROTEINS; SUBUNIT	Recent genetic studies have linked the tyk2 gene, which encodes a novel type of non-receptor tyrosine kinase, to the interferon-alpha intracellular signaling pathway. In this report, biochemical evidence is presented which supports this proposed function for the tyk2 tyrosine kinase and further defines its role in the interferon-alpha signaling cascade. Specifically, the tyk2 gene is shown to encode a 135-kDa protein which is rapidly phosphorylated on tyrosine in response to interferon-alpha treatment. Indirect evidence suggests that the tyrosine phosphorylation of p135tyk2 is the result of autokinase activity, implying that the Tyk2 tyrosine kinase is activated by interferon-alpha treatment. Two complementary methods demonstrate a physical association between p135tyk2 and the alpha-subunit of the interferon-alpha receptor. First, immunoblots show that monoclonal antibodies against the alpha-subunit of the interferon-alpha receptor can coimmunoprecipitate p135tyk2. Second, interferon-alpha receptor proteins which have been labeled by affinity cross-linking with I-125-interferon-alpha2 can be coimmuno-precipitated using anti-tyk2 antisera. Taken together, these data suggest that an interferon-a receptor-p135tyk2 complex functions, in a manner analogous to the CD4-Ick tyrosine kinase complex, to initiate the interferon-alpha signaling cascade.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,ROOM P&S 14-451,630 W 168TH ST,NEW YORK,NY 10032; UNIV TENNESSEE CTR HLTH SCI,DEPT PATHOL,MEMPHIS,TN 38163; COLUMBIA UNIV COLL PHYS & SURG,COLUMBIA PRESBYTERIAN CANC CTR,NEW YORK,NY 10032	Columbia University; University of Tennessee System; University of Tennessee Health Science Center; Columbia University					NATIONAL CANCER INSTITUTE [R01CA056862] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005395] Funding Source: NIH RePORTER; NCI NIH HHS [CA56862] Funding Source: Medline; NCRR NIH HHS [2S07RR5395] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BENOIT P, 1993, J IMMUNOL, V150, P707; BERNARDS A, 1991, ONCOGENE, V6, P1185; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1992, BLOOD, V80, P744; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1991, PHARMACOL THERAPEUT, V52, P227, DOI 10.1016/0163-7258(91)90010-J; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; EISEMAN E, 1992, NATURE, V355, P78; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HARPUR AG, 1992, ONCOGENE, V7, P1347; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; MERLIN G, 1985, J GEN VIROL, V66, P1149, DOI 10.1099/0022-1317-66-5-1149; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P146; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SUDOL M, 1993, MOL BASIS HUMAN CANC, P203; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VALAZQUEZ L, 1992, CELL, V70, P313; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	37	149	151	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3518	3522						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106393				2022-12-27	WOS:A1994MV63100060
J	RITCHIE, HH; HOU, H; VEIS, A; BUTLER, WT				RITCHIE, HH; HOU, H; VEIS, A; BUTLER, WT			CLONING AND SEQUENCE DETERMINATION OF RAT DENTIN SIALOPROTEIN, A NOVEL DENTIN PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE TEETH; INCISOR; PHOSPHOPROTEIN; PHOSPHOPHORYNS; LOCALIZATION; SPECIFICITY; RIBOSOMES; PEPTIDES; MATRIX; BONE	Dentin sialoprotein (DSP) is a 53-kDa protein isolated from rat dentin. It contains 29.6% carbohydrate (including 9% sialic acid) and has an overall composition similar to that of the bone sialoproteins osteopontin and bone sialoprotein (i.e. rich in Asp, Ser, Glu, and Gly). Using a monospecific anti-DSP polyclonal antibody to screen a rat incisor odontoblast cDNA library, a cDNA clone was isolated and sequenced. This approximately 750-base pair clone contained a DNA sequence corresponding to the NH2-terminal 9 amino acids of DSP. A second cDNA clone was isolated by using the first cDNA as a probe to rescreen the library. This second clone had the full-length DSP coding region. From the sequence, we deduced that the DSP cDNA coded for 366 amino acids, predominantly Asp, Ser, Glu, and Gly. The amino acid composition calculated for this sequence was very similar to that for purified DSP reported earlier; likewise the deduced molecular weight (53,045) was essentially identical to that determined by sedimentation equilibrium. Six potential N-linked glycosylation sites were present in the predicted DSP sequence. No Arg-Gly-Asp sequence was found, and the sequence for DSP was dissimilar to those of osteopontin and bone sialoprotein. Multiple transcripts near 4.6 and 1.5 kilobases were detected by Northern blot analysis in the incisor of 21-day-old rat and the tooth germ of the newborn rat. Consistent with previous immunohistochemical findings, no transcripts were detected in brain, salivary gland, heart, muscle, spleen, kidney, intestine, lung, liver, pancreas, tibia, calvaria, or osteoblast-like osteosarcoma (ROS 17/2.8) cells, indicating that DSP is specifically expressed by odontoblasts and related cells.	NORTHWESTERN UNIV, DEPT ORAL BIOL, CHICAGO, IL 60611 USA	Northwestern University	RITCHIE, HH (corresponding author), UNIV TEXAS, DENT BRANCH, DEPT BIOL CHEM, HOUSTON, TX 77030 USA.				NCI NIH HHS [CA 16672] Funding Source: Medline; NIDCR NIH HHS [R37 DE 05092] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE005092] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Bronckers A L, 1989, Connect Tissue Res, V22, P65; BRONCKERS ALJJ, 1987, BONE MINER, V2, P361; BRONCKERS ALJJ, 1993, CELL TISSUE RES, V272, P237, DOI 10.1007/BF00302729; Butler W T, 1991, J Biol Buccale, V19, P83; BUTLER WT, 1992, MATRIX, V12, P343, DOI 10.1016/S0934-8832(11)80030-2; DEVRIES IG, 1986, ARCH ORAL BIOL, V31, P57, DOI 10.1016/0003-9969(86)90114-7; DIMUZIO MT, 1978, J BIOL CHEM, V253, P6845; DIMUZIO MT, 1985, CHEM BIOL MINERALIZE, P296; DSOUZA RN, 1992, J HISTOCHEM CYTOCHEM, V40, P359, DOI 10.1177/40.3.1552175; GEORGE A, 1992, INT CONGR SER, V1002, P203; GORSKI JP, 1992, CALCIFIED TISSUE INT, V50, P391, DOI 10.1007/BF00296767; Heinegard D, 1989, Connect Tissue Res, V21, P3, DOI 10.3109/03008208909049990; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; JONTELL M, 1983, BIOCHEM J, V214, P769, DOI 10.1042/bj2140769; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LINDE A, 1989, ANAT REC, V224, P154, DOI 10.1002/ar.1092240206; MACDOUGALL M, 1985, BIOCHEM J, V232, P493, DOI 10.1042/bj2320493; Maniatis T., 1982, MOL CLONING; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; RABIE A M, 1991, Journal of Dental Research, V70, P380; RAHIMA M, 1988, J HISTOCHEM CYTOCHEM, V36, P153, DOI 10.1177/36.2.3335773; RITCHIE HH, 1990, NUCLEIC ACIDS RES, V18, P6857, DOI 10.1093/nar/18.23.6857; ROBEY PG, 1989, ENDOCRIN METAB CLIN, V18, P859, DOI 10.1016/S0889-8529(18)30347-5; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STETLERSTEVENSON WG, 1987, CALCIFIED TISSUE INT, V40, P97, DOI 10.1007/BF02555712; Veis A, 1985, CHEM BIOL MINERALIZE, P170; VEIS A, 1978, IONS MACROMOLECULAR, P259; WEINSTOCK M, 1973, J CELL BIOL, V56, P838, DOI 10.1083/jcb.56.3.838; WU CB, 1992, J BIOL CHEM, V267, P16588; YOUNG MF, 1992, CLIN ORTHOP RELAT R, P275	35	128	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3698	3702						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106414				2022-12-27	WOS:A1994MV63100083
J	DEPAIVA, A; POULAIN, B; LAWRENCE, GW; SHONE, CC; TAUC, L; DOLLY, JO				DEPAIVA, A; POULAIN, B; LAWRENCE, GW; SHONE, CC; TAUC, L; DOLLY, JO			A ROLE FOR THE INTERCHAIN DISULFIDE OR ITS PARTICIPATING THIOLS IN THE INTERNALIZATION OF BOTULINUM NEUROTOXIN-A REVEALED BY A TOXIN DERIVATIVE THAT BINDS TO ECTO-ACCEPTORS AND INHIBITS TRANSMITTER RELEASE INTRACELLULARLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDULLARY CHROMAFFIN CELLS; MOTOR-NERVE TERMINALS; CHOLERA-TOXIN; NEUROTRANSMITTER RELEASE; CLOSTRIDIUM-BOTULINUM; DIPHTHERIA-TOXIN; TETANUS TOXIN; LIGHT-CHAINS; CATECHOLAMINE SECRETION; APLYSIA NEURONS	Botulinum neurotoxin type A consists of a disulfide-linked light and heavy chain, with an intradisulfide present within the C-terminal half of the latter. The functional consequences of reducing these bonds and alkylating the thiols were investigated. Modification of free cysteine residues had no effect on the toxicity in mouse bioassays or on acetylcholine release in the mouse nerve-diaphragm and the buccal ganglion of Aplysia californica. However, reduction of the toxin prior to alkylation drastically decreased neuroparalytic potency; yet, this derivative inhibited transmitter release if injected directly into a presynaptic neuron in the Aplysia ganglion or added to bovine permeabilized adrenal chromaffin cells. Its antagonism of the action of botulinum neurotoxin A at mammalian motor nerve endings and Aplysia neurons indicates retention of the ability to bind to the toxin's productive ecto-acceptors. Thus, the abolition of the toxicity of extracellularly applied botulinum neurotoxin A by the cleavage of both disulfides, and the alkylation of the half-cystines involved, results from ineffective uptake. Modified forms of the isolated chains of botulinum neurotoxin A were utilized to determine which of the disulfides were necessary for internalization. Alkylation of the cysteines in the light and heavy chains, including those involved in the interchain bond but excluding those of the intact disulfide in the heavy chain, revealed that the intermolecular bond must be present, or the thiols concerned unmodified, for botulinum neurotoxin A to undergo membrane translocation into Aplysia neurons.	IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AY, ENGLAND; PUBL HLTH LAB SERV, SALISBURY SP4 0JG, WILTS, ENGLAND; CNRS, NEUROBIOL CELLULAIRE & MOLEC LAB, F-91198 GIF SUR YVETTE, FRANCE	Imperial College London; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Dolly, Oliver/G-1532-2012; Lawrence, Gary/F-3949-2012; Dolly, Oliver/ABH-6677-2020	Dolly, Oliver/0000-0002-0861-5320; Dolly, Oliver/0000-0002-0861-5320				AHNERTHILGER G, 1989, J NEUROCHEM, V52, P1751, DOI 10.1111/j.1471-4159.1989.tb07253.x; BANDYOPADHYAY S, 1987, J BIOL CHEM, V262, P2660; BARBIERI L, 1982, ARCH BIOCHEM BIOPHYS, V216, P380, DOI 10.1016/0003-9861(82)90224-7; BINZ T, 1990, J BIOL CHEM, V265, P9153; BITTNER MA, 1989, J BIOL CHEM, V264, P10354; BLACK JD, 1987, NEUROSCIENCE, V23, P767, DOI 10.1016/0306-4522(87)90094-7; BLACK JD, 1986, J CELL BIOL, V103, P521, DOI 10.1083/jcb.103.2.521; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; Dasgupta B.R., 1981, BIOMEDICAL ASPECTS B, P1; DAYANITHI G, 1990, NEUROSCIENCE, V39, P711, DOI 10.1016/0306-4522(90)90254-2; DEPAIVA A, 1990, FEBS LETT, V277, P171, DOI 10.1016/0014-5793(90)80836-8; DOLLY JO, 1988, E H S BIOT, P79; DOLLY JO, 1984, NATURE, V307, P457, DOI 10.1038/307457a0; DOLLY JO, 1992, BACTERIAL PROTEIN TO, P31; DUNN LA, 1983, J BIOL CHEM, V258, P4989; DWYER JD, 1982, BIOCHEMISTRY-US, V21, P3227, DOI 10.1021/bi00256a030; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Gill D M, 1977, Adv Cyclic Nucleotide Res, V8, P85; KNOX JN, 1970, BIOCHIM BIOPHYS ACTA, V214, P350, DOI 10.1016/0005-2795(70)90012-7; KURAZONO H, 1992, J BIOL CHEM, V267, P14721; LIVETT BG, 1984, PHYSIOL REV, V64, P1103, DOI 10.1152/physrev.1984.64.4.1103; LOMNETH R, 1990, NEUROSCI LETT, V113, P211, DOI 10.1016/0304-3940(90)90305-S; LOMNETH R, 1991, J NEUROCHEM, V57, P1414; MAISEY EA, 1988, EUR J BIOCHEM, V177, P683, DOI 10.1111/j.1432-1033.1988.tb14423.x; MCINNES C, 1990, FEBS LETT, V261, P323, DOI 10.1016/0014-5793(90)80582-4; MOSKAUG JO, 1987, J BIOL CHEM, V262, P10339; MOSS J, 1983, J BIOL CHEM, V258, P1879; POULAIN B, 1989, EUR J BIOCHEM, V185, P197, DOI 10.1111/j.1432-1033.1989.tb15102.x; POULAIN B, 1988, P NATL ACAD SCI USA, V85, P4090, DOI 10.1073/pnas.85.11.4090; POULAIN B, 1989, J BIOL CHEM, V264, P21928; POULAIN B, 1992, NEUROSCI LETT, V139, P289, DOI 10.1016/0304-3940(92)90573-P; RIBI HO, 1988, SCIENCE, V239, P1272, DOI 10.1126/science.3344432; SCHIAVO G, 1990, INFECT IMMUN, V58, P4136, DOI 10.1128/IAI.58.12.4136-4141.1990; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SHONE CC, 1985, EUR J BIOCHEM, V151, P75, DOI 10.1111/j.1432-1033.1985.tb09070.x; SIMPSON LL, 1981, PHARMACOL REV, V33, P155; SIMPSON LL, 1980, J PHARMACOL EXP THER, V212, P16; STECHER B, 1989, FEBS LETT, V248, P23, DOI 10.1016/0014-5793(89)80424-7; SUGIYAMA H, 1973, P SOC EXP BIOL MED, V143, P58; Tacket CO., 1989, BOTULINUM NEUROTOXIN, P351; TAUC L, 1974, NATURE, V250, P496, DOI 10.1038/250496a0; THOMPSON DE, 1990, EUR J BIOCHEM, V189, P73, DOI 10.1111/j.1432-1033.1990.tb15461.x; TOMASI M, 1981, J BIOL CHEM, V256, P1177; TSE CK, 1982, EUR J BIOCHEM, V122, P493; VONEULER US, 1955, ACTA PHYSIOL SCAND, V33, P45; WHITAKER JR, 1980, ANAL BIOCHEM, V109, P156, DOI 10.1016/0003-2697(80)90024-X; WISNIESKI BJ, 1981, NATURE, V289, P319, DOI 10.1038/289319a0; WRIGHT HT, 1984, J BIOL CHEM, V259, P1649; WRIGHT HT, 1987, ARCH BIOCHEM BIOPHYS, V256, P280, DOI 10.1016/0003-9861(87)90447-4; [No title captured]; [No title captured]	52	70	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20838	20844						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8104936				2022-12-27	WOS:A1993MA28800033
J	BRUN, T; ROCHE, E; KIM, KH; PRENTKI, M				BRUN, T; ROCHE, E; KIM, KH; PRENTKI, M			GLUCOSE REGULATES ACETYL-COA CARBOXYLASE GENE-EXPRESSION IN A PANCREATIC BETA-CELL LINE (INS-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; CARBOHYDRATE RESPONSE ELEMENT; INDUCED INSULIN-SECRETION; PYRUVATE-KINASE GENE; MALONYL-COA; RAT-LIVER; S14 GENE; ISLETS; METABOLISM; PROMOTER	Acetyl-CoA carboxylase (ACC) catalyzes the production of malonyl-CoA which may act as a metabolic coupling factor in nutrient-induced insulin release. We have studied the long term regulation of ACC by nutrients using the cell line INS-1. Glucose, from 5 to 20 mm, elicited a 15-fold increase in ACC mRNA. The effect was detected after 4 h and reached a maximum by 24 h. ACC protein accumulation followed that of ACC mRNA, and glucose did not modify the half-life of the ACC transcript. Glucose caused a dose-dependent rise in the glucose 6-phosphate content of INS-1 cells. 2-Deoxyglucose, which is phosphorylated by glucokinase but is not further metabolized, induced ACC mRNA. The effect of glucose was blocked by the glucokinase inhibitors mannoheptulose and glucosamine and was not mimicked by the 3-O-methyl or 6-deoxy analogues of glucose, which are not phosphorylated. Activation of the Ca2+, cAMP, and C-kinase pathways with high K+, forskolin, and phorbol 12-myristate 13 acetate, respectively, caused insulin release but not ACC mRNA induction. Basal insulin release, at 5 mm glucose, correlated with the ACC protein content of INS-1 cells preincubated for 24 h at various glucose concentrations. In conclusion, glucose is a potent inducer of the ACC gene, and glucose 6-phosphate may mediate its effect. Different signaling systems mediate the action of glucose on insulin release and ACC gene expression. The data strengthen the view that ACC plays a pivotal role in nutrient-induced insulin release.	UNIV GENEVA, CMU, DIV BIOCHIM CLIN, 9 AV CHAMPEL, CH-1211 GENEVA 4, SWITZERLAND; PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	University of Geneva; Purdue University System; Purdue University; Purdue University West Lafayette Campus			Roche, Enrique/V-5738-2017	Roche, Enrique/0000-0001-5128-1672; BRUN, Thierry/0000-0002-1659-4283				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BAI DH, 1986, J BIOL CHEM, V261, P2395; BEDOYA FJ, 1991, DIABETES, V40, P15, DOI 10.2337/diabetes.40.1.15; BERGMEYER HU, 1974, METHODS ENZYMATIC AN; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BONNERWEIR S, 1989, DIABETES, V38, P49, DOI 10.2337/diabetes.38.1.49; BUSSO N, 1986, J BIOL CHEM, V261, P9309; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLART MA, 1989, ONCOGENE, V4, P237; COLLINS H, 1992, J BIOL CHEM, V267, P1357; COLLINS HW, 1990, P NATL ACAD SCI USA, V87, P5494, DOI 10.1073/pnas.87.14.5494; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; DECAUX JF, 1991, J BIOL CHEM, V266, P3432; EIZIRIK DL, 1992, J CLIN INVEST, V90, P1263, DOI 10.1172/JCI115989; EVANS JL, 1988, ARCH BIOCHEM BIOPHYS, V264, P103, DOI 10.1016/0003-9861(88)90575-9; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FUKUDA H, 1992, J BIOCHEM-TOKYO, V111, P25, DOI 10.1093/oxfordjournals.jbchem.a123713; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JANJIC D, 1992, DIABETOLOGIA, V35, P482, DOI 10.1007/BF02342448; KATSURADA A, 1990, EUR J BIOCHEM, V190, P435, DOI 10.1111/j.1432-1033.1990.tb15593.x; KIM KH, 1983, CURR TOP CELL REGUL, V22, P143; KING DL, 1976, ENDOCRINOLOGY, V99, P1003, DOI 10.1210/endo-99-4-1003; LEAHY JL, 1986, J CLIN INVEST, V77, P908, DOI 10.1172/JCI112389; LIANG Y, 1991, DIABETES, V40, P327, DOI 10.2337/diabetes.40.3.327; LIANG Y, 1990, J BIOL CHEM, V265, P16863; LOPEZCASILLAS F, 1992, METABOLISM, V41, P201, DOI 10.1016/0026-0495(92)90154-3; LOPEZCASILLAS F, 1991, ENDOCRINOLOGY, V129, P1049, DOI 10.1210/endo-129-2-1049; LUO XC, 1990, NUCLEIC ACIDS RES, V18, P3249, DOI 10.1093/nar/18.11.3249; MCDONALD MJ, 1991, J BIOL CHEM, V266, P1335; MCDONALD MJ, 1991, J BIOL CHEM, V266, P22392; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; PARK KR, 1991, J BIOL CHEM, V266, P12249; PHILIPPE J, 1991, ENDOCR REV, V12, P252, DOI 10.1210/edrv-12-3-252; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; PRENTKI M, 1991, INT CONGR SER, V1000, P156; RUTTER GA, 1992, BIOCHIM BIOPHYS ACTA, V1175, P107, DOI 10.1016/0167-4889(92)90016-5; SALAS J, 1965, J BIOL CHEM, V240, P1014; SHIH HM, 1992, J BIOL CHEM, V267, P13222; SWENNE I, 1980, DIABETES, V29, P686, DOI 10.2337/diab.29.9.686; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; WEIR G C, 1986, Diabetes Metabolism Reviews, V2, P125; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914	49	130	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18905	18911						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8103051				2022-12-27	WOS:A1993LV65900079
J	HIXSON, JE; KAMMERER, CM; MOTT, GE; BRITTEN, ML; BIRNBAUM, S; POWERS, PK; VANDEBERG, JL				HIXSON, JE; KAMMERER, CM; MOTT, GE; BRITTEN, ML; BIRNBAUM, S; POWERS, PK; VANDEBERG, JL			BABOON APOLIPOPROTEIN-A-IV - IDENTIFICATION OF LYS(76)-] GLU THAT DISTINGUISHES 2 COMMON ISOFORMS AND DETECTION OF LENGTH POLYMORPHISMS AT THE CARBOXYL-TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PROTEIN INTERACTIONS; PLASMA LIPOPROTEINS; SERUM-CHOLESTEROL; GENE; NUCLEOTIDE; FREQUENCY; CDNA; SUBSTITUTIONS; AMPLIFICATION; POPULATION	Various protein isoforms have been identified for human apolipoprotein A-IV (apoA-IV). However, investigations of their physiological effects have been limited because of low frequencies for many of the apoA-IV variants. Recent discovery of extensive variation in baboon apoA-IV using isoelectric focusing (IEF) makes this primate species an excellent model for genetic studies of apoA-IV. In this study, the molecular basis for net charge differences between two common apoA-IV isoforms (I and E) was determined by cloning and sequencing of intestinal cDNAs from homozygous baboons. An A --> G substitution was found in the third amphipathic repeat of the E isoform. This substitution causes a Lys --> Glu substitution at amino acid position 76 (Lys76 --> Glu), adding two negative charges to the E isoform compared to the I isoform, consistent with their relative mobilities on IEF gels. Restriction isotyping was used to identify the substitution in leukocyte DNA from 15 baboons that had been typed by IEF, thus verifying Lys76 --> Glu as the basis for the charge differences between the I and E isoforms. Physiological effects of the Lys76 --> Glu substitution on high density lipoprotein-C levels were investigated in 431 baboons carrying the E and I isoforms. These studies revealed that the I isoform was associated with higher levels of high density lipoprotein-C on a high cholesterol, saturated fat diet (p = 0.04). The cDNA sequences showed that the carboxyl terminus of baboon apoA-IV contains a region of hydrophilic repeats (Glu-Gln-X-Gln) that is the largest yet found in any species (nine repeats compared to three to five repeats in human, mouse, and rat). A common length polymorphism was identified that inserts a single amino acid to form a five amino acid repeat. This is the first report of this type of length variation (insertion of a single amino acid rather than insertion of an entire repeat) in this region. In addition, a rare variant was found that inserts an entire four-amino-acid repeat, similar to the human apoA-IV-0 isoform.	UNIV TEXAS, HLTH SCI CTR, DEPT PATHOL, SAN ANTONIO, TX 78228 USA	University of Texas System; University of Texas Health San Antonio	HIXSON, JE (corresponding author), SW FDN BIOMED RES, DEPT GENET, POB 28147, SAN ANTONIO, TX 78228 USA.			Kammerer, Candace M/0000-0002-2841-4761; Hixson, James/0000-0002-0849-9315	NHLBI NIH HHS [HL-28972, HV-53030] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028972] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; BIGGIN MD, 1983, P NATL ACAD SCI USA, V380, P963; BLANGERO J, 1992, AM J PRIMATOL, V27, P119, DOI 10.1002/ajp.1350270207; BOERWINKLE E, 1986, ANN HUM GENET, V50, P181, DOI 10.1111/j.1469-1809.1986.tb01037.x; BOERWINKLE E, 1990, NUCLEIC ACIDS RES, V18, P4966, DOI 10.1093/nar/18.16.4966; BOGUSKI MS, 1984, P NATL ACAD SCI-BIOL, V81, P5021, DOI 10.1073/pnas.81.16.5021; DEKNIJFF P, 1988, J LIPID RES, V29, P1621; DVORIN E, 1986, J BIOL CHEM, V261, P5714; EICHNER JE, 1989, GENET EPIDEMIOL, V6, P493, DOI 10.1002/gepi.1370060404; ELSHOURBAGY NA, 1986, J BIOL CHEM, V261, P1998; FERRELL RE, 1990, J LIPID RES, V31, P131; GOLDBERG IJ, 1990, J BIOL CHEM, V265, P4266; GREEN PHR, 1980, J CLIN INVEST, V65, P911, DOI 10.1172/JCI109745; HANIS CL, 1991, HUM GENET, V86, P323; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Hixson JE, 1988, GENOMICS, V2, P315, DOI 10.1016/0888-7543(88)90020-1; HIXSON JE, 1988, GENE, V64, P33, DOI 10.1016/0378-1119(88)90478-7; HIXSON JE, 1991, J LIPID RES, V32, P1529; HIXSON JE, 1990, J LIPID RES, V31, P545; HIXSON JE, 1988, GENE, V74, P483, DOI 10.1016/0378-1119(88)90181-3; HIXSON JE, 1989, ARTERIOSCLEROSIS, V9, P829, DOI 10.1161/01.ATV.9.6.829; KAISER ET, 1983, P NATL ACAD SCI USA, V80, P1137, DOI 10.1073/pnas.80.4.1137; KAMMERER CM, 1993, ATHEROSCLEROSIS, V98, P153, DOI 10.1016/0021-9150(93)90125-E; KARATHANASIS SK, 1985, P NATL ACAD SCI USA, V82, P6374, DOI 10.1073/pnas.82.19.6374; KARATHANASIS SK, 1986, BIOCHEMISTRY-US, V25, P3962, DOI 10.1021/bi00361a034; LANGE K, 1988, GENET EPIDEMIOL, V5, P471, DOI 10.1002/gepi.1370050611; LOHSE P, 1990, J BIOL CHEM, V265, P10061; LOHSE P, 1990, J BIOL CHEM, V265, P12734; LOHSE P, 1991, J BIOL CHEM, V266, P13513; MCGILL HC, 1988, ARTERIOSCLEROSIS, V8, P33, DOI 10.1161/01.ATV.8.1.33; MENZEL HJ, 1982, HUM GENET, V62, P349, DOI 10.1007/BF00304554; MENZEL HJ, 1990, HUM GENET, V84, P344; MENZEL HJ, 1988, HUM GENET, V79, P368; MORRISETT JD, 1977, BIOCHIM BIOPHYS ACTA, V472, P93, DOI 10.1016/0304-4157(77)90015-6; MOTT GE, 1982, ATHEROSCLEROSIS, V45, P191, DOI 10.1016/0021-9150(82)90138-1; PASTORCIC M, 1992, GENOMICS, V13, P368, DOI 10.1016/0888-7543(92)90255-Q; RAINWATER DL, 1992, ARTERIOSCLER THROMB, V12, P682, DOI 10.1161/01.ATV.12.6.682; REUE K, 1991, J BIOL CHEM, V266, P12715; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHERALDI CA, 1988, CIRCULATION S2, V78, P199; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; STEIN O, 1986, BIOCHIM BIOPHYS ACTA, V878, P7, DOI 10.1016/0005-2760(86)90337-1; STEINMETZ A, 1990, J BIOL CHEM, V265, P7859; STEINMETZ A, 1985, J BIOL CHEM, V260, P2258; VISVIKIS S, 1990, CLIN GENET, V37, P435; VONECKARDSTEIN A, 1992, AM J HUM GENET, V50, P1115; WEINBERG RB, 1990, J BIOL CHEM, V265, P18372; WILLIAMS SC, 1986, MOL CELL BIOL, V6, P3807, DOI 10.1128/MCB.6.11.3807; WITTE DL, 1974, CLIN CHEM, V20, P1282; 1974, USDHEW NIH75628 PUBL	50	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15667	15673						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8101842				2022-12-27	WOS:A1993LN30500053
J	DOWBENKO, D; WATSON, SR; LASKY, LA				DOWBENKO, D; WATSON, SR; LASKY, LA			CLONING OF A RAT HOMOLOG OF MOUSE GLYCAM-1 REVEALS CONSERVATION OF STRUCTURAL DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE HOMING RECEPTOR; ENDOTHELIAL LIGAND; LECTIN DOMAIN; SIALIC-ACID; IDENTIFICATION; SEQUENCES; PROTEINS; CELLS; MUCIN	Recently we described the isolation of a mouse cDNA clone encoding a mucin-like endothelial glycoprotein that appears to function as an adhesive ligand for L selectin. This ligand has been named GlyCAM 1 (Gly-cosylation-dependent Cell Adhesion Molecule 1) because its adhesive interactions with the L selectin lectin domain require that the GlyCAM 1 polypeptide chain be appropriately modified with carbohydrates. These carbohydrate modifications include the addition of sialic acid as well as sulfate residues to O-linked carbohydrate side chains that are clustered in two serine/threonine-rich domains of the mucin. An additional interesting structure that may have relevance to the association of GlyCAM 1 with the lumenal surface of the endothelium was a potential amphipathic helix at the C terminus of the glycoprotein. In order to examine the importance of the postulated O-linked domains as well as the potential amphipathic helix, we have cloned the rat homologue of GlyCAM 1. The sequence of this clone reveals a serine/threonine-rich protein that is highly homologous with the mouse GlyCAM 1. As was found for the mouse GlyCAM 1, the rat homologue shows a clustering of these potential O-linked carbohydrate acceptors in two domains of the protein. Interestingly, many of the serines and threonines are found to be spaced identically in the two homologues, consistent with the possibility that both density and position of the O-linked side chains may be important for appropriate L selectin-mediated adhesion. In support of its postulated functional importance, the C-terminal potential amphipathic helix is conserved in the rat homologue. Finally, immunoprecipitation analysis of [S-35]sulfate-labeled rat lymph nodes with either a mouse L selectin IgG chimera or a peptide antiserum directed against a relatively conserved portion of mouse GlyCAM 1 demonstrates a approximately 45-kDa sulfated ligand in rat lymph nodes that is analogous to that previously described for mouse lymph nodes.			DOWBENKO, D (corresponding author), GENENTECH INC, DEPT IMMUNOL, S SAN FRANCISCO, CA 94080 USA.							ANDREWS P, 1982, J CELL SCI, V57, P277; BOWEN BR, 1990, J CELL BIOL, V110, P147, DOI 10.1083/jcb.110.1.147; BUTCHER EC, 1990, AM J PATHOL, V136, P3; CARRAWAY K L, 1991, Glycobiology, V1, P131, DOI 10.1093/glycob/1.2.131; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; DOWBENKO D, 1993, J BIOL CHEM, V268, P4525; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GUM JR, 1991, J BIOL CHEM, V266, P22733; HARDING SE, 1989, ADV CARBOHYD CHEM BI, V47, P345; IMAI Y, 1993, NATURE, V361, P555; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LASKY LA, 1992, INFLAMMATION BASIC P, P407; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; Sambrook J, 1989, MOL CLONING LABORATO; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STOOLMAN LM, 1987, BLOOD, V70, P1842; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TRUE DD, 1990, J CELL BIOL, V111, P2757, DOI 10.1083/jcb.111.6.2757; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221	26	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14399	14403						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8100229				2022-12-27	WOS:A1993LJ82500088
J	FINCH, RA; REVANKAR, GR; CHAN, PK				FINCH, RA; REVANKAR, GR; CHAN, PK			NUCLEOLAR LOCALIZATION OF NUCLEOPHOSMIN/B23 REQUIRES GTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE-INHIBITORY PROPERTIES; RIBOSOMAL-RNA SYNTHESIS; MURINE TUMOR-CELLS; IMP DEHYDROGENASE; HELA-CELLS; PROTEIN-B23 TRANSLOCATION; GENE-EXPRESSION; B23; 2-BETA-D-RIBOFURANOSYLTHIAZOLE-4-CARBOXAMIDE; NUCLEAR	Incubation of HeLa cells with the IMP dehydrogenase inhibitors: ribavirin (100 muM, 4 h), tiazofurin (100 muM, 4 h), selenazofurin (100 muM, 4 h), or mycophenolic acid (10 muM, 4 h) resulted in approximately 70% reduction in cellular GTP pools and shifting of nucleophosmin/B23 from nucleoli to nucleoplasm as detected by immunofluorescence (B23-translocation). Enzyme-linked immunosorbent assay and Western blot assay showed there is no loss or degradation of nucleophosmin/B23 protein during drug treatment. This translocation effect could be prevented by co-incubation with guanosine (100 muM) or reversed by addition of guanosine (100 muM) to the culture medium after B23-translocation had been induced by these inhibitors. Under these conditions of guanosine supplementation, cellular GTP pool concentrations were maintained at the control level. These results indicate that localization of nucleophosmin/B23 into the nucleolus is dependent, on the cellular GTP level.	BAYLOR COLL MED,DEPT PHARMACOL,1 BAYLOR PLAZA,HOUSTON,TX 77030; TRIPLEX PHARMACEUT CORP,THE WOODLANDS,TX 77380	Baylor College of Medicine					NATIONAL CANCER INSTITUTE [R01CA042476] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42476] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACS G, 1964, P NATL ACAD SCI USA, V52, P493, DOI 10.1073/pnas.52.2.493; BALLAL NR, 1974, LIFE SCI, V14, P1835; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Busch H., 1970, NUCLEOLUS; BUSCH RK, 1984, LIFE SCI, V35, P1777, DOI 10.1016/0024-3205(84)90275-3; CHAN PK, 1988, CANCER LETT, V40, P143, DOI 10.1016/0304-3835(88)90004-3; CHAN PK, 1992, EXP CELL RES, V203, P174, DOI 10.1016/0014-4827(92)90053-B; CHAN PK, 1987, CANCER RES, V47, P3798; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; COONEY DA, 1982, BIOCHEM PHARMACOL, V31, P2133, DOI 10.1016/0006-2952(82)90436-1; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; DANG CV, 1989, J BIOL CHEM, V264, P18019; DEVER TE, 1989, GUANINE NUCLEOTIDE B, P35; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FEUERSTEIN N, 1987, J BIOL CHEM, V262, P11389; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; FINCH RA, 1992, ONCOLOGY, V49, P223; FRANKLIN TJ, 1969, BIOCHEM J, V113, P515, DOI 10.1042/bj1130515; GEBEYEHU G, 1985, J MED CHEM, V28, P99, DOI 10.1021/jm00379a018; GILBERT BE, 1986, ANTIMICROB AGENTS CH, V30, P201, DOI 10.1128/AAC.30.2.201; Hadjiolov AA, 1985, NUCLEOLUS RIBOSOME B; JAYARAM HN, 1983, BIOCHEM PHARMACOL, V32, P2633, DOI 10.1016/0006-2952(83)90038-2; JAYARAM HN, 1982, BIOCHEM PHARMACOL, V31, P2371, DOI 10.1016/0006-2952(82)90532-9; KHYM JX, 1975, CLIN CHEM, V21, P1245; KUTTAN R, 1982, BIOCHEM BIOPH RES CO, V107, P862, DOI 10.1016/0006-291X(82)90602-7; LOWE JK, 1977, CANCER RES, V37, P736; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MATSUMOTO SS, 1990, BIOCHEM PHARMACOL, V39, P455, DOI 10.1016/0006-2952(90)90050-U; MCCORMICK JB, 1986, NEW ENGL J MED, V314, P20, DOI 10.1056/NEJM198601023140104; PRESTAYKO AW, 1974, BIOCHEMISTRY-US, V13, P1945, DOI 10.1021/bi00706a026; SAUNDERS PP, 1983, MOL PHARMACOL, V23, P534; SCHMIDTZACHMANN MS, 1988, CHROMOSOMA, V96, P417, DOI 10.1007/BF00303035; SMITH CM, 1974, BIOCHEM PHARMACOL, V23, P2727, DOI 10.1016/0006-2952(74)90043-4; SMITH RA, 1984, CLIN APPLICATIONS RI; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; SRIVASTAVA PC, 1983, J MED CHEM, V26, P445, DOI 10.1021/jm00357a024; SRIVASTAVA PC, 1977, J MED CHEM, V20, P256, DOI 10.1021/jm00212a014; STREETER DG, 1973, P NATL ACAD SCI USA, V70, P1174, DOI 10.1073/pnas.70.4.1174; SWEET P, 1989, CANCER RES, V49, P677; VARMUS H, 1988, GENE DEV, V2, P1055, DOI 10.1101/gad.2.9.1055; WALTON TH, 1989, J VIROL, V63, P3651, DOI 10.1128/JVI.63.9.3651-3660.1989; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WARNER JR, 1977, J MOL BIOL, V115, P315, DOI 10.1016/0022-2836(77)90157-7; WEISS JW, 1974, CANCER RES, V34, P581; WELDON SL, 1990, J BIOL CHEM, V265, P7308; WITKOWSKI JT, 1972, J MED CHEM, V15, P1150, DOI 10.1021/jm00281a014; YUNG BY, 1990, CANCER RES, V50, P5987; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; YUNG BYM, 1986, CANCER RES, V46, P922	51	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5823	5827						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8095498				2022-12-27	WOS:A1993KR82200070
J	NAKANISHI, S; CATT, KJ; BALLA, T				NAKANISHI, S; CATT, KJ; BALLA, T			INHIBITION OF AGONIST-STIMULATED INOSITOL 1,4,5-TRISPHOSPHATE PRODUCTION AND CALCIUM SIGNALING BY THE MYOSIN LIGHT-CHAIN KINASE INHIBITOR, WORTMANNIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL GLOMERULOSA CELLS; PLASMA-MEMBRANE; ANGIOTENSIN-II; HUMAN NEUTROPHIL; PHOSPHOLIPASE-C; RECEPTOR; ACTIVATION; ENTRY; MECHANISM; RELEASE	The myosin light chain kinase inhibitor, wortmannin (WT), caused dose dependent inhibition of the sustained increases but not the initial spikes of inositol 1,4,5-trisphosphate (Ins-1,4,5-P-3) and cytoplasmic Ca2+ concentration ([Ca2+](i)) in angiotensin II (AII)-stimulated adrenal glomerulosa cells. In contrast, WT did not affect the [Ca2+](i) increases evoked by K+-induced depolarization or by depletion of intracellular Ca2+ stores with ionomycin or thapsigargin, suggesting that its inhibitory effects on Ins-1,4,5-P-3 and [Ca2+](i) responses are closely related. The inhibitory effect of WT on the lns-1,4,5-P-3 response was not secondary to its reduction of Ca2+ entry, since ionomycin induced elevation of [Ca2+](i) did not restore Ins-1,4,5-P-3 formation. Also, WT inhibited agonist- and GTP gamma S-stimulated Ins 1,4,5-P-3 formation in permeabilized cells maintained at fixed Ca2+ concentrations. Thus, inhibition of Ca2+ influx by WT is a consequence of reduced Ins-1,4,5-P-3 formation and could reflect the resultant refilling of the agonist-sensitive Ca2+ pool. Indeed, AII-depleted Ca2+ pools were found to refill by a thapsigargin-sensitive mechanism in WT-treated cells. Other structurally unrelated inhibitors of myosin light chain kinase (MS-347a, KT5926, and ML-9) also inhibited AII-induced inositol phosphate formation, albeit with lower potencies than WT. MS-347a, like WT, inhibited only the second phase of the inositol phosphate and [Ca2+](i) responses to AII. These findings demonstrate that WT is a potent inhibitor of the Ins-1,4,5-P-3-Ca2+ signaling pathway and acts primarily on a mechanism that promotes Ins-1,4,5-P-3 formation and is sensitive to inhibitors of myosin light chain kinase activity.	NIH,ENDOCRINOL & REPROD RES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA				Balla, Tamas/0000-0002-9077-3335				AMBROZ C, 1992, ENDOCRINOLOGY, V131, P408, DOI 10.1210/en.131.1.408; BAGGIOLINI M, 1987, EXP CELL RES, V169, P408, DOI 10.1016/0014-4827(87)90201-1; BALLA T, 1991, J BIOL CHEM, V266, P24719; BALLA T, 1989, ARCH BIOCHEM BIOPHYS, V270, P398, DOI 10.1016/0003-9861(89)90043-X; BALLA T, 1988, J BIOL CHEM, V263, P4083; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BONSER RW, 1991, BRIT J PHARMACOL, V103, P1237, DOI 10.1111/j.1476-5381.1991.tb12330.x; Catt KJ, 1993, CELLULAR MOL BIOL RE, P307; DEWALD B, 1988, J BIOL CHEM, V263, P16179; ELY JA, 1991, J BIOL CHEM, V266, P18635; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GRIENDLING KK, 1987, J BIOL CHEM, V262, P14555; GUILLEMETTE G, 1987, BIOCHEM BIOPH RES CO, V142, P15, DOI 10.1016/0006-291X(87)90445-1; GUILLEMETTE G, 1988, J BIOL CHEM, V263, P4541; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P17078; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HUNYADY L, 1991, J BIOL CHEM, V266, P2783; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KITANI S, 1992, BIOCHEM BIOPH RES CO, V183, P48, DOI 10.1016/0006-291X(92)91607-R; KNOL EF, 1991, EUR J IMMUNOL, V21, P881, DOI 10.1002/eji.1830210404; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NAKANISHI S, 1993, IN PRESS J ANTIBIOT; OHARAIMAIZUMI M, 1992, BIOCHEM BIOPH RES CO, V185, P1016, DOI 10.1016/0006-291X(92)91728-9; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SIMPLES JE, 1993, 75TH ANN M END SOC L, P360; YOSHIDA S, 1992, J PHYSIOL-LONDON, V458, P307, DOI 10.1113/jphysiol.1992.sp019419; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295; 1989, BIOCHEM J, V258, P1	43	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6528	6535						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120005				2022-12-27	WOS:A1994MZ50300043
J	SULPICE, JC; ZACHOWSKI, A; DEVAUX, PF; GIRAUD, F				SULPICE, JC; ZACHOWSKI, A; DEVAUX, PF; GIRAUD, F			REQUIREMENT FOR PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE IN THE CA2+-INDUCED PHOSPHOLIPID REDISTRIBUTION IN THE HUMAN ERYTHROCYTE-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; PLASMA-MEMBRANE; LIPID ASYMMETRY; AMINOPHOSPHOLIPID TRANSLOCASE; TRANSBILAYER DISTRIBUTION; DIVALENT-CATIONS; INDUCED FUSION; SHAPE CHANGES; POLYPHOSPHOINOSITIDES; PHOSPHATIDYLSERINE	In order to investigate how calcium on the cytosolic side of human erythrocytes induces the transmembrane redistribution of phospholipids, we studied the effect of this cation on the transmembrane movements of spin-labeled phospholipids (phosphatidylserine (PS) and phosphatidylcholine (PC)) incorporated into inside-out vesicles derived from human erythrocytes. We found that the extent of the Ca2+-induced lipid scrambling was dependent upon the level of phosphatidylinositol 4,5-bisphosphate (PIP2) contained in the external leaflet of inside out vesicles. The level of PIP2 in this leaflet, which normally accounts for 80% of the total membrane PIP2, was manipulated either by ATP depletion of the original erythrocytes or by incorporation of exogenous PIP2. Similarly loading the outer monolayer of the membrane of intact erythrocytes with exogenous PIP2 caused, in a dose-dependent way, the scrambling of spin-labeled phosphatidylethanolamine, sphingomyelin, PC, and PS and in parallel the stomatocytic conversion of the cells. Both scrambling and stomatocytosis were strictly dependent on the presence of divalent cations in the medium. Mg2+ could replace Ca2+ but required a 10 times higher concentration. The effect was specific for PIP2, the other phosphoinositides being unable to induce the lipid redistribution. The shape change, but not the scrambling, required a normal ATP level. These results show that Ca2+ or Mg2+ trigger the lipid redistribution either from the internal or the external side of the membrane, provided that enough PIP, is present on that side. Thus, no specific protein is required for this process. We infer that the ATP-dependent shape change of erythrocytes after incubation with PIP2 and Ca2+ results from the bilayer imbalance due to the activity of the aminophospholipid translocase which relocates PS and phosphatidylethanolamine to the inner monolayer without simultaneous outward diffusion of PC and sphingomyelin.	INST BIOL PHYSICOCHIM,CNRS,URA 526,F-75005 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS)	SULPICE, JC (corresponding author), UNIV PARIS 11,BIOMEMBRANES & MESSAGERS CELLULAIRES LAB,CNRS,URA 1116,BAT 447,F-91405 ORSAY,FRANCE.		ZACHOWSKI, Alain/A-9029-2011					AIKEN NR, 1992, BIOCHIM BIOPHYS ACTA, V1136, P155, DOI 10.1016/0167-4889(92)90251-6; ALLAN D, 1978, BIOCHIM BIOPHYS ACTA, V508, P277, DOI 10.1016/0005-2736(78)90330-9; ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BALDWIN JM, 1990, BIOCHIM BIOPHYS ACTA, V1028, P14, DOI 10.1016/0005-2736(90)90259-Q; BAZENET CE, 1990, J BIOL CHEM, V265, P7369; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BEVERS EM, 1989, BIOCHEMISTRY-US, V28, P2282; BITBOL M, 1987, BIOCHIM BIOPHYS ACTA, V904, P268, DOI 10.1016/0005-2736(87)90376-2; BUTIKOFER P, 1989, BLOOD, V73, P1699; BUTIKOFER P, 1990, J BIOL CHEM, V265, P16035; CHANDRA R, 1987, BIOCHIM BIOPHYS ACTA, V902, P253, DOI 10.1016/0005-2736(87)90303-8; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; CONNOR J, 1990, BIOCHIM BIOPHYS ACTA, V1025, P82, DOI 10.1016/0005-2736(90)90193-R; DAWSON RMC, 1965, BIOCHEM J, V97, P134, DOI 10.1042/bj0970134; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; FERRELL JE, 1985, BIOCHEMISTRY-US, V24, P2849, DOI 10.1021/bi00333a006; FERRELL JE, 1984, J CELL BIOL, V98, P1992, DOI 10.1083/jcb.98.6.1992; GADELLA TWJ, 1990, BIOCHEMISTRY-US, V29, P3389, DOI 10.1021/bi00465a035; GASCARD P, 1989, BIOCHEM J, V264, P547, DOI 10.1042/bj2640547; GASCARD P, 1991, BIOCHIM BIOPHYS ACTA, V1069, P27, DOI 10.1016/0005-2736(91)90100-M; GASCARD P, 1993, BIOCHEM SOC T, V21, P253, DOI 10.1042/bst0210253; GASCARD P, 1993, EUR J BIOCHEM, V211, P671, DOI 10.1111/j.1432-1033.1993.tb17595.x; GIRAUD F, 1984, BIOCHIM BIOPHYS ACTA, V778, P191, DOI 10.1016/0005-2736(84)90462-0; HENSELEIT U, 1990, BIOCHIM BIOPHYS ACTA, V1029, P127, DOI 10.1016/0005-2736(90)90445-T; JOINER CH, 1993, AM J PHYSIOL, V264, pC251, DOI 10.1152/ajpcell.1993.264.2.C251; KHODAKHAH K, 1993, P NATL ACAD SCI USA, V90, P4976, DOI 10.1073/pnas.90.11.4976; KONISHI M, 1991, J GEN PHYSIOL, V97, P271, DOI 10.1085/jgp.97.2.271; MISSIAEN L, 1989, BIOCHEM J, V264, P609, DOI 10.1042/bj2640609; MORROT G, 1989, BIOCHEMISTRY-US, V28, P3456, DOI 10.1021/bi00434a046; OBRIAN CA, 1987, FEBS LETT, V214, P339, DOI 10.1016/0014-5793(87)80083-2; RHODA MD, 1988, BIOCHEM J, V254, P161, DOI 10.1042/bj2540161; SARKADI B, 1980, BIOCHIM BIOPHYS ACTA, V598, P326, DOI 10.1016/0005-2736(80)90010-3; SCHEWE M, 1992, J BIOL CHEM, V267, P5910; SCHRIER SL, 1978, BLOOD CELLS, V4, P339; SCHRIER SL, 1986, BLOOD, V68, P1008; SCHRIER SL, 1992, BLOOD, V79, P782; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; SIEGEL DP, 1989, BIOCHEMISTRY-US, V28, P3703, DOI 10.1021/bi00435a012; Steck T L, 1974, Methods Enzymol, V31, P172; TANAKA Y, 1983, J BIOL CHEM, V258, P1335; THOMPSON MG, 1987, CANCER RES, V47, P2799; TILLEY L, 1986, FEBS LETT, V194, P21, DOI 10.1016/0014-5793(86)80044-8; TONER M, 1988, BIOCHEMISTRY-US, V27, P7435, DOI 10.1021/bi00419a039; VANPARIDON PA, 1986, BIOCHIM BIOPHYS ACTA, V877, P216, DOI 10.1016/0005-2760(86)90137-2; VERHOVEN B, 1992, BIOCHIM BIOPHYS ACTA, V1104, P15, DOI 10.1016/0005-2736(92)90126-7; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; WILLIAMSON P, 1985, J CELL PHYSIOL, V123, P209, DOI 10.1002/jcp.1041230209; ZACHOWSKI A, 1986, BIOCHEMISTRY-US, V25, P2585, DOI 10.1021/bi00357a046; ZWAAL RFA, 1992, BIOCHIM BIOPHYS ACTA, V1180, P1, DOI 10.1016/0925-4439(92)90019-J	52	79	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6347	6354						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119984				2022-12-27	WOS:A1994MZ50300017
J	ADAMS, RM; YOAST, S; MAINZER, SE; MOON, K; PALOMBELLA, AL; ESTELL, DA; POWER, SD; SCHMIDT, BF				ADAMS, RM; YOAST, S; MAINZER, SE; MOON, K; PALOMBELLA, AL; ESTELL, DA; POWER, SD; SCHMIDT, BF			CHARACTERIZATION OF 2 COLD-SENSITIVE MUTANTS OF THE BETA-GALACTOSIDASE FROM LACTOBACILLUS-DELBRUCKII SUBSP BULGARICUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTANTS; ESCHERICHIA-COLI; DIRECTED MUTAGENESIS; DNA; DENATURATION; EFFICIENT; SECRETION; GLU-461; VECTORS; ACID	Methoxylamine mutagenesis of the beta-galactosidase gene from Lactobacillus delbruckii subsp. bulgaricus was used to generate cold-sensitive variants. Two variants, P429S and L317F, were characterized kinetically in order to determine the enzymatic consequences of these mutations. The kinetic parameters K-m and V-max on the synthetic substrate o-nitrophenyl-beta-D-galactopyranoside have been determined over a temperature range of 11-45 degrees C. Only the V-max of the two variants was significantly different than the wild-type enzyme over the temperature range studied. The V-max of the L317F variant is reduced proportionately at all temperatures compared to the wild-type enzyme while the value of V,, for the P429S mutant deviates from wild-type only at lower temperatures (in 2 mM Mg2+). This temperature-dependent effect on the V-max of P429S can be suppressed by increasing the Mg2+ concentration. The results suggest that the binding of this essential metal ion is altered in the P429S variant such that its dissociation is increased by lowering the temperature.	GENENCOR INT INC,S SAN FRANCISCO,CA 94080									BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BRANDTS JF, 1964, J AM CHEM SOC, V86, P4291, DOI 10.1021/ja01074a013; CUPPLES CG, 1990, J BIOL CHEM, V265, P5512; EDWARDS RA, 1990, BIOCHEMISTRY-US, V29, P11001, DOI 10.1021/bi00501a019; EDWARDS RA, 1990, BIOCHEM BIOPH RES CO, V171, P33, DOI 10.1016/0006-291X(90)91352-S; ESTELL DA, 1985, J BIOL CHEM, V260, P6518; FINK A, 1975, BIOCHEM BIOPH RES CO, V62, P701; HUBER RE, 1976, BIOCHEMISTRY-US, V15, P1994, DOI 10.1021/bi00654a029; KADONAGA JT, 1985, NUCLEIC ACIDS RES, V13, P1733, DOI 10.1093/nar/13.5.1733; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MARTINEZBILBAO M, 1991, J BIOL CHEM, V266, P4979; OKA T, 1985, P NATL ACAD SCI USA, V82, P7212, DOI 10.1073/pnas.82.21.7212; PORTZEHL H, 1964, BIOCHIM BIOPHYS ACTA, V79, P581, DOI 10.1016/0926-6577(64)90224-4; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; PRIVALOV PL, 1986, J MOL BIOL, V190, P487, DOI 10.1016/0022-2836(86)90017-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT BF, 1989, J BACTERIOL, V171, P625, DOI 10.1128/jb.171.2.625-635.1989; Segel I. H., 1975, ENZYME KINETICS, P931; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STROM R, 1971, EUR J BIOCHEM, V23, P118, DOI 10.1111/j.1432-1033.1971.tb01598.x; TENU JP, 1972, EUR J BIOCHEM, V26, P112, DOI 10.1111/j.1432-1033.1972.tb01746.x; ULLMANN A, 1969, BIOCHEM BIOPH RES CO, V35, P35, DOI 10.1016/0006-291X(69)90479-3; Wallenfels K., 1972, ENZYMES, V7, P617; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIPSER D, 1963, J MOL BIOL, V7, P113, DOI 10.1016/S0022-2836(63)80040-6; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	26	23	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5666	5672						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119903				2022-12-27	WOS:A1994MY84000031
J	PARK, K; CHOE, J; OSIFCHIN, NE; TEMPLETON, DJ; ROBBINS, PD; KIM, SJ				PARK, K; CHOE, J; OSIFCHIN, NE; TEMPLETON, DJ; ROBBINS, PD; KIM, SJ			HUMAN RETINOBLASTOMA SUSCEPTIBILITY GENE PROMOTER IS POSITIVELY AUTOREGULATED BY ITS OWN PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; CELL-CYCLE; BINDING PROTEIN; C-MYC; TRANSCRIPTION; EXPRESSION; IDENTIFICATION; CLONING; PHOSPHORYLATION; INACTIVATION	The product of the retinoblastoma susceptibility gene is a 1O5-kDa protein that has properties of a cell cycle regulatory factor. Previous reports indicated that two distinct DNA-binding factors, RBF-1 and ATF, play an important part in the transcription of the human retinoblastoma gene (Rb). Recently, we demonstrated that pRb activates expression of the human transforming growth factor-beta 2 gene through ATF-B Since the human Rb gene promoter also contains an ATF-a-like binding site, we examined whether pRb can regulate its own expression through ATF-2. Here we report that overexpression of Rb stimulates Rb promoter activity through the ATF binding site in a variety of different cell types. Mutation of the ATF binding site of the Rb promoter abolishes the Rb autoinduction. We have also determined that the carboxyl-terminal domain of pRb is responsible for the Rb autoinduction through ATF-2. Rb autoinduction may be important for maintaining the action of pRb during cell growth, and loss of autoinducibility may contribute to retinoblastoma.	NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892; UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261; CASE WESTERN RESERVE UNIV,SCH MED,INST PATHOL,CLEVELAND,OH 44106	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Case Western Reserve University			Templeton, Dennis J/F-7695-2011		NATIONAL CANCER INSTITUTE [R01CA055227] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55227] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YK, 1987, SCIENCE, V236, P1675; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; OREILLY MA, 1992, J BIOL CHEM, V267, P19938; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578	40	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6083	6088						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119953				2022-12-27	WOS:A1994MY84000091
J	RUNQUIST, M; ERICSSON, J; THELIN, A; CHOJNACKI, T; DALLNER, G				RUNQUIST, M; ERICSSON, J; THELIN, A; CHOJNACKI, T; DALLNER, G			ISOPRENOID BIOSYNTHESIS IN RAT-LIVER MITOCHONDRIA - STUDIES ON FARNESYL PYROPHOSPHATE SYNTHASE AND TRANS-PRENYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLANESYL-DIPHOSPHATE SYNTHASE; UBIQUINONE BIOSYNTHESIS; CIS-PRENYLTRANSFERASE; PARA-HYDROXYBENZOATE; MOLECULAR-CLONING; CHAIN-LENGTH; PEROXISOMES; SYNTHETASE; REDUCTASE; DOLICHOL	Mevalonate pathway enzyme activities in rat liver mitochondria were investigated, and it was found that isopentenyl pyrophosphate can be utilized for the synthesis of all-trans-polyprenyl pyrophosphates in vitro. In this reaction sequence intermediate formation of farnesyl pyrophosphate (FPP) predominates, and the FPP synthase activity was studied in more detail. The mitochondrial activity constitutes 13% of the total hepatic capacity for FPP synthesis, exceeding the corresponding microsomal, nuclear, and peroxisomal activities by 10-fold. Mitochondrial FPP synthase exhibits trypsin sensitivity only after sonication of intact mitochondria and upon subfractionation the activity is found localized in the matrix. FPP synthase activities at different locations responded distinctly when rats were treated with a diet enriched in cholesterol or containing mevinolin or cholestyramine. With the high cholesterol diet, mitochondrial FPP synthase activity increased 2-fold, while the cytosolic activity was slightly decreased. Both mevinolin and cholestyramine treatment resulted in 3-fold increases in cytosolic FPP synthase activities, without altering the mitochondrial activity. FPP was utilized as substrate for trans-prenyltransferase activity in the inner mitochondrial membrane. The products formed in this reaction were identified as nona- and decaprenyl-PP, and the reaction was influenced by changes in both substrate and Mg2+ concentration, giving more decaprenyl-PP when the concentrations of these substances were increased. These results demonstrate that mitochondria utilize endogenously produced FPP for isoprenoid biosynthesis and that the biosynthetic steps in mitochondria are regulated independently from those occurring in other subcellular compartments.	KAROLINSKA INST,NOVUM,CLIN RES CTR,S-14186 HUDDINGE,SWEDEN; POLISH ACAD SCI,INST BIOCHEM & BIOPHYS,PL-02532 WARSAW,POLAND	Karolinska Institutet; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	RUNQUIST, M (corresponding author), STOCKHOLM UNIV,ARRHENIUS LABS NAT SCI,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN.		Ericsson, Johan/AAA-6664-2020; Runquist, Marten/AAF-7613-2019	Ericsson, Johan/0000-0003-1186-6574; 				ABERG F, 1992, ARCH BIOCHEM BIOPHYS, V295, P230, DOI 10.1016/0003-9861(92)90511-T; APPELKVIST EL, 1990, ARCH BIOCHEM BIOPHYS, V282, P318, DOI 10.1016/0003-9861(90)90123-G; ASHBY MN, 1992, J BIOL CHEM, V267, P4128; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BROWN MS, 1980, J LIPID RES, V21, P505; CARSON DD, 1981, J BIOL CHEM, V256, P4679; CAUGHEY WS, 1975, J BIOL CHEM, V250, P7602; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; DALLNER G, 1966, J CELL BIOL, V30, P97, DOI 10.1083/jcb.30.1.97; DANILOV LL, 1989, CHEM PHYS LIPIDS, V51, P191, DOI 10.1016/0009-3084(89)90006-6; DAVISSON VJ, 1985, METHOD ENZYMOL, V110, P130; ERICSSON J, 1992, J BIOL CHEM, V267, P18708; ERICSSON J, 1992, J BIOL CHEM, V267, P19730; ERICSSON J, 1993, J BIOL CHEM, V268, P832; ERNSTER L, 1962, J CELL BIOL, V15, P563, DOI 10.1083/jcb.15.3.563; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRANICK S, 1978, METHOD ENZYMOL, V78, P33; HEMMING FW, 1981, BIOCH ISOPRENOID COM, P305; JONES MS, 1969, BIOCHEM J, V113, P507, DOI 10.1042/bj1130507; KALEN A, 1990, J BIOL CHEM, V265, P1158; KANG D, 1991, EUR J BIOCHEM, V198, P599, DOI 10.1111/j.1432-1033.1991.tb16056.x; KEENAN RW, 1975, ANAL BIOCHEM, V69, P504, DOI 10.1016/0003-2697(75)90153-0; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KELLER RK, 1986, J BIOL CHEM, V261, P2053; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTKEBRINKHAUS F, 1984, EUR J BIOCHEM, V141, P537, DOI 10.1111/j.1432-1033.1984.tb08226.x; MOMOSE K, 1972, J BIOL CHEM, V247, P3930; NISHINO T, 1977, BIOCHEMISTRY-US, V16, P605, DOI 10.1021/bi00623a008; OHNUMA S, 1991, J BIOL CHEM, V266, P23706; OHNUMA S, 1992, J BIOCHEM-TOKYO, V112, P743, DOI 10.1093/oxfordjournals.jbchem.a123969; OLSON RE, 1983, VITAM HORM, V40, P1, DOI 10.1016/S0083-6729(08)60431-8; Poulter C. D., 1981, BIOSYNTHESIS ISOPREN, V1, P161; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; Rilling H. C., 1985, STEROLS BILE ACIDS, P1; SAIKI K, 1993, BIOCHEM BIOPH RES CO, V186, P1491; SHIMIZU S, 1991, ARCH BIOCHEM BIOPHYS, V284, P35, DOI 10.1016/0003-9861(91)90259-L; SINENSKY M, 1992, BIOESSAYS, V14, P25, DOI 10.1002/bies.950140106; Sottocasa G. L., 1967, METHOD ENZYMOL, V10, P448; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; SWIEZEWSKA E, 1992, BIOCHEM CELL BIOL, V70, P448; SWIEZEWSKA E, 1993, J BIOL CHEM, V268, P1494; TECLEBRHAN H, 1993, J BIOL CHEM, V268, P23081; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; THOMPSON SL, 1990, J BIOL CHEM, V265, P5731; TOLLBOM O, 1988, J BIOL CHEM, V263, P1347; TRUMPOWER BL, 1974, J BIOL CHEM, V249, P3041; Tzagoloff A, 1982, MITOCHONDRIA; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WEINSTEIN JD, 1986, ARCH BIOCHEM BIOPHYS, V245, P44, DOI 10.1016/0003-9861(86)90188-8; YAMAMOTO T, 1989, ARCH BIOCHEM BIOPHYS, V269, P86, DOI 10.1016/0003-9861(89)90089-1	52	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5804	5809						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119922				2022-12-27	WOS:A1994MY84000052
J	BENEVOLENSKY, SV; CLIFTON, D; FRAENKEL, DG				BENEVOLENSKY, SV; CLIFTON, D; FRAENKEL, DG			THE EFFECT OF INCREASED PHOSPHOGLUCOSE ISOMERASE ON GLUCOSE-METABOLISM IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED INTERCONVERSION; ISOTOPIC DISCRIMINATION; HEXOSE-PHOSPHATES; GLYCOLYSIS; YEAST; HYDROGEN; MUTANTS; CELLS	Comparison of microbial strains with normal and high content of single enzymes is coming into use for metabolic analysis and in vivo assessment of enzyme function. We present an example for phosphoglucose isomerase and glucose metabolism in the yeast Saccharomyces cerevisiae. We use cell suspensions in conditions of inhibited protein synthesis and respiration, with low assimilation, rapid and linear glucose utilization, fermentation almost quantitative, and high enough cell density for direct preparation of extracts for metabolite analysis. The mass action ratio and fitting of fructose-6-P and glucose-6-P concentrations and kinetic parameters of the enzyme are not inconsistent with near equilibrium of the reaction in the wild-type strain and small if any change in the high level strain. However, this conclusion would require that the V-max values underestimate the activity in the cell. On the other hand, the specific activities of glucose-6-P and fructose-1,6-P-2 during metabolism of [2-H-3]glucose are quite high which, together with knowledge of tritium exchange and isotope effects for the reaction in vitro, would point to the reaction in the wildtype strain being far from equilibrium; the specific activities are lower in the high level strain, indicating that extra enzyme is functional. One way to reconcile the latter results would be for tritium exchange to be considerably lower in vivo than known in vitro.	HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School					PHS HHS [GB21098] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BABUL J, 1993, BIOCHEMISTRY-US, V32, P4685, DOI 10.1021/bi00068a029; BARWELL CJ, 1971, EUR J BIOCHEM, V18, P59, DOI 10.1111/j.1432-1033.1971.tb01214.x; BETZ A, 1965, ARCH BIOCHEM BIOPHYS, V109, P585, DOI 10.1016/0003-9861(65)90404-2; BRINDLE KM, 1988, BIOCHEMISTRY-US, V27, P6187, DOI 10.1021/bi00416a054; CLIFTON D, 1978, GENETICS, V88, P1; CORNISHBOWDEN A, 1993, EUR J BIOCHEM, V213, P87, DOI 10.1111/j.1432-1033.1993.tb17737.x; CRABTREE B, 1985, CURR TOP CELL REGUL, V25, P21; DAVIES SEC, 1992, BIOCHEMISTRY-US, V31, P4729, DOI 10.1021/bi00134a028; DENHOLLANDER JA, 1979, P NATL ACAD SCI USA, V76, P6096; DORRER HD, 1966, Z NATURFORSCH PT B, VB 21, P557, DOI 10.1515/znb-1966-0612; FRAENKEL DG, 1985, P NATL ACAD SCI USA, V82, P4740, DOI 10.1073/pnas.82.14.4740; FRAENKEL DG, 1992, ANNU REV GENET, V26, P159; GARFINKEL L, 1979, EUR J BIOCHEM, V96, P183, DOI 10.1111/j.1432-1033.1979.tb13028.x; Gunsalus I. C., 1961, BACTERIA, V2, P1; HARDEN A, 1923, ALCOHOLIC FERMENTATI; KATZ J, 1969, J BIOL CHEM, V244, P99; Katz J, 1976, Curr Top Cell Regul, V10, P237; KAWASAKI G, 1982, BIOCHEM BIOPH RES CO, V108, P1107, DOI 10.1016/0006-291X(82)92114-3; KELL DB, 1986, FEMS MICROBIOL LETT, V39, P305, DOI 10.1016/0378-1097(86)90020-0; KRETSCHMER M, 1992, FIT WINDOW CHEM SOFT; LANG JM, 1987, J BACTERIOL, V169, P2932, DOI 10.1128/jb.169.7.2932-2937.1987; LIEMANS V, 1989, BIOCHIM BIOPHYS ACTA, V998, P111, DOI 10.1016/0167-4838(89)90261-6; LIEMANS V, 1991, Medical Science Research, V19, P427; MALAISSE WJ, 1991, INT J BIOCHEM, V23, P1471, DOI 10.1016/0020-711X(91)90290-4; MALAISSELAGAE F, 1989, MOL CELL BIOCHEM, V89, P57; NAVAS MA, 1993, P NATL ACAD SCI USA, V90, P1290, DOI 10.1073/pnas.90.4.1290; Newsholme EA, 1973, REGULATION METABOLIS; NOLTMANN EA, 1972, ENZYMES, V6, P271; Rose I.A., 1969, COMPR BIOCHEM, V17, P93; ROSE IA, 1961, J BIOL CHEM, V236, P3086; ROSE IA, 1964, J BIOL CHEM, V239, P12; ROSE IA, 1975, ADV ENZYMOL RAMB, V43, P491; SEEHOLZER SH, 1993, P NATL ACAD SCI USA, V90, P1237, DOI 10.1073/pnas.90.4.1237; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22934; SOLS A, 1981, CURR TOP CELL REGUL, V19, P77; SRIVASTAVA DK, 1986, CURR TOP CELL REGUL, V28, P1; WALSH RB, 1991, GENETICS, V128, P521; WRIGHT BE, 1981, CURR TOP CELL REGUL, V19, P103; WURSTER B, 1970, H-S Z PHYSIOL CHEM, V351, P961, DOI 10.1515/bchm2.1970.351.2.961	39	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4878	4882						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106459				2022-12-27	WOS:A1994MX57100030
J	MATSOUKAS, JM; HONDRELIS, J; KERAMIDA, M; MAVROMOUSTAKOS, T; MAKRIYANNIS, A; YAMDAGNI, R; WU, Q; MOORE, GJ				MATSOUKAS, JM; HONDRELIS, J; KERAMIDA, M; MAVROMOUSTAKOS, T; MAKRIYANNIS, A; YAMDAGNI, R; WU, Q; MOORE, GJ			ROLE OF THE NH2-TERMINAL DOMAIN OF ANGIOTENSIN-II (ANG-II) AND [SAR(1)]ANGIOTENSIN-II ON CONFORMATION AND ACTIVITY - NMR EVIDENCE FOR AROMATIC RING CLUSTERING AND PEPTIDE BACKBONE FOLDING COMPARED WITH [DES-1,2,3]ANGIOTENSIN-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOLOGICAL-ACTIVITY; MAGNETIC-RESONANCE; ANALOGS; SPECTROSCOPY; H-1-NMR; DIMETHYLSULFOXIDE; RELAXATION; SARMESIN; PROTEIN	The role of the NH2 termini of angiotensin II (ANG II) and [Sar(1)]ANG II on conformation and activity were examined by proton NMR two-dimensional-J-correlated spectroscopy and one-dimensional nuclear Overhauser effect studies in the relatively nonpolar ''receptor-simulating'' environment provided by dimethyl sulfoxide-d(6), using the biologically inactive COOH-terminal pentapeptide [des1,2,3]ANG II as control. Irradiation of C alpha H, C2H, and C4H proton resonances in ANG II and [Sar(1)]ANG II resulted in enhancements of Tyr and Phe ring proton resonances, indicating that the three aromatic rings cluster together. Very strong enhancements (17-22%) of the C alpha Y proton resonance in ANG II slid [Sar(1)]ANG II upon irradiation of the C alpha H proton resonance, and vice versa, revealed that a Tyr-Ile-His bend is a predominant feature of the conformation of the two agonists. In contrast, saturation of the C alpha H and C alpha Y proton resonances in the control pentapeptide [des1,2,3]ANG II did not produce, respectively, any C alpha Y or C alpha H proton nuclear Overhauser effect enhancement, illustrating the absence of a Tyr-Ile-His bend in the truncated ANG II peptide. The present findings indicate that the NH2-terminal domain of ANG II appears to have an essential role in generating the biologically active charge relay conformation of the hormone.	NATL HELLEN RES FDN,INST ORGAN & PHARMACEUT CHEM,GR-11635 ATHENS,GREECE; UNIV CALGARY,DEPT CHEM,CALGARY T2N 4N1,AB,CANADA; UNIV CALGARY,DEPT PHARMACOL & THERAPEUT,CALGARY T2N 4N1,AB,CANADA	National Hellenic Research Foundation; University of Calgary; University of Calgary	MATSOUKAS, JM (corresponding author), UNIV PATRAS,DEPT CHEM,GR-26000 PATRAI,GREECE.		Makriyannis, Alexandros/GRF-1518-2022; Matsoukas, John/AAN-5039-2020; Mavromoustakos, Thomas/C-4696-2017	Makriyannis, Alexandros/0000-0003-3272-3687; Mavromoustakos, Thomas/0000-0001-5309-992X				BARLOS K, 1989, LIEBIGS ANN CHEM, P951; BARLOS K, 1991, ANGEW CHEM INT EDIT, V30, P590, DOI 10.1002/anie.199105901; DESLAURIERS R, 1975, BIOCHEMISTRY-US, V14, P878, DOI 10.1021/bi00676a003; DESLAURIERS R, 1977, J MOL BIOL, V113, P697, DOI 10.1016/0022-2836(77)90231-5; DIXON RAF, 1988, ANNU REP MED CHEM, V23, P221; FERMANDJIAN S, 1971, EUR J BIOCHEM, V24, P252, DOI 10.1111/j.1432-1033.1971.tb19678.x; GROSS E, 1983, PEPTIDES, V5, P257; LENKINSKI RE, 1981, BIOCHEMISTRY-US, V20, P3122, DOI 10.1021/bi00514a021; MARION D, 1985, FEBS LETT, V192, P99, DOI 10.1016/0014-5793(85)80051-X; MATSOUKAS J, 1988, J MED CHEM, V31, P1418, DOI 10.1021/jm00402a028; MATSOUKAS JM, 1990, PEPTIDES, V11, P359, DOI 10.1016/0196-9781(90)90093-K; MATSOUKAS JM, 1985, J MED CHEM, V28, P780, DOI 10.1021/jm00383a015; MATSOUKAS JM, 1990, PEPTIDES, V11, P367, DOI 10.1016/0196-9781(90)90094-L; MATSOUKAS JM, 1984, BIOCHEM BIOPH RES CO, V122, P434, DOI 10.1016/0006-291X(84)90494-7; MATSOUKAS JM, 1993, J MED CHEM, V36, p90J; MOORE GJ, 1985, BIOSCIENCE REP, V4, P407; NOGGLE JH, 1971, NUCL OVERHAUSER EFFE, P76; ONDETTI MA, 1982, ANNU REV BIOCHEM, V51, P283, DOI 10.1146/annurev.bi.51.070182.001435; OTTER A, 1988, BIOCHEMISTRY-US, V27, P3560, DOI 10.1021/bi00410a006; OTTER A, 1991, BIOPOLYMERS, V31, P449, DOI 10.1002/bip.360310410; PAIVA TB, 1963, BIOCHEMISTRY-US, V2, P1327, DOI 10.1021/bi00906a026; PRINTZ MP, 1972, P NATL ACAD SCI USA, V69, P378, DOI 10.1073/pnas.69.2.378; SARGENT DF, 1986, P NATL ACAD SCI USA, V83, P5774, DOI 10.1073/pnas.83.16.5774; SMEBY RR, 1962, BIOCHIM BIOPHYS ACTA, V58, P550, DOI 10.1016/0006-3002(62)90065-3; SMEBY RR, 1976, CHEM BIOCH AMINO ACI, P117; TURNER RJ, 1991, BIOCHIM BIOPHYS ACTA, V1065, P21, DOI 10.1016/0005-2736(91)90005-S; WAHHAB A, 1994, DRUG RES, V43, P1157; WEINKAM RJ, 1971, J AM CHEM SOC, V93, P7038, DOI 10.1021/ja00754a059; WEINKAM WJ, 1971, J AM CHEM SOC, V93, P7033; ZHOU N, 1991, J PROTEIN CHEM, V10, P333, DOI 10.1007/BF01025632	30	85	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5303	5312						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106515				2022-12-27	WOS:A1994MX57100092
J	MORI, S; RONNSTRAND, L; CLAESSONWELSH, L; HELDIN, CH				MORI, S; RONNSTRAND, L; CLAESSONWELSH, L; HELDIN, CH			A TYROSINE RESIDUE IN THE JUXTAMEMBRANE SEGMENT OF THE PLATELET-DERIVED GROWTH-FACTOR BETA-RECEPTOR IS CRITICAL FOR LIGAND-MEDIATED ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; LYSOSOMAL ACID-PHOSPHATASE; FACTOR-II RECEPTOR; B-TYPE RECEPTOR; PDGF RECEPTOR; CYTOPLASMIC TAIL; INTERNALIZATION SIGNAL; INSULIN-RECEPTOR; FAMILIAL HYPERCHOLESTEROLEMIA; AUTOPHOSPHORYLATION SITES	The importance of tyrosine residues in ligand-mediated endocytosis of the platelet-derived growth factor beta-receptor was analyzed using a series of tyrosine residue-mutated beta-receptors, which together cover all of the tyrosine residues in the juxtamembrane segment, the kinase insert, and the carboxyl-terminal tail; also certain of the tyrosine residues within the first and second parts of the kinase domain were examined. Of all of these tyrosine residues, only Tyr-579 seemed to be important for internalization, since mutation of this residue resulted in substantial reduction in the rate of ligand-induced receptor internalization (approximate to 60% of the wild-type level). Replacement of Tyr-579 by either an aromatic (Phe) or a nonaromatic (Asp) residue reduced the efficiency of the mutant receptors in internalization to the same extent, suggesting that the role of Tyr-579 in the beta-receptor is different from that of the previously described tyrosine-based internalization motifs, which were first determined for the low density lipoprotein receptor. Tyr-579 has been found to be an autophosphorylation site in the beta-receptor. Moreover, the internalization rate of a kinase negative receptor mutant was not altered by the additional mutation of Tyr-579. Thus, it is likely that phosphorylation of Tyr-579 is important for ligand-induced internalization of the beta-receptor.	BIOMED CTR,LUDWIG INST CANC RES,S-75124 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research			Ronnstrand, Lars/A-2429-2011	Ronnstrand, Lars/0000-0003-1275-5809				BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; GIRONES N, 1991, J BIOL CHEM, V266, P19006; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1982, J BIOL CHEM, V257, P4216; JADOT M, 1992, J BIOL CHEM, V267, P11069; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; MORI S, 1991, J BIOL CHEM, V266, P21158; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MORI S, 1993, J BIOL CHEM, V268, P577; NILSSON J, 1983, P NATL ACAD SCI-BIOL, V80, P5592, DOI 10.1073/pnas.80.18.5592; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSENFELD ME, 1984, J CELL PHYSIOL, V121, P263, DOI 10.1002/jcp.1041210202; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; THIES RS, 1990, J BIOL CHEM, V265, P10132; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WILEY HS, 1982, J BIOL CHEM, V257, P4222; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	49	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4917	4921						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106465				2022-12-27	WOS:A1994MX57100036
J	RYU, S; GARGES, S				RYU, S; GARGES, S			PROMOTER SWITCH IN THE ESCHERICHIA-COLI PTS OPERON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PHOSPHOTRANSFERASE SYSTEM; CYCLIC-AMP; TRANSCRIPTION ACTIVATION; SALMONELLA-TYPHIMURIUM; POSITIVE REGULATION; RECEPTOR PROTEIN; MESSENGER-RNA; 2 PROMOTERS; CRR GENES; DNA	The ptsH operon of Escherichia coli is controlled by two promoters P0 and P1, each of which is regulated by cyclic AMP receptor protein (CRP) complexed with cAMP (CRP.cAMP). We have studied the in vitro as well as in vivo transcriptional regulation of these two promoters. Each promoter exhibits a switching mechanism in vitro, where, depending upon the presence or absence of CRP.cAMP, transcription is initiated from different start sites termed a and b.P0 (P0a) is affected by supercoliing: when the template is linear, transcription initiation is switched to a site 3 base pairs upstream (P0b) and becomes more CRP.cAMP dependent. Transcription from the P1 promoter (P1a) switches initiation sites to 7 base pairs downstream (P1b) in the presence of CRP.cAMP. Most transcription in vivo was from P1a, and P0b could not be detected in vivo. Glucose has independent positive effects on pts expression in vivo. The results indicate that the two different regulatory mechanisms (one through CRP.cAMP, the other through glucose) are working together for fine control of pts expression.			RYU, S (corresponding author), NCI, MOLEC BIOL LAB, BLDG 37, RM 2E06, BETHESDA, MD 20892 USA.							Adhya S, 1987, ESCHERICHIA COLI SAL, P1503; BLAKE VL, 1987, J BACTERIOL, V169, P4499; BOTSFORD JL, 1992, MICROBIOL REV, V56, P100, DOI 10.1128/MMBR.56.1.100-122.1992; BRAHMS JG, 1985, J MOL BIOL, V181, P455, DOI 10.1016/0022-2836(85)90419-X; BYRNE CR, 1988, J BACTERIOL, V170, P3150, DOI 10.1128/jb.170.7.3150-3157.1988; CORDARO JC, 1972, J BACTERIOL, V112, P17, DOI 10.1128/JB.112.1.17-29.1972; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; DEREUSE H, 1988, J BACTERIOL, V170, P3827, DOI 10.1128/jb.170.9.3827-3837.1988; DEREUSE H, 1992, J MOL BIOL, V226, P623, DOI 10.1016/0022-2836(92)90620-Y; DEREUSE H, 1991, J BACTERIOL, V173, P727, DOI 10.1128/jb.173.2.727-733.1991; DEREUSE H, 1985, GENE, V35, P199; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; EMORY SA, 1992, GENE DEV, V6, P135, DOI 10.1101/gad.6.1.135; FOX DK, 1992, P NATL ACAD SCI USA, V89, P7056, DOI 10.1073/pnas.89.15.7056; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; IRANI M, 1989, J BACTERIOL, V171, P1623, DOI 10.1128/jb.171.3.1623-1630.1989; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; LAU E, 1985, RECOMBINANT DNA TECH, V6, P21; MAHADEVAN S, 1987, J BACTERIOL, V169, P2570, DOI 10.1128/jb.169.6.2570-2578.1987; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; PAGEL JM, 1992, J MOL BIOL, V224, P919, DOI 10.1016/0022-2836(92)90460-2; PLUMBRIDGE JA, 1990, J BACTERIOL, V172, P2728, DOI 10.1128/jb.172.5.2728-2735.1990; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; REPHAELI AW, 1980, J BACTERIOL, V141, P658, DOI 10.1128/JB.141.2.658-663.1980; ROSENBAUM V, 1993, J MOL BIOL, V229, P656, DOI 10.1006/jmbi.1993.1070; RYU S, 1993, P NATL ACAD SCI USA, V90, P75, DOI 10.1073/pnas.90.1.75; SAFFEN DW, 1987, J BIOL CHEM, V262, P16241; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; SAIER MH, 1993, J CELL BIOCHEM, V51, P62, DOI 10.1002/jcb.240510112; Sambrook J, 1989, MOL CLONING LABORATO; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; TRAVERS AA, 1992, CURR OPIN STRUC BIOL, V2, P71	32	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4767	4772						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106445				2022-12-27	WOS:A1994MX57100014
J	LAGROST, L; PERSEGOL, L; LALLEMANT, C; GAMBERT, P				LAGROST, L; PERSEGOL, L; LALLEMANT, C; GAMBERT, P			INFLUENCE OF APOLIPOPROTEIN COMPOSITION OF HIGH-DENSITY-LIPOPROTEIN PARTICLES ON CHOLESTERYL ESTER TRANSFER PROTEIN-ACTIVITY - PARTICLES CONTAINING VARIOUS PROPORTIONS OF APOLIPOPROTEIN-A-I AND APOLIPOPROTEIN-AII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-TRANSFER PROTEIN; GRADIENT GEL-ELECTROPHORESIS; I-CONTAINING LIPOPROTEINS; CORONARY-ARTERY DISEASE; HUMAN-PLASMA; TRANSGENIC MICE; FATTY-ACIDS; ACYLTRANSFERASE; SUBPOPULATIONS; LECITHIN	The effect of apolipoprotein (apo) composition of high density lipoproteins (HDL) on cholesteryl ester transfer protein (CETP) activity was studied by, measuring the rate of radiolabeled cholesteryl esters transferred between low density lipoproteins (LDL) and HDL3 which contained various proportions of apoAI and apoAII. Ultracentrifugally isolated HDL3, which contained virtually only apoAI and apoAII in their protein moiety, were progressively enriched with apoAII upon the incubation with increasing amounts of delipidated HDL apolipoproteins. The substitution of apoAII for apoAI in HDL3 did not induce marked alteration of the lipid composition of the lipoprotein particles. The rates of cholesteryl ester exchanges with LDL in the presence of purified human CETP were significantly reduced with apoAII-enriched HDL3 as compared with non-enriched homologous particles. Consistent results were obtained by determining the rate of cholesteryl esters transferred either from LDL toward HDL3, or in the opposite direction, from HDL3 to LDL. The effect of the apoAI and apoAII content of HDL particles on CETP activity was also investigated by measuring the rate of cholesteryl esters transferred from LDL to plasma HDL3 particles which contained either only apoAI, HDL3-AI, or both apoAI and apoAII, HDL3-AIAII. HDL3-AI and HDL3-AIAII particles were isolated from human plasma by a sequential procedure which combined ultracentrifugation and anti-apoAII immunoaffinity chromatography. As observed with HDL3 artificially enriched with apoAII, cholesteryl ester transfer rates were significantly lower with plasma HDL3-AIAII than with plasma HDL3-AI particles. Kinetic analysis of the interaction of CETP with apoAII-enriched HDL3 revealed that apoAII could act as an uncompetitive inhibitor of the cholesteryl ester transfer reaction. Since the plasma levels of HDL-AI, HDL-AIAII, and HDL-AII may undergo significant physiological fluctuation, the present study suggests that HDL apoproteins may be important factors in modulating cholesteryl ester transfer rates in vivo.	FAC MED DIJON,BIOCHIM LIPOPROT LAB,F-21033 DIJON,FRANCE	Universite de Bourgogne								AGELLON LB, 1991, J BIOL CHEM, V266, P10796; ATMEH RF, 1983, BIOCHIM BIOPHYS ACTA, V751, P175, DOI 10.1016/0005-2760(83)90172-8; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BARTER PJ, 1990, ATHEROSCLEROSIS, V84, P13, DOI 10.1016/0021-9150(90)90003-2; BARTER PJ, 1990, BIOCHIM BIOPHYS ACTA, V1045, P81, DOI 10.1016/0005-2760(90)90206-D; BARTER PJ, 1980, J LIPID RES, V21, P238; BEKAERT ED, 1991, J LIPID RES, V32, P1587; BEKAERT ED, 1992, BIOCHIM BIOPHYS ACTA, V1126, P105, DOI 10.1016/0005-2760(92)90223-I; BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V665, P408, DOI 10.1016/0005-2760(81)90253-8; CHAM BE, 1976, J LIPID RES, V17, P176; CHEUNG MC, 1986, J LIPID RES, V27, P1135; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; CHEUNG MC, 1988, J LIPID RES, V29, P15; CHEUNG MC, 1991, J LIPID RES, V32, P383; CHUNG J, 1979, J BIOL CHEM, V254, P7456; EISENBERG S, 1985, J LIPID RES, V26, P487; FIELDING CJ, 1984, P NATL ACAD SCI-BIOL, V81, P2512, DOI 10.1073/pnas.81.8.2512; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FLESS GM, 1986, J BIOL CHEM, V261, P8712; FRUCHART JC, 1992, CLIN CHEM, V38, P793; GAMBERT P, 1990, J LIPID RES, V31, P1199; GROOT PHE, 1982, J LIPID RES, V23, P1342; HAYEK T, 1992, J CLIN INVEST, V90, P505, DOI 10.1172/JCI115887; IHM J, 1982, J LIPID RES, V23, P1328; JAHN CE, 1981, FEBS LETT, V131, P366, DOI 10.1016/0014-5793(81)80405-X; JAMES RW, 1988, J LIPID RES, V29, P1557; JOHANSSON J, 1991, ARTERIOSCLER THROMB, V11, P74; KILSDONK EPC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P205, DOI 10.1016/0005-2760(90)90121-D; KIM YC, 1979, J BIOL CHEM, V254, P9621; KINISHITA M, 1993, J LIPID RES, V34, P261; KUNITAKE ST, 1982, J LIPID RES, V23, P936; LAGOCKI PA, 1980, J BIOL CHEM, V255, P3701; LAGROST L, 1992, BIOCHIM BIOPHYS ACTA, V1126, P143, DOI 10.1016/0005-2760(92)90284-3; LAGROST L, 1991, BIOCHIM BIOPHYS ACTA, V1085, P209, DOI 10.1016/0005-2760(91)90096-Z; LAGROST L, 1990, J LIPID RES, V31, P1569; LAGROST L, 1993, ARTERIOSCLER THROMB, V13, P815, DOI 10.1161/01.ATV.13.6.815; LASUNCION MA, 1990, BIOCHEM J, V270, P441, DOI 10.1042/bj2700441; MARZ W, 1988, BIOCHIM BIOPHYS ACTA, V962, P155, DOI 10.1016/0005-2760(88)90107-5; MCVICAR JP, 1984, P NATL ACAD SCI-BIOL, V81, P1356, DOI 10.1073/pnas.81.5.1356; MILNER TG, 1991, BIOCHIM BIOPHYS ACTA, V1082, P71, DOI 10.1016/0005-2760(91)90301-W; MORTON RE, 1985, J BIOL CHEM, V260, P2593; MORTON RE, 1990, J LIPID RES, V31, P1559; MORTON RE, 1981, J BIOL CHEM, V256, P1992; MORTON RE, 1983, J BIOL CHEM, V258, P1751; MORTON RE, 1988, J BIOL CHEM, V263, P12235; NISHIDA HI, 1990, J BIOL CHEM, V265, P4876; NISHIDE T, 1989, J LIPID RES, V30, P149; NISHIKAWA O, 1988, J BIOCHEM, V103, P188, DOI 10.1093/oxfordjournals.jbchem.a122229; PUCHOIS P, 1987, ATHEROSCLEROSIS, V68, P35, DOI 10.1016/0021-9150(87)90091-8; RADER DJ, 1991, J LIPID RES, V32, P1849; RIFAI N, 1986, CLIN CHEM, V32, P957; ROSSENEU M, 1981, EUR J BIOCHEM, V117, P347, DOI 10.1111/j.1432-1033.1981.tb06344.x; RYE KA, 1989, J LIPID RES, V30, P335; RYE KA, 1992, J LIPID RES, V33, P215; SAMMETT D, 1985, J BIOL CHEM, V260, P6687; SON YSC, 1984, BIOCHIM BIOPHYS ACTA, V795, P473; SPARKS D, 1991, AM HEART J, V122, P601, DOI 10.1016/0002-8703(91)91031-H; SPARKS DL, 1989, J LIPID RES, V30, P1491; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; SWENSON TL, 1989, J BIOL CHEM, V264, P14318; TALL AR, 1993, J LIPID RES, V34, P1255; TALL AR, 1977, BIOCHIM BIOPHYS ACTA, V487, P145, DOI 10.1016/0005-2760(77)90051-0; TOLLEFSON JH, 1988, AM J PHYSIOL, V255, pE894, DOI 10.1152/ajpendo.1988.255.6.E894; VADIVELOO PK, 1990, BIOCHIM BIOPHYS ACTA, V1045, P135, DOI 10.1016/0005-2760(90)90142-K; VADIVELOO PK, 1992, BIOCHEM J, V284, P145, DOI 10.1042/bj2840145; VANTORNOUT P, 1981, BIOCHIM BIOPHYS ACTA, V663, P630, DOI 10.1016/0005-2760(81)90073-4; Webb JL, 1963, ENZYME METABOLIC INH, VI	67	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3189	3197						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106353				2022-12-27	WOS:A1994MV63100014
J	SCHIAVI, SC; WELLINGTON, CL; SHYU, AB; CHEN, CYA; GREENBERG, ME; BELASCO, JG				SCHIAVI, SC; WELLINGTON, CL; SHYU, AB; CHEN, CYA; GREENBERG, ME; BELASCO, JG			MULTIPLE ELEMENTS IN THE C-FOS PROTEIN-CODING REGION FACILITATE MESSENGER-RNA DEADENYLATION AND DECAY BY A MECHANISM COUPLED TO TRANSLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A) BINDING-PROTEIN; SYNTHESIS INHIBITORS; SECONDARY STRUCTURE; GENE-EXPRESSION; XENOPUS-LAEVIS; MYC; DEGRADATION; STABILITY; SEQUENCE; INSTABILITY	The c-fos proto-oncogene transcript is one of the most labile mammalian mRNAs known. Rapid degradation of c-fos mRNA is mediated by both the c-fos protein-coding region and an AU-rich element in the 3'-untranslated region. Here we present evidence that the c-fos coding region contains multiple destabilizing elements that can function independently to facilitate both deadenylation and decay of mRNA. The ability of these coding region destabilizing elements to direct deadenylation and decay requires the assembly of ribosomes at the 5' end of this domain and, most likely, translation of the message.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School					NCI NIH HHS [CA43855] Funding Source: Medline; NIGMS NIH HHS [GM42720] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042720] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; ATWATER JA, 1990, ANNU REV GENET, V24, P19; BAER BW, 1980, P NATL ACAD SCI-BIOL, V77, P1890, DOI 10.1073/pnas.77.4.1890; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BOUVET P, 1991, MOL CELL BIOL, V11, P3115, DOI 10.1128/MCB.11.6.3115; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHEN CYA, 1992, MOL CELL BIOL, V12, P5748, DOI 10.1128/MCB.12.12.5748; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GALILI G, 1988, J BIOL CHEM, V263, P5764; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KROWCZYNSKA A, 1985, J MOL BIOL, V181, P231, DOI 10.1016/0022-2836(85)90087-7; LAIRDOFFRINGA IA, 1991, NUCLEIC ACIDS RES, V19, P2387, DOI 10.1093/nar/19.9.2387; LAIRDOFFRINGA IA, 1992, BIOESSAYS, V14, P119, DOI 10.1002/bies.950140209; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; PARKER R, 1990, P NATL ACAD SCI USA, V87, P2780, DOI 10.1073/pnas.87.7.2780; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95, DOI 10.1016/0304-419X(92)90009-N; SEHGAL PB, 1978, P NATL ACAD SCI USA, V75, P5030, DOI 10.1073/pnas.75.10.5030; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WADA K, 1991, NUCLEIC ACIDS RES, V19, P1981, DOI 10.1093/nar/19.suppl.1981; WELLINGTON CL, 1993, MOL CELL BIOL, V13, P5034, DOI 10.1128/MCB.13.8.5034; WHITTEMORE LA, 1990, MOL CELL BIOL, V10, P1329, DOI 10.1128/MCB.10.4.1329; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	48	118	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3441	3448						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106384				2022-12-27	WOS:A1994MV63100049
J	CARRAWAY, CAC; CARVAJAL, ME; LI, YQ; CARRAWAY, KL				CARRAWAY, CAC; CARVAJAL, ME; LI, YQ; CARRAWAY, KL			ASSOCIATION OF P185(NEU) WITH MICROFILAMENTS VIA A LARGE GLYCOPROTEIN COMPLEX IN MAMMARY-CARCINOMA MICROVILLI - EVIDENCE FOR A MICROFILAMENT-ASSOCIATED SIGNAL TRANSDUCTION PARTICLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TUMOR-CELL MICROVILLI; FACTOR RECEPTORS; A431 CELLS; ASCITES ADENOCARCINOMA; MORPHOLOGICAL-CHANGES; PHOSPHOLIPASE-C; TYROSINE KINASE; MEMBRANE; REORGANIZATION	The protein product of the neu (proto)oncogene P185neu is an analog of the epidermal growth factor receptor. Immunoblot analyses of cell surface fractions (microvilli) from the ascites 13762 rat mammary adenocarcinoma indicate that these cells contain p185neu but not epidermal growth factor receptor. Phalloidin shift velocity sedimentation analysis indicated that essentially all of the microvillar p185 co-migrated with microvillar microfilament cores when extractions were performed under microfilament-stabilizing conditions. Fractionation studies of these microvilli indicated that the association of p185 with the microfilament core is mediated by its stable interaction with a previously described transmembrane complex (TMC), composed minimally of at least four glycoproteins, a 58-kDa cytoplasmic membrane protein, and actin (Carraway, C. A. C., Jung, G., and Carraway, K. L. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 430-434). A fraction of the p185 co-purifies with a large (>2 x 10(6) kDa) complex of the TMC glycoproteins on gel filtration of microvilli, microfilament cores, or microvillar membranes in buffer containing 1 M KCl at pH 9.5, which are conditions required for the dissociation of actin from the complex. We propose that p185-containing TMC serves as a signal transduction particle at the surface of the 13762 cells and may be a prototype for similar microfilament-associated signal-transducing complexes in other cells.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33136	University of Miami	CARRAWAY, CAC (corresponding author), UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,R-629,MIAMI,FL 33136, USA.				NATIONAL CANCER INSTITUTE [P30CA014395, R01CA052498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033795] Funding Source: NIH RePORTER; NCI NIH HHS [CA 14395, CA 52498] Funding Source: Medline; NIGMS NIH HHS [GM 33795] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARRAWAY C A C, 1992, P123; CARRAWAY CAC, 1983, P NATL ACAD SCI-BIOL, V80, P430, DOI 10.1073/pnas.80.2.430; CARRAWAY CAC, 1985, EXP CELL RES, V161, P150, DOI 10.1016/0014-4827(85)90499-9; CARRAWAY CAC, 1982, BIOCHIM BIOPHYS ACTA, V719, P126; CARRAWAY CAC, 1991, J BIOL CHEM, V266, P16238; CARRAWAY CAC, 1985, EXP CELL RES, V157, P71, DOI 10.1016/0014-4827(85)90153-3; CARRAWAY CAC, 1983, CELL MOTIL CYTOSKEL, V3, P491, DOI 10.1002/cm.970030516; CARRAWAY KL, 1980, NATURE, V285, P508, DOI 10.1038/285508a0; CARRAWAY KL, 1982, J CELL BIOL, V94, P624, DOI 10.1083/jcb.94.3.624; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CARRAWAY KL, 1979, J CELL BIOL, V83, P529, DOI 10.1083/jcb.83.3.529; CHINKERS M, 1981, J CELL BIOL, V88, P422, DOI 10.1083/jcb.88.2.422; CHINKERS M, 1979, J CELL BIOL, V83, P260, DOI 10.1083/jcb.83.1.260; DEFIZE LHK, 1989, J CELL BIOL, V107, P939; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; HENEGOUWEN PMP, 1989, J CELL BIOCHEM, V39, P455; HENEGOUWEN PMP, 1992, EXP CELL RES, V199, P90; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; JUNG G, 1986, J CELL BIOCHEM, V28, P243; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KING AC, 1982, J BIOL CHEM, V257, P3053; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LANDRETH GE, 1985, J CELL BIOL, V101, P1341, DOI 10.1083/jcb.101.4.1341; LIU YC, 1989, J BIOL CHEM, V264, P1208; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; RIJKEN PJ, 1991, J CELL SCI, V100, P491; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; TODARO GJ, 1990, CANCER BIOL, V1, P257; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERPUYE OA, 1988, EXP CELL RES, V178, P211, DOI 10.1016/0014-4827(88)90392-8; WAHL M, 1991, BIOESSAYS, V13, P107, DOI 10.1002/bies.950130303; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WIEGANT FAC, 1986, J CELL BIOL, V103, P87, DOI 10.1083/jcb.103.1.87; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YE XH, 1989, EXP CELL RES, V182, P160, DOI 10.1016/0014-4827(89)90288-7	40	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5582	5587						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8095497				2022-12-27	WOS:A1993KR82200037
J	KOLLER, KJ; LIPARI, MT; GOEDDEL, DV				KOLLER, KJ; LIPARI, MT; GOEDDEL, DV			PROPER GLYCOSYLATION AND PHOSPHORYLATION OF THE TYPE-A NATRIURETIC PEPTIDE RECEPTOR ARE REQUIRED FOR HORMONE-STIMULATED GUANYLYL CYCLASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PORCINE BRAIN; ATRIAL; ACTIVATION; FAMILY; SYSTEM; FORM; CNP	The natriuretic peptide receptor type A (NPR-A) is a receptor-guanylyl cyclase whose cytoplasmic enzymatic activity is stimulated by atrial natriuretic peptide binding to the extracellular domain. NPR-A expressed in COS cells is heterogeneously glycosylated, and the more highly glycosylated protein is also phosphorylated. Upon hormone binding, dephosphorylation occurs from both serine and threonine residues, probably within the kinase homology domain of NPR-A, and may be involved with receptor desensitization. Using site-specific mutations in the kinase homology domain of NPR-A, we have identified several residues that are important for regulating the guanylyl cyclase activity of NPR-A. Some of these amino acids are probably essential for maintaining the proper tertiary structure of the intracellular domain, and others may form loops that allow for binding of ATP, which is required for proper enzymatic activity. The site-specific mutants which have greatly reduced enzymatic activity are not phosphorylated and are incompletely glycosylated. These results suggest a correlation between phosphorylation and complete glycosylation of NPR-A and that both are required for hormone-induced enzymatic activity.	GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech								ATLAS SA, 1987, ATRIAL HORMONES OTHE, P53; BENTLEY JK, 1986, J BIOL CHEM, V261, P4859; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; Bylund D.B., 1990, METHODS NEUROTRANSMI, P1; CHANG CH, 1990, BIOCHIM BIOPHYS ACTA, V1052, P159, DOI 10.1016/0167-4889(90)90071-K; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARDMAN JG, 1971, ANN NY ACAD SCI, V185, P27; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JEWETT JRS, 1993, IN PRESS EMBO J; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; LOWE DG, 1992, J BIOL CHEM, V267, P21691; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; POTTER LR, 1992, J BIOL CHEM, V267, P14531; RAMARAO CS, 1988, J BIOL CHEM, V263, P1524; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; ULLRICH A, 1984, NATURE, V309, P416; YOSHIMURA M, 1991, CIRCULATION, V84, P1581, DOI 10.1161/01.CIR.84.4.1581	28	98	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5997	6003						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8095500				2022-12-27	WOS:A1993KR82200095
J	GEGG, CV; ETZLER, ME				GEGG, CV; ETZLER, ME			PHOTOAFFINITY-LABELING OF THE ADENINE BINDING-SITES OF 2 DOLICHOS-BIFLORUS LECTINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEED LECTIN; 3-DIMENSIONAL STRUCTURE; PHASEOLUS-LUNATUS; CONCANAVALIN-A; PROTEIN; CARBOHYDRATE; LEAVES; RESOLUTION; SUBUNITS; COMPLEX	Two differentially expressed lectins from the legume Dolichos biflorus, the seed lectin and a stem and leaf lectin (DB58), were photoaffinity-labeled at their adenine binding sites using the probe [2-H-3]8-azidoadenine. Both heteromeric subunits I and II of the seed lectin and alpha and beta of DB58 were specifically labeled. This result, combined with the adenine binding site stoichiometries of two identical sites/seed lectin tetramer or one site/DB58 dimer, indicates that the adenine binding site resides at a heterologous subunit interface. Three radiolabeled peaks from seed lectin and one from DB58 were isolated from chymotryptic digests of the labeled lectins by reverse phase chromatography at pH 7.0. From these four peaks, six unique peptide sequences were determined. When aligned with the concanavalin A sequence, four of these peptides map to three loops in the metal binding domain of concanavalin A. The remaining two sequences represent carboxyl-terminal peptides unique to the D. biflorus lectins which may extend to the putative binding site from adjacent, heterologous subunits. It thus appears that the adenine binding sites of these D. biflorus lectins are within the metal binding domain and adjacent to the carbohydrate binding site.	UNIV CALIF DAVIS, DEPT BIOCHEM & BIOPHYS, DAVIS, CA 95616 USA	University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021882] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21882] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bayley H, 1977, Methods Enzymol, V46, P69; BECKER JW, 1983, CHEM TAXONOMY MOL BI, P31; BORREBAECK CAK, 1981, BIOCHEMISTRY-US, V20, P4119, DOI 10.1021/bi00517a026; BRINEGAR AC, 1988, P NATL ACAD SCI USA, V85, P5927, DOI 10.1073/pnas.85.16.5927; BUNKER TW, 1993, IN PRESS PLANTA; CARTER WG, 1975, J BIOL CHEM, V250, P2756; DELBAERE LTJ, 1990, CAN J CHEM, V68, P1116, DOI 10.1139/v90-172; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; ETZLER ME, 1984, PLANT PHYSIOL, V76, P871, DOI 10.1104/pp.76.4.871; ETZLER ME, 1981, J BIOL CHEM, V256, P2367; ETZLER ME, 1980, BIOCHEM BIOPH RES CO, V96, P92, DOI 10.1016/0006-291X(80)91185-7; ETZLER ME, 1992, GLYCOCONJUGATES COMP, P521; FOX JE, 1975, BIOCHEM BIOPH RES CO, V64, P694, DOI 10.1016/0006-291X(75)90376-9; FRIMER AA, 1983, OXY RADICALS THEIR S, P270; GEGG CV, 1992, BIOCHEMISTRY-US, V31, P6938, DOI 10.1021/bi00145a011; Goldstein I. J., 1986, LECTINS PROPERTIES F, P35; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; HARADA JJ, 1990, J BIOL CHEM, V265, P4997; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; INOUE H, 1986, BIOCHEM BIOPH RES CO, V137, P372, DOI 10.1016/0006-291X(86)91220-9; JAYABASKARAN C, 1990, PLANT GROWTH REGUL, V9, P9, DOI 10.1007/BF00025274; KING SM, 1991, METHOD ENZYMOL, V196, P449; LESHEM YY, 1981, PHYSIOL PLANTARUM, V53, P9, DOI 10.1111/j.1399-3054.1981.tb05037.x; LESHEM YY, 1988, FREE RADICAL BIO MED, V5, P39, DOI 10.1016/0891-5849(88)90060-3; MALIARIK MJ, 1988, J BIOL CHEM, V263, P11274; MARTIN RL, 1991, ARCH BIOCHEM BIOPHYS, V284, P26, DOI 10.1016/0003-9861(91)90257-J; MOMOTANI E, 1992, PLANT CELL PHYSIOL, V33, P407; Moore T.C., 1989, BIOCH PHYSL PLANT HO, P158; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; QUINN JM, 1989, PLANT PHYSIOL, V91, P1382, DOI 10.1104/pp.91.4.1382; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; REEKE GN, 1975, J BIOL CHEM, V250, P1525; REEKE GN, 1986, SCIENCE, V234, P1108, DOI 10.1126/science.3775378; ROBERTS DD, 1986, PHYTOCHEMISTRY, V25, P589, DOI 10.1016/0031-9422(86)88004-9; ROBERTS DD, 1983, ARCH BIOCHEM BIOPHYS, V224, P479, DOI 10.1016/0003-9861(83)90235-7; ROBERTS DD, 1983, J BIOL CHEM, V258, P3820; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; RUOHO AE, 1973, P NATL ACAD SCI USA, V70, P2567, DOI 10.1073/pnas.70.9.2567; SAKAI S, 1992, BIOSCI BIOTECH BIOCH, V56, P504, DOI 10.1271/bbb.56.504; SCHNELL DJ, 1987, J BIOL CHEM, V262, P7220; SCHNELL DJ, 1988, J BIOL CHEM, V263, P14648; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; Sharon N., 1986, LECTINS PROPERTIES F, P294; TALBOT CF, 1978, BIOCHEMISTRY-US, V17, P1474, DOI 10.1021/bi00601a018	45	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5687	5692						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119905				2022-12-27	WOS:A1994MY84000034
J	GUIHARD, G; BOULANGER, P; BENEDETTI, H; LLOUBES, R; BESNARD, M; LETELLIER, L				GUIHARD, G; BOULANGER, P; BENEDETTI, H; LLOUBES, R; BESNARD, M; LETELLIER, L			COLICIN-A AND THE TOL PROTEINS INVOLVED IN ITS TRANSLOCATION ARE PREFERENTIALLY LOCATED IN THE CONTACT SITES BETWEEN THE INNER AND OUTER MEMBRANES OF ESCHERICHIA-COLI-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; INVIVO PROPERTIES; CROSS-RESISTANCE; CHANNEL ACTIVITY; ENVELOPE; K-12; RECEPTOR; ENTRY; BTUB; PORE	Colicin A is a bacterial toxin which forms channels in the cytoplasmic membrane of Escherichia coli. Its translocation through the envelope requires the participation of bacterial proteins encoded by the tolQ, -R, -A, and -B genes. Overproduction of the Tol proteins decreased the time needed for colicin A translocation and increased the number of channels formed in vivo. Cells overproducing radioactively labeled Tol proteins and containing or not colicin A were fractionated. The Tol proteins were mainly recovered in the inner membrane and in the contact sites between the two membranes. The presence of colicin A increased the specific radioactivity of the Tol proteins in the contact sites. Our data suggest that the Tol proteins form a complex of definite stoichiometry in the membranes and that colicin A is associated to this complex upon channel formation. We discuss the possibility that the channel activity determined in vivo is due to the colicin A-Tol proteins complex.	UNIV PARIS 11,BIOMEMBRANES LAB,CNRS,URA 1116,F-91405 ORSAY,FRANCE; LAB INGN & DYNAM SYST MEMBRANAIRES,UPR 9027,F-13402 MARSEILLE 9,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay				LLOUBES, Roland/0000-0002-9520-1053				AMES GF, 1974, J BACTERIOL, V117, P406, DOI 10.1128/JB.117.2.406-416.1974; BENEDETTI H, 1991, EMBO J, V10, P1989, DOI 10.1002/j.1460-2075.1991.tb07728.x; BENEDETTI H, 1992, EMBO J, V11, P441, DOI 10.1002/j.1460-2075.1992.tb05073.x; BENEDETTI H, 1991, J MOL BIOL, V217, P429, DOI 10.1016/0022-2836(91)90747-T; BENEDETTI H, 1989, J GEN MICROBIOL, V135, P3413; BOULANGER P, 1988, J BIOL CHEM, V263, P9767; BOURDINEAUD JP, 1989, J BACTERIOL, V171, P2458, DOI 10.1128/jb.171.5.2458-2465.1989; BOURDINEAUD JP, 1990, P NATL ACAD SCI USA, V87, P1037, DOI 10.1073/pnas.87.3.1037; CAVARD D, 1981, FEMS MICROBIOL LETT, V12, P311; CHAI TJ, 1982, J BACTERIOL, V151, P983, DOI 10.1128/JB.151.2.983-988.1982; COLLARINI M, 1987, EUR BIOPHYS J BIOPHY, V14, P147, DOI 10.1007/BF00253839; DAVIES JK, 1975, J BACTERIOL, V123, P102, DOI 10.1128/JB.123.1.102-117.1975; DAVIES JK, 1975, J BACTERIOL, V123, P96, DOI 10.1128/JB.123.1.96-101.1975; FISCHER E, 1989, J BACTERIOL, V171, P5127, DOI 10.1128/jb.171.9.5127-5134.1989; FRENETTE M, 1991, J MOL BIOL, V217, P421, DOI 10.1016/0022-2836(91)90746-S; GELI V, 1992, BIOCHEMISTRY-US, V31, P11089, DOI 10.1021/bi00160a019; GUIHARD G, 1993, J BIOL CHEM, V268, P17775; GUIHARD G, 1992, J BIOL CHEM, V267, P3173; ISHIDATE K, 1986, J BIOL CHEM, V261, P428; KAMPFERZEL K, 1993, BACTERIOLOGY, V175, P4485; KAMPFERZEL K, 1992, BACTERIOLOGY, V1174, P5485; KARLSSON M, 1993, MOL MICROBIOL, V8, P379, DOI 10.1111/j.1365-2958.1993.tb01581.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZDUNSKI CJ, 1988, BIOCHIM BIOPHYS ACTA, V947, P445, DOI 10.1016/0304-4157(88)90003-2; LETELLIER L, 1992, BIOCHIM BIOPHYS ACTA, V1101, P218; LEVENGOOD SK, 1991, P NATL ACAD SCI USA, V88, P5939, DOI 10.1073/pnas.88.14.5939; LEVENGOOD SK, 1989, J BACTERIOL, V171, P6600, DOI 10.1128/jb.171.12.6600-6609.1989; LEVENGOODFREYERMUTH SK, 1993, J BACTERIOL, V175, P222, DOI 10.1128/JB.175.1.222-228.1993; LUPI N, 1989, MOL IMMUNOL, V26, P1027, DOI 10.1016/0161-5890(89)90067-9; Maniatis T., 1982, MOL CLONING; MEURY J, 1985, EUR J BIOCHEM, V151, P613, DOI 10.1111/j.1432-1033.1985.tb09148.x; PATTUS F, 1990, EXPERIENTIA, V46, P180; Pattus F., 1983, PHYSICAL CHEM TRANSM, P407; SABET SF, 1973, J BIOL CHEM, V248, P1797; SUN TP, 1986, J BACTERIOL, V165, P107, DOI 10.1128/jb.165.1.107-115.1986; SUN TP, 1987, J BACTERIOL, V169, P2667, DOI 10.1128/jb.169.6.2667-2674.1987; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TILBY M, 1978, J BACTERIOL, V136, P1189, DOI 10.1128/JB.136.3.1189-1191.1978; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x	39	88	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5874	5880						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119930				2022-12-27	WOS:A1994MY84000061
J	DEBLAQUIERE, J; WALKER, F; MICHELANGELI, VP; FABRI, L; BURGESS, AW				DEBLAQUIERE, J; WALKER, F; MICHELANGELI, VP; FABRI, L; BURGESS, AW			PLATELET-DERIVED GROWTH-FACTOR STIMULATES THE RELEASE OF PROTEIN-KINASE-A FROM THE CELL-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; PHOSPHOLIPASE C-II; SWISS 3T3 CELLS; TYROSINE PHOSPHORYLATION; FACTOR RECEPTOR; SRC-FAMILY; SIGNAL TRANSDUCTION; EGF RECEPTOR; MAP KINASE; IDENTIFICATION	The mitogenic action of growth factors involves the stimulation of intracellular protein kinases. In this report we have characterized the major protein kinase released from Balb/c 3T3 and normal rat kidney plasma membranes by the action of platelet-derived growth factor (PDGF). PDGF appears to stimulate the release of approximately 10 proteins, at least one of which is a kinase capable of phosphorylating proteins on Ser or Thr (as determined by the lability of the phosphate to alkali treatment). More than 90% of the Ser/Thr kinase activity was inhibited by PKI5-22, a specific peptide inhibitor of the cAMP-dependent protein kinase (PKA). We used immunoblotting to confirm that the kinase released in response to PDGF was PRA. cAMP also stimulated the release of PKA, and the set of protein substrates phosphorylated was similar following PDGF or cAMP stimulation. Interestingly, in the presence of a cAMP analogue ((R(p))-cAMPS), cAMP could not induce dissociation of PKA from the membranes, whereas stimulation by PDGF increased the level of PKA activation. Furthermore, unlike Swiss 3T3 cells, neither Balb/c 3T3 fibroblasts nor normal rat kidney cells accumulate cAMP in response to PDGF, yet the level of PKA in the cytosol of these intact cells increases in response to PDGF. Thus, it appears as though PDGF activation of the membrane-associated form of the PKA holoenzyme occurs by a mechanism independent of an elevation in cAMP levels.	LUDWIG INST CANC RES,MELBOURNE TUMOR BIOL BRANCH,MELBOURNE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT DIABET & ENDOCRINOL,MELBOURNE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital				fabri, louis/0000-0003-4033-3304				ABDELGHANY M, 1989, P NATL ACAD SCI USA, V86, P6072, DOI 10.1073/pnas.86.16.6072; AGOSTINIS P, 1992, J BIOL CHEM, V267, P9732; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAMSON HN, 1984, CRC CR REV BIOCH MOL, V15, P93, DOI 10.3109/10409238409102298; BRAUN RK, 1991, ARCH BIOCHEM BIOPHYS, V289, P187, DOI 10.1016/0003-9861(91)90460-Z; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COOPER JA, 1982, CELL, V31, P263, DOI 10.1016/0092-8674(82)90426-3; COURTNEIDGE SA, 1991, CELL GROWTH DIFFER, V2, P483; DOSTMANN WRG, 1991, BIOCHEMISTRY-US, V30, P8710, DOI 10.1021/bi00099a032; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FISCHER TH, 1990, J BIOL CHEM, V265; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GRAF T, 1976, VIROLOGY, V71, P423, DOI 10.1016/0042-6822(76)90370-6; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; HATA Y, 1991, J BIOL CHEM, V266, P6571; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KERYER G, 1991, J CELL BIOL, V115, P284; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LAMB NJC, 1991, EMBO J, V10, P1523, DOI 10.1002/j.1460-2075.1991.tb07672.x; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MICHELANGELI VP, 1984, BIOCHEM J, V224, P371, DOI 10.1042/bj2240371; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RADZIEJEWSKI C, 1989, BIOCHEMISTRY-US, V28, P9047, DOI 10.1021/bi00449a013; RAPP UR, 1991, ONCOGENE, V6, P495; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THOMAS G, 1979, P NATL ACAD SCI USA, V76, P3952, DOI 10.1073/pnas.76.8.3952; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; USHIRO H, 1980, J BIOL CHEM, V255, P8363; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WALKER F, 1991, J BIOL CHEM, V266, P2746; WALKER F, 1993, J BIOL CHEM, V268, P19552; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WOLFE L, 1992, J BIOL CHEM, V267, P9749; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	63	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4812	4818						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106451				2022-12-27	WOS:A1994MX57100020
J	OKADA, T; SAKUMA, L; FUKUI, Y; HAZEKI, O; UI, M				OKADA, T; SAKUMA, L; FUKUI, Y; HAZEKI, O; UI, M			BLOCKAGE OF CHEMOTACTIC PEPTIDE-INDUCED STIMULATION OF NEUTROPHILS BY WORTMANNIN AS A RESULT OF SELECTIVE-INHIBITION OF PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-KINASE; SIGNAL TRANSDUCTION; ACTIVATED NEUTROPHILS; KINASE-ACTIVITY; HUMAN PLATELETS; RAT ADIPOCYTES; BOVINE BRAIN; THROMBIN; POLYPHOSPHOINOSITIDES; PHOSPHORYLATION	Wortmannin, a fungal metabolite, inhibited P-32 labeling of phosphatidylinositol trisphosphate, a product of phosphatidylinositol 3-kinase (PI 3-kinase), selectively in formyl peptide-stimulated P-32-loaded guinea pig neutrophils. The inhibition was of the same concentration dependence (with the half-maximal inhibition around 50 nM) as was observed for the simultaneous inhibition of formyl peptide-induced superoxide anion production. Wortmannin inhibited all three of the PI 3-kinase activities found in the cytosol fraction of guinea pig neutrophils, with a similar dose dependence (the half-maximal effects at 5 nM). Wortmannin was also effective on an immunologically purified preparation of the enzyme. The inhibition was of a noncompetitive type with regard to ATP and was observed consistently when PI, PI monophosphate, or PI bisphosphate was used as substrate. PI 4-kinase activity was not affected. It is concluded, therefore, that wortmannin abolished the formyl peptide-induced stimulation of neutrophils as a result of the inhibition of PI 3-kinase. An essential role of PI 3-kinase in receptor-mediated signaling in neutrophils thus evidenced with the use of wortmannin will be expanded to other cellular signaling systems.	INST PHYS & CHEM RES,UI LAB,HIROSAWA 2-1,WAKO 35101,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC AGR,DEPT AGR CHEM,BIOCHEM LAB,BUNKYO KU,TOKYO 113,JAPAN	RIKEN; University of Tokyo; University of Tokyo			Fukui, Yasuhisa/E-8806-2010					AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAGGIOLINI M, 1987, EXP CELL RES, V169, P408, DOI 10.1016/0014-4827(87)90201-1; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DEWALD B, 1988, J BIOL CHEM, V263, P16179; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; EBERLE M, 1990, J BIOL CHEM, V265, P16725; GIORGETTI S, 1992, EUR J BIOCHEM, V207, P599; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LIPS DL, 1989, J BIOL CHEM, V264, P8759; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; OKADA T, 1994, J BIOL CHEM, V269, P3568; OKAJIMA F, 1984, J BIOL CHEM, V259, P3863; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WIESINGE.D, 1974, EXPERIENTIA, V30, P135, DOI 10.1007/BF01927691; YATOMI Y, 1992, BIOCHEM J, V285, P745, DOI 10.1042/bj2850745; ZHANG J, 1992, J BIOL CHEM, V267, P4686	30	451	480	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3563	3567						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106399				2022-12-27	WOS:A1994MV63100067
J	RAHMATULLAH, M; ROBISHAW, JD				RAHMATULLAH, M; ROBISHAW, JD			DIRECT INTERACTION OF THE ALPHA-SUBUNIT AND GAMMA-SUBUNIT OF THE G-PROTEINS - PURIFICATION AND ANALYSIS BY LIMITED PROTEOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEINS; TRANSDUCING G-PROTEINS; MUSCARINIC K+-CHANNEL; AMINO-TERMINAL REGION; ROD OUTER SEGMENTS; BETA-SUBUNIT; PHOSPHOLIPASE-C; MOLECULAR-CLONING; BRAIN; CDNA	The heterotrimeric G proteins are often regarded functionally as a heterodimer, consisting of a guanine nucleotide-binding alpha subunit and a betagamma subunit complex. Since the tightly associated betagamma subunit complex can be separated only under denaturing conditions, studies aimed at determining the individual contributions of the beta and gamma subunits in terms of binding to the various a subunits, interacting with receptors, and regulating effectors, have not been possible. To circumvent this problem, we have used baculovirus-infected cells to direct the individual expression of the beta1 and gamma2 subunits. Application of extracts from baculovirus-infected cells to an a subunit of G protein (G(o)alpha)-affinity matrix resulted in the selective retention and AMF-specific elution of the expressed gamma2 subunit, but not the expressed beta1 subunit. Overall, these and other data provide the first evidence of a direct association between the gamma and alpha subunits, which is dependent on prenylation of gamma. The apparent direct association between the gamma and alpha subunits was further probed by limited trypsin proteolysis. Upon addition of trypsin, the G(o)alpha subunit was rapidly cleaved to a 24-kDa fragment. However, in the presence of the purified gamma2 subunit, trypsin cleavage of the G(o)alpha subunit was completely prevented. This demonstration of a direct association between the gamma and alpha subunits is particularly intriguing in light of the increasingly large number of known alpha, beta, and gamma subunits, which raises important questions regarding the assembly of these subunits into functionally distinct G proteins. Thus, a direct association between the gamma and alpha subunits, which exhibit the greatest structural diversity, may provide the basis for the selective assembly of these subunits into G proteins with functional diversity.	GEISINGER MED CLIN,WEIS CTR RES,100 N ACAD AVE,DANVILLE,PA 17822	Geisinger Medical Center					NIGMS NIH HHS [GM39867] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039867, R01GM039867] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASANO T, 1986, FEBS LETT, V203, P135, DOI 10.1016/0014-5793(86)80729-3; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BUBIS J, 1990, J BIOL CHEM, V265, P12995; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CODINA J, 1987, SCIENCE, V236, P442, DOI 10.1126/science.2436299; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; EWALD DA, 1989, NEURON, V2, P1185, DOI 10.1016/0896-6273(89)90185-2; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FOSTER KA, 1990, AM J PHYSIOL, V259, pH432, DOI 10.1152/ajpheart.1990.259.2.H432; FUNG BKK, 1990, FEBS LETT, V260, P313, DOI 10.1016/0014-5793(90)80132-3; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRABER SG, 1992, J BIOL CHEM, V267, P13123; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; KATADA T, 1986, J BIOL CHEM, V261, P8182; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LOGOTHETIS DE, 1988, P NATL ACAD SCI USA, V85, P5814, DOI 10.1073/pnas.85.16.5814; LUPAS AN, 1992, FEBS LETT, V314, P105, DOI 10.1016/0014-5793(92)80952-D; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEER EJ, 1988, J BIOL CHEM, V263, P8996; PENG YW, 1992, P NATL ACAD SCI USA, V89, P10882, DOI 10.1073/pnas.89.22.10882; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; ROBISHAW JD, 1989, ANNU REV PHYSIOL, V51, P229, DOI 10.1146/annurev.ph.51.030189.001305; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; ROBISHAW JD, 1992, BIOCHEM J, V286, P677, DOI 10.1042/bj2860677; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VAILLANCOURT RR, 1990, P NATL ACAD SCI USA, V87, P3645, DOI 10.1073/pnas.87.10.3645; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390	51	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3574	3580						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106401				2022-12-27	WOS:A1994MV63100069
J	SHAH, MA; TRACKMAN, PC; GALLOP, PM; KAGAN, HM				SHAH, MA; TRACKMAN, PC; GALLOP, PM; KAGAN, HM			REACTION OF LYSYL OXIDASE WITH TRANS-2-PHENYLCYCLOPROPYLAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOAMINE-OXIDASE; AMINE OXIDASE; MECHANISM; INHIBITORS; QUINONE; TRANYLCYPROMINE; DEHYDROGENASE; INACTIVATION; COFACTOR; CLEAVAGE	trans-2-Phenylcyclopropylamine hydrochloride (tranylcypromine; TCP) was found to be both an inhibitor and a substrate of lysyl oxidase, the enzyme which oxidizes peptidyl lysine in elastin and collagen to initiate cross-linking in these proteins. The reaction of TCP with this enzyme was further characterized in view of the potential interference that chronic administration of this antidepressant compound may exert on the development and repair of connective tissues. In contrast to the irreversible and/or competitive inhibitors of lysyl oxidase previously described, TCP noncompetitively and reversibly inhibited the oxidation of both alkylamine and elastin substrates with K(i) values of 386 and 375 muM, respectively. The noncompetitive mode of interaction affected the accessibility of the active site to productive amine substrates since the reductive trapping of n-hexylamine to lysyl oxidase was largely prevented by the presence of TCP. It was of additional interest that lysyl oxidase catalyzed a limited degree of conversion of TCP to cinnamaldehyde accompanied by the production of hydrogen peroxide. The lack of significant incorporation of protein-bound tritium accompanying reduction of the enzyme-TCP complex with [H-3]NaBH4 argued against the formation of a Schiff base between the enzyme and the cinnamaldehyde product as the basis of the inhibitory effect. Spectral evidence was also obtained for an additional interaction between TCP and lysyl oxidase that was independent of the inhibitory effect of TCP. Cyclopropylamine, lacking the benzene moiety of TCP, inhibited lysyl oxidase irreversibly and competitively, and was not a substrate, pointing toward a defining role for the benzene moiety in the interaction of TCP with lysyl oxidase.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; HARVARD UNIV,SCH MED,DEPT BIOL CHEM,BOSTON,MA 02115; HARVARD UNIV,SCH DENT MED,DEPT ORAL BIOL,CAMBRIDGE,MA 02138	Boston University; Harvard University; Harvard Medical School; Harvard University; Harvard School of Dental Medicine			Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018880, R37AR018880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007723] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 18880] Funding Source: Medline; NIA NIH HHS [AG-07723] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABELES RH, 1978, ENZYME ACTIVATED IRR, P1; BRIGGS NC, 1990, J CLIN PSYCHIAT, V51, P426; CRABBE MJC, 1974, BIOCHEM PHARMACOL, V23, P2983; DAVIDSON VL, 1991, BIOCHEMISTRY-US, V30, P1924, DOI 10.1021/bi00221a027; DUINE JA, 1989, ANNU REV BIOCHEM, V58, P403; ESTERBAUER H, 1976, TETRAHEDRON, V32, P285, DOI 10.1016/0040-4020(76)87015-9; GACHERU SN, 1989, J BIOL CHEM, V264, P12963; HARTMANN C, 1987, J BIOL CHEM, V262, P962; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; KAGAN HM, 1989, PQQ AND QUINOPROTEINS, P317; KAGAN HM, 1982, METHOD ENZYMOL, V82, P637; KAGAN HM, 1979, BIOCHEM J, V177, P203, DOI 10.1042/bj1770203; KAGAN HM, 1986, BIOL EXTRACELLULAR M, P321; KECK PE, 1989, J CLIN PSYCHOPHARM, V9, P48; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PAECH C, 1980, J BIOL CHEM, V255, P2700; PARE CMB, 1976, CIBA F S, V39, P271; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; REMICK RA, 1989, PROG NEURO-PSYCHOPH, V13, P497, DOI 10.1016/0278-5846(89)90137-1; SAYRE LM, 1991, J ORG CHEM, V56, P1353, DOI 10.1021/jo00004a004; SHAH MA, 1993, J BIOL CHEM, V268, P11573; SILVERMAN RB, 1983, J BIOL CHEM, V258, P4766; SULLIVAN KA, 1982, J BIOL CHEM, V257, P13520; TANG SS, 1983, J BIOL CHEM, V258, P4331; TRACKMAN PC, 1981, ANAL BIOCHEM, V113, P336, DOI 10.1016/0003-2697(81)90086-5; WIECHELMAN K, 1979, ANAL BIOCHEM, V100, P201; WILLIAMS MA, 1985, ANAL BIOCHEM, V149, P430, DOI 10.1016/0003-2697(85)90594-9; WILLIAMSON PR, 1986, BIOCHEM J, V235, P597, DOI 10.1042/bj2350597; WILLIAMSON PR, 1987, J BIOL CHEM, V262, P14520; WILLIAMSON PR, 1986, J BIOL CHEM, V261, P9477; WISEMAN JS, 1979, BIOCHEMISTRY-US, V18, P427, DOI 10.1021/bi00570a006	32	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11580	11585						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8099355				2022-12-27	WOS:A1993LF28400022
J	LAW, SF; YASUDA, K; BELL, GI; REISINE, T				LAW, SF; YASUDA, K; BELL, GI; REISINE, T			G(I-ALPHA-3) AND G(O-ALPHA) SELECTIVELY ASSOCIATE WITH THE CLONED SOMATOSTATIN RECEPTOR SUBTYPE-SSTR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT NEOCORTICAL NEURONS; RIBONUCLEIC-ACID; CALCIUM CURRENTS; G-PROTEIN	The interaction of the SRIF receptor subtype SSTR2 with pertussis toxin-sensitive G proteins was investigated using an immunoprecipitation approach employing peptide-directed antisera against G(ialpha) and G(oalpha). Antisera directed against either the COOH terminus of G(ialpha) or G(oalpha) uncoupled SSTR2-G protein complexes from CHO cells stably expressing the cloned receptor indicating that both G proteins form complexes with SSTR2. Chinese hamster ovary cells primarily express G(ialpha3) and G(oalpha2) immunoreactivity, with much lower levels of the other pertussis toxin-sensitive G proteins. Antiserum against G(ialpha3) uncoupled SSTR2/G protein complexes to a similar extent as G(1alpha) common antiserum while antisera against G(ialpha1) and G(ialpha2) did not. These findings indicate that SSTR2 expressed in Chinese hamster ovary cells predominantly associates with G(ialpha3) and G(oalpha2). In HEK 293 cells which endogenously express low densities of SSTR2 and similar levels of G(ialpha1) and G(ialpha3) immunoreactivity but no G(oalpha), only antiserum directed against G(ialpha3) immunoprecipitated SSTR2-G protein complexes, indicating that in these cells SSTR2 primarily associates with G(ialpha3). SRIF can not inhibit forskolin-stimulated cAMP formation in wild-type HEK 293 cells nor in HEK 293 cells transfected with SSTR2. In contrast, SRIF can inhibit cAMP formation in HEK 293 cells expressing the cloned SRIF receptor SSTR3, which requires the presence of G(ialpha1) to functionally couple to adenylyl cyclase. The lack of efficient association of SSTR2 with G(ialpha1) may be the cause of its inability to mediate inhibition of cAMP formation. Differences in the G protein-coupling domains of the cloned SRIF receptors may be responsible for their differences in G protein association and ability to effect various signaling pathways.	UNIV PENN,SCH MED,DEPT PHARMACOL,36TH ST & HAMILTON WALK,PHILADELPHIA,PA 19104; UNIV PENN,GRAD GRP CELL BIOL,PHILADELPHIA,PA 19104; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	University of Pennsylvania; University of Pennsylvania; University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago					NIDDK NIH HHS [DK20595] Funding Source: Medline; NIMH NIH HHS [MH45533, MH48518] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595, P30DK020595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048518] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; EPELBAUM J, 1986, PROG NEUROBIOL, V27, P63, DOI 10.1016/0301-0082(86)90012-2; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLUXEN FW, 1992, P NATL ACAD SCI USA, V89, P4618, DOI 10.1073/pnas.89.10.4618; LAW S, 1991, J BIOL CHEM, V268, P17885; LAW SF, 1992, MOL PHARMACOL, V42, P398; MAHY N, 1988, J PHARMACOL EXP THER, V247, P390; OKUMA Y, 1992, J BIOL CHEM, V267, P14826; Patel Y. C., 1992, Society for Neuroscience Abstracts, V18, P448; RAYNOR K, 1989, J PHARMACOL EXP THER, V251, P510; RAYNOR K, 1991, MOL PHARMACOL, V40, P248; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; TALLENT M, 1992, MOL PHARMACOL, V41, P452; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; WANG HL, 1989, P NATL ACAD SCI USA, V86, P9616, DOI 10.1073/pnas.86.23.9616; WANG HL, 1990, NEUROSCIENCE, V38, P335, DOI 10.1016/0306-4522(90)90032-Y; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YASUDA K, 1992, J BIOL CHEM, V267, P20422; YATANI A, 1987, MOL ENDOCRINOL, V1, P283, DOI 10.1210/mend-1-4-283	22	149	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10721	10727						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8098703				2022-12-27	WOS:A1993LD46600006
J	DOLLA, A; FLORENS, L; BIANCO, P; HALADJIAN, J; VOORDOUW, G; FOREST, E; WALL, J; GUERLESQUIN, F; BRUSCHI, M				DOLLA, A; FLORENS, L; BIANCO, P; HALADJIAN, J; VOORDOUW, G; FOREST, E; WALL, J; GUERLESQUIN, F; BRUSCHI, M			CHARACTERIZATION AND OXIDOREDUCTION PROPERTIES OF CYTOCHROME-C(3) AFTER HEME AXIAL LIGAND REPLACEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-VULGARIS HILDENBOROUGH; DESULFURICANS NORWAY STRAIN; ELECTRON-TRANSFER MECHANISMS; REDOX POTENTIALS; 4 HEMES; GENE; CLONING; HYDROGENASE; REDUCTION; PROTEINS	Cytochrome c(3) (M(r) 13,000) is a tetrahemic cytochrome in which the four heme iron atoms are coordinated by 2 histidine residues at the axial positions. The presence of several oxidoreduction centers in the same molecule raises the question of their coupling. To investigate this mechanism, four single mutations were introduced in cytochrome c(3) by site-directed mutagenesis, leading to the replacement of each histidine, the sixth axial ligand of the heme iron atom, by a methionine residue. Characterization of the new set of molecules using biochemical and biophysical techniques was carried out. The novel methionine was correctly coordinated to the iron atom of hemes 3 and 4 in H25M and H70M cytochromes c(3), respectively, and this coordination induced a large increase in the oxidoreduction potential of the mutated heme. In contrast, in the case of H22M and H35M cytochromes c(3), in which the corresponding methionine is in an oxidized form, only slight changes in redox potential values were observed. In H22M, H25M, and H35M cytochromes c(3), two conformations of the molecule were possible, in which the methionine is either free or coordinated to the iron atom. The rate constants for the electron exchange reactions between the cytochrome mutants and the hydrogenase were measured using electrochemical techniques. Distinct behaviors were revealed depending on the mutation. The values of the rate constants for the electron exchange reactions are interpreted in terms of intramolecular electron exchange among the four hemes of the cytochrome.	UNIV PROVENCE,CHIM & ELECTROCHIM COMPLEXES LAB,F-13331 MARSEILLE 3,FRANCE; UNIV PROVENCE,CHIM BACTERIENNE LAB,F-13331 MARSEILLE 3,FRANCE; UNIV CALGARY,DEPT BIOL SCI,CALGARY T2N 1N4,AB,CANADA; CEA,CNRS,INST BIOL STRUCT,SPECTROMETRIE MASSE PROT LAB,F-38027 GRENOBLE 1,FRANCE; UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65211	UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; University of Calgary; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); University of Missouri System; University of Missouri Columbia	DOLLA, A (corresponding author), CNRS,CHIM BACTERIENNE LAB,BP 71,F-13277 MARSEILLE 9,FRANCE.		Voordouw, Gerrit/F-5327-2013; Forest, Eric/E-9042-2012	Florens, Laurence/0000-0002-9310-6650				AKUTSU H, 1992, BIOCHIM BIOPHYS ACTA, V1140, P144, DOI 10.1016/0005-2728(92)90003-K; AMBLER RP, 1991, BIOCHIM BIOPHYS ACTA, V1058, P42, DOI 10.1016/S0005-2728(05)80266-X; BENOSMAN H, 1989, EUR J BIOCHEM, V182, P51, DOI 10.1111/j.1432-1033.1989.tb14799.x; BIANCO P, 1992, BIOCHEM BIOPH RES CO, V189, P633, DOI 10.1016/0006-291X(92)92247-U; BRUMLIK MJ, 1989, J BACTERIOL, V171, P4996, DOI 10.1128/jb.171.9.4996-5004.1989; BRUSCHI M, 1984, BIOCHEM BIOPH RES CO, V120, P384, DOI 10.1016/0006-291X(84)91265-8; BRUSCHI M, 1981, BIOCHIM BIOPHYS ACTA, V671, P219, DOI 10.1016/0005-2795(81)90137-9; CAPEILLEREBLANDIN C, 1986, BIOCHIM BIOPHYS ACTA, V848, P279, DOI 10.1016/0005-2728(86)90202-1; CATARINO T, 1991, EUR J BIOCHEM, V202, P1107, DOI 10.1111/j.1432-1033.1991.tb16477.x; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; Dickerson R., 1975, ENZYMES, V11, P397; DOLLA A, 1989, BIOCHIM BIOPHYS ACTA, V975, P395, DOI 10.1016/S0005-2728(89)80348-2; Dolla A, 1991, J Mol Recognit, V4, P27, DOI 10.1002/jmr.300040105; FAN K, 1990, BIOCHEMISTRY-US, V29, P2257, DOI 10.1021/bi00461a008; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; GAYDA JP, 1988, EUR J BIOCHEM, V177, P199, DOI 10.1111/j.1432-1033.1988.tb14362.x; GUERLESQUIN F, 1985, BIOCHIM BIOPHYS ACTA, V830, P296, DOI 10.1016/0167-4838(85)90286-9; GUIGLIARELLI B, 1990, J MOL BIOL, V216, P161, DOI 10.1016/S0022-2836(05)80067-1; HIGUCHI Y, 1984, J MOL BIOL, V172, P109, DOI 10.1016/0022-2836(84)90417-0; JUNGST A, 1991, FEBS LETT, V279, P205, DOI 10.1016/0014-5793(91)80150-2; KAY CJ, 1992, BIOCHEMISTRY-US, V31, P11376, DOI 10.1021/bi00161a015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MOORE GR, 1977, FEBS LETT, V79, P229, DOI 10.1016/0014-5793(77)80793-X; MOORE GR, 1987, CYTOCHROMES BIOL ASP; MOORE GR, 1987, CYTOCHROMES EVOLUTIO; MORIMOTO Y, 1991, J BIOCHEM-TOKYO, V110, P532, DOI 10.1093/oxfordjournals.jbchem.a123615; MOURA JJG, 1982, EUR J BIOCHEM, V127, P151, DOI 10.1111/j.1432-1033.1982.tb06849.x; MUKAI K, 1989, J BIOCHEM-TOKYO, V106, P479, DOI 10.1093/oxfordjournals.jbchem.a122877; MUSVETEAU I, 1992, J BIOL CHEM, V267, P16851; NAKAHARA Y, 1980, CHEM PHYS LETT, V73, P31, DOI 10.1016/0009-2614(80)85195-5; NICHOLSON RS, 1964, ANAL CHEM, V36, P706, DOI 10.1021/ac60210a007; PIERROT M, 1982, J BIOL CHEM, V257, P4341; POLLOCK WBR, 1991, J BACTERIOL, V173, P220, DOI 10.1128/jb.173.1.220-228.1991; Postgate JR, 1984, SULPHATE REDUCING BA, V2nd; PRICKRIL BC, 1991, BIOCHEMISTRY-US, V30, P11118, DOI 10.1021/bi00110a014; RAPHAEL AL, 1991, J AM CHEM SOC, V113, P1038, DOI 10.1021/ja00003a045; SALGUEIRO CA, 1992, FEBS LETT, V314, P155, DOI 10.1016/0014-5793(92)80963-H; SANTOS H, 1984, EUR J BIOCHEM, V141, P283, DOI 10.1111/j.1432-1033.1984.tb08190.x; VANDERWESTEN HM, 1978, FEBS LETT, V86, P122, DOI 10.1016/0014-5793(78)80112-4; VANROOIJEN GJH, 1989, J BACTERIOL, V171, P3575, DOI 10.1128/jb.171.6.3575-3578.1989; VERMA AL, 1988, J AM CHEM SOC, V110, P6617, DOI 10.1021/ja00228a004; VOORDOUW G, 1985, EUR J BIOCHEM, V148, P509, DOI 10.1111/j.1432-1033.1985.tb08868.x; VOORDOUW G, 1990, J BACTERIOL, V172, P6122, DOI 10.1128/jb.172.10.6122-6126.1990; VOORDOUW G, 1986, EUR J BIOCHEM, V159, P347, DOI 10.1111/j.1432-1033.1986.tb09874.x	46	54	54	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6340	6346						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119983				2022-12-27	WOS:A1994MZ50300016
J	CHAPMAN, ER; JAHN, R				CHAPMAN, ER; JAHN, R			CALCIUM-DEPENDENT INTERACTION OF THE CYTOPLASMIC REGION OF SYNAPTOTAGMIN WITH MEMBRANES - AUTONOMOUS FUNCTION OF A SINGLE C-2-HOMOLOGOUS DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; SYNAPTIC VESICLES; ACTIVE ZONES; BOVINE; P65; BINDING; RELEASE; CELLS; GAP; P38	The synaptic vesicle protein synaptotagmin has been implicated in the docking and subsequent calcium-regulated exocytosis of synaptic vesicles. We demonstrate that synaptotagmin is a major constituent of synaptic vesicle membranes, comprising 7-8% of the total vesicle protein. A proteolytic fragment of synaptotagmin, containing two repeats homologous to the C-2-domain of protein kinase C, bound to a variety of natural membranes in a calcium-dependent manner (EC(50) similar to 30 mu M calcium). Binding was insensitive to proteolysis of the acceptor membranes suggesting an interaction with the lipid constituents. This interaction was confirmed using a recom- binant fusion protein, containing both C-2-like domains of synaptotagmin, that bound to artificial liposomes in a calcium-dependent manner. Phospholipid binding properties were preserved in a 114-amino acid domain corresponding to the first C-2-like repeat of the protein and represents the shortest functional cassette yet reported. Furthermore, deletion of a highly conserved 9-amino acid moth, within this region, was sufficient to abolish the calcium-dependent phospholipid binding properties of this domain. This mutation may provide a means to selectively disrupt individual C-2-domains in order to assess their relative contributions to function.	YALE UNIV, SCH MED, BOYER CTR MOLEC MED, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA	Yale University	CHAPMAN, ER (corresponding author), YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA.			Chapman, Edwin/0000-0001-9787-8140; Jahn, Reinhard/0000-0003-1542-3498				BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FOHR KJ, 1994, IN PRESS METHODS ENZ; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GOELZ SE, 1981, P NATL ACAD SCI-BIOL, V78, P2130, DOI 10.1073/pnas.78.4.2130; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JAHN R, 1987, ANN NY ACAD SCI, V493, P497, DOI 10.1111/j.1749-6632.1987.tb27235.x; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MOEHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TUGAL HB, 1991, BIOCHEM J, V279, P699, DOI 10.1042/bj2790699; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALCHSOOLIMENA C, 1993, IN PRESS NEUROSCIENC; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V	33	194	196	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5735	5741						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119912				2022-12-27	WOS:A1994MY84000042
J	SHIRABE, K; FUJIMOTO, Y; YUBISUI, T; TAKESHITA, M				SHIRABE, K; FUJIMOTO, Y; YUBISUI, T; TAKESHITA, M			AN IN-FRAME DELETION OF CODON-298 OF THE NADH-CYTOCHROME B(5) REDUCTASE GENE RESULTS IN HEREDITARY METHEMOGLOBINEMIA TYPE-II (GENERALIZED TYPE) - A FUNCTIONAL IMPLICATION FOR THE ROLE OF THE COOH-TERMINAL REGION OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NADH-CYTOCHROME-B5 REDUCTASE; SITE-DIRECTED MUTAGENESIS; RAT-LIVER MICROSOMES; AMINO-ACID SEQUENCE; MENTAL-RETARDATION; NITRATE REDUCTASE; MESSENGER-RNA; BINDING SITE; B5; IDENTIFICATION	The nucleotide sequence was determined for the gene of NADH-cytochrome b(5) reductase of a patient of type II hereditary methemoglobinemia found in Yokohama, Japan. An in-frame deletion of 3 base pairs corresponding to codon 298 (TTC) was identified in the patient. The patient was homozygous for the mutation as shown by hybridization experiments using allele-specific oligonucleotides. The mutation causes deletion of Phe-298, which is the third to the COOH-terminal residue, indicating that in this mutant enzyme the sequence of this region has changed from -Cys-Phe-Val-Phe-COOH to -Cys-Val-Phe-COOH. The mutant enzyme, whose Phe-298 was deleted (F298 Delta), was prepared by means of a bacterial expression system and site-directed mutagenesis. The k(cat)/K-m value (NADH) of the enzyme was 5.7 s(-1) M(-1), which corresponds to 0.4% of that of the wild type. Moreover, the enzyme was much less thermostable than the wild type. To examine further the role of the COOH-terminal portion of the enzyme, various mutant enzymes were also prepared and characterized. The enzymatic properties of F298L, F300L, and F298L/F300L were essentially the same as that of the wild type. The kinetic properties of F298A, and F300A were not greatly affected, but the stability of the enzymes was somewhat impaired. Since Val-299 is naturally Ala in steer enzyme, no specific residues in the carboxyl-terminal region (298-300) are essential to the enzyme function. The instability of the F298A/F300A double mutant indicates that the hydrophobicity of the carboxyl-terminal region of the enzyme might be important to maintain the conformation of the enzyme. High impairment of the activity of the F298 Delta, F298stop, and F300stop mutants might be caused by the loss of the residue(s) in the carboxyl-terminal portion, These results indicate that the hydrophobicity, but not the specific amino acid residues, of the carboxyl-terminal portion of the enzyme is important for the stability of the enzyme.			SHIRABE, K (corresponding author), OITA MED UNIV, DEPT BIOCHEM, HASAMA, OITA 87955, JAPAN.							ADAMS JG, 1981, P NATL ACAD SCI-BIOL, V78, P469, DOI 10.1073/pnas.78.1.469; AOYAMA T, 1990, P NATL ACAD SCI USA, V87, P5425, DOI 10.1073/pnas.87.14.5425; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CAILLAUD C, 1991, J BIOL CHEM, V266, P9351; CASEY R, 1976, BRIT J HAEMATOL, V33, P143; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; CURIEL DT, 1989, J BIOL CHEM, V264, P13938; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; HIDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66; HYDE GE, 1991, J BIOL CHEM, V266, P23542; IYANAGI T, 1977, BIOCHEMISTRY-US, V16, P2725, DOI 10.1021/bi00631a021; JAFFE ER, 1989, METABOLIC BASIS INHE, P2267; JONES RT, 1966, SCIENCE, V154, P1024, DOI 10.1126/science.154.3752.1024; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KEYES SR, 1980, J BIOL CHEM, V255, P1357; KOBAYASHI Y, 1990, BLOOD, V75, P1408; LEROUX A, 1975, NATURE, V258, P619, DOI 10.1038/258619a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTCHER CL, 1976, BLOOD, V47, P99; MAEDAYORITA K, 1991, BIOCHEMISTRY-US, V30, P11788, DOI 10.1021/bi00115a008; MOOPENN WF, 1975, BIOCHEM BIOPH RES CO, V65, P8, DOI 10.1016/S0006-291X(75)80054-4; NAGAI T, 1993, BLOOD, V81, P808; OSHINO N, 1971, J BIOCHEM, V69, P155, DOI 10.1093/oxfordjournals.jbchem.a129444; OZOLS J, 1985, J BIOL CHEM, V260, P1953; PARAD RB, 1990, P NATL ACAD SCI USA, V87, P6786, DOI 10.1073/pnas.87.17.6786; PIETRINI G, 1992, J CELL BIOL, V117, P975, DOI 10.1083/jcb.117.5.975; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; REDDY VVR, 1977, J BIOL CHEM, V252, P2797; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOENMAKERS JGG, 1968, NATURE, V220, P788; SCOTT EM, 1959, BIOCHIM BIOPHYS ACTA, V34, P584, DOI 10.1016/0006-3002(59)90324-5; SHIRABE K, 1989, BIOCHIM BIOPHYS ACTA, V1008, P189, DOI 10.1016/0167-4781(80)90007-X; SHIRABE K, 1992, J BIOL CHEM, V267, P20416; SHIRABE K, 1991, J BIOL CHEM, V266, P7531; STRITTMATTER P, 1965, J BIOL CHEM, V240, P4481; STRITTMATTER P, 1957, J BIOL CHEM, V228, P785; SUTTER TR, 1990, J BIOL CHEM, V265, P16428; TAKANO T, 1994, IN PRESS FLAVINS FLA; TAKESHITA M, 1982, J MED GENET, V19, P204, DOI 10.1136/jmg.19.3.204; TANISHIMA K, 1985, BLOOD, V66, P1288; TISCHLER ME, 1977, FEBS LETT, V76, P99, DOI 10.1016/0014-5793(77)80129-4; TOMATSU S, 1989, GENE, V80, P353; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; WAJCMAN H, 1973, BIOCHIM BIOPHYS ACTA, V295, P495, DOI 10.1016/0005-2795(73)90045-7; WILLIAMS GT, 1985, EXP CELL RES, V160, P419, DOI 10.1016/0014-4827(85)90189-2; YUBISUI T, 1987, P NATL ACAD SCI USA, V84, P3609, DOI 10.1073/pnas.84.11.3609; YUBISUI T, 1986, J BIOCHEM-TOKYO, V99, P407, DOI 10.1093/oxfordjournals.jbchem.a135495; YUBISUI T, 1991, J BIOL CHEM, V266, P66	52	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5952	5957						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119939				2022-12-27	WOS:A1994MY84000073
J	KLEMAN, MI; POELLINGER, L; GUSTAFSSON, JA				KLEMAN, MI; POELLINGER, L; GUSTAFSSON, JA			REGULATION OF HUMAN DIOXIN RECEPTOR FUNCTION BY INDOLOCARBAZOLES, RECEPTOR LIGANDS OF DIETARY ORIGIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON HYDROXYLASE; DNA-BINDING ACTIVITY; HEAT-SHOCK PROTEIN; AH-RECEPTOR; AROMATIC-HYDROCARBONS; NUCLEAR RECEPTORS; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; INDOLE-3-CARBINOL; INDUCTION; ELEMENTS	The intracellular basic helix-loop helix (bHLH) dioxin receptor mediates signal transduction by dioxin (2,3,7,8--tetrachlorodibenzo-p- dioxin). In analogy to nuclear receptors that are members of the steroid hormone receptor superfamily the dioxin receptor is a ligand-inducible transcriptional regulator that directly binds to response elements within regulated genes. The most commonly studied dioxin receptor ligands are dioxin itself and structurally related environmental contaminants. A physiological ligand has not yet been identified. Interestingly, however, indolo[3,2-b]carbazole, a compound formed from precursors in the diet, has been shown to bind the murine dioxin receptor with high affinity in vitro. In the present study we show that this compound and its methylated derivative 5,11-dimethylindolo[3,2-b]carbazole very potently activated transcription from a dioxin or xenobiotic response element (XRE)-driven reporter gene in both murine and human hepatoma cells. This effect was not observed in mutant, dioxin-resistant hepatoma cells which are either deficient in expression of dioxin receptor or the bHLH receptor partner factor Arnt. In vitro indolocarbazoles induced XRE binding activity by the human dioxin receptor-Arnt complex in a dose-dependent manner. Thus, both dioxin- and indolocarbazole-activated forms of dioxin receptor regulate target gene expression by the same mechanism involving recruitment of the bHLH factor Arnt and recognition of the XRE element. Finally, the indole [3,2-b]carbazole-activated human dioxin receptor appeared to generate more stable complexes with the XRE target sequence relative to those produced by the dioxin activated receptor form, indicating interesting mechanistic differences between different classes of dioxin receptor ligands in their abilities to modulate human dioxin receptor function.	KAROLINSKA INST, HUDDINGE UNIV HOSP F60, NOVUM, CTR NUTR & TOXICOL, S-14186 HUDDINGE, SWEDEN	Karolinska Institutet	KLEMAN, MI (corresponding author), KAROLINSKA INST, HUDDINGE UNIV HOSP F60, NOVUM, DEPT MED NUTR, S-14186 HUDDINGE, SWEDEN.							BAILAR JC, 1991, NEW ENGL J MED, V324, P261; BERGHARD A, 1992, CARCINOGENESIS, V13, P651, DOI 10.1093/carcin/13.4.651; BERGMAN J, 1984, TETRAHEDRON LETT, V25, P1957, DOI 10.1016/S0040-4039(01)90086-3; BERGMAN J, 1970, TETRAHEDRON, V26, P3353, DOI 10.1016/S0040-4020(01)92913-8; BJELDANES LF, 1991, P NATL ACAD SCI USA, V88, P9543, DOI 10.1073/pnas.88.21.9543; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CONNEY AH, 1982, CANCER RES, V42, P4875; CUTHILLS, 1991, MOL CELL BIOL, V11, P412; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GILLNER M, 1985, MOL PHARMACOL, V28, P357; GILLNER M, 1993, MOL PHARMACOL, V44, P336; GRADIN K, 1993, J BIOL CHEM, V268, P4061; GROSE KR, 1992, CHEM RES TOXICOL, V5, P188, DOI 10.1021/tx00026a007; HANKINSON O, 1983, SOMAT CELL GENET, V9, P497, DOI 10.1007/BF01543050; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HARPER PA, 1992, MOL PHARMACOL, V42, P603; HARPER PA, 1991, ARCH BIOCHEM BIOPHYS, V290, P27, DOI 10.1016/0003-9861(91)90587-9; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUNIG S, 1976, LIEBIGS ANN CHEM, P1090; JELLINCK PH, 1993, BIOCHEM PHARMACOL, V45, P1129, DOI 10.1016/0006-2952(93)90258-X; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KLEMAN MI, 1992, CARCINOGENESIS, V13, P1619, DOI 10.1093/carcin/13.9.1619; LABRUZZO P, 1989, BIOCHEM PHARMACOL, V38, P2339, DOI 10.1016/0006-2952(89)90474-7; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; MANCHESTER DK, 1987, CANCER RES, V47, P4861; MASON GGF, 1994, IN PRESS J BIOL CHEM, V269; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1991, NUTR CANCER, V16, P209, DOI 10.1080/01635589109514159; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; ROBERTS EA, 1990, ARCH BIOCHEM BIOPHYS, V276, P442, DOI 10.1016/0003-9861(90)90743-I; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x	39	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5137	5144						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106494				2022-12-27	WOS:A1994MX57100070
J	VANGINKEL, PR; HAUSWIRTH, WW				VANGINKEL, PR; HAUSWIRTH, WW			PARALLEL REGULATION OF FETAL GENE-EXPRESSION IN DIFFERENT PHOTORECEPTOR CELL-TYPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VISUAL PIGMENT GENES; OPSIN EXPRESSION; BOVINE RHODOPSIN; MOUSE RETINAS; COLOR-VISION; CYCLIC-GMP; RAT RETINA; GREEN; RED; SEQUENCE	Transcriptional induction for multiple bovine rod-specific photoreceptor genes has been shown to coincide with the first emergence of rod outer segments (two-thirds gestation) suggesting a coordinate regulation of these genes. Since cone visual transduction proteins are encoded for by distinct genes and mammalian cone cell genesis has been found to precede rod cell genesis it is important to determine when induction of photoreceptor-specific gene expression occurs in cone cells and how the timing of this event compares to that in rods. RNase protection assays specific for each cell type-specific gene were used to compare mRNA levels for bovine rod and blue cone gamma subunits of cGMP phosphodiesterase and rhodopsin and red cone opsin from before transcriptional induction (4 months gestation) to the adult. Both pairs of rod and cone visual transduction mRNAs exhibit indistinguishable transcriptional induction points at around 6 months of gestation. Before this time, transcripts of all four genes are present at low, but detectable levels. Thus, although rod and cone cells are distinct cell types and cone cells may be committed well before rod cells early in development, during the final trimester when elaboration of outer segments begins, there appears to be a coordinated regulation of both rod- and cone-specific visual transduction genes.	UNIV FLORIDA,DEPT IMMUNOL & MED MICROBIOL,GAINESVILLE,FL 32610; UNIV FLORIDA,DEPT OPHTHALMOL,GAINESVILLE,FL 32610	State University System of Florida; University of Florida; State University System of Florida; University of Florida					NEI NIH HHS [EY07132, EY07864] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007864] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BISTNER SI, 1973, AM J VET RES, V34, P1; BOWES C, 1988, EXP EYE RES, V47, P369, DOI 10.1016/0014-4835(88)90049-8; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P908; COLLINS C, 1992, GENOMICS, V13, P698, DOI 10.1016/0888-7543(92)90144-H; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; DELEEUW WJF, 1989, NUCLEIC ACIDS RES, V17, P10137, DOI 10.1093/nar/17.23.10137; DESJARDIN LE, 1993, J BIOL CHEM, V268, P6953; FALK JD, 1986, PROG RETIN RES, V7, P89; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HAMILTON SE, 1990, J BIOL CHEM, V265, P11259; HANSWIRTH WW, 1992, EXP EYE RES, V54, P661; HAO Y, 1992, INVEST OPHTHALMOL  S, V38, P1004; HARGRAVE PA, 1992, INT REV CYTOL, V137B, P49; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; KNIGHT JK, 1990, DEVELOPMENT, V110, P1115; LAVAIL MM, 1991, J COMP NEUROL, V309, P86, DOI 10.1002/cne.903090107; LEM J, 1991, NEURON, V6, P201, DOI 10.1016/0896-6273(91)90356-5; LOLLEY RN, 1990, FASEB J, V4, P3001, DOI 10.1096/fasebj.4.12.1697545; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; OZANICS V, 1982, OCULAR ANATOMY EMBRY, P54; ROBERTS SJ, 1971, VET OBSTETRICS GENIT, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRYER L, 1991, J BIOL CHEM, V266, P10711; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TIMMERS AM, 1993, EXP EYE RES, V56, P257, DOI 10.1006/exer.1993.1034; TOKUNAGA F, 1990, BIOCHEM BIOPH RES CO, V173, P1212, DOI 10.1016/S0006-291X(05)80915-5; TREISMAN JE, 1988, MOL CELL BIOL, V8, P1570, DOI 10.1128/MCB.8.4.1570; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WATANABE T, 1990, NEURON, V4, P461, DOI 10.1016/0896-6273(90)90058-N; WIKLER KC, 1991, NATURE, V351, P397, DOI 10.1038/351397a0; YOKOYAMA R, 1990, P NATL ACAD SCI USA, V87, P9315, DOI 10.1073/pnas.87.23.9315; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4	37	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4986	4992						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106474				2022-12-27	WOS:A1994MX57100047
J	JOHNSON, AW; KOLODNER, RD				JOHNSON, AW; KOLODNER, RD			THE ACTIVITY OF THE SACCHAROMYCES-CEREVISIAE STRAND EXCHANGE PROTEIN-1 INTRINSIC EXONUCLEASE DURING JOINT MOLECULE FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RECA PROTEIN; ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; DUPLEX DNA; GENETIC-RECOMBINATION; BETA-PROTEIN; BREAKS; MODEL; PURIFICATION; RENATURATION	Strand exchange protein 1 (Sep1) from Saccharomyces cerevisiae catalyzes the formation of heteroduplex DNA from single-stranded and homologous linear duplex DNA. The initial pairing reaction requires limited exonucleolytic digestion of the double-stranded DNA (dsDNA) by the intrinsic 5' to 3' exonuclease of Sep1 or by an exogenous exonuclease. Subsequent strand exchange proceeds without the need for exonuclease activity. Sep1 degrades linear dsDNA at a rate of 20 nucleotides/min with an average processivity of 45 nucleotides. During strand exchange reactions joint molecules are first observed after 1-2 min, suggesting that only limited digestion is necessary for pairing. The linear dsDNA was found to pair with single-stranded DNA (ssDNA) when it was resected by only 22 nucleotides, and linear dsDNA digested by more than 22 nucleotides was observed only in joint molecules. Approximately 20 nucleotides were also the minimum extent of digestion that could support pairing. In the absence of exonuclease activity, Sep1-promoted pairing requires dsDNA molecules with single-stranded tails homologous to the circular ssDNA. These results suggest that Sep1-promoted strand exchange requires a single-strand annealing event prior to the strand displacement phase of the reaction.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,44 BINNEY ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Johnson, Arlen/0000-0002-4742-085X	NIGMS NIH HHS [GM13594, GM29383] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013594, R01GM029383] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1992, GENE DEV, V6, P1679, DOI 10.1101/gad.6.9.1679; Anfinsen C.B., 1971, ENZYMES, V4; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CLARK AJ, 1973, ANNU REV GENET, V7, P67, DOI 10.1146/annurev.ge.07.120173.000435; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; DYKSTRA CC, 1990, J BIOL CHEM, V265, P10968; FISHEL R, 1991, BIOCHIMIE, V73, P257, DOI 10.1016/0300-9084(91)90211-I; FISHMAN LJ, 1992, SCIENCE, V258, P480; HALBROOK J, 1989, J BIOL CHEM, V264, P21403; HALL SD, 1993, J BACTERIOL, V175, P277, DOI 10.1128/JB.175.1.277-287.1993; HALL SD, 1993, IN PRESS P NATL ACAD; HEYER WD, 1988, J BIOL CHEM, V263, P15189; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; JOHNSON AW, 1994, J BIOL CHEM, V269, P3673; JOSEPH JW, 1983, J BIOL CHEM, V258, P418; KHORANA HG, 1961, ENZYMES, V5, P71; KMIEC E, 1981, J BIOL CHEM, V256, P2636; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; KOWALCZYKOWSKI SC, 1987, TRENDS BIOCHEM SCI, V12, P141, DOI 10.1016/0968-0004(87)90070-3; KOWALCZYKOWSKI SC, 1987, P NATL ACAD SCI USA, V84, P3127, DOI 10.1073/pnas.84.10.3127; LITTLE JW, 1967, J BIOL CHEM, V242, P679; Maniatis T., 1982, MOL CLONING; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; MUNIYAPPA K, 1986, J BIOL CHEM, V261, P7472; NAG DK, 1993, MOL CELL BIOL, V13, P2324, DOI 10.1128/MCB.13.4.2324; NORRIS D, 1990, BIOCHEMISTRY-US, V29, P7911, DOI 10.1021/bi00486a019; PUGH BF, 1987, J BIOL CHEM, V262, P1337; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RESNICK MA, 1976, J THEOR BIOL, V59, P97, DOI 10.1016/S0022-5193(76)80025-2; RICHARDSON CC, 1966, J MOL BIOL, V15, P49, DOI 10.1016/S0022-2836(66)80208-5; ROSE D, 1993, MOL CELL BIOL, V13, P3445, DOI 10.1128/MCB.13.6.3445; SANDER M, 1991, P NATL ACAD SCI USA, V88, P6780, DOI 10.1073/pnas.88.15.6780; SANDER M, 1993, J BIOL CHEM, V268, P2075; SHANER SL, 1987, J BIOL CHEM, V262, P9211; SHUSTER EO, 1989, GENETICS, V123, P29; SMITH GR, 1988, MICROBIOL REV, V52, P1; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; WEST SC, 1988, TRENDS GENET, V4, P8, DOI 10.1016/0168-9525(88)90121-7; WEST SC, 1980, P NATL ACAD SCI-BIOL, V77, P2569, DOI 10.1073/pnas.77.5.2569; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x	46	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3664	3672						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106411				2022-12-27	WOS:A1994MV63100079
J	MILLERMARTINI, DM; CHIRGWIN, JM; HOROWITZ, PM				MILLERMARTINI, DM; CHIRGWIN, JM; HOROWITZ, PM			MUTATIONS OF NONCATALYTIC SULFHYDRYL-GROUPS INFLUENCE THE STABILITY, FOLDING, AND OXIDATIVE SUSCEPTIBILITY OF RHODANESE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE LIVER RHODANESE; ENDOPLASMIC-RETICULUM; SPINACH FERREDOXIN; DISULFIDE BONDS; GROWTH-FACTOR; PROTEIN; THIOSULFATE; DNA; INACTIVATION; MUTAGENESIS	Mutants of rhodanese (EC 2.8.1.1) which substitute serine residues for each of the 4 cysteine residues have been studied to determine the roles of cysteines in the structure and function of the enzyme. The proteins compared in these studies were: the wild-type, C63S, C247S, C254S, C263S, C254S/C263S, and C63S/C254S/C263S. These current studies show that cysteine 247 is the only cysteine required for the activity of the enzyme. Although the other sulfhydryl groups do not participate in sulfur transfer, mutations of the noncatalytic cysteines result in the destabilization of the native structure of the enzyme. All the active proteins had similar kinetic parameters. Mutants substituting cysteine 254, compared with the other species, were: (a) more resistant than wild-type to inactivation by dithiothreitol, (b) more readily reactivated following oxidative inactivation, and (c) found to adopt conformations that show increased exposure of hydrophobic surfaces following removal of the transferable sulfur. On the other hand, cysteine to serine substitutions had very little effect on: (a) the rates of oxidative inactivation, (b) the increased fluorescence following the removal of transferable sulfur, or (c) the effectiveness of spontaneous refolding after urea denaturation. Forms of rhodanese that were formerly considered to be irreversibly oxidized can be reactivated if the protein is denatured in urea before reductants are used. It is proposed that these forms differ from reversibly oxidized states due to the inaccessibility of intramolecular disulfides to reductants and not to the formation of higher oxidation states of the protein.	UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio	MILLERMARTINI, DM (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284, USA.				NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRO AF, 1972, EUR J BIOCHEM, V28, P83; Atkinson T., 1984, OLIGONUCLEOTIDE SYNT, P35; BLUMENTHAL KM, 1971, J BIOL CHEM, V246, P2430; BONOMI F, 1977, FEBS LETT, V84, P149, DOI 10.1016/0014-5793(77)81076-4; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANNELLA C, 1972, ITAL J BIOCHEM, V21, P1; CANNELLA C, 1974, FEBS LETT, V49, P22, DOI 10.1016/0014-5793(74)80622-8; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; FINAZZIAGRO A, 1971, FEBS LETT, V16, P172; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUIDO K, 1975, BIOCHEM BIOPH RES CO, V67, P670, DOI 10.1016/0006-291X(75)90864-5; HANAHAN D, 1983, METHOD ENZYMOL, V100, P333; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HEINRIKSON RL, 1983, FRONTIERS BIOCH BIOP, P163; Hol W G, 1985, Adv Biophys, V19, P133, DOI 10.1016/0065-227X(85)90053-X; HOROWITZ PM, 1989, J BIOL CHEM, V264, P3311; HOROWITZ PM, 1987, J BIOL CHEM, V262, P8728; HOROWITZ PM, 1990, J BIOL CHEM, V265, P2576; HOROWITZ PM, 1992, BIOCATALYST DESIGN S, V516, P167; JAMBOU RC, 1988, P NATL ACAD SCI USA, V85, P9426, DOI 10.1073/pnas.85.24.9426; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lang K, 1933, BIOCHEM Z, V259, P243; MILLER DM, 1992, BIOCHIM BIOPHYS ACTA, V1121, P286, DOI 10.1016/0167-4838(92)90158-A; MILLER DM, 1991, J BIOL CHEM, V266, P4686; NISBET IT, 1985, GENE ANAL TECH, V2, P23, DOI 10.1016/0735-0651(85)90001-9; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OGATA K, 1989, J BIOL CHEM, V264, P2718; PAGANI S, 1982, BIOCHIM BIOPHYS ACTA, V700, P154, DOI 10.1016/0167-4838(82)90092-9; PAGANI S, 1986, BIOCHIM BIOPHYS ACTA, V870, P538, DOI 10.1016/0167-4838(86)90263-3; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; PLOEGMAN JH, 1973, THESIS U GRONINGEN; RINAS U, 1992, BIO-TECHNOL, V10, P435, DOI 10.1038/nbt0492-435; SACHDEV D, 1992, ADV EXP MED BIOL, V306, P335; SCHLESINGER P, 1974, J BIOL CHEM, V249, P780; SORBO BH, 1955, METHOD ENZYMOL, V2, P3534; SZCZEPKOWSKI TW, 1967, BIOCHIM BIOPHYS ACTA, V139, P469, DOI 10.1016/0005-2744(67)90050-2; TANDON S, 1989, J BIOL CHEM, V264, P9859; ULLRICH A, 1984, EMBO J, V3, P361, DOI 10.1002/j.1460-2075.1984.tb01812.x; WASYLEWSKI Z, 1982, BIOCHIM BIOPHYS ACTA, V701, P12, DOI 10.1016/0167-4838(82)90305-3; WEILAND KL, 1991, BIOCHEM J, V275, P227, DOI 10.1042/bj2750227; WENG L, 1978, J BIOL CHEM, V253, P8109; WESTLEY J, 1973, ADV ENZYMOL RAMB, V39, P327	44	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3423	3428						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106382				2022-12-27	WOS:A1994MV63100046
J	BURGERS, PMJ; YODER, BL				BURGERS, PMJ; YODER, BL			ATP-INDEPENDENT LOADING OF THE PROLIFERATING CELL NUCLEAR ANTIGEN REQUIRES DNA ENDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POLYMERASE-III HOLOENZYME; REPLICATION FACTOR-C; CEREVISIAE CDC2 GENE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; BETA-SUBUNIT; CALF THYMUS; DELTA; INTERACTS; MECHANISM	The proliferating cell nuclear antigen (PCNA) is a processivity subunit for eukaryotic DNA polymerase delta. We present biochemical evidence that yeast PCNA likely adopts a toroidal structure containing an inside cavity through which double-stranded DNA slides. A comparative study of DNA replication reactions on circular versus linear model substrates shows that PCNA can only interact productively with DNA polymerase delta if the substrate is linear. This combined with the observation that a large molar excess of PCNA is required for maximal stimulatory activity is consistent with a model in which PCNA slips onto the end of the DNA in an ATP-independent manner.			BURGERS, PMJ (corresponding author), WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.		Burgers, Peter M/AAW-6621-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32431, R01 GM032431] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; BUDD M, 1987, P NATL ACAD SCI USA, V84, P2838, DOI 10.1073/pnas.84.9.2838; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; ODAY CL, 1992, NUCLEIC ACIDS RES, V20, P5403, DOI 10.1093/nar/20.20.5403; ODONNELL ME, 1985, J BIOL CHEM, V260, P2875; Sambrook J, 1989, MOL CLONING LABORATO; SITNEY KC, 1989, CELL, V56, P599, DOI 10.1016/0092-8674(89)90582-5; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TAN CK, 1986, J BIOL CHEM, V261, P2310; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; YODER BL, 1991, J BIOL CHEM, V266, P22689	18	100	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					19923	19926						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8104181				2022-12-27	WOS:A1993LY01900003
J	KONDO, T; YOSHIDA, K; URATA, Y; GOTO, S; GASA, S; TANIGUCHI, N				KONDO, T; YOSHIDA, K; URATA, Y; GOTO, S; GASA, S; TANIGUCHI, N			GAMMA-GLUTAMYLCYSTEINE SYNTHETASE AND ACTIVE-TRANSPORT OF GLUTATHIONE S-CONJUGATE ARE RESPONSIVE TO HEAT-SHOCK IN K562 ERYTHROID-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBONIC ANHYDRASE-I; RAT; DISULFIDE; MEMBRANES; PROTEINS; TRANSFERASES; METABOLISM; INDUCTION; ATPASE; ASSAY	Effect of heat shock on a glutathione-synthesizing enzyme, gamma-glutamylcysteine synthetase (gamma-GCS), and ATP-dependent outward transport of glutathione S-conjugate was characterized using K562 erythroid cells. When K562 cells grown at 37-degrees-C were shifted to 42-degrees-C for 2 h, an approximate 1.7-fold increase in the activity of gamma-GCS was observed. Treatment of K562 cells with erythropoietin (EP) for 12 h resulted in a decrease in the activity of gamma-GCS to 64% of the control. However, responsiveness of this enzyme activity in the cells treated with EP to heat shock was similar to that in untreated cells. Changes in the immunological activity of gamma-GCS were also observed in parallel with those in the enzymatic activity. On Northern blot analysis of total RNAs isolated from the cells with human cDNA for gamma-GCS, a substantial induction of mRNA level was found by heat shock and a reduction by EP. These changes were modest but correlated to the mRNA expression of a heat shock protein, HSP 70. Heat shock also had an effect of 1.8-fold stimulation on glutathione S-conjugate transport in K562 cells previously incubated with 1-chloro-2,4-dinitrobenzene. Treatment of the cells with EP resulted in a decrease in this transport by 62%. Similarly, the levels of glutathione S-conjugate-stimulated Mg2+-ATPase, which enzyme is thought to be involved in the transport of glutathione S-conjugate, were responsive to heat shock and EP. These results suggest that glutathione synthesis and transport process of glutathione metabolites are responsive to heat shock and play a role in the defense system against stresses. It is also suggested that the regulatory site of the expression of these enzymes by heat shock is independent of that by EP.	HOKKAIDO UNIV,SCH MED,DEPT MED 1,SAPPORO,HOKKAIDO 060,JAPAN; SAPPORO MED COLL,DEPT CHEM,SAPPORO 064,JAPAN; OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN	Hokkaido University; Sapporo Medical University; Osaka University	KONDO, T (corresponding author), NAGASAKI UNIV,SCH MED,INST ATOM DIS,DEPT PATHOL BIOCHEM,NAGASAKI 852,JAPAN.		Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				AMEMIYA Y, 1988, NATURE, V336, P89, DOI 10.1038/336089a0; AWASTHI YC, 1983, BRIT J HAEMATOL, V55, P419, DOI 10.1111/j.1365-2141.1983.tb02156.x; BEUTLER E, 1986, CLIN CHIM ACTA, V158, P115, DOI 10.1016/0009-8981(86)90122-1; Beutler E, 1984, RED CELL METABOLISM, P122; Beutler E, 1984, RED CELL METABOLISM, P77; BOARD PG, 1981, FEBS LETT, V124, P163, DOI 10.1016/0014-5793(81)80127-5; CALTABIANO MM, 1986, J BIOL CHEM, V261, P3381; GOLDWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070; ISHIKAWA T, 1984, J BIOL CHEM, V259, P3838; KAPLOW LS, 1979, FLOW CYTOMETRY SORTI, P531; KOBAYASHI K, 1990, J BIOL CHEM, V265, P7737; KONDO T, 1989, BIOCHEM BIOPH RES CO, V162, P1, DOI 10.1016/0006-291X(89)91953-0; KONDO T, 1987, P NATL ACAD SCI USA, V84, P7373, DOI 10.1073/pnas.84.21.7373; KONDO T, 1982, EUR J BIOCHEM, V125, P551, DOI 10.1111/j.1432-1033.1982.tb06717.x; KONDO T, 1991, AM J HEMATOL, V38, P201, DOI 10.1002/ajh.2830380309; KONDO T, 1987, AM J HEMATOL, V26, P37, DOI 10.1002/ajh.2830260105; KRANZ SB, 1991, BLOOD, V177, P419; LABELLE EF, 1988, FEBS LETT, V228, P53, DOI 10.1016/0014-5793(88)80583-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU SC, 1991, J CLIN INVEST, V88, P260, DOI 10.1172/JCI115286; Mannervik B, 1981, Methods Enzymol, V77, P231; MEISTER A, 1985, METHOD ENZYMOL, V113, P571; MORIMOTO RI, 1990, STRESS PROTEINS BIOL, P212; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6; RIABOWOL KT, 1988, SCIENCE, V256, P500; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; SAMBROOK J, 1989, MOL CLONING LAB MANU, P7; SHARMA R, 1990, TOXICOL APPL PHARM, V104, P421, DOI 10.1016/0041-008X(90)90164-P; VETTORE L, 1980, AM J HEMATOL, V8, P291, DOI 10.1002/ajh.2830080307; VILLEVAL JL, 1985, BLOOD, V66, P1162; WAHLLANDER A, 1979, EUR J BIOCHEM, V98, P441; WANG C, 1981, P NATL ACAD SCI-BIOL, V78, P3531, DOI 10.1073/pnas.78.6.3531; YAN N, 1990, J BIOL CHEM, V265, P1588; ZHANG W, 1992, BIOCHEM BIOPH RES CO, V183, P733, DOI 10.1016/0006-291X(92)90544-U	36	87	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20366	20372						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8104187				2022-12-27	WOS:A1993LY01900067
J	USUI, T; TAKAGI, J; SAITO, Y				USUI, T; TAKAGI, J; SAITO, Y			PROPOLYPEPTIDE OF VONWILLEBRAND-FACTOR SERVES AS A SUBSTRATE FOR FACTOR-XIIIA AND IS CROSS-LINKED TO LAMININ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRIN-STABILIZING FACTOR; BASEMENT-MEMBRANE; ANTIGEN-II; ALPHA-2-PLASMIN INHIBITOR; TISSUE TRANSGLUTAMINASE; ENDOTHELIAL-CELLS; HUMAN-PLATELETS; LINKING; COLLAGEN; FIBRONECTIN	The propolypeptide of von Willebrand factor (pp-vWF) was found to serve as a substrate for Factor XIIIa (FXIIIa). FXIIIa catalyzed polymerization of pp-vWF as well as the incorporation of monodansyleadaverine and [C-14]putrescine into pp-vWF in a Ca2+- and time-dependent manner. The amount of putrescine incorporated into pp-vWF was increased as a function of putrescine concentration and reached a maximum of 3 mol/mol of pp-vWF, indicating that there are at least 3 glutamine residues in the pp-vWF molecule responsible for the reaction. I-125-pp-vWF was incubated with FXIIIa in the presence of various adhesive glycoproteins. Laminin, among the proteins tested, specifically formed a large molecular weight complex with I-125-pp-vWF in a Ca2+- and time-dependent manner. It was also found that FXIIIa catalyzed polymerization of laminin as well as the incorporation of monodansylcadaverine into laminin. The high molecular weight complexes of I-125-pp-vWF (or I-125-laminin) formed in the presence of laminin (or pp-vWF) were immunoprecipitated with anti-laminin (or anti-pp-vWF) antibodies. Taking all the data together it can be concluded that both pp-vWF and laminin have glutamine and lysine residues responsive to FXIIIa and make copolymers by virtue of FXIIIa.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT BIOLOG SCI,MEGURO KU,TOKYO 152,JAPAN	Tokyo Institute of Technology								AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; BOCKENSTEDT P, 1986, J CLIN INVEST, V78, P551, DOI 10.1172/JCI112608; BOHN H, 1978, MOL CELL BIOCHEM, V20, P67; BORTH W, 1991, J BIOL CHEM, V266, P18149; COHEN I, 1980, BIOCHIM BIOPHYS ACTA, V628, P365, DOI 10.1016/0304-4165(80)90386-4; COHEN I, 1979, ARCH BIOCHEM BIOPHYS, V192, P100, DOI 10.1016/0003-9861(79)90075-4; DOOLITTLE RF, 1971, BIOCHEM BIOPH RES CO, V44, P94, DOI 10.1016/S0006-291X(71)80163-8; FAY PJ, 1986, SCIENCE, V232, P995, DOI 10.1126/science.3486471; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FRANCIS RT, 1986, J BIOL CHEM, V261, P9787; FUJISAWA T, 1991, EUR J BIOCHEM, V196, P673, DOI 10.1111/j.1432-1033.1991.tb15864.x; GRINNELL F, 1980, CELL, V19, P517, DOI 10.1016/0092-8674(80)90526-7; HADA M, 1986, BLOOD, V68, P95; HASHIMOTO K, 1992, BIOCHIM BIOPHYS ACTA, V1165, P27, DOI 10.1016/0005-2760(92)90071-3; HASHIMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P1571, DOI 10.1016/0006-291X(91)90467-L; JELENSKA MM, 1980, BIOCHIM BIOPHYS ACTA, V616, P167, DOI 10.1016/0005-2744(80)90135-7; KIRBY EP, 1982, J LAB CLIN MED, V100, P963; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYNCH GW, 1987, J BIOL CHEM, V262, P1772; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MCDONAGH J, 1976, BIOCHIM BIOPHYS ACTA, V446, P345, DOI 10.1016/0005-2795(76)90002-7; MCKEE PA, 1970, P NATL ACAD SCI USA, V66, P738, DOI 10.1073/pnas.66.3.738; MONTGOMERY RR, 1978, J CLIN INVEST, V61, P1498, DOI 10.1172/JCI109070; Mosher D F, 1978, Ann N Y Acad Sci, V312, P38, DOI 10.1111/j.1749-6632.1978.tb16791.x; MOSHER DF, 1980, J BIOL CHEM, V255, P1181; NACHMAN R, 1977, J CLIN INVEST, V60, P914, DOI 10.1172/JCI108846; PAYE M, 1986, J CELL SCI, V86, P95; PEERSCHKE EI, 1980, BLOOD, V55, P841; PRINCE CW, 1991, BIOCHEM BIOPH RES CO, V177, P1205, DOI 10.1016/0006-291X(91)90669-X; SAKATA Y, 1982, J CLIN INVEST, V69, P536, DOI 10.1172/JCI110479; SANE DC, 1988, BIOCHEM BIOPH RES CO, V157, P115, DOI 10.1016/S0006-291X(88)80020-2; TAKAGI J, 1989, J BIOL CHEM, V264, P10425; TAKAGI J, 1989, J BIOL CHEM, V264, P6017; TAMAKI T, 1981, BIOCHIM BIOPHYS ACTA, V661, P280, DOI 10.1016/0005-2744(81)90016-4; TAMAKI T, 1982, J BIOL CHEM, V257, P4767; TIMPL R, 1979, J BIOL CHEM, V254, P9933; USUI T, 1992, EUR J BIOCHEM, V205, P363, DOI 10.1111/j.1432-1033.1992.tb16788.x; WAGNER DD, 1987, P NATL ACAD SCI USA, V84, P1955, DOI 10.1073/pnas.84.7.1955; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636	40	22	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12311	12316						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8099582				2022-12-27	WOS:A1993LG65800016
J	SCHRADER, M; BECKERANDRE, M; CARLBERG, C				SCHRADER, M; BECKERANDRE, M; CARLBERG, C			THYROID-HORMONE RECEPTOR FUNCTIONS AS MONOMERIC LIGAND-INDUCED TRANSCRIPTION FACTOR ON OCTAMERIC HALF-SITES - CONSEQUENCES ALSO FOR DIMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; RESPONSE ELEMENTS; DNA-BINDING; NUCLEAR RECEPTORS; ACID RECEPTORS; RXR-ALPHA; HETERODIMERS; SUPERFAMILY; ORIENTATION; HOMODIMERS	The thyroid hormone (3,5,3'-triiodothyronine) receptor (T(3)R) belongs to the nuclear receptor superfamily of ligand-inducible transcription factors. T(3)Rs are known to bind as homodimers and heterodimers with retinoid X receptors (RXRs) to two hexameric half-sites in directly repeated, palindromic, and inverted palindromic orientations. The binding of T(3)R monomers to individual half-sites was often reported, but no clear ligand-induced transactivational activity has been shown. Here, we analyzed interactions of T(3)R monomers with individual half-sites of the sequence NNAGGTCA. We found that the two nucleotides 5' of the AGGTCA core half-site strongly influence T(3)R binding and transcriptional activity: octameric half sites of the consensus sequence (T/C)(A/G)AGGTCA were bound by T(3)Rs with the highest affinity. This suggests T(3)R functioning also as a monomeric transcription factor like the orphan nuclear receptors NGFI-B and FTZ-F1. Moreover, we observed that the function of T(3)R-RXR heterodimers on response elements composed of two half-sites in a directly repeated orientation spaced by 4 nucleotides is determined in major parts by the 5'-flanking sequence of the upstream half-site. Consequently, we noted that the affinity of T(3)R homodimers is influenced by both 5'-flanking sequences. Our findings suggest that the binding of dimerizing receptors like T(3)R and other nuclear receptors to their cognate response elements is determined not only by the half-site core sequence, orientation, and number of spacing nucleotides, but also by the nucleotide sequence preceding the half-sites.	HOP CANTONAL UNIV,DERMATOL CLIN,CH-1211 GENEVA 14,SWITZERLAND; GLAXO INST MOLEC BIOL,CH-1228 PLAN LES OUATES,SWITZERLAND	University of Geneva; GlaxoSmithKline			Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1993, BIOCHEM J, V295, P343, DOI 10.1042/bj2950343; CARLBERG C, 1993, BIOCHEM BIOPH RES CO, V195, P1345, DOI 10.1006/bbrc.1993.2191; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KIM HS, 1992, MOL ENDOCRINOL, V6, P1489, DOI 10.1210/me.6.9.1489; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MUSCAT GEO, 1993, CELL GROWTH DIFFER, V4, P269; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHRADER M, 1993, NUCLEIC ACIDS RES, V21, P1231, DOI 10.1093/nar/21.5.1231; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; Yu Victor C., 1992, Current Opinion in Biotechnology, V3, P597, DOI 10.1016/0958-1669(92)90002-Z; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	41	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6444	6449						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119995				2022-12-27	WOS:A1994MZ50300031
J	BREYER, RM; EMESON, RB; TARNG, JL; BREYER, MD; DAVIS, LS; ABROMSON, RM; FERRENBACH, SM				BREYER, RM; EMESON, RB; TARNG, JL; BREYER, MD; DAVIS, LS; ABROMSON, RM; FERRENBACH, SM			ALTERNATIVE SPLICING GENERATES MULTIPLE ISOFORMS OF A RABBIT PROSTAGLANDIN E(2) RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE REGULATORY PROTEIN; BETA-ADRENERGIC-RECEPTOR; COLLECTING TUBULE CELLS; BOVINE ADRENAL-MEDULLA; PERTUSSIS TOXIN; MESSENGER-RNAS; GROWTH-FACTOR; ADENYLATE-CYCLASE; EXPRESSION; BINDING	Four cDNA clones homologous with a murine prostaglandin E(2) receptor have been isolated from a rabbit kidney cortex cDNA library. These cDNAs encode related proteins that differ only in their COOH-terminal sequences. Southern blot analysis of rabbit genomic DNA indicates that these receptor cDNAs represent alternatively spliced variants derived from a single gene. This was confirmed by isolation and sequence analysis of genomic clones containing common region exons and unique 3'-coding exons, which contained intron/exon boundaries at the predicted splice junctions. Transient expression of a novel full-length cDNA in COS1 cells confirmed the ligand binding profile typical of an EP3 receptor subtype. Ribonuclease protection assays indicate that the gene encoding these receptors is most highly expressed in kidney, adrenal, and stomach with lower but significant expression in uterus; lung, heart, ileum, spleen, and brain. Moreover, each of the cloned isoforms is expressed in the kidney. In situ hybridization analyses of rabbit kidney demonstrated that the level of expression is highest in the outer medulla with lesser expression in the cortex and no detectable expression in the inner medulla. The ligand binding profile and tissue distribution of these receptors is consistent with a functional role for this family of EP3 receptors in mediating the renal actions of prostaglandins as well as the effects of prostaglandins on gastric acid secretion and adrenal function.	VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,VET ADM MED CTR,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,NASHVILLE,TN 37232	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vanderbilt University; Vanderbilt University	BREYER, RM (corresponding author), VANDERBILT UNIV,DIV NEPHROL,NASHVILLE,TN 37232, USA.			Breyer, Matthew/0000-0003-1880-371X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039261, R01DK046205] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-46205-01, DK-39261-05] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; ARMSTRONG RA, 1990, ADV PROSTAGLANDIN TH, V21, P375; ATWELL MM, 1988, BIOCHIM BIOPHYS ACTA, V971, P282; AUSEBEL F, 1990, CURRENT PROTOCOLS MO; BARR DB, 1988, J PHYSIOL-LONDON, V405, P39, DOI 10.1113/jphysiol.1988.sp017320; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BREYER M D, 1992, Journal of the American Society of Nephrology, V3, P452; BREYER MD, 1990, KIDNEY INT, V38, P618, DOI 10.1038/ki.1990.251; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643; DUNN MJ, 1977, AM J PHYSIOL, V233, pF169, DOI 10.1152/ajprenal.1977.233.3.F169; EASON MG, 1992, J BIOL CHEM, V267, P11754; EDWARDS RH, 1986, NATURE, V319, P784, DOI 10.1038/319784a0; EDWARDS RM, 1985, AM J PHYSIOL, V248, pF779, DOI 10.1152/ajprenal.1985.248.6.F779; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARDINER PJ, 1990, ADV PROSTAG THROMB L, V20, P110; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; HAGA T, 1977, P NATL ACAD SCI USA, V74, P2016, DOI 10.1073/pnas.74.5.2016; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HEBERT RL, 1991, J CLIN INVEST, V87, P1992, DOI 10.1172/JCI115227; HEBERT RL, 1993, AM J PHYSIOL, V265, pF643, DOI 10.1152/ajprenal.1993.265.5.F643; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAWRENCE RA, 1992, BRIT J PHARMACOL, V105, P271, DOI 10.1111/j.1476-5381.1992.tb14245.x; LEFKOWITZ RJ, 1977, J BIOL CHEM, V252, P5295; LOUTTIT JB, 1992, 8TH P INT C PROST RE, P67; LOUTTIT JB, 1992, 8TH INT C PROST REL, P68; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKAO A, 1989, AM J PHYSIOL, V256, pC652, DOI 10.1152/ajpcell.1989.256.3.C652; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NAWA H, 1984, NATURE, V312, P729, DOI 10.1038/312729a0; NEGISHI M, 1987, J BIOL CHEM, V262, P12077; NEGISHI M, 1989, J BIOL CHEM, V264, P3916; NEGISHI M, 1993, J BIOL CHEM, V268, P9517; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; PELTON RW, 1989, DEVELOPMENT, V106, P759; RICHELSEN B, 1984, J LIPID RES, V26, P127; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SONNENBURG WK, 1988, J BIOL CHEM, V263, P6155; SONNENBURG WK, 1990, J BIOL CHEM, V265, P8479; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; WATANABE T, 1986, J BIOL CHEM, V261, P3430; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; [No title captured]	52	93	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6163	6169						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119961				2022-12-27	WOS:A1994MY84000102
J	HOWE, G; MERCHANT, S				HOWE, G; MERCHANT, S			ROLE OF HEME IN THE BIOSYNTHESIS OF CYTOCHROME C(6)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE CYTOCHROMES; CHLAMYDOMONAS-REINHARDTII; SACCHAROMYCES-CEREVISIAE; RHODOBACTER-SPHAEROIDES; APOCYTOCHROME-C; IMPORT; MITOCHONDRIA; LYASE; PROTEINS; COPPER	Cytochrome c(6), a nuclear-encoded protein, is synthesized in the cytoplasm in a precursor form (pre-apocytochrome c(6)). Time course radiolabeling experiments support the model that the pre-protein is the substrate for a lumen-targeting post-translational pathway which includes two proteolytic cleavage events and the covalent attachment of heme to cysteinyl thiols on the polypeptide. Cell fractionation studies indicate that the fully processed protein fractionates with other soluble proteins, whereas the precursor and intermediate forms appear to be membrane-associated. To determine whether either of the processing steps is influenced by heme attachment, the biosynthetic pathway was examined 1) in a Chlamydomonas reinhardtii mutant (B6) that is defective in the heme attachment step and 2) in wild-type cells treated with gabaculine, an inhibitor of heme synthesis. In vivo radiolabeling experiments with the B6 mutant showed that a defect in heme attachment affects neither the synthesis of the pre-apoprotein nor its processing to the mature apoform to any significant extent, supporting the notion that heme attachment and processing are not obligatorily coupled in this pathway. A similar conclusion is reached from examination of cytochrome c(6) synthesis in gabaculine-treated cells where inhibition of heme attachment did not prevent either of the two processing steps. The fully processed apoprotein is a suitable substrate for heme attachment in vivo, since the apoprotein was indeed converted to holoprotein in gabaculine-treated cells, albeit more slowly than in untreated cells. Despite the lack of effect of gabaculine treatment on the accumulation of cytochrome cg encoding messages, the amount of holocytochrome c6 precursors synthesized during a brief labeling period is 4-7-fold less than in untreated cells, suggesting that synthesis of the polypeptide may be coupled to home availability by a control mechanism operating at the translational level.	UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles					NIGMS NIH HHS [GM 00594] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K04GM000594] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON CM, 1991, PLANT PHYSIOL, V96, P584, DOI 10.1104/pp.96.2.584; BECKMAN DL, 1992, GENE DEV, V6, P268, DOI 10.1101/gad.6.2.268; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRANDNER JP, 1991, J BACTERIOL, V173, P3958, DOI 10.1128/jb.173.13.3958-3965.1991; DAVIDSON E, 1987, BIOCHIM BIOPHYS ACTA, V890, P292, DOI 10.1016/0005-2728(87)90156-3; DUMONT MD, 1990, J BIOL CHEM, V265, P2733; DUMONT ME, 1991, MOL CELL BIOL, V11, P5487, DOI 10.1128/MCB.11.11.5487; DUMONT ME, 1988, J BIOL CHEM, V263, P15928; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; GAL A, 1990, CURRENT RES PHOTOSYN, V2, P779; GARRARD WT, 1972, J BIOL CHEM, V247, P5935; GOLDSCHMIDTCLERMONT M, 1989, PLANT PHYSIOL, V89, P15, DOI 10.1104/pp.89.1.15; GRANICK S, 1971, METABOLIC REGULATION, P74; GRAY JC, 1992, PHOTOSYNTH RES, V34, P359, DOI 10.1007/BF00029811; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HAKVOORT TBM, 1990, P NATL ACAD SCI USA, V87, P4996, DOI 10.1073/pnas.87.13.4996; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HILL KL, 1991, J BIOL CHEM, V266, P15060; HILL KL, 1992, PLANT PHYSIOL, V100, P319, DOI 10.1104/pp.100.1.319; HOWE G, 1993, P NATL ACAD SCI USA, V90, P1862, DOI 10.1073/pnas.90.5.1862; HOWE G, 1992, EMBO J, V11, P2789, DOI 10.1002/j.1460-2075.1992.tb05346.x; HOWE G, 1994, IN PRESS PHOTOSYN RE; JASPER F, 1991, J PHOTOCH PHOTOBIO B, V11, P139, DOI 10.1016/1011-1344(91)80256-H; JOHANNINGMEIER U, 1988, EUR J BIOCHEM, V177, P417, DOI 10.1111/j.1432-1033.1988.tb14391.x; JOHANNINGMEIER U, 1984, J BIOL CHEM, V259, P3541; KAHN A, 1987, CARLSBERG RES COMMUN, V52, P73, DOI 10.1007/BF02910429; KIRWIN PM, 1988, J BIOL CHEM, V263, P18128; KRANZ RG, 1989, J BACTERIOL, V171, P456, DOI 10.1128/jb.171.1.456-464.1989; KUMAR CC, 1980, J BIOL CHEM, V255, P1130; LEMAIRE C, 1986, BIOCHIM BIOPHYS ACTA, V851, P229, DOI 10.1016/0005-2728(86)90130-1; LONDON IM, 1987, ENZYMES, V18, P360; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; MERCHANT S, 1991, EMBO J, V10, P1383, DOI 10.1002/j.1460-2075.1991.tb07658.x; MERCHANT S, 1987, J BIOL CHEM, V262, P9062; NARGANG FE, 1988, J BIOL CHEM, V263, P9388; NICHOLSON DW, 1987, EUR J BIOCHEM, V164, P147, DOI 10.1111/j.1432-1033.1987.tb11006.x; NICHOLSON DW, 1988, J BIOL CHEM, V263, P19034; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; OHASHI A, 1982, J BIOL CHEM, V257, P3042; PAGE MD, 1990, MOL MICROBIOL, V4, P1181, DOI 10.1111/j.1365-2958.1990.tb00693.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHILKE BA, 1992, J MOL BIOL, V226, P101, DOI 10.1016/0022-2836(92)90127-6; SCHILKE BA, 1992, J BIOL CHEM, V266, P12152; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; TANIUCHI H, 1983, J BIOL CHEM, V258, P963; TAYLOR WC, 1989, ANNU REV PLANT PHYS, V40, P211, DOI 10.1146/annurev.pp.40.060189.001235; TOGASAKI RK, 1992, 5TH INT C CELL MOL B, P51; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x	49	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5824	5832						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119924				2022-12-27	WOS:A1994MY84000055
J	KITAMURA, M; KOJIMA, S; OGASAWARA, K; NAKAYA, T; SAGARA, T; NIKI, K; MIURA, K; AKUTSU, H; KUMAGAI, I				KITAMURA, M; KOJIMA, S; OGASAWARA, K; NAKAYA, T; SAGARA, T; NIKI, K; MIURA, K; AKUTSU, H; KUMAGAI, I			NOVEL FMN-BINDING PROTEIN FROM DESULFOVIBRIO-VULGARIS (MIYAZAKI-F) - CLONING AND EXPRESSION OF ITS GENE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; FLAVODOXIN GENE; OXIDIZED FLAVODOXIN; HILDENBOROUGH; RESOLUTION; GIGAS; RUBREDOXIN; FORM	A gene encoding a novel FMN-binding protein from Desulfovibrio vulgaris (Miyazaki F) was cloned, and its expression system was constructed in Escherichia coli. The 1.4-kilobase pair DNA fragment isolated from D. vulgaris (Miyazaki F) by double digestion with KpnI and SmaI was found to express a protein binding FMN as a prosthetic group under control of the lac promoter in E. coli. This DNA fragment contained several putative open reading frames. The partial amino acid sequence of the polypeptide portion of the purified FMN-binding protein and its tryptic peptides were completely consistent with those deduced from the nucleotide sequence of the third open reading frame in the cloned SmaI-SmaI fragment of D. vulgaris (Miyazaki F) DNA, which may include promoter and regulatory sequences. The nucleotide sequence of FMN-binding protein indicated that the protein is composed of 122 amino acids including an initiator Met residue and lacks a signal peptide for secretion. The main redox potential of the FMN-binding protein was measured as -325 mV using direct current cyclic and differential pulse voltammetric techniques and an electroreflectance method, suggesting that this FMN-binding protein functions as a redox protein like other FMN-binding; proteins. Immunoblot analysis of the whole proteins from D. vulgaris (Miyazaki F) clearly indicated that this protein is expressed in this bacteria. However, the protein was found to have a primary structure distinct from those of other FWN-binding proteins and to be the smallest FMN-binding protein yet reported.	OSAKA CITY UNIV,FAC ENGN,DEPT BIOAPPL CHEM,SUMIYOSHI KU,OSAKA 558,JAPAN; GAKUSHUIN UNIV,INST BIOMOLEC SCI,TOSHIMA KU,TOKYO 171,JAPAN; YOKOHAMA NATL UNIV,FAC ENGN,DEPT BIOPHYS CHEM,HODOGAYA KU,YOKOHAMA 240,JAPAN; NAGASAKI UNIV,FAC ENGN,DEPT APPL CHEM,NAGASAKI 852,JAPAN	Osaka Metropolitan University; Gakushuin University; Yokohama National University; Nagasaki University	KITAMURA, M (corresponding author), UNIV TOKYO,FAC ENGN,DEPT IND CHEM,BUNKYO KU,TOKYO 113,JAPAN.			Akutsu, Hideo/0000-0001-7236-5285				BRUMLIK MJ, 1989, J BACTERIOL, V171, P4996, DOI 10.1128/jb.171.9.4996-5004.1989; BURNETT RM, 1974, J BIOL CHEM, V249, P4383; CURLEY GP, 1988, FEMS MICROBIOL LETT, V49, P295; FREY M, 1987, J MOL BIOL, V197, P525, DOI 10.1016/0022-2836(87)90562-6; FUKUYAMA K, 1990, J BIOL CHEM, V265, P15804; HELMS LR, 1992, BIOCHIM BIOPHYS ACTA, V1131, P325, DOI 10.1016/0167-4781(92)90034-W; HELMS LR, 1991, BIOCHIM BIOPHYS ACTA, V1089, P417, DOI 10.1016/0167-4781(91)90190-W; HELMS LR, 1990, BIOCHEM BIOPH RES CO, V168, P809, DOI 10.1016/0006-291X(90)92393-E; HIGUCHI Y, 1984, J MOL BIOL, V172, P109, DOI 10.1016/0022-2836(84)90417-0; INOUYE S, 1987, SYNTHESIS APPLICATIO, P181; KISSINGER CR, 1989, FEBS LETT, V244, P447, DOI 10.1016/0014-5793(89)80580-0; Kitamura Masaya, 1993, Protein Sequences and Data Analysis, V5, P193; KNIGHT E, 1966, J BIOL CHEM, V241, P2752; KREY GD, 1988, J BIOL CHEM, V263, P15436; KSENZHEK OS, 1983, BIOELECTROCH BIOENER, V11, P105, DOI 10.1016/0302-4598(83)80086-5; KUMAGAI I, 1990, PROTEIN ENG, V3, P449, DOI 10.1093/protein/3.5.449; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQVIST Y, 1985, P NATL ACAD SCI USA, V82, P6855, DOI 10.1073/pnas.82.20.6855; Mayhew S.G., 1975, ENZYMES, V12, P57; MAYHEW SG, 1969, J BIOL CHEM, V244, P803; MAYHEW SG, 1971, BIOCHIM BIOPHYS ACTA, V235, P276, DOI 10.1016/0005-2744(71)90206-3; NAKAGAWA A, 1990, J BIOCHEM-TOKYO, V108, P701, DOI 10.1093/oxfordjournals.jbchem.a123267; POLLOCK WBR, 1991, J BACTERIOL, V173, P220, DOI 10.1128/jb.173.1.220-228.1991; Postgate JR, 1984, SULPHATE REDUCING BA, P32; PRICKRIL BC, 1991, BIOCHEMISTRY-US, V30, P11118, DOI 10.1021/bi00110a014; SAGARA T, 1991, LANGMUIR, V7, P1005, DOI 10.1021/la00053a032; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; SMITH WW, 1983, J MOL BIOL, V165, P737, DOI 10.1016/S0022-2836(83)80277-0; TAN J, 1991, BIOCHEMISTRY-US, V30, P9900, DOI 10.1021/bi00105a013; VANROOIJEN GJH, 1989, J BACTERIOL, V171, P3575, DOI 10.1128/jb.171.6.3575-3578.1989; VOORDOUW G, 1986, EUR J BIOCHEM, V159, P347, DOI 10.1111/j.1432-1033.1986.tb09874.x; VOORDOUW G, 1985, EUR J BIOCHEM, V148, P515, DOI 10.1111/j.1432-1033.1985.tb08869.x; WATT W, 1991, J MOL BIOL, V218, P195, DOI 10.1016/0022-2836(91)90884-9; XIA ZX, 1987, P NATL ACAD SCI USA, V84, P2629, DOI 10.1073/pnas.84.9.2629	34	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5566	5573						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119891				2022-12-27	WOS:A1994MY84000018
J	KULMACZ, RJ; PENDLETON, RB; LANDS, WEM				KULMACZ, RJ; PENDLETON, RB; LANDS, WEM			INTERACTION BETWEEN PEROXIDASE AND CYCLOOXYGENASE ACTIVITIES IN PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE - INTERPRETATION OF REACTION-KINETICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER OXIDATION-STATES; H SYNTHASE; TYROSYL RADICALS; VESICULAR GLAND; BIOSYNTHESIS; HYDROPEROXIDES; CYANIDE; INACTIVATION; SIMILARITIES; SYNTHETASE	Prostaglandin-endoperoxide syntheses have two distinct enzymatic activities in the biosynthesis of prostanoids: a peroxidase and a fatty acid oxygenase. Hydroperoxides, such as the cyclooxygenase reaction product, prostaglandin G(2), act both as substrates for the synthase peroxidase and as obligatory initiators of the cyclooxygenase reaction itself. A mechanistic scheme was devised to describe the interactions between the two activities of the synthase. This mechanism was based on a heme-dependent peroxidase mechanism such as that observed with horseradish peroxidase and initiation of the cyclooxygenase reaction by intramolecular reaction with a peroxidase intermediate. Rate equations derived from the mechanism were numerically integrated by an interactive computer program that consolidated the diverse phenomena to provide quantitative predictions of the reaction kinetics of the synthase. The predictions agreed well with experimental observations of the purified ovine seminal vesicle enzyme under a wide variety of conditions, including inhibition by exogenous hydroperoxide scavenger and by cyanide, stimulation by exogenous hydroperoxide, and inhibition of eicosapentaenoic acid oxygenation under conditions where arachidonic acid reacts rapidly. The detailed analyses of reaction kinetics made possible with the computer simulation provide important insights into the interactions between the two catalytic activities of the synthase in the control of prostaglandin biosynthesis.	UNIV ILLINOIS,DEPT BIOCHEM,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	KULMACZ, RJ (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV HEMATOL,POB 20708,HOUSTON,TX 77225, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030509] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 34422] Funding Source: Medline; NIGMS NIH HHS [GM 30509] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V41, P416, DOI 10.1016/0003-9861(52)90470-0; CULP BR, 1979, PROSTAG LEUKOTR ESS, V3, P269, DOI 10.1016/0161-4630(79)90068-5; DEGRAY JA, 1992, J BIOL CHEM, V267, P23583; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; ELING TE, 1991, J BIOL CHEM, V266, P12348; GRAFF G, 1982, METHOD ENZYMOL, V86, P376; GUNZLER WA, 1972, H-S Z PHYSIOL CHEM, V353, P1001; HEMLER ME, 1978, BIOCHEMISTRY-US, V17, P1772, DOI 10.1021/bi00602a031; HEMLER ME, 1979, ARCH BIOCHEM BIOPHYS, V193, P340, DOI 10.1016/0003-9861(79)90038-9; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; HSUANYU YC, 1990, BIOCHEM CELL BIOL, V68, P965, DOI 10.1139/o90-142; HSUANYU YC, 1992, J BIOL CHEM, V267, P17649; HSUANYU YC, 1992, ARCH BIOCHEM BIOPHYS, V292, P213, DOI 10.1016/0003-9861(92)90070-D; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1985, PROSTAGLANDINS, V29, P175, DOI 10.1016/0090-6980(85)90200-X; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1987, J BIOL CHEM, V262, P10524; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; KULMACZ RJ, 1987, PROSTAGLANDINS, V34, P225, DOI 10.1016/0090-6980(87)90246-2; KULMACZ RJ, 1986, ARCH BIOCHEM BIOPHYS, V249, P273, DOI 10.1016/0003-9861(86)90003-2; KULMACZ RJ, 1990, METHOD ENZYMOL, V186, P431; KULMACZ RJ, 1983, ADV PROSTAG THROMB L, V11, P93; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LANDS W, 1971, ANN NY ACAD SCI, V180, P107, DOI 10.1111/j.1749-6632.1971.tb53190.x; LANDS WEM, 1973, ADV BIOSCI, V9, P15; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; LAWRENCE RA, 1974, EXP EYE RES, V18, P563, DOI 10.1016/0014-4835(74)90062-1; MACDONALD ID, 1989, J INORG BIOCHEM, V37, P35, DOI 10.1016/0162-0134(89)80027-3; MACDONALD ID, 1989, BIOCHEM CELL BIOL, V67, P301; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; MARSHALL PJ, 1985, ANAL BIOCHEM, V145, P192, DOI 10.1016/0003-2697(85)90347-1; MARSHALL PJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P162, DOI 10.1016/0003-9861(88)90246-9; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; MARSHALL PJ, 1984, OXYGEN RADICALS CHEM, P299; MORENO SNJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P267, DOI 10.1016/0003-9861(88)90127-0; OHKI S, 1979, J BIOL CHEM, V254, P829; PENDELTON RB, 1990, THESIS U ILLINOIS UR; PENDLETON RB, 1991, EICOSANOIDS OTHER BI, P209; POTTER DW, 1987, J BIOL CHEM, V262, P974; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; TSAI AL, 1992, J BIOL CHEM, V267, P17753; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	46	114	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5527	5536						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119886				2022-12-27	WOS:A1994MY84000012
J	RAHA, A; WAGNER, C; MACDONALD, RG; BRESNICK, E				RAHA, A; WAGNER, C; MACDONALD, RG; BRESNICK, E			RAT-LIVER CYTOSOLIC 4-S POLYCYCLIC AROMATIC HYDROCARBON-BINDING PROTEIN IS GLYCINE N-METHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; CYP1A1 GENE-EXPRESSION; AH-RECEPTOR; 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE; CYTOCHROME-P-450C GENE; NUCLEOTIDE-SEQUENCE; NUCLEAR UPTAKE; MOUSE-LIVER; CDNA CLONE; PURIFICATION	In the rat, cytochrome P-450IA1 gene expression, which is most closely associated with aryl hydrocarbon hydroxylase activity, is thought to be regulated by several trans-acting factors, including the 4 S polycyclic aromatic hydrocarbon (PAH)-binding protein. This protein has been purified to homogeneity from rat liver using ion exchange, gel permeation, hydrophobic interaction, and affinity chromatographies. Partial sequencing of the 33-kDa band indicated its identity as glycine N-methyltransferase (GNMT). Polyclonal antibodies to GNMT immunoprecipitated PAH-binding activity from rat liver cytosol. Methyltransferase and PAH-binding activities copurified during the course of protein purification. GNMT protein and PAH binding activity were co localized in various cytosolic fractions. These data all indicate that the 4 S PAH-binding protein and GNMT are one and the same protein or very similar proteins. Western blot analyses yielded a positive signal under denaturing (33 kDa) and nondenaturing (150 kDa, tetramer) conditions; the PAH-binding protein also was an oligomer, GNMT was detected by immunohistochemistry in nuclei from H4IIE rat hepatoma cells and rat liver. The localization of GNMT in liver nuclei is in accordance with a role in modulating cytochrome P-450IA1 gene expression.	DARTMOUTH COLL SCH MED,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03755; NORRIS COTTON CANC CTR,HANOVER,NH 03755; VANDERBILT UNIV,DEPT BIOCHEM,NASHVILLE,TN 37232; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM & MOLEC BIOL,OMAHA,NE 68198	Dartmouth College; Norris Cotton Cancer Center; Vanderbilt University; University of Nebraska System; University of Nebraska Medical Center					NATIONAL CANCER INSTITUTE [R01CA036106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003980, T32ES007104] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36106] Funding Source: Medline; NIEHS NIH HHS [ES 03980, ES 07104] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ARNOLD PS, 1987, BIOCHEM J, V242, P375, DOI 10.1042/bj2420375; BIGELOW SW, 1982, TOXICOL LETT, V10, P109, DOI 10.1016/0378-4274(82)90276-4; BLUMENSTEIN J, 1960, BIOCHEM BIOPH RES CO, V3, P259, DOI 10.1016/0006-291X(60)90235-7; BRESNICK E, 1988, CANCER METAST REV, V7, P51, DOI 10.1007/BF00048278; CITRON BA, 1992, P NATL ACAD SCI USA, V89, P11891, DOI 10.1073/pnas.89.24.11891; COLLINS S, 1984, MOL PHARMACOL, V26, P353; COLLINS S, 1985, BIOCHEM BIOPH RES CO, V129, P155, DOI 10.1016/0006-291X(85)91416-0; CONNEY AH, 1967, PHARMACOL REV, V19, P317; COOK RJ, 1981, ARCH BIOCHEM BIOPHYS, V208, P358, DOI 10.1016/0003-9861(81)90520-8; COOK RJ, 1984, P NATL ACAD SCI-BIOL, V81, P3631, DOI 10.1073/pnas.81.12.3631; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FOLDES RL, 1985, ARCH BIOCHEM BIOPHYS, V239, P137, DOI 10.1016/0003-9861(85)90820-3; GIBBONS JA, 1992, CHEM-BIOL INTERACT, V83, P203, DOI 10.1016/0009-2797(92)90098-6; GIBBONS JA, 1990, TOXICOLOGIST, V10, P193; GILLETTE JR, 1974, ANNU REV PHARMACOL, V14, P271, DOI 10.1146/annurev.pa.14.040174.001415; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GROVES WE, 1968, ANAL BIOCHEM, V22, P195, DOI 10.1016/0003-2697(68)90307-2; GUENTHNER TM, 1977, J BIOL CHEM, V252, P8981; HAMILTON JW, 1988, BIOCHEM J, V255, P267; HEINTZ NH, 1981, CANCER RES, V41, P1794; HINES RN, 1988, CARCINOGENESIS, V9, P1599, DOI 10.1093/carcin/9.9.1599; HOLDER GM, 1981, CANCER RES, V41, P4408; HOUSER WH, 1986, ARCH BIOCHEM BIOPHYS, V251, P361, DOI 10.1016/0003-9861(86)90083-4; HOUSER WH, 1985, BIOCHEMISTRY-US, V24, P7839, DOI 10.1021/bi00347a050; HOUSER WH, 1992, MOL CARCINOGEN, V5, P232, DOI 10.1002/mc.2940050310; HOUSER WH, 1987, ARCH BIOCHEM BIOPHYS, V259, P215, DOI 10.1016/0003-9861(87)90488-7; KAMPS C, 1987, CANCER LETT, V36, P129; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KERR SJ, 1972, J BIOL CHEM, V247, P4248; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NEBERT DW, 1989, INT J BIOCHEM, V21, P243, DOI 10.1016/0020-711X(89)90182-1; NEBERT DW, 1988, GENES ENCODING DRUG, P45; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; OGAWA H, 1987, EUR J BIOCHEM, V168, P141, DOI 10.1111/j.1432-1033.1987.tb13398.x; OGAWA H, 1982, J BIOL CHEM, V257, P3447; OKEY AB, 1990, PHARMACOL THERAPEUT, V45, P241, DOI 10.1016/0163-7258(90)90030-6; PENNING TM, 1984, BIOCHEM J, V222, P601, DOI 10.1042/bj2220601; PENNING TM, 1991, J BIOL CHEM, V266, P8826; PISKORSKAPLISZCZYNSKA J, 1986, TOXICOL LETT, V34, P67, DOI 10.1016/0378-4274(86)90146-3; POLAND A, 1976, J BIOL CHEM, V251, P4936; RAHA A, 1990, J TOXICOL ENV HEALTH, V29, P339, DOI 10.1080/15287399009531397; RAHA A, 1991, TOXICOLOGY, V66, P175, DOI 10.1016/0300-483X(91)90217-O; RAVAL P, 1991, BIOCHEM PHARMACOL, V41, P1719, DOI 10.1016/0006-2952(91)90175-5; SMITHGALL TE, 1985, BIOCHEM PHARMACOL, V34, P831, DOI 10.1016/0006-2952(85)90763-4; SUZUKI N, 1980, ARCH BIOCHEM BIOPHYS, V199, P236, DOI 10.1016/0003-9861(80)90277-5; TIERNEY B, 1980, ARCH BIOCHEM BIOPHYS, V200, P513, DOI 10.1016/0003-9861(80)90383-5; TIERNEY B, 1983, ARCH BIOCHEM BIOPHYS, V225, P826, DOI 10.1016/0003-9861(83)90095-4; VOGEL K, 1980, J BIOL CHEM, V255, P9621; WEN LP, 1990, P NATL ACAD SCI USA, V87, P8545, DOI 10.1073/pnas.87.21.8545; WHITLOCK JP, 1987, PHARMACOL REV, V39, P147; YEO EJ, 1994, IN PRESS P NATL ACAD; YUEN SW, 1989, BIOTECHNIQUES, V7, P74; ZYTKOVICZ TH, 1982, CANCER RES, V42, P4387	57	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5750	5756						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119914				2022-12-27	WOS:A1994MY84000044
J	YAMATO, I; KOTANI, M; OKA, Y; ANRAKU, Y				YAMATO, I; KOTANI, M; OKA, Y; ANRAKU, Y			SITE-SPECIFIC ALTERATION OF ARGININE-376, THE UNIQUE POSITIVELY CHARGED AMINO-ACID RESIDUE IN THE MID-MEMBRANE-SPANNING REGIONS OF THE PROLINE CARRIER OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/PROLINE SYMPORT CARRIER; NUCLEOTIDE-SEQUENCE; LAC PERMEASE; GLUTAMATE TRANSPORTER; EXPRESSION CLONING; COTRANSPORT SYSTEM; CARBOXYL TERMINUS; ACTIVE-TRANSPORT; RAT-BRAIN; GENE	An alignment of 5 amino acids in the Escherichia coli proline carrier (G(328)-A(366)-L(371)-GR(376)) is common in the amino acid sequences of several Na+ symport carriers, and it has been proposed as the putative sodium binding motif (Deguchi, Y., Yamato, I., and Anraku, Y. (1990) J. Biol. Chem. 265, 21704-21708). To determine whether these amino acids are essential for Na+ symport activity as the Na+ binding site, one of the amino acids in this alignment, Arg-376, which is the only positively charged amino acid in the innermost part of the predicted membrane-spanning regions, was changed to either lysine, glutamine, or glutamic acid by oligonucleotide dependent site-specific mutagenesis. The transport and binding activities of the proline of the R376K mutant carrier were not detected at all. The activities of the other mutant carriers for uptake and binding of proline were as high as those of the wild-type carrier. These two mutant carriers were as sensitive to the proline analogue azetidine-2-carboxylate and to N-ethylmaleimide as the wildtype carrier, indicating that they have the same properties as the wild-type, The amounts of the carrier proteins expressed from these mutated putP genes were similar to that from the wild-type gene. These results imply that the Arg-376 in the proline carrier does not reside at the sodium binding site, suggesting that the similar alignment found in the amino acid sequences of several Na+ symport carriers is not essential for the transport or binding activities, although this similar alignment may have some relevance to the structure of the Na+ symporter. Furthermore, that the only Arg residue in the middle part of the predicted membrane-spanning regions is dispensable for the energy coupling activity indicates a unique difference of the coupling mechanism from the other secondary active transport systems, such as that of the lactose permease and the tetracycline/H+ antiporter.	UNIV TOKYO, FAC SCI, DEPT BIOL, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo	YAMATO, I (corresponding author), SCI UNIV TOKYO, DEPT BIOL SCI & TECHNOL, 2641 YAMAZAKI, NODA, CHIBA 278, JAPAN.							CHEN CC, 1985, J MEMBRANE BIOL, V84, P157, DOI 10.1007/BF01872213; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; FRANK L, 1969, J BACTERIOL, V100, P329, DOI 10.1128/JB.100.1.329-336.1969; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HANADA K, 1985, FEBS LETT, V191, P278, DOI 10.1016/0014-5793(85)80024-7; HANADA K, 1988, J BIOL CHEM, V263, P7181; HANADA K, 1992, BIOCHIM BIOPHYS ACTA, V1105, P61, DOI 10.1016/0005-2736(92)90162-F; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; HOSHINO T, 1990, MOL GEN GENET, V220, P461, DOI 10.1007/BF00391754; JAHNIG F, 1990, TRENDS BIOCHEM SCI, V15, P93, DOI 10.1016/0968-0004(90)90188-H; KABACK HR, 1990, TRENDS BIOCHEM SCI, V15, P309; KABACK HR, 1989, HARVEY LECT, V83, P77; KAMATA H, 1992, J BIOL CHEM, V267, P21650; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KOMEIJI Y, 1989, FEBS LETT, V256, P135, DOI 10.1016/0014-5793(89)81733-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEBLANC G, 1988, MOL BASIS BIOMEMBRAN, P53; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLEOD PR, 1992, MOL MICROBIOL, V6, P2673, DOI 10.1111/j.1365-2958.1992.tb01444.x; Maniatis T, 1989, MOL CLONING; MENICK DR, 1987, BIOCHEMISTRY-US, V26, P6638, DOI 10.1021/bi00395a012; MILLER K, 1990, NUCLEIC ACIDS RES, V18, P3057, DOI 10.1093/nar/18.10.3057; MOGI T, 1986, MOL GEN GENET, V202, P35, DOI 10.1007/BF00330513; MOGI T, 1984, J BIOL CHEM, V259, P7797; MOTOJIMA K, 1979, P NATL ACAD SCI USA, V76, P6255, DOI 10.1073/pnas.76.12.6255; NAKAO T, 1987, MOL GEN GENET, V208, P70, DOI 10.1007/BF00330424; OHSAWA M, 1988, J BACTERIOL, V170, P5185, DOI 10.1128/jb.170.11.5185-5191.1988; PADAN E, 1992, ALKALI CATION TRANSP, P3; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; PUTTNER IB, 1986, BIOCHEMISTRY-US, V25, P4483; SECKLER R, 1986, BIOCHEMISTRY-US, V25, P2403, DOI 10.1021/bi00357a016; TOLNER B, 1992, J BACTERIOL, V174, P2391, DOI 10.1128/JB.174.7.2391-2393.1992; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608; WOOD JM, 1979, CAN J BIOCHEM CELL B, V57, P1191, DOI 10.1139/o79-155; YAMAGUCHI A, 1991, J BIOL CHEM, V266, P6045; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMATO I, 1990, J BIOL CHEM, V265, P2450; YAMATO I, 1975, J BIOCHEM, V77, P705, DOI 10.1093/oxfordjournals.jbchem.a130774; YAMATO I, 1992, FEBS LETT, V298, P1, DOI 10.1016/0014-5793(92)80008-5; YAMATO I, 1988, J BIOL CHEM, V263, P16055; YAMATO I, 1990, J MEMBRANE BIOL, V114, P143, DOI 10.1007/BF01869095; Yamato I., 1992, ALKALI CATION TRANSP, p[53, 76]; YAZYU H, 1984, J BIOL CHEM, V259, P4320	48	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5720	5724						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119910				2022-12-27	WOS:A1994MY84000039
J	GRAHAM, GJ; MACKENZIE, J; LOWE, S; TSANG, MLS; WEATHERBEE, JA; ISSACSON, A; MEDICHERLA, J; FANG, F; WILKINSON, PC; PRAGNELL, IB				GRAHAM, GJ; MACKENZIE, J; LOWE, S; TSANG, MLS; WEATHERBEE, JA; ISSACSON, A; MEDICHERLA, J; FANG, F; WILKINSON, PC; PRAGNELL, IB			AGGREGATION OF THE CHEMOKINE MIP-1-ALPHA IS A DYNAMIC AND REVERSIBLE PHENOMENON - BIOCHEMICAL AND BIOLOGICAL ANALYSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; COLONY FORMATION INVITRO; STEM-CELL PROLIFERATION; 3-DIMENSIONAL STRUCTURE; RECEPTOR-BINDING; INTERLEUKIN-8; PROTEIN; INVIVO; INHIBITOR	Macrophage inhibitory protein (MIP)-1 alpha is a potent inhibitor of hemopoietic stem cell proliferation and is a member of a family of pro-inflammatory mediators, the chemokine family. This molecule along with other members of the chemokine family exists as a peptide of 8 kDa but has a strong tendency for noncovalent extensive self-aggregation. As this aggregation may interfere with biological activity, we have produced nonaggregating variants of MIP-1 alpha which display a range of molecular sizes. The mutants, produced by sequential neutralization of carboxyl-terminal acidic residues, display native molecular masses representative of tetramers, dimers, and monomers. Intriguingly when these mutants are assessed in comparison with native MIP-1 alpha for bioactivity in vitro, they are seen to be equipotent in both stem cell assays and in monocyte shape-change assays, suggesting that there is no requirement for aggregation in either of these biological contexts. This indicates that the aggregated MIP-1 alpha and the aggregated mutants spontaneously disaggregate under assay conditions and ultimately function as monomers. We have further demonstrated the ability of MIP-1 alpha to disaggregate spontaneously in dilute solution by enzyme-linked immunosorbent assay analysis of fractions obtained from gel filtration of varying concentrations of MIP-1 alpha. The aggregation of MIP-1 alpha is therefore a dynamic and reversible phenomenon which has little, if any impact on bioactivity in vitro.	RES & DEV SYST INC, MINNEAPOLIS, MN 55413 USA; UNIV GLASGOW, DEPT IMMUNOL, GLASGOW G12 8QQ, LANARK, SCOTLAND	University of Glasgow	GRAHAM, GJ (corresponding author), BEATSON INST CANC RES, CANC RES CAMPAIGN, BEATSON LABS, GARSCUBE ESTATE, GLASGOW G61 1BD, LANARK, SCOTLAND.		Graham, Gerard/D-1240-2009	Graham, Gerard/0000-0002-7801-204X				BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BROXMEYER HE, 1990, BLOOD, V76, P1110; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLEMENTS JM, 1992, CYTOKINE, V4, P76, DOI 10.1016/1043-4666(92)90040-X; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1991, J MOL BIOL, V217, P611, DOI 10.1016/0022-2836(91)90518-B; DUNLOP DJ, 1992, BLOOD, V79, P2221; Graham GJ, 1992, GROWTH FACTORS, V7, P151, DOI 10.3109/08977199209046404; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; GRAHAM GJ, 1991, EUR J CANCER, V27, P952, DOI 10.1016/0277-5379(91)90256-D; GRAHAM GJ, 1993, CELL GROWTH DIFFER, V4, P137; GRAHAM GJ, 1992, DEV BIOL, V151, P377, DOI 10.1016/0012-1606(92)90177-I; GRONENBORN AM, 1991, PROTEIN ENG, V4, P263, DOI 10.1093/protein/4.3.263; HASTON WS, 1988, METHOD ENZYMOL, V162, P17; HEUFLER C, 1992, J EXP MED, V176, P1221, DOI 10.1084/jem.176.4.1221; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORD BI, 1992, BLOOD, V79, P2605; LORIMORE SA, 1990, LEUKEMIA RES, V14, P481, DOI 10.1016/0145-2126(90)90036-9; MANTEL C, 1993, P NATL ACAD SCI USA, V90, P2232, DOI 10.1073/pnas.90.6.2232; MAZE R, 1992, J IMMUNOL, V149, P1004; MOSER B, 1993, J BIOL CHEM, V268, P7125; NEWMAN I, 1992, J IMMUNOL METHODS, V147, P43, DOI 10.1016/S0022-1759(12)80027-5; OBARU K, 1986, J BIOCHEM-TOKYO, V99, P885, DOI 10.1093/oxfordjournals.jbchem.a135549; PARKINSON EK, 1993, J INVEST DERMATOL, V101, P113, DOI 10.1111/1523-1747.ep12363603; PATEL SR, 1993, BIOCHEMISTRY-US, V32, P5466, DOI 10.1021/bi00071a024; PRAGNELL IB, 1988, BLOOD, V72, P196; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; STOECKLE M Y, 1990, New Biologist, V2, P313; WANG JM, 1993, J EXP MED, V177, P699, DOI 10.1084/jem.177.3.699; WEIR MP, 1987, BIOCHEM J, V245, P85, DOI 10.1042/bj2450085; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068	33	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4974	4978						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106472				2022-12-27	WOS:A1994MX57100045
J	SHOJI, W; YAMAMOTO, T; OBINATA, M				SHOJI, W; YAMAMOTO, T; OBINATA, M			THE HELIX-LOOP-HELIX PROTEIN ID INHIBITS DIFFERENTIATION OF MURINE ERYTHROLEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC; DNA-BINDING; ERYTHROID-DIFFERENTIATION; GENE; EXPRESSION; ENHANCER; COMMITMENT; MYOD; SCL; REGULATOR	Id is considered to be a negative regulator of basic helix-loop-helix proteins, which play important roles in cell type-specific transcription and cell lineage commitment. The Id gene was first cloned in murine erythroleukemia (MEL) cells, which can be induced to differentiate toward erythrocytes with Me(2)SO, and its mRNA decreases after differentiation in various types of cells. In this report, we demonstrate that overexpression of Id interferes with MEL cell differentiation and that inhibition of differentiation is accompanied by reduction in expression of three erythroid-specific genes. While down-regulation of Id is an early event in the differentiation process of MEL cells, E-box binding activity of these cells increases only at a later stage of differentiation, and this late increase is reduced by the overexpression of Id in the early stage. Sequential changes in the activity of several basic helix-loop-helix proteins thus appeared to be involved in erythroid differentiation.	TOHOKU UNIV,INST DEV AGING & CANC,DEPT CELL BIOL,AOBA KU,SENDAI 980,JAPAN	Tohoku University			Yamamoto, Tohru/A-3801-2012	Yamamoto, Tohru/0000-0002-1652-0233				APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENEZRA R, 1990, CELL, V61, P40; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BRIDGES K, 1981, J CELL BIOL, V90, P542, DOI 10.1083/jcb.90.2.542; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DOREN MV, 1991, DEVELOPMENT, V113, P245; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; FALETTO DL, 1985, CELL, V43, P315, DOI 10.1016/0092-8674(85)90037-6; FALETTO DL, 1985, J BIOL CHEM, V260, P4884; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GREEN AR, 1991, ONCOGENE, V6, P475; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KARRIN M, 1984, CELL, V36, P371; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LANNIGAN DA, 1985, J BIOL CHEM, V260, P7322; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MAGER D, 1978, J CELL PHYSIOL, V94, P275, DOI 10.1002/jcp.1040940305; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; OMORI Y, 1993, ONCOGENE, V8, P379; ONCLERCQ R, 1989, ONCOGENE RES, V4, P293; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; Sambrook J, 1989, MOL CLONING LABORATO; SHOJI W, 1993, JPN J CANCER RES, V84, P885, DOI 10.1111/j.1349-7006.1993.tb02062.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; VISVADER J, 1991, ONCOGENE, V6, P187; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	43	73	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5078	5084						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106486				2022-12-27	WOS:A1994MX57100061
J	WOOD, DR; POULLET, P; WILSON, BA; KHALIL, M; TANAKA, K; CANNON, JF; TAMANOI, F				WOOD, DR; POULLET, P; WILSON, BA; KHALIL, M; TANAKA, K; CANNON, JF; TAMANOI, F			BIOCHEMICAL-CHARACTERIZATION OF YEAST RAS2 MUTANTS REVEALS A NEW REGION OF RAS PROTEIN INVOLVED IN THE INTERACTION WITH GTPASE-ACTIVATING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GUANINE-NUCLEOTIDE; GENE-PRODUCT; CATALYTIC DOMAIN; BINDING DOMAIN; GAP; P21; REQUIREMENT; SENSITIVITY; MUTATION	We report biochemical characterization of two recently identified mutants of yeast RAS2, RAS2-E99K and RAS2-E130K. These mutants exhibit dominant activating phenotypes in yeast. Characterization of their intrinsic GTPase and GDP dissociation as well as their ability to stimulate adenylate cyclase showed that these activities of RAS2-E99K mutant protein were similar to those of the wild type protein. RAS2-E130K protein, on the other hand, differed from the wild type protein with a fast GDP dissociation rate and 2-fold higher activation of adenylate cyclase. When the sensitivity to GTPase-activating protein (GAP) was examined, we found that the RAS2-E99K protein was approximately 1200-fold less sensitive to NF1-GAP activity. In addition, the affinity for NF1 as revealed by competition binding experiments was reduced more than 150-fold with RAS2-E99K protein. Thus, the RAS2-E99K mutation affects interaction with GAP proteins. This mutation is particularly interesting because it is the first mutation identified in the alpha 3 region of ras protein that affects GAP interaction. The alpha 3 region appears to be directly involved in interaction with NF1, since peptides containing the sequence encompassing residue 99 of RAS2 inhibit NF1-GAP activity. These results suggest that the interaction between ras and GAP involves a larger region within ras than previously recognized.	UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; UNIV MISSOURI, DEPT MOLEC MICROBIOL & IMMUNOL, COLUMBIA, MO 65212 USA; KOBE UNIV, DEPT BIOCHEM, KOBE, HYOGO 650, JAPAN	University of California System; University of California Los Angeles; University of Missouri System; University of Missouri Columbia; Kobe University	WOOD, DR (corresponding author), UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA.			Cannon, John/0000-0001-6698-176X	NINDS NIH HHS [NS30054] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030054] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CAMONIS JH, 1988, MOL CELL BIOL, V8, P2980, DOI 10.1128/MCB.8.7.2980; CRECHET JB, 1986, EUR J BIOCHEM, V161, P647, DOI 10.1111/j.1432-1033.1986.tb10489.x; CRECHET JB, 1990, J BIOL CHEM, V265, P1563; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; HU JS, 1993, BIOCHEMISTRY-US, V32, P6763, DOI 10.1021/bi00077a031; LACAL JC, 1986, MOL CELL BIOL, V6, P4214, DOI 10.1128/MCB.6.12.4214; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; MARSHALL MS, 1987, MOL CELL BIOL, V7, P2309, DOI 10.1128/MCB.7.7.2309; MARSHALL MS, 1993, ONCOGENE, V8, P425; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; TAMANOI F, 1984, P NATL ACAD SCI-BIOL, V81, P6924, DOI 10.1073/pnas.81.22.6924; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1992, MOL CELL BIOL, V12, P631, DOI 10.1128/MCB.12.2.631; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILSON BA, 1993, ONCOGENE, V8, P3441; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZHANG K, 1991, SCIENCE, V254, P1630, DOI 10.1126/science.1749934	32	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5322	5327						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106517				2022-12-27	WOS:A1994MX57100094
J	CHANDRASEKARAN, S; TANZER, ML; GINIGER, MS				CHANDRASEKARAN, S; TANZER, ML; GINIGER, MS			OLIGOMANNOSIDES INITIATE CELL SPREADING OF LAMININ-ADHERENT MURINE MELANOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-MANNOSE; CARBOHYDRATE MOIETIES; MULTIDOMAIN PROTEIN; A-CHAIN; ADHESION; BINDING; GLYCOPROTEIN; OLIGOSACCHARIDES; ATTACHMENT; MIGRATION	Murine melanoma cells readily bind and spread on murine laminin. Uncoupling of spreading from adhesion occurs when unglycosylated laminin is used as the cellular substratum; spreading is restored by soluble glycosylated laminin or soluble glycopeptides of laminin. In this study, using kifunensine, we produced and characterized an oligomannoside-rich glycoform of laminin. When used as a substratum for cell attachment and spreading, this laminin was as effective as mature glycosylated laminin. When added in solution to unglycosylated laminin-adherent cells, kifunensine-laminin was more effective in promoting cell spreading than mature glycosylated laminin. Reconstitution with soluble polysaccharides showed that cell spreading was initiated rapidly by microgram amounts of mannan but not other polysaccharides and approached a maximum within 1 h; titration with mannan yielded an adsorption isotherm profile. Mannose was an antagonist, preventing mannan from restoring cell spreading, but it was not an agonist. A Pronase digest of mature glycosylated laminin, depleted of its oligomannoside-peptides, was unable to restore cell spreading, whereas a control digest was fully active. Melanoma cells were unable to bind to three different neoglycoprotein surfaces, but when soluble unglycosylated laminin was present in the medium the cells adhered to and spread only upon mannosylated bovine serum albumin. Of the various cell lines known to interact with glycosylated laminin only murine melanoma cells showed oligomannoside-dependent, spreading on an unglycosylated laminin substratum. The composite results indicate that oligomannosides are necessary to initiate murine melanoma cell spreading on laminin but are not sufficient for cell adhesion.	UNIV CONNECTICUT,CTR HLTH,SCH DENT MED,DEPT BIOSTRUCT & FUNCT,FARMINGTON,CT 06030	University of Connecticut					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR017220] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-17220] Funding Source: Medline; NIDCR NIH HHS [DE-00157] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARUMUGHAM RG, 1986, BIOCHIM BIOPHYS ACTA, V883, P112, DOI 10.1016/0304-4165(86)90142-X; AUMAILLEY M, 1987, J BIOL CHEM, V262, P11532; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BRONNERFRASER M, 1985, J CELL BIOL, V101, P610, DOI 10.1083/jcb.101.2.610; CHANDRASEKARAN S, 1991, J CELL BIOCHEM, V46, P115, DOI 10.1002/jcb.240460205; CHANDRASEKARAN S, 1994, J BIOL CHEM, V269, P3367; CODOGNO P, 1988, J CELL PHYSIOL, V136, P463, DOI 10.1002/jcp.1041360310; DEAN JW, 1988, BIOCHEM BIOPH RES CO, V156, P411, DOI 10.1016/S0006-291X(88)80856-8; DEAN JW, 1990, J BIOL CHEM, V265, P12553; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; FAHRIG T, 1990, EUR J NEUROSCI, V2, P153, DOI 10.1111/j.1460-9568.1990.tb00407.x; FLIEGEL SEG, 1986, CLIN EXP METASTAS, V4, P259; FUJIWARA S, 1988, BIOCHEM J, V252, P453, DOI 10.1042/bj2520453; HOWE CC, 1984, MOL CELL BIOL, V4, P1; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES GE, 1986, J CELL BIOL, V103, P1663, DOI 10.1083/jcb.103.5.1663; KNIBBS RN, 1989, BIOCHEMISTRY-US, V28, P6379, DOI 10.1021/bi00441a034; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LU ML, 1992, J CELL SCI, V101, P873; MERRIL CR, 1983, METHOD ENZYMOL, V96, P230; MUCHMORE A, 1990, CANCER RES, V50, P6285; MUCHMORE AV, 1990, J LEUKOCYTE BIOL, V48, P457, DOI 10.1002/jlb.48.5.457; OKA JA, 1986, J CELL BIOL, V103, P1055, DOI 10.1083/jcb.103.3.1055; RAO CN, 1983, ARCH BIOCHEM BIOPHYS, V227, P118, DOI 10.1016/0003-9861(83)90354-5; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SATHYAMOORTHY N, 1991, MOL CELL BIOCHEM, V102, P139; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TIMPL R, 1979, J BIOL CHEM, V254, P9933; TRIMBLE RB, 1991, J BIOL CHEM, V266, P1646; TRINKAUSRANDALL V, 1988, CELL TISSUE RES, V251, P315, DOI 10.1007/BF00215839; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	36	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3356	3366						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106375				2022-12-27	WOS:A1994MV63100037
J	GEKAKIS, N; JOHNSON, RC; JERKINS, A; MAINS, RE; SUL, HS				GEKAKIS, N; JOHNSON, RC; JERKINS, A; MAINS, RE; SUL, HS			STRUCTURE, DISTRIBUTION, AND FUNCTIONAL EXPRESSION OF THE PHOSPHOFRUCTOKINASE-C ISOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PHOSPHOFRUCTOKINASE; MUSCLE PHOSPHOFRUCTOKINASE; RABBIT BRAIN; REGULATORY PROPERTIES; MESSENGER-RNA; RAT; ISOENZYMES; FORMS; SITES; GENE	To elucidate the structure, tissue-specific expression, and allosteric properties of phosphofructokinase-C (PFK-C), we cloned the cDNA for PFK-C from a rat hypothalamic cDNA library. The cDNA is 2643 base pairs long and encodes a protein of 765 amino acids. The deduced amino acid sequence is highly homologous to PFK-M (muscle) and PFK-L (liver), 69 and 65% amino acid identity, respectively, especially at substrate binding and catalytic sites, while the allosteric binding sites are less conserved. Tissue-specific expression of PFK-C was investigated by Northern blot analysis. PFK-C mRNA was detected in several brain regions and the anterior pituitary but not in liver, skeletal muscle, or several other tissues. In situ hybridization showed that PFK-C is expressed at a higher level in higher brain regions such as the cortex, compared with the midbrain and basal ganglia, while PFK-L is expressed at approximately equal levels throughout the brain. Expression plasmids containing PFK-C and PFK-L coding sequences were constructed and expressed by transient transfection into CMT cells. Expression of transfected PFKs was demonstrated by PFK enzymatic activity and by Western blotting with anti-rat brain and liver PFK antisera. Allosteric regulatory properties of PFK-C and PFK-L expressed in CMT cells were compared. Fructose 2,6-bisphosphate, a potent activator of PFK, decreased the K(m) of PFK-C for fructose 6-phosphate from 200 to 60 mum while decreasing that of PFK-L from 300 to 55 muM. The properties of PFK-C and PFK-L expressed in CMT cells clearly demonstrate the allosteric differences between the different PFK isozymes.	HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA	Harvard University; Harvard T.H. Chan School of Public Health; Johns Hopkins University			Han, Zaiqi/AAI-2233-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040518, R01DK036264] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00097] Funding Source: Medline; NIDDK NIH HHS [DK-36264, DK-40518] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BHAT RV, 1992, J PHARMACOL EXP THER, V263, P343; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DUNAWAY GA, 1985, J BIOL CHEM, V260, P4180; DUNAWAY GA, 1983, MOL CELL BIOCHEM, V52, P75; DUNAWAY GA, 1974, ARCH BIOCHEM BIOPHYS, V162, P620, DOI 10.1016/0003-9861(74)90224-0; EVANS PR, 1981, PHILOS T ROY SOC B, V293, P53, DOI 10.1098/rstb.1981.0059; FENG DF, 1990, METHOD ENZYMOL, V183, P375; FOE LG, 1985, J BIOL CHEM, V260, P726; FOE LG, 1982, J BIOL CHEM, V257, P6368; GEHNRICH SC, 1988, J BIOL CHEM, V263, P11755; GEKAKIS N, 1989, J BIOL CHEM, V264, P3658; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; HELLINGA HW, 1987, NATURE, V327, P437, DOI 10.1038/327437a0; HELLINGA HW, 1985, EUR J BIOCHEM, V149, P363, DOI 10.1111/j.1432-1033.1985.tb08934.x; ISHIKAWA E, 1990, J BIOL CHEM, V265, P18875; KEMP RG, 1983, MOL CELL BIOCHEM, V57, P147, DOI 10.1007/BF00849191; LEE CP, 1987, J BIOL CHEM, V262, P4195; NAKAJIMA H, 1987, FEBS LETT, V223, P113, DOI 10.1016/0014-5793(87)80519-7; NARABAYASHI H, 1985, J BIOL CHEM, V260, P9750; OGUSHI S, 1990, J BIOL CHEM, V265, P10943; POORMAN RA, 1984, NATURE, V309, P467, DOI 10.1038/309467a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STOFFERS DA, 1989, P NATL ACAD SCI USA, V86, P735, DOI 10.1073/pnas.86.2.735; TSAI MY, 1974, J BIOL CHEM, V249, P6590; Uyeda K, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P193; VALAITIS AP, 1987, J BIOL CHEM, V262, P5044; VALAITIS AP, 1989, BIOCHIM BIOPHYS ACTA, V995, P187, DOI 10.1016/0167-4838(89)90079-4; VALDEZ BC, 1989, J BIOL CHEM, V264, P131	29	23	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3348	3355						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106374				2022-12-27	WOS:A1994MV63100036
J	HUBBARD, SC; WALLS, L; RULEY, HE; MUCHMORE, EA				HUBBARD, SC; WALLS, L; RULEY, HE; MUCHMORE, EA			GENERATION OF CHINESE-HAMSTER OVARY CELL GLYCOSYLATION MUTANTS BY RETROVIRAL INSERTIONAL MUTAGENESIS - INTEGRATION INTO A DISCRETE LOCUS GENERATES MUTANTS EXPRESSING HIGH-LEVELS OF N-GLYCOLYLNEURAMINIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEAT-GERM-AGGLUTININ; GOLGI VESICLE MEMBRANES; MOUSE-LIVER CYTOSOL; ACETYLNEURAMINIC ACID; ANIMAL-CELLS; SIALIC-ACID; PROMOTER TRAP; GLOBIN GENES; HUMAN-COLON; HYDROXYLATION	Retroviral insertional mutagenesis can both generate somatic cell mutants and pinpoint the genomic locus associated with a mutant phenotype. In the present study, this approach was applied to Chinese hamster ovary cells (CHO) made susceptible to Moloney murine leukemia virus (MoMuLV) infection by stable expression of an ecotropic retrovirus receptor. These CHO cells were infected with a replication incompetent MoMuLV construct with a promoterless hygromycin phosphotransferase (hygro) gene inserted into the U3 region of the long terminal repeat and a second selectable marker, neomycin phosphotransferase (neo), expressed from an internal promoter. CHO clones containing integrated proviruses were selected with hygromycin or G418, and the subset of these with reduced cell surface Neu5Ac were then selected with wheat germ agglutinin (WGA). The majority of the resulting clones had a phenotype not previously described for WGA-resistant CHO mutants arising spontaneously or from chemical mutagenesis: Neu5Ac was almost completely replaced by Neu5Gc. We have provisionally termed these clones SAP mutants, for sialic acid phenotype. Southern analysis of HindIII digested DNA from four SAP mutants revealed that the MoMuLV provirus is present in a 10.4-kilobase (kb) fragment. Probing with a flanking CHO sequence resulted in equivalent hybridization to a 4.6-kb fragment and the 10.4-kb provirus-containing fragment in all four cases, while uninfected parental cells and non-SAP glycosylation mutants generated in the same retrovirus insertional mutagenesis experiments yielded only the 4.6-kb fragment. Sequencing of the 3'-flanking DNA revealed that each of the four SAP mutants had a unique provirus integration site falling within a 796 bp region of the CHO genome. The frequency with which SAP mutants arise suggests that this may be a preferred site for retrovirus integration.	VET ADM MED CTR, DEPT MED, DIV HEMATOL ONCOL, 3350 LA JOLLA VILLAGE DR, SAN DIEGO, CA 92161 USA; UCSD, CTR CANC, SAN DIEGO, CA 92161 USA; MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; Massachusetts Institute of Technology (MIT)					NCI NIH HHS [R01-CA40602] Funding Source: Medline; NHGRI NIH HHS [R01 HG00684] Funding Source: Medline; NIGMS NIH HHS [R29-GM43165] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040602] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043165] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BHAVANANDAN VP, 1979, J BIOL CHEM, V254, P4000; CHANG W, 1993, VIROLOGY, V193, P737, DOI 10.1006/viro.1993.1182; CHEN J, IN PRESS METHODS MOL, V4; DENNIS JW, 1986, CANCER RES, V46, P4594; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DIAZ S, 1985, ANAL BIOCHEM, V150, P32, DOI 10.1016/0003-2697(85)90438-5; FUJII Y, 1982, MOL IMMUNOL, V19, P87, DOI 10.1016/0161-5890(82)90250-4; GAHM SJ, 1991, P NATL ACAD SCI USA, V88, P10267, DOI 10.1073/pnas.88.22.10267; GOFF SP, 1987, METHOD ENZYMOL, V152, P469; HAMADA H, 1982, NATURE, V298, P396, DOI 10.1038/298396a0; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HIRABAYASHI Y, 1987, JPN J CANCER RES, V78, P251; HUBBARD SC, 1988, J BIOL CHEM, V263, P19303; HUBBARD SC, 1987, J BIOL CHEM, V262, P16403; JAROLIM P, 1991, P NATL ACAD SCI USA, V88, P11022, DOI 10.1073/pnas.88.24.11022; KILPATRICK MW, 1984, J BIOL CHEM, V259, P7268; KOZUTSUMI Y, 1991, J BIOCHEM, V110, P429, DOI 10.1093/oxfordjournals.jbchem.a123598; KOZUTSUMI Y, 1990, J BIOCHEM, V108, P704, DOI 10.1093/oxfordjournals.jbchem.a123268; MAGETDANA R, 1981, EUR J BIOCHEM, V114, P11; MERRICK JM, 1978, INT ARCH ALLER A IMM, V57, P477, DOI 10.1159/000232140; MUCHMORE EA, 1987, FASEB J, V1, P229, DOI 10.1096/fasebj.1.3.3623000; MUCHMORE EA, 1989, J BIOL CHEM, V264, P20216; MUCHMORE EA, 1992, GLYCOBIOLOGY, V2, P337, DOI 10.1093/glycob/2.4.337; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; OLEE TW, 1992, J EXP MED, V175, P831, DOI 10.1084/jem.175.3.831; Sambrook J, 1989, MOL CLONING LABORATO; SANDMEYER SB, 1990, ANNU REV GENET, V24, P491; SCHAUER R, 1982, CELL BIOL MONOGR, V10, P374; SHAW L, 1991, GLYCOCONJUGATE J, V8, P434, DOI 10.1007/BF00731295; SHAW L, 1988, BIOL CHEM H-S, V369, P477, DOI 10.1515/bchm3.1988.369.1.477; SHEN SH, 1981, CELL, V26, P191, DOI 10.1016/0092-8674(81)90302-0; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SIMINOVITCH L, 1985, MOL CELL GENETICS, P869; SLIGHTOM JL, 1980, CELL, V21, P627, DOI 10.1016/0092-8674(80)90426-2; STANLEY P, 1985, MOL CELL BIOL, V5, P1204, DOI 10.1128/MCB.5.6.1204; STANLEY P, 1981, MOL CELL BIOL, V1, P687, DOI 10.1128/MCB.1.8.687; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; STANLEY P, 1975, SOMAT CELL GENET, V1, P3, DOI 10.1007/BF01538729; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; STANLEY P, 1983, METHOD ENZYMOL, V96, P157; STANLEY P, 1985, MOL CELL BIOL, V5, P923, DOI 10.1128/MCB.5.5.923; STANLEY P, 1985, MOL CELL GENETICS CH, P745; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARMUS HE, 1981, CELL, V25, P23, DOI 10.1016/0092-8674(81)90228-2; VONMELCHNER H, 1989, J VIROL, V63, P3227, DOI 10.1128/JVI.63.8.3227-3233.1989; VONMELCHNER H, 1990, P NATL ACAD SCI USA, V87, P3733, DOI 10.1073/pnas.87.10.3733; WEICKERT MJ, 1989, USB EDITORIAL COMMEN, V16, P5	51	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3717	3724						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106417				2022-12-27	WOS:A1994MV63100086
J	TEAL, SB; HSU, VW; PETERS, PJ; KLAUSNER, RD; DONALDSON, JG				TEAL, SB; HSU, VW; PETERS, PJ; KLAUSNER, RD; DONALDSON, JG			AN ACTIVATING MUTATION IN ARF1 STABILIZES COATOMER BINDING TO GOLGI MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADP-RIBOSYLATION FACTOR; SENSITIVE G-PROTEIN; BREFELDIN-A; GUANINE-NUCLEOTIDE; COATED VESICLES; BETA-COP; GTP; EXPRESSION; CISTERNAE; TRANSPORT	The Ras-related protein ADP-ribosylation factor 1 (ARF1) is a low molecular weight GTP binding protein, which in its GTP state supports the binding of coatomer, a cytosolic coat protein complex, to Golgi membranes. To create an ''active'' ARF, we constructed a point mutation in ARF1, Q71I, which was predicted to slow the rate of GTP hydrolysis. We demonstrate that Q71I, in contrast to wild type ARF1, exhibits a 2-3-fold increase in the half-life of ARF-GTP and is able to promote stable coatomer binding to Golgi membranes in the presence of GTP in vitro. Additionally, Q71I is able to support the binding of a significant amount of coatomer to membranes in the absence of added nucleotides, effectively bypassing the brefeldin A (BFA)-sensitive exchange activity. Furthermore, transfection of cells with Q71I, but not ARF1, renders the Golgi association of coatomer resistant to the effects of BFA in vivo. These observations provide compelling evidence that ARF1 is a necessary GTP binding protein that regulates the reversible binding of coat proteins to Golgi membranes and that the effects of BFA on this process in living cells must be a consequence of BFA's inhibition of guanine nucleotide exchange onto ARF1.	NICHHD,CELL BIOL & METAB BRANCH,BLDG 18T-101,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Teal, Stephanie/A-3097-2019	Teal, Stephanie/0000-0002-0167-1071				BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; ORCI L, 1991, CELL, V64, P1183; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PATEL G, 1992, ONCOGENE, V7, P283; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; SERAFINI T, 1992, METHOD ENZYMOL, V219, P286; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WEISS O, 1989, J BIOL CHEM, V264, P21066	24	92	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3135	3138						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106346				2022-12-27	WOS:A1994MV63100004
J	COFFEY, ET; SIHRA, TS; NICHOLLS, DG				COFFEY, ET; SIHRA, TS; NICHOLLS, DG			PROTEIN-KINASE-C AND THE REGULATION OF GLUTAMATE EXOCYTOSIS FROM CEREBROCORTICAL SYNAPTOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED NERVE-TERMINALS; RAT CORTICAL SYNAPTOSOMES; ADRENAL CHROMAFFIN CELLS; GAMMA-AMINOBUTYRIC-ACID; SUBSTRATE B-50 GAP-43; CYTOSOLIC FREE CA-2+; PHORBOL ESTER; NEUROTRANSMITTER RELEASE; NORADRENALINE RELEASE; RECEPTOR STIMULATION	The role of protein kinase C (PKC) in the regulation of transmitter glutamate release from rat cerebral cortical synaptosomes is investigated. Two depolarization protocols are used: first, elevated KCl, which produces a clamped depolarization, and second, 4-aminopyridine, which evokes spontaneous ''action potentials'' allowing any potential modulation of Na+ or K+ channels to influence release. Although the PKC inhibitor Ro 31-8220 prevents both the depolarization-evoked and phorbol dibutyrate (PDBu)-evoked phosphorylation of the major presynaptic PKC substrate, myristoylated alanine-rich C kinase substrate, it is without effect on KCl-evoked Ca2+-dependent glutamate release. Ro 31-8220 totally inhibits the Ca2+-dependent 4-aminopyridine-evoked release of glutamate in the presence and absence of PDBu and again decreases the phosphorylation of myristoylated alanine-rich C kinase substrate. Ro 31-8220 strongly inhibits the 4-aminopyridine-evoked increase in [Ca2+] both in the presence and absence of PDBu and antagonizes the PDBu enhancement of depolarization. This indicates that PKC isoforms activatable by PDBu and sensitive to Ro 31-8220 play no discernable role in Ca2+-secretion coupling per se in cerebral cortical glutamatergic nerve terminals, but that the kinase plays a major role in regulating the depolarization of the terminal.	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	University of Dundee			Sihra, Talvinder S/A-4581-2009; NICHOLLS, DAVID G/K-4300-2012	Coffey, Eleanor/0000-0002-9717-5610				ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; ALLGAIER C, 1991, J PHARMACOL EXP THER, V258, P143; AUGUSTINE GJ, 1990, J PHYSIOL-LONDON, V431, P343, DOI 10.1113/jphysiol.1990.sp018333; BARRIE AP, 1991, J NEUROCHEM, V57, P1398, DOI 10.1111/j.1471-4159.1991.tb08306.x; BARRIE AP, 1993, J NEUROCHEM, V60, P1081; BARTMANN P, 1989, N-S ARCH PHARMACOL, V339, P302; BERNSTEIN BW, 1989, NEURON, V3, P257, DOI 10.1016/0896-6273(89)90039-1; BITTNER MA, 1990, J NEUROCHEM, V54, P205, DOI 10.1111/j.1471-4159.1990.tb13302.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P174, DOI 10.1016/0304-4157(91)90024-Q; BURGOYNE RD, 1989, CELL SIGNAL, V1, P323, DOI 10.1016/0898-6568(89)90051-X; COGGINS PJ, 1991, J NEUROCHEM, V56, P1095, DOI 10.1111/j.1471-4159.1991.tb11398.x; COGGINS PJ, 1990, J NEUROCHEM, V54, P274, DOI 10.1111/j.1471-4159.1990.tb13311.x; COHEN LB, 1974, J MEMBRANE BIOL, V19, P1, DOI 10.1007/BF01869968; DEGRAAN PNE, 1990, J NEUROCHEM, V55, P2139; DEKKER LV, 1990, J NEUROCHEM, V54, P1645, DOI 10.1111/j.1471-4159.1990.tb01217.x; DEKKER LV, 1991, J NEUROCHEM, V56, P1146, DOI 10.1111/j.1471-4159.1991.tb11404.x; DIVIRGILIO F, 1986, J BIOL CHEM, V261, P32; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; FAZELI MS, 1992, TRENDS NEUROSCI, V15, P115, DOI 10.1016/0166-2236(92)90350-H; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; HERRERO I, 1992, J NEUROCHEM, V59, P1574, DOI 10.1111/j.1471-4159.1992.tb08478.x; HUANG HY, 1989, EUR J PHARMACOL, V169, P115; HUANG HY, 1988, EUR J PHARMACOL, V153, P175; KACZMAREK LK, 1987, TRENDS NEUROSCI, V10, P30, DOI 10.1016/0166-2236(87)90122-6; KAUPPINEN RA, 1988, NEUROSCIENCE, V27, P175, DOI 10.1016/0306-4522(88)90228-X; KNIGHT DE, 1983, FEBS LETT, V160, P98, DOI 10.1016/0014-5793(83)80944-2; LINDEN DJ, 1992, J NEUROSCI, V12, P3601; MCMAHON HT, 1991, J NEUROCHEM, V56, P86, DOI 10.1111/j.1471-4159.1991.tb02566.x; MCMAHON HT, 1992, J BIOL CHEM, V267, P21338; MURPHY CT, 1992, BIOCHEM J, V283, P159, DOI 10.1042/bj2830159; NEUMANN R, 1991, SCIENCE, V254, P115; NICHOLLS DG, 1992, NATURE, V360, P106, DOI 10.1038/360106a0; NICHOLS RA, 1987, J NEUROCHEM, V48, P615, DOI 10.1111/j.1471-4159.1987.tb04137.x; POCOCK JM, 1992, EUR J PHARM-MOLEC PH, V226, P343, DOI 10.1016/0922-4106(92)90052-W; RAMDINE R, 1989, SYNAPSE, V3, P173, DOI 10.1002/syn.890030302; RANE SG, 1989, NEURON, V3, P239, DOI 10.1016/0896-6273(89)90037-8; SCHROEDER JE, 1990, J NEUROSCI, V10, P947; SHEARMAN MS, 1991, J NEUROCHEM, V56, P1255, DOI 10.1111/j.1471-4159.1991.tb11419.x; TANAKA C, 1986, FEBS LETT, V195, P129, DOI 10.1016/0014-5793(86)80146-6; TIBBS GR, 1989, J NEUROCHEM, V53, P1693, DOI 10.1111/j.1471-4159.1989.tb09232.x; TIBBS GR, 1989, J NEUROCHEM, V52, P201, DOI 10.1111/j.1471-4159.1989.tb10917.x; VERHAGE M, 1991, NEURON, V6, P517, DOI 10.1016/0896-6273(91)90054-4; VERSTEEG DHG, 1987, BRAIN RES, V416, P343, DOI 10.1016/0006-8993(87)90916-4; VITALE ML, 1992, NEUROSCIENCE, V51, P463, DOI 10.1016/0306-4522(92)90330-5; WANG JKT, 1988, J NEUROSCI, V8, P281; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; ZURGIL N, 1986, NEUROSCIENCE, V19, P1255, DOI 10.1016/0306-4522(86)90140-5	51	101	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21060	21065						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8104937				2022-12-27	WOS:A1993MA28800065
J	MACBEATH, JRE; SHACKLETON, DR; HULMES, DJS				MACBEATH, JRE; SHACKLETON, DR; HULMES, DJS			TYROSINE-RICH ACIDIC MATRIX PROTEIN (TRAMP) ACCELERATES COLLAGEN FIBRIL FORMATION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELF-ASSEMBLY INVITRO; LYSYL OXIDASE; I COLLAGEN; ARTICULAR-CARTILAGE; LIGHT-SCATTERING; FIBER FORMATION; FIBRILLOGENESIS; PROTEOGLYCANS; SKIN; FIBRONECTIN	Tyrosine-rich acidic matrix protein (TRAMP) is a recently discovered protein that co-purifies with porcine skin lysyl oxidase and is equivalent to the M(r) 22,000 extracellular matrix protein from bovine skin that co-purifies with dermatan sulfate proteoglycans (Cronshaw, A. D., MacBeath, J. R. E., Shackleton, D. R., Collins, J. F., Fothergill-Gilmore, L. A., and Hulmes, D. J. S. (1993) Matrix 13, 255-266; Neame, P. J., Choi, H. U., and Rosenberg, L. C. (1989) J. Biol. Chem. 264, 5474-5479). The effect of TRAMP on collagen fibril formation was studied in vitro by reconstitution of fibrils from lathyritic rat skin collagen I. Fibril formation was initiated by the warm start procedure, in which acidic collagen solutions and double strength neutral buffer, both preincubated separately at 34-degrees-C, were mixed. When monitored by turbidimetry, TRAMP was found to accelerate collagen fibril formation. Acceleration occurred at sub-stoichiometric molar ratios of TRAMP to collagen, and the presence of TRAMP stabilized the fibrils against low temperature dissociation. It was confirmed by centrifugation that the amount of fibrillar collagen formed in the presence of TRAMP was greater than in its absence. By SDS-polyacrylamide gel electrophoresis and scanning densitometry, binding of TRAMP to collagen was detected that approached saturation with a molar ratio of TRAMP to collagen of approximately 1:2. Fibrils formed in the presence of TRAMP were normal when observed by electron microscopy, although fibril diameters were smaller than the controls. TRAMP was found to partially reverse the inhibitory effects of urea and increased ionic strength on the kinetics of fibril formation, although inhibition by glucose was unaffected. TRAMP also accelerated the assembly of pepsin-treated collagen, where the non-helical, telopeptide regions were partially removed. Acceleration of collagen fibril formation by TRAMP is discussed in the light of the known effects of other extracellular matrix components on this process.	UNIV EDINBURGH,DEPT BIOCHEM,HUGH ROBSON BLDG,GEORGE SQ,EDINBURGH EH8 9XD,SCOTLAND	University of Edinburgh				Hulmes, David/0000-0002-0651-1317	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADELMANN B, 1966, BIOCHEM Z, V346, P282; AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; ANDERSON JC, 1977, BIOCHEM J, V168, P345; ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; BERNENGO JC, 1983, J BIOL CHEM, V258, P1001; BIRK DE, 1981, BIOCHIM BIOPHYS ACTA, V670, P362, DOI 10.1016/0005-2795(81)90108-2; BORNSTEIN P, 1980, ANNU REV BIOCHEM, V49, P957, DOI 10.1146/annurev.bi.49.070180.004521; BRENNAN M, 1980, BIOPOLYMERS, V19, P1861, DOI 10.1002/bip.1980.360191013; BROKAW JL, 1985, INT J BIOL MACROMOL, V7, P135, DOI 10.1016/0141-8130(85)90015-7; CARR ME, 1978, MACROMOLECULES, V11, P46, DOI 10.1021/ma60061a009; CHANDRAKASAN G, 1976, J BIOL CHEM, V251, P6062; Chapman JA, 1984, ULTRASTRUCTURE CONNE; CHOI HU, 1989, J BIOL CHEM, V264, P2876; COCKINGJOHNSON D, 1983, BIOCHIM BIOPHYS ACTA, V742, P49, DOI 10.1016/0167-4838(83)90357-6; COMPER WD, 1977, BIOPOLYMERS, V16, P2133, DOI 10.1002/bip.1977.360161005; CRONLUND AL, 1985, CONNECT TISSUE RES, V14, P109, DOI 10.3109/03008208509015017; CRONSHAW AD, 1993, MATRIX, V13, P255, DOI 10.1016/S0934-8832(11)80009-0; DOMBI GW, 1985, BIOCHEM J, V228, P551, DOI 10.1042/bj2280551; DRAKE MP, 1966, BIOCHEMISTRY-US, V5, P301, DOI 10.1021/bi00865a039; FESSLER JH, 1975, J SUPRAMOL STR CELL, V3, P17, DOI 10.1002/jss.400030103; GARG AK, 1989, BIOMATERIALS, V10, P413, DOI 10.1016/0142-9612(89)90133-6; GAVRIEL P, 1988, BIOCHEMISTRY-US, V27, P2811, DOI 10.1021/bi00408a022; GELMAN RA, 1979, J BIOL CHEM, V254, P1741; HAY ED, 1991, CELL BIOL EXTRACELLU, P1; HAYASHI T, 1972, J BIOCHEM-TOKYO, V72, P749, DOI 10.1093/oxfordjournals.jbchem.a129953; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HOLMES DF, 1986, INT J BIOL MACROMOL, V8, P161, DOI 10.1016/0141-8130(86)90020-6; Hulmes DJS, 1992, ESSAYS BIOCHEM, V27, P49; KADLER KE, 1986, ANN NY ACAD SCI, V460, P456; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KARVONEN RL, 1992, CONNECT TISSUE RES, V27, P235, DOI 10.3109/03008209209006999; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLEINMAN HK, 1981, BIOCHEMISTRY-US, V20, P2325, DOI 10.1021/bi00511a039; KUIJER R, 1988, CONNECT TISSUE RES, V17, P83, DOI 10.3109/03008208809015022; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWANDOWSKA K, 1991, J CELL SCI, V99, P657; LIEN YH, 1984, SCIENCE, V225, P1489, DOI 10.1126/science.6147899; MATHEWS MB, 1968, BIOCHEM J, V109, P517, DOI 10.1042/bj1090517; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MILLER EJ, 1971, BIOCHEMISTRY-US, V10, P1652, DOI 10.1021/bi00785a024; NEAME PJ, 1989, J BIOL CHEM, V264, P5474; OBRINK B, 1973, EUR J BIOCHEM, V34, P129, DOI 10.1111/j.1432-1033.1973.tb02739.x; OEGEMA TR, 1975, ARCH BIOCHEM BIOPHYS, V170, P698, DOI 10.1016/0003-9861(75)90167-8; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; OLDBERG A, 1990, BIOCHEM SOC T, V18, P789, DOI 10.1042/bst0180789; PAYNE KJ, 1986, BIOPOLYMERS, V25, P1185, DOI 10.1002/bip.360250703; RATHI AN, 1989, BIOCHEM MED METAB B, V42, P209, DOI 10.1016/0885-4505(89)90057-1; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SCOTT JE, 1991, INT J BIOL MACROMOL, V13, P157, DOI 10.1016/0141-8130(91)90041-R; SHACKLETON DR, 1990, ANAL BIOCHEM, V185, P359, DOI 10.1016/0003-2697(90)90308-V; SHACKLETON DR, 1990, BIOCHEM J, V266, P917; SIEGEL RC, 1974, P NATL ACAD SCI USA, V71, P4826, DOI 10.1073/pnas.71.12.4826; SILVER FH, 1979, BIOPOLYMERS, V18, P2523, DOI 10.1002/bip.1979.360181011; SNOWDEN JM, 1979, BIOCHIM BIOPHYS ACTA, V580, P372, DOI 10.1016/0005-2795(79)90149-1; SNOWDEN JM, 1980, BIOPOLYMERS, V19, P767, DOI 10.1002/bip.1980.360190405; SPERANZA ML, 1987, COLLAGEN REL RES, V7, P115; TANG SS, 1983, J BIOL CHEM, V258, P4331; TOOLE BP, 1968, ARCH BIOCHEM BIOPHYS, V128, P567, DOI 10.1016/0003-9861(68)90064-7; TOOLE BP, 1969, NATURE, V222, P872, DOI 10.1038/222872a0; TOOLE BP, 1968, BIOCHEM J, V109, P857, DOI 10.1042/bj1090857; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; Veis A, 1988, COLLAGEN, V1, P113; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WARD NP, 1986, J MOL BIOL, V190, P107, DOI 10.1016/0022-2836(86)90079-3; WILLIAMS BR, 1978, J BIOL CHEM, V253, P6578; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0; WOOD GC, 1960, BIOCHEM J, V75, P605, DOI 10.1042/bj0750605	67	57	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19826	19832						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8103522				2022-12-27	WOS:A1993LW81900100
J	GALANOPOULOU, AS; KENT, G; RABBANI, SN; SEIDAH, NG; PATEL, YC				GALANOPOULOU, AS; KENT, G; RABBANI, SN; SEIDAH, NG; PATEL, YC			HETEROLOGOUS PROCESSING OF PROSOMATOSTATIN IN CONSTITUTIVE AND REGULATED SECRETORY PATHWAYS - PUTATIVE ROLE OF THE ENDOPROTEASES FURIN, PC1, AND PC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPEPTIDE CONVERTING ENZYME; MONOBASIC SITES; CELLS; PROHORMONE; SOMATOSTATIN; CLEAVAGE; SEQUENCE; KEX2; RAT; PREPROSOMATOSTATIN	Mammalian prosomatostatin (PSS) is cleaved at a dibasic Arg-Lys site to produce somatostatin-14 (SS-14) and at monobasic Arg and Lys sites to yield SS-28 and PSS(1-10) (antrin), respectively. Furin, PC1, and PC2 are three recently discovered mammalian endoproteases localized either to the constitutive (furin) or regulated (PC1, PC2) secretory pathways. In this study we have compared the heterologous processing of PSS in transiently transfected endocrine (AtT-20 pituitary) and nonendocrine (COS-7 monkey kidney, PC12 pheochromocytoma) tumor cells. We have correlated the efficiency of processing of PSS to SS-14, SS-28, and PSS(1-10) with (i) secretion through the constitutive or regulated pathways; (ii) endogenous expression of mRNA for furin, PC1, and PC2; and (iii) exogenous expression of PC1 and PC2 in cells that do not contain these enzymes in order to delineate the putative role of these enzymes in mediating PSS cleavage at dibasic and monobasic sites and to localize the proteolytic events to specific compartments of the secretory pathways. COS-7 and PC12 cells expressed only furin, secreted constitutively, and processed PSS preferentially at monobasic sites to SS-28 (40-43%) and antrin (27-29%). Processing, however, was inefficient as suggested by large amounts of unprocessed PSS. In contrast, AtT-20 cells showed regulated secretion, expressed all three endoproteases (with high levels of PCI), and processed PSS efficiently to mainly SS-14. PCI, but not PC2, exogenously coexpressed with PSS in COS-7 cells produced significant conversion to SS-14 but not SS-28. This study shows that PSS is capable of monobasic cleavage in the constitutive secretory pathway. Such processing could be mediated by a furin-like enzyme but is relatively inefficient. PC1 can effect dibasic cleavage of PSS whereas PC2 is without influence on PSS processing at least within the constitutive secretory pathway. Although monobasic and dibasic processing of PSS in COS-7 cells correlates with furin-like and PC1 activity, respectively, the relative inefficiency of such processing suggests that compartmentalization of proteolytic events in secretory vesicles or other more specific endoproteases may be required.	ROYAL VICTORIA HOSP, DEPT MED, 687 PINE AVE W, MONTREAL H3A 1A1, QUEBEC, CANADA; ROYAL VICTORIA HOSP, DEPT NEUROL & NEUROSURG, MONTREAL H3A 1A1, QUEBEC, CANADA; MCGILL UNIV, FRASER LABS, MONTREAL H3A 1A1, QUEBEC, CANADA; MONTREAL NEUROL HOSP & INST, MONTREAL H3A 2B4, QUEBEC, CANADA; CLIN RES INST MONTREAL, MONTREAL H2W 1R7, QUEBEC, CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342				ARGOS P, 1983, J BIOL CHEM, V258, P8788; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BEINFELD MC, 1989, J BIOL CHEM, V264, P4460; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BENOIT R, 1984, BRAIN RES, V311, P23, DOI 10.1016/0006-8993(84)91394-5; BENOIT R, 1982, P NATL ACAD SCI-BIOL, V79, P917, DOI 10.1073/pnas.79.3.917; BENOIT R, 1987, SCIENCE, V238, P1126, DOI 10.1126/science.2891188; BENOIT R, 1990, METABOLISM, V39, P22, DOI 10.1016/0026-0495(90)90202-N; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRAZEAU P, 1973, SCIENCE, V179, P77, DOI 10.1126/science.179.4068.77; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONLON JM, 1990, PROG CLIN BIOL RES, V342, P10; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; EIPPER BA, 1986, TRENDS NEUROSCI, V9, P463, DOI 10.1016/0166-2236(86)90149-9; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; HAKES DJ, 1991, ENDOCRINOLOGY, V129, P3053, DOI 10.1210/endo-129-6-3053; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KORNER J, 1991, P NATL ACAD SCI USA, V88, P11393, DOI 10.1073/pnas.88.24.11393; KUKS PFM, 1989, J BIOL CHEM, V264, P14609; LINGAPPA VR, 1989, J CLIN INVEST, V83, P739, DOI 10.1172/JCI113952; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P1951, DOI 10.1210/endo-129-4-1951; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P2263, DOI 10.1210/endo-129-4-2263; MCDONALD JK, 1987, J HISTOCHEM CYTOCHEM, V35, P155, DOI 10.1177/35.2.2878951; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MURTHY KK, 1989, ENDOCRINOLOGY, V125, P948, DOI 10.1210/endo-125-2-948; ORCI L, 1985, CELL, V42, P67; PATEL YC, 1988, J BIOL CHEM, V263, P745; PATEL YC, 1985, SOMATOSTATIN, P71; PRADAYROL L, 1980, FEBS LETT, V109, P55, DOI 10.1016/0014-5793(80)81310-X; RABBANI SN, 1990, ENDOCRINOLOGY, V126, P2054, DOI 10.1210/endo-126-4-2054; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SEVARINO KA, 1987, J BIOL CHEM, V262, P4987; SEVARINO KA, 1989, CELL, V57, P11, DOI 10.1016/0092-8674(89)90167-0; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; Steiner D F, 1980, Ann N Y Acad Sci, V343, P1, DOI 10.1111/j.1749-6632.1980.tb47238.x; STOLLER TJ, 1988, J CELL BIOL, V107, P2087, DOI 10.1083/jcb.107.6.2087; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; WARREN TG, 1984, CELL, V39, P547, DOI 10.1016/0092-8674(84)90461-6; WETSEL WC, 1992, 74TH ANN M END SOC S; ZINGG HH, 1982, J CLIN INVEST, V70, P1101, DOI 10.1172/JCI110698	48	92	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					6041	6049						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	8095501				2022-12-27	WOS:A1993KR82200100
J	JAYADEV, S; LINARDIC, CM; HANNUN, Y				JAYADEV, S; LINARDIC, CM; HANNUN, Y			IDENTIFICATION OF ARACHIDONIC-ACID AS A MEDIATOR OF SPHINGOMYELIN HYDROLYSIS IN RESPONSE TO TUMOR-NECROSIS-FACTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DIFFERENTIATION; FATTY-ACIDS; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; PROTEIN; CERAMIDE; RELEASE; PHOSPHATIDYLCHOLINE; STIMULATION; SPHINGOSINE	A sphingomyelin (SM)-signaling cycle has been described in human leukemia-derived HL-60 cells (Okazaki, T., Bell, R. M., and Hannun, Y. A. (1989) J. Biol. Chem. 264, 19076-19080). Activation of the cycle by tumor necrosis factor alpha (TNF alpha) occurs rapidly, with peak levels of approximately 30% SM hydrolysis observed within 45-60 min. The mechanisms by which TNF alpha induces this SM turnover remain largely unexplored. In this study, arachidonic acid (AA) was investigated as a potential mediator of TNF alpha effects on SM turnover. In HL-60 cells, 30 nM TNF alpha stimulated the release of AA within 5-10 min. In turn, AA stimulated SM hydrolysis and concomitant ceramide generation within 20 min of addition to cells, Other fatty acids, notably oleate, mimicked the effects of AA on SM hydrolysis, but the methyl ester and alcohol analogs of fatty acids were inactive. Diacylglycerol, a candidate mediator of TNF alpha responses, failed to stimulate SM hydrolysis even at con centrations as high as 300 mu M. Moreover, in an in vitro assay, AA activated a cytosolic sphingomyelinase dose dependently, with 10-100 mu M AA inducing 3-4-fold activation, thus suggesting a direct effect of AA on sphingomyelinase. Melittin, a potent phospholipase Az activator, induced SM hydrolysis at concentrations as low as 35 nM. However, unlike AA, melittin was unable to stimulate sphingomyelinase activation in an in vitro assay system. Finally, exogenous addition of AA also produced antiproliferative effects reminiscent of ceramide effects. Thus, a role for the phospholipase A(2)/AA pathway in mediating TNF alpha induction of the SM cycle is supported by multiple lines of evidence. These studies begin to elucidate a mechanism of TNF alpha signaling and identify a close rela tionship between glycerophospholipid and sphingolipid signaling. AA, therefore, may be pivotal to understanding the sphingomyelin-signaling cascade.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University					NIGMS NIH HHS [GM43825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON YH, 1990, IMMUNOLOGY, V70, P82; BEGIN ME, 1986, PROG LIPID RES, V25, P573, DOI 10.1016/0163-7827(86)90116-5; BEGIN ME, 1985, PROSTA LEUKOTR MED, V19, P177, DOI 10.1016/0262-1746(85)90084-8; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CLARK MA, 1987, J BIOL CHEM, V262, P4402; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FOLCH J, 1957, J BIOL CHEM, V226, P497; GODFREY RW, 1987, BIOCHEM BIOPH RES CO, V142, P235, DOI 10.1016/0006-291X(87)90476-1; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GRANDISON L, 1984, ENDOCRINOLOGY, V114, P1; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; NEALE ML, 1988, IMMUNOLOGY, V64, P81; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAPUANO BE, 1991, BIOCHIM BIOPHYS ACTA, V1091, P374, DOI 10.1016/0167-4889(91)90203-A; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SIEGEL I, 1987, J NATL CANCER I, V78, P271; STOFFEL W, 1971, H-S Z PHYSIOL CHEM, V352, P1058, DOI 10.1515/bchm2.1971.352.2.1058; SUFFYS P, 1987, BIOCHEM BIOPH RES CO, V149, P735, DOI 10.1016/0006-291X(87)90429-3; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; YANAGA F, 1992, J BIOL CHEM, V267, P5114	29	320	323	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5757	5763						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119915				2022-12-27	WOS:A1994MY84000045
J	AKIYAMA, Y; OGURA, T; ITO, K				AKIYAMA, Y; OGURA, T; ITO, K			INVOLVEMENT OF FTSH IN PROTEIN ASSEMBLY INTO AND THROUGH THE MEMBRANE .1. MUTATIONS THAT REDUCE RETENTION EFFICIENCY OF A CYTOPLASMIC REPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; ALKALINE-PHOSPHATASE FUSIONS; ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; GENETIC-ANALYSIS; EXPORT; SECY; TRANSLOCATION; INSERTION; TOPOLOGY	To identify cellular factors that assist in membrane protein biogenesis, we looked for mutants affected in the ''stop transfer'' anchoring process. Using a SecY-PhoA fusion protein in which alkaline phosphatase (PhoA) mature sequence is attached to the last cytoplasmic domain following the 1Oth transmembrane segment of SecY, we isolated a mutation (std101) that allowed significant export of the PhoA moiety across the membrane. The mutation did not cause nonspecific leakage of cytoplasmic proteins. The mutation was identified as a single base change in the ftsH gene, causing an amino acid substitution in the proposed periplasmic region of FtsH, a putative membrane-bound ATPase. In addition, the ftsH1 temperature-sensitive mutation caused a similar phenotype. Disruption of the chromosomal ftsH in combination with a lac promoter-controlled copy of ftsH on a plasmid rendered the cell viability dependent on lac induction. Repression of this system resulted in a strong Std phenotype as well as significant export defects of beta-lactamase and OmpA Thus, the loss of ftsH function enhances translocation of normally anchored protein segments and retards that of normally translocated proteins. These results suggest that FtsH participates in assembly of proteins into and through the membrane. It is needed for the cell to assure efficient stop-transfer of some transmembrane proteins.	KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,KUMAMOTO 862,JAPAN	Kumamoto University	AKIYAMA, Y (corresponding author), KYOTO UNIV,INST VIRUS RES,KYOTO 60601,JAPAN.			Ogura, Teru/0000-0003-3784-0970				AKIYAMA Y, 1989, J BIOL CHEM, V264, P437; AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5225; ANDERSON DJ, 1982, J CELL BIOL, V93, P501, DOI 10.1083/jcb.93.2.501; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BEGG KJ, 1992, J BACTERIOL, V174, P2416, DOI 10.1128/JB.174.7.2416-2417.1992; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; Boyd D, 1987, PHOSPHATE METABOLISM, P89; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Davis R., 1980, ADV BACTERIAL GENETI; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; ITO K, 1992, MOL MICROBIOL, V6, P2423; ITO K, 1981, CELL, V24, P707, DOI 10.1016/0092-8674(81)90097-0; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; ITO K, 1983, CELL, V32, P789, DOI 10.1016/0092-8674(83)90065-X; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KLECKNER N, 1978, GENETICS, V90, P427; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JI, 1992, J BIOL CHEM, V267, P938; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MCGOVERN K, 1991, J BIOL CHEM, V266, P20870; MCGOVERN K, 1991, EMBO J, V10, P2773, DOI 10.1002/j.1460-2075.1991.tb07826.x; Miller J.H., 1972, EXPT MOL GENETICS; NAKAI M, 1993, J BIOL CHEM, V268, P24262; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; NOBREGA FG, 1992, EMBO J, V11, P3821, DOI 10.1002/j.1460-2075.1992.tb05474.x; OGURA T, 1991, RES MICROBIOL, V142, P279, DOI 10.1016/0923-2508(91)90041-8; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; PUZISS JW, 1992, J BACTERIOL, V174, P92, DOI 10.1128/jb.174.1.92-101.1992; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; SAIER MH, 1989, MICROBIOL REV, V53, P333, DOI 10.1128/MMBR.53.3.333-366.1989; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SHIMOIKE T, 1992, MOL MICROBIOL, V6, P1205, DOI 10.1111/j.1365-2958.1992.tb01559.x; SINGER M, 1989, MICROBIOL REV, V53, P1; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1015, DOI 10.1073/pnas.84.4.1015; SPIESS M, 1989, J BIOL CHEM, V264, P19117; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TOMOYASU T, 1993, J BACTERIOL, V175, P1352, DOI 10.1128/JB.175.5.1352-1357.1993; TOMOYASU T, 1993, J BACTERIOL, V175, P1344, DOI 10.1128/JB.175.5.1344-1351.1993; TRAXLER B, 1992, J BIOL CHEM, V267, P5339; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; YOST CS, 1983, CELL, V34, P756	54	137	139	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5218	5224						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106504				2022-12-27	WOS:A1994MX57100081
J	MIDDLEMAS, DS; MEISENHELDER, J; HUNTER, T				MIDDLEMAS, DS; MEISENHELDER, J; HUNTER, T			IDENTIFICATION OF TRKB AUTOPHOSPHORYLATION SITES AND EVIDENCE THAT PHOSPHOLIPASE C-GAMMA-1 IS A SUBSTRATE OF THE TRKB RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; AFFINITY NGF RECEPTOR; INSULIN-RECEPTOR; NEUROTROPHIC FACTOR; C-GAMMA; PC12 CELLS; SIGNAL TRANSDUCTION; EGF RECEPTOR; DOMAIN AUTOPHOSPHORYLATION	The TrkB receptor protein-tyrosine kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. In response to brain-derived neurotrophic factor and neurotrophin-3 treatment, TrkB expressed exogenously in Rat-2 cells is rapidly phosphorylated on tyrosine residues. At least 2 regions of TrkB contain phosphorylated tyrosines. The major sites of autophosphorylation are in the region containing Tyr-670, Tyr-674, and Tyr-675, which lies in the kinase domain and corresponds by sequence homology to the Tyr-416 autophosphorylation site in p60(c-Src). Tyr-785, which lies just to the COOH-terminal side of the kinase domain in a relatively short tail characteristic of the Trk family of protein-tyrosine kinase receptors, is also phosphorylated in response to neurotrophin-3 treatment. The sequence around Tyr-785 fits a consensus sequence for binding phospholipase C-gamma 1. The simplest interpretation of these results is that, in response to neurotrophin binding, at least two and perhaps all three of the tyrosines in the Tyr-670/674/675 region are autophosphorylated independently and Tyr-785 is autophosphorylated in vivo. Following activation of TrkB, phospholipase C-gamma 1 is phosphorylated on Tyr-783, Tyr-771, and Tyr-1254. Phospholipase C-gamma 1 also forms a complex with TrkB in response to neurotrophin-3 treatment, consistent with the possibility that one of the TrkB autophosphorylation sites provides a binding site for the phospholipase C-gamma 1 SH2 domains, as is the case for other receptor protein-tyrosine kinases. We conclude that phospholipase C-gamma 1 is directly phosphorylated by TrkB. Since phosphorylation of Tyr-783 and Tyr-1254 results in activation of phospholipase C-gamma 1, we predict that neurotrophin-3 leads to activation of phospholipase C-gamma 1 following binding to TrkB in Rat-2 cells.			MIDDLEMAS, DS (corresponding author), SALK INST, MOLEC BIOL & VIROL LAB, SAN DIEGO, CA 92186 USA.				NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS008123] Funding Source: NIH RePORTER; NCI NIH HHS [CA39780, CA14195] Funding Source: Medline; NINDS NIH HHS [2F32NS08123-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; ALTIN JG, 1990, J NEUROCHEM, V54, P1666, DOI 10.1111/j.1471-4159.1990.tb01220.x; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DICKENS M, 1992, BIOCHEM BIOPH RES CO, V186, P244, DOI 10.1016/S0006-291X(05)80799-5; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; DUGICHDJORDJEVIC MM, 1992, NEURON, V8, P1127, DOI 10.1016/0896-6273(92)90133-X; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERNFORS P, 1991, NEURON, V7, P165, DOI 10.1016/0896-6273(91)90084-D; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; FRISEN J, 1992, P NATL ACAD SCI USA, V89, P11282, DOI 10.1073/pnas.89.23.11282; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAMPS MP, 1991, METHOD ENZYMOL, V201, P101; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1990, J BIOL CHEM, V265, P3940; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KLEIN R, 1992, CELL, V8, P947; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEVINE BA, 1991, J BIOL CHEM, V266, P3565; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MEISENHELDER J, 1991, METHOD ENZYMOL, V197, P288; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MERLIO JP, 1993, NEURON, V10, P151, DOI 10.1016/0896-6273(93)90307-D; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MIDDLEMAS DS, 1993, METHODS NEUROSCI, V12, P139; MITRA G, 1991, ONCOGENE, V6, P2237; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OHMICHI M, 1992, J BIOL CHEM, V267, P21601; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; PAWSON T, 1988, ONCOGENE, V3, P491; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; RAFAELOFF R, 1991, BIOCHEM BIOPH RES CO, V179, P912, DOI 10.1016/0006-291X(91)91905-R; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; SCHARFMANN R, 1991, P NATL ACAD SCI USA, V88, P4626, DOI 10.1073/pnas.88.11.4626; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SUH PG, 1988, J BIOL CHEM, V263, P14497; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAVARE JM, 1991, J BIOL CHEM, V266, P1390; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YONEZAWA K, 1991, MOL ENDOCRINOL, V5, P194, DOI 10.1210/mend-5-2-194; ZHANG B, 1991, J BIOL CHEM, V266, P990; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	103	91	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5458	5466						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106527				2022-12-27	WOS:A1994MX57100112
J	DAHMS, NM; WICK, DA; BRZYCKIWESSELL, MA				DAHMS, NM; WICK, DA; BRZYCKIWESSELL, MA			THE BOVINE MANNOSE 6-PHOSPHATE INSULIN-LIKE GROWTH FACTOR-II RECEPTOR - LOCALIZATION OF THE INSULIN-LIKE GROWTH FACTOR-II BINDING-SITE TO DOMAINS 5-11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGF-II; MANNOSE-6-PHOSPHATE RECEPTOR; BETA-GALACTOSIDASE; SERUM; PROTEINS; AFFINITY; CHICKEN; LIGAND; REGION; CELLS	The mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF-II receptor) binds two distinct ligands, mannose 6-phosphate (Man-6-P) and insulin-like growth factor II (IGF-II). The extracytoplasmic region of the receptor is composed of 15 homologous repeating domains and domains 1-3 and 7-9 have been shown to contain the two Man-6-P binding sites. To determine the location of the single IGF-II binding site, truncated forms of the M6P/IGF-II receptor were expressed transiently in COS-1 cells and assayed for their ability to bind iodinated human recombinant IGF-II. The binding of [I-125]IGF-II to the receptors in the presence or absence of excess unlabeled IGF-II, IGF-I, or insulin was determined by incubation with homobifunctional cross-linking agents followed by SDS-polyacrylamide gel electrophoresis. These binding studies demonstrated that a construct encoding domains 5-11 bound 0.9 mol of IGF-II/mol of receptor, whereas a construct encoding domains 5-10 exhibited no detectable binding to IGF-II. These results indicate that the IGF-II binding site of the M6P/IGF-II receptor is contained within domains 5-11 and that residues in domain 11 play an important role in IGF-II binding.			DAHMS, NM (corresponding author), MED COLL WISCONSIN,DEPT BIOCHEM,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226, USA.				NIDDK NIH HHS [DK42667] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042667, R01DK042667, R56DK042667] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACH LA, 1993, J BIOL CHEM, V268, P9246; BRINKMAN A, 1991, MOL ENDOCRINOL, V5, P987, DOI 10.1210/mend-5-7-987; BRINKMAN A, 1991, FEBS LETT, V291, P264, DOI 10.1016/0014-5793(91)81298-M; BRZYCKI M, 1909, MOL BIOL CELL, V3, pA297; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CANFIELD WM, 1989, J BIOL CHEM, V264, P7100; CAUSIN C, 1988, BIOCHEM J, V252, P795, DOI 10.1042/bj2520795; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CLAIRMONT KB, 1989, J BIOL CHEM, V264, P16390; DAHMS NM, 1993, ENDOCRINOLOGY, V133, P440, DOI 10.1210/en.133.2.440; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; GELATO MC, 1989, ENDOCRINOLOGY, V124, P2935, DOI 10.1210/endo-124-6-2935; GELATO MC, 1988, J CLIN ENDOCR METAB, V67, P669, DOI 10.1210/jcem-67-4-669; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; KIESS W, 1988, J BIOL CHEM, V263, P9339; KIESS W, 1991, MOL ENDOCRINOL, V5, P281, DOI 10.1210/mend-5-2-281; KIESS W, 1990, EUR J BIOCHEM, V190, P71, DOI 10.1111/j.1432-1033.1990.tb15547.x; KIESS W, 1989, J BIOL CHEM, V264, P4710; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MACDONALD RG, 1989, J BIOL CHEM, V264, P3256; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NISHIMOTO I, 1991, J BIOL CHEM, V266, P12747; Nolan C M, 1987, Adv Exp Med Biol, V225, P199; NOLAN CM, 1990, CELL REGUL, V1, P197, DOI 10.1091/mbc.1.2.197; OKA Y, 1985, J BIOL CHEM, V260, P9435; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; ROTH RA, 1987, BIOCHEM BIOPH RES CO, V149, P600, DOI 10.1016/0006-291X(87)90410-4; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKANO KI, 1991, J BIOL CHEM, V266, P20626; TAIT JF, 1981, J BIOL CHEM, V256, P1086; TONG PY, 1988, J BIOL CHEM, V263, P2585; TONG PY, 1989, J BIOL CHEM, V264, P7962; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1988, BIOCHEM BIOPH RES CO, V152, P1248, DOI 10.1016/S0006-291X(88)80419-4; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; YANG YWH, 1991, ENDOCRINOLOGY, V128, P1177, DOI 10.1210/endo-128-2-1177	46	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3802	3809						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106425				2022-12-27	WOS:A1994MV63100098
J	GLUCK, MR; KRUEGER, MJ; RAMSAY, RR; SABLIN, SO; SINGER, TP; NICKLAS, WJ				GLUCK, MR; KRUEGER, MJ; RAMSAY, RR; SABLIN, SO; SINGER, TP; NICKLAS, WJ			CHARACTERIZATION OF THE INHIBITORY MECHANISM OF 1-METHYL-4-PHENYLPYRIDINIUM AND 4-PHENYLPYRIDINE ANALOGS IN INNER MEMBRANE PREPARATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINERGIC NEUROTOXIN 1-METHYL-4-PHENYLPYRIDINIUM; MITOCHONDRIAL RESPIRATION; NADH DEHYDROGENASE; PARKINSONS-DISEASE; MONOAMINE-OXIDASE; ELECTRON-TRANSPORT; REACTION SITES; BINDING-SITE; ION MPP+; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE	We have investigated the mechanism of the inhibition of membrane-bound NADH dehydrogenase by 1-methyl-4-phenylpyridinium (MPP+) and a series of its 4'-alkyl-substituted analogs of increasing hydrophobicity, as well as their neutral, desmethyl congeners. Comparison of hydrophobicity, as measured by partition coefficients, with the IC50 for the inhibition of NADH oxidase activity in mitochondrial inner membrane preparations shows a negative correlation, but the cationic inhibitors are more effective than the neutral analogs with similar hydrophobicity. The presence of 10 mum tetraphenylboron (TPB-) potentiates the inhibitory power of positively charged analogs up to 4'-pentyl-MPP', while the neutral inhibitors are unaffected by TPB-. Without TPB-, the more hydrophilic analogs give incomplete inhibition, but the inclusion of TPB- permits the attainment of complete inhibition, accompanied by the appearance of sigmoidal titration curves. These data support the hypothesis that MPP+ analogs, like rotenone, are bound at two sites on the enzyme and occupancy of both is required for complete inhibition. TPB-, by forming ion pairs with the cationic analogs, facilitates their equilibration to both sites in membrane preparations. When present in molar excess over the MPP+ analog, TPB- partially reverses the inhibition by decreasing its concentration in the more hydrophilic binding site. The effect of temperature and of pH on the IC50 values for inhibition support the concept of dual binding sites, and the pH dependence of the inhibition reveals the participation of two ionized protein groups in the binding, one of which may be a thiol group.	DEPT VET AFFAIRS MED CTR,DIV MOLEC BIOL,4150 CLEMENT ST,MAILSTOP 151-S,SAN FRANCISCO,CA 94121; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT NEUROL,PISCATAWAY,NJ 08854; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV TOXICOL,SAN FRANCISCO,CA 94143	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Ramsay, Rona R./A-6681-2008; Ramsay, Rona/A-4065-2009	Ramsay, Rona R./0000-0003-1535-4904; 	NHLBI NIH HHS [HL-16251] Funding Source: Medline; NINDS NIH HHS [NS-21469] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS021469] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUICHI T, 1988, NEUROCHEM INT, V12, P525; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; CHIBA K, 1984, BIOCHEM BIOPH RES CO, V120, P574, DOI 10.1016/0006-291X(84)91293-2; CHUNG KH, 1989, Z NATURFORSCH C, V44, P609; CRANE FL, 1956, BIOCHIM BIOPHYS ACTA, V22, P475, DOI 10.1016/0006-3002(56)90058-0; DIXON M, 1953, BIOCHEM J, V55, P161, DOI 10.1042/bj0550161; GIOVANNI A, 1991, J PHARMACOL EXP THER, V257, P691; GONDAL JA, 1985, J BIOL CHEM, V260, P2690; GUTMAN M, 1970, P NATL ACAD SCI USA, V65, P763, DOI 10.1073/pnas.65.3.763; GUTMAN M, 1970, J BIOL CHEM, V245, P1992; GUTMAN M, 1970, BIOCHEMISTRY-US, V9, P2678, DOI 10.1021/bi00815a016; Hatefi Y, 1967, METHOD ENZYMOL, V10, P235; HEFTI F, 1988, PROGR PARKINSON RES, P137; HEIKKILA RE, 1990, J NEUROCHEM, V54, P743, DOI 10.1111/j.1471-4159.1990.tb02314.x; HEIKKILA RE, 1984, SCIENCE, V224, P1451, DOI 10.1126/science.6610213; HOPPEL CL, 1987, BIOCHEM BIOPH RES CO, V148, P684, DOI 10.1016/0006-291X(87)90931-4; HORGAN DJ, 1968, J BIOL CHEM, V243, P834; KRUEGER MJ, 1992, BIOCHEMISTRY-US, V31, P5611, DOI 10.1021/bi00139a026; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; PALMER G, 1968, J BIOL CHEM, V243, P844; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; PRESSMAN BC, 1992, ANN NY ACAD SCI, V648, P320, DOI 10.1111/j.1749-6632.1992.tb24568.x; RAMSAY RR, 1987, ARCH BIOCHEM BIOPHYS, V259, P645, DOI 10.1016/0003-9861(87)90531-5; RAMSAY RR, 1989, P NATL ACAD SCI USA, V86, P9168, DOI 10.1073/pnas.86.23.9168; RAMSAY RR, 1989, BIOCHEM BIOPH RES CO, V159, P983, DOI 10.1016/0006-291X(89)92205-5; RAMSAY RR, 1986, BIOCHEM BIOPH RES CO, V135, P269, DOI 10.1016/0006-291X(86)90972-1; RAMSAY RR, 1991, J NEUROCHEM, V56, P1184, DOI 10.1111/j.1471-4159.1991.tb11409.x; RAMSAY RR, 1991, BIOCHEM J, V273, P481, DOI 10.1042/bj2730481; SALACH JI, 1984, BIOCHEM BIOPH RES CO, V125, P831, DOI 10.1016/0006-291X(84)90614-4; SAYRE LM, 1990, ARCH BIOCHEM BIOPHYS, V280, P274, DOI 10.1016/0003-9861(90)90330-2; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SHOFFNER JM, 1991, ANN NEUROL, V30, P332, DOI 10.1002/ana.410300304; SINGER TP, 1986, BIOCHEM J, V235, P785, DOI 10.1042/bj2350785; SINGH MP, 1991, ARCH BIOCHEM BIOPHYS, V286, P138, DOI 10.1016/0003-9861(91)90019-F; TIPTON KF, 1986, BIOCHEM J, V240, P379, DOI 10.1042/bj2400379; YOUNGSTER SK, 1990, BIOCHEM BIOPH RES CO, V169, P758, DOI 10.1016/0006-291X(90)90396-5	38	98	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3167	3174						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106350				2022-12-27	WOS:A1994MV63100011
J	LIN, J; ADDISON, R				LIN, J; ADDISON, R			TOPOLOGY OF THE NEUROSPORA PLASMA-MEMBRANE H+-ATPASE - LOCALIZATION OF A TRANSMEMBRANE SEGMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRASSA; SEQUENCE; IDENTIFICATION; TRANSLOCATION; HOMOLOGY; PROTEINS; INVITRO; AMINO; GENE; K+	The Neurospora plasma membrane H+-ATPase is a polytopic integral membrane protein. To localize transmembrane segments, mutants were constructed that contained the amino and carboxyl termini of the H+-ATPase with putative transmembrane segment. A stretch of amino acid residues from yeast invertase that has three consensus N-linked glycosylation sites was placed carboxyl terminal of the putative transmembrane segment. RNA transcripts of these mutants were translated in a Neurospora in vitro system that was supplemented with microsomes from Neurospora. By the criteria of glycosylation of the polypeptide chain, resistance to extraction at pH 11.5, and protection from proteinase K digestion, only one transmembrane segment could be identified within the amino acid residues 272-314 of the primary sequence of the H+-ATPase.	UNIV TENNESSEE CTR HLTH SCI,HLTH SCI CTR,DEPT BIOCHEM,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center								ADDISON R, 1990, BIOCHIM BIOPHYS ACTA, V1030, P127, DOI 10.1016/0005-2736(90)90247-L; ADDISON R, 1987, J BIOL CHEM, V262, P17031; ADDISON R, 1986, J BIOL CHEM, V261, P4896; ADDISON R, 1981, J BIOL CHEM, V256, P3165; ADDISON R, 1991, BIOCHIM BIOPHYS ACTA, V1065, P130, DOI 10.1016/0005-2736(91)90222-T; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; DAME JB, 1981, J BIOL CHEM, V256, P724; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; Harlow E., 1988, ANTIBODIES LAB MANUA, P55; HENNESSEY JP, 1990, J BIOL CHEM, V265, P532; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; MANDALA SM, 1989, J BIOL CHEM, V264, P16276; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MITCHELL P, 1982, ANN NY ACAD SCI, V402, P584, DOI 10.1111/j.1749-6632.1982.tb25785.x; MITCHELL P, 1973, J BIOENERG, V4, P63, DOI 10.1007/BF01516051; RAO US, 1991, J BIOL CHEM, V266, P14740; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; TAUSSIG R, 1983, NUCLEIC ACIDS RES, V11, P1943, DOI 10.1093/nar/11.6.1943; [No title captured]	23	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3887	3890						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106434				2022-12-27	WOS:A1994MV63100110
J	MOL, CD; MUIR, AKS; LEE, JS; ANDERSON, WF				MOL, CD; MUIR, AKS; LEE, JS; ANDERSON, WF			STRUCTURE OF AN IMMUNOGLOBULIN FAB FRAGMENT SPECIFIC FOR POLY(DG)CENTER-DOT-POLY(DC)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR REPLACEMENT METHOD; MULTIWIRE AREA DETECTOR; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; TRANSLATION-FUNCTION; NUCLEIC-ACIDS; STRANDED-DNA; ANTIBODY; COMPLEX; BINDING	Jel 72 is a murine monoclonal antibody that is highly specific for the right-handed DNA duplex formed by poly(dG).poly(dC). The three-dimensional structure of the antigen-binding fragment (Fab) of Jel 72 has been determined by x-ray crystallographic methods and refined to 2.7-angstrom resolution. The structure has been determined using a combination of molecular replacement and multiple isomorphous replacement techniques. Crystals of Jel 72 contain two Fab fragments/asymmetric unit. The orientation of each of the four separate constant and variable domain pairs was determined from rotation function searches against appropriately oriented model Fab fragments. The rotated Fab domain pairs were placed within the unit cell using a phased translation search procedure with low resolution phases calculated from three derivatives. The two crystallographically independent Fab fragments possess ''elbow'' angles (relating the variable and constant domain pairs) that differ by 14-degrees (146-degrees versus 132-degrees). The shape and electrostatic surface potential of the combining site suggest a possible model for the recognition of double helical DNA. The model proposes that residues in the third hypervariable region of the heavy chain interact with the DNA bases via the major groove of poly(dG).poly(dC). This model may be applicable to the recognition of double-stranded DNA by autoimmune antibodies that occur in systemic lupus erythematosus.	VANDERBILT UNIV,DEPT BIOCHEM,NASHVILLE,TN 37232; NATL RES COUNCIL CANADA,DIV BIOL SCI,OTTAWA K1A 0R6,ONTARIO,CANADA; UNIV SASKATCHEWAN,DEPT BIOCHEM,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA	Vanderbilt University; National Research Council Canada; University of Saskatchewan					NIDDK NIH HHS [DK42502] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; ARNOTT S, 1974, J MOL BIOL, V88, P551, DOI 10.1016/0022-2836(74)90502-6; BALLARD DW, 1985, J IMMUNOL, V135, P3372; BARRY MM, 1994, J BIOL CHEM, V269, P3623; BHAT TN, 1988, J APPL CRYSTALLOGR, V21, P279, DOI 10.1107/S0021889887012755; Blundell T.L., 1976, PROTEIN CRYSTALLOGRA; BOODHOO A, 1988, J BIOL CHEM, V263, P18578; BRAM S, 1971, NATURE-NEW BIOL, V233, P161, DOI 10.1038/newbio233161a0; BRAUN RP, 1986, NUCLEIC ACIDS RES, V14, P5049, DOI 10.1093/nar/14.12.5049; BRAUN RP, 1987, J IMMUNOL, V139, P175; BRAUN RP, 1988, J IMMUNOL, V141, P2084; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; CYGLER M, 1988, ACTA CRYSTALLOGR A, V44, P38, DOI 10.1107/S0108767387008365; CYGLER M, 1987, J BIOL CHEM, V262, P643; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; EILAT D, 1991, J IMMUNOL, V147, P361; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P517, DOI 10.1107/S0021889887086102; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; LANGE A, 1978, CLIN EXP IMMUNOL, V31, P472; LASCOMBE MB, 1989, P NATL ACAD SCI USA, V86, P607, DOI 10.1073/pnas.86.2.607; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE JS, 1982, BIOCHEMISTRY-US, V21, P4940, DOI 10.1021/bi00263a017; LEE JS, 1984, BIOCHEMISTRY-US, V23, P3277, DOI 10.1021/bi00309a024; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MCCALL M, 1985, J MOL BIOL, V183, P385, DOI 10.1016/0022-2836(85)90009-9; MOL CD, 1994, J BIOL CHEM, V269, P3615; NAVIA MA, 1979, P NATL ACAD SCI USA, V76, P4071, DOI 10.1073/pnas.76.8.4071; PADLAN E, 1973, NATURE, V145, P165; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; RADIC MZ, 1993, J IMMUNOL, V150, P4966; RADIC MZ, 1989, COLD SPRING HARB SYM, V54, P933; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; READ RJ, 1988, J APPL CRYSTALLOGR, V21, P490, DOI 10.1107/S002188988800562X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROSSMANN MG, 1990, ACTA CRYSTALLOGR A, V46, P73, DOI 10.1107/S0108767389009815; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STOLLAR BD, 1986, CRC CR REV BIOCH MOL, V20, P1, DOI 10.3109/10409238609115899; STRONG RK, 1991, BIOCHEMISTRY-US, V30, P3739, DOI 10.1021/bi00229a022; TORMO J, 1992, PROTEIN SCI, V1, P1154, DOI 10.1002/pro.5560010909; TULIP WR, 1992, J MOL BIOL, V227, P122, DOI 10.1016/0022-2836(92)90687-F; WILSON AJC, 1949, ACTA CRYSTALLOGR, V2, P318, DOI 10.1107/S0365110X49000813; XUONG NH, 1985, ACTA CRYSTALLOGR B, V41, P267, DOI 10.1107/S0108768185002105	52	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3605	3614						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106405				2022-12-27	WOS:A1994MV63100073
J	QIN, N; BAEHR, W				QIN, N; BAEHR, W			EXPRESSION AND MUTAGENESIS OF MOUSE ROD PHOTORECEPTOR CGMP PHOSPHODIESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; DROSOPHILA DUNCE+ GENE; BETA-SUBUNIT GENE; ALPHA-SUBUNIT; CAMP PHOSPHODIESTERASE; GAMMA-SUBUNIT; SACCHAROMYCES-CEREVISIAE; RETINAL DEGENERATION; MOLECULAR-CLONING; MEMBRANE-BINDING	Using recombinant baculovirus vectors, the three sub. units of mouse rod photoreceptor cGMP phosphodiesterase (PDE) (alphabetagamma2) have been expressed in insect cells. The recombinant alpha,beta subunits accumulate to 5 mg/liter culture, but most (98%) of the expressed polypeptides are insoluble. In the soluble fraction, individually expressed a and 13 subunits showed insignificant PDE activity, but coexpression (by coinfection) of alphabeta subunits elevated PDE activity 7-fold and coexpression of alphabetagamma up to 15-fold. The soluble expressed holoenzyme associated with ROS membranes under isotonic, but not hypotonic, conditions. The K(m) of the soluble holoenzyme was 11-16 muM both for coexpressed alphabeta subunits and for alphabetagamma subunits, similar to the K(m) (6-80 muM) of native PDE. Site-directed mutagenesis of cysteine to serine in the C-terminal CAAX box of both alpha and beta subunits substantially decreased the protein expression level, abolished post-translational isoprenylation, and prevented subunit binding to the rod outer segment (ROS) membranes. The mutant holoenzyme, however, showed a cGMP hydrolytic activity comparable with that of the normal recombinant enzyme. These results suggest that both alpha and beta subunits are required for the formation of a functional enzyme and that isoprenylation of the subunits is essential for membrane association and stability of PDE.	BAYLOR COLL MED, DEPT OPHTHALMOL, 6501 FANNIN ST, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT BIOCHEM, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine					NATIONAL EYE INSTITUTE [R01EY008123] Funding Source: NIH RePORTER; NEI NIH HHS [EY08123] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; AKESON AL, 1989, J CELL BIOCHEM, V39, P217, DOI 10.1002/jcb.240390302; ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; ANANT JS, 1992, J BIOL CHEM, V267, P687; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BAEHR W, 1991, FEBS LETT, V278, P107, DOI 10.1016/0014-5793(91)80095-K; BAEHR W, 1982, J BIOL CHEM, V257, P6452; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BENTLEY JK, 1992, J BIOL CHEM, V267, P18676; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; CATTY P, 1992, J BIOL CHEM, V267, P19489; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; GILLESPIE PG, 1993, ADV SEC MESS PHOSPH, P163; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; JANSEN JJM, 1991, BIOCHIM BIOPHYS ACTA, V1089, P68, DOI 10.1016/0167-4781(91)90086-2; JIN SLC, 1992, J BIOL CHEM, V267, P18929; KLOC M, 1991, J BIOL CHEM, V266, P8206; KOCH KW, 1991, J BIOL CHEM, V266, P8634; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEM J, 1992, P NATL ACAD SCI USA, V89, P4422, DOI 10.1073/pnas.89.10.4422; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MCLAUGHLIN MM, 1993, J BIOL CHEM, V268, P6470; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; MOORES SL, 1991, J BIOL CHEM, V266, P14603; OHGURO H, 1990, BIOCHEM BIOPH RES CO, V167, P1235, DOI 10.1016/0006-291X(90)90656-8; OHGURO H, 1991, EMBO J, V10, P3669, DOI 10.1002/j.1460-2075.1991.tb04934.x; ONG OC, 1989, P NATL ACAD SCI USA, V86, P9238, DOI 10.1073/pnas.86.23.9238; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PITTLER SJ, 1991, PROG CLIN BIOL RES, V362, P33; PITTLER SJ, 1990, GENOMICS, V6, P272, DOI 10.1016/0888-7543(90)90567-E; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; QIN N, 1992, J BIOL CHEM, V267, P8458; QIN N, 1993, FEBS LETT, V321, P6, DOI 10.1016/0014-5793(93)80609-X; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SONNENBURG WK, 1993, J BIOL CHEM, V268, P645; STROOP SD, 1992, ADV SEC MESS PHOSPH, V25, P55; STRYER L, 1991, J BIOL CHEM, V266, P10711; SUBER ML, 1993, P NATL ACAD SCI USA, V90, P3968, DOI 10.1073/pnas.90.9.3968; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; TANG WJ, 1991, J BIOL CHEM, V266, P8595; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; WASHBURN T, 1992, GENETICS, V130, P585; WEBB N R, 1990, Technique (Philadelphia), V2, P173; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; ZUSMAN DR, 1978, ANAL BIOCHEM, V84, P551, DOI 10.1016/0003-2697(78)90074-X	64	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3265	3271						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106363				2022-12-27	WOS:A1994MV63100024
J	ZHANG, FL; DIEHL, RE; KOHL, NE; GIBBS, JB; GIROS, B; CASEY, PJ; OMER, CA				ZHANG, FL; DIEHL, RE; KOHL, NE; GIBBS, JB; GIROS, B; CASEY, PJ; OMER, CA			CDNA CLONING AND EXPRESSION OF RAT AND HUMAN PROTEIN GERANYLGERANYLTRANSFERASE TYPE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; ALPHA-SUBUNIT; FARNESYLTRANSFERASE; YEAST; GENE; DISTINCT; ENCODE; BRAIN; CDC43	Protein geranylgeranyltransferase type-I (GGTase-I) transfers a geranylgeranyl group to the cysteine residue of candidate proteins containing a carboxyl-terminal CAAX (C, cysteine; A, aliphatic amino acid; X, any amino acid) motif in which the ''X'' residue is leucine. The enzyme is composed of a 48-kilodalton alpha subunit and a 43-kilodalton beta subunit. Peptides isolated from the alpha subunit of GGTase-I were shown to be identical with the alpha subunit of a related enzyme, protein farnesyltransferase. Overlapping cDNA clones containing the complete coding sequence for the beta subunit of GGTase-I were obtained from rat and human cDNA libraries. The cDNA clones from both species each predicted a protein of 377 amino acids with molecular masses of 42.4 kilodaltons (human) and 42.5 kilodaltons (rat). Amino acid sequence comparison suggests that the protein encoded by the Saccharomyces cerevisiae gene CDC43 is the yeast counterpart of the mammalian GGTase-I beta subunit. Co-expression of the GGTase-I beta subunit cDNA together with the alpha subunit of protein farnesyltransferase in Escherichia coli produced recombinant GGTase-I with electrophoretic and enzymatic properties indistinguishable from native GGTase-I.	MERCK SHARP & DOHME LTD,DEPT CANC RES,WP16-302,W POINT,PA 19486; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,CELL GROWTH REGULAT & ONCOGENESIS SECT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104	Merck & Company; Duke University; Duke University; Duke University; University of Pennsylvania			GIROS, Bruno/ABD-5790-2021	GIROS, Bruno/0000-0001-5876-9822; Casey, Patrick/0000-0002-7366-9309				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; CASEY PJ, 1992, J LIPID RES, V33, P1731; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; KELLERMANN OK, 1982, METHOD ENZYMOL, V90, P459; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; KOHL NE, 1991, J BIOL CHEM, V266, P18884; MAYER ML, 1992, J BIOL CHEM, V267, P20589; MENARD L, 1992, EUR J BIOCHEM, V206, P537, DOI 10.1111/j.1432-1033.1992.tb16957.x; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; OHYA Y, 1991, J BIOL CHEM, V266, P12356; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAMBROOK J, 1990, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; TEMELES GG, 1985, NATURE, V335, P90; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	36	103	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3175	3180						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106351				2022-12-27	WOS:A1994MV63100012
J	ZHU, H; JOLIOT, V; PRYWES, R				ZHU, H; JOLIOT, V; PRYWES, R			ROLE OF TRANSCRIPTION FACTOR-TFIIF IN SERUM RESPONSE FACTOR-ACTIVATED TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TATA-BINDING PROTEIN; PREINITIATION COMPLEX; INITIATION-FACTOR; SMALL SUBUNIT; INVITRO; DNA; PURIFICATION; IDENTIFICATION; COACTIVATORS	We have found that the general transcription factor TFIIF has an important role in serum response factor (SRF)-activated transcription in vitro. A low amount of TFIIF was sufficient for basal transcription, whereas higher amounts were required for SRF, but not Spl, activation. High TFIIF levels also increased activation by GALA-VP16, whereas none of the other general transcription factors had these properties. TFIIF could also relieve squelching by SRF in vitro, suggesting that SRF may directly bind TFIIF. We found more direct evidence for SRF-TFIIF interaction by DNA binding assays where the RAP74 subunit of TFIIF bound DNA in conjunction with SRF, but not alone. RAP74 also bound DNA with GAL4-VP16, but not with Spl or the DNA binding domain of GAL4. These results suggest that the mechanism of transcriptional activation by SRF, and perhaps some other activators, involves their interaction with TFIIF.	COLUMBIA UNIV,DEPT BIOL SCI,FAIRCHILD 813B,116TH & BROADWAY,NEW YORK,NY 10027	Columbia University					NATIONAL CANCER INSTITUTE [R01CA050329] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50329-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAI H, 1987, J BIOL CHEM, V262, P298; CHANG CH, 1993, J BIOL CHEM, V268, P20482; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; ING NH, 1992, J BIOL CHEM, V267, P17617; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; KATAGIRI F, 1990, GENE DEV, V4, P1899, DOI 10.1101/gad.4.11.1899; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MANAK JR, 1993, ONCOGENE, V8, P703; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PETERSON MG, 1990, SCIENCE, V248, P1626; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PRYWES R, 1992, NUCLEIC ACIDS RES, V20, P513, DOI 10.1093/nar/20.3.513; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; WHITE JH, 1991, P NATL ACAD SCI USA, V88, P7674, DOI 10.1073/pnas.88.17.7674; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHU H, 1991, NEW BIOL, V3, P455; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5291, DOI 10.1073/pnas.89.12.5291	52	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3489	3497						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106390				2022-12-27	WOS:A1994MV63100056
J	LEE, JI; HWANG, PP; WILSON, TH				LEE, JI; HWANG, PP; WILSON, TH			LYSINE-319 INTERACTS WITH BOTH GLUTAMIC ACID-269 AND ASPARTIC ACID-240 IN THE LACTOSE CARRIER OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MUTAGENESIS; SALT BRIDGES; BACTERIORHODOPSIN; TRANSPORT; MEMBRANE; RESIDUES; PERMEASE; PROTEIN; MUTANTS; GENE	It is believed that there are several charged amino acid residues in membrane-spanning alpha-helices of the lactose carrier of Escherichia coli. Evidence has previously been presented for two different salt bridges in membrane-spanning regions of the lactose carrier. One of these involves an interaction between Asp-237 and Lys-358; another involves interaction between Asp-240 and Lys-319. Additional studies of Lys-319 suggest that it may intereact with Glu-269 as well as Asp-240. A cell containing the LacY gene with the mutation Lys-319 --> Asn failed to ferment melibiose and after several days melibiose-positive mutants arose on indicator plates. These revertants showed second site mutations which replaced Asp-240 by neutral amino acids (Val or Gly). In addition, a second site mutation showed Glu-269 changed to Asn. Cells containing the mutation Lys-319 --> Leu also failed to ferment melibiose and melibiose-positive revertants showed Asp-240 --> Ala and Asp-240 --> Tyr as well as Tyr-236 --> Phe and His-322 --> Arg. Second site revertants were also sought from the mutant Glu-269 --> Asn which grew poorly on melibiose minimal plates. Melibiose-positive revertants included the double mutant Gln-269/Asn-319. All of the Glu-269 --> Asn mutants were extremely defective in transport. It was concluded thet Lys-319 interacts with Glu-269 and Asp-240 probably as salt bridges.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School			Hwang, Pung-Pung/AAH-1538-2022; Hwang, Pung-Pung/AEQ-4633-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK005736, R01DK005736] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK05736] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASLANIDIS C, 1989, J BACTERIOL, V171, P6753, DOI 10.1128/jb.171.12.6753-6763.1989; BOCKMANN J, 1992, MOL GEN GENET, V235, P22, DOI 10.1007/BF00286177; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BROOKER RJ, 1985, J BIOL CHEM, V260, P6181; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; COHEN G N, 1956, Ann Inst Pasteur (Paris), V91, P693; GARTY H, 1988, J BIOL CHEM, V263, P5550; HINKLE PC, 1990, BIOCHEMISTRY-US, V29, P10989, DOI 10.1021/bi00501a017; HOBSON AC, 1977, J BACTERIOL, V131, P830, DOI 10.1128/JB.131.3.830-838.1977; HONIG BH, 1984, P NATL ACAD SCI-BIOL, V81, P5412, DOI 10.1073/pnas.81.17.5412; KARLISH SJD, 1985, SODIUM PUMP, P487; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; KING SC, 1989, J BIOL CHEM, V264, P7390; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KLINGENBERG M, 1988, BIOCHEMISTRY-US, V27, P781, DOI 10.1021/bi00402a044; LEE JI, 1992, J BIOL CHEM, V267, P20758; LOLKEMA JS, 1988, BIOCHEMISTRY-US, V27, P8307, DOI 10.1021/bi00422a003; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; MACARA IG, 1981, BIOCHEMISTRY-US, V20, P5695, DOI 10.1021/bi00523a009; MCMORROW I, 1988, BIOCHIM BIOPHYS ACTA, V945, P315, DOI 10.1016/0005-2736(88)90494-4; PERSSON B, 1992, BIOCHEMISTRY-US, V31, P8892, DOI 10.1021/bi00152a028; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; STERN LJ, 1989, J BIOL CHEM, V264, P14202; SUBRAMANIAM S, 1992, J BIOL CHEM, V267, P25730; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; WEST IC, 1970, BIOCHEM BIOPH RES CO, V41, P655, DOI 10.1016/0006-291X(70)90063-X; WILSON DM, 1986, METHOD ENZYMOL, V125, P377	31	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20007	20015						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8104184				2022-12-27	WOS:A1993LY01900017
J	DELAUNEY, AJ; HU, CAA; KISHOR, PBK; VERMA, DPS				DELAUNEY, AJ; HU, CAA; KISHOR, PBK; VERMA, DPS			CLONING OF ORNITHINE DELTA-AMINOTRANSFERASE CDNA FROM VIGNA-ACONITIFOLIA BY TRANSCOMPLEMENTATION IN ESCHERICHIA-COLI AND REGULATION OF PROLINE BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DELTA-1-PYRROLINE-5-CARBOXYLATE REDUCTASE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; MITOCHONDRIAL; GENE	Proline prototrophy was restored to an Escherichia coli proBA proline auxotroph by ornithine and a moth-bean (Vigna aconitifolia) cDNA expression library. This novel strategy, ''trans-complementation,'' allowed isolation of a cDNA encoding ornithine delta-aminotransferase (delta-OAT). This enzyme transaminates ornithine to glutamic-gamma-semialdehyde (GSA), thereby bypassing the block in GSA synthesis from glutamate in the proBA mutant. The identity of the mothbean enzyme was confirmed by its high sequence homology to mammalian and yeast delta-OATs as well as to a family of bacterial and fungal omega-aminotransferases and an absence of significant homology to various alpha-aminotransferases. The V. aconitifolia OAT cDNA encodes a polypeptide of 48.1 kDa. The native enzyme expressed in E. coli appears to be a monomer with K(m) of 2 mM for ornithine and 0.75 mm for alpha-ketoglutarate. Levels of mRNA in V. aconitifolia for DELTA1-pyrroline-5-carboxylate synthetase (P5CS) and delta-OAT, the two key enzymes for proline synthesis, were monitored under different physiological conditions. Salt stress and nitrogen starvation induced P5CS mRNA levels and depressed OAT mRNA levels. Conversely, OAT mRNA level was elevated in plants supplied with excess nitrogen while the P5CS mRNA level was reduced. These data suggest that the glutamate pathway is the primary route for proline synthesis in plants during conditions of osmotic stress and nitrogen limitation whereas the ornithine pathway assumes prominence under high nitrogen input.	OHIO STATE UNIV,CTR BIOTECHNOL,240 RIGHTMIRE HALL,1060 CARMACK RD,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210; UNIV W INDIES,DEPT BIOL,BRIDGETOWN,BARBADOS	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University West Indies Mona Jamaica; University of the West Indies Open Campus				Kavi Kishor, Polavarapu/0000-0002-9587-7547				ADAMS E, 1980, ANNU REV BIOCHEM, V49, P1005, DOI 10.1146/annurev.bi.49.070180.005041; Aspinall D., 1981, The physiology and biochemistry of drought resistance in plants., P205; BRANDRISS MC, 1979, J BACTERIOL, V138, P816, DOI 10.1128/JB.138.3.816-822.1979; BRANDRISS MC, 1980, J BACTERIOL, V143, P1403, DOI 10.1128/JB.143.3.1403-1410.1980; BRYAN JK, 1990, BIOCH PLANTS COMPREH, V16, P197; DEGOLS G, 1987, EUR J BIOCHEM, V169, P193, DOI 10.1111/j.1432-1033.1987.tb13597.x; DELAUNEY AJ, 1990, MOL GEN GENET, V221, P299, DOI 10.1007/BF00259392; DELAUNEY AJ, 1993, IN PRESS PLANT J; DELAVAL E, 1990, J DEV PHYSIOL, V14, P1; DURANTON HENRI, 1965, PHYSIOL VEGETALE, V3, P7; GANTT JS, 1992, PLANT PHYSIOL, V98, P868, DOI 10.1104/pp.98.3.868; HARGROVE JL, 1989, J BIOL CHEM, V264, P45; HEIMBERG H, 1990, GENE, V90, P69, DOI 10.1016/0378-1119(90)90440-3; Hoagland D.R., 1938, The Water Culture Methods for Growing Plants without Soil, V347, P1, DOI DOI 10.1017/CBO9781107415324.004; HU CAA, 1992, P NATL ACAD SCI USA, V89, P9354, DOI 10.1073/pnas.89.19.9354; INANA G, 1986, P NATL ACAD SCI USA, V83, P1203, DOI 10.1073/pnas.83.5.1203; LEE NG, 1993, PLANT J, V3, P599, DOI 10.1046/j.1365-313X.1993.03040599.x; LEISINGER T, 1987, ESCHERICHIA COLI SAL, V1, P345; MAZELIS M, 1969, PHYTOCHEMISTRY, V8, P801, DOI 10.1016/S0031-9422(00)85863-X; MESTICHELLI LJJ, 1979, J BIOL CHEM, V254, P640; MILLER JH, 1972, EXPT MOL GENETICS, P17; MUECKLER MM, 1985, J BIOL CHEM, V260, P2993; OTSUKA AJ, 1988, J BIOL CHEM, V263, P19577; REYNOLDS PHS, 1992, PLANT MOL BIOL, V19, P465, DOI 10.1007/BF00023394; RHODES D, 1986, PLANT PHYSIOL, V82, P890, DOI 10.1104/pp.82.4.890; RICHARDSON IB, 1989, MOL GEN GENET, V217, P118, DOI 10.1007/BF00330950; ROISE D, 1988, J BIOL CHEM, V263, P4509; SPLITTSTOESSER WE, 1973, PHYTOCHEMISTRY, V12, P785, DOI 10.1016/0031-9422(73)80678-8; Stewart C. R., 1981, The physiology and biochemistry of drought resistance in plants., P243; SZOKE A, 1992, PLANT PHYSIOL, V99, P1642, DOI 10.1104/pp.99.4.1642; TAYLOR AA, 1981, BIOCHEM BIOPH RES CO, V101, P1281, DOI 10.1016/0006-291X(81)91586-2; VERMA DPS, 1992, BIOSYNTHESIS MOL REG, P128; VERMA DPS, 1993, IN PRESS ADAPTATION; VOET D, 1990, BIOCHEMISTRY-US, P718; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WALLSGROVE RM, 1977, J EXP BOT, V28, P5988; WONG PTH, 1980, J NEUROCHEM, V36, P501; WRENCH P, 1980, AUST J PLANT PHYSIOL, V7, P149, DOI 10.1071/PP9800149; WRENCH P, 1977, AUST J PLANT PHYSIOL, V4, P703, DOI 10.1071/PP9770703; YONAHA K, 1992, J BIOL CHEM, V267, P12506	40	204	257	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18673	18678						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8103048				2022-12-27	WOS:A1993LV65900049
J	ZHENG, XX; ROSENBERG, LE; KALOUSEK, F; FENTON, WA				ZHENG, XX; ROSENBERG, LE; KALOUSEK, F; FENTON, WA			GROEL, GROES, AND ATP-DEPENDENT FOLDING AND SPONTANEOUS ASSEMBLY OF ORNITHINE TRANSCARBAMYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; STREPTOCOCCUS-FAECALIS; MITOCHONDRIAL PROTEIN; BOVINE LIVER; RAT-LIVER; CHAPERONIN; PURIFICATION; BINDING; HSP60; CARBOXYLASE	When purified rat liver ornithine transcarbamylase (OTC), a trimer of 36 kDa subunits, was denatured in 6 M guanidine hydrochloride and then diluted 50-100-fold, no activity was recovered, and the OTC subunits aggregated. In contrast, when the chaperonin groEL was included in the dilution buffer, OTC did not aggregate but instead comigrated in a sucrose density gradient with the groEL oligomer, indicating that a complex had been formed. Upon addition of the co-chaperonin groES and ATP to the isolated OTC-groEL complex, OTC monomers were folded, released, and assembled into active trimer. Neither groES nor ATP alone was sufficient to release active OTC from groEL The extent of recovery of activity was proportional to the concentration of the complex, reaching approximately 80-90% at monomer concentrations above 0.6 muM. At low complex concentrations, kinetic studies revealed an initial lag in the reconstitution reaction, suggesting that assembly is the rate-limiting step under these conditions. We could trap folded, released, inactive OTC monomers at early times that assembled into active trimers with longer incubation. A nonhydrolyzable ATP analog could release bound OTC from groEL in the presence of groES, but the OTC monomers were not competent for assembly. These data show that recovery of OTC activity in vitro can be efficiently directed by the bacterial chaperonins in the presence of ATP and suggest that the mechanism of reconstitution involves ATP and groES-dependent folding and release of OTC monomers from groEL, followed by spontaneous assembly of trimers.	YALE UNIV, SCH MED, DEPT GENET, 333 CEDAR ST, NEW HAVEN, CT 06510 USA	Yale University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009527] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 09527] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOOGENRAAD NJ, 1980, ANAL BIOCHEM, V101, P97, DOI 10.1016/0003-2697(80)90045-7; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; KALOUSEK F, 1988, P NATL ACAD SCI USA, V85, P7536, DOI 10.1073/pnas.85.20.7536; KALOUSEK F, 1978, J BIOL CHEM, V253, P3939; KALOUSEK F, 1984, J BIOL CHEM, V259, P5392; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARSHALL M, 1972, J BIOL CHEM, V247, P1654; MARSHALL M, 1972, J BIOL CHEM, V247, P1641; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SZTUL ES, 1987, J CELL BIOL, V105, P2631, DOI 10.1083/jcb.105.6.2631; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WANG Z, 1992, PROTEIN SCI, V1, P522	31	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7489	7493						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8096512				2022-12-27	WOS:A1993KV14100095
J	CAMANI, C; BACHMANN, F; KRUITHOF, EKO				CAMANI, C; BACHMANN, F; KRUITHOF, EKO			THE ROLE OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IN THE CLEARANCE OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR BY RAT HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; ALPHA-2-MACROGLOBULIN RECEPTOR; T-PA; UROKINASE RECEPTOR; COMPLEXES; LIVER; BINDING; IDENTIFICATION; INTERNALIZES; DEGRADATION	The role of plasminogen activator inhibitor type 1 (PAI-1) in the clearance of tissue-type plasminogen activator (t-PA) by hepatocyte like cells was studied. Rat (Novikoff) hepatoma cells were able to bind and degrade t-PA in a PAI-1 independent fashion, but PAI-I markedly increased the rate of degradation and t-PA/PAI-1 was a more efficient inhibitor of I-125-t-PA or of I-125-t-PA/PAI-1 degradation than free t-PA. Competition studies revealed that the effect of PAI-1 is unlikely to involve determinants located on the PAI-1 part of the complex: 1) an excess of fi ee PAI had no effect on the rate of degradation of I-125-t-PA/PAI-1. 2) Complexes of PAI-1 with urokinase-type PA or with a t-PA mutant lacking the finger and growth factor domains were unable to compete for the binding and degradation of free or PAI-l-complexed I-125-t-PA.3) t-PA KHRR296-299AAAA, a mutant which reacts 2 orders of magnitude slower with PAI-1 than wild type t-PA, behaved similar to wild type t-PA. The clearance via both the PAI-1-dependent and the PAI-1-independent mechanisms was inhibited by the receptor-associated protein, a general inhibitor of clearance mediated by the LDL receptor-related protein. We conclude that t-PA can be cleared by rat hepatoma cells in a PAI-1 independent fashion, but after complex formation with PAI-1, binding of BPA to the cells is increased and clearance accelerated. Both mechanisms seem to involve the same receptor.	CHU VAUDOIS,DEPT INTERNAL MED,DIV HEMATOL,CH-1011 LAUSANNE,SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)			Kruithof, Egbert/AGR-4755-2022					ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BASSELDUBY R, 1992, J BIOL CHEM, V267, P9668; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; EINARSSON M, 1988, THROMB HAEMOSTASIS, V59, P474; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; KUIPER J, 1988, J BIOL CHEM, V263, P18220; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIJNEN HR, 1990, J BIOL CHEM, V265, P5677; MORTON PA, 1990, J BIOL CHEM, V265, P14093; MORTON PA, 1989, J BIOL CHEM, V264, P7228; NGUYEN G, 1992, J BIOL CHEM, V267, P6249; NGUYEN G, 1992, BIOCHEM J, V287, P911, DOI 10.1042/bj2870911; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OLSON D, 1992, J BIOL CHEM, V267, P9129; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; OWENSBY DA, 1989, J BIOL CHEM, V264, P18180; PAONI NF, 1993, THROMB HAEMOSTASIS, V70, P307; SEYDEL W, 1991, DRUG RES, V41, P182; SMEDSROD B, 1990, THROMB HAEMOSTASIS, V63, P60; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WING LR, 1991, FEBS LETT, V278, P95, DOI 10.1016/0014-5793(91)80092-H; WING LR, 1991, J LAB CLIN MED, V117, P109	34	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5770	5775						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119917				2022-12-27	WOS:A1994MY84000047
J	WELHAM, MJ; DURONIO, V; SCHRADER, JW				WELHAM, MJ; DURONIO, V; SCHRADER, JW			INTERLEUKIN-4-DEPENDENT PROLIFERATION DISSOCIATES P44(ERK-1), P42(ERK-2) AND P21(RAS) ACTIVATION FROM CELL-GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; MAP KINASE-KINASE; INDUCED TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE; XENOPUS OOCYTES; RECEPTOR; P21RAS; EXPRESSION; INSULIN	The activation of erk/mitogen-activated protein kinases and p21(ras) is strongly associated with progression through the cell cycle. Cell growth induced by the cytokine interleukin-4 (IL-4) effectively dissociates the activation of p44(erk-1) and p42(erk-2) mitogen-activated protein kinases and p21(ras) from cell proliferation. In two cell lines of T lymphocyte and myeloid origin that were dependent upon IL-4 for continuous growth, IL-4 failed to detectably activate or induce tyrosine phosphorylation of p44(erk-1) and p42(erk-2). The activation of p21(ras) was also not detectably affected by IL-4 treatment of these cells. Treatment of the same cells with other growth factors (colony-stimulating factor-1 and Steel factor) or phorbol esters induced the tyrosine phosphorylation and activation of p44(erk-1) and p42(erk-2) and stimulated p21(ras) activity. The presence of IL-4 neither diminished nor enhanced the activation of p44(erk-1) and p42(erk-2) by colony-stimulating factor 1, Steel factor, or 12-O-tetradecanoylphorbol-13-acetate. Furthermore, IL-4 also failed to activate p44(erk-1), p42(erk-2), and p21(ras) in normal T lymphocytes and mast cells derived from spleen and bone marrow, respectively. Significantly, these findings demonstrate that IL-4-induced cell growth may be dissociated from the activation of p44(erk-1), p42(erk-2), and p21(ras), suggesting that their activation may not be an absolute requirement for growth factor-stimulated mitogenesis.			WELHAM, MJ (corresponding author), UNIV BRITISH COLUMBIA, BIOMED RES CTR, 2222 HLTH SCI MALL, VANCOUVER V6T 1Z3, BC, CANADA.							AHN NG, 1990, J BIOL CHEM, V265, P11495; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BECKMANN MP, 1992, CHEM IMMUNOL, V51, P107; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CALLARD RE, 1990, IMMUNOL TODAY, V11, P200, DOI 10.1016/0167-5699(90)90082-K; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; GOLD MR, 1992, BIOCHEM J, V287, P269, DOI 10.1042/bj2870269; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HULI J, 1989, J IMMUNOL, V142, P800; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IZUHARA K, 1993, J BIOL CHEM, V268, P13097; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MIRESLUIS AR, 1991, J BIOL CHEM, V266, P18113; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; NEL AE, 1990, J IMMUNOL, V144, P2683; OKUDA K, 1992, BLOOD, V79, P2880; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAUL WE, 1991, BLOOD, V77, P1859; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RAINES MA, 1992, BLOOD, V79, P3350; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RENNICK DM, 1992, IL4 STRUCTURE FUNCTI, P51; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WELHAM MJ, 1992, J IMMUNOL, V149, P2772; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	53	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5865	5873						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119929				2022-12-27	WOS:A1994MY84000060
J	LUI, JX; LEE, WK; JIANG, C; KELLER, EB				LUI, JX; LEE, WK; JIANG, C; KELLER, EB			START SITE SELECTION BY SP1 IN THE TATA-LESS HUMAN HA-RAS PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; BLADDER-CARCINOMA ONCOGENE; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; INITIATOR; BINDING; ELEMENT; REQUIREMENT; INVITRO; PROTEIN	Th promoter of the human Ha-ras gene is very GC-rich, has four Sp1-binding sites and no TATA element. Transcription initiates at multiple start sites spread over a 90-base pair region, with a major cluster between +1 and +11. We detected the binding of a HeLa nuclear protein to the region from +6 to +20, a region which overlaps the major cluster and includes nine start sites within its boundaries. When part of this region was mutated, the nine start sites were abolished, so the region may be an initiator. The regulatory elements of the promoter have no differential effect on start site usage. But Sp1 bound to GCIV located at -38 acts as a start site selector, increasing the activity of the start sites from +1 downstream but not the upstream sites at -31, -21, and -10. When spacers of increasing length were inserted 3' to GCIV, the major cluster dwindled, and the upstream sites became strong sites, first the one at -10 and then the one at -21. Thus start sites were strongest when put into an Sp1-selected locus 36 to 53 base pairs downstream from GCIV and weak when outside this locus. The start sites with these properties may be due to initiators.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853; AMC,CANC RES CTR,DENVER,CO 80214; MYONGJI UNIV,DEPT BIOL,KYUNGGI DO 449728,SOUTH KOREA	Cornell University; AMC Cancer Research Center; Myongji University				Lu, Junxuan/0000-0002-2354-7186	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM010791] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM10791] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRERASALDANA H, 1985, EMBO J, V4, P3839, DOI 10.1002/j.1460-2075.1985.tb04156.x; BASU A, 1993, J BIOL CHEM, V268, P4188; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CICHUTEK K, 1986, P NATL ACAD SCI USA, V83, P2340, DOI 10.1073/pnas.83.8.2340; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; DAMANTE G, 1987, P NATL ACAD SCI USA, V84, P774, DOI 10.1073/pnas.84.3.774; Favaloro J, 1980, Methods Enzymol, V65, P718; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; HONKAWA H, 1987, MOL CELL BIOL, V7, P2933, DOI 10.1128/MCB.7.8.2933; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JOLLIFF K, 1991, NUCLEIC ACIDS RES, V19, P2267, DOI 10.1093/nar/19.9.2267; KOTEWICZ ML, 1988, NUCLEIC ACIDS RES, V16, P265, DOI 10.1093/nar/16.1.265; LEE W, 1991, TRANSCRIPTIONAL REGU; LEE WK, 1991, J MOL BIOL, V220, P599, DOI 10.1016/0022-2836(91)90103-D; LOWNDES NF, 1989, MOL CELL BIOL, V9, P3758, DOI 10.1128/MCB.9.9.3758; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY EP, 1983, SCIENCE, V220, P1061, DOI 10.1126/science.6844927; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Sambrook J, 1989, MOL CLONING LABORATO; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WIELAND S, 1990, NUCLEIC ACIDS RES, V18, P5113, DOI 10.1093/nar/18.17.5113	37	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5391	5402						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106522				2022-12-27	WOS:A1994MX57100104
J	NOESKEJUNGBLUT, C; KRATZSCHMAR, J; HAENDLER, B; ALAGON, A; POSSANI, L; VERHALLEN, P; DONNER, P; SCHLEUNING, WD				NOESKEJUNGBLUT, C; KRATZSCHMAR, J; HAENDLER, B; ALAGON, A; POSSANI, L; VERHALLEN, P; DONNER, P; SCHLEUNING, WD			AN INHIBITOR OF COLLAGEN-INDUCED PLATELET-AGGREGATION FROM THE SALIVA OF TRIATOMA-PALLIDIPENNIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAEMENTERIA-OFFICINALIS LEECH; IDENTIFICATION; ADHESION; GLANDS; ACTIVATION; PROTEINS; RECEPTOR; PEPTIDE; BLOOD	The saliva of Triatoma pallidipennis, a blood-sucking triatomine bug (Hemiptera, family Reduviidae, subfamily Triatominae) was found to contain a factor that specifically inhibits collagen-induced platelet aggregation. The 19-kDa protein was purified to homogeneity and named pallidipin. Collagen-mediated aggregation of platelets in plasma and of washed platelets was inhibited with the same efficacy. No inhibition of aggregation stimulated by other effecters (ADP, thrombin, thromboxane A(2) mimetic U46619, phorbol ester) was detected. Pallidipin had no effect on platelet adhesion to collagen but inhibited ATP release from platelets. It interacted reversibly with platelets and may share with collagen a common target on them. The protein exhibits a unique primary structure (predicted from cDNA clones) with no significant similarity to other previously described sequences. The protein produced in recombinant baby hamster kidney cells had antiaggregatory effects similar to those of native pallidipin. Availability of recombinant pallidipin will allow further investigation of the precise mechanism of action.	UNIV NACL AUTONOMA MEXICO, INST BIOTECNOL, CUERNAVACA 62271, MORELOS, MEXICO	Universidad Nacional Autonoma de Mexico	NOESKEJUNGBLUT, C (corresponding author), SCHERING AG, RES LABS, D-13342 BERLIN, GERMANY.		Possani, Lourival D/J-2397-2013					BAUMGARTNER HR, 1977, THROMB HAEMOSTASIS, V37, P1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLER BS, 1989, BLOOD, V74, P182; CONNOLLY TM, 1992, J BIOL CHEM, V267, P6893; HARLOW E, 1988, ANTIBODIES LAB MANUA, P508; KELLER PM, 1993, J BIOL CHEM, V268, P5450; KELLER PM, 1992, J BIOL CHEM, V267, P6899; KRATZSCHMAR J, 1992, GENE, V116, P281, DOI 10.1016/0378-1119(92)90526-U; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Peitsch M C, 1990, New Biol, V2, P197; RIBEIRO JMC, 1989, SCIENCE, V243, P212, DOI 10.1126/science.2783496; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TARR GE, 1986, METHODS PROTEIN MICR, P162; WAXMAN L, 1993, J BIOL CHEM, V268, P5445; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; WIRTH M, 1988, GENE, V73, P419, DOI 10.1016/0378-1119(88)90506-9; ZUCKER MB, 1989, METHOD ENZYMOL, V169, P117	22	87	91	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5050	5053						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106481				2022-12-27	WOS:A1994MX57100056
J	WANG, X; FOLK, WR				WANG, X; FOLK, WR			TERMINATION OF TRANSCRIPTION BY RNA-POLYMERASE-III FROM WHEAT-GERM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVITRO TRANSCRIPTION; BINDING PROTEIN; PAUSE SITE; DNA; ELONGATION; SEQUENCES; PURIFICATION; INITIATION; EFFICIENCY; COMPLEXES	A novel system has been established to study transcription by RNA polymerase III. Purified wheat germ RNA polymerase III will initiate transcription on SV40 DNA templates amplified by polymerase chain reaction. Transcription initiates primarily at a thymidine 3 residues from a PvuII terminus at nucleotide 272 and terminates at a downstream A(8):T-8 sequence at nucleotides 21-28. Termination is enhanced if the RNA polymerase is caused to pause downstream of the A(8):T-8 sequence, but termination is unaffected by upstream sequences. Transcription of heteroduplex DNA templates with mismatches in the A(8):T-8 sequence indicates that termination is dependent upon the integrity of the A(8) sequence in the template strand and is only slightly affected by changes in the T-8 sequence of the non-template strand. However, templates containing 2'-deoxyuridine or 5'-bromo-2'-deoxyuridine in place of thymidine in the nontemplate strand reduce termination efficiency, as does incorporation of 5'-bromouracil into RNA. There is no obvious correlation between DNA bending and termination efficiency.	UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65212	University of Missouri System; University of Missouri Columbia				Folk, William/0000-0003-2216-3233				BARTSCH I, 1988, MOL CELL BIOL, V8, P3891, DOI 10.1128/MCB.8.9.3891; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BROWN RD, 1976, J MOL BIOL, V102, P1, DOI 10.1016/0022-2836(76)90070-X; CAMPBELL FE, 1992, MOL CELL BIOL, V12, P2260, DOI 10.1128/MCB.12.5.2260; CHAMBERLIN M, 1963, J MOL BIOL, V7, P334, DOI 10.1016/S0022-2836(63)80028-5; CHAN CL, 1989, J BIOL CHEM, V264, P20796; CHENG SWC, 1991, SCIENCE, V254, P1205, DOI 10.1126/science.1835546; COZZARELLI NR, 1983, CELL, V34, P829, DOI 10.1016/0092-8674(83)90540-8; DEDRICK RL, 1985, BIOCHEMISTRY-US, V24, P2245, DOI 10.1021/bi00330a019; DEDRICK RL, 1987, J BIOL CHEM, V262, P9098; DIEKMANN S, 1992, J MOL BIOL, V225, P729, DOI 10.1016/0022-2836(92)90397-3; ENRIQUEZHARRIS P, 1991, EMBO J, V10, P1833, DOI 10.1002/j.1460-2075.1991.tb07709.x; FISHER RF, 1985, J MOL BIOL, V182, P397, DOI 10.1016/0022-2836(85)90199-8; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; GRUMMT I, 1986, CELL, V45, P837, DOI 10.1016/0092-8674(86)90558-1; JAMES P, 1990, GENETICS, V125, P293; JENDRISAK J, 1981, PLANT PHYSIOL, V67, P438, DOI 10.1104/pp.67.3.438; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KASSAVETIS GA, 1992, J MOL BIOL, V226, P47, DOI 10.1016/0022-2836(92)90123-2; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; LEDNICKY J, 1992, J VIROL, V66, P6379, DOI 10.1128/JVI.66.11.6379-6390.1992; MATSUMOTO K, 1989, J BIOL CHEM, V264, P1124; MCSTAY B, 1990, MOL CELL BIOL, V10, P2793, DOI 10.1128/MCB.10.6.2793; PAULY M, 1992, NUCLEIC ACIDS RES, V20, P975, DOI 10.1093/nar/20.5.975; PENNINGROTH SM, 1980, J BIOL CHEM, V255, P9545; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RICHARDSON JP, 1993, CRIT REV BIOCHEM MOL, V28, P1, DOI 10.3109/10409239309082571; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; TELESNITSKY APW, 1989, J MOL BIOL, V205, P315, DOI 10.1016/0022-2836(89)90343-4; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WATSON JB, 1984, NUCLEIC ACIDS RES, V12, P5369, DOI 10.1093/nar/12.13.5369; WIEST DK, 1990, MOL CELL BIOL, V10, P5782, DOI 10.1128/MCB.10.11.5782; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2484, DOI 10.1021/bi00789a009	42	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4993	5004						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106475				2022-12-27	WOS:A1994MX57100048
J	CRAIG, L; JOHNSON, JE; CORNELL, RB				CRAIG, L; JOHNSON, JE; CORNELL, RB			IDENTIFICATION OF THE MEMBRANE-BINDING DOMAIN OF RAT-LIVER CTP - PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE USING CHYMOTRYPSIN PROTEOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; HAMSTER OVARY CELLS; PHOSPHORYLCHOLINE CYTIDYLYLTRANSFERASE; CHOLINEPHOSPHATE CYTIDYLYLTRANSFERASE; PHOSPHATIDYLCHOLINE SYNTHESIS; ENDOPLASMIC-RETICULUM; PHOSPHOLIPASE-C; FATTY-ACIDS; TRANSLOCATION; CYTOSOL	Limited chymotrypsin proteolysis of CTP:phosphocholine cytidylyltransferase (CT; EC 2.7.7.15) produced several distinct fragments which were mapped to the N terminus of CT using antibodies directed against the N and C terminus and the conserved central domain. A time course of chymotrypsin proteolysis showed a progression in digestion as follows: 42 --> 39 --> 35 --> 30 --> 28 --> 26 kDa. The binding of CT and of the chymotrypsin fragments to lipid vesicles was assessed by floatation analysis. The ability of the fragments to bind to activating lipid vesicles correlated with the presence of a putative amphipathic alpha-helix, helix-1, between residues 236 and 293. Fragments lacking this helix could, however, bind to phosphatidylcholine/sphingosine vesicles, which inhibit CT activity, and were capable of dimer formation. The degree of resistance to chymotrypsin degradation increased when CT was bound to the strongly activating lipid vesicles phosphatidylcholine/oleic acid (1:1) and phosphatidylcholine/phosphatidylglycerol (1:1). Conversion of the 39- and 35-kDa fragments, which contain the intact helix-1, to the 30-, 28-, and 26-kDa bands, which lack helix-1, required longer proteolysis times, suggesting that this helical domain is more shielded from solvent upon membrane binding. These results support the theory that CT has a bipartite tertiary structure composed of a globular N-terminal domain and an extended C-terminal domain and that CT interacts with membranes via its putative amphipathic helix which intercalates into the membrane bilayer of activating phospholipids.	SIMON FRASER UNIV,DEPT CHEM BIOCHEM,BURNABY V5A 1S6,BC,CANADA; SIMON FRASER UNIV,INST MOLEC BIOL & BIOCHEM,BURNABY V5A 1S6,BC,CANADA	Simon Fraser University; Simon Fraser University				Craig, Lisa/0000-0001-8515-9915				BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P9317, DOI 10.1021/bi00450a011; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARLTON LA, 1992, J BIOL CHEM, V267, P8840; CORNELL R, 1989, J BIOL CHEM, V264, P9077; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5881, DOI 10.1021/bi00238a011; EDELSTEIN C, 1979, J LIPID RES, V20, P143; FELDMAN DA, 1987, J BIOL CHEM, V262, P9075; HATCH GM, 1992, J BIOL CHEM, V267, P15751; JOHNSON JE, 1992, BIOCHEM J, V285, P815, DOI 10.1042/bj2850815; JOHNSON JE, 1994, IN PRESS BIOCHEMISTR; KALAFATIS M, 1990, J BIOL CHEM, V265, P21580; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KAY R, 1991, Methods in Molecular and Cellular Biology, V2, P254; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOLESNICK RN, 1990, J BIOL CHEM, V265, P10900; KUMAR N, 1981, J BIOL CHEM, V256, P5886; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTY I, 1992, BIOCHEMISTRY-US, V31, P4058, DOI 10.1021/bi00131a023; MAUEL C, 1991, J GEN MICROBIOL, V137, P929, DOI 10.1099/00221287-137-4-929; MYHER JJ, 1979, CAN J BIOCHEM CELL B, V57, P117, DOI 10.1139/o79-015; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P433, DOI 10.1016/0005-2760(84)90169-3; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; SOHAL PS, 1990, J BIOL CHEM, V265, P11746; STERN W, 1976, BIOCHIM BIOPHYS ACTA, V441, P280, DOI 10.1016/0005-2760(76)90171-5; TERCE F, 1992, BIOCHEM J, V282, P333, DOI 10.1042/bj2820333; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; WANG YL, 1993, J BIOL CHEM, V268, P5512; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WEINHOLD PA, 1984, J BIOL CHEM, V259, P315; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WEINHOLD PA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P299, DOI 10.1016/0005-2760(89)90017-9; YAO ZM, 1990, J BIOL CHEM, V265, P4326; ZWERLING SJ, 1991, J BIOL CHEM, V266, P4574; [No title captured]	37	75	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3311	3317						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106370				2022-12-27	WOS:A1994MV63100031
J	NISHITA, K; TANAKA, H; OJIMA, T				NISHITA, K; TANAKA, H; OJIMA, T			AMINO-ACID-SEQUENCE OF TROPONIN-C FROM SCALLOP STRIATED ADDUCTOR MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN SKELETAL-MUSCLE; CHLAMYS-NIPPONENSIS-AKAZARA; 2 MAJOR ISOFORMS; PROTEOLYTIC FRAGMENTS; LOBSTER TROPONIN; BINDING-SITES; CALCIUM; PROTEINS; RESOLUTION; TROPOMYOSIN	Troponin and its Ca2+-binding subunit troponin C (TnC) of the Ezo-giant scallop, Patinopecten yessoensis, have been revealed to bind only 1 mol of Ca2+/mol irrespective of the presence and absence of Mg2+. The amino acid sequence of the TnC has been determined by the automated Edman degradation. TnC is composed of 152 residues including 3 tryptophans at positions 53, 70, and 109, 4 cysteines at positions 19, 31, 67, and 145, and no proline. The molecular weight is calculated as 17,410. The NH2 terminus of TnC is blocked by an acetyl group. The sequence of scallop TnC required deletion of three residues in the D/E linker region to maximize sequence homology to other TnCs and shows considerably lower homology to vertebrate skeletal TnCs (27-30%), ascidian TnC (26%), arthropoda TnCs (30-37%), and chicken calmodulin (37%). Further, we conclude that Ezo-giant scallop TnC binds Ca2+ at site IV, a site specific for Ca2+. The other sites I, II, and III appeared to lose the Ca2+ binding ability due to substitutions of some important residues.			NISHITA, K (corresponding author), HOKKAIDO UNIV,FAC FISHERIES,DEPT CHEM,HAKODATE,HOKKAIDO 041,JAPAN.							BENZONANA G, 1974, BIOCHIM BIOPHYS ACTA, V368, P247, DOI 10.1016/0005-2728(74)90153-4; BOGUTA G, 1988, J THEOR BIOL, V135, P41, DOI 10.1016/S0022-5193(88)80173-5; COLLINS JH, 1991, BIOCHEMISTRY-US, V30, P702, DOI 10.1021/bi00217a017; COLLINS JH, 1976, SOC EXP BIOL S, V30, P303; DRABIKOWSKI W, 1982, J BIOL CHEM, V257, P1584; DRABIKOWSKI W, 1978, BIOCHIM BIOPHYS ACTA, V532, P373; EBASHI S, 1966, J BIOCHEM-TOKYO, V60, P733, DOI 10.1093/oxfordjournals.jbchem.a128504; EBASHI S, 1968, J BIOCHEM-TOKYO, V64, P465, DOI 10.1093/oxfordjournals.jbchem.a128918; EBASHI S, 1972, COLD SPRING HARB SYM, V37, P215; ENDO T, 1981, J BIOCHEM, V89, P1599, DOI 10.1093/oxfordjournals.jbchem.a133355; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GARONE L, 1991, ARCH BIOCHEM BIOPHYS, V291, P89, DOI 10.1016/0003-9861(91)90108-U; GOLDBERG A, 1978, BIOCHEM J, V171, P413, DOI 10.1042/bj1710413; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; Greaser M. L., 1972, COLD SPRING HARB SYM, V37, P235; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; HARTSHOR.DJ, 1968, BIOCHEM BIOPH RES CO, V31, P647, DOI 10.1016/0006-291X(68)90610-4; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; KENDRICK-JONES J, 1970, Journal of Molecular Biology, V54, P313, DOI 10.1016/0022-2836(70)90432-8; KENDRICKJONES J, 1976, J MOL BIOL, V104, P747, DOI 10.1016/0022-2836(76)90180-7; KOBAYASHI T, 1989, J BIOCHEM-TOKYO, V105, P823, DOI 10.1093/oxfordjournals.jbchem.a122752; KOBAYASHI T, 1989, J BIOL CHEM, V264, P18247; KONNO K, 1978, J BIOCHEM, V84, P1431, DOI 10.1093/oxfordjournals.jbchem.a132265; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEHMAN W, 1981, BIOCHIM BIOPHYS ACTA, V668, P349, DOI 10.1016/0005-2795(81)90168-9; NISHITA K, 1979, J BIOCHEM, V86, P663, DOI 10.1093/oxfordjournals.jbchem.a132570; NISHITA K, 1990, J BIOCHEM-TOKYO, V108, P677, DOI 10.1093/oxfordjournals.jbchem.a123262; OJIMA T, 1992, ARCH BIOCHEM BIOPHYS, V299, P344, DOI 10.1016/0003-9861(92)90285-5; OJIMA T, 1986, J BIOCHEM-TOKYO, V100, P821, DOI 10.1093/oxfordjournals.jbchem.a121777; OJIMA T, 1991, J BIOCHEM-TOKYO, V110, P847, DOI 10.1093/oxfordjournals.jbchem.a123675; OJIMA T, 1990, J BIOCHEM-TOKYO, V108, P519, DOI 10.1093/oxfordjournals.jbchem.a123234; OJIMA T, 1992, COMP BIOCHEM PHYS B, V103, P727, DOI 10.1016/0305-0491(92)90397-A; OJIMA T, 1986, J BIOL CHEM, V261, P6749; OJIMA T, 1988, J BIOCHEM-TOKYO, V104, P91; POTTER JD, 1986, BIOPHYS J, V49, pA249; POTTER JD, 1975, J BIOL CHEM, V250, P4628; PUCCI P, 1985, J CHROMATOGR, V331, P425, DOI 10.1016/0021-9673(85)80051-0; PUTKEY JA, 1983, J BIOL CHEM, V258, P1864; REGENSTEIN JM, 1975, BIOCHEMISTRY-US, V14, P917, DOI 10.1021/bi00676a007; REINACH FC, 1988, J BIOL CHEM, V263, P2371; SCHAUB MC, 1969, BIOCHEM J, V115, P993, DOI 10.1042/bj1150993; SHIMA Y, 1984, COMP BIOCHEM PHYS B, V79, P525, DOI 10.1016/0305-0491(84)90360-2; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; SZENTGYO.AG, 1973, J MOL BIOL, V74, P179, DOI 10.1016/0022-2836(73)90106-X; TAKAGI T, 1983, J BIOCHEM-TOKYO, V94, P1753, DOI 10.1093/oxfordjournals.jbchem.a134526; VANEERD JP, 1976, BIOCHEMISTRY-US, V15, P1171, DOI 10.1021/bi00650a033; VANEERD JP, 1975, BIOCHEM BIOPH RES CO, V64, P122, DOI 10.1016/0006-291X(75)90227-2; WELLNER D, 1990, P NATL ACAD SCI USA, V87, P1947, DOI 10.1073/pnas.87.5.1947; WILKINSON JM, 1976, FEBS LETT, V70, P254, DOI 10.1016/0014-5793(76)80769-7; WILKINSON JM, 1980, EUR J BIOCHEM, V103, P179, DOI 10.1111/j.1432-1033.1980.tb04302.x; WNUK W, 1989, J BIOL CHEM, V264, P18240	53	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3464	3468						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106387				2022-12-27	WOS:A1994MV63100052
J	TANG, SQ; MIKALA, G; BAHINSKI, A; YATANI, A; VARADI, G; SCHWARTZ, A				TANG, SQ; MIKALA, G; BAHINSKI, A; YATANI, A; VARADI, G; SCHWARTZ, A			MOLECULAR LOCALIZATION OF ION SELECTIVITY SITES WITHIN THE PORE OF A HUMAN L-TYPE CARDIAC CALCIUM-CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SODIUM-CHANNEL; FUNCTIONAL EXPRESSION; SKELETAL-MUSCLE; K+ CHANNELS; GUINEA-PIG; PERMEATION; CELLS	A highly conserved position of negatively charged amino acids is present in the SS2 segments of the S5-S6 linker regions among calcium channels. We report here that replacing Glu residues at this position alters the ion selectivity of the human cardiac calcium channel. Substituting Glu334 in motif I or Glu1086 in motif III with Lys produced mutant calcium channels that permeated sodium ions 10-fold more effectively than barium ions. More conservative changes such as substitution of Glu1086 with Gln or substitution of Glu1387 with Ala also increased sodium permeation through the mutant calcium channels. Sodium currents through the mutant calcium channels could be modulated by dihydropyridines and blocked by external divalent cations. These results suggest that Glu334, Glu1086, and Glu1387 are part of a ring of glutamate residues formed in the pore-lining SS1-SS2 region and are critical in determining ion selectivity and permeability of a human cardiac calcium channel.	UNIV CINCINNATI, COLL MED, DEPT PHARMACOL & CELL BIOPHYS, 231 BETHESDA AVE, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619, T32HL007382, R37HL043231] Funding Source: NIH RePORTER; NHLBI NIH HHS [5R37 HL43231-04, T32 HL07382-16, P01 HL22619-15] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACKX PH, 1992, SCIENCE, V257, P248, DOI 10.1126/science.1321496; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Erlich H.A., 1989, PCR TECHNOLOGY; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; Hille B, 1992, IONIC CHANNELS EXCIT, P362; KOSTYUK PG, 1983, J MEMBRANE BIOL, V76, P83, DOI 10.1007/BF01871455; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE KS, 1984, J PHYSIOL-LONDON, V354, P253, DOI 10.1113/jphysiol.1984.sp015374; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MATSUDA H, 1986, PFLUG ARCH EUR J PHY, V407, P465, DOI 10.1007/BF00657502; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; SCHULTZ D, 1993, IN PRESS P NATL ACAD; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	25	161	166	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13026	13029						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8099908				2022-12-27	WOS:A1993LH55300005
J	HASSLACHER, M; IVESSA, AS; PALTAUF, F; KOHLWEIN, SD				HASSLACHER, M; IVESSA, AS; PALTAUF, F; KOHLWEIN, SD			ACETYL-COA CARBOXYLASE FROM YEAST IS AN ESSENTIAL ENZYME AND IS REGULATED BY FACTORS THAT CONTROL PHOSPHOLIPID-METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; FATTY-ACID SYNTHESIS; ACTIVATED PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; PYRUVATE-CARBOXYLASE; CODING SEQUENCE; INO1 PROMOTER; PHOSPHORYLATION; BIOTIN; TRANSCRIPTION	We have isolated a 1.2-kilobase pair cDNA fragment in a screening for yeast genes regulated at the level of transcription by soluble lipid precursors, inositol and choline. Sequence analysis and comparison of the deduced amino acid sequence to protein databases unveiled 68% similarity of a 374-amino acid peptide fragment to published C termini of chicken and rat acetyl-CoA carboxylase and almost 100% identity to the product of the FAS3 gene from yeast. Several lines of evidence confirm that the cloned gene represents the yeast structural gene ACC1 encoding acetyl-CoA carboxylase. Overexpression of the ACC1 gene from a high copy number plasmid resulted in overexpression of a 250-kDa biotin-enzyme and enzymatic activity of acetyl-CoA carboxylase. Disruption of one ACC1 allele in a diploid wild-type strain resulted in 50% reduction of ACC1-specific mRNA and acetyl-CoA carboxylase specific activity and a marked decrease of biotin associated with a 250-kDa protein, compared to wild-type. After sporulation of diploid disruptants, spores containing the disrupted acc1 allele failed to enter vegetative growth, despite fatty acid supplementation, suggesting that acetyl-CoA carboxylase activity is essential for a process other than de novo fatty acid synthesis and that only a single functional copy of the ACC1 gene exists. ACC1 transcription was repressed 3-fold by lipid precursors, inositol and choline, and was also controlled by regulatory factors Ino2p, Ino4p, and Opi1p, providing evidence that the key step of fatty acid synthesis is regulated in conjunction with phospholipid synthesis at the level of gene expression. The 5'-untranslated region of the ACC1 gene contains a sequence reminiscent of an inositol/choline-responsive element identified in genes encoding phospholipid biosynthetic enzymes.	GRAZ TECH UNIV,INST BIOCHEM & LEBENSMITTELCHEM,PETERSGASSE 12-II,A-8010 GRAZ,AUSTRIA	Graz University of Technology				Kohlwein, Sepp Dieter/0000-0002-1030-0598				ABDEL HM, 1985, COMP BIOCH PHYSL B, V81, P9; ALFEEL W, 1992, P NATL ACAD SCI USA, V89, P4534, DOI 10.1073/pnas.89.10.4534; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO, V2; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BEATY NB, 1985, ANN NY ACAD SCI, V447, P23, DOI 10.1111/j.1749-6632.1985.tb18423.x; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BULOCK JD, 1979, POLYKETIDE BIOSYNTHE, P927; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CHANDLER CS, 1986, BIOCHEM J, V237, P123, DOI 10.1042/bj2370123; CHIRALA SS, 1992, P NATL ACAD SCI USA, V89, P10232, DOI 10.1073/pnas.89.21.10232; ELION EA, 1984, CELL, V39, P663, DOI 10.1016/0092-8674(84)90473-2; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HARDIE DG, 1989, PROG LIPID RES, V28, P117, DOI 10.1016/0163-7827(89)90010-6; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HARINGTON A, 1992, YEAST, V8, pS414; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HAYSTAD TA, 1990, EUR J BIOCHEM, V87, P199; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOLM C, 1986, GENE, V42, P169, DOI 10.1016/0378-1119(86)90293-3; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HORI T, 1987, J BIOCHEM-TOKYO, V101, P949, DOI 10.1093/oxfordjournals.jbchem.a121964; JAMIL H, 1987, J BIOL CHEM, V262, P638; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; KING J, 1971, J MOL BIOL, V62, P465, DOI 10.1016/0022-2836(71)90148-3; KLIMOV A N, 1987, Biokhimiya, V52, P239; KLIMOV A N, 1983, Biokhimiya, V48, P1862; KLIMOV A N, 1990, Biokhimiya, V55, P549; KODAKI T, 1991, J BIOCHEM-TOKYO, V109, P276; KRAUS JP, 1986, P NATL ACAD SCI USA, V83, P8049, DOI 10.1073/pnas.83.21.8049; LAMHONWAH AM, 1986, P NATL ACAD SCI USA, V83, P4864, DOI 10.1073/pnas.83.13.4864; LIM F, 1987, ARCH BIOCHEM BIOPHYS, V258, P259, DOI 10.1016/0003-9861(87)90343-2; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P3987, DOI 10.1093/nar/19.14.3987; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; MABROUK GM, 1990, J BIOL CHEM, V265, P6330; MATSUHASHI M, 1964, BIOCHEM Z, V340, P243; MISHINA M, 1980, EUR J BIOCHEM, V111, P79; MISHINA M, 1976, EUR J BIOCHEM, V71, P295, DOI 10.1111/j.1432-1033.1976.tb11115.x; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; MUNDAY MR, 1986, BIOCHEM J, V237, P85, DOI 10.1042/bj2370085; MUNDAY MR, 1988, FEBS LETT, V235, P144, DOI 10.1016/0014-5793(88)81251-1; MUNDAY MR, 1988, EUR J BIOCHEM, V175, P331, DOI 10.1111/j.1432-1033.1988.tb14201.x; MUNDAY MR, 1986, BIOCHEM SOC T, V14, P559, DOI 10.1042/bst0140559; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; OBERMAYER M, 1976, TRENDS BIOCHEM SCI, V1, P169, DOI 10.1016/0968-0004(76)90198-5; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROGGENKAMP R, 1980, P NATL ACAD SCI-BIOL, V77, P1814, DOI 10.1073/pnas.77.4.1814; ROTHSTEIN RJ, 1983, 1 STEP GENE DISRUPTI, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULLER HJ, 1992, EUR J BIOCHEM, V203, P607, DOI 10.1111/j.1432-1033.1992.tb16590.x; SCHULLER HJ, 1992, EMBO J, V11, P107, DOI 10.1002/j.1460-2075.1992.tb05033.x; SPIESS J, 1976, THESIS U MUNICH FRG; SWENSON TL, 1985, J BIOL CHEM, V260, P3791; SWIERCZYNSKI J, 1991, J BIOL CHEM, V266, P17459; TAKAI T, 1988, J BIOL CHEM, V263, P2651; TAKAI T, 1987, FEBS LETT, V212, P98, DOI 10.1016/0014-5793(87)81564-8; TIPPER JP, 1983, ARCH BIOCHEM BIOPHYS, V227, P386, DOI 10.1016/0003-9861(83)90468-X; VERNON RG, 1991, BIOCHEM J, V274, P543, DOI 10.1042/bj2740543; WELLS GB, 1983, J BIOL CHEM, V258, P200; WITTERS LA, 1990, BIOCHEM BIOPH RES CO, V169, P369, DOI 10.1016/0006-291X(90)90341-J; WURTELE ES, 1990, ARCH BIOCHEM BIOPHYS, V278, P179, DOI 10.1016/0003-9861(90)90246-U	64	133	145	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10946	10952						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8098706				2022-12-27	WOS:A1993LD46600038
J	LEHOTZKY, A; TELEGDI, M; LILIOM, K; OVADI, J				LEHOTZKY, A; TELEGDI, M; LILIOM, K; OVADI, J			INTERACTION OF PHOSPHOFRUCTOKINASE WITH TUBULIN AND MICROTUBULES - QUANTITATIVE-EVALUATION OF THE MUTUAL EFFECTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT MUSCLE PHOSPHOFRUCTOKINASE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; STRUCTURAL PROTEINS; GLYCOLYTIC-ENZYMES; SELF-ASSOCIATION; SKELETAL-MUSCLE; BINDING; PURIFICATION; DISSOCIATION; MODULATION	The linked equilibria involved in the binding of phosphofructokinase (EC 2.7.1.11, ATP:D-fructose-6-phosphate 1-phosphotransferase) to tubulin and microtubules were studied at high ionic strength in vitro. The concentration-dependent dissociation of phosphofructokinase was analyzed in the absence and presence of tubulin or microtubules, and the binding of kinase to the tubulin dimer and microtubules was compared. Enzyme activity of phosphofructokinase was inhibited by both tubulin and microtubules: the relative inhibition increased with decreasing enzyme concentration. The complex formation between phosphofructokinase and tubulin was demonstrated by means of fluorescent anisotropy. Concentration-dependent copelleting of the kinase with taxol-stabilized microtubules revealed binding of the enzyme to microtubules as well as phosphofructokinase-enhanced pelleting of microtubules. The binding data agree with the enzyme kinetic findings that the inactive dissociated forms of phosphofructokinase (monomer-dimer) are involved in the heterologous complex formation. Microtubule reorganization (bundle formation) by phosphofructokinase was established by turbidity measurements and sedimentation experiments. The binding data are consistent with a simple molecular model for the interactions in phosphofructokinase-tubulin/microtubules systems.	HUNGARIAN ACAD SCI, BIOL RES CTR, INST ENZYMOL, POB 27, H-1518 BUDAPEST, HUNGARY	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences			Lehotzky, Attila/B-1837-2009; Liliom, Karoly/A-6563-2011	Liliom, Karoly/0000-0002-7177-6872; Ovadi, Judit/0000-0002-3420-682X; Attila, Lehotzky/0000-0001-5235-1812				BOSCA L, 1985, J BIOL CHEM, V260, P2100; BRONSTEIN WW, 1981, CAN J BIOCHEM CELL B, V59, P494, DOI 10.1139/o81-069; CLARKE F, 1983, ACTIN STRUCTURE FUNC; CLARKE FM, 1975, BIOCHIM BIOPHYS ACTA, V381, P37, DOI 10.1016/0304-4165(75)90187-7; COLLINS CA, 1991, METHOD ENZYMOL, V196, P246; DAVIDSON M, 1983, BIOCHEM J, V214, P703, DOI 10.1042/bj2140703; DEFARIA JB, 1978, DEV BIOL, V65, P547, DOI 10.1016/0012-1606(78)90051-9; DURRIEU C, 1987, MOL CELL BIOCHEM, V74, P55; FOE LG, 1984, ARCH BIOCHEM BIOPHYS, V228, P503, DOI 10.1016/0003-9861(84)90016-X; GELFAND VI, 1991, ANNU REV CELL BIOL, V7, P93, DOI 10.1146/annurev.cb.07.110191.000521; HESTERBERG LK, 1982, BIOCHEMISTRY-US, V21, P216, DOI 10.1021/bi00531a003; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; HUITOREL P, 1985, EUR J BIOCHEM, V150, P265, DOI 10.1111/j.1432-1033.1985.tb09016.x; KAHN A, 1980, PEDIATR RES, V14, P1162, DOI 10.1203/00006450-198011000-00003; KELETI T, 1989, PROG BIOPHYS MOL BIO, V53, P105, DOI 10.1016/0079-6107(89)90016-3; KNULL HR, 1990, STRUCTURAL ORG ASPEC; KRIEGEL T, 1986, STUD BIOPHYS, V113, P247; KUMAGAI H, 1983, J BIOCHEM-TOKYO, V93, P1259, DOI 10.1093/oxfordjournals.jbchem.a134260; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JC, 1989, ALLOSTERIC ENZYMES; LILLING G, 1990, INT J BIOCHEM, V22, P857, DOI 10.1016/0020-711X(90)90289-F; LIOU RS, 1980, BIOCHEMISTRY-US, V19, P2684, DOI 10.1021/bi00553a022; LITTLE M, 1988, COMP BIOCHEM PHYS B, V90, P655, DOI 10.1016/0305-0491(88)90320-3; LUTHER MA, 1985, BIOCHEMISTRY-US, V24, P2463, DOI 10.1021/bi00331a011; LUTHER MA, 1986, BIOCHEMISTRY-US, V25, P7931, DOI 10.1021/bi00372a022; MAYR GW, 1987, METHOD ENZYMOL, V139, P745; NA GC, 1986, BIOCHEMISTRY-US, V25, P6214, DOI 10.1021/bi00368a057; NA GC, 1985, METHOD ENZYMOL, V117, P459; OROSZ F, 1987, BIOCHEM BIOPH RES CO, V147, P1121, DOI 10.1016/S0006-291X(87)80186-9; OVADI J, 1982, BIOCHEMISTRY-US, V21, P6375, DOI 10.1021/bi00268a009; OVADI J, 1978, EUR J BIOCHEM, V90, P499, DOI 10.1111/j.1432-1033.1978.tb12629.x; OVADI J, 1988, TRENDS BIOCHEM SCI, V13, P486, DOI 10.1016/0968-0004(88)90237-X; OVADI J, 1986, BIOCHEM BIOPH RES CO, V135, P852, DOI 10.1016/0006-291X(86)91006-5; RAWITCH AB, 1972, J BIOL CHEM, V247, P680; SLOBODA RD, 1976, BIOCHEMISTRY-US, V15, P4497, DOI 10.1021/bi00665a026; Sokal RR, 1969, BIOMETRY, P204; SOMERS M, 1990, EUR J BIOCHEM, V193, P437, DOI 10.1111/j.1432-1033.1990.tb19357.x; TAYLOR JF, 1948, J BIOL CHEM, V173, P591; THRASHER JR, 1981, J BIOL CHEM, V256, P7844; TIMASHEFF SN, 1980, ANNU REV BIOCHEM, V49, P565, DOI 10.1146/annurev.bi.49.070180.003025; TORNHEIM K, 1976, J BIOL CHEM, V251, P7322; TSAI MY, 1973, J BIOL CHEM, V248, P785; WALSH JL, 1989, BIOCHIM BIOPHYS ACTA, V999, P64, DOI 10.1016/0167-4838(89)90031-9	43	80	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10888	10894						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8098705				2022-12-27	WOS:A1993LD46600029
J	OSHEROV, N; GAZIT, A; GILON, C; LEVITZKI, A				OSHEROV, N; GAZIT, A; GILON, C; LEVITZKI, A			SELECTIVE-INHIBITION OF THE EPIDERMAL GROWTH-FACTOR AND HER2/NEU RECEPTORS BY TYRPHOSTINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; CELLS	The HER2 (neu/erb-B2) proto-oncogene codes for a transmembrane receptor with tyrosine kinase activity and with high homology to the EGF receptor (HER1). The high incidence of HER2 overexpression in breast and ovary carcinomas prompted us to synthesize protein tyrosine kinase inhibitors (tyrphostins) which selectively inhibit the HER2 kinase activity. Two groups of tyrphostins were developed: one highly selective in inhibiting HER1 as opposed to HER2, the other highly selective in inhibiting HER2. Both the HER1 and the HER2 selective blockers were competitive with ATP binding. This suggests that even though the kinase domains of the respective receptors show an 80% degree of homology it is possible to design small molecules capable of discriminating between them. These results also show that the two kinases differ in their ATP binding sites. Mitogenic signaling induced by EGF in NIH3T3 cells overexpressing either HER1 or HER1-2 (possessing the HER2 kinase domain) was blocked identically by the agents that discriminate between the two in vitro. This paradox was further explored and elucidated. We propose that high intracellular ATP levels prevent inhibitor binding to the receptor. The antiproliferative action of the two distinct selective tyrphostins observed may result from the inhibition of a downstream element, presumably a tyrosine kinase, which mediates mitogenic signaling.	HEBREW UNIV JERUSALEM, INST LIFE SCI, DEPT BIOL CHEM, GIVAT RAM, IL-91904 JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, INST LIFE SCI, DEPT ORGAN CHEM, IL-91904 JERUSALEM, ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem								ABLER A, 1992, J BIOL CHEM, V267, P3946; AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; ANAFI M, 1992, J BIOL CHEM, V267, P4518; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DeLuca M., 1978, METHOD ENZYMOL, V57, P3, DOI DOI 10.1016/0076-6879(78)57003-1; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FAALAND CA, 1991, MOL CELL BIOL, V11, P2697, DOI 10.1128/MCB.11.5.2697; GAZIT A, 1991, J MED CHEM, V34, P1896, DOI 10.1021/jm00110a022; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; LYALL RM, 1989, J BIOL CHEM, V264, P14503; ROTIN D, 1992, J BIOL CHEM, V267, P9678; SCHECHTER Y, 1989, EMBO J, V8, P1671, DOI 10.1002/j.1460-2075.1989.tb03558.x; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; UMEZAWA K, 1991, METHOD ENZYMOL, V201, P379; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	20	183	201	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11134	11142						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8098709				2022-12-27	WOS:A1993LD46600063
J	LEVEQUE, C; ELFAR, O; MARTINMOUTOT, N; SATO, K; KATO, R; TAKAHASHI, M; SEAGAR, MJ				LEVEQUE, C; ELFAR, O; MARTINMOUTOT, N; SATO, K; KATO, R; TAKAHASHI, M; SEAGAR, MJ			PURIFICATION OF THE N-TYPE CALCIUM-CHANNEL ASSOCIATED WITH SYNTAXIN AND SYNAPTOTAGMIN - A COMPLEX IMPLICATED IN SYNAPTIC VESICLE EXOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONOTOXIN GVIA RECEPTOR; PROTEIN-KINASE-C; SKELETAL-MUSCLE; NEUROTRANSMITTER RELEASE; FUNCTIONAL EXPRESSION; MONOCLONAL-ANTIBODY; CA-2+ CHANNELS; CA2+ CHANNELS; ACTIVE ZONES; BETA-SUBUNIT	omega-Conotoxin-sensitive N-type calcium channels control neurotransmitter release at the nerve terminal and interact with proteins implicated in secretion. Solubilized omega-conotoxin receptors from rat brain synaptic membranes were immunoprecipitated by antibodies against calcium channel alpha 1 subunits, syntaxin, and a 105-kDa plasma membrane protein. A multimeric complex, composed of calcium channel subunits, and synaptic proteins that showed varying degrees of association, was purified by a procedure involving anti-syntaxin immunoaffinity chromatography. A 250-kDa N-type alpha 1 subunit, containing cAMP-dependent phosphorylation site(s), was identified by photoaffinity labelling with I-125-azidonitrobenzoyl omega-conotoxin and immunoblotting with sequence-directed antibodies. An immunologically related 210-kDa form of the alpha 1 subunit was detected that displayed different pharmacological and regulatory properties. Protein bands of 140, 70, 58, and 35 kDa comigrated with purified alpha 1 subunits upon sucrose gradient centrifugation, whereas the 105-kDa protein was removed. The 58- and 35-kDa bands contained, respectively, the synaptic vesicle protein synaptotagmin and syntaxin, a plasma membrane protein that binds synaptic vesicle proteins. Purified omega-conotoxin receptors were quantitatively immunoprecipitated by anti-syntaxin antibodies. These proteins may constitute an isolated exo-cytotic complex in which the N-type calcium channel tightly interacts with a synaptic vesicle docking site.	FAC MED MARSEILLE,INST JEAN ROCHE,INST NATL SANTE & RECH MED,U374,SECTEUR NORD,F-13916 MARSEILLE 20,FRANCE; MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			leveque, christian/GVU-3567-2022; Far, Oussama El/D-4225-2017; EL FAR, Oussama/P-9915-2019	leveque, christian/0000-0003-2583-2148; Far, Oussama El/0000-0002-7473-8345; EL FAR, Oussama/0000-0002-7473-8345				ABE T, 1987, J BIOL CHEM, V262, P9877; AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192; BARHANIN J, 1988, BIOCHEM BIOPH RES CO, V150, P1051, DOI 10.1016/0006-291X(88)90736-X; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; CRUZ LJ, 1986, J BIOL CHEM, V261, P6230; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FUJITA Y, 1993, NEURON, V10, P585, DOI 10.1016/0896-6273(93)90162-K; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MALOUF NN, 1992, NEURON, V8, P899, DOI 10.1016/0896-6273(92)90204-Q; MARQUEZE B, 1988, MOL PHARMACOL, V34, P87; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; MORITA T, 1992, BIOMED RES-TOKYO, V13, P357, DOI 10.2220/biomedres.13.357; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OCONNOR VM, 1993, FEBS LETT, V326, P255, DOI 10.1016/0014-5793(93)81802-7; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; SAISU H, 1991, BIOCHEM BIOPH RES CO, V181, P59, DOI 10.1016/S0006-291X(05)81381-6; SAKAMOTO J, 1991, J BIOL CHEM, V266, P18914; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHMID A, 1986, BIOCHEMISTRY-US, V25, P3492, DOI 10.1021/bi00360a002; SCOTT RH, 1991, PROG NEUROBIOL, V36, P485, DOI 10.1016/0301-0082(91)90014-R; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; TAKAHASHI M, 1989, BIOCHEM BIOPH RES CO, V163, P1182, DOI 10.1016/0006-291X(89)92345-0; TAKAHASHI M, 1991, BRAIN RES, V551, P279, DOI 10.1016/0006-8993(91)90942-O; TAKAHASHI M, 1987, SCIENCE, V236, P88, DOI 10.1126/science.2436296; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; Walch-Solimena C, 1993, Curr Opin Neurobiol, V3, P329, DOI 10.1016/0959-4388(93)90125-I; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925; YOSHIDA A, 1992, FEBS LETT, V309, P343, DOI 10.1016/0014-5793(92)80804-P	46	186	191	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6306	6312						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119979				2022-12-27	WOS:A1994MZ50300011
J	CHAO, CP; LAULEDERKIND, SJF; BALLOU, LR				CHAO, CP; LAULEDERKIND, SJF; BALLOU, LR			SPHINGOSINE-MEDIATED PHOSPHATIDYLINOSITOL METABOLISM AND CALCIUM MOBILIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FACTOR RECEPTOR PHOSPHORYLATION; EPIDERMOID CARCINOMA-CELLS; NECROSIS-FACTOR-ALPHA; PAROTID ACINAR-CELLS; HUMAN-FIBROBLASTS; PROSTAGLANDIN-E2 PRODUCTION; SPHINGOMYELIN TURNOVER; CELLULAR PROLIFERATION; INOSITOL TRISPHOSPHATE	The cytokine mediated stimulation of sphingomyelin (SM) metabolism is emerging as an important signal transduction pathway via the generation of ceramide and sphingosine, products which have been shown to affect a wide variety of biological processes. Because SM-mediated signal transduction is initiated via the hydrolysis of an integral membrane phospholipid by a phospholipase C-like enzyme (sphingomyelinase) to yield lipids which modulate protein kinase C activity, the SM and phosphatidylinositol (PI) signaling pathways share certain similarities. The present study was undertaken to examine the potential for interplay between SM and PI turnover by testing the effects of sphingosine, sphingosine-1-phosphate, and ceramide on PI turnover. In dermal fibroblasts, sphingosine stimulated a rapid dose-dependent hydrolysis of PI, yielding inositol 1,4,5-triphosphate, followed by increased levels of intracellular calcium, Sphingosine-induced inositol phosphate (IF) accumulation was observed between 5 and 30 mu M sphingosine with a maximal accumulation of 2.7-fold over control levels. Enhanced IP formation was measured as early as 5 s following sphingosine treatment and IP levels remained elevated for more than 60 min. Intracellular calcium mobilization accompanied the dose dependent accumulation of IPs in response to sphingosine, although this effect was not apparent until after a 30-40 s lag period. Interestingly sphingosine-1-phosphate stimulated a more rapid release of intracellular Ca2+ than sphingosine, but it had no effect on PI turnover. DL-threo-Dihydrosphingosine, a competitive inhibitor of sphingosine kinase, stimulates both PI turnover and Ca2+ flux, but does not block the action of sphingosine relative to those two processes. Ceramide (added as C-2-ceramide), N-stearylamine, and stearoyl-D-sphingosine did not affect PI turnover or Ca2+ mobilization. Pretreatment of intact cells with pertussis toxin partially inhibited sphingosine-mediated IP accumulation, suggesting a role for guanine nucleotide binding protein(s) (G protein) in sphingosine-stimulated PI turnover. Furthermore, guanosine 5'-O-(3-thiotriphosphate) stimulated, whereas guanosine 5'-O-(2-thiodiphosphate) inhibited, sphingosine-induced IP accumulation in permeabilized cells. Collectively, these data suggest that sphingosine enhances PI turnover by stimulating phospholipase C activity, and the activation of this process may be modulated by G protein interactions. Thus, the regulation of PI turnover and Ca2+ mobilization by sphingosine may represent another mechanism by which sphingosine modulates cell function and that these effects can be distinguished from those of ceramide.	UNIV TENNESSEE,DEPT MED,DIV CONNECT TISSUE DIS,MEMPHIS,TN 38163; UNIV TENNESSEE,DEPT PEDIAT,MEMPHIS,TN 38163; UNIV TENNESSEE,DEPT BIOCHEM,MEMPHIS,TN 38163; DEPT VET AFFAIRS,MEMPHIS,TN	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center			Laulederkind, Stanley/GLQ-8970-2022		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR026034, P50AR039166] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR26034, AR39166] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARNOLD RS, 1991, BIOCHEMISTRY-US, V30, P7747, DOI 10.1021/bi00245a011; BALLOU LR, 1992, IMMUNOL TODAY, V13, P339, DOI 10.1016/0167-5699(92)90167-6; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BALLOU LR, 1990, J IMMUNOL, V145, P4245; BALLOU LR, 1991, J CLIN INVEST, V89, P299; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CANDELA M, 1991, J EXP MED, V174, P1363, DOI 10.1084/jem.174.6.1363; COCKCROFT S, 1992, BIOCHEM J, V288, P1; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; FINE J, 1989, BIOCHEM J, V263, P371, DOI 10.1042/bj2630371; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HASHIZUME T, 1992, BIOCHEM J, V282, P243, DOI 10.1042/bj2820243; HUANG CL, 1989, J BIOL CHEM, V264, P4391; JENNINGS LK, 1989, BLOOD, V74, P2674; KIM MY, 1991, J BIOL CHEM, V266, P484; KISS Z, 1990, J BIOL CHEM, V265, P7345; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LITOSCH I, 1987, BIOCHEM J, V244, P35, DOI 10.1042/bj2440035; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; PAWELCZYK T, 1992, ARCH BIOCHEM BIOPHYS, V297, P328, DOI 10.1016/0003-9861(92)90680-U; PUSHKAREVA MY, 1992, J BIOL CHEM, V267; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SABBADINI RA, 1992, J BIOL CHEM, V267, P15475; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SUGIYA H, 1991, FEBS LETT, V286, P113, DOI 10.1016/0014-5793(91)80953-Z; SUGIYA H, 1990, CELL CALCIUM, V11, P469, DOI 10.1016/0143-4160(90)90079-A; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZHANG H, 1990, J BIOL CHEM, V265, P21309	44	85	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5849	5856						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119927				2022-12-27	WOS:A1994MY84000058
J	CHICHEPORTICHE, Y; VASSALLI, P				CHICHEPORTICHE, Y; VASSALLI, P			CLONING AND EXPRESSION OF A MOUSE MACROPHAGE CDNA CODING FOR A MEMBRANE GLYCOPROTEIN OF THE SCAVENGER RECEPTOR CYSTEINE-RICH DOMAIN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROPOIETIN GENE; ANCHOR ATTACHMENT; MESSENGER-RNA; MAC-2 ANTIGEN; PROTEIN; CELLS; IDENTIFICATION; SEQUENCE; BINDING; LECTIN	We have cloned from murine macrophages a cDNA coding for a new protein of the scavenger receptor family whose mRNA is increased very strongly by adherence and moderately by exposure to tumor necrosis factor and interferon-gamma. The nucleotidic sequence extends for 2168 bases and encodes a protein of 559 amino acids with six potential glycosylation sites. The first 100 NH2-terminal amino acids represent a single scavenger receptor cysteine-rich domain, whereas the COOH-terminal end of the molecule is compatible either with a transmembrane hydrophobic peptide followed by a very short intracytoplasmic sequence or a signal sequence for an anchoring via a glycophosphatidylinositol. The protein is highly homologous to most of the very recently identified human MAC-2-binding protein and murine cyclophilin C-associated protein.	CTR MED UNIV GENEVA,DEPT PATHOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva								ARUFFO A, 1991, J EXP MED, V174, P949, DOI 10.1084/jem.174.4.949; CARAS IW, 1991, J CELL BIOL, V113, P77, DOI 10.1083/jcb.113.1.77; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DANGOTT LJ, 1989, P NATL ACAD SCI USA, V86, P2128, DOI 10.1073/pnas.86.7.2128; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERLANGER BF, 1992, IMMUNOL TODAY, V13, P487, DOI 10.1016/0167-5699(92)90023-Z; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; FRIEDMAN J, 1993, P NATL ACAD SCI USA, V90, P6815, DOI 10.1073/pnas.90.14.6815; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GOLBBERGER G, 1987, J BIOL CHEM, V262, P10065; GRUBER DF, 1977, EXP HEMATOL, V5, P392; HO MK, 1982, J IMMUNOL, V128, P1221; JONES NH, 1986, NATURE, V323, P346, DOI 10.1038/323346a0; KOTHS K, 1993, J BIOL CHEM, V268, P14245; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LINSLEY PS, 1986, BIOCHEMISTRY-US, V25, P2978, DOI 10.1021/bi00358a037; LUSSOW AR, 1990, P NATL ACAD SCI USA, V87, P2960, DOI 10.1073/pnas.87.8.2960; MCDONALD JD, 1986, MOL CELL BIOL, V6, P842, DOI 10.1128/MCB.6.3.842; MORAN P, 1991, J CELL BIOL, V115, P1595, DOI 10.1083/jcb.115.6.1595; MORAN P, 1991, J BIOL CHEM, V266, P1250; NATALI PG, 1982, CANCER RES, V42, P583; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; ODA Y, 1991, GENE, V99, P279; PAUL P, 1984, EXP HEMATOL, V12, P825; PENNMAN M, 1991, J BIOL CHEM, V266, P23985; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RICH IN, 1982, J RETICULOENDOTH SOC, V31, P17; RICH IN, 1982, BLOOD, V60, P1007; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SHERRY B, 1992, P NATL ACAD SCI USA, V89, P3511, DOI 10.1073/pnas.89.8.3511; SHOEMAKER CB, 1986, MOL CELL BIOL, V6, P849, DOI 10.1128/MCB.6.3.849; Strauss W. M., 1990, CURRENT PROTOCOLS MO; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; TURNER AJ, 1991, CELL BIOL INT REP, V15, P1083, DOI 10.1016/0309-1651(91)90057-P; WIJNGAARD PLJ, 1992, J IMMUNOL, V149, P3273; WOO HJ, 1990, J BIOL CHEM, V265, P7097	39	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5512	5517						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119883				2022-12-27	WOS:A1994MY84000009
J	RUPPRECHT, HD; DRUMMOND, IA; MADDEN, SL; RAUSCHER, FJ; SUKHATME, VP				RUPPRECHT, HD; DRUMMOND, IA; MADDEN, SL; RAUSCHER, FJ; SUKHATME, VP			THE WILMS-TUMOR SUPPRESSOR GENE WT1 IS NEGATIVELY AUTOREGULATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGER PROTEIN; GROWTH-FACTOR; HUMAN CHROMOSOME-11; AUTO-REGULATION; BINDING-SITE; KIDNEY-CELLS; DNA; EXPRESSION; DELETION; LOCUS	The Wilms' tumor suppressor gene WT1 encodes a zinc-finger DNA-binding protein that functions as a transcriptional repressor. WT1 is expressed in a dramatic spatial and temporal pattern during kidney development and is thought to be critical during mesenchymal-epithelial conversion. The WT1 protein bound multiple sites in the WT1 promoter and functioned as a powerful transcriptional repressor of its gene in vivo (>50-fold). The WT1 protein carrying an NH2-terminal 17-amino acid insertion and a 3-amino acid insertion (KTS) between zinc fingers 3 and 4, arising from the most abundant of four alternatively spliced transcripts, was the most powerful repressor. Of importance, a subset of WT1-binding sites differs from the Egr-1 consensus sequence, which has been shown to bind one splice variant of the WT1 protein (WT1(-KTS)). We characterized two of these sites and show that they bind bath -KTS and +KTS forms of the WT1 zinc-finger protein and can confer repression on a heterologous promoter construct. Our data demonstrate that WT1, in addition to its known effects on insulin-like growth factor II, platelet-derived growth factor A, and Pax-2 transcription, is a powerful repressor of its own gene. These observations emphasize its critical role as a transcriptional regulatory protein during normal kidney development.	BETH ISRAEL HOSP,DIV RENAL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19107	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; The Wistar Institute			Sukhatme, Vikas/W-2776-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045617, R01DK044921] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 44921, DK 45617] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1988, MOL REPROD DEV; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; BURNSTEIN KL, 1991, STEROIDS, V56, P52, DOI 10.1016/0039-128X(91)90124-E; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAVENEE W, 1989, RECESSIVE ONCOGENES; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COMPTON DA, 1988, CELL, V55, P827, DOI 10.1016/0092-8674(88)90138-9; COWELL JK, 1991, ONCOGENE, V6, P595; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FRAIZER GE, 1987, J CELL PHYSIOL, V133, P169, DOI 10.1002/jcp.1041330122; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; FREBOURG T, 1988, GENE, V65, P315, DOI 10.1016/0378-1119(88)90468-4; GASHLER AL, 1992, P NATL ACAD SCI US, V89; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1989, AM J HUM GENET, V44, P486; GLASER T, 1986, NATURE, V321, P882, DOI 10.1038/321882a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HUFF V, 1991, AM J HUM GENET, V48, P997; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAGA E, 1981, HUM GENET, V57, P231; MORRIS JF, 1991, ONCOGENE, V6, P2339; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; RIO DC, 1983, CELL, V32, P1227, DOI 10.1016/0092-8674(83)90305-7; Sambrook J, 1989, MOL CLONING LABORATO; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828	45	129	135	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6198	6206						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119964				2022-12-27	WOS:A1994MY84000107
J	TSUJITA, T; OKUDA, H				TSUJITA, T; OKUDA, H			FATTY-ACID ETHYL ESTER-SYNTHESIZING ACTIVITY OF LIPOPROTEIN-LIPASE FROM RAT POSTHEPARIN PLASMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYLESTER LIPASE; ETHANOL-METABOLISM; KINETIC-PROPERTIES; LIPID INTERFACE; SYNTHASE; PURIFICATION; EXCHANGE	Lipoprotein lipase (LPL) was obtained from rat postheparin plasma by chromatographies on heparin-Sepharose and hydroxyapatite. The enzyme was associated with fatty acid ethyl ester synthase (FAEE synthase) as judged by their co-elution profiles and identical profiles of inhibition by diisopropyl fluorophosphate. Only one polypeptide of molecular weight 57,000 in purified LPL fraction was labeled by affinity labeling with [H-3]-diisopropyl fluorophosphate. The FAEE synthase activity of LPL was not affected by addition of apolipoprotein C-II. Digestion of the enzyme with trypsin resulted in almost complete loss of the triolein-hydrolyzing activity without change in FAEE synthase activity. The tributyrin-hydrolyzing activity of LPL was also not affected by addition of apolipoprotein C-II or trypsin digestion. On addition at progressively higher concentrations, bovine serum albumin increased FAEE synthesis to a maximum at 2 mg/ml and at higher concentrations inhibited its activity. On incubation of purified LPL with chylomicrons in an ethanol/water mixture, FAEE was formed in the presence of a high concentration of bovine serum albumin. The specific activity of FAEE synthesis from chylomicrons was about 65 times that from oleic acid. Triolein/gum arabic emulsion was used for identification of reaction products. We propose the following mechanism of FAEE formation from chylomicrons by LPL. The enzyme attacks chylomicrons forming an acyl-enzyme intermediate, and during the deacylation process, ethanol binds to fatty acids as an acceptor. These results suggest that LPL contributes to nonoxidative ethanol metabolism (FAEE formation) through degradation of triglyceride-rich lipoproteins such as chylomicrons.			TSUJITA, T (corresponding author), EHIME UNIV,SCH MED,DEPT MED BIOCHEM,SHIGENOBU,EHIME 79102,JAPAN.							BELFRAGE P, 1969, J LIPID RES, V10, P341; BENGTSSON G, 1981, EUR J BIOCHEM, V113, P547, DOI 10.1111/j.1432-1033.1981.tb05097.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brockman HL, 1984, LIPASES, P1; CHEN RF, 1967, J BIOL CHEM, V242, P173; DUGI KA, 1992, J BIOL CHEM, V267, P25086; HIDE WA, 1992, J LIPID RES, V33, P167; KOBAYASHI J, 1989, EUR J CLIN INVEST, V19, P424, DOI 10.1111/j.1365-2362.1989.tb00254.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE LG, 1983, J CLIN INVEST, V72, P724, DOI 10.1172/JCI111022; LANGE LG, 1982, P NATL ACAD SCI-BIOL, V79, P3954, DOI 10.1073/pnas.79.13.3954; LAPOSATA EA, 1990, J BIOL CHEM, V265, P9688; LAPOSATA EA, 1986, SCIENCE, V231, P476; MOGELSON S, 1984, BIOCHEMISTRY-US, V23, P4075, DOI 10.1021/bi00313a010; MUDERHWA JM, 1992, BIOCHEMISTRY-US, V31, P141, DOI 10.1021/bi00116a021; OLIVECRONA T, 1977, PROTIDES BIOL FLUIDS, V25, P201; RILEY DJS, 1990, BIOCHEMISTRY-US, V29, P3848, DOI 10.1021/bi00468a007; ROJAS C, 1989, BIOCHEMISTRY-US, V28, P4475, DOI 10.1021/bi00436a053; SHIRAI K, 1984, BIOCHIM BIOPHYS ACTA, V795, P1; Smith L.C., 1984, P263; TSUJITA T, 1987, BIOCHEMISTRY-US, V26, P8423, DOI 10.1021/bi00399a059; TSUJITA T, 1990, PROG CLIN BIOL RES, V344, P915; TSUJITA T, 1992, J BIOL CHEM, V267, P23489; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; WONG H, 1991, P NATL ACAD SCI USA, V88, P11290, DOI 10.1073/pnas.88.24.11290	26	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5884	5889						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119932				2022-12-27	WOS:A1994MY84000063
J	WAKABAYASHI, S; BERTRAND, B; SHIGEKAWA, M; FAFOURNOUX, P; POUYSSEGUR, J				WAKABAYASHI, S; BERTRAND, B; SHIGEKAWA, M; FAFOURNOUX, P; POUYSSEGUR, J			GROWTH-FACTOR ACTIVATION AND H+-SENSING OF THE NA+/H+ EXCHANGER ISOFORM-1 (NHE1) - EVIDENCE FOR AN ADDITIONAL MECHANISM NOT REQUIRING DIRECT PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH REGULATION; INDEPENDENT MECHANISM; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; PROTEIN-KINASE; ALPHA-THROMBIN; CYTOPLASMIC PH; OKADAIC ACID; ANTIPORTER; FIBROBLASTS	Growth factors stimulate the Na+/H+ exchange activity (NHE1 human isoform) and at the same time increase the phosphorylation state of the exchanger at serine residues. To determine the role of NHE1 phosphorylation, a set of deletion and point mutants has been generated. Functional characterization of deletion mutants expressed in fibroblastic cells revealed that the cytoplasmic region between amino acids 567 and 635 is required for both growth factor-induced cytoplasmic alkalinization and maintenance of high intracellular pH (pH(i)) sensitivity. In contrast to the loss of growth factor activation and pH(i) sensitivity caused by the deletion of amino acids 567-635, the same deletion had no apparent effect on the pattern of growth factor-induced phosphorylation. In addition, individual replacement of any of the serine residues between amino acids 567 and 635 with alanine also had no effect on growth factor activation of the exchange activity. Comparison of phosphopeptide maps for the wild type with those for the internal deletion mutant exchangers and the expressed cytoplasmic domain revealed that all major in vivo phosphorylation sites including growth factor-sensitive ones map to the cytoplasmic tail (amino acids 636-815). Deletion of these sites preserves high pH(i) sensitivity and reduces by only 50% growth factor-induced cytoplasmic alkalinization. Taken together, these data support the existence of a mechanism not requiring direct phosphorylation of NHE1, by which growth factor signals transmit to the ''H+-sensor'' and control the set point value of the exchanger. We propose that a regulatory factor(s) controls NHE1, presumably through its interaction with the critical cytoplasmic region prior to amino acid 635.	UNIV NICE,CTR BIOCHIM,CNRS,UMR 134,F-06108 NICE 2,FRANCE; NATL CARDIOVASC CTR,RES INST,SUITA,OSAKA 565,JAPAN	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; National Cerebral & Cardiovascular Center - Japan								ARONSON P, 1986, NA PLUS H PLUS EXCHA; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; Battey, 1986, BASIC METHODS MOL BI; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BORGESE F, 1992, P NATL ACAD SCI USA, V89, P6765, DOI 10.1073/pnas.89.15.6765; CASSEL D, 1986, J BIOL CHEM, V261, P5460; FAFOURNOUX P, 1991, BIOCHEMISTRY-US, V30, P9510, DOI 10.1021/bi00103a018; GANZ MB, 1989, NATURE, V337, P648, DOI 10.1038/337648a0; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GRINSTEIN S, 1988, NA PLUS H PLUS; GRINSTEIN S, 1993, IN PRESS EMBO J; HELMEKOB C, 1993, IN PRESS EUR J PHYSL; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; LALLEMAIN G, 1985, J BIOL CHEM, V260, P4877; MALY K, 1989, J BIOL CHEM, V264, P11839; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; PARIS S, 1984, J BIOL CHEM, V259, P989; POUYSSEGUR J, 1985, TRENDS BIOCHEM SCI, V10, P453, DOI 10.1016/0968-0004(85)90030-1; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1991, J BIOL CHEM, V266, P19166; SCHWARTZ MA, 1989, P NATL ACAD SCI USA, V86, P4525, DOI 10.1073/pnas.86.12.4525; TADA M, 1989, BIOESSAYS, V10, P157, DOI 10.1002/bies.950100505; TSE C M, 1991, Gastroenterology, V100, pA258; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; TSE CM, 1992, J BIOL CHEM, V267, P9340; VANOBBERGHENSCHILLING E, 1985, EMBO J, V4, P2927, DOI 10.1002/j.1460-2075.1985.tb04025.x; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WEINMAN EJ, 1993, ANNU REV PHYSIOL, V55, P289, DOI 10.1146/annurev.ph.55.030193.001445; WEINMAN EJ, 1990, AM J PHYSIOL, V258, pF1254; ZIEGELSTEIN RC, 1992, SCIENCE, V258, P656, DOI 10.1126/science.1329207	37	172	172	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5583	5588						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119893				2022-12-27	WOS:A1994MY84000020
J	BENSON, FE; WEST, SC				BENSON, FE; WEST, SC			SUBSTRATE-SPECIFICITY OF THE ESCHERICHIA-COLI RUVC PROTEIN - RESOLUTION OF 3-STRANDED AND 4-STRANDED RECOMBINATION INTERMEDIATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLLIDAY JUNCTIONS INVITRO; T4 ENDONUCLEASE-VII; RECA-PROTEIN; 3-STRANDED DNA; EXCHANGE-REACTIONS; BRANCH MIGRATION; REPAIR; PURIFICATION; INSERTIONS; SEQUENCES	The specificity of the Escherichia coli RuvC Holliday junction resolvase has been investigated in vitro. RuvC protein cleaves synthetic DNA substrates that model three- or four-stranded recombination intermediates but fails to act upon Y junctions, G/A mismatches, heterologous loop structures, or two-stranded branched junctions RuvC therefore differs from endonuclease VII of bacteriophage T4 which exhibits broad range specificity. Using related three- and four-stranded synthetic DNA junctions, we show that RuvC cleaves both junctions at the same DNA sequence and requires a region of homology at the junction point. The action of RuvC on three- and four-stranded recombination intermediates made by RecA was also investigated. We found that RuvC fails to resolve three stranded intermediates in the presence of RecA, although four-stranded intermediates are resolved under the same conditions. However both three and four-stranded intermediates are substrates for the nuclease after removal of RecA. We interpret these differences in terms of the contiguity of the RecA nucleoprotein filament which may, under certain conditions, limit access to the Holliday junction resolvase.	IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND					Benson, Fiona Elizabeth/0000-0002-3918-7015; West, Stephen/0000-0001-8848-9418				BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BHATTACHARYYA A, 1991, J MOL BIOL, V221, P1191, DOI 10.1016/0022-2836(91)90928-Y; BIANCHI ME, 1983, CELL, V35, P511, DOI 10.1016/0092-8674(83)90185-X; CHIU SK, 1990, J BIOL CHEM, V265, P21262; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; DUNDERDALE HJ, 1994, J BIOL CHEM, V269, P5187; HAHN TR, 1988, J BIOL CHEM, V263, P7431; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; JENSCH F, 1986, EMBO J, V5, P181, DOI 10.1002/j.1460-2075.1986.tb04194.x; KEMPER B, 1981, EUR J BIOCHEM, V115, P133; KEMPER B, 1990, STRUCTURE METHODS, V1, P215; KLEFF S, 1988, EMBO J, V7, P1527, DOI 10.1002/j.1460-2075.1988.tb02972.x; KOSAK HG, 1990, EUR J BIOCHEM, V194, P779, DOI 10.1111/j.1432-1033.1990.tb19469.x; Maxam A M, 1980, Methods Enzymol, V65, P499; MINAGAWA T, 1978, VIROLOGY, V91, P222, DOI 10.1016/0042-6822(78)90371-9; MUELLER JE, 1988, P NATL ACAD SCI USA, V85, P9441, DOI 10.1073/pnas.85.24.9441; MULLER B, 1990, CELL, V60, P329, DOI 10.1016/0092-8674(90)90747-3; MULLER B, 1992, EMBO J, V11, P2685, DOI 10.1002/j.1460-2075.1992.tb05334.x; MURCHIE AIH, 1993, J MOL BIOL, V233, P77, DOI 10.1006/jmbi.1993.1486; PARSONS CA, 1990, NUCLEIC ACIDS RES, V18, P4377, DOI 10.1093/nar/18.15.4377; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; RAO BJ, 1991, P NATL ACAD SCI USA, V88, P2984, DOI 10.1073/pnas.88.8.2984; RAO BJ, 1993, J MOL BIOL, V229, P328, DOI 10.1006/jmbi.1993.1038; SAMBROOK E, 1989, MOL CLONING LABORATO; SHIAU A, 1988, GENE, V67, P295, DOI 10.1016/0378-1119(88)90406-4; SHIBA T, 1993, MOL GEN GENET, V237, P395, DOI 10.1007/BF00279443; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SOLARO PC, 1993, J MOL BIOL, V230, P868, DOI 10.1006/jmbi.1993.1207; STASIAK A, 1992, MOL MICROBIOL, V6, P3267, DOI 10.1111/j.1365-2958.1992.tb02194.x; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; WEST SC, 1982, MOL GEN GENET, V187, P209, DOI 10.1007/BF00331119; WEST SC, 1982, MOL GEN GENET, V186, P333, DOI 10.1007/BF00729451; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	42	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5195	5201						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106501				2022-12-27	WOS:A1994MX57100078
J	GROBLER, JA; WANG, M; PIKE, ACW; BREW, K				GROBLER, JA; WANG, M; PIKE, ACW; BREW, K			STUDY BY MUTAGENESIS OF THE ROLES OF 2 AROMATIC CLUSTERS OF ALPHA-LACTALBUMIN IN ASPECTS OF ITS ACTION IN THE LACTOSE SYNTHASE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GALACTOSYL TRANSFERASE; BOVINE; GALACTOSYLTRANSFERASE; SITE; LYSOZYME; SELECTION	A new system for the bacterial expression of a variant of bovine alpha-lactalbumin has been developed. Eighteen mutant proteins containing single site substitutions in a cluster of predominantly aromatic residues adjacent to the cleft (aromatic cluster I) and in the hydrophobic box were expressed. The proteins were extracted from inclusion bodies and treated to generate native folding and disulfide bonds to provide appropriately folded protein samples for nine of the mutants. These were characterized with respect to kinetic parameters reflecting aspects of alpha-lactalbumin activity in modulating the specificity of bovine galactosyltransferase. In aromatic cluster I, changes at tryptophan 118 or glutamine 117 were found to specifically reduce affinity for galactosyltransferase, whereas substitutions for phenylalanine 31 or histidine 32 have major effects on the ability to promote glucose binding (13-200-fold) and lesser effects on galactosyltransferase affinity (1.5-70-fold). Substitutions in the hydrophobic box were found to affect folding rather than activity. Thus, the binding of alpha-lactalbumin to galactosyltransferase and its ability to promote glucose binding can be separately perturbed and are associated with distinct but adjacent structures. Aromatic cluster I is directly involved in activity whereas the hydrophobic box appears to have a structural rather than functional role.	UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,MIAMI,FL 33101	University of Miami			Brew, Keith/A-6746-2009; Brew, Keith/W-1643-2019	Brew, Keith/0000-0003-1306-1032; 	NIGMS NIH HHS [GM21363] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021363] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHARYA KR, 1989, J MOL BIOL, V208, P99, DOI 10.1016/0022-2836(89)90091-0; ALEXANDRESCU AT, 1992, EUR J BIOCHEM, V210, P699, DOI 10.1111/j.1432-1033.1992.tb17471.x; BELL JE, 1975, J BIOL CHEM, V250, P7579; BELL JE, 1976, J BIOL CHEM, V251, P3003; Brew K., 1992, Advanced dairy chemistry-1: Proteins., P191; BREW K, 1993, MIAMI SHORT REPORTS, V3, P98; BREW K, 1979, GENE PROTEIN INFORMA, P443; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3677, DOI 10.1021/bi00065a022; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HILL RL, 1975, ADV ENZYMOL RAMB, V43, P411; HIROAKA Y, 1980, BIOCHEM BIOPH RES CO, V93, P1098; KHATRA BS, 1974, EUR J BIOCHEM, V44, P537, DOI 10.1111/j.1432-1033.1974.tb03513.x; KOGA K, 1985, BIOCHEMISTRY-US, V24, P7257, DOI 10.1021/bi00346a035; KRONMAN MJ, 1989, CRIT REV BIOCHEM MOL, V24, P565, DOI 10.3109/10409238909080054; KUMAGAI I, 1992, P NATL ACAD SCI USA, V89, P5887, DOI 10.1073/pnas.89.13.5887; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MORRISON JF, 1971, J BIOL CHEM, V246, P3985; POWELL JT, 1976, J BIOL CHEM, V251, P3645; POWELL JT, 1974, EUR J BIOCHEM, V48, P217, DOI 10.1111/j.1432-1033.1974.tb03759.x; POWELL JT, 1976, J BIOL CHEM, V251, P3653; PRIEELS JP, 1979, BIOCHEMISTRY-US, V18, P1771, DOI 10.1021/bi00576a021; PRIEELS JP, 1975, EUR J BIOCHEM, V60, P533, DOI 10.1111/j.1432-1033.1975.tb21032.x; RAO KR, 1989, BIOCHEM BIOPH RES CO, V163, P1390, DOI 10.1016/0006-291X(89)91133-9; RICHARDSON RH, 1980, J BIOL CHEM, V255, P3377; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SAWANO H, 1992, FEBS LETT, V303, P11, DOI 10.1016/0014-5793(92)80466-T; SCHECHTER Y, 1974, J BIOL CHEM, V249, P413; SHEWALE JG, 1984, J BIOL CHEM, V259, P4947; SINHA SK, 1981, J BIOL CHEM, V256, P4193; VIAENE A, 1991, EUR J BIOCHEM, V202, P471, DOI 10.1111/j.1432-1033.1991.tb16396.x; WANG M, 1989, J BIOL CHEM, V264, P21116	35	60	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5106	5114						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106490				2022-12-27	WOS:A1994MX57100065
J	KISHINO, J; OHARA, O; NOMURA, K; KRAMER, RM; ARITA, H				KISHINO, J; OHARA, O; NOMURA, K; KRAMER, RM; ARITA, H			PANCREATIC-TYPE PHOSPHOLIPASE A(2) INDUCES GROUP-II PHOSPHOLIPASE A(2) EXPRESSION AND PROSTAGLANDIN BIOSYNTHESIS IN RAT MESANGIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; FORSKOLIN-INDUCED SYNTHESIS; BINDING-SITES; PURIFICATION; PROTEIN; CLONING; RELEASE; LUNG; RNA	The effect of pancreatic group I phospholipase Az (PLA(2)-I) on receptor-mediated expression of arthritic group II phospholipase A(2) (PLA(2)-II) and its correlation with prostaglandin E(2) (PGE(2)) synthesis were examined in cultured rat mesangial cells. Scatchard analysis using I-125-PLA(2)-I revealed the existence of a single class of specific binding sites for PLA(2)-I in rat mesangial cells with an equilibrium dissociation constant (K-d) of 1.6 nM and a maximum binding capacity of 10.1 fmol/10(6) cells. The mammalian mature type of PLA(2)-I specifically recognized this binding site, whereas its inactive zymogen and mammalian PLA(2)-II showed much lower affinities. PLA(2)-I markedly increased PLA(2)-II mRNA levels as well as PLA(2)-II secretion from the cells in a time- and dose-dependent manner that was closely correlated with PGE(2) production. Both PLA(2)-II expression and PGE(2) synthesis were completely suppressed by pretreatment of the cells with actinomycin D, cycloheximide, or dexamethasone. These results strongly suggest that there may be crosstalk between PLA(2)-I and PLA(2)-II via the specific PLA(2)-I receptor that elicits PGE(2) synthesis.	SHIONOGI & CO LTD,SHIONOGI RES LABS,FUKUSHIMA KU,OSAKA,OSAKA 553,JAPAN; ELI LILLY & CO,LILLY RES LABS,INDIANAPOLIS,IN 46285	Shionogi & Company Limited; Eli Lilly			Ohara, Osamu/A-9119-2012; Ohara, Osamu/G-5448-2015	Ohara, Osamu/0000-0002-3328-9571				ARITA H, 1991, J BIOL CHEM, V266, P19139; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; HANASAKI K, 1992, BIOCHIM BIOPHYS ACTA, V1127, P233, DOI 10.1016/0005-2760(92)90226-L; HARPER PA, 1984, KIDNEY INT, V26, P875, DOI 10.1038/ki.1984.231; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; ISHIZAKI J, 1989, BIOCHEM BIOPH RES CO, V162, P1030, DOI 10.1016/0006-291X(89)90777-8; KANEMASA T, 1992, FEBS LETT, V303, P217, DOI 10.1016/0014-5793(92)80523-J; KANEMASA T, 1992, BIOCHIM BIOPHYS ACTA, V1125, P210, DOI 10.1016/0005-2760(92)90047-Y; KISHINO J, 1992, BIOCHEM BIOPH RES CO, V186, P1025, DOI 10.1016/0006-291X(92)90849-G; KORTESUO PT, 1993, INT J PANCREATOL, V13, P111; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN LL, 1992, J BIOL CHEM, V267, P23451; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAKAJIMA M, 1992, FEBS LETT, V309, P261, DOI 10.1016/0014-5793(92)80785-F; NAKANO T, 1990, J BIOL CHEM, V265, P1274; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; NISHIJIMA J, 1983, J BIOCHEM, V94, P137, DOI 10.1093/oxfordjournals.jbchem.a134322; PFEILSCHIFTER J, 1989, BIOCHEM BIOPH RES CO, V159, P385, DOI 10.1016/0006-291X(89)90003-X; RADEKE HH, 1992, CLIN INVESTIGATOR, V70, P825; SAKATA T, 1989, BIOCHIM BIOPHYS ACTA, V1007, P124, DOI 10.1016/0167-4781(89)90141-3; SCHALKWIJK C, 1991, BIOCHEM BIOPH RES CO, V180, P46, DOI 10.1016/S0006-291X(05)81252-5; SCHALKWIJK C, 1992, J BIOL CHEM, V267, P8846; SCHALKWIJK CG, 1992, EUR J BIOCHEM, V210, P169, DOI 10.1111/j.1432-1033.1992.tb17405.x; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; SHARP JD, 1991, J BIOL CHEM, V266, P14850; TOHKIN M, 1993, J BIOL CHEM, V268, P2865; TOJO H, 1988, J BIOL CHEM, V263, P5724; TOPLEY N, 1989, J IMMUNOL, V143, P1989; YASUDA T, 1990, BIOCHIM BIOPHYS ACTA, V1046, P18	31	86	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5092	5098						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106488				2022-12-27	WOS:A1994MX57100063
J	KOFUJI, P; LEDERER, WJ; SCHULZE, DH				KOFUJI, P; LEDERER, WJ; SCHULZE, DH			MUTUALLY EXCLUSIVE AND CASSETTE EXONS UNDERLIE ALTERNATIVELY SPLICED ISOFORMS OF THE NA/CA EXCHANGER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; NA-CA EXCHANGE; SYNAPTIC PLASMA-MEMBRANE; NA+-CA2+ EXCHANGER; IMMUNOLOGICAL IDENTIFICATION; MOLECULAR-CLONING; CARDIAC MYOCYTES; MUSCLE; EXPRESSION; STOICHIOMETRY	We have analyzed the gene structure that gives rise to tissue-specific isoforms of the Na/Ca exchanger. Five distinct isoforms of the Na/Ca exchanger from rabbit brain, kidney, and heart have been identified previously to which we now add a new brain isoform. Reverse-transcribed polymerase chain reaction, library screening, and sequence analysis of cDNA coding regions indicate that the only significant alteration of the Na/Ca exchanger cDNA in rabbit brain, kidney, and heart isoforms is located in the carboxyl end of the putative intracellular loop of the protein, a region recently linked to ionic and metabolic regulation of the Na/Ca exchanger. Additionally, we find that the Na/Ca exchanger isoforms found in lung and skeletal muscle may arise from among these same six isoforms. Examination of the gene structure of the Na/Ca exchanger in rabbit indicates how the single gene that encodes for the Na/Ca exchanger is alternatively spliced to give rise to the five rabbit isoforms. Specifically, sequence analysis of the intron-exon boundaries reveals the presence of two ''mutually exclusive'' exons in conjunction with four ''cassette'' exons in the region of the Na/Ca exchanger gene that codes for the carboxyl end of the predicted intracellular loop region. This unusual arrangement of exons in the Na/Ca exchanger gene could allow for the generation of up to 32 different Na/Ca exchanger mRNAs and accounts for the isoforms identified to date.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT PHARMACOL & EXPTL THERAPEUT,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT MICROBIOL & IMMUNOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR MED BIOTECHNOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore			Lederer, William/B-1285-2010; Kofuji, Paulo/AAR-7835-2021	Kofuji, Paulo/0000-0002-4840-9986	NHLBI NIH HHS [HL25675] Funding Source: Medline; NIA NIH HHS [AG08191] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008191] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ACETO JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P553, DOI 10.1016/0003-9861(92)90449-7; BAKER PF, 1969, J PHYSIOL-LONDON, V200, P431, DOI 10.1113/jphysiol.1969.sp008702; BARZILAI A, 1987, J BIOL CHEM, V262, P10315; BLAUSTEIN MP, 1991, ANN NY ACAD SCI, V639, P254, DOI 10.1111/j.1749-6632.1991.tb17315.x; BLAUSTEIN MP, 1991, ANN NY ACAD SCI, V639, P1; BREITBART RE, 1987, CELL, V49, P793, DOI 10.1016/0092-8674(87)90617-9; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; CANNELL MB, 1991, ANN NY ACAD SCI, V639, P428, DOI 10.1111/j.1749-6632.1991.tb17330.x; CASTILLO E, 1991, ANN NY ACAD SCI, V639, P554, DOI 10.1111/j.1749-6632.1991.tb17349.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRESPO LM, 1990, NATURE, V345, P618, DOI 10.1038/345618a0; DOMINGUEZ JH, 1992, J LAB CLIN MED, V119, P640; DURKIN JT, 1991, ARCH BIOCHEM BIOPHYS, V290, P369, DOI 10.1016/0003-9861(91)90553-U; FURMAN I, 1993, FEBS LETT, V319, P105, DOI 10.1016/0014-5793(93)80046-W; HELMS C, 1985, DNA-J MOLEC CELL BIO, V4, P39, DOI 10.1089/dna.1985.4.39; HERCHUELZ A, 1991, ANN NY ACAD SCI, V639, P642, DOI 10.1111/j.1749-6632.1991.tb17361.x; HIDALGO C, 1991, ANN NY ACAD SCI, V639, P483; KIMURA J, 1986, NATURE, V319, P596, DOI 10.1038/319596a0; KIMURA M, 1993, J BIOL CHEM, V268, P6874; KOFUJI P, 1993, AM J PHYSIOL, V265, pF598, DOI 10.1152/ajprenal.1993.265.4.F598; KOFUJI P, 1992, AM J PHYSIOL, V263, pC121; KOMURO I, 1992, P NATL ACAD SCI USA, V89, P4769, DOI 10.1073/pnas.89.10.4769; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI ZP, 1991, J BIOL CHEM, V266, P1014; LOW W, 1993, FEBS LETT, V316, P63, DOI 10.1016/0014-5793(93)81737-K; LUTHER PW, 1992, J NEUROSCI, V12, P4898; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; MCDANIEL LD, 1993, CYTOGENET CELL GENET, V63, P192, DOI 10.1159/000133532; MILOVANOVIC S, 1991, AM J PHYSIOL, V261, pF207, DOI 10.1152/ajprenal.1991.261.2.F207; NICOLL DA, 1991, ANN NY ACAD SCI, V639, P181, DOI 10.1111/j.1749-6632.1991.tb17305.x; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; RAHAMIMOFF H, 1991, ANN NY ACAD SCI, V639, P210, DOI 10.1111/j.1749-6632.1991.tb17308.x; REEVES JP, 1984, J BIOL CHEM, V259, P7733; REILLY RF, 1992, AM J PHYSIOL, V262, pF1105, DOI 10.1152/ajprenal.1992.262.6.F1105; REUTER H, 1968, J PHYSIOL-LONDON, V195, P451, DOI 10.1113/jphysiol.1968.sp008467; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SCHACHAT FH, 1987, J MOL BIOL, V198, P551, DOI 10.1016/0022-2836(87)90300-7; SHOEH BH, 1992, GENOMICS, V9, P770; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; WINDHAGER EE, 1991, ANN NY ACAD SCI, V639, P577, DOI 10.1111/j.1749-6632.1991.tb17356.x; YIP RK, 1992, NEUROSCI LETT, V136, P123, DOI 10.1016/0304-3940(92)90663-R	42	199	201	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5145	5149						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106495				2022-12-27	WOS:A1994MX57100071
J	TENNEY, DJ; HURLBURT, WW; MICHELETTI, PA; BIFANO, M; HAMATAKE, RK				TENNEY, DJ; HURLBURT, WW; MICHELETTI, PA; BIFANO, M; HAMATAKE, RK			THE UL8 COMPONENT OF THE HERPES-SIMPLEX VIRUS HELICASE-PRIMASE COMPLEX STIMULATES PRIMER SYNTHESIS BY A SUBASSEMBLY OF THE UL5 AND UL52 COMPONENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA HELICASE; GENE-PRODUCTS; INSECT CELLS; TYPE-1; PROTEIN; REPLICATION; BACTERIOPHAGE-T7; IDENTIFICATION; LOCALIZATION; ASSOCIATION	The herpes simplex virus type 1 (HSV) UL5, UL8, and UL52 proteins form a helicase-primase complex in infected cells, Several laboratories have demonstrated that helicase and nucleoside triphosphatase activities of the heterotrimer (UL5/8/52) are indistinguishable from that of a subassembly of UL5 and UL52 (UL5/52). Although the UL5/52 subassembly functions in coupled primase-polymerase assays on homopolymeric templates, its activity on natural DNA templates has been reported to require UL8. To determine the role of UL8 in primase assays, the activity of the UL5/52 subassembly was compared to that of the heterotrimer reconstituted by adding UL8 to UL5/52. We detected significant activity of the UL5/52 subassembly in coupled primase-polymerase and oligoribonucleotide primer synthesis assays on phi X174 and M13 virion DNAs. However the addition of UL8 to UL5/52 stimulated this activity in a dose-dependent manner. We demonstrate that stimulation occurred at the level of primer synthesis. UL8 did not affect the amount or size of primers annealed to template, their utilization by DNA polymerase, or the use of specific initiation sites within the template. In kinetic studies, the rate of primer synthesis was increased by UL8 but the K-m for phi X174 DNA template was unchanged. These results suggest that a function of the UL8 component of the HSV helicase-primase complex is to increase the efficiency of primer synthesis by UL5/52.			TENNEY, DJ (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT VIROL,PRINCETON,NJ 08543, USA.							CALDER JM, 1990, NUCLEIC ACIDS RES, V18, P3573, DOI 10.1093/nar/18.12.3573; CALDER JM, 1992, J GEN VIROL, V73, P531, DOI 10.1099/0022-1317-73-3-531; CARMICHAEL EP, 1989, J VIROL, V63, P591, DOI 10.1128/JVI.63.2.591-599.1989; CHALLBERG MD, 1986, P NATL ACAD SCI USA, V83, P9094, DOI 10.1073/pnas.83.23.9094; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1991, J BIOL CHEM, V266, P21252; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; GAO M, 1992, MOL CELL BIOL, V12, P1330, DOI 10.1128/MCB.12.3.1330; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLDSTEIN DJ, 1988, J VIROL, V62, P2970, DOI 10.1128/JVI.62.8.2970-2977.1988; HAMATAKE RK, 1993, J GEN VIROL, V74, P2181, DOI 10.1099/0022-1317-74-10-2181; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; HINTON DM, 1987, J BIOL CHEM, V262, P10873; KORNBERG A, 1992, DNA REPLICATION, P275; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10638, DOI 10.1073/pnas.89.22.10638; PATEL SS, 1992, J BIOL CHEM, V267, P15013; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; Sambrook J, 1989, MOL CLONING LABORATO; SHERMAN G, 1992, J VIROL, V66, P4884, DOI 10.1128/JVI.66.8.4884-4892.1992; STOW ND, 1992, J GEN VIROL, V73, P313, DOI 10.1099/0022-1317-73-2-313; TENEY DJ, 1993, J VIROL, V67, P543; TENNEY DJ, 1993, J VIROL, V67, P1959, DOI 10.1128/JVI.67.4.1959-1966.1993; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WELLER SK, 1991, HERPESVIRUS TRANSCRI, P105; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988; ZHU L, 1992, J VIROL, V66, P458, DOI 10.1128/JVI.66.1.458-468.1992	31	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5030	5035						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106478				2022-12-27	WOS:A1994MX57100053
J	BROWN, WC; CAMPBELL, JL				BROWN, WC; CAMPBELL, JL			INTERACTION OF PROLIFERATING CELL NUCLEAR ANTIGEN WITH YEAST DNA POLYMERASE-DELTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION INVITRO; CALF THYMUS; III HOLOENZYME; MECHANISM; PROTEIN; ACTIVATOR-1; SUBUNIT; CYCLIN; ALPHA; CLAMP	Previously, we described the purification of the catalytic core subunit of yeast DNA polymerase delta from Escherichia coli carrying the yeast POL3 gene cloned in a vector that allowed efficient expression. The basic catalytic properties of the single subunit enzyme are virtually identical to the heterodimeric core enzyme purified from yeast cells (Brown, W. C., Duncan, J. A., and Campbell, J. L. (1993) J. Biol. Chem. 268, 982-990). In this work, we investigate the ability of yeast proliferating cell nuclear antigen (PCNA) to stimulate processive synthesis by the bacterially produced, single-subunit DNA polymerase delta. Yeast PCNA was found to stimulate the full-length single-subunit yeast DNA polymerase delta and to increase its processivity. A truncated version of DNA polymerase delta, from which the NH2-terminal 220 amino acids had been removed, was prepared and similarly investigated. While the catalytic properties of the truncated protein were nearly identical to those of the full-length enzyme, neither the extent of synthesis nor processivity was increased in the presence of PCNA. Thus, we conclude that the single-subunit DNA polymerase can associate productively with PCNA in the absence of other proteins and that the NH2-terminal domain of the catalytic subunit must be intact for this interaction.	CALTECH,BRAUN LABS,147-75CH,PASADENA,CA 91125	California Institute of Technology					NCI NIH HHS [NRSA CA-08692] Funding Source: Medline; NIGMS NIH HHS [GM25508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA008692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BRAVO R, 1980, J CELL BIOL, V84, P795, DOI 10.1083/jcb.84.3.795; BROWN WC, 1993, GENE, V127, P99, DOI 10.1016/0378-1119(93)90622-A; BROWN WC, 1993, J BIOL CHEM, V268, P982; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CAMPBELL JL, 1991, MOL CELLULAR BIOL YE, P85; DEMORENO MR, 1985, ANAL BIOCHEM, V151, P466, DOI 10.1016/0003-2697(85)90206-4; DIGARD P, 1990, J BIOL CHEM, V265, P17393; GOULIAN M, 1990, J BIOL CHEM, V265, P16402; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; MIYACHI K, 1978, J IMMUNOL, V121, P2228; NG L, 1991, J BIOL CHEM, V266, P11699; ODONNELL M, 1992, BIOESSAYS, V14, P105, DOI 10.1002/bies.950140206; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TAN CK, 1986, J BIOL CHEM, V261, P2310; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; ZHANG J, 1991, BIOCHEMISTRY-US, V30, P11742, DOI 10.1021/bi00115a002	24	32	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21706	21710						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8104944				2022-12-27	WOS:A1993MC80900044
J	SAUTER, SL; RUTHERFURD, SM; WAGENER, C; SHIVELY, JE; HEFTA, SA				SAUTER, SL; RUTHERFURD, SM; WAGENER, C; SHIVELY, JE; HEFTA, SA			IDENTIFICATION OF THE SPECIFIC OLIGOSACCHARIDE SITES RECOGNIZED BY TYPE-1 FIMBRIAE FROM ESCHERICHIA-COLI ON NONSPECIFIC CROSS-REACTING ANTIGEN, A CD66 CLUSTER GRANULOCYTE GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CEA GENE FAMILY; CARCINOEMBRYONIC ANTIGEN; CROSSREACTING ANTIGEN; MONOCLONAL-ANTIBODIES; BILIARY GLYCOPROTEIN; HUMAN-NEUTROPHILS; CARCINOMA-CELLS; DE-GRANULATION; CDNA CLONE	Nonspecific cross-reacting antigen (NCA), a CD66 cluster antigen, is a well characterized glycoprotein on granulocytes, macrophages, and lung epithelium. Structural studies at the protein and genomic levels have revealed that NCA is a member of the immunoglobulin (Ig) supergene family and contains a domain structure similar to Ig with an amino-terminal variable-like domain followed by disulfide loop-containing constant-like domains. Previous work by this laboratory and others has demonstrated that NCA is a receptor for binding of bacteria expressing type 1 fimbriae (pili). This binding is mediated by interaction between lectins on the bacteria fimbriae and carbohydrate chains on NCA. In the present work we further characterize the specificity for bacterial binding by NCA using endoglycosidases and site-directed mutagenesis. Results of these studies demonstrate that Escherichia coli expressing type 1 fimbriae binds to high mannose oligosaccharide structures on NCA and that the functionally relevant sites are located in the variable-like domain of NCA.	CITY HOPE NATL MED CTR,BECKMAN RES INT,DIV IMMUNOL,DUARTE,CA 91010; UNIV HAMBURG,KRANKENHAUS EPPENDORF,DEPT CLIN CHEM,MED CLIN,W-2000 HAMBURG 20,GERMANY	City of Hope; Beckman Research Institute of City of Hope; University of Hamburg			Rutherfurd, Shane M/D-8254-2011		NATIONAL CANCER INSTITUTE [P30CA033572] Funding Source: NIH RePORTER; NCI NIH HHS [CA33572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM SN, 1987, J BACTERIOL, V169, P5530, DOI 10.1128/jb.169.12.5530-5536.1987; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARAKAWA F, 1990, BIOCHEM BIOPH RES CO, V166, P1063, DOI 10.1016/0006-291X(90)90975-S; AUDETTE M, 1987, MOL IMMUNOL, V24, P1177, DOI 10.1016/0161-5890(87)90164-7; BABIOR BM, 1984, J CLIN INVEST, V73, P599, DOI 10.1172/JCI111249; BERLING B, 1990, CANCER RES, V50, P6534; BLUMENSTOCK E, 1982, INFECT IMMUN, V35, P264, DOI 10.1128/IAI.35.1.264-269.1982; BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x; BUCHEGGER F, 1984, INT J CANCER, V33, P643, DOI 10.1002/ijc.2910330515; BURTIN P, 1975, NATURE, V255, P714, DOI 10.1038/255714a0; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DRZENIEK Z, 1991, CANCER LETT, V56, P173, DOI 10.1016/0304-3835(91)90093-W; EISENSTEINBI, 1988, REV INFECT DIS, V10, pS341; ESHDAT Y, 1981, J BACTERIOL, V148, P308, DOI 10.1128/JB.148.1.308-314.1981; FIRON N, 1983, CARBOHYD RES, V120, P235, DOI 10.1016/0008-6215(83)88019-7; GBARAH A, 1991, INFECT IMMUN, V59, P4524, DOI 10.1128/IAI.59.12.4524-4530.1991; GBARAH A, 1989, BIOCHEM BIOPH RES CO, V165, P1243, DOI 10.1016/0006-291X(89)92735-6; GOETZ MB, 1989, J INFECT DIS, V159, P533, DOI 10.1093/infdis/159.3.533; GOETZ MB, 1987, INFECT IMMUN, V55, P534, DOI 10.1128/IAI.55.3.534-540.1987; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HEFTA LJF, 1992, CANCER RES, V52, P5647; HEFTA SA, 1990, J BIOL CHEM, V265, P8618; HINODA Y, 1989, P NATL ACAD SCI USA, V86, P1668; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HOFFSTEIN ST, 1982, J CELL BIOL, V95, P234, DOI 10.1083/jcb.95.1.234; KANTOR J, 1989, CANCER RES, V49, P2651; KLEMM P, 1987, MOL GEN GENET, V208, P439, DOI 10.1007/BF00328136; KORHONEN TK, 1982, INFECT IMMUN, V37, P286, DOI 10.1128/IAI.37.1.286-291.1982; KUROKI M, 1992, J LEUKOCYTE BIOL, V52, P551, DOI 10.1002/jlb.52.5.551; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEUSCH HG, 1990, FEBS LETT, V261, P405, DOI 10.1016/0014-5793(90)80603-G; LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779; MAURER L, 1987, J BACTERIOL, V169, P640, DOI 10.1128/jb.169.2.640-645.1987; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NEUMAIER M, 1988, J BIOL CHEM, V263, P3202; OFEK I, 1988, INFECT IMMUN, V56, P539, DOI 10.1128/IAI.56.3.539-547.1988; PERRY A, 1983, INFECT IMMUN, V39, P1334, DOI 10.1128/IAI.39.3.1334-1345.1983; RODRIGUEZORTEGA M, 1987, INFECT IMMUN, V55, P968, DOI 10.1128/IAI.55.4.968-973.1987; RUDERT F, 1989, J MOL EVOL, V29, P126, DOI 10.1007/BF02100111; SAUTER SL, 1991, INFECT IMMUN, V59, P2485, DOI 10.1128/IAI.59.7.2485-2493.1991; SHARON N, 1987, FEBS LETT, V217, P145, DOI 10.1016/0014-5793(87)80654-3; SILVERBLATT FJ, 1979, INFECT IMMUN, V24, P218, DOI 10.1128/IAI.24.1.218-223.1979; SPITZNAGEL JK, 1983, REV INFECT DIS, V5, pS806; STEADMAN R, 1988, INFECT IMMUN, V56, P815, DOI 10.1128/IAI.56.4.815-822.1988; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P63; von Kleist S, 1972, Proc Natl Acad Sci U S A, V69, P2492; WAGENER C, 1983, J IMMUNOL, V130, P2308	47	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15510	15516						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8101840				2022-12-27	WOS:A1993LN30500031
J	FISHER, MT				FISHER, MT			ON THE ASSEMBLY OF DODECAMERIC GLUTAMINE-SYNTHETASE FROM STABLE CHAPERONIN COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; AGGREGATION; RECONSTITUTION; DEHYDROGENASE; PROTEINS; STATE	For many in vitro protein-folding reactions, the fraction of correctly folded product declines as the initial protein concentration increases due primarily to misfolding and aggregation reactions. Under optimal conditions and in the presence of ATP, chaperonins (groEL and groES) enhanced the renaturation of dodecameric glutamine synthetase (GS) with yields of active enzyme between 75 and 85% of the original activity (Fisher, M. T. (1992) Biochemistry 31, 3955-3963). In spite of this enhancement, a concentration-dependent decline in recoverable activity was observed when increasing concentrations of unfolded GS were rapidly mixed with renaturation buffer containing a 2-fold molar excess (GS subunits:groEL oligomer) of chaperonins. When a stable groEL-GS complex, formed under optimal conditions, was concentrated 4-fold by centrifugal ultrafiltration prior to ATP addition, the amount of total active GS (percent of the original activity) recovered remained at optimal levels and no longer showed a concentration-dependent decline. The GS subunits that are initially bound and then released from groEL by ATP are assembly-competent. It is proposed that the subunits are no longer able to kinetically equilibrate with folding intermediates that misfold or aggregate. If a stable groEL-protein substrate complex can be amassed without loss of activity, this will facilitate studies on molecular aspects of chaperonin release mechanisms and oligomeric protein assembly.			FISHER, MT (corresponding author), UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,KANSAS CITY,KS 66160, USA.							BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; FISHER MT, 1992, J BIOL CHEM, V267, P1872; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; Garel Jean-Renaud, 1992, P405; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRIMM R, 1993, J BIOL CHEM, V268, P5220; JAENICKE R, 1990, PROTEIN STRUCTURE PR, P191; KEPES A, 1966, BIOCHIM BIOPHYS ACTA, V123, P546, DOI 10.1016/0005-2787(66)90222-X; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MAURIZI MR, 1982, J BIOL CHEM, V257, P7246; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; MITAKI A, 1989, BIOTECHNOLOGY, V7, P690; STADTMAN ER, 1979, ANAL BIOCHEM, V95, P275, DOI 10.1016/0003-2697(79)90217-3; TEIPEL JW, 1971, BIOCHEMISTRY-US, V10, P792, DOI 10.1021/bi00781a011; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007	19	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13777	13779						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8100224				2022-12-27	WOS:A1993LJ82500004
J	POLLEGIONI, L; LANGKAU, B; TISCHER, W; GHISLA, S; PILONE, MS				POLLEGIONI, L; LANGKAU, B; TISCHER, W; GHISLA, S; PILONE, MS			KINETIC MECHANISM OF D-AMINO-ACID OXIDASES FROM RHODOTORULA-GRACILIS AND TRIGONOPSIS-VARIABILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE	The reaction of two D-amino acid oxidases from the yeasts Rhodotorula gracilis and Trigonopsis variabilis with the substrates alanine and valine in their 2-H-1 and 2-H-2 forms was studied employing the stopped-flow spectrophotometric technique. The turnover numbers at infinite substrate and oxygen concentrations were: 20,700/4,250 and 1,730/360 ([2-H-1]/[2-H-2]alanine and valine, respectively) for the Rhodotorula and 3,150/440 and 2,500/520 ([2-H-1]/[2-H-2]alanine and valine, respectively) for the Trigonopsis enzymes. The rates of anaerobic enzyme flavin reduction were 20,100/4,000 and 1,820/350 ([2-H-1]/[2-H-2]alanine and valine, respectively) for the Rhodotorula and 3,470/350 and 2,460/480 ([2-H-1]/[2-H-2]alanine and valine, respectively) for the Trigonopsis enzymes. The isotope effects on enzyme reduction were 5.0 and 5.2 for Rhodotorula and 9.9 and 5.1 for Trigonopsis D-amino acid oxidases with alanine and valine, respectively. This suggests that the intrinsic isotope effect on rupture of the substrate alpha-C-H bond can be as high as 10. The rate-determining step corresponds to the enzyme reductive half-reaction in contrast to the mammalian kidney enzyme where it is the product release from oxidized enzyme (Massey, V., and Gibson, Q. H. (1964) Fed. Proc. 23, 18-29). Upon anaerobic reaction with substrate, the yeast enzymes do not form the transient long wavelength absorbing species which are characteristic of the mammalian protein. This is due only in part to rapid dissociation of iminoacid product and is ascribed to intrinsic differences between the charge-transfer complexes of reduced enzyme flavin and product of the yeast as compared to the mammalian enzyme. With the Trigonopsis enzyme the flavin radical anion appears to be strongly stabilized and can be produced quantitatively.	UNIV MILAN,DEPT GEN PHYSIOL & BIOCHEM,26 VIA CELORIA,I-20133 MILAN,ITALY; UNIV KONSTANZ,FAK BIOL,W-7747 CONSTANCE,GERMANY; BOEHRINGER MANNHEIM GMBH,W-8122 PENZBERG,GERMANY	University of Milan; University of Konstanz				POLLEGIONI, LOREDANO/0000-0003-1733-7243				BORCH RF, 1971, J AM CHEM SOC, V93, P2897, DOI 10.1021/ja00741a013; CASALIN P, 1991, EUR J BIOCHEM, V197, P513, DOI 10.1111/j.1432-1033.1991.tb15939.x; Curti B., 1991, CHEM BIOCH FLAVOENZY, V3, P69; DENU JM, 1992, BIOCHEMISTRY-US, V31, P8207, DOI 10.1021/bi00150a013; FITZPATRICK PF, 1982, J BIOL CHEM, V257, P2916; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; Ghisla S., 1991, CHEM BIOCH FLAVOENZY, P243; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; LANGKAU B, 1992, THESIS U KONSTANZ; LEDERER F, 1991, CHEM BIOCH FLAVOENZY, V2, P153; LOCKRIDGE O, 1972, J BIOL CHEM, V247, P8097; MASSEY V, 1974, ANN NY ACAD SCI, V227, P446, DOI 10.1111/j.1749-6632.1974.tb14407.x; MASSEY V, 1964, FED PROC, V23, P18; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; MASSEY V, 1961, BIOCHIM BIOPHYS ACTA, V48, P1, DOI 10.1016/0006-3002(61)90508-X; Massey V., 1975, FLAVINS FLAVOPROTEIN, P199; MULLER F, 1973, BIOCHEMISTRY-US, V12, P4654; Palmer G, 1968, BIOL OXIDATIONS, P263; POLLEGIONI L, 1992, BIOCHEM J, V286, P389, DOI 10.1042/bj2860389; POLLEGIONI L, 1992, BIOCHIM BIOPHYS ACTA, V1120, P11, DOI 10.1016/0167-4838(92)90418-D; POLLEGIONI L, 1992, PROTEIN EXPRES PURIF, V3, P165, DOI 10.1016/S1046-5928(05)80034-8; PORTER DJT, 1977, J BIOL CHEM, V252, P4464; RAICHLE P, 1981, THESIS U KONSTANZ; SCHOPFER LM, 1988, BIOCHEMISTRY-US, V27, P6599, DOI 10.1021/bi00417a059; SIMONETTA MP, 1989, J GEN MICROBIOL, V135, P593; SIMONETTA MP, 1989, EUR J BIOCHEM, V180, P199; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; YAGI K, 1973, BIOCHIM BIOPHYS ACTA, V321, P64; YAGI K, 1967, BIOCHIM BIOPHYS ACTA, V146, P77, DOI 10.1016/0005-2744(67)90074-5; YAGI K, 1970, FEBS LETT, V6, P22, DOI 10.1016/0014-5793(70)80031-X	30	87	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13850	13857						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8100225				2022-12-27	WOS:A1993LJ82500016
J	HOROVITZ, A; BOCHKAREVA, ES; GIRSHOVICH, AS				HOROVITZ, A; BOCHKAREVA, ES; GIRSHOVICH, AS			THE N-TERMINUS OF THE MOLECULAR CHAPERONIN GROEL IS A CRUCIAL STRUCTURAL ELEMENT FOR ITS ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BACTERIOPHAGE-T7 DNA-POLYMERASE; HEAT-SHOCK OPERON; ESCHERICHIA-COLI; MITOCHONDRIAL PROTEIN; STREPTOMYCES-ALBUS; GENES; SEQUENCE; CLONING; ANTIGEN; PURIFICATION	The Escherichia coli heat-shock protein GroEL is a member of the highly conserved family of tetradecameric chaperonins 60, which assist in the folding and assembly of other proteins. Using site-directed mutagenesis, it is shown that replacement of the absolutely conserved amino acid residue Lys-3 by arginine or isoleucine destabilizes the GroEL particle and that the replacement Lys-3 --> Glu completely blocks its formation. The rank order of effects of these mutations on the stability of the GroEL particle correlates with the associated changes in net charge at that position. Our results show that the N terminus of GroEL is a crucial structural element for its assembly.			HOROVITZ, A (corresponding author), WEIZMANN INST SCI,DEPT STRUCT BIOL,IL-76100 REHOVOT,ISRAEL.							BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; CERRONE MC, 1991, INFECT IMMUN, V59, P79, DOI 10.1128/IAI.59.1.79-90.1991; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHITNIS PR, 1991, J BIOL CHEM, V266, P58; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GUGLIELMI G, 1991, J BACTERIOL, V173, P7374, DOI 10.1128/jb.173.22.7374-7381.1991; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOFFMAN PS, 1990, INFECT IMMUN, V58, P3380, DOI 10.1128/IAI.58.10.3380-3387.1990; HOROVITZ A, 1993, IN PRESS J MOL BIOL; HOUSTON LS, 1990, J BACTERIOL, V172, P2862, DOI 10.1128/jb.172.6.2862-2870.1990; HUTCHINSON EG, 1989, EMBO J, V8, P1485, DOI 10.1002/j.1460-2075.1989.tb03532.x; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MARTEL R, 1990, GENE, V94, P181, DOI 10.1016/0378-1119(90)90385-5; MAZODIER P, 1991, J BACTERIOL, V173, P7382, DOI 10.1128/jb.173.22.7382-7386.1991; MCLENNAN NF, 1993, MOL MICROBIOL, V7, P49, DOI 10.1111/j.1365-2958.1993.tb01096.x; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MEHRA V, 1986, P NATL ACAD SCI USA, V83, P7013, DOI 10.1073/pnas.83.18.7013; NARBERHAUS F, 1992, J BACTERIOL, V174, P3282, DOI 10.1128/jb.174.10.3282-3289.1992; PANNEKOEK Y, 1992, J BACTERIOL, V174, P6928, DOI 10.1128/JB.174.21.6928-6937.1992; PICKETTS DJ, 1989, J BIOL CHEM, V264, P12001; PUSHKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379, DOI 10.1016/0167-4838(82)90169-8; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SHINNICK TM, 1987, J BACTERIOL, V169, P1080, DOI 10.1128/jb.169.3.1080-1088.1987; SIPOS A, 1991, INFECT IMMUN, V59, P3219, DOI 10.1128/IAI.59.9.3219-3226.1991; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1989, J BIOL CHEM, V264, P6447; TAGUCHI H, 1991, J BIOL CHEM, V266, P22411; TAMADA H, 1991, BIOCHEM BIOPH RES CO, V179, P565, DOI 10.1016/0006-291X(91)91408-5; TERLESKY KC, 1991, BIOCHEMISTRY-US, V30, P8181, DOI 10.1021/bi00247a013; THOLE JER, 1987, INFECT IMMUN, V55, P1466, DOI 10.1128/IAI.55.6.1466-1475.1987; THORNTON JM, 1983, J MOL BIOL, V167, P443, DOI 10.1016/S0022-2836(83)80344-1; VODKIN MH, 1988, J BACTERIOL, V170, P1227, DOI 10.1128/jb.170.3.1227-1234.1988; WEBB R, 1990, J BACTERIOL, V172, P5079, DOI 10.1128/jb.172.9.5079-5088.1990	44	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					9957	9959						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8098040				2022-12-27	WOS:A1993LB80000006
J	EAKLE, KA; KABALIN, MA; WANG, SG; FARLEY, RA				EAKLE, KA; KABALIN, MA; WANG, SG; FARLEY, RA			THE INFLUENCE OF BETA-SUBUNIT STRUCTURE ON THE STABILITY OF NA+/K+-ATPASE COMPLEXES AND INTERACTION WITH K+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; NA,K-ATPASE; H,K-ATPASE; BINDING; YEAST; CELLS; NA,K-PUMP; CLONING	Heterologous expression of the beta subunit of H+/K+-ATPase (HK beta) with alpha subunits of Na+/K+-ATPase (NK alpha) in yeast leads to the formation of ouabain binding complexes, indicating assembly of the two subunits into active ion pumps (Eakle, K. A., Kim, K. S., Kabalin, M. A., and Farley, R. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2834-2838). Complexes of NK alpha and HK beta are less sensitive to inhibition of ouabain binding by K+, suggesting that HK beta lowers the affinity of K+ binding sites. This effect is particularly pronounced when HK beta is combined with the alpha 3 isoform of NK alpha. In this case, titration with K+ yields a biphasic curve, suggesting that there are two nonequivalent sites for K+ binding. Attempts at purifying complexes formed with either alpha 1 + HK beta or alpha 3 + HK beta using SDS extraction of microsomal membranes resulted in the loss of ouabain binding. Controls show that alpha 1 + beta 1 and alpha 3 + beta 1 complexes still retain ouabain binding after SDS extraction under the same conditions. This suggests that the HK beta subunit forms a less stable complex with NK alpha subunits. We have created chimeric beta subunits comprised of the amino-terminal cytoplasmic and transmembrane regions of HK beta combined with the carboxyl-terminal extracellular region of Na+/K+-ATPase beta 1 (HN beta 1) and the complementary chimera with amino-terminal cytoplasmic and transmembrane regions of beta 1 combined with the carboxyl-terminal extracellular region of HK beta (NH beta 1). When NH beta 1 is combined with either alpha 1 or alpha 3, the complexes show profiles of K+ inhibition of ouabain binding that are very similar to HK beta combined with either alpha 1 or alpha 3. The data suggest that the extracellular region of HK beta is primarily responsible for the effect on apparent K+ affinity. When the HN beta 1 subunit is expressed with the alpha 3 subunit, less than 5% of the amount of ouabain binding complexes are formed compared with HN beta 1 + alpha 1. This observation suggests that the HN beta 1 subunit either assembles poorly or forms an unstable complex with alpha 3. After SDS extraction, complexes of alpha 1 + NH beta 1 and alpha 3 + NH beta 1 retain ouabain binding, while alpha 1 + HN beta 1 complexes are sensitive to SDS extraction. Together, these data indicate that the cytoplasmic/transmembrane region of beta 1 is important for the assembly and stability of alpha + beta Na+/K+-ATPase complexes.	UNIV SO CALIF,SCH MED,DEPT BIOCHEM,LOS ANGELES,CA 90033	University of Southern California	EAKLE, KA (corresponding author), UNIV SO CALIF,SCH MED,DEPT PHYSIOL & BIOPHYS,LOS ANGELES,CA 90033, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028673] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39295] Funding Source: Medline; NIGMS NIH HHS [GM28673] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CANFIELD VA, 1990, J BIOL CHEM, V265, P19878; CHOW DC, 1992, AM J PHYSIOL, V263, pC39, DOI 10.1152/ajpcell.1992.263.1.C39; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; EAKLE KA, 1993, IN PRESS 7TH P INT C; EAKLE KA, 1991, SODIUM PUMP RECENT D, P125; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; HOROWITZ B, 1988, NA PLUS K PLUS PUM B, P85; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MERCER RW, 1986, MOL CELL BIOL, V6, P3884, DOI 10.1128/MCB.6.11.3884; NOGUCHI S, 1992, BIOCHEM BIOPH RES CO, V182, P659, DOI 10.1016/0006-291X(92)91783-M; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; SHERMAN F, 1979, METHODS YEAST GENETI, P164; SHULL GE, 1990, J BIOL CHEM, V265, P12123; SKOU JC, 1960, BIOCHIM BIOPHYS ACTA, V42, P6, DOI 10.1016/0006-3002(60)90746-0; WANG K, 1992, J BIOL CHEM, V267, P3577; YODA S, 1986, J BIOL CHEM, V261, P1147	28	103	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6550	6557						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120007				2022-12-27	WOS:A1994MZ50300046
J	JOSEPH, SK				JOSEPH, SK			BIOSYNTHESIS OF THE INOSITOL TRISPHOSPHATE RECEPTOR IN WB RAT-LIVER EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR PURKINJE-CELLS; 1,4,5-TRISPHOSPHATE RECEPTOR; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; INSP3 RECEPTOR; FUNCTIONAL EXPRESSION; LOCALIZATION; PURIFICATION; PROTEIN; LYMPHOCYTES	We have studied the biosynthesis and turnover of the inositol 1,4,5-trisphosphate receptor (IP,R) in WB cells, a rat liver epithelial cell line. In detergent extracts of S-35-labeled WB cells, an affinity-purified antibody directed at the C terminus of the IP(3)R immunoprecipitated two labeled polypeptides, a major band at 233 kDa and a minor band at 222 kDa. The major band was shown to correspond to the IP(3)R by immunoblotting. The minor band was not a proteolytic clip of the IP(3)R because, unlike the IP(3)R, the 222-kDa band was not a glycoprotein or a substrate for protein kinase A and was-not recognized by three different IP(3)R antibodies on immunoblots. The identity and function of this co-immunoprecipitating protein is unknown. The IP(3)R in WB cells was 5 kDa smaller than the rat cerebellar IP(3)R. Significant changes in the molecular weight of the IP(3)R were not observed in pulse-chase experiments, indicating that extensive proteolytic or carbohydrate processing events do not occur during biosynthesis of the receptor. From the analysis of such experiments in confluent WB cells, it was determined that the half-life of the IP(3)R protein was 11 h. Chromatography of the S-35-labeled extracts on Sephacryl S-400 columns revealed rapid oligomerization of newly synthesized protein with >95% of newly synthesized protein forming tetramers during a short (10 min) pulse labeling period. However, significant amounts of mature IP(3)R were found as incompletely oligomerized forms. Mature IP(3)R was bound by concanavalin A-Sepharose beads, and binding was greatly reduced by endoglycosidase H treatment of the receptor. Endoglycosidase H sensitivity, absence of binding to wheat germ agglutinin-Sepharose, and insensitivity of biosynthesis or oligomerization to brefeldin A suggest that processing of the WB IP(3)R does not involve transit through the Golgi apparatus.			JOSEPH, SK (corresponding author), THOMAS JEFFERSON UNIV, SCH MED, DEPT PATHOL & CELL BIOL, RM 230AJAH, 1020 LOCUST ST, PHILADELPHIA, PA 19107 USA.				NIAAA NIH HHS [AA-07186] Funding Source: Medline; NIDDK NIH HHS [R01-DK-34804] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; BRADFORD PG, 1992, J BIOL CHEM, V267, P20959; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; CORREIA MA, 1991, METHOD ENZYMOL, V206, P315; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GUILLEMETTE G, 1988, J BIOL CHEM, V263, P4541; HARLOW E, 1988, ANTIBODIES LABORATOR; HINGORANI SR, 1992, METHOD ENZYMOL, V207, P573; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; JOSEPH SK, 1992, ANNU REP MED CHEM, P261; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MATTER N, 1993, J BIOL CHEM, V268, P732; Meldolesi Jacopo, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P187; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; OTSU H, 1990, CELL STRUCT FUNCT, V15, P163, DOI 10.1247/csf.15.163; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PETER F, 1992, J BIOL CHEM, V267, P10631; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SCHMIDT JW, 1986, CELL, V46, P437, DOI 10.1016/0092-8674(86)90664-1; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKEI K, 1992, J NEUROSCI, V12, P489; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; TSAO MS, 1984, EXP CELL RES, V154, P38, DOI 10.1016/0014-4827(84)90666-9; VAN PN, 1989, J BIOL CHEM, V264, P17494; WOJCIKIEWICZ RJH, 1992, J NEUROCHEM, V59, P383, DOI 10.1111/j.1471-4159.1992.tb08916.x; ZAMMIT V, 1901, BIOCHEM J, V279, P377	46	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5673	5679						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119904				2022-12-27	WOS:A1994MY84000032
J	KURABAYASHI, M; JEYASEELAN, R; KEDES, L				KURABAYASHI, M; JEYASEELAN, R; KEDES, L			DOXORUBICIN REPRESSES THE FUNCTION OF THE MYOGENIC HELIX-LOOP-HELIX TRANSCRIPTION FACTOR MYOD - INVOLVEMENT OF ID GENE INDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE DIFFERENTIATION PROGRAM; ALPHA-ACTIN PROMOTER; DNA-BINDING; ENHANCER-BINDING; CARDIAC-MUSCLE; C-JUN; EXPRESSION; PROTEINS; ACTIVATION; CELLS	We have shown recently that Doxorubicin (Hox, Adriamycin), a potent broad spectrum chemotherapeutic agent with a major side effect of cardiomyopathy, completely prevents myoblast fusion and accumulation of muscle-specific transcripts in the mouse C2 skeletal muscle cell line. Here we use mouse embryonic fibroblast 10T1/2 cells to demonstrate that Hox represses muscle-specific gene expression by interfering with MyoD activity. As assayed by transient cotransfection, Hox inhibits the ability of MyoD to trans-activate muscle-specific reporter genes. A stable cell system was developed in which MyoD is constitutively expressed in 10T1/2 cells (M10 cells). Dox-treated M10 cells express MyoD from a long terminal repeat-driven vector but fail to activate endogenous MyoD and myogenin loci. Dox did not effect E2A gene transcript levels, but Id mRNA levels are significantly increased in Dox-treated M10 cells. Interestingly, overexpression of E2-5, which forms inactive heterodimers with Id, can overcome the Dox-induced suppression of the trans activation function of MyoD in 10T1/2 cells, Furthermore, we demonstrate that the 5'-flanking region of the Id2 gene mediates its Dox-inducible transcriptional expression. These findings support a model in which Dox inhibits muscle specific gene expression by interfering with the function of MyoD protein through, at least in part, induction of Id gene expression. The implications of our results for the molecular mechanisms underlying the myofibrillar loss observed in Dox-induced cardiomyopathy are discussed.	UNIV SO CALIF,SCH MED,DEPT MED,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,INST GENET MED,DEPT BIOCHEM & MOLEC BIOL,LOS ANGELES,CA 90033	University of Southern California; University of Southern California								ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DOROSHOW JH, 1985, AM J PATHOL, V118, P288; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; GAHLMANN R, 1990, J BIOL CHEM, V265, P12520; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREENE RF, 1983, CANCER RES, V43, P3417; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; GUSTAFSON TA, 1989, MOL CELL BIOL, V9, P3269, DOI 10.1128/MCB.9.8.3269; HAQ MM, 1985, CANCER-AM CANCER SOC, V56, P1361, DOI 10.1002/1097-0142(19850915)56:6<1361::AID-CNCR2820560624>3.0.CO;2-S; HARLAND R, 1985, J CELL BIOL, V101, P1094, DOI 10.1083/jcb.101.3.1094; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HERRLICH P, 1986, ADV ENZYME REGUL, V25, P485, DOI 10.1016/0065-2571(86)90030-0; ITO H, 1990, P NATL ACAD SCI USA, V87, P4275, DOI 10.1073/pnas.87.11.4275; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KURABAYASHI M, 1993, J BIOL CHEM, V268, P5524; KURABAYASHI M, 1988, J BIOL CHEM, V263, P13930; KURABAYASHI M, 1994, IN PRESS GENE AMST; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEWIS W, 1986, LAB INVEST, V54, P416; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SINGAL PK, 1987, J MOL CELL CARDIOL, V19, P817, DOI 10.1016/S0022-2828(87)80392-9; SPRINGHORN JP, 1992, J BIOL CHEM, V267, P14360; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	55	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6031	6039						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119948				2022-12-27	WOS:A1994MY84000084
J	KUSKE, CR; TICKNOR, LO; GUZMAN, E; GURLEY, LR; VALDEZ, JG; THOMPSON, ME; JACKSON, PJ				KUSKE, CR; TICKNOR, LO; GUZMAN, E; GURLEY, LR; VALDEZ, JG; THOMPSON, ME; JACKSON, PJ			PURIFICATION AND CHARACTERIZATION OF O-ACETYLSERINE SULFHYDRYLASE ISOENZYMES FROM DATURA-INNOXIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-SERINE SULFHYDRYLASE; CYSTEINE SYNTHASE; GLUTATHIONE; METABOLISM; CADMIUM; LEAVES; O-ACETYLSERINE(THIOL)LYASE; MECHANISM; PROTEINS; OLERACEA	Three isoenzyme forms (designated A, B, and C) of O-acetylserine sulfhydrylase were purified from Datura innoxia suspension cultures. Isoenzyme A is the most abundant form, comprising 45-60% of the total activity. Isoenzymes C and B comprise 35-40% and 10-20% of the activity, respectively. The specific activities of the purified isoenzymes are similar (870-893 mu mol of cysteine/min/mg of protein). Molecular masses for isoenzymes A, B, and C, estimated by analytical size exclusion high performance Liquid chromatography, are 63, 86, and 63 kDa, respectively. Isoenzymes A and B are homodimers; isoenzyme C is a heterodimer. Spectral analysis indicates that these isoenzymes possess a pyridoxal 5'-phosphate cofactor that binds the O-acetylserine substrate. Binding is reversible by addition of the sulfide substrate. The O-acetylserine sulfhydrylase isoenzymes are active over a broad temperature range, with maximum activity between 42 and 58 degrees C. They are active only between pH 7 and 8, with optimal activity at pH 7.6. Kinetic analysis indicates these enzymes are allosterically regulated and exhibit positive cooperativity with respect to both substrates. They are inhibited by sulfide concentrations above 200 mu M. The kinetic analysis together with the physical and spectrophotometric characteristics indicate that the O-acetylserine sulfhydrylase enzymes have two active sites.	LOS ALAMOS NATL LAB, DIV ANAL & ASSESSMENT, STAT GRP, LOS ALAMOS, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory	KUSKE, CR (corresponding author), LOS ALAMOS NATL LAB, DIV LIFE SCI, LOS ALAMOS, NM 87545 USA.							ASCANO A, 1977, PHYTOCHEMISTRY, V16, P889, DOI 10.1016/S0031-9422(00)86686-8; BECKER MA, 1969, J BIOL CHEM, V244, P2418; BERTAGNOLLI BL, 1977, PLANT PHYSIOL, V60, P115, DOI 10.1104/pp.60.1.115; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BORONAT A, 1984, J GEN MICROBIOL, V130, P673; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN SA, 1989, PICO TAG METHOD MANU, P1; COOK PF, 1992, BIOCHEMISTRY-US, V31, P2298, DOI 10.1021/bi00123a013; COOK PF, 1976, J BIOL CHEM, V251, P2023; DELHAIZE E, 1989, PLANT PHYSIOL, V89, P700, DOI 10.1104/pp.89.2.700; DENEKE SM, 1989, AM J PHYSIOL, V257, pL163, DOI 10.1152/ajplung.1989.257.4.L163; DROUX M, 1992, ARCH BIOCHEM BIOPHYS, V295, P379, DOI 10.1016/0003-9861(92)90531-Z; FAHEY RC, 1991, ADV ENZYMOL RAMB, V64, P1; FERSHT A, 1985, ENZYME STRUCTURE MEC, P263; GAITONDE MK, 1967, BIOCHEM J, V104, P627, DOI 10.1042/bj1040627; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; Hill R, 1926, P R SOC LOND B-CONTA, V100, P419, DOI 10.1098/rspb.1926.0064; IKEGAMI F, 1988, PHYTOCHEMISTRY, V27, P697, DOI 10.1016/0031-9422(88)84078-0; IKEGAMI F, 1987, PHYTOCHEMISTRY, V26, P2699, DOI 10.1016/S0031-9422(00)83575-X; Jackson Paul J., 1993, P157; JACKSON PJ, 1987, P NATL ACAD SCI USA, V84, P6619, DOI 10.1073/pnas.84.19.6619; JACKSON PJ, 1992, PLANT SOIL, V146, P281, DOI 10.1007/BF00012022; JACKSON PJ, 1984, PLANT PHYSIOL, V75, P914, DOI 10.1104/pp.75.4.914; KALLEN RG, 1985, TRANSAMINASES, P37; KAPLAN MM, 1966, J BIOL CHEM, V241, P5781; KENNEDY WJ, 1980, STATISTICAL COMPUTIN, P480; KREDICH NM, 1969, J BIOL CHEM, V244, P2428; KREDICH NM, 1966, J BIOL CHEM, V241, P4955; KUSKE CR, 1992, J CELL BIOCHEM, V16, P122; LEON J, 1987, PLANT SCI, V53, P93, DOI 10.1016/0168-9452(87)90118-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNN JE, 1990, PLANT PHYSIOL, V94, P1345, DOI 10.1104/pp.94.3.1345; MASADA M, 1975, J BIOCHEM, V77, P1107, DOI 10.1093/oxfordjournals.jbchem.a130811; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MORGAN PH, 1975, P NATL ACAD SCI USA, V72, P4327, DOI 10.1073/pnas.72.11.4327; MURAKOSHI I, 1985, PHYTOCHEMISTRY, V24, P1907, DOI 10.1016/S0031-9422(00)83090-3; NAKAMURA K, 1989, AGR BIOL CHEM TOKYO, V53, P2537, DOI 10.1080/00021369.1989.10869671; NIETOSOTELO J, 1986, PLANT PHYSIOL, V82, P1031, DOI 10.1104/pp.82.4.1031; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Ratkowsky D.A., 1983, NONLINEAR REGRESSION, P61; RATKOWSKY DA, 1986, BIOCHEM J, V240, P357, DOI 10.1042/bj2400357; Ratkowsky DD, 1990, HDB NONLINEAR REGRES, P128; RAUSER WE, 1990, ANNU REV BIOCHEM, V59, P61, DOI 10.1146/annurev.bi.59.070190.000425; REED D J, 1984, Pharmacological Reviews, V36, p25S; Roberts D.V., 1977, ENZYME KINETICS; ROBINSON NJ, 1988, PLANT SCI, V56, P197, DOI 10.1016/0168-9452(88)90098-2; ROLLAND N, 1992, PLANT PHYSIOL, V98, P927, DOI 10.1104/pp.98.3.927; SCHMIDT A, 1992, ANNU REV PLANT PHYS, V43, P325, DOI 10.1146/annurev.pp.43.060192.001545; SCHNACKERZ KD, 1979, BIOCHEMISTRY-US, V18, P3557, DOI 10.1021/bi00583a019; SMITH IK, 1971, BIOCHIM BIOPHYS ACTA, V227, P288, DOI 10.1016/0005-2744(71)90061-1; TAMURA G, 1976, AGR BIOL CHEM TOKYO, V40, P637, DOI 10.1080/00021369.1976.10862100; Tierney L., 1990, LISP STAT OBJECT ORI; WILSON DA, 1965, J BIOL CHEM, V240, P4801; ZEFFREN E, 1973, STUDY ENZYME MECHANI, P133	55	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6223	6232						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119966				2022-12-27	WOS:A1994MY84000110
J	LI, YL; VALAITIS, AP; LATSHAW, SP; KWIATKOWSKA, D; TRIPATHI, RL; CAMPBELL, MC; KEMP, RG				LI, YL; VALAITIS, AP; LATSHAW, SP; KWIATKOWSKA, D; TRIPATHI, RL; CAMPBELL, MC; KEMP, RG			STRUCTURE AND EXPRESSION OF THE CDNA FOR THE C ISOZYME OF PHOSPHOFRUCTO-1-KINASE FROM RABBIT BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PHOSPHOFRUCTOKINASE; LIVER-TYPE PHOSPHOFRUCTOKINASE; MUSCLE PHOSPHOFRUCTOKINASE; MESSENGER-RNA; PROTEIN; PHOSPHORYLATION; ISOENZYMES; SEQUENCE; GENE; SITE	Rabbit brain contains three phosphofructo-1-kinase (PFK) isozymic subunits designated A, B, and C. The primary structures of the first of these two isozyme types have been determined previously. The isozyme C of rabbit brain was isolated by immunoaffinity chromatography and subjected to proteolytic and chemical digestion. A large number of peptides were sequenced, the total number of amino acids identified being equal to about 80% of the total structure. The sequence of the cDNA derived from brain mRNA for C isozyme was determined from polymerase chain reaction fragments synthesized using oligonucleotides designed on the basis of the peptide sequences. The deduced size of the C isozyme was 86,371 Da, slightly larger than PFKs described previously. The amino acid sequence identity with the rabbit A isozyme was 68.9% and a range of identity to other sequenced mammalian PFKs was 67-69%. Using these data plus previously published data on chemical modification, assignments of the 6 organic ligand binding sites of PFK were inferred. The full-length cDNA was cloned into and expressed in Escherichia coli. Phosphofructokinase C was purified to homogeneity from the bacterial extracts.	UNIV HLTH SCI CHICAGO MED SCH, DEPT BIOL CHEM, N CHICAGO, IL 60064 USA	Chicago Medical School					NIDDK NIH HHS [DK19912] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019912] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COTTREAU D, 1979, BIOCHIM BIOPHYS ACTA, V568, P183, DOI 10.1016/0005-2744(79)90285-7; DEFARIA JD, 1978, DEV BIOL, V65, P75; DUNAWAY GA, 1988, BRAIN RES, V456, P310, DOI 10.1016/0006-8993(88)90233-8; DUNAWAY GA, 1985, J BIOL CHEM, V260, P4180; DUNAWAY GA, 1987, BIOCHEM J, V242, P667, DOI 10.1042/bj2420667; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FOE LG, 1984, ARCH BIOCHEM BIOPHYS, V228, P503, DOI 10.1016/0003-9861(84)90016-X; FOE LG, 1985, J BIOL CHEM, V260, P726; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GEHNRICH SC, 1988, J BIOL CHEM, V263, P11755; GEKAKIS N, 1989, J BIOL CHEM, V264, P3658; GONZALEZ F, 1975, COMP BIOCHEM PHYS B, V52, P315, DOI 10.1016/0305-0491(75)90071-1; HELLINGA HW, 1985, EUR J BIOCHEM, V149, P363, DOI 10.1111/j.1432-1033.1985.tb08934.x; HOTTA K, 1991, EUR J BIOCHEM, V202, P293, DOI 10.1111/j.1432-1033.1991.tb16375.x; KEMP RG, 1987, BIOCHEMISTRY-US, V26, P3443, DOI 10.1021/bi00386a029; KEMP RG, 1981, J BIOL CHEM, V256, P7282; KEMP RG, 1990, FRUCTOSE 2 6 BISPHOS, P17; KHAN A, 1979, HUM GENET, V48, P93; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU FTK, 1989, BIOCHEMISTRY-US, V28, P6841, DOI 10.1021/bi00443a010; LEE CP, 1987, J BIOL CHEM, V262, P4195; LEVANON D, 1989, DNA-J MOLEC CELL BIO, V8, P733, DOI 10.1089/dna.1989.8.733; POORMAN RA, 1984, NATURE, V309, P467, DOI 10.1038/309467a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARMA PM, 1989, GENE, V77, P177, DOI 10.1016/0378-1119(89)90372-7; SIMPSON CJ, 1991, BIOCHEM BIOPH RES CO, V180, P197, DOI 10.1016/S0006-291X(05)81276-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSAI MY, 1974, J BIOL CHEM, V249, P6590; TSAI MY, 1973, J BIOL CHEM, V248, P785; VALAITIS AP, 1988, BIOCHIM BIOPHYS ACTA, V956, P232, DOI 10.1016/0167-4838(88)90140-9; VALAITIS AP, 1989, BIOCHIM BIOPHYS ACTA, V995, P187, DOI 10.1016/0167-4838(89)90079-4; VORA S, 1981, BLOOD, V57, P724; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F	36	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5781	5787						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119919				2022-12-27	WOS:A1994MY84000049
J	MOUSTAID, N; BEYER, RS; SUL, HS				MOUSTAID, N; BEYER, RS; SUL, HS			IDENTIFICATION OF AN INSULIN-RESPONSE ELEMENT IN THE FATTY-ACID SYNTHASE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONAL-REGULATION; 3T3-L1 CELLS; GENE; PROTEIN; TRANSCRIPTION; EXPRESSION; LIVER; TRIIODOTHYRONINE; RESPONSIVENESS; GLUCAGON	We have previously reported that insulin increases fatty acid synthase (FAS) gene transcription, and that sequences responsible for positive regulation are located within the first 332 base pairs of the FAS promoter. To define minimal sequences required for insulin regulation within this region, chimeric constructs containing serial 5' deletions starting at -318 and extending through position +67 of the rat FAS gene ligated to the luciferase reporter gene were transfected into 3T3-L1 adipocytes. Insulin treatment at 10 nm increased luciferase activity 2-3-fold in 3T3-L1 adipocytes transfected with constructs containing progressive deletions from -318 to -67. This stimulation of the FAS promoter activity by insulin was dose-dependent. However, no effect of insulin was observed when fusion constructs containing FAS promoter sequences spanning from -25 or from -19 to +67 were transfected into adipocytes. These results suggest that the insulin response sequences of the FAS gene may be located in the region from -67 to -25. DNase I footprinting using liver nuclear extracts revealed a protected region spanning -71 and -50 in addition to a region near the putative TATA box. Gel mobility shift assays using the sequence from -71 to -50 as a probe revealed nuclear factor(s) from mouse liver and 3T3-L1 adipocytes that specifically complexed with this sequence. Mutational analysis of this region showed that sequences between -68 and -60 are essential for recognition and interaction with a trans-acting factor(s). Moreover, when three tandem repeats of the sequences spanning -68 to -52 were linked to the SV40 promoter and used for transfection, luciferase activity increased 3.6-fold in response to insulin treatment. Thus, we have identified novel cis-acting DNA sequences responsible for insulin regulation of the FAS gene, which interact with nuclear protein(s) from liver and adipocytes and which are found to share limited homology to insulin response sequences present in other genes.	HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health			Han, Zaiqi/AAI-2233-2019; Moustaid-Moussa, Naima/B-9067-2014	Moustaid-Moussa, Naima/0000-0002-7508-8030	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008814, R01DK036264] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 36264, F2 DK 08814] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; JOHNSON TM, 1993, J BIOL CHEM, V268, P464; KINGSTON RE, 1989, CURRENT PROTOCOLS MO; LAKSHMAN.MR, 1972, P NATL ACAD SCI USA, V69, P3516, DOI 10.1073/pnas.69.12.3516; LAKSHMAN MR, 1989, J PHARMACOL EXP THER, V248, P62; LEIDIG F, 1992, J BIOL CHEM, V267, P913; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKIM JM, 1991, LIPIDS, V26, P521, DOI 10.1007/BF02536597; MOUSTAID N, 1991, J BIOL CHEM, V266, P18550; MOUSTAID N, 1993, BIOCHEM J, V292, P767, DOI 10.1042/bj2920767; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OSBORN L, 1988, J BIOL CHEM, V263, P16519; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; PRAGER D, 1990, J CLIN INVEST, V85, P1680, DOI 10.1172/JCI114620; RONGNOPARUT P, 1991, J BIOL CHEM, V266, P8086; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541	31	130	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5629	5634						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119899				2022-12-27	WOS:A1994MY84000026
J	WALKEY, CJ; KALMAR, GB; CORNELL, RB				WALKEY, CJ; KALMAR, GB; CORNELL, RB			OVEREXPRESSION OF RAT-LIVER CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE ACCELERATES PHOSPHATIDYLCHOLINE SYNTHESIS AND DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPASE-C; HELA-CELLS; DIACYLGLYCEROL PRODUCTION; ENDOPLASMIC-RETICULUM; SIGNAL TRANSDUCTION; INDUCED INHIBITION; CULTURED-CELLS; CDP-CHOLINE; HEPATOCYTES	Two rat liver cDNAs encoding CTP:phosphocholine cytidylyltransferase (CT-1 and CT2) were expressed in COS cells. The specific activity of CT in the microsomes increased approximately 20- or 100-fold after transfection with CT-1 or CT-2, respectively, but there was only a 3-5-fold increase in the rate of [H-3]choline or [H-3]glycerol incorporation into phosphatidylcholine (PC). The phosphocholine pool decreased similar to 40% in keeping with a stimulation of the CT-catalyzed reaction. The CDP-choline pool increased 12-fold suggesting that the conversion of CDP choline to PC, catalyzed by cholinephosphotransferase, could not keep pace with the CT-catalyzed reaction. This could account for the discrepancy between the increases in the amount of active (membrane-bound) CT and the rate of PC synthesis. Incubation of CT-transfected cells with sodium oleate to increase the supply of cellular diacylglycerol resulted in a further 2-fold increase in the rate of PC synthesis. This suggests that the diacylglycerol supply may be a Limiting factor in the degree of stimulation of PC synthesis in CT-transfected COS cells. Despite the increased rate of PC synthesis, the total cellular PC mass increased only 17%, due to a 3-fold acceleration of the PC degradation rate. To determine which degradative pathway far PC was accelerated in the CT-transfected cells, we measured the pool sizes of several catabolites. Neither diacylglycerol nor phosphatidic acid mass was altered. The pool of glycerophosphocholine (GPC) was increased similar to 4-fold, and there was elevated release of GPC from the CT-transfected cells. The turnover of choline in GPC and lyse-PC was very slow compared with that of choline, phosphocholine, or CDP-choline, suggesting that GPC and lyso-PC were derived from slowly degraded choline-labeled PC. The metabolism of GPC and lyse-PC was stimulated in the cells overexpressing CT. These data suggest that PC synthesis and degradation are coordinated and that PC catabolism involving PC --> lyso-PC --> GPC is accelerated in COS cells overexpressing CT.	SIMON FRASER UNIV,INST MOLEC BIOL & BIOCHEM,BURNABY V5A 1S6,BC,CANADA; SIMON FRASER UNIV,DEPT CHEM,BURNABY V5A 1S6,BC,CANADA	Simon Fraser University; Simon Fraser University								ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOUDHURY GG, 1991, J BIOL CHEM, V266, P23147; CORNELL R, 1989, J BIOL CHEM, V264, P9077; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; CRAIG L, 1994, J BIOL CHEM, V269, P3311; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; EXTON JH, 1990, J BIOL CHEM, V265, P1; FLORINCHRISTENSEN J, 1992, J BIOL CHEM, V267, P14783; GELAS P, 1989, FEBS LETT, V251, P213, DOI 10.1016/0014-5793(89)81457-7; HAMMARSKJOLD ML, 1986, GENE, V43, P41, DOI 10.1016/0378-1119(86)90006-5; HATCH GM, 1992, J BIOL CHEM, V267, P15751; HOFFMAN JM, 1991, BIOCHEMISTRY-US, V30, P3315, DOI 10.1021/bi00227a021; HUANG CF, 1990, J BIOL CHEM, V265, P14858; HUI GS, 1991, J BIOL CHEM, V266, P20238; JAMIL H, 1990, J BIOL CHEM, V265, P4332; JAMIL H, 1992, J BIOL CHEM, V267, P1752; JOHNSON JE, 1992, BIOCHEM J, V285, P815, DOI 10.1042/bj2850815; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KANOH H, 1973, BIOCHIM BIOPHYS ACTA, V326, P17, DOI 10.1016/0005-2760(73)90023-4; KAY R, 1991, Methods in Molecular and Cellular Biology, V2, P254; KOLESNICK RN, 1987, J BIOL CHEM, V262, P14525; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LIM P, 1986, BIOCHEM CELL BIOL, V64, P692, DOI 10.1139/o86-095; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; MACDONALD JIS, 1993, PROTEIN EXPRES PURIF, V4, P1, DOI 10.1006/prep.1993.1001; MORASH SC, 1989, BIOCHIM BIOPHYS ACTA, V1004, P221, DOI 10.1016/0005-2760(89)90271-3; MORASH SC, 1988, BIOCHIM BIOPHYS ACTA, V961, P194, DOI 10.1016/0005-2760(88)90114-2; PAI JK, 1988, J BIOL CHEM, V263, P12472; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P433, DOI 10.1016/0005-2760(84)90169-3; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; PREISS J, 1986, J BIOL CHEM, V261, P8597; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SLEIGHT R, 1983, J BIOL CHEM, V258, P831; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TERCE F, 1991, BIOCHIM BIOPHYS ACTA, V1084, P69, DOI 10.1016/0005-2760(91)90057-O; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; TIJBURG LBM, 1991, BIOCHIM BIOPHYS ACTA, V1085, P167, DOI 10.1016/0005-2760(91)90091-U; TIJBURG LBM, 1989, BIOCHEM J, V257, P645, DOI 10.1042/bj2570645; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; VANCE DE, 1984, TRENDS BIOCHEM SCI, V9, P17, DOI 10.1016/0968-0004(84)90041-0; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P3345	50	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5742	5749						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119913				2022-12-27	WOS:A1994MY84000043
J	HIRAIZUMI, S; SPOHR, U; SPIRO, RG				HIRAIZUMI, S; SPOHR, U; SPIRO, RG			LIGAND AFFINITY CHROMATOGRAPHIC PURIFICATION OF RAT-LIVER GOLGI ENDOMANNOSIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALPHA-D-MANNOSIDASE; N-LINKED OLIGOSACCHARIDES; GLUCOSIDASE-II-DEFICIENT; PATHWAY; CELLS; GLYCOPROTEINS; MEMBRANES; PROTEINS	In order to achieve isolation of endo-alpha-D-mannosidase, a GoIgi-located processing enzyme that accomplishes deglucosylation of glycoproteins with N-linked carbohydrate units by cleaving the linkage between the glucose-substituted mannose residue and the remainder of the oligosaccharide, we have prepared an affinity matrix (Glc alpha 1-->3Man-O-(CH2)8CONH-Affi-Gel 102) containing the derivative of the characteristic disaccharide product of this enzyme. Chromatography of a Triton extract of rat liver Golgi membranes on a column of this gel in the presence of castanospermine to prevent binding of alpha-glucosidases permitted a rapid purification of the endomannosidase (70,000-fold over the homogenate) with a 12% yield. This purified enzyme was free of other processing glycosidases and was completely inhibited by Glc alpha 1-->3(1-deoxy)mannojirimycin. Examination of the endomannosidase by SDS-polyacrylamide gel electrophoresis revealed a doublet (M(r) 60,000 and 56,000) with the bands being of approximately equal density. Gel permeation high performance liquid chromatography indicated that in its native form the enzyme has an oligomeric structure (M(r) similar to 560,000) consisting of eight to ten subunits.	JOSLIN DIABET CTR,ELLIOTT P JOSLIN RES LAB,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT BIOL CHEM,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; UNIV ALBERTA,DEPT CHEM,EDMONTON T6G 2G2,AB,CANADA; CHEMBIOMED LTD,EDMONTON T6G 2G2,AB,CANADA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Alberta					NIDDK NIH HHS [DK 17477] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017477] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONAY P, 1991, EUR J BIOCHEM, V197, P229, DOI 10.1111/j.1432-1033.1991.tb15903.x; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; FUJIMOTO K, 1991, J BIOL CHEM, V266, P3571; HETTKAMP H, 1984, EUR J BIOCHEM, V142, P85, DOI 10.1111/j.1432-1033.1984.tb08253.x; HIRAIZUMI S, 1993, J BIOL CHEM, V268, P9927; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LEMIEUX RU, 1975, J AM CHEM SOC, V97, P4076, DOI 10.1021/ja00847a035; LEMIEUX RU, 1975, J AM CHEM SOC, V97, P4056, DOI 10.1021/ja00847a032; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MOORE SEH, 1992, J BIOL CHEM, V267, P8443; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PINTO BM, 1983, CARBOHYD RES, V124, P313, DOI 10.1016/0008-6215(83)88466-3; RABOUILLE C, 1992, J BIOL CHEM, V267, P11573; SAXENA S, 1987, BIOCHEM J, V247, P563, DOI 10.1042/bj2470563; SRIVASTAVA OP, 1987, CARBOHYD RES, V161, P195, DOI 10.1016/S0008-6215(00)90077-6; TULSIANI DRP, 1988, J BIOL CHEM, V263, P5408; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227	22	18	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4697	4700						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106437				2022-12-27	WOS:A1994MX57100002
J	TSAI, AL; HSI, LC; KULMACZ, RJ; PALMER, G; SMITH, WL				TSAI, AL; HSI, LC; KULMACZ, RJ; PALMER, G; SMITH, WL			CHARACTERIZATION OF THE TYROSYL RADICALS IN OVINE PROSTAGLANDIN-H SYNTHASE-1 BY ISOTOPE REPLACEMENT AND SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; HIGHER OXIDATION-STATES; SHEEP VESICULAR GLAND; HEME-BINDING; COMPOUND ES; YEAST; TRANSLOCATION; BIOSYNTHESIS; KINETICS; ACID	Several free radical species, attributed to tyrosyl radicals, have been previously observed by electron paramagnetic resonance (EPR) spectroscopy during reaction of pure ovine prostaglandin H synthase-1 (PGHS-1) with hydroperoxide or fatty acid substrates. The identity and location of amino acid residue(s) involved in formation of these radicals has been investigated using wild type and mutant PGHS-1 expressed in transfected COS-1 cells. Upon reaction with hydroperoxide, detergent extracts from microsomes of cells expressing wild type ovine PGHS-1 rapidly produced EPR signals made up of a broad component, resembling either either the wide doublet or the wide singlet seen in reactions of the purified ovine enzyme, mixed with a variable proportion of a narrow component. Isotope replacement with perdeuterated tyrosine and phenylalanine in wild type PGHS-1 caused no change in enzymatic activity or capability to form a peroxide-induced radical, but the radical was an isotropic singlet without any wide features. This loss of splitting in the deuterated enzyme establishes that the wide radical signal in PGHS-1 is indeed a tyrosyl radical, validating the earlier assignment based on spectral similarities with a tyrosyl radical in ribonucleotide reductase. A Y385F mutation abolished cyclooxygenase but not peroxidase activity, and the peroxide-induced EPR was narrowed to a singlet essentially identical with that obtained with indomethacin-treated ovine enzyme. Isotopic replacement with perdeuterated tyrosine and phenylalanine in the Y385F mutant led to further narrowing of the peroxide-induced EPR to an isotropic singlet, establishing that this radical also involved a tyrosine residue. A Y355F mutant exhibited some decrease in cyclooxygenase activity, but the peroxidase activity and the peroxide-induced radical characteristics were not significantly different from those of the wild type enzyme, indicating that Tyr(355) is not involved in tyrosyl radical formation in PGHS-1. An interpretation consistent with the results is that the peroxide-induced radical is formed on Tyr(385) in wild type PGHS-1, but cyclooxygenase inactivation by a Y385F mutation or by indomethacin results in radical formation on an alternate tyrosine residue.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Michigan State University; Rice University	TSAI, AL (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV HEMATOL,HOUSTON,TX 77030, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042509, R01DK022042, R37DK022042] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 07404] Funding Source: Medline; NIDDK NIH HHS [DK 42509, DK 22042] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRY BA, 1990, J BIOL CHEM, V265, P20139; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; DEGRAY JA, 1992, J BIOL CHEM, V267, P23583; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DREZTEN D, 1981, ANAL BIOCHEM, V112, P295; GRAFF G, 1982, METHOD ENZYMOL, V86, P386; HEMLER ME, 1978, BIOCHEM BIOPH RES CO, V85, P1325, DOI 10.1016/0006-291X(78)91148-8; HORI H, 1985, J BIOL CHEM, V260, P349; HSI LC, 1993, J LIPID MEDIATOR, V6, P131; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KULMACZ RJ, 1991, MOL PHARMACOL, V40, P833; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1987, J BIOL CHEM, V262, P10524; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LASSMANN G, 1991, J BIOL CHEM, V266, P2004; MAURO JM, 1988, BIOCHEMISTRY-US, V27, P6243, DOI 10.1021/bi00417a008; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; NELSON MJ, 1993, FASEB J, V7, pA1059; PRINCE RC, 1988, TRENDS BIOCHEM SCI, V13, P286, DOI 10.1016/0968-0004(88)90119-3; RUAN KH, 1993, J IMMUNOL METHODS, V162, P23, DOI 10.1016/0022-1759(93)90403-T; Sambrook J., 1989, MOL CLONING LAB MANU, P916; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P2007; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SJOBERG BM, 1977, J BIOL CHEM, V252, P536; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH WL, 1990, ADV PROSTAG THROMB L, V20, P14; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; TSAI AL, 1992, J BIOL CHEM, V267, P17753; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WILKS A, 1992, J BIOL CHEM, V267, P8827	35	93	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5085	5091						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106487				2022-12-27	WOS:A1994MX57100062
J	MERY, L; BOULAY, F				MERY, L; BOULAY, F			THE NH2-TERMINAL REGION OF C5AR BUT NOT THAT OF FPR IS CRITICAL FOR BOTH PROTEIN-TRANSPORT AND LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BETA-ADRENERGIC-RECEPTOR; HUMAN INTERLEUKIN-8 RECEPTOR; FORMYL PEPTIDE RECEPTOR; EXTRACELLULAR DOMAIN; HIGH-AFFINITY; NEUROKININ-1 RECEPTOR; SUBTYPE SPECIFICITY; ANTAGONIST BINDING; LUTROPIN RECEPTOR	The N-formylated tripeptide, formylmethionylleucyl-phenylalanine (fMLP), and the 74-amino-acid long human C5a anaphylatoxin activate phagocytic cells via two structurally related G protein-coupled receptors (FPR and C5aR), which are 34% identical in amino acid sequence. C5aR chimeras were constructed in which the entire NH2-terminal extracellular sequence or part of it was replaced by the counterparts from FPR or FPRH. Although the NH2-terminal region of C5aR presents an extremely high interspecies variability, substitution of the entire NH2-terminal sequence of C5aR by that of FPR or FPRH surprisingly resulted in chimeras that were apparently retained in the endoplasmic reticulum. In contrast, when the NH2-terminal domain of FPR was replaced by the corresponding region from C5aR or FPRH normal expression to the plasma membrane and high affinity binding of N-formylated peptides were observed. Thus, the NH2-terminal region of C5aR, in contradistinction to that of FPR, seems to be required either for the translocation of C5aR through the ER membrane or for correct folding and sorting of C5aR to the plasma membrane. Replacement of the first 8 residues of C5aR by the corresponding region of FPR did not alter the cellular transport and the C5a binding capacity, whereas the exchange of the first 13 residues resulted in a chimera that was readily transported to the plasma membrane but showed no capability to bind C5a. Mutations of Asp into Asn in the NH2-terminal segment of C5aR further indicated that negative charges are required to endow the receptor with a C5a binding capacity. The residues critical for binding are either involved directly by interacting with cationic residues of C5a, or indirectly by influencing the overall structure of the ligand-binding site.			MERY, L (corresponding author), CEN,DEPT BIOL MOLEC & STRUCT,CNRS,BIOCHEM LAB,URA 1130,85X,F-38041 GRENOBLE,FRANCE.							ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BAO L, 1992, Genomics, V13, P437, DOI 10.1016/0888-7543(92)90265-T; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHENOWETH DE, 1980, MOL IMMUNOL, V17, P151, DOI 10.1016/0161-5890(80)90067-X; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; EMBER JA, 1992, J IMMUNOL, V148, P3165; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FRASER CM, 1989, MOL PHARMACOL, V36, P840; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GERARD C, 1992, J IMMUNOL, V149, P2600; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HASHIDO K, 1992, BIOCHEM BIOPH RES CO, V187, P1241, DOI 10.1016/0006-291X(92)90436-O; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JI I, 1991, J BIOL CHEM, V266, P13076; JI IH, 1991, J BIOL CHEM, V266, P14953; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KAWAI M, 1991, J MED CHEM, V34, P2068, DOI 10.1021/jm00111a022; KOHL J, 1993, EUR J IMMUNOL, V23, P646, DOI 10.1002/eji.1830230311; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; MOLLISON KW, 1989, P NATL ACAD SCI USA, V86, P292, DOI 10.1073/pnas.86.1.292; MORGAN EL, 1992, J IMMUNOL, V148, P3937; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; MURPHY PM, 1992, J BIOL CHEM, V267, P7636; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; PEREZ HD, 1993, J BIOL CHEM, V268, P2292; PERRET JJ, 1992, BIOCHEM J, V288, P911, DOI 10.1042/bj2880911; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; TARDIF M, 1993, J IMMUNOL, V150, P3534; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WESS J, 1993, EMBO J, V12, P331, DOI 10.1002/j.1460-2075.1993.tb05661.x; XIE YB, 1990, J BIOL CHEM, V265, P21411; YE RD, 1992, BIOCHEM BIOPH RES CO, V184, P582, DOI 10.1016/0006-291X(92)90629-Y; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P172, DOI 10.1021/bi00427a025	48	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3457	3463						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106386				2022-12-27	WOS:A1994MV63100051
J	HEBERT, CA; CHUNTHARAPAI, A; SMITH, M; COLBY, T; KIM, J; HORUK, R				HEBERT, CA; CHUNTHARAPAI, A; SMITH, M; COLBY, T; KIM, J; HORUK, R			PARTIAL FUNCTIONAL MAPPING OF THE HUMAN INTERLEUKIN-8 TYPE-A RECEPTOR - IDENTIFICATION OF A MAJOR LIGAND-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL CHEMOTACTIC FACTOR; ACTIVATING FACTOR; PURIFICATION; MUTAGENESIS; MONOCYTES; RESIDUES; SKIN; IL-8	We have previously demonstrated that a basic amino acid residue of interleukin (IL)-8, namely Arg-6, is critical for the binding of IL-8 to its receptor. We reasoned that this residue is likely to be poised to directly interact with a counterpart acidic residue on the receptor. To identify this key residue, we systematically mutated to Ala all acidic residues present on the ligand accessible surface of IL-8 receptor type A. Using this strategy, we demonstrate that two residues which are present in extracellular loop 3 of the receptor, namely Glu-275 and Arg-80, are critical for ligand binding. In addition, we show that although Asp-11 is critical for ligand binding, a conservative mutation of Asp-11 to Glu or a substitution of Asp-11 with Lys (the residue found at position 11 in IL-8 receptor type B) does not affect the K(d) of the receptor/ligand interaction. These data suggest that Lys-11 recruits a new and favorable interaction with IL-8 (analogous to that of IL-8 receptor type B with IL-8) or that the cavity created by mutating Asp-11 to Ala is particularly deleterious. Finally, we discuss fluorescence-activated cell sorter staining data which support the hypothesis that the N-terminal region and the extracellular loop 3 of the receptor may lie in close proximity of one another and constitute a major binding domain for IL-8.	GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MED & ANALYT CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech	HEBERT, CA (corresponding author), GENENTECH INC,DEPT IMMUNOL,S SAN FRANCISCO,CA 94080, USA.							BROADDUS VC, 1992, IN PRESS AM REV RESP; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; COLDITZ I, 1989, AM J PATHOL, V134, P755; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; GREGORY H, 1988, BIOCHEM BIOPH RES CO, V151, P883, DOI 10.1016/S0006-291X(88)80364-4; GROTZINGER J, 1991, PROTEIN ENG, V4, P767, DOI 10.1093/protein/4.7.767; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; KOCH AE, 1991, J IMMUNOL, V147, P2187; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PACAUD JP, 1990, BIOCHEM BIOPH RES CO, V166, P187; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RAMPART M, 1989, AM J PATHOL, V135, P21; RICHMANEISENSTA.JB, 1993, IN PRESS AM J PHYSL; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; TERKELTAUB R, 1991, ARTHRITIS RHEUM, V34, P894, DOI 10.1002/art.1780340716; VANDAMME J, 1988, J EXP MED, V167, P1364, DOI 10.1084/jem.167.4.1364; WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; YOSHIMURA T, 1987, J IMMUNOL, V139, P788	23	134	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18549	18553						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8103045				2022-12-27	WOS:A1993LV65900029
J	PARK, K; KIM, KH				PARK, K; KIM, KH			THE SITE OF CAMP ACTION IN THE INSULIN INDUCTION OF GENE-EXPRESSION OF ACETYL-COA CARBOXYLASE IS AP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; DEPENDENT PROTEIN-KINASE; TUMOR NECROSIS FACTOR; FATTY-ACID SYNTHESIS; RNA POLYMERASE-II; TRANSCRIPTION FACTOR; MESSENGER-RNA; CYCLIC-AMP; HOUSEKEEPING GENE; 5' END	Insulin induction of acetyl-CoA carboxylase (ACC) and differentiation of 30A5 preadipocytes into adipocytes requires a brief exposure of the cells to cAMP. Using the techniques of DNase I footprinting, DNA band shift, and analysis of the point and deletion mutations, a region from -113 to -95 has been identified as the site through which cAMP sensitizes the cell for the response to insulin. One sequence-specific DNA-protein complex, b3, is formed in the DNA-mobility shift assay when nuclear extract from 30A5 cells is mixed with the oligonucleotide representing this region. Purified human AP-2 also generates the complex corresponding to b3 with the same ACC PII probe or with the AP-2 consensus sequence probe from SV40 promoter. Substitution of A for G in the sequence GGGGCTGGG abolishes the formation of b3 sequence-specific complex. Stably transfected 30A5 cells with the same mutations in the plasmid no longer respond to insulin in spite of their exposure to cAMP. These results establish that the 21 base pair region in ACC promoter II and the binding of AP-2 protein to this sequence are required for cAMP action. cAMP-dependent protein kinase phosphorylates AP-2 both in vitro and in vivo and the phosphorylation of AP-2 does not affect its binding activity.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NCI NIH HHS [CA 46882] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046882] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAI DH, 1986, J BIOL CHEM, V261, P2395; BATENBURG JJ, 1989, BIOCHIM BIOPHYS ACTA, V1006, P329, DOI 10.1016/0005-2760(89)90020-9; BOYER TG, 1989, J BIOL CHEM, V264, P5177; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLSON CA, 1974, ARCH BIOCHEM BIOPHYS, V164, P490, DOI 10.1016/0003-9861(74)90059-9; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FARNHAM PJ, 1985, J BIOL CHEM, V260, P7675; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P19; HAYSTEAD TAJ, 1990, EUR J BIOCHEM, V187, P199, DOI 10.1111/j.1432-1033.1990.tb15295.x; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KATSURADA A, 1990, EUR J BIOCHEM, V190, P435, DOI 10.1111/j.1432-1033.1990.tb15593.x; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; Lane M D, 1974, Curr Top Cell Regul, V8, P139; LOPEZCASILLAS F, 1987, ARCH BIOCHEM BIOPHYS, V257, P63, DOI 10.1016/0003-9861(87)90543-1; LOPEZCASILLAS F, 1989, J BIOL CHEM, V264, P7176; LUO XC, 1990, NUCLEIC ACIDS RES, V18, P3249, DOI 10.1093/nar/18.11.3249; LUO XC, 1989, P NATL ACAD SCI USA, V86, P4042, DOI 10.1073/pnas.86.11.4042; MELTON DW, 1986, CELL, V44, P319, DOI 10.1016/0092-8674(86)90766-X; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Numa S, 1984, FATTY ACID METABOLIS, P1; PAPE ME, 1988, ARCH BIOCHEM BIOPHYS, V267, P104, DOI 10.1016/0003-9861(88)90013-6; PAPE ME, 1988, MOL ENDOCRINOL, V2, P395, DOI 10.1210/mend-2-5-395; PAPE ME, 1989, MOL CELL BIOL, V9, P974, DOI 10.1128/MCB.9.3.974; PAPE ME, 1989, THESIS PURDUE U; PARK KR, 1991, J BIOL CHEM, V266, P12249; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKAI T, 1988, ARCH BIOCHEM BIOPHYS, V266, P313, DOI 10.1016/0003-9861(88)90263-9; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; VOLPE JJ, 1973, ANNU REV BIOCHEM, V42, P21, DOI 10.1146/annurev.bi.42.070173.000321; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WHITEHOUSE S, 1982, J BIOL CHEM, V257, P6028; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WITTERS LA, 1985, MOL BASIS INSULIN AC, P315; ZHU Z, 1989, J BIOL CHEM, V264, P6550	42	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17811	17819						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8102369				2022-12-27	WOS:A1993LT74300029
J	MENKHAUS, M; ULLRICH, C; KLUGE, B; VATER, J; VOLLENBROICH, D; KAMP, RM				MENKHAUS, M; ULLRICH, C; KLUGE, B; VATER, J; VOLLENBROICH, D; KAMP, RM			STRUCTURAL AND FUNCTIONAL-ORGANIZATION OF THE SURFACTIN SYNTHETASE MULTIENZYME SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE PHOSPHODIESTERASE; BACILLUS-SUBTILIS; POLYACRYLAMIDE GELS; BIOSYNTHESIS; PROTEINS; ACID; IDENTIFICATION; ACYLPEPTIDES; INHIBITORS; QUANTITIES	By gel filtration of a crude extract of Bacillus subtilis ATCC 21332 and OKB 105, the multienzyme system that forms the lipoheptapeptide surfactin was separated into three enzyme fractions, E1, E2, and E3. E1, which appeared near the exclusion limit of the column, activates all amino acid components of surfactin as aminoacyladenylates and thioesters according to the thioester mechanism. In addition, a leucine-activating enzyme (E2) and an acyltransferase (E3) were detected that show molecular masses of approximately 160 and 40 kDa, respectively. The surfactin synthetase multienzyme system was reconstituted by complementation of all three enzyme fractions, yielding high rates of lipopeptide formation. E1 is composed of two multifunctional polypeptides (E1A and E1B) with molecular masses of 460 and 435 kDa, respectively, that can be separated by high-resolution anion-exchange chromatography on Pharmacia Mono Q. E1A binds L-Glu and L-Leu in a molar ratio of 1:2, whereas E1B incorporates L-Val, L-Asp, and L-Leu in a molar ratio of 1:1:1. The hydroxy fatty acid moiety is contributed by the acyltransferase accepting the hydroxy fatty acid coenzyme A thioester as substrate. The transfer of the hydroxy fatty acid to E1A and the formation of the hydroxyacyl-L-glutamate intermediate are the initiation steps in the biosynthesis of surfactin. The amino acid-activating enzyme components E1A, E1B, and E2 have been highly purified and partially characterized.	TECH UNIV BERLIN,INST BIOCHEM & MOLEK BIOL,FRANKLINSTR 29,W-1000 BERLIN 10,GERMANY; TECH UNIV BERLIN,FACHBEREICH CHEM & BIOTECHNOL 3,W-1000 BERLIN 65,GERMANY	Technical University of Berlin; Technical University of Berlin				Vater, Joachim/0000-0002-4478-4244				ARIMA K, 1968, BIOCHEM BIOPH RES CO, V31, P488, DOI 10.1016/0006-291X(68)90503-2; BAUMGART F, 1991, BIOCHEM BIOPH RES CO, V177, P998, DOI 10.1016/0006-291X(91)90637-M; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; GILHUUSMOE CC, 1970, FEBS LETT, V7, P287, DOI 10.1016/0014-5793(70)80183-1; HOSONO K, 1983, J ANTIBIOT, V36, P674, DOI 10.7164/antibiotics.36.674; HOSONO K, 1983, J ANTIBIOT, V36, P667, DOI 10.7164/antibiotics.36.667; KAKINUMA A, 1969, AGR BIOL CHEM TOKYO, V33, P1669, DOI 10.1080/00021369.1969.10859524; KAKINUMA A, 1969, AGR BIOL CHEM TOKYO, V33, P973, DOI 10.1080/00021369.1969.10859409; KAKINUMA A, 1969, AGR BIOL CHEM TOKYO, V33, P971, DOI 10.1080/00021369.1969.10859408; KAKINUMA A, 1969, AGR BIOL CHEM TOKYO, V33, P1523, DOI 10.1080/00021369.1969.10859499; KANDA M, 1978, J BIOCHEM, V84, P435, DOI 10.1093/oxfordjournals.jbchem.a132144; KANDA M, 1989, J BIOCHEM-TOKYO, V105, P653, DOI 10.1093/oxfordjournals.jbchem.a122720; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; KURAHASHI K, 1974, ANNU REV BIOCHEM, V43, P445, DOI 10.1146/annurev.bi.43.070174.002305; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laland S G, 1973, Essays Biochem, V9, P31; LAPIDOT Y, 1967, J LIPID RES, V8, P142; LIPMANN F, 1973, ACCOUNTS CHEM RES, V6, P361, DOI 10.1021/ar50071a001; Loeffler W., 1990, FORUM MIKROBIOL, V3, P156; MARFEY P, 1984, CARLSBERG RES COMMUN, V49, P591, DOI 10.1007/BF02908688; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NAKANO MM, 1989, J BACTERIOL, V171, P5347, DOI 10.1128/jb.171.10.5347-5353.1989; NAKANO MM, 1991, J BACTERIOL, V173, P1770, DOI 10.1128/jb.173.5.1770-1778.1991; NAKANO MM, 1988, J BACTERIOL, V170, P5662, DOI 10.1128/jb.170.12.5662-5668.1988; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PUGH EL, 1965, J BIOL CHEM, V240, P4727; Smith S, 1981, Methods Enzymol, V71 Pt C, P188, DOI 10.1016/0076-6879(81)71027-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH C, 1991, BIOCHEMISTRY-US, V30, P6503, DOI 10.1021/bi00240a022; VATER J, 1986, PROG COLLOID POLYM S, V72, P12; VATER J, 1989, BIOL ACTIVE MOL, P27; Warburg O., 1942, BIOCHEM Z, V310, P384; YAMADA M, 1968, J BIOCHEM, V63, P59, DOI 10.1093/oxfordjournals.jbchem.a128748; YAMADA M, 1969, J BIOCHEM, V66, P529, DOI 10.1093/oxfordjournals.jbchem.a129178; Zimmer T L, 1975, Methods Enzymol, V43, P567	35	73	78	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7678	7684						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8096516				2022-12-27	WOS:A1993KW97900017
J	ANTOINE, R; LOCHT, C				ANTOINE, R; LOCHT, C			THE NAD-GLYCOHYDROLASE ACTIVITY OF THE PERTUSSIS TOXIN S1 SUBUNIT - INVOLVEMENT OF THE CATALYTIC HIS-35 RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLTRANSFERASE ACTIVITY; ISLET-ACTIVATING PROTEIN; ESCHERICHIA-COLI; CHOLERA-TOXIN; PSEUDOMONAS-AERUGINOSA; ENZYMATIC-ACTIVITIES; NUCLEOTIDE-SEQUENCE; ADENYLATE-CYCLASE; CRYSTAL-STRUCTURE; DIPHTHERIA-TOXIN	Pertussis toxin is a member of ADP-ribosylating bacterial toxins that are capable of catalyzing the cleavage of the N-glycosidic bond of NAD(+) and the transfer of its ADP-ribose moiety to G proteins. The catalytic S1 subunit of pertussis toxin uses signal transducing G proteins as acceptor substrates but can also catalyze the transfer of the ADP-ribose moiety to water in the absence of G proteins. Site-directed mutagenesis followed by kinetic analyses of truncated soluble mutant proteins revealed that His-35 of S1 is a catalytic residue because alterations of this residue affect the turnover rate of NAD-glycohydrolysis by approximately two orders of magnitude without significantly affecting substrate binding. Replacement of the imidazole of His-35 by the side chain of glutamine maintained the highest residual activity. The pH dependence of the enzyme activity showed only slight variations over the experimental range with an optimum at pH 7.5 and an approximate pK(a) of 6.5 to 7. This pH dependence was abolished by the Gln substitution, which still retained significant activity, suggesting that His-35 probably does not act as a true base but rather as a proton acceptor. Direct catalytic roles for several other residues were ruled out. Ser-52 substitutions resulted in slight alterations of both K-cat and K-m for NAD(+) suggesting an involvement in maintaining the local geometry of the active site rather than a direct role in catalysis for this residue. Kinetic studies on mutants with substitutions of Ser-40 indicate a role in NAD(+) binding for this residue. In conjunction with previous findings, these studies suggest that the NAD-glycohydrolase activity of S1 utilizes 2 catalytic residues, His-35 and the previously identified Glu-129. The enzyme mechanism could therefore proceed through an activation by polarization of the acceptor substrate water or G protein by His-35, and the stabilization of an oxocarbonium-like transition state intermediate by Glu-129.	INST PASTEUR, INSERM, MICROBIOL GENET & MOLEC LAB, CJF9109, F-59019 LILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Locht, Camille/L-3516-2018; Antoine, Rudy/CAH-6653-2022; Antoine, Rudy/L-1630-2018	Antoine, Rudy/0000-0002-7369-0626; Antoine, Rudy/0000-0002-7369-0626				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; ANTOINE R, 1993, J BIOL CHEM, V268, P24149; ANTOINE R, 1990, INFECT IMMUN, V58, P1518, DOI 10.1128/IAI.58.6.1518-1526.1990; BARBIERI JT, 1987, INFECT IMMUN, V55, P1321, DOI 10.1128/IAI.55.5.1321-1323.1987; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1988, BIO-TECHNOL, V6, P699, DOI 10.1038/nbt0688-699; BURNETTE WN, 1988, SCIENCE, V242, P72, DOI 10.1126/science.2459776; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; CIEPLAK W, 1990, BIOCHEM J, V268, P547, DOI 10.1042/bj2680547; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; CORTINA G, 1991, J BIOL CHEM, V266, P23810; DOUGLAS CM, 1990, BIOCHEMISTRY-US, V29, P5043, DOI 10.1021/bi00473a007; Drenth J, 1971, ENZYMES, V3, P485; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; Fishman P.H., 1990, ADP RIBOSYLATING TOX, P127; Francotte M., 1989, VACCINES 89, P243; HARFORD S, 1989, EUR J BIOCHEM, V183, P311, DOI 10.1111/j.1432-1033.1989.tb14930.x; JACOBSON MK, 1989, ADP RIBOSE TRANSFER; KASLOW HR, 1989, J BIOL CHEM, V264, P6386; KASLOW HR, 1992, VAC RES, V1, P47; KATADA T, 1982, J BIOL CHEM, V257, P7210; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOCHT C, 1989, P NATL ACAD SCI USA, V86, P3075, DOI 10.1073/pnas.86.9.3075; LOCHT C, 1990, J BIOL CHEM, V265, P4552; LOCHT C, 1986, NUCLEIC ACIDS RES, V14, P3251, DOI 10.1093/nar/14.8.3251; LOCHT C, 1987, INFECT IMMUN, V55, P2546, DOI 10.1128/IAI.55.11.2546-2553.1987; LOCHT C, 1986, SCIENCE, V232, P1258, DOI 10.1126/science.3704651; MEI B, 1989, J BIOL CHEM, V264, P16613; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; MONZINGO AF, 1992, J MOL BIOL, V227, P1136, DOI 10.1016/0022-2836(92)90526-P; MURAYAMA T, 1983, J BIOL CHEM, V258, P3319; NICOSIA A, 1987, INFECT IMMUN, V55, P963, DOI 10.1128/IAI.55.4.963-967.1987; NICOSIA A, 1986, P NATL ACAD SCI USA, V83, P4631, DOI 10.1073/pnas.83.13.4631; PIZZA M, 1988, P NATL ACAD SCI USA, V85, P7521, DOI 10.1073/pnas.85.20.7521; Sambrook J, 1989, MOL CLONING LABORATO; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SIXMA TK, 1993, J MOL BIOL, V230, P890, DOI 10.1006/jmbi.1993.1209; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; THANABALU T, 1991, J BACTERIOL, V173, P2776, DOI 10.1128/JB.173.9.2776-2785.1991; WATKINS PA, 1985, J BIOL CHEM, V260, P3478; WEST RE, 1985, J BIOL CHEM, V260, P4428; WILSON BA, 1990, BIOCHEMISTRY-US, V29, P8643, DOI 10.1021/bi00489a021; YAMAMOTO T, 1984, FEBS LETT, V169, P241, DOI 10.1016/0014-5793(84)80326-9	45	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6450	6457						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119996				2022-12-27	WOS:A1994MZ50300032
J	BULLIS, BL; LEMIRE, BD				BULLIS, BL; LEMIRE, BD			ISOLATION AND CHARACTERIZATION OF THE SACCHAROMYCES-CEREVISIAE SDH4 GENE ENCODING A MEMBRANE ANCHOR SUBUNIT OF SUCCINATE-DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FUMARATE REDUCTASE; FLAVOPROTEIN SUBUNIT; NUCLEOTIDE-SEQUENCE; UBIQUINONE REDUCTASE; PROTEINS; IMPORT; ELECTROPHORESIS; MITOCHONDRIA; HELICES	Succinate dehydrogenase (EC 1.3.99.1) is an intrinsic bacterial or inner mitochondrial membrane protein that catalyses the oxidation of succinate and donates electrons to the respiratory chain via quinone accepters. It is a heterotetramer composed of a flavoprotein, an iron-sulfur, and two hydrophobic subunits. We purified succinate dehydrogenase by blue native gel electrophoresis, determined the amino-terminal sequence of the Sdh4p subunit and used this information to clone the SDH4 gene. It encodes a precursor protein of 181 amino acids that is converted to the 150-amino acid mature Sdh4p protein with a mass of 16,638 Da. Hydrophobicity analysis predicts that Sdh4p forms three transmembrane alpha-helices. We have constructed an SDH4 mutant by targeted gene disruption; it retains the ability to grow on rich glycerol medium. Western blot analysis of SDH4 disruption mutant membrane fractions indicates that membrane attachment of the flavoprotein and iron-sulfur subunits is impaired but not abolished, This membrane-bound enzyme is able to reduce ubiquinone, although less efficiently than the wild-type enzyme. These findings indicate that Sdh4p contributes both to the membrane attachment of the catalytic flavoprotein and iron-sulfur subunits and to electron transfer to ubiquinone.	UNIV ALBERTA, DEPT BIOCHEM, EDMONTON T6G 2H7, AB, CANADA	University of Alberta								Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; CHAPMAN KB, 1992, GENE, V118, P131, DOI 10.1016/0378-1119(92)90260-V; COLE ST, 1987, EUR J BIOCHEM, V167, P481, DOI 10.1111/j.1432-1033.1987.tb13362.x; COLE ST, 1985, BIOCHIM BIOPHYS ACTA, V811, P381, DOI 10.1016/0304-4173(85)90008-4; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FLEIG UN, 1986, GENE, V46, P237, DOI 10.1016/0378-1119(86)90408-7; GASSER SM, 1982, J BIOL CHEM, V257, P3034; GRUNDSTROM T, 1982, P NATL ACAD SCI-BIOL, V79, P1111, DOI 10.1073/pnas.79.4.1111; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; KITA K, 1989, J BIOL CHEM, V264, P2672; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LATOUR DJ, 1987, J GEN MICROBIOL, V133, P597; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; LOMBARDO A, 1990, J BIOL CHEM, V265, P10419; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; OWEN P, 1982, TECHN LIPID MEMBR B, V407, P1; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROBINSON KM, 1991, J BIOL CHEM, V266, P21347; ROBINSON KM, 1992, J BIOL CHEM, V267, P10101; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHILLING RJ, 1982, FED PROC, V41, P896; SCHULKE N, 1992, P NATL ACAD SCI USA, V89, P8011, DOI 10.1073/pnas.89.17.8011; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; WEINER JH, 1984, J CELL BIOCHEM, V24, P207, DOI 10.1002/jcb.240240303; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; WESTENBERG DJ, 1990, J BIOL CHEM, V265, P19560; WOOD D, 1984, BIOCHEM J, V222, P519, DOI 10.1042/bj2220519; XU Y, 1987, BIOCHEM BIOPH RES CO, V144, P315, DOI 10.1016/S0006-291X(87)80512-0; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; YU CA, 1982, J BIOL CHEM, V257, P6127; YU L, 1987, J BIOL CHEM, V262, P1137; YU L, 1992, J BIOL CHEM, V267, P24508	35	59	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6543	6549						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120006				2022-12-27	WOS:A1994MZ50300045
J	DESNOYERS, L; MANJUNATH, P				DESNOYERS, L; MANJUNATH, P			MAJOR PROTEINS OF BOVINE SEMINAL FLUID BIND TO INSULIN-LIKE GROWTH FACTOR-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; AMINO-ACID SEQUENCE; MOLECULAR-CLONING; PLASMA; EXPRESSION; IDENTIFICATION; FIBRONECTIN; CELLS; CDNA; POLYPEPTIDES	Bovine seminal plasma (BSP) contains a family of four closely related proteins previously designated as BSP-A1, BSP-A2, BSP-A3, and BSP-30-kDa (collectively called BSP proteins). They are secreted by seminal vesicles and they bind to the choline phospholipids composing the sperm plasma membrane upon ejaculation. These proteins contain two homologous domains that are similar to the type II structure present in the putative insulinlike growth factor II (IGF-II) binding domain of the IGF-II receptor. Thus, it was of interest to verify the interaction between the IGF-II and these proteins. The interaction between the IGF-II and BSP proteins was demonstrated by solid phase assay, analytical gel filtration, affinity cross-linking, and gel overlay binding technique. Ah techniques showed that I-125-IGF-II interacted specifically with BSP proteins and that the binding could be inhibited with an excess of unlabeled IGF-II. No structural homology has been found between BSP proteins and any IGF-binding proteins (IGFBP) identified to date, and therefore, they represent a new family of IGFBP. Since BSP cross-reacting proteins are ubiquitous, we propose that the specific binding of these proteins to IGF-II could modulate the activity of this growth factor.	HOP MAISON NEUVE ROSEMONT, RES CTR, ENDOCRINE LAB, MONTREAL H1T 2M4, PQ, CANADA; UNIV MONTREAL, DEPT MED, MONTREAL H1T 2M4, PQ, CANADA	Universite de Montreal; Universite de Montreal								Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BAXTER RC, 1991, ACTA PAEDIATR SCAND, P107; BINKERT C, 1989, EMBO J, V8, P2497, DOI 10.1002/j.1460-2075.1989.tb08386.x; BREWER MT, 1988, BIOCHEM BIOPH RES CO, V152, P1289, DOI 10.1016/S0006-291X(88)80425-X; BRINKMAN A, 1988, EMBO J, V7, P2417, DOI 10.1002/j.1460-2075.1988.tb03087.x; CHANDONNET L, 1990, MOL REPROD DEV, V26, P313, DOI 10.1002/mrd.1080260404; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DESNOYERS L, 1993, ARCH BIOCHEM BIOPHYS, V305, P341, DOI 10.1006/abbi.1993.1431; DESNOYERS L, 1992, J BIOL CHEM, V267, P10149; ENGVALL E, 1978, J EXP MED, V147, P1584, DOI 10.1084/jem.147.6.1584; ESCH FS, 1983, BIOCHEM BIOPH RES CO, V113, P861, DOI 10.1016/0006-291X(83)91078-1; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GLENNEY JR, 1983, METHOD ENZYMOL, V102, P204; GUYDA HJ, 1981, PHYSL PEPTIDES NEW T, P173; HSU D, 1992, J BIOL CHEM, V267, P25576; KEMME M, 1988, DNA-J MOLEC CELL BIO, V7, P595, DOI 10.1089/dna.1988.7.595; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLOND E, 1993, MOL REPROD DEV, V34, P443, DOI 10.1002/mrd.1080340414; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MACDONALD RG, 1989, J BIOL CHEM, V264, P3256; MANJUNATH P, 1987, BIOSCIENCE REP, V7, P231, DOI 10.1007/BF01124794; MANJUNATH P, 1982, J BIOL CHEM, V257, P7109; MANJUNATH P, 1989, J BIOL CHEM, V264, P16853; MANJUNATH P, 1993, J REPROD FERTIL, V97, P75, DOI 10.1530/jrf.0.0970075; MANJUNATH P, 1987, BIOCHEM J, V241, P685, DOI 10.1042/bj2410685; Manjunath P, 1984, GONADAL PROTEINS PEP, P49; Manjunath P, 1988, MOL BIOL BRAIN ENDOC, P259; MCMULLEN BA, 1985, J BIOL CHEM, V260, P5328; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; RINDERKNECHT E, 1978, FEBS LETT, V89, P283, DOI 10.1016/0014-5793(78)80237-3; RINDERKNECHT E, 1978, J BIOL CHEM, V253, P2769; ROSENFELD RG, 1990, J CLIN ENDOCR METAB, V70, P551, DOI 10.1210/jcem-70-2-551; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SEIDAH NG, 1987, BIOCHEM J, V243, P195, DOI 10.1042/bj2430195; SEPPALA M, 1985, ANN NY ACAD SCI, V442, P212, DOI 10.1111/j.1749-6632.1985.tb37522.x; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; WOOD WI, 1988, MOL ENDOCRINOL, V2, P1176, DOI 10.1210/mend-2-12-1176	42	12	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5776	5780						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119918				2022-12-27	WOS:A1994MY84000048
J	THOMA, B; BIRD, TA; FRIEND, DJ; GEARING, DP; DOWER, SK				THOMA, B; BIRD, TA; FRIEND, DJ; GEARING, DP; DOWER, SK			ONCOSTATIN-M AND LEUKEMIA INHIBITORY FACTOR TRIGGER OVERLAPPING AND DIFFERENT SIGNALS THROUGH PARTIALLY SHARED RECEPTOR COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASES; GROWTH-FACTOR; MAP KINASE; TYROSINE PHOSPHORYLATION; STIMULATING FACTOR; CELLS; PROTEIN; IDENTIFICATION; TRANSDUCER; ACTIVATION	Leukemia inhibitory factor (LIF) and oncostatin M (OSM) both bind to the same receptor with high affinity and thus mediate an overlapping spectrum of biological activities, the signal transduction mechanisms for which are unclear. We show that mitogen-activated protein kinases are involved in both the LIF and OSM signal transduction pathways. However, we found that OSM is a much more potent inducer of both mitogen-activated protein kinase activity and biological response, both of which correlate with the expression of a second OSM receptor that does not bind LIF. In addition, different patterns of tyrosine-phosphorylated proteins were stimulated by OSM and LIF. We therefore suggest that the two receptors for OSM can be coupled to different signal transduction events.	IMMUNEX CORP,DEPT MOLEC BIOL,SEATTLE,WA 98101	Immunex Corporation	THOMA, B (corresponding author), IMMUNEX CORP,DEPT BIOCHEM,SEATTLE,WA 98101, USA.			dower, steve/0000-0002-4675-4225				AHN NG, 1990, J BIOL CHEM, V265, P11487; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAUMANN H, 1992, CIBA F SYMP, V167, P100; BENJAMIN D, 1990, BLOOD, V75, P2017; BIRD TA, 1992, CYTOKINE, V4, P429, DOI 10.1016/1043-4666(92)90003-A; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BROWN TJ, 1991, J IMMUNOL, V147, P2175; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; EISENBERG SP, 1990, NATURE, V343, P342; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; GEARING DP, 1993, ADV IMMUNOL, V53, P31, DOI 10.1016/S0065-2776(08)60497-6; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1991, J CELL PHYSIOL, V146, P207, DOI 10.1002/jcp.1041460204; KRONHEIM SR, 1986, BIO-TECHNOL, V4, P1078, DOI 10.1038/nbt1286-1078; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LAYTON MJ, 1992, P NATL ACAD SCI USA, V89, P8616, DOI 10.1073/pnas.89.18.8616; LINSLEY PS, 1989, J BIOL CHEM, V264, P4282; LIU JW, 1992, J BIOL CHEM, V267, P16763; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; MOREAU JF, 1988, NATURE, V336, P690, DOI 10.1038/336690a0; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; PARK LS, 1987, P NATL ACAD SCI USA, V84, P1669, DOI 10.1073/pnas.84.6.1669; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SCHIEVEN GL, 1992, J IMMUNOL, V149, P1676; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SLACK J, 1993, J BIOL CHEM, V268, P2513; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; VANLINT J, 1992, J BIOL CHEM, V267, P25916; WANG XY, 1993, J BIOL CHEM, V268, P3573; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	47	169	173	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6215	6222						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119965				2022-12-27	WOS:A1994MY84000109
J	BOLDYREFF, B; MEGGIO, F; PINNA, LA; ISSINGER, OG				BOLDYREFF, B; MEGGIO, F; PINNA, LA; ISSINGER, OG			EFFICIENT AUTOPHOSPHORYLATION AND PHOSPHORYLATION OF THE BETA-SUBUNIT BY CASEIN KINASE-2 REQUIRE THE INTEGRITY OF AN ACIDIC CLUSTER 50 RESIDUES DOWNSTREAM FROM THE PHOSPHOACCEPTOR SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA; EXPRESSION	Various beta-mutants were investigated either as subunits or as substrates for casein kinase 2 (CK-2), in the absence or presence of polylysine. A total of 21 beta-mutants were characterized for their susceptibility to au- tophosphorylation, by combining them in equimolar amounts with the recombinant cy-subunit. Six mutants, i.e. beta A(5,6), beta A(59-61,63,64), beta A(55,57), beta A(55-57), beta Delta 171-215, and beta Delta 150-215 exhibited a >70% reduction in autophosphorylation. This strongly suggests that in addition to amino acid residues 5,6, distant amino acid residues within the sequence 55-64 are also involved in the process of autophosphorylation, possibly by means of a loop formation. The results obtained with the COOH-terminal-deleted mutants support the view that reconstitution of a functional holoenzyme must occur to allow efficient autophosphorylation. Polylysine prevents the autophosphorylation of beta(wt) (86% inhibition) inducing a parallel increase of the alpha-subunit autophosphorylation. The autophosphorylation of all mutants, with the exception of beta A(55-57) and beta A(59-61,63,64), is also inhibited by polylysine (>64%). The alpha-subunit autophosphorylation is increased with all mutants reconstituting a tetrameric holoenzyme. Only with the three largest COOH-terminal deletion mutants beta Delta 150-215, beta Delta 171-215, and beta Delta 181-215 is no significant alpha-subunit autophosphorylation observed. The phosphorylation of the beta-subunit mutants added in large molar excess to CK-2 holoenzyme (either native or recombinant) is also severly impaired by Ala for Glu/Asp substitutions at position 5,6 and in the 55-64 region and by the deletion of the COOH-terminal segments 150-215 and 171-215. Such a phosphorylation is inhibited by polylysine, with the exception of mutants beta Delta 171-215 and beta Delta 150-215, whose phosphorylation is conversely stimulated by polylysine. The decreased phosphorylation efficiency of those mutants that are poor substrates is invariably accounted for by lower V-max values, whereas the affinity for CK-2 is actually increased (K-m values lower than that of beta(wt)).	UNIV SAARLAND, INST HUMANGENET, D-66421 HOMBURG, GERMANY; UNIV PADUA, DEPT BIOL CHEM, I-35121 PADUA, ITALY	Saarland University; University of Padua								ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; AGOSTINIS P, 1987, BIOCHEM J, V248, P785, DOI 10.1042/bj2480785; BIDWAI AP, 1993, ARCH BIOCHEM BIOPHYS, V300, P256; BIRNBAUM MJ, 1992, PROTEIN EXPRES PURIF, V3, P142, DOI 10.1016/S1046-5928(05)80098-1; BOLDYREFF B, 1992, BIOCHEM BIOPH RES CO, V188, P228, DOI 10.1016/0006-291X(92)92374-7; BOLDYREFF B, 1993, IN PRESS BIOCHEMISTR; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; HATHAWAY GM, 1981, J BIOL CHEM, V256, P1442; ISSINGER OG, 1992, BIOCHEMISTRY-US, V31, P6098, DOI 10.1021/bi00141a020; JAKOBI R, 1992, J BIOL CHEM, V267, P23894; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1981, J BIOL CHEM, V256, P1958; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; MEGGIO F, 1993, BIOCHIM BIOPHYS ACTA, V1164, P223, DOI 10.1016/0167-4838(93)90252-M; MEGGIO F, 1983, FEBS LETT, V160, P203, DOI 10.1016/0014-5793(83)80967-3; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123	18	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4827	4831						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106453				2022-12-27	WOS:A1994MX57100022
J	HENICS, T; SANFRIDSON, A; HAMILTON, BJ; NAGY, E; RIGBY, WFC				HENICS, T; SANFRIDSON, A; HAMILTON, BJ; NAGY, E; RIGBY, WFC			ENHANCED STABILITY OF INTERLEUKIN-2 MESSENGER-RNA IN MLA-144 CELLS - POSSIBLE ROLE OF CYTOPLASMIC AU-RICH SEQUENCE-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; T-CELLS; GENE; CYTOKINE; IDENTIFICATION; ACCUMULATION; RECOGNIZES; LYMPHOKINE; TURNOVER	The MLA 144 gibbon T cell line is infected with a type C retrovirus and constitutively expresses interleukin-2 (IL-2) and granulocyte macrophage colony-stimulating factor (GM-CSF). IL-2 mRNA levels are 10-fold more abundant than GM-CSF in these cells. Comparable transcriptional rates for these lymphokines suggested the involvement of post-transcriptional mechanisms in selective IL-2 mRNA accumulation, IL-2 mRNA is exceptionally stable in MLA cells with a t(1/2) of more than 8 h. The presence of reiterated AUUUA sequences in the 3'-untranslated region (UTR) has been shown to confer mRNA lability. The provirally altered MLA IL-2 allele encodes an mRNA in which three AUUUA motifs have been deleted. Six major cytoplasmic proteins bound in vitro transcribed RNA probes containing sequences from the 3'-UTR of normal human IL-2 (3'-IL-2), GM-CSF (Delta 2R1), and the virally altered MLA IL-2 (3'-IL-2 PV) mRNA. Increased binding of these proteins to 3'-IL-2 PV was observed relative to 3'-IL-2 or Delta 2R1. Northwestern blotting demonstrated similar differential ability of a 36- and 43-kDa protein to bind, as well as showed that these proteins colocalized by immunoblotting as hnRNP Al and C, respectively. These findings suggest a direct correlation between differential binding of cytoplasmic proteins to AU-rich 3'-UTRs in vitro and lymphokine mRNA stability in vivo.	DARTMOUTH COLL SCH MED,DEPT BIOCHEM,LEBANON,NH 03766; DARTMOUTH COLL SCH MED,DEPT MED & MICROBIOL,LEBANON,NH 03766	Dartmouth College; Dartmouth College	HENICS, T (corresponding author), VET ADM MED CTR,RES LABS,RES BLDG 44,WHITE RIVER JCT,VT 05009, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI000910] Funding Source: NIH RePORTER; NIAID NIH HHS [R0 1 AI2438, KO4 AI00910] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATWATER JA, 1990, ANNU REV GENET, V24, P519; BICKEL M, 1990, J IMMUNOL, V145, P840; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; BUVOLI M, 1990, EMBO J, V9, P1229, DOI 10.1002/j.1460-2075.1990.tb08230.x; CERVERA M, 1981, CELL, V23, P113, DOI 10.1016/0092-8674(81)90276-2; CHEN SJ, 1985, P NATL ACAD SCI USA, V82, P7284, DOI 10.1073/pnas.82.21.7284; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILLIS P, 1991, J BIOL CHEM, V266, P3172; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HOLBROOK NJ, 1987, VIROLOGY, V159, P178, DOI 10.1016/0042-6822(87)90364-3; IWAI Y, 1991, J BIOL CHEM, V266, P17959; KAWAKAMI TG, 1972, NATURE-NEW BIOL, V235, P170, DOI 10.1038/newbio235170a0; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RABIN H, 1981, J IMMUNOL, V127, P1852; ROSS HJ, 1991, BLOOD, V77, P1787; ROSS J, 1988, MOL BIOL MED, V5, P1; SCHIAVI SC, 1985, BIOCHIM BIOPHYS ACTA, V1114, P589; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355	32	92	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5377	5383						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106521				2022-12-27	WOS:A1994MX57100101
J	HULFORD, A; HAZELL, L; MOULD, RM; ROBINSON, C				HULFORD, A; HAZELL, L; MOULD, RM; ROBINSON, C			2 DISTINCT MECHANISMS FOR THE TRANSLOCATION OF PROTEINS ACROSS THE THYLAKOID MEMBRANE, ONE REQUIRING THE PRESENCE OF A STROMAL PROTEIN FACTOR AND NUCLEOTIDE TRIPHOSPHATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; PRECURSOR PROTEIN; ESCHERICHIA-COLI; PROCESSING PEPTIDASE; CHROMOPHYTIC ALGA; TRANSIT PEPTIDE; CHLOROPLASTS; TRANSPORT; SEQUENCE; IMPORT	Cytosolically synthesized thylakoid lumen proteins are normally transported across the thylakoid membrane of chloroplasts as intermediate forms following cleavage Of the full PreCursor polypeptides by a stromal peptidase. We have examined the mechanisms by which two lumenal proteins, the 33- and 23-kDa components of the oxygen-evolving complex, are translocated across the thylakoid membrane using an in vitro import assay and synthetic engineered intermediate forms of the two proteins as substrates. Efficient transport of the 23-kDa protein is observed in both the presence and absence of stromal extracts, but efficient import of the 33-kDa protein into thylakoids is completely dependent on the presence of stroma. The required stromal factor is heat-sensitive, macromolecular, and trypsin-sensitive. These findings thus represent the first evidence for the active participation of one or more stromal proteins in thylakoidal protein transport. We also show that import into thylakoids of the 33-kDa protein, but not of the 23-kDa protein, is absolutely dependent on the presence of nucleotide triphosphates. The data therefore indicate that at least two distinct mechanisms exist for the translocation of Iumenal proteins across the thylakoid membrane.	UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	University of Warwick								BASSHAM DC, 1991, J BIOL CHEM, V266, P23606; BAUERLE C, 1991, J BIOL CHEM, V266, P5876; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1986, J BIOL CHEM, V261, P4804; FLACHMANN R, 1993, J BIOL CHEM, V268, P7514; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; HOWE G, 1993, P NATL ACAD SCI USA, V90, P1862, DOI 10.1073/pnas.90.5.1862; JAMES HE, 1991, PLANT MOL BIOL, V17, P179, DOI 10.1007/BF00036827; JAMES HE, 1989, J BIOL CHEM, V264, P19573; JANSEN T, 1987, FEBS LETT, V216, P234, DOI 10.1016/0014-5793(87)80696-8; KIRWIN PM, 1988, J BIOL CHEM, V263, P18128; KIRWIN PM, 1989, EMBO J, V8, P3917; KLOSGEN RB, 1992, PLANT MOL BIOL, V18, P1031, DOI 10.1007/BF00019226; KNOETZEL J, 1993, PLANT MOL BIOL, V22, P337, DOI 10.1007/BF00014940; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; MEADOWS JW, 1991, PLANT MOL BIOL, V16, P1085, DOI 10.1007/BF00016082; MOULD RM, 1991, J BIOL CHEM, V266, P17286; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; SCARAMUZZI CD, 1992, FEBS LETT, V304, P119, DOI 10.1016/0014-5793(92)80601-C; SCARAMUZZI CD, 1992, CURR GENET, V22, P421, DOI 10.1007/BF00352444; SEIDLER A, 1990, EMBO J, V9, P1743, DOI 10.1002/j.1460-2075.1990.tb08298.x; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; TYAGI A, 1987, MOL GEN GENET, V207, P288, DOI 10.1007/BF00331591; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; YALOVSKY S, 1992, P NATL ACAD SCI USA, V89, P5616, DOI 10.1073/pnas.89.12.5616	27	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3251	3256						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106361				2022-12-27	WOS:A1994MV63100022
J	TAKAHASHI, K; TSUCHIDA, K; TANABE, Y; MASU, M; NAKANISHI, S				TAKAHASHI, K; TSUCHIDA, K; TANABE, Y; MASU, M; NAKANISHI, S			ROLE OF THE LARGE EXTRACELLULAR DOMAIN OF METABOTROPIC GLUTAMATE RECEPTORS IN AGONIST SELECTIVITY DETERMINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-2-ADRENERGIC RECEPTORS; SIGNAL TRANSDUCTION; SUBTYPE SPECIFICITY; LUTROPIN RECEPTOR; ALPHA-SUBUNITS; HIGH-AFFINITY; BINDING; CHORIOGONADOTROPIN; DELINEATION; EXPRESSION	Metabotropic glutamate receptors consist of at least six different subtypes termed mGluR1-mGluR6. They belong to the family of G protein-coupled receptors and commonly possess an unusually large extracellular domain preceding the seven transmembrane segments. mGluR1 and mGluR2 show similar affinities for L-glutamate but distinct patterns in their responsiveness to quisqualate and trans-1-amino-1,3-cyclopentane-dicarboxylate (tACPD). To assign structural determinants for the different agonist selectivities, we constructed a series of chimeric receptors at the extracellular domains of mGluR1 and mGluR2 and determined their agonist selectivities by measuring their electro-physiological responses to L-glutamate, quisqualate, and tACPD in Xenopus oocytes. Replacement of the extracellular domain up to about one-half of the amino-terminal extracellular domain of mGluR1 with the corresponding portion of mGluR2 generated a pattern of the agonist selectivity characteristic of mGluR2. The acquirement of this property in agonist selectivity was further indicated by the selective responses of these chimeric receptors to an mGluR2-specific agonist, (2S,1'R,2'R,3'R)-2-(2,3-dicarboxycyclopropyl) glycine. This investigation demonstrates that the extracellular domain of mGluR is critical in determining agonist selectivity and that the mode of determination of agonist selectivity of mGluR is different from that of other G protein-coupled receptors for small molecule transmitters.	KYOTO UNIV,FAC MED,INST IMMUNOL,SAKYO KU,KYOTO 606,JAPAN	Kyoto University			Tsuchida, Kunihiro/A-4501-2012	Tsuchida, Kunihiro/0000-0002-3983-5756				ABE T, 1992, J BIOL CHEM, V267, P13361; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; HAYASHI Y, 1992, BRIT J PHARMACOL, V107, P539, DOI 10.1111/j.1476-5381.1992.tb12780.x; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; JI I, 1991, J BIOL CHEM, V266, P13076; JI IH, 1991, J BIOL CHEM, V266, P14953; KAKIZUKA A, 1990, J BIOL CHEM, V265, P10102; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NAKAMURA F, 1991, J BIOL CHEM, V266, P12676; NAKAMURA K, 1992, NEUROSCI RES       S, V17, pS85; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OHFUNE Y, 1993, BIOORG MED CHEM LETT, V3, P15, DOI 10.1016/S0960-894X(00)80083-9; PEREZ HD, 1993, J BIOL CHEM, V268, P2292; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TANABE Y, 1993, J NEUROSCI, V13, P1372; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; XIE YB, 1990, J BIOL CHEM, V265, P21411; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x	28	139	157	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19341	19345						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8103516				2022-12-27	WOS:A1993LW81900031
J	PAN, Y; SHENOUDA, NS; WILSON, GE; SCHAEFER, J				PAN, Y; SHENOUDA, NS; WILSON, GE; SCHAEFER, J			CROSS-LINKS IN CELL-WALLS OF BACILLUS-SUBTILIS BY ROTATIONAL-ECHO DOUBLE-RESONANCE N-15 NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERATOMIC DISTANCE; HELICAL PEPTIDE; GAFFKYA-HOMARI; REDOR NMR; PEPTIDOGLYCAN; SPECTROSCOPY	The cross-link index of peptidoglycan of intact cell walls of Bacillus subtilis grown in media containing L-[2-C-13, N-15]aspartic acid has been determined by rotational-echo double-resonance N-15 NMR. A cross-link index of 72% decreased to 47% when the bacteria were exposed to the antibiotic cephalosporin C. The fraction of N-15 label routed from aspartic acid in the media to glutamic acid in the peptidoglycan peptide stems more than doubled for the cephalosporin-exposed cells, indicating interference with general cell wall nitrogen metabolism by the antibiotic.	WASHINGTON UNIV,DEPT CHEM,ST LOUIS,MO 63130; UNIV AKRON,DEPT CHEM,AKRON,OH 44325	Washington University (WUSTL); University System of Ohio; University of Akron								CHRISTENSEN AM, 1991, J AM CHEM SOC, V113, P6799, DOI 10.1021/ja00018a013; CHRISTENSEN AM, 1993, BIOCHEMISTRY-US, V32, P2868, DOI 10.1021/bi00062a018; FORREST TM, 1991, J BIOL CHEM, V266, P24485; GULLION T, 1989, J MAGN RESON, V81, P196, DOI 10.1016/0022-2364(89)90280-1; GULLION T, 1991, J MAGN RESON, V92, P439, DOI 10.1016/0022-2364(91)90286-3; GULLION T, 1989, ADV MAGN RESON, V13, P57; HING AW, 1993, IN PRESS BIOCHEMISTR; HOLL SM, 1993, ARCH BIOCHEM BIOPHYS, V302, P255, DOI 10.1006/abbi.1993.1207; HOLL SM, 1992, J AM CHEM SOC, V114, P4830, DOI 10.1021/ja00038a056; MARSHALL GR, 1990, J AM CHEM SOC, V112, P963, DOI 10.1021/ja00159a009; ROGERS HJ, 1980, MICROBIAL CELL WALLS, P200; SINHA RK, 1991, ANTIMICROB AGENTS CH, V35, P1753, DOI 10.1128/AAC.35.9.1753; WILSON GE, 1985, BIOCHEM BIOPH RES CO, V126, P1006, DOI 10.1016/0006-291X(85)90285-2; WORTH AD, 1971, BIOCHEMISTRY-US, V10, P4349	14	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18692	18695						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8103049				2022-12-27	WOS:A1993LV65900052
J	GOVARDHAN, CP; OPRIAN, DD				GOVARDHAN, CP; OPRIAN, DD			ACTIVE-SITE-DIRECTED INACTIVATION OF CONSTITUTIVELY ACTIVE MUTANTS OF RHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIFF-BASE COUNTERION; POINT-CHARGE MODEL; BOVINE RHODOPSIN; TRANSDUCIN ACTIVATION; WAVELENGTH REGULATION; VISUAL PIGMENTS; G-PROTEIN; CHROMOPHORE; ATTACHMENT; EXPRESSION	Recently, mutations of the active site Lys(296) residue in rhodopsin (Lys(296) --> Glu and Lys(296) --> Met) have been found as the cause of disease in some patients with autosomal dominant retinitis pigmentosa. In vitro, these mutations result in constitutive activation of the protein. In an effort to develop a potential therapeutic agent for treatment of the disease, we have examined various amine derivatives of 11-cis- and 9-cis-retinal for ability to irreversibly inactivate a related constitutively active mutant, K296G. Three amines were prepared by reductive amination of retinal: 11-cis-retinylpropylamine, 11-cis-retinylamine, and 9-cis-retinylamine. All three compounds inactivated K296G, and the inactivation could not be reversed upon exposure to light. None of the compounds inactivated the wild-type protein. Although the amines were not effective on the naturally occurring retinitis pigmentosa mutants, presumably because of unfavorable steric interactions with the bulky Glu and Met side chains at position 296, the success with K296G makes it highly encouraging that this approach will evolve related compounds that are capable of inactivating the naturally occurring mutants as well.	BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254	Brandeis University					NEI NIH HHS [R01 EY007965, EY07965] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007965] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKITA H, 1980, J AM CHEM SOC, V102, P6370, DOI 10.1021/ja00540a047; BAEHR W, 1982, J BIOL CHEM, V257, P6452; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; BLATZ PE, 1972, BIOCHEMISTRY-US, V11, P848, DOI 10.1021/bi00755a026; BOWNDS D, 1967, NATURE, V216, P1178, DOI 10.1038/2161178a0; CALHOON RD, 1985, BIOCHEMISTRY-US, V24, P6446, DOI 10.1021/bi00344a021; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; DEGRIP WJ, 1990, EUR J BIOCHEM, V191, P211; DRYJA TP, 1993, NAT GENET, V4, P280, DOI 10.1038/ng0793-280; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HONIG B, 1979, J AM CHEM SOC, V101, P7084, DOI 10.1021/ja00517a060; HUBBARD R, 1956, J AM CHEM SOC, V78, P4662, DOI 10.1021/ja01599a037; ITO M, 1982, CHEM PHARM BULL, V30, P1913; KEEN TJ, 1991, GENOMICS, V11, P199, DOI 10.1016/0888-7543(91)90119-Y; KHORANA HG, 1992, J BIOL CHEM, V267, P1; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; MORTON RA, 1955, BIOCHEM J, V59, P128, DOI 10.1042/bj0590128; NAKANISHI K, 1980, J AM CHEM SOC, V102, P7945, DOI 10.1021/ja00547a028; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; OPRIAN DD, 1991, BIOCHEMISTRY-US, V30, P11367, DOI 10.1021/bi00112a002; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OSEROFF AR, 1974, BIOCHEMISTRY-US, V13, P4243, DOI 10.1021/bi00717a027; RANDO RR, 1990, ANGEW CHEM INT EDIT, V29, P461, DOI 10.1002/anie.199004611; RAO VR, 1994, IN PRESS NATURE; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SIEVING PA, 1992, INVEST OPHTH VIS SCI, V33, P1397; SULLIVAN JM, 1993, INVEST OPHTH VIS SCI, V34, P1149; WANG JK, 1980, BIOCHEMISTRY-US, V19, P5111, DOI 10.1021/bi00563a027; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; ZHUKOVSKY EA, 1991, SCIENCE, V251, P558, DOI 10.1126/science.1990431; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154; [No title captured]	36	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6524	6527						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120004				2022-12-27	WOS:A1994MZ50300042
J	MAKINGS, LR; TSIEN, RY				MAKINGS, LR; TSIEN, RY			CAGED NITRIC-OXIDE - STABLE ORGANIC-MOLECULES FROM WHICH NITRIC-OXIDE CAN BE PHOTORELEASED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RELEASE; CALCIUM; PHARMACOLOGY; DISSOCIATION; INHIBITION; COMPLEXES; PLATELETS; CHELATORS; NO	We report the synthesis and testing of a series of ''caged'' nitric oxide compounds that are stable indefinitely in oxygen-containing solutions until photolyzed by ultraviolet irradiation, whereupon they release nitric oxide (NO) with quantum yields of Delta 5% for 3a (CNO-1) and Delta 2% for compounds 3b-e (CNO2-5). After a flash, NO release is complete within 5 ms, so that precise temporal control of NO release is possible. NO donor 3d (CNO-4) includes two carboxylate negative charges at physiological pH, which reduce membrane permeability and enable photolytic generation of NO to be selectively confined to either extracellular or intracellular compartments. Esterification of these carboxyls with acetoxymethyl groups produces 3e (CNO-5), which is membrane-permeant and intracellularly hydrolyzable. Therefore, large populations of intact cells can be conveniently intracellularly loaded with ''caged'' NO donor 3d by incubation with 3e (CNO-5). The biological efficacy of these NO donors and their absolute dependence on UV-irradiation was demonstrated by inhibition of thrombin-stimulated platelet aggregation. Extracellular hemoglobin blocked the effects of NO generated outside but not inside platelets, verifying the sidedness of the NO donors and the limited spatial range of NO action. These molecules should permit precise spatial, temporal, and concentration control of NO release for investigation of its important biological functions.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027177, R37NS027177] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27177] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS SR, 1989, J AM CHEM SOC, V111, P7957, DOI 10.1021/ja00202a042; ADAMS SR, 1993, ANNU REV PHYSIOL, V55, P755, DOI 10.1146/annurev.ph.55.030193.003543; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P1; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOULTON CL, 1993, J PHYSIOL-LONDON, V467, pP181; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; CARTER TD, 1993, J PHYSIOL-LONDON, V467, pP165; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; CHAMULITRAT W, 1993, J BIOL CHEM, V268, P11520; Di Iorio E E, 1981, Methods Enzymol, V76, P57; DOYLE MP, 1984, J AM CHEM SOC, V106, P3678, DOI 10.1021/ja00324a049; DRAGO RS, 1960, J AM CHEM SOC, V82, P96, DOI 10.1021/ja01486a021; DRAGO RS, 1961, J AM CHEM SOC, V83, P1819, DOI 10.1021/ja01469a012; FEELISCH M, 1989, J CARDIOVASC PHARM, V14, pS13, DOI 10.1097/00005344-198906152-00004; FLITNEY FW, 1993, J PHYSIOL-LONDON, V459, pP89; FLITNEY FW, 1993, J PHYSIOL-LONDON, V459, pP90; FLITNEY FW, 1992, BRIT J PHARMACOL, V107, P842, DOI 10.1111/j.1476-5381.1992.tb14534.x; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; HALLAM TJ, 1984, BIOCHEM J, V218, P819, DOI 10.1042/bj2180819; HRABIE JA, 1993, J ORG CHEM, V58, P1472, DOI 10.1021/jo00058a030; IVANOVA K, 1993, EUR J PHARM-MOLEC PH, V244, P37, DOI 10.1016/0922-4106(93)90057-G; IZUMI Y, 1992, SCIENCE, V257, P1273, DOI 10.1126/science.1519065; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MCCALL T, 1992, TRENDS PHARMACOL SCI, V13, P1, DOI 10.1016/0165-6147(92)90002-N; MCCRAY JA, 1989, ANNU REV BIOPHYS BIO, V18, P239, DOI 10.1146/annurev.biophys.18.1.239; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULLER JG, 1990, INORG CHEM, V29, P2185, DOI 10.1021/ic00336a032; NOACK E, 1992, NEUROPROTOCOLS DETEC, P133; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P181, DOI 10.1111/j.1476-5381.1987.tb11310.x; ROSE EJ, 1983, J AM CHEM SOC, V105, P2866, DOI 10.1021/ja00347a056; SAAVEDRA JE, 1992, J ORG CHEM, V57, P6134, DOI 10.1021/jo00049a017; SALVEMINI D, 1990, BRIT J PHARMACOL, V101, P991, DOI 10.1111/j.1476-5381.1990.tb14194.x; SHARMA VS, 1983, BIOCHEMISTRY-US, V22, P3897, DOI 10.1021/bi00285a026; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SMITH RP, 1990, BIOL REACT INTERMED, V4, P365; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; TRACEY WR, 1992, NEUROPROTOCOLS DETEC, P125; TSIEN RY, 1986, BIOPHYS J, V50, P843, DOI 10.1016/S0006-3495(86)83525-1; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; TSIEN RY, 1981, NATURE, V290, P527, DOI 10.1038/290527a0; WILCOX M, 1990, J ORG CHEM, V55, P1585, DOI 10.1021/jo00292a038; WILLIAMS JH, 1993, J PHYSIOL-LONDON, V467, pP166	42	110	114	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6282	6285						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119976				2022-12-27	WOS:A1994MZ50300007
J	KHARITONOV, VG; SUNDQUIST, AR; SHARMA, VS				KHARITONOV, VG; SUNDQUIST, AR; SHARMA, VS			KINETICS OF NITRIC-OXIDE AUTOXIDATION IN AQUEOUS-SOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN MONOXIDE; OXYGEN; OXIDATION	A kinetic study of the reaction of NO with O-2 in aqueous solution has been carried out using a colorimetric method based on a pH indicator and a stopped-flow spectrophotometer. The reaction is second order in NO concentration and first order in O-2 concentration; the overall third order rate constant is 6.3 (+/- 0.4) x 10(6) (M(-1))(2) s(-1). Model calculations for the reaction at estimated physiological concentrations of NO and O-2 indicate that the simple autoxidation of NO will not limit its diffusion from the site of production in endothelial cells to a spatially removed target molecule such as guanylate cyclase in myocytes and platelets.			KHARITONOV, VG (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093, USA.				NHLBI NIH HHS [HL48014, HL1358] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; CHALLIS BC, 1979, J CHEM SOC PERK T 1, P299, DOI 10.1039/p19790000299; EGUCHI W, 1989, KAGAKU KOGAKU RONBUN, V15, P1115, DOI 10.1252/kakoronbunshu.15.1115; KELM M, 1990, CIRC RES, V66, P1561, DOI 10.1161/01.RES.66.6.1561; MALINSKI T, 1993, J CEREBR BLOOD F MET, V13, P355, DOI 10.1038/jcbfm.1993.48; MCCALL T, 1992, TRENDS PHARMACOL SCI, V13, P1, DOI 10.1016/0165-6147(92)90002-N; MONCADA S, 1991, PHARMACOL REV, V43, P109; OLBREGTS J, 1985, INT J CHEM KINET, V17, P835, DOI 10.1002/kin.550170805; Olson J S, 1981, Methods Enzymol, V76, P652; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; TAHA Z, 1992, BIOCHEM BIOPH RES CO, V188, P734, DOI 10.1016/0006-291X(92)91117-9; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857	17	194	196	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5881	5883						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119931				2022-12-27	WOS:A1994MY84000062
J	TAKATA, Y; KONISHI, K; GOMI, T; FUJIOKA, M				TAKATA, Y; KONISHI, K; GOMI, T; FUJIOKA, M			RAT GUANIDINOACETATE METHYLTRANSFERASE - EFFECT OF SITE-DIRECTED ALTERATION OF AN ASPARTIC-ACID RESIDUE THAT IS CONSERVED ACROSS MOST MAMMALIAN S-ADENOSYLMETHIONINE-DEPENDENT METHYLTRANSFERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; ESCHERICHIA-COLI; GLYCINE METHYLTRANSFERASE; N-METHYLTRANSFERASE; NUCLEOTIDE-SEQUENCE; O-METHYLTRANSFERASE; SULFHYDRYL-GROUPS; LIVER; CDNA; MUTAGENESIS	Most mammalian S-adenosylmethionine (AdoMet)dependent methyltransferases have a conserved aspartate residue in a sequence oDso (o denotes a hydrophobic amino acid and s denotes a small neutral amino acid). Rat guanidinoacetate methyltransferase has two aspartate residues (Asp-129 and Asp-134) conforming to the motif in close proximity to Tyr-136 that is photoaffinity-labeled by AdoMet (Takata, Y., and Fujioka, M. (1992) Biochemistry 31, 4369-4374). In order to investigate the role of these residues, we prepared variant forms of the enzyme by oligonucleotide-directed mutagenesis. Conversion of Asp-129 to asparagine or alanine resulted in a functional enzyme. Alteration of Asp-134 to glutamate (D134E) and asparagine (D134N) decreased activity, and replacement with alanine (D134A) led to inactivation. Decreases of 3- and 120-fold were found for k(cat) values of D134E and D134N, respectively. The K-m values of D134E for AdoMet and those for guanidinoacetate were increased about 160- and 80-fold over the respective values of wild type. The corresponding increases in D134N were 800- and 50-fold, respectively. Conservative changes of the residues flanking Asp-134 had little effect on activity. Guanidinoacetate methyltransferase obeys an ordered Bi Bi mechanism in which AdoMet binds first. Thus, the large decreases in k(cat)/K-m values for AdoMet indicate that Asp-134 is crucial for binding AdoMet. Spectroscopic studies indicated that the amino acid substitutions of Asp-134 resulted in no significant changes in the secondary and tertiary structures, and urea denaturation experiments showed that the altered enzymes were not destabilized.	TOYAMA MED & PHARMACEUT UNIV,FAC MED,DEPT BIOCHEM,TOYAMA,TOYAMA 93001,JAPAN	University of Toyama								BAETGE EE, 1986, P NATL ACAD SCI USA, V83, P5454, DOI 10.1073/pnas.83.15.5454; DARBRE A, 1986, PRACTICAL PROTEIN CH, P227; FUJIOKA M, 1986, J BIOL CHEM, V261, P6346; FUJIOKA M, 1991, ARCH BIOCHEM BIOPHYS, V285, P181, DOI 10.1016/0003-9861(91)90347-L; FUJIOKA M, 1988, BIOCHEMISTRY-US, V27, P7658, DOI 10.1021/bi00420a013; GOMI T, 1992, INT J BIOCHEM, V24, P1639; GOMI T, 1989, J BIOL CHEM, V264, P16138; HENZEL WJ, 1989, J BIOL CHEM, V264, P15905; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; ISHIDA I, 1987, J BIOL CHEM, V262, P2895; KONISHI K, 1991, ARCH BIOCHEM BIOPHYS, V289, P90, DOI 10.1016/0003-9861(91)90446-P; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OGAWA H, 1987, EUR J BIOCHEM, V168, P141, DOI 10.1111/j.1432-1033.1987.tb13398.x; OGAWA H, 1988, P NATL ACAD SCI USA, V85, P694, DOI 10.1073/pnas.85.3.694; OGAWA H, 1983, ARCH BIOCHEM BIOPHYS, V226, P265, DOI 10.1016/0003-9861(83)90293-X; Pace C N, 1986, Methods Enzymol, V131, P266; SALMINEN M, 1990, GENE, V93, P241, DOI 10.1016/0378-1119(90)90231-F; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKATA Y, 1992, BIOCHEMISTRY-US, V31, P4369, DOI 10.1021/bi00132a030; TAKATA Y, 1990, INT J BIOCHEM, V22, P1333; TAKATA Y, 1991, BIOCHEM J, V277, P399, DOI 10.1042/bj2770399; TAKEMURA M, 1992, J BIOL CHEM, V267, P15687; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	25	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5537	5542						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119887				2022-12-27	WOS:A1994MY84000013
J	BEDALOV, A; BREAULT, DT; SOKOLOV, BP; LICHTLER, AC; BEDALOV, I; CLARK, SH; MACK, K; KHILLAN, JS; WOODY, CO; KREAM, BE; ROWE, DW				BEDALOV, A; BREAULT, DT; SOKOLOV, BP; LICHTLER, AC; BEDALOV, I; CLARK, SH; MACK, K; KHILLAN, JS; WOODY, CO; KREAM, BE; ROWE, DW			REGULATION OF THE ALPHA-1(I) COLLAGEN PROMOTER IN VASCULAR SMOOTH-MUSCLE CELLS - COMPARISON WITH OTHER ALPHA-1(I) COLLAGEN-PRODUCING CELLS IN TRANSGENIC ANIMALS AND CULTURED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1ST INTRON CONTRIBUTE; MESSENGER-RNA LEVELS; MAMMALIAN-CELLS; TRANSCRIPTIONAL CONTROL; GENE-EXPRESSION; MICE; ATHEROSCLEROSIS; ELASTIN; AORTA; DNA	We have previously reported that the expression of the ColCAT3.6 transgene containing 3.5 kilobases (kb) of alpha 1(I) collagen (COL1A1) promoter sequence fused to the chloramphenicol acetyltransferase (CAT) reporter gene paralleled the expression of the endogenous gene in several connective tissues. We report here that the activity of the reporter gene in aorta from 7-day-old transgenic mice is 10-64-fold lower than in tendon or bone, whereas the endogenous gene is highly expressed in all three tissues. In contrast, the COL1A1 minigene containing 2.3 kb of upstream sequence, the first five exon/intron units, the last six exon/intron units, and 2 kb of 3'-flanking sequence showed high CAT activity in aorta. These results suggest that cia sequences found in ColCAT3.6 mediate high levels of COL1A1 expression in bone and tendon, but not in vascular smooth muscle cells (VSMC), whereas sequences located within the minigene, but not found in ColCAT3.6, mediate VSMC-specific expression. Analysis of promoter activity in cultured cells derived from transgenic tissues further suggests the presence of VSMC-specific regulatory domains. Transient transfection studies, however, failed to shows differential regulation. These differences stress the importance of not relying exclusively on transient transfection data when mapping tissue-specific regulatory domains.	UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,FARMINGTON,CT 06032; UNIV CONNECTICUT,CTR HLTH,DEPT MED,FARMINGTON,CT 06032; THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107; DEPT VET AFFAIRS MED CTR,NEWINGTON,CT 06111; UNIV CONNECTICUT,DEPT ANIM SCI,STORRS,CT 06269; UNIV ZAGREB,SCH MED,41000 ZAGREB,CROATIA; UNIV ZAGREB,SCH DENT MED,41000 ZAGREB,CROATIA	University of Connecticut; University of Connecticut; Jefferson University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; University of Connecticut; University of Zagreb; University of Zagreb; University of Zagreb, School of Dental Medicine			Breault, David/HDN-6048-2022		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR029983] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR29983] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANG AH, 1990, BIOCHEM J, V265, P461, DOI 10.1042/bj2650461; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; BAKER CC, 1990, RECOMBINANT SYSTEMS IN PROTEIN EXPRESSION, P75; BARNES MJ, 1988, COLLAGEN, P275; BOAST S, 1990, J BIOL CHEM, V265; BORNSTEIN P, 1987, P NATL ACAD SCI USA, V84, P8869, DOI 10.1073/pnas.84.24.8869; BRASIER AR, 1989, BIOTECHNIQUES, V7, P116; BRINSTER RL, 1981, CELL, V27, P233; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CAMPBELL GR, 1985, EXP MOL PATHOL, V42, P139, DOI 10.1016/0014-4800(85)90023-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENTE L, 1988, GENE DEV, V2, P259, DOI 10.1101/gad.2.2.259; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DEYL Z, 1987, BLOOD VESSELS, V24, P313; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Higgins CF, 1991, CURR OPIN CELL BIOL, V3, P1013, DOI 10.1016/0955-0674(91)90122-F; HOGAN B, 1986, MANIPULATING MOUSE E; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KREAM BE, 1980, P NATL ACAD SCI-BIOL, V77, P5654, DOI 10.1073/pnas.77.10.5654; LEUSHNER JRA, 1986, PATHOL BIOL, V34, P14; LICHTLER A, 1989, J BIOL CHEM, V264, P3072; MECHAM RP, 1987, SCIENCE, V237, P423, DOI 10.1126/science.3603030; MORTON LF, 1982, ATHEROSCLEROSIS, V42, P41, DOI 10.1016/0021-9150(82)90124-1; OAKES BW, 1982, EUR J CELL BIOL, V27, P34; OLSEN AS, 1991, J BIOL CHEM, V266, P1117; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; PFARR DS, 1986, DNA-J MOLEC CELL BIO, V5, P115, DOI 10.1089/dna.1986.5.115; RAMIREZ F, 1990, FASEB J, V4, P1616, DOI 10.1096/fasebj.4.6.2180769; RIPPE RA, 1989, MOL CELL BIOL, V9, P2224, DOI 10.1128/MCB.9.5.2224; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROWE DW, 1978, BIOCHEMISTRY-US, V17, P1581, DOI 10.1021/bi00602a001; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; Sambrook J, 1989, MOL CLONING LABORATO; SHERWOOD AL, 1990, GENE, V89, P239, DOI 10.1016/0378-1119(90)90011-F; SJOLUND M, 1986, DIFFERENTIATION, V32, P173, DOI 10.1111/j.1432-0436.1986.tb00570.x; SLACK JL, 1992, MOL CELL BIOL, V12, P4714, DOI 10.1128/MCB.12.10.4714; SLACK JL, 1991, MOL CELL BIOL, V11, P2066, DOI 10.1128/MCB.11.4.2066; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WINSTON HW, 1992, J BIOL CHEM, V267	44	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4903	4909						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106463				2022-12-27	WOS:A1994MX57100034
J	KAST, C; STIEGER, B; WINTERHALTER, KH; MEIER, PJ				KAST, C; STIEGER, B; WINTERHALTER, KH; MEIER, PJ			HEPATOCELLULAR TRANSPORT OF BILE-ACIDS - EVIDENCE FOR DISTINCT SUBCELLULAR LOCALIZATIONS OF ELECTROGENIC AND ATP-DEPENDENT TAUROCHOLATE TRANSPORT IN RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANALICULAR MEMBRANE-VESICLES; PLASMA-MEMBRANE; SALT TRANSPORT; GOLGI-APPARATUS; LIVER-CELLS; SYSTEM; MECHANISMS; PROTEINS; GLYCOPROTEIN; SECRETION	To investigate whether electrogenic and ATP-dependent taurocholate transport activities are both mediated by the same bile acid-transporting polypeptide in rat liver, we further purified isolated canalicular membrane vesicles by free flow electrophoresis. Removal of most of the contaminating endoplasmic reticulum resulted in a complete loss of electrogenic taurocholate transport from an ecto-ATPase-enriched canalicular membrane subfraction. In contrast, ATP-dependent taurocholate transport remained associated with both an ecto-ATPase enriched and an ecto-ATPase-free canalicular membrane subfraction. Microsomes containing 64% of total endoplasmic reticulum exhibited saturable electrogenic (K-m approximate to 270 mu M), but no ATP-dependent taurocholate uptake. Golgi membrane vesicles were devoid of any taurocholate transport activity. These results indicate that electrogenic taurocholate transport resides entirely in the endoplasmic reticulum, whereas ATP-dependent bile acid transport is an intrinsic function of the canalicular membrane as well as of a so far unidentified intracellular membrane bound compartment. Hence, the two transport activities are most probably mediated by two different bile acid transporting poly peptides. Furthermore, the finding of ATP-dependent taurocholate transport in virtually ecto-ATPase-free vesicles argues against the concept of primary active bile acid transport being exclusively mediated by the canalicular ecto-ATPase.	UNIV HOSP ZURICH,DEPT MED,DIV CLIN PHARMACOL & TOXICOL,CH-8091 ZURICH,SWITZERLAND; ETH ZURICH,BIOCHEM LAB,CH-8091 ZURICH,SWITZERLAND	University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich			Stieger, Bruno/U-6323-2017	Stieger, Bruno/0000-0002-7190-5785				ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ADACHI Y, 1991, HEPATOLOGY, V14, P655, DOI 10.1016/0270-9139(91)90053-X; ARIAS IM, 1990, HEPATOLOGY, V12, P159, DOI 10.1002/hep.1840120125; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BERGERON JJM, 1982, J CELL BIOL, V92, P139, DOI 10.1083/jcb.92.1.139; BOSSARD R, 1993, J CLIN INVEST, V91, P2714, DOI 10.1172/JCI116511; BOYER JL, 1992, ANNU REV PHYSIOL, V54, P415, DOI 10.1146/annurev.ph.54.030192.002215; BOYER JL, 1993, P NATL ACAD SCI USA, V90, P435, DOI 10.1073/pnas.90.2.435; BOYWER JL, 1990, MEHTODS ENZYMOL, V192, P517; BRUCK R, 1992, AM J PHYSIOL, V262, pG806, DOI 10.1152/ajpgi.1992.262.5.G806; CASSANO G, 1984, PFLUG ARCH EUR J PHY, V400, P309, DOI 10.1007/BF00581565; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CRAWFORD JM, 1991, AM J PHYSIOL, V260, pG119, DOI 10.1152/ajpgi.1991.260.1.G119; Fitz Greg, 1993, P281; FRICKER G, 1987, BIOL CHEM H-S, V368, P1143, DOI 10.1515/bchm3.1987.368.2.1143; FRIMMER M, 1988, BIOCHIM BIOPHYS ACTA, V947, P75, DOI 10.1016/0304-4157(88)90020-2; HAASE W, 1978, BIOCHEM J, V172, P57, DOI 10.1042/bj1720057; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HAUSSINGER D, 1993, BIOCHEM J, V291, P355; INOUE M, 1984, J CLIN INVEST, V73, P659, DOI 10.1172/JCI111257; KEEFFE EB, 1979, J CLIN INVEST, V64, P1590, DOI 10.1172/JCI109620; LAMRI Y, 1988, J CLIN INVEST, V82, P1173, DOI 10.1172/JCI113714; LEVY D, 1991, HEPATOLOGY, V14, pA136; LEVY D, 1991, HEPATOLOGY, V14, P356; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V166, P562, DOI 10.1016/0006-291X(90)90845-E; Meier Peter J., 1993, P587; MEIER PJ, 1990, METHOD ENZYMOL, V192, P534; MEIER PJ, 1984, J BIOL CHEM, V259, P614; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MEIER PJ, 1981, BIOCHIM BIOPHYS ACTA, V646, P283, DOI 10.1016/0005-2736(81)90335-7; MICHAL G, 1993, METHOD ENZYMAT AN, V1, P197; MULLER M, 1991, J BIOL CHEM, V266, P18920; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; NEVILLE DM, 1976, BIOCH ANAL MEMBRANES, P27; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; NISHIDA T, 1992, HEPATOLOGY, V16, pA149; REUBEN A, 1988, GASTROENTEROLOGY, V94, pA584; REUBEN A, 1990, Gastroenterology, V98, pA624; REYNIER MO, 1992, GASTROENTEROLOGY, V102, P2024, DOI 10.1016/0016-5085(92)90328-V; ROMAN LM, 1983, J CELL BIOL, V96, P1548, DOI 10.1083/jcb.96.6.1548; RUETZ S, 1987, J BIOL CHEM, V262, P11324; RUETZ S, 1988, P NATL ACAD SCI USA, V85, P6147, DOI 10.1073/pnas.85.16.6147; SCALERA V, 1980, BIOCHEM J, V186, P177, DOI 10.1042/bj1860177; SCHAFFNER F, 1969, LANCET, V2, P355; SIMION FA, 1984, BIOCHEMISTRY-US, V23, P6459, DOI 10.1021/bi00321a028; SIMION FA, 1984, J BIOL CHEM, V259, P814; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SIPPEL CJ, 1990, AM J PHYSIOL, V258, pG728, DOI 10.1152/ajpgi.1990.258.5.G728; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; STIEGER B, 1986, J MEMBRANE BIOL, V91, P19, DOI 10.1007/BF01870211; STIEGER B, 1992, BIOCHEM J, V284, P67, DOI 10.1042/bj2840067; STOLZ A, 1989, ANNU REV PHYSIOL, V51, P161, DOI 10.1146/annurev.ph.51.030189.001113; SUCHY FJ, 1983, AM J PHYSIOL, V245, pG681, DOI 10.1152/ajpgi.1983.245.5.G681; VEITH CM, 1992, BIOCHIM BIOPHYS ACTA, V1103, P51, DOI 10.1016/0005-2736(92)90056-R; VERDON B, 1983, METHOD ENZYMAT AN, V3, P374; WEINMAN SA, 1989, AM J PHYSIOL, V256, pG826, DOI 10.1152/ajpgi.1989.256.5.G826; YEH HI, 1991, HEPATOLOGY, V13, P523, DOI 10.1016/0270-9139(91)90307-H	59	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5179	5186						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106499				2022-12-27	WOS:A1994MX57100076
J	SPRINGHORN, JP; SINGH, K; KELLY, RA; SMITH, TW				SPRINGHORN, JP; SINGH, K; KELLY, RA; SMITH, TW			POSTTRANSCRIPTIONAL REGULATION OF ID1 ACTIVITY IN CARDIAC-MUSCLE - ALTERNATIVE SPLICING OF NOVEL ID1 TRANSCRIPT PERMITS HOMODIMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; PREPROENKEPHALIN MESSENGER-RNA; DNA-BINDING PROTEINS; NEGATIVE REGULATOR; RAT-HEART; GENE; EXPRESSION; DOMAIN; CELL; DIFFERENTIATION	The transcriptional regulatory protein Id, a negatively trans-acting protein with a helix-loop-helix moth that is expressed in many proliferating tissues early in development, continues to be expressed in postmitotic adult cardiac myocytes and vascular smooth muscle. Following the observation of a ''doublet'' band of 1.1 and 1.25 kilobases on Northern hybridizations of Id1 cDNA with mRNA isolated hom both cardiac muscle and vascular smooth muscle cells, we identified and sequenced an alternatively spliced Id1 gene product containing an insert of 214 base pairs within the coding domain of the original Id1 cDNA. A protein with a molecular mass corresponding to that predicted by the Id1.25-kilobase mRNA sequence could be identified on immunoblots of cell lysates from neonatal and adult rat ventricular myocytes. The insert appears to be a ''coding intron,'' based on the presence of intron-exon consensus sequences at the insert boundaries and the presence of the originally described Id1 carboxyl-terminal coding sequence immediately downstream from, and out of frame with, this insert. In contrast to Id1 and Id2, which do not form homodimers, the carboxyl-terminal sequence of this alternatively spliced Id1 transcript, termed Id1.25, permits homodimerization. Thus, alternative splicing of Id1 may allow for tissue-specific expression of Id1, while formation of homodimers could provide a post-translational mechanism to regulate the ability of Id1.25 to bind and inactivate E2A gene products.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036141] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL-36141] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CLAYCOMB WC, 1980, DEV BIOL, V80, P466, DOI 10.1016/0012-1606(80)90419-4; DEED RW, 1993, ONCOGENE, V8, P599; DIBELLO PR, 1991, GENETICS, V129, P385; DUNCAN M, 1992, DEV BIOL, V154, P1, DOI 10.1016/0012-1606(92)90042-F; EVANS SM, 1993, CIRC RES, V73, P569, DOI 10.1161/01.RES.73.3.569; FINKEL T, 1993, J BIOL CHEM, V268, P5; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GOGOS JA, 1992, SCIENCE, V257, P1951, DOI 10.1126/science.1290524; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KAWAGUCHI N, 1992, P NATL ACAD SCI USA, V89, P4569, DOI 10.1073/pnas.89.10.4569; KEMP PR, 1991, BIOCHEM J, V277, P285, DOI 10.1042/bj2770285; KOMURO I, 1990, CIRC RES, V66, P979, DOI 10.1161/01.RES.66.4.979; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; LI XY, 1992, J BIOL CHEM, V267, P8984; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OGATA T, 1991, BIOCHEM BIOPH RES CO, V180, P1194, DOI 10.1016/S0006-291X(05)81322-1; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; SARTORELLI V, 1993, CIRC RES, V72, P925, DOI 10.1161/01.RES.72.5.925; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SPRINGHORN JP, 1992, AM J PHYSIOL, V263, pH1560, DOI 10.1152/ajpheart.1992.263.5.H1560; SPRINGHORN JP, 1992, J BIOL CHEM, V267, P14360; SPRINGHORN JP, 1989, BIOCHEM J, V258, P73, DOI 10.1042/bj2580073; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	40	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5132	5136						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106493				2022-12-27	WOS:A1994MX57100069
J	KRUPNICK, JG; GUREVICH, VV; SCHEPERS, T; HAMM, HE; BENOVIC, JL				KRUPNICK, JG; GUREVICH, VV; SCHEPERS, T; HAMM, HE; BENOVIC, JL			ARRESTIN-RHODOPSIN INTERACTION - MULTISITE BINDING DELINEATED BY PEPTIDE INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; LIGHT-DEPENDENT PHOSPHORYLATION; ROD OUTER SEGMENTS; 48-KDA PROTEIN; SYNTHETIC PEPTIDES; PHOSPHATIDYLINOSITOL HYDROLYSIS; BETA-2-ADRENERGIC RECEPTOR; PHOTORECEPTOR-MEMBRANES; PHOTOEXCITED RHODOPSIN; TRANSDUCIN	Visual arrestin modulates the intracellular response of retinal rod cells to light by specifically binding to the phosphorylated light-activated form of the photoreceptor rhodopsin (P-Rh*). In order to characterize the molecular interaction between rhodopsin and arrestin, we have studied the ability of synthetic peptides from the proposed cytoplasmic loops of rhodopsin to inhibit arrestin binding. A third cytoplasmic loop peptide competed most effectively for arrestin binding to P-Rh*, exhibiting an IC50 of 34 muM, while a first cytoplasmic loop peptide weakly inhibited binding with an IC50 Of approximately 1100 muM. The first and third cytoplasmic loop peptides also inhibited P-Rh* interaction with both ARR[DELTA(2-16)-404], an arrestin mutant that lacks residues 2-16, and ARR[11911, a mutant that contains only the amino half of arrestin. However, the third loop peptide had an approximately 5-fold lower affinity at inhibiting the binding of ARR[1-191] to P-Rh*. While the first and third loop peptides also inhibited arrestin binding to light-activated rhodopsin and a truncated rhodopsin lacking its C-terminal sites of phosphorylation, the peptides modestly enhanced arrestin binding to phosphorylated dark rhodopsin. These results suggest that the third and, to a lesser extent, the first cytoplasmic loops of rhodopsin may play an important role in arrestin binding to light-activated forms of rhodopsin.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,233 S 10TH ST,PHILADELPHIA,PA 19107; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60612	Jefferson University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Hamm, Heidi E/G-2374-2014; Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NATIONAL EYE INSTITUTE [R01EY006062] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NEI NIH HHS [EY06062] Funding Source: Medline; NHLBI NIH HHS [HL45964] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; BENOVIC JL, 1990, BRIT J CLIN PHARMACO, V30, pS3, DOI 10.1111/j.1365-2125.1990.tb05462.x; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; CHEN CY, 1993, J BIOL CHEM, V268, P7825; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FOWLES C, 1988, FEBS LETT, V238, P56, DOI 10.1016/0014-5793(88)80224-2; FRANK RN, 1973, J BIOL CHEM, V248, P596; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HARGRAVE PA, 1992, MOL BIOL RECEPTORS T, P49; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; KIM CM, 1993, RECEPTOR, V3, P39; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; KUHN H, 1972, FEBS LETT, V20, P1, DOI 10.1016/0014-5793(72)80002-4; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; MORRISON DF, 1991, J BIOL CHEM, V266, P20118; MUNCH G, 1991, EUR J BIOCHEM, V198, P357, DOI 10.1111/j.1432-1033.1991.tb16023.x; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; STRADER CD, 1987, J BIOL CHEM, V262, P16439; WEISS ER, 1988, J BIOL CHEM, V263, P6150; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; WONG SKF, 1990, J BIOL CHEM, V265, P6219; ZOZULYA SA, 1990, PROTEIN ENG, V3, P453, DOI 10.1093/protein/3.5.453; ZOZULYA SA, 1988, Patent No. 1547313	49	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3226	3232						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106358				2022-12-27	WOS:A1994MV63100019
J	NIRANJANAKUMARI, S; GOPINATHAN, KP				NIRANJANAKUMARI, S; GOPINATHAN, KP			ISOLATION AND CHARACTERIZATION OF DNA POLYMERASE-EPSILON FROM THE SILK GLANDS OF BOMBYX-MORI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; CALF THYMUS; SACCHAROMYCES-CEREVISIAE; HUMAN-FIBROBLASTS; REPAIR SYNTHESIS; HELA-CELLS; DELTA; ALPHA; PURIFICATION; REPLICATION	The silk gland of Bombyx mori, an endomitotically replicative tissue shows high levels of DNA polymerases alpha, delta, and epsilon activities. The ratio of polymerase alpha to that of delta plus epsilon is maintained at 1.1 to 1.3 in both the posterior and middle silk glands for the entire duration of late larval development. The three activities copurify in the initial stages of fractionation through phosphocellulose and DE52 but polymerase alpha gets resolved from the others on hydroxylapatite column. Separation between polymerase delta and epsilon is achieved by chromatography on QAE-Sephadex. DNA polymerase epsilon is a heterodimer comprising of 215- and 42-kDa subunits. The activity is maximum at pH 6.5 and the K(m) values for dNTPs vary between 3-9 muM. The enzyme possesses an intrinsically associated exonuclease activity which functions in the mismatch repair during DNA synthesis. Both polymerase and 3' --> 5' exonuclease activities are associated with the 215-kDa subunit. By itself, DNA polymerase epsilon is processive and the catalytic activity is not enhanced by externally added bPCNA (Bombyx-proliferating cell nuclear antigen, an auxiliary protein for DNA polymerase delta). The enzyme resembles polymerase delta in having the exonuclease activity and in its response to aphidicolin or substrate analogs, but could be distinguished from the latter by its lack of response to the bPCNA and sensitivity to dimethyl sulfoxide. The two enzymes show partial immunological cross-reactivity with each other but no immunological relatedness to polymerase alpha. The absence of the repair enzyme DNA polymerase beta and the presence of substantial levels of polymerase epsilon in the silk glands suggest a possible role for the latter in DNA repair in that tissue.	INDIAN INST SCI,DEPT MICROBIOL & CELL BIOL,BANGALORE 560012,KARNATAKA,INDIA; INDIAN INST SCI,CTR GENET ENGN,BANGALORE 560012,KARNATAKA,INDIA	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore								BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; CRUTE JJ, 1986, BIOCHEMISTRY-US, V25, P26, DOI 10.1021/bi00349a005; FOCHER F, 1989, NUCLEIC ACIDS RES, V17, P1805, DOI 10.1093/nar/17.5.1805; FOCHER F, 1988, NUCLEIC ACIDS RES, V16, P6279, DOI 10.1093/nar/16.14.6279; GAGE LP, 1974, CHROMOSOMA, V45, P27; HAMMOND RA, 1990, BIOCHEMISTRY-US, V29, P286, DOI 10.1021/bi00453a039; KEENEY S, 1990, MUTAT RES, V236, P239, DOI 10.1016/0921-8777(90)90008-S; Kornberg A., 1992, DNA REPLICATION, VSecond, P113; LEE MYWT, 1987, BIOCHEMISTRY-US, V26, P1076, DOI 10.1021/bi00378a014; LEE SH, 1991, J BIOL CHEM, V266, P22707; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; NIRANJANAKUMARI S, 1992, J BIOL CHEM, V267, P17531; NIRANJANAKUMARI S, 1991, EUR J BIOCHEM, V201, P431, DOI 10.1111/j.1432-1033.1991.tb16301.x; NIRANJANAKUMARI S, 1993, INSECT BIOCHEM MOLEC, V23, P345, DOI 10.1016/0965-1748(93)90018-N; NISHIDA C, 1988, J BIOL CHEM, V263, P501; SABATINO RD, 1988, BIOCHEMISTRY-US, V27, P2998, DOI 10.1021/bi00408a050; SUGINO A, 1990, CELL, V62, P1561; SYVAOJA J, 1989, J BIOL CHEM, V264, P2489; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TURCHI JJ, 1992, BIOCHEMISTRY-US, V31, P9008, DOI 10.1021/bi00152a043; WAHL AF, 1986, BIOCHEMISTRY-US, V25, P7821, DOI 10.1021/bi00372a006; WANG TSF, 1991, ANN REV BIOCH, V60, P477; WONG SW, 1989, J BIOL CHEM, V264, P5924; YODER BL, 1991, J BIOL CHEM, V266, P22689	27	15	15	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15557	15564						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8101841				2022-12-27	WOS:A1993LN30500038
J	KIM, IG; GORMAN, JJ; PARK, SC; CHUNG, SI; STEINERT, PM				KIM, IG; GORMAN, JJ; PARK, SC; CHUNG, SI; STEINERT, PM			THE DEDUCED SEQUENCE OF THE NOVEL PROTRANSGLUTAMINASE-E (TGASE3) OF HUMAN AND MOUSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HUMAN EPIDERMAL TRANSGLUTAMINASE; CROSS-LINKED ENVELOPE; FACTOR-XIII; GUINEA-PIG; KERATINOCYTE TRANSGLUTAMINASE; TERMINAL DIFFERENTIATION; ERYTHROCYTE-MEMBRANE; I TRANSGLUTAMINASE; MOLECULAR-CLONING	At least three transglutaminases are involved in terminal differentiation events in the epidermis and its derivatives, such as the hair follicle, presumably in cross-linking structural proteins and in the formation of the cornified cell envelope. Of these, only the transglutaminase 3 is a proenzyme, requiring activation by proteolytic cleavage, and is the least understood. Using oligonucleotides designed from the amino acid sequences of peptides of the guinea pig enzyme, we amplified mRNA and deduced the complete amino acid sequences of the mouse and human protransglutaminase 3 enzymes. Both proteins contain 692 amino acids of molecular mass about 77 kDa. Following expression in yeast, the proenzymes encoded by the full-length cDNA clones are active enzymes and can be further activated 15-fold on treatment with dispase. Although these proteins share 38-53% identity to other members of the transglutaminase family, surprisingly, the mouse, human, and guinea pig enzymes have not been highly conserved and show only 50-75% identity to each other. Much of the sequence variation occurs in the vicinity of the proteolytic activation site which lies at the most flexible and hydrophilic region of the molecule and is flanked by a sequence of 12 residues that are absent from other transglutaminases. We suggest that cleavage of this exposed flexible hinge region promotes a conformational change in the protein to a more compact form, resulting in activation of the enzyme. Expression of mouse and human protransglutaminase 3 mRNAs is regulated by calcium, as for other late differentiation products of the epidermis, suggesting that this enzyme is responsible for the later stages of cell envelope formation in the epidermis and hair follicle.	NIH, BLDG 6, RM 425, BETHESDA, MD 20892 USA; BIOMOLEC RES INST, PARKVILLE, VIC 3052, AUSTRALIA; SEOUL NATL UNIV, SCH MED, DEPT BIOCHEM, SEOUL 110460, SOUTH KOREA; NIDA, CELLULAR DEV & ONCOL LAB, BETHESDA, MD USA; NIAMSD, SKIN BIOL BRANCH, BETHESDA, MD USA	National Institutes of Health (NIH) - USA; Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)								BECKER DM, 1991, METHOD ENZYMOL, V194, P319; CARDINALI M, 1990, CANCER RES, V50, P8010; CHANG SK, 1986, J BIOL CHEM, V261, P8112; CHEN R, 1970, P NATL ACAD SCI USA, V66, P472, DOI 10.1073/pnas.66.2.472; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CHUNG SI, 1972, ANN NY ACAD SCI, V202, P240, DOI 10.1111/j.1749-6632.1972.tb16338.x; CHUNG SI, 1972, P NATL ACAD SCI USA, V69, P303, DOI 10.1073/pnas.69.2.303; CURTIS CG, 1974, BIOCHEMISTRY-US, V13, P3257, DOI 10.1021/bi00713a012; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GENTILE V, 1991, J BIOL CHEM, V266, P478; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; HOHL D, 1991, J BIOL CHEM, V266, P6626; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P4633, DOI 10.1021/bi00364a027; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1992, J BIOL CHEM, V267, P7710; KORSGREN C, 1990, P NATL ACAD SCI USA, V87, P613, DOI 10.1073/pnas.87.2.613; LICHTI U, 1991, ANN NY ACAD SCI, V642, P82; LICHTI U, 1985, J BIOL CHEM, V260, P1422; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MICHEL S, 1988, J INVEST DERMATOL, V90, P472, DOI 10.1111/1523-1747.ep12460922; MICHEL S, 1992, J INVEST DERMATOL, V98, P364, DOI 10.1111/1523-1747.ep12499806; NEGI M, 1985, J INVEST DERMATOL, V85, P75, DOI 10.1111/1523-1747.ep12275357; OGAWA H, 1976, J BIOL CHEM, V251, P7281; PARENTEAU NL, 1986, DIFFERENTIATION, V33, P130, DOI 10.1111/j.1432-0436.1986.tb00418.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERSON LL, 1984, MOL CELL BIOCHEM, V58, P99, DOI 10.1007/BF00240609; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PHILLIPS MA, 1992, J BIOL CHEM, V267, P2282; POLAKOWSKA R, 1991, J INVEST DERMATOL, V96, P285, DOI 10.1111/1523-1747.ep12464554; Polakowska R. R., 1991, PHYSL BIOCH MOL BIOL, P168; POLAKOWSKA RR, 1992, P NATL ACAD SCI USA, V89, P4476, DOI 10.1073/pnas.89.10.4476; RICE RH, 1978, J CELL BIOL, V76, P705, DOI 10.1083/jcb.76.3.705; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; ROOP DR, 1983, P NATL ACAD SCI-BIOL, V80, P716, DOI 10.1073/pnas.80.3.716; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT R, 1988, J INVEST DERMATOL, V90, P475, DOI 10.1111/1523-1747.ep12460936; SCHROEDER WT, 1992, J INVEST DERMATOL, V99, P27, DOI 10.1111/1523-1747.ep12611394; STEINERT PM, 1985, J BIOL CHEM, V260, P7142; SUNG LA, 1990, P NATL ACAD SCI USA, V87, P955, DOI 10.1073/pnas.87.3.955; TAKAGI T, 1974, BIOCHEMISTRY-US, V13, P750, DOI 10.1021/bi00701a018; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; THACHER SM, 1989, J INVEST DERMATOL, V92, P578; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; YAMANISHI K, 1991, BIOCHEM BIOPH RES CO, V175, P906, DOI 10.1016/0006-291X(91)91651-R; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	56	115	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12682	12690						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8099584				2022-12-27	WOS:A1993LG65800068
J	CHO, HS; CRONAN, JE				CHO, HS; CRONAN, JE			ESCHERICHIA-COLI THIOESTERASE-I, MOLECULAR-CLONING AND SEQUENCING OF THE STRUCTURAL GENE AND IDENTIFICATION AS A PERIPLASMIC ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; FATTY-ACID SYNTHASE; COENZYME-A THIOESTERASE; PROMOTER PLASMIDS; OUTER-MEMBRANE; K-12; DNA; PURIFICATION; SYNTHETASE; RESISTANCE	The structural gene for Escherichia coli thioesterase I (called tesA) has been cloned by use of sequence data obtained from the purified protein. The tesA gene was mapped at 530 kilobase pair of the E. coli physical map (minute 11.6 of E. coli genetic map). The DNA sequence of the tesA gene was obtained and the deduced protein sequence showed that thioesterase I consists of 182 amino acids and has a molecular mass of 20.5 kDa. Comparison of the DNA and protein sequence data suggested that a leader sequence of 26 amino acid residues is cleaved from the primary translation product, and this processing was confirmed by NH2-terminal sequencing of the primary translation product synthesized in vitro. These data predicted that thioesterase I (long believed to be a cytoplasmic protein) is exported to the cell periplasm, a prediction supported by release of the enzyme from cells upon osmotic shock. The TesA protein sequence does not exhibit any significant overall sequence similarity with other known proteins, although the sequence does contain two small sequence elements found in several other thioesterases. One of these elements is a sequence similar to the serine esterase active sites found in serine proteases and four other thioesterases. A serine residue within this TesA element was shown to be covalently labeled with [H-3] diisopropyl fluorophosphate, a potent inhibitor of TesA activity. The second sequence element is a histidine-containing sequence found close to the carboxyl terminus that is also found in the carboxyl termini of the four known active serine thioesterases. The physiological role of thioesterase I is unclear. A strain carrying a null mutation of the tesA gene was constructed and found to have no growth phenotype. Moreover, a strain carrying a plasmid that gave massive overproduction of TesA (approximately 100-fold higher than that of the wild type) also grew normally. In addition a strain containing double null mutations in both tesA and tesB (the structural gene for E. coli thioesterase II) also failed to display any growth phenotype. Analysis of the fatty acid compositions of phospholipid, lipid A, and lipoprotein of the above strains showed no significant changes from a wild type strain.	UNIV ILLINOIS,DEPT MICROBIOL,131 BURRILL HALL,407 S GOODWIN AVE,URBANA,IL 61801; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			Cronan, John/V-6626-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015650, R37AI015650] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15650] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; Barnes E M Jr, 1975, Methods Enzymol, V35, P102, DOI 10.1016/0076-6879(75)35144-6; BARNES EM, 1970, J BIOL CHEM, V245, P3122; BARNES EM, 1968, J BIOL CHEM, V243, P2955; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONNER WM, 1972, J BIOL CHEM, V247, P3123; BOYCE SG, 1984, BIOCHEMISTRY-US, V23, P141, DOI 10.1021/bi00296a023; BYERS D, 1985, J BIOL CHEM, V260, P6938; COLEMAN WG, 1979, J BACTERIOL, V139, P899, DOI 10.1128/JB.139.3.899-910.1979; CRONAN JE, 1984, J BACTERIOL, V159, P773, DOI 10.1128/JB.159.2.773-775.1984; CRONAN JE, 1987, ESCHERICHIA COLI SAL, V1, P474; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GREENWAY DLA, 1983, J BIOL CHEM, V258, P3034; HAMES BD, 1981, GEL ELECTROPHORESIS, P23; HIREL P, 1989, P NATL ACAD SCI USA, V68, P8247; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LUGTENBERG B, 1983, BIOCHIM BIOPHYS ACTA, V737, P51, DOI 10.1016/0304-4157(83)90014-X; MARTIN FH, 1985, NUCLEIC ACIDS RES, V13, P8927, DOI 10.1093/nar/13.24.8927; MEAD DA, 1985, NUCLEIC ACIDS RES, V13, P1103, DOI 10.1093/nar/13.4.1103; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MONSON KD, 1980, J BIOL CHEM, V255, P1435; NAGGERT J, 1991, J BIOL CHEM, V266, P11044; NAGGERT J, 1988, J BIOL CHEM, V263, P1146; NARASHIMHAN ML, 1986, J BACTERIOL, V165, P911, DOI 10.1128/jb.165.3.911-917.1986; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, V1, P7; ODEN KL, 1990, GENE, V96, P29, DOI 10.1016/0378-1119(90)90337-Q; OLIVER DB, 1987, ESCHERICHIA COLI SAL, V1, P56; PAZIRANDEH M, 1989, J BIOL CHEM, V264, P18195; POULOSE AJ, 1985, J BIOL CHEM, V260, P5953; POULOSE AJ, 1981, BIOCHEM BIOPH RES CO, V103, P377, DOI 10.1016/0006-291X(81)90463-0; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; RANDHAWA ZI, 1987, BIOCHEMISTRY-US, V26, P1365, DOI 10.1021/bi00379a024; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPENCER AK, 1978, J BIOL CHEM, V253, P5922; TAMAKI S, 1971, J BACTERIOL, V105, P968, DOI 10.1128/JB.105.3.968-975.1971; TANFORD C, 1980, HYDROPHOBIC EFFECT F, P36; VONHEIJNE G, 1987, SEQUENCE ANAL MOL BI, P112; WIJSMAN HJW, 1974, MOL GEN GENET, V128, P349, DOI 10.1007/BF00268522; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; WITKOWSKI A, 1992, J BIOL CHEM, V267, P18488; YANG C, 1988, BIOCHEM, V27, P2773; YEM DW, 1978, J BACTERIOL, V133, P1419, DOI 10.1128/JB.133.3.1419-1426.1978	44	110	134	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9238	9245						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8098033				2022-12-27	WOS:A1993LA68900017
J	SKACH, WR; CALAYAG, MC; LINGAPPA, VR				SKACH, WR; CALAYAG, MC; LINGAPPA, VR			EVIDENCE FOR AN ALTERNATE MODEL OF HUMAN P-GLYCOPROTEIN STRUCTURE AND BIOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; STOP TRANSFER; BACTERIAL TRANSPORT; PRION PROTEIN; SEQUENCE; MEMBRANE; ORIENTATION; INVITRO; GLYCOSYLATION; ANTIBODIES	We have studied the transmembrane topology of human P-glycoprotein (MDR1) using protein chimeras in Xenopus oocytes and full-length native protein in a cell-free translation system. We find both in vivo and in vitro, that the peptide region between putative transmembrane helices (TM) 8 and 9 resides in the endoplasmic reticulum lumen not in the cytosol as predicted. The topology of the carboxyl-terminal half of MDR1 therefore appears distinct from the homologous amino-terminal half in which the corresponding region between TM2 and TM3 is cytosolic. Thus, topogenic sequences encoded in the homologous amino and carboxyl domains of MDR1 direct fundamentally different events in biogenesis of the two halves of MDR1. We conclude that the transmembrane topology of MDR1, an important member of the ATP binding cassette (ABC) transporter superfamily, is not as predicted and should be revised.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Lingappa, Vishwanath R./0000-0003-0962-6571	NATIONAL CANCER INSTITUTE [K11CA001614] Funding Source: NIH RePORTER; NCI NIH HHS [CA01614] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUGGEMANN EP, 1991, BIOTECHNIQUES, V10, P202; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; CASTILLO G, 1990, P NATL ACAD SCI USA, V87, P4737, DOI 10.1073/pnas.87.12.4737; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN MM, 1991, BIOCH BASIS MULTIDRU; HASEGAWA H, 1992, SCIENCE, V258, P1477, DOI 10.1126/science.1279809; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KATZ FN, 1977, P NATL ACAD SCI USA, V74, P3278, DOI 10.1073/pnas.74.8.3278; KATZ FN, 1979, J CELL BIOL, V80, P416, DOI 10.1083/jcb.80.2.416; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; POLLACK L, 1983, J CELL BIOL, V97, P293, DOI 10.1083/jcb.97.2.293; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; SKACH WR, 1992, INTRACELLULAR TRAFFI, P19; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; YOST CS, 1983, CELL, V34, P759; ZHANG JT, 1991, J BIOL CHEM, V266, P18224	28	130	132	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6903	6908						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8096508				2022-12-27	WOS:A1993KV14100019
J	PAHL, HL; SCHEIBE, RJ; ZHANG, DE; CHEN, HM; GALSON, DL; MAKI, RA; TENEN, DG				PAHL, HL; SCHEIBE, RJ; ZHANG, DE; CHEN, HM; GALSON, DL; MAKI, RA; TENEN, DG			THE PROTOONCOGENE PU.1 REGULATES EXPRESSION OF THE MYELOID-SPECIFIC CD11B PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMYELOCYTIC LEUKEMIA FUSES; LUCIFERASE REPORTER GENE; TRANSCRIPTION FACTOR; PUTATIVE ONCOGENE; RAR-ALPHA; DIFFERENTIATION; CELLS; SPI-1; TRANSLOCATION; MACROPHAGE	The myeloid integrin CD11b is expressed selectively on the surface of mature monocytes, macrophages, granulocytes, and natural killer cells. Tissue-specific and developmentally regulated expression of CD11b is controlled at the level of mRNA transcription, and recent characterization of the human CD11b promoter indicates that the first 92 bp of 5'-flanking DNA are sufficient to direct tissue-specific expression of a reporter gene. Here we show that the sequence AAAAGGAGAAG at base pair -20 of the CD11b promoter binds the proto-oncogene PU.1 in vitro and that mutation of this site significantly reduces the ability of the CD11b promoter to direct expression of a reporter gene in myeloid cells but not in nonmyeloid cells. PU.1 may thus represent a major determinant of the myeloid expression of CD11b.	BETH ISRAEL HOSP,DEPT MED,DIV HEMATOL ONCOL,RES E 219,330 BROOKLINE AVE,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Sanford Burnham Prebys Medical Discovery Institute			Pahl, Heike/AGM-5260-2022; Galson, Deborah L./E-9370-2010	Galson, Deborah L./0000-0002-2045-8807; Tenen, Daniel/0000-0002-6423-3888	NATIONAL CANCER INSTITUTE [R01CA041456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030656] Funding Source: NIH RePORTER; NCI NIH HHS [CA41456] Funding Source: Medline; NIAID NIH HHS [AI30656] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DINGHAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475; GALSON DL, 1988, MOL CELL BIOL, V8, P381, DOI 10.1128/MCB.8.1.381; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LARRICK JW, 1980, J IMMUNOL, V125, P6; Maxam A M, 1980, Methods Enzymol, V65, P499; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PAHL HL, 1992, BLOOD, V79, P865; PAHL HL, 1991, EXP HEMATOL, V19, P1038; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; RAY D, 1990, ONCOGENE, V5, P663; ROBERTS WM, 1992, BLOOD, V79, P586; ROSMARIN AG, 1989, BLOOD, V73, P131; ROSMARIN AG, 1992, BLOOD, V79, P2598; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHAPIRO LH, 1991, J BIOL CHEM, V266, P11999; TODD RF, 1981, J IMMUNOL, V126, P1435; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469	30	299	301	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5014	5020						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	8095266				2022-12-27	WOS:A1993KP88400068
J	KAPPELER, F; ITIN, C; SCHINDLER, R; HAURI, HP				KAPPELER, F; ITIN, C; SCHINDLER, R; HAURI, HP			A DUAL ROLE FOR COOH-TERMINAL LYSINE RESIDUES IN PRE-GOLGI RETENTION AND ENDOCYTOSIS OF ERGIC-53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ENDOPLASMIC-RETICULUM; CYTOPLASMIC DOMAIN; MDCK CELLS; RETROGRADE TRANSPORT; PROTEIN-TRANSPORT; EPITHELIAL-CELLS; BREFELDIN-A; RECEPTOR; IDENTIFICATION; COMPARTMENT	ERGIC-53 (former designation, p53) is a 53-kDa non-glycosylated, dimeric, and hexameric type I membrane protein that has been established as a marker protein for a tubulovesicular intermediate compartment in which protein transport from the endoplasmic reticulum to the Golgi apparatus is blocked at 15 degrees C. Although ERGIC-53 is not a resident protein of the rough endoplasmic reticulum its cDNA sequence carries a double lysine endoplasmic reticulum retention motif at the cytoplasmically exposed COOH terminus. Here we report that overexpression of ERGIC-53 in COS cells saturates its intracellular retention system leading to the appearance of ERGIC-53 at the cell surface. Cell surface ERGIC-53 is efficiently endocytosed by a mechanism that is disturbed when the two critical lysines of the endoplasmic reticulum retention motif are replaced by serines. The results suggest a mechanistic similarity of pre-Golgi retention by the double lysine motif and lysine based. endocytosis.	UNIV BASEL,BIOZENTRUM,DEPT PHARMACOL,CH-4056 BASEL,SWITZERLAND	University of Basel								BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CULLEN BR, 1987, METHOD ENZYMOL, V152, P692; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LOUVARD D, 1980, P NATL ACAD SCI-BIOL, V77, P4132, DOI 10.1073/pnas.77.7.4132; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MALLABIABARRENA A, 1992, NATURE, V357, P593, DOI 10.1038/357593a0; MATTER K, 1990, J BIOL CHEM, V265, P3503; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SCHWEIZER A, 1993, J CELL SCI, V104, P671; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185	31	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6279	6281						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119975				2022-12-27	WOS:A1994MZ50300006
J	MONTESANORODITIS, L; GLITZ, DG				MONTESANORODITIS, L; GLITZ, DG			TRACING THE PATH OF MESSENGER-RNA ON THE ESCHERICHIA-COLI SMALL RIBOSOMAL-SUBUNIT - IMMUNE ELECTRON-MICROSCOPY USING DEFINED OLIGODEOXYNUCLEOTIDE ANALOGS OF MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPLATE POLYNUCLEOTIDES; PROTEIN-SYNTHESIS; ELONGATION CYCLE; DECODING REGION; 30-S SUBUNIT; LOCALIZATION; TRANSLATION; SITE; INITIATION; BINDING	Oligodeoxynucleotide models of mRNA were used to determine the ribosomal site of specific nucleotides 3' to the initiation codon. Each mRNA analog had a 5'-terminal 9-base Shine-Dalgarno sequence, a 7-nucleotide spacer, and an ATG initiation signal, followed by up to 31 nucleotides, one of which carried an antibody-recognizable marker. All probes bound efficiently to activated Escherichia coli 30 S ribosomal subunits. Complexes were formed using ribosomal subunits, initiator tRNA, an oligodeoxynucleotide probe, and antibodies. Electron microscopy was then used to place specific positions in the mRNA analog on the subunit and thus to trace the pathway of the messenger. As viewed from the cytoplasmic side of the subunit, the 5' segment of the mRNA lies on the left, along the inner surface of the platform. The initiation codon and the next 9 nucleotides are located in the cleft between the subunit platform and body; within this segment the mRNA makes a U turn and emerges from the cleft at the left of the neck that separates the subunit head and body. The mRNA then loops around the neck to the right, along the cytoplasmic surface of the subunit and toward the site of the 7-methylguanosine residue of the 16 S ribosomal RNA.	UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								BACKENDORF C, 1980, EUR J BIOCHEM, V110, P599, DOI 10.1111/j.1432-1033.1980.tb04904.x; BAKIN AV, 1991, J MOL BIOL, V221, P441, DOI 10.1016/0022-2836(91)80065-3; BRETSCHER MS, 1969, J MOL BIOL, V42, P595, DOI 10.1016/0022-2836(69)90247-2; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; BROUDE NE, 1983, EUR J BIOCHEM, V132, P139, DOI 10.1111/j.1432-1033.1983.tb07338.x; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; CZWORKOWSKI J, 1991, BIOCHEMISTRY-US, V30, P4821, DOI 10.1021/bi00233a026; DONTSOVA O, 1992, EMBO J, V11, P3105, DOI 10.1002/j.1460-2075.1992.tb05383.x; EVSTAFIEVA AG, 1983, EMBO J, V2, P799, DOI 10.1002/j.1460-2075.1983.tb01503.x; FIERS W, 1975, NATURE, V256, P273, DOI 10.1038/256273a0; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GOODWIN GH, 1982, GEL ELECTROPHORESIS, P199; GORNICKI P, 1984, J BIOL CHEM, V259, P493; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; HARTZ D, 1990, RIBOSOME, P275; HARTZ D, 1991, J MOL BIOL, V218, P83, DOI 10.1016/0022-2836(91)90875-7; HOLLAND JJ, 1964, P NATL ACAD SCI USA, V52, P1554, DOI 10.1073/pnas.52.6.1554; LAKE JA, 1977, P NATL ACAD SCI USA, V74, P1903, DOI 10.1073/pnas.74.5.1903; LAKE JA, 1976, J MOL BIOL, V105, P131, DOI 10.1016/0022-2836(76)90200-X; LAKE JA, 1978, ADV TECHNIQUES BIOL, V2, P173; LASATER LS, 1988, BIOCHEMISTRY-US, V27, P4687, DOI 10.1021/bi00413a016; LASATER LS, 1990, NUCLEIC ACIDS RES, V18, P477, DOI 10.1093/nar/18.3.477; LIM V, 1992, NUCLEIC ACIDS RES, V20, P2627, DOI 10.1093/nar/20.11.2627; MILSTONE DS, 1978, NUCLEIC ACIDS RES, V5, P3439, DOI 10.1093/nar/5.9.3439; MOAZED D, 1986, J MOL BIOL, V191, P483, DOI 10.1016/0022-2836(86)90143-9; MONTESANORODITIS L, 1993, J BIOL CHEM, V268, P18701; MORGAN AR, 1967, J MOL BIOL, V26, P477, DOI 10.1016/0022-2836(67)90316-6; MURAKAWA GJ, 1989, BIOCHEMISTRY-US, V28, P8067, DOI 10.1021/bi00446a015; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; OAKES MI, 1986, P NATL ACAD SCI USA, V83, P275, DOI 10.1073/pnas.83.2.275; OFENGAND J, 1986, STRUCTURE FUNCTION G, P473; OLSON HM, 1979, P NATL ACAD SCI USA, V76, P3769, DOI 10.1073/pnas.76.8.3769; OLSON HM, 1988, J BIOL CHEM, V263, P15196; PEACOCK AC, 1967, BIOCHEMISTRY-US, V6, P1818, DOI 10.1021/bi00858a033; RICKER RD, 1991, NUCLEIC ACIDS RES, V19, P6573, DOI 10.1093/nar/19.23.6573; RINKEAPPEL J, 1993, NUCLEIC ACIDS RES, V21, P2853, DOI 10.1093/nar/21.12.2853; SCHEINMAN A, 1992, BIOCHIMIE, V74, P307, DOI 10.1016/0300-9084(92)90108-Q; SHABAROVA ZA, 1991, NUCLEIC ACIDS RES, V19, P4247, DOI 10.1093/nar/19.15.4247; SHATSKY IN, 1991, BIOCHIMIE, V73, P937, DOI 10.1016/0300-9084(91)90135-N; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SPIRIN AS, 1989, BIOL CELL, V66, P215, DOI 10.1016/0248-4900(89)90174-3; STEITZ JA, 1975, P NATL ACAD SCI USA, V72, P4734, DOI 10.1073/pnas.72.12.4734; STOFFLER G, 1986, STRUCTURE FUNCTION G, P28; TREMPE MR, 1982, J BIOL CHEM, V257, P9822; WALLECZEK J, 1990, J BIOL CHEM, V265, P11338; WOWER J, 1991, BIOCHIMIE, V73, P961, DOI 10.1016/0300-9084(91)90137-P; ZAMIR A, 1971, J MOL BIOL, V60, P347, DOI 10.1016/0022-2836(71)90299-3	48	14	14	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6458	6470						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119997				2022-12-27	WOS:A1994MZ50300033
J	FABRE, S; MANIN, M; PAILHOUX, E; VEYSSIERE, G; JEAN, C				FABRE, S; MANIN, M; PAILHOUX, E; VEYSSIERE, G; JEAN, C			IDENTIFICATION OF A FUNCTIONAL ANDROGEN RESPONSE ELEMENT IN THE PROMOTER OF THE GENE FOR THE ANDROGEN-REGULATED ALDOSE REDUCTASE-LIKE PROTEIN-SPECIFIC TO THE MOUSE VAS-DEFERENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; PROSTATIC BINDING-PROTEIN; MESSENGER-RNA EXPRESSION; GLUCOCORTICOID RECEPTOR; ORNITHINE DECARBOXYLASE; TRANSCRIPTION FACTORS; GENOMIC ORGANIZATION; MEDIATES INDUCTION; STEROID-HORMONES; MAJOR PROTEIN	Mouse vas deferens protein (MVDP), a member of the aldo-keto reductase superfamily, is exclusively produced in the epithelial cells of the deferent duct under androgenic regulation. To better understand androgen-regulated MVDP gene expression, the location and sequences of androgen response elements (AREs) in the 5'-flanking DNA were determined. Sequence analysis revealed two putative AREs as follows: one between positions -1186 and -1171 (distal ARE) and the other between -111 and -97 (proximal ARE). To study hormonal regulation, fragments of the MVDP promoter region, extending from residue -1804 to +41, were linked to the chloramphenicol acetyltransferase (CAT) reporter gene and cotransfected with a human androgen receptor expression vector into T47D cells in a transient expression assay. A minimal region (-121 to +41) was identified as being sufficient for androgen-regulated gene expression. A mutation in proximal ARE almost completely abolished androgen induction of CAT. One copy of the sequence TGAAGT tcc TGTTCT, cloned in the opposite orientation in front of the thymidine kinase promoter, confers androgen responsiveness to the CAT reporter gene. Androgen transcriptional activity was not detected with the distal ARE. The data provide strong evidence that transcriptional regulation of the MVDP gene occurs via the sequence TGAAGT tcc TGTTCT.			FABRE, S (corresponding author), UNIV CLERMONT FERRAND,PHYSIOL COMPAREE & ENDOCRINOL LAB,CNRS,UA 360,F-63177 CLERMONT FERRAND,FRANCE.							ADLER AJ, 1991, MOL ENDOCRINOL, V5, P1587, DOI 10.1210/mend-5-11-1587; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BONDY CA, 1989, MOL ENDOCRINOL, V3, P1409, DOI 10.1210/mend-3-9-1409; BONDY CA, 1989, MOL ENDOCRINOL, V3, P1417, DOI 10.1210/mend-3-9-1417; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BURANT CF, 1992, J BIOL CHEM, V267, P14523; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; CLAESSENS F, 1990, MOL CELL ENDOCRINOL, V74, P203, DOI 10.1016/0303-7207(90)90225-W; CROSSLEY M, 1992, SCIENCE, V257, P377, DOI 10.1126/science.1631558; CROZAT A, 1992, ENDOCRINOLOGY, V130, P1131, DOI 10.1210/en.130.3.1131; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DASSOULI A, 1994, IN PRESS J STEROID B; DENISON SH, 1989, ENDOCRINOLOGY, V124, P1091, DOI 10.1210/endo-124-2-1091; EISENBERG LM, 1989, NUCLEIC ACIDS RES, V17, P2359, DOI 10.1093/nar/17.6.2359; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GHYSELINCK NB, 1993, MOL ENDOCRINOL, V7, P258, DOI 10.1210/me.7.2.258; GRAHAM A, 1991, J BIOL CHEM, V266, P6872; GRAHAM C, 1991, GENE, V107, P259, DOI 10.1016/0378-1119(91)90326-7; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; IWATA N, 1990, ARCH BIOCHEM BIOPHYS, V282, P70, DOI 10.1016/0003-9861(90)90088-G; JEFFERY J, 1983, P NATL ACAD SCI-BIOL, V80, P901, DOI 10.1073/pnas.80.4.901; KINOSHITA JH, 1981, JAMA-J AM MED ASSOC, V246, P257, DOI 10.1001/jama.246.3.257; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LORENI F, 1988, MOL CELL BIOL, V8, P2350, DOI 10.1128/MCB.8.6.2350; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUND SD, 1991, MOL CELL BIOL, V11, P5426, DOI 10.1128/MCB.11.11.5426; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MANIN M, 1992, ENDOCRINOLOGY, V131, P2378, DOI 10.1210/en.131.5.2378; MANN T, 1964, BIOCH SEMEN MALE REP, P237; MARTINEZ A, 1989, J ENDOCRINOL, V120, P67, DOI 10.1677/joe.0.1200067; MARTINEZ A, 1991, MOL CELL ENDOCRINOL, V76, P191, DOI 10.1016/0303-7207(91)90273-U; MARTINEZ A, 1990, MOL CELL ENDOCRINOL, V72, P201, DOI 10.1016/0303-7207(90)90144-W; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1966; PAILHOUX E, 1992, J STEROID BIOCHEM, V42, P561, DOI 10.1016/0960-0760(92)90445-O; PAILHOUX EA, 1990, J BIOL CHEM, V265, P19932; PARKER MG, 1987, J CELL BIOCHEM, V35, P285, DOI 10.1002/jcb.240350403; PETRASH JM, 1992, BIOCHEM BIOPH RES CO, V187, P201, DOI 10.1016/S0006-291X(05)81479-2; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; RUSHMERE NK, 1987, MOL CELL ENDOCRINOL, V51, P259, DOI 10.1016/0303-7207(87)90036-0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; STAVENHAGEN JB, 1988, CELL, V55, P247, DOI 10.1016/0092-8674(88)90047-5; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TAN JA, 1992, J BIOL CHEM, V267, P4456; TARAGNAT C, 1988, J REPROD FERTIL, V83, P835, DOI 10.1530/jrf.0.0830835; TARAGNAT C, 1990, J ANDROL, V11, P279; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZHANG HY, 1991, J BIOL CHEM, V266, P24332	63	63	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5857	5864						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119928				2022-12-27	WOS:A1994MY84000059
J	HANSSON, L; EDLUND, M; EDLUND, A; JOHANSSON, T; MARKLUND, SL; FROMM, S; STROMQVIST, M; TORNELL, J				HANSSON, L; EDLUND, M; EDLUND, A; JOHANSSON, T; MARKLUND, SL; FROMM, S; STROMQVIST, M; TORNELL, J			EXPRESSION AND CHARACTERIZATION OF BIOLOGICALLY-ACTIVE HUMAN EXTRACELLULAR-SUPEROXIDE DISMUTASE IN MILK OF TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CELL-LINES; BETA-LACTOGLOBULIN; FREE-RADICALS; REPERFUSION; RAT; BINDING; ISOENZYMES; SEQUENCE; ISCHEMIA; PROTEINS	We have targeted the expression of recombinant human extracellular superoxide dismutase, a glycosylated tetrameric metalloprotein, to the mammary gland of transgenic mice. This was achieved by using regulatory elements from either the murine whey acidic protein gene or the ovine beta-lactoglobulin gene to control expression of human extracellular superoxide dismutase cDNA. Whey acidic protein regulatory sequences directed high level mammary gland-specific expression of the recombinant gene and secretion of biologically active extracellular superoxide dismutase into the milk. The produced recombinant protein was fully active, it was in tetrameric form, it showed heparin affinity, and its mass was similar to that of the native enzyme. In addition, the in vivo plasma clearance in a rabbit model was similar to the previously studied native and recombinant forms. To our knowledge, this is the first example of efficient production of a tetrameric, protease-susceptible metalloprotein in milk of transgenic animals. Production at equivalent levels in transgenic farm animals would yield sufficient extracellular superoxide dismutase for therapeutic purposes.	UMEA UNIV HOSP, DEPT CLIN CHEM, S-90185 UMEA, SWEDEN; UNIV OSLO, MOLEC EMBRYOL LAB, N-0316 OSLO 3, NORWAY; UNIV GOTEBORG, DEPT PHYSIOL, S-41390 GOTHENBURG, SWEDEN	Umea University; University of Oslo; University of Gothenburg	HANSSON, L (corresponding author), SYMBICOM AB, POB 1451, S-90124 UMEA, SWEDEN.							ABRAHAMSSON T, 1992, CIRC RES, V70, P264, DOI 10.1161/01.RES.70.2.264; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO, pCH2; BANNISTER JV, 1987, CRC CR REV BIOCH MOL, V22, P111, DOI 10.3109/10409238709083738; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL SM, 1984, NUCLEIC ACIDS RES, V12, P8685, DOI 10.1093/nar/12.22.8685; ERLANSSON M, 1990, FREE RADICAL BIO MED, V9, P59, DOI 10.1016/0891-5849(90)90050-S; FERRARI R, 1989, PHARMACOL RES, V21, P57, DOI 10.1016/S1043-6618(89)80018-0; HARRIS S, 1988, NUCLEIC ACIDS RES, V16, P10379, DOI 10.1093/nar/16.21.10379; HATORI N, 1992, FREE RADICAL BIO MED, V13, P221, DOI 10.1016/0891-5849(92)90018-C; HATORI N, 1992, FREE RADICAL BIO MED, V13, P137, DOI 10.1016/0891-5849(92)90075-R; HENNIGHAUSEN L, 1990, Protein Expression and Purification, V1, P3, DOI 10.1016/1046-5928(90)90037-Y; Hennighausen L, 1990, Curr Opin Biotechnol, V1, P74, DOI 10.1016/0958-1669(90)90013-B; HJALMARSSON K, 1987, P NATL ACAD SCI USA, V84, P6340, DOI 10.1073/pnas.84.18.6340; HOGAN B, 1986, MANIPULATING MOUSE E, P153; JOHANSSON MH, 1990, CARDIOVASC RES, V24, P500, DOI 10.1093/cvr/24.6.500; KARLSSON K, 1988, BIOCHEM J, V255, P223; KARLSSON K, 1993, BIOCHEM J, V290, P623, DOI 10.1042/bj2900623; KARLSSON K, 1988, BIOCHEM J, V256, P29, DOI 10.1042/bj2560029; KARLSSON K, 1987, BIOCHEM J, V242, P55, DOI 10.1042/bj2420055; KARLSSON K, 1988, J CLIN INVEST, V82, P762, DOI 10.1172/JCI113676; KARLSSON K, 1993, FREE RADICAL BIO MED, V14, P185, DOI 10.1016/0891-5849(93)90009-J; KARLSSON K, 1989, LAB INVEST, V60, P659; KEELE BB, 1970, J BIOL CHEM, V245, P6176; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKLUND S, 1976, J BIOL CHEM, V251, P7504; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MARKLUND SL, 1990, BIOCHEM J, V266, P213, DOI 10.1042/bj2660213; MARKLUND SL, 1984, BIOCHEM J, V222, P649, DOI 10.1042/bj2220649; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; MARKLUND SL, 1982, CLIN CHIM ACTA, V126, P41, DOI 10.1016/0009-8981(82)90360-6; MARKLUND SL, 1986, ANN RHEUM DIS, V45, P847, DOI 10.1136/ard.45.10.847; MARKLUND SL, 1985, CRC HDB METHODS OXYG, P249; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MOSS DW, 1985, ENZYME, V34, P212, DOI 10.1159/000469387; Omar B A, 1992, Adv Pharmacol, V23, P109, DOI 10.1016/S1054-3589(08)60964-3; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PITTIUS CW, 1988, P NATL ACAD SCI USA, V85, P5874, DOI 10.1073/pnas.85.16.5874; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; SANDSTROM J, 1993, BIOCHEM J, V294, P853, DOI 10.1042/bj2940853; SANDSTROM J, 1992, J BIOL CHEM, V267, P18205; SANFEY H, 1984, ANN SURG, V200, P405, DOI 10.1097/00000658-198410000-00003; SCHOENBERG MH, 1990, CHEM-BIOL INTERACT, V76, P141, DOI 10.1016/0009-2797(90)90085-2; SIMONS JP, 1987, NATURE, V328, P530, DOI 10.1038/328530a0; SJOQUIST PO, 1991, J CARDIOVASC PHARM, V17, P678; SJOQUIST PO, 1992, J CARDIOVASC PHARM, V26, P347; STROMQVIST M, 1991, J CHROMATOGR, V548, P293, DOI 10.1016/S0021-9673(01)88611-8; STROMQVIST M, 1992, BIOTECHNIQUES, V13, P744; TIBELL L, 1987, P NATL ACAD SCI USA, V84, P6634, DOI 10.1073/pnas.84.19.6634; WAHLUND G, 1992, FREE RADICAL RES COM, V17, P41, DOI 10.3109/10715769209061087; WALL RJ, 1991, P NATL ACAD SCI USA, V88, P1696, DOI 10.1073/pnas.88.5.1696; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WILMUT I, 1991, EXPERIENTIA, V47, P905, DOI 10.1007/BF01929881	52	21	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5358	5363						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106520				2022-12-27	WOS:A1994MX57100098
J	KULIAWAT, R; ARVAN, P				KULIAWAT, R; ARVAN, P			INTRACELLULAR IODINATION OF THYROGLOBULIN IN FILTER-POLARIZED THYROCYTES LEADS TO THE SYNTHESIS AND BASOLATERAL SECRETION OF THYROID-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL PLASMA-MEMBRANE; EPITHELIAL-CELLS; FOLLICLE CELLS; THYROTROPIN REGULATION; CARBOHYDRATE UNITS; IODIDE TRANSPORT; PRIMARY CULTURE; GOLGI-COMPLEX; THYROXINE; PROTEIN	Thyroid follicles perform several functions that depend upon epithelial polarity: secretion of thyroglobulin (Tg) to the apical lumen, uptake of iodide for Tg iodination, and the manufacture of thyroid hormone for delivery to the bloodstream. In this report we examine Tg processing by thyroid epithelial monolayers cultured on porous filters. Basolateral I-125 uptake resulted in thyrotropin-dependent radiolabeling of Tg in cells and apical medium. Polarized thyrocytes iodinated exogenous gamma globulins (IgG), demonstrating labeling in the apical extracellular space. Apical catalase addition inhibited the appearance of apical, [I-125]IgG and [I-125]Tg, but had no effect on cell-associated [I-125]Tg, indicating additional iodination of Tg in an intracellular compartment. A similar conclusion was drawn from radioiodination experiments at 20 degrees C. Intracellular iodination was selective for Tg forms receiving prior Golgi carbohydrate modifications. During a 2-h chase, [I-125]Tg was exported from cells to apical medium, while modest amounts of thyroxine were secreted with a majority to the basolateral medium. Neither radioiodination at 20 degrees C nor apical catalase addition blocked formation or secretion of [I-125]thyroxine during the chase. Thus in filter-grown thyroid epithelial cells, prior to apical extracellular iodination, intracellular iodination of Tg begins the process leading to formation of thyroxine.	HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV ENDOCRINOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, CELL & DEV BIOL PROGRAM, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School				Kuliawat, Regina/0000-0001-8386-2279	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK107516, T32DK007516, R01DK040344, R29DK040344] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07516, DK40344] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLUCHONGERARD MJ, 1979, ARCH ANAT MICROSC MO, V68, P43; ARIMA T, 1972, J BIOL CHEM, V247, P1825; ARVAN P, 1991, J CELL BIOL, V112, P365, DOI 10.1083/jcb.112.3.365; BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BARRIERE H, 1986, CELL TISSUE RES, V245, P159; BJORKMAN U, 1988, ENDOCRINOLOGY, V122, P488; CHAMBARD M, 1990, J MOL ENDOCRINOL, V4, P193, DOI 10.1677/jme.0.0040193; CHAMBARD M, 1983, J CELL BIOL, V96, P1172, DOI 10.1083/jcb.96.4.1172; CROFT CJ, 1970, BIOCHEM J, V118, P311, DOI 10.1042/bj1180311; DAMANTE G, 1989, ENDOCRINOLOGY, V124, P2889, DOI 10.1210/endo-124-6-2889; DOCTER R, 1987, J CLIN ENDOCR METAB, V65, P624, DOI 10.1210/jcem-65-4-624; DUMONT JE, 1989, METABOLIC BASIS INHE, P1843; DUNN JT, 1981, J BIOL CHEM, V256, P942; DUNN JT, 1992, WERNER INGBARS THYRO, P98; EKHOLM R, 1981, MOL CELL ENDOCRINOL, V24, P141, DOI 10.1016/0303-7207(81)90056-3; ENGLER H, 1983, ENDOCRINOLOGY, V112, P86, DOI 10.1210/endo-112-1-86; ERICSON LE, 1979, J ULTRA MOL STRUCT R, V69, P297, DOI 10.1016/S0022-5320(79)90118-7; ERICSON LE, 1981, MOL CELL ENDOCRINOL, V22, P1, DOI 10.1016/0303-7207(81)90098-8; FRANCON J, 1989, J NEUROCHEM, V53, P1456, DOI 10.1111/j.1471-4159.1989.tb08538.x; GALTON VA, 1986, ENDOCRINOLOGY, V118, P1918, DOI 10.1210/endo-118-5-1918; GERARD C, 1985, EUR J CELL BIOL, V38, P134; GERARD CM, 1988, MOL CELL ENDOCRINOL, V60, P239, DOI 10.1016/0303-7207(88)90184-0; GONCALVES E, 1990, MOL CELL ENDOCRINOL, V69, P157, DOI 10.1016/0303-7207(90)90009-W; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GROLLMAN EF, 1992, J CLIN ENDOCR METAB, V74, P43, DOI 10.1210/jc.74.1.43; GRUFFAT D, 1991, J ENDOCRINOL, V128, P51, DOI 10.1677/joe.0.1280051; HERZOG V, 1987, EMBO J, V6, P555, DOI 10.1002/j.1460-2075.1987.tb04790.x; HERZOG V, 1992, J CELL BIOL, V118, P1071, DOI 10.1083/jcb.118.5.1071; HERZOG V, 1986, EUR J CELL BIOL, V39, P399; KASTELLAKIS A, 1989, MOL CELL ENDOCRINOL, V67, P231; KIM PS, 1991, J BIOL CHEM, V266, P12412; KIM PS, 1993, AM J PHYSIOL, V265, pC704, DOI 10.1152/ajpcell.1993.265.3.C704; KIM PS, 1993, J BIOL CHEM, V268, P4873; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KOHN LD, 1985, THYROGLOBULIN PROTHY, P171; LAKSHMANAN M, 1990, ENDOCRINOLOGY, V126, P3245, DOI 10.1210/endo-126-6-3245; LAURBERG P, 1986, ENDOCRINOLOGY, V118, P895, DOI 10.1210/endo-118-3-895; LEONARD JL, 1978, ENDOCRINOLOGY, V103, P2137, DOI 10.1210/endo-103-6-2137; MAGNUSSON RP, 1987, J BIOL CHEM, V262, P13885; MAGNUSSON RP, 1985, ENDOCRINOLOGY, V116, P1493, DOI 10.1210/endo-116-4-1493; MALTHIERY Y, 1989, BIOCHIMIE, V71, P195, DOI 10.1016/0300-9084(89)90057-6; MARSH M, 1983, CELL, V32, P931, DOI 10.1016/0092-8674(83)90078-8; MAUCHAMP J, 1979, CELL TISSUE RES, V204, P417, DOI 10.1007/BF00233653; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MONACO F, 1975, ENDOCRINOLOGY, V97, P347, DOI 10.1210/endo-97-2-347; NAKAMURA Y, 1990, J ENDOCRINOL, V126, P275, DOI 10.1677/joe.0.1260275; NEVE P, 1970, Z ZELLFORSCH MIK ANA, V103, P61, DOI 10.1007/BF00335401; NILSSON M, 1987, CELL TISSUE RES, V250, P295, DOI 10.1007/BF00219074; NILSSON M, 1992, ACTA ENDOCRINOL-COP, V126, P67, DOI 10.1530/acta.0.1260067; NILSSON M, 1990, EUR J CELL BIOL, V52, P270; OSTY J, 1990, J CLIN ENDOCR METAB, V71, P1589, DOI 10.1210/jcem-71-6-1589; PALUMBO G, 1990, J BIOL CHEM, V265, P8887; PENEL C, 1989, PFLUG ARCH EUR J PHY, V414, P509, DOI 10.1007/BF00580985; PRABAKARAN D, 1993, J BIOL CHEM, V268, P9041; RAO GS, 1983, J ENDOCRINOL, V97, P277, DOI 10.1677/joe.0.0970277; REMY L, 1986, BIOL CELL, V56, P97, DOI 10.1111/j.1768-322X.1986.tb00446.x; RING P, 1987, CELL TISSUE RES, V247, P505, DOI 10.1007/BF00215743; ROLLAND M, 1976, BIOCHIM BIOPHYS ACTA, V427, P696, DOI 10.1016/0005-2795(76)90213-0; ROUSSET B, 1991, MOL CELL ENDOCRINOL, V78, pC89, DOI 10.1016/0303-7207(91)90176-S; ROUSSET B, 1991, PROGRESS IN THYROID RESEARCH, P495; SCHNEIDER AB, 1988, ENDOCRINOLOGY, V122, P2428, DOI 10.1210/endo-122-6-2428; SHEPARD TH, 1968, GEN COMP ENDOCR, V10, P174, DOI 10.1016/0016-6480(68)90024-5; STRUM J M, 1970, Journal of Cell Biology, V44, P655, DOI 10.1083/jcb.44.3.655; VEGASALAS DE, 1987, J CELL BIOL, V104, P1249, DOI 10.1083/jcb.104.5.1249	64	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4922	4927						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106466				2022-12-27	WOS:A1994MX57100037
J	SADASIVAN, E; CEDENO, MM; ROTHENBERG, SP				SADASIVAN, E; CEDENO, MM; ROTHENBERG, SP			CHARACTERIZATION OF THE GENE ENCODING A FOLATE-BINDING PROTEIN EXPRESSED IN HUMAN PLACENTA - IDENTIFICATION OF PROMOTER ACTIVITY IN A G-RICH SP1 SITE LINKED WITH THE TANDEMLY REPEATED GGAAG MOTIF FOR THE ETS ENCODED GA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CULTURED KB-CELLS; GLYCOSYL-PHOSPHATIDYLINOSITOL; TRANSCRIPTION FACTORS; GENOMIC ORGANIZATION; DNA; MEMBRANE; MILK; CDNA; RECEPTORS	The gene encoding a folate-binding protein (FBP) expressed in human placenta has been cloned by screening a genomic library with the KB cell FBP complementary DNA. This gene, contained in a 10-kilobase EcoRI fragment of this genomic clone, has 5 exons, 4 introns, the AATAA polyadenylation signal in the 3'-untranslated region, and a 5'-flanking sequence which contains the promoter elements, all of which span approximately 5 kilobases. Transcription initiation was mapped by RNase protection to a site 73 base pairs downstream from a G-rich sequence linked to a tandemly repeated GGAAG sequence which is a motif that the ets oncogene encoded GA-binding protein (GABP) transcription factor binds, Gel shift and supershift mobility assays indicate that the G-rich sequence and the ets motif bind specifically to SP1 and GABP, respectively. These cis regulatory elements in tandem drive expression of the chloramphenicol acetyltransferase reporter gene in transiently transfected mouse 3T3 cells. The location of these elements upstream of transcription initiation in this gene, which lacks an appropriately located TATA box promoter, indicates that this SP1-GA binding region most probably regulates expression of this placental FBP. The gene encoding this placental FBP has been assigned the FBP/PL-1 gene because it is a member of a multigene family that includes a gene encoding a FBP expressed in both EE cells and placenta and its unprocessed pseudogene.	SUNY HLTH SCI CTR BROOKLYN,DEPT MED,DIV HEMATOL ONCOL,BROOKLYN,NY 11209; VET AFFAIRS MED CTR,BROOKLYN,NY 11209	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [T32AM007289] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA032369] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA32369] Funding Source: Medline; NIADDK NIH HHS [5T32-AM-07289] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONY AC, 1992, BLOOD, V79, P2807; ANTONY AC, 1982, J BIOL CHEM, V257, P81; ANTONY AC, 1989, J BIOL CHEM, V264, P1911; ANTONY AC, 1981, J BIOL CHEM, V256, P9684; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CARTER RS, 1992, J BIOL CHEM, V267, P23418; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; ELWOOD PC, 1986, J BIOL CHEM, V261, P5416; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LUHRS CA, 1989, J BIOL CHEM, V264, P21446; LUHRS CA, 1991, BLOOD, V77, P1171; LUHRS CA, 1986, ARCH BIOCHEM BIOPHYS, V250, P94, DOI 10.1016/0003-9861(86)90705-8; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PAGE ST, 1993, J MOL BIOL, V229, P1175, DOI 10.1006/jmbi.1993.1116; RAGOUSSIS J, 1992, GENOMICS, V14, P423, DOI 10.1016/S0888-7543(05)80236-8; RATNAM M, 1989, BIOCHEMISTRY-US, V28, P8249, DOI 10.1021/bi00446a042; ROTHENBERG SP, 1971, J CLIN INVEST, V50, P719, DOI 10.1172/JCI106542; ROTHENBERG SP, 1976, CLIN HAEMATOL, V5, P569; SABINA RL, 1990, J BIOL CHEM, V265, P9423; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; SADASIVAN E, 1992, BIOCHIM BIOPHYS ACTA, V1131, P91, DOI 10.1016/0167-4781(92)90103-7; SADASIVAN E, 1990, J BIOL CHEM, V265, P1821; SADASIVAN E, 1987, BIOCHIM BIOPHYS ACTA, V925, P36, DOI 10.1016/0304-4165(87)90145-0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SVENDSEN IB, 1982, CARLSBERG RES COMMUN, V47, P371, DOI 10.1007/BF02907775; SVENDSEN IB, 1984, CARLSBERG RES COMMUN, V49, P123, DOI 10.1007/BF02913971; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; UDENFRIEND S, 1991, CELL BIOL INT REP, V15, P739, DOI 10.1016/0309-1651(91)90030-M; VERMA RS, 1992, J BIOL CHEM, V267, P4119; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WASYLYK B, 1988, BIOCHIM BIOPHYS ACTA, V951, P17, DOI 10.1016/0167-4781(88)90021-8	39	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4725	4735						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106441				2022-12-27	WOS:A1994MX57100009
J	COLEMAN, CS; STANLEY, BA; VISWANATH, R; PEGG, AE				COLEMAN, CS; STANLEY, BA; VISWANATH, R; PEGG, AE			RAPID EXCHANGE OF SUBUNITS OF MAMMALIAN ORNITHINE DECARBOXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; RAT-LIVER; DEGRADATION; POLYAMINES; ANTIZYME; BINDING; RECOGNITION; MUTANTS; SALTS	The subunit structure of mouse L-ornithine decarboxylase (ODC) was investigated using mutants involving single amino acid changes that greatly reduced the catalytic activity. Studies were carried out both by expressing the enzyme protein in a coupled transcription/translation system and mixing the various purified mutant ODCs and wild type enzyme together. The results confirm that ODC activity requires the formation of a dimer and that this dimer contains two active sites, each made up from part of one subunit that contains amino acids lysine 69, lysine 169, and histidine 197 and a part of the other subunit that contains cysteine 360. Mixing of the purified ODC mutant enzymes with each other and with the wild type enzyme indicated that there was a very rapid exchange of subunits between the enzyme dimers even under physiological conditions without addition of chaotropic agents. This rapid exchange may facilitate the binding of antizyme and the rapid turnover of ODC in vivo.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT CELLULAR & MOLEC PHYSIOL,POB 850,HERSHEY,PA 17033; PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT PHARMACOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health				Stanley, Bruce/0000-0003-1338-2928	NATIONAL CANCER INSTITUTE [R01CA018138, R37CA018138] Funding Source: NIH RePORTER; NCI NIH HHS [CA-18138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERCOVICH Z, 1993, EUR J BIOCHEM, V213, P205, DOI 10.1111/j.1432-1033.1993.tb17749.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLEMAN CS, 1993, J BIOL CHEM, V268, P24572; DISTEFANO MD, 1990, BIOCHEMISTRY-US, V29, P2703, DOI 10.1021/bi00463a013; DUFFAUD GD, 1987, METHOD ENZYMOL, V153, P492; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P1; KITANI T, 1984, BIOCHIM BIOPHYS ACTA, V784, P164, DOI 10.1016/0167-4838(84)90123-7; LAU FTK, 1989, BIOCHEMISTRY-US, V28, P6841, DOI 10.1021/bi00443a010; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195, DOI 10.1016/0163-7258(92)90032-U; MITCHELL JLA, 1988, ARCH BIOCHEM BIOPHYS, V260, P585, DOI 10.1016/0003-9861(88)90485-7; MITCHELL JLA, 1990, BIOCHIM BIOPHYS ACTA, V1037, P115, DOI 10.1016/0167-4838(90)90109-S; MIYAZAKI Y, 1993, EUR J BIOCHEM, V214, P837, DOI 10.1111/j.1432-1033.1993.tb17987.x; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PERRY KM, 1992, PROTEIN SCI, V1, P796, DOI 10.1002/pro.5560010611; POULIN R, 1992, J BIOL CHEM, V267, P150; ROSENBERGHASSON Y, 1991, BIOCHEM J, V277, P683, DOI 10.1042/bj2770683; SOLANO F, 1985, FEBS LETT, V190, P324, DOI 10.1016/0014-5793(85)81311-9; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TOBIAS KE, 1993, BIOCHEMISTRY-US, V32, P5842, DOI 10.1021/bi00073a017; TSIRKA S, 1992, J BIOL CHEM, V267, P23057; TSIRKA SE, 1993, BIOCHEM J, V293, P289, DOI 10.1042/bj2930289; WENTE SR, 1987, P NATL ACAD SCI USA, V84, P31, DOI 10.1073/pnas.84.1.31	28	81	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3155	3158						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106349				2022-12-27	WOS:A1994MV63100009
J	JACOB, GA; KITZMILLER, JA; LUSE, DS				JACOB, GA; KITZMILLER, JA; LUSE, DS			RNA POLYMERASE-II PROMOTER STRENGTH IN-VITRO MAY BE REDUCED BY DEFECTS AT INITIATION OR PROMOTER CLEARANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; PREINITIATION COMPLEX; ELONGATION COMPLEXES; ABORTIVE INITIATION; TRANSCRIPTION; ELEMENTS; BINDING; TATA	We have measured the ability of three TATA box promoters, adenovirus 2 major late (Ad 2 ML), Ad 2 ML with a point mutation in the TATA box, and mouse P-globin, to support abortive and productive RNA synthesis in vitro. We have also measured the ability of these promoters to direct the assembly of preinitiation complexes using a nuclease protection assay. The relative strengths in productive transcription, determined from the synthesis of RNAs 10 nucleotides or longer, were 12:6:1 for Ad 2 ML, mouse beta-globin, and the TATA mutant of Ad 2 ML. However, the TATA mutant was reduced only 4-fold in its ability to assemble preinitiation complexes, compared to Ad 2 ML. Complexes formed on the Ad 2 ML TATA mutant may therefore also be reduced in their ability to initiate transcription. The mouse beta-globin promoter directed assembly and initiation as well as Ad 2 ML, but the beta-globin transcription complexes were less able to clear the promoter, resulting in an increase in aborted transcripts at the expense of productive RNA synthesis. We have thus shown that the transcriptional strength of eukaryotic promoters may be determined not only at the step of transcription complex assembly but also at the level of promoter clearance and possibly at transcription initiation as well.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University of Cincinnati				Jacob, George/0000-0003-4120-7334	NHLBI NIH HHS [HL 15996] Funding Source: Medline; NIGMS NIH HHS [GM 29487] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL015996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029487] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CAI H, 1987, MOL CELL BIOL, V7, P3371, DOI 10.1128/MCB.7.10.3371; CHOY HE, 1993, P NATL ACAD SCI USA, V90, P472, DOI 10.1073/pnas.90.2.472; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; JACOB GA, 1991, J BIOL CHEM, V266, P22537; KAMMERER W, 1986, EMBO J, V5, P2995, DOI 10.1002/j.1460-2075.1986.tb04597.x; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MENENDEZ M, 1987, EMBO J, V6, P4227, DOI 10.1002/j.1460-2075.1987.tb02771.x; NUEZ B, 1992, P NATL ACAD SCI USA, V89, P11401, DOI 10.1073/pnas.89.23.11401; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; REINBERG D, 1993, PROG NUCL ACID RES M, V44, P67; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859	20	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3655	3663						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106410				2022-12-27	WOS:A1994MV63100078
J	ACHYUTHAN, KE; SLAUGHTER, TF; SANTIAGO, MA; ENGHILD, JJ; GREENBERG, CS				ACHYUTHAN, KE; SLAUGHTER, TF; SANTIAGO, MA; ENGHILD, JJ; GREENBERG, CS			FACTOR-XIIIA-DERIVED PEPTIDES INHIBIT TRANSGLUTAMINASE ACTIVITY - LOCALIZATION OF SUBSTRATE RECOGNITION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-XIII; AMINO-ACID-SEQUENCE; PIG LIVER TRANSGLUTAMINASE; FIBRIN-STABILIZING FACTOR; CROSS-LINKING; TISSUE TRANSGLUTAMINASE; ALPHA-CHAIN; MOLECULAR RECOGNITION; GAMMA-CHAIN; BINDING	Factor XIIIa is a transglutaminase that catalyzes intermolecular gamma-glutamyl-epsilon-lysyl bonds between fibrin and other proteins involved in hemostasis. We synthesized 25 peptides from various regions of factor XIIIa and studied their effects on cross-linking fibrin, N,N'-dimethylcasein, or fibronectin. We found that two peptides, Asn72-Asp97 (peptide-4) and Asp190-Phe230 (peptide- 7), inhibited factor XIIIa cross-linking of these substrates. The other peptides did not inhibit factor XIIIa activity. The inhibition of cross-linking was reversed by excess substrate, indicating that the peptides were interacting with fibrin and not factor XIIIa. The peptides were not pseudosubstrates since they were not cross-linked to fibrin. The peptides did not modify the primary amine binding site as increasing the primary amine concentration did not reverse inhibition. Peptides-4 and -7 also had no effect on exposure of the active site of factor XIIIa and no synergistic inhibitory effects were detected. Peptides-4 and -7 had no effect on factor XIIIa binding to fibrin suggesting that the binding sites and the substrate recognition sites were distinct. Synthetic peptides containing shorter amino acid sequences of peptide-4 were inactive. In contrast, the amino-terminal (Asp190-Lys199, Tyr194-Tyr204) and the carboxyl-terminal (Lys211-Phe230) portions of peptide-7 were 20-60-fold less inhibitory compared to intact peptide-7. Peptides-4 and -7 also inhibited guinea pig liver tissue transglutaminase from cross-linking fibrinogen, N,N'-dimethylcasein, and fibronectin. In conclusion, we have identified two regions outside the active site pocket which are important for substrate recognition in factor XIIIa and tissue transglutaminase.	DUKE UNIV,MED CTR,DEPT MED,BOX 3031,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT ANESTHESIOL,DURHAM,NC 27710	Duke University; Duke University; Duke University				Enghild, Jan Johannes/0000-0001-9292-9172	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL028391, R01HL038245, P50HL026309] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-26309, HL-28391, HL-38245] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHYUTHAN KE, 1986, BIOCHIM BIOPHYS ACTA, V872, P261, DOI 10.1016/0167-4838(86)90279-7; ACHYUTHAN KE, 1988, J BIOL CHEM, V263, P14296; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; ALTIERI DC, 1991, SCIENCE, V254, P1200, DOI 10.1126/science.1957171; BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; BALE MD, 1986, BIOCHEMISTRY-US, V25, P5667, DOI 10.1021/bi00367a048; BINNIE CG, 1991, THROMB HAEMOSTASIS, V65, P165; BOCKENSTEDT P, 1986, J CLIN INVEST, V78, P551, DOI 10.1172/JCI112608; CHATTOPADHYAY A, 1989, J BIOL CHEM, V264, P11035; CHATTOPADHYAY A, 1992, J BIOL CHEM, V267, P12323; CHUNG SI, 1972, ANN NY ACAD SCI, V202, P240, DOI 10.1111/j.1749-6632.1972.tb16338.x; CONNELLAN JM, 1971, J BIOL CHEM, V246, P1093; COTTRELL BA, 1979, BIOCHEMISTRY-US, V18, P5405, DOI 10.1021/bi00591a023; COUSSONS PJ, 1992, BIOCHEM J, V282, P929, DOI 10.1042/bj2820929; FICKENSCHER K, 1991, THROMB HAEMOSTASIS, V65, P535; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FRANCIS RT, 1986, J BIOL CHEM, V261, P9787; FUKUE H, 1992, BLOOD, V79, P64; GENTILE V, 1991, J BIOL CHEM, V266, P478; GORMAN JJ, 1980, J BIOL CHEM, V255, P419; GORMAN JJ, 1973, J BIOL CHEM, V248, P1301; GREENBERG CS, 1985, BLOOD, V66, P1028; GREENBERG CS, 1987, BLOOD, V70, P702; GREENBERG CS, 1988, ARCH BIOCHEM BIOPHYS, V262, P142, DOI 10.1016/0003-9861(88)90176-2; GREENBERG CS, 1988, BIOCHEM J, V256, P1013, DOI 10.1042/bj2561013; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HOEPRICH PD, 1983, BIOCHEMISTRY-US, V22, P2049, DOI 10.1021/bi00278a003; HORNYAK TJ, 1992, BIOCHEMISTRY-US, V31, P423, DOI 10.1021/bi00117a017; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P4633, DOI 10.1021/bi00364a027; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; KORSGREN C, 1991, P NATL ACAD SCI USA, V88, P4840, DOI 10.1073/pnas.88.11.4840; LAI TS, 1991, BLOOD S1, V78, pA391; LEE KN, 1992, BIOCHIM BIOPHYS ACTA, V1136, P12, DOI 10.1016/0167-4889(92)90078-P; LORAND L, 1964, ARCH BIOCHEM BIOPHYS, V105, P58, DOI 10.1016/0003-9861(64)90235-8; Lorand L, 1980, Prog Hemost Thromb, V5, P245; MARTINEZ J, 1989, J BIOL CHEM, V264, P20502; MARY A, 1988, ARCH BIOCHEM BIOPHYS, V261, P112, DOI 10.1016/0003-9861(88)90110-5; McDonagh J, 1987, HEMOSTASIS THROMBOSI, P289; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; MESTERS RM, 1991, J BIOL CHEM, V266, P24514; MIRAGLIA CC, 1985, ANAL BIOCHEM, V144, P165, DOI 10.1016/0003-2697(85)90099-5; MOSHER DF, 1975, J BIOL CHEM, V250, P6614; MOSHER DF, 1979, J CLIN INVEST, V64, P781, DOI 10.1172/JCI109524; MUSZBEK L, 1985, CLIN CHEM, V31, P35; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PISANO JJ, 1968, SCIENCE, V160, P892, DOI 10.1126/science.160.3830.892; PURVES L, 1987, BIOCHEMISTRY-US, V26, P4640, DOI 10.1021/bi00389a008; ROSENBERG JB, 1993, THROMB HAEMOSTASIS, V69, P217; SAKATA Y, 1980, J CLIN INVEST, V65, P290, DOI 10.1172/JCI109671; SANE DC, 1988, BIOCHEM BIOPH RES CO, V157, P115, DOI 10.1016/S0006-291X(88)80020-2; Segel I. H., 1975, ENZYME KINETICS, P203; SHAINOFF JR, 1991, J BIOL CHEM, V266, P6429; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W	54	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21284	21292						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8104938				2022-12-27	WOS:A1993MA28800094
J	FLEURY, V; LIJNEN, HR; ANGLESCANO, E				FLEURY, V; LIJNEN, HR; ANGLESCANO, E			MECHANISM OF THE ENHANCED INTRINSIC ACTIVITY OF SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR DURING ONGOING FIBRINOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOSE SYNERGISTIC COMBINATIONS; ACUTE MYOCARDIAL-INFARCTION; SITE-SPECIFIC MUTAGENESIS; HUMAN-PLASMA; PRO-UROKINASE; MONOCLONAL-ANTIBODY; CLOT LYSIS; CORONARY THROMBOLYSIS; 2-CHAIN UROKINASE; SARCOMA-CELLS	The activation of plasminogen at the surface of fibrin by single-chain urokinase-type plasminogen activator (scu-PA) was investigated using recombinant forms of a plasmin-resistant mutant of scu-PA, rscu-PA-Glu158, and an inactive catalytic site mutant of human plasminogen, rPg-Ala741. Conversion of cleavable I-125-labeled single-chain proteins to their two-chain forms, was quantitated by radioisotope counting of protein bands on reduced SDS-polyacrylamide gels. The efficiency of the activation (moles of plasmin generated per mol of plasminogen activator) of native Glu-plasminogen bound to degraded fibrin was comparable for scu-PA and its two-chain form (tcu-PA) and approximately 4-fold lower for rscu-PA-Glu158. The corresponding values with rPg-Ala741 were 4-fold or 9-fold lower for scu-PA or rscu-PA-Glu158, as compared to tcu-PA. In contrast, in solution in the absence of fibrin, the efficiency of scu-PA for activation of rPg-Ala741 was 100-fold lower than that of tcu-PA. Initial activation rates of rPg-Ala741 (32.7 fmol/well containing 50 mul of solution) with 4 nm tcu-PA were comparable in solution and bound to degraded fibrin (v(o) = 1.01 and 1.16 fmol/min, respectively). In contrast, with 4 nm scu-PA the corresponding values when rPg-Ala741 was bound to degraded fibrin were 20-fold higher as compared to the soluble phase (v(o) = 0.23 and 0.012 fmol/min, respectively). Comparable results were obtained when using Glu- or Lys-forms of rPg-Ala741. Furthermore, in the presence of normal human plasma, activation of Glu-plasminogen bound to degraded fibrin was found to be about 2.5-fold more efficient with scu-PA than with tcu-PA. These findings indicate that the fibrin specificity of scu-PA does not require its conversion to tcu-PA, nor conversion of Glu- to Lys-plasminogen, but appears to be due to the additional binding of plasminogen to partially digested fibrin; scu-PA may thus represent a physiological functional form of u-PA in plasma.	HOP BICETRE,IPC,INSERM,U143,F-94275 LE KREMLIN BICETR,FRANCE; CATHOLIC UNIV LEUVEN,CTR MOLEC & VASC BIOL,B-3000 LOUVAIN,BELGIUM	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); KU Leuven			Lijnen, Roger/AAA-4085-2020; ANGLES-CANO, Eduardo/ABA-1739-2020; ANGLES-CANO, Eduardo/G-2311-2012	ANGLES-CANO, Eduardo/0000-0001-7891-3975; ANGLES-CANO, Eduardo/0000-0001-7891-3975				ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644; ANGLESCANO E, 1990, FIBRINOLYSIS, V4, P127, DOI 10.1016/0268-9499(90)90386-X; ANGLESCANO E, 1986, ANAL BIOCHEM, V153, P201, DOI 10.1016/0003-2697(86)90082-5; ANGLESCANO E, 1984, J IMMUNOL METHODS, V69, P115, DOI 10.1016/0022-1759(84)90283-7; ANGLESCANO E, 1992, BIOCHIM BIOPHYS ACTA, V1156, P34, DOI 10.1016/0304-4165(92)90092-9; BINNEMA DJ, 1986, THROMB RES, V43, P569, DOI 10.1016/0049-3848(86)90077-0; Blomback B., 1956, ARK KEMI, V10, P415; BUSBY SJ, 1991, J BIOL CHEM, V266, P15286; CHASE T, 1970, METHOD ENZYMOL, V19, P20; COLLEN D, 1987, AM J CARDIOL, V60, P431, DOI 10.1016/0002-9149(87)90280-3; COLLEN D, 1989, J VASC MED BIOL, V1, P46; DECLERCK PJ, 1990, BLOOD, V75, P1794; DECLERCK PJ, 1991, THROMB HAEMOSTASIS, V65, P394; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DEVEER AMTJ, 1991, BIOCHEMISTRY-US, V30, P10034, DOI 10.1021/bi00105a031; ELLIS V, 1987, J BIOL CHEM, V262, P14998; FLEURY V, 1991, BIOCHEMISTRY-US, V30, P7630, DOI 10.1021/bi00244a035; FLEURY V, 1993, FIBRINOLYSIS, V7, P87, DOI 10.1016/0268-9499(93)90028-T; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GUREWICH V, 1988, J CLIN INVEST, V82, P1956, DOI 10.1172/JCI113815; GUREWICH V, 1984, J CLIN INVEST, V73, P1731, DOI 10.1172/JCI111381; HUSAIN SS, 1983, ARCH BIOCHEM BIOPHYS, V220, P31, DOI 10.1016/0003-9861(83)90383-1; HUSAIN SS, 1991, BIOCHEMISTRY-US, V30, P5797, DOI 10.1021/bi00237a024; KAZAL LA, 1963, P SOC EXP BIOL MED, V113, P989; KIRSHENBAUM JM, 1991, AM J CARDIOL, V68, P1564, DOI 10.1016/0002-9149(91)90310-H; KOPPERT PW, 1986, BLOOD, V68, P437; KOPPERT PW, 1985, BLOOD, V66, P503; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LIJNEN HR, 1980, J BIOL CHEM, V255, P214; LIJNEN HR, 1989, BLOOD, V73, P1864; LIJNEN HR, 1986, J BIOL CHEM, V261, P1253; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MASSON C, 1988, BIOCHEM J, V256, P237, DOI 10.1042/bj2560237; NELLES L, 1987, J BIOL CHEM, V262, P5682; PANNELL R, 1986, BLOOD, V67, P1215; PANNELL R, 1987, BLOOD, V69, P22; PANNELL R, 1990, THROMB HAEMOSTASIS, V64, P556; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; PONTING CP, 1992, BIOCHIM BIOPHYS ACTA, V1159, P155, DOI 10.1016/0167-4838(92)90020-E; SCULLY MF, 1991, BRIT J HAEMATOL, V79, P537, DOI 10.1111/j.1365-2141.1991.tb08078.x; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; TISSOT JD, 1982, J CLIN INVEST, V70, P1320, DOI 10.1172/JCI110733; TRANQUI L, 1979, BIOL CELLULAIRE, V34, P39; VANDEWERF F, 1986, ANN INTERN MED, V104, P345, DOI 10.7326/0003-4819-104-3-345; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; WALLEN P, 1972, BIOCHIM BIOPHYS ACTA, V257, P122, DOI 10.1016/0005-2795(72)90261-9; WIMAN B, 1973, EUR J BIOCHEM, V36, P25, DOI 10.1111/j.1432-1033.1973.tb02880.x; WUN TC, 1982, J BIOL CHEM, V257, P3276; ZAMARRON C, 1984, THROMB HAEMOSTASIS, V52, P19; 1989, LANCET, P863	52	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18554	18559						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8103046				2022-12-27	WOS:A1993LV65900030
J	SHAH, MA; SCAMAN, CH; PALCIC, MM; KAGAN, HM				SHAH, MA; SCAMAN, CH; PALCIC, MM; KAGAN, HM			KINETICS AND STEREOSPECIFICITY OF THE LYSYL OXIDASE REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA AMINE OXIDASE; BROWN ADIPOSE-TISSUE; ACTIVE-SITE; ENZYME; RAT; MECHANISM; DOPAMINE; STATE; AORTA; ACIDS	The structural specificity of amine oxidation by lysyl oxidase was investigated using kinetic and NMR spectroscopic analyses. Substrate efficiency increased with increasing molecular distance from the alpha-carbon of the aromatic moiety substituted on the aliphatic chains of a series of primary amines. The p-hydroxyl substituent of p-hydroxybenzylamine significantly increased k(cat) over that of benzylamine, whereas this was not the case when tyramine and phenethylamine were compared. Direct spectrophotometric measurement of p-hydroxybenzaldehyde formation yielded burst kinetics, the second, slower phase of which was eliminated under anaerobic conditions. Thus, enzyme reoxidation is the more rate-limiting of the two half-reactions catalyzed with this substrate by this ping-pong enzyme. H-1 NMR spectroscopy of the alcohol reductively derived from the aldehyde product of the lysyl oxidase-catalyzed oxidation of deuterated tyramine indicated that the pro-S but not the pro-R alpha-deuteron was catalytically abstracted. Moreover, lysyl oxidase catalyzed solvent exchange of protons at the C-2 position. Such stereospecificity and proton exchange uniquely differentiates lysyl oxidase from all but an aortic semicarbazide-sensitive amine oxidase among the pro-S-specific copper-dependent amine oxidases analyzed thus far.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; UNIV ALBERTA,DEPT FOOD SCI,EDMONTON T6G 2PS,AB,CANADA	Boston University; University of Alberta					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018880] Funding Source: NIH RePORTER; NIAMS NIH HHS [R 37AR 18880] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMEYAMA M, 1984, AGR BIOL CHEM TOKYO, V48, P561, DOI 10.1080/00021369.1984.10866184; BARDSLEY WG, 1973, BIOCHEM J, V131, P459, DOI 10.1042/bj1310459; BARRAND MA, 1985, BIOCHEM J, V232, P415, DOI 10.1042/bj2320415; BARRAND MA, 1984, BIOCHEM J, V222, P467, DOI 10.1042/bj2220467; BATTERSBY AR, 1976, J CHEM SOC PERK T 1, P1052, DOI 10.1039/p19760001052; BERNHEIM RA, 1966, J CHEM PHYS, V45, P2261, DOI 10.1063/1.1727920; CALLINGHAM BA, 1991, BIOCHEM SOC T, V19, P228, DOI 10.1042/bst0190228; COLEMAN AA, 1989, J BIOL CHEM, V264, P19500; COLEMAN AA, 1991, J BIOL CHEM, V266, P6795; DOOLEY DM, 1991, NATURE, V349, P262, DOI 10.1038/349262a0; FARNUM M, 1986, BIOCHEMISTRY-US, V25, P1898, DOI 10.1021/bi00356a010; FARNUM MF, 1986, BIOCHEMISTRY-US, V25, P6028, DOI 10.1021/bi00368a029; FUJIHARA H, 1984, J ORG CHEM, V49, P2819, DOI 10.1021/jo00189a037; GACHERU SN, 1989, J BIOL CHEM, V263, P16704; JANES SM, 1991, BIOCHEMISTRY-US, V30, P4599, DOI 10.1021/bi00232a034; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; KAGAN HM, 1982, METHOD ENZYMOL, V82, P637; KAGAN HM, 1979, BIOCHEM J, V177, P203, DOI 10.1042/bj1770203; KLINMAN JP, 1992, FEBS LETT, V282, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBENSTEINVERBEEK CL, 1984, FEBS LETT, V170, P305, DOI 10.1016/0014-5793(84)81333-2; MENDENHALL W, 1975, INTRO PROBABILITY ST, P250; Mondovi B, 1985, STRUCTURE FUNCTIONS; NORTHROP DB, 1981, ANNU REV BIOCHEM, V50, P103, DOI 10.1146/annurev.bi.50.070181.000535; PARKER D, 1983, J CHEM SOC PERK T 2, P83, DOI 10.1039/p29830000083; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; RIUS FX, 1984, BIOCHEM J, V220, P767, DOI 10.1042/bj2200767; SCAMAN CH, 1992, BIOCHEMISTRY-US, V31, P6829, DOI 10.1021/bi00144a025; SHIEH JJ, 1975, BIOCHIM BIOPHYS ACTA, V377, P229, DOI 10.1016/0005-2744(75)90305-8; SULLIVAN KA, 1982, J BIOL CHEM, V257, P13520; SUVA RH, 1978, BIOCHEMISTRY-US, V17, P3538, DOI 10.1021/bi00610a018; TRACKMAN PC, 1981, ANAL BIOCHEM, V113, P336, DOI 10.1016/0003-2697(81)90086-5; TRACKMAN PC, 1991, BIOCHEMISTRY-US, V30, P8282, DOI 10.1021/bi00247a025; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; WILLIAMS MA, 1985, ANAL BIOCHEM, V149, P430, DOI 10.1016/0003-2697(85)90594-9; WILLIAMSON PR, 1986, BIOCHEM J, V235, P597, DOI 10.1042/bj2350597; WILLIAMSON PR, 1987, J BIOL CHEM, V262, P14520; WILLIAMSON PR, 1986, J BIOL CHEM, V261, P9477; WILLIAMSON PR, 1986, J BIOL CHEM, V262, P8196; YU PH, 1988, BIOCHEM CELL BIOL, V66, P853, DOI 10.1139/o88-097	41	34	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11573	11579						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8099354				2022-12-27	WOS:A1993LF28400021
J	FENG, P; LIAU, G				FENG, P; LIAU, G			IDENTIFICATION OF A NOVEL SERUM AND GROWTH FACTOR-INDUCIBLE GENE IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTERIAL INJURY; MESSENGER-RNA; PARATHYROID-HORMONE; PROLIFERATION; EXPRESSION; INDUCTION; CYCLE; PDGF; ATHEROSCLEROSIS; TRANSLATION	We have used subtraction cloning to isolate a cDNA (PS4) that identified a serum-inducible mRNA of 1.9 kilobases in rabbit vascular smooth muscle cells. DNA sequence analysis revealed one major open reading frame encoding a 9,442 M(r) protein. Comparison of the DNA as well as the putative protein sequence with various data bases revealed no homology with other sequences. In vitro translation of synthesized PS4 mRNA generated a major polypeptide of 12 kDa. Serum stimulation of quiescent smooth muscle cells in culture induced a rapid increase in the level of PS4 mRNA. Expression of this message was detected by 1 h, peaked at approximately 4 h, and became undetectable by 12 h. The induction of PS4 by serum was completely blocked by cycloheximide, indicating its expression required prior protein synthesis. Epidermal growth factor, acidic fibroblast growth factor, and transforming growth factor-beta1 also induced a strong increase in PS4 expression. By contrast, platelet-derived growth factor-BB was only able to mildly stimulate the level of PS4 mRNA and insulin-like growth factor-I was unable to enhance PS4 expression. There was a high level of PS4 mRNA in rabbit fetal muscle, esophagus, kidney, and lung, a low level in fetal aorta and heart, and an undetectable level in fetal liver, brain, as well as, in the placenta. The expression of PS4 in the corresponding adult tissues was low or undetectable. Our analysis indicate that PS4 expression is developmentally regulated and tightly controlled by growth factors, suggesting this novel gene has a role in cell growth and differentiation.	AMER RED CROSS,HOLLAND LAB,DEPT MOLEC BIOL,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855	American Red Cross					NHLBI NIH HHS [HL37510] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037510] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BRAVO R, 1988, COLD SPRING HARB SYM, V53, P901, DOI 10.1101/SQB.1988.053.01.103; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; CLOWES AW, 1983, LAB INVEST, V49, P327; DEFEUDIS FV, 1991, LIFE SCI, V49, P689, DOI 10.1016/0024-3205(91)90101-G; DENHARDT DT, 1986, BIOCHIM BIOPHYS ACTA, V865, P83, DOI 10.1016/0304-419X(86)90024-7; FARNHAM PJ, 1985, J BIOL CHEM, V260, P7675; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GADEAU AP, 1991, J CELL PHYSIOL, V146, P356, DOI 10.1002/jcp.1041460304; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HONGO T, 1991, J CLIN INVEST, V88, P1841, DOI 10.1172/JCI115505; HWANG DL, 1992, EXP CELL RES, V200, P358, DOI 10.1016/0014-4827(92)90183-9; JANAT MF, 1992, J CELL PHYSIOL, V150, P232, DOI 10.1002/jcp.1041500203; JANAT MF, 1992, J CELL PHYSIOL, V151, P588, DOI 10.1002/jcp.1041510319; KINDY MS, 1986, J BIOL CHEM, V261, P2865; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; LIAU G, 1989, J BIOL CHEM, V264, P10315; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MOK LLS, 1989, ENDOCR REV, V10, P420, DOI 10.1210/edrv-10-4-420; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; NISHIDA K, 1990, ATHEROSCLEROSIS, V83, P119, DOI 10.1016/0021-9150(90)90157-E; RAUGI GJ, 1990, AM J PATHOL, V137, P179; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; THYBERG J, 1987, EXP CELL RES, V170, P160, DOI 10.1016/0014-4827(87)90125-X	34	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9387	9392						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8098034				2022-12-27	WOS:A1993LA68900038
J	WIECH, H; BUCHNER, J; ZIMMERMANN, M; ZIMMERMANN, R; JAKOB, U				WIECH, H; BUCHNER, J; ZIMMERMANN, M; ZIMMERMANN, R; JAKOB, U			HSC70, IMMUNOGLOBULIN HEAVY-CHAIN BINDING-PROTEIN, AND HSP90 DIFFER IN THEIR ABILITY TO STIMULATE TRANSPORT OF PRECURSOR PROTEINS INTO MAMMALIAN MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK COGNATE PROTEIN; M13 PROCOAT PROTEIN; GLUCOSE-REGULATED PROTEINS; ESCHERICHIA-COLI; PEPTIDE-BINDING; ENDOPLASMIC-RETICULUM; SENSITIVE METHOD; STRESS PROTEINS; ATPASE FRAGMENT; MEMBRANE	Ribonucleoparticle-independent transport of precursor proteins into mammalian microsomes is stimulated by 70-kDa heat shock proteins (Hsc70) and an additional cytosolic protein. Here we addressed the question of whether other molecular chaperones can replace Hsc70 in facilitating protein transport into the endoplasmic reticulum. Specifically, we asked if members of the same family of stress proteins, i.e. the microsomal protein immunoglobulin heavy chain binding protein or the bacterial protein DnaK, can substitute for Hsc70. Furthermore, we investigated whether molecular chaperones with a proven role in protein folding and belonging to the other two major families of stress proteins, i.e. Hsp60 or Hsp90, can substitute for Hsc70. We show that none of these stress proteins was able to substitute for Hsc70 in facilitating protein transport into mammalian microsomes. GroEL (the bacterial member of the Hsp60 family) and Hsp90, however, competed with Hsc70 for binding of the non-native precursor protein. Therefore, we conclude that there are both substrate and functional specificity in the action of molecular chaperones.	UNIV GOTTINGEN,ZENTRUM BIOCHEM,BIOCHEM ABT 2,GOSSLERSTR 12D,W-3400 GOTTINGEN,GERMANY; UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,W-8400 REGENSBURG,GERMANY	University of Gottingen; University of Regensburg			Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				ANG D, 1991, J BIOL CHEM, V266, P24233; AUSTEN BM, 1984, BIOCHEM J, V224, P317, DOI 10.1042/bj2240317; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BLUMBERG H, 1991, NATURE, V349, P627, DOI 10.1038/349627a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GAO BC, 1991, J BIOL CHEM, V266, P19565; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOODMAN JM, 1981, CELL, V24, P437, DOI 10.1016/0092-8674(81)90334-2; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KLAPPA P, 1991, EMBO J, V10, P2795, DOI 10.1002/j.1460-2075.1991.tb07828.x; KORNBERG A, 1973, NATURE, V7, P680; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MULLER G, 1988, EMBO J, V7, P639, DOI 10.1002/j.1460-2075.1988.tb02858.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Payot P, 1976, EUR J BIOCHEM, V63, P263; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHLENSTEDT G, 1990, J BIOL CHEM, V265, P13960; SCHLENSTEDT G, 1987, EMBO J, V6, P699, DOI 10.1002/j.1460-2075.1987.tb04810.x; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; WATTS C, 1983, P NATL ACAD SCI-BIOL, V80, P2809, DOI 10.1073/pnas.80.10.2809; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WIECH H, 1987, EMBO J, V6, P1011, DOI 10.1002/j.1460-2075.1987.tb04853.x; Wiech H, 1990, Semin Cell Biol, V1, P55; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WIECH H, 1991, FEBS LETT, V285, P182, DOI 10.1016/0014-5793(91)80800-I; ZIMMERMANN R, 1988, EMBO J, V7, P2875, DOI 10.1002/j.1460-2075.1988.tb03144.x	57	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7414	7421						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8096509				2022-12-27	WOS:A1993KV14100084
J	CAIRO, G; PIETRANGELO, A				CAIRO, G; PIETRANGELO, A			TRANSFERRIN RECEPTOR GENE-EXPRESSION DURING RAT-LIVER REGENERATION - EVIDENCE FOR POSTTRANSCRIPTIONAL REGULATION BY IRON REGULATORY FACTOR(B), A 2ND IRON-RESPONSIVE ELEMENT-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; MESSENGER-RNA; CELL-GROWTH; DIFFERENTIAL REGULATION; HEAVY-SUBUNIT; LIGHT-SUBUNIT; FERRITIN; SEQUENCE; PROMOTER; INVITRO	Transferrin receptor (TfR) expression is regulated by iron at the level of mRNA stability through a factor (IRF/ IRE-BP) which binds to specific iron-responsive elements (IRE). On the other hand, growth-dependent regulation of TfR expression is generally believed to be transcriptionally controlled. We analyzed the molecular mechanisms that control TfR gene expression at the onset of cell proliferation in vivo during liver regeneration after partial hepatectomy. The amount of TfR mRNA increased considerably after partial hepatectomy while run-on assays did not show significant changes in TfR gene transcription. RNA band-shift assays documented a significant activation of IRF/IRE-BP specific for the faster migrating IRE-protein complex (IRF(B)). These changes occurred in the absence of modifications of total liver iron concentration but together with a significant decrease of ferritin content. Moreover, when extreme variations of liver iron content were achieved by either chronic iron overload or severe iron deficiency, liver regeneration was unable to influence IRE-binding activity. We conclude that IRF/IRE-BP-mediated post-transcriptional control can fully account for TfR mRNA induction during liver cell proliferation in vivo. IRF/ IRE-RE activation in the absence of changes in total tissue iron content might depend either on a drop of iron levels into the regulatory pool or on a relatively iron-independent mechanism specific for the faster migrating complex.	UNIV MODENA,MED GEN & TERAPIA MED CLIN 3,MODENA,ITALY	Universita di Modena e Reggio Emilia	CAIRO, G (corresponding author), UNIV MILAN,IST PATOL GEN,CNR,CTR PATOL CELLULARE,VIA MANGIAGALLI 31,I-20133 MILAN,ITALY.		Pietrangelo, Antonello/K-1517-2016; Cairo, Gaetano/M-5104-2016	Pietrangelo, Antonello/0000-0002-7411-935X; Cairo, Gaetano/0000-0002-8147-4720				BEARD P, 1991, NUCLEIC ACIDS RES, V19, P7117, DOI 10.1093/nar/19.25.7117; BRIDGES KR, 1987, J BIOL CHEM, V262, P14773; CAIRO G, 1993, EXP CELL RES, V206, P255, DOI 10.1006/excr.1993.1145; CAIRO G, 1989, BIOCHEM J, V264, P925, DOI 10.1042/bj2640925; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CHAN LNL, 1992, J BIOL CHEM, V267, P8254; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; FRIEDMAN JM, 1984, J MOL BIOL, V179, P37, DOI 10.1016/0022-2836(84)90305-X; GUO B, 1993, FASEB J, V7, pA1084; HARFORD JB, 1991, INTRACELLULAR TRAFFI, P302; HENDERSON BC, 1993, IN PRESS J BIOL CHEM, V268; HIGGINS GM, 1931, ARCH PATHOL, V12, P281; HIROSEKUMAGAI A, 1989, BIOCHEM BIOPH RES CO, V164, P1105, DOI 10.1016/0006-291X(89)91783-X; HIROSEKUMAGAI A, 1984, INT J BIOCHEM, V16, P601; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Kuhn L., 1990, IRON TRANSPORT STORA, P149; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; KUHN LC, 1991, BRIT J HAEMATOL, V79, P1, DOI 10.1111/j.1365-2141.1991.tb07998.x; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1984, J BIOL CHEM, V259, P4327; LESLEY JF, 1985, MOL CELL BIOL, V5, P1814, DOI 10.1128/MCB.5.8.1814; MAKINO R, 1984, NATURE, V310, P687; MAKINO Y, 1983, STRUCTURE FUNCTION I, P367; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MISKIMINS WK, 1986, J CELL BIOL, V103, P1781, DOI 10.1083/jcb.103.5.1781; MISKIMINS WK, 1990, IRON TRANSPORT STORA, P119; MORELLO D, 1990, ONCOGENE, V5, P1511; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1992, EUR J BIOCHEM, V208, P597, DOI 10.1111/j.1432-1033.1992.tb17224.x; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NECKERS LM, 1991, PATHOBIOLOGY, V59, P11, DOI 10.1159/000163610; PIETRANGELO A, 1992, GASTROENTEROLOGY, V102, P802, DOI 10.1016/0016-5085(92)90161-Q; ROBERTS MR, 1989, CELL REGUL, V1, P151, DOI 10.1091/mbc.1.1.151; SARGENT TD, 1981, P NATL ACAD SCI-BIOL, V78, P243, DOI 10.1073/pnas.78.1.243; SCHIAFFONATI L, 1990, J CELL PHYSIOL, V143, P79, DOI 10.1002/jcp.1041430110; SEISER C, 1993, J BIOL CHEM, V268, P13074; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STEARNE PA, 1985, J IMMUNOL, V134, P3474; TEIXEIRA S, 1991, EUR J BIOCHEM, V202, P819, DOI 10.1111/j.1432-1033.1991.tb16438.x; TESTA U, 1991, J BIOL CHEM, V266, P13925; THEIL EC, 1990, J BIOL CHEM, V265, P4771; TROWBRIDGE IS, 1982, P NATL ACAD SCI-BIOL, V79, P1175, DOI 10.1073/pnas.79.4.1175; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485	45	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6405	6409						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119990				2022-12-27	WOS:A1994MZ50300025
J	DUCHE, D; PARKER, MW; GONZALEZMANAS, JM; PATTUS, F; BATY, D				DUCHE, D; PARKER, MW; GONZALEZMANAS, JM; PATTUS, F; BATY, D			UNCOUPLED STEPS OF THE COLICIN-A PORE FORMATION DEMONSTRATED BY DISULFIDE BOND ENGINEERING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLTAGE-DEPENDENT CHANNEL; SITE-DIRECTED MUTAGENESIS; PLANAR LIPID BILAYERS; MEMBRANE-INSERTION; FORMING DOMAIN; ESCHERICHIA-COLI; PROTEIN STABILITY; SENSORY RECEPTOR; ION SELECTIVITY; CROSS-LINKING	Four disulfide bonds were engineered into the pore-forming domain of colicin A to probe the conformational changes associated with its membrane insertion and channel formation. The soluble pore-forming domain consists of 10 alpha-helices with two outer layers (helices 1, 2, and 3-7, respectively) sandwiching a middle layer of three helices (8-10). Helices 8 and 9 form a hairpin which is completely buried and consists of hydrophobic and neutral residues only. This helical hairpin has been hypothesized to be the membrane anchor. Each double-cysteine mutant possessing an individual disulfide bond, cross-linking either helices 1 to 9 (H1/H9), 5 to 6 (H5/H6), 7 to 8 (H7/H8), or 9 to 10 (H9/H10), respectively, is unable to promote K+ efflux from sensitive Escherichia coli cells. Activity can be restored by addition of a reducing agent. In vitro studies with brominated lipid vesicles and planar lipid bilayers show that the disulfide bond which connects the helices 1 to 9 prevents colicin A membrane insertion, whereas the other disulfide bond mutants insert readily into lipid vesicles. All of the engineered bridges prevented the formation of a conducting channel in the presence of a membrane potential. This novel approach indicates that membrane insertion and channel formation are two separate steps. Moreover, the effects of the distance constraints introduced by the different disulfide bonds on colicin A activity indicate that the helical pair 1 and 2 moves away from the other helices upon membrane insertion, Helices 3-10 remain associated together. As a consequence, the results imply that the helical hairpin lies parallel to the membrane surface. In contrast, induction of the colicin channel by the membrane potential requires a profound reorganization of the helices association. These results are discussed in light of several proposed models of the membrane-bound colicin and channel structures.	CTR BIOCHEM & BIOL MOLEC,INGN & DYNAM SYST MEMBRANAIRES LAB,F-13402 MARSEILLE 20,FRANCE; ST VINCENTS INST MED RES,FITZROY,VIC 3065,AUSTRALIA; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	St. Vincent's Institute of Medical Research; European Molecular Biology Laboratory (EMBL)			Parker, Michael W/F-9069-2013	Parker, Michael W/0000-0002-3101-1138; GONZALEZ MANAS, JUAN MANUEL/0000-0002-1833-6982; Duche, Denis/0000-0002-4208-6661; Baty, Daniel/0000-0001-8443-4444	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAMS CK, 1991, J GEN PHYSIOL, V98, P77, DOI 10.1085/jgp.98.1.77; BATY D, 1987, P NATL ACAD SCI USA, V84, P1152, DOI 10.1073/pnas.84.5.1152; BOLEN EJ, 1990, BIOCHEMISTRY-US, V29, P9638, DOI 10.1021/bi00493a019; BOURDINEAUD JP, 1990, P NATL ACAD SCI USA, V87, P1037, DOI 10.1073/pnas.87.3.1037; BULLOCK JO, 1992, J MEMBRANE BIOL, V128, P1; COLLARINI M, 1987, EUR BIOPHYS J BIOPHY, V14, P147, DOI 10.1007/BF00253839; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; GELI V, 1992, BIOCHEMISTRY-US, V31, P11089, DOI 10.1021/bi00160a019; GONZALEZMANAS JM, 1993, EUR J BIOCHEM, V211, P625, DOI 10.1111/j.1432-1033.1993.tb17590.x; GONZALEZMANAS JM, 1992, BIOCHEMISTRY-US, V31, P7294, DOI 10.1021/bi00147a013; HAZES B, 1988, PROTEIN ENG, V2, P119, DOI 10.1093/protein/2.2.119; JACOBSON BL, 1991, J BIOL CHEM, V266, P5220; JAKES KS, 1990, J BIOL CHEM, V265, P6984; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; LAKEY JH, 1993, J MOL BIOL, V230, P1055, DOI 10.1006/jmbi.1993.1218; LAKEY JH, 1991, J MOL BIOL, V218, P639, DOI 10.1016/0022-2836(91)90707-D; LAKEY JH, 1992, FEBS LETT, V307, P26, DOI 10.1016/0014-5793(92)80895-N; LAKEY JH, 1991, EUR J BIOCHEM, V196, P599, DOI 10.1111/j.1432-1033.1991.tb15855.x; LLOUBES R, 1986, NUCLEIC ACIDS RES, V14, P2621, DOI 10.1093/nar/14.6.2621; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MARTINEZ MC, 1983, EMBO J, V2, P1501, DOI 10.1002/j.1460-2075.1983.tb01614.x; MASSOTTE D, 1991, COLICINE A INSERTION; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P8529, DOI 10.1021/bi00489a004; Messing J, 1979, RECOMBINANT DNA TECH, V2, P43; MITCHINSON C, 1989, BIOCHEMISTRY-US, V28, P4807, DOI 10.1021/bi00437a043; NISHIKAWA S, 1990, PROTEIN ENG, V3, P443, DOI 10.1093/protein/3.5.443; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PARKER MW, 1990, TRENDS BIOCHEM SCI, V15, P126, DOI 10.1016/0968-0004(90)90205-P; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PARKER MW, 1992, J MOL BIOL, V224, P639, DOI 10.1016/0022-2836(92)90550-4; Pattus F., 1983, PHYSICAL CHEM TRANSM, P407; PERRY LJ, 1984, SCIENCE, V226, P555, DOI 10.1126/science.6387910; RAYMOND L, 1986, J MEMBRANE BIOL, V92, P255, DOI 10.1007/BF01869394; SCHEIN SJ, 1978, NATURE, V276, P159, DOI 10.1038/276159a0; SCHINDLER H, 1976, BIOPHYS J, V16, P1109, DOI 10.1016/S0006-3495(76)85759-1; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; SLATIN SL, 1986, J MEMBRANE BIOL, V92, P247, DOI 10.1007/BF01869393; SONG HY, 1991, J BACTERIOL, V173, P2927, DOI 10.1128/JB.173.9.2927-2934.1991; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; VILLAFRANCA JE, 1983, SCIENCE, V222, P782, DOI 10.1126/science.6356360; WETZEL R, 1988, P NATL ACAD SCI USA, V85, P401, DOI 10.1073/pnas.85.2.401; WILMSEN HU, 1990, EUR BIOPHYS J, V18, P149, DOI 10.1007/BF02427374; ZHANG YL, 1992, PROTEIN SCI, V1, P1666, DOI 10.1002/pro.5560011215	47	67	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6332	6339						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119982				2022-12-27	WOS:A1994MZ50300015
J	HARE, JF; HOLOCHER, A				HARE, JF; HOLOCHER, A			SOLUBILITY IN NONIONIC DETERGENTS DISTINGUISHES BETWEEN SLOWLY AND RAPIDLY DEGRADED PLASMA-MEMBRANE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE PHOTOBLEACHING RECOVERY; LATERAL MOBILITY; ANCHORED PROTEINS; CELL-SURFACE; SKELETON; DEGRADATION; ENDOCYTOSIS; RECEPTOR; CYTOSKELETON; MECHANISMS	Four cell surface-exposed, integral membrane proteins from H4-II-E-3 hepatoma monolayer cultures, derivatized by the membrane-impermeant reagent sulfosuccinimidyl 2-(biotin-amido)ethyl-1,3-dithioproprionate, were resistant to extraction with Triton X-100 at 0 degrees C. Thirty-three other similarly derivatized proteins were solubilized under these same conditions. Antisera were prepared that reacted only with Triton X-100-insoluble proteins. All four Triton X-100-insoluble proteins precipitated with the antibody were slowly degraded (t(1/2) > 100 h). By contrast, all but four Triton X-100-soluble proteins were rapidly degraded (t(1/2) = 24 h). The detergent-insoluble proteins did not possess glycosylphosphatidylinositol anchors nor were they solubilized by Triton X-100 after disruption of the cytoskeleton. In addition, they were insoluble in Triton X-100 in isolated membrane preparations but soluble when isolated on streptavidin-agarose and removed from other membrane proteins. We conclude that protein-protein interactions within the membrane itself result in insolubility in non-ionic detergents for a small cohort of plasma membrane proteins and that this may be directly related to the increased metabolic stability for this class of proteins.			HARE, JF (corresponding author), OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201, USA.							ALEXANDER RR, 1985, BASIC BIOCH METHODS, P117; APGAR JR, 1985, J CELL BIOL, V100, P1369, DOI 10.1083/jcb.100.5.1369; ASH JF, 1977, P NATL ACAD SCI USA, V74, P5584, DOI 10.1073/pnas.74.12.5584; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Cabral F, 1979, Methods Enzymol, V56, P602; CHANG CH, 1981, J BIOCHEM-TOKYO, V90, P997, DOI 10.1093/oxfordjournals.jbchem.a133586; DELBECCO R, 1954, J EXP MED, V99, P167; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DOERING TL, 1990, J BIOL CHEM, V265; FABER JL, 1981, ARCH BIOCHEM BIOPHYS, V211, P312; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; GOLAN DE, 1980, P NATL ACAD SCI-BIOL, V77, P2537, DOI 10.1073/pnas.77.5.2537; GONCALVES E, 1993, P NATL ACAD SCI USA, V90, P5762, DOI 10.1073/pnas.90.12.5762; HARE JF, 1985, EXP CELL RES, V161, P331, DOI 10.1016/0014-4827(85)90090-4; HARE JF, 1991, P NATL ACAD SCI USA, V88, P5902, DOI 10.1073/pnas.88.13.5902; HARE JF, 1990, BIOCHIM BIOPHYS ACTA, V1031, P71, DOI 10.1016/0304-4157(90)90003-U; JEMMERSON R, 1987, BIOCHEMISTRY-US, V26, P5703, DOI 10.1021/bi00392a019; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MAIZEL JV, 1969, FUNDAMENTAL TECHNIQU, P334; MAO SY, 1992, P NATL ACAD SCI USA, V89, P222, DOI 10.1073/pnas.89.1.222; MEIRI KF, 1990, J NEUROSCI, V10, P256; MIETTINEN HM, 1992, J CELL BIOL, V116, P875, DOI 10.1083/jcb.116.4.875; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; PETELL JK, 1987, LYSOSOMES THEIR ROLE, P519; RENFREW CA, 1991, J BIOL CHEM, V266, P21265; SHEETZ MP, 1980, NATURE, V285, P510, DOI 10.1038/285510a0; SNIDER MD, 1986, J CELL BIOL, V103, P265, DOI 10.1083/jcb.103.1.265; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATTS C, 1992, J CELL SCI, V103, P1; WIEGANT FAC, 1988, J CELL BIOL, V103, P387; WIKSTROM L, 1993, J BIOL CHEM, V268, P14412; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308; ZAMBETTI G, 1990, EXP CELL RES, V191, P246, DOI 10.1016/0014-4827(90)90011-X	38	8	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5981	5988						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119944				2022-12-27	WOS:A1994MY84000078
J	KOBAYASHI, T; TAO, T; GERGELY, J; COLLINS, JH				KOBAYASHI, T; TAO, T; GERGELY, J; COLLINS, JH			STRUCTURE OF THE TROPONIN COMPLEX - IMPLICATIONS OF PHOTOCROSS-LINKING OF TROPONIN-I TO TROPONIN-C THIOL MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; NUCLEAR-MAGNETIC-RESONANCE; CALCIUM-BINDING SITES; X-RAY-SCATTERING; INHIBITORY REGION; PROTEOLYTIC FRAGMENTS; REGULATORY DOMAIN; PEPTIDE COMPLEX; CROSS-LINKING; CALMODULIN	Ca2+ regulation of vertebrate-striated muscle contraction is initiated by conformational changes in the Ca2+-binding protein troponin C (TnC) and subsequent changes in the interaction of TnC with the inhibitory protein TnI. We have constructed mutants of rabbit skeletal muscle TnC in which natural Cys-98 was replaced by Leu, and a single Cys residue was introduced at position 12 (TnC12) or 89 (TnC89). Cys residues of mutant TnCs were derivatized with 4-maleimidobenzophenone and photocross-linked to TnI in binary TnC.TnI complexes. After digestion with CNBr or proteases, crosslinked peptides were purified and sequenced. TnC12 cross-linked at or near TnI Met-134 in a region known to be sensitive not only to occupancy of the regulatory Ca2+-binding sites of TnC but also to the contractile state of the thin filament. TnC89 cross-linked to TnI(108-113) in the inhibitory region. Taken together with earlier findings, these results indicate that in the Tnc TnI complex, both domains of TnC, as well as the linker region between them, make contact with the inhibitory region of TnI. Our data also indicate that the N- and C-terminal domains of TnC interact with opposite ends of the TnI inhibitory region.	UNIV MARYLAND, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21201 USA; UNIV MARYLAND, CTR MED BIOTECHNOL, INST BIOTECHNOL, BALTIMORE, MD 21201 USA; BOSTON BIOMED RES INST, DEPT MUSCLE RES, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, NEUROL SERV, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Boston Biomedical Research Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL005949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR021673, R37AR021673] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37-HL05949] Funding Source: Medline; NIAMS NIH HHS [AR-21673] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BLECHNER SL, 1992, BIOCHEMISTRY-US, V31, P11326, DOI 10.1021/bi00161a010; CACHIA PJ, 1983, BIOCHEMISTRY-US, V22, P4145, DOI 10.1021/bi00286a024; CAMPBELL AP, 1991, J MOL BIOL, V222, P405, DOI 10.1016/0022-2836(91)90219-V; CHEN Q, 1988, FEBS LETT, V228, P22, DOI 10.1016/0014-5793(88)80576-3; CHEUNG HC, 1989, BIOPHYS J, V55; CHONG PCS, 1982, J BIOL CHEM, V257, P2549; COLLINS JH, 1977, J BIOL CHEM, V252, P6356; COLLINS JH, 1973, FEBS LETT, V36, P268, DOI 10.1016/0014-5793(73)80388-6; DALGARNO DC, 1982, FEBS LETT, V150, P54, DOI 10.1016/0014-5793(82)81303-3; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; FUJISAWA T, 1987, J APPL CRYSTALLOGR, V20, P349, DOI 10.1107/S0021889887086497; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GREASER ML, 1973, J BIOL CHEM, V248, P2125; GREENE LE, 1986, J BIOL CHEM, V261, P1279; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; KATAYAMA E, 1982, J BIOCHEM-TOKYO, V91, P1449, DOI 10.1093/oxfordjournals.jbchem.a133835; KOBAYASHI T, 1991, J BIOL CHEM, V266, P13746; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7042, DOI 10.1021/bi00396a028; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; NOZAKI S, 1980, CHEM LETT, P345, DOI 10.1246/cl.1980.345; OGAWA Y, 1985, J BIOCHEM-TOKYO, V97, P1011, DOI 10.1093/oxfordjournals.jbchem.a135143; OHTUSKI I, 1986, ADV PROTEIN CHEM, V38, P1; POTTER JD, 1975, J BIOL CHEM, V250, P4628; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; SIN IL, 1978, BIOCHEM BIOPH RES CO, V82, P1132, DOI 10.1016/0006-291X(78)90304-2; SLUPSKY CM, 1992, PROTEIN SCI, V1, P1595, DOI 10.1002/pro.5560011207; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; SWENSON CA, 1992, BIOCHEMISTRY-US, V31, P3420, DOI 10.1021/bi00128a017	39	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5725	5729						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119911				2022-12-27	WOS:A1994MY84000040
J	NAKAMURA, S; SAKURAI, T; NONOMURA, Y				NAKAMURA, S; SAKURAI, T; NONOMURA, Y			DIFFERENTIAL EXPRESSION OF BOVINE ADSEVERIN IN ADRENAL-GLAND REVEALED BY IN-SITU HYBRIDIZATION - CLONING OF A CDNA FOR ADSEVERIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENT-SEVERING PROTEIN; ACTIN-BINDING PROTEINS; CHROMAFFIN CELLS; 74-KDA PROTEIN; GELSOLIN; SEQUENCE; DOMAIN; VILLIN; IDENTIFICATION; TRANSFORMATION	Adseverin is a Ca2+-dependent actin filament-severing protein that is presumed to have a regulatory function in exocytosis by affecting the organization of the microfilament network underneath the plasma membrane. As the first step to investigate whether adseverin has the expected function in vivo, we have cloned a cDNA for bovine adseverin. Analysis of the nucleotide sequence revealed the following points. 1) Adseverin consisted of 715 amino acid residues, and its predicted molecular mass was 80.5 kDa. 2) Adseverin belonged to the gelsolin family of proteins, which consists of six homologous segments. 3) Adseverin had two putative polyphosphoinositide binding sequences, very similar to but distinct from those in gelsolin. Adseverin was produced in Escherichia coli and purified to homogeneity. The adseverin reacted with adseverin-specific antibody and showed Ca2+-dependent actin filament severing activity like authentic adseverin. In situ hybridization demonstrated that adseverin mRNA was differentially expressed in the bovine adrenal gland; it was expressed in the adrenal medulla but not in most parts of the adrenal cortex, although both have a secretory function. The observation strongly suggested that adseverin is not involved in secretory processes in general but is specifically involved in exocytosis.	UNIV TOKYO, FAC MED, DEPT PHARMACOL, TOKYO 113, JAPAN	University of Tokyo								ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; BADER MF, 1986, J CELL BIOL, V102, P636, DOI 10.1083/jcb.102.2.636; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; BRETSCHER A, 1979, P NATL ACAD SCI USA, V76, P2321, DOI 10.1073/pnas.76.5.2321; BURGOYNE RD, 1984, BIOCHIM BIOPHYS ACTA, V779, P201, DOI 10.1016/0304-4157(84)90009-1; CHEEK TR, 1986, FEBS LETT, V207, P110, DOI 10.1016/0014-5793(86)80022-9; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; CLACKSON T, 1902, PCR PRACTICAL APPROA, P187; DELCASTILLO AR, 1990, EMBO J, V9, P43, DOI 10.1002/j.1460-2075.1990.tb08078.x; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KNIGHT DE, 1987, ANN NY ACAD SCI, V493, P504, DOI 10.1111/j.1749-6632.1987.tb27237.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LEE CC, 1990, PCR PROTOCOLS GUIDE, P46; LELKES PI, 1986, FEBS LETT, V208, P357, DOI 10.1016/0014-5793(86)81049-3; MADIN SH, 1958, P SOC EXP BIOL MED, V98, P574, DOI 10.3181/00379727-98-24111; MAEKAWA S, 1989, J BIOL CHEM, V264, P7458; MAEKAWA S, 1990, J BIOL CHEM, V265, P10940; MATSUDAIRA P, 1988, CELL, V54, P139, DOI 10.1016/0092-8674(88)90542-9; SAKURAI T, 1990, NEUROSCIENCE, V38, P743, DOI 10.1016/0306-4522(90)90067-E; SAKURAI T, 1991, J BIOL CHEM, V266, P15979; SAKURAI T, 1991, J BIOL CHEM, V266, P4581; SAKURAI T, 1981, BIOMED RES S2, V12, P179; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YU FX, 1992, J BIOL CHEM, V267, P14616; [No title captured]	34	16	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5890	5896						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119933				2022-12-27	WOS:A1994MY84000064
J	CHERNIACK, AD; KLARLUND, JK; CZECH, MP				CHERNIACK, AD; KLARLUND, JK; CZECH, MP			PHOSPHORYLATION OF THE RAS NUCLEOTIDE EXCHANGE FACTOR SON OF SEVENLESS BY MITOGEN-ACTIVATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EPIDERMAL GROWTH-FACTOR; SACCHAROMYCES-CEREVISIAE; GENE-PRODUCT; SUBSTRATE RECOGNITION; SIGNAL TRANSDUCTION; FACTOR RECEPTOR; CDC25 GENE; MAP KINASE; TYROSINE; P21RAS	Son of sevenless-1 and -2 (Sos-1 and -2) are guanosine nucleotide exchange factors implicated in the activation of Pas by both the insulin and epidermal growth factor signal transduction pathways. Pas appears to function by initiating the activation of cellular protein kinases including mitogen-activated protein (MAP) kinases. Sos proteins contain numerous sequences in their carboxylterminal regions which correspond to consensus sites for MAP kinase phosphorylation. To examine whether these sites are substrates for MAP kinases, the cDNA encoding Drosophila Sos (dSos) was tagged with sequences encoding the major antigenic epitope of the influenza virus hemagglutinin (HA) to create a dSosHA fusion construct. dSosHA was transiently expressed in COS-1 cells and immunoprecipitated with anti-HA antibodies. When immune complexes were incubated with purified MAP kinase and [gamma-P-32]ATP, a phosphorylated band of 180 kDa was observed when analyzed by SDS-polyacrylamide gel electrophoresis. This band was not present in immunoprecipitations from cells transfected with vector alone. No phosphorylation of the 180 kDa band was seen when immunoprecipitates were incubated with [gamma(32)P]ATP in the absence of MAP kinase. Two dimensional analysis of tryptic peptides from dSosHA phosphorylated by MAP kinase in vitro revealed two major phosphorylated species that were also found in dSosHA isolated from COS-1 cells labeled with P-32(i). These results are consistent with the hypothesis that a feedback loop exits wherein growth factor-activated MAP kinases phosphorylate and regulate Sos proteins.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	CHERNIACK, AD (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.		Cherniack, Andrew D./AAY-8132-2020	Cherniack, Andrew D./0000-0003-0470-0111	NIDDK NIH HHS [DK30648] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LEE RM, 1992, J BIOL CHEM, V267, P1088; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LINLING L, 1993, CELL, V72, P269; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SETH A, 1992, J BIOL CHEM, V267, P24796; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; THOMAS SM, 1992, CELL, V68, P1032; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	46	82	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4717	4720						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106439				2022-12-27	WOS:A1994MX57100007
J	LOKUTA, AJ; COOPER, C; GAA, ST; WANG, HE; ROGERS, TB				LOKUTA, AJ; COOPER, C; GAA, ST; WANG, HE; ROGERS, TB			ANGIOTENSIN-II STIMULATES THE RELEASE OF PHOSPHOLIPID-DERIVED 2ND MESSENGERS THROUGH MULTIPLE RECEPTOR SUBTYPES IN HEART-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC-FREE CALCIUM; PROTEIN-KINASE-C; ARACHIDONIC-ACID; RAT-HEART; PITUITARY-CELLS; HUMAN-LUNG; MYOCYTES; ACTIVATE; IDENTIFICATION; BIOSYNTHESIS	The octapeptide angiotensin II (Ang-II) induces both acute functional changes and longer lasting molecular changes in cultured mammalian heart myocytes, yet the underlying molecular mechanisms are poorly understood. In this study, Ang-II was found to stimulate a sustained release (>30 min) of arachidonic acid (ARA) from cultured neonatal rat cardiac myocytes, with a half-maximal response observed at 0.1 nM. Mass spectroscopy analysis showed that Ang-II stimulated a specific release equivalent to 104 fmol of ARA/mu g of protein in 10 min. Only Ang-II type 1 (AT(1)) receptor-specific antagonists were potent inhibitors of hormone-evoked [H-3]inositol phosphate accumulation (DuP 753 IC50 approximate to 7 nM compared to CGP 42112A IC50 > 1 mu M). In contrast, only AT(2) receptor-specific antagonists were potent inhibitors of [H-3]ARA release (CGP 42112A IC50 approximate to 7 nM) EXP 3880 IC50 approximate to 2 nM and PD 123177 IC50 approximate to 10 nM). Further studies with phospholipase inhibitors (p-amylcinnamoylanthranilic acid and U73122) revealed that the production of [H-3]inositol phosphates and [H-3]ARA occurs through parallel and independent pathways involving phospholipase C and phospholipase Az, respectively. Ang-II also increased the level of lysophosphatidylcholine by 49%, direct evidence that this peptide activated phospholipase Az. Thus, Ang-II stimulates distinct phospholipases in parallel through AT(1) and AT(2) receptors. These results reveal coordinate signaling roles for multiple Ang-II receptor subtypes in heart.	UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BIOMED RES FACIL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT SURG,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore					NHLBI NIH HHS [HL-28138] Funding Source: Medline; NIGMS NIH HHS [GM-08414, GM-08181] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008414, T32GM008181] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELLATIF MM, 1991, CIRC RES, V69, P800, DOI 10.1161/01.RES.69.3.800; ALLEN IS, 1988, CIRC RES, V62, P524, DOI 10.1161/01.RES.62.3.524; BAKER KM, 1989, J PHARMACOL EXP THER, V251, P578; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; CATT K, 1991, TRENDS PHARMACOL SCI, V12, P279, DOI 10.1016/0165-6147(91)90573-B; CHAREST R, 1985, BIOCHEM J, V227, P79, DOI 10.1042/bj2270079; CRANE JK, 1982, J BIOL CHEM, V257, P4959; DAMRON DS, 1993, CIRC RES, V72, P376, DOI 10.1161/01.RES.72.2.376; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DOSEMECI A, 1988, CIRC RES, V62, P347, DOI 10.1161/01.RES.62.2.347; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; ENGELS W, 1990, AM J PHYSIOL, V258, pH1865, DOI 10.1152/ajpheart.1990.258.6.H1865; ERNSBERGER P, 1992, AM J PHYSIOL, V263, pF411, DOI 10.1152/ajprenal.1992.263.3.F411; FREYSSBEGUIN M, 1989, AM J PHYSIOL, V257, pH444, DOI 10.1152/ajpheart.1989.257.2.H444; GONG MC, 1992, J BIOL CHEM, V267, P21492; GROSS RW, 1992, TRENDS CARDIOVAS MED, V2, P115, DOI 10.1016/1050-1738(92)90016-L; HUANG JMC, 1992, P NATL ACAD SCI USA, V89, P6452, DOI 10.1073/pnas.89.14.6452; HUBBARD WC, 1989, CANCER RES, V49, P826; HUBBARD WC, 1986, PROSTAGLANDINS, V32, P889, DOI 10.1016/0090-6980(86)90097-3; JASWAL N, 1991, HYPERTENSION, V17, P1115; JI H, 1991, MOL PHARMACOL, V39, P120; KEM DC, 1991, AM J PHYSIOL, V261, pC77, DOI 10.1152/ajpcell.1991.261.1.C77; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; KOHOUT TA, 1993, AM J PHYSIOL, V264, pC1350, DOI 10.1152/ajpcell.1993.264.5.C1350; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KONRAD RJ, 1992, BIOCHIM BIOPHYS ACTA, V1135, P216; KOZAWA O, 1992, PROSTAG LEUKOTR ESS, V47, P215, DOI 10.1016/0952-3278(92)90242-B; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; LOKUTA AJ, 1994, IN PRESS J CARDIOVAS; LONG CS, 1990, J HYPERTENS, V8, pS219; MARSHALL LA, 1992, BIOCHEM PHARMACOL, V44, P1849, DOI 10.1016/0006-2952(92)90081-S; MARTIN TFJ, 1989, J BIOL CHEM, V264, P10299; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; NAGANO M, 1992, HYPERTENSION, V19, P708, DOI 10.1161/01.HYP.19.6.708; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PONZONI M, 1992, FEBS LETT, V310, P17, DOI 10.1016/0014-5793(92)81136-A; ROGG H, 1990, BIOCHEM BIOPH RES CO, V173, P416, DOI 10.1016/S0006-291X(05)81074-5; SANDBERG K, 1992, J BIOL CHEM, V267, P9455; SANFELIU C, 1990, BRAIN RES, V526, P241, DOI 10.1016/0006-8993(90)91228-9; SCHMID PC, 1981, J LIPID RES, V22, P882; SCHNEIDER MD, 1990, CIRCULATION, V81, P1443, DOI 10.1161/01.CIR.81.5.1443; SCOTT AL, 1992, J PHARMACOL EXP THER, V261, P931; SECHI LA, 1992, CIRC RES, V71, P1482, DOI 10.1161/01.RES.71.6.1482; SMALLRIDGE RC, 1992, ENDOCRINOLOGY, V131, P1883, DOI 10.1210/en.131.4.1883; SMITH RD, 1992, ANNU REV PHARMACOL, V32, P135; SPAARGAREN M, 1992, BIOCHEM J, V287, P37, DOI 10.1042/bj2870037; TAKUWA N, 1991, J BIOL CHEM, V266, P14237; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; TIMMERMANS PBMWM, 1992, AM J HYPERTENS, V5, P406, DOI 10.1093/ajh/5.6.406; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; VANOVERVELD FJ, 1992, PROSTAGLANDINS, V44, P101, DOI 10.1016/0090-6980(92)90071-Z; WALLUKAT G, 1991, MOL CELL BIOCHEM, V102, P35	58	119	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4832	4838						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106454				2022-12-27	WOS:A1994MX57100023
J	SEKINE, N; CIRULLI, V; REGAZZI, R; BROWN, LJ; GINE, E; TAMARITRODRIGUEZ, J; GIROTTI, M; MARIE, S; MACDONALD, MJ; WOLLHEIM, CB; RUTTER, GA				SEKINE, N; CIRULLI, V; REGAZZI, R; BROWN, LJ; GINE, E; TAMARITRODRIGUEZ, J; GIROTTI, M; MARIE, S; MACDONALD, MJ; WOLLHEIM, CB; RUTTER, GA			LOW LACTATE-DEHYDROGENASE AND HIGH MITOCHONDRIAL GLYCEROL PHOSPHATE DEHYDROGENASE IN PANCREATIC BETA-CELLS - POTENTIAL ROLE IN NUTRIENT SENSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN RELEASE; LINKED ISOCITRATE DEHYDROGENASE; GLUCOSE-METABOLISM; GLUCOKINASE GENE; COUPLING MECHANISMS; ADENINE-NUCLEOTIDES; CALCIUM-IONS; LINE RINM5F; RAT ISLETS; HIT CELLS	Nutrient metabolism was examined with regard to insulin secretion in purified rat islet beta- and non-beta-cells, beta-cell lines, and hepatocytes. Lactate dehydrogenase (LDH) activity (nanomoles.min(-1).mg protein(-1)) was remarkably low in the glucose-sensitive INS-1 cell line (15.7) and in beta-cells (22.3), Thus, beta-cell LDH was respectively 8-, 122-, 17-, and 136-fold lower than in islet non-beta-, liver, HIT-T15, and RINm5F cells. plasma membrane lactate transport activity was 3-10-fold lower in beta- or INS-1 cells than in the other cell types. Conversely, mitochondrial glycerol phosphate dehydrogenase was strongly expressed only in beta- and INS-1 cells. The significance of these findings to nutrient recognition was explored using INS-1 cells as a model of native beta-cells. Glucose-stimulated lactate output and glucose utilization were, respectively, 12- and 5 fold lower in INS-1 than in RINm5F cells. Each process was entirely blocked by respiratory chain inhibitors in INS-1 cells, whereas glucose utilization was barely affected and lactate output stimulated in RINm5F cells. Glucose oxidation represented 73% of total utilization in INS-1 cells, but only 9% in RINm5F cells. Absolute rates of glucose oxidation, and the extent of mitochondrial NAD(P) reduction, were similar in the two cell types, and glucose stimulated insulin secretion 1.9-fold in INS-1 and 1.4-fold in RINm5F cells. The mitochondrial substrates, monomethyl succinate, pyruvate, and leucine, each triggered secretion in INS-1 cells. The balance of LDH, plasma membrane lactate transport, and mitochondrial glycerol phosphate dehydrogenase activities therefore appear to be important in beta- and INS-1 cell glucose recognition to ensure that mitochondrial oxidation is the principle fate of pyruvate and NADH produced by glycolysis. The resultant close coupling of glycolysis with mitochondrial oxidation explains the absence in beta-cells of Crabtree and Pasteur effects.	UNIV GENEVA, DEPT MED, DIV BIOCHIM CLIN, CH-1211 GENEVA 4, SWITZERLAND; UNIV GENEVA, LAB RECH LOUIS JEANTET, CH-1211 GENEVA 4, SWITZERLAND; UNIV WISCONSIN, DEPT PAEDIAT DIABET & ENDOCRINOL, MADISON, WI 53706 USA; UNIV COMPLUTENSE MADRID, FAC MED, DEPT BIOQUIM, E-28040 MADRID, SPAIN	University of Geneva; University of Geneva; University of Wisconsin System; University of Wisconsin Madison; Complutense University of Madrid			Gine, Elena/I-3205-2012; Dominguez, Elena Giné/ABF-9419-2020	Gine, Elena/0000-0001-6305-6237; Dominguez, Elena Giné/0000-0001-6305-6237; Rutter, Guy/0000-0001-6360-0343	NIDDK NIH HHS [DK 28348] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028348, R55DK028348] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BAETENS D, 1979, SCIENCE, V206, P1323, DOI 10.1126/science.390711; BEGGS M, 1990, FEBS LETT, V267, P217, DOI 10.1016/0014-5793(90)80928-C; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; BEST L, 1991, BIOCHEM PHARMACOL, V41, P405, DOI 10.1016/0006-2952(91)90537-F; BEST L, 1992, MOL CELL ENDOCRINOL, V86, P49, DOI 10.1016/0303-7207(92)90174-5; BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503; BRUN T, 1993, J BIOL CHEM, V268, P18905; DENTON RM, 1978, BIOCHEM J, V176, P899, DOI 10.1042/bj1760899; DIXIT PK, 1964, METABOLISM, V13, P285, DOI 10.1016/0026-0495(64)90107-6; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; GIROIX MH, 1991, DIABETES, V40, P227, DOI 10.2337/diabetes.40.2.227; HALBAN PA, 1983, BIOCHEM J, V212, P439, DOI 10.1042/bj2120439; HALBAN PA, 1980, BIOCHEM PHARMACOL, V29, P2625, DOI 10.1016/0006-2952(80)90077-5; Hay RJ, 1986, ANIMAL CELL CULTURE, P71; HEDESKOV CJ, 1978, REGULATORY MECHANISM, V42, P237; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; HELLMAN B, 1975, DIABETOLOGIA, V11, P495, DOI 10.1007/BF01222098; HELLMAN B, 1967, ENDOCRINOLOGY, V81, P125, DOI 10.1210/endo-81-1-125; HUTTON JC, 1980, ENDOCRINOLOGY, V106, P203, DOI 10.1210/endo-106-1-203; INGLEDEW WJ, 1977, BIOCHEM J, V164, P617, DOI 10.1042/bj1640617; IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; IYNEDJIAN PB, 1989, J BIOL CHEM, V264; JAIN K, 1978, BIOCHEM J, V176, P31, DOI 10.1042/bj1760031; JANJIC D, 1992, DIABETOLOGIA, V35, P482, DOI 10.1007/BF02342448; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; KISSANE JM, 1964, STRUCTURE METABOLISM, P281; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1988, DIABETES, V37, P997, DOI 10.2337/diabetes.37.7.997; MALAISSE WJ, 1979, ARCH BIOCHEM BIOPHYS, V194, P49, DOI 10.1016/0003-9861(79)90594-0; MALAISSE WJ, 1974, EUR J BIOCHEM, V47, P365, DOI 10.1111/j.1432-1033.1974.tb03701.x; MALAISSE WJ, 1988, DIABETES RES CLIN EX, V7, P53; MARIE S, 1993, J BIOL CHEM, V268, P23881; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MCCORMACK JG, 1989, METHOD ENZYMOL, V174, P95; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MEGLASSON MD, 1987, DIABETES, V36, P477, DOI 10.2337/diabetes.36.4.477; MEGLASSON MD, 1989, AM J PHYSIOL, V256, pE173, DOI 10.1152/ajpendo.1989.256.1.E173; Newsholme EA, 1973, REGULATION METABOLIS; NICHOLLS D, 1982, BIOENERGETICS INTRO, P119; OHTA M, 1990, J BIOL CHEM, V265, P17525; OSTENSON CG, 1993, DIABETOLOGIA, V36, P722, DOI 10.1007/BF00401142; PANTEN U, 1982, ENDOCRINOLOGY, V111, P1595, DOI 10.1210/endo-111-5-1595; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3; Reed LJ, 1987, ENZYMES, P77; REGAZZI R, 1990, J BIOL CHEM, V265, P15003; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; ROUILLER DG, 1990, EXP CELL RES, V191, P305, DOI 10.1016/0014-4827(90)90019-7; RUTTER GA, 1988, BIOCHEM J, V252, P181, DOI 10.1042/bj2520181; RUTTER GA, 1993, J BIOL CHEM, V268, P22385; RUTTER GA, 1992, BIOCHIM BIOPHYS ACTA, V1175, P107, DOI 10.1016/0167-4889(92)90016-5; RUTTER GA, 1989, BIOCHEM J, V263, P445, DOI 10.1042/bj2630445; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SENER A, 1978, BIOCHEM J, V176, P218; SENER A, 1988, J BIOL CHEM, V2634, P88; STRYER L, 1988, BIOCHEMISTRY-US, P495; TAMARITRODRIGUEZ J, 1992, DIABETOLOGIA, V35, pA125; THELEN AP, 1991, ARCH BIOCHEM BIOPHYS, V286, P645, DOI 10.1016/0003-9861(91)90094-Y; TRUS MD, 1981, DIABETES, V30, P911, DOI 10.2337/diabetes.30.11.911; VISCHER U, 1987, BIOCHEM J, V241, P249, DOI 10.1042/bj2410249; ZAWALICH WS, 1993, DIABETES, V42, P843, DOI 10.2337/diabetes.42.6.843; ZHANG HJ, 1989, DIABETES, V38, P44, DOI 10.2337/diabetes.38.1.44; ZIVKOVIC RV, 1975, EXPERIENTIA, V31, P1258	71	363	365	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4895	4902						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106462				2022-12-27	WOS:A1994MX57100033
J	SA, G; FOX, PL				SA, G; FOX, PL			BASIC FIBROBLAST GROWTH FACTOR-STIMULATED ENDOTHELIAL-CELL MOVEMENT IS MEDIATED BY A PERTUSSIS-TOXIN-SENSITIVE PATHWAY REGULATING PHOSPHOLIPASE-A(2) ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SIGNALING PATHWAYS; G-PROTEINS; FACTOR RECEPTOR; DNA-SYNTHESIS; PLASMINOGEN-ACTIVATOR; POSSIBLE INVOLVEMENT; GUANINE-NUCLEOTIDES; HUMAN-NEUTROPHILS; TYROSINE KINASES; BINDING PROTEINS	Basic fibroblast growth factor (bFGF) stimulates migration and proliferation of vascular endothelial cells (EC). Fibroblast growth factor (FGF) receptors have an intrinsic tyrosine kinase activity involved in FGF-mediated proliferation, but the signal transduction path-, way(s) responsible for movement is not known. We, compared the role of signal-transducing G-proteins in migratory and proliferative responses of bovine aortic EC in vitro. Pertussis toxin, which ADP-ribosylates susceptible G-proteins, reduced bFGF-stimulated EC migration by 80%. The toxin did not block serum-stimulated movement, indicating that structural components required for motility were not impaired. The toxin did not inhibit bFGF-stimulated EC proliferation, showing that distinct intracellular signaling mechanisms are involved in the migratory and proliferative responses to bFGF. Three experimental approaches indicated that promigratory responses were due to release of arachidonic acid: (i) of the second messengers induced by G-protein-coupled effectors, only arachidonic acid overcame the pertussis toxin block, (ii) bFGF stimulated arachidonic acid release from EC in a pertussis toxin-sensitive manner, and (iii) phospholipase A2 inhibitors blocked the EC migration in response to bFGF. These data provide evidence that the migratory response of vascular EC to bFGF may be mediated by a G-protein-coupled phospholipase A2 activity.	CLEVELAND CLIN, RES INST, DEPT CELL BIOL, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040352, R01HL041178] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40352, HL41178] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BELL L, 1992, J CLIN INVEST, V89, P315, DOI 10.1172/JCI115578; BICKNELL R, 1989, P NATL ACAD SCI USA, V86, P1573, DOI 10.1073/pnas.86.5.1573; BJORNSSON TD, 1991, P NATL ACAD SCI USA, V88, P8651, DOI 10.1073/pnas.88.19.8651; BOUTHERINFALSON O, 1990, BIOCHEM BIOPH RES CO, V172, P306, DOI 10.1016/S0006-291X(05)80210-4; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHURCH JG, 1988, J BIOL CHEM, V263, P4242; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COCKCROFT S, 1991, BIOCHEM SOC T, V19, P333, DOI 10.1042/bst0190333; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; FOX PL, 1984, J CELL PHYSIOL, V121, P298, DOI 10.1002/jcp.1041210206; FOX PL, 1992, LAB INVEST, V66, P467; GAUDRY M, 1992, J LEUKOCYTE BIOL, V51, P103, DOI 10.1002/jlb.51.2.103; GOSPODAROWICZ D, 1991, ANN NY ACAD SCI, V638, P1, DOI 10.1111/j.1749-6632.1991.tb49012.x; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; HASSELAAR P, 1992, J CELL BIOCHEM, V49, P272, DOI 10.1002/jcb.240490310; HOWE PH, 1990, BIOCHEM J, V266, P537, DOI 10.1042/bj2660537; IM MJ, 1990, J BIOL CHEM, V265, P18944; JARVIS MF, 1992, J PHARMACOL EXP THER, V263, P253; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KELVIN DJ, 1989, J CELL BIOL, V108, P169, DOI 10.1083/jcb.108.1.169; KITAGAWA K, 1987, BIOCHIM BIOPHYS ACTA, V931, P110, DOI 10.1016/0167-4889(87)90056-5; KOO C, 1983, J CLIN INVEST, V72, P748, DOI 10.1172/JCI111045; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LESTER BR, 1991, INT J CANCER, V48, P113; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LINDNER V, 1990, J CLIN INVEST, V85, P2004, DOI 10.1172/JCI114665; LOGAN A, 1991, CELL SIGNAL, V3, P215, DOI 10.1016/0898-6568(91)90047-X; LUTTRELL LM, 1988, J BIOL CHEM, V263, P6134; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MONTESANO R, 1988, J CELL PHYSIOL, V134, P460, DOI 10.1002/jcp.1041340318; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; MURAYAMA T, 1987, J BIOL CHEM, V262, P12463; MURUGESAN G, 1993, J CELL BIOL, V120, P1011, DOI 10.1083/jcb.120.4.1011; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NISHIMOTO I, 1987, BIOCHEM BIOPH RES CO, V148, P403, DOI 10.1016/0006-291X(87)91125-9; PATTE C, 1992, CELL MOL BIOL, V38, P429; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; ROSENTHAL MD, 1989, BIOCHIM BIOPHYS ACTA, V1001, P1, DOI 10.1016/0005-2760(89)90299-3; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SCHENK PW, 1991, DEV BIOL, V145, P110, DOI 10.1016/0012-1606(91)90217-Q; SELDEN SC, 1981, J CELL PHYSIOL, V108, P195, DOI 10.1002/jcp.1041080210; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRACKE ML, 1987, BIOCHEM BIOPH RES CO, V146, P339, DOI 10.1016/0006-291X(87)90730-3; TERRANOVA VP, 1985, J CELL BIOL, V101, P2330, DOI 10.1083/jcb.101.6.2330; THYBERG J, 1984, EXP CELL RES, V155, P1, DOI 10.1016/0014-4827(84)90761-4; TSUBOI R, 1990, J CELL BIOL, V110, P511, DOI 10.1083/jcb.110.2.511; UI M, 1990, ADV SEC MESS PHOSPH, V24, P63; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; WAKELAM MJO, 1992, SIGNAL TRANSDUCTION, P153; XING MZ, 1992, J BIOL CHEM, V267, P25966	58	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3219	3225						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106357				2022-12-27	WOS:A1994MV63100018
J	KUBO, T; MIZOBATA, T; KAWATA, Y				KUBO, T; MIZOBATA, T; KAWATA, Y			REFOLDING OF YEAST ENOLASE IN THE PRESENCE OF THE CHAPERONIN GROE - THE NUCLEOTIDE SPECIFICITY OF GROE AND THE ROLE OF GROES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE-DENATURED RHODANESE; ESCHERICHIA-COLI; RIBULOSEBISPHOSPHATE CARBOXYLASE; MOLECULAR CHAPERONE; ATP HYDROLYSIS; PROTEIN; COOPERATIVITY; PURIFICATION; DETERGENT; SURFACE	GroE, a chaperonin protein from Escherichia coli, facilitates the folding of numerous proteins by binding to protein-folding intermediates and suppressing aggregation (Gething, M., and Sambrook, J. (1992) Nature 355, 33-45). The specific mechanism of GroE-facilitated folding involves numerous interactions between GroEL, GroES, the refolding protein, and ATP. In the present study, we have probed the molecular characteristics of the refolding reaction of yeast enolase in the presence of GroE. We have found that (a) GroEL interacts specifically with enolase during the folding reaction, resulting in folding arrest; (b) the release of partially folded molecules of enolase from the GroE complex may be mediated by the addition of nucleotides other than ATP (ADP, CTP, and UTP); and (c) GroES is required for enolase to be released from GroEL in the presence of ADP, CTP, and UTP but not required in the presence of ATP. The nucleotide binding mechanism of GroEL and the specific role of GroES during the refolding reaction are discussed in detail.	TOTTORI UNIV,FAC ENGN,DEPT BIOTECHNOL,TOTTORI 680,JAPAN; KYOTO UNIV,FAC SCI,DEPT CHEM,KYOTO 60601,JAPAN	Tottori University; Kyoto University			Mizobata, Tomohiro/V-6672-2019; Kawata, Yasushi/ABA-9608-2021	Mizobata, Tomohiro/0000-0002-7808-2099; Kawata, Yasushi/0000-0002-2744-1506				BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BORDERS CL, 1978, BIOCHEM BIOPH RES CO, V82, P901, DOI 10.1016/0006-291X(78)90868-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHIN CCQ, 1981, J BIOL CHEM, V256, P1377; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; TANDON S, 1986, J BIOL CHEM, V261, P5615; TANDON S, 1987, J BIOL CHEM, V262, P4486; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; Wold F., 1971, ENZYMES, P499	34	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19346	19351						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8103517				2022-12-27	WOS:A1993LW81900032
J	KANAJI, T; OZAKI, H; TAKAO, T; KAWAJIRI, H; IDE, H; MOTOKI, M; SHIMONISHI, Y				KANAJI, T; OZAKI, H; TAKAO, T; KAWAJIRI, H; IDE, H; MOTOKI, M; SHIMONISHI, Y			PRIMARY STRUCTURE OF MICROBIAL TRANSGLUTAMINASE FROM STREPTOVERTICILLIUM SP STRAIN-S-8112	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BOMBARDMENT MASS-SPECTROMETRY; ERYTHROCYTE-MEMBRANE; CDNA CLONES; FACTOR-XIII; MOLECULAR-CLONING; PROTEIN; MICROORGANISMS; SUBUNIT	The complete amino acid sequence of transglutaminase (EC 2.3.2.13) (TGase), which is produced by a microorganism, Streptoverticillium sp. strain s-8112, and catalyzes the acyl transfer reaction between gamma-carboxyamide groups of glutamine residues in proteins and various primary amines, has been established by a combination of fast atom bombardment mass spectrometry and standard Edman degradation of peptide fragments produced by treatment of the TGase with various proteolytic enzymes and purified by a reversed-phase high performance liquid chromatography. The TGase consists of 331 amino acid residues with a chemical molecular weight of 37,863, in agreement with the observed molecular weight (37,869.2 +/- 8.8) determined from its electrospray ionization mass spectrum. The sequence of the enzyme is very different from those of mammalian TGases represented by guinea pig liver enzyme. The enzyme contains a sole Cys residue, which is essential for its catalytic activity. Hydropathy analysis indicated that the secondary structure of the region around the active site Cys residue is similar to those of mammalian TGases. These results suggest that this microbial protein evolved by a different pathway from that of mammalian TGases and acquired acyl transfer activity during the evolutional process.	OSAKA UNIV,INST PROT RES,YAMADAOKA 3-2,SUITA,OSAKA 565,JAPAN; AJINOMOTO CO INC,FOOD RES & DEV LABS,KAWASAKI KU,KAWASAKI,KANAGAWA 210,JAPAN	Osaka University; Ajinomoto Co Inc								ANDO H, 1989, AGR BIOL CHEM TOKYO, V53, P2613, DOI 10.1080/00021369.1989.10869735; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHUNG SI, 1972, ANN NY ACAD SCI, V202, P240, DOI 10.1111/j.1749-6632.1972.tb16338.x; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GENTILE V, 1991, J BIOL CHEM, V266, P478; GRUNDMANN U, 1986, P NATL ACAD SCI USA, V83, P8024, DOI 10.1073/pnas.83.21.8024; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P6900, DOI 10.1021/bi00370a025; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; KIM HC, 1991, J BIOL CHEM, V266, P536; KLEIN JD, 1992, J BACTERIOL, V174, P2599, DOI 10.1128/jb.174.8.2599-2605.1992; KORSGREN C, 1991, P NATL ACAD SCI USA, V88, P4840, DOI 10.1073/pnas.88.11.4840; KORSGREN C, 1990, P NATL ACAD SCI USA, V87, P613, DOI 10.1073/pnas.87.2.613; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lorand L, 1980, Prog Hemost Thromb, V5, P245; NAKANISHI K, 1991, EUR J BIOCHEM, V202, P15, DOI 10.1111/j.1432-1033.1991.tb16338.x; NONAKA M, 1989, AGR BIOL CHEM TOKYO, V53, P2619, DOI 10.1080/00021369.1989.10869736; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; POLAKOWSKA R, 1991, J INVEST DERMATOL, V96, P285, DOI 10.1111/1523-1747.ep12464554; POLAKOWSKA RR, 1992, P NATL ACAD SCI USA, V89, P2599; ROBSON B, 1976, J MOL BIOL, V107, P327, DOI 10.1016/S0022-2836(76)80008-3; ROSE K, 1988, BIOCHEM J, V250, P253, DOI 10.1042/bj2500253; RUSH HP, 1969, FED PROC, V28, P1761; SUNG LA, 1990, P NATL ACAD SCI USA, V87, P955, DOI 10.1073/pnas.87.3.955; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; TAKAO T, 1984, J BIOL CHEM, V259, P6105; YAMANISHI K, 1991, BIOCHEM BIOPH RES CO, V175, P906, DOI 10.1016/0006-291X(91)91651-R	29	157	173	3	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11565	11572						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8099353				2022-12-27	WOS:A1993LF28400020
J	DEMARCO, L; MAZZUCATO, M; MASOTTI, A; RUGGERI, ZM				DEMARCO, L; MAZZUCATO, M; MASOTTI, A; RUGGERI, ZM			LOCALIZATION AND CHARACTERIZATION OF AN ALPHA-THROMBIN-BINDING SITE ON PLATELET GLYCOPROTEIN IB-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; AMINO-ACID-SEQUENCE; MONOCLONAL-ANTIBODIES; CHLOROMETHYL KETONE; IX COMPLEX; RECEPTOR; HIRUDIN; DOMAIN; ACTIVATION; IDENTIFICATION	Glycoprotein (GP) Ib alpha is required for expression of the highest affinity alpha-thrombin binding site on platelets, possibly contributing to platelet activation through a pathway involving cleavage of a specific receptor. This function may be important for the initiation of hemostasis and may also play a role in the development of pathological vascular occlusion. We have now identified a discrete sequence in the extracytoplasmic domain of GP Ib alpha, including residues 271-284 of the mature protein, which appears to be part of the high affinity alpha-thrombin-binding site. Synthetic peptidyl mimetics of this sequence inhibit alpha-thrombin binding to GP Ib as well as platelet activation and aggregation induced by subnanomolar concentrations of the agonist; they also inhibit alpha-thrombin binding to purified glycocalicin, the isolated extracytoplasmic portion of GP Ib alpha. The inhibitory peptides interfere with the clotting of fibrinogen by alpha-thrombin but not with the amidolytic activity of the enzyme on a small synthetic substrate, a finding compatible with the concept that the identified GP Ib alpha sequence interacts with the anion-binding exosite of alpha-thrombin but not with its active proteolytic site. The crucial structural elements of this sequence necessary for thrombin binding appear to be a cluster of negatively charged residues as well as three tyrosine residues that, in the native protein, may be sulfated. GP Ib alpha has no significant overall sequence homology with the thrombin inhibitor, hirudin, nor with the specific thrombin receptor on platelets; all three molecules, however, possess a distinct region rich in negatively charged residues that appear to be involved in thrombin binding. This may represent a case of convergent evolution of unrelated proteins for high affinity interaction with the same ligand.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV EXPTL HEMOSTASIS & THROMBOSIS, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; CTR RIFERIMENTO ONCOL, SERV IMMUNOTRASFUS & ANAL CLIN, I-33081 AVIANO, ITALY	Scripps Research Institute; Scripps Research Institute; IRCCS Aviano (CRO)			Mazzucato, Mario/ABF-5472-2020	Mazzucato, Mario/0000-0001-8319-053X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042846, R37HL042846] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-42846] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAIN JP, 1975, J LAB CLIN MED, V85, P318; BLOMBACK M, 1974, THROMB RES, V5, P621, DOI 10.1016/0049-3848(74)90052-8; BRASS LF, 1992, J BIOL CHEM, V267, P13795; BRESLOW N, 1970, BIOMETRIKA, V57, P579, DOI 10.2307/2334776; DAVIDSON JF, 1988, J CLIN PATHOL, V41, P1322; DEMARCO L, 1990, J CLIN INVEST, V86, P25, DOI 10.1172/JCI114692; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; DODT J, 1984, FEBS LETT, V165, P180, DOI 10.1016/0014-5793(84)80165-9; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HANDA M, 1986, J BIOL CHEM, V261, P2579; HANSON SR, 1988, P NATL ACAD SCI USA, V85, P3184, DOI 10.1073/pnas.85.9.3184; HARMON JT, 1986, J BIOL CHEM, V261, P5928; HARMON JT, 1986, J BIOL CHEM, V261, P3224; HARMON JT, 1985, BIOCHEMISTRY-US, V24, P58, DOI 10.1021/bi00322a010; HORTIN G, 1986, BIOCHEM BIOPH RES CO, V141, P326, DOI 10.1016/S0006-291X(86)80372-2; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; JAKUBOWSKI JA, 1990, BLOOD, V75, P399; JANDROTPERRUS M, 1991, THROMB HAEMOSTASIS, V66, P300; KATAGIRI Y, 1990, THROMB HAEMOSTASIS, V63, P122; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; MAO SJT, 1988, BIOCHEMISTRY-US, V27, P8170, DOI 10.1021/bi00421a027; MICHELSON AD, 1991, BLOOD, V77, P770; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P542; MURATA M, 1991, J BIOL CHEM, V266, P15474; OKUMURA T, 1978, J BIOL CHEM, V253, P3435; PARHAM P, 1983, J IMMUNOL, V131, P2895; POLLOCK WK, 1986, BIOCHEM J, V235, P869, DOI 10.1042/bj2350869; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SUGIMOTO M, 1991, J BIOL CHEM, V266, P18172; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; VICENTE V, 1988, J BIOL CHEM, V263, P18473; VU TH, 1991, NATURE, V353, P673; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALSH PN, 1977, BRIT J HAEMATOL, V36, P281, DOI 10.1111/j.1365-2141.1977.tb00649.x	40	135	139	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6478	6484						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119999				2022-12-27	WOS:A1994MZ50300035
J	GAIKWAD, AS; CUMSKY, MG				GAIKWAD, AS; CUMSKY, MG			THE USE OF CHEMICAL CROSS-LINKING TO IDENTIFY PROTEINS THAT INTERACT WITH A MITOCHONDRIAL PRESEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; SOLID-PHASE SYNTHESIS; INNER MEMBRANE; YEAST MITOCHONDRIA; PRECURSOR PROTEINS; DIHYDROFOLATE-REDUCTASE; PEPTIDE-SYNTHESIS; IMPORT MACHINERY; 45-KDA PROTEIN; IDENTIFICATION	Previous work has shown that when yeast mitochondria are incubated in the presence of the presequence peptide pL4(1-22), the peptide is imported and accumulates within the mitochondrial membranes, presumably at the import sites. If the extramitochondrial concentration of peptide is sufficiently high, enough peptide accumulates within the import sites to prevent the uptake of authentic precursor proteins. We have used chemical cross-linking to probe the interaction of this peptide with yeast mitochondrial proteins. We found that radiolabeled pL4(1-22) could be reproducibly cross-linked to a number of polypeptides. Interestingly, nearly all were membrane proteins. Several of the cross-linked proteins were located in the outer membrane, while others were located in the inner membrane, The interaction between the peptide and many of the cross-linked products was shown to be specific by two independent criteria, First, an excess of unlabeled peptide acted as a competitor in the cross-linking reaction, and, second, treatment of the peptide with the alkylating agent N-ethylmaleimide dramatically reduced its ability to form cross-links. Two of the cross-linked species corresponded to the outer membrane proteins, Mas70p and ISP42. Significantly, both of these proteins have previously been shown to play critical roles in mitochondrial protein import. While the role of the other cross-linked proteins in the import process remains to be determined, the results of this study demonstrate that our experimental approach may be useful in identifying components of the import machinery as well as proteins that interact with mitochondrial presequences.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717	University of California System; University of California Irvine					NIGMS NIH HHS [GM 36675] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036675] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATHERTON E, 1981, J CHEM SOC PERK T 1, P538, DOI 10.1039/p19810000538; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; DIHANICH M, 1990, EXPERIENTIA, V46, P146, DOI 10.1007/BF02027310; DRYLAND A, 1986, J CHEM SOC PERK T 1, P125, DOI 10.1039/p19860000125; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; GILLESPIE LL, 1987, J BIOL CHEM, V262, P7939; GLASER SM, 1990, J BIOL CHEM, V265, P8817; GLASER SM, 1990, J BIOL CHEM, V265, P8808; GLASER SM, 1990, MOL CELL BIOL, V10, P1873, DOI 10.1128/MCB.10.5.1873; GLICK B, 1991, ANNU REV GENET, V25, P21; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HINES V, 1993, J BIOL CHEM, V268, P449; HORWICH AL, 1985, EMBO J, V4, P1129, DOI 10.1002/j.1460-2075.1985.tb03750.x; HURT EC, 1985, EMBO J, V4, P2061, DOI 10.1002/j.1460-2075.1985.tb03892.x; HURT EC, 1984, EMBO J, V3, P3149, DOI 10.1002/j.1460-2075.1984.tb02272.x; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; JENSEN RE, 1988, EMBO J, V7, P3868; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MEYER DI, 1990, NATURE, V347, P424, DOI 10.1038/347424a0; MILLER BR, 1993, J CELL BIOL, V121, P1021, DOI 10.1083/jcb.121.5.1021; MILLER BR, 1991, J CELL BIOL, V112, P833, DOI 10.1083/jcb.112.5.833; MURAKAMI H, 1990, NATURE, V347, P488, DOI 10.1038/347488a0; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; MURAKAMI H, 1993, P NATL ACAD SCI USA, V90, P3358, DOI 10.1073/pnas.90.8.3358; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; MURAKAMI K, 1992, J BIOL CHEM, V267, P13119; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PFALLER R, 1990, EXPERIENTIA, V46, P153, DOI 10.1007/BF02027311; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFALLER R, 1989, J BIOL CHEM, V264, P34; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PFANNER N, 1988, EUR J BIOCHEM, V175, P205, DOI 10.1111/j.1432-1033.1988.tb14185.x; PON L, 1989, J CELL BIOL, V109, P2603, DOI 10.1083/jcb.109.6.2603; ROISE D, 1988, J BIOL CHEM, V263, P4509; SCHERER PE, 1992, P NATL ACAD SCI USA, V89, P11930, DOI 10.1073/pnas.89.24.11930; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; YAFFE MP, 1989, J BIOL CHEM, V264, P21091	45	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6437	6443						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119994				2022-12-27	WOS:A1994MZ50300030
J	PAN, BT; CHEN, CT; LIN, SM				PAN, BT; CHEN, CT; LIN, SM			ONCOGENIC RAS BLOCKS CELL-CYCLE PROGRESSION AND INHIBITS P34(CDC2) KINASE IN ACTIVATED XENOPUS EGG EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P34CDC2 PROTEIN-KINASE; FISSION YEAST; TYROSINE PHOSPHORYLATION; CDC25 PROTEIN; SARCOMA-VIRUS; M-PHASE; MITOSIS; DEPHOSPHORYLATION; GENE; PHOSPHATASE	The effect of purified, bacterially expressed human Ras(H) proteins on embryonic cell cycle progression in activated Xenopus egg extracts was studied. Bacterially expressed human oncogenic Ras(H) protein is able to block the progression of the Xenopus embryonic cell cycle into M-phase. In contrast, the corresponding normal human Ras protein is relatively ineffective when assayed in a like manner. The observed arresting activity can be blocked by the addition of Y13-259 anti-Ras monoclonal antibody but not by nonspecific IgG. Oncogenic Ras also induces unique morphological changes in the reconstituted nuclei; the nuclei appear to be enlarged, and the chromatin partially condenses into fiber-like structures. This induced arrest is associated with suppression of p34(cdc2) kinase activity, indicating that the oncogenic Ras protein induces the arrest by inactivating p34(cdc2). This inactivation by oncogenic Ras protein does not result from inhibition of the synthesis of cyclin B or of the binding of the newly synthesized cyclin B to the p34(cdc2).	UNIV KENTUCKY,MED CTR,DEPT MICROBIOL & IMMUNOL,LEXINGTON,KY 40536; UNIV KENTUCKY,MED CTR,DEPT SURG,LEXINGTON,KY 40536	University of Kentucky; University of Kentucky	PAN, BT (corresponding author), UNIV KENTUCKY,MED CTR,LUCILLE P MARKEY CANC CTR,RM 310,COMBS BLDG,LEXINGTON,KY 40536, USA.			CHEN, CHIN-TIN/0000-0002-7439-8774				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BIRSCHMEIER CD, 1985, CELL, V43, P615; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; DURKIN JP, 1987, MOL CELL BIOL, V7, P444, DOI 10.1128/MCB.7.1.444; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KHOSRAVIFAR R, 1992, CELL GROWTH DIFFER, V3, P461; KIRSCHNER M, 1985, TRENDS GENET, V1, P41, DOI 10.1016/0168-9525(85)90021-6; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAN BT, 1990, MOL CELL BIOL, V10, P923, DOI 10.1128/MCB.10.3.923; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0	58	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5968	5975						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119942				2022-12-27	WOS:A1994MY84000076
J	SHAW, SK; CEPEK, KL; MURPHY, EA; RUSSELL, GJ; BRENNER, MB; PARKER, CM				SHAW, SK; CEPEK, KL; MURPHY, EA; RUSSELL, GJ; BRENNER, MB; PARKER, CM			MOLECULAR-CLONING OF THE HUMAN MUCOSAL LYMPHOCYTE INTEGRIN ALPHA(E) SUBUNIT - UNUSUAL STRUCTURE AND RESTRICTED RNA DISTRIBUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY HML-1; AMINO-ACID-SEQUENCE; HAIRY-CELL LEUKEMIA; LEUKOCYTE ADHESION GLYCOPROTEIN; MESSENGER-RNAS; INTESTINAL LYMPHOCYTES; BETA-7 SUBUNIT; CHEMICAL MODIFICATION; CLEAVAGE SITES; T-CELLS	The human mucosal lymphocyte-1 (HML-1) antigen is expressed on a subclass of T-lymphocytes known as intra epithelial lymphocytes which are located between mucosal epithelial cells. The HML-1 complex is known to mediate adhesion of intra-epithelial T-lymphocytes to epithelial cell monolayers in vitro. We and others have shown that the HBL-1 antigen is an integrin composed of the beta(7) subunit in association with a novel alpha subunit, alpha(E). Here we report the cloning of the alpha(E) cDNA and its primary amino acid sequence. alpha(E) contained an inserted or I domain and was more homologous to the other I domain containing integrins than to the cleaved group of integrin alpha subunits. However, alpha(E) contained a unique extra domain of 55 amino acids located just NH2-terminal 60 the I domain without counterpart in other integrins. This extra domain contained a stretch of 18 consecutive charged residues and included a proteolytic cleavage site. Thus alpha(E) is the only I domain containing integrin a subunit that is also cleaved, and the cleavage site is distinct from that of members of the cleaved group of integrin alpha subunits. These structural features mark alpha(E) as an unusual member of the integrin family. High levels of alpha(E) and beta(7) mRNA were restricted to mucosal lymphocytes supporting the hypothesis that alpha(E) beta(7) plays a role in the localization or site-specific functions of intra-epithelial T-lymphocytes.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School; Massachusetts General Hospital	SHAW, SK (corresponding author), BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL IMMUNOL,DIV MED SCI,LYMPHOCYTE BIOL SECT,RM 507,SGMB,BOSTON,MA 02115, USA.			Shaw, Sunil/0000-0001-9701-6065	NIAMS NIH HHS [AR 36308] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BEDNARCZYK JL, 1992, CLIN EXP METASTAS, V10, P281; BOSSY B, 1991, EMBO J, V10, P2375, DOI 10.1002/j.1460-2075.1991.tb07776.x; BRAY PF, 1990, J BIOL CHEM, V265, P9587; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; CALVETE JJ, 1990, FEBS LETT, V272, P37, DOI 10.1016/0014-5793(90)80443-M; CEPEK KL, 1993, J IMMUNOL, V150, P3459; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CERFBENSUSSAN N, 1986, J IMMUNOL, V136, P76; CERFBENSUSSAN N, 1992, EUR J IMMUNOL, V22, P273, DOI 10.1002/eji.1830220140; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; CORBI AL, 1990, J BIOL CHEM, V265, P2782; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; FLEMING JC, 1993, J IMMUNOL, V150, P480; GEORGES E, 1987, EUR J BIOCHEM, V165, P281, DOI 10.1111/j.1432-1033.1987.tb11439.x; HANSEN JA, 1984, LEUKOCYTE TYPING HUM, P195; HARLOW E, 1988, ANTIBODIES LABORATOR; HAURY M, 1993, J IMMUNOL, V23, P313; HEIDENREICH R, 1990, BIOCHEMISTRY-US, V29, P1232, DOI 10.1021/bi00457a020; HOCHSTENBACH F, 1988, J EXP MED, V168, P761, DOI 10.1084/jem.168.2.761; HOGERVORST F, 1991, EUR J BIOCHEM, V199, P425, DOI 10.1111/j.1432-1033.1991.tb16140.x; HOGG N, 1989, IMMUNOL TODAY, V10, P111, DOI 10.1016/0167-5699(89)90238-7; HOLZMANN B, 1989, IMMUNOL REV, V108, P45, DOI 10.1111/j.1600-065X.1989.tb00012.x; HOTCHIN NA, 1992, J BIOL CHEM, V267, P14852; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; KANSAS GS, 1991, J IMMUNOL, V147, P4094; KILSHAW PJ, 1990, EUR J IMMUNOL, V20, P2201, DOI 10.1002/eji.1830201008; KIMLT, 1992, J CELLSCI, V103, P743; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRISSANSEN GW, 1992, FEBS LETT, V296, P25, DOI 10.1016/0014-5793(92)80395-W; KRUSCHWITZ M, 1991, J CLIN PATHOL, V44, P636, DOI 10.1136/jcp.44.8.636; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LOFTUS JC, 1988, J BIOL CHEM, V263, P11025; MATAGNE A, 1991, BIOCHEM J, V280, P553, DOI 10.1042/bj2800553; MICKLEM KJ, 1991, AM J PATHOL, V139, P1297; MOLLER P, 1990, AM J PATHOL, V136, P509; NEUMAN E, 1992, J IMMUNOL, V148, P3520; PALLESEN G, 1990, LANCET, V335, P537, DOI 10.1016/0140-6736(90)90768-Z; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; ROBERTS AI, 1993, CANCER RES, V53, P1608; ROBERTS K, 1993, EUR J IMMUNOL, V23, P1630, DOI 10.1002/eji.1830230735; RUBIO M, 1992, EUR J IMMUNOL, V22, P1099, DOI 10.1002/eji.1830220434; Sambrook J, 1989, MOL CLONING LABORATO; SCHIEFERDECKER HL, 1990, J IMMUNOL, V144, P2541; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; SONNENBERG A, 1990, J CELL SCI, V96, P207; SPITS H, 1983, HYBRIDOMA, V2, P423, DOI 10.1089/hyb.1983.2.423; STASHENKO P, 1980, J IMMUNOL, V125, P1678; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TAMURA RN, 1991, P NATL ACAD SCI USA, V88, P10183, DOI 10.1073/pnas.88.22.10183; TEIXIDO J, 1992, J BIOL CHEM, V267, P1786; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; VANVOORHIS WC, 1983, J EXP MED, V158, P126, DOI 10.1084/jem.158.1.126; VISSER L, 1989, BLOOD, V74, P320; VISSER L, 1990, BRIT J HAEMATOL, V75, P359, DOI 10.1111/j.1365-2141.1990.tb04349.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YUAN Q, 1990, INT IMMUNOL, V2, P1097, DOI 10.1093/intimm/2.11.1097; YUAN Q, 1992, J BIOL CHEM, V267, P7352; ZIMRIN AB, 1990, J BIOL CHEM, V265, P8590	75	102	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6016	6025						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119947				2022-12-27	WOS:A1994MY84000082
J	WILLIAMS, FMR; MURRAY, RC; UNDERHILL, TM; FLINTOFF, WF				WILLIAMS, FMR; MURRAY, RC; UNDERHILL, TM; FLINTOFF, WF			ISOLATION OF A HAMSTER CDNA CLONE CODING FOR A FUNCTION INVOLVED IN METHOTREXATE UPTAKE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLATE-BINDING-PROTEIN; HUMAN KB CELLS; MEDIATED GENE-TRANSFER; L1210 LEUKEMIA-CELLS; OVARY CELLS; TRANSPORT-SYSTEM; TUMOR-CELLS; TETRAHYDROFOLATE COFACTOR; MEMBRANE-TRANSPORT; MOLECULAR-CLONING	A clone has been isolated from a Chinese hamster ovary cell cDNA expression library that complements mutant cells defective in the uptake of the folate analogue methotrexate. When transfected with this clone, the mutant cells regain the ability to bind and transport the drug and, as a consequence, become sensitive to its cytotoxic action. The clone is 2314 base pairs long and has an open reading frame of 1557 base pairs that codes for a putative protein of 58 kDa. This novel putative protein has a high content of hydrophobic residues and has a large part of its predicted secondary structure in the form of P-sheets. In the wild-type cell Line and in one of the mutant cell lines, this clone detects an mRNA of 2.5 kilobases, while in another mutant cell line, this message is absent. The data are consistent with this clone encoding either the reduced folate transporter or an auxiliary function that interacts with this transporter. This is the first report of a cDNA coding for a function, other than folate-binding protein, that is involved in the transport of methotrexate.	UNIV WESTERN ONTARIO,DEPT MICROBIOL & IMMUNOL,LONDON N6A 5C1,ON,CANADA	Western University (University of Western Ontario)								ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANTONY AC, 1985, J BIOL CHEM, V260, P4911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; CAMPBELL IG, 1991, CANCER RES, V51, P5329; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CHUNG KN, 1992, J CLIN INVEST, V91, P1289; CONEY LR, 1991, CANCER RES, V51, P6125; DEMBO M, 1984, J MEMBRANE BIOL, V78, P9, DOI 10.1007/BF01872527; DEUTSCH JC, 1989, ARCH BIOCHEM BIOPHYS, V274, P327, DOI 10.1016/0003-9861(89)90446-3; DIXON KH, 1992, J BIOL CHEM, V267, P24140; ELWOOD PC, 1986, J BIOL CHEM, V261, P5416; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; FAN JG, 1991, J BIOL CHEM, V266, P14862; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLINTOFF WF, 1976, IN VITRO CELL DEV B, V12, P749, DOI 10.1007/BF02835450; FLINTOFF WF, 1976, SOMAT CELL GENET, V2, P245, DOI 10.1007/BF01538963; FLINTOFF WF, 1983, ARCH BIOCHEM BIOPHYS, V223, P433, DOI 10.1016/0003-9861(83)90607-0; FLINTOFF WF, 1989, DRUG RESISTANCE MAMM, V1, P1; GALIVAN J, 1979, CANCER RES, V39, P735; GOLDMAN ID, 1969, J BIOL CHEM, V244, P3779; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; HENDERSON GB, 1980, ARCH BIOCHEM BIOPHYS, V202, P144, DOI 10.1016/0003-9861(80)90416-6; HENDERSON GB, 1983, ARCH BIOCHEM BIOPHYS, V221, P438, DOI 10.1016/0003-9861(83)90162-5; HENDERSON GB, 1986, FOLATES PTERINS, V3, P208; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HSUEH CT, 1992, ONCOL RES, V4, P497; JANSEN G, 1989, CANCER RES, V49, P1959; JANSEN G, 1990, J BIOL CHEM, V265, P18272; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAMEN BA, 1991, J CLIN INVEST, V87, P1442, DOI 10.1172/JCI115150; KANE MA, 1989, LAB INVEST, V60, P737; KANE MA, 1986, J BIOL CHEM, V261, P44; KANE MA, 1986, J BIOL CHEM, V261, P5625; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; MATHERLY LH, 1992, J BIOL CHEM, V267, P23253; MATHERLY LH, 1991, CANCER RES, V51, P3420; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P7853, DOI 10.1021/bi00420a040; ROSOWSKY A, 1985, CANCER RES, V45, P1815; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; SAIKAWA Y, 1993, J BIOL CHEM, V268, P5293; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUETZ JD, 1989, J BIOL CHEM, V264, P16261; SIROTNAK FM, 1981, CANCER RES, V41, P966; SIROTNAK FM, 1985, CANCER RES, V45, P3992; SIROTNAK FM, 1981, CANCER RES, V41, P447; UNDERHILL TM, 1989, MOL CELL BIOL, V9, P1754, DOI 10.1128/MCB.9.4.1754; UNDERHILL TM, 1989, SOMAT CELL MOLEC GEN, V15, P49, DOI 10.1007/BF01534669; UNDERHILL TM, 1992, SOMAT CELL MOLEC GEN, V18, P337, DOI 10.1007/BF01235757; WEITMAN SD, 1992, CANCER RES, V52, P3396; WESTERHOF GR, 1991, CANCER RES, V51, P5507; YANG CH, 1984, J MEMBRANE BIOL, V79, P285, DOI 10.1007/BF01871067; 1991, PROGRAM MANUAL GCG P	59	118	122	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5810	5816						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119923				2022-12-27	WOS:A1994MY84000053
J	FALLER, DV; MUNDSCHAU, LJ; FORMAN, LW; QUINONES, MA				FALLER, DV; MUNDSCHAU, LJ; FORMAN, LW; QUINONES, MA			V-MOS SUPPRESSES PLATELET-DERIVED GROWTH-FACTOR (PDGF) TYPE-BETA RECEPTOR AUTOPHOSPHORYLATION AND INHIBITS PDGF-BB-MEDIATED SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EJ-RAS ONCOGENE; PHOSPHOLIPASE-C-GAMMA; GLUCOCORTICOID RECEPTOR; CELL-CYCLE; TYROSINE PHOSPHORYLATION; TRANSFORMING ACTIVITY; MEIOTIC MATURATION; XENOPUS OOCYTES; KINASE-ACTIVITY; CDNA CLONING	The function of mos protein in somatic cells, the mechanisms underlying its ability to transform cells, and its relationship to growth factor autonomy and growth factor-mediated signal transduction are not well defined. This report demonstrates that the expression of transforming mos (v-mos) can block the stimulation of growth-related gene expression mediated by the platelet-derived growth factor (PDGF-BB). This blockade by v-mos of PDGF-BB signal transduction occurs very early in the signalling pathway at the level of PDGF type-beta receptor autophosphorylation. Although the expression of PDGF type-beta receptor, as detected by Western blot with anti-PDGF type-beta receptor antibody, was not diminished in v-mos transformed BALB/c-3T3 murine fibroblasts, the autophosphorylation of PDGF-beta receptor in response to ligand (recombinant PDGF-BB homodimer) stimulation was profoundly suppressed. This same phenomenon of v-mos-mediated PDGF type-beta receptor autophosphorylation inhibition was also demonstrated in NIH-3T3 fibroblasts. A v-mos mutant gene, which was incapable of binding ATP and was kinase-defective, did not block ligand-mediated receptor autophosphorylation. Factor(s) present in v-mos expressing fibroblasts, and found in the membrane fractions of these cells, dominantly inhibit the autophosphorylation of the PDGF type-beta receptor obtained from normal fibroblasts. This trans-acting factor does not appear to be a protein-tyrosine phosphatase. These findings suggest a role for mos, or a similar serine/threonine kinase, as a control mechanism in one of the earliest steps of the PDGF signal transduction pathway, and may provide a model for the functional interaction of mos with growth factor receptors.			FALLER, DV (corresponding author), BOSTON UNIV,SCH MED,CANC RES CTR,80 E CONCORD ST,E-124,BOSTON,MA 02118, USA.			Kasman, Laura/0000-0002-8661-2918				AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; BAI WL, 1992, ONCOGENE, V7, P1757; BENJAMIN CW, 1988, P NATL ACAD SCI USA, V85, P4345, DOI 10.1073/pnas.85.12.4345; BENJAMIN CW, 1987, P NATL ACAD SCI USA, V84, P546, DOI 10.1073/pnas.84.2.546; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOLD RJ, 1985, MOL CELL BIOL, V5, P3131, DOI 10.1128/MCB.5.11.3131; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COHEN S, 1980, J BIOL CHEM, V255, P4834; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DOPPLER W, 1987, GENE, V54, P147, DOI 10.1016/0378-1119(87)90357-X; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; ESCOBEDO JA, 1988, SCIENCE, V240, P1532, DOI 10.1126/science.2836953; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERAMISCO J, 1985, CANCER CELLS GROWTH, V3; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HUNT T, 1992, NATURE, V355, P587, DOI 10.1038/355587a0; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OFFERMANN MK, 1989, MOL CELL BIOL, V9, P1969, DOI 10.1128/MCB.9.5.1969; OKAZAKI K, 1992, EMBO J, V11, P2447, DOI 10.1002/j.1460-2075.1992.tb05309.x; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; PAULES RS, 1992, ONCOGENE, V7, P2489; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; QUINONES MA, 1991, J BIOL CHEM, V266, P14055; RAKE JB, 1991, J BIOL CHEM, V266, P5348; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SIEFERT RA, 1989, J BIOL CHEM, V264, P8771; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TOURAY M, 1991, ONCOGENE, V6, P211; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WILLIAMS LT, 1984, J BIOL CHEM, V259, P5287; WOOD TG, 1983, J VIROL, V46, P726, DOI 10.1128/JVI.46.3.726-736.1983; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHOU R, 1992, SCIENCE, V251, P671; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	64	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5022	5029						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106477				2022-12-27	WOS:A1994MX57100052
J	WINNING, BM; BOURGUIGNON, J; LEAVER, CJ				WINNING, BM; BOURGUIGNON, J; LEAVER, CJ			PLANT MITOCHONDRIAL NAD(+)-DEPENDENT MALIC ENZYME - CDNA CLONING, DEDUCED PRIMARY STRUCTURE OF THE 59-KDA AND 62-KDA SUBUNITS, IMPORT, GENE COMPLEXITY AND EXPRESSION ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE; PROTEINS; DEHYDROGENASE; PEPTIDE	The 59- and 62-kDa subunits of the mitochondrial NAD(+)-dependent malic enzyme (EC 1.1.1.39) were purified from Solanum tuberosum L. (potato). NH2-terminal and internal amino acid sequence information was used to identify cDNAs encoding the two subunits. Comparison of the nucleotide sequences revealed that the subunits have 60% identity at the DNA level and 65% identity at the deduced amino acid level, implying that they are derived from a common ancestral gene. The plant NAD(+)-dependent malic enzymes belong to a family of related enzymes, including cytosolic and chloroplastic NADP(+)-dependent malic enzymes (EC 1.1.1.40) and bacterial NAD(+)-dependent malic enzymes (EC 1.1.1.38). The cDNAs were transcribed and translated in vitro and the resultant polypeptides imported into isolated mitochondria and shown to be processed. Southern blot analysis of potato genomic DNA revealed a simple pattern of hybridization for both subunits, indicating a simple gene structure or small number of genes encoding the two subunits. Northern blot analysis of RNA from a range of potato tissues has shown that the steady state levels for the two subunits are equivalent, suggesting that they are coordinately expressed.	UNIV OXFORD,DEPT PLANT SCI,OXFORD OX1 3RB,ENGLAND	University of Oxford				Bourguignon, jacques/0000-0001-7517-0600				ARTUS NN, 1985, FEBS LETT, V182, P225, DOI 10.1016/0014-5793(85)80305-7; BOCANEGRA JA, 1993, BIOCHEMISTRY-US, V32, P2737, DOI 10.1021/bi00062a001; BORSCH D, 1990, FEBS LETT, V273, P111, DOI 10.1016/0014-5793(90)81063-T; CLANCY LL, 1992, J MOL BIOL, V226, P565, DOI 10.1016/0022-2836(92)90971-L; CUSHMAN JC, 1992, EUR J BIOCHEM, V208, P259, DOI 10.1111/j.1432-1033.1992.tb17181.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOUCE R, 1987, METHOD ENZYMOL, V148, P403; Douce R., 1985, MITOCHONDRIA HIGHER; DRAPER J, 1988, PLANT GENETIC TRANSF, P213; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLANNERY AV, 1989, PROTEOLYTIC ENZYMES; GROVER SD, 1984, ARCH BIOCHEM BIOPHYS, V234, P418, DOI 10.1016/0003-9861(84)90288-1; GURR SJ, 1991, MOL PLANT PATHOLOGY, V1, P109; HURKMAN WJ, 1986, PLANT PHYSIOL, V81, P802, DOI 10.1104/pp.81.3.802; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P9627, DOI 10.1093/nar/15.23.9627; KOBAYASHI K, 1989, J BIOL CHEM, V264, P3200; KULKARNI G, 1993, ARCH BIOCHEM BIOPHYS, V300, P231, DOI 10.1006/abbi.1993.1032; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; LOEBER G, 1991, J BIOL CHEM, V266, P3016; PASCAL N, 1990, PLANT PHYSIOL, V94, P189, DOI 10.1104/pp.94.1.189; POULOSE AJ, 1983, ARCH BIOCHEM BIOPHYS, V220, P652, DOI 10.1016/0003-9861(83)90459-9; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; ROTHERMEL BA, 1989, J BIOL CHEM, V264, P19587; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; TWELL D, 1988, MOL GEN GENET, V212, P325, DOI 10.1007/BF00334703; VANDOORSSELAERE J, 1991, PLANT PHYSIOL, V96, P1385, DOI 10.1104/pp.96.4.1385; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WALTER MH, 1990, PLANT MOL BIOL, V15, P525, DOI 10.1007/BF00019173; WEDDING RT, 1989, PLANT PHYSIOL, V90, P367, DOI 10.1104/pp.90.2.367; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WILLEFORD KO, 1987, PLANT PHYSIOL, V84, P1084, DOI 10.1104/pp.84.4.1084; WILLEFORD KO, 1987, J BIOL CHEM, V262, P8423; WINNING BM, 1992, PLANT J, V2, P763, DOI 10.1046/j.1365-313X.1992.t01-15-00999.x; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	35	37	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4780	4786						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106447				2022-12-27	WOS:A1994MX57100016
J	DEVER, TE; WEI, CL; BENKOWSKI, LA; BROWNING, K; MERRICK, WC; HERSHEY, JWB				DEVER, TE; WEI, CL; BENKOWSKI, LA; BROWNING, K; MERRICK, WC; HERSHEY, JWB			DETERMINATION OF THE AMINO-ACID-SEQUENCE OF RABBIT, HUMAN, AND WHEAT-GERM PROTEIN-SYNTHESIS FACTOR EIF-4C BY CLONING AND CHEMICAL SEQUENCING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION FACTOR-4C; HYPUSINE-CONTAINING PROTEIN; MESSENGER-RNA; RETICULOCYTES; PURIFICATION; ACTIVATORS; MECHANISM; SUBUNIT; YEAST; CDNA	The small eukaryotic initiation factor (eIF)-4C is implicated in the initiation pathway, where it enhances ribosome dissociation into subunits and stabilizes the binding of the initiator Met-tRNA(i) to 40 S ribosomal subunits. In order to elucidate the function of eIF-4C, its structure has been further characterized. The amino acid sequence of many peptides from rabbit reticulocyte and wheat germ eIF-4C have been determined chemically. From the chemical sequencing of the rabbit protein, it was noted that at least two different eIF-4C molecules were present which differed by conservative substitutions at three positions (2 aspartic acid for glutamic acid switches and 1 valine for isoleucine switch). By the use of unique sequences with low codon degeneracy, primers were used to obtain a polymerase chain reaction product of appropriate size and sequence. This product was then used to isolate full-length coding sequence cDNA clones for human eIF-4C. A similar strategy was used to design PCR primers and then isolate a wheat cDNA clone which lacked the coding region for the first 23 amino acids, but contained a complete 3'-untranslated region. The protein amino acid sequence of wheat germ eIF-4C is 68% identical with the mammalian protein, and, allowing for the most conservative substitutions, the proteins are 76% similar. Both the mammalian and wheat germ proteins are 143 amino acids in length and have molecular weights of abo 16,400. A unique feature of eIF-4C is.its apparent ''polarity'' as 9 of the first 15 amino acids are basic while 13 of the last 20 amino acids are acidic. This dipole.nature may enable the protein to interact with both the ribosome (perhaps via the rRNA) and other translation initiation factors.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616; UNIV TEXAS,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712	Case Western Reserve University; University of California System; University of California Davis; University of Texas System; University of Texas Austin			Dever, Thomas/GSE-0966-2022	Dever, Thomas/0000-0001-7120-9678	NIADDK NIH HHS [AM 07319] Funding Source: Medline; NIGMS NIH HHS [GM 26796, GM 22135] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135, R01GM026796] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON RD, 1988, J BIOL CHEM, V263, P5462; ALLEN ML, 1992, J BIOL CHEM, V267, P23232; BENNE R, 1978, J BIOL CHEM, V253, P3078; CAVALLIUS J, 1993, GTPASES BIOL; COOPER HL, 1983, P NATL ACAD SCI-BIOL, V80, P1854, DOI 10.1073/pnas.80.7.1854; DEVER TE, 1989, J BIOL CHEM, V264, P20518; ERNST H, 1987, J BIOL CHEM, V262, P1206; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HILL DE, 1993, NUCLEIC ACIDS RES, V13, P1920; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; KEMPER WM, 1976, J BIOL CHEM, V251, P5551; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Merrick W C, 1979, Methods Enzymol, V60, P101, DOI 10.1016/S0076-6879(79)60010-1; MERRICK WC, 1990, BIOCHIM BIOPHYS ACTA, V1050, P235, DOI 10.1016/0167-4781(90)90173-Y; MERRICK WC, 1992, TRANSLATIONALLY REGU, P7; MILBURN SC, 1990, EMBO J, V9, P2783, DOI 10.1002/j.1460-2075.1990.tb07466.x; PAIN VM, 1986, BIOCHEM J, V235, P625, DOI 10.1042/bj2350625; PATHAK VK, 1988, CELL, V54, P633, DOI 10.1016/S0092-8674(88)80007-2; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; SEAL SN, 1983, J BIOL CHEM, V258, P866; SEAL SN, 1982, J BIOL CHEM, V257, P8634; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P1578; THOMAS A, 1980, EUR J BIOCHEM, V107, P39, DOI 10.1111/j.1432-1033.1980.tb04621.x; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; VANNESS BG, 1978, J BIOL CHEM, V253, P8687; YANG WN, 1993, J BIOL CHEM, V268, P392	32	29	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3212	3218						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106356				2022-12-27	WOS:A1994MV63100017
J	HANNUN, YA				HANNUN, YA			THE SPHINGOMYELIN CYCLE AND THE 2ND MESSENGER FUNCTION OF CERAMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NECROSIS-FACTOR-ALPHA; FACTOR RECEPTOR PHOSPHORYLATION; EPIDERMOID CARCINOMA-CELLS; LEUKEMIA HL-60 CELLS; PROTEIN-KINASE-C; SIGNAL TRANSDUCTION; SERINE PALMITOYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; SPHINGOSINE; DIFFERENTIATION				HANNUN, YA (corresponding author), DUKE UNIV,MED CTR,DEPT MED,BOX 3355,DURHAM,NC 27710, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BIELAWSKA A, 1992, J BIOL CHEM, V267, P18493; BISHOP WR, 1988, ONCOGENE RES, V2, P205; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; CHATTERJEE S, 1993, ADV LIPID RES, V26, P25; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; FELDINGHABERMANN B, 1990, BIOCHEMISTRY-US, V29, P6314, DOI 10.1021/bi00478a028; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HAMPTON RY, 1989, SCIENCE, V246, P1050, DOI 10.1126/science.2555921; HANADA K, 1992, J BIOL CHEM, V267, P23527; HANADA K, 1990, J BIOL CHEM, V265, P22137; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HANNUN YA, 1993, IN PRESS BIOCH BIOPH; HOLLERAN WM, 1991, J LIPID RES, V32, P1151; INOKUCHI JI, 1989, J CELL PHYSIOL, V141, P573, DOI 10.1002/jcp.1041410316; JAYADEV S, 1994, IN PRESS J BIOL CHEM; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KALEN A, 1992, BIOCHIM BIOPHYS ACTA, V1125, P90, DOI 10.1016/0005-2760(92)90160-W; KAN CC, 1992, J BIOL CHEM, V267, P9663; KERR JFR, 1972, J PATHOL, V107, P41, DOI 10.1002/path.1711070107; KIM MY, 1991, J BIOL CHEM, V266, P484; KISS Z, 1988, ARCH BIOCHEM BIOPHYS, V265, P38, DOI 10.1016/0003-9861(88)90368-2; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; KUBOTA M, 1989, JPN J EXP MED, V59, P59; LESTER RL, 1993, J BIOL CHEM, V268, P845; LINARDIC CM, 1992, J BIOL CHEM, V267, P14909; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MAURICE A, 1989, BIOCHIMIE, V71, P373, DOI 10.1016/0300-9084(89)90009-6; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1992, NUTR REV, V50, P78; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; MICHAELSON J, 1991, APOPTOSIS MOL BASIS, P31; MUMBY MC, 1991, CELL REGUL, V2, P589, DOI 10.1091/mbc.2.8.589; NICULESCU F, 1993, J IMMUNOL, V150, P214; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; PATTON JL, 1992, J BACTERIOL, V174, P7180, DOI 10.1128/jb.174.22.7180-7184.1992; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RAMACHANDRAN CK, 1990, BIOCHEM BIOPH RES CO, V167, P607, DOI 10.1016/0006-291X(90)92068-B; ROSENWALD AG, 1993, J BIOL CHEM, V268, P4577; ROSENWALD AG, 1993, ADV LIPID RES, V26, P101; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SPENCE MW, 1993, ADV LIPID RES, V26, P3; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; TURINSKY J, 1990, J BIOL CHEM, V265, P16880; UEMURA K, 1990, J BIOCHEM-TOKYO, V108, P525; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VANVELDHOVEN PP, 1993, ADV LIPID RES, V26, P69; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; WEGMANN K, 1992, J BIOL CHEM, V267, P17997; WERTZ PW, 1990, FEBS LETT, V268, P110, DOI 10.1016/0014-5793(90)80985-R; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WRIGHT SC, 1992, J CELL BIOCHEM, V48, P344, DOI 10.1002/jcb.240480403; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YANAGA F, 1992, FEBS LETT, V314, P297, DOI 10.1016/0014-5793(92)81493-6	83	1182	1218	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3125	3128						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106344				2022-12-27	WOS:A1994MV63100001
J	HU, GZ; RONNE, H				HU, GZ; RONNE, H			OVEREXPRESSION OF YEAST PAM1 GENE PERMITS SURVIVAL WITHOUT PROTEIN PHOSPHATASE-2A AND INDUCES A FILAMENTOUS PHENOTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL DIVISION CYCLE; SACCHAROMYCES-CEREVISIAE; OKADAIC ACID; S-CEREVISIAE; COILED COILS; DNA; ENCODES; KINASE; SUBUNIT; TYPE-1	Protein phosphatase 2A (PP2A) is an essential enzyme which is present in all eukaryotic cells. PP2A has been implicated in regulating various metabolic processes and also in the control of cell cycle progression. In the yeast Saccharomyces cerevisiae, the catalytic subunit of PP2A is encoded by two duplicated genes, PPH21 and PPH22. A third related gene, PPH3, also contributes some PP2A activity. We have used a yeast strain in which a single functional PP2A gene is expressed from a regulated promoter to screen for high copy number suppressors of PP2A depletion. A new gene was cloned, PAM1 (PP2A multicopy suppressor), which in high copy number can bypass the need for a PP2A catalytic subunit. The PAM1 gene encodes a hydrophilic 93-kDa protein that contains two coiled coil motifs and has a highly basic C-terminal tail. High level overexpression of PAM1 inhibits growth and induces a filamentous phenotype.	UPPSALA BIOMED CTR,LUDWIG INST CANC RES,UPPSALA BRANCH,BOX 595,S-75124 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research				Ronne, Hans/0000-0002-1645-6091				ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; COHEN PTW, 1990, FEBS LETT, V268, P355, DOI 10.1016/0014-5793(90)81285-V; DENIS CL, 1991, MOL GEN GENET, V229, P395, DOI 10.1007/BF00267461; ELLERSTROM M, 1992, PLANT MOL BIOL, V18, P557, DOI 10.1007/BF00040671; ERHART E, 1983, J BACTERIOL, V156, P625, DOI 10.1128/JB.156.2.625-635.1983; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; HARTWELL LH, 1971, J MOL BIOL, V59, P183, DOI 10.1016/0022-2836(71)90420-7; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KINOSHITA N, 1993, GENE DEV, V7, P1059, DOI 10.1101/gad.7.6.1059; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; KOUPRINA N, 1993, YEAST, V9, P11, DOI 10.1002/yea.320090103; KOUPRINA N, 1993, GENETICS, V135, P327; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LORCA T, 1991, MOL CELL BIOL, V11, P1171, DOI 10.1128/MCB.11.2.1171; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; LUNDIN M, 1991, J BIOL CHEM, V266, P12168; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MA C, 1983, MOL CELL BIOL, V3, P1886, DOI 10.1128/MCB.3.10.1886; MARTINEZARIAS A, 1984, NATURE, V307, P740, DOI 10.1038/307740b0; MATSUMOTO T, 1993, MOL BIOL CELL, V4, P337, DOI 10.1091/mbc.4.3.337; MORTIMER RK, 1973, GENETICS, V74, P33; MUMBY MC, 1991, CELL REGUL, V2, P589, DOI 10.1091/mbc.2.8.589; NEHLIN JO, 1989, GENE, V85, P313, DOI 10.1016/0378-1119(89)90423-X; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; NEHLIN JO, 1992, NUCLEIC ACIDS RES, V20, P5271, DOI 10.1093/nar/20.20.5271; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELECH S, 1985, EUR J BIOCHEM, V148, P245, DOI 10.1111/j.1432-1033.1985.tb08832.x; PENG ZY, 1991, J BIOL CHEM, V266, P10925; RONNE H, 1991, MOL CELL BIOL, V11, P4876, DOI 10.1128/MCB.11.10.4876; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUSSELL P, 1987, CELL, V49, P145; SHIMANUKI M, 1993, MOL BIOL CELL, V4, P303, DOI 10.1091/mbc.4.3.303; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; SNEDDON AA, 1991, ADV PROTEIN PHOSPHAT, V6, P307; SPENCER F, 1990, GENETICS, V124, P237; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; THOMPSONJAEGER S, 1991, GENETICS, V129, P697; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; UEMURA T, 1993, GENE DEV, V7, P429, DOI 10.1101/gad.7.3.429; VANZYL W, 1992, MOL CELL BIOL, V12, P4946, DOI 10.1128/MCB.12.11.4946; VERDIER JM, 1990, YEAST, V6, P271, DOI 10.1002/yea.320060402; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WILSON RB, 1991, MOL CELL BIOL, V11, P3369, DOI 10.1128/MCB.11.6.3369; WOOTTON JC, 1989, PROTEIN ENG, V2, P535, DOI 10.1093/protein/2.7.535; WRIGHT RM, 1993, CURR GENET, V23, P388, DOI 10.1007/BF00312623; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	63	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3429	3435						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106383				2022-12-27	WOS:A1994MV63100047
J	KIRK, K; HORNER, HA; ELFORD, BC; ELLORY, JC; NEWBOLD, CI				KIRK, K; HORNER, HA; ELFORD, BC; ELLORY, JC; NEWBOLD, CI			TRANSPORT OF DIVERSE SUBSTRATES INTO MALARIA-INFECTED ERYTHROCYTES VIA A PATHWAY SHOWING FUNCTIONAL-CHARACTERISTICS OF A CHLORIDE CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; CA2+-ACTIVATED K+ CHANNEL; PLASMODIUM-FALCIPARUM; MEMBRANE-TRANSPORT; HOST ERYTHROCYTE; MAMMALIAN ERYTHROCYTES; ACTIVATED CHANNEL; EPITHELIAL-CELLS; PERMEABILITY; PARASITE	Following infection by the malaria parasite, Plasmodium falciparum, human erythrocytes show increased permeability to a variety of low molecular weight,solutes. In this study a number of anion transport blockers were identified as potent inhibitors of the transport of a wide range of solutes into human erythrocytes infected in vitro with P. falciparum. 5-Nitro-2-(3-phenyl-propylamino)benzoic acid (NPPB), furosemide, and niflumate blocked the malaria-induced transport of monovalent cations, neutral amino acids, sugars, nucleosides, and monovalent anions. For all of the substrates tested the order of potency of these three inhibitors was the same (NPPB > furosemide > niflumate) and dose-response curves for the effect of these inhibitors on malaria-induced choline transport were similar to those for malaria-induced thymidine transport. The data suggest that much, if not all, of the high capacity (non-saturable) transport of low molecular weight solutes into P. falciparum-infected erythrocytes is via a single type of pathway. The broad specificity of the pathway, its non-saturability in the physiological concentration range, and its failure to distinguish between stereoisomers (L- and D-alanine) are consistent with its being a type of pore or channel. For those substrates for which quantitative influx measurements were made the magnitude of the malaria-induced (inhibitor-sensitive) transport was in the order: Cl- > lactate > thymidine, adenosine > carnitine > choline > K+. The pathway is therefore anion-selective. The pharmacological and substrate-selectivity properties of the pathway show marked similarities to those of chloride channels in other cell types; this raises the possibility that the high capacity transport of small organic solutes may be an important and, as yet, largely unrecognized role for such channels in other tissues.	JOHN RADCLIFFE HOSP, INST MOLEC MED, OXFORD OX3 9DU, ENGLAND	University of Oxford	KIRK, K (corresponding author), UNIV OXFORD, PHYSIOL LAB, PARKS RD, OXFORD OX1 3PT, ENGLAND.		Kirk, Kiaran/C-8299-2009	Kirk, Kiaran/0000-0002-5613-2622; Newbold, Chris/0000-0002-9274-3789	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AABIN B, 1986, ACTA PHYSIOL SCAND, V128, pA42; BANDERALI U, 1992, AM J PHYSIOL, V263, pC1200, DOI 10.1152/ajpcell.1992.263.6.C1200; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BODAMMER JE, 1973, LAB INVEST, V28, P708; BOOKCHIN RM, 1980, J PHYSL, V312, pP65; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CABANTCHIK ZI, 1990, BLOOD CELLS, V16, P421; CABANTCHIK ZI, 1989, BLOOD, V74, P1464; CABANTCHIK ZI, 1990, UCLA SYM BI, V118, P267; DEUTICKE B, 1978, BIOCHIM BIOPHYS ACTA, V507, P137, DOI 10.1016/0005-2736(78)90381-4; Elford B.C., 1991, P377; ELFORD BC, 1990, BLOOD CELLS, V16, P433; ELFORD BC, 1985, MOL BIOCHEM PARASIT, V16, P43, DOI 10.1016/0166-6851(85)90048-9; ELFORD BC, 1990, J PHYSIOL-LONDON, V426, pP100; ELFORD BC, 1992, BIOCHEM SOC T, V20, P790, DOI 10.1042/bst0200790; ELLORY JC, 1988, PARASITOLOGY, V96, pS5, DOI 10.1017/S0031182000085942; ELLORY JC, 1992, FEBS LETT, V296, P219, DOI 10.1016/0014-5793(92)80383-R; EVANS MG, 1986, PFLUG ARCH EUR J PHY, V406, P65, DOI 10.1007/BF00582955; FINCHAM DA, 1987, J MEMBRANE BIOL, V96, P45, DOI 10.1007/BF01869333; FRANCIOLINI F, 1992, BIOCHIM BIOPHYS ACTA, V1113, P1, DOI 10.1016/0304-4157(92)90031-5; FRANCIOLINI F, 1987, J GEN PHYSIOL, V90, P453, DOI 10.1085/jgp.90.4.453; FRANCIOLINI F, 1990, BIOCHIM BIOPHYS ACTA, V1031, P247, DOI 10.1016/0304-4157(90)90009-2; FRIZZELL R A, 1992, Current Biology, V2, P285, DOI 10.1016/0960-9822(92)90862-5; FUJIOKA H, 1993, EXP PARASITOL, V76, P302, DOI 10.1006/expr.1993.1036; GATI WP, 1990, BIOCHEM J, V272, P277, DOI 10.1042/bj2720277; Gero A.M., 1991, P387; GERO AM, 1988, MOL BIOCHEM PARASIT, V27, P159, DOI 10.1016/0166-6851(88)90035-7; GERO AM, 1991, MOL BIOCHEM PARASIT, V44, P195, DOI 10.1016/0166-6851(91)90005-Q; GERO AM, 1992, PARASITOL TODAY, V8, P283, DOI 10.1016/0169-4758(92)90147-T; GINSBERG H, 1990, COMP BIOCHEM PHYS A, V95, P31, DOI 10.1016/0300-9629(90)90006-E; GINSBURG H, 1987, BIOSCIENCE REP, V7, P455, DOI 10.1007/BF01116501; GINSBURG H, 1988, P188; GINSBURG H, 1983, MOL BIOCHEM PARASIT, V8, P177, DOI 10.1016/0166-6851(83)90008-7; GINSBURG H, 1985, MOL BIOCHEM PARASIT, V14, P313, DOI 10.1016/0166-6851(85)90059-3; GINSBURG H, 1987, J MEMBRANE BIOL, V96, P1, DOI 10.1007/BF01869329; GREGER R, 1990, METHOD ENZYMOL, V191, P793; HALDAR K, 1992, MOL BIOCHEM PARASIT, V50, P161, DOI 10.1016/0166-6851(92)90253-G; HALM DR, 1992, J GEN PHYSIOL, V99, P339, DOI 10.1085/jgp.99.3.339; JARVIS SM, 1982, BIOCHEM J, V208, P83, DOI 10.1042/bj2080083; JOSHI P, 1987, BIOCHEM J, V246, P103, DOI 10.1042/bj2460103; KANAANI J, 1991, J CELL PHYSIOL, V149, P469, DOI 10.1002/jcp.1041490316; KIRK K, 1991, BIOCHEM J, V278, P521, DOI 10.1042/bj2780521; KIRK K, 1992, J PHYSIOL-LONDON, V452, pP342; KIRK K, 1992, J BIOL CHEM, V267, P23475; KIRK K, 1991, BIOCHIM BIOPHYS ACTA, V1061, P305, DOI 10.1016/0005-2736(91)90296-K; KIRK K, 1992, BIOCHIM BIOPHYS ACTA, V1135, P8, DOI 10.1016/0167-4889(92)90159-9; KUTNER S, 1983, J CELL PHYSIOL, V114, P245, DOI 10.1002/jcp.1041140215; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LOYEVSKY M, 1993, J CLIN INVEST, V91, P218, DOI 10.1172/JCI116174; MANNING SD, 1989, J MEMBRANE BIOL, V109, P113, DOI 10.1007/BF01870850; NAGEL W, 1985, PFLUG ARCH EUR J PHY, V403, P337, DOI 10.1007/BF00589243; PASVOL G, 1978, ANN TROP MED PARASIT, V72, P87, DOI 10.1080/00034983.1978.11719283; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; POLLARD CE, 1991, J MEMBRANE BIOL, V124, P275, DOI 10.1007/BF01994360; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; POPE AJ, 1991, BIOCHIM BIOPHYS ACTA, V1067, P51, DOI 10.1016/0005-2736(91)90025-4; POUVELLE B, 1991, NATURE, V353, P73, DOI 10.1038/353073a0; RASOLA A, 1992, BIOCHIM BIOPHYS ACTA, V1139, P319, DOI 10.1016/0925-4439(92)90108-Y; ROY G, 1992, J MEMBRANE BIOL, V130, P83; SARKADI B, 1985, AM J PHYSIOL, V248, pC480, DOI 10.1152/ajpcell.1985.248.5.C480; SCHOFIELD AE, 1992, NATURE, V355, P836, DOI 10.1038/355836a0; SHERMAN IW, 1992, PARASITOL TODAY, V8, P2, DOI 10.1016/0169-4758(92)90294-C; SHERMAN IW, 1988, PARASITOLOGY, V96, pS57, DOI 10.1017/S003118200008598X; Stein W., 1990, CHANNELS CARRIERS PU; TARASCHI TF, 1986, SCIENCE, V232, P102, DOI 10.1126/science.3006251; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WANGEMANN P, 1986, PFLUG ARCH EUR J PHY, V407, pS128, DOI 10.1007/BF00584942; WHITE MM, 1990, MOL PHARMACOL, V37, P720; YOUNG GPH, 1984, P NATL ACAD SCI-BIOL, V81, P5155, DOI 10.1073/pnas.81.16.5155; ZARCHIN S, 1986, BIOCHEM PHARMACOL, V35, P2435, DOI 10.1016/0006-2952(86)90473-9	70	205	210	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3339	3347						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106373				2022-12-27	WOS:A1994MV63100035
J	MATTIE, M; BROOKER, G; SPIEGEL, S				MATTIE, M; BROOKER, G; SPIEGEL, S			SPHINGOSINE-1-PHOSPHATE, A PUTATIVE 2ND MESSENGER, MOBILIZES CALCIUM FROM INTERNAL STORES VIA AN INOSITOL TRISPHOSPHATE-INDEPENDENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDIC-ACID LEVELS; PAROTID ACINAR-CELLS; CELLULAR PROLIFERATION; ENDOGENOUS GANGLIOSIDE; LYSOPHOSPHATIDIC ACID; HUMAN-NEUTROPHILS; 3T3 FIBROBLASTS; PHOSPHOLIPASE-D; TUMOR PROMOTER	Sphingosine-1-phosphate, a metabolite of sphingolipids which has previously been shown to stimulate DNA synthesis and cell division in quiescent cultures of Swiss 3T3 fibroblasts (Zhang, H., Desai, N. N., Olivera, A., Seki, T., Brooker, G., and Spiegel, S. (1991) J. Cell Biol. 114, 155-167), induced a transient increase in intracellular free calcium independent of extracellular calcium. The increase in calcium was completely abolished when intracellular calcium pools were depleted with thapsigargin, an inhibitor of the endoplasmic reticulum Ca2+-ATPase. The dose-response for calcium release induced by sphingosine-1-phosphate correlated closely with the concentration required for stimulation of DNA synthesis. The magnitude of the calcium response decreased with successive challenges, although sphingosine-1-phosphate did not attenuate the responses to either bradykinin or ionomycin. Conversely, prior stimulation of the cells with bradykinin had no effect on the sphingosine-1-phosphate-induced calcium signal. Although sphingosine-1-phosphate increased inositol (1,4,5)-trisphosphate levels, complete inhibition of inositol phosphate formation by pretreament with 12-0-tetradecanoylphorbol-13-acetate did not block sphingosine-1-phosphate-mediated calcium responses. Moreover, in permeabilized cells, heparin, an inositol (1,4,5)-trisphosphate antagonist, blocked Ca2+ release induced by inositol (1,4,5)-trisphosphate, but did not significantly alter the Ca2+ release induced by sphingosine-1-phosphate. Sphingosine-1-phosphate did not stimulate the release of arachidonic acid, another signaling molecule known to elevate [Ca2+]i without inositol lipid turnover or calcium influx. Our data suggest that sphingosine-1-phosphate mobilizes Ca+ from internal stores primarily through a mechanism independent of inositol lipid hydrolysis and arachidonic acid release and that sphingolipid metabolism may be important in calcium homeostasis.	GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,357 BASIC SCI BLDG,3900 RESERVOIR RD,WASHINGTON,DC 20007	Georgetown University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039718, R01GM043880] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 28940] Funding Source: Medline; NIGMS NIH HHS [1R29 GM 39718, 1RO1 GM43880] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; CHOW SC, 1990, J BIOL CHEM, V265, P902; DEERAUSQUIN GA, 1990, P NATL ACAD SCI USA, V87, P8017, DOI 10.1073/pnas.87.20.8017; DESAI NN, 1992, J BIOL CHEM, V267, P23122; DESAI NN, 1991, BIOCHEM BIOPH RES CO, V181, P361, DOI 10.1016/S0006-291X(05)81427-5; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; JALINK K, 1990, J BIOL CHEM, V265, P12232; KIM MY, 1991, J BIOL CHEM, V266, P484; KISS Z, 1990, J BIOL CHEM, V265, P7345; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; OLIVERA A, 1992, GLYCOCONJUGATE J, V9, P109; POWIS G, 1990, J BIOL CHEM, V265, P10266; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RINK TJ, 1990, FEBS LETT, V268, P381, DOI 10.1016/0014-5793(90)81290-5; RITCHIE T, 1992, BIOCHEM BIOPH RES CO, V186, P790, DOI 10.1016/0006-291X(92)90815-3; SABBADINI RA, 1992, J BIOL CHEM, V267, P15475; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SPIEGEL S, 1989, J BIOL CHEM, V264, P16512; SPIEGEL S, 1993, ADV LIPID RES, V25, P105; SPIEGEL S, 1988, EXP CELL RES, V177, P414, DOI 10.1016/0014-4827(88)90474-0; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P562, DOI 10.1515/bchm2.1973.354.1.562; SUGIYA H, 1991, FEBS LETT, V286, P113, DOI 10.1016/0014-5793(91)80953-Z; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMAS AP, 1988, J BIOL CHEM, V263, P2704; TOMBES RM, 1989, J CELL BIOL, V109, P627, DOI 10.1083/jcb.109.2.627; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; VANVELDHOVEN PP, 1989, J LIPID RES, V30, P611; WILSON E, 1986, J BIOL CHEM, V261, P2616; YAMASHITA T, 1987, J BIOL CHEM, V262, P5536; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZHANG H, 1990, J BIOL CHEM, V265, P21309	46	255	262	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3181	3188						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106352				2022-12-27	WOS:A1994MV63100013
J	SLESAREV, AI; LAKE, JA; STETTER, KO; GELLERT, M; KOZYAVKIN, SA				SLESAREV, AI; LAKE, JA; STETTER, KO; GELLERT, M; KOZYAVKIN, SA			PURIFICATION AND CHARACTERIZATION OF DNA TOPOISOMERASE-V - AN ENZYME FROM THE HYPERTHERMOPHILIC PROKARYOTE METHANOPYRUS-KANDLERI THAT RESEMBLES EUKARYOTIC TOPOISOMERASE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; EXTREMELY THERMOPHILIC ARCHAEBACTERIA; ESCHERICHIA-COLI; REVERSE GYRASE; DESULFUROCOCCUS-AMYLOLYTICUS; GENE-PRODUCT; PROTEIN; IDENTIFICATION; MECHANISM; CLEAVAGE	DNA topoisomerase V is a novel prokaryotic enzyme related to eukaryotic topoisomerase I. The enzyme is a type I DNA topoisomerase and is recognized by polyclonal antibody against human topoisomerase I. We describe its purification from the hyperthermophilic methanogen Methanopyrus kandleri. The enzyme has high activity in crude extracts and is present in at least 1,500 copies/cell. Topoisomerase V migrates as a 110-kDa polypeptide in SDS-polyacrylamide gel electrophoresis and as a 142-kDa globular protein in gel filtration. It is active up to at least 100-degrees-C on both positively and negatively supercoiled DNA and is not inhibited by single-stranded DNA. The enzyme works from 1 to 650 mm NaCl and up to 3.1 m potassium glutamate. It acts processively at low ionic strength and distributively at high NaCl or KCl concentration. Magnesium is not required and does not stimulate the enzymatic activity. Under DNA denaturing conditions, topoisomerase V catalyzes an unlinking reaction which results in substantial reduction in the linking number of closed circular DNA. The driving force for this process is DNA melting. Camptothecin is not nearly as good an inhibitor for topoisomerase V as it is for eukaryotic topoisomerase 1. The unique occurrence of two major type I topoisomerases (reverse gyrase and topoisomerase V) in M. kandleri may shed new light on the evolution of this family of enzymes and supports the concept of a distant but significant relationship between some hyperthermophilic organisms and eukaryotes.	UNIV CALIF LOS ANGELES, DEPT BIOL, LOS ANGELES, CA 90024 USA; UNIV REGENSBURG, D-93053 REGENSBURG, GERMANY; NIDDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA	University of California System; University of California Los Angeles; University of Regensburg; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	SLESAREV, AI (corresponding author), UNIV CALIF LOS ANGELES, INST MOLEC BIOL, 405 HILGARD AVE, LOS ANGELES, CA 90024 USA.			Kozyavkin, Sergei/0000-0001-5605-5113				ABREMSKI K, 1986, J BIOL CHEM, V261, P391; ABREMSKI K, 1986, J MOL BIOL, V192, P17, DOI 10.1016/0022-2836(86)90460-2; AGRIS PF, 1990, EXP CELL RES, V189, P276, DOI 10.1016/0014-4827(90)90247-8; ANDERA L, 1993, FEMS MICROBIOL LETT, V110, P107, DOI 10.1111/j.1574-6968.1993.tb06303.x; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BAILIS AM, 1992, MOL CELL BIOL, V12, P4988, DOI 10.1128/MCB.12.11.4988; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; BURGGRAF S, 1991, SYST APPL MICROBIOL, V14, P346, DOI 10.1016/S0723-2020(11)80308-5; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CRAIG NL, 1983, CELL, V35, P795, DOI 10.1016/0092-8674(83)90112-5; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; DEAN F, 1982, COLD SPRING HARB SYM, V47, P769; DEAN FB, 1985, J BIOL CHEM, V260, P4984; DELATOUR CB, 1990, J BACTERIOL, V172, P6803, DOI 10.1128/jb.172.12.6803-6808.1990; DIGATE RJ, 1992, J BIOL CHEM, V267, P20532; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; FINK GR, 1989, CELL, V58, P225, DOI 10.1016/0092-8674(89)90832-5; GARABEDIAN PAD, 1991, BIOCHEMISTRY-US, V30, P9940; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GUPTA M, 1992, J BIOL CHEM, V267, P24177; HENSEL R, 1988, FEMS MICROBIOL LETT, V49, P75, DOI 10.1111/j.1574-6968.1988.tb02685.x; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; HUBER R, 1989, NATURE, V342, P833, DOI 10.1038/342833a0; Kandler O, 1992, Biochem Soc Symp, V58, P195; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; KIKUCHI Y, 1979, P NATL ACAD SCI USA, V76, P3760, DOI 10.1073/pnas.76.8.3760; KIM RA, 1992, J BIOL CHEM, V267, P17178; KIRKEGAARD K, 1985, J MOL BIOL, V185, P625, DOI 10.1016/0022-2836(85)90075-0; KLETZIN A, 1992, NUCLEIC ACIDS RES, V20, P5389, DOI 10.1093/nar/20.20.5389; KORNBERG A, 1992, DNA REPLICATION, P379; KOVALSKY OI, 1990, NUCLEIC ACIDS RES, V18, P2801, DOI 10.1093/nar/18.9.2801; KOZYAVKIN S, 1991, Journal of Biomolecular Structure and Dynamics, V8, pA111; KOZYAVKIN SA, 1990, EUR J BIOCHEM, V191, P105, DOI 10.1111/j.1432-1033.1990.tb19099.x; KOZYAVKIN SA, 1987, J BIOMOL STRUCT DYN, V5, P119, DOI 10.1080/07391102.1987.10506380; Kristjansson Jakob K., 1992, P1; KURR M, 1991, ARCH MICROBIOL, V156, P239, DOI 10.1007/BF00262992; LAKE JA, 1988, NATURE, V331, P184, DOI 10.1038/331184a0; LIU LF, 1979, J BIOL CHEM, V254, P1082; LIU LF, 1990, DNA TOPOLOGY ITS BIO, P371; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MORHAM SG, 1990, GENE DEV, V4, P515, DOI 10.1101/gad.4.4.515; NASH HA, 1980, COLD SPRING HARB SYM, V45, P417, DOI 10.1101/SQB.1981.045.01.056; NASH HA, 1981, ENZYMES, V14, P471; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; OUZOUNIS C, 1992, CELL, V71, P189, DOI 10.1016/0092-8674(92)90347-F; PACE NR, 1991, CELL, V65, P531, DOI 10.1016/0092-8674(91)90082-A; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; RICHARD RE, 1989, J BIOL CHEM, V264, P4704; RICHARD RE, 1991, DEV BIOL, V146, P4, DOI 10.1016/0012-1606(91)90441-5; RIVERA MC, 1992, SCIENCE, V257, P74, DOI 10.1126/science.1621096; RIVERA MC, 1992, DETERMINING ORIGIN E; SCHOFIELD MA, 1992, J BACTERIOL, V174, P5168, DOI 10.1128/JB.174.15.5168-5170.1992; SHIBATA T, 1987, J BIOL CHEM, V262, P10419; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SLESAREV A, 1990, 20TH FEBS M BUD, P309; SLESAREV AI, 1991, J BIOL CHEM, V266, P12321; SLESAREV AI, 1990, J BIOMOL STRUCT DYN, V7, P935, DOI 10.1080/07391102.1990.10508533; SLESAREV AI, 1988, EUR J BIOCHEM, V173, P395, DOI 10.1111/j.1432-1033.1988.tb14012.x; SLESAREV AI, 1993, NATURE, V364, P735, DOI 10.1038/364735a0; SRIVENUGOPAL KS, 1984, BIOCHEMISTRY-US, V23, P1899, DOI 10.1021/bi00304a002; TSE YC, 1980, J BIOL CHEM, V255, P5560; VOLOGODSKII AV, 1992, TOPOLOGY PHYSICS CIR; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; Wang J. C., 1990, DNA TOPOLOGY ITS BIO, P321; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JC, 1981, ENYZMES A, V14, P331; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	73	45	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3295	3303						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106368				2022-12-27	WOS:A1994MV63100029
J	TAYLOR, RW; BIRCHMACHIN, MA; BARTLETT, K; LOWERSON, SA; TURNBULL, DM				TAYLOR, RW; BIRCHMACHIN, MA; BARTLETT, K; LOWERSON, SA; TURNBULL, DM			THE CONTROL OF MITOCHONDRIAL OXIDATIONS BY COMPLEX-III IN RAT MUSCLE AND LIVER-MITOCHONDRIA - IMPLICATIONS FOR OUR UNDERSTANDING OF MITOCHONDRIAL CYTOPATHIES IN MAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSPORT; MYXOTHIAZOL; PHOSPHORYLATION; RESPIRATION; INHIBITOR; ENERGY; STATE; STEPS; FLUX; FAT	We have studied the control by complex III of both succinate-cytochrome c reductase and of oxidative flux measured polarographically in rat muscle and liver mitochondria using the specific inhibitor, myxothiazol, to induce partial inhibitions of complex III activity. Complex III exerted a low degree of control on electron flux through succinate-cytochrome c reductase, and a 30-50% decrease in complex III activity remained undetected by this assay. However, when overall oxidative flux was measured polarographically there was a considerable difference in the effect of lowered complex III activity on this pathway between rat muscle and liver mitochondria. Small changes in complex III activity (approximately 5% inhibition) in muscle mitochondria caused marked changes in succinate-stimulated respiration, whereas in liver mitochondria complex III had to be inhibited by about 45% before changes in maximum oxidation rates could be detected. These differences between muscle and liver mitochondria occurred despite rat liver mitochondria having at least a 4-fold lower complex III activity. This suggests that when considering the biochemical consequences of defects of the respiratory chain an important factor is the degree to which an individual complex can be lowered before major changes in overall flux occur. In addition, since many patients with respiratory chain disease present with predominantly muscle symptoms, this latter finding suggests that an understanding of the control of mitochondrial oxidations by different tissues may be important when considering the tissue-specific nature of defects of the respiratory chain.	UNIV NEWCASTLE UPON TYNE, SCH MED,DEPT CHILD HLTH,DIV CLIN NEUROSCI, FRAMLINGTON PL, NEWCASTLE UPON TYNE NE2 4HH, ENGLAND; UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT CLIN BIOCHEM, NEWCASTLE UPON TYNE NE2 4HH, ENGLAND; UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT BIOCHEM & GENET, NEWCASTLE UPON TYNE NE2 4HH, ENGLAND	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK								ABERG F, 1992, ARCH BIOCHEM BIOPHYS, V295, P230, DOI 10.1016/0003-9861(92)90511-T; BIRCHMACHIN MA, 1993, METHODS TOXICOL, V2, P621; BIRCHMACHIN MA, 1993, METHODS TOXICOL, V2, P324; BOHNENSACK R, 1982, BIOCHIM BIOPHYS ACTA, V680, P271, DOI 10.1016/0005-2728(82)90139-6; BROWN GC, 1985, BIOCHEM J, V225, P399, DOI 10.1042/bj2250399; CHAZOTTE B, 1988, J BIOL CHEM, V263, P14359; GATLEY SJ, 1976, BIOCHEM J, V158, P307, DOI 10.1042/bj1580307; GELLERICH FN, 1990, FEBS LETT, V274, P167, DOI 10.1016/0014-5793(90)81355-R; GERTH K, 1980, J ANTIBIOT, V33, P1474, DOI 10.7164/antibiotics.33.1474; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; GROEN AK, 1982, J BIOL CHEM, V257, P2754; HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x; HUERTAS JR, 1991, FEBS LETT, V287, P89, DOI 10.1016/0014-5793(91)80022-U; KACSER H, 1973, RATE CONTROL BIOL PR, P65; LETELLIER T, 1993, BIOCHIM BIOPHYS ACTA, V1141, P58, DOI 10.1016/0005-2728(93)90189-M; MAZAT JP, 1986, BIOCHIM BIOPHYS ACTA, V849, P7, DOI 10.1016/0005-2728(86)90090-3; MOODY AJ, 1989, BIOCHIM BIOPHYS ACTA, V973, P29, DOI 10.1016/S0005-2728(89)80398-6; MORENOSANCHEZ R, 1991, BIOCHIM BIOPHYS ACTA, V1060, P284, DOI 10.1016/S0005-2728(05)80318-4; NALECZ MJ, 1985, ARCH BIOCHEM BIOPHYS, V236, P619; NEAT CE, 1981, BIOCHEM J, V196, P149, DOI 10.1042/bj1960149; PARKER WD, 1988, BIOCHIM BIOPHYS ACTA, V936, P133, DOI 10.1016/0005-2728(88)90260-5; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Ragan CI, 1988, MITOCHONDRIA PRACTIC, P79; ROTTENBERG H, 1977, BIOCHEMISTRY-US, V16, P3220, DOI 10.1021/bi00633a028; Shepherd D., 1969, METHODS ENZYMOL, V13, P11, DOI [10.1016/0076-6879(69)13006-2, DOI 10.1016/0076-6879(69)13006-2]; SHERRATT HSA, 1988, METHOD BIOCHEM ANAL, V33, P243; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; TAGER JM, 1983, FEBS LETT, V151, P1, DOI 10.1016/0014-5793(83)80330-5; TERVOORT MJ, 1981, BIOCHIM BIOPHYS ACTA, V637, P245, DOI 10.1016/0005-2728(81)90163-8; THIERBACH G, 1981, BIOCHIM BIOPHYS ACTA, V638, P282, DOI 10.1016/0005-2728(81)90238-3; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; VONJAGOW G, 1981, FEBS LETT, V136, P19, DOI 10.1016/0014-5793(81)81206-9; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WATMOUGH NJ, 1988, BIOCHEM J, V253, P541, DOI 10.1042/bj2530541	35	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3523	3528						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106394				2022-12-27	WOS:A1994MV63100061
J	WU, L; EINSTEIN, M; GEISSLER, WM; CHAN, HK; ELLISTON, KO; ANDERSSON, S				WU, L; EINSTEIN, M; GEISSLER, WM; CHAN, HK; ELLISTON, KO; ANDERSSON, S			EXPRESSION CLONING AND CHARACTERIZATION OF HUMAN 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-2, A MICROSOMAL-ENZYME POSSESSING 20-ALPHA-HYDROXYSTEROID DEHYDROGENASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLACENTA; 3-BETA,20-ALPHA-HYDROXYSTEROID OXIDOREDUCTASE; 3-ALPHA,20-BETA-HYDROXYSTEROID DEHYDROGENASE; STEROID 5-ALPHA-REDUCTASE; VILLI INVITRO; DUAL ACTIVITY; SEQUENCE; SITE; PROTEINS; CYTOCHROME-P-450	17Beta-hydroxysteroid dehydrogenase (17beta-HSD) is an enzyme crucial to the regulation of intracellular levels of biologically active steroid hormones in a variety of tissues. Here, we report the isolation, structure, and characterization of a cDNA encoding the human 17beta-HSD type 2. A 1.4-kilobase cDNA was identified, and DNA sequence analysis indicated that 17beta-HSD type 2 was a protein of 387 amino acids with a predicted molecular weight of 42,782. The protein contained an amino-terminal type II signal-anchor motif and a carboxyl-terminal endoplasmic reticulum retention motif, which suggested that 17beta-HSD type 2 was associated with the membranes of the endoplasmic reticulum. 17beta-HSD type 2 was capable of catalyzing the inter-conversion of testosterone and androstenedione as well as estradiol and estrone. The enzyme also demonstrated 20alpha-HSD activity toward 20alpha-dihydroprogesterone. The amount of 17beta-HSD type 2 mRNA in placenta was found to be high. The data suggest that the 17beta-HSD type 2 cDNA encodes the microsomal 17beta-HSD of human placenta, described by several laboratories.	MERCK SHARP & DOHME LTD,DEPT BIOCHEM,R-80M-213,POB 2000,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,DEPT BIOL DATA,RAHWAY,NJ 07065	Merck & Company; Merck & Company				Elliston, Keith/0000-0002-9110-9233				ANDERSSON S, 1990, P NATL ACAD SCI USA, V87, P3640, DOI 10.1073/pnas.87.10.3640; ANDERSSON S, 1989, J BIOL CHEM, V264, P16249; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDERSSON S, 1991, NATURE, V354, P159, DOI 10.1038/354159a0; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BLOMQUIST CH, 1985, ARCH BIOCHEM BIOPHYS, V239, P206, DOI 10.1016/0003-9861(85)90828-8; BLOMQUIST CH, 1991, J STEROID BIOCHEM, V39, P735, DOI 10.1016/0960-0760(91)90374-E; BLOMQUIST CH, 1987, J CLIN ENDOCR METAB, V65, P647, DOI 10.1210/jcem-65-4-647; CHEN QX, 1989, BIOCHEMISTRY-US, V28, P8856, DOI 10.1021/bi00448a026; CHIN CC, 1973, STEROIDS, V22, P373; DELAUNOIT Y, 1992, ENDOCRINOLOGY, V130, P553, DOI 10.1210/en.130.1.553; DESCOMPS B, 1968, B SOC CHIM BIOL, V50, P1681; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FOURNETDULGUEROV N, 1987, J CLIN ENDOCR METAB, V65, P757, DOI 10.1210/jcem-65-4-757; GOEBELSMANN U, 1975, J CLIN ENDOCR METAB, V41, P1136, DOI 10.1210/jcem-41-6-1136; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; Grumbach M. M., 1992, WILLIAMS TXB ENDOCRI, P853; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JARABAK J, 1969, BIOCHEMISTRY-US, V8, P2203, DOI 10.1021/bi00833a062; Jarabak J, 1969, METHOD ENZYMOL, V15, P746, DOI DOI 10.1016/S0076-6879(69)15041-7; KARAVOLAS HJ, 1970, J BIOL CHEM, V245, P4948; KROZOWSKI Z, 1992, MOL CELL ENDOCRINOL, V84, pC25, DOI 10.1016/0303-7207(92)90064-D; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANN WD, 1967, H-S Z PHYSIOL CHEM, V348, P1633, DOI 10.1515/bchm2.1967.348.1.1633; LEHRMAN MA, 1987, J BIOL CHEM, V262, P3354; Luu The V, 1989, Mol Endocrinol, V3, P1301; LUU-THE V, 1990, Molecular Endocrinology, V4, P268; MARTEL C, 1992, J STEROID BIOCHEM, V41, P597, DOI 10.1016/0960-0760(92)90390-5; MURDOCK GL, 1986, BIOCHEMISTRY-US, V25, P641, DOI 10.1021/bi00351a019; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELTOKETO H, 1988, FEBS LETT, V239, P73, DOI 10.1016/0014-5793(88)80548-9; PITTAWAY DE, 1976, J CLIN ENDOCR METAB, V43, P457; POLLOW K, 1975, Z NATURFORSCH C, VC 30, P17; POLLOW K, 1975, Z NATURFORSCH C, VC 30, P4; POLLOW K, 1971, Z NATURFORSCH PT B, VB 26, P710; POLLOW K, 1974, H-S Z PHYSIOL CHEM, V355, P515, DOI 10.1515/bchm2.1974.355.1.515; RUNNEBAUM B, 1975, ACTA ENDOCRINOL-COP, V80, P569, DOI 10.1530/acta.0.0800569; RUNNEBAUM B, 1975, ACTA ENDOCRINOL-COP, V80, P558, DOI 10.1530/acta.0.0800558; Sambrook J, 1989, MOL CLONING LABORATO; SHARAF MA, 1982, BIOCHEMISTRY-US, V21, P4615, DOI 10.1021/bi00262a016; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; STANCZYK FZ, 1978, J STEROID BIOCHEM, V9, P153, DOI 10.1016/0022-4731(78)90077-8; STRICKLER RC, 1980, BIOCHEMISTRY-US, V19, P4950, DOI 10.1021/bi00563a002; STRICKLER RC, 1981, J BIOL CHEM, V256, P316; SWEET F, 1980, BIOCHEMISTRY-US, V19, P978, DOI 10.1021/bi00546a023; THOMAS CMG, 1976, ACTA ENDOCRINOL-COP, V82, P150; TSENG L, 1972, ENDOCRINOLOGY, V90, P405, DOI 10.1210/endo-90-2-405; ULLOAAGUIRRE A, 1985, J CLIN ENDOCR METAB, V60, P639, DOI 10.1210/jcem-60-4-639; VONHEIJNE G, 1990, PROTEIN ENG, V4, P109, DOI 10.1093/protein/4.2.109; WENZEL M, 1974, H-S Z PHYSIOL CHEM, V355, P969, DOI 10.1515/bchm2.1974.355.2.969	52	417	425	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12964	12969						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8099587				2022-12-27	WOS:A1993LG65800106
J	FUNDERBURGH, JL; FUNDERBURGH, ML; BROWN, SJ; VERGNES, JP; HASSELL, JR; MANN, MM; CONRAD, GW				FUNDERBURGH, JL; FUNDERBURGH, ML; BROWN, SJ; VERGNES, JP; HASSELL, JR; MANN, MM; CONRAD, GW			SEQUENCE AND STRUCTURAL IMPLICATIONS OF A BOVINE CORNEAL KERATAN SULFATE PROTEOGLYCAN CORE PROTEIN - PROTEIN-37B REPRESENTS BOVINE LUMICAN AND PROTEIN-37A AND PROTEIN-25 ARE UNIQUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL INTERSTITIAL PROTEOGLYCANS; FIBROMODULIN; DECORIN; GENE; GLYCOSAMINOGLYCAN; IDENTIFICATION; LOCALIZATION; GLYCOPROTEIN; PERIODICITY; EXPRESSION	Amino acid sequence from tryptic peptides of three different bovine corneal keratan sulfate proteoglycan (KSPG) core proteins (designated 37A, 37B, and 25) showed similarities to the sequence of a chicken KSPG core protein lumican. Bovine lumican cDNA was isolated from a bovine corneal expression library by screening with chicken lumican cDNA. The bovine cDNA codes for a 342-amino acid protein, M(r) 38,712, containing amino acid sequences identified in the 37B KSPG core protein. The bovine lumican is 68% identical to chicken lumican, with an 83% identity excluding the N-terminal 40 amino acids. Location of 6 cysteine and 4 consensus N-glycosylation sites in the bovine sequence were identical to those in chicken lumican. Bovine lumican had about 50% identity to bovine fibromodulin and 20% identity to bovine decorin and biglycan. About two-thirds of the lumican protein consists of a series of 10 amino acid leucine-rich repeats that occur in regions of calculated high beta-hydrophobic moment, suggesting that the leucine-rich repeats contribute to beta-sheet formation in these proteins. Sequences obtained from 37A and 25 core proteins were absent in bovine lumican, thus predicting a unique primary structure and separate mRNA for each of the three bovine KSPG core proteins.	UNIV PITTSBURGH,SCH MED,INST EYE & EAR,DEPT OPHTHALMOL,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	FUNDERBURGH, JL (corresponding author), KANSAS STATE UNIV AGR & APPL SCI,DIV BIOL,ACKERT HALL,MANHATTAN,KS 66506, USA.			Brown, Susan/0000-0002-7984-0445	NEI NIH HHS [5-P30-EY08089, EY08104, EY00952] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008104, R01EY000952, R01EY008089, R37EY008104] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONRAD GW, 1982, J BIOL CHEM, V257, P464; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FRESCO LD, 1991, MOL CELL BIOL, V11, P1578, DOI 10.1128/MCB.11.3.1578; FUNDERBURGH JL, 1983, CURR EYE RES, V2, P769; FUNDERBURGH JL, 1983, INVEST OPHTH VIS SCI, V24, P208; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P24773; FUNDERBURGH JL, 1987, J BIOL CHEM, V262, P11634; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; FUNDERBURGH JL, 1992, INVEST OPHTH VIS SCI, V33, P894; FUNDERBURGH ML, 1992, INVEST OPHTH VIS SCI, V33, P895; HASSELL J, 1985, HEREDITY VISUAL DEV; HEIEGARD D, 1986, J BIOL CHEM, V261, P13866; HEINEGARD D, 1985, BIOCHEM J, V230, P181, DOI 10.1042/bj2300181; JOST CJ, 1991, J BIOL CHEM, V266, P13336; KRANTZ DD, 1991, J BIOL CHEM, V266, P16801; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI W, 1992, ARCH BIOCHEM BIOPHYS, V296, P190, DOI 10.1016/0003-9861(92)90562-B; MADISEN L, 1990, DNA CELL BIOL, V9, P303, DOI 10.1089/dna.1990.9.303; MIKOL DD, 1990, J CELL BIOL, V111, P2673, DOI 10.1083/jcb.111.6.2673; Nei M., 1987, MOL EVOLUT GENET, P293; OHKURA H, 1991, CELL, V64, P149, DOI 10.1016/0092-8674(91)90216-L; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PLAAS AHK, 1990, J BIOL CHEM, V265, P20634; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; Sambrook J, 1989, MOL CLONING LABORATO; SMILEY BL, 1990, MOL CELL BIOL, V10, P6436, DOI 10.1128/MCB.10.12.6436; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5	34	107	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11874	11880						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8099356				2022-12-27	WOS:A1993LF28400063
J	BAHNSON, TD; PANDOL, SJ; DIONNE, VE				BAHNSON, TD; PANDOL, SJ; DIONNE, VE			CYCLIC-GMP MODULATES DEPLETION-ACTIVATED CA2+ ENTRY IN PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD GUANYLATE-CYCLASE; PLASMA-MEMBRANE; CALCIUM ENTRY; INOSITOL PHOSPHATES; TUMOR PROMOTER; SMOOTH-MUSCLE; CA-2+ INFLUX; CHANNELS; THAPSIGARGIN; MECHANISM	In the pancreatic acinar cell, hormonal stimulation causes a rise in the intracellular free Ca2+ concentration by activating the inositol 1,4,5-trisphosphate-mediated release of Ca2+ from intracellular stores (Berridge, M. J., and Irvine, R. F. (1989) Nature 341, 197-205). The released Ca2+ is, for the most part, extruded from the cell, necessitating a mechanism for Ca2+ entry and reloading of intracellular Ca2+ stores (Putney, J. W., Jr. (1990) Cell Calcium 11, 611-624; Rink, T. J. (1990) FEBS Lett. 268, 381-385). However, neither the mechanism of depletion-activated Ca2+ entry nor the signal that activates it is known. We report here that a sustained inward current of depletion-activated Ca2+ entry can be measured in pancreatic acinar cells using patch-clamp recording methods. Furthermore, the current can be blocked by an inhibitor of guanylyl cyclase, can be reactivated by 8-bromo-cGMP after inhibition, and can be activated in the absence of Ca2+ depletion by perfusing the cell with cGMP, but not cAMP. Intracellular perfusion with 1,3,4,5-inositol tetrakisphosphate did not activate an inward current, whereas perfusion with 2,4,5-inositol trisphosphate did activate an inward current. We conclude that cGMP may be an intracellular messenger that regulates depletion-activated Ca2+ entry.	VET ADM MED CTR,DEPT MED,DIV GASTROENTEROL,LA JOLLA,CA 92161; UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,LA JOLLA,CA 92093	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego	BAHNSON, TD (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,LA JOLLA,CA 92093, USA.							BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1981, MOL CELL ENDOCRINOL, V24, P115, DOI 10.1016/0303-7207(81)90055-1; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BREER H, 1993, TRENDS NEUROSCI, V16, P5, DOI 10.1016/0166-2236(93)90040-S; BRUZZONE R, 1985, BIOCHEM J, V226, P621, DOI 10.1042/bj2260621; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CASTEELS R, 1981, J PHYSIOL-LONDON, V317, P263, DOI 10.1113/jphysiol.1981.sp013824; CHANGYA L, 1989, FEBS LETT, V251, P43, DOI 10.1016/0014-5793(89)81425-5; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; GOY MF, 1991, TRENDS NEUROSCI, V14, P293, DOI 10.1016/0166-2236(91)90140-P; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOKIN MR, 1953, J BIOL CHEM, V203, P967; HOTH H, 1992, NATURE, V355, P353; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; KAUPP UB, 1992, ANNU REV PHYSIOL, V54, P153; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; KWAN CY, 1990, J BIOL CHEM, V265, P678; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; MULSCH A, 1988, J PHARMACOL EXP THER, V247, P283; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PANDOL SJ, 1990, J BIOL CHEM, V265, P12846; PANDOL SJ, 1990, CELL CALCIUM, V11, P447; PAPE HC, 1989, NATURE, V340, P715, DOI 10.1038/340715a0; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RINK TJ, 1990, FEBS LETT, V268, P381, DOI 10.1016/0014-5793(90)81290-5; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; SASAKI T, 1990, FEBS LETT, V264, P130, DOI 10.1016/0014-5793(90)80782-E; SCHULZ S, 1991, TRENDS PHARMACOL SCI, V12, P116, DOI 10.1016/0165-6147(91)90519-X; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; WHALLEY R, 1992, MOL BIOL CELL, V3, P373	42	129	130	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10808	10812						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8098704				2022-12-27	WOS:A1993LD46600018
J	CHEON, CI; HONG, ZL; VERMA, DPS				CHEON, CI; HONG, ZL; VERMA, DPS			NODULIN-24 FOLLOWS A NOVEL PATHWAY FOR INTEGRATION INTO THE PERIBACTEROID MEMBRANE IN SOYBEAN ROOT-NODULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE CLEAVAGE SITES; SIGNAL-SEQUENCE; ENDOPLASMIC-RETICULUM; PROTEINS; PEPTIDE; CELL; GENE; COMPARTMENT; ENDOCYTOSIS; SIMILARITY	Nodulin-24 is a nodule-specific protein of the peribacteroid membrane (PBM) in soybean. It has an apparent molecular mass of 33 kDa while its full-length cDNA encodes a polypeptide of only 24 kDa, In vitro transcription of nodulin-24 cDNA followed by translation resulted in a peptide translocated into microsomal membranes with cleavage of a signal sequence. The cleavage site of the signal sequence in nodulin-24 was determined to be between Ala (A25) and Arg (R26) by microsequencing of the [H-3]leucine-labeled processed peptide. Fusion of the signal sequence of nodulin-24 with the beta-glucuronidase peptide prevented co-translational cleavage of the signal sequence although the translocation of the fused protein into microsomes occurred co-translationally. Trypsin treatment of membrane-translocated nodulin-24 did not result in any alteration in size suggesting that the newly synthesized peptide is fully protected in the membrane vesicle. Fusion of nodulin-24 with beta-glucuronidase also showed no change in size following trypsin treatment, suggesting that nodulin-24 has no membrane-spanning region. In addition, in vitro synthesized nodulin-24 was present in the supernatant fraction after sonication of microsomal membranes. Mature nodulin-24, on the other hand, is not solubilized from PBM by sodium carbonate (pH 11) or EGTA and is soluble only in detergent. These data suggest that nodulin-24 is synthesized as a lumenal protein in the endoplasmic reticulum and post-translationally attached to the membranes en route to the PBM. This processing results in a significant increase in the apparent molecular mass of nodulin-24 which may be due to the attachment of membrane lipids as this protein shares characteristics with membrane lipoproteins of many pathogenic bacteria.	OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR BIOTECHNOL,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Hong, Zonglie/F-5679-2010	Hong, Zonglie/0000-0001-9057-4128				ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BREWIN NJ, 1991, ANNU REV CELL BIOL, V7, P191, DOI 10.1146/annurev.cb.07.110191.001203; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHEON CI, 1993, EMBO J, V12, P4125, DOI 10.1002/j.1460-2075.1993.tb06096.x; CHRISPEELS MJ, 1991, ANNU REV PLANT PHYS, V42, P21, DOI 10.1146/annurev.pp.42.060191.000321; COLEMAN J, 1985, CELL, V43, P351, DOI 10.1016/0092-8674(85)90040-6; DELAUNEY AJ, 1988, PLANT MOL BIOL REP, V6, P279; FOLZ RJ, 1987, J BIOL CHEM, V2622, P17221; FORTIN MG, 1987, NUCLEIC ACIDS RES, V15, P813, DOI 10.1093/nar/15.2.813; FORTIN MG, 1985, EMBO J, V4, P3041, DOI 10.1002/j.1460-2075.1985.tb04043.x; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GAROFF H, 1985, ANNU REV CELL BIOL, V1, P403, DOI 10.1146/annurev.cb.01.110185.002155; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; ITURRIAGA G, 1989, PLANT CELL, V1, P381, DOI 10.1105/tpc.1.3.381; JACOBS FA, 1987, NUCLEIC ACIDS RES, V15, P1271, DOI 10.1093/nar/15.3.1271; JENNINGS ML, 1989, ANNU REV BIOCHEM, V58, P999; KATINAKIS P, 1985, P NATL ACAD SCI USA, V82, P4157, DOI 10.1073/pnas.82.12.4157; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; Magee Tony, 1992, Trends in Cell Biology, V2, P318, DOI 10.1016/0962-8924(92)90172-J; MAURO VP, 1985, NUCLEIC ACIDS RES, V13, P239, DOI 10.1093/nar/13.1.239; MIAO GH, 1992, J CELL BIOL, V118, P481, DOI 10.1083/jcb.118.2.481; MORRISON N, 1987, PLANT MOL BIOL, V9, P185, DOI 10.1007/BF00166455; NIRUNSUKSIRI W, 1990, PLANT MOL BIOL, V15, P835, DOI 10.1007/BF00039424; NOTHWEHR SF, 1989, J BIOL CHEM, V264, P4642; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; SANDAL NN, 1992, PLANT MOL BIOL, V18, P607, DOI 10.1007/BF00040679; Sankaran K, 1993, LIPID MODIFICATIONS, P163; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V16, P338, DOI 10.1016/0968-0004(91)90139-M; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; VANRENSWOUDE J, 1984, METHOD ENZYMOL, V104, P329; VASSAROTTI A, 1987, J BIOL CHEM, V262, P411; VERMA DPS, 1978, J CELL BIOL, V78, P919, DOI 10.1083/jcb.78.3.919; VERMA DPS, 1992, PLANT CELL, V4, P373, DOI 10.1105/tpc.4.4.373; VERMA DPS, 1989, MOL BIOL PLANT NUCLE, P329; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17	37	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6598	6602						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120012				2022-12-27	WOS:A1994MZ50300053
J	LUCHT, JM; DERSCH, P; KEMPF, B; BREMER, E				LUCHT, JM; DERSCH, P; KEMPF, B; BREMER, E			INTERACTIONS OF THE NUCLEOID-ASSOCIATED DNA-BINDING PROTEIN H-NS WITH THE REGULATORY REGION OF THE OSMOTICALLY CONTROLLED PROU OPERON OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE-LIKE PROTEINS; SALMONELLA-TYPHIMURIUM; GENE-EXPRESSION; CURVED DNA; PROLINE TRANSPORT; STRUCTURAL GENE; BENT DNA; IDENTIFICATION; SEQUENCES; MUTATIONS	The Escherichia coli hns gene encodes the abundant nucleoid-associated DNA-binding protein H-NS. Mutations in hns alter the expression of many genes with unrelated functions and result in a derepression of the proU operon (proVWX) without abolishing the osmotic control of its transcription. We have investigated the interactions of H-NS with the proU regulatory region by deletion analysis of cis-acting sequences, competitive gel retardation assays, and DNase I footprinting. The negative effect of H-NS on proU transcription was mediated by cis-acting sequences within proV but did not depend on the presence of a curved DNA segment upstream of the proU -35 region previously characterized as a target for H-NS binding in vitro. We detected a 46-base pair high affinity H-NS binding region downstream of the proU promoter at the 5' end of the proV gene and a complex array of additional H-NS binding sites which suggest the presence of an extended H-NS nucleoprotein complex. Most of the H-NS binding sites were highly A + T-rich and carried stretches of 5 or more consecutive A-T base pairs. The implications of our results for the osmotic regulation of proU transcription are discussed.	MAX PLANCK INST TERR MIKROBIOL, D-35043 MARBURG, GERMANY; UNIV KONSTANZ, DEPT BIOL, D-78434 CONSTANCE, GERMANY	Max Planck Society; University of Konstanz				Lucht, Jan/0000-0002-4722-1244; Dersch, Petra/0000-0001-8177-3280				BARRON A, 1986, J BACTERIOL, V167, P433, DOI 10.1128/jb.167.2.433-438.1986; BERTIN P, 1990, BIOCHIMIE, V72, P889, DOI 10.1016/0300-9084(90)90008-5; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; CAIRNEY J, 1985, J BACTERIOL, V164, P1224, DOI 10.1128/JB.164.3.1224-1232.1985; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; DATTANANDA CS, 1991, J BACTERIOL, V173, P7481, DOI 10.1128/jb.173.23.7481-7490.1991; DERSCH P, 1993, MOL MICROBIOL, V8, P875, DOI 10.1111/j.1365-2958.1993.tb01634.x; DORMAN CJ, 1990, NATURE, V344, P789, DOI 10.1038/344789a0; DRI AM, 1992, GENE, V120, P11, DOI 10.1016/0378-1119(92)90003-8; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; DUNLAP VJ, 1985, J BACTERIOL, V163, P296, DOI 10.1128/JB.163.1.296-304.1985; DURRENBERGER M, 1991, RES MICROBIOL, V142, P373, DOI 10.1016/0923-2508(91)90106-K; FALCONI M, 1988, MOL MICROBIOL, V2, P323, DOI 10.1111/j.1365-2958.1988.tb00035.x; FALCONI M, 1991, NEW BIOL, V3, P615; FORSMAN K, 1992, P NATL ACAD SCI USA, V89, P9880, DOI 10.1073/pnas.89.20.9880; FRIEDRICH K, 1988, FEBS LETT, V229, P197, DOI 10.1016/0014-5793(88)80826-3; GORANSSON M, 1990, NATURE, V344, P682, DOI 10.1038/344682a0; GOWRISHANKAR J, 1989, J BACTERIOL, V171, P1923, DOI 10.1128/jb.171.4.1923-1931.1989; GOWRISHANKAR J, 1985, J BACTERIOL, V164, P434, DOI 10.1128/JB.164.1.434-445.1985; GRAEMECOOK KA, 1989, MOL MICROBIOL, V3, P1287, DOI 10.1111/j.1365-2958.1989.tb00279.x; GUTIERREZ C, 1991, J MOL BIOL, V220, P959, DOI 10.1016/0022-2836(91)90366-E; HIGGINS CF, 1988, CELL, V52, P569, DOI 10.1016/0092-8674(88)90470-9; HIGGINS CF, 1992, NUCLEIC ACIDS MOL BI, V6, P67; HINTON JCD, 1992, MOL MICROBIOL, V6, P2327, DOI 10.1111/j.1365-2958.1992.tb01408.x; HROMOCKYJ AE, 1992, MOL MICROBIOL, V6, P2113, DOI 10.1111/j.1365-2958.1992.tb01385.x; HULTON CSJ, 1990, CELL, V63, P631, DOI 10.1016/0092-8674(90)90458-Q; JORDI BJAM, 1992, EMBO J, V11, P2627, DOI 10.1002/j.1460-2075.1992.tb05328.x; JOVANOVICH SB, 1989, J BIOL CHEM, V264, P7821; KANO Y, 1993, GENE, V126, P93; KAWULA TH, 1991, J BACTERIOL, V173, P4116, DOI 10.1128/jb.173.13.4116-4123.1991; LATEANA A, 1989, FEBS LETT, V244, P34, DOI 10.1016/0014-5793(89)81156-1; LATEANA A, 1991, P NATL ACAD SCI USA, V88, P10907, DOI 10.1073/pnas.88.23.10907; LEJEUNE P, 1990, P NATL ACAD SCI USA, V87, P360, DOI 10.1073/pnas.87.1.360; LIU QY, 1993, P NATL ACAD SCI USA, V90, P1761, DOI 10.1073/pnas.90.5.1761; LUCHT JM, 1991, J BACTERIOL, V173, P801, DOI 10.1128/jb.173.2.801-809.1991; MARSH M, 1990, NUCLEIC ACIDS RES, V18, P3397, DOI 10.1093/nar/18.11.3397; MAY G, 1990, MOL GEN GENET, V224, P81, DOI 10.1007/BF00259454; MAY G, 1986, MOL GEN GENET, V205, P225, DOI 10.1007/BF00430432; MAY G, 1989, MOL MICROBIOL, V3, P1521, DOI 10.1111/j.1365-2958.1989.tb00138.x; Miller J.H., 1972, EXPT MOL GENETICS; MINTON NP, 1984, GENE, V31, P269, DOI 10.1016/0378-1119(84)90220-8; MIZUNO T, 1987, NUCLEIC ACIDS RES, V15, P6827, DOI 10.1093/nar/15.17.6827; MORSCHHAUSER J, 1993, MOL GEN GENET, V238, P97; OHYAMA T, 1992, NUCLEIC ACIDS RES, V20, P1617, DOI 10.1093/nar/20.7.1617; OLSEN A, 1993, MOL MICROBIOL, V7, P523, DOI 10.1111/j.1365-2958.1993.tb01143.x; OVERDIER DG, 1989, J BACTERIOL, V171, P4694, DOI 10.1128/jb.171.9.4694-4706.1989; OVERDIER DG, 1992, P NATL ACAD SCI USA, V89, P3140, DOI 10.1073/pnas.89.7.3140; OWENHUGHES TA, 1992, CELL, V71, P255, DOI 10.1016/0092-8674(92)90354-F; PETTIJOHN DE, 1988, J BIOL CHEM, V263, P12793; PRINCE WS, 1990, J BIOL CHEM, V265, P17673; RIMSKY S, 1990, BIOCHEMISTRY-US, V29, P3765, DOI 10.1021/bi00467a024; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID MB, 1990, CELL, V63, P451, DOI 10.1016/0092-8674(90)90438-K; SERRANO M, 1993, TRENDS BIOCHEM SCI, V18, P202, DOI 10.1016/0968-0004(93)90187-R; SHI XL, 1993, J BACTERIOL, V175, P1182, DOI 10.1128/JB.175.4.1182-1186.1993; Silhavy T. J., 1984, EXPT GENE FUSIONS; SPASSKY A, 1984, NUCLEIC ACIDS RES, V12, P5321, DOI 10.1093/nar/12.13.5321; SPEARS PA, 1986, J BACTERIOL, V168, P179, DOI 10.1128/jb.168.1.179-185.1986; SPURIO R, 1992, MOL GEN GENET, V231, P201, DOI 10.1007/BF00279792; TANAKA K, 1991, MOL GEN GENET, V226, P367, DOI 10.1007/BF00260648; UEGUCHI C, 1993, EMBO J, V12, P1039, DOI 10.1002/j.1460-2075.1993.tb05745.x; UEGUCHI C, 1993, MOL GEN GENET, V236, P171, DOI 10.1007/BF00277109; VARSHAVSKY AJ, 1977, NUCLEIC ACIDS RES, V4, P2725, DOI 10.1093/nar/4.8.2725; YAMADA H, 1990, J BIOCHEM-TOKYO, V108, P420, DOI 10.1093/oxfordjournals.jbchem.a123216; YAMADA H, 1991, MOL GEN GENET, V230, P332, DOI 10.1007/BF00290685; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	69	169	172	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6578	6586						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120010				2022-12-27	WOS:A1994MZ50300050
J	ROTHMAN, A; WOLNER, B; BUTTON, D; TAYLOR, P				ROTHMAN, A; WOLNER, B; BUTTON, D; TAYLOR, P			IMMEDIATE-EARLY GENE-EXPRESSION IN RESPONSE TO HYPERTROPHIC AND PROLIFERATIVE STIMULI IN PULMONARY ARTERIAL SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SPONTANEOUSLY HYPERTENSIVE RATS; FOS MESSENGER-RNA; GROWTH-FACTOR; ANGIOTENSIN-II; CELLULAR HYPERTROPHY; RESISTANCE VESSELS; VASCULAR-DISEASE; JUN PROTEINS; SHORT FORM	Remodeling of the pulmonary vascular tree in pulmonary hypertension is associated with hypertrophy and proliferation of smooth muscle cells. Since the stimuli and signaling pathways for these processes are not well understood, we used a rat pulmonary arterial smooth muscle cell line (PAC1) to examine the effects of thrombin and platelet-derived growth factor (PDGF) on cellular growth and immediate-early gene expression, Over 72 h, thrombin (1 unit/ml) caused hypertrophy as reflected by a 102 +/- 12% increase in protein synthesis and a 49 +/- 11% increase in protein content per cell, but no change in cell number. PDGF (2.5 ng/ml) stimulated proliferation as evidenced by an increase in cell number (doubling in 5 days), but no significant change in protein content per cell. Immediate-early gene expression was examined by Northern blotting: both thrombin and PDGF induced egr(-1), c-fos, c-jun,junB, and fra-1 mRNAs within 15 min; the response was maximal at 30-60 min (increases ranging from 2.9- to 9.3-fold over control serum-deprived cells) and returned to base-line levels within 2-4 h. Neither agent affected junD mRNA levels. However, thrombin, but not PDGF, caused an increase in fosB mRNA levels (7.7 +/- 4.0-fold higher than control, n = 12, p < 0.0005). The immediate-early gene response to both agonists was generally dependent on extracellular Ca2+, Na+/H+ exchange, and protein kinase C activation, but not on cAMP. The exception was c-jun mRNA, the levels of which were not affected by inhibition of protein kinase C, but decreased significantly by prevention of cAMP formation. Thapsigargin-sensitive intracellular Ca2+ stores were necessary for the response to thrombin, but not to PDGF. These results demonstrate that thrombin is a hypertrophic agent and that PDGF is a proliferative agent in PAC1 cells. These two agonists stimulate increases in a variety of immediate-early gene mRNAs, but only thrombin induces fosB mRNA.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	ROTHMAN, A (corresponding author), UCSD, MED CTR,DEPT PEDIAT,DIV PEDIAT CARDIOL,8445, 200 W ARBOR DR, SAN DIEGO, CA 92103 USA.		Wolner, Branden/A-9615-2015	Wolner, Branden/0000-0003-0021-2073				BARSHAVIT R, 1990, CELL REGUL, V1, P453, DOI 10.1091/mbc.1.6.453; BENDHACK LM, 1992, HYPERTENSION, V19, P142; BERK BC, 1990, J BIOL CHEM, V265, P19632; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERK BC, 1990, J BIOL CHEM, V265, P17334; BERK BC, 1991, BIOCHEM J, V274, P799, DOI 10.1042/bj2740799; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIALECKI RA, 1991, J CLIN INVEST, V88, P1894, DOI 10.1172/JCI115512; BOSWELL CA, 1992, MICROVASC RES, V43, P178, DOI 10.1016/0026-2862(92)90015-H; BRAVO R, 1989, GROWTH FACTORS DIFFE, P324; BUTTON D, 1994, J BIOL CHEM, V269, P6390; CAMPBELL JH, 1991, BASIC RES CARDIOL, V86, P3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; EISENBERG PR, 1990, CIRCULATION, V82, P841, DOI 10.1161/01.CIR.82.3.841; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; GRIENDLING KK, 1987, HYPERTENSION, V9, P181; HALL SM, 1992, J PATHOL, V166, P183, DOI 10.1002/path.1711660216; HAWORTH SG, 1977, AM J CARDIOL, V40, P781, DOI 10.1016/0002-9149(77)90197-7; HELDIN CH, 1985, MOL CELL ENDOCRINOL, V39, P169, DOI 10.1016/0303-7207(85)90061-9; HOFFMAN JIE, 1981, CIRCULATION, V64, P873, DOI 10.1161/01.CIR.64.5.873; HORGAN MJ, 1987, J APPL PHYSIOL, V63, P1993, DOI 10.1152/jappl.1987.63.5.1993; HUANG CL, 1989, J BIOL CHEM, V264, P4391; ILKIW R, 1989, CIRC RES, V64, P814, DOI 10.1161/01.RES.64.4.814; ITOH H, 1990, J CLIN INVEST, V86, P1690, DOI 10.1172/JCI114893; KINDY MS, 1986, J BIOL CHEM, V261, P2865; KOVARY K, 1991, NEW BIOL, V3, P870; KULIK TJ, 1991, BIOCHEM BIOPH RES CO, V180, P982, DOI 10.1016/S0006-291X(05)81162-3; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LAZO PS, 1992, NUCLEIC ACIDS RES, V20, P343, DOI 10.1093/nar/20.2.343; LIBBY P, 1988, J CLIN INVEST, V81, P487, DOI 10.1172/JCI113346; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUMOTO H, 1989, BIOCHEM BIOPH RES CO, V158, P105, DOI 10.1016/S0006-291X(89)80183-4; MEYRICK B, 1983, CLIN CHEST MED, V4, P199; MEYRICK B, 1979, AM J PATHOL, V96, P51; MULVANY MJ, 1978, CIRC RES, V43, P854, DOI 10.1161/01.RES.43.6.854; MULVANY MJ, 1985, CIRC RES, V57, P794, DOI 10.1161/01.RES.57.5.794; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NABEL EG, 1988, CIRC RES, V62, P486, DOI 10.1161/01.RES.62.3.486; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; OWENS GK, 1982, CIRC RES, V51, P280, DOI 10.1161/01.RES.51.3.280; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; RABINOVITCH M, 1980, HUM PATHOL, V11, P499; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RAO GN, 1990, J BIOL CHEM, V265, P19393; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1990, ONCOGENE, V5, P1091; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAUBMAN MB, 1992, CIRC RES, V70, P314, DOI 10.1161/01.RES.70.2.314; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TREJO J, 1991, J BIOL CHEM, V266, P7876; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	64	88	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6399	6404						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119989				2022-12-27	WOS:A1994MZ50300024
J	KUPKE, T; KEMPTER, C; GNAU, V; JUNG, G; GOTZ, F				KUPKE, T; KEMPTER, C; GNAU, V; JUNG, G; GOTZ, F			MASS SPECTROSCOPIC ANALYSIS OF A NOVEL ENZYMATIC-REACTION - OXIDATIVE DECARBOXYLATION OF THE LANTIBIOTIC PRECURSOR PEPTIDE EPIA CATALYZED BY THE FLAVOPROTEIN EPID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMIN; BIOSYNTHESIS; PREPEPTIDE; SEQUENCE; GENES; ACIDS	The epidermin biosynthetic reaction between the flavoprotein EpiD and the precursor peptide EpiA was investigated by reversed-phase chromatography and ion spray mass spectrometry. Several products with molecular masses 46 and 104 Da less than that of EpiA were observed; these results were confirmed by using an MBP-EpiD fusion protein as enzyme and the mutant peptides EpiAR-1Q and K-EpiA as substrates. The reaction was inhibited by Zn2+ ions. Modifications were localized in the C-terminal fragment of EpiA as shown by factor Xa cleavage of the products followed by mass spectrometry analysis. In addition, EpiD reacted with the precursor peptides and with proepidermin, indicating that the leader peptide is not necessary for the recognition of EpiA by EpiD. Sequence analysis of modified proepidermin revealed that at least the amino acids Ile(+1)-Tyr(+20) are unmodified. The observed decrease in mass of 46 Da and the modification at the C terminus of EpiA is in agreement with the proposed enzymatic function of EpiD, the oxidative decarboxylation of the precursor peptide. In addition, the increased absorbance at 260 nm of the modified peptides indicates the presence of a thioenol group in the C-terminal proepidermin.	UNIV TUBINGEN,INST ORGAN CHEM,D-72076 TUBINGEN,GERMANY	Eberhard Karls University of Tubingen	KUPKE, T (corresponding author), UNIV TUBINGEN,WALDHAUSERSTR 70-8,D-72076 TUBINGEN,GERMANY.			Kupke, Thomas/0000-0003-2341-1710				ALLGAIER H, 1985, ANGEW CHEM INT EDIT, V24, P1051, DOI 10.1002/anie.198510511; AUGUSTIN J, 1992, EUR J BIOCHEM, V204, P1149, DOI 10.1111/j.1432-1033.1992.tb16740.x; AUGUSTIN J, 1991, NISIN NOVEL LANTIBIO, P277; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHMAN GW, 1988, J BIOL CHEM, V263, P16260; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; GOTZ F, 1990, PATHOGENESIS OF WOUND AND BIOMATERIAL-ASSOCIATED INFECTIONS, P285; HAWKE D, 1987, APPLIED BIOSYSTEMS U, V28, P1; JANSON JC, 1989, PROTEIN PURIFICATION; JOHNSTON TC, 1986, J BIOL CHEM, V261, P4805; JUNG G, 1991, ANGEW CHEM INT EDIT, V30, P1051, DOI 10.1002/anie.199110513; KLEIN C, 1993, APPL ENVIRON MICROB, V59, P296, DOI 10.1128/AEM.59.1.296-303.1993; KUIPERS OP, 1993, EUR J BIOCHEM, V216, P281, DOI 10.1111/j.1432-1033.1993.tb18143.x; KUPKE T, 1993, FEMS MICROBIOL LETT, V112, P43, DOI 10.1016/0378-1097(93)90535-A; KUPKE T, 1992, J BACTERIOL, V174, P5354, DOI 10.1128/JB.174.16.5354-5361.1992; PESCHEL A, 1993, MOL MICROBIOL, V9, P31, DOI 10.1111/j.1365-2958.1993.tb01666.x; REIS M, 1991, NISIN NOVEL LANTIBIO, P320; RIGGS P, 1990, CURRENT PROTOCOLS MO; Sahl H. G., 1991, NISIN NOVEL LANTIBIO, P347; SAHL HG, 1991, NISIN NOVEL LANTIBIO, P332; SCHNELL N, 1992, EUR J BIOCHEM, V204, P57, DOI 10.1111/j.1432-1033.1992.tb16605.x; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; SUROVOY A, 1992, PEPTIDES 1992, P563; VANDERMEER JR, 1993, J BACTERIOL, V175, P2578, DOI 10.1128/JB.175.9.2578-2588.1993; WEIL HP, 1990, EUR J BIOCHEM, V194, P217, DOI 10.1111/j.1432-1033.1990.tb19446.x	26	78	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5653	5659						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119901				2022-12-27	WOS:A1994MY84000029
J	KURODA, S; OTAKA, S; FUJISAWA, Y				KURODA, S; OTAKA, S; FUJISAWA, Y			FERMENTABLE AND NONFERMENTABLE CARBON-SOURCES SUSTAIN CONSTITUTIVE LEVELS OF EXPRESSION OF YEAST TRIOSEPHOSPHATE DEHYDROGENASE-3 GENE FROM DISTINCT PROMOTER ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS SURFACE-ANTIGEN; DNA-BINDING PROTEIN; UPSTREAM ACTIVATING SEQUENCES; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCES; EFFICIENT EXPRESSION; ENOLASE GENES; GCR1; TRANSCRIPTION; ENCODES	The triosephosphate dehydrogenase 3 gene (TDH3) is a glycolytic enzyme gene and is abundantly transcribed in Saccharomyces cerevisiae. The promoter region of the TDH3 gene is known to exhibit high transcriptional activity regardless of the fermentability of the carbon source and has been widely utilized to synthesize heterologous gene products in S. cerevisiae. To clarify the mechanism of constitutive transcription by the promoter, we constructed mutant promoters and analyzed the in vivo transcriptional activity of these promoters. The majority of the transcriptional potential is contained within a DNA fragment extending from nucleotides -524 to -255 (-524/-255; relative to the translation initiation codon), which consists of three cia-acting elements: a fermentable carbon source-dependent upstream activation sequence (UAS) 1 (-524/-426), a fermentable carbon source-dependent upstream repression sequence (URS) (-426/-393), and a nonfermentable carbon source-dependent UAS2 (-305/-255). This result indicates that the promoter involves two apparent promoter elements. One is fermentable carbon source-dependent, and another is nonfermentable carbon source-dependent. Southwestern analyses indicated that a novel 20-kDa protein is induced in yeast cells by shifting from a fermentable to nonfermentable carbon source. The protein interacts with two UAS1 13-base pair elements and one URS 18-base pair element, one of which had been previously designated GPE (general regulatory factor 1 (GRF1) binding site potentiator element) (Bitter, G. A., Chang, K. K. H., and Egan, K. M. (1991) Mol. Gen. Genet. 231, 22-32). We therefore termed the 20-kDa protein GPEB (GRF1-binding site potentiator element-binding protein). In addition, mutational analyses strongly suggested that UAS 1, URS, and UAS2 interact with GRF1 and GPEB, GPEB, and the GCR1 (glycolysis regulation 1) gene product, respectively. We therefore concluded that constitutive transcription by the TDH3 promoter is sustained by two promoter elements and that the switch between them might be controlled by the nonfermentable carbon source-inducible GPEB.			KURODA, S (corresponding author), TAKEDA CHEM IND LTD,PHARMACEUT GRP,DIV DISCOVERY RES,DISCOVERY RES LABS 2 DEPT 5,YODOGAWA KU,OSAKA 532,JAPAN.							BAKER HV, 1986, MOL CELL BIOL, V6, P3774, DOI 10.1128/MCB.6.11.3774; BAKER HV, 1991, P NATL ACAD SCI USA, V88, P9443, DOI 10.1073/pnas.88.21.9443; BITTER GA, 1991, MOL GEN GENET, V231, P22, DOI 10.1007/BF00293817; BRINDLE PK, 1990, MOL CELL BIOL, V10, P4872, DOI 10.1128/MCB.10.9.4872; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P5086, DOI 10.1128/MCB.8.12.5086; BUCHMAN AR, 1986, MOL CELL BIOL, V8, P5079; CHAMBER A, 1988, MOL CELL BIOL, V9, P5516; CHAMBER A, 1988, NUCLEIC ACIDS RES, V16, P8254; CLIFTON D, 1981, J BIOL CHEM, V256, P3074; COHEN R, 1987, MOL CELL BIOL, V7, P2753, DOI 10.1128/MCB.7.8.2753; DELVIN C, 1991, MOL CELL BIOL, V11, P3624; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; HESS B, 1986, ADV ENZYME REGUL, V7, P149; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; HOLLAND JP, 1979, J BIOL CHEM, V254, P9839; HOLLAND JP, 1980, J BIOL CHEM, V255, P2596; HOLLAND JP, 1983, J BIOL CHEM, V258, P5291; HOLLAND MJ, 1981, J BIOL CHEM, V256, P1385; HOLLAND MJ, 1987, MOL CELL BIOL, V7, P813, DOI 10.1128/MCB.7.2.813; HOLLAND MJ, 1976, J BIOL CHEM, V254, P5466; HUET J, 1987, P NATL ACAD SCI USA, V84, P3648, DOI 10.1073/pnas.84.11.3648; HUET J, 1985, EMBO J, V4, P3539, DOI 10.1002/j.1460-2075.1985.tb04114.x; HUIE MA, 1992, MOL CELL BIOL, V12, P2690, DOI 10.1128/MCB.12.6.2690; ITOH Y, 1986, BIOCHEM BIOPH RES CO, V138, P268, DOI 10.1016/0006-291X(86)90275-5; JAYARAM M, 1983, CELL, V34, P95, DOI 10.1016/0092-8674(83)90139-3; KAISHO Y, 1989, YEAST, V5, P91, DOI 10.1002/yea.320050204; KITANO K, 1987, BIO-TECHNOL, V5, P281, DOI 10.1038/nbt0387-281; KNISKERN PJ, 1986, GENE, V46, P135, DOI 10.1016/0378-1119(86)90177-0; KREBS EG, 1953, J BIOL CHEM, V200, P471; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURODA S, 1992, J BIOL CHEM, V267, P1953; KURODA S, 1989, GENE, V78, P297; MARSCHALL M, 1989, GENE, V81, P109, DOI 10.1016/0378-1119(89)90341-7; MCALISTER L, 1985, J BIOL CHEM, V260, P5013; MCALISTER L, 1985, J BIOL CHEM, V260, P5019; NISHIZAWA M, 1989, MOL CELL BIOL, V9, P442, DOI 10.1128/MCB.9.2.442; OGDEN JE, 1986, MOL CELL BIOL, V6, P4335, DOI 10.1128/MCB.6.12.4335; PAVLOVIC B, 1988, MOL CELL BIOL, V8, P5513, DOI 10.1128/MCB.8.12.5513; SANTANGELO GM, 1990, MOL CELL BIOL, V10, P859, DOI 10.1128/MCB.10.2.859; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; STANWAY C, 1987, NUCLEIC ACIDS RES, V15, P6855, DOI 10.1093/nar/15.17.6855; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; WILLETT CE, 1993, MOL CELL BIOL, V13, P2623, DOI 10.1128/MCB.13.4.2623; WOUDT LP, 1986, EMBO J, V5, P1037, DOI 10.1002/j.1460-2075.1986.tb04319.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOSHIMURA K, 1987, BIOCHEM BIOPH RES CO, V145, P712, DOI 10.1016/0006-291X(87)91023-0	47	19	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6153	6162						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119960				2022-12-27	WOS:A1994MY84000101
J	LING, JS; SAHLIN, M; SJOBERG, BM; LOEHR, TM; SANDERSLOEHR, J				LING, JS; SAHLIN, M; SJOBERG, BM; LOEHR, TM; SANDERSLOEHR, J			DIOXYGEN IS THE SOURCE OF THE MU-OXO BRIDGE IN IRON RIBONUCLEOTIDE REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; ESCHERICHIA-COLI; HORSERADISH-PEROXIDASE; METHANE MONOOXYGENASE; ACTIVE-SITES; PROTEINS; ACTIVATION; MECHANISM; SUBUNIT; ENZYME	The formation of the iron-radical cofactor in the R2 subunit of ribonucleotide reductase has been monitored by resonance Raman spectroscopy. The diferrous cluster in reduced R2 functions as a tyrosine oxidase; it uses O-2 to oxidize Tyr-122 to a stable radical and results in an ore-bridged diferric cluster. The Phe-122 mutant produces an identical dinuclear iron center and provides a simplified model for O-2 activation. Oxidation with O-18(2) results in quantitative incorporation of O-18 into the diferric cluster as evidenced by the 13-cm(-1) downshift in the Fe-O-Fe stretching vibration at 500 cm(-1). Thus, O-2 must be coordinated to the diiron center during O-O bond cleavage. When the Phe-208 adjacent to the diferrous cluster is mutated to Tyr, reaction with O-2 results in its oxidation to dihydroxyphenylalanine (DOPA-208) and subsequent coordination to Fe as a catecholate ligand. The Fe-O/(catecholate) stretching modes at 512 and 592 cm(-1) shift by -13 and -8 cm(-1), respectively, when the oxidation is performed in (H2O)-O-18, These isotope shifts indicate that the second oxygen atom of DOPA-208 originates from H2O rather than O-2. Taken together, our re suits are consistent with a mu-1,1-peroxide and a high valent iron-ore species as reaction intermediates. A common pathway for oxygen activation by the related iron-ore enzymes methane monooxygenase and fatty acid desaturase is proposed.	OREGON GRAD INST SCI & TECHNOL, DEPT CHEM BIOCHEM & MOLEC BIOL, PORTLAND, OR 97291 USA; UNIV STOCKHOLM, DEPT MOLEC BIOL, S-10691 STOCKHOLM, SWEDEN	Stockholm University				Sjoberg, Britt-Marie/0000-0001-5953-3360	NIGMS NIH HHS [GM-18865] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018865] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERG A, 1993, BIOCHEMISTRY-US, V32, P9845; ABERG A, 1993, THESIS U STOCKHOLM; ANDERSSON KK, 1988, J BIOL CHEM, V263, P18621; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; ATTA M, 1992, J BIOL CHEM, V267, P20682; BACKES G, 1989, BIOCHEMISTRY-US, V28, P1923, DOI 10.1021/bi00430a074; BENDER CJ, 1989, J AM CHEM SOC, V111, P8076, DOI 10.1021/ja00203a002; BOLLINGER JM, 1991, J AM CHEM SOC, V113, P6289, DOI 10.1021/ja00016a066; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BOLLINGER JM, 1993, J INORG BIOCHEM, V51, P6; BUIST PH, 1992, J AM CHEM SOC, V114, P5073, DOI 10.1021/ja00039a018; CHUANG WJ, 1989, J BIOL CHEM, V264, P14209; COX DD, 1988, J AM CHEM SOC, V110, P2026, DOI 10.1021/ja00215a002; DALTON H, 1980, ADV APPL MICROBIOL, V26, P71; DEMONTELLANO PRO, 1987, J BIOL CHEM, V262, P11641; DEROSE VJ, 1993, J AM CHEM SOC, V115, P6440, DOI 10.1021/ja00067a081; DORDICK JS, 1986, BIOCHEMISTRY-US, V25, P2946, DOI 10.1021/bi00358a032; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FONTECAVE M, 1990, BIOCHEM BIOPH RES CO, V168, P659, DOI 10.1016/0006-291X(90)92371-6; FONTECAVE M, 1992, ADV ENZYMOL RAMB, V65, P147; FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013; FOX BG, 1993, P NATL ACAD SCI USA, V90, P2486, DOI 10.1073/pnas.90.6.2486; GERBER NC, 1992, J AM CHEM SOC, V114, P8742, DOI 10.1021/ja00048a081; HASHIMOTO S, 1986, P NATL ACAD SCI USA, V83, P2417, DOI 10.1073/pnas.83.8.2417; HENDRA PJ, 1968, CHEM IND-LONDON, P718; HESTER RE, 1964, INORG CHEM, V3, P513, DOI 10.1021/ic50014a012; HOLMES MA, 1991, J MOL BIOL, V218, P583, DOI 10.1016/0022-2836(91)90703-9; KARLIN KD, 1988, J AM CHEM SOC, V110, P6769, DOI 10.1021/ja00228a027; KARLSSON M, 1992, J BIOL CHEM, V267, P12622; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LEE SK, 1993, J AM CHEM SOC, V115, P6450, DOI 10.1021/ja00067a086; LOEHR TM, 1993, METHOD ENZYMOL, V226, P431; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9752, DOI 10.1021/bi00155a031; NORDLUND P, 1992, FEBS LETT, V307, P257, DOI 10.1016/0014-5793(92)80690-I; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; ORMO M, 1992, J BIOL CHEM, V267, P8711; PEDERSEN JZ, 1993, FEBS LETT, V325, P53, DOI 10.1016/0014-5793(93)81412-S; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; POULOS TL, 1988, ADV INORG BIOCHEM, V7, P1; PYRZ JW, 1985, J AM CHEM SOC, V107, P614, DOI 10.1021/ja00289a013; QUE L, 1991, SCIENCE, V253, P273, DOI 10.1126/science.1857963; RARDIN RL, 1991, NEW J CHEM, V15, P417; RAVI N, 1993, BIOCHEMISTRY-US, V32, P8487, DOI 10.1021/bi00084a013; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SALAMA S, 1978, BIOCHEMISTRY-US, V17, P3781, DOI 10.1021/bi00611a017; SANDERSLOEHR J, 1989, IRON CARRIERS IRON P, P373; SJOBERG BM, 1982, BIOCHEMISTRY-US, V21, P96; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; SJOBERG BM, 1987, BIOCHEMISTRY-US, V26, P4242; SOLOMON EI, 1992, ACCOUNTS CHEM RES, V25, P343, DOI 10.1021/ar00020a004; SPYROU G, 1991, J BACTERIOL, V173, P3673, DOI 10.1128/JB.173.12.3673-3679.1991; STENKAMP RE, 1992, AM CRYST ASS ABSTR, V20, P140; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; THEWALT U, 1967, J AM CHEM SOC, V89, P6364, DOI 10.1021/ja01000a074; THOMANN H, 1993, J AM CHEM SOC, V115, P8881, DOI 10.1021/ja00072a068; THOMPSON DC, 1993, CHEM-BIOL INTERACT, V86, P129, DOI 10.1016/0009-2797(93)90117-H; TOLMAN WB, 1991, J AM CHEM SOC, V113, P152, DOI 10.1021/ja00001a023; VALENTINE JS, 1994, IN PRESS ACTIVATION; VAROTSIS C, 1993, P NATL ACAD SCI USA, V90, P237, DOI 10.1073/pnas.90.1.237; VINCENT JB, 1990, CHEM REV, V90, P1447, DOI 10.1021/cr00106a004; VOLBEDA A, 1989, J MOL BIOL, V206, P531, DOI 10.1016/0022-2836(89)90499-3; Wagner H.-U., 1974, CHEM QUINONOID COMPO, P1145	64	91	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5595	5601						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119895				2022-12-27	WOS:A1994MY84000022
J	STRAUSFELD, U; FERNANDEZ, A; CAPONY, JP; GIRARD, F; LAUTREDOU, N; DERANCOURT, J; LABBE, JC; LAMB, NJC				STRAUSFELD, U; FERNANDEZ, A; CAPONY, JP; GIRARD, F; LAUTREDOU, N; DERANCOURT, J; LABBE, JC; LAMB, NJC			ACTIVATION OF P34(CDC2) PROTEIN-KINASE BY MICROINJECTION OF HUMAN CDC25C INTO MAMMALIAN-CELLS - REQUIREMENT FOR PRIOR PHOSPHORYLATION OF CDC25C BY P34(CDC2) AT MITOSIS ON SITES PHOSPHORYLATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P80CDC25 MITOTIC INDUCER; FISSION YEAST CDC25; TYROSINE PHOSPHORYLATION; DNA-REPLICATION; P34CDC2 KINASE; STARFISH OOCYTES; CYCLE CONTROL; PHOSPHATASE; MPF; XENOPUS	Human cdc25C protein, a specific tyrosine phosphatase that activates the p34(cdc2) protein kinase at mitosis, is itself a phosphoprotein that shows increased phosphorylation during the G(2)-M transition. In vitro, cdc25C protein is substantially phosphorylated by purified p34(cdc2)-cyclin B protein kinase. Of seven putative phosphorylation sites for p34(cdc2) protein kinase present in human cdc25C, five are phosphorylated by p34(cdc2) protein kinase in vitro, as assessed by tryptic phosphopeptide mapping and peptide sequencing. These same sites are also phosphorylated in vivo during the G(2)-M transition in normal mammalian fibroblasts and have been precisely mapped. The cdc25C phosphorylated in vitro by p34(cdc2) protein kinase exhibits a 2-3-fold higher activity than the nonphosphorylated cdc25C, as assayed by activation of inactive cdca prokinase. Microinjection of purified cdc25C proteins into living fibroblasts reveals that only the phosphorylated form of cdc25 is highly effective in activating G(2) cells into premature prophase in a manner similar to microinjection of purified active p34(cdc2) protein kinase. Together these data show that multisite phosphorylation of cdc25C by p34(cdc2)-cyclin B protein kinase occurs at the G(2)-M transition and is sufficient to induce the autoamplification of cdc2/M-phase promoting factor necessary to drive somatic mammalian cells into mitosis.	CTR RECH BIOCHIM MACROMOLEC, DEPT CELL BIOL, CNRS, INSERM, F-34033 MONTPELLIER, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier			labbe, jean-claude/B-2277-2009	Girard, Franck/0000-0003-2587-4495				AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GIRARD F, 1992, J CELL BIOL, V118, P785, DOI 10.1083/jcb.118.4.785; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; JESSUS C, 1992, CELL, V68, P323, DOI 10.1016/0092-8674(92)90473-P; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUMAGAI A, 1991, COLD SPRING HARB SYM, V56, P585; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1991, METHOD ENZYMOL, V200, P291; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1992, BIOCHEM SOC T, V20, P239, DOI 10.1042/bst0200239; PINES J, 1990, New Biologist, V2, P389; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0	44	133	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5989	6000						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119945				2022-12-27	WOS:A1994MY84000079
J	TSUKAMOTO, T; HATA, S; YOKOTA, S; MIURA, S; FUJIKI, Y; HIJIKATA, M; MIYAZAWA, S; HASHIMOTO, T; OSUMI, T				TSUKAMOTO, T; HATA, S; YOKOTA, S; MIURA, S; FUJIKI, Y; HIJIKATA, M; MIYAZAWA, S; HASHIMOTO, T; OSUMI, T			CHARACTERIZATION OF THE SIGNAL PEPTIDE AT THE AMINO-TERMINUS OF THE RAT PEROXISOMAL 3-KETOACYL-COA THIOLASE PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-TRANSFER PROTEIN; COENZYME-A OXIDASE; 3-KETOACYL-COA THIOLASE; TARGETING SIGNAL; 3-OXOACYL-COA THIOLASE; EXPRESSION VECTORS; LIVER PEROXISOMES; CARBOXY TERMINUS; MAMMALIAN-CELLS; BETA-OXIDATION	The amino-terminal presequences of rat peroxisomal 3-ketoacyl-CoA thiolase precursors (types A and B) were reported to be cleavable signal peptides for peroxisomal protein translocation. In the present study, this was proven by immunoelectron microscopy of the cultured Chinese hamster ovary cells stably expressing fusion proteins of the amino-terminal sequences of the thiolase precursor and Escherichia coli dihydrofolate reductase. The fusion proteins were processed into mature forms of the apparently correct sizes. Site-directed mutagenesis studies of the charged residues in the B-type presequence (26 amino acid residues) revealed that arginine at position -24 and histidine at position -17 were both indispensable. Even replacement of these residues with other basic amino acids abolished the import activity. Both Arg(-24) and His(-17) were also required in a longer presequence (36 amino acid residues) of the thiolase A, thereby suggesting that the signal can function in an internal position. When glutamic acid at position -11 was changed to amino acids other than aspartic acid, the signal peptide became apparently effective in both peroxisomal and mitochondrial targeting. All of these data indicate that the thiolase signal peptide is a newly defined type of peroxisomal targeting signal recognized by a mechanism presumably different from that for a known peroxisomal signal, the carboxyl-terminal Ser-Lys-Leu-COOH motif.	HIMEJI INST TECHNOL,DEPT LIFE SCI,KAMIGORI,HYOGO 67812,JAPAN; YAMANASKI MED COLL,DEPT ANAT,TAMAHO,YAMANASHI 40938,JAPAN; MEIJI INST HLTH SCI,MOLEC CELL BIOL LAB,ODAWARA,KANAGAWA 250,JAPAN; SHINSHU UNIV,SCH MED,DEPT BIOCHEM,MATSUMOTO,NAGANO 390,JAPAN	University of Hyogo; University of Yamanashi; Shinshu University								BASCHONG W, 1985, HISTOCHEMISTRY, V83, P409, DOI 10.1007/BF00509201; BENDAYAN M, 1982, J HISTOCHEM CYTOCHEM, V30, P81, DOI 10.1177/30.1.6172469; BLATTNER J, 1992, J CELL BIOL, V119, P1129, DOI 10.1083/jcb.119.5.1129; BODNAR AG, 1990, GENE, V91, P193, DOI 10.1016/0378-1119(90)90088-9; BOUT A, 1988, NUCLEIC ACIDS RES, V16, P10369, DOI 10.1093/nar/16.21.10369; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEROE C, 1987, J HISTOCHEM CYTOCHEM, V35, P1191, DOI 10.1177/35.11.3655323; FAIRBAIRN LJ, 1989, NUCLEIC ACIDS RES, V17, P3588, DOI 10.1093/nar/17.9.3588; FOECKING MK, 1986, GENE, V45, P101, DOI 10.1016/0378-1119(86)90137-X; FUJIKI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7127, DOI 10.1073/pnas.81.22.7127; FUNG K, 1991, MOL BIOCHEM PARASIT, V45, P261, DOI 10.1016/0166-6851(91)90093-L; GIETL C, 1990, P NATL ACAD SCI USA, V87, P5773, DOI 10.1073/pnas.87.15.5773; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; HASHIMOTO T, 1982, ANN NY ACAD SCI, V386, P5, DOI 10.1111/j.1749-6632.1982.tb21403.x; HIJIKATA M, 1987, J BIOL CHEM, V262, P8151; HIJIKATA M, 1990, J BIOL CHEM, V265, P4600; HUANG MTF, 1990, MOL CELL BIOL, V10, P1805, DOI 10.1128/MCB.10.4.1805; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; IWAKURA M, 1992, J BIOCHEM-TOKYO, V111, P31, DOI 10.1093/oxfordjournals.jbchem.a123714; KAMIRYO T, 1989, AGR BIOL CHEM TOKYO, V53, P179, DOI 10.1080/00021369.1989.10869248; KRAGLER F, 1993, J CELL BIOL, V120, P665, DOI 10.1083/jcb.120.3.665; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MIURA S, 1984, J BIOL CHEM, V259, P6397; MIURA S, 1992, J BIOL CHEM, V267, P14405; MIYAZAWA S, 1980, EUR J BIOCHEM, V103, P589, DOI 10.1111/j.1432-1033.1980.tb05984.x; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MORI T, 1991, P NATL ACAD SCI USA, V88, P4338, DOI 10.1073/pnas.88.10.4338; OSSENDORP BC, 1991, EUR J BIOCHEM, V201, P233, DOI 10.1111/j.1432-1033.1991.tb16279.x; OSUMI T, 1990, BIOESSAYS, V12, P217, DOI 10.1002/bies.950120505; OSUMI T, 1992, BIOCHEM BIOPH RES CO, V186, P811, DOI 10.1016/0006-291X(92)90818-6; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; Roth J, 1982, TECHNIQUES IMMUNOCYT, V1, P108; Sambrook J, 1989, MOL CLONING LABORATO; SINGH KK, 1992, MOL CELL BIOL, V12, P5593, DOI 10.1128/MCB.12.12.5593; SMALL GM, 1988, EMBO J, V7, P1167, DOI 10.1002/j.1460-2075.1988.tb02927.x; SWINKELS BW, 1992, FEBS LETT, V305, P133, DOI 10.1016/0014-5793(92)80880-P; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; ZOELLER RA, 1986, P NATL ACAD SCI USA, V83, P5170, DOI 10.1073/pnas.83.14.5170	45	92	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6001	6010						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119946				2022-12-27	WOS:A1994MY84000080
J	HUTCHISON, KA; DITTMAR, KD; CZAR, MJ; PRATT, WB				HUTCHISON, KA; DITTMAR, KD; CZAR, MJ; PRATT, WB			PROOF THAT HSP70 IS REQUIRED FOR ASSEMBLY OF THE GLUCOCORTICOID RECEPTOR INTO A HETEROCOMPLEX WITH HSP90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; STEROID-BINDING DOMAIN; PROGESTERONE-RECEPTOR; COMPLEX; 90-KDA; RECONSTITUTION; ASSOCIATION; CYTOSOL; CELL; MR	Incubation of immunopurified glucocorticoid receptor with rabbit reticulocyte lysate forms a complex between the receptor and hsp90, with simultaneous conversion of the receptor from a non-steroid binding but DNA binding state typical of the transformed receptor back to the steroid binding, non-DNA binding state typical of the untransformed receptor (Scherrer, L. C., Dalman, F. C., Masse, E., Meshinchi, S., and Pratt, W. B. (1990) J. Biol. Chem. 265, 21397-21400). The receptor heterocomplex formed by the lysate also contains hsp70 and is formed in an ATP-dependent and cation-selective manner (Hutchison, K. A., Czar, M. J., Scherrer, L. C., and Pratt, W. B. (1992) J. Biol. Chem. 267, 14047-14053). In this work, we selectively depleted reticulocyte lysate of hsp70 by passing it through a column of ATP-agarose. The hsp70-depleted lysate contains hsp90, but it cannot form a receptor-hsp90 heterocomplex. hsp70 purified from mouse L cells binds to immunopurified glucocorticoid receptor but does not convert it to the steroid binding state. Addition of purified hsp70 to the hsp70-depleted lysate reactivates the heterocomplex assembly system, permitting formation of a receptor-hsp90-hsp70 complex, with the receptor being returned to the high affinity steroid-binding conformation. These data are consistent with a model in which the protein-unfolding activity of hsp70 is required for hsp90 binding to the hormone binding domain of the glucocorticoid receptor. The hsp56 immunophilin component of the native receptor heterocomplex is also present in the reconstituted receptor heterocomplex in an hsp70-dependent manner. In addition to hsp70, other as yet unidentified factors in reticulocyte lysate are required for receptor heterocomplex assembly.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER; NCI NIH HHS [CA28010] Funding Source: Medline; NIDDK NIH HHS [DK31573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXIS MN, 1992, EUR J BIOCHEM, V204, P75, DOI 10.1111/j.1432-1033.1992.tb16607.x; BRESNICK EH, 1990, BIOCHEMISTRY-US, V29, P520, DOI 10.1021/bi00454a028; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CHAKRABORTI PK, 1991, BIOCHEM BIOPH RES CO, V176, P1338, DOI 10.1016/0006-291X(91)90433-8; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DENIS M, 1988, J BIOL CHEM, V263, P18520; ERHART JC, 1988, ONCOGENE, V3, P595; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13952; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; HUTCHISON KA, 1993, BIOCHEMISTRY-US, V32, P3953, DOI 10.1021/bi00066a015; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PRATT WB, 1988, J BIOL CHEM, V263, P267; PRATT WB, 1992, TRENDS ENDOCRIN MET, V3, P326, DOI 10.1016/1043-2760(92)90111-D; REXIN M, 1991, J BIOL CHEM, V266, P24601; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHOWALTER DB, 1991, J BIOL CHEM, V266, P21165; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436	33	163	165	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5043	5049						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106480				2022-12-27	WOS:A1994MX57100055
J	MARSZALEK, J; KAGUNI, JM				MARSZALEK, J; KAGUNI, JM			DNAA PROTEIN DIRECTS THE BINDING OF DNAB PROTEIN IN INITIATION OF DNA-REPLICATION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIALIZED NUCLEOPROTEIN STRUCTURES; P1 PLASMID REPLICATION; LAMBDA-O-PROTEIN; MINI-F PLASMID; BACTERIOPHAGE-LAMBDA; NUCLEOTIDE-SEQUENCE; GENE-PRODUCT; PHYSICAL-PROPERTIES; AUTONOMOUS REPLICATION; ENCODED PROTEINS	DnaA protein of Escherichia coli acts in the initiation of chromosomal replication to bind to sequences in the chromosomal origin. On binding, it promotes the assembly of other replication proteins that serve to prime DNA replication and assemble the replication apparatus for bidirectional replication fork movement. A collection of monoclonal antibodies to DnaA protein have been produced, one of which is described here, that interferes with the action of DnaA protein in promoting formation of a prepriming complex. On the analysis of this process, the antibody appears to interfere with the physical interaction between DnaA and DnaB protein in the DnaB.DnaC complex. Cross-linking studies confirm that DnaA and DnaB proteins interact directly These results provide the first direct evidence that one of the roles of DnaA protein is to act as a site for binding of DnaB protein to the DNA and perhaps orients DnaB helicase to account for the directionality of replication fork movement.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA; UNIV GDANSK, DEPT MOLEC BIOL, PL-80822 GDANSK, POLAND	Michigan State University; Fahrenheit Universities; University of Gdansk			Marszalek, Jaroslaw/F-5824-2011	Kaguni, Jon/0000-0002-3096-4447; Marszalek, Jaroslaw/0000-0002-6978-1189	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033992] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM033992, GM33992] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELES AL, 1984, J MOL BIOL, V173, P307, DOI 10.1016/0022-2836(84)90123-2; ABELES AL, 1989, J BACTERIOL, V171, P43, DOI 10.1128/jb.171.1.43-52.1989; ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; ALLEN GC, 1991, J BIOL CHEM, V266, P22096; ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1981, J BIOL CHEM, V256, P5247; ARAI K, 1981, J BIOL CHEM, V256, P5253; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CHURCHWARD G, 1983, NUCLEIC ACIDS RES, V11, P5645, DOI 10.1093/nar/11.16.5645; DIAZ R, 1982, J BACTERIOL, V150, P1077, DOI 10.1128/JB.150.3.1077-1084.1982; DODSON M, 1985, P NATL ACAD SCI USA, V82, P4678, DOI 10.1073/pnas.82.14.4678; DODSON M, 1989, J BIOL CHEM, V264, P10719; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; FELTON J, 1979, MOL GEN GENET, V175, P231, DOI 10.1007/BF00425541; FILUTOWICZ M, 1986, J MOL BIOL, V187, P225, DOI 10.1016/0022-2836(86)90230-5; FREY J, 1979, MOL GEN GENET, V174, P117, DOI 10.1007/BF00268349; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1986, CELL, V38, P5616; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; FURTH ME, 1978, J MOL BIOL, V126, P195, DOI 10.1016/0022-2836(78)90359-5; GAYLO PJ, 1987, J BACTERIOL, V169, P4703, DOI 10.1128/jb.169.10.4703-4709.1987; GERMINO J, 1983, CELL, V32, P131, DOI 10.1016/0092-8674(83)90503-2; HANSEN EB, 1986, P NATL ACAD SCI USA, V83, P4423, DOI 10.1073/pnas.83.12.4423; HARING V, 1989, PROMISCUOUS PLASMIDS, P95; Harlow E., 1988, ANTIBODIES LABORATOR, P310; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; HWANG DS, 1992, J BIOL CHEM, V267, P23087; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KLEIN A, 1980, EUR J BIOCHEM, V105, P1, DOI 10.1111/j.1432-1033.1980.tb04467.x; KOBORI JA, 1982, J BIOL CHEM, V257, P13763; KOLTER R, 1982, J MOL BIOL, V161, P45, DOI 10.1016/0022-2836(82)90277-7; LANKA E, 1978, P NATL ACAD SCI USA, V75, P799, DOI 10.1073/pnas.75.2.799; LANKA E, 1983, NUCLEIC ACIDS RES, V11, P987, DOI 10.1093/nar/11.4.987; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; MACALLISTER TW, 1991, J BIOL CHEM, V266, P16056; MALLORY JB, 1990, J BIOL CHEM, V265, P13297; MARSZALEK J, 1992, J BIOL CHEM, V267, P19334; MASAI H, 1990, J BIOL CHEM, V265, P15134; MASAI H, 1987, P NATL ACAD SCI USA, V84, P4781, DOI 10.1073/pnas.84.14.4781; MASSON L, 1986, NUCLEIC ACIDS RES, V14, P5693, DOI 10.1093/nar/14.14.5693; MEIJER M, 1979, P NATL ACAD SCI USA, V76, P580, DOI 10.1073/pnas.76.2.580; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MUROTSU T, 1981, GENE, V15, P257, DOI 10.1016/0378-1119(81)90135-9; NAKAYAMA N, 1984, J BIOL CHEM, V259, P97; OHTSUBO E, 1977, PLASMID, V1, P8, DOI 10.1016/0147-619X(77)90004-X; OKA A, 1980, MOL GEN GENET, V178, P9, DOI 10.1007/BF00267207; ORTEGA S, 1986, NUCLEIC ACIDS RES, V14, P4865, DOI 10.1093/nar/14.12.4865; ORTEGAJIMENEZ S, 1992, NUCLEIC ACIDS RES, V20, P2547, DOI 10.1093/nar/20.10.2547; PARDA CA, 1991, J BIOL CHEM, V266, P18895; PINKNEY M, 1988, J MOL BIOL, V203, P927, DOI 10.1016/0022-2836(88)90118-0; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4051; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; RYDER T, 1981, ICN UCLA S MOL CELL, V22, P91; SCHOLZ P, 1985, PLASMIDS BACTERIA, P243; SCLAFANI RA, 1981, J BACTERIOL, V146, P418, DOI 10.1128/JB.146.1.418-421.1981; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SEUFERT W, 1988, J BIOL CHEM, V263, P2719; STALKER DM, 1979, P NATL ACAD SCI USA, V76, P1150, DOI 10.1073/pnas.76.3.1150; STALKER DM, 1981, MOL GEN GENET, V181, P8, DOI 10.1007/BF00338997; STENZEL TT, 1991, GENE DEV, V5, P1453, DOI 10.1101/gad.5.8.1453; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; TANG XB, 1989, J BACTERIOL, V171, P5290, DOI 10.1128/jb.171.10.5290-5295.1989; TOKINO T, 1986, P NATL ACAD SCI USA, V83, P4109, DOI 10.1073/pnas.83.12.4109; TSURIMOTO T, 1991, NUCLEIC ACIDS RES, V9, P1789; VOCKE C, 1983, CELL, V35, P495, DOI 10.1016/0092-8674(83)90183-6; VOCKE C, 1983, P NATL ACAD SCI USA, V80, P580; WAHLE E, 1989, J BIOL CHEM, V264, P2469; WAHLE E, 1989, J BIOL CHEM, V264, P2463; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921; WICKNER SH, 1979, COLD SPRING HARB SYM, V43, P303, DOI 10.1101/SQB.1979.043.01.037; WICKNER SH, 1986, J BIOL CHEM, V261, P7537; WICKNER SH, 1987, P NATL ACAD SCI USA, V84, P3668, DOI 10.1073/pnas.84.11.3668; WU F, 1992, NUCLEIC ACIDS RES, V20, P811, DOI 10.1093/nar/20.4.811; YAMAGUCHI K, 1984, GENE, V29, P311; ZAHN K, 1985, EMBO J, V4, P3605, DOI 10.1002/j.1460-2075.1985.tb04124.x; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1984, MOL GEN GENET, V196, P401, DOI 10.1007/BF00436186	80	176	177	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4883	4890						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106460				2022-12-27	WOS:A1994MX57100031
J	OGATA, S; FUKUDA, M				OGATA, S; FUKUDA, M			LYSOSOMAL TARGETING OF LIMP-II MEMBRANE GLYCOPROTEIN REQUIRES A NOVEL LEU-ILE MOTIF AT A PARTICULAR POSITION IN ITS CYTOPLASMIC TAIL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; ANCHORED FORM; PROTEIN; CDNA; CLONING; SEQUENCE; EXPRESSION; SIGNAL; GOLGI; DNA	A class of integral membrane glycoproteins specific to lysosomes has been identified, and they are classified into two separate groups depending on whether or not their cytoplasmic sequence contains a tyrosine residue. Lamp-1 and lamp-2 have a tyrosine-containing motif in their cytoplasmic segments, and this motif was found to direct the glycoproteins to lysosomes. Limp II glycoprotein, on the other hand, lacks a tyrosine in its cytoplasmic segment and it must be directed to lysosomes by a different signal (Fukuda, M. (1991) J. Biol. Chem. 266, 21327-21330). In order to elucidate the targeting signal of Limp II, a cDNA encoding its cytoplasmic segment was fused with a reporter molecule, a chimeric protein of human gonadotropin alpha chain-vesicular stomatitis G-protein transmembrane. After various mutations its expression was examined by immunofluorescence. First it was shown that a chimeric protein with a Limp II wildtype tail is transported to lysosomes. Deletion of the three amino acids of the cytoplasmic tail at the carboxyl terminus abolished this sorting to lysosomes. Substitution of individual amino acids revealed that the Leu-Ile motif in the Leu-Ile-Arg-Thr sequence at the carboxyl terminus is crucial to the sorting signal. When this motif was brought closer to the transmembrane domain by deletion of nine amino acids next to the transmembrane domain, this sorting function was abolished. In addition, substitution of alanine for the serine, which is at 5 residues from the transmembrane also abolished the sorting capacity, although there was no evidence that the phosphorylation of serine is involved in sorting. Altered proteins that were not transported to lysosomes were found to accumulate at the cell surface and, unlike proteins with a wild-type cytoplasmic tail, were unable to undergo endocytosis. These results indicate that the carboxyl-terminal amino acid sequence, including the Leu-Ile motif and the sequence that connects the motif to the transmembrane domain, is critical for the sorting of Limp II to lysosomes.	LA JOLLA CANC RES FDN,CANC RES CTR,GLYCOBIOL PROGRAM,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA048737] Funding Source: NIH RePORTER; NCI NIH HHS [CA48737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRIOCANAL JG, 1986, J BIOL CHEM, V261, P6755; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CARLSSON SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P630, DOI 10.1016/0003-9861(92)90619-8; CHA Y, 1990, J BIOL CHEM, V265, P5008; CHEN JW, 1988, J BIOL CHEM, V263, P8754; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; FAMBROUGH DM, 1988, J CELL BIOL, V106, P61, DOI 10.1083/jcb.106.1.61; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUJITA H, 1992, BIOCHEM BIOPH RES CO, V184, P604, DOI 10.1016/0006-291X(92)90632-U; FUKUDA M, 1988, J BIOL CHEM, V263, P5314; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GRANGER BL, 1990, J BIOL CHEM, V265, P12036; GREENWALT DE, 1992, BLOOD, V80, P1105; GREENWALT DE, 1991, THROMB HAEMOSTASIS, V65, P1153; GUAN JL, 1988, J BIOL CHEM, V263, P5306; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIMENO M, 1989, FEBS LETT, V244, P351, DOI 10.1016/0014-5793(89)80561-7; HOWE CL, 1988, P NATL ACAD SCI USA, V85, P7577, DOI 10.1073/pnas.85.20.7577; JADOT M, 1992, J BIOL CHEM, V267, P11069; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUDO S, 1990, J BIOL CHEM, V265, P1102; LEEN, 1990, J BIOL CHEM, V265, P20476; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LOBEL P, 1987, P NATL ACAD SCI USA, V84, P2233, DOI 10.1073/pnas.84.8.2233; MATHEWS PM, 1992, J CELL BIOL, V118, P1027, DOI 10.1083/jcb.118.5.1027; MERESSE S, 1990, J BIOL CHEM, V265, P18833; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; NOGUCHI Y, 1989, BIOCHEM BIOPH RES CO, V164, P1113, DOI 10.1016/0006-291X(89)91784-1; ODA K, 1992, J BIOL CHEM, V267, P17465; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PILLER V, 1989, J BIOL CHEM, V264, P18824; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANDON NN, 1989, J BIOL CHEM, V264, P7576; VEGA MA, 1991, J BIOL CHEM, V266, P16818; VEGA MA, 1991, J BIOL CHEM, V266, P16269; VIITALA J, 1988, P NATL ACAD SCI USA, V85, P3743, DOI 10.1073/pnas.85.11.3743; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	50	95	99	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5210	5217						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106503				2022-12-27	WOS:A1994MX57100080
J	SANADI, AR; SUROLIA, A				SANADI, AR; SUROLIA, A			STUDIES ON A CHITOOLIGOSACCHARIDE-SPECIFIC LECTIN FROM COCCINIA-INDICA - THERMODYNAMICS AND KINETICS OF UMBELLIFERYL GLYCOSIDE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; WHEAT-GERM-AGGLUTININ; TOMATO LYCOPERSICON-ESCULENTUM; TEMPERATURE-JUMP RELAXATION; ALPHA-D-MANNOPYRANOSIDE; DIMERIC CONCANAVALIN-A; CARBOHYDRATE-BINDING; SACCHARIDE-BINDING; SOYBEAN AGGLUTININ; PEANUT AGGLUTININ	Coccinia indica agglutinin (CIA) is a chitooligosaccharide-specific lectin with two binding sites/homodimer of M(r) 32,000. Quenching studies implied tryptophan involvement in binding activity, which was confirmed by chemical modification experiments (A. R. Sanadi and A. Surolia, submitted for publication). Binding of 4-methylumbelliferyl chitooligosaccharides has been carried out to study their binding by CIA. Reversal experiments confirm the validity of the data previously obtained (A. R. Sanadi and A. Surolia, submitted for publication) from intrinsic fluorescence studies. Surprisingly, unlike wheat germ agglutinin, there is no consistent thermodynamic effect of the chromophoric label on binding activities as compared with the native sugars. From the changes in the optical properties of the chromophoric group upon binding to CIA, it has been possible to confirm that the tryptophan located in the binding site is closest to the fourth subsite. Thermodynamic analysis shows that the binding of the labeled tetrasaccharide is very strongly entropically driven, with the terminal, nonreducing sugar residue protruding from the binding pocket. The results of stopped-flow kinetic studies on the binding of the chromophoric trisaccharide by CIA show that the mechanism of binding is a one-step process.	INDIAN INST SCI,UNIV GRANTS COMMISS CTR ADV STUDY,MOLEC BIOPHYS UNIT,BANGALORE 560012,INDIA	Indian Institute of Science (IISC) - Bangalore			SUROLIA, AVADESHA/C-5442-2009; Sanadi, Anand/C-4420-2015	Sanadi, Anand/0000-0002-6382-9225				ALLEN AK, 1979, BIOCHEM J, V183, P133, DOI 10.1042/bj1830133; ALLEN AK, 1973, BIOCHEM J, V135, P307, DOI 10.1042/bj1350307; ANANTHARAM V, 1986, J BIOL CHEM, V261, P4621; BARONDES SH, 1981, ANNU REV BIOCHEM, V50, P207, DOI 10.1146/annurev.bi.50.070181.001231; BESSLER W, 1974, J BIOL CHEM, V249, P2819; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER CF, 1973, BIOCHEMISTRY-US, V12, P4448, DOI 10.1021/bi00746a023; BREWER CF, 1979, BIOCHEMISTRY-US, V18, P2555, DOI 10.1021/bi00579a019; BROEKAERT WF, 1989, SCIENCE, V245, P1100, DOI 10.1126/science.245.4922.1100; CHIPMAN DM, 1967, J BIOL CHEM, V242, P4388; CLEGG RM, 1977, BIOCHEMISTRY-US, V16, P167, DOI 10.1021/bi00621a002; CLEGG RM, 1983, BIOCHEMISTRY-US, V22, P4797, DOI 10.1021/bi00289a028; DEBOECK H, 1984, J BIOL CHEM, V259, P7067; DELMOTTE FM, 1975, CARBOHYD RES, V40, P353, DOI 10.1016/S0008-6215(00)82616-6; DIAZ CL, 1989, NATURE, V338, P579, DOI 10.1038/338579a0; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; GRAY RD, 1973, J BIOL CHEM, V248, P7547; GREENAWAY PJ, 1973, NATURE-NEW BIOL, V241, P191, DOI 10.1038/newbio241191a0; HARRINGTON PC, 1981, ISRAEL J CHEM, V21, P48, DOI 10.1002/ijch.198100012; KHAN MI, 1986, J BIOL CHEM, V261, P3013; KILPATRICK DC, 1980, BIOCHEM J, V185, P269, DOI 10.1042/bj1850269; KILPATRICK DC, 1978, BIOCHEM J, V175, P1151, DOI 10.1042/bj1751151; Laidler K. J., 1979, THEORIES CHEM REACTI, P41; LIENER IE, 1976, ANNU REV PLANT PHYS, V27, P291, DOI 10.1146/annurev.pp.27.060176.001451; LIS H, 1986, ANNU REV BIOCHEM, V55, P35, DOI 10.1146/annurev.bi.55.070186.000343; Lis H., 1986, LECTINS PROPERTIES F, P293; LOONTIENS FG, 1977, BIOCHEMISTRY-US, V16, P159, DOI 10.1021/bi00621a001; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NACHBAR MS, 1980, J BIOL CHEM, V255, P2056; NEUROHR KJ, 1982, BIOCHEMISTRY-US, V21, P498, DOI 10.1021/bi00532a013; NEUROHR KJ, 1981, BIOCHEMISTRY-US, V20, P3499, DOI 10.1021/bi00515a030; PEREIRA M E A, 1979, Critical Reviews in Immunology, V1, P33; PODDER SK, 1978, FEBS LETT, V85, P313, DOI 10.1016/0014-5793(78)80481-5; POOLA I, 1986, CARBOHYD RES, V146, P205, DOI 10.1016/0008-6215(86)85040-6; READ SM, 1983, PLANTA, V158, P119, DOI 10.1007/BF00397704; READ SM, 1983, EUR J BIOCHEM, V134, P561, DOI 10.1111/j.1432-1033.1983.tb07603.x; SABNIS DD, 1978, PLANTA, V142, P97, DOI 10.1007/BF00385126; SABNIS DD, 1979, PLANTA, V145, P459, DOI 10.1007/BF00380100; SEQUEIRA L, 1978, ANNU REV PHYTOPATHOL, V16, P453, DOI 10.1146/annurev.py.16.090178.002321; SWAMY MJ, 1986, BIOCHEM J, V234, P515, DOI 10.1042/bj2340515; VANLANDSCHOOT A, 1977, EUR J BIOCHEM, V79, P275; VANLANDSCHOOT A, 1978, EUR J BIOCHEM, V83, P277	42	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5072	5077						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106485				2022-12-27	WOS:A1994MX57100060
J	CASPARI, T; STADLER, R; SAUER, N; TANNER, W				CASPARI, T; STADLER, R; SAUER, N; TANNER, W			STRUCTURE-FUNCTION RELATIONSHIP OF THE CHLORELLA GLUCOSE/H+ SYMPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT ACTIVITY; LACTOSE PERMEASE; EXPRESSION; SEQUENCE; CLONING; PROTEIN; GENE; TRYPTOPHAN-412; CARRIER; INVIVO	The Clorella kessleri HUP1 gene coding for a hexose/H+ symporter has been expressed in a glucose uptake-deficient mutant of Schizosaccharomyces pombe. The transformants are able to grow on glucose and to accumulate 3-O-methylglucose 100-fold. This system has been used to test the activity of specifically mutated HUP1 cDNAs. All three histidyl residues were exchanged with arginine (H73R, H170R, and H495R) without a major effect on transport activity. When Asp-44 within the first transmembrane helix was replaced by Asn, the transporter was inactive; replacement by Glu (D44E) resulted in a loss of activity by 90% and a 15-fold increased K(m) value. Glutamine residues conserved in all glucose transporters sequenced so far were exchanged: Q179N (in helix 5), Q298G and Q299N (both in helix 7). Whereas Q298G only resulted in a small K(m) change, both Q179N and Q299N showed an increase in K(m) by a factor of 10. Inserting 4 additional amino acids each into the two largest loops (1 and 6) reduced the activity dramatically; only in the latter case this was due to decreased protein synthesis or stability. Two COOH-terminal deletions (-27 and -43 amino acids) were also tested. The 27 COOH-terminal amino acids, but not the 43 COOH-terminal amino acids, could be removed without affecting transporter activity.	UNIV REGENSBURG,LEHRSTUHL ZELLBIOL & PFLANZENPHYSIOL,D-93040 REGENSBURG,GERMANY	University of Regensburg				Caspari, Thomas/0000-0002-1450-4774				BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; BURGLIN TR, 1987, EMBO J, V6, P2617, DOI 10.1002/j.1460-2075.1987.tb02552.x; CELENZA JL, 1988, P NATL ACAD SCI USA, V85, P2130, DOI 10.1073/pnas.85.7.2130; CHENG Q, 1989, GENETICS, V123, P477; CONSLER TG, 1993, P NATL ACAD SCI USA, V90, P6934, DOI 10.1073/pnas.90.15.6934; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HOFER M, 1987, J GEN MICROBIOL, V133, P2163; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KABACK HR, 1992, INT REV CYTOL, V137A, P97; KATAGIRI H, 1991, J BIOL CHEM, V266, P7769; KOMOR E, 1974, J GEN PHYSIOL, V64, P568, DOI 10.1085/jgp.64.5.568; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCKENNA E, 1992, P NATL ACAD SCI USA, V89, P11954, DOI 10.1073/pnas.89.24.11954; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SAGERS JR, 1988, NUCLEIC ACIDS RES, V16, P791; SANDERS D, 1989, PLANT MEMBRANE TRANS, P3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER N, 1990, EMBO J, V9, P3045, DOI 10.1002/j.1460-2075.1990.tb07500.x; SAUER N, 1989, FEBS LETT, V259, P43, DOI 10.1016/0014-5793(89)81489-9; SAUER N, 1990, P NATL ACAD SCI USA, V87, P7949, DOI 10.1073/pnas.87.20.7949; SCHMETTERER GR, 1990, PLANT MOL BIOL, V14, P697, DOI 10.1007/BF00016502; SILVERMAN M, 1991, ANNU REV BIOCHEM, V60, P757, DOI 10.1146/annurev.bi.60.070191.003545; STADLER R, 1993, PLANT J, V4, P601; TANNER W, 1975, BIOMEMBRANES STRUCTU, P145; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WRUBEL W, 1990, J BACTERIOL, V172, P5374, DOI 10.1128/jb.172.9.5374-5381.1990	31	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3498	3502						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106391				2022-12-27	WOS:A1994MV63100057
J	GOMBAU, L; SCHLEEF, RR				GOMBAU, L; SCHLEEF, RR			PROCESSING OF TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR (PAI-1) INTO THE REGULATED SECRETORY PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; HUMAN-PLATELETS; ATT-20 CELLS; P-SELECTIN; PROTEIN; GRANULES; PLASMA; PROPOLYPEPTIDE; VITRONECTIN; TRYPSINOGEN	To understand the processing of type 1 plasminogen activator inhibitor (PAI-1) into the storage granules of platelets, we utilized a eukaryotic expression vector (pRC/CMV) to transfer the human cDNA for PAI-1 into AtT-20 cells, a mouse pituitary cell line known to sort proteins in a regulated fashion. Immunofluorescence staining of PAI-1-transfected AtT-20 clones revealed colocalization of PAI-1 with an endogenously produced and stored hormone (i.e. adrenocorticotropic hormone, ACTH). Stimulation of PAI-1-transfected AtT-20 cells with a secretagogue resulted in the release of both active PAI-1 and the latent form. In comparison, PAI-1-transfected Chinese hamster ovary cells (i.e. a nonpackaging cell line) did not release PAI-1 in response to a secretagogue and exhibited immunoreactivity for PAI-1 primarily confined to the Golgi region. Percoll density gradient fractionation of AtT-20 cells revealed a codistribution of PAI-1 and ACTH in cellular compartments of the same density.The half-life of PAI-1 activity at 37-degrees-C was prolonged in intact granules (t1/2, 5 h) in comparison with its half-life in lysed granules (t1/2, 2 h). These studies demonstrate the presence of a new functional property associated with the PAI-1 molecule that directs this inhibitor into the storage secretory pathway.	Scripps Res Inst, DEPT VASC BIOL, CVB-3, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA	Scripps Research Institute					NHLBI NIH HHS [HL 45954] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045954] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BITHELL TC, 1993, CLIN HEMATOLOGY, P511; BOOTH NA, 1985, J CLIN PATHOL, V38, P825, DOI 10.1136/jcp.38.7.825; BOOTH NA, 1988, BRIT J HAEMATOL, V70, P327, DOI 10.1111/j.1365-2141.1988.tb02490.x; BOOTH NA, 1990, FIBRINOLYSIS, V4, P138, DOI 10.1016/0268-9499(90)90391-V; BURGESS TL, 1985, J CELL BIOL, V101, P639, DOI 10.1083/jcb.101.2.639; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURGESS TL, 1987, J CELL BIOL, V105, P659, DOI 10.1083/jcb.105.2.659; DECLERCK PJ, 1988, BLOOD, V71, P220; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; ERICKSON LA, 1984, J CLIN INVEST, V74, P1465, DOI 10.1172/JCI111559; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; GUMBINER B, 1982, CELL, V28, P51, DOI 10.1016/0092-8674(82)90374-9; KELLY R B, 1991, Current Opinion in Cell Biology, V3, P654, DOI 10.1016/0955-0674(91)90037-Y; KIZER JS, 1991, BIOCHEM BIOPH RES CO, V174, P586, DOI 10.1016/0006-291X(91)91457-N; KOEDAM JA, 1992, J CELL BIOL, V116, P617, DOI 10.1083/jcb.116.3.617; KONKLE BA, 1993, ARTERIOSCLER THROMB, V13, P669, DOI 10.1161/01.ATV.13.5.669; KRUITHOF EKO, 1987, BLOOD, V70, P1645; KRUITHOF EKO, 1986, THROMB HAEMOSTASIS, V55, P201; LANG IM, 1993, CIRCULATION, V87, P1990, DOI 10.1161/01.CIR.87.6.1990; LANG IM, 1992, BLOOD, V80, P2269; LEVI M, 1992, CIRCULATION, V85, P305, DOI 10.1161/01.CIR.85.1.305; LINDAHL TL, 1989, THROMB HAEMOSTASIS, V62, P748; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; MAYADAS TN, 1989, J BIOL CHEM, V264, P13497; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MOORE HPH, 1986, NATURE, V321, P443, DOI 10.1038/321443a0; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; PREISSNER KT, 1989, BLOOD, V74, P1989; RINDLER M J, 1992, Current Opinion in Cell Biology, V4, P616, DOI 10.1016/0955-0674(92)90080-V; SCHLEEF RR, 1991, J CELL BIOL, V113, P1413, DOI 10.1083/jcb.113.6.1413; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; SCHLEEF RR, 1989, J CLIN INVEST, V83, P1747, DOI 10.1172/JCI114076; SCHLEEF RR, 1985, J LAB CLIN MED, V106, P408; SIMPSON AJ, 1991, J CLIN PATHOL, V44, P139, DOI 10.1136/jcp.44.2.139; SIMPSON AJ, 1990, BRIT J HAEMATOL, V75, P543, DOI 10.1111/j.1365-2141.1990.tb07796.x; SPRENGERS ED, 1986, THROMB HAEMOSTASIS, V55, P325; SPRENGERS ED, 1987, BLOOD, V69, P381; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I	40	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3875	3880						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106433				2022-12-27	WOS:A1994MV63100108
J	KNEUSEL, RE; SCHILTZ, E; MATERN, U				KNEUSEL, RE; SCHILTZ, E; MATERN, U			MOLECULAR CHARACTERIZATION AND CLONING OF AN ESTERASE WHICH INACTIVATES THE MACROLIDE TOXIN BREFELDIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNARIA-CARTHAMI CHOWDHURY; HERBICIDE RESISTANCE; DETOXIFYING ENZYME; BACILLUS-SUBTILIS; FUSARIC ACID; DETOXIFICATION; PLANTS; EXPRESSION; PROTEINS; GENES	The macrolide antibiotic brefeldin A (BFA) was described as a phytotoxin and pathogenicity factor from Alternaria carthami Chowdhury, the causal agent of a devastating blight disease in safflower (Carthamus tinctorius L.). The toxin is known to inhibit the endoplasmic reticulum-Golgi flux and processing. Conventional breeding of safflower for resistance to the Alternaria blight disease has failed, and in situ detoxification of brefeldin A is a novel approach for the protection of field-grown safflower plants from the blight disease. As a first step towards this goal, a strain of Bacillus subtilis had been isolated which is capable of hydrolyzing brefeldin A to a non-toxic metabolite, brefeldin A acid. The BFA esterase was purified to homogeneity from B. subtilis extracts and shown to consist of a monomeric peptide of approximately 40 kDa. Besides brefeldin A, the esterase hydrolyzed ethyl valerate, which structurally resembles the lactone portion in the brefeldin A molecule, but failed to accept other macrolides such as erythromycin or zearalenone. Roughly 12% of the esterase sequence was identified by microsequencing tryptic peptides and the N terminus, which lacked a methionine leader residue. Corresponding oligonucleotide probes were employed to clone the esterase gene in pUC18. One of seven clones was sequenced and shown to code for the full size esterase protein of 372 amino acid residues. The esterase gene was subcloned in pT7-7 and expressed in Escherichia coli yielding a fusion protein with a specific esterase activity 3-fold over that of the enzyme purified from B. subtilis. The cloned esterase provides the basis for the generation of transgenic safflower plants as a valuable asset in the research on nonspecific phytotoxins and in supporting breeding for Alternaria blight resistance.	UNIV FREIBURG,LEHRSTUHL BIOCHEM PFLANZEN,INST BIOL 2,SCHANZLESTR 1,D-79104 FREIBURG,GERMANY; UNIV FREIBURG,INST ORGAN CHEM & BIOCHEM,D-79104 FREIBURG,GERMANY	University of Freiburg; University of Freiburg								ANZAI H, 1989, MOL GEN GENET, V219, P492, DOI 10.1007/BF00259626; ARTHUR M, 1987, J ANTIMICROB CHEMOTH, V20, P783, DOI 10.1093/jac/20.6.783; BERGMEYER HU, 1974, METHODS ENZYMATIC AN; Bohlmann F., 1973, NATURALLY OCCURRING; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BRUNING A, 1992, J BIOL CHEM, V267, P5052; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CACHET T, 1987, J CHROMATOGR, V409, P91, DOI 10.1016/S0021-9673(01)86786-8; CARUTHERS MH, 1982, GENETIC ENG, V4, P1; Chowdhury S., 1944, JOUR INDIAN BOT SOC, V23, P59; DEBLOCK M, 1987, EMBO J, V6, P2513, DOI 10.1002/j.1460-2075.1987.tb02537.x; DRIOUICH A, 1993, PLANT PHYSIOL, V101, P1363, DOI 10.1104/pp.101.4.1363; FISHBEIN WN, 1966, J BIOL CHEM, V241, P4835; FUENTEMARTINEZ JM, 1992, BIOTECHNOLOGY, V10, P905; Harwood C.R., 1990, MOL BIOL METHODS BAC; HASEGAWA S, 1980, PHYTOCHEMISTRY, V19, P1445, DOI 10.1016/0031-9422(80)80191-9; HOLMLUND CE, 1965, ARCH BIOCHEM BIOPHYS, V109, P29, DOI 10.1016/0003-9861(65)90282-1; HOU CT, 1970, J BIOL CHEM, V245, P1289; KNEUSEL RE, 1990, FEBS LETT, V275, P107, DOI 10.1016/0014-5793(90)81450-3; KNOWLES PF, 1965, SAFFLOWER; KOHMOTO K, 1991, EXPERIENTIA, V47, P755, DOI 10.1007/BF01922454; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYON BR, 1989, PLANT MOL BIOL, V13, P533, DOI 10.1007/BF00027313; MATERN U, 1989, NATO ASI SER H, V27, P419; MIYADA CG, 1987, METHOD ENZYMOL, V154, P94; MORAN CP, 1982, MOL GEN GENET, V186, P339, DOI 10.1007/BF00729452; OHARA K, 1989, ANTIMICROB AGENTS CH, V33, P1354, DOI 10.1128/AAC.33.8.1354; Parr Jr TR, 1984, ANTIMICROBIAL DRUG R, P81; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; SAITO K, 1992, J PLANT PHYSIOL, V140, P121, DOI 10.1016/S0176-1617(11)81069-2; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATIATJEUNEMAITRE B, 1993, CELL BIOL INT, V17, P183, DOI 10.1006/cbir.1993.1054; SIMPSON RJ, 1989, ANAL BIOCHEM, V177, P221, DOI 10.1016/0003-2697(89)90044-4; STALKER DM, 1988, SCIENCE, V242, P419, DOI 10.1126/science.242.4877.419; STREBER WR, 1989, BIO-TECHNOL, V7, P811, DOI 10.1038/nbt0889-811; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TIETJEN KG, 1985, PHYSIOL PLANT PATHOL, V26, P241, DOI 10.1016/0048-4059(85)90024-4; TIETJEN KG, 1984, ARCH BIOCHEM BIOPHYS, V229, P136, DOI 10.1016/0003-9861(84)90138-3; TIETJEN KG, 1983, PHYSIOL PLANT PATHOL, V23, P387, DOI 10.1016/0048-4059(83)90023-1; TOYODA H, 1988, PHYTOPATHOLOGY, V78, P1307, DOI 10.1094/Phyto-78-1307; UTSUMI R, 1988, J BIOTECHNOL, V8, P311, DOI 10.1016/0168-1656(88)90023-5	43	23	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3449	3456						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106385				2022-12-27	WOS:A1994MV63100050
J	OKADA, T; KAWANO, Y; SAKAKIBARA, T; HAZEKI, O; UI, M				OKADA, T; KAWANO, Y; SAKAKIBARA, T; HAZEKI, O; UI, M			ESSENTIAL ROLE OF PHOSPHATIDYLINOSITOL 3-KINASE IN INSULIN-INDUCED GLUCOSE-TRANSPORT AND ANTILIPOLYSIS IN RAT ADIPOCYTES - STUDIES WITH A SELECTIVE INHIBITOR WORTMANNIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; SIGNAL TRANSDUCTION; INSULINOMIMETIC AGENTS; INTACT-CELLS; FAT-CELLS; PROTEIN; PHOSPHORYLATION; STIMULATION; ACTIVATION; SUBSTRATE	Significant activity of phosphatidylinositol 3-kinase (PI 3-kinase) was detected in the membrane fractions, or in the immunoprecipitates prepared with anti-phosphotyrosine antibodies, from rat adipocytes that had been incubated with insulin for 20 min. The PI 3-kinase activity in these preparations as well as in the whole cell lysates of adipocytes not treated with insulin was inhibited by the addition of wortmannin, a fungal metabolite, to the enzyme assay mixture. The inhibition was dependent on the inhibitor concentration with IC50 being less than 10 nm and perfect inhibition at 100 nM. The effect of insulin to induce membrane PI 3-kinase activity was mostly abolished, but its effects to tyrosine-phosphorylate the beta-subunit of the insulin receptor or other cellular substrate proteins including insulin-receptor-substrate-1 were not at all antagonized, by wortmannin added to the cell incubation medium. Insulin stimulation of cellular 2-deoxyglucose uptake and inhibition of isoproterenol-induced lipolysis observable in adipocytes under the same conditions were also antagonized by wortmannin added in the same concentration range as used for the inhibition of insulin-susceptible PI 3-kinase. It is concluded, therefore, that activation of wort-mannin-sensitive PI 3-kinase plays a pivotal role in the intracellular signaling pathways arising from the insulin receptor autophosphorylation and leading to certain metabolic responses.	INST PHYS & CHEM RES,UI LAB,HIROSAWA 2-1,WAKO 35101,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,BUNKYO KU,TOKYO 113,JAPAN	RIKEN; University of Tokyo								ABLER A, 1992, J BIOL CHEM, V267, P3946; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COUGHLIN SR, 1989, SCIENCE, V243, P1191; Cuatrecasas P, 1974, Methods Enzymol, V34, P653; CZECH MP, 1974, P NATL ACAD SCI USA, V71, P4173, DOI 10.1073/pnas.71.10.4173; DESBOIS C, 1992, J BIOL CHEM, V267, P13488; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GIORGETTI S, 1992, EUR J BIOCHEM, V207, P599; GLIEMANN J, 1972, BIOCHIM BIOPHYS ACTA, V286, P1, DOI 10.1016/0304-4165(72)90082-7; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HAYES GR, 1987, P NATL ACAD SCI USA, V84, P8115, DOI 10.1073/pnas.84.22.8115; INOUE G, 1993, J BIOL CHEM, V268, P5272; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P736; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KONO T, 1973, J BIOL CHEM, V248, P7417; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; MOONEY RA, 1989, J BIOL CHEM, V264, P6850; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; OKADA T, 1994, J BIOL CHEM, V269, P3563; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHECHTER Y, 1989, EMBO J, V8, P1671, DOI 10.1002/j.1460-2075.1989.tb03558.x; SHISHEVA A, 1992, FEBS LETT, V300, P93, DOI 10.1016/0014-5793(92)80171-C; SHISHEVA A, 1993, J BIOL CHEM, V268, P6463; SHISHEVA A, 1992, BIOCHEMISTRY-US, V31, P8059, DOI 10.1021/bi00149a041; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YANO H, 1993, J BIOL CHEM, V268, P25846	43	923	958	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3568	3573						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106400				2022-12-27	WOS:A1994MV63100068
J	LOLLO, BA; CHAN, KWH; HANSON, EM; MOY, VT; BRIAN, AA				LOLLO, BA; CHAN, KWH; HANSON, EM; MOY, VT; BRIAN, AA			DIRECT EVIDENCE FOR 2 AFFINITY STATES FOR LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1 ON ACTIVATED T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; MONOCLONAL-ANTIBODY; BETA-SUBUNIT; INDUCED PHOSPHORYLATION; COMPLEMENT RECEPTORS; CYTOPLASMIC DOMAIN; LIGAND-BINDING; CROSS-LINKING; B-CELLS; LFA-1	Lymphocytes activated by antigen receptor cross-linking or phorbol esters adhere avidly to surfaces bearing intercellular adhesion molecule 1 (ICAM-1) through the adhesion receptor lymphocyte function-associated antigen 1 (LFA-1). It is not known whether avid adhesion by stimulated lymphocytes is due to higher affinity binding of ICAM-1 or due solely to post-receptor mechanisms. We have used a recombinant, soluble form of the ICAM-1 molecule to measure the affinity of binding to LFA-1 on unstimulated T cells and T cells stimulated with phorbol esters. The affinity was found to be too low for direct measurements, requiring instead the use of competition protocols in which ICAM-1 competes for binding with radiolabeled Fab from a monoclonal antibody specific for LFA-1. By analysis of the equilibrium and kinetics of competitive binding, we found that the affinity on unstimulated T cells is very low, about 100 muM. Activation of the T cells by phorbol esters caused a small increase in average binding affinity. Further analysis suggested that the change in average affinity reflected the conversion of a fraction of LFA-1 molecules to a state with a 200-fold higher affinity.	UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048054] Funding Source: NIH RePORTER; NCI NIH HHS [CA01974] Funding Source: Medline; NIGMS NIH HHS [GM48054, GM07313] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; ALTIERI DC, 1988, J IMMUNOL, V141, P2656; BUYON JP, 1990, J IMMUNOL, V144, P191; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; CONTRERAS ML, 1986, J PHARMACOL EXP THER, V239, P136; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DAVIGNON D, 1981, J IMMUNOL, V127, P590; DEFRANCO AL, 1982, J EXP MED, V155, P1523, DOI 10.1084/jem.155.5.1523; DETMERS PA, 1987, J CELL BIOL, V105, P1137, DOI 10.1083/jcb.105.3.1137; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIMINNO G, 1983, BLOOD, V61, P140; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FINE JS, 1991, J IMMUNOL, V147, P2852; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GULINO D, 1990, J BIOL CHEM, V265, P9575; HAMANN A, 1988, J IMMUNOL, V140, P693; HAVERSTICK DM, 1992, AM J PHYSIOL, V262, pC916, DOI 10.1152/ajpcell.1992.262.4.C916; HEDMAN H, 1992, J IMMUNOL, V149, P2295; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; ISENBERG WM, 1987, J CELL BIOL, V104, P1655, DOI 10.1083/jcb.104.6.1655; KANE KP, 1989, MOL IMMUNOL, V26, P759, DOI 10.1016/0161-5890(89)90036-9; KELLEHER D, 1990, EUR J IMMUNOL, V20, P2351, DOI 10.1002/eji.1830201028; KUHLMAN P, 1991, J IMMUNOL, V146, P1773; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MOINGEON PE, 1991, EUR J IMMUNOL, V21, P605, DOI 10.1002/eji.1830210311; MOTULSKY HJ, 1984, MOL PHARMACOL, V25, P1; MOY VT, 1992, J EXP MED, V175, P1, DOI 10.1084/jem.175.1.1; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; PALS ST, 1988, J IMMUNOL, V140, P1851; PARDI R, 1992, J CELL BIOL, V116, P1211, DOI 10.1083/jcb.116.5.1211; PRESS WH, 1988, NUMERICAL RECIPES C, P305; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SANCHEZMADRID F, 1983, J EXP MED, V158, P586, DOI 10.1084/jem.158.2.586; SAYRE PH, 1989, J EXP MED, V169, P995, DOI 10.1084/jem.169.3.995; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SHIMIZU Y, 1992, J EXP MED, V175, P577, DOI 10.1084/jem.175.2.577; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SINGER KH, 1990, J LEUKOCYTE BIOL, V48, P367, DOI 10.1002/jlb.48.4.367; SIU G, 1989, J IMMUNOL, V143, P3813; TEDDER TF, 1986, EUR J IMMUNOL, V16, P1539, DOI 10.1002/eji.1830161212; TOHMA S, 1991, J IMMUNOL, V146, P492; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; WRIGHT SD, 1986, J IMMUNOL, V136, P1759	51	199	200	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21693	21700						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8104943				2022-12-27	WOS:A1993MC80900042
J	BORNANCIN, F; AUDIGIER, Y; CHABRE, M				BORNANCIN, F; AUDIGIER, Y; CHABRE, M			ADP-RIBOSYLATION OF G(S) BY CHOLERA-TOXIN IS POTENTIATED BY AGONIST ACTIVATION OF BETA-ADRENERGIC RECEPTORS IN THE ABSENCE OF GTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; ADENYLATE-CYCLASE; PHOTOEXCITED RHODOPSIN; REGULATORY COMPONENT; ALPHA-SUBUNIT; HL-60 CELLS; GS-ALPHA; TRANSDUCIN; MEMBRANES; SITE	Purified G(s) is a substrate for ADP-ribosylation catalyzed by cholera toxin (CTx). In S49 cyc- membranes complemented with in vitro translated G(s)alpha, the beta-adrenergic agonist isoproterenol enhanced the ADP-ribosylation rate. This effect was maximal if all guanyl nucleotides were suppressed but was blocked by the beta-adrenergic antagonist alprenolol. Enhancement was partially diminished if addition of GDP followed that of isoproterenol. When added in the absence of agonist, the GTP analogues guanosine 5'-O-(gamma-thiotriphosphate) and guanosine 5'-(beta,gamma-imido)triphosphate potentiated CTx-catalyzed ADP-ribosylation of G(s)alpha consistent with their activating ADP-ribosylation factors. However, this effect was lessened when the same nucleotides were tested in the presence of agonist. Taken altogether, these results indicate that like G(t) and G(i), G(s) is an optimal substrate for CTx when coupled to an agonist-activated receptor and depleted of nucleotide. Therefore, coupling to the receptor and subsequent departure of the GDP turn out to be the common features underlying the sensitivity of all GTP-binding proteins to CTx-catalyzed ADP-ribosylation.	INST PHARMACOL MOLEC & CELLULAIRE, CNRS, SOPHIA ANTIPOLIS, F-06560 VALBONNE, FRANCE; UNIV TOULOUSE 3, CTR BIOL DEV, CNRS, UMR 9925, F-31062 TOULOUSE, FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier								ABOOD ME, 1982, J BIOL CHEM, V257, P540; BORNANCIN F, 1989, EUR J BIOCHEM, V184, P687, DOI 10.1111/j.1432-1033.1989.tb15068.x; BORNANCIN F, 1991, FEBS LETT, V291, P273, DOI 10.1016/0014-5793(91)81300-W; BORNANCIN F, 1992, EUR J BIOCHEM, V210, P33, DOI 10.1111/j.1432-1033.1992.tb17387.x; BOURNE HR, 1975, SCIENCE, V187, P750, DOI 10.1126/science.163487; BRUCKERT F, 1992, BIOPHYS J, V63, P616, DOI 10.1016/S0006-3495(92)81650-8; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; ENOMOTO K, 1980, J BIOL CHEM, V255, P1252; GIERSCHIK P, 1987, FEBS LETT, V224, P219, DOI 10.1016/0014-5793(87)80451-9; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GIERSCHIK P, 1992, HDB EXPT PHARM, V102, P807; GILL DM, 1991, METHOD ENZYMOL, V195, P267; GILL DM, 1987, BIOCHEMISTRY-US, V26, P6364, DOI 10.1021/bi00394a009; GILL DM, 1978, P NATL ACAD SCI USA, V75, P3050, DOI 10.1073/pnas.75.7.3050; HARRIS BA, 1985, SCIENCE, V229, P1274, DOI 10.1126/science.3839937; IIRI T, 1989, J BIOL CHEM, V264, P21394; JOHNSON GL, 1978, J BIOL CHEM, V253, P7120; JOURNOT L, 1989, FEBS LETT, V251, P230, DOI 10.1016/0014-5793(89)81460-7; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; KAHN RA, 1984, J BIOL CHEM, V259, P6235; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1990, G PROTEINS, P201; KLINZ FJ, 1989, BIOCHEM BIOPH RES CO, V165, P554, DOI 10.1016/S0006-291X(89)80002-6; MILLIGAN G, 1988, BIOCHEM J, V252, P369, DOI 10.1042/bj2520369; MOSS J, 1991, METHOD ENZYMOL, V195, P243; NAVON SE, 1984, J BIOL CHEM, V259, P6686; NORTHUP JK, 1980, P NATL ACAD SCI-BIOL, V77, P6516, DOI 10.1073/pnas.77.11.6516; RANSNAS LA, 1988, J BIOL CHEM, V263, P9482; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0	31	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17026	17029						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8102365				2022-12-27	WOS:A1993LQ98800024
J	SOARES, H; GALEGO, L; COIAS, R; RODRIGUESPOUSADA, C				SOARES, H; GALEGO, L; COIAS, R; RODRIGUESPOUSADA, C			THE MECHANISMS OF TUBULIN MESSENGER REGULATION DURING TETRAHYMENA-PYRIFORMIS RECILIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK; BETA-TUBULIN; AUTOREGULATORY CONTROL; RNA STABILITY; STARVED TETRAHYMENA; PROTEIN-SYNTHESIS; GENE-EXPRESSION; ALPHA-TUBULIN; REGENERATION; THERMOPHILA	The reciliation of Tetrahymena pyriformis cells is accompanied in the first minutes by a transient induction of stress mRNAs, i.e. hsp70 and ubiquitin. At the same time an accentuated and coordinate reduction in the amount of alpha- and beta-tubulin mRNAs is observed as analyzed by Northern blot hybridization using the homologous genomic tubulin probes. Between 60 and 120 min after the onset of reciliation, tubulin transcripts in the cytoplasm reach higher values than in exponentially growing cells. Run-on transcription assays reveal that the decrease in tubulin mRNA levels is not caused by a decrease in transcription of tubulin genes. The results obtained show that the apparent tubulin gene transcription rate is increased in reciliating cells from 15 min up to 90 min. The block of transcription using actinomycin D shows that hsps are not implicated in the destabilization of tubulin mRNA during the first minutes of reciliation. The effects of the inhibitors of protein synthesis, cycloheximide and pactamycin, on tubulin mRNA levels suggest that the translational apparatus plays a role in the stability of tubulin mRNA in cells reciliating for 15 and 30 min. Experiments using the microtubule-polymerizing drug taxol also show that tubulin mRNA destabilization is not a simple consequence of a temporary increase in free tubulin subunit pools resulting from cilia resorption.	INST GULBENKIAN CIENCIAS,GENET MOLEC LAB,APARTADO 14,P-2781 OEIRAS,PORTUGAL	Instituto Gulbenkian de Ciencia			Antunes Soares, Maria Helena/G-3065-2010	Antunes Soares, Maria Helena/0000-0001-6180-7041; Galego, Lisete/0000-0002-8832-7651; Rodrigues-Pousada, Claudina/0000-0002-5075-3639				AMARAL M, 1993, IN PRESS BIOCH BIOPH; AMARAL MD, 1988, EUR J BIOCHEM, V171, P463, DOI 10.1111/j.1432-1033.1988.tb13812.x; BAKER EJ, 1986, MOL CELL BIOL, V6, P54, DOI 10.1128/MCB.6.1.54; BARAHONA I, 1985, FEBS LETT, V188, P227, DOI 10.1016/0014-5793(85)80377-X; BARAHONA I, 1988, J MOL BIOL, V202, P365, DOI 10.1016/0022-2836(88)90271-9; BRODL MR, 1990, PLANT PHYSIOL, V92, P1133, DOI 10.1104/pp.92.4.1133; CARON JM, 1985, NATURE, V317, P618; CLEVELAND DW, 1983, J CELL BIOL, V97, P919, DOI 10.1083/jcb.97.3.919; CLEVELAND DW, 1981, CELL, V25, P537, DOI 10.1016/0092-8674(81)90072-6; COIAS R, 1988, EUR J BIOCHEM, V175, P467, DOI 10.1111/j.1432-1033.1988.tb14218.x; GALEGO L, 1985, EUR J BIOCHEM, V149, P571, DOI 10.1111/j.1432-1033.1985.tb08963.x; GALEGO L, 1984, EUR J BIOCHEM, V139, P163, DOI 10.1111/j.1432-1033.1984.tb07990.x; GAY DA, 1989, P NATL ACAD SCI USA, V86, P5763, DOI 10.1073/pnas.86.15.5763; GAY DA, 1987, CELL, V50, P671, DOI 10.1016/0092-8674(87)90325-4; GONG ZY, 1987, MOL CELL BIOL, V7, P4238, DOI 10.1128/MCB.7.12.4238; GUTTMAN SD, 1980, CELL, V22, P299, DOI 10.1016/0092-8674(80)90177-4; GUTTMAN SD, 1979, CELL, V17, P307, DOI 10.1016/0092-8674(79)90156-9; HALLBERG RL, 1984, MOL CELL BIOL, V4, P2170, DOI 10.1128/MCB.4.10.2170; HALLBERG RL, 1985, MOL CELL BIOL, V5, P2061, DOI 10.1128/MCB.5.8.2061; HEIDEMANN SR, 1980, DEV BIOL, V80, P489, DOI 10.1016/0012-1606(80)90421-2; HOFFMAN EP, 1984, MOL CELL BIOL, V4, P2883, DOI 10.1128/MCB.4.12.2883; JULIANI MH, 1990, J BIOL CHEM, V265, P9077; KLEMENZ R, 1985, EMBO J, V4, P2053, DOI 10.1002/j.1460-2075.1985.tb03891.x; LEFEBVRE PA, 1986, ANNU REV CELL BIOL, V2, P517, DOI 10.1146/annurev.cb.02.110186.002505; LOVE HD, 1988, MOL CELL BIOL, V8, P427, DOI 10.1128/MCB.8.1.427; Maniatis T., 1982, MOL CLONING; MAY GS, 1980, J CELL BIOL, V87, P272; NEVES AM, 1988, GENE, V73, P87, DOI 10.1016/0378-1119(88)90315-0; NEVES AM, 1991, MOL GEN GENET, V230, P186, DOI 10.1007/BF00290667; NEVES AM, 1991, J DNA SEQUENCING MAP, V2, P173; NOVER L, 1991, HEAT SHOCK RESPONSE, P299; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PENQUE D, 1991, EUR J BIOCHEM, V195, P487, DOI 10.1111/j.1432-1033.1991.tb15729.x; PITTENGER MF, 1985, J CELL BIOL, V101, P1941, DOI 10.1083/jcb.101.5.1941; RANNESTA.J, 1974, J CELL BIOL, V63, P1009, DOI 10.1083/jcb.63.3.1009; RODRIGUESPOUSAD.C, 1975, EUR J BIOCHEM, V56, P117; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SOARES H, 1991, EUR J BIOCHEM, V197, P291, DOI 10.1111/j.1432-1033.1991.tb15910.x; VAZQUEZ D, 1979, INHIBITORS PROTEIN S, P36; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; YEN TJ, 1988, MOL CELL BIOL, V8, P1224, DOI 10.1128/MCB.8.3.1224; ZEFF RA, 1987, FOCUS, V9, P1	42	17	17	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16623	16630						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8102139				2022-12-27	WOS:A1993LQ33600078
J	HUNTER, J; JEPSON, MA; TSURUO, T; SIMMONS, NL; HIRST, BH				HUNTER, J; JEPSON, MA; TSURUO, T; SIMMONS, NL; HIRST, BH			FUNCTIONAL EXPRESSION OF P-GLYCOPROTEIN IN APICAL MEMBRANES OF HUMAN INTESTINAL CACO-2 CELLS - KINETICS OF VINBLASTINE SECRETION AND INTERACTION WITH MODULATORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-COLON-CARCINOMA; MULTIDRUG-RESISTANCE; MONOCLONAL-ANTIBODY; CALCIUM CHANNELS; DRUG-RESISTANCE; TUMOR-CELLS; TRANSPORT; GENE; VERAPAMIL; TISSUES	The functional expression of P-glycoprotein has been studied in confluent epithelial layers of human Caco-2 cells, a polarized, highly differentiated cell line demonstrating an intestinal absorptive cell phenotype. Expression of P-glycoprotein was localized, by indirect immunofluorescence with monoclonal antibody MRK16, to the apical brush-border, approximately 20 mum above the base of the cells. Functional, high capacity expression of P-glycoprotein in Caco-2 cell layers was demonstrated by the saturable secretion of vinblastine, a typical substrate, from basolateral to apical surfaces: K(m) 18.99 +/- 5.55 mum, V(max) 1285.9 +/- 281.2 pmol.cm-2 h-1. The direct correlation of apical P-glycoprotein expression with vinblastine net secretory flux was demonstrated by the reduction of this flux after treatment with MRK16 antibodies. Vinblastine secretory flux was also reduced by treatment with verapamil (R- and S-isomers with equal affinity), nifedipine, taxotere, and 1,9-dideoxyforskolin. Kinetic analyses suggest that the inhibition of vinblastine secretory flux by verapamil and nifedipine was competitive, while that by dideoxyforskolin was non-competitive, in nature. The polarized expression and activity of P-glycoprotein in Caco-2 cells is direct evidence for its secretory detoxifying function in the intestine, subserving at least one role of the gastrointestinal epithelial barrier.	UNIV NEWCASTLE UPON TYNE,SCH MED,GASTROINTESTINAL DRUG DELIVERY RES CTR,NEWCASTLE TYNE NE2 4HH,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PHYSIOL SCI,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK; Newcastle University - UK								AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; Beck W T, 1991, Cancer Treat Res, V57, P151; BROXTERMAN HJ, 1989, INT J CANCER, V43, P340, DOI 10.1002/ijc.2910430229; CABRAL F, 1989, FASEB J, V3, P1593, DOI 10.1096/fasebj.3.5.2646163; CHANTRET I, 1988, CANCER RES, V48, P1936; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; DIX CJ, 1990, GASTROENTEROLOGY, V98, P1272, DOI 10.1016/0016-5085(90)90344-Z; FERRY DR, 1985, BRIT J PHARMACOL, V84, P811, DOI 10.1111/j.1476-5381.1985.tb17375.x; FORD JM, 1990, PHARMACOL REV, V42, P155; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOLDSTEIN LJ, 1992, CRIT REV ONCOL HEMAT, V12, P243, DOI 10.1016/1040-8428(92)90057-W; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HORIO M, 1989, J BIOL CHEM, V264, P14880; HORIO M, 1990, BIOCHIM BIOPHYS ACTA, V1027, P116, DOI 10.1016/0005-2736(90)90074-X; HORIO M, 1991, BIOCHIM BIOPHYS ACTA, V1061, P106, DOI 10.1016/0005-2736(91)90274-C; HUET S, 1988, INT J CANCER, V41, P283, DOI 10.1002/ijc.2910410220; HUNTER J, 1991, BRIT J CANCER, V64, P437, DOI 10.1038/bjc.1991.328; HUNTER J, 1991, BIOCHEM BIOPH RES CO, V181, P671, DOI 10.1016/0006-291X(91)91243-6; HUNTER J, 1992, J PHYSIOL-LONDON, V446, pP32; MEYERS MB, 1991, CANCER COMMUN, V3, P159, DOI 10.3727/095535491820873335; MORRIS DI, 1991, BIOCHEMISTRY-US, V30, P8371, DOI 10.1021/bi00098a014; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; PEARSON JW, 1991, J NATL CANCER I, V83, P1386, DOI 10.1093/jnci/83.19.1386; PETERS WHM, 1992, CANCER RES, V52, P1886; PLUMB JA, 1990, BIOCHEM PHARMACOL, V39, P787, DOI 10.1016/0006-2952(90)90160-M; RILEY SA, 1991, BIOCHIM BIOPHYS ACTA, V1066, P175, DOI 10.1016/0005-2736(91)90184-A; RINGEL I, 1991, J NATL CANCER I, V83, P288, DOI 10.1093/jnci/83.4.288; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; SUGAWARA I, 1988, CANCER RES, V48, P1926; TATSUTA T, 1992, J BIOL CHEM, V267, P20383; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; THWAITES DT, 1993, J BIOL CHEM, V268, P7640; TREZISE AEO, 1992, EMBO J, V11, P4291, DOI 10.1002/j.1460-2075.1992.tb05528.x; WEINSTEIN RS, 1991, CANCER RES, V51, P2720; WOODCOCK S, 1991, J CELL SCI, V98, P323	39	338	347	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14991	14997						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8100817				2022-12-27	WOS:A1993LL75900068
J	CHAMULITRAT, W; JORDAN, SJ; MASON, RP; SAITO, K; CUTLER, RG				CHAMULITRAT, W; JORDAN, SJ; MASON, RP; SAITO, K; CUTLER, RG			NITRIC-OXIDE FORMATION DURING LIGHT-INDUCED DECOMPOSITION OF PHENYL N-TERT-BUTYLNITRONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN RESONANCE; BUTYL-ALPHA-PHENYLNITRONE; SOLUBLE GUANYLATE-CYCLASE; HYDROXYL RADICAL ADDUCT; AQUEOUS-SOLUTIONS; L-ARGININE; TRANSDUCTION MECHANISM; OXIDATIVE DAMAGE; TRAPPING AGENTS; ENZYME-ACTIVITY	Phenyl N-tert-butylnitrone (PBN) is a spin trap commonly employed in free radical research. PBN has been shown to have adverse and beneficial effects on various biological systems. We report here evidence that photolysis (or even ambient light) decomposes PBN to nitric oxide in aqueous solutions. Non-heme and heme proteins have been employed to form nitrosyl complexes, which were detected using EPR spectroscopy. Concomitantly, nitrite formation was detected after light-induced decomposition of PBN. In addition, we found that tert-nitrosobutane and decomposed PBN caused an activation of guanylate cyclase. We propose a mechanism where PBN is decomposed by light to tert-nitrosobutane. The latter compound is, in turn, decomposed to nitric oxide. This study suggests the possibility that PBN or PBN radical adducts may be sources of nitric oxide in biological environments. When using PBN as a spin trap in biological samples, not only is the trapping of reactive free radicals operative, but nitric oxide produced from PBN decomposition may play an important role in altering biological functions.	NIA,GERONTOL RES CTR,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	CHAMULITRAT, W (corresponding author), NIEHS,MOLEC BIOPHYS LAB,POB 12233,RES TRIANGLE PK,NC 27709, USA.		Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109				BLASIG IE, 1991, OXIDATIVE DAMAGE & REPAIR, P421; BOUCHER JL, 1992, BIOCHEM BIOPH RES CO, V184, P1158, DOI 10.1016/S0006-291X(05)80004-X; BOWMAN DF, 1971, J AM CHEM SOC, V93, P6551, DOI 10.1021/ja00753a037; BRADAMANTE S, 1992, J MOL CELL CARDIOL, V24, P375, DOI 10.1016/0022-2828(92)93192-M; BRITIGAN BE, 1990, J BIOL CHEM, V265, P17533; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; CARNEY JM, 1991, J MOL NEUROSCI, V3, P47, DOI 10.1007/BF02896848; CHAMULITRAT W, 1985, J PHYS CHEM-US, V89, P4989, DOI 10.1021/j100269a021; CHARLON V, 1988, BASIC RES CARDIOL, V83, P306, DOI 10.1007/BF01907364; DOCAMPO R, 1981, J BIOL CHEM, V256, P930; Garbers D L, 1979, Adv Cyclic Nucleotide Res, V10, P57; HEARSE DJ, 1987, CIRC RES, V60, P375, DOI 10.1161/01.RES.60.3.375; HENRY Y, 1991, EUR BIOPHYS J, V20, P1; HILLE R, 1979, J BIOL CHEM, V254, P2110; HINOJOSA O, 1989, PHOTOCHEM PHOTOBIOL, V49, P1, DOI 10.1111/j.1751-1097.1989.tb04069.x; IGNARRO LJ, 1990, HYPERTENSION, V16, P477, DOI 10.1161/01.HYP.16.5.477; IGNARRO LJ, 1989, SEMIN HEMATOL, V26, P63; JANZEN EG, 1978, J AM CHEM SOC, V100, P2923, DOI 10.1021/ja00477a075; JANZEN EG, 1990, FREE RADICAL RES COM, V9, P325, DOI 10.3109/10715769009145691; JANZEN EG, 1990, FREE RADICAL RES COM, V9, P353, DOI 10.3109/10715769009145694; KALYANARAMAN B, 1991, FEBS LETT, V280, P17, DOI 10.1016/0014-5793(91)80194-8; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; KON H, 1975, BIOCHIM BIOPHYS ACTA, V379, P103, DOI 10.1016/0005-2795(75)90012-4; KONOREV EA, 1993, FREE RADICAL BIO MED, V14, P127, DOI 10.1016/0891-5849(93)90003-D; KOTAKE Y, 1991, J AM CHEM SOC, V113, P9503, DOI 10.1021/ja00025a013; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LAROFF GP, 1972, J AM CHEM SOC, V94, P9062, DOI 10.1021/ja00781a013; LI ASW, 1988, J MAGN RESON, V79, P140, DOI 10.1016/0022-2364(88)90329-0; LION Y, 1982, J PHOTOCHEM, V20, P169, DOI 10.1016/0047-2670(82)85032-6; LOURO SRW, 1981, BIOCHIM BIOPHYS ACTA, V670, P56, DOI 10.1016/0005-2795(81)90048-9; MAKINO K, 1981, RADIAT RES, V86, P294, DOI 10.2307/3575507; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MASON RP, 1985, J INORG BIOCHEM, V24, P161, DOI 10.1016/0162-0134(85)80008-8; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MONTI E, 1991, FREE RADICAL RES COM, V14, P41, DOI 10.3109/10715769109088940; MORENO SNJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P267, DOI 10.1016/0003-9861(88)90127-0; NOVELLI GP, 1990, FREE RADICAL BIO MED, V8, P9, DOI 10.1016/0891-5849(90)90138-9; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; OKEEFFE DH, 1978, J BIOL CHEM, V253, P3509; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; PHILLIS JW, 1990, NEUROSCI LETT, V116, P315, DOI 10.1016/0304-3940(90)90093-O; SARGENT FP, 1976, CAN J CHEM, V54, P275, DOI 10.1139/v76-041; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; VANIN AF, 1975, STUD BIOPHYS, V49, P13; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WOOLUM JC, 1968, BIOCHIM BIOPHYS ACTA, V160, P311, DOI 10.1016/0005-2795(68)90204-3; Ziegler DM., 1980, ENZYMATIC BASIS DETO, VI, P201	47	70	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11520	11527						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8099352				2022-12-27	WOS:A1993LF28400013
J	LUO, GX; HOROWITZ, PM				LUO, GX; HOROWITZ, PM			THE FOLDING AND STABILITY OF RHODANESE ARE INFLUENCED BY THE REPLACEMENT OF GLUTAMIC-ACID 17 IN THE NH2-TERMINAL HELIX BY PROLINE BUT NOT BY GLUTAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME RHODANESE; INTERMEDIATE(S); DENATURATION; MUTAGENESIS; PROTEINS; COMPLEX	Two site-directed mutants of the enzyme rhodanese which replace glutamic acid 17 with either glutamine (E17Q) or with proline (E17P) were produced and purified. Both mutants displayed specific activities similar to the wild type enzyme. E17Q was equivalent to the wild type enzyme in all assayed characteristics, except that the mutant had slightly more solvent exposure of hydrophobic surfaces. Results with E17Q suggest that the charge on Glu17 is not required for helix stabilization, nor is its titration required for the low pH structural transitions seen previously. In contrast, E17P was significantly different from the wild type enzyme. For example, E17P had (a) higher exposure of hydrophobic surfaces in the unperturbed state; (b) considerably lower stability to perturbation by urea; (c) easier exposure of organized hydrophobic surfaces on initial unfolding, even though denaturation to the final disorganized state was the same as for the wild type; (d) the ability to refold without assistants but with lower yields and somewhat slower folding; and (e) similar susceptibility to trypsin and evidence of a new clip site closer to the NH2 terminus. However, E17P and the wild type enzyme had very similar recoveries with chaperonin-assisted refolding, and the chaperonin protein groEL had a very similar ability to suppress unassisted refolding. These results indicate that changes in the NH2-terminal sequence can have dramatic effects on the stability of rhodanese and on its ability to be refolded in the absence of assistants. They further suggest that interactions with chaperonins do not rely exclusively on the detailed conformation at the NH2 terminus. A model that incorporates observations here includes step(s) in which the NH2-terminal sequence folds onto the NH2-terminal domain late in the folding process after the protein has adopted a near native conformation.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atkinson T., 1984, OLIGONUCLEOTIDE SYNT, P35; BANKIER AT, 1983, TECHNIQUES NUCLEIC B, V5, P1; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; CHOW SF, 1986, J BIOL CHEM, V261, P7264; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HOL WGJ, 1987, BIOL MACROMOL, V3, P483; HOROWITZ PM, 1988, J BIOL CHEM, V263, P10278; HOROWITZ PM, 1986, J BIOL CHEM, V261, P13887; HOROWITZ PM, 1993, J BIOL CHEM, V268, P2500; HOROWITZ PM, 1992, J BIOL CHEM, V267, P19464; HOROWITZ PM, 1990, J BIOL CHEM, V265, P2576; HOROWITZ PM, 1991, CONFORMATION FORCES, P185; HOROWITZ PM, 1992, IN PRESS PROTEIN FOL; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY SJ, 1991, TRENDS BIOCHEM SCI, V16, P159, DOI 10.1016/0968-0004(91)90060-9; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; MAXFIELD FR, 1975, MACROMOLECULES, V8, P491, DOI 10.1021/ma60046a022; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1992, J BIOL CHEM, V267, P24648; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MILLER DM, 1992, BIOCHIM BIOPHYS ACTA, V1121, P286, DOI 10.1016/0167-4838(92)90158-A; MILLER DM, 1991, J BIOL CHEM, V266, P4686; NISBET IT, 1985, GENE ANAL TECH, V2, P23, DOI 10.1016/0735-0651(85)90001-9; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; Ploegman J.H., 1978, NATURE, V273, P1245; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; STELLWAGEN E, 1979, J MOL BIOL, V135, P217, DOI 10.1016/0022-2836(79)90348-6; TANDON S, 1989, J BIOL CHEM, V264, P9859; TANDON S, 1986, J BIOL CHEM, V261, P5615; TANDON S, 1990, J BIOL CHEM, V265, P5967; ZARDENETA G, 1992, J BIOL CHEM, V267, P5811; ZARDENETA G, 1992, EUR J BIOCHEM, V210, P831, DOI 10.1111/j.1432-1033.1992.tb17486.x	34	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10246	10251						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8098037				2022-12-27	WOS:A1993LB80000045
J	SAMUEL, CE				SAMUEL, CE			THE EIF-2-ALPHA PROTEIN-KINASES, REGULATORS OF TRANSLATION IN EUKARYOTES FROM YEASTS TO HUMANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-II; TRANSFER RNA-SYNTHETASES; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; ALPHA-SUBUNIT; FUNCTIONAL EXPRESSION; ANTIVIRAL ACTION; GCN4 EXPRESSION; INTERFERON; IDENTIFICATION		UNIV CALIF SANTA BARBARA, GRAD PROGRAM BIOCHEM & MOLEC BIOL, SANTA BARBARA, CA 93106 USA	University of California System; University of California Santa Barbara	SAMUEL, CE (corresponding author), UNIV CALIF SANTA BARBARA, DEPT BIOL SCI, DIV MOLEC & CELLULAR BIOL, SANTA BARBARA, CA 93106 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012520, R37AI012520, R01AI020611] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20611, AI-12520] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; BARBER GN, 1991, BIOCHEMISTRY-US, V30, P10356, DOI 10.1021/bi00106a038; BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P315, DOI 10.1073/pnas.88.2.315; CHEN JJ, 1989, J BIOL CHEM, V264, P9559; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHOI SY, 1992, J BIOL CHEM, V267, P286; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DOOHAN JP, 1992, VIROLOGY, V186, P409, DOI 10.1016/0042-6822(92)90006-B; ERNST H, 1987, J BIOL CHEM, V262, P1206; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; ICELY PL, 1991, J BIOL CHEM, V266, P16073; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KATZE MG, 1992, J INTERFERON RES, V12, P241, DOI 10.1089/jir.1992.12.241; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KITAJEWSKI J, 1986, CELL, V45, P195, DOI 10.1016/0092-8674(86)90383-1; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LANGLAND JO, 1992, J BIOL CHEM, V267, P10729; LANKER S, 1992, CELL, V70, P647, DOI 10.1016/0092-8674(92)90433-D; LONDON IM, 1987, ENZYMES, V18, P359; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MENDEZ R, 1992, J BIOL CHEM, V267, P11500; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; PAL JK, 1991, BIOCHEMISTRY-US, V30, P2555, DOI 10.1021/bi00223a037; PATEL RC, 1992, J BIOL CHEM, V267, P7671; PATEL RC, 1992, J INTERFERON RES, V12, P389, DOI 10.1089/jir.1992.12.389; PATHAK VK, 1988, MOL CELL BIOL, V8, P993, DOI 10.1128/MCB.8.2.993; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PROUD CG, 1991, EUR J BIOCHEM, V195, P771, DOI 10.1111/j.1432-1033.1991.tb15765.x; RAMIREZ M, 1992, MOL CELL BIOL, V12, P5801, DOI 10.1128/MCB.12.12.5801; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RICE AP, 1989, J BIOL CHEM, V264, P20632; ROUSSOU I, 1988, MOL CELL BIOL, V8, P2132, DOI 10.1128/MCB.8.5.2132; SAMUEL CE, 1982, J INTERFERON RES, V2, P441, DOI 10.1089/jir.1982.2.441; SAMUEL CE, 1990, VIROLOGY, V176, P106, DOI 10.1016/0042-6822(90)90235-J; SAMUEL CE, 1988, PROG NUCLEIC ACID RE, V35, P27, DOI 10.1016/S0079-6603(08)60609-1; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SAMUEL CE, 1992, PHARMACOL THERAPEUT, V54, P307, DOI 10.1016/0163-7258(92)90005-K; SAMUEL CE, 1986, METHOD ENZYMOL, V119, P499; SCHWEMMLE M, 1992, P NATL ACAD SCI USA, V89, P10292, DOI 10.1073/pnas.89.21.10292; SEN GC, 1992, J BIOL CHEM, V267, P5017; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; SZYSZKA R, 1989, J BIOL CHEM, V264, P3827; THOMIS DC, 1992, P NATL ACAD SCI USA, V89, P10837, DOI 10.1073/pnas.89.22.10837; THOMIS DC, 1992, VIROLOGY, V188, P33, DOI 10.1016/0042-6822(92)90732-5; TZAMARIAS D, 1988, EMBO J, V7, P3547, DOI 10.1002/j.1460-2075.1988.tb03231.x; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WEK RC, 1990, MOL CELL BIOL, V10, P2820, DOI 10.1128/MCB.10.6.2820; YANG JM, 1992, J BIOL CHEM, V267, P20519	66	365	382	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7603	7606						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8096514				2022-12-27	WOS:A1993KW97900001
J	NISHI, K; YOSHIDA, M; FUJIWARA, D; NISHIKAWA, M; HORINOUCHI, S; BEPPU, T				NISHI, K; YOSHIDA, M; FUJIWARA, D; NISHIKAWA, M; HORINOUCHI, S; BEPPU, T			LEPTOMYCIN-B TARGETS A REGULATORY CASCADE OF CRM1, A FISSION YEAST NUCLEAR-PROTEIN, INVOLVED IN CONTROL OF HIGHER-ORDER CHROMOSOME STRUCTURE AND GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-FUNGAL ANTIBIOTICS; SCHIZOSACCHAROMYCES-POMBE; CELL-CYCLE; ANTITUMOR-ACTIVITY; TRICHOSTATIN-A; KAZUSAMYCIN; FIBROBLASTS; INHIBITION; CHROMATIN; EXPOSURE	The molecular action of leptomycin B (LMB), an agent inducing arrest of the eukaryotic cell cycle at G1 and G2 phases, was investigated by analyzing an LMB resistance gene of Schizosaccharomyces pombe. A genomic library of ah LMB-resistant mutant was screened for LMB resistance, and a DNA fragment containing an open reading frame (ORF) of 1078 amino acids was cloned on a multicopy vector. The plasmid was found to confer drug resistance specifically to LMB. Nucleotide sequencing revealed that the ORF was a mutant gene for the essential nuclear protein crm1, which had been reported to complement a cold-sensitive mutation causing deformed nuclear morphology. The gene product named crm1-N1 had two amino acid replacements (Gly-503 to Asp and Met-546 to Ile). Two allelic mutants of crm1 (crm1-809 and crm1-119) were found to be hypersensitive and resistant, respectively, to LMB. Nuclear morphology of the cold-sensitive crm1-809 mutant at the restrictive temperature was almost the same as that of the wild-type cells treated with LMB. Furthermore, a low concentration of LMB induced the intracellular accumulation of a 25-kDa protein in the wild-type cells, which was immunologically identical to the protein accumulating in the crm1-809 mutant cells. These results strongly suggest that LMB primarily inhibits the function of the crm1 gene which is required for maintaining higher order chromosome structures, correct gene expression, and cell growth in the fission yeast.	UNIV TOKYO, FAC AGR, DEPT AGR CHEM, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, BIOTECHNOL RES CTR, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo; University of Tokyo			Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674				ABE K, 1993, J ANTIBIOT, V46, P728, DOI 10.7164/antibiotics.46.728; ABE K, 1993, J ANTIBIOT, V46, P735, DOI 10.7164/antibiotics.46.735; ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; BEACH D, 1982, MOL GEN GENET, V187, P326, DOI 10.1007/BF00331138; CRISSMAN HA, 1988, CANCER RES, V48, P5742; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; Gutz H., 1974, HDB GENETICS, V1, P395; HAMAMOTO T, 1983, J ANTIBIOT, V36, P639, DOI 10.7164/antibiotics.36.639; HAMAMOTO T, 1983, J ANTIBIOT, V36, P646, DOI 10.7164/antibiotics.36.646; HAMAMOTO T, 1985, J ANTIBIOT, V38, P1573, DOI 10.7164/antibiotics.38.1573; HAYAKAWA Y, 1987, J ANTIBIOT, V40, P1349, DOI 10.7164/antibiotics.40.1349; ISHIDA R, 1991, CANCER RES, V51, P4909; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KOMIYAMA K, 1985, J ANTIBIOT, V38, P220, DOI 10.7164/antibiotics.38.220; KOMIYAMA K, 1985, J ANTIBIOT, V38, P427, DOI 10.7164/antibiotics.38.427; KOMIYAMA K, 1985, J ANTIBIOT, V38, P224, DOI 10.7164/antibiotics.38.224; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKS KW, 1990, CANCER RES, V50, P4776; LARNO S, 1984, J CELL PHYSIOL, V120, P384, DOI 10.1002/jcp.1041200317; Maniatis T., 1982, MOL CLONING LABORATO; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NISHI K, 1992, MOL MICROBIOL, V6, P761, DOI 10.1111/j.1365-2958.1992.tb01526.x; REEVES R, 1984, BIOCHIM BIOPHYS ACTA, V782, P343, DOI 10.1016/0167-4781(84)90044-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI H, 1992, RADIAT RES, V129, P163, DOI 10.2307/3578153; TODA T, 1981, J CELL SCI, V52, P271; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X	32	394	402	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6320	6324						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119981				2022-12-27	WOS:A1994MZ50300013
J	ZHOU, J; LEINONEN, A; TRYGGVASON, K				ZHOU, J; LEINONEN, A; TRYGGVASON, K			STRUCTURE OF THE HUMAN TYPE-IV COLLAGEN COL4A5 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED ALPORT SYNDROME; SINGLE-BASE MUTATION; LONG ARM; ALPHA-2(IV) CHAINS; X-CHROMOSOME; IDENTIFICATION; ALPHA-5(IV); MEMBRANE; ALPHA-1(IV); DNA	The complete exon size and distribution pattern of the human alpha 5(IV) collagen gene COL4A5 has been determined. Seventeen genomic lambda phage clones, eight of which have been described previously (Zhou, J., Hostikka, S. L., Chow, L. T., and Tryggvason, K. (1991) Genomics 9, 1-9), spanning about 160 kilobases of DNA contained 140 kilobases of the gene itself. The clones covered the entire gene with the exception of exons 2 and 37 and their flanking regions so that the exact gene size could not be determined. The sequences of these two exons were, however, determined from polymerase chain reaction products. The COL4A5 gene has a structure highly homologous with that of COL4A5 which encodes the alpha 1(IV) chain, However, the COL4A5 gene contains 51 exons, or one less than COL4A1. The exon size pattern of the genes are similar, with 41 exons having identical sizes. Ah the exons were assigned to distinct EcoRI restriction fragments. The results may be useful for characterization of mutations in COL4A5 in patients with X chromosome-linked Alport syndrome.	UNIV OULU,BIOCTR,SF-90570 OULU,FINLAND; UNIV OULU,DEPT BIOCHEM,SF-90570 OULU,FINLAND	University of Oulu; Finland National Institute for Health & Welfare; University of Oulu								ANTIGNAC C, 1992, KIDNEY INT, V42, P1178, DOI 10.1038/ki.1992.402; ATKIN CL, 1988, AM J HUM GENET, V42, P249; BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BOEDTKER H, 1985, ANN NY ACAD SCI, V460, P85, DOI 10.1111/j.1749-6632.1985.tb51159.x; BOYD CD, 1986, HUM GENET, V74, P121, DOI 10.1007/BF00282074; BOYE E, 1991, GENOMICS, V11, P1125, DOI 10.1016/0888-7543(91)90040-L; CHU ML, 1984, NATURE, V310, P337, DOI 10.1038/310337a0; CUTTING GR, 1988, GENOMICS, V3, P256, DOI 10.1016/0888-7543(88)90086-9; FLINTER FA, 1988, LANCET, V2, P1005, DOI 10.1016/S0140-6736(88)90753-2; GRIFFIN CA, 1987, P NATL ACAD SCI USA, V84, P512, DOI 10.1073/pnas.84.2.512; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; HOSTIKKA SL, 1987, FEBS LETT, V224, P297, DOI 10.1016/0014-5793(87)80473-8; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; KLEPPEL M, 1987, J CLIN INVEST, V89, P263; KNEBELMANN B, 1992, AM J HUM GENET, V51, P135; Maniatis T, 1989, DECONTAMINATION DILU; MARIYAMA M, 1992, GENOMICS, V13, P809, DOI 10.1016/0888-7543(92)90157-N; MORRISON KE, 1991, AM J HUM GENET, V49, P545; NETZER KO, 1993, KIDNEY INT, V43, P486, DOI 10.1038/ki.1993.71; NETZER KO, 1992, KIDNEY INT, V42, P1336, DOI 10.1038/ki.1992.425; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P13758; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; RENIERI A, 1992, HUM GENET, V89, P120, DOI 10.1007/BF00207059; Renieri Alessandra, 1992, Human Molecular Genetics, V1, P127, DOI 10.1093/hmg/1.2.127; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUS J, 1988, J BIOL CHEM, V263, P13374; SMEETS HJM, 1992, KIDNEY INT, V42, P83, DOI 10.1038/ki.1992.264; SOININEN R, 1988, J BIOL CHEM, V263, P17217; SOININEN R, 1989, J BIOL CHEM, V264, P13565; SOININEN R, 1987, FEBS LETT, V225, P188; Spear G S, 1973, Clin Nephrol, V1, P336; TIKKA L, 1991, J BIOL CHEM, V266, P17713; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TRYGGVASON K, 1993, KIDNEY INT, V43, P38, DOI 10.1038/ki.1993.8; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449; ZHOU J, 1992, AM J HUM GENET, V50, P1291; ZHOU J, 1991, GENOMICS, V9, P10, DOI 10.1016/0888-7543(91)90215-Z; ZHOU J, 1993, KIDNEY INT, V43, P722, DOI 10.1038/ki.1993.103; ZHOU J, 1992, J BIOL CHEM, V267, P12475; ZHOU J, 1991, GENOMICS, V9, P1, DOI 10.1016/0888-7543(91)90214-Y; [No title captured]	42	68	88	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6608	6614						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120014				2022-12-27	WOS:A1994MZ50300055
J	WAGNER, F; GIMONA, M; AHORN, H; PESCHEK, GA; FALKNER, G				WAGNER, F; GIMONA, M; AHORN, H; PESCHEK, GA; FALKNER, G			ISOLATION AND FUNCTIONAL RECONSTITUTION OF A PHOSPHATE-BINDING PROTEIN OF THE CYANOBACTERIUM ANACYSTIS-NIDULANS INDUCED DURING PHOSPHATE-LIMITED GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSPORT PROTEIN	Adaptation of the blue-green algae Anacystis nidulans to phosphate-deficient growth leads to the expression of two membrane proteins, which appear as major constituents after separation by gel electrophoresis. One of these proteins, referred to as high affinity phosphate binding protein, has been isolated and its function reconstituted in liposomes. Partial sequencing showed no significant homologies to other proteins. The binding capacity of the proteoliposomes could be inhibited by arsenate but not by sulfhydryl reagents. Scatchard plot analyses of phosphate binding to reconstituted proteoliposomes suggested the existence of two different binding sites, one with a dissociation constant below micromolar and the other in the micromolar range.	AUSTRIAN ACAD SCI, INST MOLEC BIOL, A-5020 SALZBURG, AUSTRIA; UNIV VIENNA, INST PHYS CHEM, A-1090 VIENNA, AUSTRIA; BENDER & CO, A-1120 VIENNA, AUSTRIA	Austrian Academy of Sciences; University of Vienna								BAUW G, 1987, P NATL ACAD SCI USA, V84, P4806, DOI 10.1073/pnas.84.14.4806; FALKNER G, 1989, ARCH MICROBIOL, V152, P353, DOI 10.1007/BF00425173; Helenius A, 1979, Methods Enzymol, V56, P734; KRATZ WA, 1955, AM J BOT, V42, P282, DOI 10.2307/2438564; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MATSUDAIRA PT, 1978, ANAL BIOCHEM, V87, P386, DOI 10.1016/0003-2697(78)90688-7; MEDVECZKY N, 1970, BIOCHIM BIOPHYS ACTA, V211, P158, DOI 10.1016/0005-2736(70)90090-8; MOLITOR V, 1987, CURR MICROBIOL, V14, P263, DOI 10.1007/BF01568134; PLANAS D, 1978, J PHYCOL, V14, P337, DOI 10.1111/j.1529-8817.1978.tb00309.x; RIGLER FH, 1956, ECOLOGY, V37, P550, DOI 10.2307/1930179; Rosenberg H., 1987, ION TRANSPORT PROKAR, P205; SATO N, 1988, METHOD ENZYMOL, V167, P251; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SILVER S, 1992, MICROBIOL REV, V56, P195, DOI 10.1128/MMBR.56.1.195-228.1992; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; VANDEKERCKHOVE J, 1987, METHODS PROTEIN SEQU, P261; WAGNER F, 1992, J PLANT PHYSIOL, V140, P163, DOI 10.1016/S0176-1617(11)80928-4; WEIDEMAN.MJ, 1970, EUR J BIOCHEM, V16, P313, DOI 10.1111/j.1432-1033.1970.tb01086.x; WOHLRAB H, 1980, J BIOL CHEM, V255, P8170; ZIERLER K, 1989, TRENDS BIOCHEM SCI, V14, P314, DOI 10.1016/0968-0004(89)90157-6	21	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5509	5511						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119882				2022-12-27	WOS:A1994MY84000008
J	KIVIRIKKO, S; HEINAMAKI, P; REHN, M; HONKANEN, N; MYERS, JC; PIHLAJANIEMI, T				KIVIRIKKO, S; HEINAMAKI, P; REHN, M; HONKANEN, N; MYERS, JC; PIHLAJANIEMI, T			PRIMARY STRUCTURE OF THE ALPHA-1 CHAIN OF HUMAN TYPE-XV COLLAGEN AND EXON-INTRON ORGANIZATION IN THE 3(') REGION OF THE CORRESPONDING GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITES; PROTEINS	Types XV and XVIII collagens form a new subgroup within the diverse family of collagens, both being characterized by extensive interruptions in their collagenous sequences. We isolated human alpha 1(XV) chain cDNAs that extend beyond the sequences previously derived from a 2127-nucleotide clone. The cDNAs cover 5172 nucleotides of the 5300-4400 nucleotide mRNAs and encode a polypeptide of 1388 residues, including a 25-residue signal peptide, a 530-residue NH2-terminal noncollagenous domain (NCI), a 577-residue collagenous sequence with eight interruptions of 7-45 residues, and a 256-residue COOH-terminal noncollagenous domain (NC10). A thrombospondin sequence motif found previously in certain other collagen types was identified in the NC1 domain of type XV collagen, whereas the NC10 domain was characterized by the presence of four cysteine residues. The exon-intron organization of the human gene was determined, corresponding to the extreme COOH-terminal 2/3 + 275 residues. NC10 is encoded by seven exons, six of which encode solely protein sequences and vary in size between 60 and 186 base pairs, whereas the last one corresponds to the end of the polypeptide and the 3'-untranslated sequences. The extreme 5' exon analyzed was a junction exon encoding both collagenous and noncollagenous sequences. This initial characterization is indicative of a multiexon arrangement for the alpha 1(XV) gene.	UNIV OULU,DEPT MED BIOCHEM,SF-90220 OULU,FINLAND; UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; UNIV OULU,BIOCTR OULU,COLLAGEN RES UNIT,SF-90220 OULU,FINLAND	University of Oulu; University of Pennsylvania; University of Oulu				Pihlajaniemi, Taina/0000-0002-1664-9045	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR020553] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 20553] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS J, 1993, CURR BIOL, V3, P188, DOI 10.1016/0960-9822(93)90270-X; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APTE SS, 1993, MATRIX, V13, P165, DOI 10.1016/S0934-8832(11)80075-2; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BORK P, 1992, FEBS LETT, V307, P49, DOI 10.1016/0014-5793(92)80900-2; BRUCKNER P, 1985, P NATL ACAD SCI USA, V82, P2608, DOI 10.1073/pnas.82.9.2608; BUTTICE G, 1990, J MOL EVOL, V30, P479, DOI 10.1007/BF02101102; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELIMA K, 1993, BIOCHEM J, V289, P247, DOI 10.1042/bj2890247; HUEBNER K, 1992, GENOMICS, V14, P220, DOI 10.1016/S0888-7543(05)80209-5; KERE J, 1992, GENOMICS, V14, P241, DOI 10.1016/S0888-7543(05)80212-5; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KOZAK M, 1991, J BIOL CHEM, V266, P19867; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCCORMICK D, 1987, P NATL ACAD SCI USA, V84, P4044, DOI 10.1073/pnas.84.12.4044; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MYERS JC, 1992, P NATL ACAD SCI USA, V89, P10144, DOI 10.1073/pnas.89.21.10144; MYERS JC, 1993, GENE, V123, P211, DOI 10.1016/0378-1119(93)90126-N; NAEME PJ, 1990, J BIOL CHEM, V265, P20401; OH PS, 1994, IN PRESS P NATL ACAD; PAN TC, 1992, P NATL ACAD SCI USA, V89, P6565, DOI 10.1073/pnas.89.14.6565; PIHLAJANIEMI T, 1987, METHOD ENZYMOL, V145, P213; REHN M, 1994, IN PRESS P NATL ACAD; Sambrook J, 1989, MOL CLONING LABORATO; SANDELL LJ, 1990, EXTRACELLULAR MATRIX, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALCHLI C, 1993, EUR J BIOCHEM, V212, P483, DOI 10.1111/j.1432-1033.1993.tb17685.x; WATT SL, 1992, J BIOL CHEM, V267, P20093; YAMAGUCHI N, 1991, J BIOL CHEM, V266, P4508; YOSHIOKA H, 1992, GENOMICS, V13, P884, DOI 10.1016/0888-7543(92)90176-S; ZHIDKOVA NI, 1993, FEBS LETT, V326, P25, DOI 10.1016/0014-5793(93)81753-M	33	49	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4773	4779						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106446				2022-12-27	WOS:A1994MX57100015
J	LOCATI, M; ZHOU, D; LUINI, W; EVANGELISTA, V; MANTOVANI, A; SOZZANI, S				LOCATI, M; ZHOU, D; LUINI, W; EVANGELISTA, V; MANTOVANI, A; SOZZANI, S			RAPID INDUCTION OF ARACHIDONIC-ACID RELEASE BY MONOCYTE CHEMOTACTIC PROTEIN-1 AND RELATED CHEMOKINES - ROLE OF CA2+ INFLUX, SYNERGISM WITH PLATELET-ACTIVATING-FACTOR AND SIGNIFICANCE FOR CHEMOTAXIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ENDOTHELIAL-CELLS; PHOSPHOLIPASE-A2 ACTIVATION; VENOM PHOSPHOLIPASE-A2; INTRACELLULAR CALCIUM; POTASSIUM CHANNELS; CYTOKINE FAMILY; FATTY-ACIDS; KINASE-C; MEMBRANE	Monocyte Chemotactic Protein-1 (MCP-1), a member of the Cys-Cys branch of the chemokine superfamily, induced a mepacrine- and manoalide-sensitive increase in the release of [H-3]arachidonic acid from prelabeled human monocytes and monocytic THP-1 leukemic cells. The effect was rapid (<30 s), reached maximum at optimal chemotactic concentrations, and was completely blocked by pretreatment of monocytes with Bordetella pertussis toxin. A specific antiserum and heat inactivation blocked the induction of arachidonic release by MCP-1. No [H-3]arachidonic acid release was observed in the absence of Ca2+ influx (5 mM EGTA or 5 mM Ni2+) or in monocytes loaded with a Ca2+-buffering agent. However, using ionophore-permeabilized monocytes and controlled intracellular Ca2+ concentration it was possible to dissociate MCP-1-induced Ca2+ influx from [H-3]arachidonic acid release. Thus, the MCP-1-induced increase in [Ca2+](i) is necessary but not sufficient for arachidonic acid accumulation. Phospholipase A(2) inhibitors (mepacrine, p-bromophenacyl bromide, and manoalide) blocked monocyte polarization and chemotaxis induced by MCP-1. The related Cys-Cys chemokines RANTES and LD78/MIP1(alpha) also induced a rapid release of [H-3]arachidonic acid, and their chemotactic activity was blocked by phospholipase A(2) inhibitors. Brief (5 min) pretreatment of monocytes with platelet-activating factor amplified MCP-1-induced arachidonic acid release and, at MCP-1 suboptimal concentrations, synergized in inducing monocyte migration. Since MCP-1 and platelet-activating factor are induced concomitantly by inflammatory cytokines in monocytes and endothelial cells, we speculate that the observed synergism may have in vivo relevance, The results presented here show that the Cgs-Cys chemokines MCP-1, LD78/MIP1(alpha), and RANTES cause rapid release of arachidonic acid in monocytes and that this may be important in inducing monocyte chemotaxis.	IST RIC FARMACOL MARIO NEGRI,I-20157 MILAN,ITALY; IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,I-66030 SANTA MARIA IMBAR,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS			Locati, Massimo/H-8404-2015; Locati, Massimo/ABF-6807-2021; Sozzani, Silvano/C-1447-2009; Mantovani, Alberto/HCI-7449-2022	Locati, Massimo/0000-0003-3077-590X; Sozzani, Silvano/0000-0002-3144-8743; Mantovani, Alberto/0000-0001-5578-236X				ADEREM AA, 1986, J EXP MED, V163, P139, DOI 10.1084/jem.163.1.139; AEPFELBACHER M, 1992, J IMMUNOL, V148, P2186; ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BALSINDE J, 1990, J IMMUNOL, V144, P4298; BATES EJ, 1993, J LEUKOCYTE BIOL, V53, P420, DOI 10.1002/jlb.53.4.420; BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; BROOKS RC, 1989, J BIOL CHEM, V264, P20147; BUSSOLINO F, 1986, J CLIN INVEST, V77, P2027, DOI 10.1172/JCI112532; COLOTTA F, 1984, J IMMUNOL, V132, P936; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; DISE CA, 1982, J BIOL CHEM, V257, P4701; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GLASER KB, 1986, BIOCHEM PHARMACOL, V35, P449, DOI 10.1016/0006-2952(86)90218-2; GOLDYNE ME, 1984, J BIOL CHEM, V259, P8815; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALENDA SP, 1987, BIOCHEM J, V248, P471, DOI 10.1042/bj2480471; HIRATA F, 1980, P NATL ACAD SCI-BIOL, V77, P2533, DOI 10.1073/pnas.77.5.2533; HIRATA F, 1979, P NATL ACAD SCI USA, V76, P2640, DOI 10.1073/pnas.76.6.2640; HOFFMAN T, 1991, J IMMUNOL, V146, P692; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; KUIJPERS TW, 1992, J IMMUNOL, V148, P72; KUIJPERS TW, 1991, J IMMUNOL, V147, P1369; KUNA P, 1992, J IMMUNOL, V149, P636; LEFKOWITH JB, 1991, J BIOL CHEM, V266, P1071; LEFKOWITH JB, 1992, J IMMUNOL, V149, P1729; LOMBARDO D, 1985, J BIOL CHEM, V260, P7234; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MANTOVANI A, 1989, IMMUNOL TODAY, V10, P370, DOI 10.1016/0167-5699(89)90270-3; MANTOVANI A, 1992, TODAY, V13, P265; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MCPHAIL LC, 1993, NATURAL IMMUNE SYSTE, P63; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; PAWLOWSKI NA, 1983, J EXP MED, V158, P393, DOI 10.1084/jem.158.2.393; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; REHFELDT W, 1991, BIOCHEM J, V276, P631, DOI 10.1042/bj2760631; ROLLINS BJ, 1991, BLOOD, V78, P1112; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SICA A, 1990, J IMMUNOL, V144, P3034; SOZZANI S, 1993, J IMMUNOL, V150, P1544; SOZZANI S, 1991, J IMMUNOL, V147, P2215; TAKUWA N, 1991, J BIOL CHEM, V266, P14237; VALONE FH, 1988, J IMMUNOL, V141, P3945; VANDAMME J, 1989, EUR J IMMUNOL, V19, P2367; VOLWERK JJ, 1974, BIOCHEMISTRY-US, V13, P1446, DOI 10.1021/bi00704a020; WANG JM, 1986, J IMMUNOL, V137, P2726; WANG JM, 1993, J EXP MED, V177, P699, DOI 10.1084/jem.177.3.699; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068; YORIO T, 1978, NATURE, V271, P79, DOI 10.1038/271079a0; YOSHIMURA T, 1990, J IMMUNOL, V145, P292; ZACHARIAE COC, 1990, J EXP MED, V171, P2177, DOI 10.1084/jem.171.6.2177	56	93	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4746	4753						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106442				2022-12-27	WOS:A1994MX57100011
J	MAY, TB; SHINABARGER, D; BOYD, A; CHAKRABARTY, AM				MAY, TB; SHINABARGER, D; BOYD, A; CHAKRABARTY, AM			IDENTIFICATION OF AMINO-ACID-RESIDUES INVOLVED IN THE ACTIVITY OF PHOSPHOMANNOSE ISOMERASE-GUANOSINE 5'-DIPHOSPHO-D-MANNOSE PYROPHOSPHORYLASE - A BIFUNCTIONAL ENZYME IN THE ALGINATE BIOSYNTHETIC-PATHWAY OF PSEUDOMONAS-AERUGINOSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-GLUCOSE SYNTHETASE; SITE-DIRECTED MUTAGENESIS; INHIBITOR-BINDING SITE(S); RFB GENE-CLUSTER; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; BACTERIAL GLYCOGEN; COVALENT MODIFICATION; CYSTIC-FIBROSIS; STRUCTURAL CHARACTERIZATION	Phosphomannose isomerase-guanosine 5'-diphospho-D-mannose pyrophosphorylase (PMI-GMP), which is encoded by the algA gene, catalyzes two noncontiguous steps in the alginate biosynthetic pathway of Pseudomonas aeruginosa: the isomerization of D-fructose 6-phosphate to D-mannose 6-phosphate and the synthesis of GDP-D-mannose and PPi from GTP and D-mannose 1-phosphate. Amino acids that are required for the GMP enzyme activity were identified through site-directed mutagenesis of the algA gene. Mutation of Lys-175 to arginine, glutamine, or glutamate produced an enzyme whose K-m for D-mannose 1-phosphate was 470-3,200-fold greater than that measured for the wild type enzyme. In addition, these mutant enzymes had a lower V-max for the GMP activity as compared with the wild type PMI-GMP. These results indicate that Lys-175 is primarily involved in the binding of the substrate D-mannose 1-phosphate, although it is likely that other residues are required for the specificity of binding. Mutation of Arg-19 to glutamine, histidine, or leucine resulted in a 2-fold lower V-max for the GMP enzyme activity and a 4-7-fold increase in the K-m for GTP as compared with the wild type enzyme. Thus, it appears that Arg-19 functions in the binding of GTP. In addition, chymotryptic digestion of PMI-GMP showed that the carboxyl terminus is critical for PMI activity but not for GMP activity. Taken together, these results support the hypothesis that the bifunctional PMI-GMP protein is composed of two independent enzymatic domains.	UNIV ILLINOIS,COLL MED,DEPT MICROBIOL & IMMUNOL MC 790,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Boyd, Aoife/A-4775-2011	Boyd, Aoife/0000-0002-4631-9792	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016790, R37AI016790] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-16790-13] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEKER PA, 1983, J BIOL CHEM, V258, P5084; BOYD A, 1993, GENE, V131, P1, DOI 10.1016/0378-1119(93)90662-M; BREDE G, 1991, J BACTERIOL, V173, P7042, DOI 10.1128/jb.173.21.7042-7045.1991; CARLSON CA, 1981, BIOCHEMISTRY-US, V20, P7519, DOI 10.1021/bi00529a029; CARLSON CA, 1982, BIOCHEMISTRY-US, V21, P1929, DOI 10.1021/bi00537a036; CHITNIS CE, 1990, J BACTERIOL, V172, P2894, DOI 10.1128/jb.172.6.2894-2900.1990; CHU L, 1991, GENE, V107, P1, DOI 10.1016/0378-1119(91)90290-R; COLLINS LV, 1991, GENE, V103, P135, DOI 10.1016/0378-1119(91)90406-2; COTTON FA, 1973, J AM CHEM SOC, V95, P2367, DOI 10.1021/ja00788a047; DARZINS A, 1984, J BACTERIOL, V159, P9, DOI 10.1128/JB.159.1.9-18.1984; DARZINS A, 1986, GENE, V42, P293, DOI 10.1016/0378-1119(86)90233-7; DAVIDSON IW, 1977, J GEN MICROBIOL, V98, P603, DOI 10.1099/00221287-98-2-603; DERETIC V, 1987, NUCLEIC ACIDS RES, V15, P4567, DOI 10.1093/nar/15.11.4567; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; EVANS LR, 1973, J BACTERIOL, V116, P915, DOI 10.1128/JB.116.2.915-924.1973; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GARDIOL A, 1990, ARCH BIOCHEM BIOPHYS, V280, P175, DOI 10.1016/0003-9861(90)90533-5; HAUGEN TH, 1979, J BIOL CHEM, V254, P127; HILL MA, 1992, J BIOL CHEM, V266, P12455; JIANG XM, 1991, MOL MICROBIOL, V5, P695, DOI 10.1111/j.1365-2958.1991.tb00741.x; KAZARINOFF MN, 1976, J BIOL CHEM, V251, P6179; KOPLIN R, 1992, J BACTERIOL, V174, P191; KUMAR A, 1988, J BIOL CHEM, V263, P14634; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN CE, 1986, J BIOL CHEM, V261, P5402; LARSEN CE, 1986, BIOCHEMISTRY-US, V25, P4371, DOI 10.1021/bi00363a029; LEE SJ, 1992, J GEN MICROBIOL, V138, P305, DOI 10.1099/00221287-138-2-305; LEE YM, 1986, J BIOL CHEM, V261, P1058; LEUNG PSC, 1987, J BACTERIOL, V169, P4355, DOI 10.1128/jb.169.9.4355-4360.1987; LINKER A, 1966, J BIOL CHEM, V241, P3845; MAHARAJ R, 1993, IN PRESS GENE AMST; MARCUS F, 1975, BIOCHEMISTRY-US, V14, P3916, DOI 10.1021/bi00688a029; MAROLDA CL, 1993, J BACTERIOL, V175, P148, DOI 10.1128/JB.175.1.148-158.1993; MAY TB, 1991, CLIN MICROBIOL REV, V4, P191, DOI 10.1128/CMR.4.2.191-206.1991; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MILES JS, 1984, GENE, V32, P41, DOI 10.1016/0378-1119(84)90030-1; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; PADGETT PJ, 1986, CURR MICROBIOL, V14, P187, DOI 10.1007/BF01568516; PARSONS TF, 1978, J BIOL CHEM, V253, P7638; PIGGOTT NH, 1981, EUR J APPL MICROBIOL, V13, P179, DOI 10.1007/BF00703050; REYNOLDS HY, 1975, ANN INTERN MED, V82, P819, DOI 10.7326/0003-4819-82-6-819; RIORDAN JF, 1977, SCIENCE, V195, P884, DOI 10.1126/science.190679; ROYCHOUDHURY S, 1989, J BIOL CHEM, V264, P9380; RUVKUN GB, 1981, NATURE, V289, P85, DOI 10.1038/289085a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT M, 1992, GENE, V122, P35, DOI 10.1016/0378-1119(92)90029-O; SHINABARGER D, 1993, MOL MICROBIOL, V9, P1027, DOI 10.1111/j.1365-2958.1993.tb01232.x; SHINABARGER D, 1991, J BIOL CHEM, V266, P2080; SLEIN MW, 1955, METHOD ENZYMOL, V1, P299, DOI 10.1016/0076-6879(55)01041-0; SMITHWHITE BJ, 1992, J MOL EVOL, V34, P449, DOI 10.1007/BF00162999; STEVENSON G, 1991, MOL GEN GENET, V227, P173, DOI 10.1007/BF00259668; VARON D, 1993, J BACTERIOL, V175, P3964; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIELINSKI NA, 1991, J BIOL CHEM, V266, P9754	57	47	49	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4872	4877						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106458				2022-12-27	WOS:A1994MX57100029
J	NADAL, M; COUDERC, E; DUGUET, M; JAXEL, C				NADAL, M; COUDERC, E; DUGUET, M; JAXEL, C			PURIFICATION AND CHARACTERIZATION OF REVERSE GYRASE FROM SULFOLOBUS-SHIBATAE - ITS PROTEOLYTIC PRODUCT APPEARS AS AN ATP-INDEPENDENT TOPOISOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-LIKE PARTICLE; COLI PROTEIN-OMEGA; DNA TOPOISOMERASE; DESULFUROCOCCUS-AMYLOLYTICUS; SUPERHELICAL TURNS; HIGH-TEMPERATURE; SUPERCOILED DNA; I TOPOISOMERASE; ARCHAEBACTERIUM; ACIDOCALDARIUS	Sulfolobus shibatae B12 is a thermophilic archaebacterium that contains an inducible virus named SSV1. The viral DNA has been shown to be positively supercoiled before encapsidation. We have previously purified an archaebacterial DNA topoisomerase from Sulfolobus acidocaldarius DSM 639, reverse gyrase, likely responsible for this positive supercoiling reaction. In order to study an homogeneous system containing both reverse gyrase and one of its preferential substrate, SSV1 DNA, we have purified this enzyme from S. shibatae. During the course of the purification, we have detected another topoisomerase activity. In order to separate and purify these two topoisomerases, we have devised a new purification procedure. Purified S. shibatae reverse gyrase is a 124-kDa monomer, with a Stokes radius of 43 Angstrom and a sedimentation coefficient of 6.2 S. It is able to perform a DNA reverse gyration per se at 10 mM NaCl in a Mg- and ATP-dependent manner. The other topoisomerase is a monomer of about 40 kDa, with a Stokes radius of 25 Angstrom and a sedimentation coefficient of 4 S. This additional topoisomerase activity is Mg-dependent and ATP-independent and catalyzes only a relaxation reaction of negatively supercoiled DNA at 150 mM NaCl. This new ATP-independent topoisomerase activity seems to be a proteolysis product of reverse gyrase.	UNIV PARIS 11,INST GENET MICROBIOL,ENZYMOL ACIDES NUCL LAB,F-91405 ORSAY,FRANCE	UDICE-French Research Universities; Universite Paris Saclay				NADAL, Marc/0000-0001-9637-7694				BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; CHAMPOUX JJ, 1972, P NATL ACAD SCI USA, V69, P143, DOI 10.1073/pnas.69.1.143; CHARBONNIER F, 1992, J BACTERIOL, V174, P6103, DOI 10.1128/JB.174.19.6103-6108.1992; COLLIN RG, 1988, FEMS MICROBIOL LETT, V55, P235, DOI 10.1111/j.1574-6968.1988.tb13940.x; CONFALONIERI F, 1993, P NATL ACAD SCI USA, V90, P4753, DOI 10.1073/pnas.90.10.4753; DELATOUR CB, 1993, BIOCHIM BIOPHYS ACTA, V1216, P213, DOI 10.1016/0167-4781(93)90147-6; DELATOUR CB, 1990, J BACTERIOL, V172, P6803, DOI 10.1128/jb.172.12.6803-6808.1990; DELATOUR CB, 1991, J BACTERIOL, V173, P3921, DOI 10.1128/JB.173.12.3921-3923.1991; DEPEW RE, 1978, J BIOL CHEM, V253, P511; DRLICA K, 1984, MICROBIOL REV, V48, P273, DOI 10.1128/MMBR.48.4.273-289.1984; DUGUET M, 1983, NUCLEIC ACIDS RES, V11, P1059, DOI 10.1093/nar/11.4.1059; FORTERRE P, 1985, EMBO J, V4, P2123, DOI 10.1002/j.1460-2075.1985.tb03902.x; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GROGAN D, 1990, ARCH MICROBIOL, V154, P594; Hames B.D., 1981, GEL ELECTROPHORESIS, P71; JAXEL C, 1989, EMBO J, V8, P3135, DOI 10.1002/j.1460-2075.1989.tb08466.x; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; MARTIN A, 1984, EMBO J, V3, P2165, DOI 10.1002/j.1460-2075.1984.tb02107.x; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MENZEL R, 1983, CELL, V34, P105, DOI 10.1016/0092-8674(83)90140-X; MILLER KG, 1981, J BIOL CHEM, V256, P9334; MIRAMBEAU G, 1984, J MOL BIOL, V179, P559, DOI 10.1016/0022-2836(84)90080-9; NADAL M, 1988, BIOCHEMISTRY-US, V27, P9102, DOI 10.1021/bi00426a006; NADAL M, 1986, NATURE, V321, P256, DOI 10.1038/321256a0; NAKASU S, 1985, EMBO J, V4, P2705, DOI 10.1002/j.1460-2075.1985.tb03990.x; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SLESAREV AI, 1991, J BIOL CHEM, V266, P12321; SLESAREV AI, 1988, EUR J BIOCHEM, V173, P395, DOI 10.1111/j.1432-1033.1988.tb14012.x; SRIVENUGOPAL KS, 1985, BIOCHEMISTRY-US, V24, P4766, DOI 10.1021/bi00339a009; SVOBODA M, 1985, ANAL BIOCHEM, V151, P16, DOI 10.1016/0003-2697(85)90046-6; UPTON C, 1990, VIROLOGY, V176, P439, DOI 10.1016/0042-6822(90)90013-H; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; YEATS S, 1982, EMBO J, V1, P1035, DOI 10.1002/j.1460-2075.1982.tb01292.x	40	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5255	5263						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106509				2022-12-27	WOS:A1994MX57100086
J	VOYNOYASENETSKAYA, T; CONKLIN, BR; GILBERT, RL; HOOLEY, R; BOURNE, HR; BARBER, DL				VOYNOYASENETSKAYA, T; CONKLIN, BR; GILBERT, RL; HOOLEY, R; BOURNE, HR; BARBER, DL			G-ALPHA-13 STIMULATES NA-H EXCHANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-ADRENERGIC-RECEPTOR; CYCLIC-AMP ACCUMULATION; SMOOTH-MUSCLE CELLS; PROTEIN-KINASE-C; INTRACELLULAR PH; NA+/H+ EXCHANGE; PERTUSSIS TOXIN; ADENYLYL CYCLASE; PHOSPHOLIPASE-C; CYTOPLASMIC PH	Activity of the ubiquitous Na-H exchanger (NHE1) is regulated by a number of receptors with tyrosine kinase activity as well as by several classes of receptors coupled to heterotrimeric GTP-binding proteins. We previously demonstrated that the beta(2)-adrenergic receptor and other receptors that stimulate adenylyl cyclase by activating G(s) stimulate NHE1 by a guanine nucleotide-dependent mechanism that is independent of receptor coupling to G(s). Now we report that a recently identified G alpha subunit, alpha 13, activates the exchanger. Transient expression of mutationally activated alpha 13 constitutively stimulates Na-H exchange; moreover, an alpha 13/alpha(z) chimera, designed to respond to stimulation by G(i)-coupled receptors, mediates stimulation of Na-H exchange by one such receptor, the dopamine(2), receptor. Mutationally activated alpha 13, however, does not stimulate adenylyl cyclase activity or phosphoinositide hydrolysis, indicating that its action on NHE1 occurs independently of these two effector pathways. These findings reveal the first known signaling function of alpha 13 and identify a new G protein involved in the regulation of NHE1.	UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Conklin, Bruce/E-4738-2019	Conklin, Bruce/0000-0003-1463-6061	NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047413, R37GM027800, R01GM027800] Funding Source: NIH RePORTER; NCI NIH HHS [CA 54427] Funding Source: Medline; NIGMS NIH HHS [GM 27800, GM 47413] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER DL, 1989, J BIOL CHEM, V264, P21038; BARBER DL, 1992, J BIOL CHEM, V267, P20607; BARBER DL, 1992, MOL PHARMACOL, V41, P1056; BORGESE F, 1992, P NATL ACAD SCI USA, V89, P6765, DOI 10.1073/pnas.89.15.6765; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; CLARK JD, 1991, AM J PHYSIOL, V261, pC945, DOI 10.1152/ajpcell.1991.261.6.C945; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; FARAGO A, 1990, FEBS LETT, V268, P350, DOI 10.1016/0014-5793(90)81284-U; GANZ MB, 1990, J BIOL CHEM, V265, P8989; GANZ MB, 1988, AM J PHYSIOL, V254, pF737; GRINSTEIN S, 1986, BIOCHIM BIOPHYS ACTA, V889, P301, DOI 10.1016/0167-4889(86)90192-8; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAZAV P, 1989, CANCER RES, V49, P72; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HUANG CL, 1987, J BIOL CHEM, V262, P14134; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MENDOZA SA, 1986, J CELL BIOL, V102, P2223, DOI 10.1083/jcb.102.6.2223; MOOLENAAR WH, 1984, NATURE, V312, P371, DOI 10.1038/312371a0; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; RAO GN, 1991, J BIOL CHEM, V266, P1385; RESNICK RJ, 1986, CANCER RES, V46, P1800; SARDET C, 1991, J BIOL CHEM, V266, P19166; SIFFERT W, 1987, THROMB RES, V44, P235; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRATHMANN M, 1989, P NATL ACAD SCI USA, V88, P5582; SWEATT JD, 1985, J BIOL CHEM, V260, P2910; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VARIO G, 1990, J BIOL CHEM, V265, P16929; VIGNE P, 1988, J BIOL CHEM, V263, P18023; VOLPI M, 1985, P NATL ACAD SCI USA, V82, P2708, DOI 10.1073/pnas.82.9.2708; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU DQ, 1992, J BIOL CHEM, V267, P1811	40	155	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4721	4724						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106440				2022-12-27	WOS:A1994MX57100008
J	BARRY, MM; MOL, CD; ANDERSON, WF; LEE, JS				BARRY, MM; MOL, CD; ANDERSON, WF; LEE, JS			SEQUENCING AND MODELING OF ANTI-DNA IMMUNOGLOBULIN-FV DOMAINS - COMPARISON WITH CRYSTAL-STRUCTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; 3-DIMENSIONAL STRUCTURE; HYPERVARIABLE REGIONS; COMBINING SITES; MESSENGER-RNA; STRANDED-DNA; FAB COMPLEX; AUTOANTIBODIES; BINDING; ACID	Models for the three-dimensional structures of the combining regions of six DNA-binding antibodies have been derived from the sequence data for their Fv domains presented here. Using the amino acid sequences and the canonical structure classes described by Chothia and Lesk (Chothia, C., and Lesk, A. M. (1987) J. Mol. Biol. 196, 901), model loops were selected from immunoglobulin domains of known structure for five of the six antibody hypervariable regions. Models for the third complementarity-determining region of the heavy chain were constructed from known immunoglobulin loops of similar length and sequence. Comparison of three of the models with the respective crystal structure indicates that this procedure can generate a working model of the antibody combining region that provides useful information on the nature of the interactions between antibodies and nucleic acids. As part of our continuing investigation into the structural basis of antibody-DNA recognition, the observed and predicted models for the combining regions of nucleic acid-binding antibodies have been examined. In general, single strand-specific antibodies have deep clefts where the antigen might bind, whereas duplex-specific antibodies present a relatively flat surface. In addition, on the basis of both sequence and structure, there is little to distinguish autoimmune antibodies from those produced by immunization. Testable hypotheses for how these antibodies might interact with single- and double-stranded nucleic acids are presented.	VANDERBILT UNIV,DEPT BIOCHEM,NASHVILLE,TN 37232; UNIV SASKATCHEWAN,DEPT BIOCHEM,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA	Vanderbilt University; University of Saskatchewan					NIDDK NIH HHS [DK42502] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BEHAR SM, 1988, P NATL ACAD SCI USA, V85, P3970, DOI 10.1073/pnas.85.11.3970; BELLON B, 1987, J CLIN INVEST, V79, P1044, DOI 10.1172/JCI112917; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRAUN RP, 1986, NUCLEIC ACIDS RES, V14, P5049, DOI 10.1093/nar/14.12.5049; BRIGIDO MM, 1991, J IMMUNOL, V146, P2005; BRUCCOLERI RE, 1987, BIOPOLYMERS, V26, P137, DOI 10.1002/bip.360260114; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CHOTHIA C, 1986, SCIENCE, V233, P755, DOI 10.1126/science.3090684; CYGLER M, 1987, J BIOL CHEM, V262, P643; DELAPAZ P, 1986, EMBO J, V5, P415, DOI 10.1002/j.1460-2075.1986.tb04227.x; EILAT D, 1988, J IMMUNOL, V141; FINE R M, 1986, Proteins Structure Function and Genetics, V1, P342, DOI 10.1002/prot.340010408; HENDRICKSON WA, 1980, BIOMOLECULAR STRUCTU, V1, P43; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; KAARTINEN M, 1983, NATURE, V304, P320, DOI 10.1038/304320a0; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; LEE JS, 1981, NUCLEIC ACIDS RES, V9, P1707, DOI 10.1093/nar/9.7.1707; LEE JS, 1982, BIOCHEMISTRY-US, V21, P4940, DOI 10.1021/bi00263a017; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; LEE JS, 1984, BIOCHEMISTRY-US, V23, P3277, DOI 10.1021/bi00309a024; MARTIN ACR, 1989, P NATL ACAD SCI USA, V86, P9268, DOI 10.1073/pnas.86.23.9268; MOL CD, 1994, J BIOL CHEM, V269, P3615; MOL CD, 1994, J BIOL CHEM, V269, P3605; MOULT J, 1986, Proteins Structure Function and Genetics, V1, P146, DOI 10.1002/prot.340010207; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; RADIC MZ, 1991, J IMMUNOL, V146, P176; ROSSMANN MG, 1990, ACTA CRYSTALLOGR A, V46, P73, DOI 10.1107/S0108767389009815; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SHLOMCHIK MJ, 1987, P NATL ACAD SCI USA, V84, P9150, DOI 10.1073/pnas.84.24.9150; SIBLEY JT, 1988, J IMMUNOL, V140, P3502; SIBLEY JT, 1986, CLIN EXP IMMUNOL, V64, P563; SMITHGILL SJ, 1987, J MOL BIOL, V194, P713, DOI 10.1016/0022-2836(87)90249-X; STEIPE B, 1992, J MOL BIOL, V225, P739, DOI 10.1016/0022-2836(92)90398-4; STOLLAR BD, 1986, CRC CR REV BIOCH MOL, V20, P1, DOI 10.3109/10409238609115899; SUH S W, 1986, Proteins Structure Function and Genetics, V1, P74, DOI 10.1002/prot.340010112; TREPICCHIO W, 1987, J IMMUNOL, V138, P2323; WEIR DM, 1986, HDB EXPT IMMUNOLOGY, V1	46	60	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3623	3632						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106407				2022-12-27	WOS:A1994MV63100075
J	HAGIWARA, H; YORIFUJI, H; SATOYOSHITAKE, R; HIROKAWA, N				HAGIWARA, H; YORIFUJI, H; SATOYOSHITAKE, R; HIROKAWA, N			COMPETITION BETWEEN MOTOR MOLECULES (KINESIN AND CYTOPLASMIC DYNEIN) AND FIBROUS MICROTUBULE-ASSOCIATED PROTEINS IN BINDING TO MICROTUBULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN KINESIN; MEMBRANOUS ORGANELLES INVIVO; CARBOXYL-TERMINAL DOMAIN; IMMUNOELECTRON MICROSCOPY; TAU PROTEINS; SYNTHETIC PEPTIDES; REGULATORY DOMAIN; QUICK-FREEZE; DEEP-ETCH; TUBULIN	In neuronal cells, microtubule-associated proteins (MAPs) can be classified into two distinct groups. One consists of force-producing MAPs, the main components of which are kinesin and cytoplasmic dynein. The other is composed of fibrous MAPs, which include tau and MAP2. Many studies have been performed on the respective groups to understand their structures and functions. However, the problem of how the groups interact with each other on microtubules is still unresolved. To elucidate the interaction between kinesin or cytoplasmic dynein and tau or MAP2, we performed three experiments: competition, motility assay, and cosedimentation. To distinguish whether the binding competition is caused by steric hindrance of the projection domains of MAPs or by the competition of the binding sites on microtubules, we used microtubule binding domains of tau and MAP2 as well as native proteins. Our results revealed that kinesin or cytoplasmic dynein and tau or MAP2 compete for almost the same binding domains located on the carboxyl-terminal side of alpha- and the amino-terminal side of beta-tubulin from the site of subtilisin cleavage. Furthermore, the projection of tau, and probably of MAP2, might inhibit the binding of kinesin or cytoplasmic dynein to microtubules by steric hindrance. These findings will provide a useful step toward understanding the regulation system of intracellular organelle transport.	UNIV TOKYO, SCH MED, DEPT ANAT & CELL BIOL, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								AMOS LA, 1989, J CELL SCI, V93, P19; BERNHARDT R, 1982, J CELL BIOL, V92, P589, DOI 10.1083/jcb.92.2.589; BLOOM GS, 1984, J CELL BIOL, V98, P320, DOI 10.1083/jcb.98.1.320; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; GARNER CC, 1988, J NEUROCHEM, V50, P609, DOI 10.1111/j.1471-4159.1988.tb02954.x; GILBERT SP, 1986, J CELL BIOL, V103, P947, DOI 10.1083/jcb.103.3.947; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; HEINS S, 1991, J CELL SCI, P121; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HIROKAWA N, 1988, J NEUROSCI, V8, P2769; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1990, J CELL BIOL, V111, P1027, DOI 10.1083/jcb.111.3.1027; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; HIROKAWA N, 1985, J CELL BIOL, V101, P277; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; KANAI Y, 1992, EMBO J, V11, P3953, DOI 10.1002/j.1460-2075.1992.tb05489.x; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KNOPS J, 1991, J CELL BIOL, V114, P725, DOI 10.1083/jcb.114.4.725; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1990, CELL MOTIL CYTOSKEL, V15, P199, DOI 10.1002/cm.970150402; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LITTAUER UZ, 1986, P NATL ACAD SCI USA, V83, P7162, DOI 10.1073/pnas.83.19.7162; LOPEZ LA, 1993, CELL MOTIL CYTOSKEL, V24, P1, DOI 10.1002/cm.970240102; LYE RJ, 1987, CELL, V51, P309, DOI 10.1016/0092-8674(87)90157-7; MACCIONI RB, 1988, EMBO J, V7, P1957, DOI 10.1002/j.1460-2075.1988.tb03033.x; MACCIONI RB, 1986, EUR J BIOCHEM, V156, P375, DOI 10.1111/j.1432-1033.1986.tb09593.x; MASSOW A, 1989, CELL MOTIL CYTOSKEL, V14, P562; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; MELKI R, 1991, BIOCHEMISTRY-US, V30, P11536, DOI 10.1021/bi00113a008; MURPHY DB, 1975, P NATL ACAD SCI USA, V72, P2696, DOI 10.1073/pnas.72.7.2696; NUNEZ J, 1988, TRENDS NEUROSCI, V11, P477, DOI 10.1016/0166-2236(88)90004-5; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PENNINGROTH SM, 1987, FEBS LETT, V222, P204, DOI 10.1016/0014-5793(87)80220-X; PORTER ME, 1987, J BIOL CHEM, V262, P2794; RIVAS CI, 1988, P NATL ACAD SCI USA, V85, P6092, DOI 10.1073/pnas.85.16.6092; RODIONOV VI, 1990, J BIOL CHEM, V265, P5702; SACKETT DL, 1985, J BIOL CHEM, V260, P43; SATOYOSHITAKE R, 1989, NEURON, V3, P229, DOI 10.1016/0896-6273(89)90036-6; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SERRANO L, 1984, P NATL ACAD SCI-BIOL, V81, P5989, DOI 10.1073/pnas.81.19.5989; SHIOMURA Y, 1987, J CELL BIOL, V104, P1575, DOI 10.1083/jcb.104.6.1575; SHIOMURA Y, 1987, J NEUROSCI, V7, P1461; UMEYAMA T, 1993, J CELL BIOL, V120, P451, DOI 10.1083/jcb.120.2.451; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; VALE RD, 1985, CELL, V40, P559, DOI 10.1016/0092-8674(85)90204-1; Vallee R, 1991, Trends Cell Biol, V1, P25, DOI 10.1016/0962-8924(91)90066-I; VALLEE RB, 1983, P NATL ACAD SCI-BIOL, V80, P1342, DOI 10.1073/pnas.80.5.1342; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; VALLEE RB, 1988, NATURE, V332, P561, DOI 10.1038/332561a0; VINA S, 1988, BIOCHEMISTRY-US, V27, P5352; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; YOUNG JT, 1988, P NATL ACAD SCI USA, V85, P1864	67	98	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3581	3589						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106402				2022-12-27	WOS:A1994MV63100070
J	HSIEH, JT; LIN, SH				HSIEH, JT; LIN, SH			ANDROGEN REGULATION OF CELL-ADHESION MOLECULE GENE-EXPRESSION IN RAT PROSTATE DURING ORGAN DEGENERATION - C-CAM BELONGS TO A CLASS OF ANDROGEN-REPRESSED GENES ASSOCIATED WITH ENRICHED STEM AMPLIFYING CELL-POPULATION AFTER PROLONGED CASTRATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-BETA; VENTRAL PROSTATE; E-CADHERIN; CARCINOEMBRYONIC ANTIGEN; SURFACE GLYCOPROTEIN; CANCER; TISSUES; DEATH; BASAL; IDENTIFICATION	Androgen is required for maintaining the differentiated state of prostatic epithelium, and that cell adhesion molecules play active roles in controlling the development of epithelial cells. However, little is known about the regulation of cell adhesion molecules during prostate development. In this study, we demonstrated that the expression of an epithelial cell adhesion molecule, C-CAM, in rat ventral prostatic epithelium are repressed by androgen. A similar regulatory pattern was also observed in the seminal vesicle but not in other androgen-dependent organs (the coagulating gland and the dorsolateral prostate), or other organs (the liver and kidney). These observations suggest that regulation of C-CAM expression by androgen is tissue-specific. Unlike the other androgen-repressed genes associated with apoptosis, which have transient expression patterns, the elevated level of C-CAM in the ventral prostate persisted for more than 30 days postcastration, suggesting that C-CAM belongs to a class of androgen-repressed genes which are not associated with apoptosis. Immunohistochemical study detected C-CAM on the apical surface of secretory epithelium in control rats; castration resulted in an altered localization of C-CAM expression from columnar epithelium to cuboidal basal epithelium. Taken together, the up-regulation and altered expression pattern of C-CAM in ventral prostatic epithelium by androgen deprivation may be associated with the enriched epithelial stem/amplifying cell population in degenerated ventral prostate. These observations suggest that C-CAM may play an active role in the process of prostatic epithelial differentiation.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MOLEC PATHOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	HSIEH, JT (corresponding author), UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT UROL, HOUSTON, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R29CA059939] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043189] Funding Source: NIH RePORTER; NCI NIH HHS [CA59939] Funding Source: Medline; NIGMS NIH HHS [GM43189] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABAJKO S, 1993, P NATL ACAD SCI USA, V90, P272, DOI 10.1073/pnas.90.1.272; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BUSSEMAKERS MJG, 1992, CANCER RES, V52, P2916; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CHEN WC, 1991, J CELL BIOL, V114, P319, DOI 10.1083/jcb.114.2.319; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; CHEUNG PH, 1993, BIOCHEM J, V295, P427, DOI 10.1042/bj2950427; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFEY DS, 1990, UROL CLIN N AM, V17, P461; CULIC O, 1992, BIOCHEM J, V285, P47, DOI 10.1042/bj2850047; DEKLERK DP, 1975, BENIGN PROSTATIC HYP, P43; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EDELMAN GM, 1984, P NATL ACAD SCI-BIOL, V81, P1460, DOI 10.1073/pnas.81.5.1460; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GETZENBERG RH, 1990, MOL ENDOCRINOL, V4, P1336, DOI 10.1210/mend-4-9-1336; GLEAVE M, 1991, CANCER RES, V51, P3753; HIXSON DC, 1989, CANCER RES, V49, P6788; HSIEH JT, 1992, J BIOL CHEM, V267, P2303; ISAACS JT, 1989, PROSTATE, P33; KYPRIANOU N, 1988, ENDOCRINOLOGY, V123, P2124, DOI 10.1210/endo-123-4-2124; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P552, DOI 10.1210/endo-122-2-552; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; Lee C., 1987, GENITAL SYSTEM, P239; LEGER JG, 1987, BIOCHEM BIOPH RES CO, V147, P196, DOI 10.1016/S0006-291X(87)80106-7; LESSER B, 1974, BIOCHEM J, V142, P429, DOI 10.1042/bj1420429; LIAO S, 1977, BIOCHEM ACTION HORM, V4, P351; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; MATSUURA K, 1992, BRIT J CANCER, V66, P1122, DOI 10.1038/bjc.1992.421; MCCORMICK BA, 1992, PHARMACOL THERAPEUT, V53, P239, DOI 10.1016/0163-7258(92)90011-N; MOWERY J, 1991, HEPATOLOGY, V13, P47; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; OCKLIND C, 1982, J BIOL CHEM, V257, P6788; ODIN P, 1988, J HISTOCHEM CYTOCHEM, V36, P729, DOI 10.1177/36.7.3290331; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; OIKAWA S, 1991, J BIOL CHEM, V266, P7995; RAYNAUD JP, 1988, AM J CLIN ONCOL-CANC, V11, pS132, DOI 10.1097/00000421-198801102-00034; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; SALTZMAN AG, 1987, J BIOL CHEM, V262, P432; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; THOMPSON NL, 1993, CELL GROWTH DIFFER, V4, P257; TINGSTROM A, 1990, J CELL SCI, V96, P17; UMBAS R, 1992, CANCER RES, V52, P5104; VERHAGEN APM, 1988, PROSTATE, V13, P25, DOI 10.1002/pros.2990130104; VISKOCHIL DH, 1983, J BIOL CHEM, V258, P8861	46	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3711	3716						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106416				2022-12-27	WOS:A1994MV63100085
J	KADOWAKI, M; VENERANDO, R; MIOTTO, G; MORTIMORE, GE				KADOWAKI, M; VENERANDO, R; MIOTTO, G; MORTIMORE, GE			DE-NOVO AUTOPHAGIC VACUOLE FORMATION IN HEPATOCYTES PERMEABILIZED BY STAPHYLOCOCCUS-AUREUS ALPHA-TOXIN - INHIBITION BY NONHYDROLYZABLE GTP ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID CONTROL; ISOLATED RAT HEPATOCYTES; BINDING PROTEINS; COLLOIDAL SILICA; PLASMA-MEMBRANE; INTRACELLULAR DEGRADATION; HEPATIC PROTEOLYSIS; LIVER LYSOSOMES; CELLS; TRANSPORT	The role of GTP-binding proteins in autophagic vacuole formation was investigated in isolated rat hepatocytes permeabilized by alpha-toxin from Staphylococcus aureus, an agent which creates stable plasma membrane channels allowing exchange of small (less-than-or-equal-to 1000 Da) molecules. Vacuole formation was monitored from the uptake of I-125-tyramine-cellobiitol ((ITC)-I-125) into osmotically sensitive vacuoles isolated on colloidal silica density gradients. Separation was based on an established observation that autophagic vacuoles are retained in a heavy midgradient band when samples are layered, but are selectively shifted to dense fractions when they are previously dispersed in the gradient material. The vacuolar uptake of (ITC)-I-125 was concentration-dependent and required exogenous ATP: 94% was directly mediated by sequestration; 6% was acquired by fluid-phase endocytosis as monitored by [carboxyl-C-14]dextran-carboxyl. Although the amino acid control of proteolysis was lost, addition of the nonhydrolyzable GTP analog GTPgammaS (as well as GMP-PNP) decreased fractional rates of direct vacuolar (ITC)-I-125 uptake and long-lived proteolysis by similar amounts (1.02-1.03% h-1), substantiating the notion that the effects were the direct result of autophagic inhibition. These and associated findings, supported by quantitative electron microscopy, indicate the presence of ongoing macro- and microautophagy in alpha-toxin-permeabilized cells and suggest that one or more GTP-binding proteins is required in macroautophagic vacuole formation.	UNIV PADUA, DIPARTIMENTO CHIM BIOL, I-35121 PADUA, ITALY	University of Padua	KADOWAKI, M (corresponding author), PENN STATE UNIV, MILTON S HERSHEY MED CTR, COLL MED, DEPT CELLULAR & MOLEC PHYSIOL, HERSHEY, PA 17033 USA.		Miotto, Giovanni/S-1903-2016	Miotto, Giovanni/0000-0002-4278-4873	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021624] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 21624] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARION WJ, 1980, J BIOL CHEM, V255, P387; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALDINI G, 1991, J BIOL CHEM, V266, P4037; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; BHAKDI S, 1987, REV PHYSIOL BIOCH P, V107, P147, DOI 10.1007/BFb0027646; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; CARO LHP, 1988, EUR J BIOCHEM, V175, P325, DOI 10.1111/j.1432-1033.1988.tb14200.x; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GORDON PB, 1988, BIOCHEM BIOPH RES CO, V151, P40, DOI 10.1016/0006-291X(88)90556-6; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HARSHMAN S, 1988, METHOD ENZYMOL, V165, P3; HENDIL KB, 1980, J CELL PHYSIOL, V105, P449, DOI 10.1002/jcp.1041050309; HIRSIMAKI P, 1983, PATHOBIOLOGY CELL ME, V3, P201; HOHMAN RJ, 1988, P NATL ACAD SCI USA, V85, P1624, DOI 10.1073/pnas.85.5.1624; KADOWAKI M, 1992, J BIOL CHEM, V267, P22060; KINDBERG GM, 1987, J BIOL CHEM, V262, P7066; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; MCEWEN BF, 1985, J CELL BIOL, V100, P1922, DOI 10.1083/jcb.100.6.1922; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MIOTTO G, 1992, J BIOL CHEM, V267, P22066; MORTIMORE GE, 1988, J BIOL CHEM, V263, P2506; MORTIMORE GE, 1991, J BIOL CHEM, V266, P1021; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; MORTIMORE GE, 1994, IN PRESS CELLULAR PR; OSE L, 1980, EXP CELL RES, V126, P109, DOI 10.1016/0014-4827(80)90475-9; Pittman R C, 1986, Methods Enzymol, V129, P612; PLOMP PJAM, 1989, J BIOL CHEM, V264, P6699; SCHWARTZ AL, 1992, AM J PHYSIOL, V262, pC1031, DOI 10.1152/ajpcell.1992.262.4.C1031; SCHWORER CM, 1981, J BIOL CHEM, V256, P7652; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SEGLEN PO, 1984, J CELL BIOL, V99, P435, DOI 10.1083/jcb.99.2.435; SEGLEN PO, 1986, EXP CELL RES, V162, P273, DOI 10.1016/0014-4827(86)90446-5; SEGLEN PO, 1987, LYSOSOMES THEIR ROLE, P371; SURMACZ CA, 1983, AM J PHYSIOL, V245, pC52, DOI 10.1152/ajpcell.1983.245.1.C52; SURMACZ CA, 1983, AM J PHYSIOL, V245, pC61, DOI 10.1152/ajpcell.1983.245.1.C61; SURMACZ CA, 1987, BIOCHEM J, V242, P453, DOI 10.1042/bj2420453; SURMACZ CA, 1982, BIOCHEM BIOPH RES CO, V107, P1425, DOI 10.1016/S0006-291X(82)80158-7; THELESTAM M, 1983, BIOCHIM BIOPHYS ACTA, V762, P481, DOI 10.1016/0167-4889(83)90050-2; TOOZE J, 1990, J CELL BIOL, V111, P329, DOI 10.1083/jcb.111.2.329; VENERANDO R, 1991, FASEB J, V5, pA1178	43	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3703	3710						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106415				2022-12-27	WOS:A1994MV63100084
J	KWAK, SP; HAKES, DJ; MARTELL, KJ; DIXON, JE				KWAK, SP; HAKES, DJ; MARTELL, KJ; DIXON, JE			ISOLATION AND CHARACTERIZATION OF A HUMAN DUAL-SPECIFICITY PROTEIN-TYROSINE-PHOSPHATASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; TRANS-ACTING FACTOR; CDC25 PROTEIN; TRANSCRIPTION INVITRO; VACCINIA VIRUS; FISSION YEAST; SEQUENCE; CELLS; PROMOTER; P34CDC2	Vaccinia phosphatase VH-1 and its mammalian counterparts, including protein-tyrosine phosphatases (PTPase) CL100 and VHR, constitute a novel subfamily of protein-tyrosine phosphatases that exhibits dual substrate specificity for phosphotyrosine- and phosphoserine/threonine-containing substrates. The expression of human VH-1-like PTPase CL100 is rapidly inducible by mitogen stimulation and oxidative stress, suggesting that this gene is transcriptionally regulated. In order to study the mechanism underlying this transcriptional regulation, we isolated the first human gene of this subfamily, the CL100 gene, and characterized its promoter. The gene consists of four exons intervened by three short introns 400-500 base pairs in length. Analysis of the protein sequence encoded by each exon revealed that there is a second region of similarity between CL100 protein and cdc25 in addition to the PTPase catalytic domain. Promoter analysis of the CL100 gene indicates that an 800-base pair region flanking the transcriptional initiation site is sufficient to confer a transcriptional response to serum and 12-0-tetradecanoylphorbol-13-acetate stimulation. The CL100 gene is expressed in numerous tissues, including nonmitotic cells in the brain. Within the brain, CL100 mRNA is localized in discrete neuronal populations, suggesting that this PTPase is likely to play a key role in neurotransmission as well as in mitotic signaling. Finally, although extracellular signal-regulated kinase has recently been shown to act as substrate for CL100 in vitro, we find no clear correspondence between the distribution of extracellular signal-regulated kinase and CL100 mRNA in the brain. The potential significance of a second cdc25 homology domain of.CL100 is discussed.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR00042] Funding Source: Medline; PHS HHS [18024] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GARCIA J, 1987, NUCLEIC ACIDS RES, V15, P8367, DOI 10.1093/nar/15.20.8367; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GIRARD F, 1992, J CELL BIOL, V118, P785, DOI 10.1083/jcb.118.4.785; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HAKES DJ, 1993, P NATL ACAD SCI USA, V90, P4017, DOI 10.1073/pnas.90.9.4017; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KELLY K, 1992, ONCOGENE, V7, P1463; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; Maniatis T, 1989, DECONTAMINATION DILU; MARQUARDT B, 1992, GENE, V120, P297, DOI 10.1016/0378-1119(92)90109-3; MCLAUGHLIN S, 1993, J BIOL CHEM, V268, P6839; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; WATSON S, 1988, SOC NEUROSCIENCE SHO, P4; XU YL, 1990, J BIOL CHEM, V265, P20285; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	40	159	167	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3596	3604						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106404				2022-12-27	WOS:A1994MV63100072
J	SCHROEDER, JJ; CRANE, HM; XIA, J; LIOTTA, DC; MERRILL, AH				SCHROEDER, JJ; CRANE, HM; XIA, J; LIOTTA, DC; MERRILL, AH			DISRUPTION OF SPHINGOLIPID METABOLISM AND STIMULATION OF DNA-SYNTHESIS BY FUMONISIN-B(1) - A MOLECULAR MECHANISM FOR CARCINOGENESIS ASSOCIATED WITH FUSARIUM-MONILIFORME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HAMSTER OVARY CELLS; GROWTH-FACTOR RECEPTOR; PHOSPHATIDATE PHOSPHOHYDROLASE; EQUINE LEUKOENCEPHALOMALACIA; SPHINGOMYELIN TURNOVER; CELLULAR PROLIFERATION; COMPLEX SPHINGOLIPIDS; SPHINGOSINE; INHIBITION	Consumption of grains contaminated with Fusarium moniliforme (Sheldon) causes liver cancer in rats and has been correlated with esophageal cancer in humans. The causative agents are believed to be a family of compounds known as fumonisins, which bear remarkable structural resemblances to sphingosine and sphinganine, the long-chain (sphingoid) base backbones of sphingolipids. Recently, fumonisin B1 has been shown to block de novo synthesis of sphingolipids by inhibiting sphingosine (sphinganine) N-acyltransferase, which leads to accumulation of sphingoid bases. Because the exogenous addition of sphingosine and sphingosine 1-phosphate to Swiss 3T3 cells has been shown to stimulate DNA synthesis (Zhang, H., Buckley, N. E., Gibson, K., and Spiegel, S. (1990) J. Biol. Chem. 265,76-81; Zhang, H., Desai, N. N., Olivera, A., Seki, T., Brooker, G., and Spiegel, S. (1991) J. Cell Biol. 114,155-167), we hypothesized that fumonisins might stimulate DNA synthesis by disrupting sphingolipid metabolism. Fumonisin B1 caused accumulation of sphinganine and sphingosine in Swiss 3T3 fibroblasts and, as occurred when these sphingoid bases were added exogenously, stimulated thymidine incorporation into DNA and augmented the mitogenic effect of insulin in a concentration-dependent manner. The mechanism underlying the mitogenic effect of fumonisin B1 was further investigated by using beta-fluoroalanine to block the initial step of sphingolipid biosynthesis catalyzed by serine palmitoyltransferase. beta-Fluoroalanine reduced sphingoid base accumulation in fumonisin B1-treated fibroblasts and inhibited fumonisin B1-stimulated DNA synthesis, but had no effect on mitogenesis when added alone. Fumonisin B1 did not cause accumulation of sphinganine 1-phosphate; therefore, it appears that sphingoid bases per se can stimulate DNA synthesis. To prove that the 1-phosphate is not obligatory, a 1-deoxysphinganine was synthesized, and it was as potent as sphinganine in stimulating DNA synthesis. These results establish that fumonisin B1 is mitogenic via accumulation of sphingoid bases rather than inhibition of complex sphingolipid biosynthesis per se. Because mitogens can often affect cell transformation, this provides a plausible molecular mechanism to explain the carcinogenicity of fumonisins.	EMORY UNIV,SCH MED,DEPT BIOCHEM,4113 ROLLINS RES CTR,ATLANTA,GA 30322; EMORY UNIV,DEPT CHEM,ATLANTA,GA 30322	Emory University; Emory University				Merrill, Alfred/0000-0002-6673-968X	NIGMS NIH HHS [GM14733, GM46368, GM33369] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014733, R01GM033369, R01GM046368] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; BEZUIDENHOUT CS, 1988, J CHEM SOC CHEM COMM, P743; BREMER EG, 1984, J BIOL CHEM, V259, P6818; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; Gelderblom W C, 1991, Mycotoxin Res, V7, P46, DOI 10.1007/BF03192165; GELDERBLOM WCA, 1988, APPL ENVIRON MICROB, V54, P1806, DOI 10.1128/AEM.54.7.1806-1811.1988; GELDERBLOM WCA, 1992, CARCINOGENESIS, V13, P433, DOI 10.1093/carcin/13.3.433; GELDERBLOM WCA, 1992, MYCOPATHOLOGIA, V117, P11, DOI 10.1007/BF00497273; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; Harrison L R, 1990, J Vet Diagn Invest, V2, P217; HASEGAWASASAKI H, 1985, BIOCHEM J, V232, P99, DOI 10.1042/bj2320099; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; KELLERMAN T S, 1972, Onderstepoort Journal of Veterinary Research, V39, P205; KIM MY, 1991, J BIOL CHEM, V266, P484; KRIEK NPJ, 1981, ONDERSTEPOORT J VET, V48, P129; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LIN M, 1980, GENETIC ENV FACTORS, P139; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marasas W. F. O., 1982, CANCER ESOPHAGUS, V1, P29; MARASAS WFO, 1984, INT J CANCER, V34, P383, DOI 10.1002/ijc.2910340315; MARASAS WFO, 1988, ONDERSTEPOORT J VET, V55, P197; MARASAS WFO, 1984, TOXIGENIC FUSARIUM S; MEDLOCK KA, 1988, BIOCHEMISTRY-US, V27, P7079, DOI 10.1021/bi00418a061; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1993, ADV LIPID RES, V26, P215; MERRILL AH, 1993, ADV LIPID RES, V25, P1; MERRILL AH, 1983, BIOCHIM BIOPHYS ACTA, V754, P284, DOI 10.1016/0005-2760(83)90144-3; MERRILL AH, 1985, J LIPID RES, V26, P617; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; MESSMER TO, 1989, J NUTR, V119, P534, DOI 10.1093/jn/119.4.534; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; NIMKAR S, 1988, TETRAHEDRON LETT, V29, P3037, DOI 10.1016/0040-4039(88)85079-2; NORED WP, 1992, FOOD CHEM TOXICOL, V30, P233; NORRED WP, 1992, MYCOPATHOLOGIA, V117, P73, DOI 10.1007/BF00497281; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OGURA K, 1992, EXP CELL RES, V199, P169, DOI 10.1016/0014-4827(92)90475-N; OISHI K, 1990, J BIOL CHEM, V265, P70; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; PUSHKAREVA MY, 1992, J BIOL CHEM, V267, P15246; RAMEL C, 1988, MUTAT RES, V205, P13, DOI 10.1016/0165-1218(88)90004-3; RILEY RT, 1993, TOXICOL APPL PHARM, V118, P105, DOI 10.1006/taap.1993.1015; ROSS PF, 1990, APPL ENVIRON MICROB, V56, P3225, DOI 10.1128/AEM.56.10.3225-3226.1990; SPIEGEL S, 1987, P NATL ACAD SCI USA, V84, P141, DOI 10.1073/pnas.84.1.141; SPIEGEL S, 1988, EXP CELL RES, V177, P414, DOI 10.1016/0014-4827(88)90474-0; STEVENS VL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P37, DOI 10.1016/0167-4889(90)90171-9; SYDENHAM EW, 1990, J AGR FOOD CHEM, V38, P285, DOI 10.1021/jf00091a064; VANVELDHOVEN PP, 1989, J LIPID RES, V30, P611; VOSS KA, 1990, MYCOPATHOLOGIA, V112, P81, DOI 10.1007/BF00436503; VOSS KA, 1989, FOOD CHEM TOXICOL, V27, P89, DOI 10.1016/0278-6915(89)90002-1; WANG E, 1992, J NUTR, V122, P1706, DOI 10.1093/jn/122.8.1706; WANG E, 1991, J BIOL CHEM, V266, P14486; WEDEGAERTNER PB, 1989, J BIOL CHEM, V264, P11346; YANG CS, 1980, CANCER RES, V40, P2633; YOO HS, 1992, TOXICOL APPL PHARM, V114, P9, DOI 10.1016/0041-008X(92)90090-F; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	61	145	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3475	3481						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106389				2022-12-27	WOS:A1994MV63100054
J	SIMBOLICAMPBELL, M; GAGNON, A; FRANKS, DJ; WELSH, J				SIMBOLICAMPBELL, M; GAGNON, A; FRANKS, DJ; WELSH, J			1,25-DIHYDROXYVITAMIN-D3 TRANSLOCATES PROTEIN KINASE-C-BETA TO NUCLEUS AND ENHANCES PLASMA-MEMBRANE ASSOCIATION OF PROTEIN KINASE-C-ALPHA IN RENAL EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; VITAMIN-D RECEPTOR; PHORBOL ESTERS; HL-60 CELLS; MDBK CELLS; RAT; INVOLVEMENT; EXPRESSION; ZETA; PHOSPHORYLATION	1,25-Dihydroxycholecalciferol (1,25-(OH)2-D3) increases membrane-associated protein kinase C (PKC) activity and immunoreactivity in renal epithelial (Madin Darby bovine kidney, MDBK) cells (Simboli-Campbell, M., Franks, D. J., and Welsh, J. E. (1992) Cell Signalling 4, 99-109). We have now characterized the effects of 1,25-(OH)2-Ds on the subcellular localization of three individual isozymes by immunofluorescence and immunoblotting. Although the total amount of PKCalpha, PKCbeta, and PKCzeta are unaffected by 1,25-(OH)2-D3, this steroid hormone induces subcellular redistribution of both PKCalpha and PKCbeta. Treatment with 1,25-(OH)2-D3 (100 nM, 24 h) enhances plasma membrane association of PKCalpha and induces translocation of PKCbeta to the nuclear membrane. The effects of 1,25-(OH)2-D3 appear to be limited to the calcium-dependent PKC isozymes, since 1,25-(OH)2-D3 has no effect on the calcium independent isozyme, PKCzeta. In contrast to rapid transient PKC translocation seen in response to agents which interact with membrane receptors to induce phospholipid hydrolysis, modulation of PKCalpha and PKCbeta is observed after 24 h treatment with 1,25-(OH)2-D3. In MDBK cells, the phorbol ester 12-0-tetradecanoylphorbol-13-acetate (TPA) (100 nM, 24 h) down-regulates PKCalpha and, to a lesser extent, PKCzeta, without altering their subcellular distribution. TPA also induces translocation of PKCbeta to the nuclear membrane. MDBK cells treated with 1,25-(OH)2-D3, but not TPA, exhibit enhanced phosphorylation of endogenous nuclear proteins. In addition to the distinct effects of 1,25-(OH)2-D3 and TPA on PKC isozyme patterns, 1,25-(OH)2-Ds up-regulates both the vitamin D receptor and calbindin D-28K, whereas TPA down-regulates the expression of both proteins. These data support the involvement of PKC in the mechanism of action of 1,25-(OH)2-Ds and specifically implicate PKCbeta in 1,25-(OH)2-Ds-mediated nuclear events.	UNIV OTTAWA,DEPT BIOCHEM,451 SMYTH RD,OTTAWA K1H 8M5,ONTARIO,CANADA	University of Ottawa				Gagnon, AnneMarie/0000-0002-6522-4879				BELLIDO T, 1991, VITAMIN D, P409; BINDELS RJM, 1991, AM J PHYSIOL, V261, pF799, DOI 10.1152/ajprenal.1991.261.5.F799; BLOBE GC, 1993, J BIOL CHEM, V268, P10627; BORNER C, 1992, J BIOL CHEM, V267, P12892; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN TA, 1990, J BIOL CHEM, V265, P10025; CAFFREY JM, 1989, J BIOL CHEM, V264, P20265; COHEN P, 1977, METHOD ENZYMOL, V47, P208; FRANKE WW, 1987, CELL, V48, P3, DOI 10.1016/0092-8674(87)90345-X; FRANKS DJ, 1984, J CELL PHYSIOL, V119, P41, DOI 10.1002/jcp.1041190108; GAGNON AM, 1994, IN PRESS KIDNEY INT; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HENRICH CJ, 1992, FOCUS, V13, P133; HENRY HL, 1989, ENDOCRINOLOGY, V124, P2228, DOI 10.1210/endo-124-5-2228; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; KOSAKA Y, 1988, BIOCHEM BIOPH RES CO, V151, P973, DOI 10.1016/S0006-291X(88)80461-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEACH KL, 1988, J BIOL CHEM, V263, P13223; MADIN SH, 1958, P SOC EXP BIOL MED, V98, P574, DOI 10.3181/00379727-98-24111; MANDLA S, 1990, ENDOCRINOLOGY, V127, P2639, DOI 10.1210/endo-127-6-2639; MARTELL RE, 1992, J BIOL CHEM, V267, P7511; MILLER BE, 1983, METHOD ENZYMOL, V102, P291; MULER RE, 1983, J BIOL CHEM, V258, P9227; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; OBEID LM, 1990, J BIOL CHEM, V265, P2370; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PIKE JW, 1985, BIOCHEM BIOPH RES CO, V131, P378, DOI 10.1016/0006-291X(85)91813-3; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; SIMBOLICAMPBELL M, 1992, CELL SIGNAL, V4, P99, DOI 10.1016/0898-6568(92)90011-V; SIMBOLICAMPBELL M, 1992, MOL CELL ENDOCRINOL, V83, P143, DOI 10.1016/0303-7207(92)90155-Y; SIMBOLICAMPBELL M, 1993, FOCUS, V15, P12; SIMPSON RU, 1989, J BIOL CHEM, V264, P19710; SOLOMON DH, 1991, CELL GROWTH DIFFER, V2, P187; STANDAERT ML, 1993, ENDOCRINOLOGY, V132, P689, DOI 10.1210/en.132.2.689; TAYLOR AN, 1982, KIDNEY INT, V21, P765, DOI 10.1038/ki.1982.95; TORNQUIST K, 1989, ENDOCRINOLOGY, V124, P2765, DOI 10.1210/endo-124-6-2765; VANLEEUWEN JPTM, 1992, J BIOL CHEM, V267, P12562; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WEAVER VM, 1992, CELL SIGNAL, V4, P293, DOI 10.1016/0898-6568(92)90069-K; WELSH J, 1991, BIOCHEM CELL BIOL, V69, P768, DOI 10.1139/o91-118; WETSEL CM, 1991, J CELL BIOL, V117, P121; WIESE RJ, 1992, J BIOL CHEM, V267, P20082	45	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3257	3264						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106362				2022-12-27	WOS:A1994MV63100023
J	SINDHWANI, R; ISMAILBEIGI, F; LEINWAND, LA				SINDHWANI, R; ISMAILBEIGI, F; LEINWAND, LA			POSTTRANSCRIPTIONAL REGULATION OF RAT ALPHA-CARDIAC MYOSIN HEAVY-CHAIN GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; FULL LENGTH CDNA; MESSENGER-RNA; THYROID-HORMONE; GROWTH-HORMONE; HEART; BOUNDARIES; ISOFORMS; POLY(A); TAIL	The cardiac myosin heavy chain genes, alpha and beta, have been shown to change their patterns of expression rapidly and dramatically in response to a variety of stimuli. A major means of achieving these changes in gene expression is transcriptional control; however, the role of post-transcriptional regulation in cardiac myosin gene expression has not been investigated. We have identified two post-transcriptional events in rat a cardiac myosin heavy chain (alpha-MHC) gene expression and investigated their regulatory significance in different developmental and thyroid hormone states. The polyadenylation of alpha-MHC mRNA occurs at three different sites: 12, 18, and 23 bases downstream from a single polyadenylation signal. Hyperthyroid hearts did not demonstrate any change in the proportion of the three alpha-MHC mRNA subspecies. Hypothyroid hearts (which have a decreased amount of total alpha-MHC mRNA) showed a significant increase in the proportion of the longest subspecies and a decrease in the shortest subspecies. The second post-transcriptional event in alpha-MHC gene expression which was demonstrated was the inclusion or exclusion of a codon, CAG, encoding glutamine at position 1931, resulting from alternate splicing of the alpha-MHC transcript. The ratio of CAG+ and CAG- forms of mRNA in the adult euthyroid hearts is 40:60% which was unchanged in hypo- and hyperthyroid states. This is the first example of alternate splicing in a vertebrate sarcomeric myosin heavy chain gene. We conclude that the rat alpha-MHC gene transcript is post-transcriptionally modified.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, RM 416, FORCHHEIMER BLDG, BRONX, NY 10461 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA	Yeshiva University; Albert Einstein College of Medicine; Columbia University				LEINWAND, LESLIE/0000-0003-1470-4810	NHLBI NIH HHS [R01HL50560, 1T32HL07675, P01HL37412] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050560, P01HL037412, T32HL007675] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BERNSTEIN SI, 1986, MOL CELL BIOL, V6, P2511, DOI 10.1128/MCB.6.7.2511; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOHELER KR, 1992, J BIOL CHEM, V267, P12979; BOUVAGNET P, 1987, CIRC RES, V61, P329, DOI 10.1161/01.RES.61.3.329; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECHESNE CA, 1987, DEV BIOL, V123, P169, DOI 10.1016/0012-1606(87)90439-8; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; EVERETT AW, 1984, BIOCHEMISTRY-US, V23, P1596, DOI 10.1021/bi00303a002; HIGGS DR, 1983, NATURE, V306, P398, DOI 10.1038/306398a0; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JIN JP, 1992, J MOL BIOL, V227, P1269, DOI 10.1016/0022-2836(92)90540-Z; KITSIS RN, 1991, P NATL ACAD SCI USA, V88, P4138, DOI 10.1073/pnas.88.10.4138; KRAFT R, 1989, NUCLEIC ACIDS RES, V17, P7529, DOI 10.1093/nar/17.18.7529; KUROO M, 1989, J BIOL CHEM, V264, P18272; LOMPRE AM, 1981, DEV BIOL, V84, P286, DOI 10.1016/0012-1606(81)90396-1; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; MAHDAVI V, 1984, P NATL ACAD SCI-BIOL, V81, P2626, DOI 10.1073/pnas.81.9.2626; MAHDAVI V, 1982, NATURE, V297, P659, DOI 10.1038/297659a0; MANLEY JL, 1989, GENE DEV, V3, P2218, DOI 10.1101/gad.3.12b.2218; MAURER RA, 1981, J BIOL CHEM, V256, P524; MCNALLY EM, 1989, NUCLEIC ACIDS RES, V17, P7527, DOI 10.1093/nar/17.18.7527; MORKIN E, 1983, PROG CARDIOVASC DIS, V25, P435, DOI 10.1016/0033-0620(83)90004-X; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ A, 1991, J BIOL CHEM, V266, P22419; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; TSIKA RW, 1990, P NATL ACAD SCI USA, V87, P379, DOI 10.1073/pnas.87.1.379; WALLIS M, 1980, NATURE, V284, P512, DOI 10.1038/284512a0; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F	30	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3272	3276						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106364				2022-12-27	WOS:A1994MV63100025
J	HANSEN, JE; GAFNI, A				HANSEN, JE; GAFNI, A			THERMAL SWITCHING BETWEEN ENHANCED AND ARRESTED REACTIVATION OF BACTERIAL GLUCOSE-6-PHOSPHATE-DEHYDROGENASE ASSISTED BY GROEL IN THE ABSENCE OF ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HOST PROTEIN; LEUCONOSTOC-MESENTEROIDES; CHAPERONIN; IDENTIFICATION; GENE; PURIFICATION; PRECURSOR; PRODUCT; INVITRO	Facilitation of protein folding by GroEL usually requires involvement of GroES and ATP. In their absence nascent proteins tend to be arrested on GroEL or, if released, fail to show enhancement of reactivation yield relative to that observed without the chaperonin. In contrast, the yield of reactivation of glucose-6-phosphate dehydrogenase (Glu-6-PDH) from Leuconostoc mesenteroides at 20-degrees-C is increased 2-3-fold (to over 80%) by GroEL alone. ATP greatly enhances the rate of GroEL-assisted reactivation and slightly increases its yield to 90%. The efficiency of the GroEL-assisted reactivation of Glu-6-PDH is strongly dependent on temperature. A switch from enhanced to fully arrested reactivation occurs over a narrow temperature range from 25 to 30-degrees-C in the presence of GroEL when ATP is absent. At physiological temperature therefore, reactivation is fully arrested by GroEL if ATP is absent and in its presence the protein is released in a form not committed to correct folding. The data shows that the committing step in Glu-6-PDH refolding occurs while the nascent protein is bound to GroEL, a step which is temperature-sensitive. The extreme temperature sensitivity of this step indicates a sharp structural transition in GroEL.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,INST GERONTOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE ON AGING [R01AG009761] Funding Source: NIH RePORTER; NIA NIH HHS [AG09761] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GEORGOPOULOS CP, 1978, P NATL ACAD SCI USA, V75, P131, DOI 10.1073/pnas.75.1.131; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LEE WT, 1991, J BIOL CHEM, V266, P13028; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; PLOMER JJ, 1992, BIOCHIM BIOPHYS ACTA, V1122, P234, DOI 10.1016/0167-4838(92)90398-W; PLOMER JJ, 1993, BIOCHIM BIOPHYS ACTA, V1163, P89, DOI 10.1016/0167-4838(93)90283-W; SAIBIL H, 1993, CURR OPIN STRUC BIOL, V3, P207, DOI 10.1016/S0959-440X(05)80154-X; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WICKNER W, 1989, TRENDS BIOCHEM SCI, V14, P280, DOI 10.1016/0968-0004(89)90064-9	25	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21632	21636						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8104942				2022-12-27	WOS:A1993MC80900033
J	LI, M; KEDDIE, JS; SMITH, LJ; CLARK, DC; MURPHY, DJ				LI, M; KEDDIE, JS; SMITH, LJ; CLARK, DC; MURPHY, DJ			EXPRESSION AND CHARACTERIZATION OF THE N-TERMINAL DOMAIN OF AN OLEOSIN PROTEIN FROM SUNFLOWER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BODY MEMBRANE-PROTEIN; SODIUM DODECYL-SULFATE; CIRCULAR-DICHROISM; ESCHERICHIA-COLI; BRASSICA-NAPUS; IMMUNOGOLD-LOCALIZATION; SECONDARY STRUCTURE; RNA-POLYMERASE; SIGMA-SUBUNIT; LIPID BODIES	Oil bodies of plant seeds contain a triacylglycerol matrix surrounded by a monolayer of phospholipids embedded with alkaline proteins termed oleosins. Although oleosins are amphipathic proteins, they are unlike bilayer membrane proteins since they are associated with a single lipid:water interface at the oil body surface. Oleosins are unusual proteins because they contain a 70-80-residue uninterrupted nonpolar domain, flanked by relative polar C- and N-terminal domains. In the present study, we report the expression of the N-terminal domain of the 18-kDa oleosin isoform from sunflower as a recombinant fusion protein in Escherichia coli and the determination of its secondary structure using CD and Fourier transform infrared spectroscopy either as a purified but partially denatured peptide or reconstituted into liposomes. The structure derived from physical studies was then compared and assigned with those predicted from analysis of the primary sequence of the N-terminal domain. Based on data derived from CD spectroscopy analysis of purified and partially renatured N-terminal polypeptide, it contains about 10% alpha-helical structure, 20-30% beta-strand structure, approximately 8% beta-turn structure, and 60% random coil structure. However, analysis of the polypeptide reconstituted into liposomes showed an increased content of alpha-helical structure to about 20% and an increased beta-strand structure content to about 30-40%. Data derived from Fourier transform infrared spectroscopy studies and compared with the data predicted from the primary sequence showed the peptide is well structured with some antiparallel beta-strand structure from residues 2-9, parallel beta-strand structure from residues 30-37 and/or 42-49, and alpha-helical structure from residues 10-23 and/or 43-49. There is potential amphipathic alpha-helix from residues 10-23. Based on these results, the following model for the secondary structure of the N-terminal domain of sunflower oleosin can be proposed. Residues 2-9 would produce amphipathic antiparallel beta-strand structure. Residues 10-23 would produce an amphipathic alpha-helical structure. Residues 30-37 and/or 42-49 would give parallel beta-strand structure, or residues 42-49 could form a nonpolar alpha-helical structure that would insert into the oil matrix.	JOHN INNES CTR PLANT SCI RES,DEPT BRASSICA & OILSEEDS RES,NORWICH NR4 7UH,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center			Murphy, Denis J/ABC-1734-2020	Murphy, Denis J/0000-0002-5291-2445				BARANY G, 1980, PEPTIDES, P1; BROWN KL, 1992, MOL MICROBIOL, V6, P1133, DOI 10.1111/j.1365-2958.1992.tb01551.x; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHANG LH, 1990, BIOCHEMISTRY-US, V29, P744, DOI 10.1021/bi00455a022; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLARK DC, 1989, J AGR FOOD CHEM, V37, P627, DOI 10.1021/jf00087a011; CUMMINS I, 1992, PLANT MOL BIOL, V19, P873, DOI 10.1007/BF00027084; FERNANDEZ DE, 1988, PLANT PHYSIOL, V86, P270, DOI 10.1104/pp.86.1.270; FTZEN JTC, 1992, J BIOL CHEM, V267, P15626; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GREIGHTON TE, 1991, NATURE, V352, P17; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HERMAN EM, 1987, PLANTA, V172, P336, DOI 10.1007/BF00398662; KEDDIE JS, 1992, PLANT MOL BIOL, V19, P1079, DOI 10.1007/BF00040541; KNNO T, 1975, ANAL BIOCHEM, V67, P226; Koening J. K., 1980, ANAL APPLICATIONS FT, P241; KRIMM S, 1982, SCIENCE, V216, P407, DOI 10.1126/science.6280277; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI M, 1992, J BIOL CHEM, V267, P8245; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MURPHY DJ, 1990, PROG LIPID RES, V29, P299; MURPHY DJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P86, DOI 10.1016/0167-4781(91)90156-G; MURPHY DJ, 1989, J PLANT PHYSIOL, V135, P63, DOI 10.1016/S0176-1617(89)80225-1; MURPHY DJ, 1989, J SCI FOOD AGR, V48, P209, DOI 10.1002/jsfa.2740480208; MURPHY DJ, 1989, PLANT SCI, V60, P47, DOI 10.1016/0168-9452(89)90042-3; MURPHY DJ, 1989, BIOCHEM J, V258, P285, DOI 10.1042/bj2580285; MURPHY DJ, 1981, PHYTOCHEMISTRY OXF, V28, P2063; ORBAN J, 1992, BIOCHEMISTRY-US, V31, P3604, DOI 10.1021/bi00129a008; PARKER FS, 1983, APPLICATION IR RAMAN; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RENUGOPALAKRISH.V, BIOCHEM BIOPH RES CO, V126, P1029; Saiki R. K., 1990, PCR PROTOCOLS GUIDE, P13; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIZER PJH, 1987, BIOCHEMISTRY-US, V26, P5106, DOI 10.1021/bi00390a032; SMITH DB, 1988, MOL BIOCHEM PARASIT, V27, P249, DOI 10.1016/0166-6851(88)90044-8; Takakuwa T, 1985, ANAL SCI, V1, P215, DOI DOI 10.2116/ANALSCI.1.215; VANCE VB, 1987, J BIOL CHEM, V262, P11275; YANG JT, 1986, METHOD ENZYMOL, V130, P208; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505; ZHENG Z, 1992, BIOCHEMISTRY-US, V31, P4426, DOI 10.1021/bi00133a006	46	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17504	17512						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8102367				2022-12-27	WOS:A1993LQ98800090
J	KLOCKNER, U; STORCK, T; CONRADT, M; STOFFEL, W				KLOCKNER, U; STORCK, T; CONRADT, M; STOFFEL, W			ELECTROGENIC L-GLUTAMATE UPTAKE IN XENOPUS-LAEVIS OOCYTES EXPRESSING A CLONED RAT-BRAIN L-GLUTAMATE L-ASPARTATE TRANSPORTER (GLAST-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLIAL-CELLS; NERVOUS-SYSTEM; SYNAPTOSOMES; MEMBRANE; RETINA	The transport of L-glutamate into Xenopus laevis oocytes expressing the cloned L-glutamate/L-aspartate transporter (GLAST-1) from rat brain was studied using the voltage clamp technique. At a holding potential of -90 mV, a bath application of 100 muM L-glutamate induced an inward current (I(GLAST)) with an amplitude ranging from -5 to -30 nA. I(GLAST) did not require extracellular Ca2+, Mg2+, or Cl-, was larger at negative potentials, and did not reverse up to +80 mV. The current was dependent on external L-glutamate and Na+ with half-maximal amplitudes at 11 muM L-glutamate and 41 mM Na+. I(GLAST) saturated at 100 muM L-glutamate and 80 mM Na+. The Hill coefficient for Na+ and L-glutamate was 3.3 and 1.3, respectively, suggesting that 3 Na+ accompany the transport of 1 L-glutamate molecule. At low [Na+]o, I(GLAST) was enhanced by reducing [K+]o, an indication for the countertransport of K+. Reducing external pH from 7.4 to 6.0 did not change the amplitude of I(GLAST). This argues against a glutamate/proton cotransport. The results provide evidence for GLAST-1 carrying out a high affinity, sodium-dependent L-glutamate transport with a proposed stoichiometry of 3 Na+, 1 L-glutamate-/1 K+.	UNIV COLOGNE, FAC MED, INST BIOCHEM, JOSEPH STELZMANN STR 52, W-5000 COLOGNE 41, GERMANY; UNIV COLOGNE, DEPT PHYSIOL, W-5000 COLOGNE, GERMANY	University of Cologne; University of Cologne								BALCAR VJ, 1972, J NEUROCHEM, V19, P2657, DOI 10.1111/j.1471-4159.1972.tb01325.x; BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; BENNETT JP, 1973, J NEUROCHEM, V21, P1533, DOI 10.1111/j.1471-4159.1973.tb06037.x; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; ERECINSKA M, 1983, J BIOL CHEM, V258, P9069; FLOTT B, 1991, GLIA, V4, P293, DOI 10.1002/glia.440040307; GAZZOLA GC, 1981, J BIOL CHEM, V256, P6064; GORDON RD, 1983, J NEUROCHEM, V40, P1090, DOI 10.1111/j.1471-4159.1983.tb08097.x; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V114, P62; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; SCHWARTZ EA, 1990, J PHYSIOL-LONDON, V426, P43, DOI 10.1113/jphysiol.1990.sp018126; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; WANIEWSKI RA, 1984, J NEUROSCI, V4, P2237	20	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14594	14596						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8100815				2022-12-27	WOS:A1993LL75900012
J	CAPRIOGLIO, DR; PADILLA, C; WERNERWASHBURNE, M				CAPRIOGLIO, DR; PADILLA, C; WERNERWASHBURNE, M			ISOLATION AND CHARACTERIZATION OF AAP1 - A GENE ENCODING AN ALANINE ARGININE AMINOPEPTIDASE IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; SACCHAROMYCES-CEREVISIAE; NUTRIENT LIMITATION; MOLECULAR-CLONING; ESCHERICHIA-COLI; HOST STRAINS; PROTEIN; VECTORS; GROWTH; CDNA	The yeast AAP1 gene, encoding a putative aminopeptidase, was isolated based on its ability to suppress the temperature-sensitive growth on nonfermentable carbon sources of spr5, a stationary phase regulatory mutant. AAP1 was physically mapped to chromosome VIII between PUT2 and CUP1. Sequence analysis of the AAP1 gene showed a 1581-nucleotide open reading frame capable of encoding a 59-kilodalton protein. The protein encoded by this open reading frame exhibits approximately 40% sequence identity to human, rat, and mouse aminopeptidases. In limited regions, sequence identity between Aap1 and the mammalian aminopeptidases ranges from 53% to 93%. Insertional inactivation of the AAP1 gene resulted in a decrease in glycogen accumulation and the loss of the major band of arginine/alanine aminopeptidase activity. Strains carrying the AAP1 gene on a high copy plasmid show an increase in the major arginine/alanine aminopeptidase activity, a dramatic increase in glycogen accumulation, and an increase in transcription from a vector carrying lacZ fused to the promoter of a gene (SSA3) expressed during post-diauxic and stationary phases of the culture cycle. We conclude that although the AAP1 gene is not essential for viability, the Aap1 protein positively affects glycogen accumulation in yeast.	UNIV NEW MEXICO,DEPT BIOL,ALBUQUERQUE,NM 87131	University of New Mexico								ACHSTETTER T, 1983, ARCH BIOCHEM BIOPHYS, V226, P292, DOI 10.1016/0003-9861(83)90296-5; ALGERI AA, 1981, GENETICS, V97, P27; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BALLY M, 1984, MOL GEN GENET, V195, P507, DOI 10.1007/BF00341454; Bollag D.M., 1991, PROTEIN METHODS, P143; BOORSTEIN WR, 1990, MOL CELL BIOL, V10, P3262, DOI 10.1128/MCB.10.6.3262; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; CHANG SYP, 1989, J BACTERIOL, V171, P4071, DOI 10.1128/jb.171.7.4071-4072.1989; CHANG YH, 1992, J BIOL CHEM, V267, P8007; CUEVA R, 1989, FEBS LETT, V259, P125, DOI 10.1016/0014-5793(89)81510-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P397; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; Fourney R.M., 1988, FOCUS, V10, P5; FUNK CD, 1987, P NATL ACAD SCI USA, V84, P6677, DOI 10.1073/pnas.84.19.6677; GARCIAALVAREZ N, 1991, EUR J BIOCHEM, V202, P993, DOI 10.1111/j.1432-1033.1991.tb16461.x; GONDA DK, 1989, J BIOL CHEM, V264, P16700; HIRSCH HH, 1988, EUR J BIOCHEM, V173, P589, DOI 10.1111/j.1432-1033.1988.tb14040.x; Hirsch HH., 1989, MOL CELL BIOL YEASTS, P134; JONES EW, 1984, ANNU REV GENET, V18, P233, DOI 10.1146/annurev.ge.18.120184.001313; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KESTER WR, 1977, J BIOL CHEM, V252, P7704; LAGOSKY PA, 1987, NUCLEIC ACIDS RES, V15, P10355, DOI 10.1093/nar/15.24.10355; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; Maniatis T., 1982, MOL CLONING; NAYSMYTH KA, 1980, CELL, V19, P753; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; REYNOLDS A, 1992, CURRENT PROTOCOLS MO, V2; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SIKORSKI RS, 1989, GENETICS, V122, P19; TATCHELL K, 1985, P NATL ACAD SCI USA, V82, P3785, DOI 10.1073/pnas.82.11.3785; THOMPSONJAEGER S, 1991, GENETICS, V129, P697; WATT VM, 1989, J BIOL CHEM, V264, P5480; WERNERWASHBURNE M, 1989, J BACTERIOL, V171, P2680, DOI 10.1128/jb.171.5.2680-2688.1989; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568; WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; [No title captured]	40	24	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14310	14315						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8100228				2022-12-27	WOS:A1993LJ82500077
J	KIDO, H; KAMOSHITA, K; FUKUTOMI, A; KATUNUMA, N				KIDO, H; KAMOSHITA, K; FUKUTOMI, A; KATUNUMA, N			PROCESSING PROTEASE FOR GP160 HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-I ENVELOPE GLYCOPROTEIN PRECURSOR IN HUMAN T4+ LYMPHOCYTES - PURIFICATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CELL-LINES; ENDOPROTEOLYTIC CLEAVAGE; PROHORMONE; ENZYME; RETROVIRUS; RECEPTOR; HIV-1; ACID; SITE; IDENTIFICATION	A processing protease for the human immunodeficiency virus type I (HIV-I) envelope glycoprotein gp160 precursor has been purified to homogeneity from the post-nuclear membrane fraction of a human T4+ lymphocyte clone. Most of the processing activity was found to be present in the fractions of endoplasmic reticulum and Golgi apparatus of the cells. The purified enzyme has a monomeric structure with a molecular mass of 26 +/- 3 kDa, as judged by gel-permeation liquid chromatography and sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing and nonreducing conditions. The purified enzyme converted gp160 to gp120 and gp41, showing a pH optimum of 6.5-7.0. Direct amino acid sequencing of the amino terminus of the product gp41 revealed that the cleavage site of gp160 was between Arg511 and Ala512. The enzyme activity was inhibited by trypsin-type protease inhibitors, but was not affected by CaCl2, MgCl2 or chelating agents. The properties of the purified enzyme are clearly distinct from those of processing proteases reported previously. Although the significance of the enzyme in vivo is not currently certain, judging from its cleavage specificity and subcellular localization, this endopeptidase appears to be a processing enzyme for the human immunodeficiency virus type I gp160 precursor protein in human T cells.			KIDO, H (corresponding author), UNIV TOKUSHIMA, INST ENZYME RES, DIV ENZYME CHEM, TOKUSHIMA 770, JAPAN.							BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BEDGOOD RM, 1992, J BIOL CHEM, V267, P7060; BENTLEY AK, 1986, CELL, V45, P343, DOI 10.1016/0092-8674(86)90319-3; BRENNAN SO, 1990, J BIOL CHEM, V265, P21494; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; CROMLISH JA, 1986, J BIOL CHEM, V261, P850; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; ESTIVARIZ FE, 1992, J BIOL CHEM, V267, P7456; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GUO HG, 1990, VIROLOGY, V174, P217, DOI 10.1016/0042-6822(90)90070-8; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; KAWABATA S, 1992, J BIOL CHEM, V267, P10331; KIDO H, 1990, J BIOL CHEM, V265, P21979; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KIKUKAWA R, 1986, J VIROL, V57, P1159, DOI 10.1128/JVI.57.3.1159-1162.1986; KIM WS, 1990, J BIOL CHEM, V265, P5930; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOGA Y, 1990, J IMMUNOL, V144, P94; KOGA Y, 1990, J VIROL, V64, P4661, DOI 10.1128/JVI.64.10.4661-4671.1990; KORNER J, 1991, P NATL ACAD SCI USA, V88, P11393, DOI 10.1073/pnas.88.24.11393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNMARK A, 1976, J CELL BIOL, V71, P606, DOI 10.1083/jcb.71.2.606; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MILSOM DW, 1972, BIOCHEM J, V128, P331, DOI 10.1042/bj1280331; MIZUNO K, 1989, BIOCHEM BIOPH RES CO, V159, P305, DOI 10.1016/0006-291X(89)92438-8; MORRE DJ, 1971, METHOD ENZYMOL, V22, P130; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; PEREZ LG, 1987, J VIROL, V61, P1609, DOI 10.1128/JVI.61.5.1609-1614.1987; SHINAGAWA T, 1990, P NATL ACAD SCI USA, V87, P1927, DOI 10.1073/pnas.87.5.1927; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEIN BS, 1990, J BIOL CHEM, V265, P2640; Strobel H W, 1978, Methods Enzymol, V52, P89; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223; Wharton DC., 1967, METHOD ENZYMOL, P245; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; YOSHIMASA Y, 1990, J BIOL CHEM, V265, P17230	41	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13406	13413						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8099909				2022-12-27	WOS:A1993LH55300057
J	CHARPENTIER, N; PREZEAU, L; CARRETTE, J; BERTORELLI, R; LECAM, G; MANZONI, O; BOCKAERT, J; HOMBURGER, V				CHARPENTIER, N; PREZEAU, L; CARRETTE, J; BERTORELLI, R; LECAM, G; MANZONI, O; BOCKAERT, J; HOMBURGER, V			TRANSFECTED G01-ALPHA INHIBITS THE CALCIUM-DEPENDENCE OF BETA-ADRENERGIC STIMULATED CAMP ACCUMULATION IN C6 GLIOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GLIAL TUMOR-CELLS; ADENYLATE-CYCLASE; GAMMA-SUBUNITS; ALPHA-SUBUNIT; CYCLIC-AMP; RAT; GO; MECHANISM; BRAIN	Increasing evidence indicates that heterotrimeric G proteins, and in particular G(o), regulate ionic channel activities. In order to investigate the role of G(o) proteins in the modulation of the Ca2+ influx, C6 glioma cells were stably transfected with alpha(o1) cDNA. Expression of the G(o1)alpha protein was checked by Bordetella pertussis toxin-catalyzed ADP-ribosylation and Western blots using one- and two-dimensional gel analyses. Three clones were selected based on their degree of G(o1)alpha expression. In alpha(o1)-transfected cells, cAMP accumulations, in response to isoproterenol or forskolin, were lower than in control cells. This inhibitory effect was a function of the amount of expressed G(o1)alpha. In contrast, G(o1)alpha expression was not followed by a significant inhibition of isoproterenol- or forskolin-stimulated adenylyl cyclase activities in particulate fractions. In C6 parental cells, 50-60% of the isoproterenol-induced cAMP accumulation was dependent on external Ca2+ concentration. This Ca2+-dependent cAMP accumulation was related to an induced transient Ca2+ influx. In transfected cells, expression of G(o1)alpha inhibited the Ca2+ influx and the Ca2+-dependent component of isoproterenol-induced cAMP accumulation. In conclusion, beta-adrenergic agonists stimulate an entry of Ca2+ which exerts a positive feedback on cAMP production, and G(o1)alpha blocks this positive feedback by inhibiting the Ca2+ influx.	CNRS,INSERM,RUE CARDONVILLE,F-34094 MONTPELLIER 5,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier			Manzoni, Olivier/M-7899-2016; bertorelli, rosalia/A-2989-2012	Manzoni, Olivier/0000-0002-5579-6208; BERTORELLI, Rosalia/0000-0002-7913-3564				ASANO T, 1988, J NEUROCHEM, V50, P1164, DOI 10.1111/j.1471-4159.1988.tb10588.x; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLOCH DB, 1989, MOL CELL BIOL, V9, P5434, DOI 10.1128/MCB.9.12.5434; BOCKAERT J, 1990, G PROTEINS, P81; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRABET P, 1988, J NEUROSCI, V8, P701; BRABET P, 1990, J NEUROCHEM, V54, P1310, DOI 10.1111/j.1471-4159.1990.tb01964.x; BRABET P, 1988, BIOCHEM BIOPH RES CO, V152, P1185, DOI 10.1016/S0006-291X(88)80410-8; BROSTROM MA, 1983, MOL PHARMACOL, V23, P399; BROSTROM MA, 1979, J BIOL CHEM, V254, P7548; BROWNING ET, 1974, MOL PHARMACOL, V12, P32; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P6111; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; CHEUNG WY, 1975, BIOCHEM BIOPH RES CO, V66, P1055, DOI 10.1016/0006-291X(75)90747-0; DOORE BJ, 1975, J BIOL CHEM, V250, P4371; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARRISWARRICK RM, 1988, NEURON, V1, P27, DOI 10.1016/0896-6273(88)90206-1; HOMBURGER V, 1980, J BIOL CHEM, V255, P436; HSU WH, 1990, J BIOL CHEM, V265, P11220; HUFF RM, 1986, J BIOL CHEM, V261, P1105; JONES DT, 1987, J BIOL CHEM, V262, P14241; KATADA T, 1987, J BIOL CHEM, V262, P11897; KATADA T, 1982, J BIOL CHEM, V257, P3739; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; LUCAS M, 1977, MOL PHARMACOL, V13, P314; MANZONI O, 1992, NEURON, V8, P653, DOI 10.1016/0896-6273(92)90087-T; MARES V, 1981, EXP NEUROL, V71, P154, DOI 10.1016/0014-4886(81)90078-9; MARIN P, 1991, J NEUROCHEM, V56, P1270, DOI 10.1111/j.1471-4159.1991.tb11421.x; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MURPHY PM, 1992, J BIOL CHEM, V267, P883; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NEER EJ, 1984, J BIOL CHEM, V259, P4222; OEY J, 1975, NATURE, V257, P317, DOI 10.1038/257317a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ROUOT B, 1992, MOL PHARMACOL, V41, P273; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SHIMIZU H, 1969, J NEUROCHEM, V16, P1609, DOI 10.1111/j.1471-4159.1969.tb10360.x; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; TSUKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P2974, DOI 10.1073/pnas.88.8.2974; VANDONGEN AMJ, 1988, SCIENCE, V242, P1433, DOI 10.1126/science.3144040; VITKOVIC L, 1988, P NATL ACAD SCI USA, V85, P8296, DOI 10.1073/pnas.85.21.8296; WEISS S, 1985, J NEUROCHEM, V45, P864; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4	51	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8980	8989						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8097196				2022-12-27	WOS:A1993KX81100087
J	MADDEN, MJ; MORROW, CS; NAKAGAWA, M; GOLDSMITH, ME; FAIRCHILD, CR; COWAN, KH				MADDEN, MJ; MORROW, CS; NAKAGAWA, M; GOLDSMITH, ME; FAIRCHILD, CR; COWAN, KH			IDENTIFICATION OF 5' AND 3' SEQUENCES INVOLVED IN THE REGULATION OF TRANSCRIPTION OF THE HUMAN MDR1 GENE INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; S-TRANSFERASE-PI; CELL-LINES; DRUG-RESISTANCE; FUNCTIONAL-ANALYSIS; GLYCOPROTEIN GENE; INITIATION SITE; OVARIAN-CANCER; DNA-SEQUENCES; HUMAN-TUMORS	The human mdr1 gene encodes a putative drug efflux pump (P-glycoprotein) whose overexpression is associated with the development of multidrug resistance (MDR). The promoter and 5'-flanking DNA of this gene were isolated from a human genomic DNA library and used to prepare a series of chloramphenicol acetyltransferase (CAT) fusion vectors under the transcriptional control of the mdr1 promoter (mdrCAT vectors). Transient transfection of these mdrCAT vectors produced CAT activities similar to those produced by transfection of CAT vectors containing viral promoters. The regulation of mdr1 expression was examined in two MDR tumor cell lines selected for resistance to doxorubicin and their corresponding parental cell lines. Although nuclear run-on analysis indicates that the expression of the mdr1 gene in these two MDR cell lines is regulated by transcriptional mechanisms, mdrCAT expression was not significantly increased in either of these lines relative to parental cells. Thus, the sequences involved in the transcriptional regulation in these cells are apparently not included in the constructs studied (-4741 to +286). Analyses of a series of deletion constructs show that the basal mdr1 promoter activity is encoded by sequences that span a region adjacent to the transcription start site (-134 to +286) and that sequences 3' to the start of mdr1 transcription are necessary for proper initiation of transcription in vivo. Structural and functional studies indicate that an initiator (Inr) sequence surrounding the major transcription start site governs accurate initiation of mdr1 transcription.	NCI,MED BRANCH,9000 ROCKVILLE PIKE,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BATES SE, 1989, MOL CELL BIOL, V9, P4337, DOI 10.1128/MCB.9.10.4337; BEAUPAIN D, 1990, NUCLEIC ACIDS RES, V18, P6509, DOI 10.1093/nar/18.22.6509; BELL DR, 1985, J CLIN ONCOL, V3, P311, DOI 10.1200/JCO.1985.3.3.311; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOURHIS J, 1989, CANCER RES, V49, P5062; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; BURT RK, 1988, J NATL CANCER I, V80, P1383, DOI 10.1093/jnci/80.17.1383; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CHAN HSL, 1990, J CLIN ONCOL, V8, P689, DOI 10.1200/JCO.1990.8.4.689; CHIN KV, 1990, J BIOL CHEM, V265, P221; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHIN KV, 1990, CELL GROWTH DIFFER, V1, P361; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; COHEN D, 1991, J BIOL CHEM, V266, P2239; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; CORNWELL MM, 1990, CELL GROWTH DIFFER, V1, P607; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DENISON MS, 1988, J BIOL CHEM, V263, P17221; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FAIRCHILD CR, 1990, MOL PHARMACOL, V37, P801; FAIRCHILD CR, 1987, P NATL ACAD SCI USA, V84, P7701, DOI 10.1073/pnas.84.21.7701; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; GERLACH JH, 1987, J CLIN ONCOL, V5, P1452, DOI 10.1200/JCO.1987.5.9.1452; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GOLDSMITH ME, 1983, P NATL ACAD SCI-BIOL, V80, P2318, DOI 10.1073/pnas.80.8.2318; GOLDSMITH ME, 1993, IN PRESS J BIOL CHEM; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOLDSTEIN LJ, 1990, J CLIN ONCOL, V8, P128, DOI 10.1200/JCO.1990.8.1.128; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GUILD BC, 1988, P NATL ACAD SCI USA, V85, P1595, DOI 10.1073/pnas.85.5.1595; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; HILL BT, 1990, J NATL CANCER I, V82, P607, DOI 10.1093/jnci/82.7.607; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KAKEHI Y, 1988, J UROLOGY, V139, P862, DOI 10.1016/S0022-5347(17)42663-2; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KOHNO K, 1990, J BIOL CHEM, V265, P19690; KOHNO K, 1989, BIOCHEM BIOPH RES CO, V165, P1415, DOI 10.1016/0006-291X(89)92761-7; LAI GM, 1991, INT J CANCER, V49, P696, DOI 10.1002/ijc.2910490512; LOUIE KG, 1986, BIOCHEM PHARMACOL, V35, P467, DOI 10.1016/0006-2952(86)90221-2; Maniatis T., 1982, MOL CLONING; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MICKLEY LA, 1989, J BIOL CHEM, V264, P18031; MORROW CS, 1989, GENE, V75, P3, DOI 10.1016/0378-1119(89)90377-6; MORROW CS, 1992, J BIOL CHEM, V267, P10544; MORROW CS, 1990, GENE, V88, P215, DOI 10.1016/0378-1119(90)90034-O; PELHAM H, 1985, TRENDS GENET, V1, P31, DOI 10.1016/0168-9525(85)90012-5; RAYMOND M, 1990, MOL CELL BIOL, V10, P6036, DOI 10.1128/MCB.10.11.6036; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TANIMURA H, 1992, BIOCHEM BIOPH RES CO, V183, P917, DOI 10.1016/0006-291X(92)90571-2; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; UEDA K, 1987, J BIOL CHEM, V262, P17432; UEDA K, 1987, J BIOL CHEM, V262, P505; UEDA K, 1989, JPN J CANCER RES, V80, P1127, DOI 10.1111/j.1349-7006.1989.tb02269.x; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629	69	92	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8290	8297						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8096520				2022-12-27	WOS:A1993KW97900102
J	BERGLER, H; WALLNER, P; EBELING, A; LEITINGER, B; FUCHSBICHLER, S; ASCHAUER, H; KOLLENZ, G; HOGENAUER, G; TURNOWSKY, F				BERGLER, H; WALLNER, P; EBELING, A; LEITINGER, B; FUCHSBICHLER, S; ASCHAUER, H; KOLLENZ, G; HOGENAUER, G; TURNOWSKY, F			PROTEIN ENVM IS THE NADH-DEPENDENT ENOYL-ACP REDUCTASE (FABI) OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SEQUENCE; GENE	The EnvM protein was purified from an overproducing Escherichia coli strain. It showed NADH-dependent enoyl-acyl carrier protein (ACP) reductase activity using both crotonyl-ACP and crotonyl-CoA as substrates. The protein bound a radioactive diazaborine derivative in the presence of NAD(+) and radioactive NAD(+) in the presence of the drug. Based on these data, it is concluded that EnvM is the NADH-dependent enoyl-ACP reductase (EC 1.3.1.9) of E. coli and we propose to rename the corresponding gene fabI.	GRAZ UNIV,INST MIKROBIOL,A-8010 GRAZ,AUSTRIA; GRAZ UNIV,INST ORGAN CHEM,A-8010 GRAZ,AUSTRIA; SANDOZ GMBH,FORSCHUNGSINST,A-1235 VIENNA,AUSTRIA	University of Graz; University of Graz; Novartis; Sandoz			Aschauer, Harald/G-8850-2016	Aschauer, Harald/0000-0002-4449-372X; Bergler, Helmut/0000-0002-7724-309X				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BANEYX F, 1991, J BACTERIOL, V173, P2696, DOI 10.1128/jb.173.8.2696-2703.1991; BERGLER H, 1992, J GEN MICROBIOL, V138, P2093, DOI 10.1099/00221287-138-10-2093; Borsche W, 1926, LIEBIGS ANN CHEM, V450, P75; BROWN HC, 1958, J AM CHEM SOC, V80, P5377, DOI 10.1021/ja01553a014; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; EGAN AF, 1973, GENET RES, V21, P139, DOI 10.1017/S001667230001332X; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GRASSBERGER MA, 1984, J MED CHEM, V27, P947, DOI 10.1021/jm00374a003; HUNKAPILLER MW, 1983, SCIENCE, V219, P650, DOI 10.1126/science.6687410; KATER MM, 1991, PLANT MOL BIOL, V17, P895, DOI 10.1007/BF00037070; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MULLER BW, 1978, HELV CHIM ACTA, V61, P325, DOI 10.1002/hlca.19780610128; SCHMID H, 1954, HELV CHIM ACTA, V37, P1706; SCHWEIZER M, 1986, MOL GEN GENET, V203, P479, DOI 10.1007/BF00422073; Shapiro R. H, 1976, ORG REACTIONS, V23, P405; TURNOWSKY F, 1989, J BACTERIOL, V171, P6555, DOI 10.1128/jb.171.12.6555-6565.1989; WEEKS G, 1968, J BIOL CHEM, V243, P1180	19	141	171	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5493	5496						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119879				2022-12-27	WOS:A1994MY84000004
J	CALA, SE; JONES, LR				CALA, SE; JONES, LR			GRP94 RESIDES WITHIN CARDIAC SARCOPLASMIC-RETICULUM VESICLES AND IS PHOSPHORYLATED BY CASEIN KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING GLYCOPROTEIN; MOLECULAR-WEIGHT PROTEINS; GLUCOSE-REGULATED PROTEIN; ENDOPLASMIC-RETICULUM; SKELETAL-MUSCLE; RYANODINE RECEPTOR; CALSEQUESTRIN; PURIFICATION; CLONING; SITE	Cardiac sarcoplasmic reticulum (SR) plays a dominant role in cellular Ca2+ homeostasis by storing and releasing Ca2+. SDS-polyacrylamide gel electrophoresis and Stains Ah staining reveals that at feast six Ca2+-binding proteins are contained in cardiac SR vesicles, five of which have now been identified. These five SR proteins comprise a set of high capacity Ca2+-binding proteins, localized to the SR lumen, that exhibit properties expected for physiological Ca2+ stores. In this study, we have purified and isolated cDNA clones for the sixth major Stains All blue-staining protein of dog cardiac SR and identified it as GRP94 (glucose-regulated protein, M(r) = 94,000). Previously, this prominent Ca2+-binding component has only been described in non-muscle endoplasmic reticulum. Cardiac GRP94 co-sedimented with cardiac SR vesicles and all previously described SR markers and was completely contained within the SR lumen. GRP94, like several other SR Ca2+-binding proteins, was a substrate for casein kinase II and was phosphorylated at two or more sites located near the two ends of the molecule. A low level of endogenous casein kinase II activity was found in crude preparations of cardiac SR but did not co-purify with SR vesicles after calcium oxalate loading, suggesting that casein kinase II phosphorylation in vivo occurs at a site other than the SB	INDIANA UNIV, SCH MED, KRANNERT INST CARDIOL, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	CALA, SE (corresponding author), INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028556, R01HL049428, R37HL049428] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49428, HL28556] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Cala S E, 1990, Semin Cell Biol, V1, P265; CALA SE, 1983, J BIOL CHEM, V258, P1932; CALA SE, 1993, J BIOL CHEM, V268, P2969; CALA SE, 1992, BIOCHIM BIOPHYS ACTA, V1118, P277, DOI 10.1016/0167-4838(92)90285-L; CALA SE, 1991, J BIOL CHEM, V266, P391; CALA SE, 1993, BIOPHYS J, V64, pA194; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1197; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; FLIEGEL L, 1990, J BIOL CHEM, V265, P15496; HOFMANN SL, 1989, J BIOL CHEM, V264, P18083; JONES LR, 1993, J BIOL CHEM, V268, P11486; JONES LR, 1979, J BIOL CHEM, V254, P530; JONES LR, 1981, J BIOL CHEM, V256, P1809; JONES LR, 1988, METHOD ENZYMOL, V157, P85; KANG HS, 1991, J BIOL CHEM, V266, P5643; KOCH G, 1986, J CELL SCI, V86, P217; KOCH GLE, 1987, J CELL SCI, V87, P491; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; KULOMAA MS, 1986, BIOCHEMISTRY-US, V25, P6244, DOI 10.1021/bi00368a061; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1989, P NATL ACAD SCI USA, V86, P6047, DOI 10.1073/pnas.86.16.6047; LEBERER E, 1990, J BIOL CHEM, V265, P10118; LEE A, 1987, TRENDS BIOCHEM SCI, V23, P20; LEWIS MJ, 1985, J BIOL CHEM, V260, P6926; LEWIS MJ, 1985, J BIOL CHEM, V260, P3050; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON J, 1992, HEART CARDIOVASCULAR, P1203; MACDOUGALL LK, 1991, EUR J BIOCHEM, V196, P725, DOI 10.1111/j.1432-1033.1991.tb15871.x; MacLennan D., 1983, CALCIUM CELL FUNCT, V4, P151; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; MAHONY L, 1986, J BIOL CHEM, V261, P5257; Maniatis T., 1982, MOL CLONING; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OSTWALD TJ, 1974, J BIOL CHEM, V249, P974; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RARDON DP, 1989, CIRC RES, V64, P779, DOI 10.1161/01.RES.64.4.779; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; SCOTT BT, 1988, J BIOL CHEM, V263, P8958; SEILER S, 1984, J BIOL CHEM, V259, P8550; SLUPSKY JR, 1987, BIOCHEMISTRY-US, V26, P6539, DOI 10.1021/bi00394a038; SORGER PK, 1987, J MOL BIOL, V194, P341, DOI 10.1016/0022-2836(87)90380-9; SUKO J, 1976, EUR J BIOCHEM, V64, P123, DOI 10.1111/j.1432-1033.1976.tb10280.x; VOLPE P, 1992, P NATL ACAD SCI USA, V89, P6142, DOI 10.1073/pnas.89.13.6142; VOLPE P, 1991, FEBS LETT, V278, P274, DOI 10.1016/0014-5793(91)80134-O; WADA I, 1991, J BIOL CHEM, V266, P19599; WITCHER DR, 1992, J BIOL CHEM, V267, P4963; WITCHER DR, 1991, J BIOL CHEM, V266, P11144	57	65	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5926	5931						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119936				2022-12-27	WOS:A1994MY84000069
J	LEI, BF; CHO, KW; TU, SC				LEI, BF; CHO, KW; TU, SC			MECHANISM OF ALDEHYDE INHIBITION OF VIBRIO-HARVEYI LUCIFERASE - IDENTIFICATION OF 2 ALDEHYDE SITES AND RELATIONSHIP BETWEEN ALDEHYDE AND FLAVIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL LUCIFERASE; DIRECTED MUTATION; SUBSTRATE	Vibrio harveyi luciferase is sensitive to aldehyde substrate inhibition, and two kinetic schemes have been previously postulated to account for such an inhibition, One scheme depicts a sequential binding of 2 aldehyde molecules, yielding an active enzyme-aldehyde binary complex and subsequently an inactive enzyme-(aldehyde)(2) ternary complex (Holzman, T. F., and Baldwin, T. O. (1983) Biochemistry 22, 2838-2846). This two-aldehyde model was later withdrawn, and recently, a different scheme was proposed, following which the prior binding of one aldehyde to the native luciferase farms an inactive dead-end complex (Abu-Soud, H. M., Clark, A. C., Francisco, W. A, Baldwin, T. O., and Raushel, F.M. (1993) J. Biol. Chem. 268, 7699-7706). In this work, kinetic and equilibrium studies were carried out to elucidate further the mechanism of aldehyde inhibition. Two, presumably independent, aldehyde-binding sites were detected, with a higher affinity site for the aldehyde substrate and a weaker affinity site for the aldehyde inhibitor. Binding to and dissociation from the inhibitor site by decanal were revealed by chemical relaxation analysis to be slow processes. Furthermore, whereas the binding of the decanal substrate enhances the affinity of the reduced riboflavin 5'-phosphate (FMNH(2)) site, the binding of decanal to the inhibitor site competes against FMNH(2) binding, thus resulting in inhibition of luciferase activity. These findings are not compatible with either of the two earlier schemes mentioned above. A new kinetic model is formulated for the mechanism of aldehyde inhibition. Theoretical kinetic behaviors predicted on the basis of this model are in excellent agreement with experimental observations. A particularly reactive cysteine (residue 106) on the alpha subunit has been previously demonstrated to be at or near an aldehyde site (Fried, A., and Tu, S.-C. (1984) J. Biol. Chem. 259, 10754-10759). Evidence is presented to indicate that this residue is at or near the aldehyde inhibitor site. Relative locations of this residue and binding sites for FMNH(2), the aldehyde substrate, and the aldehyde inhibitor are proposed.	UNIV HOUSTON,DEPT BIOCHEM & BIOPHYS SCI,HOUSTON,TX 77204; UNIV HOUSTON,DEPT CHEM,HOUSTON,TX 77204	University of Houston System; University of Houston; University of Houston System; University of Houston				Lei, Benfang Lei/0000-0001-8133-6021	NIGMS NIH HHS [GM25953] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025953] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1993, J BIOL CHEM, V268, P7699; BALDWIN TO, 1989, J BIOLUM CHEMILUM, V4, P40, DOI 10.1002/bio.1170040111; BALDWIN TO, 1992, CHEM BIOCH FLAVOENZY, P467; FRIED A, 1984, J BIOL CHEM, V259, P754; GAJIWALA KS, 1988, THESIS U TEXAS EL PA; GIBSON QH, 1962, BIOCHEM J, V83, P368, DOI 10.1042/bj0830368; HASTINGS JW, 1969, BIOCHEMISTRY-US, V8, P4681, DOI 10.1021/bi00840a004; HASTINGS JW, 1963, J OPT SOC AM, V53, P1410, DOI 10.1364/JOSA.53.001410; HASTINGS JW, 1963, J BIOL CHEM, V238, P2537; Hastings JW., 1978, METHOD ENZYMOL, V57, P135; HEMMERICH P, 1963, EXPERIENTIA, V19, P488, DOI 10.1007/BF02150666; HOLZMAN TF, 1981, BIOCHEMISTRY-US, V20, P5524, DOI 10.1021/bi00522a027; HOLZMAN TF, 1983, BIOCHEMISTRY-US, V22, P2838, DOI 10.1021/bi00281a011; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P532; Job P, 1928, ANN CHIM FRANCE, V9, P113; LEI BF, 1991, PHOTOCHEM PHOTOBIOL, V54, P473, DOI 10.1111/j.1751-1097.1991.tb02043.x; MEIGHEN EA, 1973, BIOCHEMISTRY-US, V12, P1482, DOI 10.1021/bi00732a003; NICOLI MZ, 1974, J BIOL CHEM, V249, P2385; PAQUATTE O, 1989, PHOTOCHEM PHOTOBIOL, V50, P817, DOI 10.1111/j.1751-1097.1989.tb02913.x; RAUSHEL FM, 1991, FLAVINS FLAVOPROTEIN, P281; SUNDBERG L, 1974, J CHROMATOGR, V90, P87, DOI 10.1016/S0021-9673(01)94777-6; TU SC, 1994, IN PRESS CRC HDB ORG; TU SC, 1991, ADV OXYGENATED PROCE, V3, P115; XI L, 1991, J BACTERIOL, V173, P1399, DOI 10.1128/jb.173.4.1399-1405.1991; XI L, 1990, J BIOL CHEM, V265, P4200; XIN X, 1991, BIOCHEMISTRY-US, V30, P11255, DOI 10.1021/bi00111a010	26	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5612	5618						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119897				2022-12-27	WOS:A1994MY84000024
J	MARUYAMA, K; MIYATA, K; YOSHIMURA, A				MARUYAMA, K; MIYATA, K; YOSHIMURA, A			PROLIFERATION AND ERYTHROID-DIFFERENTIATION THROUGH THE CYTOPLASMIC DOMAIN OF THE ERYTHROPOIETIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; SIGNAL TRANSDUCTION; LIGAND-BINDING; ACTIVATION; PHOSPHORYLATION; SUPERFAMILY; HORMONE; COMPLEX; PROTEIN	Interaction of erythropoietin (EPO) and its membrane receptor induces the proliferation and differentiation of erythroid progenitors. The molecular mechanism of the EPO receptor-mediated signal transduction remains unclear because the cloned EPO receptor does not contain any enzyme-related or nucleotide-binding consensus sequences in its cytoplasmic domain. We have previously shown that epidermal growth factor (EGF) induces dimerization of a chimeric receptor carrying the extracellular domain of the EGF receptor linked to the cytoplasmic domain of the EPO receptor, resulting in producing proliferation signals in interleukin-3-dependent cells. Here we show that this chimeric receptor transmits an EGF-dependent erythroid differentiation signal in the EPO-responsive erythroleukemia cell line, TSA8. EGF as well as EPO had little effect on the proliferation of TSA8 cells expressing the chimeric receptor, but both of them induced globin synthesis in these cells. Moreover, a truncated chimeric receptor carrying the membrane proximal 127 amino acids of the cytoplasmic domain of the EPO receptor linked to the extracellular domain of the EGF receptor conferred EGF-dependent proliferation on Ba/F3 cells and globin induction on TSA8 cells. These findings indicate that the membrane proximal region of the cytoplasmic domain of the EPO receptor is sufficient to produce both proliferation and differentiation signals if it is properly activated by receptor dimerization.	KAGOSHIMA UNIV, FAC MED, INST CANC RES, KAGOSHIMA 890, JAPAN; KAGOSHIMA UNIV, FAC MED, DEPT PEDIAT, KAGOSHIMA 890, JAPAN	Kagoshima University; Kagoshima University			Yoshimura, Akihiko/K-5515-2013					BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUH G, 1992, SCIENCE, V256, P1677; FUKUMOTO H, 1989, DEVELOPMENT, V105, P109; HARRIS KW, 1992, J BIOL CHEM, V267, P15205; JUBINSKY PT, 1993, BLOOD, V81, P587; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KRANTZ SB, 1991, BLOOD, V77, P419; MAYEUX P, 1991, J BIOL CHEM, V266, P23380; MUI ALF, 1992, P NATL ACAD SCI USA, V89, P10812, DOI 10.1073/pnas.89.22.10812; OHASHI H, 1993, IN PRESS P NATL ACAD; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; SHIBUYA T, 1983, P NATL ACAD SCI-BIOL, V80, P3721, DOI 10.1073/pnas.80.12.3721; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; YOSHIMURA A, 1992, J BIOL CHEM, V267, P11619; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	26	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5976	5980						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119943				2022-12-27	WOS:A1994MY84000077
J	REILLY, A; MORGAN, P; DAVIS, K; KELLY, SM; GREENE, J; ROWE, AJ; HARDING, SE; PRICE, NC; COGGINS, JR; KLEANTHOUS, C				REILLY, A; MORGAN, P; DAVIS, K; KELLY, SM; GREENE, J; ROWE, AJ; HARDING, SE; PRICE, NC; COGGINS, JR; KLEANTHOUS, C			PRODUCT-INDUCED STABILIZATION OF TERTIARY AND QUATERNARY STRUCTURE IN ESCHERICHIA-COLI DEHYDROQUINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The effects of irreversibly attaching product at the active site of type I dehydroquinase from Escherichia coli have been investigated at the level of the secondary, tertiary, and quaternary structure of the protein by spectroscopic and hydrodynamic techniques. The results agree with the previously identified stabilization of the enzyme but show for the first time that the protein dimer is also stabilized and suggest that the E. coli dehydroquinase subunit may be bilobal.	UNIV E ANGLIA, SCH BIOL SCI, NORWICH NR4 7TJ, NORFOLK, ENGLAND; UNIV NOTTINGHAM, DEPT APPL BIOCHEM & FOOD SCI, SUTTON LE12 5RD, LEICS, ENGLAND; UNIV STIRLING, DEPT BIOL & MOLEC SCI, STIRLING FK9 4LA, SCOTLAND; UNIV LEICESTER, DEPT BIOCHEM, LEICESTER LE1 7RH, ENGLAND; UNIV GLASGOW, DEPT BIOCHEM, GLASGOW G12 8QQ, SCOTLAND	University of East Anglia; University of Nottingham; University of Stirling; University of Leicester; University of Glasgow				Harding, Stephen E./0000-0002-7798-9692; Kelly, Sharon/0000-0002-3516-1387				BENTLEY R, 1990, CRIT REV BIOCHEM MOL, V25, P307, DOI 10.3109/10409239009090615; BOYS CWG, 1992, J MOL BIOL, V227, P352, DOI 10.1016/0022-2836(92)90704-N; CHAUDHURI S, 1987, METHOD ENZYMOL, V142, P320; CHAUDHURI S, 1991, BIOCHEM J, V275, P1; GILES NH, 1985, MICROBIOL REV, V49, P338, DOI 10.1128/MMBR.49.3.338-358.1985; HANSON KR, 1963, P NATL ACAD SCI USA, V50, P981, DOI 10.1073/pnas.50.5.981; HARRIS J, 1993, J CHEM SOC CHEM COMM, P1080, DOI 10.1039/c39930001080; KLEANTHOUS C, 1990, J BIOL CHEM, V265, P10929; KLEANTHOUS C, 1992, BIOCHEM J, V282, P687, DOI 10.1042/bj2820687; KLEANTHOUS C, 1991, J BIOL CHEM, V266, P10893; REILLY A, 1993, BIOORG MED CHEM LETT, V3, P1429, DOI 10.1016/S0960-894X(01)80424-8; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SHNEIER A, 1991, J AM CHEM SOC, V113, P9416, DOI 10.1021/ja00024a085; SHNEIER A, 1993, BIOORG MED CHEM LETT, V3, P1399, DOI 10.1016/S0960-894X(01)80419-4; VANHOLDE KE, 1985, PHYSICAL BIOCH, P117	15	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5523	5526						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119885				2022-12-27	WOS:A1994MY84000011
J	SCHRADER, M; MULLER, KM; CARLBERG, C				SCHRADER, M; MULLER, KM; CARLBERG, C			SPECIFICITY AND FLEXIBILITY OF VITAMIN-D SIGNALING - MODULATION OF THE ACTIVATION OF NATURAL VITAMIN-D RESPONSE ELEMENTS BY THYROID-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RETINOIC ACID; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; OSTEOCALCIN GENE; DNA-BINDING; SUPERFAMILY	Cellular responsiveness to 1,25-dihydroxyvitamin D-3 (VD) is conferred by its intracellular receptor (VDR), which belongs to the nuclear receptor superfamily of ligand-inducible transcription factors. VDRs are known to bind to specific response elements in the promoter region of VD-regulated genes. Two types of natural VD response elements (VDREs) have been identified so far. One is bound by VDR homodimers and is found in the human osteocalcin gene promoter (DR6-type), and the other is bound by heterodimers of VDR with retinoid X receptors (RXRs) as in the mouse osteopontin promoter (DR3-type). Here, we demonstrate that VDRs directly interact in solution not only with RXR but also with retinoid acid receptors (RARs) and, interestingly, with thyroid hormone receptors (T(3)Rs). All three heterodimeric partners were able to enhance the in vitro DNA binding affinity of MDR as compared to VDR homodimers, but they showed different affinities for the two types of VDREs, as determined by Scatchard analysis. Moreover, functional assays showed that VDR-T(3)R heterodimers act differently on the two types of VDREs; on the DR3-type we observed highest induction by thyroid hormone (3,5,3'-triiodothyronine, T-3) alone, whereas on a DRG-type VDRE VD and T-3 together provided maximal gene activity. Our data suggest that the expression levels of VDRs, RXRs, RARs, and T(3)Rs and their specific ligands regulate the transcription of VD-responsive genes and illustrates the complexity of this interactive network of nuclear receptors.	HOP CANTONAL UNIV,DERMATOL CLIN,CH-1211 GENEVA 14,SWITZERLAND	University of Geneva			Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				ALLAIN TJ, 1993, J ENDOCRINOL, V139, P9, DOI 10.1677/joe.0.1390009; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1993, BIOCHEM BIOPH RES CO, V195, P1345, DOI 10.1006/bbrc.1993.2191; DEGROOT LJ, 1993, ENDOCRINOLOGY, V133, P963, DOI 10.1210/en.133.3.963; DELUCA HF, 1990, KIDNEY INT, V38, pS2; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GREEN S, 1993, NATURE, V361, P590, DOI 10.1038/361590a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; NORMAN AW, 1992, J STEROID BIOCHEM, V41, P231, DOI 10.1016/0960-0760(92)90349-N; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; ROSS DS, 1991, J ENDOCRINOL INVEST, V14, P763, DOI 10.1007/BF03347911; ROSS TK, 1992, P NATL ACAD SCI USA, V89, P256, DOI 10.1073/pnas.89.1.256; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; SCHRADER M, 1993, NUCLEIC ACIDS RES, V21, P1231, DOI 10.1093/nar/21.5.1231; SONE T, 1991, MOL ENDOCRINOL, V5, P1578, DOI 10.1210/mend-5-11-1578; SUGAWARA A, 1993, ENDOCRINOLOGY, V133, P965, DOI 10.1210/en.133.3.965; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	28	111	111	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5501	5504						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119880				2022-12-27	WOS:A1994MY84000006
J	DEANS, DA; KASAMATSU, H				DEANS, DA; KASAMATSU, H			SIGNAL-DEPENDENT AND ENERGY-DEPENDENT NUCLEAR TRANSPORT OF SV40 VP3 BY ISOLATED-NUCLEI - ESTABLISHMENT OF A FILTRATION ASSAY FOR NUCLEAR-PROTEIN IMPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER NUCLEI; PORE COMPLEX; T-ANTIGEN; NUCLEOCYTOPLASMIC TRANSPORT; ENVELOPE VESICLES; 2 STEPS; BINDING; TRANSLOCATION; INVITRO; CYTOPLASM	Nuclear transport signal (NTS)-containing proteins are transported into the nucleus through the nuclear pore complex by a mechanism that is not well understood. To better characterize the mechanisms of transport, we have established an homologous in vitro system using an NTS-containing structural protein of simian virus 40 (SV40) and isolated nuclei from cultured cells of its natural host. Isolated nuclei accumulated either fluorescently labeled SV40 Vp3-NTS peptide-BSA conjugates (NTSwt-BSA), as assayed cytochemically, or I-125-NTSwt-BSA, as assayed by filtration, in a signal- and ATP-dependent manner. Nuclear accumulation required nuclear membrane integrity and was inhibited by the lectin wheat germ agglutinin but not concanavalin A. Unlike several other systems, this system is not dependent on cytoplasmic extracts for the transport of SV40 proteins. NTSwt-BSA was transported with an apparent K-m of 0.8 mu m and V-max of 0.8 nmol/min/10(8) nuclei. Thin section autoradiography confirmed the transport. This system faithfully reproduced what occurs in vivo: nuclear import of the SV40 capsid protein Vp3 was dependent on the presence of its functional NTS. Full-length Vp3, expressed as a glutathione S-transferase fusion protein, and a deletion mutant which retains its NTS, Vp3 Delta C13, were transported by the nuclei but Vp3 Delta C35, which lacks the NTS, and an NTS mutant, VP3(202E/204T), were not transported.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	DEANS, DA (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024, USA.				NATIONAL CANCER INSTITUTE [R01CA050574] Funding Source: NIH RePORTER; NCI NIH HHS [CA50574, CA09148] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; AKEY CW, 1990, BIOPHYS J, V58, P341, DOI 10.1016/S0006-3495(90)82381-X; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CLEVER J, 1993, J BIOL CHEM, V268, P20877; CLEVER J, 1991, P NATL ACAD SCI USA, V88, P7333, DOI 10.1073/pnas.88.16.7333; CLEVER J, 1991, VIROLOGY, V181, P78, DOI 10.1016/0042-6822(91)90472-N; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; GHARAKHANIAN E, 1987, VIROLOGY, V157, P440, DOI 10.1016/0042-6822(87)90286-8; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; IMAMOTOSONOBE N, 1988, P NATL ACAD SCI USA, V85, P3426, DOI 10.1073/pnas.85.10.3426; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MARKLAND W, 1987, MOL CELL BIOL, V7, P4255, DOI 10.1128/MCB.7.12.4255; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MICHAUD N, 1992, J CELL BIOL, V116, P851, DOI 10.1083/jcb.116.4.851; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; NEWMEYER DD, 1986, J CELL BIOL, V103, P2091, DOI 10.1083/jcb.103.6.2091; NEWMEYER DD, 1990, J CELL BIOL, V110, P547, DOI 10.1083/jcb.110.3.547; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIEDEL N, 1987, BIOCHEM J, V241, P213, DOI 10.1042/bj2410213; RIEDEL N, 1987, BIOCHEM J, V241, P203, DOI 10.1042/bj2410203; SEGARINI PR, 1983, J CELL PHYSIOL, V116, P311, DOI 10.1002/jcp.1041160308; TOOZE J, 1980, MOL BIOL TUMOR VIRUS; Worthington CC, 1988, WORTHINGTON MANUAL; YAMADA M, 1993, J VIROL, V67, P119, DOI 10.1128/JVI.67.1.119-130.1993	41	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4910	4916						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106464				2022-12-27	WOS:A1994MX57100035
J	HAPAK, RC; ZHAO, HM; BOSCHI, JM; HENZL, MT				HAPAK, RC; ZHAO, HM; BOSCHI, JM; HENZL, MT			NOVEL AVIAN THYMIC PARVALBUMIN DISPLAYS HIGH-DEGREE OF SEQUENCE HOMOLOGY TO ONCOMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; AMINO-ACID-SEQUENCE; FULL LENGTH CDNA; MUSCLE PARVALBUMIN; RAT ONCOMODULIN; XENOPUS-LAEVIS; CHICKEN MUSCLE; MESSENGER-RNA; HORMONE; GENE	CPV3 is a novel avian parvalbumin. It displays an isoelectric point of 4.6, intermediate between that of avian thymic hormone (pI = 4.3) and the muscle parvalbumin isoform (pI = 5.2). Expression of CPV3, like that of avian thymic hormone (ATH), is restricted to the thymic stroma, However, the CPV3 content of chicken thymus tissue (120 mu g/g tissue) is 4 times lower than that of ATH (500 mu g/g tissue). The polymerase chain reaction (PCR) was used to gain access to the nucleotide sequence of CPV3. A 147-base pair fragment of the coding sequence, corresponding to residues 48-97, was amplified from total chicken cDNA using degenerate PCR primers. A RACE-PCR strategy was then used to extend the known sequence in both the 5' and 3' directions. The cDNA sequence thus obtained includes 671 base pairs. Primer extension analysis suggests that the cloned cDNA corresponds to a full-length transcript. Northern analysis of chicken mRNA indicates that the average CPV3 transcript is approximately 800 nucleotides in length, significantly smaller than the ATH message (approximately 1000 nucleotides). Southern analysis suggests the presence of a single CPV3 gene in the chicken genome. The translated nucleotide sequence, displaying 108 residues between the initiator and termination codons, is that of a beta-parvalbumin. The CPV3 sequence exhibits 58% identity with ATH and 52% identity with the chicken muscle isoform. Interestingly, CPV3 and the mammalian oncodevelopmental parvalbumin called oncomodulin are identical at 73 of 108 residues (68% identity). Correspondingly, now-dialysis measurements with Ca-45(2+) indicate that the Ca2+-binding domains are inequivalent, as in oncomodulin. The apparent dissociation constants, at pH 7.4 in 150 mM NaCl, are approximately 10 nM and 80 nM.	UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65211	University of Missouri System; University of Missouri Columbia								AHMED FR, 1990, J MOL BIOL, V216, P127, DOI 10.1016/S0022-2836(05)80065-8; BANVILLE D, 1989, J MOL BIOL, V207, P481, DOI 10.1016/0022-2836(89)90458-0; Berchtold M W, 1989, Adv Exp Med Biol, V255, P251; BERCHTOLD MW, 1987, J BIOL CHEM, V262, P8696; BERCHTOLD MW, 1984, J BIOL CHEM, V259, P5189; BERCHTOLD MW, 1982, BIOCHEMISTRY-US, V21, P6552, DOI 10.1021/bi00268a035; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER JM, 1990, BIOCHIMIE, V72, P653, DOI 10.1016/0300-9084(90)90047-K; BREWER JM, 1989, BIOCHEM BIOPH RES CO, V160, P1155, DOI 10.1016/S0006-291X(89)80124-X; BREWER LM, 1987, PLACENTA, V8, P351, DOI 10.1016/0143-4004(87)90063-4; Bucy R P, 1991, Semin Immunol, V3, P109; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; CLAYSHULTE TM, 1990, J BIOL CHEM, V265, P1800; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; COX JA, 1990, J BIOL CHEM, V265, P6633; EPSTEIN P, 1986, J BIOL CHEM, V261, P5886; FEINBERG A, 1982, ANAL BIOCHEM, V132, P6; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILLEN MF, 1988, CANCER LETT, V40, P151, DOI 10.1016/0304-3835(88)90005-5; GILLEN MF, 1987, J BIOL CHEM, V262, P5308; GILLIS JM, 1985, BIOCHIM BIOPHYS ACTA, V811, P97, DOI 10.1016/0304-4173(85)90016-3; GOODMAN M, 1979, J MOL EVOL, V13, P331, DOI 10.1007/BF01731373; GROSS E, 1962, J BIOL CHEM, V237, P1856; GURR SJ, 1991, PCR PRACTICAL APPROA, P153; HAIECH J, 1979, BIOCHEMISTRY-US, V18, P2752, DOI 10.1021/bi00580a010; HANER M, 1984, ANAL BIOCHEM, V138, P229, DOI 10.1016/0003-2697(84)90793-0; HAPAK RC, 1989, J BIOL CHEM, V264, P18751; HEIZMANN CW, 1979, J BIOL CHEM, V254, P4296; HEIZMANN CW, 1982, P NATL ACAD SCI-BIOL, V79, P7243, DOI 10.1073/pnas.79.23.7243; Heizmann CW, 1988, CALCIUM CALCIUM BIND, P93; HENZL MT, 1991, BIOCHEM BIOPH RES CO, V177, P881, DOI 10.1016/0006-291X(91)91872-A; KOBAYASHI T, 1991, NEUROSCI LETT, V131, P221, DOI 10.1016/0304-3940(91)90618-4; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; KUSTER T, 1991, BIOCHEMISTRY-US, V30, P8812, DOI 10.1021/bi00100a012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACMANUS JP, 1979, CANCER RES, V39, P3000; MACMANUS JP, 1983, CALCIUM CELL FUNCTIO, V4, P411; MAEDA N, 1984, MOL BIOL EVOL, V1, P473; Maniatis T., 1982, MOL CLONING; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; McPherson M.J., 1991, PCR PRACTICAL APPROA, P171; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P302; MURTHY KK, 1984, THYMUS, V6, P43; MURTHY KK, 1984, CHEM REGULATION IMMU, P481; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; PALMISANO WA, 1990, BIOCHEM BIOPH RES CO, V167, P1286, DOI 10.1016/0006-291X(90)90663-8; PALMISANO WA, 1991, ARCH BIOCHEM BIOPHYS, V285, P211, DOI 10.1016/0003-9861(91)90351-I; PALMISANO WA, 1990, J BIOL CHEM, V265, P14450; PALMISANO WA, 1991, BIOCHEM BIOPH RES CO, V176, P328, DOI 10.1016/0006-291X(91)90928-Z; PECHERE JF, 1971, BIOCHIM BIOPHYS ACTA, V236, P391, DOI 10.1016/0005-2795(71)90220-0; Perbal B., 1988, PRACTICAL GUIDE MOL; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SCHWARTZ LM, 1988, DEV BIOL, V128, P441, DOI 10.1016/0012-1606(88)90306-5; SERDA RE, 1991, J BIOL CHEM, V266, P7291; SIMONIDES WS, 1989, BIOCHIM BIOPHYS ACTA, V998, P137, DOI 10.1016/0167-4838(89)90265-3; STREHLER EE, 1977, FEBS LETT, V78, P127, DOI 10.1016/0014-5793(77)80289-5; SWAIN AL, 1989, J BIOL CHEM, V264, P16620; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREVINO CL, 1991, J BIOL CHEM, V266, P11301; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; Wnuk W., 1982, CALCIUM CELL FUNCTIO, V2, P243; [No title captured]	64	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5288	5296						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106513				2022-12-27	WOS:A1994MX57100090
J	CHANDRASEKARAN, S; TANZER, ML; GINIGER, MS				CHANDRASEKARAN, S; TANZER, ML; GINIGER, MS			CHARACTERIZATION OF OLIGOMANNOSIDE BINDING TO THE SURFACE OF MURINE MELANOMA-CELLS - POTENTIAL RELATIONSHIP TO OLIGOMANNOSIDE-INITIATED CELL SPREADING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; OLIGOSACCHARIDE RECOGNITION; EXTRACELLULAR-MATRIX; INTEGRIN EXPRESSION; LAMININ; PROTEIN; RECEPTOR; ADHESION; AFFINITY; LECTINS	The spreading of murine melanoma cells on unglycosylated laminin is initiated by soluble glycosylated laminins containing oligomannosides, or by mannan, and is inhibited by mannose (Chandrasekaran, S., Tanzer, M. L., and Giniger, M. S. (1994) J. BioL Chem. 269, 3356-3366). In the present study, melanoma cell recognition of oligomannosides was explored by several different methods. Comparison of cell spreading, initiated by related branched oligomannosides, showed that micromolar concentrations of Man6 and Man9 were able to restore cell spreading maximally, whereas Man3 was ineffective. Man9 bound to the melanoma cells in a bimodal manner at micromolar concentrations, reaching saturation, whereas Man3 showed linear binding in the same and higher ranges. Comparison of Man9 binding with Man9-initiated cell spreading demonstrated that maximal spreading occurred at approximately half-saturation. Competition experiments showed that mannose or mannan effectively impaired Man9 binding to the cells, whereas galactose or fucose was ineffective. Mannan-conjugated fluorescent beads bound in a diffuse pattern to the surface of melanoma cells, whereas underivatized beads did not bind. The distribution of laminin-binding beta1 integrin on the cell surface was compared with surface mannan binding. The beta1 integrin staining pattern did not match the mannan staining pattern either in attached, nonspread cells or in attached, spread cells. The composite results support a model in which occupancy of both an integrin and a cell surface lectin is required for murine melanoma cells to spread on glycosylated laminin.	UNIV CONNECTICUT, CTR HLTH, SCH DENT MED, DEPT BIOSTRUCT & FUNCT, FARMINGTON, CT 06030 USA	University of Connecticut					NIAMS NIH HHS [AR-17220] Funding Source: Medline; NIDCR NIH HHS [DE-00157] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR017220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K16DE000157] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; ARUMUGHAM RG, 1986, BIOCHIM BIOPHYS ACTA, V883, P112, DOI 10.1016/0304-4165(86)90142-X; AUMAILLEY M, 1987, J BIOL CHEM, V262, P11532; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BEGOVAC PC, 1990, J CELL BIOL, V110, P461, DOI 10.1083/jcb.110.2.461; BRAY D, 1992, CELL MOVEMENTS, P102; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHAMMAS R, 1993, P NATL ACAD SCI USA, V90, P1795, DOI 10.1073/pnas.90.5.1795; CHAMMAS R, 1991, J BIOL CHEM, V266, P3349; CHANDRASEKARAN S, 1991, J CELL BIOCHEM, V46, P115, DOI 10.1002/jcb.240460205; CHANDRASEKARAN S, 1994, J BIOL CHEM, V269, P3356; CHILDS RA, 1989, BIOCHEM J, V262, P131, DOI 10.1042/bj2620131; DEAN JW, 1988, BIOCHEM BIOPH RES CO, V156, P411, DOI 10.1016/S0006-291X(88)80856-8; DEAN JW, 1990, J BIOL CHEM, V265, P12553; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FUJIWARA S, 1988, BIOCHEM J, V252, P453, DOI 10.1042/bj2520453; GEHLSEN KR, 1992, CLIN EXP METASTAS, V10, P111, DOI 10.1007/BF00114587; GINGELL D, 1993, SYM SOC EXP BIOL, V47, P1; HEMLER ME, 1992, COLD SPRING HARB SYM, V57, P213, DOI 10.1101/SQB.1992.057.01.026; HYNES RO, 1992, COLD SPRING HARB SYM, V57, P249, DOI 10.1101/SQB.1992.057.01.030; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KNIBBS RN, 1989, BIOCHEMISTRY-US, V28, P6379, DOI 10.1021/bi00441a034; KRAMER RH, 1991, CANCER METAST REV, V10, P49, DOI 10.1007/BF00046843; MECHAM RP, 1991, J CELL BIOL, V113, P187, DOI 10.1083/jcb.113.1.187; MORITA A, 1985, BIOCHEM J, V229, P259, DOI 10.1042/bj2290259; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; QUN Z, 1993, ARCH BIOCHEM BIOPHYS, V300, P6, DOI 10.1006/abbi.1993.1002; ROBERTS DD, 1985, P NATL ACAD SCI USA, V82, P1306, DOI 10.1073/pnas.82.5.1306; SKUBITZ APN, 1988, J BIOL CHEM, V263, P4861; STAHL PD, 1984, BIOL CELL, V51, P215, DOI 10.1111/j.1768-322X.1984.tb00301.x; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WOO HJ, 1990, J BIOL CHEM, V265, P7097; YAMAGUCHI M, 1992, J BIOL CHEM, V267, P22035; YEDNOCK TA, 1987, J CELL BIOL, V104, P713, DOI 10.1083/jcb.104.3.713	36	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3367	3373						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106376				2022-12-27	WOS:A1994MV63100038
J	KIM, SJ; PARK, K; RUDKIN, BB; DEY, BR; SPORN, MB; ROBERTS, AB				KIM, SJ; PARK, K; RUDKIN, BB; DEY, BR; SPORN, MB; ROBERTS, AB			NERVE GROWTH-FACTOR INDUCES TRANSCRIPTION OF TRANSFORMING GROWTH-FACTOR-BETA-1 THROUGH A SPECIFIC PROMOTER ELEMENT IN PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; FACTOR-BETA; TRANSACTIVATION; DIFFERENTIATION; IDENTIFICATION; REPRESSION; E1A; FOS; WT1	Nerve growth factor (NGF) stimulates the differentiation of PC12 pheochromocytoma cells to those resembling sympathetic neurons. We have investigated whether NGF regulates transforming growth factor (TGF)-beta gene expression and protein secretion in PC12 cells. These cells constitutively express TGF-beta1 mRNA, whereas TGF-beta2 and -beta3 mRNAs are expressed at very low levels. TGF-beta1 gene expression was stimulated greater than 10-fold when PC12 cells were treated with NGF. Sequences between -119 and -98 in the TGF-beta1 promoter, homologous to an Egr-1 binding site, were shown to be important for both basal and NGF-induced promoter activity. We also found that a factor(s) present in nuclear extracts from PC12 cells interacted with the sequences between -119 and -98 and that expression of this factor was induced by NGF treatment. Moreover, specific binding to TGF-beta1 promoter fragments between -119 and -98 was seen using the bacterially expressed transcription factor Egr-1. These results indicate that activation of TGF-beta1 expression is one of the cellular responses of PC12 cells to NGF and suggest that TGF-beta may play a role in the differentiation of sympathetic neurons.	NICHHD,GROWTH FACTORS SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	KIM, SJ (corresponding author), NCI,CHEMOPREVENT LAB,BLDG 41,RM C629,BETHESDA,MD 20892, USA.			RUDKIN, Brian B./0000-0003-3700-1982				BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; Danielpour D, 1989, GROWTH FACTORS, V2, P61, DOI 10.3109/08977198909069082; Denhez F, 1990, GROWTH FACTORS, V3, P139, DOI 10.3109/08977199009108276; DICKSON G, 1986, EMBO J, V5, P3449, DOI 10.1002/j.1460-2075.1986.tb04668.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FEIGE JJ, 1987, J BIOL CHEM, V262, P13491; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; GILARDI P, 1984, NUCLEIC ACIDS RES, V12, P7877, DOI 10.1093/nar/12.20.7877; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HOTTA M, 1986, P NATL ACAD SCI USA, V83, P7795, DOI 10.1073/pnas.83.20.7795; KIM SJ, 1992, J BIOL CHEM, V267, P13702; KIM SJ, 1989, J BIOL CHEM, V264, P402; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; LEVI-MONTALCINI RITA, 1966, HARVEY LECT, V60, P217; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Noma T, 1991, GROWTH FACTORS, V4, P247, DOI 10.3109/08977199109043910; OREILLY MA, 1992, J BIOL CHEM, V267, P19938; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; SING GK, 1990, CELL GROWTH DIFFER, V1, P511; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; WU BY, 1989, J BIOL CHEM, V264, P9000	35	87	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3739	3744						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106419				2022-12-27	WOS:A1994MV63100089
J	NIELSEN, VS; MANT, A; KNOETZEL, J; MOLLER, BL; ROBINSON, C				NIELSEN, VS; MANT, A; KNOETZEL, J; MOLLER, BL; ROBINSON, C			IMPORT OF BARLEY PHOTOSYSTEM-I SUBUNIT-N INTO THE THYLAKOID LUMEN IS MEDIATED BY A BIPARTITE PRESEQUENCE LACKING AN INTERMEDIATE PROCESSING SITE - ROLE OF THE DELTA-PH IN TRANSLOCATION ACROSS THE THYLAKOID MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; ESCHERICHIA-COLI; PRECURSOR PROTEIN; PEA-CHLOROPLASTS; PROTON GRADIENT; TRANSIT PEPTIDE; FULL PRECURSOR; TRANSPORT; REQUIREMENTS; PLASTOCYANIN	Translocation across the thylakoid membrane of the recently identified photosystem I polypeptide, PSI-N, has been analyzed in pea (Pisum sativum) and barley (Hordeum vulgare). PSI-N from barley is synthesized in the cytosol with a bipartite presequence similar in structural terms to those of other cytosolically synthesized proteins routed to the thylakoid lumen. In vitro reconstitution assays demonstrate that translocation into thylakoids is absolutely dependent on the trans-thylakoidal DELTApH, but that nucleotide triphosphates are not required; the translocation mechanism is thus similar in these respects to those utilized by the 23- and 16-kDa proteins of the oxygen-evolving complex. The translocation of PSI-N is unique in that the presequence of PSI-N does not contain an intermediate cleavage site for the stromal processing peptidase; import experiments using intact chloroplasts depleted of a DELTApH by nigericin treatment demonstrate the accumulation of the full precursor protein in the stroma. Translocation across the thylakoid membrane can take place in the absence of stromal factors, although the presence of stromal extracts leads to a consistent but slight enhancement of translocation efficiency. We also show that efficient translocation of the 33-kDa protein of the oxygen-evolving complex can take place in the complete absence of DELTApH, in apparent contradiction with earlier findings; the translocation of this protein is thus similar in several respects to that of plastocyanin. The data indicate the operation of two very different types of translocation mechanism, with PSI-N exhibiting additional separate characteristics.	UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND; UNIV BREMEN,INST CELL BIOL BIOCHEM & BIOTECHNOL,W-2833 BREMEN,GERMANY	University of Warwick; University of Bremen	NIELSEN, VS (corresponding author), ROYAL VET & AGR UNIV,DEPT PLANT BIOL,PLANT BIOCHEM LAB,40 THORVALDSENSVEJ,DK-1871 FREDERIKSBERG C,DENMARK.		Møller, Birger Lindberg/H-2657-2014; Møller, Birger Lindberg/GQI-1792-2022	Møller, Birger Lindberg/0000-0002-3252-3119; Møller, Birger Lindberg/0000-0002-3252-3119; Mant, Alexandra/0000-0001-7169-209X				BASSHAM DC, 1991, J BIOL CHEM, V266, P23606; BAUERLE C, 1991, J BIOL CHEM, V266, P5876; CLARK SE, 1991, J CELL BIOL, V114, P681, DOI 10.1083/jcb.114.4.681; CLINE K, 1992, J BIOL CHEM, V267, P2688; DAHLIN C, 1991, PLANT CELL, V3, P1131, DOI 10.1105/tpc.3.10.1131; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; HERRMANN RG, 1993, FEBS LETT, V326, P192, DOI 10.1016/0014-5793(93)81789-3; HOWE G, 1993, P NATL ACAD SCI USA, V90, P1862, DOI 10.1073/pnas.90.5.1862; JAMES HE, 1989, J BIOL CHEM, V264, P19573; KIRWIN PM, 1989, EMBO J, V8, P3917; KLOSGEN RB, 1992, PLANT MOL BIOL, V18, P1031, DOI 10.1007/BF00019226; KNOETZEL J, 1993, PLANT MOL BIOL, V22, P337, DOI 10.1007/BF00014940; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; KONISHI T, 1993, PLANT CELL PHYSIOL, V34, P315; KUWABARA T, 1987, P NATL ACAD SCI USA, V84, P8230, DOI 10.1073/pnas.84.23.8230; MEADOWS JW, 1991, PLANT MOL BIOL, V17, P1241, DOI 10.1007/BF00028739; MOULD RM, 1991, J BIOL CHEM, V266, P17286; MOULD RM, 1991, J BIOL CHEM, V266, P12189; MUSGROVE JE, 1989, PLANT PHYSIOL, V90, P1616, DOI 10.1104/pp.90.4.1616; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; ROBERTS LM, 1991, FEBS LETT, V293, P134, DOI 10.1016/0014-5793(91)81169-9; SEIDLER A, 1990, EMBO J, V9, P1743, DOI 10.1002/j.1460-2075.1990.tb08298.x; SHACKLETON JB, 1991, J BIOL CHEM, V266, P12152; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; THEG SM, 1989, J BIOL CHEM, V264, P6730; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535	28	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3762	3766						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106420				2022-12-27	WOS:A1994MV63100092
J	LI, R; NORTAMO, P; KANTOR, C; KOVANEN, P; TIMONEN, T; GAHMBERG, CG				LI, R; NORTAMO, P; KANTOR, C; KOVANEN, P; TIMONEN, T; GAHMBERG, CG			A LEUKOCYTE INTEGRIN BINDING PEPTIDE FROM INTERCELLULAR-ADHESION MOLECULE-2 STIMULATES T-CELL ADHESION AND NATURAL-KILLER-CELL ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FUNCTION-ASSOCIATED ANTIGEN-1; LARGE GRANULAR LYMPHOCYTES; MONOCLONAL-ANTIBODY; COUNTER-RECEPTOR; PHORBOL ESTER; COSTIMULATORY SIGNAL; BETA-SUBUNIT; CD11 CD18; LFA-1; ICAM-1	Adhesion is of pivotal importance for a number of leukocyte functions. Little is known about the binding between leukocyte integrins and the intercellular adhesion molecules (ICAMs). Normally integrins are nonadhesive, and require a stimulus to become active. We have now identified a peptide from ICAM-2, which binds to leukocyte integrins and activates adhesion. Furthermore, the peptide strongly increased the binding and cytotoxicity of natural killer cells. These findings show that adhesion-dependent leukocyte functions can be activated by ligand-derived peptides, and therefore provide evidence that the avidity of leukocyte integrins is up-regulated by integrin-ligand interactions.	UNIV HELSINKI,DEPT BIOCHEM,POB 5,UNIONINKATU 35,SF-00014 HELSINKI,FINLAND; UNIV HELSINKI,DEPT PATHOL,SF-00014 HELSINKI,FINLAND	Finland National Institute for Health & Welfare; University of Helsinki; University of Helsinki			Gahmberg, Carl/AAE-1876-2019	Gahmberg, Carl/0000-0001-9892-9296				ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARNAOUT MA, 1990, BLOOD, V75, P1037; ARNAOUT MA, 1990, IMMUNOL REV, V114, P145, DOI 10.1111/j.1600-065X.1990.tb00564.x; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BUYON JP, 1990, J IMMUNOL, V144, P1916; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; DAMLE NK, 1992, J IMMUNOL, V148, P665; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; HEDMAN H, 1992, J IMMUNOL, V149, P2295; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; JAASKELAINEN J, 1992, J IMMUNOL, V149, P260; KOOPMAN G, 1992, EUR J IMMUNOL, V22, P1851, DOI 10.1002/eji.1830220726; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LI R, 1993, J BIOL CHEM, V268, P17513; NORTAMO P, 1988, SCAND J IMMUNOL, V28, P537, DOI 10.1111/j.1365-3083.1988.tb01485.x; NORTAMO P, 1991, J IMMUNOL, V146, P2530; PATARROYO M, 1990, IMMUNOL REV, V114, P67, DOI 10.1111/j.1600-065X.1990.tb00562.x; PATARROYO M, 1985, SCAND J IMMUNOL, V22, P171, DOI 10.1111/j.1365-3083.1985.tb01869.x; PATARROYO M, 1987, FEBS LETT, V210, P127, DOI 10.1016/0014-5793(87)81321-2; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; TIMONEN T, 1981, J EXP MED, V153, P569, DOI 10.1084/jem.153.3.569; TIMONEN T, 1990, INT J CANCER, V46, P1035, DOI 10.1002/ijc.2910460615; TIMONEN T, 1988, J IMMUNOL, V141, P1041; VALMU L, 1991, EUR J IMMUNOL, V21, P2857, DOI 10.1002/eji.1830211130; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; WALLIS WJ, 1986, BLOOD, V67, P1007; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	40	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21474	21477						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8104939				2022-12-27	WOS:A1993MC80900006
J	COLLER, BS; SPRINGER, KT; SCUDDER, LE; KUTOK, JL; CERUSO, M; PRESTWICH, GD				COLLER, BS; SPRINGER, KT; SCUDDER, LE; KUTOK, JL; CERUSO, M; PRESTWICH, GD			SUBSTITUTING ISOSERINE FOR SERINE IN THE THROMBIN RECEPTOR ACTIVATION PEPTIDE SFLLRN CONFERS RESISTANCE TO AMINOPEPTIDASE-M-INDUCED CLEAVAGE AND INACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AGONIST PEPTIDES; PH-DEPENDENCE; MECHANISM	Peptides containing sequences derived from the new NH2 terminus of the seven-transmembrane domain thrombin receptor after thrombin cleavage can activate platelets directly. We recently demonstrated that such peptides are readily cleaved and inactivated by plasma, serum, and endothelial cell-associated aminopeptidase M. The rapid degradation and inactivation of the peptides makes it difficult to assess dose-response relationships precisely or to conduct long term incubations with cells in the presence of plasma or serum. To overcome these problems, we first substituted D-serine for the NH2-terminal L-serine in an active peptide ligand (SFLLRNPNDKY). The D-serine derivative resisted degradation in plasma, but it is less than 1% as active as the L-serine peptide. Substituting a racemic mixture of the beta-amino acid isoserine for serine in a related peptide ligand (SFLLRN) produced an active peptide ((iso-S)FLLRN) that is approximately 15-20% as potent as SFLLRN as judged by platelet aggregation. To assess the stability of the peptides in plasma, SFLLRN (1 mM) was incubated with 50% plasma for various periods of time; after 15 min, 65% of the peptide remained intact, and after 2 h only 4% remained intact. Loss of aggregating activity paralleled the loss of intact peptide. In contrast, even after 2 h of incubation with plasma, 83% of the (iso-S)FLLRN remained intact and the aggregating activity was essentially unchanged. Qualitative differences in the patterns of platelet aggregation produced by the peptides were also observed. Thus, the distinct pattern of aggregation followed by rapid disaggregation observed with submaximal aggregating doses of SFLLRN was less evident with (iso-S)FLLRN, and inhibition of aminopeptidase M by amastatin enhanced aggregation in platelet-rich plasma induced by SFLLRN but not (iso-S)FLLRN. The (iso-S)FLLRN peptide should permit improved analysis of the effects of constant levels of peptide-induced thrombin receptor stimulation in the presence of plasma or serum, or when testing the effects of the peptide on cells that contain surface-associated aminopeptidase M.	SUNY,DEPT CHEM,STONY BROOK,NY 11794; SUNY,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College	COLLER, BS (corresponding author), SUNY,DEPT MED,DIV HAEMATOL,STONY BROOK,NY 11794, USA.		CERUSO, MARCO/C-5164-2009; Ceruso, Marco/AAL-9179-2020		NCRR NIH HHS [RR65547A] Funding Source: Medline; PHS HHS [45791, 19278] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CHAO BH, 1992, BIOCHEMISTRY-US, V31, P6175, DOI 10.1021/bi00142a001; COLLER BS, 1976, BLOOD, V47, P841; COLLER BS, 1992, BIOCHEMISTRY-US, V31, P11713, DOI 10.1021/bi00162a007; HUI KY, 1992, BIOCHEM BIOPH RES CO, V184, P790, DOI 10.1016/0006-291X(92)90659-9; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; PALMIERI FE, 1989, BIOCHEM PHARMACOL, V38, P173, DOI 10.1016/0006-2952(89)90165-2; SABO T, 1992, BIOCHEM BIOPH RES CO, V188, P604, DOI 10.1016/0006-291X(92)91099-C; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	11	31	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20741	20743						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8104935				2022-12-27	WOS:A1993MA28800016
J	MANIE, S; SCHMIDALLIANA, A; KUBAR, J; FERRUA, B; ROSSI, B				MANIE, S; SCHMIDALLIANA, A; KUBAR, J; FERRUA, B; ROSSI, B			DISRUPTION OF MICROTUBULE NETWORK IN HUMAN MONOCYTES INDUCES EXPRESSION OF INTERLEUKIN-1 BUT NOT THAT OF INTERLEUKIN-6 NOR TUMOR-NECROSIS-FACTOR-ALPHA - INVOLVEMENT OF PROTEIN KINASE-A STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; RAT 3Y1 CELLS; DNA-SYNTHESIS; ADENYLATE-CYCLASE; HUMAN IL-1-ALPHA; TAXOL; MACROPHAGES; IL-1-BETA; INITIATION; INHIBITION	We have reported recently that colchicine and other microtubule-disrupting agents stimulated interleukin-1 (IL-1) alpha and beta synthesis in human monocytes. In this study we found that unexpectedly colchicine failed to stimulate the expression of two other potent immune mediators, namely tumor necrosis factor-alpha and interleukin-6. Remarkably, taxol which induces stable microtubule bundles, antagonized the colchicine but not the LPS-induced IL-1 synthesis. These results suggested that the colchicine- mediated IL-1 induction was generated by microtubule disassembly. We next demonstrated that microtubule disruption triggered an elevation of intracellular levels of cAMP and a subsequent stimulation of protein kinase A. The use of different protein kinase inhibitors supported a role of the PKA, but not the PKC, in the colchicine-induced IL-1 production. Furthermore, elevation of intracellular cAMP levels by 8-bromo-cAMP, forskolin, or cholera toxin potentiated the effect of suboptimal concentration of colchicine on IL-1 synthesis. However, these agents alone were unable to induce IL-1 synthesis. Therefore, our data indicate that the cAMP/protein kinase A-signaling pathway is necessary but not sufficient to generate IL-1 synthesis by microtubule disruption. Thus, microtubule-disrupting drugs appear as useful tools to further characterize the molecular events which regulate IL-1 production in human monocytes.	FAC MED NICE, INSERM, U364, AVE VALOMBROSE, F-06107 NICE 02, FRANCE; FAC MED NICE, PHARMACOL LAB, F-06107 NICE 02, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur			Manie, Serge/ABC-8331-2021; SCHMID-ALLIANA, Annie/P-4366-2016	SCHMID-ALLIANA, Annie/0000-0003-2321-7408				AVILA J, 1990, FASEB J, V4, P3284, DOI 10.1096/fasebj.4.15.2253844; BAKOUCHE O, 1992, J IMMUNOL, V148, P84; BIRCHMEIER W, 1984, TRENDS BIOCHEM SCI, V9, P478; BOTTERI FM, 1990, J BIOL CHEM, V265, P13327; BOZOU JC, 1986, MOL PHARMACOL, V29, P489; BROWN DL, 1985, EUR J CELL BIOL, V37, P130; CARTER KC, 1989, J BIOL CHEM, V264, P515; CAVAILLON JM, 1990, CYTOKINE, V2, P1; CLEVELAND DW, 1990, CELL, V60, P701, DOI 10.1016/0092-8674(90)90083-Q; CROSSIN KL, 1981, CELL, V23, P61, DOI 10.1016/0092-8674(81)90270-1; CROSSIN KL, 1981, CELL, V27, P341, DOI 10.1016/0092-8674(81)90417-7; DINARELLO CA, 1991, BLOOD, V77, P1627; DING AH, 1990, SCIENCE, V248, P370, DOI 10.1126/science.1970196; DING AH, 1990, J EXP MED, V171, P715, DOI 10.1084/jem.171.3.715; FERRUA B, 1990, CELL IMMUNOL, V131, P391, DOI 10.1016/0008-8749(90)90263-Q; FERRUA B, 1988, J IMMUNOL METHODS, V114, P41, DOI 10.1016/0022-1759(88)90151-2; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HURME M, 1990, BLOOD, V76, P2198; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOVACS EJ, 1988, J IMMUNOL, V141, P3101; KRONKE M, 1990, CELL SIGNAL, V2, P1, DOI 10.1016/0898-6568(90)90027-8; MANFREDI JJ, 1982, J CELL BIOL, V94, P688, DOI 10.1083/jcb.94.3.688; MANIE S, 1993, EUR CYTOKINE NETW, V4, P51; MANTHEY CL, 1992, J IMMUNOL, V149, P2459; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; RAVINDRA R, 1991, FASEB J, V5, pA1498; RUDOLPH SA, 1977, P NATL ACAD SCI USA, V74, P3403; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCOTT CW, 1989, BIOCHEM J, V263, P207, DOI 10.1042/bj2630207; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P5732, DOI 10.1073/pnas.82.17.5732; SERRANO L, 1989, EXP CELL RES, V181, P263, DOI 10.1016/0014-4827(89)90200-0; SHINOHARA Y, 1989, EUR J BIOCHEM, V183, P275, DOI 10.1111/j.1432-1033.1989.tb14924.x; SHINOHARAGOTOH Y, 1991, EXP CELL RES, V193, P161, DOI 10.1016/0014-4827(91)90551-5; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; SUNG SSJ, 1991, J CLIN INVEST, V88, P1915, DOI 10.1172/JCI115515; TURNER M, 1989, J IMMUNOL, V143, P3556; VALLANO ML, 1985, P NATL ACAD SCI USA, V83, P3203; VALLEE RB, 1981, J CELL BIOL, V90, P568, DOI 10.1083/jcb.90.3.568; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WANG N, 1991, BIOCHEMISTRY-US, V30, P10957, DOI 10.1021/bi00109a021; WANG N, 1990, J BIOL CHEM, V265, P1239	41	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13675	13681						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8099911				2022-12-27	WOS:A1993LH55300092
J	PIEKARZ, RL; COHEN, D; HORWITZ, SB				PIEKARZ, RL; COHEN, D; HORWITZ, SB			PROGESTERONE REGULATES THE MURINE MULTIDRUG RESISTANCE MDR1B GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							P-GLYCOPROTEIN EXPRESSION; HUMAN ESTROGEN-RECEPTOR; FUNCTIONAL-ANALYSIS; REPORTER GENE; DNA; PROMOTERS; SEQUENCE; CELLS; FORM; ENDOMETRIUM	P-glycoprotein, the product of the multidrug resistance (mdr) gene family, is a major determinant in the development of resistance to a large number of cancer chemotherapeutic agents and is also expressed normally in a variety of mammalian tissues. In rodents during pregnancy, there is a dramatic overproduction of the mdr1b form of P-glycoprotein at the lumenal surface of the secretory epithelium of the gravid uterus (1). An expression vector, mdr1b-CAT, was constructed by fusion of this promoter region to a reporter gene, the bacterial chloramphenicol acetyltransferase (CAT) gene (2). R5020, a progesterone agonist, increased approximately 3-fold the expression of mdr1b-CAT when transfected into T47D cells, a cell line that constitutively expresses the progesterone receptor. A far greater response to R5020 was observed when the cells were co-transfected with an expression vector for the A form of the progesterone receptor, but not the B form. A series of 5'-deleted clones of the mdr1b-CAT construct indicated that the region of responsiveness was located in the first untranslated exon of the gene. Furthermore, sequences from the first exon were able to confer responsiveness to the non-responsive thymidine kinase-CAT vector. This study demonstrates that progesterone specifically regulates the activity of the mdr1b promoter and that this response is directed solely by the A form of the progesterone receptor.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,1300 MORRIS PK AVE,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine			Piekarz, Richard/GXH-9978-2022		NATIONAL CANCER INSTITUTE [K04CA001330, R35CA039821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007260] Funding Source: NIH RePORTER; NCI NIH HHS [5P303CA1330, CA 39821] Funding Source: Medline; NIGMS NIH HHS [5T32GM 07260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACRECI RJ, 1990, MOL REPROD DEV, V25, P101; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; AXIOTIS CA, 1991, LAB INVEST, V65, P577; BECKER KF, 1992, HORM METAB RES, V24, P210, DOI 10.1055/s-2007-1003295; BRADLEY G, 1990, J CELL PHYSIOL, V145, P398, DOI 10.1002/jcp.1041450303; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COHEN D, 1991, J BIOL CHEM, V266, P2239; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GURPIDE E, 1991, JNCI-J NATL CANCER I, V83, P405, DOI 10.1093/jnci/83.6.405; HORWITZ KB, 1985, CANCER RES, V45, P167; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KAUPPILA A, 1980, CANCER, V46, P2162, DOI 10.1002/1097-0142(19801115)46:10<2162::AID-CNCR2820461010>3.0.CO;2-V; KIRSCHNER LS, 1992, BIOCHEM PHARMACOL, V43, P77, DOI 10.1016/0006-2952(92)90664-5; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARIE JP, 1991, BLOOD, V78, P586; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PIRKER R, 1991, J NATL CANCER I, V83, P708, DOI 10.1093/jnci/83.10.708; SCHNEIDER W, 1991, J STEROID BIOCHEM, V38, P285, DOI 10.1016/0960-0760(91)90099-Q; SCHOTT DR, 1991, BIOCHEMISTRY-US, V30, P7014, DOI 10.1021/bi00242a029; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; WANG YL, 1991, MOL ENDOCRINOL, V5, P1707, DOI 10.1210/mend-5-11-1707; YANG CPH, 1989, J BIOL CHEM, V264, P782; YANG CPH, 1990, J BIOL CHEM, V265, P10282	30	63	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7613	7616						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8096515				2022-12-27	WOS:A1993KW97900004
J	BARAK, D; KRONMAN, C; ORDENTLICH, A; ARIEL, N; BROMBERG, A; MARCUS, D; LAZAR, A; VELAN, B; SHAFFERMAN, A				BARAK, D; KRONMAN, C; ORDENTLICH, A; ARIEL, N; BROMBERG, A; MARCUS, D; LAZAR, A; VELAN, B; SHAFFERMAN, A			ACETYLCHOLINESTERASE PERIPHERAL ANIONIC SITE DEGENERACY CONFERRED BY AMINO-ACID ARRAYS SHARING A COMMON CORE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN ACETYLCHOLINESTERASE; TORPEDO-CALIFORNICA; BINDING-SITES; ACTIVE-CENTER; DERIVATIVES; HYDROLYSIS; INHIBITION; CATALYSIS; SECRETION; PROPIDIUM	Several of the residues constituting the peripheral anionic site (PAS) in human acetylcholinesterase (HuAChE) were identified by a combination of kinetic studies with 19 single and multiple HuAChE mutants, fluorescence binding studies with the Trp-286 mutant, and by molecular modelling. Mutants were analyzed with three structurally distinct positively charged PAS ligands, propidium, decamethonium, and di(p-allyl-N-dimethylaminophenyl)pentane-3-one (BW284C51), as well as with selective active center inhibitors, hexamethonium and edrophonium. Single mutations of residues Tyr-72, Tyr-124, Glu-285, Trp-286, and Tyr-341 resulted in up to 10-fold increase in inhibition constants for PAS ligands, whereas for multiple mutants up to 400-fold increase was observed. The 6th PAS element residue Asp-74 is unique in its ability to affect conformation of both the active site and the PAS (Shafferman, A., Velan, B., Ordentlich, A., Kronman, C., Grosfeld, H., Leitner, M., Flashner, Y., Cohen, S., Barak, D., and Ariel, N. (1992) EMBO J. 11, 3561-3568) as demonstrated by the several hundred-fold increase in K-i for D74N inhibition by the bisquaternary ligands decamethonium and BW284C51. Based on these studies, singular molecular models for the various HuAChE inhibitor complexes were defined. Yet, for the decamethonium complex two distinct conformations were generated, accommodating the quaternary ammonium group by interactions with either Trp-286 or with Tyr-341. We propose that the PAS consists of a number of binding sites, close to the entrance of the active site gorge, sharing residues Asp-74 and Trp-286 as a common core. Binding of ligands to these residues may be the key to the allosteric modulation of HuAChE catalytic activity. This functional degeneracy is a result of the ability of the Trp-286 indole moiety to interact either via stacking, aromatic-aromatic, or via pi-cation attractions and the involvement of the carboxylate of Asp-74 in charge-charge or H-bond interactions.	ISRAEL INST BIOL RES, DEPT BIOCHEM, IL-70450 NESS ZIONA, ISRAEL; ISRAEL INST BIOL RES, DEPT ORGAN CHEM, IL-70450 NESS ZIONA, ISRAEL; ISRAEL INST BIOL RES, DEPT PHYS CHEM, IL-70450 NESS ZIONA, ISRAEL; ISRAEL INST BIOL RES, DEPT BIOTECHNOL, IL-70450 NESS ZIONA, ISRAEL									BARAK D, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P195; BARNETT P, 1977, J BIOL CHEM, V252, P7200; BERMAN HA, 1981, BIOCHEMISTRY-US, V20, P4803, DOI 10.1021/bi00519a043; BERMAN HA, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P149; BERMAN HA, 1986, BIOCHIM BIOPHYS ACTA, V872, P125, DOI 10.1016/0167-4838(86)90155-X; BERMAN HA, 1987, MOL PHARMACOL, V31, P610; BERMAN HA, 1990, BIOCHEMISTRY-US, V29, P10640, DOI 10.1021/bi00499a010; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CHANGEUX JP, 1966, MOL PHARMACOL, V2, P369; CYGLER M, 1993, PROTEIN SCI, V2, P366; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; GIACOBINI R, 1988, CURRENT RES ALZHEIME, P113; HAAS R, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P131; HAN SY, 1992, EUR J MED CHEM, V27, P673, DOI 10.1016/0223-5234(92)90087-H; HODGE AS, 1992, MOL PHARMACOL, V41, P937; HUCHO F, 1991, TRENDS PHARMACOL SCI, V12, P422; KAY MI, 1971, ACTA CRYSTALL B-STRU, VB 27, P26, DOI 10.1107/S0567740871001663; KRONMAN C, 1992, GENE, V121, P295, DOI 10.1016/0378-1119(92)90134-B; KRUPKA RM, 1966, BIOCHEMISTRY-US, V5, P1988, DOI 10.1021/bi00870a029; LAZAR A, 1993, ANIMAL CELL TECHNOLO; LULLMANN H, 1971, BIOCHEM PHARMACOL, V20, P2579, DOI 10.1016/0006-2952(71)90166-3; MASSOULIE J, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P285; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MCCURDY A, 1992, J AM CHEM SOC, V114, P10314, DOI 10.1021/ja00052a031; MOOSER G, 1972, BIOCHEMISTRY-US, V11, P1595, DOI 10.1021/bi00759a008; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1991, MOL PHARMACOL, V39, P98; ROSENBERRY TL, 1972, BIOCHEMISTRY-US, V11, P4308, DOI 10.1021/bi00773a018; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; ROUFOGALIS BD, 1972, MOL PHARMACOL, V8, P41; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; SHAFFERMAN A, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P165; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; SUSSMAN JL, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P95; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; TAYLOR P, 1974, MOL PHARMACOL, V10, P703; VELAN B, 1991, J BIOL CHEM, V266, P23977; VELAN B, 1991, CELL MOL NEUROBIOL, V11, P143, DOI 10.1007/BF00712806; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; WEISE C, 1990, EMBO J, V9, P3885, DOI 10.1002/j.1460-2075.1990.tb07607.x; WILSON IB, 1958, ARCH BIOCHEM BIOPHYS, V73, P131, DOI 10.1016/0003-9861(58)90248-0	44	152	154	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6296	6305						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119978				2022-12-27	WOS:A1994MZ50300010
J	CABISCOL, E; AGUILAR, J; ROS, J				CABISCOL, E; AGUILAR, J; ROS, J			METAL-CATALYZED OXIDATION OF FE2+ DEHYDROGENASES - CONSENSUS TARGET SEQUENCE BETWEEN PROPANEDIOL OXIDOREDUCTASE OF ESCHERICHIA-COLI AND ALCOHOL-DEHYDROGENASE-II OF ZYMOMONAS-MOBILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; LACTATE-DEHYDROGENASE; CHEMICAL MODIFICATION; HISTIDINE RESIDUE; PURIFICATION; PROTEINS; EXPRESSION; EVOLUTION; ENZYMES; REAGENT	We have studied two enzymes of a newly described family of dehydrogenases with high sequence homology, 1,2-propanediol oxidoreductase of Escherichia coli and alcohol dehydrogenase II of Zymomonas mobilis. These enzymes perform their metabolic role under anaerobic conditions; in the presence of oxygen, they show a very similar inactivation pattern by a metal-catalyzed oxidation system. Titration of histidine residues with diethyl pyrocarbonate showed one histidine residue less in the oxidized enzymes. Comparison of subtilisin peptide maps of active and inactivated enzymes showed a difference in one histidine-containing peptide, the sequence of which is YNTPH(277)GVAN for propanediol oxidoreductase and YNLPH(277)GV for alcohol dehydrogenase II. This histidine residue lies 10 residues away from a proposed metal-binding site, H(263)XXXH(267), necessary to explain a site-specific free radical mechanism. The three histidine residues here described are strictly conserved in all enzymes of this family. In this report we propose that histidine 277 is a target for oxidation by a metal-catalyzed oxidation system and that this modification leads to the irreversible inactivation of both enzymes.	UNIV LLEIDA,FAC MED,DEPT CIENCIES MED BASIQUES,E-25198 LLEIDA,SPAIN; UNIV BARCELONA,FAC FARM,DEPT BIOQUIM,E-08028 BARCELONA,SPAIN	Universitat de Lleida; University of Barcelona			ROS, Joaquim/ABG-7487-2020; Ros, Joaquim/A-7507-2010; Cabiscol, Elisa/A-4584-2009	ROS, Joaquim/0000-0003-0901-8648; Cabiscol, Elisa/0000-0003-2795-7999				AMICI A, 1989, J BIOL CHEM, V264, P3341; BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; BADETDENISOT MA, 1992, ARCH BIOCHEM BIOPHYS, V292, P475, DOI 10.1016/0003-9861(92)90018-R; BLOXHAM DP, 1981, BIOCHEM J, V193, P93, DOI 10.1042/bj1930093; BORONAT A, 1979, J BACTERIOL, V140, P320, DOI 10.1128/JB.140.2.320-326.1979; BORONAT A, 1983, J BACTERIOL, V153, P134, DOI 10.1128/JB.153.1.134-139.1983; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P134; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P141; CABISCOL E, 1990, J BACTERIOL, V172, P5514, DOI 10.1128/jb.172.9.5514-5515.1990; CABISCOL E, 1992, BIOCHIM BIOPHYS ACTA, V1118, P155, DOI 10.1016/0167-4838(92)90144-3; CHENG KC, 1989, J BIOL CHEM, V264, P19666; COCKS GT, 1974, J BACTERIOL, V118, P83, DOI 10.1128/JB.118.1.83-88.1974; CONWAY T, 1989, J BACTERIOL, V171, P3754, DOI 10.1128/jb.171.7.3754-3759.1989; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; DEVRIES GE, 1992, J BACTERIOL, V174, P5346, DOI 10.1128/JB.174.16.5346-5353.1992; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FERSHT A, 1985, ENZYME STRUCTURE MEC, P389; HIGAKI JN, 1992, TRENDS BIOCHEM SCI, V17, P100, DOI 10.1016/0968-0004(92)90245-5; JORNVALL H, 1987, EUR J BIOCHEM, V167, P195, DOI 10.1111/j.1432-1033.1987.tb13323.x; KINOSHITA S, 1985, APPL MICROBIOL BIOT, V22, P249; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEVY HM, 1963, J BIOL CHEM, V238, P3654; LIN ECC, 1976, ANNU REV MICROBIOL, V30, P535, DOI 10.1146/annurev.mi.30.100176.002535; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, V1, P105; MACKENZIE KF, 1989, J BACTERIOL, V171, P1063, DOI 10.1128/jb.171.2.1063-1067.1989; Miles E W, 1977, Methods Enzymol, V47, P431; MONTENECOURT BS, 1985, BIOL IND MICROORGANI; NEALE AD, 1987, J BACTERIOL, V169, P1024, DOI 10.1128/jb.169.3.1024-1028.1987; NEALE AD, 1986, EUR J BIOCHEM, V154, P119, DOI 10.1111/j.1432-1033.1986.tb09366.x; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; TOPHAM CM, 1986, EUR J BIOCHEM, V155, P87, DOI 10.1111/j.1432-1033.1986.tb09461.x; TUENGLER P, 1977, BIOCHIM BIOPHYS ACTA, V484, P1, DOI 10.1016/0005-2744(77)90108-5; VIIKARI L, 1988, Critical Reviews in Biotechnology, V7, P237, DOI 10.3109/07388558809146603; WALTER KA, 1992, J BACTERIOL, V174, P7149, DOI 10.1128/jb.174.22.7149-7158.1992	37	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6592	6597						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120011				2022-12-27	WOS:A1994MZ50300052
J	HU, LM; BODWELL, J; HUO, JM; ORTI, E; MUNCK, A				HU, LM; BODWELL, J; HUO, JM; ORTI, E; MUNCK, A			GLUCOCORTICOID RECEPTORS IN ATP-DEPLETED CELLS - DEPHOSPHORYLATION, LOSS OF HORMONE-BINDING, HSP90 DISSOCIATION, AND ATP-DEPENDENT CYCLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; SITE-SPECIFIC MUTAGENESIS; RAT THYMUS-CELLS; PROGESTERONE-RECEPTOR; PHENOTYPIC SELECTION; NUCLEAR MATRIX; INTACT-CELLS; PHOSPHORYLATION; COMPLEXES; MODEL	Dependence of hormone binding to glucocorticoid receptors (GRs) on cellular ATP levels suggested that GRs traverse an ATP-dependent cycle, and without ATP accumulate in forms that cannot bind hormone. Such ''null'' receptors (NRs) were identified in ATP-depleted WEHI-7 cells, where they are tightly associated with the nuclear fraction and partly dephosphorylated. With WCL2 cells (Chinese hamster ovary cells with overexpressed GRs) depleted of ATP with azide, we have now identified dephosphorylated sites on NRs, studied possible roles of phosphorylation using GR mutants, and measured association with the 90-kDa heat shock protein (hsp90). Most NRs in WCL2 cells are dephosphorylated at serines 220 and 234, but G;Rs with those serines mutated to alanines do not resemble NRs since they bind hormone. They do not associate strongly with nuclei. On azide treatment, however, mutated GRs lose hormone binding capacity faster than normal GRs. Association of hsp90 (and presumably other heat shock proteins) with cytosolic GRs is drastically reduced by azide treatment, sufficient to account for decreased hormone binding. We conclude that: (a) dephosphorylation of GRs does not yield NRs, but may weaken association with hsp90. (b) The postulated ATP-dependent GR cycle can be accounted for by dissociation, and ATP-dependent reconstitution, of GR.hsp90 complexes. (c) ATP depletion blocks reconstitution of complexes. Uncomplexed GRs may accumulate as one form of NR; they are probably also the precursors for other forms of NR.	DARTMOUTH COLL SCH MED, DEPT PHYSIOL, LEBANON, NH 03756 USA	Dartmouth College					FIC NIH HHS [1FOS TWO3923-01] Funding Source: Medline; NCI NIH HHS [CA 23108] Funding Source: Medline; NIDDK NIH HHS [DK 03535] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK003535] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL PA, 1973, BIOCHEM J, V136, P97, DOI 10.1042/bj1360097; BEREZNEY R, 1991, J CELL BIOCHEM, V47, P109, DOI 10.1002/jcb.240470204; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CIDLOWSKI JA, 1980, J STEROID BIOCHEM, V13, P105, DOI 10.1016/0022-4731(80)90180-6; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; DANIELSEN M, 1989, CANCER RES, V49, pS2286; DISTELHORST CW, 1989, J BIOL CHEM, V264, P13080; HIRST MA, 1990, MOL ENDOCRINOL, V4, P162, DOI 10.1210/mend-4-1-162; HOCK W, 1989, J STEROID BIOCHEM, V34, P71, DOI 10.1016/0022-4731(89)90067-8; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOUSLEY PR, 1983, J BIOL CHEM, V258, P4630; HUTCHISON KA, 1992, J BIOL CHEM, V267, P3190; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; Kaufmann S H, 1986, Methods Achiev Exp Pathol, V12, P141; KAUFMANN SH, 1986, J BIOL CHEM, V261, P1962; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MENDEL DB, 1990, PROG CLIN BIOL RES, V322, P97; MENDEL DB, 1988, J BIOL CHEM, V263, P6695; MENDEL DB, 1987, J BIOL CHEM, V262, P5644; MENDEL DB, 1986, J BIOL CHEM, V261, P3758; MENDEL DB, 1986, NATURE, V324, P478, DOI 10.1038/324478a0; MESHINCHI S, 1990, J BIOL CHEM, V265, P4863; MUNCK A, 1968, J BIOL CHEM, V243, P5556; MUNCK A, 1984, J BIOL CHEM, V259, P820; MUNCK A, 1972, J STEROID BIOCHEMIST, V3, P567, DOI 10.1016/0022-4731(72)90103-3; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; ORTI E, 1989, J BIOL CHEM, V264, P9728; ORTI E, 1989, J STEROID BIOCHEM, V34, P85, DOI 10.1016/0022-4731(89)90069-1; ORTI E, 1993, J BIOL CHEM, V268, P7779; RAAKA BM, 1983, J BIOL CHEM, V258, P417; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P555, DOI 10.1007/BF01671941; WERB Z, 1978, J EXP MED, V147, P1684, DOI 10.1084/jem.147.6.1684	40	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6571	6577						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120009				2022-12-27	WOS:A1994MZ50300049
J	REGNSTROM, K; ABERG, A; ORMO, M; SAHLIN, M; SJOBERG, BM				REGNSTROM, K; ABERG, A; ORMO, M; SAHLIN, M; SJOBERG, BM			THE CONSERVED SERINE-211 IS ESSENTIAL FOR REDUCTION OF THE DINUCLEAR IRON CENTER IN PROTEIN R2 OF ESCHERICHIA-COLI RIBONUCLEOTIDE REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; SMALL SUBUNIT; PHENOTYPIC SELECTION; CRYSTAL-STRUCTURE; B2 PROTEIN; SPECTROSCOPY; ACTIVATION; MOSSBAUER; FORMS; AID	The R2 protein family of class I ribonucleotide reductases contains a highly conserved serine residue close to the essential tyrosyl radical and the dinuclear iron center. In order to test its physiological importance, we have engineered the Ser-211 of Escherichia coli R2 to an alanine and a cysteine residue. The three-dimensional structure of R2 S211A solved to 2.4-Angstrom resolution is virtually identical to the wild-type structure apart from the substituted residue. Both mutant proteins contain oxidized dinuclear iron and tyrosyl radical, and their specific enzyme activity per radical are comparable to that of the wild-type protein. In R2 S211A the stability of the tyrosyl radical is substantially decreased, probably caused by movement of Gln-80 into hydrogen bonding distance of Tyr-122. The major defect in R2 S211A, however, is the inability of its iron center to be reduced by enzymic or chemical means, a characteristic not found in R2 S211C. We propose that Ser-211 is needed as a proton donor/transporter during reduction of the iron center of R2, a reaction which in vivo precedes reconstitution of the tyrosyl radical. This offers a physiological explanation for the high conservation of a serine residue at this position in the R2 family.	STOCKHOLM UNIV,DEPT MOLEC BIOL,S-10891 STOCKHOLM,SWEDEN	Stockholm University				Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1993, NATURE, V361, P276, DOI 10.1038/361276a0; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; ATTA M, 1992, J BIOL CHEM, V267, P20682; BACKES G, 1989, BIOCHEMISTRY-US, V28, P1923, DOI 10.1021/bi00430a074; Bernitz U, 1993, NYA KONKURRENSLAGEN; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P285; BOURSNELL M, 1991, VIROLOGY, V184, P411, DOI 10.1016/0042-6822(91)90860-E; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARLSON J, 1984, P NATL ACAD SCI-BIOL, V81, P4294, DOI 10.1073/pnas.81.14.4294; CLIMENT I, 1992, P NATL ACAD SCI USA, V31, P4801; Creighton T. E., 1993, PROTEINS STRUCTURES, P6; ELGREN TE, 1991, J BIOL CHEM, V266, P19265; ELIASSON R, 1986, P NATL ACAD SCI USA, V83, P2373, DOI 10.1073/pnas.83.8.2373; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FONTECAVE M, 1989, J BIOL CHEM, V264, P9164; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; GEREZ C, 1992, BIOCHEMISTRY-US, V31, P780, DOI 10.1021/bi00118a020; GEREZ C, 1991, ANGEW CHEM INT EDIT, V80, P1135; GREENE PJ, 1974, METHODS MOLECULAR BI, V7, P87; HENDRICH MP, 1991, BIOCHEM BIOPH RES CO, V176, P705, DOI 10.1016/S0006-291X(05)80241-4; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LURIA SE, 1957, J BACTERIOL, V74, P461, DOI 10.1002/path.1700740226; LYNCH JB, 1989, J BIOL CHEM, V264, P8091; Maniatis T., 1982, MOL CLONING; NORDLUND P, 1992, FEBS LETT, V307, P257, DOI 10.1016/0014-5793(92)80690-I; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NORDLUND P, 1989, FEBS LETT, V258, P251, DOI 10.1016/0014-5793(89)81666-7; ORMO M, 1993, UNPUB; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAAG R, 1991, BIOCHEMISTRY-US, V30, P11420, DOI 10.1021/bi00112a008; RARDIN RL, 1991, NEW J CHEM, V15, P417; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SAHLIN M, 1989, BIOCHEMISTRY-US, V28, P2618, DOI 10.1021/bi00432a039; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SJOBERG BM, 1982, BIOCHEMISTRY-US, V21, P96; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; Thelander L, 1978, Methods Enzymol, V51, P227; VINCENT JB, 1990, CHEM REV, V90, P1447, DOI 10.1021/cr00106a004; WATSON JD, MOL BIOL GENE, P339	50	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6355	6361						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119985				2022-12-27	WOS:A1994MZ50300018
J	OKAZAKI, K; NIKI, I; IINO, S; KOBAYASHI, S; HIDAKA, H				OKAZAKI, K; NIKI, I; IINO, S; KOBAYASHI, S; HIDAKA, H			A ROLE OF CALCYCLIN, A CA2+-BINDING PROTEIN, ON THE CA2+-DEPENDENT INSULIN RELEASE FROM THE PANCREATIC BETA-CELL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; KINASE-C; SECRETION; CALMODULIN; EXPRESSION; STIMULUS; GROWTH; IDENTIFICATION; PARTICIPATION; EXOCYTOSIS	Exocytosis is an important example of cell activation. Ca2+ and calcium-binding proteins are considered to modulate signal transduction in exocytosis. We examined the role of calcyclin, calcium-binding protein, in the stimulus-secretion coupling in pancreatic beta cells. The presence of calcyclin in these cells was demonstrated immunologically. We permeabilized rat pancreatic islets with streptolysin-O and examined the effects of calcyclin on insulin release. The Ca2+-stimulated insulin release was enhanced by calcyclin, in a dose-dependent manner, whereas this calcium-binding protein had no effect on insulin release from islets in low Ca2+ buffer or from the islets not subjected to the streptolysin-O treatment. Calgizzarin, another member of the S-100 protein family had no apparent effect on the Ca2+ stimulated secretion under parallel conditions. An anticalcyclin antibody suppressed the increase in insulin release induced by calcyclin. We propose that calcyclin may be involved in signal transduction of the Ca2+-induced release of insulin.	NAGOYA UNIV, SCH MED, DEPT PHARMACOL, SHOWA KU, NAGOYA 466, JAPAN; NAGOYA UNIV, SCH MED, DEPT GERIATR, SHOWA KU, NAGOYA 466, JAPAN; NAGOYA UNIV, SCH MED, DEPT ANAT, SHOWA KU, NAGOYA 466, JAPAN; NAGOYA UNIV, SCH MED, DEPT INTERNAL MED 3, SHOWA KU, NAGOYA 466, JAPAN	Nagoya University; Nagoya University; Nagoya University; Nagoya University								ADLER EM, 1991, J NEUROSCI, V11, P1496; ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; BIESIADA E, 1988, CELL BIOL INT REP, V12, P483, DOI 10.1016/0309-1651(88)90140-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKINGHAM L, 1983, BIOCHIM BIOPHYS ACTA, V729, P115, DOI 10.1016/0005-2736(83)90462-5; BUFFA R, 1989, HISTOCHEMISTRY, V91, P107, DOI 10.1007/BF00492384; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; DOUBELL AF, 1991, HYPERTENSION, V18, P648, DOI 10.1161/01.HYP.18.5.648; FILIPEK A, 1991, EUR J BIOCHEM, V195, P795, DOI 10.1111/j.1432-1033.1991.tb15768.x; FOREMAN JC, 1973, NATURE, V245, P249, DOI 10.1038/245249a0; GAGLIARDINO JJ, 1980, BIOCHEM J, V192, P919, DOI 10.1042/bj1920919; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIRSCHHORN RR, 1984, P NATL ACAD SCI-BIOL, V81, P6004, DOI 10.1073/pnas.81.19.6004; HUTTON JC, 1986, CELL CALCIUM, V7, P339, DOI 10.1016/0143-4160(86)90037-0; KRAUSZ Y, 1987, ACTA ENDOCRINOL-COP, V116, P241, DOI 10.1530/acta.0.1160241; KUZNICKI J, 1992, EXP CELL RES, V200, P425, DOI 10.1016/0014-4827(92)90191-A; LINDAU M, 1991, BIOCHIM BIOPHYS ACTA, V1071, P429, DOI 10.1016/0304-4157(91)90006-I; NICAISE G, 1992, BIOL CELL, V75, P89, DOI 10.1016/0248-4900(92)90128-N; NIKI I, 1993, BIOCHEM BIOPH RES CO, V191, P255, DOI 10.1006/bbrc.1993.1210; ONAYA T, 1987, ENDOCRINOL JAPON, V34, P89; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; SUGDEN MC, 1979, FEBS LETT, V105, P95, DOI 10.1016/0014-5793(79)80894-7; TAMAGAWA T, 1985, FEBS LETT, V183, P433, DOI 10.1016/0014-5793(85)80825-5; THORDARSON G, 1991, ENDOCRINOLOGY, V129, P1257, DOI 10.1210/endo-129-3-1257; TODOROKI H, 1991, J BIOL CHEM, V266, P18668; TOKUMITSU H, 1992, J BIOL CHEM, V267, P8919; TOKUMITSU H, 1991, ARCH BIOCHEM BIOPHYS, V288, P202, DOI 10.1016/0003-9861(91)90184-K; UCHIDA T, 1989, CELL TISSUE RES, V255, P379; WETERMAN MAJ, 1992, CANCER RES, V52, P1291; WOOD L, 1991, J INVEST DERMATOL, V96, P383, DOI 10.1111/1523-1747.ep12466230	31	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6149	6152						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119959				2022-12-27	WOS:A1994MY84000100
J	GASPAR, NJ; KINZY, TG; SCHERER, BJ; HUMBELIN, M; HERSHEY, JWB; MERRICK, WC				GASPAR, NJ; KINZY, TG; SCHERER, BJ; HUMBELIN, M; HERSHEY, JWB; MERRICK, WC			TRANSLATION INITIATION FACTOR-EIF-2 - CLONING AND EXPRESSION OF THE HUMAN CDNA-ENCODING THE GAMMA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC PROTEIN-SYNTHESIS; ELONGATION-FACTOR-TU; CAP-BINDING PROTEIN; AMINO-ACID-SEQUENCE; FACTOR-II; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; ALPHA-SUBUNIT; BETA-SUBUNIT	Translation initiation factor eIF-2 is a heterotrimeric GTP-binding protein involved in the recruitment of methionyl-tRNA(i) to the 40 S ribosomal subunit. To complete our characterization of eIF-2, we cloned and characterized a human cDNA encoding the largest subunit, eIF-2gamma. From limited peptide sequence data, degenerate oligonucleotide primers were designed to amplify-a 118-base pair DNA fragment from a cDNA library. This fragment was used as a probe to screen for larger cDNAs and eventually a clone containing the complete eIF-2gamma coding region (1416 base pairs) was identified. It encodes a 472-amino acid protein (51.8 kDa) and contains the three consensus GTP-binding elements. The protein shares strong homology to EF-Tu, GCD11 (the yeast homolog of eIF-2gamma), and other EF-Tu-like proteins. Transfection of COS-1 cells with the cDNA results in overexpression of a 52-kDa protein which is specifically recognized by anti-eIF-2gamma antibodies. Cross-linking experiments with diepoxybutane and trans-diaminedichloroplatinum(II) indicate that both the beta- and gamma-subunits of eIF-2 are in close proximity to methionyl-tRNA(i) in ternary complexes. Possession of the eIF-2gamma cDNA will facilitate future investigations of the interactions of GTP and methionyl-tRNA(i) with eIF-2.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	University of California System; University of California Davis; Case Western Reserve University				Kinzy, Terri/0000-0003-1394-9226	NIGMS NIH HHS [GM-36467, GM-22135, GM-26796] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135, R01GM036467, R01GM026796] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN M, 1989, J BIOL CHEM, V264, P12145; ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; AN G, 1980, GENE, V12, P33, DOI 10.1016/0378-1119(80)90013-X; ANTHONY DD, 1990, ARCH BIOCHEM BIOPHYS, V281, P157, DOI 10.1016/0003-9861(90)90426-Y; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BARRIEUX A, 1977, J BIOL CHEM, V252, P3843; BOMMER UA, 1991, BIOCHIM BIOPHYS ACTA, V1079, P308, DOI 10.1016/0167-4838(91)90074-A; BOMMER UA, 1989, FEBS LETT, V244, P323, DOI 10.1016/0014-5793(89)80555-1; BUSHMAN JL, 1993, MOL CELL BIOL, V13, P1920, DOI 10.1128/MCB.13.3.1920; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P10524; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; DAS K, 1993, P NATL ACAD SCI USA, V90, P3058, DOI 10.1073/pnas.90.7.3058; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P20638; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; ERNST H, 1987, J BIOL CHEM, V262, P1206; GONSKY R, 1992, BIOCHIMIE, V74, P427, DOI 10.1016/0300-9084(92)90082-P; GONSKY R, 1990, J BIOL CHEM, V265, P9083; GROUP GC, 1991, PROGRAM MANUAL GCG P; HANNIG EM, 1993, MOL CELL BIOL, V13, P506, DOI 10.1128/MCB.13.1.506; HARASHIMA S, 1986, MOL CELL BIOL, V6, P3990, DOI 10.1128/MCB.6.11.3990; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; JURNAK F, 1990, BIOCHIM BIOPHYS ACTA, V1050, P209, DOI 10.1016/0167-4781(90)90168-2; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KINZY TG, 1992, J BIOL CHEM, V267, P1623; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDER P, 1989, P NATL ACAD SCI USA, V86, P2286, DOI 10.1073/pnas.86.7.2286; LLOYD MA, 1980, J BIOL CHEM, V255, P1189; MADSEN HO, 1990, NUCLEIC ACIDS RES, V18, P1513, DOI 10.1093/nar/18.6.1513; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MERRICK WC, 1993, IN PRESS TRANSLATION; METZBOUTIGUE MH, 1989, FEBS LETT, V245, P194, DOI 10.1016/0014-5793(89)80220-0; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; MEYER LJ, 1981, J BIOL CHEM, V256, P351; MILBURN SC, 1990, EMBO J, V9, P2783, DOI 10.1002/j.1460-2075.1990.tb07466.x; MUKOUYAMA EB, 1992, BIOSCI BIOTECH BIOCH, V56, P680, DOI 10.1271/bbb.56.680; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; NYGARD O, 1980, FEBS LETT, V113, P125, DOI 10.1016/0014-5793(80)80510-2; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATHAK VK, 1988, CELL, V54, P633, DOI 10.1016/S0092-8674(88)80007-2; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; SACERDOT C, 1984, P NATL ACAD SCI-BIOL, V81, P7787, DOI 10.1073/pnas.81.24.7787; SAFER B, 1975, J BIOL CHEM, V250, P9076; SCHAFER MP, 1987, ARCH BIOCHEM BIOPHYS, V255, P337, DOI 10.1016/0003-9861(87)90401-2; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SHARP NA, 1989, ONCOGENE, V4, P1043; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P1578; SUZUKI H, 1990, J BIOCHEM-TOKYO, V108, P635, DOI 10.1093/oxfordjournals.jbchem.a123255; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; WETTENHALL REH, 1986, J BIOL CHEM, V261, P2444	57	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3415	3422						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106381				2022-12-27	WOS:A1994MV63100045
J	JACKOWSKI, S				JACKOWSKI, S			COORDINATION OF MEMBRANE PHOSPHOLIPID-SYNTHESIS WITH THE CELL-CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; HAMSTER OVARY CELLS; PROTEIN-KINASE-C; CULTURED RAT HEPATOCYTES; GH3 PITUITARY-CELLS; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; FACTOR-I; GROWTH-FACTOR; DIACYLGLYCEROL LEVELS	The formation of membrane phospholipid is coordinated with the cell cycle in a colony-stimulating factor 1-dependent macrophage cell line. Net phospholipid accumulation occurs as cells enter S phase and results from an interaction between cell cycle-dependent oscillations in the rates of phosphatidylcholine (PtdCho) biosynthesis and degradation. CTP-phosphocholine cytidylyltransferase (CT) is the rate-controlling step in PtdCho biosynthesis, and its activity is inhibited by cell cycle-dependent phosphorylation. CT phosphorylation is low in early G1, begins to rise in late G1, increases steadily through S and G2/M, and then declines precipitously as cells exit mitosis and reenter G1. CT activity increases in early G1 and then decreases steadily as the cells progress through late G1, S, and G2/M, reflecting the elevated phosphorylation state of the protein. Membrane phospholipid degradation is also periodic: the rate is rapid in G1, slows significantly during S phase, and accelerates again as cells reenter G1. The data support the hypothesis that CT dephosphorylation accelerates PtdCho synthesis in response to the increased membrane phospholipid degradation to maintain membrane phospholipid mass during G1 and that the periodic cessation of phospholipid degradation during S phase accounts for the transition to net membrane phospholipid accumulation. Inactivation of CT associated with hyper-phosphorylation of the protein during G2/M likely plays a determining role in the cessation of net membrane accumulation prior to cell division.	UNIV TENNESSEE CTR HLTH SCI, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	JACKOWSKI, S (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, 332 N LAUDERDALE, POB 318, MEMPHIS, TN 38101 USA.		Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NCI NIH HHS [CA21765] Funding Source: Medline; NIGMS NIH HHS [GM45737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOUDHURY GG, 1991, FEBS LETT, V282, P351, DOI 10.1016/0014-5793(91)80511-Z; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5881, DOI 10.1021/bi00238a011; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5873, DOI 10.1021/bi00238a010; COTTRELL SF, 1981, J BIOL CHEM, V256, P973; DEAN PN, 1980, CELL TISSUE KINET, V13, P299, DOI 10.1111/j.1365-2184.1980.tb00468.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ESKO JD, 1981, J BIOL CHEM, V256, P7388; EXTON JH, 1990, J BIOL CHEM, V265, P1; GALLAGHER S, 1988, CURRENT PROTOCOLS MO; GROSS G, 1988, BIOCHIM BIOPHYS ACTA, V962, P220, DOI 10.1016/0005-2760(88)90163-4; HABENICHT AJR, 1985, J BIOL CHEM, V260, P1370; HATCH GM, 1992, J BIOL CHEM, V267, P15751; IMAMURA K, 1990, EMBO J, V9, P2423, DOI 10.1002/j.1460-2075.1990.tb07418.x; JACKOWSKI S, 1990, J BIOL CHEM, V265, P6611; JAMIL H, 1992, J BIOL CHEM, V267, P1752; JONES GA, 1992, ARCH BIOCHEM BIOPHYS, V288, P331; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; KOFF A, 1992, EMBO J, V11, P961; KOLESNICK RN, 1990, J BIOL CHEM, V265, P10900; KOLESNICK RN, 1987, J BIOL CHEM, V262, P9204; KOLESNICK RN, 1990, BIOCHEM J, V267, P17, DOI 10.1042/bj2670017; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LUCHE MM, 1993, ARCH BIOCHEM BIOPHYS, V301, P114, DOI 10.1006/abbi.1993.1122; MATOZAKI T, 1991, J BIOL CHEM, V266, P22246; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORAND JN, 1989, J BIOL CHEM, V264, P13785; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; OKUDA T, 1992, ONCOGENE, V7, P2249; ONEILL EA, 1987, J BACTERIOL, V169, P2618, DOI 10.1128/jb.169.6.2618-2623.1987; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P447, DOI 10.1016/0005-2760(84)90171-1; PELECH SL, 1982, J BIOL CHEM, V257, P4198; PELECH SL, 1981, J BIOL CHEM, V256, P8283; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PRIESS J, 1986, J BIOL CHEM, V261, P8597; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SANGHERA JS, 1989, J BIOL CHEM, V264, P1215; SCHWARZBAUM S, 1984, J IMMUNOL, V132, P1158; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SLEIGHT R, 1983, J BIOL CHEM, V258, P836; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; STANLEY ER, 1978, NATURE, V274, P168, DOI 10.1038/274168a0; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; TUSHINISKI RJ, 1985, J CLEL PHYSL, V122, P71; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; UTAL AK, 1991, J BIOL CHEM, V266, P24084; VANCE DE, 1984, TRENDS BIOCHEM SCI, V9, P17, DOI 10.1016/0968-0004(84)90041-0; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P33; VARIO G, 1991, IMMUNOL TODAY, V12, P362; VEIS N, 1991, J CELL PHYSIOL, V147, P298, DOI 10.1002/jcp.1041470215; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; WANG YL, 1993, J BIOL CHEM, V268, P5512; WANG YL, 1993, J BIOL CHEM, V268, P5899; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WATKINS JD, 1992, ARCH BIOCHEM BIOPHYS, V292, P360, DOI 10.1016/0003-9861(92)90003-F; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WRIGHT PS, 1985, J BIOL CHEM, V260, P7919; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XU XX, 1993, MOL CELL BIOL, V13, P1522, DOI 10.1128/MCB.13.3.1522; YAO ZM, 1990, J BIOL CHEM, V265, P4326	78	244	248	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3858	3867						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106431				2022-12-27	WOS:A1994MV63100106
J	MATZARIS, M; JACKSON, SP; LAXMINARAYAN, KM; SPEED, CJ; MITCHELL, CA				MATZARIS, M; JACKSON, SP; LAXMINARAYAN, KM; SPEED, CJ; MITCHELL, CA			IDENTIFICATION AND CHARACTERIZATION OF THE PHOSPHATIDYLINOSITOL-(4,5)-BISPHOSPHATE 5-PHOSPHATASE IN HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; INOSITOL POLYPHOSPHATE-5-PHOSPHATASE; HUMAN-ERYTHROCYTES; PHOSPHOLIPASE-C; RAT-BRAIN; 4,5-BISPHOSPHATE; PURIFICATION; PHOSPHOMONOESTERASE; 4-PHOSPHATE; PHOSPHATE	Phosphatidylinositol (4,5)-bisphosphate (PtdIns(4,5)P2) is the precursor of several second messenger molecules. In unstimulated cells PtdIns(4,5)P2 is hydrolyzed by a PtdIns(4,5)P2 5-phosphatase to form phosphatidylinositol 4-phosphate (PtdIns(4)P) which is subsequently recycled to phosphatidylinositol. PtdIns(4,5)P2 5-phosphatase activity was detected in platelet cytosolic and particulate fractions. The platelet Ptdins(4,5)P2 5-phosphatase activity was magnesium but not calcium dependent. The elution profile of platelet cytosolic PtdIns(4,5)P2 5-phosphatase from anion exchange resins, exactly matched that of the 75-kDa inositol-polyphosphate 5-phosphatase (Ins(1,4,5)P3 5-phosphatase). The latter is a signal terminating enzyme responsible for the hydrolysis of inositol (1,4,5)-trisphosphate (Ins(1,4,5)Ps) to inositol (1,4)-bisphosphate (Mitchell, C. A., Connolly, T. M., and Majerus, P. W. (1989) J. Biol. Chem. 264, 8873-8877). Polyclonal antibodies raised against recombinant 75-kDa Ins(1,4,5)P3 5-phosphatase specifically immunoprecipitated all PtdIns(4,5)P2 5-phosphatase activity from both the platelet membrane and cytosolic fractions. Purified 75-kDa Ins(1,4,5)Ps 5-phosphatase hydrolyzed PtdIns(4,5)P2 forming PtdIns(4)P (K(m) = 250 muM). By contrast, purified membrane-associated 43-kDa Ins(1,4,5)P3 5-phosphatase did not hydrolyze Ptdins(4,5)P2. In the unstimulated platelet, recycling of PtdIns(4,5)P2 to PtdIns(4)P is mediated by the 75-kDa Ins(1,4,5)P3 5-phosphatase.	BOX HILL HOSP,MONASH MED SCH,DEPT MED,NELSON RD,MELBOURNE 3128,AUSTRALIA	Box Hill Hospital; Monash University				Mitchell, Christina A/0000-0001-9372-3192; Jackson, Shaun/0000-0002-4750-1991				ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; Baenziger N L, 1974, Methods Enzymol, V31, P149; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1984, NATURE, V341, P194; BROCKERHOFF H, 1962, J BIOL CHEM, V237, P1764; CALDWELL KK, 1991, J BIOL CHEM, V266, P18378; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; CONNOLLY TM, 1986, J BIOL CHEM, V261, P122; COOPER PH, 1975, BIOCHEM J, V150, P537, DOI 10.1042/bj1500537; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; HOKIN LE, 1961, NATURE, V189, P836, DOI 10.1038/189836a0; JAMNEY PA, 1989, J BIOL CHEM, V264, P4825; JAMNEY PA, 1992, J BIOL CHEM, V267, P11818; JOSEPH SK, 1984, J BIOL CHEM, V259, P3077; KING CE, 1989, BIOCHEM J, V259, P893, DOI 10.1042/bj2590893; KING CE, 1987, BIOCHEM J, V244, P209, DOI 10.1042/bj2440209; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LAXMINARAYAN KM, 1993, J BIOL CHEM, V268, P4968; MACK SE, 1984, J LIPID RES, V25, P75; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; MULLER E, 1986, BIOCHEM J, V235, P775; NIJJAR MS, 1977, BIOCHIM BIOPHYS ACTA, V480, P390, DOI 10.1016/0005-2744(77)90032-8; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PALMER FBS, 1990, BIOCHEM CELL BIOL, V68, P800; PALMER FBS, 1994, J BIOL CHEM, V269, P3403; PALMER FBSC, 1976, BIOCHIM BIOPHYS ACTA, V441, P477, DOI 10.1016/0005-2760(76)90244-7; ROACH PD, 1981, BIOCHIM BIOPHYS ACTA, V661, P323, DOI 10.1016/0005-2744(81)90021-8; ROSS TS, 1991, J BIOL CHEM, V266, P20283; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; STREB H, 1985, J BIOL CHEM, V260, P7309; SUN GY, 1990, METHODS INOSITIDE RE, P153; UNO I, 1988, NATURE, V333, P188, DOI 10.1038/333188a0; VEDIA LMM, 1986, J BIOL CHEM, V261, P10493	41	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3397	3402						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106379				2022-12-27	WOS:A1994MV63100042
J	VANDERMEER, JR; ROLLEMA, HS; SIEZEN, RJ; BEERTHUYZEN, MM; KUIPERS, OP; DEVOS, WM				VANDERMEER, JR; ROLLEMA, HS; SIEZEN, RJ; BEERTHUYZEN, MM; KUIPERS, OP; DEVOS, WM			INFLUENCE OF AMINO-ACID SUBSTITUTIONS IN THE NISIN LEADER PEPTIDE ON BIOSYNTHESIS AND SECRETION OF NISIN BY LACTOCOCCUS-LACTIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPEPTIDE SEQUENCE; LANTIBIOTIC NISIN; ANTIBIOTIC NISIN; GENE; PROTEIN; CLONING; EXPRESSION; PRECURSOR; PEP5	Structural genes for small lanthionine-containing antimicrobial peptides, known as lantibiotics, encode N-terminal leader sequences which are not present in the mature peptide, but are cleaved off at some stage in the maturation process. Leader sequences of the different lantibiotics share a number of identical amino acid residues, but they are clearly different from sec-dependent protein export signal sequences. We studied the role of the leader sequence of the lantibiotic nisin, which is produced and secreted by Lactococcus lactis, by creating site-directed mutations at various positions in the leader peptide sequence. Mutations at Arg-1 and Ala-4, but not at the conserved Pro-2, strongly affected the processing of the leader sequence and resulted in the extracellular accumulation of a biologically inactive precursor peptide. Amino acid analysis and H-1 NMR studies indicated that the precursor peptide with an Ala-4 --> Asp mutation contained a modified nisin structural part with the (mutated) unmodified leader sequence still attached to it. The Ala-4 --> Asp precursor peptide could be activated in vitro by enzymatic cleavage with trypsin, liberating nisin. These results confirmed that cleavage of the leader peptide is the last step in nisin maturation and is necessary to generate a biologically active peptide. Several mutations, i.e. Pro-2 --> Gly, Pro-2 --> Val, Asp-7 --> Ala, Lys-9 --> Leu, Ser-10 --> Ala/Ser-12 --> Ala and Val-11 --> Asp/Val-13 --> Glu in the leader peptide did not have any detectable effect on nisin production and secretion, although some of them affected highly conserved residues. When mutations were created in the -18 to -15 region of the nisin leader peptide (i.e. Phe-18 --> Leu, Leu-16 --> Lys, Asp-15 --> Ala), no secretion or intracellular accumulation could be detected of nisin or its precursors. This suggested that these conserved residues are involved in the maturation process and may interact with lantibiotic-specific modifying enzymes.	NIZO, DEPT BIOPHYS CHEM, POB 20, 6710 BA EDE, NETHERLANDS	NIZO Food Research			Siezen, Roland J/P-5745-2015; van der Meer, Jan Roelof/G-6610-2012; Kuipers, Oscar/B-6752-2009	van der Meer, Jan Roelof/0000-0003-1485-3082; Kuipers, Oscar/0000-0001-5596-7735				BANERJEE S, 1988, J BIOL CHEM, V263, P9508; BUCHMAN GW, 1988, J BIOL CHEM, V263, P16260; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CHAN WC, 1989, FEBS LETT, V252, P29, DOI 10.1016/0014-5793(89)80884-1; DEVOS WM, 1993, APPL ENVIRON MICROB, V59, P213, DOI 10.1128/AEM.59.1.213-218.1993; DEVUYST L, 1992, J GEN MICROBIOL, V138, P571, DOI 10.1099/00221287-138-3-571; DODD HM, 1990, J GEN MICROBIOL, V136, P555, DOI 10.1099/00221287-136-3-555; ENGELKE G, 1992, APPL ENVIRON MICROB, V58, P3730, DOI 10.1128/AEM.58.11.3730-3743.1992; GROSS E, 1971, J AM CHEM SOC, V93, P4634, DOI 10.1021/ja00747a073; JUNG G, 1991, ANGEW CHEM, V103, P1067, DOI DOI 10.1002/ANGE.19911030904; KALETTA C, 1989, J BACTERIOL, V171, P1597, DOI 10.1128/jb.171.3.1597-1601.1989; KALETTA C, 1989, ARCH MICROBIOL, V152, P16, DOI 10.1007/BF00447005; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4558, DOI 10.1093/nar/19.16.4558; KUIPERS OP, 1992, J BIOL CHEM, V267, P24340; KUIPERS OP, 1993, FEBS LETT, V330, P23, DOI 10.1016/0014-5793(93)80911-D; KUIPERS OP, 1993, EUR J BIOCHEM, V216, P281, DOI 10.1111/j.1432-1033.1993.tb18143.x; MULDERS JWM, 1991, EUR J BIOCHEM, V201, P581, DOI 10.1111/j.1432-1033.1991.tb16317.x; RAUCH PJG, 1992, J BACTERIOL, V174, P1280, DOI 10.1128/jb.174.4.1280-1287.1992; Sambrook J, 1989, MOL CLONING LAB MANU, V1 and 3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; SIEZEN RJ, 1993, IN PRESS SUBTILISIN; STEEN MT, 1991, APPL ENVIRON MICROB, V57, P1181, DOI 10.1128/AEM.57.4.1181-1188.1991; VANDERMEER JR, 1993, J BACTERIOL, V175, P2578, DOI 10.1128/JB.175.9.2578-2588.1993; VANROOIJEN RJ, 1990, J BIOL CHEM, V265, P18499; WEIL HP, 1990, EUR J BIOCHEM, V194, P217, DOI 10.1111/j.1432-1033.1990.tb19446.x	27	135	139	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3555	3562						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106398				2022-12-27	WOS:A1994MV63100066
J	WATANABE, T; KOBORI, K; MIYASHITA, K; FUJII, T; SAKAI, H; UCHIDA, M; TANAKA, H				WATANABE, T; KOBORI, K; MIYASHITA, K; FUJII, T; SAKAI, H; UCHIDA, M; TANAKA, H			IDENTIFICATION OF GLUTAMIC ACID-204 AND ASPARTIC ACID-200 IN CHITINASE-A1 OF BACILLUS-CIRCULANS WL-12 AS ESSENTIAL RESIDUES FOR CHITINASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-N-ACETYLGLUCOSAMINIDASE; LYSOZYME CHITINASE; STREPTOMYCES; GENES; HOMOLOGY; ENZYME; SITE; PURIFICATION; MUTAGENESIS; MEMBRANE	Prokaryotic chitinases, class III plant chitinases, yeast chitinases, and endo-beta-N-acetylglucosaminidases share weak amino acid sequence similarities at the certain region of each enzyme. These regions have been assumed to be important for catalytic activities of the enzymes. To verify this assumption, three amino acid residues (Ser-160, Asp-200, Glu-204) in chitinase A1 of Bacillus circulans WL-12 were chosen, based on the amino acid sequence alignment of the regions sharing sequence similarity, and were replaced by site-directed mutagenesis. Kinetic parameters for 4-methylumbelliferyl-N,N',N''-triacetylchitotriose hydrolysis were determined with wild-type and seven mutant chitinases. Chitinases with Glu-204 --> Gln mutation and Glu-204 --> Asp mutation were essentially inactive and k(cat) values of these chitinases were approximately 1/5,000 and 1/17,000 of that of wild-type chitinase, respectively. Asp-200 --> Asn mutation decreased the k(cat) value to approximately 1/350 of that of the wild-type enzyme, while the K(m) value decreased only slightly. On the other hand, neither the k(cat) value nor the K(m) value was affected by Asp-200 --> Glu mutation. Thus, it appeared that Glu-204 and Asp-200 are directly involved in the catalytic events of chitinase A1. The role of the carboxyl group of Asp-200 can be fully substituted by that of Glu residue. The Ser-160 --> Ala mutant retained 10% activity of the wild-type chitinase indicating that the hydroxyl group of Ser-160 is not absolutely required for the catalytic activity. These results indicate a lysozyme-type catalytic mechanism of the chitinase.	NATL INST AGROENVIRONM SCI,TSUKUBA 305,JAPAN; UNIV TOKYO,FAC AGR,DEPT AGR CHEM,BUNKYO KU,TOKYO 113,JAPAN	National Institute for Agro-Environmental Sciences (NIAES) Japan; University of Tokyo	WATANABE, T (corresponding author), NIIGATA UNIV,FAC AGR,DEPT APPL BIOL CHEM,8050 IKARASHI 2,NIIGATA 95021,JAPAN.							ABELES FB, 1970, PLANT PHYSIOL, V47, P129; AMES GFL, 1974, J BIOL CHEM, V249, P634; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; Boller T, 1985, CELLULAR MOL BIOL PL, P247; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; HARPSTER MH, 1989, NUCLEIC ACIDS RES, V17, P5396; HENRISSAT B, 1990, Protein Sequences and Data Analysis, V3, P523; IMOTO T, 1971, AGR BIOL CHEM TOKYO, V35, P1154, DOI 10.1080/00021369.1971.10860050; JEKEL PA, 1991, EUR J BIOCHEM, V200, P123, DOI 10.1111/j.1432-1033.1991.tb21057.x; Jeuniaux C., 1966, METHOD ENZYMOL, V8, P644, DOI [DOI 10.1016/0076-6879(66)08117-5, 10.1016/0076-6879(66)08117-5]; JONES JDG, 1986, EMBO J, V5, P467, DOI 10.1002/j.1460-2075.1986.tb04235.x; KAMEI K, 1989, J BIOCHEM-TOKYO, V105, P979, DOI 10.1093/oxfordjournals.jbchem.a122791; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWYTON K, 1992, PLANT MOL BIOL, V19, P735; LIN TY, 1969, J BIOL CHEM, V244, P505; MALCOLM BA, 1989, P NATL ACAD SCI USA, V86, P133, DOI 10.1073/pnas.86.1.133; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; METRAUX JP, 1989, P NATL ACAD SCI USA, V86, P896, DOI 10.1073/pnas.86.3.896; PHILLIPS DC, 1967, P NATL ACAD SCI USA, V57, P484; PRICE JS, 1975, J BACTERIOL, V124, P1574, DOI 10.1128/JB.124.3.1574-1585.1975; ROBBINS PW, 1984, J BIOL CHEM, V259, P7577; ROBBINS PW, 1992, GENE, V111, P69, DOI 10.1016/0378-1119(92)90604-N; SAMAC DA, 1990, PLANT PHYSIOL, V93, P907, DOI 10.1104/pp.93.3.907; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINSHI H, 1990, PLANT MOL BIOL, V14, P357, DOI 10.1007/BF00028772; STARK MJR, 1990, YEAST, V6, P1, DOI 10.1002/yea.320060102; TAKEGAWA K, 1991, EUR J BIOCHEM, V202, P175, DOI 10.1111/j.1432-1033.1991.tb16359.x; TSUJIBO H, 1993, J BACTERIOL, V175, P176, DOI 10.1128/JB.175.1.176-181.1993; VERBURG JG, 1992, J BIOL CHEM, V267, P3886; WATANABE T, 1992, J BACTERIOL, V174, P408, DOI 10.1128/jb.174.2.408-414.1992; WATANABE T, 1990, J BACTERIOL, V172, P4017, DOI 10.1128/jb.172.7.4017-4022.1990; WATANABE T, 1990, J BIOL CHEM, V265, P15659; YAMADA H, 1981, CARBOHYD RES, V92, P160, DOI 10.1016/S0008-6215(00)85993-5; YANAI K, 1992, J BACTERIOL, V174, P7398, DOI 10.1128/jb.174.22.7398-7406.1992	36	329	351	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18567	18572						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8103047				2022-12-27	WOS:A1993LV65900032
J	ZHANG, JT; DUTHIE, M; LING, V				ZHANG, JT; DUTHIE, M; LING, V			MEMBRANE TOPOLOGY OF THE N-TERMINAL HALF OF THE HAMSTER P-GLYCOPROTEIN MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT PROTEINS; MULTIDRUG RESISTANCE; HOMOLOGY; ORIENTATION; GENE	P-glycoprotein (Pgp) is a tandemly duplicated plasma membrane protein containing 12 predicted transmembrane (TM) segments and two cytoplasmic ATP-binding domains. Pgp appears to be responsible for multidrug resistance in cancer cells. A detailed knowledge of the topological structure of Pgp will be required for understanding its mechanism of action. Previously, we have investigated the membrane orientation of Pgp using a cell free translation/translocation system supplemented with canine pancreatic microsomal membranes. We observed unexpectedly that the C-terminal half of the Pgp molecules was present in two different topological orientations (Zhang, J.-T., and Ling, V. (1991) J. Biol. Chem. 266, 18224-18232). In the present study, using a similar approach, we have investigated in detail the topological structure of the N-terminal half of the Pgp molecule. Again, two orientations were observed. One has all six predicted TM segments in the membrane bilayer, the other has only four TM segments in the bilayer with predicted TM3 and TM5 in a cytoplasmic and extracellular location, respectively. Although the primary sequence of Pgp appears to be a tandem duplication, the new topological structure of N-terminal half is not a simple tandem duplication of that in the C-terminal half. Thus it appears that the insertion and orientation of Pgp TM segments are dictated by specific localized sequences. These results, together with our previous findings, raise the possibility that Pgp in the native membrane may be present in different topological orientations and this feature may be important for its function.	UNIV TORONTO, DEPT MED BIOPHYS,ONTARIO CANC INST, DIV MOLEC & STRUCT BIOL,500 SHERBOURNE ST, TORONTO M4X 1K9, ON, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto			Zhang, Jian-Ting/L-8334-2015		NATIONAL CANCER INSTITUTE [R01CA037130] Funding Source: NIH RePORTER; NCI NIH HHS [CA-37130] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS D, 1989, BIOTECHNIQUES, V7, P960; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; BRANDOLIN G, 1989, BIOCHEMISTRY-US, V28, P1093, DOI 10.1021/bi00429a025; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Stein W., 1990, CHANNELS CARRIERS PU; Vignais P. V., 1985, STRUCTURE PROPERTIES, V2, P139; WEBER K, 1969, J BIOL CHEM, V244, P4406; ZHANG JT, 1991, J BIOL CHEM, V266, P18224	18	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15101	15110						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8100818				2022-12-27	WOS:A1993LL75900082
J	DYE, RB; FINK, SP; WILLIAMS, RC				DYE, RB; FINK, SP; WILLIAMS, RC			TAXOL-INDUCED FLEXIBILITY OF MICROTUBULES AND ITS REVERSAL BY MAP-2 AND TAU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							STRUCTURAL-CHANGES; TUBULIN SHEETS; PROTEINS; INVITRO; CELLS; BRAIN; REMOVAL	When microtubules, ordinarily quite rigid structures, are treated in vitro with the anti-tumor drug taxol, they rapidly develop a wavy appearance and become strikingly flexible. A quantitative measure of their flexibility, the reciprocal statistical length, lambda, increases by an order of magnitude when taxol is bound. Subsequent addition of either of the microtubule-associated proteins MAP-2 or tau causes the flexibility to disappear. It can be restored again by removing the microtubule-associated protein. These results show that taxol changes microtubular structure substantially, probably by weakening the interactions between protofilaments, and that microtubule-associated proteins reverse these effects, possibly by bridging protofilaments. This structural change and the accompanying flexibility may contribute importantly to taxol's cytotoxic activity.	VANDERBILT UNIV, DEPT MOLEC BIOL, NASHVILLE, TN 37235 USA	Vanderbilt University				Fink, Stephen/0000-0003-4107-7912	NIGMS NIH HHS [GM-25638] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025638] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMINHANJANI S, 1991, CELL MOTIL CYTOSKEL, V20, P136, DOI 10.1002/cm.970200206; Amos L.A., 1979, MICROTUBULES, P1; AMOS LA, 1991, J CELL SCI, P95; BAUDIER J, 1987, J BIOL CHEM, V262, P17584; BERG HC, 1984, J GEN MICROBIOL, V130, P2915; COLLINS CA, 1987, J CELL BIOL, V105, P2847, DOI 10.1083/jcb.105.6.2847; CORREIA JJ, 1987, J BIOL CHEM, V262, P17278; CROSS AR, 1991, CELL MOTIL CYTOSKEL, V20, P272, DOI 10.1002/cm.970200403; DEBRABANDER M, 1981, P NATL ACAD SCI-BIOL, V78, P5608; EDSON K, 1993, IN PRESS DEVELOPMENT, V117; HEIDEMANN SR, 1990, CELL MOTIL CYTOSKEL, V17, P6, DOI 10.1002/cm.970170103; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Inoue S, 1986, VIDEO MICROSCOPY; KNOPS J, 1991, J CELL BIOL, V114, P725, DOI 10.1083/jcb.114.4.725; MCEWEN BF, 1983, J MOL BIOL, V166, P119, DOI 10.1016/S0022-2836(83)80002-3; MIZUSHIMASUGANO J, 1983, BIOCHIM BIOPHYS ACTA, V755, P257, DOI 10.1016/0304-4165(83)90212-X; NAGASHIMA H, 1980, J MOL BIOL, V136, P169, DOI 10.1016/0022-2836(80)90311-3; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; RINGEL I, 1991, J PHARMACOL EXP THER, V259, P855; ROBERTS RL, 1982, J IMMUNOL, V129, P2134; ROWINSKY EK, 1988, CANCER RES, V48, P4093; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SLICHENMYER WJ, 1990, J CLIN PHARMACOL, V30, P770, DOI 10.1002/j.1552-4604.1990.tb01873.x; SMALHEISER NR, 1991, DEV BRAIN RES, V58, P271, DOI 10.1016/0165-3806(91)90015-B; TURNER PF, 1984, J CELL BIOL, V99, P940, DOI 10.1083/jcb.99.3.940; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WEISSHAAR B, 1992, DEVELOPMENT, V116, P1151; WILLIAMS R C JR, 1992, P151; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376; WINCKLER B, 1991, P NATL ACAD SCI USA, V88, P6033, DOI 10.1073/pnas.88.14.6033; YAMAZAKI S, 1982, BIOL FUNCTIONS MICRO	34	121	124	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6847	6850						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8096507				2022-12-27	WOS:A1993KV14100007
J	LANG, V; ZANCHIN, NIT; LUNSDORF, H; TUITE, M; MCCARTHY, JEG				LANG, V; ZANCHIN, NIT; LUNSDORF, H; TUITE, M; MCCARTHY, JEG			INITIATION-FACTOR EIF-4E OF SACCHAROMYCES-CEREVISIAE - DISTRIBUTION WITHIN THE CELL, BINDING TO MESSENGER-RNA, AND CONSEQUENCES OF ITS OVERPRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PROTEIN-SYNTHESIS; SECONDARY STRUCTURE; CAP RECOGNITION; DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; CROSS-LINKING; YEAST; TRANSLATION; TRANSCRIPTION	The eukaryotic translational initiation factor 4E (eIF-4E) is an essential protein that binds the 5' cap structure with high specificity and affinity. Yeast eIF-4E is homologous to eIF-4E of higher eukaryotes, but interacts with a different set of cap-binding complex proteins. In the present study the distribution of yeast eIF-4E in Saccharomyces cerevisiae was found to be similar to that observed in higher cells, whereby the yeast factor was more concentrated in the nucleus than in the cytoplasm. Overexpression of yeast eIF-4E in S. cerevisiae exerted at most a minimal effect on growth in liquid minimal medium and was not found to influence the translation of reporter gene mRNAs bearing secondary structure in their leader regions. In a new method to study mRNA-protein interactions, biotinylated mRNAs were synthesized in vitro for use in studies of the binding of eIF-4E in yeast extracts. Streptavidin was used to adsorb the biotinylated mRNAs plus bound initiation factors. Stem-loop structures in the leader region did not influence the binding of eIF-4E or, in comparative experiments, of eIF-4A Thus yeast eIF-4E shows both similarities and differences with respect to the distribution and function of its counterparts in higher eukaryotes.	GESELL BIOTECHNOL FORSCH MBH,DEPT GENE EXPRESS,D-38124 BRAUNSCHWEIG,GERMANY; GESELL BIOTECHNOL FORSCH MBH,DEPT MICROBIOL,D-38124 BRAUNSCHWEIG,GERMANY; UNIV KENT,BIOL LAB,CANTERBURY,KENT,ENGLAND	Gesellschaft fur Biotechnologische Forschung mbH; Gesellschaft fur Biotechnologische Forschung mbH; University of Kent			Tuite, Mick/ABC-7909-2020; Zanchin, Nilson Ivo Tonin/AAB-4907-2019	Tuite, Mick/0000-0002-5214-540X; Zanchin, Nilson Ivo Tonin/0000-0002-1153-0694				ALTMANN M, 1985, BIOCHEMISTRY-US, V24, P6085, DOI 10.1021/bi00343a009; ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P5923, DOI 10.1093/nar/17.15.5923; ALTMANN M, 1989, MOL CELL BIOL, V9, P4467, DOI 10.1128/MCB.9.10.4467; ALTMANN M, 1988, J BIOL CHEM, V263, P17229; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1988, GENE, V74, P517, DOI 10.1016/0378-1119(88)90184-9; GERSTEL B, 1992, MOL MICROBIOL, V6, P2339, DOI 10.1111/j.1365-2958.1992.tb01409.x; GOYER C, 1989, J BIOL CHEM, V264, P7603; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; JOBLING SA, 1988, NUCLEIC ACIDS RES, V16, P4483, DOI 10.1093/nar/16.10.4483; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; LANKER S, 1992, J BIOL CHEM, V267, P21167; LASO MRV, 1993, J BIOL CHEM, V268, P6453; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEE KAW, 1983, J BIOL CHEM, V258, P707; LEIBKOMICZH F, 1992, P NATL ACAD SCI USA, V89, P9612; LUNSDORF H, 1991, J BACTERIOL, V173, P978; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OLIVEIRA CC, 1993, MOL MICROBIOL, V9, P521, DOI 10.1111/j.1365-2958.1993.tb01713.x; PELLETIER J, 1985, MOL CELL BIOL, V5, P3222, DOI 10.1128/MCB.5.11.3222; RAY BK, 1985, J BIOL CHEM, V260, P7651; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; Tuite M F, 1986, Yeast, V2, P35, DOI 10.1002/yea.320020103; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	37	77	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6117	6123						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119957				2022-12-27	WOS:A1994MY84000096
J	REHAKRANTZ, LJ; NONAY, RL				REHAKRANTZ, LJ; NONAY, RL			MOTIF-A OF BACTERIOPHAGE-T4 DNA-POLYMERASE - ROLE IN PRIMER EXTENSION AND DNA-REPLICATION FIDELITY - ISOLATION OF NEW ANTIMUTATOR AND MUTATOR DNA-POLYMERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; ESCHERICHIA-COLI; REVERSE-TRANSCRIPTASE; WILD-TYPE; ACCESSORY PROTEINS; BIOCHEMICAL BASIS; MUTANT; ACID; GENE; TRIPHOSPHOHYDROLASE	Polymerases in general share only a few regions of amino acid similarity. One of the most conserved regions, called motif A, has the sequence DXXSLYPSII or a similar sequence in many eukaryotic and viral DNA polymerases and in bacteriophage T4 DNA polymerase. We designed genetic techniques to isolate mutant T4 DNA polymerases with amino acid substitutions in this highly conserved motif. The mutant DNA polymerases differed from wild type T4 DNA polymerase in several ways. For one mutant DNA polymerase, the pyrophosphate analog, phosphonoacetic acid, was a potent inhibitor of DNA replication, and this mutant DNA polymerase replicated DNA with reduced fidelity. Another mutant DNA polymerase replicated DNA with increased accuracy, but this mutant DNA polymerase was less processive in primer extension reactions, and DNA replication required high concentrations of deoxynucleoside triphosphates. We provide evidence that indicates that all of these changes to DNA polymerase function are due to differences in how the mutant DNA polymerases partition between states active for DNA replication or exonucleolytic proofreading. These studies also provide further support for the hypothesis that the accuracy of DNA replication observed for DNA polymerases depends on the interplay between polymerase and 3' --> 5' exonuclease activities (Muzyczka, N., Poland, R. L., and Bessman, M. J. (1972) J. Biol. Chem. 247, 7116-7122).			REHAKRANTZ, LJ (corresponding author), UNIV ALBERTA,DEPT GENET,EDMONTON T6G 2E9,AB,CANADA.		Reha-Krantz, Linda/A-3748-2014	Reha-Krantz, Linda/0000-0003-4497-423X				ALLEN EF, 1970, GENETICS, V65, P187; BEAUCHAMP BB, 1988, P NATL ACAD SCI USA, V85, P2563, DOI 10.1073/pnas.85.8.2563; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BESSMAN MJ, 1974, J MOL BIOL, V88, P409, DOI 10.1016/0022-2836(74)90491-4; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CLAYTON LK, 1979, J BIOL CHEM, V254, P1902; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DRAKE JW, 1969, NATURE, V221, P1128, DOI 10.1038/2211128a0; ERIKSSON B, 1982, BIOCHIM BIOPHYS ACTA, V696, P115, DOI 10.1016/0167-4781(82)90018-5; FERSHT AR, 1982, J MOL BIOL, V156, P37, DOI 10.1016/0022-2836(82)90457-0; GAUSS P, 1983, P NATL ACAD SCI-BIOL, V80, P1669, DOI 10.1073/pnas.80.6.1669; GIBBS JS, 1988, P NATL ACAD SCI USA, V85, P6672, DOI 10.1073/pnas.85.18.6672; GILLIN FD, 1976, J BIOL CHEM, V251, P5219; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; HALL JD, 1985, P NATL ACAD SCI USA, V82, P3889, DOI 10.1073/pnas.82.11.3889; JARVIK J, 1975, P NATL ACAD SCI USA, V72, P2738, DOI 10.1073/pnas.72.7.2738; Joyce CM, 1991, CURR OPIN STRUC BIOL, V1, P123, DOI 10.1016/0959-440X(91)90020-T; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUNKEL TA, 1992, J BIOL CHEM, V267, P18251; LARDER BA, 1987, EMBO J, V6, P169, DOI 10.1002/j.1460-2075.1987.tb04735.x; LEINBACH SS, 1976, BIOCHEMISTRY-US, V15, P426, DOI 10.1021/bi00647a029; LIN TC, 1987, P NATL ACAD SCI USA, V84, P7000, DOI 10.1073/pnas.84.20.7000; MACE DC, 1984, J MOL BIOL, V177, P313, DOI 10.1016/0022-2836(84)90459-5; MAO JCH, 1975, J VIROL, V15, P1281, DOI 10.1128/JVI.15.5.1281-1283.1975; MCPHEETERS DS, 1986, NUCLEIC ACIDS RES, V14, P5813, DOI 10.1093/nar/14.14.5813; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; OLESON AE, 1964, J BIOL CHEM, V239, P2935; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; REDDY MK, 1992, J BIOL CHEM, V267, P14157; REHAKRANTZ LJ, 1986, J MOL BIOL, V189, P261, DOI 10.1016/0022-2836(86)90508-5; REHAKRANTZ LJ, 1993, J BIOL CHEM, V268, P27100; REHAKRANTZ LJ, 1993, J VIROL, V67, P60, DOI 10.1128/JVI.67.1.60-66.1993; REHAKRANTZ LJ, 1985, J MOL BIOL, V186, P505, DOI 10.1016/0022-2836(85)90125-1; REHAKRANTZ LJ, 1989, J VIROL, V63, P4762, DOI 10.1128/JVI.63.11.4762-4766.1989; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; ROZOVSKAYA T A, 1981, Molekulyarnaya Biologiya (Moscow), V15, P1205; SETO D, 1988, J BIOL CHEM, V263, P1494; SPICER EK, 1988, J BIOL CHEM, V263, P7478; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; VENKATESAN M, 1982, J BIOL CHEM, V257, P2435; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867; WURGLER SM, 1990, P NATL ACAD SCI USA, V87, P2740, DOI 10.1073/pnas.87.7.2740; YU H, 1992, J BIOL CHEM, V267, P10888	47	72	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5635	5643						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119900				2022-12-27	WOS:A1994MY84000027
J	COHENFIX, O; LIVNEH, Z				COHENFIX, O; LIVNEH, Z			IN-VITRO UV MUTAGENESIS ASSOCIATED WITH NUCLEOTIDE EXCISION-REPAIR GAPS IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-III; ALPHA-SUBUNIT; BETA-SUBUNIT; BACTERIOPHAGE-LAMBDA; ULTRAVIOLET-LIGHT; COLI; HOLOENZYME; REPLICATION; GENE; PURIFICATION	Using a cell-free system for UV mutagenesis we have recently shown that extracts prepared from Escherichia coli cells promote a W mutagenesis pathway that depends on the uvrABC repair genes independent of DNA replication (type II UV mutagenesis; Cohen-Fix, O., and Livneh, Z. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 3300-3304). Type II W mutagenesis was defective also in extracts prepared from a uvrD strain. These deficiencies were complemented by adding purified UvrA, UvrB, UvrC, or UvrD proteins to the respective cell extracts. The Uvr proteins act at an early stage in the process, probably preparing a premutagenic single-stranded DNA gap, which subsequently serves as a substrate for the mutagenic reaction. Type II UV mutagenesis was not dependent on DNA polymerases I or on DNA polymerase II, but it was dependent on DNA polymerase III. Thus, similar to the in vivo situation, only DNA polymerase III is essential for UV mutagenesis. Antibodies against the beta subunit of DNA polymerase III holoenzyme inhibited DNA replication but not W mutagenesis. Thus, the processivity subunit of the holoenzyme is not required for type II W mutagenesis, in agreement with a mechanism involving filling-in of short single-stranded DNA gaps.	WEIZMANN INST SCI, DEPT BIOCHEM, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								[Anonymous], 1985, DNA REPAIR; BATES H, 1989, J BACTERIOL, V171, P2480, DOI 10.1128/jb.171.5.2480-2484.1989; BONNER CA, 1990, P NATL ACAD SCI USA, V87, P7663, DOI 10.1073/pnas.87.19.7663; BRESLER SE, 1975, MUTAT RES, V29, P467, DOI 10.1016/0027-5107(75)90065-2; BRIDGES BA, 1971, MUTAT RES, V13, P1, DOI 10.1016/0027-5107(71)90120-5; BRIDGES BA, 1976, MOL GEN GENET, V144, P53, DOI 10.1007/BF00277304; BRIDGES BA, 1990, MUTAGENESIS, V5, P35, DOI 10.1093/mutage/5.1.35; BRIDGES BA, 1992, MUTAT RES, V270, P135, DOI 10.1016/0027-5107(92)90124-K; BROTCORNELANNOYE A, 1985, MOL GEN GENET, V199, P64, DOI 10.1007/BF00327511; BRYAN SK, 1990, MUTAT RES, V243, P313, DOI 10.1016/0165-7992(90)90149-E; BURCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811, DOI 10.1073/pnas.85.6.1811; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; COHENFIX O, 1992, P NATL ACAD SCI USA, V89, P3300, DOI 10.1073/pnas.89.8.3300; DUTREIX M, 1989, J BACTERIOL, V171, P2415, DOI 10.1128/jb.171.5.2415-2423.1989; FAY PJ, 1981, J BIOL CHEM, V256, P976; GROSSMAN L, 1990, MUTAT RES, V236, P213, DOI 10.1016/0921-8777(90)90006-Q; HAGENSEE ME, 1987, P NATL ACAD SCI USA, V84, P4195, DOI 10.1073/pnas.84.12.4195; IWASAKI H, 1990, J BACTERIOL, V172, P6268, DOI 10.1128/jb.172.11.6268-6273.1990; JOYCE CM, 1984, J BACTERIOL, V158, P636, DOI 10.1128/JB.158.2.636-643.1984; KATO T, 1977, MOL GEN GENET, V156, P121, DOI 10.1007/BF00283484; KENYON CJ, 1980, P NATL ACAD SCI-BIOL, V77, P2819, DOI 10.1073/pnas.77.5.2819; KITAGAWA Y, 1985, P NATL ACAD SCI USA, V82, P4336, DOI 10.1073/pnas.82.13.4336; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1991, DNA REPLICATION; KOW YW, 1993, J BACTERIOL, V175, P561, DOI 10.1128/JB.175.2.561-564.1993; LAM LH, 1987, MUTAT RES, V178, P167, DOI 10.1016/0027-5107(87)90266-1; LIVNEH Z, 1993, IN PRESS CRC CRIT RE; MAKI H, 1989, J BACTERIOL, V171, P3139, DOI 10.1128/jb.171.6.3139-3143.1989; MAKI H, 1985, J BIOL CHEM, V260, P2982; MAKI H, 1985, J BIOL CHEM, V260, P2987; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; Miller J.H., 1972, EXPT MOL GENETICS; MOK M, 1987, J BIOL CHEM, V262, P16644; NISHIOKA H, 1970, MUTAT RES, V9, P349, DOI 10.1016/0027-5107(70)90017-5; NISHIOKA H, 1969, MUTAT RES, V8, P215, DOI 10.1016/0027-5107(69)90001-3; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; PERRY KL, 1985, P NATL ACAD SCI USA, V82, P4331, DOI 10.1073/pnas.82.13.4331; PERRY KL, 1982, NATURE, V300, P278, DOI 10.1038/300278a0; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SHAVITT O, 1989, J BIOL CHEM, V264, P11275; SHAVITT O, 1989, J BACTERIOL, V171, P3530, DOI 10.1128/jb.171.6.3530-3538.1989; SHWARTZ H, 1988, J BIOL CHEM, V263, P18277; SKALITER R, 1992, MUTAT RES, V267, P139, DOI 10.1016/0027-5107(92)90118-L; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; SVOBODA DL, 1993, J BIOL CHEM, V268, P10694; SWEASY JB, 1990, J BACTERIOL, V172, P303; TADMOR Y, 1992, J BACTERIOL, V174, P2517, DOI 10.1128/jb.174.8.2517-2524.1992; TAIT RC, 1974, P NATL ACAD SCI USA, V71, P675, DOI 10.1073/pnas.71.3.675; THOMAS DC, 1985, J BIOL CHEM, V260, P9875; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WASHBURN BK, 1991, J BACTERIOL, V173, P2569, DOI 10.1128/jb.173.8.2569-2575.1991; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976; WOODGATE R, 1989, P NATL ACAD SCI USA, V86, P7301, DOI 10.1073/pnas.86.19.7301; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535; YOUNGS DA, 1973, NATURE-NEW BIOL, V244, P240, DOI 10.1038/newbio244240a0	58	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4953	4958						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106470				2022-12-27	WOS:A1994MX57100042
J	FERREIRA, PA; PAK, WL				FERREIRA, PA; PAK, WL			BOVINE PHOSPHOLIPASE-C HIGHLY HOMOLOGOUS TO THE NORPA PROTEIN OF DROSOPHILA IS EXPRESSED SPECIFICALLY IN CONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYCLIC-GMP; PHOTORECEPTORS; PHOTOTRANSDUCTION; EXCITATION; GENE; ADAPTATION; RETINA; LIGHT	The Drosophila norpA gene encodes a phosphatidylinositol-specific phospholipase C (PI-PLC) expressed predominantly in photoreceptors and involved in phototransduction. However, no direct role for a phospholipase C in vertebrate phototransduction has been identified to date. Recently, we reported the isolation and characterization of bovine cDNAs encoding PI-PLC isoforms expressed predominantly in the retina and with higher homology to the NorpA protein than to any other known PI-PLC. Here, we present evidence that the norpA-homologous bovine retinal PI-PLCs, although found in other retinal neurons as well, are found in cones but not in rods. The results suggest that the phototransduction cascade in cones may utilize phospholipase C in addition to phosphodiesterase.			FERREIRA, PA (corresponding author), PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA.		Ferreira, Paulo/A-3893-2008; Ferreira, Paulo A/S-4209-2016	Ferreira, Paulo A/0000-0003-4585-1717	NATIONAL EYE INSTITUTE [R01EY000033, R37EY000033] Funding Source: NIH RePORTER; NEI NIH HHS [EY00033] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSEN V, 1988, OCEANOL ACTA, V9, P211; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; DAS ND, 1986, CELL STRUCT FUNCT, V11, P53, DOI 10.1247/csf.11.53; FEIN A, 1986, TRENDS NEUROSCI, V9, P110, DOI 10.1016/0166-2236(86)90037-8; FERREIRA PA, 1993, P NATL ACAD SCI USA, V90, P6042, DOI 10.1073/pnas.90.13.6042; HAYNES LW, 1990, J PHYSIOL-LONDON, V429, P451, DOI 10.1113/jphysiol.1990.sp018267; JELSEMA CL, 1989, ANN NY ACAD SCI, V559, P158; KAUPP UB, 1992, ANNU REV PHYSIOL, V54, P153; LEE CW, 1993, J BIOL CHEM, V268, P21318; LEREA CL, 1989, NEURON, V3, P367, DOI 10.1016/0896-6273(89)90261-4; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; MEYERTHOLEN EP, 1987, J COMP PHYSIOL A, V161, P793, DOI 10.1007/BF00610221; PAK WL, 1991, PHOTOCHEM PHOTOBIOL, V53, P871, DOI 10.1111/j.1751-1097.1991.tb09901.x; PAYNE R, 1986, PHOTOBIOCH PHOTOBIOP, V13, P373; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; ROSENFELD PJ, 1992, NAT GENET, V1, P209, DOI 10.1038/ng0692-209; SCHNEUWLY S, 1991, J BIOL CHEM, V266, P24314; SOLESSIO E, 1993, NATURE, V364, P442, DOI 10.1038/364442a0; STRYER L, 1991, J BIOL CHEM, V266, P10711; TOMITA T, 1965, COLD SPRING HARB SYM, V30, P559, DOI 10.1101/SQB.1965.030.01.054; TOYOSHIMA S, 1990, J BIOL CHEM, V265, P14842; ZHU LQ, 1993, J BIOL CHEM, V268, P15994	23	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3129	3131						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106345				2022-12-27	WOS:A1994MV63100002
J	JETTON, TL; LIANG, Y; PETTEPHER, CC; ZIMMERMAN, EC; COX, FG; HORVATH, K; MATSCHINSKY, FM; MAGNUSON, MA				JETTON, TL; LIANG, Y; PETTEPHER, CC; ZIMMERMAN, EC; COX, FG; HORVATH, K; MATSCHINSKY, FM; MAGNUSON, MA			ANALYSIS OF UPSTREAM GLUCOKINASE PROMOTER ACTIVITY IN TRANSGENIC MICE AND IDENTIFICATION OF GLUCOKINASE IN RARE NEUROENDOCRINE CELLS IN THE BRAIN AND GUT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; FACILITATIVE GLUCOSE TRANSPORTER; DEPENDENT DIABETES-MELLITUS; HUMAN GROWTH-HORMONE; HYPOTHALAMIC NEURONS; INSITU HYBRIDIZATION; CHOROID-PLEXUS; ISLET CELLS; K+ CHANNELS; PEPTIDE-I	A transgene consisting of an upstream glucokinase (GK) promoter fragment linked to coding sequences of the human growth hormone gene was expressed in certain neuroendocrine cells of the pancreas, pituitary, brain, gut, thyroid, and lungs of mice. In pancreas, the transgene was expressed in a nonuniform manner among beta cells and in a variable but substantial fraction of the other islet cell types. In pituitary, it was expressed in corticotropes, and in brain, it was expressed in cells of the medial hypothalamus. Within the gut transgene expression was detected in a subset of enteroendocrine cells of the stomach and duodenal epithelium, some of which also exhibited glucagon-like polypeptide-1 immunoreactivity. In thyroid, transgene expression was observed in C cells of neonatal animals, whereas in the lung, it was expressed among rare endocrine cells of the bronchopulmonary mucosa. RNA polymerase chain reaction analysis of human growth hormone mRNA corroborated the tissue-specific transgene expression pattern. Prompted by the finding of transgene expression in specific neuroendocrine cells, we sought to determine whether GK mRNA and GK itself was also expressed in the brain and gut, tissues not previously associated with the expression of this enzyme. Using rat tissues, GK mRNA was detected by RNA polymerase chain reaction in both the brain and intestine and was localized to specific cells in the hypothalamus and enteric mucosa by in situ hybridization. A high K(m) glucose phosphorylating activity was detected from isolated rat jejunal enterocytes that displayed a chromatographic elution profile identical to hepatic GK. GK immunoreactivity was detected in cells of the medial hypothalamus with many of the same cells also displaying GLUT2 immunoreactivity. Together, these studies provide evidence for upstream GK promoter activity, GK mRNA, and GK itself in certain neuroendocrine cells outside the pancreatic islet and lead us to suggest that GK may play a broader role in glucose sensing by neuroendocrine cells than was thought previously.	VANDERBILT UNIV, MED CTR,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS, 702 LIGHT HALL, NASHVILLE, TN 37232 USA; UNIV PENN, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA; UNIV PENN, DIABET RES CTR, PHILADELPHIA, PA 19104 USA; HAHNEMANN UNIV, DEPT PEDIAT, PHILADELPHIA, PA 19102 USA	Vanderbilt University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Drexel University			Magnuson, Mark/AAY-7172-2021; Magnuson, Mark A/B-1335-2009	Magnuson, Mark/0000-0002-8824-6499; Magnuson, Mark A/0000-0002-8824-6499	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042612] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07563, DK42612, DK42502] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; ANDREONE TL, 1989, J BIOL CHEM, V264, P363; ANGERER LM, 1987, IN SITU HYBRIDIZATIO, P42; ASHFORD MLJ, 1990, PFLUG ARCH EUR J PHY, V415, P479, DOI 10.1007/BF00373626; BEDOYA FJ, 1985, ANAL BIOCHEM, V144, P504, DOI 10.1016/0003-2697(85)90147-2; BRANT AM, 1993, BIOCHEM BIOPH RES CO, V192, P1297, DOI 10.1006/bbrc.1993.1557; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVAGNINO J, 1980, J BIOL CHEM, V255, P2633; DEANE R, 1985, J PHYSIOL-LONDON, V362, P245, DOI 10.1113/jphysiol.1985.sp015674; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; EISSELE R, 1992, EUR J CLIN INVEST, V22, P283, DOI 10.1111/j.1365-2362.1992.tb01464.x; FARRELL CL, 1992, J HISTOCHEM CYTOCHEM, V40, P193, DOI 10.1177/40.2.1552163; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; GEFEL D, 1990, ENDOCRINOLOGY, V126, P2164, DOI 10.1210/endo-126-4-2164; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056/NEJM199205143262003; HACKER HJ, 1991, HISTOCHEMISTRY, V96, P435, DOI 10.1007/BF00316001; HOGAN B, 1986, MANIPULATING MOUSE E; HOLZ GG, 1992, TRENDS BIOCHEM SCI, V17, P388, DOI 10.1016/0968-0004(92)90006-U; HUGHES SD, 1991, J BIOL CHEM, V266, P4521; IYNEDJIAN PB, 1986, P NATL ACAD SCI USA, V83, P1998, DOI 10.1073/pnas.83.7.1998; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; Le Douarin N.M., 1982, NEURAL CREST; LIANG Y, 1991, J BIOL CHEM, V266, P6999; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MEGLASSON MD, 1983, P NATL ACAD SCI-BIOL, V80, P85, DOI 10.1073/pnas.80.1.85; MEI N, 1978, J PHYSIOL-LONDON, V282, P485, DOI 10.1113/jphysiol.1978.sp012477; MISLER S, 1992, DIABETES, V41, P1221, DOI 10.2337/diabetes.41.10.1221; MOBBS CV, 1990, REV BIOL RES AGING, V4, P201; MOJSOV S, 1990, J BIOL CHEM, V265, P8001; NAGAMATSU S, 1992, J BIOL CHEM, V267, P467; OOMURA Y, 1992, AM J CLIN NUTR, V55, P278; PALMITER RD, 1982, NATURE, V300, P611, DOI 10.1038/300611a0; PARDRIDGE WM, 1990, J BIOL CHEM, V265, P18035; PICTET R, 1972, HDB PHYSL ENDOCRINOL, V7, P25; PRASAD AS, 1972, J LAB CLIN MED, V80, P598; PRELLER A, 1992, ARCH BIOCHEM BIOPHYS, V294, P482, DOI 10.1016/0003-9861(92)90715-9; PRICE JM, 1950, CANCER RES, V10, P18; PRINTZ RL, 1993, ANNU REV NUTR, V13, P463, DOI 10.1146/annurev.nu.13.070193.002335; SALAS J, 1965, J BIOL CHEM, V240, P1014; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHELTON KD, 1992, MOL CELL BIOL, V12, P4578, DOI 10.1128/MCB.12.10.4578; SHIMIZU N, 1983, BRAIN RES, V265, P49, DOI 10.1016/0006-8993(83)91332-X; STEWART TA, 1993, TRENDS ENDOCRIN MET, V4, P136, DOI 10.1016/1043-2760(93)90038-G; SUZUE K, 1989, NUCLEIC ACIDS RES, V17, P10099, DOI 10.1093/nar/17.23.10099; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; TREHERNE JM, 1992, P ROY SOC B-BIOL SCI, V247, P121, DOI 10.1098/rspb.1992.0017; TRUS MD, 1981, DIABETES, V30, P911, DOI 10.2337/diabetes.30.11.911; UNGER RH, 1969, ARCH INTERN MED, V123, P261, DOI 10.1001/archinte.123.3.261; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V11, P1; WEISER MM, 1971, J BIOL CHEM, V246, P2331; YIN L, 1992, DIABETES, V41, P792	55	262	269	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3641	3654						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106409				2022-12-27	WOS:A1994MV63100077
J	MILLER, CC; HALE, P; PENTLAND, AP				MILLER, CC; HALE, P; PENTLAND, AP			ULTRAVIOLET-B INJURY INCREASES PROSTAGLANDIN SYNTHESIS THROUGH A TYROSINE KINASE-DEPENDENT PATHWAY - EVIDENCE FOR UVB-INDUCED EPIDERMAL GROWTH-FACTOR RECEPTOR ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; MAMMALIAN-CELLS; FACTOR BINDING; HUMAN-SKIN; PHOSPHOLIPASE-A2; IRRADIATION; INHIBITION; KERATINOCYTES; LIGHT; FIBROBLASTS	To study the signal transduction mechanisms by which unltraviolet B (UVB) leads to increased prostaglandin E2 (PGE2) Synthesis, human epidermal cultures were irradiated with 30 mJ/cm2 UVB and assayed for 6-h cumulative PGE2. Supernatants from irradiated cultures showed a 4-fold increase in PGE2 synthesis (113.6 +/- 26.8 pg/mg protein) when compared to supernatants from sham-irradiated cultures (25.6 +/- 3.9 pg/mg protein). Pretreatment of irradiated cultures with genistein (10 pg/ml) or tyrphostin-23 (50 muM), inhibitors of tyrosine kinases, blocked UVB-stimulated PGE2 synthesis. Treatment of nonirradiated cultures with epidermal growth factor (EGF), which acts through the receptor tyrosine kinase EGF-R, produced a 4-fold increase in PGE2 Synthesis. However, addition of EGF to irradiated cultures did not further enhance their PGE2 synthesis, indicating irradiation rendered them refractory to EGF stimulation. In contrast, irradiated cultures could still significantly increase their PGE2 synthesis in response to the calcium ionophore A23187 or the protein kinase C activator 12-0-tetradecanoylphorbol-13-acetate, suggesting that the lack of response to EGF was selective. Furthermore, anti-phosphotyrosine immunoblot analysis revealed UVB-induced phosphorylation of tyrosine residues of EGF-R, an indicator of receptor activation. Phosphorylation was maximal 30-60 min after irradiation and was blocked by the tyrosine kinase inhibitors, genistein and tyrphostin. The antioxidant N-acetylcysteine decreased UVB-induced EGF-R tyrosine phosphorylation and PGE2 Synthesis to near-basal levels. Conversely, treatment of unirradiated cultures with the potent oxidant tert-butyl-hydroperoxide (100 muM) increased both PGE2 synthesis and EGF-R phosphorylation. Collectively, these data suggest that antioxidant depletion induced by UV results in tyrosine phosphorylation and activation of the EGF-R. This activation may subsequently activate epidermal phospholipase at early time points after UVB exposure.	WASHINGTON UNIV, SCH MED,DEPT MED,DIV DERMATOL,660 S EUCLID AVE, CAMPUS BOX 8123, ST LOUIS, MO 63110 USA	Washington University (WUSTL)					NIAMS NIH HHS [K04 AR01849, AR40574] Funding Source: Medline; NIDDK NIH HHS [DK38111] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040574, K04AR001849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038111] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x; ANDERSON RR, 1981, J INVEST DERMATOL, V77, P13, DOI 10.1111/1523-1747.ep12479191; BLACK AK, 1978, BRIT J CLIN PHARMACO, V5, P431, DOI 10.1111/j.1365-2125.1978.tb01650.x; BLACK AK, 1980, BRIT J CLIN PHARMACO, V10, P453, DOI 10.1111/j.1365-2125.1980.tb01788.x; BROOKS G, 1990, CARCINOGENESIS, V11, P1223, DOI 10.1093/carcin/11.7.1223; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CLARK S, 1991, BIOCHEM J, V274, P715, DOI 10.1042/bj2740715; COYNE DW, 1990, BIOCHEM BIOPH RES CO, V173, P718, DOI 10.1016/S0006-291X(05)80094-4; DELEO VA, 1985, PHOTOCHEM PHOTOBIOL, V41, P51; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FUCHS J, 1989, J INVEST DERMATOL, V93, P769, DOI 10.1111/1523-1747.ep12284412; FUCHS J, 1989, PHOTOCHEM PHOTOBIOL, V50, P739, DOI 10.1111/j.1751-1097.1989.tb02904.x; GOLDBERG HJ, 1990, BIOCHEM J, V267, P461, DOI 10.1042/bj2670461; GOLDMAN R, 1992, FEBS LETT, V309, P190, DOI 10.1016/0014-5793(92)81092-Z; GUPTA N, 1973, BRIT J PHARMACOL, V47, P240, DOI 10.1111/j.1476-5381.1973.tb08321.x; HACK N, 1991, BIOCHEM J, V275, P563, DOI 10.1042/bj2750563; HAWK JLM, 1983, PHOTOIMMUNOLOGY, P219; HELIN K, 1991, ONCOGENE, V6, P825; HRUZA LL, 1993, J INVEST DERMATOL, V100, pS35, DOI 10.1111/1523-1747.ep12355240; KANGROTONDO CH, 1993, AM J PHYSIOL, V264, pC396, DOI 10.1152/ajpcell.1993.264.2.C396; KING J, 1971, J MOL BIOL, V62, P465, DOI 10.1016/0022-2836(71)90148-3; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MATSUI MS, 1989, J INVEST DERMATOL, V92, P617, DOI 10.1111/1523-1747.ep12712158; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; NISHI J, 1991, J INVEST DERMATOL, V97, P115, DOI 10.1111/1523-1747.ep12478534; PENTLAND AP, 1990, J CLIN INVEST, V86, P566, DOI 10.1172/JCI114746; PENTLAND AP, 1992, J BIOL CHEM, V267, P15578; PENTLAND AP, 1991, AM J PHYSIOL, V261, pR543, DOI 10.1152/ajpregu.1991.261.3.R543; PUNNONEN K, 1992, J INVEST DERMATOL, V99, P221, DOI 10.1111/1523-1747.ep12650445; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; SNYDER DS, 1974, J INVEST DERMATOL, V62, P47, DOI 10.1111/1523-1747.ep12676722; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SPAARGAREN M, 1992, BIOCHEM J, V287, P37, DOI 10.1042/bj2870037; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233	40	138	142	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3529	3533						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106395				2022-12-27	WOS:A1994MV63100062
J	MUKHERJEE, SK; REDDY, MK; KUMAR, D; TEWARI, KK				MUKHERJEE, SK; REDDY, MK; KUMAR, D; TEWARI, KK			PURIFICATION AND CHARACTERIZATION OF A EUKARYOTIC TYPE-1 TOPOISOMERASE FROM PEA CHLOROPLAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASES; REPLICATION; CEREVISIAE; INVITRO; TRANSCRIPTION; PROTEIN; LINKAGE; ORIGIN; CELLS	A 69-kDa protein with topoisomerase I activity has been homogeneously purified from the chloroplasts of pea leaves. The topoisomerase properties are detected in crude lysate of pea chloroplasts using the technique of transferring P-32 radioactivity from the P-32-labeled DNA to the protein. The purified enzyme relaxes both positive and negative supercoils in topological steps of unity without requiring magnesium ions. The enzyme is sensitive to topoisomerase I-specific inhibitors like camptothecin and berenil, and unaffected by reagents like novobiocin and doxorubicin at the topoisomerase II-inhibitory dosage. In the presence of the enzyme, supercoiled DNA is nicked, and the 3'-phosphoryl end of the nick becomes covalently linked with the enzyme. A tyrosine residue of the enzyme is responsible for the covalent linkage. Rabbit antiserum raised against the 16-mer peptide spanning the active residues of hu an topoisomerase I recognizes the 69-kDa protein within the crude lysate of pea chloroplasts as does the antiserum to the purified 69-kDa protein. From the enzymatic characteristics, the protein has been classified as a eukaryotic type I topoisomerase.	UNIV CALIF IRVINE, DEPT MOLEC BIOL & BIOCHEM, IRVINE, CA 92717 USA	University of California System; University of California Irvine	MUKHERJEE, SK (corresponding author), INT CTR GENET ENGN & BIOTECHNOL, NII CAMPUS, ARUNA ASAF ALI MARG, NEW DELHI 110067, INDIA.							BOGORAD L, 1991, MOL BIOL PLASTIDS, P39; CAIRNS J, 1963, J MOL BIOL, V6, P208, DOI 10.1016/S0022-2836(63)80070-4; CHIU WL, 1992, MOL GEN GENET, V232, P33, DOI 10.1007/BF00299134; CHOW K-C, 1985, Biotechniques, V3, P290; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; COLE AD, 1992, PLANT MOL BIOL, V19, P265, DOI 10.1007/BF00027348; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; FUKATA H, 1991, J BIOCHEM-TOKYO, V109, P127, DOI 10.1093/oxfordjournals.jbchem.a123332; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P3274, DOI 10.1128/MCB.5.11.3274; IKEDA JE, 1979, J BIOL CHEM, V254, P9416; KAGUNI JM, 1984, J BIOL CHEM, V259, P8578; KOLODNER RD, 1975, NATURE, V256, P708, DOI 10.1038/256708a0; LAKHANI S, 1992, BIOCHEM J, V286, P833, DOI 10.1042/bj2860833; LAM E, 1987, PLANT MOL BIOL, V8, P415, DOI 10.1007/BF00015819; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MINDEN JS, 1986, J BIOL CHEM, V261, P1906; MULLER MT, 1985, EMBO J, V4, P1237, DOI 10.1002/j.1460-2075.1985.tb03766.x; NIELSEN BL, 1988, PLANT MOL BIOL, V11, P3, DOI 10.1007/BF00016009; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; PERRY SE, 1991, J BIOL CHEM, V266, P11882; PYKE KA, 1989, FEBS LETT, V242, P305, DOI 10.1016/0014-5793(89)80490-9; ROBINSON C, 1988, PLANT MOL BIOL PRACT, P67; ROSS CF, 1983, BIOCHIM BIOPHYS ACTA, V741, P230, DOI 10.1016/0167-4781(83)90063-5; ROWE TC, 1984, J BIOL CHEM, V259, P9177; ROWE TC, 1981, J BIOL CHEM, V256, P354; Sambrook J, 1989, MOL CLONING LABORATO; SIEDLECKI J, 1983, NUCLEIC ACIDS RES, V11, P1523, DOI 10.1093/nar/11.5.1523; SLESAREV AI, 1993, NATURE, V364, P735, DOI 10.1038/364735a0; Sternglanz R, 1989, CURR OPIN CELL BIOL, V1, P533, DOI 10.1016/0955-0674(89)90016-1; STEWART AF, 1987, CELL, V50, P1109, DOI 10.1016/0092-8674(87)90177-2; SUN E, 1986, PLANT MOL BIOL, V6, P429, DOI 10.1007/BF00027135; TAKEDA Y, 1992, MOL GEN GENET, V232, P191, DOI 10.1007/BF00279996; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRASK DK, 1984, EMBO J, V3, P671, DOI 10.1002/j.1460-2075.1984.tb01865.x; TSE YC, 1980, J BIOL CHEM, V255, P5560; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665	39	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3793	3801						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106424				2022-12-27	WOS:A1994MV63100097
J	ZHANG, L; CASTELLINO, FJ				ZHANG, L; CASTELLINO, FJ			THE BINDING-ENERGY OF HUMAN COAGULATION PROTEIN-C TO ACIDIC PHOSPHOLIPID-VESICLES CONTAINS A MAJOR CONTRIBUTION FROM LEUCINE-5 IN THE GAMMA-CARBOXYGLUTAMIC ACID DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOTTING FACTOR-X; BOVINE FACTOR-IX; CONFORMATION-SPECIFIC ANTIBODIES; INVITRO ANTICOAGULANT ACTIVITY; THROMBIN-CATALYZED ACTIVATION; K-DEPENDENT PROTEINS; PROTHROMBIN FRAGMENT-1; MEMBRANE-BINDING; FACTOR-VIII; METAL-IONS	A mutant cDNA of recombinant (r)-human protein C (PC) encoding a Leu5 --> Gln substitution ([Leu5 --> Gln]r-PC) has been constructed and expressed in human 293 cells. A subpopulation of molecules was then purified that contained fully gamma-carboxylated [Leu5 --> Gln]r-PC. Intrinsic fluorescence quenching studies with this mutant protein revealed a C50 for Ca2+ binding (0.24 mM) that was essentially the same as that of wild-type (wt) r-PC (0.35 mM). Additionally, the C50 for the Ca2+ dependence of binding of a Ca2+-specific monoclonal antibody to [Leu5 --> Gln]r-PC, of 5.4 mm-6.5 nM, was similar to that of wtr-PC (4.5 mM). On the other hand, the anticoagulant activity of the activated form of this mutant ([Leu5 --> Gln]r-APC) was only 2% of that of activated wtr-PC (wtr-APC), and the inactivation rate of human factor Va catalyzed by this same mutant enzyme was approximately 10% of that of wtr-APC, at maximal levels of Ca2+. This substantial loss of activity was reconciled with the apparent retention of the integrity of the Ca2+-dependent conformation of this mutant by the finding that this Ca2+-dependent conformation of [Leu5 --> Gln]r-PC interacted poorly with mixed (60:40, w/w) phosphatidylcholine/phosphatidylserine (PL) vesicles. These results suggest that Leu5, a residue strictly conserved in vitamin K-dependent proteins, is required for functional binding of PC to PL vesicles. These findings lend support to recent observations that have shown the importance of hydrophobic interactions in the binding of coagulation factors to PL vesicles. This current work further implicates Leu5 as a possible key participant in this hydrophobic binding energy.	UNIV NOTRE DAME, DEPT CHEM & BIOCHEM, NOTRE DAME, IN 46556 USA	University of Notre Dame					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019982] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-19982] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMPHLETT GW, 1978, J BIOL CHEM, V253, P6774; ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; ATKINS JS, 1992, MOL CELL BIOCHEM, V112, P61; BAJAJ SP, 1977, J BIOL CHEM, V252, P4758; BAJAJ SP, 1976, J BIOL CHEM, V251, P6294; BEALS JM, 1986, BIOCHEM J, V236, P861, DOI 10.1042/bj2360861; BECKMANN RJ, 1985, NUCLEIC ACIDS RES, V13, P5233, DOI 10.1093/nar/13.14.5233; BOROWSKI M, 1986, J BIOL CHEM, V261, P4969; CHIBBER BAK, 1990, INT J PEPT PROT RES, V35, P73; CHURCH WR, 1989, BLOOD, V74, P2418; COLPITTS TL, 1993, INT J PEPT PROT RES, V41, P567; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESMON NL, 1982, J BIOL CHEM, V257, P859; ISAACS BS, 1986, BIOCHEMISTRY-US, V25, P4958, DOI 10.1021/bi00365a036; KEYT B, 1982, J BIOL CHEM, V257, P8687; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; KUSTER H, 1992, J BIOL CHEM, V267, P12782; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; LOWRY OH, 1946, J BIOL CHEM, V162, P421; MANN KG, 1990, BLOOD, V76, P1; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NELSESTUEN GL, 1981, BIOCHEMISTRY-US, V20, P351, DOI 10.1021/bi00505a019; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4172, DOI 10.1021/bi00638a006; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P6886; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STRICKLAND DK, 1980, ARCH BIOCHEM BIOPHYS, V199, P61, DOI 10.1016/0003-9861(80)90256-8; SUGO T, 1985, J BIOL CHEM, V260, P453; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; WAKABAYASHI K, 1986, J BIOL CHEM, V261, P1097; ZHANG L, 1990, BIOCHEMISTRY-US, V29, P10828, DOI 10.1021/bi00500a016; ZHANG L, 1993, J BIOL CHEM, V268, P12040; ZHANG L, 1992, BLOOD, V80, P942; ZHANG L, 1991, BIOCHEMISTRY-US, V30, P6696, DOI 10.1021/bi00241a009	39	65	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3590	3595						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106403				2022-12-27	WOS:A1994MV63100071
J	ROESSLER, PG; OHLROGGE, JB				ROESSLER, PG; OHLROGGE, JB			CLONING AND CHARACTERIZATION OF THE GENE THAT ENCODES ACETYL-COENZYME-A CARBOXYLASE IN THE ALGA CYCLOTELLA-CRYPTICA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; COA CARBOXYLASE; ESCHERICHIA-COLI; SILICON DEFICIENCY; MESSENGER-RNA; PURIFICATION; PROTEINS; SEQUENCE; SUBUNIT; DNA	The gene that encodes acetyl-coenzyme A carboxylase (ACCase; EC 6.4.1.2) in the eukaryotic alga Cyclotella cryptica has been isolated and cloned, representing the first time that a full-length gene for this enzyme has been isolated from a photosynthetic organism. The gene contains a 447-base pair intron that is located near the putative translation initiation codon and a 73-base pair intron that is located slightly upstream from the region that encodes the biotin binding site of the enzyme. The gene encodes a polypeptide that is predicted to be composed of 2089 amino acids and to have a molecular mass of 230 kDa. The deduced amino acid sequence exhibits strong similarity to the sequences of animal and yeast ACCases in the biotin carboxylase and carboxyltransferase domains. There is less sequence similarity in the biotin carboxyl carrier protein domain, although the highly conserved Met-Lys-Met of the biotin binding site is present. The amino terminus of the predicted ACCase sequence has characteristics of a signal sequence, suggesting that the enzyme is imported into chloroplasts via the endoplasmic reticulum, as has been shown to be the case for certain nuclear-encoded proteins that are transported into the chloroplasts of the diatom Phaeodactylum tricornutum. Southern blot analyses suggest that a single copy of this gene is present in C. cryptica.	MICHIGAN STATE UNIV,DEPT BOT & PLANT PATHOL,E LANSING,MI 48824	Michigan State University	ROESSLER, PG (corresponding author), NATL RENEWABLE ENERGY LAB,APPL BIOL SCI BRANCH,GOLDEN,CO 80401, USA.							ALFEEL W, 1992, P NATL ACAD SCI USA, V89, P4534, DOI 10.1073/pnas.89.10.4534; ALIX JH, 1989, DNA-J MOLEC CELL BIO, V8, P779, DOI 10.1089/dna.1989.8.779; BASCOMB NF, 1987, PLANT PHYSIOL, V83, P75, DOI 10.1104/pp.83.1.75; BHAYA D, 1991, MOL GEN GENET, V229, P400, DOI 10.1007/BF00267462; CHAN RL, 1990, EMBO J, V9, P333, DOI 10.1002/j.1460-2075.1990.tb08115.x; CHARLES DJ, 1986, PHYTOCHEMISTRY, V25, P1067, DOI 10.1016/S0031-9422(00)81555-1; EGINBUHLER B, 1983, EUR J BIOCHEM, V133, P335, DOI 10.1111/j.1432-1033.1983.tb07467.x; EGLI MA, 1993, PLANT PHYSIOL, V101, P499, DOI 10.1104/pp.101.2.499; FINLAYSON SA, 1983, ARCH BIOCHEM BIOPHYS, V225, P576, DOI 10.1016/0003-9861(83)90069-3; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIBBS SP, 1979, J CELL SCI, V35, P253; HARWOOD JL, 1988, ANNU REV PLANT PHYS, V39, P101, DOI 10.1146/annurev.arplant.39.1.101; JACKOWSKI S, 1991, BIOCH LIPIDS LIPOPRO, P43; JARVIS EE, 1992, J PHYCOL, V28, P356, DOI 10.1111/j.0022-3646.1992.00356.x; KATSURADA A, 1990, EUR J BIOCHEM, V190, P435, DOI 10.1111/j.1432-1033.1990.tb15593.x; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; KONDO H, 1991, P NATL ACAD SCI USA, V88, P9730, DOI 10.1073/pnas.88.21.9730; Lane M D, 1974, Curr Top Cell Regul, V8, P139; LI SJ, 1992, J BIOL CHEM, V267, P855; LI SJ, 1992, J BIOL CHEM, V267, P16841; LIVNE A, 1990, PLANT CELL PHYSIOL, V31, P851; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; MCCARTHY AD, 1984, TRENDS BIOCHEM SCI, V9, P60, DOI 10.1016/0968-0004(84)90184-1; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; NIKOLAU BJ, 1984, ARCH BIOCHEM BIOPHYS, V228, P86, DOI 10.1016/0003-9861(84)90049-3; PAPE ME, 1988, ARCH BIOCHEM BIOPHYS, V267, P104, DOI 10.1016/0003-9861(88)90013-6; POSTBEITTENMILLER D, 1992, PLANT PHYSIOL, V100, P923, DOI 10.1104/pp.100.2.923; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; ROESSLER PG, 1988, ARCH BIOCHEM BIOPHYS, V267, P521, DOI 10.1016/0003-9861(88)90059-8; ROESSLER PG, 1988, J PHYCOL, V24, P394, DOI 10.1111/j.1529-8817.1988.tb00189.x; ROESSLER PG, 1990, PLANT PHYSIOL, V92, P73, DOI 10.1104/pp.92.1.73; Sambrook J, 1989, MOL CLONING LABORATO; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SCHREINER J B, 1991, Plant Physiology (Rockville), V96, P14; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SLABAS AR, 1985, PLANT SCI, V39, P177, DOI 10.1016/0168-9452(85)90171-2; TAKAI T, 1988, J BIOL CHEM, V263, P2651; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635	40	72	96	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19254	19259						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8103514				2022-12-27	WOS:A1993LW81900019
J	DAVID, F; BERNARD, AM; PIERRES, M; MARGUET, D				DAVID, F; BERNARD, AM; PIERRES, M; MARGUET, D			IDENTIFICATION OF SERINE-624, ASPARTIC ACID-702, AND HISTIDINE-734 AS THE CATALYTIC TRIAD RESIDUES OF MOUSE DIPEPTIDYLPEPTIDASE-IV (CD26) - A MEMBER OF A NOVEL FAMILY OF NONCLASSICAL SERINE HYDROLASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMOCYTE-ACTIVATING MOLECULE; PROLYL OLIGOPEPTIDASE FAMILY; ACTIVE-SITE RESIDUES; T-CELL ACTIVATION; ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODY; SECONDARY STRUCTURE; CDNA CLONING; SUBSTANCE-P; SEQUENCE	Dipeptidyl-peptidase IV (DPP IV, CD26, EC 3.4.14.5), a multifunctional ectoenzyme, is involved not only in the proteolytic cleavage of X-Pro from the NH2 terminus of a variety of biologically active peptides, but also in activation signal transduction and cell matrix adherence processes. We recently characterized mouse DPP IV cDNA and identified the serine protease Gly-X-Ser-X-Gly consensus motif in its extracellular domain. Mouse DPP IV does not exhibit sequence similarity with any of the classical members of this enzyme family (e.g. chymotrypsin and subtilisin) but shares a conserved structural domain of approximately 200 amino acids with several nonclassical serine hydrolases. In this study, analysis of the similarity of secondary structures and amino acid sequences between these enzymes led us to identify several conserved residues likely to be involved in the catalytic site of these DPP IV-related enzymes. These amino acids (Ser624, Asp702, and His734) were found to be arranged in a novel sequential order as compared with that of archetypal serine proteases (e.g. nucleophile (Ser)-acid-His versus His-acid-nucleophile (Ser), respectively). To directly explore the involvement of these residues in the catalytic function of these enzymes, we performed in vitro site-directed mutagenesis on mouse DPP IV cDNA. Our results indicate that although conservative or non-conservative permutations at these positions do not significantly alter the surface expression and biochemical properties of the mutant molecules, they completely impair their DPP IV enzymatic function. In contrast, mutagenesis of two other aspartic residues (Asp599 and Asp657), also conserved between these DPP IV-related enzymes, did not affect the enzymatic properties of the mouse enzyme. These data provide evidence that DPP IV and its related enzymes belong to a novel family that displays a catalytic triad distinct from that of the classical serine proteases.	CNRS MARSEILLE LUMINY,INSERM,CTR IMMUNOL,CASE 906,F-13288 MARSEILLE 9,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			Marguet, Didier/B-9946-2008; Marguet, Didier/AGO-5421-2022	Marguet, Didier/0000-0003-3198-5095				ABBS MT, 1983, CLIN SCI, V65, P551, DOI 10.1042/cs0650551; AHMAD S, 1992, J PHARMACOL EXP THER, V260, P1257; BARRETT AJ, 1992, BIOL CHEM H-S, V373, P353, DOI 10.1515/bchm3.1992.373.2.353; BAUVOIS B, 1988, BIOCHEM J, V252, P723, DOI 10.1042/bj2520723; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BRISTOL LA, 1992, J IMMUNOL, V148, P332; CHEVALLIER S, 1992, J BIOL CHEM, V267, P8192; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; DELAESCALERA S, 1990, EMBO J, V9, P3593, DOI 10.1002/j.1460-2075.1990.tb07570.x; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DUGI KA, 1992, J BIOL CHEM, V267, P25086; FLEISCHER B, 1987, J IMMUNOL, V138, P1346; FOX DA, 1984, J IMMUNOL, V133, P1250; FROHMAN LA, 1989, J CLIN INVEST, V83, P1533, DOI 10.1172/JCI114049; FUJIWARA T, 1992, BIOCHEM BIOPH RES CO, V185, P776, DOI 10.1016/0006-291X(92)91693-K; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GORRELL MD, 1991, CELL IMMUNOL, V134, P205, DOI 10.1016/0008-8749(91)90343-A; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HANSKI C, 1988, EXP CELL RES, V178, P64, DOI 10.1016/0014-4827(88)90378-3; HARTEL S, 1988, HISTOCHEMISTRY, V89, P151, DOI 10.1007/BF00489918; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; KANATANI A, 1991, J BIOCHEM-TOKYO, V110, P315, DOI 10.1093/oxfordjournals.jbchem.a123577; KENNY AJ, 1976, BIOCHEM J, V155, P169; KINGSTON RE, 1991, CURRENT PROTOCOLS MO; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOBAYASHI K, 1989, J BIOL CHEM, V264, P8892; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; LIAO DI, 1990, J BIOL CHEM, V265, P6528; MARGUET D, 1992, J BIOL CHEM, V267, P2200; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MITTA M, 1989, J BIOCHEM-TOKYO, V106, P548, DOI 10.1093/oxfordjournals.jbchem.a122891; NAQUET P, 1988, J IMMUNOL, V141, P4101; NAUSCH I, 1985, J NEUROCHEM, V44, P1354, DOI 10.1111/j.1471-4159.1985.tb08769.x; NAYLOR SL, 1989, GENOMICS, V4, P355, DOI 10.1016/0888-7543(89)90342-X; OGATA S, 1992, BIOCHEMISTRY-US, V31, P2582, DOI 10.1021/bi00124a019; OGATA S, 1989, J BIOL CHEM, V264, P3596; OLSON PF, 1990, EMBO J, V9, P1219, DOI 10.1002/j.1460-2075.1990.tb08229.x; PIAZZA GA, 1989, BIOCHEM J, V262, P327, DOI 10.1042/bj2620327; POLGAR L, 1992, FEBS LETT, V311, P281, DOI 10.1016/0014-5793(92)81120-B; POLGAR L, 1992, BIOCHEMISTRY-US, V31, P7729, DOI 10.1021/bi00148a038; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCALONI A, 1992, J BIOL CHEM, V267, P3811; SCHRAG JD, 1992, J BIOL CHEM, V267, P4300; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; Shaw E., 1970, ENZYMES, V1, P91; STONE SR, 1991, BIOCHEM J, V276, P837, DOI 10.1042/bj2760837; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; SWILLENS S, 1986, BIOCH RES COMMUN, V1347, P142; TSUJI E, 1992, BIOCHEMISTRY-US, V31, P11921, DOI 10.1021/bi00162a035; VIVIER I, 1991, J IMMUNOL, V147, P447; WADA K, 1992, P NATL ACAD SCI USA, V89, P197, DOI 10.1073/pnas.89.1.197	58	78	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17247	17252						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8102366				2022-12-27	WOS:A1993LQ98800057
J	HEITZ, T; GEOFFROY, P; STINTZI, A; FRITIG, B; LEGRAND, M				HEITZ, T; GEOFFROY, P; STINTZI, A; FRITIG, B; LEGRAND, M			CDNA CLONING AND GENE-EXPRESSION ANALYSIS OF THE MICROBIAL PROTEINASE-INHIBITOR OF TOBACCO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHOGENESIS-RELATED PROTEINS; NICOTIANA-SYLVESTRIS; ACQUIRED-RESISTANCE; BIOLOGICAL FUNCTION; SALICYLIC-ACID; TOMATO LEAVES; DNA; CHITINASE; VIRUS; BETA-1,3-GLUCANASE	Tobacco mosaic virus-infected tobacco (Nicotiana tabacum var. Samsun NN) leaves produce a serine proteinase inhibitor that has evolved a specificity for microbial proteinases. We have isolated two closely related cDNAs that were shown to encode two active inhibitors. Southern analysis of genomic DNA, comparison of deduced amino acid sequences, and characterization of the two separated proteins suggest that the two genes of tobacco are homeologues originating from each parent. Amino acid sequences deduced from the cDNAs exhibit a glutamic residue at the P1 position of the active site, known to determine the specificity of this type of inhibitors. Nevertheless, the V8 proteinase from Staphylococcus aureus, an enzyme that cleaves polypeptides after glutamic acid residues, was found to be unaffected by the tobacco inhibitor. We demonstrate strong accumulation of the two mRNAs and proteins during the hypersensitive reaction of tobacco to tobacco mosaic virus. Messengers and products of the two genes are present in a 3:2 ratio, in infected leaves as well as in upper uninfected leaves, the induction being markedly lower at distance from the infection site. The transcripts were also found in sepals and petals of healthy plants, indicating that these genes are also developmentally regulated. Unlike the tomato and potato I inhibitors, the tobacco inhibitor was only weakly induced by wounding, but was expressed upon salicylic acid or ethephon treatment, as many pathogenesis-related proteins.	UNIV STRASBOURG 1, CNRS,INST BIOL MOLEC PLANTES,PHYTOPATHOL LAB, 12 RUE GEN ZIMMER, F-67084 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Geoffroy, Pierre Alexis/D-9743-2011	Geoffroy, Pierre Alexis/0000-0001-9121-209X; Stintzi, Annick/0000-0002-6479-8184				BINGHAM PM, 1981, CELL, V25, P693, DOI 10.1016/0092-8674(81)90176-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDERODE FT, 1991, PLANT MOL BIOL, V17, P1117, DOI 10.1007/BF00028729; CERVONE F, 1989, PLANT PHYSIOL, V90, P542, DOI 10.1104/pp.90.2.542; CRIQUI MC, 1992, MECH DEVELOP, V38, P121, DOI 10.1016/0925-4773(92)90004-4; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOW JM, 1990, APPL ENVIRON MICROB, V56, P2994, DOI 10.1128/AEM.56.10.2994-2998.1990; ECKER JR, 1987, P NATL ACAD SCI USA, V84, P5202, DOI 10.1073/pnas.84.15.5202; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELIX G, 1987, PLANTA, V172, P386, DOI 10.1007/BF00398668; GEOFFROY P, 1990, MOL PLANT MICROBE IN, V3, P327, DOI 10.1094/MPMI-3-327; GRAHAM JS, 1985, J BIOL CHEM, V260, P6555; GREEN TR, 1972, SCIENCE, V175, P776, DOI 10.1126/science.175.4023.776; GURUSIDDAIAH S, 1972, PLANT PHYSIOL, V50, P627, DOI 10.1104/pp.50.5.627; HENDRIKS T, 1991, PLANT MOL BIOL, V17, P385, DOI 10.1007/BF00040633; HERGET T, 1990, MOL GEN GENET, V224, P469, DOI 10.1007/BF00262442; JONGSMA MA, 1993, DEV PLANT PATHOL, V2, P364; KAUFFMANN S, 1987, EMBO J, V6, P3209, DOI 10.1002/j.1460-2075.1987.tb02637.x; KNIGHT ME, 1992, PLANT MOL BIOL, V19, P793, DOI 10.1007/BF00027075; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LEE KY, 1988, EMBO J, V7, P1241, DOI 10.1002/j.1460-2075.1988.tb02937.x; LEE SY, 1990, BIOTECHNIQUES, V9, P676; LEGRAND M, 1987, P NATL ACAD SCI USA, V84, P6750, DOI 10.1073/pnas.84.19.6750; LOTAN T, 1989, PLANT CELL, V1, P881, DOI 10.1105/tpc.1.9.881; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MARGOSSIAN LJ, 1988, P NATL ACAD SCI USA, V85, P8012, DOI 10.1073/pnas.85.21.8012; MAUCH F, 1988, PLANT PHYSIOL, V88, P936, DOI 10.1104/pp.88.3.936; MCGURL B, 1992, SCIENCE, V255, P1570, DOI 10.1126/science.1549783; MORIHARA K, 1974, ADV ENZYMOL RAMB, V41, P179; NEALE AD, 1990, PLANT CELL, V2, P673, DOI 10.1105/tpc.2.7.673; OKAMURO JK, 1985, MOL GEN GENET, V198, P290, DOI 10.1007/BF00383009; PAUTOT V, 1991, MOL PLANT MICROBE IN, V4, P284, DOI 10.1094/MPMI-4-284; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; RICHARDSON M, 1974, FEBS LETT, V45, P11, DOI 10.1016/0014-5793(74)80798-2; ROBY D, 1987, PHYSIOL MOL PLANT P, V30, P453, DOI 10.1016/0885-5765(87)90024-5; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINSHI H, 1987, P NATL ACAD SCI USA, V84, P89, DOI 10.1073/pnas.84.1.89; STONE KL, 1989, PRACTICAL GUIDE PROT, P37; Strauss WM, 1987, CURRENT PROTOCOLS MO, P631; VANBUUREN M, 1992, MOL GEN GENET, V232, P460, DOI 10.1007/BF00266251; VANHUIJSDUIJNEN RAMH, 1985, EMBO J, V4, P2167, DOI 10.1002/j.1460-2075.1985.tb03911.x; VIGERS AJ, 1992, PLANT SCI, V83, P155, DOI 10.1016/0168-9452(92)90074-V; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WINGATE VPM, 1989, J BIOL CHEM, V264, P17734; YALPANI N, 1991, PLANT CELL, V3, P809, DOI 10.1105/tpc.3.8.809	46	19	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16987	16992						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8102364				2022-12-27	WOS:A1993LQ98800019
J	SHYNG, SL; HUBER, MT; HARRIS, DA				SHYNG, SL; HUBER, MT; HARRIS, DA			A PRION PROTEIN CYCLES BETWEEN THE CELL-SURFACE AND AN ENDOCYTIC COMPARTMENT IN CULTURED NEUROBLASTOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE-ASSOCIATED FORM; BREFELDIN-A; TRANSFERRIN RECEPTOR; CYTOPLASMIC DOMAIN; MEMBRANE; PRP; INTERNALIZATION; TRANSPORT; LYSOSOMES; KINETICS	The prion protein (PrP(C)) is a glycolipid-anchored, cell surface protein of unknown function, a posttranslationally modified isoform of which has been implicated in the pathogenesis of spongiform encephalopathies in man and animals. We report here the novel observation that chPrP, the chicken homologue of mammalian PrP(C), constitutively cycles between the cell surface and an endocytic compartment with a transit time of approximately 60 min, as demonstrated by surface iodination and immunofluorescence microscopy. Most (>95%) of the internalized protein is returned to the cell surface intact, and the remainder is proteolytically cleaved within a highly conserved region in the NH2-terminal half of the molecule. Pulse-chase labeling experiments indicate that while this cleavage is slow, with a rate of approximately 1%/h, the COOH-terminal fragment produced is stable and accumulates on the cell surface for as long as 24 h. The cleavage is likely to take place in an acidified endocytic compartment, since it is reduced by lysosomotropic amines and inhibitors of lysosomal proteases. Our results raise the possibility that chPrP, and perhaps other PrP(C)s, function as cell surface receptors, and they suggest cellular pathways that might be involved in the generation of the pathogenic isoform.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,660 S EUCLID AVE,ST LOUIS,MO 63110	Washington University (WUSTL)				Harris, David/0000-0002-6985-5790	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS030137] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30137] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; BAMEZAI A, 1992, EUR J IMMUNOL, V22, P15, DOI 10.1002/eji.1830220104; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BLUM JS, 1991, J BIOL CHEM, V266, P22091; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BRETSCHER MS, 1980, P NATL ACAD SCI-BIOL, V77, P4156, DOI 10.1073/pnas.77.7.4156; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1990, J VIROL, V64, P1093, DOI 10.1128/JVI.64.3.1093-1101.1990; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; CLOUGH G, 1991, PROG BIOPHYS MOL BIO, V55, P47, DOI 10.1016/0079-6107(91)90011-G; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; GABRIEL JM, 1992, P NATL ACAD SCI USA, V89, P9097, DOI 10.1073/pnas.89.19.9097; GAJDUSEK DC, 1990, VIROLOGY, P2289; HARRIS DA, 1993, P NATL ACAD SCI USA, V90, P4309, DOI 10.1073/pnas.90.9.4309; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; HARRIS DA, 1991, P NATL ACAD SCI USA, V88, P7664, DOI 10.1073/pnas.88.17.7664; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HUBBARD AL, 1972, J CELL BIOL, V55, P390, DOI 10.1083/jcb.55.2.390; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEMANSKY P, 1990, J CELL BIOL, V110, P1525, DOI 10.1083/jcb.110.5.1525; MANSON J, 1992, DEVELOPMENT, V115, P117; MCKINLEY MP, 1991, LAB INVEST, V65, P622; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOBLEY WC, 1988, P NATL ACAD SCI USA, V85, P9811, DOI 10.1073/pnas.85.24.9811; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SCHWARTZ AL, 1982, J BIOL CHEM, V257, P4230; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; VANDENBOSCH RA, 1988, EMBO J, V7, P3345, DOI 10.1002/j.1460-2075.1988.tb03206.x	45	260	265	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15922	15928						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8101844				2022-12-27	WOS:A1993LN30500085
J	WANG, QP; TULL, D; MEINKE, A; GILKES, NR; WARREN, RAJ; AEBERSOLD, R; WITHERS, SG				WANG, QP; TULL, D; MEINKE, A; GILKES, NR; WARREN, RAJ; AEBERSOLD, R; WITHERS, SG			GLU280 IS THE NUCLEOPHILE IN THE ACTIVE-SITE OF CLOSTRIDIUM-THERMOCELLUM CELC, A FAMILY-A ENDO-BETA-1,4-GLUCANASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; CELLULASE GENE; ERWINIA-CHRYSANTHEMI; ENDOGLUCANASE GENE; MOLECULAR-CLONING; EXPRESSION; GLYCOSIDASE; MECHANISM	A new mechanism-based inactivator of beta-1,4-glucanases, 2',4'-dinitrophenyl-2-deoxy-2-fluoro-beta-D-cellobioside, was synthesized and used to trap the intermediate formed during catalysis by endoglucanase C (CelC) from Clostridium thermocellum. Ion spray mass spectrometry confirmed the 1:1 stoichiometry of the incorporation of the inactivator into the enzyme. Inactivation followed the required pseudo first-order kinetic behavior and kinetic parameters for the process were determined. Although the intermediate trapped was relatively stable (t1/2 = 25 h), turnover was facilitated by transglycosylation following the addition of phenyl-beta-D-thiocellobioside and cellobiose, thus demonstrating the catalytic competence of the trapped intermediate. The nucleophilic amino acid residue involved was identified as Glu280 by labeling the enzyme with tritiated inactivator, cleaving it into peptides and sequencing the radiolabeled peptide. Ion spray mass spectrometric analysis of the peptide confirmed the sequence and the mode of attachment of the sugar to the peptide. Alignment of all known related beta-1,4-glucanases showed that Glu280 is strictly conserved in family A enzymes, consistent with its key role in catalysis.	UNIV BRITISH COLUMBIA,DEPT CHEM,2063 MAIN MALL,VANCOUVER V6T 1Z1,BC,CANADA; UNIV BRITISH COLUMBIA,PROT ENGN NETWORKS CTR EXCELLENCE,VANCOUVER V6T 1Z1,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1Z1,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT MICROBIOL,VANCOUVER V6T 1Z1,BC,CANADA; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER V6T 1Z1,BC,CANADA	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia			Withers, Stephen G/I-7229-2019	Withers, Stephen G/0000-0002-6722-5701; Tull, Dedreia/0000-0003-2546-6707				ALTAWHEED A, 1988, THESIS U DUBLIN; BAIRD SD, 1990, BIOCHEM BIOPH RES CO, V169, P1035, DOI 10.1016/0006-291X(90)91998-8; BAIRD SD, 1990, J BACTERIOL, V172, P1576, DOI 10.1128/jb.172.3.1576-1586.1990; BARRAS F, 1992, FEBS LETT, V300, P145, DOI 10.1016/0014-5793(92)80183-H; BEGUIN P, 1990, ANNU REV MICROBIOL, V44, P219, DOI 10.1146/annurev.mi.44.100190.001251; BELAICH A, 1992, J BACTERIOL, V174, P4677, DOI 10.1128/JB.174.14.4677-4682.1992; BERGER E, 1989, MOL GEN GENET, V219, P193, DOI 10.1007/BF00261176; BERVEN LA, 1986, CARBOHYD RES, V156, P282, DOI 10.1016/S0008-6215(00)90123-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLAEYSSENS M, 1992, PROTEIN SCI, V1, P1293, DOI 10.1002/pro.5560011008; COULL JM, 1991, ANAL BIOCHEM, V194, P110, DOI 10.1016/0003-2697(91)90157-O; CUNNINGHAM C, 1991, MOL GEN GENET, V228, P320, DOI 10.1007/BF00282484; FAURE E, 1990, GENE, V65, P51; FOONG F, 1991, J GEN MICROBIOL, V137, P1729, DOI 10.1099/00221287-137-7-1729; FUJINO T, 1992, J FERMENT BIOENG, V73, P308, DOI 10.1016/0922-338X(92)90189-2; FUKIMORI F, 1987, FEMS MICROBIOL LETT, V40, P311; FUKIMORI F, 1989, GENE AMST, V76, P289; GEBLER J, 1992, J BIOL CHEM, V267, P12559; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; Gibson T.J., 1984, THESIS U CAMBRIDGE; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; GOUGH CL, 1990, GENE, V89, P53, DOI 10.1016/0378-1119(90)90205-6; GUISEPPI A, 1988, MOL MICROBIOL, V2, P159, DOI 10.1111/j.1365-2958.1988.tb00017.x; HAMAMOTO T, 1992, MOL GEN GENET, V231, P472, DOI 10.1007/BF00292718; HAZLEWOOD GP, 1990, J GEN MICROBIOL, V136, P2089, DOI 10.1099/00221287-136-10-2089; HEFFORD MA, 1992, PROTEIN ENG, V5, P433, DOI 10.1093/protein/5.5.433; HENRISSAT B, 1989, GENE, V81, P83, DOI 10.1016/0378-1119(89)90339-9; HENRISSAT B, 1993, IN PRESS GENE AMST; HUANG JZ, 1992, J BACTERIOL, V174, P1314, DOI 10.1128/jb.174.4.1314-1323.1992; JOORGESEN PL, 1990, GENE AMST, V93, P55; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KUZUHARA H, 1967, J ORG CHEM, V32, P2531, DOI 10.1021/jo01283a035; LAO G, 1991, J BACTERIOL, V173, P3397, DOI 10.1128/jb.173.11.3397-3407.1991; LEATHERBARROW RG, 1990, GRAFIT VERSION 2 0; LUTHI E, 1991, APPL ENVIRON MICROB, V57, P694; MACKAY RM, 1986, NUCLEIC ACIDS RES, V14, P9159, DOI 10.1093/nar/14.22.9159; Maniatis T., 1982, MOL CLONING; MATSUSHITA O, 1990, J BACTERIOL, V172, P3620, DOI 10.1128/jb.172.7.3620-3630.1990; MCCARTER JD, 1992, BIOCHEM J, V286, P721, DOI 10.1042/bj2860721; MCCARTER JD, IN PRESS CARBOHYDR R; MEINKE A, 1993, J BACTERIOL, V175, P1910, DOI 10.1128/JB.175.7.1910-1918.1993; NAKAMURA A, 1987, EUR J BIOCHEM, V164, P317, DOI 10.1111/j.1432-1033.1987.tb11060.x; NAVAS J, 1992, BIOCHEM BIOPH RES CO, V189, P807, DOI 10.1016/0006-291X(92)92274-2; OZAKI K, 1990, J GEN MICROBIOL, V136, P1327, DOI 10.1099/00221287-136-7-1327; PARK SH, 1991, AGR BIOL CHEM TOKYO, V55, P441, DOI 10.1080/00021369.1991.10870613; PETRE D, 1986, BIOCHIMIE, V68, P687, DOI 10.1016/S0300-9084(86)80162-6; POOLE DM, 1990, MOL GEN GENET, V223, P217, DOI 10.1007/BF00265057; PY B, 1991, PROTEIN ENG, V4, P325, DOI 10.1093/protein/4.3.325; ROBSON LM, 1986, J BACTERIOL, V165, P612, DOI 10.1128/jb.165.2.612-619.1986; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; SAKKA K, 1991, AGR BIOL CHEM TOKYO, V55, P347, DOI 10.1080/00021369.1991.10870608; SCHWARZ WH, 1988, APPL MICROBIOL BIOT, V29, P25, DOI 10.1007/BF00258346; SCHWARZ WH, 1988, GENE, V63, P23, DOI 10.1016/0378-1119(88)90542-2; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STREET IP, 1989, BIOCHEMISTRY-US, V28, P1581, DOI 10.1021/bi00430a024; STREET IP, 1992, BIOCHEMISTRY-US, V31, P9970, DOI 10.1021/bi00156a016; SUMITOMO N, 1992, BIOSCI BIOTECH BIOCH, V56, P872, DOI 10.1271/bbb.56.872; THEBERGE M, 1992, APPL ENVIRON MICROB, V58, P815; TULL D, 1991, J BIOL CHEM, V266, P15621; WANG WY, 1990, MOL GEN GENET, V222, P265, DOI 10.1007/BF00633827; WITHERS SG, 1988, J BIOL CHEM, V263, P7929; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043; YAGUE E, 1990, GENE, V89, P61, DOI 10.1016/0378-1119(90)90206-7; YOSHIGI N, 1990, J BIOCHEM-TOKYO, V108, P388, DOI 10.1093/oxfordjournals.jbchem.a123211	64	122	130	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14096	14102						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8100226				2022-12-27	WOS:A1993LJ82500048
J	PRASADARAO, NV; WASS, CA; HACKER, J; JANN, K; KIM, KS				PRASADARAO, NV; WASS, CA; HACKER, J; JANN, K; KIM, KS			ADHESION OF S-FIMBRIATED ESCHERICHIA-COLI TO BRAIN GLYCOLIPIDS MEDIATED BY SFAA GENE-ENCODED PROTEIN OF S-FIMBRIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOPLASMA-PNEUMONIAE; SULFATED GLYCOLIPIDS; SEQUENCE HOMOLOGY; K-ANTIGEN; BINDING; CELLS; GLYCOSPHINGOLIPIDS; IDENTIFICATION; GANGLIOSIDES; RECOGNITION	In an attempt to further assess the role of S-fimbriae in the pathogenesis of Escherichia coli meningitis, the adherence of E. coli strains with or without S-fimbriae were examined for this study to purified glycolipids using thin layer chromatography overlay assays. Only S-fimbriated E. coli strains bound to sulfatide, seminolipid, galactosyl ceramide, and lactosyl ceramide but not to gangliosides including sialyl neolacto-series and other neutral glycolipids. The binding of S-fimbriated E. coli to sulfatide was temperature dependent (i.e. maximal at 37-degrees-C) and inhibited by S-fimbriae, anti-S-fimbriae, and anti-S-adhesin antibodies as well as by sulfatide, galactosyl ceramide, and lactosyl ceramide. E. coli transformants which lack the sfaA gene from the Sfa gene cluster showed no binding to the glycolipids, while other transformants lacking the adhesin gene sfaS or sfaG or H and mutants obtained by site-directed mutagenesis in the sfaS gene exhibited a similar binding to the glycolipids compared to the parent S-fimbriated strain. A large amount of sulfated glycolipids was demonstrated on brain endothelial cells and the binding of S-fimbriated E. coli to brain endothelial cells was inhibited by these glycolipids. These findings suggest that the binding of S-fimbriated E. coli to brain endothelial cells occurs in part via glycolipids containing terminal Gal(3SO4)beta-1 residues and in part by S-fimbriae protein SfaA. S-adhesin was not involved in the binding of S-fimbriae to these glycolipids.	CHILDRENS HOSP LOS ANGELES, DIV INFECT DIS 51, 4650 SUNSET BLVD, LOS ANGELES, CA 90027 USA; UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90027 USA; UNIV WURZBURG, INST GENET & MIKROBIOL, W-8700 WURZBURG, GERMANY; MAX PLANCK INST IMMUNBIOL, W-7800 FREIBURG, GERMANY	Children's Hospital Los Angeles; University of Southern California; University of Wurzburg; Max Planck Society					NINDS NIH HHS [R01-NS-26310] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026310] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE C, 1988, FEMS MICROBIOL LETT, V51, P153, DOI 10.1111/j.1574-6968.1988.tb02988.x; ALPHEN LV, 1991, INFECT IMMUN, V59, P4473; BANAI M, 1978, INFECT IMMUN, V21, P365, DOI 10.1128/IAI.21.2.365-372.1978; BRENNAN MJ, 1987, INFECT IMMUN, V55, P487, DOI 10.1128/IAI.55.2.487-489.1987; BRENNAN MJ, 1991, J BIOL CHEM, V266, P18827; CROOK SJ, 1986, BIOCHEMISTRY-US, V25, P7488, DOI 10.1021/bi00371a035; CROSS AS, 1986, J INFECT DIS, V154, P497, DOI 10.1093/infdis/154.3.497; FAROOQUI AA, 1985, MOL CELL BIOCHEM, V66, P87; GEMSKI P, 1980, FEMS LETT, V9, P192; GORSKI F, 1977, FEMS MICROBIOL LETT, V1, P265, DOI 10.1016/0378-1097(77)90070-2; HANSSON GC, 1985, ANAL BIOCHEM, V146, P158, DOI 10.1016/0003-2697(85)90410-5; HOLT GD, 1989, J BIOL CHEM, V264, P12138; HOLT GD, 1990, J BIOL CHEM, V265, P2852; HU PC, 1976, INFECT IMMUN, V14, P217, DOI 10.1128/IAI.14.1.217-224.1976; KALLENIUS G, 1980, FEMS MICROBIOL LETT, V7, P297, DOI 10.1111/j.1574-6941.1980.tb01608.x; KANNAGI R, 1982, P NATL ACAD SCI-BIOL, V79, P3470, DOI 10.1073/pnas.79.11.3470; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KIM KS, 1992, J CLIN INVEST, V90, P897, DOI 10.1172/JCI115965; KIM KS, 1990, PEDIATR RES, V27, P272; KORHONEN TK, 1985, INFECT IMMUN, V48, P486, DOI 10.1128/IAI.48.2.486-491.1985; KRIVAN HC, 1989, J BIOL CHEM, V264, P9283; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; MARRE R, 1990, INFECT IMMUN, V58, P3434, DOI 10.1128/IAI.58.10.3434-3437.1990; MOCH T, 1987, P NATL ACAD SCI USA, V84, P3462, DOI 10.1073/pnas.84.10.3462; OPAL S, 1982, INFECT IMMUN, V37, P956, DOI 10.1128/IAI.37.3.956-960.1982; ORSKOV I, 1983, PROG ALLERGY, V33, P80; OTT M, 1988, J BACTERIOL, V170, P3983, DOI 10.1128/jb.170.9.3983-3990.1988; PARKKINEN J, 1986, INFECT IMMUN, V54, P37, DOI 10.1128/IAI.54.1.37-42.1986; PARKKINEN J, 1983, BIOCHEM BIOPH RES CO, V111, P456, DOI 10.1016/0006-291X(83)90328-5; PARKKINEN J, 1989, INFECT IMMUN, V57, P2256, DOI 10.1128/IAI.57.7.2256-2259.1989; PARKKINEN J, 1988, J CLIN INVEST, V81, P860, DOI 10.1172/JCI113395; PARUCHURI DK, 1990, P NATL ACAD SCI USA, V87, P333, DOI 10.1073/pnas.87.1.333; PRASADARAO N, 1990, J NEUROCHEM, V55, P2024, DOI 10.1111/j.1471-4159.1990.tb05791.x; ROBERTS DD, 1988, CANCER RES, V48, P3367; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; ROBERTS DD, 1988, ARCH BIOCHEM BIOPHYS, V267, P405, DOI 10.1016/0003-9861(88)90046-X; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SCHMOLL T, 1987, FEMS MICROBIOL LETT, V41, P229; SIEGEL JD, 1981, NEW ENGL J MED, V304, P642, DOI 10.1056/NEJM198103123041105; STROMBERG N, 1988, FEBS LETT, V232, P193, DOI 10.1016/0014-5793(88)80415-0; TOMKINS DC, 1990, J CLIN INVEST, V85, P1248; VAISANEN V, 1982, LANCET, V1, P192; WESTERLUND B, 1989, FEBS LETT, V243, P199, DOI 10.1016/0014-5793(89)80129-2; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; 1986, EUR J BIOCHEM, V159, P1	45	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10356	10363						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8098039				2022-12-27	WOS:A1993LB80000058
J	YU, LJ; COHEN, D; PIEKARZ, RL; HORWITZ, SB				YU, LJ; COHEN, D; PIEKARZ, RL; HORWITZ, SB			3 DISTINCT NUCLEAR-PROTEIN BINDING-SITES IN THE PROMOTER OF THE MURINE MULTIDRUG RESISTANCE MDR1B GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT PROTEINS; P-GLYCOPROTEIN PRECURSORS; HEAT-SHOCK FACTOR; NF-KAPPA-B; MAMMALIAN-CELLS; REGULATORY ELEMENTS; FUNCTIONAL-ANALYSIS; J774.2 CELLS; EXPRESSION; DNA	Multidrug resistance in mammalian cells is often associated with the overproduction of a membrane glycoprotein, P-glycoprotein, that is encoded by mdr genes. Multidrug resistance cell lines selected with either vinblastine, colchicine, or taxol from the drug-sensitive murine macrophage-like cell line J774.2 overexpress the mdr1a and/or mdr1b genes, and overproduce P-glycoprotein. To elucidate the mechanisms of mdr1b gene expression, the mdr1b 5'-flanking sequences have been isolated from a normal mouse liver genomic library and analyzed by gel shift and DNase I footprinting assays. These analyses have demonstrated three nuclear protein binding sites, from -82 to -59 (site 1), from -123 to -101 (site 2), and from -272 to -249 (site 3), which interact with proteins present in nuclear extracts from both sensitive and resistant cells. Although site 1 contains a partially conserved AP-2 consensus sequence, our results indicate that the nuclear protein binding to site 1 is not AP-2 protein. The sequence of site 2 is conserved in the murine mdr1a, human mdr1, and hamster pgp1 promoters. Such conservation suggests that this sequence may have an important role in mdr gene expression. The use of a transient chloramphenicol acetyltransferase expression vector containing the basal promoter for herpes simplex virus thymidine kinase (tkCAT) and either site 1 or site 2 or both revealed that the sequences of sites 1 and 2 enhanced tkCAT activity. DNase I footprinting analyses demonstrated that site 3 is recognized by human AP-1 protein, indicating that the nuclear protein binding to this site is an AP-1-like protein. These observations suggest that mdr1b gene expression is mediated by preexisting transcription factors present in sensitive and resistant cells.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,1300 MORRIS PK AVE,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine			Piekarz, Richard/GXH-9978-2022		NCI NIH HHS [CA39821, 5P30CA1330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K04CA001330, R35CA039821] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; BORELLINI F, 1990, MOL CELL BIOL, V10, P5541, DOI 10.1128/MCB.10.10.5541; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COHEN D, 1991, J BIOL CHEM, V266, P2239; CORNWELL MM, 1990, CELL GROWTH DIFFER, V1, P607; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DEUCHARS KL, 1987, MOL CELL BIOL, V7, P718, DOI 10.1128/MCB.7.2.718; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ENRIETTO PJ, 1983, CELL, V35, P369, DOI 10.1016/0092-8674(83)90170-8; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERGER LM, 1988, P NATL ACAD SCI USA, V85, P3762, DOI 10.1073/pnas.85.11.3762; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; HSU SIH, 1989, J BIOL CHEM, V264, P12053; IKEGUCHI M, 1991, DNA CELL BIOL, V10, P639, DOI 10.1089/dna.1991.10.639; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KIRSCHNER LS, 1992, BIOCHEM PHARMACOL, V43, P77, DOI 10.1016/0006-2952(92)90664-5; KOHNO K, 1990, J BIOL CHEM, V265, P19690; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; RAYMOND M, 1990, MOL CELL BIOL, V10, P1642, DOI 10.1128/MCB.10.4.1642; RAYMOND M, 1990, MOL CELL BIOL, V10, P6036, DOI 10.1128/MCB.10.11.6036; RAYMOND M, 1989, P NATL ACAD SCI USA, V86, P6488, DOI 10.1073/pnas.86.17.6488; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; ROY SN, 1985, CANCER RES, V45, P3856; SCOTTO KW, 1986, SCIENCE, V232, P751, DOI 10.1126/science.2421411; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; SUGIMOTO Y, 1987, MOL CELL BIOL, V7, P4549, DOI 10.1128/MCB.7.12.4549; TEETER LD, 1990, MOL CELL BIOL, V10, P5728, DOI 10.1128/MCB.10.11.5728; TEETER LD, 1991, CELL GROWTH DIFFER, V2, P429; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; UEDA K, 1987, J BIOL CHEM, V262, P17432; VANDERBLIEK AM, 1988, CANCER RES, V48, P5927	49	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7520	7526						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8096513				2022-12-27	WOS:A1993KV14100100
J	GUO, IC; TSAI, HM; CHUNG, BC				GUO, IC; TSAI, HM; CHUNG, BC			ACTIONS OF 2 DIFFERENT CAMP-RESPONSIVE SEQUENCES AND AN ENHANCER OF THE HUMAN CYP11A1 (P450SCC) GENE IN ADRENAL Y1 AND PLACENTAL JEG-3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN CLEAVAGE; STEROIDOGENIC ENZYMES; REGULATORY ELEMENTS; ADRENOCORTICAL EXPRESSION; PROMOTER REGION; P-450SCC GENE; TUMOR-CELLS; CYCLIC-AMP; PROTEIN; TRANSCRIPTION	We have characterized three cis-acting elements of the human CYP11A1 gene. A proximal cAMP-responsive sequence (P-CRS) functioned in both adrenal Y1 and placental JEG-3 cells. An upstream cAMP-responsive sequence (U-CRS) and an enhancer, localized by transfections of deleted gene segments linked to a reporter gene to bases -1621 to -1503 and -1931 to -1822, respectively, functioned in Y1 but not JEG-3 cells. Both regions bind proteins only from Y1 cells as identified by footprinting analysis. U-CRS contains the TCAAGGTCA sequence that binds the nuclear receptor family of proteins. The cAMP dependent transcription mediated by U-CRS, but not by P-CRS, was abolished in a cell line deficient in cAMP-dependent protein kinase. Therefore, P-CRS and U-CRS use different effecters to mediate cAMP response. Gel mobility shift, competition, and antibody supershift experiments showed that nucleotides -117 to -94, which contributed to P-CRS activity in transfection experiments, bound weakly to Sp1-like proteins. This feature is shared by many proximal regulatory elements of steroidogenic genes. Therefore, steroidogenic genes could be coordinately regulated through common regulatory elements such as P-CRS, U-CRS, and cell type-selective enhancers.	ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN; NATL TAIWAN UNIV, DEPT ANIM SCI, TAIPEI 11529, TAIWAN	Academia Sinica - Taiwan; National Taiwan University				Chung, Bon-chu/0000-0002-8612-0219				AHLGREN R, 1990, J BIOL CHEM, V265, P3313; BOGERD AM, 1990, MOL ENDOCRINOL, V4, P845, DOI 10.1210/mend-4-6-845; CHANG CY, 1992, MOL ENDOCRINOL, V6, P1362, DOI 10.1210/me.6.9.1362; CHEN JY, 1992, BIOCHEMISTRY-US, V31, P2400, DOI 10.1021/bi00123a027; CHUNG BC, 1989, BIOCHEM BIOPH RES CO, V160, P276, DOI 10.1016/0006-291X(89)91652-5; FISHER RJ, 1991, ONCOGENE, V6, P2249; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GOLOS TG, 1987, J CLIN INVEST, V80, P896, DOI 10.1172/JCI113149; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P132; GUO IC, 1993, DNA CELL BIOL, V12, P849, DOI 10.1089/dna.1993.12.849; HALES DB, 1990, ENDOCRINOLOGY, V126, P2800, DOI 10.1210/endo-126-6-2800; HANUKOGLU I, 1990, J BIOL CHEM, V265, P20602, DOI 10.1016/S0021-9258(17)30545-8; HANUKOGLU I, 1989, SERONO S REV, V23, P233; HONDA S, 1993, J BIOL CHEM, V268, P7494; HONDA SI, 1990, J BIOCHEM-TOKYO, V108, P1042, DOI 10.1093/oxfordjournals.jbchem.a123303; HU MC, 1991, BIOCHEM J, V274, P813, DOI 10.1042/bj2740813; HUM DW, 1993, ENDOCRINOLOGY, V132, P546, DOI 10.1210/en.132.2.546; INOUE H, 1991, EUR J BIOCHEM, V195, P563, DOI 10.1111/j.1432-1033.1991.tb15738.x; INOUE H, 1988, EUR J BIOCHEM, V171, P435, DOI 10.1111/j.1432-1033.1988.tb13808.x; JOHN ME, 1986, P NATL ACAD SCI USA, V83, P4715, DOI 10.1073/pnas.83.13.4715; KAGAWA N, 1991, J BIOL CHEM, V266, P11199; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KRAMER RE, 1984, J BIOL CHEM, V259, P707; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maxam A M, 1980, Methods Enzymol, V65, P499; MELLON SH, 1989, P NATL ACAD SCI USA, V86, P7775, DOI 10.1073/pnas.86.20.7775; MILLER WL, 1989, ENDOCR RES, V15, P1; MOMOI K, 1992, MOL ENDOCRINOL, V6, P1682, DOI 10.1210/me.6.10.1682; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; MOORE CCD, 1992, MOL ENDOCRINOL, V6, P2045, DOI 10.1210/me.6.12.2045; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OONK RB, 1990, J BIOL CHEM, V265, P22392; ORMEJOHNSON NR, 1990, BIOCHIM BIOPHYS ACTA, V1020, P213, DOI 10.1016/0005-2728(90)90151-S; PARISSENTI AM, 1993, MOL ENDOCRINOL, V7, P283, DOI 10.1210/me.7.2.283; PAYNE AH, 1991, 1ST INT S MOL VIEW S, P47; PICADOLEONARD J, 1988, J BIOL CHEM, V263, P3240; RICE DA, 1990, J BIOL CHEM, V265, P8052; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; RICE DA, 1990, J BIOL CHEM, V265, P11713; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; WONG M, 1989, J BIOL CHEM, V264, P12867	47	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6362	6369						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119986				2022-12-27	WOS:A1994MZ50300019
J	SUGIMOTO, H; YAMASHITA, S				SUGIMOTO, H; YAMASHITA, S			PURIFICATION, CHARACTERIZATION, AND INHIBITION BY PHOSPHATIDIC-ACID OF LYSOPHOSPHOLIPASE TRANSACYLASE FROM RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CANINE KIDNEY-CELLS; LYMPHOCYTE-T ACTIVATION; SIGNAL TRANSDUCTION; KINETIC-ANALYSIS; MIXED MICELLES; POTENTIAL ROLE; BEEF LIVER; LYSOPHOSPHATIDYLCHOLINE; PHOSPHOLIPASE-A2	Lysophospholipase transacylase was purified 214,360-fold to homogeneity from the rat Liver 100,000 x g supernatant. After DEAE chromatography, total activity increased 12.9-fold, due to the removal of endogenous inhibitors. The inhibitors were isolated and identified as phosphatidic acid and fatty acid The final preparation showed a single band on SDS-polyacrylamide electrophoresis with an M(r) of 60,000. Gel filtration through Sephacryl S-200 gave a similar value, suggesting that the enzyme exists as a monomer. Activity was highest at pH 6.0 and was not affected by Ca2+, Mg2+, and EDTA. The enzyme produced glycerophosphocholine (GPC), palmitic acid, and dipalmitoyl-GPC on incubation with 1-palmitoyl GPC, indicating that the enzyme catalyzed both deacylation and transacylation. The relative rates of deacylation and transacylation were 1:0.3 under standard assay conditions. K-m for 1-palmitoyl-GPC and V-max of hydrolase activity were 91 mu M and 12.9 mu mol/min/mg, respectively. The enzyme was selective for choline lysophospholipid. Ethanolamine, inositol, and serine lysophospholipids were not good substrates of the enzyme. Phosphatidic acid was a potent, competitive inhibitor of the enzyme with K-i of about 10 mu M as determined with 1-stearoyl-2-arachidonoyl glycerophosphate. Although less potent, lysophosphatidic said, palmitoyl-L-carnitine, and fatty acid were also inhibitory to the enzyme.	GUNMA UNIV,SCH MED,DEPT BIOCHEM,MAEBASHI,GUNMA 371,JAPAN	Gunma University								AARSMAN AJ, 1991, EUR J BIOCHEM, V200, P187, DOI 10.1111/j.1432-1033.1991.tb21066.x; ASAOKA Y, 1991, BIOCHEM BIOPH RES CO, V178, P1378, DOI 10.1016/0006-291X(91)91046-F; ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUMLEY G, 1977, J LIPID RES, V18, P523; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DEJONG JGN, 1974, BIOCHIM BIOPHYS ACTA, V369, P50, DOI 10.1016/0005-2760(74)90191-X; DOMIN J, 1993, J BIOL CHEM, V268, P8927; DUAN RD, 1993, BIOCHIM BIOPHYS ACTA, V1167, P326, DOI 10.1016/0005-2760(93)90236-3; ERBLAND JF, 1964, BIOCHIM BIOPHYS ACTA, V106, P128; EXTON JH, 1990, J BIOL CHEM, V265, P1; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GARSETTI D, 1992, BIOCHEM J, V288, P831, DOI 10.1042/bj2880831; GARSETTI DE, 1992, BIOCHIM BIOPHYS ACTA, V1165, P229, DOI 10.1016/0005-2760(92)90191-W; GROSS RW, 1982, CIRC RES, V51, P27, DOI 10.1161/01.RES.51.1.27; GROSS RW, 1983, J BIOL CHEM, V258, P5221; GROSS RW, 1983, J BIOL CHEM, V258, P5165; HABERLAND ME, 1975, J BIOL CHEM, V250, P6636; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HUANG CF, 1992, J BIOL CHEM, V267, P16859; HUANG CF, 1990, J BIOL CHEM, V265, P14858; HUGGINS C, 1947, J BIOL CHEM, V170, P467; IKUTA S, 1977, J BIOCHEM-TOKYO, V82, P157, DOI 10.1093/oxfordjournals.jbchem.a131664; JARVIS AA, 1984, J BIOL CHEM, V259, P5188; KYGER EM, 1989, BIOCHEM BIOPH RES CO, V164, P1302, DOI 10.1016/0006-291X(89)91811-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMBARDO D, 1980, BIOCHIM BIOPHYS ACTA, V611, P136, DOI 10.1016/0005-2744(80)90049-2; MARQUARDT DL, 1991, J ALLERGY CLIN IMMUN, V88, P721, DOI 10.1016/0091-6749(91)90178-Q; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OISHI K, 1988, J BIOL CHEM, V263, P6865; PARKER J, 1987, J BIOL CHEM, V262, P5385; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; Rudd E.A., 1984, P185; SHIMIZU S, 1980, ANAL BIOCHEM, V107, P193, DOI 10.1016/0003-2697(80)90511-4; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; THIBONNIER M, 1991, ENDOCRINOLOGY, V129, P2845, DOI 10.1210/endo-129-6-2845; VANDENBOSCH H, 1975, BIOCHIM BIOPHYS ACTA, V398, P244, DOI 10.1016/0005-2760(75)90140-X; VANDENBOSCH H, 1973, BIOCHIM BIOPHYS ACTA, V296, P94, DOI 10.1016/0005-2760(73)90048-9; WEISS BA, 1991, J BIOL CHEM, V266, P2126; WELLER PF, 1984, J BIOL CHEM, V259, P5100; XIA T, 1992, BIOCHIM BIOPHYS ACTA, V1126, P327, DOI 10.1016/0005-2760(92)90248-T; ZHANG Y, 1988, J BIOL CHEM, V263, P9965	46	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6252	6258						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119970				2022-12-27	WOS:A1994MY84000114
J	BRAYTON, KA; CHEN, ZD; ZHOU, GC; NAGY, PL; GAVALAS, A; TRENT, JM; DEAVEN, LL; DIXON, JE; ZALKIN, H				BRAYTON, KA; CHEN, ZD; ZHOU, GC; NAGY, PL; GAVALAS, A; TRENT, JM; DEAVEN, LL; DIXON, JE; ZALKIN, H			2 GENES FOR DE-NOVO PURINE NUCLEOTIDE SYNTHESIS ON HUMAN-CHROMOSOME-4 ARE CLOSELY LINKED AND DIVERGENTLY TRANSCRIBED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; CPG-RICH ISLANDS; FUNCTIONAL COMPLEMENTATION; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; MESSENGER-RNA; DNA; EXPRESSION; CLONING; SEQUENCE	A cDNA encoding human glutamine phosphoribosylpyrophosphate amidotransferase for step one in de novo purine nucleotide synthesis was cloned, sequenced, and expressed in Chinese hamster ovary cells to yield functional enzyme. Enzyme function was dependent upon removal of an 11-amino-acid propeptide. A mutant enzyme having three propeptide amino acid replacements was not processed and was not active. The human genes GPAT, encoding the amidotransferase, and AIRC, encoding a bifunctional enzyme for steps six and seven in the pathway, were cloned and characterized. GPAT and AIRC are closely linked and divergently transcribed from an intergenic region of approximately 625 base pairs. Expression of a luciferase reporter from the GPAT promoter was approximately 3-4-fold higher than from the AIRC promoter. The GPAT gene was mapped to the q12 region of chromosome 4.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA; UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT RADIAT ONCOL, ANN ARBOR, MI 48109 USA; CTR HUMAN GENOME STUDIES, LOS ALAMOS, NM 87545 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Gavalas, Anthony/F-5817-2015	Nagy, Peter Lajos/0000-0002-7461-8415; Gavalas, Anthony/0000-0003-4897-0359	NIAID NIH HHS [AI27713] Funding Source: Medline; NIDDK NIH HHS [DDKD 18849] Funding Source: Medline; NIGMS NIH HHS [GM46466] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018849] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARTON JW, 1991, SOMAT CELL MOLEC GEN, V17, P311, DOI 10.1007/BF01232825; BARTON JW, 1991, GENOMICS, V9, P314, DOI 10.1016/0888-7543(91)90259-H; BENTON MJ, 1990, J MOL EVOL, V30, P409, DOI 10.1007/BF02101113; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAYTON KA, 1993, THESIS PURDUE U; CHEN ZD, 1990, P NATL ACAD SCI USA, V87, P3097, DOI 10.1073/pnas.87.8.3097; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DICKERSON IM, 1987, J BIOL CHEM, V262, P13646; Dorit RL, 1991, CURR OPIN GENET DEV, V1, P464, DOI 10.1016/S0959-437X(05)80193-5; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAVALAS A, 1993, MOL CELL BIOL, V13, P4784, DOI 10.1128/MCB.13.8.4784; GOODMAN M, 1987, COLD SPRING HARB SYM, V52, P875, DOI 10.1101/SQB.1987.052.01.096; GRANDONI JA, 1989, J BIOL CHEM, V264, P6058; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUXLEY C, 1990, MOL CELL BIOL, V10, P605, DOI 10.1128/MCB.10.2.605; ITAKURA M, 1979, J BIOL CHEM, V254, P333; IWAHANA H, 1993, J BIOL CHEM, V268, P7225; IWAHANA H, 1993, BIOCHEM BIOPH RES CO, V190, P192, DOI 10.1006/bbrc.1993.1030; KUNCZT CJ, 1991, THESIS PURDUE U; LAVIA P, 1987, EMBO J, V6, P2773, DOI 10.1002/j.1460-2075.1987.tb02572.x; LEFF RL, 1984, ADV ENZYME REGUL, V22, P403, DOI 10.1016/0065-2571(84)90022-0; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; MAKAROFF CA, 1983, J BIOL CHEM, V258, P586; MANTSALA P, 1984, J BIOL CHEM, V259, P8478; MANTSALA P, 1984, J BIOL CHEM, V259, P4230; MELTZER PS, 1992, NAT GENET, V1, P24, DOI 10.1038/ng0492-24; MINET M, 1990, CURR GENET, V18, P287, DOI 10.1007/BF00318209; Neuhard J, 1987, ESCHERICHIA COLI SAL, P445; OATES DC, 1977, SOMAT CELL GENET, V3, P561, DOI 10.1007/BF01539066; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILD D, 1990, P NATL ACAD SCI USA, V87, P2916, DOI 10.1073/pnas.87.8.2916; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SOININEN R, 1988, J BIOL CHEM, V263, P17217; SOUCIET JL, 1988, J BIOL CHEM, V263, P3323; STANLEY W, 1978, CYTOGENET CELL GENET, V22, P228, DOI 10.1159/000130943; SWITZER R L, 1989, Biofactors, V2, P77; SWITZER RL, 1989, ALLOSTERIC ENZYMES, P129; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYNDALL C, 1992, J MOL BIOL, V226, P289, DOI 10.1016/0022-2836(92)90945-G; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253; ZALKIN H, 1992, PROG NUCLEIC ACID RE, V42, P259, DOI 10.1016/S0079-6603(08)60578-4; Zalkin Howard, 1993, P335; ZHOU G, 1992, J BIOL CHEM, V267, P7936; ZHOU GC, 1990, J BIOL CHEM, V265, P21152; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	54	32	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5313	5321						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106516				2022-12-27	WOS:A1994MX57100093
J	KIM, YT; RICHARDSON, CC				KIM, YT; RICHARDSON, CC			ACIDIC CARBOXYL-TERMINAL DOMAIN OF GENE-2.5 PROTEIN OF BACTERIOPHAGE-T7 IS ESSENTIAL FOR PROTEIN-PROTEIN INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING-PROTEINS; HELIX-DESTABILIZING PROTEIN; ESCHERICHIA-COLI; DEOXYRIBONUCLEIC-ACID; POLYMERASE ACTIVITY; 32 PROTEIN; PHYSICOCHEMICAL PROPERTIES; LIMITED PROTEOLYSIS; SECONDARY-STRUCTURE; UNWINDING PROTEIN	The product of gene 2.5 protein of bacteriophage T7, a single-stranded DNA-binding protein, physically interacts with phage encoded DNA polymerase and primase/helicase proteins. A truncated gene 2.5 protein (GP2.5-Delta 21C) was constructed by in vitro mutagenesis and lacks the 21 carboxyl-terminal amino acids found in wild-type gene 2.5 protein, 15 of which are acidic. GP2.5-Delta 21C cannot substitute for wild-type gene 2.5 protein in vivo; the phage are not viable and exhibit less than 1% of the DNA synthesis observed in wild-type phage-infected cells. GP2.5-Delta 21C has been purified to apparent homogeneity from cells overexpressing its cloned gene and has a conformation that differs from that of the wild-type gene 2.5 protein as judged by its circular dichroism spectra. Purified GP2.5-Delta 21C retains its ability to bind to single-stranded DNA; the association constant of the protein for single-stranded DNA, determined by nitrocellulose filter binding, is 3.2 x 10(6)M(-1) and is identical to that determined for wild-type gene 2.5 protein. However, GP2.5-Delta 21C is a monomer in solution, whereas the wildtype protein exists as a dimer. GP2.5-Delta 21C does not physically interact with T7 DNA polymerase as measured by affinity chromatography and fluorescent emission anisotropy. The mutant protein cannot stimulate T7 DNA polymerase activity on primed single-stranded DNA templates.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-06045] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P5485, DOI 10.1021/bi00696a017; ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P907, DOI 10.1021/bi00676a006; ARAKI H, 1981, MOL GEN GENET, V183, P66, DOI 10.1007/BF00270140; ARAKI H, 1981, VIROLOGY, V111, P509, DOI 10.1016/0042-6822(81)90353-6; ARGOS P, 1986, VIROLOGY, V149, P208, DOI 10.1016/0042-6822(86)90122-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; BURKE RL, 1980, J BIOL CHEM, V255, P1484; CARROLL RB, 1975, J MOL BIOL, V91, P275, DOI 10.1016/0022-2836(75)90380-0; CASASFINET JR, 1987, FEBS LETT, V220, P347, DOI 10.1016/0014-5793(87)80844-X; CASASFINET JR, 1989, FEBS LETT, V2249, P396; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; DOHERTY DH, 1982, MOL GEN GENET, V188, P77, DOI 10.1007/BF00332998; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HAUGLAND RP, 1989, HDB FLUORESCENT PROB, P20; HINKLE DC, 1972, J MOL BIOL, V70, P157, DOI 10.1016/0022-2836(72)90531-1; HOSODA J, 1978, J BIOL CHEM, V253, P7547; HUBER HE, 1986, J BIOL CHEM, V261, P5006; HUBER HE, 1987, J BIOL CHEM, V262, P16224; HUBERMAN JA, 1971, J MOL BIOL, V62, P39, DOI 10.1016/0022-2836(71)90129-X; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; KIM YT, 1992, J BIOL CHEM, V267, P15032; KIM YT, 1988, J BIOL CHEM, V263, P13712; KIM YT, 1992, J BIOL CHEM, V267, P15022; KIM YT, 1993, P NATL ACAD SCI USA, V90, P10173, DOI 10.1073/pnas.90.21.10173; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Lohman TM., 1990, BIOL NONSPECIFIC DNA, P131; LONBERG N, 1981, J MOL BIOL, V145, P122; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; MODRICH P, 1975, J BIOL CHEM, V250, P5508; MOLINEUX IJ, 1975, J MOL BIOL, V98, P811, DOI 10.1016/S0022-2836(75)80012-X; NAKAI H, 1988, J BIOL CHEM, V263, P9831; NAKAI H, 1988, J BIOL CHEM, V263, P9818; Nakai H., 1988, DNA REPLICATION MUTA, P85; NOSSAL NG, 1979, J BIOL CHEM, V254, P6032; PRASAD BVV, 1987, J MOL BIOL, V193, P579; QUIRK S, 1991, J BACTERIOL, V173, P6665, DOI 10.1128/jb.173.21.6665-6669.1991; REUBEN RC, 1974, J BIOL CHEM, V249, P3843; REUBEN RC, 1973, P NATL ACAD SCI USA, V70, P1846, DOI 10.1073/pnas.70.6.1846; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; RICHARDSON CC, 1966, J MOL BIOL, V15, P49, DOI 10.1016/S0022-2836(66)80208-5; Sambrook J, 1989, MOL CLONING LABORATO; SANCAR A, 1981, P NATL ACAD SCI-BIOL, V78, P4274, DOI 10.1073/pnas.78.7.4274; SCHERZINGER E, 1973, MOL GEN GENET, V123, P247, DOI 10.1007/BF00271243; SHAMOO Y, 1989, BIOCHEMISTRY-US, V28, P7409, DOI 10.1021/bi00444a039; STUDIER FW, 1975, J MOL BIOL, V94, P283, DOI 10.1016/0022-2836(75)90083-2; STUDIER FW, 1969, VIROLOGY, V39, P562, DOI 10.1016/0042-6822(69)90104-4; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TABOR S, 1989, J BIOL CHEM, V264, P6447; TABOR S, 1990, CURRENT PROTOCOLS MO; WILLIAMS KR, 1981, J BIOL CHEM, V256, P1754; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346	63	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5270	5278						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106511				2022-12-27	WOS:A1994MX57100088
J	SHIN, SU; FRIDEN, P; MORAN, M; MORRISON, SL				SHIN, SU; FRIDEN, P; MORAN, M; MORRISON, SL			FUNCTIONAL-PROPERTIES OF ANTIBODY INSULIN-LIKE GROWTH-FACTOR FUSION PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-BRAIN-BARRIER; SERUM BINDING-PROTEINS; AFFINITY FC RECEPTOR; FACTOR-I; PSEUDOMONAS EXOTOXIN; HUMAN-IGG; ELECTRICAL-RESISTANCE; DIPHTHERIA-TOXIN; CH2 DOMAIN; CELL-LINE	Genetic engineering and expression techniques have been used to produce antibody growth factor fusion proteins. Insulin-like growth factors (IGFs) 1 and 2 have been fused to mouse human chimeric IgG3 at the end of C(H)1, immediately after the hinge, and at the end of C(H)3. Fusion heavy chains of the expected molecular weight were expressed, assembled with a co-expressed light chain, and secreted. The resulting molecules continued to bind antigen; they also bound the growth factor receptors, albeit with decreased affinity. The molecule with IGF1 attached after C(H)3 (CH3-IGF1) had reduced ability to carry out complement-mediated cytolysis. In contrast the molecule with IGFS attached after C(H)3 (C(H)3-IGF2) showed an approximately 50-fold increase in its ability to effect complement-mediated cytolysis and so should be an effective cytolytic agent. Both C(H)3-IGF1 and C(H)3-IGF2 bound Fc gamma RI with affinity similar to that of IgG3. The growth factor fusion proteins showed small but significant uptake into the brain parenchyma.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; ALKERMES INC, CAMBRIDGE, MA 02139 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Alkermes					NATIONAL CANCER INSTITUTE [R01CA016858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029470, R37AI029470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007356] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16858] Funding Source: Medline; NIAID NIH HHS [AI 29470] Funding Source: Medline; NINDS NIH HHS [1T32-NSO7356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON CL, 1980, J IMMUNOL, V125, P2735; BABA T, 1991, J CEREBR BLOOD F MET, V11, P638, DOI 10.1038/jcbfm.1991.115; BALLARD FJ, 1986, BIOCHEM J, V233, P223, DOI 10.1042/bj2330223; BATRA JK, 1991, MOL CELL BIOL, V11, P2200, DOI 10.1128/MCB.11.4.2200; BATRA JK, 1990, J BIOL CHEM, V265, P15198; BAYNE ML, 1988, J BIOL CHEM, V263, P6233; BULLARD DE, 1984, J NEUROSURG, V61, P901, DOI 10.3171/jns.1984.61.5.0901; BUTT AM, 1990, J PHYSIOL-LONDON, V429, P47, DOI 10.1113/jphysiol.1990.sp018243; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; CASCIERI MA, 1988, ENDOCRINOLOGY, V123, P373, DOI 10.1210/endo-123-1-373; CHAPPEL MS, 1991, P NATL ACAD SCI USA, V88, P9036, DOI 10.1073/pnas.88.20.9036; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P9491, DOI 10.1073/pnas.87.23.9491; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; CRONE C, 1982, BRAIN RES, V241, P49, DOI 10.1016/0006-8993(82)91227-6; CZECH MP, 1977, ANNU REV BIOCHEM, V46, P359, DOI 10.1146/annurev.bi.46.070177.002043; CZECH MP, 1982, CELL, V31, P8, DOI 10.1016/0092-8674(82)90399-3; DAUGHADAY WH, 1982, J CLIN ENDOCR METAB, V55, P916, DOI 10.1210/jcem-55-5-916; DERCOLE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P935, DOI 10.1073/pnas.81.3.935; DUFFY KR, 1987, BRAIN RES, V420, P32, DOI 10.1016/0006-8993(87)90236-8; DUFFY KR, 1988, METABOLISM, V37, P136, DOI 10.1016/S0026-0495(98)90007-5; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; FISHMAN JB, 1987, J NEUROSCI RES, V18, P299, DOI 10.1002/jnr.490180206; FRIDEN PM, 1993, SCIENCE, V259, P373, DOI 10.1126/science.8420006; FRIDEN PM, 1991, P NATL ACAD SCI USA, V88, P4771, DOI 10.1073/pnas.88.11.4771; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GILLIES SD, 1991, J IMMUNOL, V146, P1067; HAN VKM, 1987, SCIENCE, V236, P193, DOI 10.1126/science.3563497; JOHANSSON BB, 1990, FERNS FOUND SERIES, V14, P145; KUMMER U, 1986, METHOD ENZYMOL, V121, P670; LARRICK JW, 1980, J IMMUNOL, V125, P6; MISRA P, 1986, J CLIN ENDOCR METAB, V63, P1400, DOI 10.1210/jcem-63-6-1400; MORRISON SL, 1988, CLIN CHEM, V34, P1668; NEUWELT EA, 1984, FED PROC, V43, P214; OI VT, 1986, BIOTECHNIQUES, V4, P214; Pardridge W. M., 1991, PEPTIDE DRUG DELIVER, P123; PARDRIDGE WM, 1986, ENDOCR REV, V7, P314, DOI 10.1210/edrv-7-3-314; PRIOR TI, 1991, CANCER RES, V51, P174; RINDERKNECHT E, 1978, FEBS LETT, V89, P283, DOI 10.1016/0014-5793(78)80237-3; ROSENFELD RG, 1982, DIABETES, V31, P375, DOI 10.2337/diabetes.31.5.375; SHIN SU, 1989, METHOD ENZYMOL, V178, P459; SHIN SU, 1990, P NATL ACAD SCI USA, V87, P5322, DOI 10.1073/pnas.87.14.5322; SZABO L, 1988, BIOCHEM BIOPH RES CO, V151, P207, DOI 10.1016/0006-291X(88)90580-3; TAO MH, 1993, J EXP MED, V178, P661, DOI 10.1084/jem.178.2.661; TAO MH, 1989, J IMMUNOL, V143, P2595; TAO MH, 1991, J EXP MED, V173, P1025, DOI 10.1084/jem.173.4.1025; WALTON PE, 1989, COMP BIOCHEM PHYS B, V92, P561, DOI 10.1016/0305-0491(89)90132-6	47	15	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4979	4985						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106473				2022-12-27	WOS:A1994MX57100046
J	CHEN, L; GAVINI, N; TSURUTA, H; ELIEZER, D; BURGESS, BK; DONIACH, S; HODGSON, KO				CHEN, L; GAVINI, N; TSURUTA, H; ELIEZER, D; BURGESS, BK; DONIACH, S; HODGSON, KO			MGATP-INDUCED CONFORMATIONAL-CHANGES IN THE IRON PROTEIN FROM AZOTOBACTER-VINELANDII, AS STUDIED BY SMALL-ANGLE X-RAY-SCATTERING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; MAGNESIUM ADENOSINE 5'-TRIPHOSPHATE; CLOSTRIDIUM-PASTEURIANUM; NITROGENASE; AZOFERREDOXIN	Small angle x-ray scattering experiments have been carried out on the purified iron proteins of nitrogenase from wild-type Azotobacter vinelandii and from a Nif- mutant strain, A. vinelandii UW91 (which has an A157S mutation). This study was designed to investigate the influence of MgATP and MgADP binding on the protein structure in solution. For the wild-type protein, the binding of MgATP induces a significant conformational change that is observed as a decrease of about 2.0 angstrom in the radius of gyration. In contrast, the binding of MgADP to the wild-type iron protein does not detectably affect the radius of gyration. In the absence of nucleotides, the radius of gyration for the UW91 mutant is indistinguishable from that of the wild-type. However, unlike for the wild-type protein, the radius of gyration of the UW91 iron protein is unaffected by the addition of MgATP. We have previously shown that the UW91 iron protein has a normal [4Fe-4S] cluster and MgATP binding ability but that it is completely blocked for electron transfer and MgATP hydrolysis (Gavini, N., and Burgess, B. K. (1992) J. Biol. Chem. 267, 21179-21186), These x-ray scattering measurements suggest that a conformation different from that of the native state is therefore required for the iron protein to perform electron transfer to the MoFe protein. These results also support the hypothesis that Ala-157 is crucial for the iron protein to establish the electron-transfer-favored conformation induced by MgATP binding.	STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305; STANFORD UNIV,DEPT PHYS,STANFORD,CA 94305; STANFORD UNIV,DEPT APPL PHYS,STANFORD,CA 94305; STANFORD UNIV,STANFORD SYNCHROTRON RADIAT LAB,STANFORD,CA 94305; UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717	Stanford University; Stanford University; Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; University of California System; University of California Irvine					NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043144] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-01209, RR01209] Funding Source: Medline; NIGMS NIH HHS [GM-43144] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1983, ADV NITROGEN FIXATIO, P103; BURGESS BK, 1993, MOLYBDENUM ENZYME CO; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; GLATTER O, 1981, SMALL ANGLE XRAY SCA; HUBBARD SR, 1987, THESIS STANFORD U; LJONES T, 1978, BIOCHEMISTRY-US, V17, P1866, DOI 10.1021/bi00603a010; MCDONALD RC, 1979, BIOCHEMISTRY-US, V18, P338, DOI 10.1021/bi00569a017; MORGAN TV, 1986, FEBS LETT, V206, P4, DOI 10.1016/0014-5793(86)81329-1; ORMEJOHNSON WH, 1972, P NATL ACAD SCI USA, V69, P3142, DOI 10.1073/pnas.69.11.3142; PICKOVER CA, 1979, J BIOL CHEM, V254, P1323; ROBSON RL, 1984, FEBS LETT, V173, P394, DOI 10.1016/0014-5793(84)80812-1; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V292, P246, DOI 10.1016/0005-2728(73)90269-7; SMITH BE, 1973, BIOCHEM J, V135, P331, DOI 10.1042/bj1350331; STEPHENS PJ, 1982, ELECTRON TRANSPORT O, P405; THORNELEY RNF, 1985, MOLYBDENUM ENZYMES, P222; TSO MYW, 1973, BIOCHIM BIOPHYS ACTA, V309, P263, DOI 10.1016/0005-2744(73)90024-7; WAKATSUKI S, 1992, REV SCI INSTRUM, V63, P1736, DOI 10.1063/1.1143332; WALKER GA, 1973, BIOCHEM BIOPH RES CO, V53, P904, DOI 10.1016/0006-291X(73)90177-0; WALKER GA, 1974, BIOCHEMISTRY-US, V13, P2382, DOI 10.1021/bi00708a023; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YATES MG, 1991, BIOL NITROGEN FIXATI, P685; ZUMFT WG, 1974, EUR J BIOCHEM, V46, P525, DOI 10.1111/j.1432-1033.1974.tb03646.x; ZUMFT WG, 1972, BIOCHEM BIOPH RES CO, V48, P1525, DOI 10.1016/0006-291X(72)90887-X	26	46	46	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3290	3294						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106367				2022-12-27	WOS:A1994MV63100028
J	FUHRER, C; GEFFEN, I; HUGGEL, K; SPIESS, M				FUHRER, C; GEFFEN, I; HUGGEL, K; SPIESS, M			THE 2 SUBUNITS OF THE ASIALOGLYCOPROTEIN RECEPTOR CONTAIN DIFFERENT SORTING INFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; HUMAN TRANSFERRIN RECEPTOR; HUMAN HEPATOMA-CELLS; CANINE KIDNEY-CELLS; FACTOR-II RECEPTOR; AMINO-ACID CHANGE; CYTOPLASMIC TAIL; COATED PITS; MDCK CELLS; RAPID INTERNALIZATION	The human asialoglycoprotein receptor, an endocytic transport receptor of the basolateral surface of hepatocytes, is a hetero-oligomer of two homologous subunits Hl and H2. The cytoplasmic domain of H1 has been shown previously to contain a tyrosine-based signal tor endocytosis and basolateral sorting. Here, we have investigated sorting determinants within subunit H2 and their contribution to the targeting of the hetero-oligomeric receptor complex. Despite extensive sequence homology, H2 expressed separately in fibroblast cells was endocytosed poorly, and mutation of phenylalanine 5 (corresponding to the critical tyrosine in Hl) did not further reduce internalization. Consistent with this observation, ligand uptake by receptors composed of H1 lacking tyrosine 5 and H2 was inefficient. With respect to polarized transport in Madin-Darby canine kidney cells, H2 could not be analyzed separately, because in the absence of Hl subunit H2 was completely degraded intracellularly. Coexpression of both subunits yielded ligand-binding receptors located specifically on the basolateral surface. The mutant Hl(5A) (tyrosine 5 replaced by alanine) is approximately 55% apical in the absence of H2. In cells expressing Hl(5A) together with H2, however, subunit H2 directed receptor complexes exclusively to the basolateral domain. Phenylalanine 5 is not essential for basolateral transport. Thus, whereas the endocytosis signal of the hetero-oligomeric asialoglycoprotein receptor resides exclusively in subunit Hl, polarized transport to the basolateral domain of Madin-Darby canine kidney cells may involve two signals, only one of which is active for endocytosis.	UNIV BASEL, BIOCTR, DEPT BIOCHEM, KLINGELBERGSTR 70, CH-4056 BASEL, SWITZERLAND	University of Basel				Spiess, Martin/0000-0001-7139-0550; Fuhrer, Christian/0000-0001-8216-8883				ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BISCHOFF J, 1988, J CELL BIOL, V106, P1067, DOI 10.1083/jcb.106.4.1067; BISCHOFF J, 1987, J BIOL CHEM, V262, P11825; BRAITERMAN LT, 1989, J BIOL CHEM, V264, P1682; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GEFFEN I, 1989, EMBO J, V8, P2855, DOI 10.1002/j.1460-2075.1989.tb08433.x; GIRONES N, 1991, J BIOL CHEM, V266, P19006; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GRAEVE L, 1990, J BIOL CHEM, V265, P1216; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; II M, 1990, J BIOL CHEM, V265, P11295; JADOT M, 1992, J BIOL CHEM, V267, P11069; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LODISH HF, 1991, TRENDS BIOCHEM SCI, V16, P374, DOI 10.1016/0968-0004(91)90154-N; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MCPHAUL M, 1986, P NATL ACAD SCI USA, V83, P8863, DOI 10.1073/pnas.83.23.8863; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; OZAKI K, 1992, J BIOL CHEM, V267, P9229; OZAKI K, 1993, J BIOCHEM-TOKYO, V113, P271, DOI 10.1093/oxfordjournals.jbchem.a124038; PAIETTA E, 1992, HEPATOLOGY, V15, P395, DOI 10.1002/hep.1840150307; PAIETTA E, 1992, J BIOL CHEM, V267, P11078; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RICE KG, 1990, J BIOL CHEM, V265, P18429; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; SCHWARTZ AL, 1981, J BIOL CHEM, V256, P8878; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; VERREY F, 1990, CELL REGUL, V1, P471, DOI 10.1091/mbc.1.6.471; WESSELS HP, 1989, J BIOL CHEM, V264, P17	46	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3277	3282						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106365				2022-12-27	WOS:A1994MV63100026
J	REZAIE, AR; ESMON, CT				REZAIE, AR; ESMON, CT			CONVERSION OF GLUTAMIC-ACID 192 TO GLUTAMINE IN ACTIVATED PROTEIN-C CHANGES THE SUBSTRATE-SPECIFICITY AND INCREASES REACTIVITY TOWARD MACROMOLECULAR INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-V; HUMAN FACTOR-IX; BLOOD-COAGULATION; ANTITHROMBIN-III; FACTOR-XA; ALPHA-THROMBIN; THROMBOMODULIN; CALCIUM; RECONSTITUTION; INACTIVATION	Protein C is a vitamin K-dependent serine protease zymogen that upon activation inhibits the coagulation cascade by inactivating factors Va and VIIIa. In an attempt to improve the anticoagulant activity of activated protein C (APC), we have prepared a mutant of protein C in mammalian cells in which Glu at position 192 (chymotrypsin numbering system) has been replaced with Gln (PC E192Q). Our strategy is based on the observation that the same substitution in thrombin improves the catalytic activity toward natural and synthetic substrates that contain Asp residues at P3 and P3'. Since factor Va also has an Asp at position P3 in the APC cleavage site of the factor Va heavy chain, we hypothesized that APC E192Q would inactivate factor Va more rapidly than wild type APC. The mutant inactivated factor Va approximately 2-3-fold faster than wild type. In plasma the mutant exhibited slightly less anticoagulant activity than wild type enzyme. Further characterization revealed that APC E192Q is inhibited 280 times faster than APC by alpha1-antitrypsin (K2 = 2.8 x 10(3) M-1 s-1 versus 10 M-1 s-1), and unlike APC, APC E192Q is inhibited by antithrombin III in the presence of heparin (K2 = 1.17 x 10(3) M-1 s-1) and absence of heparin (K2 = 57 M-1 s-1). Ca2+. increased K2 more than 4-fold with or without heparin. Unlike wild type APC, APC E192Q was effectively inhibited by pancreatic trypsin inhibitor (K(i) = 10.6 +/- 0.26 nm) and tissue factor pathway inhibitor (58 +/- 5 nM). Like factor Xa, APC E192Q rapidly processed factor IX to factor IXalpha. These observations suggest that even though Glu at position 192 is not an optimal residue for catalyzing factor Va inactivation, it is an evolutionary adaptation to slow inhibition by plasma protease inhibitors.	OKLAHOMA MED RES FDN, HOWARD HUGHES MED INST, 825 NE 13TH ST, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA HLTH SCI CTR, HLTH SCI CTR, HOWARD HUGHES MED INST, OKLAHOMA CITY, OK 73190 USA; UNIV OKLAHOMA HLTH SCI CTR, HLTH SCI CTR, DEPT PATHOL, OKLAHOMA CITY, OK 73190 USA; UNIV OKLAHOMA HLTH SCI CTR, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, OKLAHOMA CITY, OK 73190 USA	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; Howard Hughes Medical Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030340, R01HL029807] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL29807, R37 HL30340] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALVING BM, 1992, AM J OBSTET GYNECOL, V167, P1184, DOI 10.1016/S0002-9378(12)90409-3; BLOW DM, 1974, NATURE, V249, P55, DOI 10.1038/249054a0; BODE W, 1992, PROTEIN SCI, V1, P426; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DANGELO SV, 1986, J CLIN INVEST, V77, P416, DOI 10.1172/JCI112319; DREYFUS M, 1991, NEW ENGL J MED, V325, P1565, DOI 10.1056/NEJM199111283252207; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON CT, 1977, CHEM BIOL THROMBIN, P403; ESPANA F, 1991, BLOOD, V77, P1754; FIORE MM, 1992, BLOOD, V80, P3127; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GERSON WT, 1993, PEDIATRICS, V91, P418; GRUBER A, 1989, BLOOD, V73, P639; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HEEB MJ, 1991, J BIOL CHEM, V266, P17606; KANE WH, 1988, BLOOD, V71, P539; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; LEBONNIEC BF, 1993, J BIOL CHEM, V268, P19055; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P19341; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; MANCOJOHNSON M, 1992, AM J HEMATOL, V40, P69, DOI 10.1002/ajh.2830400116; MUNTEAN W, 1992, THROMB HAEMORRH DISO, V5, P43; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; OWEN WG, 1974, J BIOL CHEM, V249, P594; PABINGER I, 1992, BLOOD COAGUL FIBRIN, V3, P547, DOI 10.1097/00001721-199210000-00005; PREISSNER KT, 1990, CLIN SCI, V78, P351, DOI 10.1042/cs0780351; RAPAPORT SI, 1992, ARTERIOSCLER THROMB, V12, P1111, DOI 10.1161/01.ATV.12.10.1111; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STONE SR, 1985, BIOCHEM J, V230, P497, DOI 10.1042/bj2300497; SUZUKI K, 1989, THROMB HAEMOSTASIS, V61, P337; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	43	49	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					19943	19948						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8104182				2022-12-27	WOS:A1993LY01900008
J	OLMSTED, EA; OBRIEN, L; HENSHAW, EC; PANNIERS, R				OLMSTED, EA; OBRIEN, L; HENSHAW, EC; PANNIERS, R			PURIFICATION AND CHARACTERIZATION OF EUKARYOTIC INITIATION-FACTOR (EIF)-2-ALPHA KINASES FROM EHRLICH ASCITES TUMOR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-CHAIN INITIATION; NUCLEOTIDE-EXCHANGE FACTOR; DOUBLE-STRANDED-RNA; PROTEIN-SYNTHESIS INITIATION; FACTOR-II; TRANSLATIONAL INHIBITOR; RABBIT RETICULOCYTE; PHYSIOLOGICAL STRESSES; ALPHA-SUBUNIT; PHOSPHORYLATION	A major mechanism of regulation of mammalian protein synthesis initiation is accomplished by the phosphorylation of the alpha subunit of eukaryotic initiation factor (eIF) 2 . This modification inhibits the activity of another initiation factor, guanine nucleotide exchange factor, preventing conversion of eIF-2.GDP to eIF-2.GTP and hence binding of initiator tRNA and formation of ternary complex (eIF-2.GTP.Met-tRNA(f)). Inhibition of protein synthesis and phosphorylation of eIF-2 occurs in Ehrlich cells when they are amino acid- or serum-deprived or heat-shocked as well as in other nucleated cells under similar conditions. This paper describes the purification of two eIF-2alpha kinases from Ehrlich cells. Unlike the two well characterized eIF-2alpha kinases, HRI (heme-regulated inhibitor from reticulocytes) and P68 (double-stranded RNA-dependent kinase found in interferon-treated cells), the Ehrlich cell kinases do not appear to auto-phosphorylate. The two kinases chromatograph differently on DEAE-cellulose and Mono Q. Furthermore, their Michaelis constants (K(m) values) for ATP are different. Both kinases can inhibit purified guanine nucleotide exchange factor (GEF) from stimulating ternary complex formation. However, only one kinase inhibits reticulocyte lysate cell free protein synthesis. The other kinase co-purifies with a factor that suppresses inhibition of protein synthesis in reticulocyte lysates by eIF-2alpha kinases. This suppressing activity is probably guanine nucleotide exchange factor.	NIH,DIV RES GRANTS,RM 2A17,WESTWOOD BLDG,5333 WESTBARD AVE,BETHESDA,MD 20892; UNIV ROCHESTER,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,CTR CANC,ROCHESTER,NY 14642	National Institutes of Health (NIH) - USA; University of Rochester; University of Rochester					NCI NIH HHS [R01 CA21663] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA021663] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALACAZAR A, 1986, INT J DEV NEUROSCI, V4, P525; DELAUNAY J, 1977, P NATL ACAD SCI USA, V74, P2264, DOI 10.1073/pnas.74.6.2264; FARRELL PJ, 1977, CELL, V11, P182; GROSS M, 1980, J BIOL CHEM, V255, P6270; HUNT T, 1985, BIOCHIM BIOPHYS ACTA, V826, P224; HUNTER T, 1975, J BIOL CHEM, V250, P409; JEDLICKA P, 1991, J BIOL CHEM, V266, P15663; KRAMER G, 1976, P NATL ACAD SCI USA, V73, P3078, DOI 10.1073/pnas.73.9.3078; KUDLICKI W, 1987, J BIOL CHEM, V262, P9695; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LEBLEU B, 1976, P NATL ACAD SCI USA, V73, P3107, DOI 10.1073/pnas.73.9.3107; LEVIN DH, 1976, P NATL ACAD SCI USA, V73, P3112, DOI 10.1073/pnas.73.9.3112; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; OCHOA S, 1983, ARCH BIOCHEM BIOPHYS, V223, P325, DOI 10.1016/0003-9861(83)90598-2; PAIN VM, 1986, BIOCHEM J, V235, P625, DOI 10.1042/bj2350625; PANNIERS LRV, 1981, J CELL SCI, V48, P259; PANNIERS R, 1988, J BIOL CHEM, V263, P5519; PANNIERS R, 1985, J BIOL CHEM, V260, P9648; PANNIERS R, 1983, J BIOL CHEM, V258, P7928; PETERSON DT, 1979, J BIOL CHEM, V254, P7730; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; Ranu R S, 1979, Methods Enzymol, V60, P459; RANU RS, 1980, BIOCHEM BIOPH RES CO, V97, P1124, DOI 10.1016/0006-291X(80)91492-8; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2140; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; ROWLANDS AG, 1988, EUR J BIOCHEM, V175, P93, DOI 10.1111/j.1432-1033.1988.tb14170.x; SAFER B, 1980, J BIOL CHEM, V255, P6913; SARRE TF, 1989, EUR J BIOCHEM, V183, P137, DOI 10.1111/j.1432-1033.1989.tb14905.x; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; SIEKIERKA J, 1982, P NATL ACAD SCI-BIOL, V79, P2537, DOI 10.1073/pnas.79.8.2537; SIEKIERKA J, 1983, P NATL ACAD SCI-BIOL, V80, P1232, DOI 10.1073/pnas.80.5.1232; SIEKIERKA J, 1981, P NATL ACAD SCI-BIOL, V78, P220, DOI 10.1073/pnas.78.1.220; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P3654, DOI 10.1073/pnas.75.8.3654; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; WEST DK, 1979, EUR J BIOCHEM, V101, P461, DOI 10.1111/j.1432-1033.1979.tb19740.x; 1985, FPLC ION EXCHANGE CH	38	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12552	12559						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8099583				2022-12-27	WOS:A1993LG65800050
J	SUTO, N; IKURA, K; SASAKI, R				SUTO, N; IKURA, K; SASAKI, R			EXPRESSION INDUCED BY INTERLEUKIN-6 OF TISSUE-TYPE TRANSGLUTAMINASE IN HUMAN HEPATOBLASTOMA HEPG2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE-STIMULATING FACTOR; ACUTE-PHASE PROTEINS; GUINEA-PIG LIVER; GENE-EXPRESSION; CROSS-LINKING; RETINOIC ACID; CELLULAR TRANSGLUTAMINASE; SODIUM-BUTYRATE; CDNA CLONES; FACTOR-II	We examined the effect of interleukin-6 (IL-6) on the expression of transglutaminase in human hepatoblastoma HepG2 cells. Treatment of cells with IL-6 increased their transglutaminase activity in a time- and dose-dependent way. Dexamethasone strengthened the stimulation by IL-6. Half-maximum stimulation of transglutaminase activity in the cells occurred at a dose of 40 pM IL-6 regardless of the presence of dexamethasone. Based on its immunoreactivity, the transglutaminase induced was identified as tissue-type transglutaminase. Immunoblot analysis showed that the increase in transglutaminase activity was related to an increase in the amount of transglutaminase protein. Northern blot analysis with a cDNA probe specific for human tissue-type transglutaminase showed that exposure of HepG2 cells to IL-6 increased the mRNA level of the enzyme, and the increase was detectable 3 h after IL-6 was added. Induction of the mRNA was maximum between 10 and 14 h. The increase in the mRNA level was not blocked by the presence of cycloheximide, suggesting that the increase was independent of protein synthesis. Injections into mice of substances that induce inflammation such as turpentine and lipopolysaccharides increased the liver transglutaminase activity. These results indicated that transglutaminase may be involved in some biological processes in hepatocytes regulated by IL-6 signaling.	KYOTO UNIV,FAC AGR,DEPT FOOD SCI & TECHNOL,KYOTO 606,JAPAN	Kyoto University								AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANDUS T, 1987, FEBS LETT, V221, P18, DOI 10.1016/0014-5793(87)80344-7; BAUMANN H, 1988, J BIOL CHEM, V263, P17390; BAUMANN M, 1990, J BIOL CHEM, V265, P19853; Birckbichler P J, 1978, Ann N Y Acad Sci, V312, P354, DOI 10.1111/j.1749-6632.1978.tb16813.x; BIRCKBICHLER PJ, 1981, P NATL ACAD SCI-BIOL, V78, P5005, DOI 10.1073/pnas.78.8.5005; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUNGAY PJ, 1986, BIOCHEM J, V235, P269, DOI 10.1042/bj2350269; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BYRD JC, 1987, J BIOL CHEM, V262, P11699; CASTELL JV, 1988, EUR J BIOCHEM, V177, P357, DOI 10.1111/j.1432-1033.1988.tb14384.x; CASTELL JV, 1988, FEBS LETT, V232, P347, DOI 10.1016/0014-5793(88)80766-X; CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4; CHEN HM, 1991, J BIOL CHEM, V266, P2946; CHIOCCA EA, 1988, J BIOL CHEM, V263, P11584; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; Fesus L, 1988, Adv Exp Med Biol, V231, P119; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GEIGER T, 1988, EUR J IMMUNOL, V18, P717, DOI 10.1002/eji.1830180510; GENTILE V, 1991, J BIOL CHEM, V266, P478; GEORGE MD, 1990, J BIOL CHEM, V265, P11098; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAND D, 1988, BIOCHIM BIOPHYS ACTA, V970, P137, DOI 10.1016/0167-4889(88)90172-3; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; IKURA K, 1990, FEBS LETT, V268, P203, DOI 10.1016/0014-5793(90)81008-C; IKURA K, 1990, EUR J BIOCHEM, V187, P705, DOI 10.1111/j.1432-1033.1990.tb15357.x; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; KANNAGI R, 1982, BIOCHEM BIOPH RES CO, V105, P164, DOI 10.1016/S0006-291X(82)80026-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KN, 1987, BIOCHIM BIOPHYS ACTA, V928, P22, DOI 10.1016/0167-4889(87)90081-4; LORAND L, 1972, ANN NY ACAD SCI, V202, P6, DOI 10.1111/j.1749-6632.1972.tb16319.x; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1972, ANAL BIOCHEM, V50, P623, DOI 10.1016/0003-2697(72)90074-7; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; MIYAURA C, 1988, FEBS LETT, V234, P17, DOI 10.1016/0014-5793(88)81293-6; MOSHER DF, 1979, J CLIN INVEST, V64, P781, DOI 10.1172/JCI109524; MURTAUGH MP, 1984, J EXP MED, V159, P114, DOI 10.1084/jem.159.1.114; NAKAMURA T, 1988, EXP CELL RES, V179, P488, DOI 10.1016/0014-4827(88)90286-8; NAKANISHI K, 1991, EUR J BIOCHEM, V202, P15, DOI 10.1111/j.1432-1033.1991.tb16338.x; NARA K, 1989, J BIOL CHEM, V264, P19308; PIACENTINI M, 1988, BIOCHEM J, V253, P33, DOI 10.1042/bj2530033; RICE RH, 1978, J CELL BIOL, V76, P705, DOI 10.1083/jcb.76.3.705; ROSEJOHN S, 1990, EUR J BIOCHEM, V190, P79, DOI 10.1111/j.1432-1033.1990.tb15548.x; SAKATA Y, 1982, J CLIN INVEST, V69, P536, DOI 10.1172/JCI110479; SCHROEDER JJ, 1990, P NATL ACAD SCI USA, V87, P3137, DOI 10.1073/pnas.87.8.3137; SHABO Y, 1988, BLOOD, V72, P2070; SIEFRING GE, 1978, BIOCHEMISTRY-US, V17, P2598, DOI 10.1021/bi00606a022; SIVE HL, 1984, MOL CELL BIOL, V4, P2723, DOI 10.1128/MCB.4.12.2723; SLIFE CW, 1986, J BIOL CHEM, V261, P3451; SUEDHOFF T, 1990, CANCER RES, V50, P7830; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANDAMME J, 1987, J EXP MED, V165, P914, DOI 10.1084/jem.165.3.914; WEISSENBACH J, 1988, P NATL ACAD SCI USA, V79, P2768	58	87	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7469	7473						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8096510				2022-12-27	WOS:A1993KV14100092
